PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kleinman, CL; Majewski, J				Kleinman, Claudia L.; Majewski, Jacek			Comment on "Widespread RNA and DNA Sequence Differences in the Human Transcriptome"	SCIENCE			English	Editorial Material							EXPRESSION		[Kleinman, Claudia L.; Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada	McGill University	Kleinman, CL (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ, Canada.	claudia.kleinman@mcgill.ca	; Tan, Meng How/M-8605-2015	Kleinman, Claudia/0000-0002-5158-7126; Tan, Meng How/0000-0003-3627-5586; Lin, Wei/0000-0002-7506-3466				Goldsmith M, 2009, P NATL ACAD SCI USA, V106, P6197, DOI 10.1073/pnas.0809506106; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018; Meyerovich M, 2010, P NATL ACAD SCI USA, V107, P11543, DOI 10.1073/pnas.0912989107; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754	5	128	130	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074								10.1126/science.1209658	http://dx.doi.org/10.1126/science.1209658			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422964				2022-12-28	WOS:000301531600024
J	Pan, XB; Liu, FQ; Zhang, M				Pan, Xubin; Liu, Fengqiao; Zhang, Mi			Comment on "Productivity Is a Poor Predictor of Plant Species Richness"	SCIENCE			English	Editorial Material									[Pan, Xubin] Texas A&I Univ, Dept Environm Engn, Kingsville, TX 78363 USA; [Pan, Xubin] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China; [Liu, Fengqiao] Arizona State Univ, Sch Sustainabil, Tempe, AZ 85287 USA; [Zhang, Mi] Chinese Acad Sci, NW Inst Plateau Biol, Xining 81008, Peoples R China	Texas A&M University System; Texas A&M University Kingsville; Tsinghua University; Arizona State University; Arizona State University-Tempe; Chinese Academy of Sciences	Pan, XB (corresponding author), Texas A&I Univ, Dept Environm Engn, 700 Univ Blvd, Kingsville, TX 78363 USA.	xubin.hu.pan@gmail.com	smart, simon M/I-6089-2012; Liancourt, Pierre/AAT-4313-2020; Börger, Luca/C-6003-2008; Gross, Nicolas/E-2794-2010; Pierce, Simon/G-6785-2017; Cerabolini, Bruno Enrico Leone/N-6934-2014; Gross, Nicolas/I-2368-2016; Le Bagousse-Pinguet, Yoann/I-2413-2016; Brooker, Rob W/F-9569-2012; Liancourt, Pierre/H-1605-2014; Huston, Michael A./B-1434-2009	Liancourt, Pierre/0000-0002-3109-8755; Börger, Luca/0000-0001-8763-5997; Pierce, Simon/0000-0003-1182-987X; Cerabolini, Bruno Enrico Leone/0000-0002-3793-0733; Gross, Nicolas/0000-0001-9730-3240; Le Bagousse-Pinguet, Yoann/0000-0002-5615-5541; Brooker, Rob W/0000-0002-7014-0071; Huston, Michael A./0000-0001-9513-1166; Pan, Xubin/0000-0003-4943-7281; smart, simon/0000-0003-2750-7832	Natural Environment Research Council [CEH010021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Adler PB, 2011, SCIENCE, V333, P1750, DOI 10.1126/science.1204498; Bai YF, 2007, J APPL ECOL, V44, P1023, DOI 10.1111/j.1365-2664.2007.01351.x; Gillman LN, 2006, ECOLOGY, V87, P1234, DOI 10.1890/0012-9658(2006)87[1234:TIOPOT]2.0.CO;2; Whittaker RJ, 2010, ECOLOGY, V91, P2522, DOI 10.1890/08-0968.1	4	64	69	4	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075								10.1126/science.1214786	http://dx.doi.org/10.1126/science.1214786			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442464				2022-12-28	WOS:000301837000022
J	Fridley, JD; Grime, JP; Huston, MA; Pierce, S; Smart, SM; Thompson, K; Borger, L; Brooker, RW; Cerabolini, BEL; Gross, N; Liancourt, P; Michalet, R; Le Bagousse-Pinguet, Y				Fridley, Jason D.; Grime, J. Philip; Huston, Michael A.; Pierce, Simon; Smart, Simon M.; Thompson, Ken; Boerger, Luca; Brooker, Rob W.; Cerabolini, Bruno E. L.; Gross, Nicolas; Liancourt, Pierre; Michalet, Richard; Le Bagousse-Pinguet, Yoann			Comment on "Productivity Is a Poor Predictor of Plant Species Richness"	SCIENCE			English	Editorial Material							WETLANDS; CROP		[Fridley, Jason D.] Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; [Grime, J. Philip; Thompson, Ken] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; [Huston, Michael A.] Texas State Univ, Dept Biol, San Marcos, TX 78666 USA; [Pierce, Simon] Univ Milan, Dept Plant Prod, Milan, Italy; [Smart, Simon M.] Lancaster Environm Ctr, Ctr Ecol & Hydrol, Lancaster LA1 4AP, England; [Boerger, Luca; Gross, Nicolas] CNRS, UPR1934, Ctr Etud Biol Chize, F-79360 Beauvoir Sur Niort, France; [Boerger, Luca; Gross, Nicolas] INRA, USC1339, F-79360 Beauvoir Sur Niort, France; [Brooker, Rob W.] James Hutton Inst, Aberdeen AB15 8QH, Scotland; [Cerabolini, Bruno E. L.] Univ Insubria Varese, Dept Struct & Funct Biol, I-21100 Varese, Italy; [Liancourt, Pierre] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Michalet, Richard; Le Bagousse-Pinguet, Yoann] Univ Bordeaux 1, EPOC, UMR 5805, F-33405 Talence, France	Syracuse University; University of Sheffield; Texas State University System; Texas State University San Marcos; University of Milan; Lancaster University; UK Centre for Ecology & Hydrology (UKCEH); Centre National de la Recherche Scientifique (CNRS); INRAE; James Hutton Institute; University of Insubria; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite de Bordeaux	Fridley, JD (corresponding author), Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA.	fridley@syr.edu	smart, simon M/I-6089-2012; Liancourt, Pierre/AAT-4313-2020; Börger, Luca/C-6003-2008; Gross, Nicolas/E-2794-2010; Pierce, Simon/G-6785-2017; Cerabolini, Bruno Enrico Leone/N-6934-2014; Gross, Nicolas/I-2368-2016; Le Bagousse-Pinguet, Yoann/I-2413-2016; Brooker, Rob W/F-9569-2012; Liancourt, Pierre/H-1605-2014; Huston, Michael A./B-1434-2009	Liancourt, Pierre/0000-0002-3109-8755; Börger, Luca/0000-0001-8763-5997; Pierce, Simon/0000-0003-1182-987X; Cerabolini, Bruno Enrico Leone/0000-0002-3793-0733; Gross, Nicolas/0000-0001-9730-3240; Le Bagousse-Pinguet, Yoann/0000-0002-5615-5541; Brooker, Rob W/0000-0002-7014-0071; Huston, Michael A./0000-0001-9513-1166; Pan, Xubin/0000-0003-4943-7281; smart, simon/0000-0003-2750-7832	Natural Environment Research Council [CEH010021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Adler PB, 2011, SCIENCE, V333, P1750, DOI 10.1126/science.1204498; ALMUFTI MM, 1977, J ECOL, V65, P759, DOI 10.2307/2259378; FACELLI JM, 1991, BOT REV, V57, P1, DOI 10.1007/BF02858763; GOUGH L, 1994, OIKOS, V70, P271, DOI 10.2307/3545638; Grace James B., 1999, Perspectives in Plant Ecology Evolution and Systematics, V2, P1, DOI 10.1078/1433-8319-00063; GRIME JP, 1973, NATURE, V242, P344, DOI 10.1038/242344a0; HUSTON M, 1979, AM NAT, V113, P81, DOI 10.1086/283366; Keddy P, 2005, ANN BOT-LONDON, V96, P177, DOI 10.1093/aob/mci166; Kull O, 1997, ECOGRAPHY, V20, P146, DOI 10.1111/j.1600-0587.1997.tb00357.x; MOORE DRJ, 1989, BIOL CONSERV, V47, P203, DOI 10.1016/0006-3207(89)90065-7; MOORE DRJ, 1989, VEGETATIO, V79, P99; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Smart SM, 2006, J APPL ECOL, V43, P1128, DOI 10.1111/j.1365-2664.2006.01231.x; Tilman D., 1982, Monographs in Population Biology, pi; WHEELER BD, 1991, J ECOL, V79, P285, DOI 10.2307/2260713	15	64	69	4	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075								10.1126/science.1215042	http://dx.doi.org/10.1126/science.1215042			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442464				2022-12-28	WOS:000301837000023
J	Murphy, D; Bishop, H; Edgar, A				Murphy, Dermot; Bishop, Hugh; Edgar, Angela			Leukocoria and retinoblastoma-pitfalls of the digital age?	LANCET			English	Editorial Material									[Murphy, Dermot] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland; [Bishop, Hugh] Bristol Royal Hosp Children, Bristol, Avon, England; [Edgar, Angela] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland	University of Glasgow; Bristol Royal Hospital For Children	Murphy, D (corresponding author), Royal Hosp Sick Children, Dalnair St, Glasgow G3 8SJ, Lanark, Scotland.	dermot.murphy@ggc.scot.nhs.uk							0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2465	2465		10.1016/S0140-6736(11)61644-9	http://dx.doi.org/10.1016/S0140-6736(11)61644-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967NV	22445238	Bronze			2022-12-28	WOS:000305915900031
J	Kung, Y; Ando, N; Doukov, TI; Blasiak, LC; Bender, G; Seravalli, J; Ragsdale, SW; Drennan, CL				Kung, Yan; Ando, Nozomi; Doukov, Tzanko I.; Blasiak, Leah C.; Bender, Guenes; Seravalli, Javier; Ragsdale, Stephen W.; Drennan, Catherine L.			Visualizing molecular juggling within a B-12-dependent methyltransferase complex	NATURE			English	Article							IRON-SULFUR PROTEIN; DEPENDENT METHIONINE SYNTHASE; WOOD-LJUNGDAHL PATHWAY; METHYL-GROUP TRANSFER; ACETYL COENZYME-A; CLOSTRIDIUM-THERMOACETICUM; REDUCTIVE ACTIVATION; CATALYSIS; SYSTEM; DOMAIN	Derivatives of vitamin B-12 are used in methyl group transfer in biological processes as diverse as methionine synthesis in humans and CO2 fixation in acetogenic bacteria(1-3). This seemingly straightforward reaction requires large, multimodular enzyme complexes that adopt multiple conformations to alternately activate, protect and perform catalysis on the reactive B-12 cofactor. Crystal structures determined thus far have provided structural information for only fragments of these complexes(4-12), inspiring speculation about the overall protein assembly and conformational movements inherent to activity. Here we present X-ray crystal structures of a complete 220 kDa complex that contains all enzymes responsible for B-12-dependent methyl transfer, namely the corrinoid iron-sulphur protein and its methyltransferase from the model acetogen Moorella thermoacetica. These structures provide the first three-dimensional depiction of all protein modules required for the activation, protection and catalytic steps of B-12-dependent methyl transfer. In addition, the structures capture B-12 at multiple locations between its 'resting' and catalytic positions, allowing visualization of the dramatic protein rearrangements that enable methyl transfer and identification of the trajectory for B-12 movement within the large enzyme scaffold. The structures are also presented alongside in crystallo spectroscopic data, which confirm enzymatic activity within crystals and demonstrate the largest known conformational movements of proteins in a crystalline state. Taken together, this work provides a model for the molecular juggling that accompanies turnover and helps explain why such an elaborate protein framework is required for such a simple, yet biologically essential reaction.	[Kung, Yan; Ando, Nozomi; Doukov, Tzanko I.; Blasiak, Leah C.; Drennan, Catherine L.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Ando, Nozomi; Drennan, Catherine L.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Bender, Guenes; Ragsdale, Stephen W.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Seravalli, Javier] Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; [Drennan, Catherine L.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Lincoln; Massachusetts Institute of Technology (MIT)	Drennan, CL (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	cdrennan@mit.edu		Ando, Nozomi/0000-0001-7062-1644; Doukov, Tzanko/0000-0001-8625-2572; Kung, Yan/0000-0002-6132-7969	National Institutes of Health [GM69857, GM39451]; MIT Energy Initiative; National Center for Research Resources at the National Institutes of Health [RR-15301]; US Department of Energy, Office of Basic Energy Sciences [DE-AC02-06CH11357]; Office of Science, Office of Basic Energy Sciences, of the US Department of Energy [DE-AC02-05CH11231]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039451, R01GM069857, R29GM039451, T32GM008334, R01GM039451] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MIT Energy Initiative; National Center for Research Resources at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); US Department of Energy, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Office of Science, Office of Basic Energy Sciences, of the US Department of Energy(United States Department of Energy (DOE)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. E. Darty for his assistance with the purification of CFeSP. This work was supported by National Institutes of Health grants GM69857 (to C. L. D.) and GM39451 (to S. W. R.) and the MIT Energy Initiative (to C. L. D.). C. L. D. is a Howard Hughes Medical Institute Investigator. This work is based upon research conducted at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines, which are supported by award RR-15301 from the National Center for Research Resources at the National Institutes of Health. Use of the Advanced Photon Source is supported by the US Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US Department of Energy under Contract No. DE-AC02-05CH11231.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Bandarian V, 2002, NAT STRUCT BIOL, V9, P53; Bandarian V, 2003, P NATL ACAD SCI USA, V100, P8156, DOI 10.1073/pnas.1133218100; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Barstow B, 2008, P NATL ACAD SCI USA, V105, P13362, DOI 10.1073/pnas.0802252105; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Datta S, 2008, P NATL ACAD SCI USA, V105, P4115, DOI 10.1073/pnas.0800329105; Dixon MM, 1996, STRUCTURE, V4, P1263, DOI 10.1016/S0969-2126(96)00135-9; Doukov T, 2000, STRUCTURE, V8, P817, DOI 10.1016/S0969-2126(00)00172-6; Doukov TI, 2007, J BIOL CHEM, V282, P6609, DOI 10.1074/jbc.M609828200; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; Koutmos M, 2009, P NATL ACAD SCI USA, V106, P18527, DOI 10.1073/pnas.0906132106; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LJUNGDAH.LG, 1973, BIOCHEMISTRY-US, V12, P1802, DOI 10.1021/bi00733a022; LU WP, 1993, J BIOL CHEM, V268, P5605; Matthews RG, 2001, ACCOUNTS CHEM RES, V34, P681, DOI 10.1021/ar0000051; Matthews RG, 2008, CURR OPIN STRUC BIOL, V18, P658, DOI 10.1016/j.sbi.2008.11.005; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Menon S, 1998, BIOCHEMISTRY-US, V37, P5689, DOI 10.1021/bi9727996; Menon S, 1999, J BIOL CHEM, V274, P11513, DOI 10.1074/jbc.274.17.11513; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ragsdale SW, 2008, BBA-PROTEINS PROTEOM, V1784, P1873, DOI 10.1016/j.bbapap.2008.08.012; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; Royant A, 2007, J APPL CRYSTALLOGR, V40, P1105, DOI 10.1107/S0021889807044196; SCHRAUZER GN, 1969, J AM CHEM SOC, V91, P3341, DOI 10.1021/ja01040a041; Seravalli J, 1999, BIOCHEMISTRY-US, V38, P5728, DOI 10.1021/bi982473c; Stich TA, 2006, J AM CHEM SOC, V128, P5010, DOI 10.1021/ja054690o; Svetlitchnaia T, 2006, P NATL ACAD SCI USA, V103, P14331, DOI 10.1073/pnas.0601420103; WIRT MD, 1995, BIOCHEMISTRY-US, V34, P5269, DOI 10.1021/bi00015a042; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008; ZHAO SY, 1995, BIOCHEMISTRY-US, V34, P15075, DOI 10.1021/bi00046a013; ZYDOWSKY TM, 1986, J AM CHEM SOC, V108, P3152, DOI 10.1021/ja00271a081	39	52	55	3	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					265	U159		10.1038/nature10916	http://dx.doi.org/10.1038/nature10916			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22419154	Green Accepted, Green Submitted			2022-12-28	WOS:000303149900040
J	Ledermann, J; Harter, P; Gourley, C; Friedlander, M; Vergote, I; Rustin, G; Scott, C; Meier, W; Shapira-Frommer, R; Safra, T; Matei, D; Macpherson, E; Watkins, C; Carmichael, J; Matulonis, U				Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Macpherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula			Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; BRCA1; CHEMOTHERAPY; INHIBITION; REPAIR; DEFICIENT; AZD2281; TUMORS; TRIAL	BACKGROUND Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.)	[Ledermann, Jonathan] UCL, Inst Canc, UCL & UCL Hosp Comprehens Biomed Res Ctr, London W1T 4TJ, England; [Harter, Philipp] Kliniken Essen Mitte, Essen, Germany; [Meier, Werner] Evangel Krankenhaus, Dusseldorf, Germany; [Gourley, Charlie] Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Friedlander, Michael] Prince Wales Hosp, Randwick, NSW 2031, Australia; [Scott, Clare] Royal Melbourne Hosp, Parkville, Vic 3050, Australia; [Vergote, Ignace] Katholieke Univ Leuven, Louvain, Belgium; [Rustin, Gordon] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England; [Macpherson, Euan; Watkins, Claire; Carmichael, James] AstraZeneca, Macclesfield, Cheshire, England; [Shapira-Frommer, Ronnie] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; [Safra, Tamar] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Matei, Daniela] Indiana Univ Sch Med, Indianapolis, IN USA; [Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA 02115 USA	University of London; University College London; Kliniken Essen-Mitte; University of Edinburgh; Royal Melbourne Hospital; KU Leuven; AstraZeneca; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Indiana University System; Indiana University Bloomington; Harvard University; Dana-Farber Cancer Institute	Ledermann, J (corresponding author), UCL, Inst Canc, UCL & UCL Hosp Comprehens Biomed Res Ctr, 90 Tottenham Court Rd, London W1T 4TJ, England.	j.ledermann@ctc.ucl.ac.uk	friedlander, michael l/G-3490-2013; Rustin, Gordon J. S./J-9763-2019	friedlander, michael l/0000-0002-6488-0604; Matei, Daniela/0000-0003-2169-5035; friedlander, michael/0000-0003-3090-795X	AstraZeneca; Chief Scientist Office [SCD/11] Funding Source: researchfish	AstraZeneca(AstraZeneca); Chief Scientist Office	Supported by AstraZeneca.	Aghajanian C, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.18_suppl.lba5007; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaye SB, 2010, ANN ONCOL S, V21, pLBA25; Konstantinopoulos, 2010, J CLIN ONCOL, V28, P4868, DOI 10.1200/JCO.2010.33.2205; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Ledermann JA, 2011, J CLIN ONCOL, V29, P3798, DOI 10.1200/JCO.2010.33.5208; Markman Maurie, 2009, Gynecol Oncol, V114, P195, DOI 10.1016/j.ygyno.2009.04.012; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Parmar MKB, 2003, LANCET, V361, P2099; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Perren TJ, 2012, NEW ENGL J MED, V366, P284; Pfisterer J, 2006, SEMIN ONCOL, V33, pS12, DOI 10.1053/j.seminoncol.2006.03.012; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Pujade-Lauraine E, 2010, J CLIN ONCOL, V28, P3323, DOI 10.1200/JCO.2009.25.7519; Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rustin GJS, 2011, INT J GYNECOL CANCER, V21, P419, DOI 10.1097/IGC.0b013e3182070f17; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Weberpals JI, 2008, J CLIN ONCOL, V26, P3259, DOI 10.1200/JCO.2007.11.3902	34	1265	1319	1	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1382	1392		10.1056/NEJMoa1105535	http://dx.doi.org/10.1056/NEJMoa1105535			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923GV	22452356	Bronze			2022-12-28	WOS:000302608600002
J	Diamond, DA; Mattoo, TK				Diamond, David A.; Mattoo, Tej K.			Endoscopic Treatment of Primary Vesicoureteral Reflux	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEXTRANOMER/HYALURONIC ACID COPOLYMER; URINARY-TRACT-INFECTION; SUBURETERAL INJECTION; MULTIVARIATE-ANALYSIS; CHILDREN; MANAGEMENT; IMPLANTATION; URETER; TRIAL; NEPHROPATHY	A 7-year-old girl with a history of recurrent urinary tract infection since the age of 3 years is known to have bilateral, moderately severe (grade III) vesicoureteral reflux. Renal scintigraphy with technetium-99-labeled dimercaptosuccinic acid has revealed bilateral scarring in the upper poles of her kidneys, with more severe scarring on the left kidney than on the right. Despite ongoing antimicrobial prophylaxis, she has recently had another febrile urinary tract infection, which responded well to antibiotic treatment. Radionuclide cystography reveals persistent bilateral, moderately severe vesicoureteral reflux. The patient has no history of constipation or dysfunctional voiding. She is referred to a pediatric urologist, who discusses with the patient and her parents the various treatment options, including endoscopic correction.	[Diamond, David A.] Childrens Hosp Boston, Dept Urol, Boston, MA 02115 USA; [Mattoo, Tej K.] Wayne State Univ, Childrens Hosp Michigan, Div Pediat Nephrol, Sch Med, Detroit, MI USA	Harvard University; Boston Children's Hospital; Children's Hospital of Michigan; Wayne State University	Diamond, DA (corresponding author), Childrens Hosp Boston, Dept Urol, 300 Longwood Ave, Boston, MA 02115 USA.	david.diamond@childrens.harvard.edu	Mattoo, Tej K/CFB-5385-2022					Alon US, 2011, NEW ENGL J MED, V365, P266; [Anonymous], 1987, Br Med J (Clin Res Ed), V295, P237; Brandstrom P, 2010, J UROLOGY, V184, P286, DOI 10.1016/j.juro.2010.01.061; Brandstrom P, 2010, J UROLOGY, V184, P292, DOI 10.1016/j.juro.2010.01.060; Capozza N, 2004, J UROLOGY, V172, P1626, DOI 10.1097/01.ju.0000138381.75175.b9; Capozza N, 2002, J UROLOGY, V168, P1695, DOI 10.1016/S0022-5347(05)64391-1; Capozza N, 2002, J PEDIATR-US, V140, P230, DOI 10.1067/mpd.2002.121380; Cerwinka WH, 2010, AM J ROENTGENOL, V195, P234, DOI 10.2214/AJR.09.3790; Chand DH, 2003, J UROLOGY, V170, P1548, DOI 10.1097/01.ju.0000084299.55552.6c; Cooper CS, 2009, NAT REV UROL, V6, P481, DOI 10.1038/nrurol.2009.150; COTRAN RS, 1982, KIDNEY INT, V21, P528, DOI 10.1038/ki.1982.57; Dave S, 2008, J UROLOGY, V180, P1594, DOI 10.1016/j.juro.2008.03.084; Diamond DA, 2003, J UROLOGY, V170, P1556, DOI 10.1097/01.ju.0000084303.21983.26; Elder JS, 2006, J UROLOGY, V175, P716, DOI 10.1016/S0022-5347(05)00210-7; Gupta A, 2008, J UROLOGY, V180, P1589, DOI 10.1016/j.juro.2008.04.073; Higham-Kessler J, 2007, J UROLOGY, V177, P710, DOI 10.1016/j.juro.2006.09.082; Holmdahl G, 2010, J UROLOGY, V184, P280, DOI 10.1016/j.juro.2010.01.059; Kalisvaart JF, 2011, J PEDIAT UROL   0803; Khalil BA, 2010, PEDIATR SURG INT, V26, P729, DOI 10.1007/s00383-010-2621-6; Khoury A, 2007, CAMPBELL WALSH UROLO, V4, P3423; Kirsch AJ, 2004, J UROLOGY, V171, P2413, DOI 10.1097/01.ju.0000127754.79866.7f; Kobelt G, 2003, J UROLOGY, V169, P1480, DOI 10.1097/01.ju.0000056638.75652.54; Krill AJ, 2011, J UROLOGY, V186, P2040, DOI 10.1016/j.juro.2011.07.023; Lackgren G, 2001, J UROLOGY, V166, P1887, DOI 10.1016/S0022-5347(05)65713-8; LEBOWITZ RL, 1992, J UROLOGY, V148, P1640, DOI 10.1016/S0022-5347(17)36991-4; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; Lee EK, 2009, J UROLOGY, V181, P1869, DOI 10.1016/j.juro.2008.12.005; Lorenzo AJ, 2006, J UROLOGY, V176, P1851, DOI 10.1016/S0022-5347(06)00599-4; Lorenzo AJ, 2010, CUAJ-CAN UROL ASSOC, V4, P276, DOI 10.5489/cuaj.1082; Mattoo TK, 2011, ADV CHRONIC KIDNEY D, V18, P348, DOI 10.1053/j.ackd.2011.07.006; Nelson CP, 2008, PEDIATR RADIOL, V38, P104, DOI 10.1007/s00247-007-0613-z; Noe H Norman, 2008, J Pediatr Urol, V4, P88, DOI 10.1016/j.jpurol.2007.02.005; PAQUIN AJ, 1959, J UROLOGY, V82, P573, DOI 10.1016/S0022-5347(17)65934-2; Peters CA, 2010, J UROLOGY, V184, P1134, DOI 10.1016/j.juro.2010.05.065; POLITANO VA, 1958, J UROLOGY, V79, P932, DOI 10.1016/S0022-5347(17)66369-9; PURI P, 1984, BRIT MED J, V289, P5, DOI 10.1136/bmj.289.6436.5; Puri P, 2003, J UROLOGY, V170, P1541, DOI 10.1097/01.ju.0000083924.44779.80; Radmayr C, 2009, THER ADV UROL, V1, P243, DOI 10.1177/1756287209348985; RANSLEY PG, 1981, KIDNEY INT, V20, P733, DOI 10.1038/ki.1981.204; Routh JC, 2010, PEDIATRICS, V125, P1010, DOI 10.1542/peds.2009-2225; Saperston K, 2008, J UROLOGY, V180, P1626, DOI 10.1016/j.juro.2008.05.124; Sargent MA, 2000, PEDIATR RADIOL, V30, P587, DOI 10.1007/s002470000263; Schwab CW, 2002, J UROLOGY, V168, P2594, DOI 10.1016/S0022-5347(05)64225-5; Schwentner C, 2008, J Pediatr Urol, V4, P20, DOI 10.1016/j.jpurol.2007.08.002; Shaikh N, 2010, PEDIATRICS, V126, P1084, DOI 10.1542/peds.2010-0685; SKOOG SJ, 1991, PEDIATRICS, V87, P538; Snodgrass WT, 2004, J UROLOGY, V171, P395, DOI 10.1097/01.ju.0000101995.85004.95; Sorensen MD, 2010, PEDIATR SURG INT, V26, P509, DOI 10.1007/s00383-010-2558-9; STENBERG A, 1995, J UROLOGY, V154, P800, DOI 10.1016/S0022-5347(01)67168-4; Swerkersson S, 2007, J UROLOGY, V178, P647, DOI 10.1016/j.juro.2007.04.004; TAMMINENMOBIUS T, 1992, J UROLOGY, V148, P1662, DOI 10.1016/S0022-5347(17)36997-5; TANAGHO EA, 1969, J UROLOGY, V101, P824, DOI 10.1016/S0022-5347(17)62433-9; Traxel E, 2009, J UROLOGY, V182, P1708, DOI 10.1016/j.juro.2009.02.088; Urinary tract infection in children, 2007, UR TRACT INF CHILDR; Vandersteen DR, 2006, J UROLOGY, V176, P1593, DOI 10.1016/j.juro.2006.06.101; Venhola M, 2010, ACTA PAEDIATR, V99, P1875, DOI 10.1111/j.1651-2227.2010.01909.x; Wu Chan-Yao, 2004, Acta Paediatrica Taiwanica, V45, P328; Yucel S, 2007, J UROLOGY, V177, P1505, DOI 10.1016/j.juro.2006.11.077	58	32	36	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1218	1226		10.1056/NEJMct1108922	http://dx.doi.org/10.1056/NEJMct1108922			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455416				2022-12-28	WOS:000302005100010
J	Leonardi, C; Matheson, R; Zachariae, C; Cameron, G; Li, L; Edson-Heredia, E; Braun, D; Banerjee, S				Leonardi, Craig; Matheson, Robert; Zachariae, Claus; Cameron, Gregory; Li, Linda; Edson-Heredia, Emily; Braun, Daniel; Banerjee, Subhashis			Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; FAMILY-MEMBERS; INTERLEUKIN-17; TRIAL; IL-17; USTEKINUMAB; ACTIVATION; CYTOKINE; EFFICACY; THERAPY	BACKGROUND Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment. METHODS In our phase 2, double-blind, placebo-controlled trial, we randomly assigned 142 patients with chronic moderate-to-severe plaque psoriasis to receive subcutaneous injections of 10, 25, 75, or 150 mg of ixekizumab or placebo at 0, 2, 4, 8, 12, and 16 weeks. The primary end point was the proportion of patients with reduction in the psoriasis area-and-severity index (PASI) score by at least 75% at 12 weeks. Secondary end points included the proportion of patients with reduction in the PASI score by at least 90% or by 100%. RESULTS At 12 weeks, the percentage of patients with a reduction in the PASI score by at least 75% was significantly greater with ixekizumab (except with the lowest, 10-mg dose). - 150 mg (82.1%), 75 mg (82.8%), and 25 mg (76.7%) - than with placebo (7.7%, P<0.001 for each comparison), as was the percentage of patients with a reduction in the PASI score by at least 90%: 150 mg (71.4%), 75 mg (58.6%), and 25 mg (50.0%) versus placebo (0%, P<0.001 for each comparison). Similarly, a 100% reduction in the PASI score was achieved in significantly more patients in the 150-mg group (39.3%) and the 75-mg group (37.9%) than in the placebo group (0%) (P<0.001 for both comparisons). Significant differences occurred at as early as 1 week and were sustained through 20 weeks. Adverse events occurred in 63% of patients in both the combined ixekizumab groups and in the placebo group. No serious adverse events or major cardiovascular events were observed. CONCLUSIONS Use of a humanized anti-interleukin-17 monoclonal antibody, ixekizumab, improved the clinical symptoms of psoriasis. Further studies are needed to establish its long-term safety and efficacy in patients with psoriasis. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT01107457.)	[Leonardi, Craig] St Louis Univ, Dept Dermatol, Sch Med, St Louis, MO 63103 USA; [Matheson, Robert] Oregon Med Res Ctr PC, Portland, OR USA; [Zachariae, Claus] Univ Hosp Copenhagen Gentofte, Dept Dermatoallergol, Hellerup, Denmark; [Cameron, Gregory; Edson-Heredia, Emily; Braun, Daniel; Banerjee, Subhashis] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; [Li, Linda] Pharmanet I3, Indianapolis, IN USA	Saint Louis University; University of Copenhagen; Herlev & Gentofte Hospital; Eli Lilly	Leonardi, C (corresponding author), Cent Dermatol PC, 1034 S Brentwood Blvd,Suite 600, St Louis, MO 63117 USA.	leonardi@centralderm.com	Zachariae, Claus Otto Carl/G-6144-2018	Zachariae, Claus Otto Carl/0000-0001-5506-1319	Eli Lilly	Eli Lilly(Eli Lilly)	Supported by Eli Lilly.	Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006, COMMON TERMINOLOGY C; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Fitch Erin, 2007, Curr Rheumatol Rep, V9, P461, DOI 10.1007/s11926-007-0075-1; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kikly K, 2007, CURR OPIN IMMUNOL, V19, P111, DOI 10.1016/j.coi.2006.11.016; KIMBALL AB, 2004, M AM AC DERM NEW YOR; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Krueger J, 2011, BRIT J DERMATOL, V165, pE6; Kurd SK, 2009, J AM ACAD DERMATOL, V61, P507; Laan M, 1999, J IMMUNOL, V162, P2347; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li JW, 2007, J HUAZHONG U SCI-MED, V27, P330, DOI 10.1007/s11596-007-0329-1; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Rigopoulos D, 2010, J EUR ACAD DERMATOL, V24, P530, DOI 10.1111/j.1468-3083.2009.03453.x; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Tyring S, 2010, INT J DERMATOL, V49, P1328, DOI 10.1111/j.1365-4632.2010.04598.x; van de Kerkhof P C, 2001, Am J Clin Dermatol, V2, P159, DOI 10.2165/00128071-200102030-00005	28	731	818	3	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1190	1199		10.1056/NEJMoa1109997	http://dx.doi.org/10.1056/NEJMoa1109997			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455413	Bronze			2022-12-28	WOS:000302005100007
J	Rejeski, WJ; Ip, EH; Bertoni, AG; Bray, GA; Evans, G; Gregg, EW; Zhang, Q				Rejeski, W. Jack; Ip, Edward H.; Bertoni, Alain G.; Bray, George A.; Evans, Gina; Gregg, Edward W.; Zhang, Qiang		Look AHEAD Res Grp	Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; OLDER-ADULTS; WEIGHT-LOSS; PHYSICAL-ACTIVITY; US ADULTS; CARDIOVASCULAR-DISEASE; KNEE OSTEOARTHRITIS; CLINICAL-TRIAL; UNITED-STATES; RISK-FACTORS	BACKGROUND Adults with type 2 diabetes mellitus often have limitations in mobility that increase with age. An intensive lifestyle intervention that produces weight loss and improves fitness could slow the loss of mobility in such patients. METHODS We randomly assigned 5145 overweight or obese adults between the ages of 45 and 74 years with type 2 diabetes to either an intensive lifestyle intervention or a diabetes support-and-education program; 5016 participants contributed data. We used hidden Markov models to characterize disability states and mixed-effects ordinal logistic regression to estimate the probability of functional decline. The primary outcome was self-reported limitation in mobility, with annual assessments for 4 years. RESULTS At year 4, among 2514 adults in the lifestyle-intervention group, 517 (20.6%) had severe disability and 969 (38.5%) had good mobility; the numbers among 2502 participants in the support group were 656 (26.2%) and 798 (31.9%), respectively. The lifestyle-intervention group had a relative reduction of 48% in the risk of loss of mobility, as compared with the support group (odds ratio, 0.52; 95% confidence interval, 0.44 to 0.63; P<0.001). Both weight loss and improved fitness (as assessed on treadmill testing) were significant mediators of this effect (P<0.001 for both variables). Adverse events that were related to the lifestyle intervention included a slightly higher frequency of musculoskeletal symptoms at year 1. CONCLUSIONS Weight loss and improved fitness slowed the decline in mobility in overweight adults with type 2 diabetes. (Funded by the Department of Health and Human Services and others; ClinicalTrials.gov number, NCT00017953.)	[Rejeski, W. Jack] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Ip, Edward H.; Bertoni, Alain G.; Zhang, Qiang] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA; [Evans, Gina] Baylor Coll Med, Houston, TX 77030 USA; [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA	Wake Forest University; Wake Forest University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Baylor College of Medicine; Centers for Disease Control & Prevention - USA	Rejeski, WJ (corresponding author), Wake Forest Univ, Dept Hlth & Exercise Sci, Box 7868, Winston Salem, NC 27109 USA.	rejeski@wfu.edu	Soliman, Elsayed Z/AAD-7135-2020	Soliman, Elsayed Z/0000-0001-5632-8150; Hill, James/0000-0003-4690-2264; Bertoni, Alain/0000-0002-7503-6273; Gregg, Edward/0000-0003-2381-6822	Department of Health and Human Services; National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992, DK 046204]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; Centers for Disease Control and Prevention; Department of Veterans Affairs; Indian Health Service; National Heart, Lung, and Blood Institute [HL076441-01A1]; National Institute on Aging [P30-AG021332]; General Clinical Research Center [M01-RR00211]; Johns Hopkins Medical Institutions Bayview General Clinical Re-search Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center; Massachusetts Institute of Technology General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056]; Clinical Translational Research Center [UL1 RR 024153]; Frederic C. Bartter General Clinical Research Center [M01RR01346]; M01RR01346); and by FedEx; Health Management Resources; LifeScan; Nestle HealthCare Nutrition; Hoffmann-La Roche; Abbott Nutrition; Unilever North America; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153, M01RR001066, M01RR002719, M01RR000051, M01RR000056, M01RR001346, M01RR000211] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076441, U01HL101066, R18HL076441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046204, U01DK057219, U01DK057182, ZIADK075077, U01DK056990, U01DK057135, U01DK057149, U01DK057151, U01DK056992, U01DK057136, P30DK017047, U01DK057002, P30DK048520, U01DK057171, U01DK057178, U01DK057131, U01DK057078, U01DK057008, U01DK057177, U01DK057154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021332, R01AG031827] Funding Source: NIH RePORTER	Department of Health and Human Services; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Center on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Indian Health Service(United States Department of Health & Human Services); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Johns Hopkins Medical Institutions Bayview General Clinical Re-search Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Massachusetts General Hospital Mallinckrodt General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Massachusetts Institute of Technology General Clinical Research Center; University of Colorado Health Sciences Center General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical Nutrition Research Unit; University of Tennessee at Memphis General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); University of Pittsburgh General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical Translational Research Center; Frederic C. Bartter General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); M01RR01346); and by FedEx; Health Management Resources; LifeScan; Nestle HealthCare Nutrition(Nestle SA); Hoffmann-La Roche(Hoffmann-La Roche); Abbott Nutrition(Abbott Laboratories); Unilever North America(Unilever); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the Department of Health and Human Services through the following cooperative agreements with the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992; by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, the National Institute of Nursing Research, the National Center on Minority Health and Health Disparities, the Office of Research on Women's Health, the Centers for Disease Control and Prevention, the Department of Veterans Affairs, the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, and the Indian Health Service; by grants (to Dr. Rejeski) from the National Heart, Lung, and Blood Institute (HL076441-01A1), the National Institute on Aging (P30-AG021332), and the General Clinical Research Center (M01-RR00211); by grants (to Dr. Ip) from the National Institute on Aging (R01AG031827A) and the National Heart, Lung, and Blood Institute (U01HL101066-01); and by grants from the Johns Hopkins Medical Institutions Bayview General Clinical Re-search Center (M01RR02719), the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066), the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520), the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140), the University of Pittsburgh General Clinical Research Center (M01RR000056), the Clinical Translational Research Center (funded by a Clinical and Translational Science Award [UL1 RR 024153] and the National Institutes of Health [DK 046204]), and the Frederic C. Bartter General Clinical Research Center (M01RR01346); and by FedEx, Health Management Resources, LifeScan, Nestle HealthCare Nutrition, Hoffmann-La Roche, Abbott Nutrition, and Unilever North America.	American College of Sports Medicine, 2006, ASCMS GUID EX TEST P; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29; Boyle JP, 2001, DIABETES CARE, V24, P1936, DOI 10.2337/diacare.24.11.1936; Brancati F, 2003, CONTROL CLIN TRIALS, V24, P610, DOI 10.1016/S0197-2456(03)00064-3; Bruce B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2890; Centers for Disease Control and Prevention, 1980, PERC CIV NON POP DIA, P1980; Cowie CC, 2006, DIABETES CARE, V29, P1263, DOI 10.2337/dc06-0062; Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035; Fried LP, 2000, J GERONTOL A-BIOL, V55, pM43; Gregg EW, 2000, DIABETES CARE, V23, P1272, DOI 10.2337/diacare.23.9.1272; Gregg EW, 2003, ARCH INTERN MED, V163, P1440, DOI 10.1001/archinte.163.12.1440; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Imai K, 2008, OBESITY, V16, P402, DOI 10.1038/oby.2007.70; Ip EH, 2010, SOCIOL METHOD RES, V39, P222, DOI 10.1177/0049124110378095; Jakicic JM, 2009, INT J OBESITY, V33, P305, DOI 10.1038/ijo.2008.280; Koster A, 2008, J AM GERIATR SOC, V56, P636, DOI 10.1111/j.1532-5415.2007.01632.x; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; Lang IA, 2008, J AM GERIATR SOC, V56, P1474, DOI 10.1111/j.1532-5415.2008.01813.x; Look Ahead Research Group, 2006, Diab Vasc Dis Res, V3, P202, DOI 10.3132/dvdr.2006.031; MacDonald IL., 1997, HIDDEN MARKOV OTHER, V110; MacKinnon D.P., 2012, INTRO STAT MEDIATION; Mensah GA, 2007, HEALTH AFFAIR, V26, P38, DOI 10.1377/hlthaff.26.1.38; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Miller ME, 2000, J AM GERIATR SOC, V48, P1264, DOI 10.1111/j.1532-5415.2000.tb02600.x; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Park SW, 2009, DIABETES CARE, V32, P1993, DOI 10.2337/dc09-0264; Rejeski WJ, 2010, OBES REV, V11, P671, DOI 10.1111/j.1467-789X.2009.00679.x; Rejeski WJ, 2008, ARCH PHYS MED REHAB, V89, P2102, DOI 10.1016/j.apmr.2008.05.013; Rejeski WJ, 2006, OBESITY, V14, P870, DOI 10.1038/oby.2006.101; Rejeski WJ, 2011, ARCH INTERN MED, V171, P880, DOI 10.1001/archinternmed.2010.522; Rejeski WJ, 2002, HEALTH PSYCHOL, V21, P419, DOI 10.1037/0278-6133.21.5.419; Ribisl PM, 2007, DIABETES CARE, V30, P2679, DOI 10.2337/dc06-2487; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; Wadden TA, 2006, OBESITY, V14, P737; Wadden TA, 2011, OBESITY, V19, P1987, DOI 10.1038/oby.2011.230; Ware JE, 1999, MED CARE, V37, pMS40, DOI 10.1097/00005650-199905001-00004; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Williamson DA, 2009, ARCH INTERN MED, V169, P163, DOI 10.1001/archinternmed.2008.544; Wing RR, 2010, ARCH INTERN MED, V170, P1566, DOI 10.1001/archinternmed.2010.334; Zhang QA, 2010, J COMPUT GRAPH STAT, V19, P746, DOI 10.1198/jcgs.2010.09015	42	197	205	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1209	1217		10.1056/NEJMoa1110294	http://dx.doi.org/10.1056/NEJMoa1110294			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915DW	22455415	Green Accepted, Bronze			2022-12-28	WOS:000302005100009
J	Strittmatter, WJ				Strittmatter, Warren J.			Old Drug, New Hope for Alzheimer's Disease	SCIENCE			English	Editorial Material							INSULIN		[Strittmatter, Warren J.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Strittmatter, Warren J.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University	Strittmatter, WJ (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA.	warren@neuro.duke.edu						Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0	6	30	31	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1447	1448		10.1126/science.1220725	http://dx.doi.org/10.1126/science.1220725			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442467				2022-12-28	WOS:000301837000028
J	Havranek, EP				Havranek, Edward P.			Simvastatin reduced major vascular events at 5 years in at-risk patients; benefits were maintained at 11 years	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FOLLOW-UP; MORTALITY; PREVENTION		Denver Hlth Med Ctr, Denver, CO USA	Denver Health Medical Center	Havranek, EP (corresponding author), Denver Hlth Med Ctr, Denver, CO USA.							Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Sever PS, 2011, EUR HEART J, V32, P2525, DOI 10.1093/eurheartj/ehr333; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-5	10.7326/0003-4819-156-6-201203200-02005	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431691				2022-12-28	WOS:000303150900004
J	Boguslavskiy, AE; Mikosch, J; Gijsbertsen, A; Spanner, M; Patchkovskii, S; Gador, N; Vrakking, MJJ; Stolow, A				Boguslavskiy, Andrey E.; Mikosch, Jochen; Gijsbertsen, Arjan; Spanner, Michael; Patchkovskii, Serguei; Gador, Niklas; Vrakking, Marc J. J.; Stolow, Albert			The Multielectron Ionization Dynamics Underlying Attosecond Strong-Field Spectroscopies	SCIENCE			English	Article							HIGH HARMONIC-GENERATION; REAL-TIME OBSERVATION; MOLECULAR IONIZATION; THRESHOLD IONIZATION; MULTIPLE ORBITALS; LASER FIELDS; ELECTRON; PHOTOIONIZATION; INTERFEROMETRY; BUTADIENE	Subcycle strong-field ionization (SFI) underlies many emerging spectroscopic probes of atomic or molecular attosecond electronic dynamics. Extending methods such as attosecond high harmonic generation spectroscopy to complex polyatomic molecules requires an understanding of multielectronic excitations, already hinted at by theoretical modeling of experiments on atoms, diatomics, and triatomics. Here, we present a direct method which, independent of theory, experimentally probes the participation of multiple electronic continua in the SFI dynamics of polyatomic molecules. We use saturated (n-butane) and unsaturated (1,3-butadiene) linear hydrocarbons to show how subcycle SFI of polyatomics can be directly resolved into its distinct electronic-continuum channels by above-threshold ionization photoelectron spectroscopy. Our approach makes use of photoelectron-photofragment coincidences, suiting broad classes of polyatomic molecules.	[Boguslavskiy, Andrey E.; Mikosch, Jochen; Gijsbertsen, Arjan; Spanner, Michael; Patchkovskii, Serguei; Stolow, Albert] Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; [Gijsbertsen, Arjan; Vrakking, Marc J. J.] FOM Inst Atoom En Molecuulfys AMOLF, NL-1098 XG Amsterdam, Netherlands; [Gador, Niklas] Lund Univ, Dept Chem Phys, SE-22100 Lund, Sweden; [Vrakking, Marc J. J.] Max Born Inst, D-12489 Berlin, Germany	National Research Council Canada; AMOLF; Lund University; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy	Stolow, A (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	albert.stolow@nrc.ca	Vrakking, Marc JJ/F-6770-2014; Stolow, Albert/AAN-5609-2020	Vrakking, Marc JJ/0000-0002-3249-1663; 	Natural Sciences and Engineering Research Council of Canada; Alexander von Humboldt Foundation; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)(Netherlands Organization for Scientific Research (NWO))	We thank the Natural Sciences and Engineering Research Council of Canada for financial support and R. Lausten, B. J. Sussman, D. J. Moffatt, and D. Guay for expert assistance. J. M. thanks the Feodor Lynen program of the Alexander von Humboldt Foundation for financial support. Aspects of this work are part of the research program of the Stichting voor Fundamenteel Onderzoek der Materie (FOM), which is financially supported by the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO). The authors declare no competing financial interests.	AGOSTINI P, 1979, PHYS REV LETT, V42, P1127, DOI 10.1103/PhysRevLett.42.1127; Akagi H, 2009, SCIENCE, V325, P1364, DOI 10.1126/science.1175253; Armentrout PB, 1996, J PHYS CHEM-US, V100, P12866, DOI 10.1021/jp953329t; BIERI G, 1977, HELV CHIM ACTA, V60, P2213, DOI 10.1002/hlca.19770600714; Blaga CI, 2009, NAT PHYS, V5, P335, DOI 10.1038/NPHYS1228; BOMBACH R, 1983, J AM CHEM SOC, V105, P1824, DOI 10.1021/ja00345a024; CHUPKA WA, 1967, J CHEM PHYS, V47, P2921, DOI 10.1063/1.1712317; CHUPKA WA, 1974, CHEM SPECTROSCOPY PH, P433; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; DANNACHER J, 1980, CHEM PHYS, V51, P189, DOI 10.1016/0301-0104(80)80094-2; Fraser DJ, 1995, J PHYS B-AT MOL OPT, V28, pL739, DOI 10.1088/0953-4075/28/23/006; FRASINSKI LJ, 1992, PHYS REV A, V46, pR6789, DOI 10.1103/PhysRevA.46.R6789; FREEMAN RR, 1987, PHYS REV LETT, V59, P1092, DOI 10.1103/PhysRevLett.59.1092; Goulielmakis E, 2010, NATURE, V466, P739, DOI 10.1038/nature09212; Haessler S, 2010, NAT PHYS, V6, P200, DOI 10.1038/NPHYS1511; Holland DMP, 1996, J PHYS B-AT MOL OPT, V29, P3091, DOI 10.1088/0953-4075/29/14/020; Huismans Y, 2011, SCIENCE, V331, P61, DOI 10.1126/science.1198450; Itatani J, 2004, NATURE, V432, P867, DOI 10.1038/nature03183; Krausz F, 2009, REV MOD PHYS, V81, P163, DOI 10.1103/RevModPhys.81.163; Lezius M, 2001, PHYS REV LETT, V86, P51, DOI 10.1103/PhysRevLett.86.51; Li W, 2008, SCIENCE, V322, P1207, DOI 10.1126/science.1163077; Markevitch AN, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.011402; McFarland BK, 2008, SCIENCE, V322, P1232, DOI 10.1126/science.1162780; Meckel M, 2008, SCIENCE, V320, P1478, DOI 10.1126/science.1157980; Muth-Bohm J, 2000, PHYS REV LETT, V85, P2280, DOI 10.1103/PhysRevLett.85.2280; Petretti S, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.223001; Rottke H, 1996, J PHYS B-AT MOL OPT, V29, P1479, DOI 10.1088/0953-4075/29/8/012; Sansone G, 2010, NATURE, V465, P763, DOI 10.1038/nature09084; SCHAFER KJ, 1993, PHYS REV LETT, V70, P1599, DOI 10.1103/PhysRevLett.70.1599; Smirnova O, 2009, NATURE, V460, P972, DOI 10.1038/nature08253; Smits M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.203402; Spanner M, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.063411; Thomann I, 2008, J PHYS CHEM A, V112, P9382, DOI 10.1021/jp8023414; Uiberacker M, 2007, NATURE, V446, P627, DOI 10.1038/nature05648; Vozzi C, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3526752; Walters ZB, 2008, J PHYS CHEM A, V112, P9439, DOI 10.1021/jp8031226; Worner HJ, 2010, NATURE, V466, P604, DOI 10.1038/nature09185; Zhou XB, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.073902; Zhou XB, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.073902	39	158	159	2	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1336	1340		10.1126/science.1212896	http://dx.doi.org/10.1126/science.1212896			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422980				2022-12-28	WOS:000301531600044
J	Noblin, X; Rojas, NO; Westbrook, J; Llorens, C; Argentina, M; Dumais, J				Noblin, X.; Rojas, N. O.; Westbrook, J.; Llorens, C.; Argentina, M.; Dumais, J.			The Fern Sporangium: A Unique Catapult	SCIENCE			English	Article									[Noblin, X.] Univ Nice Sophia Antipolis UNS, Lab Phys Mat Condensee, CNRS UMR 7336, F-06108 Nice, France; [Rojas, N. O.; Llorens, C.; Argentina, M.] UNS, CNRS, Lab JA Dieudonne, UMR 7351, F-06108 Nice, France; [Westbrook, J.] Univ Florida, Dept Bot, Gainesville, FL 32611 USA; [Dumais, J.] Harvard Univ, Cambridge, MA 02138 USA	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI); UDICE-French Research Universities; Universite Cote d'Azur; State University System of Florida; University of Florida; Harvard University	Noblin, X (corresponding author), Univ Nice Sophia Antipolis UNS, Lab Phys Mat Condensee, CNRS UMR 7336, Parc Valrose, F-06108 Nice, France.	xavier.noblin@unice.fr	Dumais, Jacques/H-7950-2013; Rojas, Nicolás O/C-8683-2019; Argentina, Mederic/AAQ-9236-2021; Argentina, Mederic/I-8741-2014; Argentina, Mederic/AAR-8153-2021; Rojas, Nicolas O./AAV-3912-2021	Dumais, Jacques/0000-0003-2344-4766; Argentina, Mederic/0000-0002-8926-7398; Argentina, Mederic/0000-0002-8926-7398; Rojas, Nicolas O./0000-0001-7562-2670	Materials Research Science and Engineering Center (Harvard University); CNRS (PIR); Agence Nationale de la Recherche; Commission nacional de Investigacion Cientifica y Tecnologica	Materials Research Science and Engineering Center (Harvard University); CNRS (PIR); Agence Nationale de la Recherche(French National Research Agency (ANR)); Commission nacional de Investigacion Cientifica y Tecnologica	This work was supported by the Materials Research Science and Engineering Center (Harvard University), the CNRS (PIR project "EVAPLANTE"), the Agence Nationale de la Recherche (project "CAVISOFT"), and the Commission nacional de Investigacion Cientifica y Tecnologica (N.R.).	CARPITA N, 1979, SCIENCE, V205, P1144, DOI 10.1126/science.205.4411.1144; HAIDER K, 1954, PLANTA, V44, P370, DOI 10.1007/BF01940087; Ingold C. T., 1965, SPORE LIBERATION; King AL, 1944, P NATL ACAD SCI USA, V30, P155, DOI 10.1073/pnas.30.7.155; Noblin X., 2009, P 6 PLANT BIOM C CAY; Noblin X, 2009, J EXP BIOL, V212, P2835, DOI 10.1242/jeb.029975; Renner O., 1915, JAHR WISS BOT, V56, P647; RITMAN KT, 1990, J EXP BOT, V41, P1157, DOI 10.1093/jxb/41.9.1157; Skotheim JM, 2004, P ROY SOC A-MATH PHY, V460, P1995, DOI 10.1098/rspa.2003.1270; Ursprung A., 1915, BER DEUT BOT GES, V33, P153	10	115	120	6	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1322	1322		10.1126/science.1215985	http://dx.doi.org/10.1126/science.1215985			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422975	Green Submitted			2022-12-28	WOS:000301531600039
J	Scalari, G; Maissen, C; Turcinkova, D; Hagenmuller, D; De Liberato, S; Ciuti, C; Reichl, C; Schuh, D; Wegscheider, W; Beck, M; Faist, J				Scalari, G.; Maissen, C.; Turcinkova, D.; Hagenmueller, D.; De Liberato, S.; Ciuti, C.; Reichl, C.; Schuh, D.; Wegscheider, W.; Beck, M.; Faist, J.			Ultrastrong Coupling of the Cyclotron Transition of a 2D Electron Gas to a THz Metamaterial	SCIENCE			English	Article							CIRCUIT QUANTUM ELECTRODYNAMICS; MICROCAVITY; RESONATOR; CAVITY	Artificial cavity photon resonators with ultrastrong light-matter interactions are attracting interest both in semiconductor and superconducting systems because of the possibility of manipulating the cavity quantum electrodynamic ground state with controllable physical properties. We report here experiments showing ultrastrong light-matter coupling in a terahertz (THz) metamaterial where the cyclotron transition of a high-mobility two-dimensional electron gas (2DEG) is coupled to the photonic modes of an array of electronic split-ring resonators. We observe a normalized coupling ratio, Omega/omega(c) = 0.58, between the vacuum Rabi frequency, Omega, and the cyclotron frequency, omega(c). Our system appears to be scalable in frequency and could be brought to the microwave spectral range with the potential of strongly controlling the magnetotransport properties of a high-mobility 2DEG.	[Scalari, G.; Maissen, C.; Turcinkova, D.; Beck, M.; Faist, J.] ETH, Inst Quantum Elect, Zurich, Switzerland; [Hagenmueller, D.; De Liberato, S.; Ciuti, C.] Univ Paris 07, Lab Mat & Phenomenes Quant, Paris, France; [Hagenmueller, D.; De Liberato, S.; Ciuti, C.] CNRS, Paris, France; [Reichl, C.; Wegscheider, W.] ETH, Lab Solid State Phys, Zurich, Switzerland; [Schuh, D.] Univ Regensburg, Inst Expt & Angew Phys, Regensburg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Regensburg	Scalari, G (corresponding author), ETH, Inst Quantum Elect, Zurich, Switzerland.	scalari@phys.ethz.ch	De Liberato, Simone/L-6453-2013; Ciuti, Cristiano/GYR-1378-2022; Beck, Mattias/A-7959-2013; Ciuti, Cristiano/GYR-1331-2022; Ciuti, Cristiano/K-7248-2012; Faist, Jerome/A-7339-2013; Scalari, Giacomo/Q-1048-2017	De Liberato, Simone/0000-0002-4851-2633; Ciuti, Cristiano/0000-0002-1134-7013; Beck, Mattias/0000-0002-0260-5797; Ciuti, Cristiano/0000-0002-1134-7013; Faist, Jerome/0000-0003-4429-7988; Scalari, Giacomo/0000-0003-4028-803X; Maissen, Curdin/0000-0003-1944-4659	Swiss National Science Foundation (SNF) through the National Centre of Competence in Research Quantum Science and Technology; Swiss National Science Foundation (SNF) through SNF [129823]	Swiss National Science Foundation (SNF) through the National Centre of Competence in Research Quantum Science and Technology(Swiss National Science Foundation (SNSF)); Swiss National Science Foundation (SNF) through SNF	This research was supported by the Swiss National Science Foundation (SNF) through the National Centre of Competence in Research Quantum Science and Technology and through SNF grant no. 129823. We thank J. Lloyd-Hughes and K. Ohtani for their help and S. S. Dhillon for discussions. C. C. is member of Institut Universitaire de France.	Anappara AA, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.201303; Bourassa J, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.032109; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Christopoulos S, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.126405; Ciuti C, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115303; Ciuti C, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.033811; De Liberato S, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.103602; Devoret M, 2007, ANN PHYS-BERLIN, V16, P767, DOI 10.1002/andp.200710261; Dini D, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.116401; Forn-Diaz P, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.237001; Geiser M, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.106402; GRISCHKOWSKY D, 1990, J OPT SOC AM B, V7, P2006, DOI 10.1364/JOSAB.7.002006; Gunter G, 2009, NATURE, V458, P178, DOI 10.1038/nature07838; Hagenmuller D, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.235303; Hennessy K, 2007, NATURE, V445, P896, DOI 10.1038/nature05586; Mani RG, 2002, NATURE, V420, P646, DOI 10.1038/nature01277; Muravev VM, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.075309; Nataf P, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.023601; Niemczyk T, 2010, NAT PHYS, V6, P772, DOI 10.1038/NPHYS1730; O'Hara JF, 2007, ACT PASSIV ELECTRON, V2007, DOI 10.1155/2007/49691; Padilla WJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.107401; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Schurig D, 2006, SCIENCE, V314, P977, DOI 10.1126/science.1133628; Schwartz T, 2011, PHYS REV LETT, V106, DOI [10.1109/CLEOE.2011.5943715, 10.1103/PhysRevLett.106.196405]; Shelton DJ, 2011, NANO LETT, V11, P2104, DOI 10.1021/nl200689z; SMITH PR, 1988, IEEE J QUANTUM ELECT, V24, P255, DOI 10.1109/3.121; TIGNON J, 1995, PHYS REV LETT, V74, P3967, DOI 10.1103/PhysRevLett.74.3967; Todorov Y, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.196402; Umansky V, 2009, J CRYST GROWTH, V311, P1658, DOI 10.1016/j.jcrysgro.2008.09.151; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851; Walther C, 2010, SCIENCE, V327, P1495, DOI 10.1126/science.1183167	31	385	388	9	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1323	1326		10.1126/science.1216022	http://dx.doi.org/10.1126/science.1216022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422976	Green Submitted			2022-12-28	WOS:000301531600040
J	Teufel, R; Friedrich, T; Fuchs, G				Teufel, Robin; Friedrich, Thorsten; Fuchs, Georg			An oxygenase that forms and deoxygenates toxic epoxide	NATURE			English	Article							BURKHOLDERIA-CENOCEPACIA; CATABOLIC PATHWAY; ESCHERICHIA-COLI; DIAMOND CORE; ACID; COENZYME; MONOOXYGENASE; OXIDATION; CYCLE; METABOLISM	Catabolism may give rise to toxic intermediates that compromise cell vitality, such as epoxide formation in the recently elucidated and apparently universal bacterial coenzyme A (CoA)-dependent degradation of phenylacetic acid(1). This compound is central to the catabolism of a variety of aromatics, such as phenylalanine, lignin-related compounds or environmental contaminants(2,3). The key phenylacetyl-CoA monooxygenase (epoxidase) of the pathway, PaaABCE(1,4,5), is also connected to the production of various primary and secondary metabolites(6-9), as well as to the virulence of certain pathogens(1,10,11). However, the enzyme complex has so far not been investigated in detail. Here we characterize the bacterial multicomponent monooxygenase PaaABCE that, surprisingly, not only transforms phenylacetyl-CoA into its ring-1,2-epoxide, but also mediates the NADPH-dependent removal of the epoxide oxygen, regenerating phenylacetyl-CoA with formation of water. We provide evidence for a catalytic di-iron centre that is probably the key to the unprecedented deoxygenation of an organic compound by an oxygenase. Presumably, the bifunctionality is vital to avoid toxic intracellular epoxide levels if the subsequent catabolic steps are impeded. Our data suggest that detoxification is assisted by two thioesterases (PaaI and PaaY) forming non-reactive breakdown products. Hence, PaaABCE may harbour an intrinsic escape mechanism from its own toxic product and represents the archetype of a bifunctional oxygenase/deoxygenase. Analogous reactions may possibly be catalysed by other di-iron epoxidases.	[Teufel, Robin; Fuchs, Georg] Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; [Friedrich, Thorsten] Univ Freiburg, Fak Chem, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Fuchs, G (corresponding author), Univ Freiburg, Fak Biol, Schanzlestr 1, D-79104 Freiburg, Germany.	georg.fuchs@biologie.uni-freiburg.de		Teufel, Robin/0000-0001-5863-7248	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Deutsche Forschungsgemeinschaft for support; V. Mascaraque, G. Heijman and W. Ismail for their contributions in the initial stage of this work; M. Voss, M. Weiss, I. Sachelaru and T. Spatzal for technical assistance; M. Muller and V. Brecht for mass spectrometry analysis; and I. Berg and H. Heider for critical comments.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Bennett BD, 2009, NAT CHEM BIOL, V5, P593, DOI 10.1038/nchembio.186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Erb TJ, 2008, CURR MICROBIOL, V57, P27, DOI 10.1007/s00284-008-9147-3; Erb TJ, 2007, P NATL ACAD SCI USA, V104, P10631, DOI 10.1073/pnas.0702791104; Fernandez C, 2006, APPL ENVIRON MICROB, V72, P7422, DOI 10.1128/AEM.01550-06; Fuhrer T, 2009, J BACTERIOL, V191, P2112, DOI 10.1128/JB.01523-08; Gallagher SC, 1997, EUR J BIOCHEM, V247, P635, DOI 10.1111/j.1432-1033.1997.00635.x; Geng HF, 2010, J BACTERIOL, V192, P4377, DOI 10.1128/JB.00410-10; Grishin AM, 2011, J BIOL CHEM, V286, P10735, DOI 10.1074/jbc.M110.194423; Hamlin JNR, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-222; Ismail W, 2003, EUR J BIOCHEM, V270, P3047, DOI 10.1046/j.1432-1033.2003.03683.x; Johansson AJ, 2009, DALTON T, P6741, DOI 10.1039/b907263b; Khomyakova M, 2011, SCIENCE, V331, P334, DOI 10.1126/science.1196544; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law RJ, 2008, J BACTERIOL, V190, P7209, DOI 10.1128/JB.00481-08; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; LEE SK, 1993, J BIOL CHEM, V268, P21569; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; Moore BS, 1997, J ORG CHEM, V62, P2173, DOI 10.1021/jo962402o; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; Park JB, 2006, BIOTECHNOL BIOENG, V95, P501, DOI 10.1002/bit.21037; PHILLIPS DH, 1994, CRIT REV TOXICOL, V24, pS35, DOI 10.3109/10408449409020139; Ramos-Vera WH, 2011, J BACTERIOL, V193, P1201, DOI 10.1128/JB.01156-10; Rather LJ, 2011, J BIOL CHEM, V286, P29241, DOI 10.1074/jbc.M111.236893; Rather LJ, 2010, J BIOL CHEM, V285, P20615, DOI 10.1074/jbc.M110.124156; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Rowe GT, 2008, CHEM-EUR J, V14, P8303, DOI 10.1002/chem.200800283; Rowe GT, 2007, INORG CHEM, V46, P10594, DOI 10.1021/ic7011217; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Song F, 2006, J BIOL CHEM, V281, P11028, DOI 10.1074/jbc.M513896200; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Teufel R, 2010, P NATL ACAD SCI USA, V107, P14390, DOI 10.1073/pnas.1005399107; Teufel R, 2011, J BIOL CHEM, V286, P11021, DOI 10.1074/jbc.M110.196667; Teufel R, 2009, J BACTERIOL, V191, P4572, DOI 10.1128/JB.00068-09; Textor S, 1997, ARCH MICROBIOL, V168, P428, DOI 10.1007/s002030050518; Thiel V, 2010, ORG BIOMOL CHEM, V8, P234, DOI 10.1039/b909133e; Xue GQ, 2010, NAT CHEM, V2, P400, DOI [10.1038/NCHEM.586, 10.1038/nchem.586]	41	43	44	1	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					359	U161		10.1038/nature10862	http://dx.doi.org/10.1038/nature10862			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22398448				2022-12-28	WOS:000301481800055
J	Kamel, H; Navi, BB; Fahimi, J				Kamel, Hooman; Navi, Babak B.; Fahimi, Jahan			National Trends in Ambulance Use by Patients With Stroke, 1997-2008	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							OUTCOMES; REGISTRY; DELAY; TIME		[Kamel, Hooman; Navi, Babak B.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Fahimi, Jahan] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA	Cornell University; University of California System; University of California San Francisco	Kamel, H (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA.	hok9010@med.cornell.edu	Kamel, Hooman/AGG-9071-2022	Navi, Babak/0000-0001-8424-6128; Kamel, Hooman/0000-0002-5745-0307				Centers for Disease Control and Prevention, NAT AMB MED CAR SURV; Concannon TW, 2009, CIRC-CARDIOVASC QUAL, V2, P9, DOI 10.1161/CIRCOUTCOMES.108.813741; Deng YZ, 2006, NEUROLOGY, V66, P306, DOI 10.1212/01.wnl.0000196478.77152.fc; Lacy CR, 2001, STROKE, V32, P63, DOI 10.1161/01.STR.32.1.63; Ovbiagele B, 2010, STROKE, V41, P1748, DOI 10.1161/STROKEAHA.110.585455; Wojner-Alexandrov AW, 2005, STROKE, V36, P1512, DOI 10.1161/01.STR.0000170700.45340.39	6	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1026	1028		10.1001/jama.2012.285	http://dx.doi.org/10.1001/jama.2012.285			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416095	Bronze			2022-12-28	WOS:000301479700017
J	Myint, PK; Welch, AA				Myint, Phyo Kyaw; Welch, Ailsa A.			PRACTICE POINTER Healthier ageing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POPULATION; BEHAVIORS; MANAGEMENT; WOMEN; RISK; MEN		[Myint, Phyo Kyaw; Welch, Ailsa A.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Myint, Phyo Kyaw] Norfolk & Norwich Univ Hosp, Acad Dept Med Elderly, Norwich NR4 7UY, Norfolk, England	University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Myint, PK (corresponding author), Univ E Anglia, Norwich Med Sch, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	Phyo.K.Myint@uea.ac.uk						Academy of Medical Sciences, 2011, REJ AG RES; Adams JM, 2004, EUR J PUBLIC HEALTH, V14, P331, DOI 10.1093/eurpub/14.3.331; [Anonymous], 2010, CONSENSUS VITAMIN D; [Anonymous], 2010, DIETARY GUIDELINES A; Bischoff-Ferrari H A, 2009, BMJ, V339, pb3692, DOI 10.1136/bmj.b3692; Boirie Y, 2009, J NUTR HEALTH AGING, V13, P717, DOI 10.1007/s12603-009-0203-x; Bond J., 1993, AGEING SOC INTRO SOC; Department of Health Social Services and Public Safety, 2011, START ACT STAY ACT R; Eriksson MK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005195; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012; Khaw KT, 1997, BMJ-BRIT MED J, V315, P1090, DOI 10.1136/bmj.315.7115.1090; Kirkwood TBL, 2011, PHILOS T R SOC B, V366, P64, DOI 10.1098/rstb.2010.0275; McMinn J, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1732; Mead GE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub4; Morley JE, 2010, J AM MED DIR ASSOC, V11, P391, DOI 10.1016/j.jamda.2010.04.014; Myint PK, 2011, AGE AGEING, V40, P589, DOI 10.1093/ageing/afr058; Myint PK, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b349; Myint PK, 2010, HLTH AGEING DETERMIN; Prescott-Clarke P, 1998, SERIES HS, V1; U.S. Department of Health and Human Services, 2008, PHYS ACT GUID ADV CO; Van Pelt RE, 2001, AM J PHYSIOL-ENDOC M, V281, pE633, DOI 10.1152/ajpendo.2001.281.3.E633; Welch AA, 2010, AM J CLIN NUTR, V92, P1040, DOI 10.3945/ajcn.2010.29457	23	19	19	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2012	344								e1214	10.1136/bmj.e1214	http://dx.doi.org/10.1136/bmj.e1214			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BO	22411918				2022-12-28	WOS:000301846500002
J	Paige, JS; Nguyen-Duc, T; Song, WJ; Jaffrey, SR				Paige, Jeremy S.; Nguyen-Duc, Thinh; Song, Wenjiao; Jaffrey, Samie R.			Fluorescence Imaging of Cellular Metabolites with RNA	SCIENCE			English	Article							APTAMERS; SENSORS		[Paige, Jeremy S.; Nguyen-Duc, Thinh; Song, Wenjiao; Jaffrey, Samie R.] Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10065 USA	Cornell University	Jaffrey, SR (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10065 USA.	srj2003@med.cornell.edu	song, wenjiao/E-4932-2012	song, wenjiao/0000-0002-6142-5390; Jaffrey, Samie/0000-0003-3615-6958	McKnight Foundation; NIH [EB010249, T32CA062948]; NATIONAL CANCER INSTITUTE [T32CA062948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB010249] Funding Source: NIH RePORTER	McKnight Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank V. Schramm for inhibitors and M. Cohen, A. Deglincerti, W. Ping, and S. Blanchard for suggestions. Supported by the McKnight Foundation and NIH grants EB010249 and T32CA062948.	Cho EJ, 2009, ANNU REV ANAL CHEM, V2, P241, DOI 10.1146/annurev.anchem.1.031207.112851; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Lemke EA, 2011, NAT CHEM BIOL, V7, P480, DOI 10.1038/nchembio.620; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Paige JS, 2011, SCIENCE, V333, P642, DOI 10.1126/science.1207339	5	360	372	17	368	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1194	1194		10.1126/science.1218298	http://dx.doi.org/10.1126/science.1218298			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403384	Green Accepted			2022-12-28	WOS:000301225100036
J	Bradford, P				Bradford, Peter			The nuclear landscape	NATURE			English	Editorial Material									Vermont Law Sch, S Royalton, VT 05068 USA		Bradford, P (corresponding author), Vermont Law Sch, S Royalton, VT 05068 USA.	perubrad@aol.com							0	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					151	152		10.1038/483151a	http://dx.doi.org/10.1038/483151a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904DT	22398539				2022-12-28	WOS:000301174900015
J	Brodlie, M; Graham, C; McKean, MC				Brodlie, Malcolm; Graham, Chris; McKean, Michael C.			Childhood cough	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PERSISTENT COUGH; RECURRENT COUGH; PRIMARY-CARE; CHILDREN; ASTHMA; AIRWAY		[Brodlie, Malcolm] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Brodlie, Malcolm; McKean, Michael C.] Great N Childrens Hosp, Dept Paediat Resp Med, Newcastle Upon Tyne, Tyne & Wear, England; [Graham, Chris] Postgrad Sch Primary Care, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK	Brodlie, M (corresponding author), Royal Victoria Infirm, Old Childrens Outpatients Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	malcolm.brodlie@ncl.ac.uk		Brodlie, Malcolm/0000-0003-4591-8299	Academy of Medical Sciences (AMS) [AMS-SGCL6-Brodlie] Funding Source: researchfish; Medical Research Council [G0800419] Funding Source: Medline; MRC [G0800419] Funding Source: UKRI	Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arroll B, 2002, COCHRANE DB SYST REV, V3; Bettiol S, 2010, COCHRANE DB SYST REV, V1; British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011, BRIT GUID MAN ASTHM; Chang AB, 1999, PEDIATR PULM, V28, P59, DOI 10.1002/(SICI)1099-0496(199907)28:1<59::AID-PPUL10>3.0.CO;2-Y; Chang AB, 1997, ARCH DIS CHILD, V77, P331, DOI 10.1136/adc.77.4.331; Chang AB, 2011, COCHRANE DB SYST REV, V1; Chang AB, 2010, LUNG, V188, pS33, DOI 10.1007/s00408-009-9166-2; Donnelly D, 2007, THORAX, V62, P80, DOI 10.1136/thx.2006.058933; Faniran AO, 1999, CHEST, V115, P434, DOI 10.1378/chest.115.2.434; Gibson PG, 2001, AM J RESP CRIT CARE, V164, P977, DOI 10.1164/ajrccm.164.6.9910053; Gupta A, 2007, ARCH DIS CHILDHOOD-E, V92, pEP33, DOI 10.1136/adc.2005.090753; Harnden A, 2006, BRIT MED J, V333, P174, DOI 10.1136/bmj.38870.655405.AE; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Hay AD, 2004, BRIT J GEN PRACT, V54, P9; Hay AD, 2002, BRIT J GEN PRACT, V52, P401; Health Protection Agency, 2011, GUID PUBL HLTH MAN P; Marchant JM, 2008, CHEST, V134, P303, DOI 10.1378/chest.07-2236; MCKENZIE S, 1994, ARCH DIS CHILD, V70, P1, DOI 10.1136/adc.70.1.1; Medicines and Healthcare Products Regulatory Agency, 2010, CHILDR OV THE COUNT; Munyard P, 1996, ARCH DIS CHILD, V74, P531, DOI 10.1136/adc.74.6.531; *NAT I HLTH CLIN E, 2007, FEV ILLN CHILDR ASS; Pappas DE, 2008, PEDIATR INFECT DIS J, V27, P8, DOI 10.1097/INF.0b013e31814847d9; Scottish Intercollegiate Guidelines Network, 2006, BRONCH CHILDR NAT CL; Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370; Smith SM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub3; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6; Vance G, 2011, ARCH DIS CHILD, V96, pI10, DOI 10.1136/adc.2011.213462; Wright AL, 1996, AM J RESP CRIT CARE, V153, P1259, DOI 10.1164/ajrccm.153.4.8616551	28	22	23	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2012	344								e1177	10.1136/bmj.e1177	http://dx.doi.org/10.1136/bmj.e1177			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GM	22395925				2022-12-28	WOS:000301478900015
J	Neumann, I; Rada, G; Claro, JC; Carrasco-Labra, A; Thorlund, K; Akl, EA; Bates, SM; Guyatt, GH				Neumann, Ignacio; Rada, Gabriel; Claro, Juan Carlos; Carrasco-Labra, Alonso; Thorlund, Kristian; Akl, Elie A.; Bates, Shannon M.; Guyatt, Gordon H.			Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							COMPOSITE END-POINTS; DOUBLE-BLIND; PHASE-II; PULMONARY-EMBOLISM; DOSE-ESCALATION; THROMBOPROPHYLAXIS; ENOXAPARIN; RIVAROXABAN; ARTHROPLASTY; APIXABAN	Background: Thromboembolic disease is the most frequent medical complication of arthroplasty. Purpose: To evaluate the benefits and harms of oral direct factor Xa inhibitors versus low-molecular-weight heparin (LMWH) in patients undergoing total hip or knee replacement. Data Sources: MEDLINE (1966 to December 2011), EMBASE (1980 to December 2011), and the Cochrane Central Register of Controlled Trials (up to December 2011), without language restrictions. References of reviews and abstracts of conferences were hand-searched. Study Selection: Randomized trials in patients undergoing hip or knee replacement that evaluated factor Xa inhibitors versus LMWH. Data Extraction: Two reviewers independently evaluated eligibility, abstracted the data, and assessed risk for bias. Data Synthesis: In 22 trials, high-quality evidence indicated that the absolute effect of factor Xa inhibitors and LMWH does not differ in terms of all-cause mortality (risk difference, 0 fewer deaths per 1000 patients [95% CI, 2 fewer to 1 more death]) or nonfatal pulmonary embolism (risk difference, 0 fewer events per 1000 patients [CI, 1 fewer to 2 more events]). Factor Xa inhibitors can prevent 4 instances of symptomatic deep venous thrombosis per 1000 treated patients (CI, 3 to 6 fewer events; high-quality evidence) but may increase major bleeding by 2 more events per 1000 patients (CI, 0 to 4 more events; moderate-quality evidence). High, but not lower, doses of oral factor Xa inhibitors increased bleeding compared with LMWH. Limitations: Most trials did not report outcome data for a substantial proportion of the patients. In 9 trials, the follow-up period was 14 days or less. Conclusion: Compared with LMWH, lower doses of oral factor Xa inhibitors can achieve a small absolute risk reduction in symptomatic deep venous thrombosis without increasing bleeding.	[Neumann, Ignacio] McMaster Univ, Hlth Sci Ctr, Room 2C12,1280 Main St W, Hamilton, ON L8S 4K1, Canada; SUNY Buffalo, Buffalo, NY 14260 USA; Pontificia Univ Catolica Chile, Evidence Based Hlth Care Program, Santiago, Chile	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Pontificia Universidad Catolica de Chile	Neumann, I (corresponding author), McMaster Univ, Hlth Sci Ctr, Room 2C12,1280 Main St W, Hamilton, ON L8S 4K1, Canada.	ignacio.neumann@gmail.com	Neumann, Ignacio/ABB-5013-2020; Akl, Elie A/R-2079-2016; Akl, Elie/K-5269-2019; Carrasco-Labra, Alonso/ABF-9555-2020	Akl, Elie A/0000-0002-3444-8618; Carrasco-Labra, Alonso/0000-0003-3546-3526; Rada, Gabriel/0000-0003-2435-0710	Bristol-Myers Squibb; Canadian Institutes of Health Research	Bristol-Myers Squibb(Bristol-Myers Squibb); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr. Guyatt: Consultancy (money to institution): Bristol-Myers Squibb; Grants/grants pending (money to institution): Canadian Institutes of Health Research. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2601.	Agnelli G, 2007, J THROMB HAEMOST, V5, P746, DOI 10.1111/j.1538-7836.2007.02436.x; Akl EA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006776.pub2; Bates SM, 2006, BRIT J HAEMATOL, V134, P3, DOI 10.1111/j.1365-2141.2006.06134.x; Benmira Sihame, 2010, Recent Pat Cardiovasc Drug Discov, V5, P120; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Canadian Institute for Health Information, 2008, HIP KNEE REPL CAN 20; Cao YB, 2010, EUR J CLIN PHARMACOL, V66, P1099, DOI 10.1007/s00228-010-0889-z; Changes to the Cochrane, 2011, CHANGES COCHRANE RIS; Cohen AT, 2008, BLOOD, V112, P361; Dixon T, 2004, ANN RHEUM DIS, V63, P825, DOI 10.1136/ard.2003.012724; Eriksson BI, 2007, J THROMB HAEMOST, V5, P1660, DOI 10.1111/j.1538-7836.2007.02644.x; Eriksson BI, 2010, J THROMB HAEMOST, V8, P714, DOI 10.1111/j.1538-7836.2010.03748.x; Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056/NEJMoa0800374; Eriksson BI, 2007, THROMB RES, V120, P685, DOI 10.1016/j.thromres.2006.12.025; Eriksson BI, 2006, CIRCULATION, V114, P2374, DOI 10.1161/CIRCULATIONAHA.106.642074; Eriksson BI, 2006, J THROMB HAEMOST, V4, P121, DOI 10.1111/j.1538-7836.2005.01657.x; Eriksson BI, 2011, P ISTH 2011 23 C INT; Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE; Fuji T, 2009, P ANN M AM SOC HEM N; Fuji T, 2010, P ANN M AM SOC HEM O; Fuji T, 2010, 21 INT C THROMB MIL; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012; Haas SB, 2008, J BONE JOINT SURG AM, V90A, P2764; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; Huang JH, 2011, THROMB HAEMOSTASIS, V105, P245, DOI 10.1160/TH10-08-0552; Johanson NA, 2009, J AM ACAD ORTHOP SUR, V17, P183, DOI 10.5435/00124635-200903000-00007; Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140-6736(08)60880-6; Kanan Pedro Silva, 2008, Rev. bras. ortop., V43, P319, DOI 10.1590/S0102-36162008000800002; Karanicolas Paul J, 2009, Evid Based Med, V14, P130, DOI 10.1136/ebm.14.5.130-b; Kurtz S, 2005, J BONE JOINT SURG AM, V87A, P1487, DOI 10.2106/JBJS.D.02441; Lassen MR, 2007, J THROMB HAEMOST, V5, P2368, DOI 10.1111/j.1538-7836.2007.02764.x; Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056/NEJMoa076016; Lassen MR, 2010, NEW ENGL J MED, V363, P2487, DOI 10.1056/NEJMoa1006885; Lassen MR, 2010, LANCET, V375, P807, DOI 10.1016/S0140-6736(09)62125-5; Lassen MR, 2009, NEW ENGL J MED, V361, P594, DOI 10.1056/NEJMoa0810773; Lassen MR, 2003, BLOOD, V102, p15A; Mismetti P, 2004, J THROMB HAEMOST, V2, P1058, DOI 10.1111/j.1538-7836.2004.00757.x; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; Mueck W, 2008, CLIN PHARMACOKINET, V47, P203, DOI 10.2165/00003088-200847030-00006; National Center for Health Statistics, 2010, HLTH US 2009 SPEC FE; Organisation for Economic Co-operation and Development, 2010, HLTH GLANC EUR 2010; Phillips CB, 2003, J BONE JOINT SURG AM, V85A, P20, DOI 10.2106/00004623-200301000-00004; Raskob G, 2010, THROMB HAEMOSTASIS, V104, P642, DOI 10.1160/TH10-02-0142; Song TR, 2011, THROMB RES, V127, P525, DOI 10.1016/j.thromres.2011.01.016; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; Sutton Alexander J, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P367, DOI 10.1586/14737167.2.4.367; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Turpie AGG, 2005, J THROMB HAEMOST, V3, P2479, DOI 10.1111/j.1538-7836.2005.01602.x; Turpie AGG, 2009, LANCET, V373, P1673, DOI 10.1016/S0140-6736(09)60734-0; Turpie AGG, 2009, THROMB HAEMOSTASIS, V101, P68, DOI 10.1160/TH08-07-0460; Weitz JI, 2010, THROMB HAEMOSTASIS, V104, P1150, DOI 10.1160/TH10-05-0273; White RH, 1998, ARCH INTERN MED, V158, P1525, DOI 10.1001/archinte.158.14.1525; Zhan CL, 2007, J BONE JOINT SURG AM, V89A, P526, DOI 10.2106/JBJS.F.00952	57	59	60	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2012	156	10					710	+		10.7326/0003-4819-156-10-201205150-00421	http://dx.doi.org/10.7326/0003-4819-156-10-201205150-00421			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944IQ	22412038				2022-12-28	WOS:000304193400017
J	Sobieraj, DM; Lee, S; Coleman, CI; Tongbram, V; Chen, W; Colby, J; Kluger, J; Makanji, S; Ashaye, AO; White, CM				Sobieraj, Diana M.; Lee, Soyon; Coleman, Craig I.; Tongbram, Vanita; Chen, Wendy; Colby, Jennifer; Kluger, Jeffrey; Makanji, Sagar; Ashaye, Ajibade O.; White, C. Michael			Prolonged Versus Standard-Duration Venous Thromboprophylaxis in Major Orthopedic Surgery A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							MOLECULAR-WEIGHT HEPARIN; ELECTIVE HIP-ARTHROPLASTY; EXTENDED THROMBOPROPHYLAXIS; DOUBLE-BLIND; THROMBOEMBOLISM; PROPHYLAXIS; METAANALYSIS; REPLACEMENT; DALTEPARIN; THROMBOSIS	Background: The optimal duration of thromboprophylaxis after major orthopedic surgery is unclear. Purpose: To compare the benefits and harms of prolonged versus standard-duration thromboprophylaxis after major orthopedic surgery in adults. Data Sources: Cochrane Central Register of Controlled Trials and Scopus from 1980 to July 2011 and MEDLINE from 1980 through November 2011, without language restrictions. Study Selection: Randomized trials reporting thromboembolic or bleeding outcomes that compared prolonged (>= 21 days) with standard-duration (7 to 10 days) thromboprophylaxis. Data Abstraction: Two independent reviewers abstracted data and rated study quality and strength of evidence. Data Synthesis: Eight randomized, controlled trials (3 good-quality and 5 fair-quality) met the inclusion criteria. High-strength evidence showed that compared with standard-duration therapy, prolonged prophylaxis resulted in fewer cases of pulmonary embolism (PE) (5 trials; odds ratio [OR], 0.14 [95% CI, 0.04 to 0.47]; absolute risk reduction [ARR], 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [RR], 0.48 [CI, 0.31 to 0.75]; ARR, 5.8%), symptomatic DVT (4 trials; OR, 0.36 [CI, 0.16 to 0.81]; ARR, 1.5%), and proximal DVT (6 trials; RR, 0.29 [CI, 0.16 to 0.52]; ARR, 7.1%). Moderate-strength evidence showed fewer symptomatic objectively confirmed episodes of venous thromboembolism (4 trials; RR, 0.38 [CI, 0.19 to 0.77]; ARR, 5.7%), nonfatal PE (4 trials; OR, 0.13 [CI, 0.03 to 0.54]; ARR, 0.7%), and DVT (7 trials; RR, 0.37 [CI, 0.21 to 0.64]; ARR, 12.1%) with prolonged prophylaxis. High-strength evidence showed more minor bleeding events with prolonged prophylaxis (OR, 2.44 [CI, 1.41 to 4.20]; absolute risk increase, 6.3%), and insufficient evidence from 1 trial on hip fracture surgery suggested more surgical-site bleeding events (OR, 7.55 [CI, 1.51 to 37.64]) with prolonged prophylaxis. Limitations: Data relevant to knee replacement or hip fracture surgery were scant and insufficient. Most trials had few events; the strength of evidence ratings that were used may not adequately capture uncertainty in such situations. Conclusion: Prolonged prophylaxis decreases the risk for venous thromboembolism, PE, and DVT while increasing the risk for minor bleeding in patients undergoing total hip replacement.	[White, C. Michael] Univ Connecticut, Dept Pharm, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT 06102 USA	Hartford Hospital; University of Connecticut	White, CM (corresponding author), Univ Connecticut, Dept Pharm, Hartford Hosp, Evidence Based Practice Ctr, 80 Seymour St, Hartford, CT 06102 USA.	cmwhite@harthosp.org		Coleman, Craig/0000-0003-4868-7158; Ashaye, Ajibade/0000-0003-3731-0769; Sobieraj, Diana/0000-0002-5227-0681	University of Connecticut/Hartford Hospital Evidence-based Practice Center [290-2007-10067-I]; Agency for Healthcare Research and Quality; Janssen Pharmaceuticals	University of Connecticut/Hartford Hospital Evidence-based Practice Center; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	By the University of Connecticut/Hartford Hospital Evidence-based Practice Center (contract 290-2007-10067-I with the Agency for Healthcare Research and Quality).; Dr. Coleman: Grants/grants pending (money to institution): Janssen Pharmaceuticals; Consulting fee or honorarium: Janssen Pharmaceuticals; Consultancy: Acorda Therapeutics. Dr. Kluger: Payment for lectures including service on speakers bureaus: Janssen Pharmaceuticals. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2593.	AHRQ, 2011, AHRQ PUBL; American Academy of Orthopedic Surgeons, PREV VEN THROMB DIS; Andersen BS, 1997, HAEMOSTASIS, V27, P219; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Cohen AT, 2001, THROMB HAEMOSTASIS, V85, P940; Comp PC, 2001, J BONE JOINT SURG AM, V83A, P336, DOI 10.2106/00004623-200103000-00004; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; Eikelboom JW, 2009, CHEST, V135, P513, DOI 10.1378/chest.08-2655; Eikelboom JW, 2001, LANCET, V358, P9, DOI 10.1016/S0140-6736(00)05249-1; Eriksson BI, 2003, ARCH INTERN MED, V163, P1337, DOI 10.1001/archinte.163.11.1337; Fu R, 2010, METHODS GUIDE COMP E; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Higgins JPT., 2008, COCHRANE HDB SYSTEMA, V1 edn; Hull RD, 2001, ANN INTERN MED, V135, P858, DOI 10.7326/0003-4819-135-10-200111200-00006; Kapoor A, 2010, PHARMACOECONOMICS, V28, P521, DOI 10.2165/11535210-000000000-00000; Lassen MR, 1998, THROMB RES, V89, P281, DOI 10.1016/S0049-3848(98)00018-8; Nilsson PE, 1997, ORTHOPEDICS, V20, P22; O'Donnell M, 2003, ARCH INTERN MED, V163, P1362, DOI 10.1001/archinte.163.11.1362; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Planes A, 1997, ORTHOPEDICS, V20, P18; Prandoni P, 2002, ARCH INTERN MED, V162, P1966, DOI 10.1001/archinte.162.17.1966; Rucker G, 2009, STAT MED, V28, P721, DOI 10.1002/sim.3511; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753	24	23	26	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2012	156	10					720	U111		10.7326/0003-4819-156-10-201205150-00423	http://dx.doi.org/10.7326/0003-4819-156-10-201205150-00423			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944IQ	22412039				2022-12-28	WOS:000304193400018
J	Aversano, T; Lemmon, CC; Liu, L				Aversano, Thomas; Lemmon, Cynthia C.; Liu, Li		Atlantic CPORT Investigators	Outcomes of PCI at Hospitals with or without On-Site Cardiac Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; PACLITAXEL-ELUTING STENTS; THROMBOLYTIC THERAPY; VETERANS-AFFAIRS; ARTERY-DISEASE; ANGIOPLASTY; REGIONALIZATION; REGISTRY	Background Performance of percutaneous coronary intervention (PCI) is usually restricted to hospitals with cardiac surgery on site. We conducted a noninferiority trial to compare the outcomes of PCI performed at hospitals without and those with on-site cardiac surgery. Methods We randomly assigned participants to undergo PCI at a hospital with or without on-site cardiac surgery. Patients requiring primary PCI were excluded. The trial had two primary end points: 6-week mortality and 9-month incidence of major adverse cardiac events (the composite of death, Q-wave myocardial infarction, or target-vessel revascularization). Noninferiority margins for the risk difference were 0.4 percentage points for mortality at 6 weeks and 1.8 percentage points for major adverse cardiac events at 9 months. Results A total of 18,867 patients were randomly assigned in a 3:1 ratio to undergo PCI at a hospital without on-site cardiac surgery (14,149 patients) or with on-site cardiac surgery (4718 patients). The 6-week mortality rate was 0.9% at hospitals without on-site surgery versus 1.0% at those with on-site surgery (difference, -0.04 percentage points; 95% confidence interval [CI], -0.31 to 0.23; P=0.004 for noninferiority). The 9-month rates of major adverse cardiac events were 12.1% and 11.2% at hospitals without and those with on-site surgery, respectively (difference, 0.92 percentage points; 95% CI, 0.04 to 1.80; P=0.05 for noninferiority). The rate of target-vessel revascularization was higher in hospitals without on-site surgery (6.5% vs. 5.4%, P=0.01). Conclusions We found that PCI performed at hospitals without on-site cardiac surgery was non-inferior to PCI performed at hospitals with on-site cardiac surgery with respect to mortality at 6 weeks and major adverse cardiac events at 9 months.	[Aversano, Thomas; Lemmon, Cynthia C.] Johns Hopkins Univ, Baltimore, MD USA; [Liu, Li] Clin Trials & Surveys, Owings Mills, MD USA	Johns Hopkins University	Aversano, T (corresponding author), Johns Hopkins Cardiol Greater Baltimore Med Ctr, Suite 5104,6701 N Charles St, Baltimore, MD 21204 USA.	taversan@jhmi.edu	Liu, Li/K-1936-2012	Liu, Li/0000-0002-5054-2372	Cardiovascular Patient Outcomes Research Team [C-PORT]	Cardiovascular Patient Outcomes Research Team [C-PORT]	Funded by the Cardiovascular Patient Outcomes Research Team [C-PORT] participating sites; ClinicalTrials.gov number, NCT00549796.)	Aneja S, 2011, HEALTH AFFAIR, V30, P2301, DOI 10.1377/hlthaff.2011.0255; [Anonymous], AM COLL CARDIOLOGY C; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P3212; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; Jensen LO, 2012, CIRCULATION, V125, P1246, DOI 10.1161/CIRCULATIONAHA.111.063644; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kutcher MA, 2009, J AM COLL CARDIOL, V54, P16, DOI 10.1016/j.jacc.2009.03.038; Melberg T, 2006, AM HEART J, V152, P888, DOI 10.1016/j.ahj.2006.06.026; Morice MC, 2006, JAMA-J AM MED ASSOC, V295, P895, DOI 10.1001/jama.295.8.895; Naidu SS, 2006, AM J CARDIOL, V98, P447, DOI 10.1016/j.amjcard.2006.03.021; *NY STAT DEP HLTH, 2004, PERC COR INT PCI NEW; Ong ATL, 2005, J AM COLL CARDIOL, V45, P947, DOI 10.1016/j.jacc.2004.09.079; Petersen LA, 2003, NEW ENGL J MED, V348, P2209, DOI 10.1056/NEJMsa021725; Roe MT, 2008, AM HEART J, V156, P185, DOI 10.1016/j.ahj.2008.01.033; Serruys PW, 2010, NEW ENGL J MED, V363, P136, DOI 10.1056/NEJMoa1004130; Seshadri N, 2002, CIRCULATION, V106, P2346, DOI 10.1161/01.CIR.0000036595.92742.69; Singh M, 2011, JAMA-J AM MED ASSOC, V306, P2487, DOI 10.1001/jama.2011.1790; Smith SC, 2006, CIRCULATION, V113, pE166, DOI 10.1161/CIRCULATIONAHA.106.173220; Stone GW, 2005, JAMA-J AM MED ASSOC, V294, P1215, DOI 10.1001/jama.294.10.1215; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Wright SM, 1997, MED CARE, V35, P128, DOI 10.1097/00005650-199702000-00004	22	74	77	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 10	2012	366	19					1792	1802		10.1056/NEJMoa1114540	http://dx.doi.org/10.1056/NEJMoa1114540			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	939NB	22443460				2022-12-28	WOS:000303817000008
J	Melzer, S; Michael, M; Caputi, A; Eliava, M; Fuchs, EC; Whittington, MA; Monyer, H				Melzer, Sarah; Michael, Magdalena; Caputi, Antonio; Eliava, Marina; Fuchs, Elke C.; Whittington, Miles A.; Monyer, Hannah			Long-Range-Projecting GABAergic Neurons Modulate Inhibition in Hippocampus and Entorhinal Cortex	SCIENCE			English	Article							SPATIAL REPRESENTATION; THETA OSCILLATIONS; MEDIAL SEPTUM; INTERNEURONS; RAT; EXPRESSION; DIVERSITY; CA1	The hippocampus and entorhinal cortex play a pivotal role in spatial learning and memory. The two forebrain regions are highly interconnected via excitatory pathways. Using optogenetic tools, we identified and characterized long-range gamma-aminobutyric acid-releasing (GABAergic) neurons that provide a bidirectional hippocampal-entorhinal inhibitory connectivity and preferentially target GABAergic interneurons. Activation of long-range GABAergic axons enhances sub- and suprathreshold rhythmic theta activity of postsynaptic neurons in the target areas.	[Melzer, Sarah; Michael, Magdalena; Caputi, Antonio; Eliava, Marina; Fuchs, Elke C.; Monyer, Hannah] Heidelberg Univ, Fac Med, Dept Clin Neurobiol, D-69120 Heidelberg, Germany; [Melzer, Sarah; Michael, Magdalena; Caputi, Antonio; Eliava, Marina; Fuchs, Elke C.; Monyer, Hannah] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Whittington, Miles A.] Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Newcastle University - UK	Monyer, H (corresponding author), Heidelberg Univ, Fac Med, Dept Clin Neurobiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	h.monyer@dkfz-heidelberg.de	Melzer, Sarah/AAJ-9475-2021	Melzer, Sarah/0000-0001-6028-9764; Whittington, Miles Adrian/0000-0002-0247-1362; Monyer, Hannah/0000-0002-9332-5749	European Research Council [250047]; German Ministry of Education and Research (BMBF) [01GQ1003A]	European Research Council(European Research Council (ERC)European Commission); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	We thank K. Deisseroth for the AAVs, A. Vogt for help in generating mice, I. Preugschat-Gumprecht and R. Hinz for their technical assistance, and P. H. Seeburg for helpful discussions. This work was supported by a European Research Council grant (GABAcellsAndMemory grant 250047, to H. M.) and a German Ministry of Education and Research (BMBF) grant 01GQ1003A to H. M. and E.C.F.	Apergis-Schoute J, 2007, J NEUROSCI, V27, P4061, DOI 10.1523/JNEUROSCI.0068-07.2007; BRAGIN A, 1995, J NEUROSCI, V15, P47; Brun VH, 2008, NEURON, V57, P290, DOI 10.1016/j.neuron.2007.11.034; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Canto Cathrin B., 2008, Neural Plasticity, V2008, P1, DOI 10.1155/2008/381243; Cardin JA, 2010, NAT PROTOC, V5, P247, DOI 10.1038/nprot.2009.228; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; Fuchs EC, 2007, NEURON, V53, P591, DOI 10.1016/j.neuron.2007.01.031; GERMROTH P, 1989, BRAIN RES, V494, P187, DOI 10.1016/0006-8993(89)90162-5; Gillies MJ, 2002, J PHYSIOL-LONDON, V543, P779, DOI 10.1113/jphysiol.2002.024588; Jinno S, 2002, BRAIN RES, V945, P219, DOI 10.1016/S0006-8993(02)02804-4; Jinno S, 2007, J NEUROSCI, V27, P8790, DOI 10.1523/JNEUROSCI.1847-07.2007; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; Mizuseki K, 2009, NEURON, V64, P267, DOI 10.1016/j.neuron.2009.08.037; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Takacs VT, 2008, EUR J NEUROSCI, V28, P148, DOI 10.1111/j.1460-9568.2008.06319.x; Tamamaki N, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00202; Tolu S, 2010, FASEB J, V24, P723, DOI 10.1096/fj.09-139790; TOTH K, 1993, J NEUROSCI, V13, P3712; Traub RD, 2004, ANNU REV NEUROSCI, V27, P247, DOI 10.1146/annurev.neuro.27.070203.144303; Witter MP, 2006, TRENDS NEUROSCI, V29, P671, DOI 10.1016/j.tins.2006.10.003; YLINEN A, 1995, HIPPOCAMPUS, V5, P78, DOI 10.1002/hipo.450050110; Zappone CA, 2001, J COMP NEUROL, V441, P324, DOI 10.1002/cne.1415	23	221	228	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1506	1510		10.1126/science.1217139	http://dx.doi.org/10.1126/science.1217139			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442486				2022-12-28	WOS:000301837000052
J	Gallagher, JC; Sai, A; Templin, T; Smith, L				Gallagher, J. Christopher; Sai, Adarsh; Templin, Thomas, II; Smith, Lynette			Dose Response to Vitamin D Supplementation in Postmenopausal Women A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							25-HYDROXYVITAMIN D LEVELS; BONE-MINERAL DENSITY; SERUM 25-HYDROXYVITAMIN-D; ELDERLY-MEN; SECONDARY HYPERPARATHYROIDISM; CALCIOTROPIC HORMONES; D INSUFFICIENCY; FRACTURE RISK; D DEFICIENCY; CALCIUM	Background: Serum 25-hydroxyvitamin D (25-[OH]D) is considered the best biomarker of clinical vitamin D status. Objective: To determine the effect of increasing oral doses of vitamin D-3 on serum 25-(OH)D and serum parathyroid hormone (PTH) levels in postmenopausal white women with vitamin D insufficiency (defined as a 25-[OH] D level <= 50 nmol/L) in the presence of adequate calcium intake. These results can be used as a guide to estimate the Recommended Dietary Allowance (RDA) (defined as meeting the needs of 97.5% of the population) for vitamin D-3. Design: Randomized, placebo-controlled trial. (ClinicalTrials.gov registration number: NCT00472823) Setting: Creighton University Medical Center, Omaha, Nebraska. Participants: 163 healthy postmenopausal white women with vitamin D insufficiency enrolled in the winter or spring of 2007 to 2008 and followed for 1 year. Intervention: Participants were randomly assigned to receive placebo or vitamin D-3, 400, 800, 1600, 2400, 3200, 4000, or 4800 IU once daily. Daily calcium supplements were provided to increase the total daily calcium intake to 1200 to 1400 mg. Measurements: The primary outcomes were 25-(OH) D and PTH levels at 6 and 12 months. Results: The mean baseline 25-(OH) D level was 39 nmol/L. The dose response was curvilinear and tended to plateau at approximately 112 nmol/L in patients receiving more than 3200 IU/d of vitamin D3. The RDA of vitamin D3 to achieve a 25-(OH) D level greater than 50 nmol/L was 800 IU/d. A mixed-effects model predicted that 600 IU of vitamin D3 daily could also meet this goal. Compared with participants with a normal body mass index (<25 kg/m(2)), obese women (>= 30 kg/m(2)) had a 25-(OH) D level that was 17.8 nmol/L lower. Parathyroid hormone levels at 12 months decreased with an increasing dose of vitamin D-3 (P = 0.012). Depending on the criteria used, hypercalcemia occurred in 2.8% to 9.0% and hypercalciuria in 12.0% to 33.0% of participants; events were unrelated to dose. Limitation: Findings may not be generalizable to other age groups or persons with substantial comorbid conditions. Conclusion: A vitamin D-3 dosage of 800 IU/d increased serum 25-(OH) D levels to greater than 50 nmol/L in 97.5% of women; however, a model predicted the same response with a vitamin D-3 dosage of 600 IU/d. These results can be used as a guide for the RDA of vitamin D-3, but prospective trials are needed to confirm the clinical significance of these results.	[Gallagher, J. Christopher] Creighton Univ, Sch Med, Bone Metab Unit, Omaha, NE 68131 USA; Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE USA	Creighton University; University of Nebraska System; University of Nebraska Medical Center	Gallagher, JC (corresponding author), Creighton Univ, Sch Med, Bone Metab Unit, 601 N 30th St,Suite 6718, Omaha, NE 68131 USA.	jcg@creighton.edu	Sai, Adarsh/I-3204-2014	Sai, Adarsh/0000-0003-3695-962X; gallagher, john christopher/0000-0002-5129-9183	National Institute on Aging [RO1-AG28168]; NATIONAL INSTITUTE ON AGING [R01AG028168] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: By the National Institute on Aging (RO1-AG28168).	Adams JS, 2007, ANN NY ACAD SCI, V1117, P94, DOI 10.1196/annals.1402.036; Bolland Mark J, 2011, BMJ, V342, pd2040, DOI 10.1136/bmj.d2040; Carter GD, 2010, J STEROID BIOCHEM, V121, P176, DOI 10.1016/j.jsbmb.2010.03.033; Cauley JA, 2008, ANN INTERN MED, V149, P242, DOI 10.7326/0003-4819-149-4-200808190-00005; Cauley JA, 2010, J BONE MINER RES, V25, P545, DOI 10.1359/jbmr.090826; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chapuy MC, 1996, REV RHUM, V63, P135; Chel VGM, 1998, J BONE MINER RES, V13, P1238, DOI 10.1359/jbmr.1998.13.8.1238; Curhan GC, 2008, KIDNEY INT, V73, P489, DOI 10.1038/sj.ki.5002708; Curhan GC, 2001, KIDNEY INT, V59, P2290, DOI 10.1046/j.1523-1755.2001.0590062290.x; DAVIE MWJ, 1982, CLIN SCI, V63, P461, DOI 10.1042/cs0630461; Dawson-Hughes B, 2004, AM J CLIN NUTR, V80, p1763S, DOI 10.1093/ajcn/80.6.1763S; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DAWSONHUGHES B, 1995, AM J CLIN NUTR, V61, P1140, DOI 10.1093/ajcn/61.5.1140; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Ensrud KE, 2009, J CLIN ENDOCR METAB, V94, P2773, DOI 10.1210/jc.2008-2786; FREANEY R, 1993, AM J CLIN NUTR, V58, P187, DOI 10.1093/ajcn/58.2.187; Gallagher JC, 2010, J CLIN ENDOCR METAB, V95, P2630, DOI 10.1210/jc.2010-0918; Garland CF, 2009, ANN EPIDEMIOL, V19, P468, DOI 10.1016/j.annepidem.2009.03.021; Gerdhem P, 2005, OSTEOPOROSIS INT, V16, P1425, DOI 10.1007/s00198-005-1860-1; Hanley DA, 2010, CAN MED ASSOC J, V182, pE610, DOI 10.1503/cmaj.080663; Heaney RP, 2003, AM J CLIN NUTR, V77, P204, DOI 10.1093/ajcn/77.1.204; HOLICK MF, 1989, LANCET, V2, P1104; HONKANEN R, 1990, J AM GERIATR SOC, V38, P862, DOI 10.1111/j.1532-5415.1990.tb05700.x; Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, 1997, DIET REF INT CALC PH; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Jensen C, 2002, AM J CLIN NUTR, V75, P1114, DOI 10.1093/ajcn/75.6.1114; Krall EA, 1997, J GERONTOL A-BIOL, V52, pM61, DOI 10.1093/gerona/52A.2.M61; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; Looker AC, 2005, J CLIN ENDOCR METAB, V90, P635, DOI 10.1210/jc.2004-1765; Looker AC, 2008, J BONE MINER RES, V23, P143, DOI 10.1359/JBMR.071003; Macdonald HM, 2008, BONE, V42, P996, DOI 10.1016/j.bone.2008.01.011; Melhus H, 2010, J CLIN ENDOCR METAB, V95, P2637, DOI 10.1210/jc.2009-2699; National Institute on Aging, CLIN RES STUD INV TO; ODOWD KJ, 1993, J AM GERIATR SOC, V41, P414, DOI 10.1111/j.1532-5415.1993.tb06950.x; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; PAPAPOULOS SE, 1980, LANCET, V2, P612; Rapuri PB, 2002, J CLIN ENDOCR METAB, V87, P2024, DOI 10.1210/jc.87.5.2024; Ross AC, 2011, DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN D, P35; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sai AJ, 2011, J CLIN ENDOCR METAB, V96, pE436, DOI 10.1210/jc.2010-1886; STAMP TCB, 1977, LANCET, V1, P1341; TJELLESEN L, 1986, BONE MINER, V1, P407; vanderKlis FRM, 1996, BRIT J NUTR, V75, P637, DOI 10.1079/BJN19960166; Vieth R, 1999, AM J CLIN NUTR, V69, P842; Vieth R, 2001, AM J CLIN NUTR, V73, P288; Wagner D, 2011, J STEROID BIOCHEM, V126, P72, DOI 10.1016/j.jsbmb.2011.05.003; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; World Health Organization, 2003, PREVENTION MANAGEMEN; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690	52	237	245	0	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					425	U76		10.7326/0003-4819-156-6-201203200-00005	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00005			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431675				2022-12-28	WOS:000303150900015
J	Kanaya, AM				Kanaya, Alka M.			In-person or remote behavioral interventions for obesity were better than a self-directed approach	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIFE-STYLE		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kanaya, AM (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Berg AO, 2003, ANN INTERN MED, V139, P930, DOI 10.7326/0003-4819-139-11-200312020-00012; Digenio AG, 2009, ANN INTERN MED, V150, P255, DOI 10.7326/0003-4819-150-4-200902170-00006; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-10	10.7326/0003-4819-156-6-201203200-02010	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431696				2022-12-28	WOS:000303150900009
J	Cherry, ABC; Daley, GQ				Cherry, Anne B. C.; Daley, George Q.			Reprogramming Cellular Identity for Regenerative Medicine	CELL			English	Review							PLURIPOTENT STEM-CELLS; IPS CELLS; PARKINSONS-DISEASE; GENETIC CORRECTION; DNA METHYLATION; PATIENT; ADULT; FIBROBLASTS; DIFFERENTIATION; GENERATION	Although development leads unidirectionally toward more restricted cell fates, recent work in cellular reprogramming has proven that one cellular identity can strikingly convert into another, promising countless applications in biomedical research and paving the way for modeling diseases with patient-derived stem cells. To date, there has been little discussion of which disease models are likely to be most informative. Here, we review evidence demonstrating that, because environmental influences and epigenetic signatures are largely erased during reprogramming, patient-specific models of diseases with strong genetic bases and high penetrance are likely to prove most informative in the near term. We also discuss the implications of the new reprogramming paradigm in biomedicine and outline how reprogramming of cell identities is enhancing our understanding of cell differentiation and prospects for cellular therapies and in vivo regeneration.	[Cherry, Anne B. C.; Daley, George Q.] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Div Pediat Hematol Oncol,Stem Cell Transplantat P, Boston, MA 02115 USA; [Cherry, Anne B. C.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Cherry, Anne B. C.; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Cherry, Anne B. C.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Cherry, Anne B. C.; Daley, George Q.] Broad Inst, Cambridge, MA 02142 USA; [Cherry, Anne B. C.; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Daley, GQ (corresponding author), Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Div Pediat Hematol Oncol,Stem Cell Transplantat P, Boston, MA 02115 USA.	george.daley@childrens.harvard.edu	Cherry, Anne/E-7333-2011		NIH [RO1-DK70055, UO1-HL100001, RC4-DK090913, P50HG005550]; ARRA [RC2-HL102815]; Roche Foundation for Anemia Research; Alex's Lemonade Stand; Ellison Medical Foundation; Doris Duke Medical Foundation; Harvard Stem Cell Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL102815, U01HL100001] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG005550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [RC4DK090913, R01DK070055, R24DK092760, R01DK059279] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roche Foundation for Anemia Research; Alex's Lemonade Stand; Ellison Medical Foundation(Lawrence Ellison Foundation); Doris Duke Medical Foundation(Doris Duke Charitable Foundation (DDCF)); Harvard Stem Cell Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	G.Q.D. is supported by grants from the NIH (RO1-DK70055, UO1-HL100001, RC4-DK090913, P50HG005550, and special funds from the ARRA stimulus package RC2-HL102815), the Roche Foundation for Anemia Research, Alex's Lemonade Stand, Ellison Medical Foundation, Doris Duke Medical Foundation, and the Harvard Stem Cell Institute. G.Q.D. is an affiliate member of the Broad Institute and the Leukemia and Lymphoma Society, and an investigator of the Howard Hughes Medical Institute and the Manton Center for Orphan Disease Research.	Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640; Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Behr ER, 2008, EUR HEART J, V29, P1670, DOI 10.1093/eurheartj/ehn219; Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005; Chamberlain SJ, 2010, P NATL ACAD SCI USA, V107, P17668, DOI 10.1073/pnas.1004487107; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Devine MJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1453; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Do CB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002141; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164; Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107; Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262; Genereux DP, 2005, P NATL ACAD SCI USA, V102, P5802, DOI 10.1073/pnas.0502036102; Ghodsizadeh A, 2010, STEM CELL REV REP, V6, P622, DOI 10.1007/s12015-010-9189-3; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577; Ha NN, 2011, CELL STEM CELL, V8, P267, DOI 10.1016/j.stem.2011.01.013; Hamza TH, 2010, J HUM GENET, V55, P241, DOI 10.1038/jhg.2010.13; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018; Herfs M, 2009, TRENDS MOL MED, V15, P245, DOI 10.1016/j.molmed.2009.04.002; Ho JCY, 2011, AGING-US, V3, P380, DOI 10.18632/aging.100277; Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Itzhaki I, 2011, NATURE, V471, P225, DOI 10.1038/nature09747; Jang J, 2011, ANN NEUROL, V70, P402, DOI 10.1002/ana.22486; Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kazuki Y, 2010, MOL THER, V18, P386, DOI 10.1038/mt.2009.274; Khan IF, 2010, MOL THER, V18, P1192, DOI 10.1038/mt.2010.55; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Kim K, 2011, NAT BIOTECHNOL, V29, P1117, DOI 10.1038/nbt.2052; Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/clo.2004.6.217; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lahti A.L., 2011, DIS MODEL MECH; Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320; Lemonnier T, 2011, HUM MOL GENET, V20, P3653, DOI 10.1093/hmg/ddr285; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Liu GH, 2011, NATURE, V472, P221, DOI 10.1038/nature09879; Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106; Mali P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008-0346; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Mazzulli JR, 2011, CELL, V146, P37, DOI 10.1016/j.cell.2011.06.001; McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270; McNagny K, 2002, J EXP MED, V195, pf43, DOI 10.1084/jem.20020636; Mitne-Neto M, 2011, HUM MOL GENET, V20, P3642, DOI 10.1093/hmg/ddr284; Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679; Nardone G, 2007, DIGEST DIS, V25, P225, DOI 10.1159/000103890; Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987; Nishino K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002085; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Petronis A, 2006, TRENDS GENET, V22, P347, DOI 10.1016/j.tig.2006.04.010; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Rashid ST, 2010, J CLIN INVEST, V120, P3127, DOI 10.1172/JCI43122; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Seibler P, 2011, J NEUROSCI, V31, P5970, DOI 10.1523/JNEUROSCI.4441-10.2011; Sheridan SD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026203; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Somers A, 2010, STEM CELLS, V28, P1728, DOI 10.1002/stem.495; Swistowski A, 2010, STEM CELLS, V28, P1893, DOI 10.1002/stem.499; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tiscornia G, 2011, NAT MED, V17, P1570, DOI 10.1038/nm.2504; Tolar J, 2011, BLOOD, V117, P839, DOI 10.1182/blood-2010-05-287607; Tolar J, 2011, J INVEST DERMATOL, V131, P848, DOI 10.1038/jid.2010.346; Unternaehrer JJ, 2011, PHILOS T R SOC B, V366, P2274, DOI 10.1098/rstb.2011.0017; Urbach A, 2010, CELL STEM CELL, V6, P407, DOI 10.1016/j.stem.2010.04.005; Ushijima T, 2003, GENOME RES, V13, P868, DOI 10.1101/gr.969603; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Visscher PM, 2008, NAT REV GENET, V9, P255, DOI 10.1038/nrg2322; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226; Yagi T, 2011, HUM MOL GENET, V20, P4530, DOI 10.1093/hmg/ddr394; Yang JY, 2010, J BIOL CHEM, V285, P40303, DOI 10.1074/jbc.M110.183392; Ye ZH, 2009, BLOOD, V114, P5473, DOI 10.1182/blood-2009-04-217406; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang DH, 2009, CELL RES, V19, P429, DOI 10.1038/cr.2009.28; Zhang JQ, 2011, CELL STEM CELL, V8, P31, DOI 10.1016/j.stem.2010.12.002; Zhang N., 2010, PLOS CURR, V2; Zhang SQ, 2011, HUM MOL GENET, V20, P3176, DOI 10.1093/hmg/ddr223; Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314; Zou JZ, 2011, BLOOD, V118, P4599, DOI 10.1182/blood-2011-02-335554; Zou JZ, 2011, BLOOD, V117, P5561, DOI 10.1182/blood-2010-12-328161	99	127	129	0	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1110	1122		10.1016/j.cell.2012.02.031	http://dx.doi.org/10.1016/j.cell.2012.02.031			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424223	Green Accepted, Bronze			2022-12-28	WOS:000301889500010
J	Clemente, JC; Ursell, LK; Parfrey, LW; Knight, R				Clemente, Jose C.; Ursell, Luke K.; Parfrey, Laura Wegener; Knight, Rob			The Impact of the Gut Microbiota on Human Health: An Integrative View	CELL			English	Review							HELICOBACTER-PYLORI INFECTION; INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; INTESTINAL MICROBIOTA; BACTERIAL COMMUNITY; CROHNS-DISEASE; ULCERATIVE-COLITIS; IMMUNE-RESPONSES; IDENTICAL-TWINS; GIARDIA-LAMBLIA	The human gut harbors diverse microbes that play a fundamental role in the well-being of their host. The constituents of the microbiota-bacteria, viruses, and eukaryotes-have been shown to interact with one another and with the host immune system in ways that influence the development of disease. We review these interactions and suggest that a holistic approach to studying the microbiota that goes beyond characterization of community composition and encompasses dynamic interactions between all components of the microbiota and host tissue over time will be crucial for building predictive models for diagnosis and treatment of diseases linked to imbalances in our microbiota.	[Clemente, Jose C.; Ursell, Luke K.; Parfrey, Laura Wegener; Knight, Rob] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Knight, Rob] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Knight, R (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	rob.knight@colorado.edu	Parfrey, Laura/AAA-6139-2019; Knight, Rob/D-1299-2010; Parfrey, Laura Wegener/AAE-1402-2019	Parfrey, Laura Wegener/0000-0001-6959-7616; Knight, Rob/0000-0002-0975-9019	Crohn's and Colitis foundation of America; Howard Hughes Medical Institute;  [T32 GM08759]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK078669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD011389] Funding Source: NIH RePORTER	Crohn's and Colitis foundation of America; Howard Hughes Medical Institute(Howard Hughes Medical Institute); ; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Skip Virgin for insightful comments. We should also like to acknowledge Cathy Lozupone, Jessica Metcalf, and Daniel McDonald for helpful discussions and three anonymous reviewers for their thorough and detailed comments on earlier versions of this manuscript. This work was supported in part by grants from the Crohn's and Colitis foundation of America and the Howard Hughes Medical Institute as well as training grant T32 GM08759 to L.K.U.	Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; AHMAD S, 1971, ACTA MICROBIOL POL, V3, P75; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Anderson HR, 2005, BRIT MED J, V330, P1037, DOI 10.1136/bmj.330.7499.1037; Armougom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007125; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Atherton JC, 2009, J CLIN INVEST, V119, P2475, DOI 10.1172/JCI38605; Bakken JS, 2009, ANAEROBE, V15, P285, DOI 10.1016/j.anaerobe.2009.09.007; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762; Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107; Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a; BOGITSH B, 2005, HUMAN PARASITOLOGY; Bouskra D, 2008, NATURE, V456, P507, DOI 10.1038/nature07450; Breitbart M, 2008, RES MICROBIOL, V159, P367, DOI 10.1016/j.resmic.2008.04.006; Brown LM, 2000, EPIDEMIOL REV, V22, P283, DOI 10.1093/oxfordjournals.epirev.a018040; Burke C, 2011, P NATL ACAD SCI USA, V108, P14288, DOI 10.1073/pnas.1101591108; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chow J, 2010, ADV IMMUNOL, V107, P243, DOI [10.1016/B978-0-12-381300-8.00008-3, 10.1016/S0065-2776(10)07001-X]; Claesson MJ, 2011, P NATL ACAD SCI USA, V108, P4586, DOI 10.1073/pnas.1000097107; Collier L, 2011, HUMAN VIROLOGY; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Cox FEG, 2001, PARASITOLOGY, V122, pS23, DOI 10.1017/S003118200001698X; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Dicksved J, 2008, ISME J, V2, P716, DOI 10.1038/ismej.2008.37; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Feary J, 2011, ALLERGY, V66, P569, DOI 10.1111/j.1398-9995.2010.02512.x; Ghannoum MA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000713; Gilbert JA, 2010, STAND GENOMIC SCI, V3, P249, DOI 10.4056/sigs.1433550; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Giongo A, 2011, ISME J, V5, P82, DOI 10.1038/ismej.2010.92; Gonzalez Antonio, 2011, Dialogues Clin Neurosci, V13, P55; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Halfvarson J, 2006, INFLAMM BOWEL DIS, V12, P925, DOI 10.1097/01.mib.0000228998.29466.ac; Hamady M, 2008, NAT METHODS, V5, P235, DOI 10.1038/NMETH.1184; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Haynes M, 2011, METAGENOMICS OF THE HUMAN BODY, P63, DOI 10.1007/978-1-4419-7089-3_4; Hehemann JH, 2010, NATURE, V464, P908, DOI 10.1038/nature08937; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Huurre A, 2008, NEONATOLOGY, V93, P236, DOI 10.1159/000111102; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3; Jimenez E, 2008, RES MICROBIOL, V159, P187, DOI 10.1016/j.resmic.2007.12.007; Kane M, 2011, SCIENCE, V334, P245, DOI 10.1126/science.1210718; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Knights D, 2011, FEMS MICROBIOL REV, V35, P343, DOI 10.1111/j.1574-6976.2010.00251.x; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lee YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/science.1195568; Letran SE, 2011, J IMMUNOL, V186, P5406, DOI 10.4049/jimmunol.1003576; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; Ley RE, 2010, CURR OPIN GASTROEN, V26, P5, DOI 10.1097/MOG.0b013e328333d751; Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Macpherson AJ, 2011, CURR OPIN GASTROEN, V27, P529, DOI 10.1097/MOG.0b013e32834bb805; Manichanh C, 2010, GENOME RES, V20, P1411, DOI 10.1101/gr.107987.110; Galvan-Moroyoqui JM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000266; Minot S, 2011, GENOME RES, V21, P1616, DOI 10.1101/gr.122705.111; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Muller N, 2005, INT J PARASITOL, V35, P1339, DOI 10.1016/j.ijpara.2005.07.008; Nasidze I, 2009, GENOME RES, V19, P636, DOI 10.1101/gr.084616.108; NEMANIC PC, 1979, J INFECT DIS, V140, P222, DOI 10.1093/infdis/140.2.222; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Ouellette AJ, 2006, CURR TOP MICROBIOL, V306, P1; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Perry S, 2006, EMERG INFECT DIS, V12, P1701, DOI 10.3201/eid1211.060086; Perry S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008804; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Pflughoeft KJ, 2012, ANNU REV PATHOL-MECH, V7, P99, DOI 10.1146/annurev-pathol-011811-132421; Pritt BS, 2008, MAYO CLIN PROC, V83, P1154, DOI 10.4065/83.10.1154; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rappelli P, 2001, ARCH MICROBIOL, V175, P70, DOI 10.1007/s002030000240; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Robinson CJ, 2010, MICROBIOL MOL BIOL R, V74, P453, DOI 10.1128/MMBR.00014-10; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Roussos A, 2002, J GASTROENTEROL, V37, P332, DOI 10.1007/s005350200046; Roussos A, 2006, RESPIRATION, V73, P708, DOI 10.1159/000093816; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Scanlan PD, 2008, ISME J, V2, P1183, DOI 10.1038/ismej.2008.76; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Sommer MOA, 2009, SCIENCE, V325, P1128, DOI 10.1126/science.1176950; Soper D, 2004, AM J OBSTET GYNECOL, V190, P281, DOI 10.1016/j.ajog.2003.08.023; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2010, P NATL ACAD SCI USA, V107, P7503, DOI 10.1073/pnas.1002355107; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vaishampayan PA, 2010, GENOME BIOL EVOL, V2, P53, DOI 10.1093/gbe/evp057; Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Virgin HW, 2011, CELL, V147, P44, DOI 10.1016/j.cell.2011.09.009; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106	120	2091	2285	53	948	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1258	1270		10.1016/j.cell.2012.01.035	http://dx.doi.org/10.1016/j.cell.2012.01.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424233	Bronze, Green Accepted			2022-12-28	WOS:000301889500020
J	Shohat-Ophir, G; Kaun, KR; Azanchi, R; Heberlein, U				Shohat-Ophir, G.; Kaun, K. R.; Azanchi, R.; Heberlein, U.			Sexual Deprivation Increases Ethanol Intake in Drosophila	SCIENCE			English	Article							NEUROPEPTIDE Y-LIKE; SOCIAL-BEHAVIOR; NPY; MELANOGASTER; DEPRESSION; RATS; ADDICTION; RECEPTORS; SYSTEM; MEMORY	The brain's reward systems reinforce behaviors required for species survival, including sex, food consumption, and social interaction. Drugs of abuse co-opt these neural pathways, which can lead to addiction. Here, we used Drosophila melanogaster to investigate the relationship between natural and drug rewards. In males, mating increased, whereas sexual deprivation reduced, neuropeptide F (NPF) levels. Activation or inhibition of the NPF system in turn reduced or enhanced ethanol preference. These results thus link sexual experience, NPF system activity, and ethanol consumption. Artificial activation of NPF neurons was in itself rewarding and precluded the ability of ethanol to act as a reward. We propose that activity of the NPF-NPF receptor axis represents the state of the fly reward system and modifies behavior accordingly.	[Shohat-Ophir, G.; Kaun, K. R.; Azanchi, R.; Heberlein, U.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Shohat-Ophir, G (corresponding author), Janelia Farm Res Ctr, Howard Hughes Med Inst, Ashburn, VA 20147 USA.	shohatophirg@janelia.hhmi.org; ulrike.heberlein@ucsf.edu		Kaun, Karla/0000-0002-8756-9528	Sandler Research Fellowship; University of California, San Francisco; NIH-National Institute on Alcohol Abuse and Alcoholism; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010035] Funding Source: NIH RePORTER	Sandler Research Fellowship; University of California, San Francisco(University of California System); NIH-National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank F. Wolf, M. Schuldiner, O. Schuldiner, A. Devineni, K. McClure, R. Joseph, and N. Velazquez Ulloa for advice and comments on the manuscript; J. Levine for discussions; P. Shen for fly strains and antibodies; and the Bloomington Stock Center for fly strains. Funding was provided by the Sandler Research Fellowship (G.S.-O.), the Program for Breakthrough Biomedical Research at the University of California, San Francisco (U. H.), and NIH-National Institute on Alcohol Abuse and Alcoholism (U. H.). The authors declare that they have no competing interests. A detailed description of all materials and methods as well as supplementary figures are available as supporting online material.	Billeter JC, 2009, NATURE, V461, P987, DOI 10.1038/nature08495; Davies AG, 2004, NEURON, V42, P731, DOI 10.1016/j.neuron.2004.05.004; Devineni AV, 2009, CURR BIOL, V19, P2126, DOI 10.1016/j.cub.2009.10.070; Dyzma M, 2010, SLEEP MED REV, V14, P161, DOI 10.1016/j.smrv.2009.09.001; Ejima A, 2007, CURR BIOL, V17, P599, DOI 10.1016/j.cub.2007.01.053; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Horsell A, 1999, NEUROREPORT, V10, P3003, DOI 10.1097/00001756-199909290-00024; Hyman SE, 2007, AM J BIOETHICS, V7, P8, DOI 10.1080/15265160601063969; Ja WW, 2007, P NATL ACAD SCI USA, V104, P8253, DOI 10.1073/pnas.0702726104; Jimenez-Vasquez PA, 2001, DEV BRAIN RES, V131, P149, DOI 10.1016/S0165-3806(01)00264-4; JOSSELYN SA, 1993, PHARMACOL BIOCHEM BE, V46, P543, DOI 10.1016/0091-3057(93)90542-2; KALRA SP, 1988, SYNAPSE, V2, P254, DOI 10.1002/syn.890020313; Kaun KR, 2011, NAT NEUROSCI, V14, P612, DOI 10.1038/nn.2805; Kelley AE, 2002, J NEUROSCI, V22, P3306; Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043; Krashes MJ, 2009, CELL, V139, P416, DOI 10.1016/j.cell.2009.08.035; Krishnan V, 2011, CURR TOP BEHAV NEURO, V7, P121, DOI 10.1007/7854_2010_108; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; Mehren JE, 2004, CURR OPIN NEUROBIOL, V14, P745, DOI 10.1016/j.conb.2004.10.012; Redrobe JP, 2002, LIFE SCI, V71, P2921, DOI 10.1016/S0024-3205(02)02159-8; Robinson GE, 2008, SCIENCE, V322, P896, DOI 10.1126/science.1159277; Rosenzweig M, 2005, GENE DEV, V19, P419, DOI 10.1101/gad.1278205; Sah R, 2009, BIOL PSYCHIAT, V66, P705, DOI 10.1016/j.biopsych.2009.04.037; Stogner KA, 2000, EUR J PHARMACOL, V387, pR9, DOI 10.1016/S0014-2999(99)00800-6; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Thorsell A, 2002, NEUROSCI LETT, V332, P1, DOI 10.1016/S0304-3940(02)00904-7; Thorsell A, 2007, PEPTIDES, V28, P480, DOI 10.1016/j.peptides.2006.11.017; Wen TQ, 2005, P NATL ACAD SCI USA, V102, P2141, DOI 10.1073/pnas.0406814102; Wu Q, 2005, NAT NEUROSCI, V8, P1350, DOI 10.1038/nn1540; Wu Q, 2003, NEURON, V39, P147, DOI 10.1016/S0896-6273(03)00396-9; Xu J, 2010, J NEUROSCI, V30, P2504, DOI 10.1523/JNEUROSCI.3262-09.2010	33	128	131	0	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074					1351	1355		10.1126/science.1215932	http://dx.doi.org/10.1126/science.1215932			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422983	Green Accepted			2022-12-28	WOS:000301531600048
J	Stewart, JR; Stringer, CB				Stewart, J. R.; Stringer, C. B.			Human Evolution Out of Africa: The Role of Refugia and Climate Change	SCIENCE			English	Review							MITOCHONDRIAL-DNA PHYLOGEOGRAPHY; MODERN HUMAN ORIGINS; LATE PLEISTOCENE; GLACIAL REFUGIA; BROWN BEARS; POSTGLACIAL COLONIZATION; BODY PROPORTIONS; GENETIC-EVIDENCE; HUMAN DISPERSALS; SOUTHEAST-ASIA	Although an African origin of the modern human species is generally accepted, the evolutionary processes involved in the speciation, geographical spread, and eventual extinction of archaic humans outside of Africa are much debated. An additional complexity has been the recent evidence of limited interbreeding between modern humans and the Neandertals and Denisovans. Modern human migrations and interactions began during the buildup to the Last Glacial Maximum, starting about 100,000 years ago. By examining the history of other organisms through glacial cycles, valuable models for evolutionary biogeography can be formulated. According to one such model, the adoption of a new refugium by a subgroup of a species may lead to important evolutionary changes.	[Stewart, J. R.] Bournemouth Univ, Sch Appl Sci, Talbot Campus, Poole BH12 5BB, Dorset, England; [Stringer, C. B.] Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	Bournemouth University; Natural History Museum London	Stewart, JR (corresponding author), Bournemouth Univ, Sch Appl Sci, Talbot Campus, Poole BH12 5BB, Dorset, England.	jstewart@bournemouth.ac.uk; c.stringer@nhm.ac.uk	Stewart, John R./C-1075-2011	Stewart, John R./0000-0002-3506-5264	Leverhulme Trust; Human Origins Research Fund; Calleva Foundation	Leverhulme Trust(Leverhulme Trust); Human Origins Research Fund; Calleva Foundation	We thank J. Cole, M. Dover, S. Bello, R. Housley, A. Shaw, B. Scott, and W. Davies for help with Fig. 1. J. R. S. is an associate and C. B. S. is a member of the Ancient Human Occupation of Britain project, funded by the Leverhulme Trust. C.B.S.'s human origins research is supported by the Human Origins Research Fund and the Calleva Foundation.	Abi-Rached L, 2011, SCIENCE, V334, P89, DOI 10.1126/science.1209202; Anikovich MV, 2007, SCIENCE, V315, P223, DOI 10.1126/science.1133376; Arnold M. L., 1997, NATURAL HYBRIDIZATIO; Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Banks WE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003972; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; Belmaker M, 2011, QUATERNARY SCI REV, V30, P3196, DOI 10.1016/j.quascirev.2011.08.001; Benazzi S, 2011, NATURE, V479, P525, DOI 10.1038/nature10617; Bennett, 1997, EVOLUTION ECOLOGY PA; Bennett KD, 2008, QUATERNARY SCI REV, V27, P2449, DOI 10.1016/j.quascirev.2008.08.019; BENNETT KD, 1991, J BIOGEOGR, V18, P103, DOI 10.2307/2845248; Bhagwat SA, 2008, J BIOGEOGR, V35, P464, DOI 10.1111/j.1365-2699.2007.01861.x; Bilton DT, 1998, P ROY SOC B-BIOL SCI, V265, P1219, DOI 10.1098/rspb.1998.0423; Bird MI, 2005, QUATERNARY SCI REV, V24, P2228, DOI 10.1016/j.quascirev.2005.04.004; Bradtmoller M, 2012, QUATERN INT, V247, P38, DOI 10.1016/j.quaint.2010.10.015; Brown P, 2004, NATURE, V431, P1055, DOI 10.1038/nature02999; Burger J, 2004, MOL PHYLOGENET EVOL, V30, P841, DOI 10.1016/j.ympev.2003.07.020; Carrion JS, 2011, QUATERNARY SCI REV, V30, P1281, DOI 10.1016/j.quascirev.2011.04.003; Coon C. S., 1962, ORIGIN RACES; COOPE GR, 1978, DIVERSITY INSECT FAU, P176; Crevecoeur I, 2010, AM J PHYS ANTHROPOL, P87; Currat M, 2011, P NATL ACAD SCI USA, V108, P15129, DOI 10.1073/pnas.1107450108; Dalen L, 2007, P NATL ACAD SCI USA, V104, P6726, DOI 10.1073/pnas.0701341104; Darwin C., 1856, ORIGIN SPECIES MEANS; De MacPhee R, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-49; Dennell RW, 2008, EPISODES, V31, P207, DOI 10.18814/epiiugs/2008/v31i2/003; Edwards CJ, 2011, CURR BIOL, V21, P1251, DOI 10.1016/j.cub.2011.05.058; Endicott P, 2010, J HUM EVOL, V59, P87, DOI 10.1016/j.jhevol.2010.04.005; Endicott P, 2009, TRENDS ECOL EVOL, V24, P515, DOI 10.1016/j.tree.2009.04.006; Fabre V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005151; Finlayson C, 2005, TRENDS ECOL EVOL, V20, P457, DOI 10.1016/j.tree.2005.05.019; Finlayson C, 2006, NATURE, V443, P850, DOI 10.1038/nature05195; Gamble C, 2004, PHILOS T R SOC B, V359, P243, DOI 10.1098/rstb.2003.1396; Ghirotto S, 2011, AM J PHYS ANTHROPOL, V146, P242, DOI 10.1002/ajpa.21569; Gibbons A, 2011, SCIENCE, V333, P1084, DOI 10.1126/science.333.6046.1084; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Grant PR, 1997, AM NAT, V149, P1, DOI 10.1086/285976; Green RE, 2010, SCIENCE, V328, P710, DOI 10.1126/science.1188021; Grun R, 2005, J HUM EVOL, V49, P316, DOI 10.1016/j.jhevol.2005.04.006; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Hammer MF, 2011, P NATL ACAD SCI USA, V108, P15123, DOI 10.1073/pnas.1109300108; Harvati K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024024; HEUSSER CALVIN J., 1955, CANADIAN JOUR BOT, V33, P429, DOI 10.1139/b55-036; Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; Hewitt GM, 2001, MOL ECOL, V10, P537, DOI 10.1046/j.1365-294x.2001.01202.x; Higham T, 2006, P NATL ACAD SCI USA, V103, P553, DOI 10.1073/pnas.0510005103; Higham T, 2011, NATURE, V479, P521, DOI 10.1038/nature10484; Hofreiter M, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-46; Holliday TW, 1997, AM J PHYS ANTHROPOL, V104, P245, DOI 10.1002/(SICI)1096-8644(199710)104:2<245::AID-AJPA10>3.3.CO;2-8; Holliday TW, 1997, J HUM EVOL, V32, P423, DOI 10.1006/jhev.1996.0111; Huntley B., 1983, ATLAS PRESENT POLLEN; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Indriati E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021562; Jolly CJ, 2001, YEARB PHYS ANTHROPOL, V44, P177, DOI 10.1002/ajpa.10021; Krause J, 2007, NATURE, V449, P902, DOI 10.1038/nature06193; Krause J, 2010, NATURE, V464, P894, DOI 10.1038/nature08976; Lister AM, 2008, CR GEOSCI, V340, P615, DOI 10.1016/j.crte.2008.04.001; Mallet J, 2005, TRENDS ECOL EVOL, V20, P229, DOI 10.1016/j.tree.2005.02.010; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; Mellars P, 2006, NATURE, V439, P931, DOI 10.1038/nature04521; Morwood MJ, 2009, J HUM EVOL, V57, P640, DOI 10.1016/j.jhevol.2009.08.003; Muller UC, 2011, QUATERNARY SCI REV, V30, P273, DOI 10.1016/j.quascirev.2010.11.016; Orlando L, 2006, CURR BIOL, V16, pR400, DOI 10.1016/j.cub.2006.05.019; Parducci L, 2012, SCIENCE, V335, P1083, DOI 10.1126/science.1216043; Pinhasi R, 2011, P NATL ACAD SCI USA, V108, P8611, DOI 10.1073/pnas.1018938108; Potts R, 1999, EVOL ANTHROPOL, V7, P81, DOI 10.1002/(SICI)1520-6505(1998)7:3<81::AID-EVAN3>3.3.CO;2-1; Pross J, 2007, SCI DRILL, V5, P44, DOI 10.5194/sd-5-44-2007; Provan J, 2008, TRENDS ECOL EVOL, V23, P564, DOI 10.1016/j.tree.2008.06.010; Rae TC, 2011, J HUM EVOL, V60, P234, DOI 10.1016/j.jhevol.2010.10.003; Rasmussen M, 2011, SCIENCE, V334, P94, DOI 10.1126/science.1211177; Reich D, 2011, AM J HUM GENET, V89, P516, DOI 10.1016/j.ajhg.2011.09.005; Reich D, 2010, NATURE, V468, P1053, DOI 10.1038/nature09710; Santucci F, 1998, MOL ECOL, V7, P1163, DOI 10.1046/j.1365-294x.1998.00436.x; Semal P, 2009, AM J PHYS ANTHROPOL, V138, P421, DOI 10.1002/ajpa.20954; Shapiro B, 2004, SCIENCE, V306, P1561, DOI 10.1126/science.1101074; Smith CI, 2003, J HUM EVOL, V45, P203, DOI 10.1016/S0047-2484(03)00106-4; Stewart JR, 2009, J EVOLUTION BIOL, V22, P2363, DOI 10.1111/j.1420-9101.2009.01859.x; Stewart JR, 2010, P ROY SOC B-BIOL SCI, V277, P661, DOI 10.1098/rspb.2009.1272; Stewart JR, 2001, TRENDS ECOL EVOL, V16, P608, DOI 10.1016/S0169-5347(01)02338-2; Stewart JR, 2005, QUATERN INT, V137, P35, DOI 10.1016/j.quaint.2004.11.018; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; Stringer C., 2006, HOMOBRITANNICUS STOR; Stringer C, 2011, ORIGIN OUR SPECIES; Stringer CB, 2007, VERTEBR PALEOBIOL PA, P315; Taberlet P, 1998, MOL ECOL, V7, P453, DOI 10.1046/j.1365-294x.1998.00289.x; Talbot SL, 1996, MOL PHYLOGENET EVOL, V5, P477, DOI 10.1006/mpev.1996.0044; Trinkaus E, 2003, P NATL ACAD SCI USA, V100, P11231, DOI 10.1073/pnas.2035108100; Trinkaus E., 1981, ASPECTS HUMAN EVOLUT, P187; Valdiosera CE, 2007, MOL ECOL, V16, P5140, DOI 10.1111/j.1365-294X.2007.03590.x; van Andel T. H., 2003, NEANDERTHALS MODERN; Walker MJ, 2011, P NATL ACAD SCI USA, V108, P10087, DOI 10.1073/pnas.1107318108; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Weaver TD, 2008, P NATL ACAD SCI USA, V105, P4645, DOI 10.1073/pnas.0709079105; Zinner D, 2011, EVOL ANTHROPOL, V20, P96, DOI 10.1002/evan.20301; Zollikofer CPE, 2010, SEMIN CELL DEV BIOL, V21, P441, DOI 10.1016/j.semcdb.2009.10.012	96	178	181	12	375	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074					1317	1321		10.1126/science.1215627	http://dx.doi.org/10.1126/science.1215627			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908ZM	22422974				2022-12-28	WOS:000301531600038
J	Furlan, AJ; Reisman, M; Massaro, J; Mauri, L; Adams, H; Albers, GW; Felberg, R; Herrmann, H; Kar, S; Landzberg, M; Raizner, A; Wechsler, L				Furlan, Anthony J.; Reisman, Mark; Massaro, Joseph; Mauri, Laura; Adams, Harold; Albers, Gregory W.; Felberg, Robert; Herrmann, Howard; Kar, Saibal; Landzberg, Michael; Raizner, Albert; Wechsler, Lawrence		CLOSURE I Investigators	Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACK; ATRIAL SEPTAL ANEURYSM; RECURRENT CEREBROVASCULAR EVENTS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; PARADOXICAL EMBOLISM; IMAGING FINDINGS; DEVICE CLOSURE; YOUNG-ADULTS; RISK-FACTOR; FIBRILLATION	Background The prevalence of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general population. Closure with a percutaneous device is often recommended in such patients, but it is not known whether this intervention reduces the risk of recurrent stroke. Methods We conducted a multicenter, randomized, open-label trial of closure with a percutaneous device, as compared with medical therapy alone, in patients between 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) and had a patent foramen ovale. The primary end point was a composite of stroke or transient ischemic attack during 2 years of follow-up, death from any cause during the first 30 days, or death from neurologic causes between 31 days and 2 years. Results A total of 909 patients were enrolled in the trial. The cumulative incidence (Kaplan-Meier estimate) of the primary end point was 5.5% in the closure group (447 patients) as compared with 6.8% in the medical-therapy group (462 patients) (adjusted hazard ratio, 0.78; 95% confidence interval, 0.45 to 1.35; P = 0.37). The respective rates were 2.9% and 3.1% for stroke (P = 0.79) and 3.1% and 4.1% for TIA (P = 0.44). No deaths occurred by 30 days in either group, and there were no deaths from neurologic causes during the 2-year follow-up period. A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events. Conclusions In patients with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a greater benefit than medical therapy alone for the prevention of recurrent stroke or TIA. (Funded by NMT Medical; ClinicalTrials.gov number, NCT00201461.)	[Furlan, Anthony J.] Univ Hosp Case Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; [Reisman, Mark] Swedish Med Ctr, Seattle, WA USA; [Massaro, Joseph; Mauri, Laura] Harvard Clin Res Inst, Boston, MA USA; [Landzberg, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA; [Adams, Harold] Univ Iowa, Iowa City, IA USA; [Albers, Gregory W.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; [Felberg, Robert] Geisinger Med Ctr, Danville, PA 17822 USA; [Herrmann, Howard] Univ Penn, Philadelphia, PA 19104 USA; [Kar, Saibal] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Raizner, Albert] Methodist Hosp, Houston, TX 77030 USA; [Wechsler, Lawrence] Univ Pittsburgh, Pittsburgh, PA USA	Case Western Reserve University; Case Western Reserve University Hospital; Swedish Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Iowa; Stanford University; Geisinger Medical Center; University of Pennsylvania; Cedars Sinai Medical Center; The Methodist Hospital System; The Methodist Hospital - Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Furlan, AJ (corresponding author), Univ Hosp Case Med Ctr, Dept Neurol, 11100 Euclid Ave,Mail Stop HAN 5040, Cleveland, OH 44106 USA.	anthony.furlan@uhhospitals.org	Wechsler, Lawrence/AAB-9176-2020; mauri, laura/GPS-4868-2022	Albers, Gregory/0000-0003-0263-4632; Burgin, William/0000-0001-5376-8302; Massaro, Joseph/0000-0002-2682-4812	NMT Medical, Boston [NCT00201461]	NMT Medical, Boston	Funded by NMT Medical; ClinicalTrials.gov number, NCT00201461.); Supported by NMT Medical, Boston.	Alaeddini Jamshid, 2006, J Invasive Cardiol, V18, P365; Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; Bogousslavsky J, 1996, NEUROLOGY, V46, P1301, DOI 10.1212/WNL.46.5.1301; Burow A, 2008, CARDIOLOGY, V111, P47, DOI 10.1159/000113427; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; COMESS KA, 1994, J AM COLL CARDIOL, V23, P1598, DOI 10.1016/0735-1097(94)90662-9; Dalen JE, 2007, AM J MED, V120, P472, DOI 10.1016/j.amjmed.2006.03.021; De Castro S, 2000, STROKE, V31, P2407, DOI 10.1161/01.STR.31.10.2407; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Furlan AJ, 2010, STROKE, V41, P2872, DOI 10.1161/STROKEAHA.110.593376; Gaillard N, 2010, NEUROLOGY, V74, P1666, DOI 10.1212/WNL.0b013e3181e0427e; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; HAUSMANN D, 1995, J AM COLL CARDIOL, V26, P1030, DOI 10.1016/0735-1097(95)00288-9; Herrmann HC, 2005, CATHETER CARDIO INTE, V64, P197, DOI 10.1002/ccd.20260; Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44; HOMMA S, 1994, STROKE, V25, P582, DOI 10.1161/01.STR.25.3.582; JONES HR, 1983, ANN NEUROL, V13, P314, DOI 10.1002/ana.410130315; Kent DM, 2008, NEW ENGL J MED, V358, P1519; Kent DM, 2010, STROKE, V41, pS26, DOI 10.1161/STROKEAHA.110.595140; Kristensen B, 1997, STROKE, V28, P1702, DOI 10.1161/01.STR.28.9.1702; Lamy C, 2002, STROKE, V33, P706, DOI 10.1161/hs0302.104543; LECHAT P, 1989, ARCH MAL COEUR VAISS, V82, P847; Maisel WH, 2005, JAMA-J AM MED ASSOC, V294, P366, DOI 10.1001/jama.294.3.366; Mas JL, 2001, NEW ENGL J MED, V345, P1740, DOI 10.1056/NEJMoa011503; MAS JL, 1995, AM HEART J, V130, P1083, DOI 10.1016/0002-8703(95)90212-0; Meissner I, 2006, J AM COLL CARDIOL, V47, P440, DOI 10.1016/j.jacc.2005.10.044; Nendaz MR, 1998, AM HEART J, V135, P532, DOI 10.1016/S0002-8703(98)70332-1; O'Gara PT, 2009, CIRCULATION, V119, P2743, DOI 10.1161/CIRCULATIONAHA.109.192272; Ozdemir AO, 2008, J NEUROL SCI, V275, P121, DOI 10.1016/j.jns.2008.08.018; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; Sievert H, 2001, J Interv Cardiol, V14, P261, DOI 10.1111/j.1540-8183.2001.tb00745.x; Steiner MM, 1998, STROKE, V29, P944, DOI 10.1161/01.STR.29.5.944; Tayal AH, 2010, NEUROLOGY, V74, P1662, DOI 10.1212/WNL.0b013e3181e19559; WEBSTER MWI, 1988, LANCET, V2, P11	36	653	683	4	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					991	999		10.1056/NEJMoa1009639	http://dx.doi.org/10.1056/NEJMoa1009639			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417252				2022-12-28	WOS:000301482800002
J	Garcia, V; Bibes, M				Garcia, Vincent; Bibes, Manuel			ELECTRONICS Inside story of ferroelectric memories	NATURE			English	Editorial Material									[Garcia, Vincent; Bibes, Manuel] Unite Mixte Phys CNRS Thales, F-91767 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS)	Garcia, V (corresponding author), Unite Mixte Phys CNRS Thales, Campus Ecole Polytech, F-91767 Palaiseau, France.	vincent.garcia@thalesgroup.com; manuel.bibes@thalesgroup.com	Bibes, Manuel/AAC-5764-2019; Garcia, Vincent/C-9359-2012; Bibes, Manuel/C-5899-2013	Bibes, Manuel/0000-0002-6704-3422; Garcia, Vincent/0000-0002-7230-8130; Bibes, Manuel/0000-0002-6704-3422				Chanthbouala A, 2012, NAT NANOTECHNOL, V7, P101, DOI [10.1038/NNANO.2011.213, 10.1038/nnano.2011.213]; Choi T, 2009, SCIENCE, V324, P63, DOI 10.1126/science.1168636; Das S, 2011, NANO LETT, V11, P4003, DOI 10.1021/nl2023993; Fujisaki Y, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.100001; Goldman M., 2011, 3 IEEE INT MEM WORKS; Lee D, 2012, ADV MATER, V24, P402, DOI 10.1002/adma.201103679; Shiga H, 2010, IEEE J SOLID-ST CIRC, V45, P142, DOI 10.1109/JSSC.2009.2034414	8	61	64	0	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					279	281		10.1038/483279a	http://dx.doi.org/10.1038/483279a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422256				2022-12-28	WOS:000301481800033
J	Burns, PC; Ewing, RC; Navrotsky, A				Burns, Peter C.; Ewing, Rodney C.; Navrotsky, Alexandra			Nuclear Fuel in a Reactor Accident	SCIENCE			English	Review							HYDROGEN-PEROXIDE; CORROSION; URANIUM; UO2; PRODUCTS; RELEASE; DISSOLUTION; MINERALS; STUDTITE; SURFACE	Nuclear accidents that lead to melting of a reactor core create heterogeneous materials containing hundreds of radionuclides, many with short half-lives. The long-lived fission products and transuranium elements within damaged fuel remain a concern for millennia. Currently, accurate fundamental models for the prediction of release rates of radionuclides from fuel, especially in contact with water, after an accident remain limited. Relatively little is known about fuel corrosion and radionuclide release under the extreme chemical, radiation, and thermal conditions during and subsequent to a nuclear accident. We review the current understanding of nuclear fuel interactions with the environment, including studies over the relatively narrow range of geochemical, hydrological, and radiation environments relevant to geological repository performance, and discuss priorities for research needed to develop future predictive models.	[Burns, Peter C.] Univ Notre Dame, Dept Civil Engn & Geol Sci, Notre Dame, IN 46556 USA; [Burns, Peter C.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Ewing, Rodney C.] Univ Michigan, Dept Earth & Environm Sci, Ann Arbor, MI 48109 USA; [Ewing, Rodney C.] Univ Michigan, Dept Nucl Engn & Radiol Sci, Ann Arbor, MI 48109 USA; [Navrotsky, Alexandra] Univ Calif Davis, Peter A Rock Thermochem Lab, Davis, CA 95616 USA	University of Notre Dame; University of Notre Dame; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California Davis	Burns, PC (corresponding author), Univ Notre Dame, Dept Civil Engn & Geol Sci, 156 Fitzpatrick Hall, Notre Dame, IN 46556 USA.	pburns@nd.edu	Burns, Peter C/J-3359-2013	Ewing, Rodney/0000-0001-9472-4031; Burns, Peter/0000-0002-2319-9628	Materials Science of Actinides Center, an Energy Frontier Research Center; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-SC0001089]	Materials Science of Actinides Center, an Energy Frontier Research Center; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE))	This material is based on work supported as part of the Materials Science of Actinides Center, an Energy Frontier Research Center funded by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Award Number DE-SC0001089.	Abrefah J., 1998, PNNL11806; ANDERSON EB, 1993, RADIOCHIM ACTA, V60, P149; ANDERSON EB, 1992, SOV RADIOCHEM+, V34, P632; [Anonymous], 2011, SYNTH ACT CONN REL I; Armstrong FA, 2011, P NATL ACAD SCI USA, V108, P14049, DOI 10.1073/pnas.1103697108; Bruno J, 2006, ELEMENTS, V2, P343, DOI 10.2113/gselements.2.6.343; Buck E.C., 2004, GEOLOGICAL SOC LONDO, V236, P65, DOI DOI 10.1144/GSL.SP.2004.236.01; Buesseler K, 2011, ENVIRON SCI TECHNOL, V45, P9931, DOI 10.1021/es202816c; Burakov BE, 1997, MAT RES S C, V465, P1309, DOI 10.1557/PROC-465-1309; Burns PC, 2011, MINERAL MAG, V75, P1, DOI 10.1180/minmag.2011.075.1.1; Burns PC, 2005, CAN MINERAL, V43, P1839, DOI 10.2113/gscanmin.43.6.1839; Burns PC, 1997, J NUCL MATER, V245, P1, DOI 10.1016/S0022-3115(97)00006-8; Chung DY, 2010, J RADIOANAL NUCL CH, V284, P123, DOI 10.1007/s10967-009-0443-6; Clarens F, 2004, ENVIRON SCI TECHNOL, V38, P6656, DOI 10.1021/es0492891; CLARK DL, 1995, CHEM REV, V95, P25, DOI 10.1021/cr00033a002; Corbel C, 2006, J NUCL MATER, V348, P1, DOI 10.1016/j.jnucmat.2005.05.009; Douglas M, 2005, ENVIRON SCI TECHNOL, V39, P4117, DOI 10.1021/es0405169; Finch RJ, 1999, MATER RES SOC SYMP P, V556, P431, DOI 10.1557/PROC-556-431; FINCH RJ, 1992, J NUCL MATER, V190, P133, DOI 10.1016/0022-3115(92)90083-W; Finn PA, 1996, RADIOCHIM ACTA, V74, P65; Fuketa T, 1997, J NUCL MATER, V248, P249, DOI 10.1016/S0022-3115(97)00173-6; Gianguzza A, 2004, MAR CHEM, V85, P103, DOI 10.1016/j.marchem.2003.10.002; Gorman-Lewis D, 2008, J CHEM THERMODYN, V40, P335, DOI 10.1016/j.jct.2007.12.004; Hanson B, 2005, RADIOCHIM ACTA, V93, P159, DOI 10.1524/ract.93.3.159.61613; Hedin A., 1997, SKBTR9713; Hofmann P, 1999, J NUCL MATER, V270, P194, DOI 10.1016/S0022-3115(98)00899-X; Johnson L. H., 1988, Radioactive waste forms for the future, P635; Johnsson A, 2009, J RADIOANAL NUCL CH, V279, P619, DOI 10.1007/s10967-008-7302-8; KLEYKAMP H, 1985, J NUCL MATER, V131, P221, DOI 10.1016/0022-3115(85)90460-X; Kubatko KAH, 2003, SCIENCE, V302, P1191, DOI 10.1126/science.1090259; Lewis BJ, 2008, J NUCL MATER, V380, P126, DOI 10.1016/j.jnucmat.2008.07.005; Lewis BJ, 2012, COMPREHENSIVE NUCLEAR MATERIALS, VOL 2: MATERIAL PROPERTIES/OXIDE FUELS FOR LIGHT WATER REACTORS AND FAST NEUTRON REACTORS, P515; Oversby V. M., 1994, MAT SCI TECHNOLOGY B, V10B; Rogovin M., 1980, NUREGCR1250 US NUCL; Sattonnay G, 2001, J NUCL MATER, V288, P11, DOI 10.1016/S0022-3115(00)00714-5; Shoesmith DW, 2000, J NUCL MATER, V282, P1, DOI 10.1016/S0022-3115(00)00392-5; SHOESMITH DW, 1992, J NUCL MATER, V190, P20, DOI 10.1016/0022-3115(92)90072-S; Shvareva TY, 2011, GEOCHIM COSMOCHIM AC, V75, P5269, DOI 10.1016/j.gca.2011.06.041; Suzuki Y, 2002, NATURE, V419, P134, DOI 10.1038/419134a; WAITE TD, 1994, GEOCHIM COSMOCHIM AC, V58, P5465, DOI 10.1016/0016-7037(94)90243-7	40	335	342	37	477	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1184	1188		10.1126/science.1211285	http://dx.doi.org/10.1126/science.1211285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403382				2022-12-28	WOS:000301225100034
J	Kim, J; Hanna, JA; Byun, M; Santangelo, CD; Hayward, RC				Kim, Jungwook; Hanna, James A.; Byun, Myunghwan; Santangelo, Christian D.; Hayward, Ryan C.			Designing Responsive Buckled Surfaces by Halftone Gel Lithography	SCIENCE			English	Article							FABRICATION; ACTUATORS; MECHANICS; BEHAVIOR; SHEETS; LEAVES; THIN	Self-actuating materials capable of transforming between three-dimensional shapes have applications in areas as diverse as biomedicine, robotics, and tunable micro-optics. We introduce a method of photopatterning polymer films that yields temperature-responsive gel sheets that can transform between a flat state and a prescribed three-dimensional shape. Our approach is based on poly(N-isopropylacrylamide) copolymers containing pendent benzophenone units that allow cross-linking to be tuned by irradiation dose. We describe a simple method of halftone gel lithography using only two photomasks, wherein highly cross-linked dots embedded in a lightly cross-linked matrix provide access to nearly continuous, and fully two-dimensional, patterns of swelling. This method is used to fabricate surfaces with constant Gaussian curvature (spherical caps, saddles, and cones) or zero mean curvature (Enneper's surfaces), as well as more complex and nearly closed shapes.	[Hanna, James A.; Santangelo, Christian D.] Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Santangelo, CD (corresponding author), Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA.	csantang@physics.umass.edu; rhayward@mail.pse.umass.edu	Hayward, Ryan C/P-4745-2016; Santangelo, Christian D/A-5665-2012; Byun, Myunghwan/M-1678-2019	Hayward, Ryan C/0000-0001-6483-2234; Byun, Myunghwan/0000-0001-8331-2883	Army Research Office [W911NF-11-1-0080]; National Science Foundation [DMR-0846582, BBS-8714235]; NSF Materials Research Science and Engineering Center at the University of Massachusetts [DMR-0747756]; Direct For Mathematical & Physical Scien [0846582] Funding Source: National Science Foundation	Army Research Office; National Science Foundation(National Science Foundation (NSF)); NSF Materials Research Science and Engineering Center at the University of Massachusetts; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We acknowledge stimulating discussions with M. M. Muller and E. Sharon at the Aspen Center for Physics, where part of this work was done. This research was funded by the Army Research Office through W911NF-11-1-0080 and the National Science Foundation through DMR-0846582, and made use of facilities supported by the NSF Materials Research Science and Engineering Center at the University of Massachusetts (DMR-0747756) and NSF grant BBS-8714235.	Camacho-Lopez M, 2004, NAT MATER, V3, P307, DOI 10.1038/nmat1118; Cui Z, 2003, PROC SPIE, V4984, P111, DOI 10.1117/12.477831; Dervaux J, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.068101; Dias MA, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.036603; do Carmo M.P., 2017, DIFFERENTIAL GEOMETR, V2nd ed.; Efrati E, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.016602; Erdmann L, 2005, J MICROLITH MICROFAB, V4, DOI 10.1117/1.2114647; Feinberg AW, 2007, SCIENCE, V317, P1366, DOI 10.1126/science.1146885; GREEN PB, 1992, INT J PLANT SCI, V153, pS59, DOI 10.1086/297064; Howse JR, 2006, NANO LETT, V6, P73, DOI 10.1021/nl0520617; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; Ikeda T, 2003, ADV MATER, V15, P201, DOI 10.1002/adma.200390045; Jager EWH, 2000, SCIENCE, V290, P1540, DOI 10.1126/science.290.5496.1540; Kaehr B, 2008, P NATL ACAD SCI USA, V105, P8850, DOI 10.1073/pnas.0709571105; Klein Y, 2007, SCIENCE, V315, P1116, DOI 10.1126/science.1135994; Kofod G, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2695785; Kwon GH, 2008, SMALL, V4, P2148, DOI 10.1002/smll.200800315; Lendlein A, 2005, NATURE, V434, P879, DOI 10.1038/nature03496; Liang HY, 2011, P NATL ACAD SCI USA, V108, P5516, DOI 10.1073/pnas.1007808108; Muller MM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.156104; Nath U, 2003, SCIENCE, V299, P1404, DOI 10.1126/science.1079354; Peirce CS., 1879, AM, V2, P394, DOI [10.2307/2369491, DOI 10.2307/2369491]; Sharon E, 2004, AM SCI, V92, P254, DOI 10.1511/2004.47.932; Sharon E, 2002, NATURE, V419, P579, DOI 10.1038/419579a; Sharon E, 2010, SOFT MATTER, V6, P5693, DOI 10.1039/c0sm00479k; Toomey R, 2004, MACROMOLECULES, V37, P882, DOI 10.1021/ma034737v; White TJ, 2008, SOFT MATTER, V4, P1796, DOI 10.1039/b805434g	27	621	636	26	530	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1201	1205		10.1126/science.1215309	http://dx.doi.org/10.1126/science.1215309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403385				2022-12-28	WOS:000301225100038
J	Reynolds, EE; Trivedi, NS				Reynolds, Eileen E.; Trivedi, Neha S.			Update: A 37-Year-Old Man Trying to Choose a High-Quality Hospital Review of Hospital Quality Indicators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Trivedi, Neha/0000-0003-1006-1408				Howell MD, 2009, JAMA-J AM MED ASSOC, V302, P2353, DOI 10.1001/jama.2009.1684	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					965	965		10.1001/jama.2012.210	http://dx.doi.org/10.1001/jama.2012.210			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396518				2022-12-28	WOS:000301172100025
J	Zbieg, JR; Yamaguchi, E; McInturff, EL; Krische, MJ				Zbieg, Jason R.; Yamaguchi, Eiji; McInturff, Emma L.; Krische, Michael J.			Enantioselective C-H Crotylation of Primary Alcohols via Hydrohydroxyalkylation of Butadiene	SCIENCE			English	Article							TRANSITION-METAL CATALYSIS; OXIDATION LEVEL; TRANSFER HYDROGENATION; CARBONYL CROTYLATION; BRONSTED ACID; ALDEHYDES; ALLYLATION; REAGENTS; KETONES; COMPLEXES	The direct, by-product-free conversion of basic feedstocks to products of medicinal and agricultural relevance is a broad goal of chemical research. Butadiene is a product of petroleum cracking and is produced on an enormous scale (about 12 x 10(6) metric tons annually). Here, with the use of a ruthenium catalyst modified by a chiral phosphate counterion, we report the direct redox-triggered carbon-carbon coupling of alcohols and butadiene to form products of carbonyl crotylation with high levels of anti-diastereoselectivity and enantioselectivity in the absence of stoichiometric by-products.	[Zbieg, Jason R.; Yamaguchi, Eiji; McInturff, Emma L.; Krische, Michael J.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Krische, MJ (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA.	mkrische@mail.utexas.edu	Yamaguchi, Eiji/ABI-2594-2020		Robert A. Welch Foundation [F-0038]; NIH's National Institute of General Medical Sciences [RO1-GM069445]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069445] Funding Source: NIH RePORTER	Robert A. Welch Foundation(The Welch Foundation); NIH's National Institute of General Medical Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The Robert A. Welch Foundation (grant F-0038) and the NIH's National Institute of General Medical Sciences (grant RO1-GM069445) are acknowledged for financial support.	ALPER H, 1990, J AM CHEM SOC, V112, P2803, DOI 10.1021/ja00163a053; Bower JF, 2011, TOP ORGANOMETAL CHEM, V34, P107, DOI 10.1007/978-3-642-15334-1_5; BROWN HC, 1986, J AM CHEM SOC, V108, P293, DOI 10.1021/ja00262a017; BROWN HC, 1986, J AM CHEM SOC, V108, P5919, DOI 10.1021/ja00279a042; Busacca CA, 2011, ADV SYNTH CATAL, V353, P1825, DOI 10.1002/adsc.201100488; Butters M, 2006, CHEM REV, V106, P3002, DOI 10.1021/cr050982w; Denmark SE, 2003, CHEM REV, V103, P2763, DOI 10.1021/cr020050h; DOBSON A, 1975, J CHEM SOC DALTON, P370, DOI 10.1039/dt9750000370; Gao X, 2011, J AM CHEM SOC, V133, P12795, DOI 10.1021/ja204570w; Gao X, 2011, J ORG CHEM, V76, P2350, DOI 10.1021/jo200068q; Hamilton GL, 2007, SCIENCE, V317, P496, DOI 10.1126/science.1145229; Hassan A, 2011, ORG PROCESS RES DEV, V15, P1236, DOI 10.1021/op200195m; Hiraki K., 1985, CHEM SOC DALTON T, P873; HOFFMANN RW, 1979, TETRAHEDRON LETT, P4653; Jiang GX, 2011, CHEM COMMUN, V47, P10022, DOI 10.1039/c1cc12499d; Kim H, 2011, J AM CHEM SOC, V133, P6517, DOI 10.1021/ja200712f; Kim IS, 2009, J AM CHEM SOC, V131, P2514, DOI 10.1021/ja808857w; Kohlpaintner C. W, 1996, APPL HOMOGENEOUS CAT, P29; Komanduri V, 2006, J AM CHEM SOC, V128, P16448, DOI 10.1021/ja0673027; Liao SH, 2010, ANGEW CHEM INT EDIT, V49, P628, DOI 10.1002/anie.200905332; Magano J, 2011, CHEM REV, V111, P2177, DOI 10.1021/cr100346g; Maytum HC, 2007, ORG LETT, V9, P4387, DOI 10.1021/ol702029n; Mukherjee S, 2007, J AM CHEM SOC, V129, P11336, DOI 10.1021/ja074678r; Rueping M, 2007, ANGEW CHEM INT EDIT, V46, P6903, DOI 10.1002/anie.200702439; Sheldon RA, 2007, GREEN CHEM, V9, P1273, DOI 10.1039/b713736m; Shibahara F, 2008, J AM CHEM SOC, V130, P6338, DOI 10.1021/ja801213x; van Leeuwen P. W. N. M., 2004, HOMOGENEOUS CATALYSI, P139; Xu B, 2011, ANGEW CHEM INT EDIT, V50, P11483, DOI 10.1002/anie.201105485; Xue P, 2004, ORGANOMETALLICS, V23, P4735, DOI 10.1021/om049646g; Yus M, 2011, CHEM REV, V111, P7774, DOI 10.1021/cr1004474; Zbieg JR, 2011, J AM CHEM SOC, V133, P10582, DOI 10.1021/ja2046028; Zbieg JR, 2011, J AM CHEM SOC, V133, P1141, DOI 10.1021/ja1104156; Zbieg JR, 2010, ADV SYNTH CATAL, V352, P2416, DOI 10.1002/adsc.201000599	33	259	260	3	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 20	2012	336	6079					324	327		10.1126/science.1219274	http://dx.doi.org/10.1126/science.1219274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928PO	22442385	Green Accepted			2022-12-28	WOS:000302995400039
J	Berntorp, E; Shapiro, AD				Berntorp, Erik; Shapiro, Amy D.			Modern haemophilia care	LANCET			English	Review							IMMUNE TOLERANCE INDUCTION; RECOMBINANT FACTOR VIIA; PREVIOUSLY UNTREATED PATIENTS; QUALITY-OF-LIFE; PROSPECTIVE RANDOMIZED-TRIAL; MRI SCORING SYSTEM; INHIBITOR DEVELOPMENT; FACTOR-IX; PROPHYLACTIC TREATMENT; RISK-FACTORS	Haemophilia care has undergone substantial improvements during the past 40-50 years. Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s. Unfortunately, these advances led to transmission of viral diseases including HIV and hepatitis, resulting in an increased burden of morbidity and mortality, especially during the 1980s. Throughout the past two decades, product development, including the advent of recombinant concentrates, has greatly improved the safety and availability of therapy and the focus of care is shifting towards prevention and management of disease sequelae. Long-term substitution therapy (prophylaxis) of the missing clotting factor is the recommended treatment in severe haemophilia, but several research issues remain to be elucidated such as when to start and how to optimise these regimens, and when or whether to stop this expensive treatment. The major side-effect of treatment, development of inhibitors to the infused concentrate, is the main threat to the health of patients and consequently the goal of intense research. Development of new products with improved pharmacokinetics is the next step to improved therapy.	[Berntorp, Erik] Lund Univ, Skane Univ Hosp, Malmo Ctr Thrombosis & Haemostasis, Malmo, Sweden; [Shapiro, Amy D.] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA	Lund University; Skane University Hospital; Indiana Hemophilia & Thrombosis Center	Berntorp, E (corresponding author), Lund Univ, Skane Univ Hosp, Malmo Ctr Thrombosis & Haemostasis, Malmo, Sweden.	berntorp@med.lu.se			Baxter BioScience; Novo Nordisk; Bayer; Pfizer; CSL Behring; Octapharma	Baxter BioScience; Novo Nordisk(Novo Nordisk); Bayer(Bayer AG); Pfizer(Pfizer); CSL Behring; Octapharma	EB has received speaker's fees from Baxter BioScience, Novo Nordisk, Bayer, Pfizer, CSL Behring, and Octapharma; is on the Advisory Boards of Baxter BioScience, Novo Nordisk, Bayer, and Octapharma; and is on the Global Steering Committee; and is a consultant for Baxter BioScience, Biogen-Idec, and Swedish Orphan Biovitrum. ADS is a member of the Medical and Scientific Advisory Council of the National Hemophilia Foundation; is a member of the Board of Directors of the American Thrombosis and Hemostatis Network, is a member of the NHLBI Clinical Trial Review Board and NHLBI Data Safety Management Board at the National Institute of Health; has contributed to clinical research protocols for Eli Lily, Inspiration Biogen Pharmaceuticals, Biogen-Idec Pharmaceuticals, PTC Therapeutics, Bayer, Novo Nordisk, and Baxter BioScience; is a member of the Advisory Board for Inspiration Biopharmaceuticals, Novo Nordisk, and Baxter Bioscience; is a member of the Hemophilia Advisory Board-Global Steering Committee for Bayer; is a member of the Global Steering Committee for Baxter Bioscience; is a member of the Novo Nordisk Hemophilia Foundation. The Indiana Hemophilia and Thrombosis Center has received consultant or speaker's fees on ADS's behalf from Baxter BioScience, Novo Nordisk, Inspiration Biopharmaceuticals, and GTC Biotherapeutics.	ALEDORT LM, 1994, J INTERN MED, V236, P391, DOI 10.1111/j.1365-2796.1994.tb00815.x; Astermark J, 2007, J THROMB HAEMOST, V5, P263, DOI 10.1111/j.1538-7836.2007.02290.x; Astermark J, 2006, HAEMOPHILIA, V12, P363, DOI 10.1111/j.1365-2516.2006.01296.x; Astermark J, 2006, BLOOD, V107, P3167, DOI 10.1182/blood-2005-09-3918; Astermark J, 2010, HAEMOPHILIA, V16, P747, DOI 10.1111/j.1365-2516.2010.02231.x; Astermark J, 1999, BRIT J HAEMATOL, V105, P1109, DOI 10.1046/j.1365-2141.1999.01463.x; Astermark J, 2007, BLOOD, V109, P546, DOI 10.1182/blood-2006-04-017988; Astermark J, 2006, SEMIN HEMATOL, V43, pS3, DOI 10.1053/j.seminhematol.2006.03.006; Astermark J, 2006, BLOOD, V108, P3739, DOI 10.1182/blood-2006-05-024711; Baru M, 2005, THROMB HAEMOSTASIS, V93, P1061, DOI 10.1160/TH-04-08-0485; Beeton K, 2006, HAEMOPHILIA, V12, P102, DOI 10.1111/j.1365-2516.2006.01265.x; Berntorp E, 1995, B WORLD HEALTH ORGAN, V73, P691; Berntorp E, 2003, HAEMOPHILIA, V9, P1, DOI 10.1046/j.1365-2516.9.s1.17.x; BIGGS R, 1952, BRIT MED J, V2, P1378, DOI 10.1136/bmj.2.4799.1378; Bowman K, 2008, J CONTROL RELEASE, V132, P252, DOI 10.1016/j.jconrel.2008.06.019; BRACKMANN HH, 1977, LANCET, V2, P933; Calvez T, 2006, BRIT J HAEMATOL, V132, P798, DOI 10.1111/j.1365-2141.2006.05989.x; Carcao M, 2004, HAEMOPHILIA, V10, P50, DOI 10.1111/j.1355-0691.2004.00879.x; Carlsson KS, 2003, HAEMOPHILIA, V9, P555, DOI 10.1046/j.1365-2516.2003.00817.x; Carlsson M, 1998, HAEMOPHILIA, V4, P83; CARLSSON N, 1993, EUR J HAEMATOL, V51, P247; Chambost H, 2005, HAEMOPHILIA, V11, P92, DOI 10.1111/j.1365-2516.2005.01074.x; Chitlur M, 2009, HAEMOPHILIA, V15, P1027, DOI 10.1111/j.1365-2516.2009.02039.x; Colowick AB, 2000, BLOOD, V96, P1698, DOI 10.1182/blood.V96.5.1698; Darby SC, 2007, BLOOD, V110, P815, DOI 10.1182/blood-2006-10-050435; Dazzi F, 1996, BRIT J HAEMATOL, V93, P688, DOI 10.1046/j.1365-2141.1996.d01-1705.x; Dimichele D, 2007, J THROMB HAEMOST, V5, P143, DOI 10.1111/j.1538-7836.2007.02474.x; DiMichele D, 2006, HAEMOPHILIA, V12, P352, DOI 10.1111/j.1365-2516.2006.01284.x; DiMichele DM, 2006, J THROMB HAEMOST, V4, P2271, DOI 10.1111/j.1538-7836.2006.02127.x; Donadel-Claeyssens S, 2006, HAEMOPHILIA, V12, P124, DOI 10.1111/j.1365-2516.2006.01202.x; Doria AS, 2008, HAEMOPHILIA, V14, P303, DOI 10.1111/j.1365-2516.2007.01602.x; Doria AS, 2006, HAEMOPHILIA, V12, P503, DOI 10.1111/j.1365-2516.2006.01310.x; Doria AS, 2005, HAEMOPHILIA, V11, P245, DOI 10.1111/j.1365-2516.2005.01097.x; Ettingshausen CE, 2010, HAEMOPHILIA, V16, P90, DOI 10.1111/j.1365-2516.2009.02116.x; Ettingshausen CE, 2005, BLOOD COAGUL FIBRIN, V16, pS27, DOI 10.1097/01.mbc.0000167660.30886.e9; Ettingshausen CE, 2001, THROMB HAEMOSTASIS, V85, P218; Feldman BM, 2008, HAEMOPHILIA, V14, P162, DOI 10.1111/j.1365-2516.2008.01750.x; Feldman B M, 2007, Haemophilia, V13, P745, DOI 10.1111/j.1365-2516.2007.01542.x; Feldman BM, 2006, J THROMB HAEMOST, V4, P1228, DOI 10.1111/j.1538-7836.2006.01953.x; Fischer K, 2002, HAEMOPHILIA, V8, P753, DOI 10.1046/j.1365-2516.2002.00694.x; Forbes C., 1997, HAEMOPHILIA, P3; Franchini M, 2010, BRIT J HAEMATOL, V148, P522, DOI 10.1111/j.1365-2141.2009.08005.x; Franchini M, 2009, BLOOD COAGUL FIBRIN, V20, P225, DOI 10.1097/MBC.0b013e328329f265; GILBERT MS, 1993, SEMIN HEMATOL, V30, P3; Goudemand J, 2006, BLOOD, V107, P46, DOI 10.1182/blood-2005-04-1371; Gouw SC, 2007, BLOOD, V109, P4693, DOI 10.1182/blood-2006-11-056317; Gouw SC, 2007, BLOOD, V109, P4648, DOI 10.1182/blood-2006-11-056291; Gringeri A, 2011, J THROMB HAEMOST, V9, P700, DOI 10.1111/j.1538-7836.2011.04214.x; Healey JF, 2009, THROMB HAEMOSTASIS, V102, P35, DOI 10.1160/TH08-12-0818; Hilgartner MW, 2003, HAEMOPHILIA, V9, P261, DOI 10.1046/j.1365-2516.2003.00771.x; Hoots WK, 2008, HAEMOPHILIA, V14, P466, DOI 10.1111/j.1365-2516.2008.01654.x; Hvas AM, 2007, J THROMB HAEMOST, V5, P2408, DOI 10.1111/j.1538-7836.2007.02755.x; Ingerslev J, 2000, SEMIN THROMB HEMOST, V26, P425, DOI 10.1055/s-2000-8463; INGRAM GIC, 1976, J CLIN PATHOL, V29, P469, DOI 10.1136/jcp.29.6.469; Jimenez-Yuste V, 2008, HAEMOPHILIA, V14, P28, DOI 10.1111/j.1365-2516.2008.01887.x; Kavakli K, 2006, THROMB HAEMOSTASIS, V95, P600, DOI 10.1160/TH05-07-0510; Key NS, 2007, LANCET, V370, P439, DOI 10.1016/S0140-6736(07)61199-4; Konkle BA, 2007, J THROMB HAEMOST, V5, P1904, DOI 10.1111/j.1538-7836.2007.02663.x; Krudysz-Amblo J, 2009, BLOOD, V113, P2587, DOI 10.1182/blood-2008-08-174987; Leissinger C, 2010, 52 AM SOC HEM ANN M; Leissinger CA, 2007, HAEMOPHILIA, V13, P249, DOI 10.1111/j.1365-2516.2007.01442.x; Lethagen S, 2003, SEMIN THROMB HEMOST, V29, P101, DOI 10.1055/s-2003-37944; Ling M, 2003, J THROMB HAEMOST, V1, P2548, DOI 10.1046/j.1538-7836.2003.00477.x; Ljung RCR, 2002, HAEMOPHILIA, V8, P34, DOI 10.1046/j.1351-8216.2001.00118.x; Lundin B, 2005, HAEMOPHILIA, V11, P109, DOI 10.1111/j.1365-2516.2005.01049.x; Makris M, 2004, BLOOD COAGUL FIBRIN, V15, pS25, DOI 10.1097/00001721-200405001-00005; Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659; Manco-Johnson MJ, 2004, HAEMOPHILIA, V10, P88, DOI 10.1111/j.1365-2516.2004.00978.x; Mancuso ME, 2009, HAEMATOL-HEMATOL J, V94, P687, DOI 10.3324/haematol.2008.001594; Mannucci PM, 2009, BLOOD, V114, P5256, DOI 10.1182/blood-2009-07-215665; Mannucci PM, 1998, NEW ENGL J MED, V339, P245, DOI 10.1056/NEJM199807233390407; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; Mariani G, 2003, SEMIN THROMB HEMOST, V29, P69, DOI 10.1055/s-2003-37941; MARTINOWITZ U, 1992, BRIT J HAEMATOL, V82, P729, DOI 10.1111/j.1365-2141.1992.tb06951.x; Martinowitz U, 1996, CLIN ORTHOP RELAT R, P65; Mathews V, 2005, SEMIN THROMB HEMOST, V31, P538, DOI 10.1055/s-2005-922225; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MAUSERBUNSCHOTEN EP, 1995, BLOOD, V86, P983, DOI 10.1182/blood.V86.3.983.983; Mei BS, 2010, BLOOD, V116, P270, DOI 10.1182/blood-2009-11-254755; Miesbach W, 2009, HAMOSTASEOLOGIE, V29, pS29; Montgomery RR, 2010, HEMATOL-AM SOC HEMAT, P197, DOI 10.1182/asheducation-2010.1.197; NILSSON IM, 1992, J INTERN MED, V232, P25, DOI 10.1111/j.1365-2796.1992.tb00546.x; NILSSON IM, 1988, NEW ENGL J MED, V318, P947, DOI 10.1056/NEJM198804143181503; Oldenburg J, 2002, HAEMOPHILIA, V8, P23, DOI 10.1046/j.1351-8216.2001.00134.x; Oldenburg J, 1999, VOX SANG, V77, P49, DOI 10.1159/000056717; Ota S, 2007, HAEMOPHILIA, V13, P12, DOI 10.1111/j.1365-2516.2006.01409.x; Paleyanda RK, 1997, NAT BIOTECHNOL, V15, P971, DOI 10.1038/nbt1097-971; Pavlova A, 2009, J THROMB HAEMOST, V7, P2006, DOI 10.1111/j.1538-7836.2009.03636.x; Peters RT, 2010, BLOOD, V115, P2057, DOI 10.1182/blood-2009-08-239665; PETTERSSON H, 1980, CLIN ORTHOP RELAT R, P153; Pierce GF, 2007, J THROMB HAEMOST, V5, P901, DOI 10.1111/j.1538-7836.2007.02410.x; Quintana-Molina M, 2004, HAEMOPHILIA, V10, P30, DOI 10.1111/j.1365-2516.2004.00938.x; RAMGREN O, 1962, ACTA MED SCAND, V171, P237; Rangarajan S, 2011, HAEMOPHILIA, V17, P28, DOI 10.1111/j.1365-2516.2010.02360.x; Rodriguez-Merchan EC, 2010, HAEMOPHILIA, V16, P84, DOI 10.1111/j.1365-2516.2010.02223.x; Rodriguez-Merchan EC, 2004, SEMIN HEMATOL, V41, P109, DOI 10.1053/j.seminhematol.2003.11.020; Rogaev EI, 2009, SCIENCE, V326, P817, DOI 10.1126/science.1180660; Roosendaal G, 2003, SEMIN THROMB HEMOST, V29, P37, DOI 10.1055/s-2003-37938; Rottensteiner H, 2007, BLOOD, V11; Santagostino E, 2006, J THROMB HAEMOST, V4, P367, DOI 10.1111/j.1538-7836.2006.01772.x; Santagostino E, 2005, BRIT J HAEMATOL, V130, P422, DOI 10.1111/j.1365-2141.2005.05605.x; Scharrer I, 1999, HAEMOPHILIA, V5, P145; Scharrer I, 1999, HAEMOPHILIA, V5, P253; Shapiro AD, 1998, THROMB HAEMOSTASIS, V80, P773; Sharathkumar AA, 2011, HAEMOPHILIA, V17, P597, DOI 10.1111/j.1365-2516.2010.02463.x; Siboni SM, 2009, J THROMB HAEMOST, V7, P780, DOI 10.1111/j.1538-7836.2009.03318.x; Spira J, 2008, THROMB HAEMOSTASIS, V100, P429, DOI 10.1160/TH08-03-0133; Spira J, 2006, BLOOD, V108, P3668, DOI 10.1182/blood-2006-03-008276; Srivastava A, 2004, BRIT J HAEMATOL, V127, P12, DOI 10.1111/j.1365-2141.2004.05110.x; Srivastava A, 2003, HAEMOPHILIA, V9, P391, DOI 10.1046/j.1365-2516.2003.00766.x; Stonebraker JS, 2010, HAEMOPHILIA, V16, P20, DOI 10.1111/j.1365-2516.2009.02127.x; Ter Avest PC, 2008, J THROMB HAEMOST, V6, P2048, DOI 10.1111/j.1538-7836.2008.03187.x; Tjonnfjord GE, 2006, SEMIN HEMATOL, V43, pS18, DOI 10.1053/j.seminhematol.2006.03.003; Valentino LA, 2009, HAEMOPHILIA, V15, P733, DOI 10.1111/j.1365-2516.2009.01980.x; Van Cott KE, 1999, GENET ANAL-BIOMOL E, V15, P155, DOI 10.1016/S1050-3862(99)00020-0; Van Cott KE, 2004, HAEMOPHILIA, V10, P70, DOI 10.1111/j.1365-2516.2004.00983.x; van den Berg HM, 2001, BRIT J HAEMATOL, V112, P561, DOI 10.1046/j.1365-2141.2001.02580.x; van Dijk K, 2005, HAEMOPHILIA, V11, P438, DOI 10.1111/j.1365-2516.2005.01124.x; van Dijk K, 2005, BRIT J HAEMATOL, V130, P107, DOI 10.1111/j.1365-2141.2005.05546.x; Vance RE, 2000, J IMMUNOL, V165, P1725, DOI 10.4049/jimmunol.165.4.1725; VANCREVE.S, 1971, LANCET, V1, P449; Verma D, 2010, P NATL ACAD SCI USA, V107, P7101, DOI 10.1073/pnas.0912181107; Viel KR, 2009, NEW ENGL J MED, V360, P1618, DOI 10.1056/NEJMoa075760; Webster R, 2007, DRUG METAB DISPOS, V35, P9, DOI 10.1124/dmd.106.012419; Weimer T, 2008, THROMB HAEMOSTASIS, V99, P659, DOI 10.1160/TH07-08-0525; White GC, 2001, THROMB HAEMOSTASIS, V85, P560, DOI 10.1055/s-0037-1615621; Wight J, 2003, HAEMOPHILIA, V9, P436, DOI 10.1046/j.1365-2516.2003.00781.x; Yee TT, 2002, HAEMOPHILIA, V8, P76, DOI 10.1046/j.1365-2516.2002.00630.x; Yokoyama S, 2011, HPB, V13, P40, DOI 10.1111/j.1477-2574.2010.00237.x; Young G, 2008, HAEMOPHILIA, V14, P287, DOI 10.1111/j.1365-2516.2007.01601.x	130	217	225	1	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2012	379	9824					1447	1456		10.1016/S0140-6736(11)61139-2	http://dx.doi.org/10.1016/S0140-6736(11)61139-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926BR	22456059				2022-12-28	WOS:000302806800033
J	Bazzini, AA; Lee, MT; Giraldez, AJ				Bazzini, Ariel A.; Lee, Miler T.; Giraldez, Antonio J.			Ribosome Profiling Shows That miR-430 Reduces Translation Before Causing mRNA Decay in Zebrafish	SCIENCE			English	Article							DEADENYLATION IN-VITRO; MEDIATED DEADENYLATION; LET-7 MICRORNA; REPRESSION; INITIATION; INHIBITION; GW182; CCR4-NOT; ELEGANS; TARGETS	MicroRNAs regulate gene expression through deadenylation, repression, and messenger RNA (mRNA) decay. However, the contribution of each mechanism in non-steady-state situations remains unclear. We monitored the impact of miR-430 on ribosome occupancy of endogenous mRNAs in wild-type and dicer mutant zebrafish embryos and found that miR-430 reduces the number of ribosomes on target mRNAs before causing mRNA decay. Translational repression occurs before complete deadenylation, and disrupting deadenylation with use of an internal polyadenylate tail did not block target repression. Lastly, we observed that ribosome density along the length of the message remains constant, suggesting that translational repression occurs by reducing the rate of initiation rather than affecting elongation or causing ribosomal drop-off. These results show that miR-430 regulates translation initiation before inducing mRNA decay during zebrafish development.	[Bazzini, Ariel A.; Lee, Miler T.; Giraldez, Antonio J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Giraldez, Antonio J.] Yale Univ, Sch Med, Yale Stem Cell Ctr, New Haven, CT 06510 USA	Yale University; Yale University	Giraldez, AJ (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.	antonio.giraldez@yale.edu		Giraldez, Antonio/0000-0002-6823-137X	Pew Fellows Program in Biomedical Sciences; Pew Scholars Program in the Biomedical Sciences; Yale Scholar Program; NIH [R01GM081602-05]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [F32HD071697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081602, R01GM102251] Funding Source: NIH RePORTER	Pew Fellows Program in Biomedical Sciences; Pew Scholars Program in the Biomedical Sciences; Yale Scholar Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. Wolin and the Wolin laboratory for vital intellectual and technical support and access to equipment and reagents; N. Ignolia, J. Weissman, D. Schoenberg, D. Patil, A. Staton, C. Takacs, and Y. Mishima for reagents and discussions; and S. Baserga, D. Cazalla, D. Cifuentes, and S. Moxon for discussions. Supported by the Pew Fellows Program in Biomedical Sciences (A. A. B.), the Pew Scholars Program in the Biomedical Sciences, the Yale Scholar Program, and NIH grants R01GM081602-05 (A. J. G).; Contributions: A. A. B. and A. J. G. designed the project. A. A. B. performed the experiments. A. A. B. and M. T. L. performed data analysis. A. A. B., M. T. L., and A.J.G. interpreted the data and wrote the manuscript. Sequencing data are deposited in the Gene Expression Omnibus (GEO) database with accession number GSE34743.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Beilharz TH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006783; Braun JE, 2011, MOL CELL, V44, P120, DOI 10.1016/j.molcel.2011.09.007; Chekulaeva M, 2011, NAT STRUCT MOL BIOL, V18, P1218, DOI 10.1038/nsmb.2166; Cooke A, 2010, J BIOL CHEM, V285, P28506, DOI 10.1074/jbc.M110.150763; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Eulalio A, 2009, RNA, V15, P21, DOI 10.1261/rna.1399509; Fabian MR, 2011, NAT STRUCT MOL BIOL, V18, P1211, DOI 10.1038/nsmb.2149; Fabian MR, 2011, METHODS MOL BIOL, V725, P207, DOI 10.1007/978-1-61779-046-1_14; Fabian MR, 2009, MOL CELL, V35, P868, DOI 10.1016/j.molcel.2009.08.004; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fukaya T, 2011, EMBO J, V30, P4998, DOI 10.1038/emboj.2011.426; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hendrickson DG, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000238; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; Mishima Y, 2012, P NATL ACAD SCI USA, V109, P1104, DOI 10.1073/pnas.1113350109; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Thermann R, 2007, NATURE, V447, P875, DOI 10.1038/nature05878; Wu E, 2010, MOL CELL, V40, P558, DOI 10.1016/j.molcel.2010.11.003; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Zdanowicz A, 2009, MOL CELL, V35, P881, DOI 10.1016/j.molcel.2009.09.009	29	514	522	7	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 13	2012	336	6078					233	237		10.1126/science.1215704	http://dx.doi.org/10.1126/science.1215704			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924PN	22422859	Green Accepted			2022-12-28	WOS:000302703900051
J	Spaulding, AC; Thomas, DL				Spaulding, Anne C.; Thomas, David L.			Screening for HCV Infection in Jails	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							C VIRUS-INFECTION; HEPATITIS-C; PUBLIC-HEALTH		[Spaulding, Anne C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30033 USA; [Thomas, David L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Emory University; Rollins School Public Health; Johns Hopkins University	Spaulding, AC (corresponding author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd,Room 3033, Atlanta, GA 30033 USA.	aspauld@emory.edu			NIDA NIH HHS [R01 DA016078, DA R01 016078] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016078] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Colvin HM, HEPATITIS LIVER CANC; Flanigan TP, 2010, JAIDS-J ACQ IMM DEF, V55, pS78, DOI 10.1097/QAI.0b013e3181fbc94f; Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641; Lok AS, 2012, NEW ENGL J MED, V366, P216, DOI 10.1056/NEJMoa1104430; Rein DB, 2012, ANN INTERN MED, V156, P263, DOI 10.7326/0003-4819-156-4-201202210-00378; Spaulding A, 1999, PREV MED, V28, P92, DOI 10.1006/pmed.1998.0418; Spaulding AC, 2009, PLOS ONE, V4, pA16, DOI 10.1371/journal.pone.0007558; US Department of Health and Human Services, COMB SIL EP VIR HEP	10	36	36	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1259	1260		10.1001/jama.2012.374	http://dx.doi.org/10.1001/jama.2012.374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453565	Green Accepted			2022-12-28	WOS:000301978400019
J	Morandi, B; Carreira, EM				Morandi, Bill; Carreira, Erick M.			Iron-Catalyzed Cyclopropanation in 6 M KOH with in Situ Generation of Diazomethane	SCIENCE			English	Article							CYCLOPROPENES; DERIVATIVES; CHEMISTRY; ALKENES	Diazomethane is a common and versatile reagent in organic synthesis whose broader use is generally impeded by its explosiveness and toxicity. Here we report that a simple iron porphyrin complex catalyzes the cyclopropanation of styrenes, enynes, and dienes under the demanding conditions [aqueous 6 molar potassium hydroxide (KOH) solution, open to air] necessary for the in situ generation of diazomethane from a water-soluble diazald derivative. A biphasic reaction medium arising from the immiscibility of the olefin substrates with water appears essential to the overall efficiency of the process. The work we describe highlights an approach to catalysis with untoward reactive intermediates, in which the conditions for their generation under operationally safe regimes dictate catalyst selection.	[Morandi, Bill; Carreira, Erick M.] Organ Chem Lab, CH-8093 Zurich, Switzerland		Carreira, EM (corresponding author), Organ Chem Lab, HCI H335,Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	carreira@org.chem.ethz.ch	Kishore, Gade/C-6943-2011	Kishore, Gade/0000-0003-0911-4381; Morandi, Bill/0000-0003-3968-1424; Carreira, Erick/0000-0003-1472-490X	Stipendienfonds der Schweizerischen Chemischen Industrie (SSCI); ETH-Zurich [0-20744-11]	Stipendienfonds der Schweizerischen Chemischen Industrie (SSCI); ETH-Zurich(ETH Zurich)	We are grateful to Stipendienfonds der Schweizerischen Chemischen Industrie (SSCI) for a fellowship to B.M. and to ETH-Zurich for generous support through grant 0-20744-11.	[Anonymous], 2004, ALDR TECHN B AL; [Anonymous], 2011, MAT DAT SAF SHEET N; DEBOER TJ, 1963, ORG SYNTH, V4, P250; Eistert B, 1941, ANGEW CHEM-GER EDIT, V54, P99, DOI 10.1002/ange.19410540703; Enthaler S, 2008, ANGEW CHEM INT EDIT, V47, P3317, DOI 10.1002/anie.200800012; Fulton JR, 2005, EUR J ORG CHEM, V2005, P1479, DOI 10.1002/ejoc.200400700; Health and Safety Executive, 2000, DES OP SAF CHEM REAC, P16; LEWINN EB, 1949, AM J MED SCI, V218, P556, DOI 10.1097/00000441-194911000-00011; MAAS G, 1987, TOP CURR CHEM, V137, P75; Maurya RA, 2011, ANGEW CHEM INT EDIT, V50, P5952, DOI 10.1002/anie.201101977; Moody D., 2008, International Patent, Patent No. [WO/2008/040947, 2008040947]; Morandi B, 2011, ORG LETT, V13, P3080, DOI 10.1021/ol200983s; Morandi B, 2011, ANGEW CHEM INT EDIT, V50, P1101, DOI 10.1002/anie.201004269; Morandi B, 2010, ANGEW CHEM INT EDIT, V49, P4294, DOI 10.1002/anie.201000787; Morandi B, 2010, ANGEW CHEM INT EDIT, V49, P938, DOI 10.1002/anie.200905573; NEFEDOV OM, 1992, MENDELEEV COMMUN, P13; Pliekter B., 2008, IRON CATALYSIS ORGAN; Proctor LD, 2002, ORG PROCESS RES DEV, V6, P884, DOI 10.1021/op020049k; Rubin M, 2007, CHEM REV, V107, P3117, DOI 10.1021/cr050988l; Salaun J, 2000, TOP CURR CHEM, V207, P1; Struempel M, 2009, ORG PROCESS RES DEV, V13, P1014, DOI 10.1021/op900081g; U.S. Department of Health and Human Services Public Health Service National Toxicology Program, 2011, REP CARC, P316; von Pechman H., 1895, CHEM BER-RECL, V28, P855, DOI [10.1002/cber.189502801189, DOI 10.1002/CBER.189502801189]; von Pechman H., 1894, CHEM BER-RECL, V27, P1888, DOI [10.1002/cber.189402702141, DOI 10.1002/CBER.189402702141]; WOLF JR, 1995, J AM CHEM SOC, V117, P9194, DOI 10.1021/ja00141a011; Wurz RP, 2002, ORG LETT, V4, P4531, DOI 10.1021/ol0270879; Yip KT, 2011, CHEM-ASIAN J, V6, P2165, DOI 10.1002/asia.201100242	27	150	157	4	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1471	1474		10.1126/science.1218781	http://dx.doi.org/10.1126/science.1218781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442479				2022-12-28	WOS:000301837000041
J	Schmerr, N				Schmerr, Nicholas			The Gutenberg Discontinuity: Melt at the Lithosphere-Asthenosphere Boundary	SCIENCE			English	Article							UPPER-MANTLE; LOW-VELOCITY; HEAT-FLOW; ORIGIN; WATER; TEMPERATURE; RHEOLOGY; ZONE	The lithosphere-asthenosphere boundary (LAB) beneath ocean basins separates the upper thermal boundary layer of rigid, conductively cooling plates from the underlying ductile, convecting mantle. The origin of a seismic discontinuity associated with this interface, known as the Gutenberg discontinuity (G), remains enigmatic. High-frequency SS precursors sampling below the Pacific plate intermittently detect the G as a sharp, negative velocity contrast at 40- to 75-kilometer depth. These observations lie near the depth of the LAB in regions associated with recent surface volcanism and mantle melt production and are consistent with an intermittent layer of asthenospheric partial melt residing at the lithospheric base. I propose that the G reflectivity is regionally enhanced by dynamical processes that produce melt, including hot mantle upwellings, small-scale convection, and fluid release during subduction.	[Schmerr, Nicholas] Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Schmerr, N (corresponding author), NASA, Goddard Space Flight Ctr, Planetary Geodynam Lab, Code 698, Greenbelt, MD 20771 USA.	nschmerr@dtm.ciw.edu	Schmerr, Nicholas/D-7338-2012	Schmerr, Nicholas/0000-0002-3256-1262	Carnegie Institution of Washington Department of Terrestrial Magnetism; NASA	Carnegie Institution of Washington Department of Terrestrial Magnetism; NASA(National Aeronautics & Space Administration (NASA))	This work was supported by a Carnegie Institution of Washington Department of Terrestrial Magnetism Postdoctoral Fellowship and by the NASA Postdoctoral Program. The facilities of the IRIS Data Management Center were used for access to the data required in this study. I am grateful to three anonymous referees for constructive comments and reviews. I appreciatively recognize the contribution to this work of many prior discussions with Paul Silver (deceased).	Anderson D.L., 1970, PHYS EARTH PLANET IN, V3, P41, DOI DOI 10.1016/0031-9201(70)90042-7; Ballmer MD, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031636; Conrad CP, 2011, NAT GEOSCI, V4, P317, DOI [10.1038/NGEO1111, 10.1038/ngeo1111]; Faul UH, 2005, EARTH PLANET SC LETT, V234, P119, DOI 10.1016/j.epsl.2005.02.008; Fischer KM, 2010, ANNU REV EARTH PL SC, V38, P551, DOI 10.1146/annurev-earth-040809-152438; Gaherty JB, 1996, J GEOPHYS RES-SOL EA, V101, P22291, DOI 10.1029/96JB01882; Gutenberg B., 1926, Z GEOPHYS, V2, P24; Hirschmann MM, 2010, PHYS EARTH PLANET IN, V179, P60, DOI 10.1016/j.pepi.2009.12.003; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Humler E, 1999, EARTH PLANET SC LETT, V173, P7, DOI 10.1016/S0012-821X(99)00218-6; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; KARATO S, 1993, SCIENCE, V260, P771, DOI 10.1126/science.260.5109.771; Karato SI, 2012, EARTH PLANET SC LETT, V321, P95, DOI 10.1016/j.epsl.2012.01.001; Kawakatsu H, 2009, SCIENCE, V324, P499, DOI 10.1126/science.1169499; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; Mitrovica JX, 1997, J GEOPHYS RES-SOL EA, V102, P2751, DOI 10.1029/96JB03175; Nettles M, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2006JB004819; PARSONS B, 1977, J GEOPHYS RES, V82, P803, DOI 10.1029/JB082i005p00803; Priestley K, 2006, EARTH PLANET SC LETT, V244, P285, DOI 10.1016/j.epsl.2006.01.008; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; Richards MA, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000115; Ritzwoller MH, 2004, EARTH PLANET SC LETT, V226, P69, DOI 10.1016/j.epsl.2004.07.032; Rychert CA, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB008070; Rychert CA, 2009, SCIENCE, V324, P495, DOI 10.1126/science.1169754; SATO H, 1989, J GEOPHYS RES-SOLID, V94, P5689, DOI 10.1029/JB094iB05p05689; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; Takei Y, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005850; Tan Y, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004853; Yuan HY, 2011, GEOPHYS J INT, V184, P1237, DOI 10.1111/j.1365-246X.2010.04901.x; Zhu WL, 2011, SCIENCE, V332, P88, DOI 10.1126/science.1202221	30	169	172	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1480	1483		10.1126/science.1215433	http://dx.doi.org/10.1126/science.1215433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442480				2022-12-28	WOS:000301837000044
J	Wang, LHV; Hu, S				Wang, Lihong V.; Hu, Song			Photoacoustic Tomography: In Vivo Imaging from Organelles to Organs	SCIENCE			English	Review							OPTICAL COHERENCE TOMOGRAPHY; MICROSCOPY; RESOLUTION; RECONSTRUCTION; ULTRASOUND	Photoacoustic tomography (PAT) can create multiscale multicontrast images of living biological structures ranging from organelles to organs. This emerging technology overcomes the high degree of scattering of optical photons in biological tissue by making use of the photoacoustic effect. Light absorption by molecules creates a thermally induced pressure jump that launches ultrasonic waves, which are received by acoustic detectors to form images. Different implementations of PAT allow the spatial resolution to be scaled with the desired imaging depth in tissue while a high depth-to-resolution ratio is maintained. As a rule of thumb, the achievable spatial resolution is on the order of 1/200 of the desired imaging depth, which can reach up to 7 centimeters. PAT provides anatomical, functional, metabolic, molecular, and genetic contrasts of vasculature, hemodynamics, oxygen metabolism, biomarkers, and gene expression. We review the state of the art of PAT for both biological and clinical studies and discuss future prospects.	[Wang, Lihong V.; Hu, Song] Washington Univ, Opt Imaging Lab, Dept Biomed Engn, St Louis, MO 63130 USA	Washington University (WUSTL)	Wang, LHV (corresponding author), Washington Univ, Opt Imaging Lab, Dept Biomed Engn, St Louis, MO 63130 USA.	lhwang@wustl.edu	Hu, Song/ABD-6256-2021; Wang, Lihong V./A-7147-2009	Hu, Song/0000-0002-5760-8012; Wang, Lihong V./0000-0001-9783-4383	NIH [R01 EB000712, R01 EB008085, R01 CA134539, U54 CA136398, R01 CA157277, R01 EB010049, R01 CA159959]; NATIONAL CANCER INSTITUTE [R01CA159959, R01CA134539, U54CA136398, R01CA157277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000712, R01EB008085, R01EB010049] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank J. Ballard for close reading of the manuscript, and J. Yao for providing Fig. 3H. Supported by NIH grants R01 EB000712, R01 EB008085, R01 CA134539, U54 CA136398, R01 CA157277, R01 EB010049, and R01 CA159959. L.V.W. has financial interests in Microphotoacoustics Inc. and Endra Inc., which, however, did not support this work.	Brecht HP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3259361; Culver JP, 2001, OPT LETT, V26, P701, DOI 10.1364/OL.26.000701; De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231; Erpelding TN, 2010, RADIOLOGY, V256, P102, DOI 10.1148/radiol.10091772; Fang H, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.184501; Favazza CP, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3528661; Finch D, 2004, SIAM J MATH ANAL, V35, P1213, DOI 10.1137/S0036141002417814; Guo ZJ, 2009, MED PHYS, V36, P4084, DOI 10.1118/1.3187231; Hu S., 2010, FRONT NEUROENERG, V2; Hu S, 2011, OPT LETT, V36, P1134, DOI 10.1364/OL.36.001134; Hu S, 2010, OPT LETT, V35, P1, DOI 10.1364/OL.35.000001; Hu S, 2009, OPT LETT, V34, P3899, DOI 10.1364/OL.34.003899; Jansen K, 2011, OPT LETT, V36, P597, DOI 10.1364/OL.36.000597; Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967; Jin YD, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1042; Kim C, 2010, BIOMED OPT EXPRESS, V1, P278, DOI 10.1364/BOE.1.000278; Kim C, 2010, ACS NANO, V4, P4559, DOI 10.1021/nn100736c; Kostli KP, 2001, IEEE J SEL TOP QUANT, V7, P918, DOI 10.1109/2944.983294; Kruger RA, 2010, MED PHYS, V37, P6096, DOI 10.1118/1.3497677; Li CH, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302807; Li L, 2008, J INNOV OPT HEAL SCI, V1, P207, DOI 10.1142/S1793545808000212; Maslov K, 2008, OPT LETT, V33, P929, DOI 10.1364/OL.33.000929; Maslov K, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2904965; Oladipupo S, 2011, P NATL ACAD SCI USA, V108, P13264, DOI 10.1073/pnas.1101321108; Oladipupo SS, 2011, BLOOD, V117, P4142, DOI 10.1182/blood-2010-09-307538; Pramanik M, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3247155; Razansky D, 2007, OPT LETT, V32, P2891, DOI 10.1364/OL.32.002891; Razansky D, 2009, NAT PHOTONICS, V3, P412, DOI 10.1038/NPHOTON.2009.98; Shah J, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2940362; Song KH, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2818045; Song LA, 2011, OPT LETT, V36, P1236, DOI 10.1364/OL.36.001236; Wang B, 2009, NANO LETT, V9, P2212, DOI 10.1021/nl801852e; Wang HW, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.238106; Wang L. V., 2011, I NEWT I MATH SCI IN; Wang LV, 2008, IEEE J SEL TOP QUANT, V14, P171, DOI 10.1109/JSTQE.2007.913398; Wang LV, 2009, NAT PHOTONICS, V3, P503, DOI 10.1038/NPHOTON.2009.157; Wang LV., 2012, BIOMEDICAL OPTICS PR; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Xu MH, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.016706; Xu MH, 2002, IEEE T MED IMAGING, V21, P814, DOI 10.1109/TMI.2002.801176; Xu XA, 2011, NAT PHOTONICS, V5, P154, DOI 10.1038/NPHOTON.2010.306; Xu Y, 2004, MED PHYS, V31, P724, DOI 10.1118/1.1644531; Xu Z, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3584847; Yang JM, 2012, PROC SPIE, V8223, DOI 10.1117/12.909163; Yang JM, 2009, OPT LETT, V34, P1591, DOI 10.1364/OL.34.001591; Yang Y, 2011, BIOMED OPT EXPRESS, V2, P2551, DOI 10.1364/BOE.2.002551; Yao DK, 2010, OPT LETT, V35, P4139, DOI 10.1364/OL.35.004139; Yao JJ, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3594786; Yao JJ, 2010, OPT LETT, V35, P1419, DOI 10.1364/OL.35.001419; Zemp RJ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2709850; Zhang C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.2.020501; Zhang C, 2010, OPT LETT, V35, P3195, DOI 10.1364/OL.35.003195; Zhang EZ, 2011, BIOMED OPT EXPRESS, V2, P2202, DOI 10.1364/BOE.2.002202; Zhang HF, 2006, NAT BIOTECHNOL, V24, P848, DOI 10.1038/nbt1220	54	2960	3063	114	1823	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1458	1462		10.1126/science.1216210	http://dx.doi.org/10.1126/science.1216210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442475	Green Accepted			2022-12-28	WOS:000301837000036
J	Smith, J				Smith, Jeremy			A Display of Affection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Wisconsin, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Smith, J (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	jpsmith@medicine.wisc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1149	1150		10.1001/jama.2012.314	http://dx.doi.org/10.1001/jama.2012.314			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436954				2022-12-28	WOS:000301708000022
J	Pallan, S; Rahman, MO; Khan, AA				Pallan, Shelley; Rahman, Mohammed Omair; Khan, Aliya A.			Diagnosis and management of primary hyperparathyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BONE-MINERAL DENSITY; MILD PRIMARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN; ORAL ALENDRONATE; SURGERY; PARATHYROIDECTOMY; RISK; PATHOPHYSIOLOGY; RADIATION		[Pallan, Shelley; Khan, Aliya A.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Rahman, Mohammed Omair] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada	McMaster University; McMaster University	Khan, AA (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	aliya@mcmaster.ca			Amgen; Merck; NPS	Amgen(Amgen); Merck(Merck & Company); NPS	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; AK has received investigator initiated research funding from Amgen, Merck, and NPS in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Adami S, 2002, J BONE MINER RES, V17, pN18; Al-Azem H, 2011, CAN MED ASSOC J, V183, pE685, DOI 10.1503/cmaj.090675; Ambrogini E, 2007, J CLIN ENDOCR METAB, V92, P3114, DOI 10.1210/jc.2007-0219; BEARD CM, 1989, ARCH INTERN MED, V149, P1887, DOI 10.1001/archinte.149.8.1887; Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008-1763; Bollerslev J, 2007, J CLIN ENDOCR METAB, V92, P1687, DOI 10.1210/jc.2006-1836; Bollerslev J, 2009, J CLIN ENDOCR METAB, V94, P2255, DOI 10.1210/jc.2008-2742; Cheung K, 2012, ANN SURG ONCOL, V19, P577, DOI 10.1245/s10434-011-1870-5; Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002-020890; Eastell R, 2009, J CLIN ENDOCR METAB, V94, P340, DOI 10.1210/jc.2008-1758; Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003-4819-125-5-199609010-00002; Haden ST, 1997, J CLIN ENDOCR METAB, V82, P2844, DOI 10.1210/jc.82.9.2844; Khan A, 2000, CAN MED ASSOC J, V163, P184; Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003-030908; Khan AA, 2003, ENDOCR PRACT, V9; Khan A, 2009, J CLIN ENDOCR METAB, V94, P373, DOI 10.1210/jc.2008-1762; Khan AA, 2009, J CLIN ENDOCR METAB, V94, P333, DOI 10.1210/jc.2008-1757; Lowe H, 2007, J CLIN ENDOCR METAB, V92, P3001, DOI 10.1210/jc.2006-2802; Mollerup CL, 2002, BMJ-BRIT MED J, V325, P807, DOI 10.1136/bmj.325.7368.807; Morris GS, 2010, ANN SURG, V251, P832, DOI 10.1097/SLA.0b013e3181d76bb3; Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004-0842; Phitayakorn R, 2006, AM J SURG, V191, P418, DOI 10.1016/j.amjsurg.2005.10.049; Rao DS, 2004, J CLIN ENDOCR METAB, V89, P5415, DOI 10.1210/jc.2004-0028; Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113; Rubin Mishaela R, 2002, Curr Rheumatol Rep, V4, P179, DOI 10.1007/s11926-002-0014-0; Rubin MR, 2003, J CLIN ENDOCR METAB, V88, P1174, DOI 10.1210/jc.2002-020667; Sankaran S, 2010, J CLIN ENDOCR METAB, V95, P1653, DOI 10.1210/jc.2009-2384; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; Silverberg SJ, 2009, J CLIN ENDOCR METAB, V94, P351, DOI 10.1210/jc.2008-1760; Silverberg SJ, 1999, NEW ENGL J MED, V341, P1249, DOI 10.1056/NEJM199910213411701; Starker LF, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/206502; Stefenelli T, 1997, J CLIN ENDOCR METAB, V82, P106, DOI 10.1210/jc.82.1.106; Tfelt-Hansen J, 2005, CRIT REV CL LAB SCI, V42, P35, DOI 10.1080/10408360590886606; Udelsman R, 2009, J CLIN ENDOCR METAB, V94, P366, DOI 10.1210/jc.2008-1761; VanderWalde LH, 2009, WORLD J SURG, V33, P406, DOI 10.1007/s00268-008-9720-8; Vignali E, 2009, J CLIN ENDOCR METAB, V94, P2306, DOI 10.1210/jc.2008-2006; Wermers RA, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.07.044	37	62	67	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2012	344								e1013	10.1136/bmj.e1013	http://dx.doi.org/10.1136/bmj.e1013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431655				2022-12-28	WOS:000301848400001
J	Malhotra, D; Sebat, J				Malhotra, Dheeraj; Sebat, Jonathan			CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics	CELL			English	Review							COPY-NUMBER VARIATION; AUTISM SPECTRUM DISORDERS; VASOACTIVE-INTESTINAL-PEPTIDE; DE-NOVO CNVS; BIPOLAR-DISORDER; STRUCTURAL VARIATION; RECURRENT REARRANGEMENTS; MICRODELETION SYNDROME; MENTAL-RETARDATION; HIGH-RISK	The genetic bases of neuropsychiatric disorders are beginning to yield to scientific inquiry. Genome-wide studies of copy number variation (CNV) have given rise to a new understanding of disease etiology, bringing rare variants to the forefront. A proportion of risk for schizophrenia, bipolar disorder, and autism can be explained by rare mutations. Such alleles arise by de novo mutation in the individual or in recent ancestry. Alleles can have specific effects on behavioral and neuroanatomical traits; however, expressivity is variable, particularly for neuropsychiatric phenotypes. Knowledge from CNV studies reflects the nature of rare alleles in general and will serve as a guide as we move forward into a new era of whole-genome sequencing.	[Malhotra, Dheeraj; Sebat, Jonathan] Univ Calif San Diego, Beyster Ctr Genom Psychiat Dis, La Jolla, CA 92093 USA; [Malhotra, Dheeraj; Sebat, Jonathan] Univ Calif San Diego, Dept Psychiat, La Jolla, CA USA; [Sebat, Jonathan] Univ Calif San Diego, Dept Cellular Mol & Mol Med, La Jolla, CA USA; [Sebat, Jonathan] Univ Calif San Diego, Inst Genom Med, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Sebat, J (corresponding author), Univ Calif San Diego, Beyster Ctr Genom Psychiat Dis, La Jolla, CA 92093 USA.	jsebat@ucsd.edu		Sebat, Jonathan/0000-0002-9087-526X	NIH [MH076431, HG05725]; NARSAD; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG004222, U01HG005725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH094411, R01MH076431] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NARSAD(NARSAD); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors would like to thank Ryan Mills, Klaudia Walter, Jan Korbel, and the 1000 Genomes Project for use of Figure 2A from their manuscript. We thank Andy Itsara and Evan Eichler for providing CNV call sets on autism genetic research exchange (AGRE) samples. Work in Sebat laboratory is supported by NIH grants to J.S. (MH076431, HG05725), NARSAD grant to J.S., and a gift to J.S. from the Beyster family foundation.	Alkan C, 2011, NAT REV GENET, V12, P363, DOI 10.1038/nrg2958; Alkuraya FS, 2010, GENET MED, V12, P236, DOI 10.1097/GIM.0b013e3181ceb95d; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Bakkaloglu B, 2008, AM J HUM GENET, V82, P165, DOI 10.1016/j.ajhg.2007.09.017; Ballif BC, 2008, MOL CYTOGENET, V1, DOI 10.1186/1755-8166-1-8; Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802; Berkel S, 2010, NAT GENET, V42, P489, DOI 10.1038/ng.589; Bijlsma EK, 2009, EUR J MED GENET, V52, P77, DOI 10.1016/j.ejmg.2009.03.006; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Bourgeron T, 2009, CURR OPIN NEUROBIOL, V19, P231, DOI 10.1016/j.conb.2009.06.003; Braun MM, 2010, NAT REV DRUG DISCOV, V9, P519, DOI 10.1038/nrd3160; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Brunetti-Pierri N, 2008, NAT GENET, V40, P1466, DOI 10.1038/ng.279; Bucan M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000536; Buizer-Voskamp JE, 2011, BIOL PSYCHIAT, V70, P655, DOI 10.1016/j.biopsych.2011.02.015; Burnside R, 2011, HUM GENET, V130, P517, DOI 10.1007/s00439-011-0970-4; Carvalho CMB, 2011, NAT GENET, V43, P1074, DOI 10.1038/ng.944; Chaudhury D, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-63; Cheung AYL, 2011, HUM MOL GENET, V20, P2103, DOI 10.1093/hmg/ddr093; Clayton-Smith J, 2010, CLIN DYSMORPHOL, V19, P128, DOI 10.1097/MCD.0b013e32833a1e3c; Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Cooper GM, 2011, NAT GENET, V43, P838, DOI 10.1038/ng.909; Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640; Devriendt K, 1998, J MED GENET, V35, P789, DOI 10.1136/jmg.35.9.789-a; Dolmetsch R, 2011, CELL, V145, P831, DOI 10.1016/j.cell.2011.05.034; Doornbos M, 2009, EUR J MED GENET, V52, P108, DOI 10.1016/j.ejmg.2009.03.010; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Elia J, 2012, NAT GENET, V44, P78, DOI 10.1038/ng.1013; Etherton MR, 2009, P NATL ACAD SCI USA, V106, P17998, DOI 10.1073/pnas.0910297106; Faraone SV, 2003, BIOL PSYCHIAT, V53, P970, DOI 10.1016/S0006-3223(02)01893-0; Fernandez BA, 2010, J MED GENET, V47, P195, DOI 10.1136/jmg.2009.069369; Fernandez T, 2004, AM J HUM GENET, V74, P1286, DOI 10.1086/421474; Fernandez T, 2008, AM J HUM GENET, V82, P1385, DOI 10.1016/j.ajhg.2008.04.021; FOLSTEIN S, 1977, NATURE, V265, P726, DOI 10.1038/265726a0; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Freitag CM, 2010, EUR CHILD ADOLES PSY, V19, P169, DOI 10.1007/s00787-009-0076-x; Gauthier J, 2009, AM J MED GENET B, V150B, P421, DOI 10.1002/ajmg.b.30822; Gillberg C, 1998, J AUTISM DEV DISORD, V28, P415, DOI 10.1023/A:1026004505764; Gilman SR, 2011, NEURON, V70, P898, DOI 10.1016/j.neuron.2011.05.021; Girard SL, 2011, NAT GENET, V43, P860, DOI 10.1038/ng.886; Girirajan S, 2010, HUM MOL GENET, V19, pR176, DOI 10.1093/hmg/ddq366; Girirajan S, 2010, NAT GENET, V42, P203, DOI 10.1038/ng.534; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Grigoroiu-Serbanescu M, 2001, AM J MED GENET, V105, P765, DOI 10.1002/ajmg.10047; Grozeva D, 2012, SCHIZOPHR RES, V135, P1, DOI 10.1016/j.schres.2011.11.004; Grozeva D, 2010, ARCH GEN PSYCHIAT, V67, P318, DOI 10.1001/archgenpsychiatry.2010.25; Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Hastings PJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000327; Hirasawa R, 2010, ESSAYS BIOCHEM, V48, P187, DOI [10.1042/bse0480187, 10.1042/BSE0480187]; Horev G, 2011, P NATL ACAD SCI USA, V108, P17076, DOI 10.1073/pnas.1114042108; Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ingason A, 2011, MOL PSYCHIATR, V16, P17, DOI 10.1038/mp.2009.101; Ingason A, 2011, AM J PSYCHIAT, V168, P408, DOI 10.1176/appi.ajp.2010.09111660; Itsara A, 2010, GENOME RES, V20, P1469, DOI 10.1101/gr.107680.110; Jacquemont S, 2011, NATURE, V478, P97, DOI 10.1038/nature10406; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Judd LL, 2005, ARCH GEN PSYCHIAT, V62, P1322, DOI 10.1001/archpsyc.62.12.1322; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Kim HG, 2008, AM J HUM GENET, V82, P199, DOI 10.1016/j.ajhg.2007.09.011; Kirov G, 2012, MOL PSYCHIATR, V17, P142, DOI 10.1038/mp.2011.154; Kirov G, 2009, HUM MOL GENET, V18, P1497, DOI 10.1093/hmg/ddp043; Klein RJ, 2010, CELL, V142, P350, DOI 10.1016/j.cell.2010.07.026; Krueger DD, 2011, ANNU REV MED, V62, P411, DOI 10.1146/annurev-med-061109-134644; Lam KWG, 2007, P NATL ACAD SCI USA, V104, P10950, DOI 10.1073/pnas.0703856104; Lam KWG, 2006, P NATL ACAD SCI USA, V103, P8921, DOI 10.1073/pnas.0602690103; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Lee JA, 2007, CELL, V131, P1235, DOI 10.1016/j.cell.2007.11.037; Leibenluft E, 2011, AM J PSYCHIAT, V168, P129, DOI 10.1176/appi.ajp.2010.10050766; Leucht S, 2009, LANCET, V373, P31, DOI 10.1016/S0140-6736(08)61764-X; Levinson DF, 2011, AM J PSYCHIAT, V168, P302, DOI 10.1176/appi.ajp.2010.10060876; Levy D, 2011, NEURON, V70, P886, DOI 10.1016/j.neuron.2011.05.015; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu PF, 2011, AM J HUM GENET, V89, P580, DOI 10.1016/j.ajhg.2011.09.009; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Lupski JR, 2010, CELL, V141, P1110, DOI 10.1016/j.cell.2010.06.014; Malhotra D, 2011, NEURON, V72, P951, DOI 10.1016/j.neuron.2011.11.007; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; McCarthy SE, 2009, NAT GENET, V41, P1223, DOI 10.1038/ng.474; McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032; McQuillin A, 2011, EUR J HUM GENET, V19, P588, DOI 10.1038/ejhg.2010.221; Mefford HC, 2008, NEW ENGL J MED, V359, P1685, DOI 10.1056/NEJMoa0805384; Mefford HC, 2009, GENOME RES, V19, P1579, DOI 10.1101/gr.094987.109; Mefford HC, 2009, CURR OPIN GENET DEV, V19, P196, DOI 10.1016/j.gde.2009.04.003; Miles JH, 2011, GENET MED, V13, P278, DOI 10.1097/GIM.0b013e3181ff67ba; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Miller DT, 2009, J MED GENET, V46, P242, DOI 10.1136/jmg.2008.059907; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Moessner R, 2007, AM J HUM GENET, V81, P1289, DOI 10.1086/522590; Moreno-De-Luca D, 2010, AM J HUM GENET, V87, P618, DOI 10.1016/j.ajhg.2010.10.004; Mulle JG, 2010, AM J HUM GENET, V87, P229, DOI 10.1016/j.ajhg.2010.07.013; Murphy KC, 1999, ARCH GEN PSYCHIAT, V56, P940, DOI 10.1001/archpsyc.56.10.940; Nagamani SCS, 2011, EUR J HUM GENET, V19, P280, DOI 10.1038/ejhg.2010.184; Najmabadi H, 2011, NATURE, V478, P57, DOI 10.1038/nature10423; Nakatani J, 2009, CELL, V137, P1235, DOI 10.1016/j.cell.2009.04.024; Noor A, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001267; O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835; Pasca SP, 2011, NAT MED, V17, P1657, DOI 10.1038/nm.2576; Peca J, 2011, NATURE, V472, P437, DOI 10.1038/nature09965; Penagarikano O, 2011, CELL, V147, P235, DOI 10.1016/j.cell.2011.08.040; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Potash JB, 2007, AM J PSYCHIAT, V164, P1229, DOI 10.1176/appi.ajp.2007.06122045; Priebe L, 2012, MOL PSYCHIATR, V17, P421, DOI 10.1038/mp.2011.8; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Ramalingam A, 2011, J HUM GENET, V56, P541, DOI 10.1038/jhg.2011.42; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Ripke S, 2011, NAT GENET, V43, P969, DOI 10.1038/ng.940; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roohi J, 2009, J MED GENET, V46, P176, DOI 10.1136/jmg.2008.057505; Rosenberg RE, 2009, ARCH PEDIAT ADOL MED, V163, P907, DOI 10.1001/archpediatrics.2009.98; Rucker JJH, 2013, MOL PSYCHIATR, V18, P183, DOI 10.1038/mp.2011.144; Sahoo T, 2011, GENET MED, V13, P868, DOI 10.1097/GIM.0b013e3182217a06; Sanders SJ, 2011, NEURON, V70, P863, DOI 10.1016/j.neuron.2011.05.002; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Sebat J, 2009, TRENDS GENET, V25, P528, DOI 10.1016/j.tig.2009.10.004; Sharp AJ, 2008, NAT GENET, V40, P322, DOI 10.1038/ng.93; Shinawi M, 2010, J MED GENET, V47, P332, DOI 10.1136/jmg.2009.073015; Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943; Skuse DH, 2007, TRENDS GENET, V23, P387, DOI 10.1016/j.tig.2007.06.003; State MW, 2011, NAT NEUROSCI, V14, P1499, DOI 10.1038/nn.2924; STEFFENBURG S, 1989, J CHILD PSYCHOL PSYC, V30, P405, DOI 10.1111/j.1469-7610.1989.tb00254.x; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Strauss KA, 2006, NEW ENGL J MED, V354, P1370, DOI 10.1056/NEJMoa052773; Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; Tamada K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015126; Toffolatti L, 2002, GENOMICS, V80, P523, DOI 10.1006/geno.2002.6861; Turner DJ, 2008, NAT GENET, V40, P90, DOI 10.1038/ng.2007.40; Vacic V, 2011, NATURE, V471, P499, DOI 10.1038/nature09884; van Bon BWM, 2009, J MED GENET, V46, P511, DOI 10.1136/jmg.2008.063412; van Os J, 2009, LANCET, V374, P635, DOI [10.1016/S0140-6736(09)60995-8, 10.1016/S0140-6736(15)01121-6]; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Volkmar FR, 2009, J CHILD PSYCHOL PSYC, V50, P108, DOI 10.1111/j.1469-7610.2008.02010.x; Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174; WASCHEK JA, 1995, DEV NEUROSCI-BASEL, V17, P1, DOI 10.1159/000111268; Webber C, 2011, CYTOGENET GENOME RES, V135, P277, DOI 10.1159/000331670; Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974; Williams NM, 2012, AM J PSYCHIAT, V169, P195, DOI 10.1176/appi.ajp.2011.11060822; Xu B, 2008, NAT GENET, V40, P880, DOI 10.1038/ng.162; Xu B, 2011, NAT GENET, V43, P864, DOI 10.1038/ng.902; Zhang D, 2009, MOL PSYCHIATR, V14, P376, DOI 10.1038/mp.2008.144; Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217; Zhang F, 2009, NAT GENET, V41, P849, DOI 10.1038/ng.399; Zhao X, 2007, P NATL ACAD SCI USA, V104, P12831, DOI 10.1073/pnas.0705803104	160	551	567	9	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1223	1241		10.1016/j.cell.2012.02.039	http://dx.doi.org/10.1016/j.cell.2012.02.039			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424231	Bronze, Green Accepted			2022-12-28	WOS:000301889500018
J	Zars, T				Zars, Troy			She Said No, Pass Me a Beer	SCIENCE			English	Editorial Material							DROSOPHILA		Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Zars, T (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	zarst@missouri.edu		Zars, Troy/0000-0003-4114-9322				Griffith LC, 2009, LEARN MEMORY, V16, P743, DOI 10.1101/lm.956309; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Kaun KR, 2011, NAT NEUROSCI, V14, P612, DOI 10.1038/nn.2805; Shohat-Ophir G, 2012, SCIENCE, V335, P1351, DOI 10.1126/science.1215932; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Wen TQ, 2005, P NATL ACAD SCI USA, V102, P2141, DOI 10.1073/pnas.0406814102	7	2	2	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1309	1310		10.1126/science.1220225	http://dx.doi.org/10.1126/science.1220225			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422968				2022-12-28	WOS:000301531600032
J	Insel, TR; Sahakian, BJ				Insel, Thomas R.; Sahakian, Barbara J.			A plan for mental illness	NATURE			English	Editorial Material							HEALTH		[Insel, Thomas R.] NIMH, NIH, Bethesda, MD 20892 USA; [Sahakian, Barbara J.] Univ Cambridge, Dept Psychiat, Cambridge CB2 1TN, England; [Sahakian, Barbara J.] Univ Cambridge, MRC Wellcome Trust Behav & Clin Neurosci Inst, Cambridge CB2 1TN, England	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Cambridge; University of Cambridge	Insel, TR (corresponding author), NIMH, NIH, Bethesda, MD 20892 USA.	bjs1001@cam.ac.uk	Marston, Hugh M/G-8555-2011; Sahakian, Barbara/AAW-1198-2020; Nye, Jeffrey/G-6520-2012; Brown, Verity/A-5235-2011	Marston, Hugh M/0000-0002-7460-0581; Sahakian, Barbara/0000-0001-7352-1745; Nye, Jeffrey/0000-0002-6056-281X; Brown, Verity/0000-0001-5762-1797				[Anonymous], NATURE; Collins PY, 2011, NATURE, V475, P27, DOI 10.1038/475027a; Cressey D., 2011, NATURE; Julius RJ, 2009, J PSYCHIATR PRACT, V15, P34, DOI 10.1097/01.pra.0000344917.43780.77; Ledford H, 2011, NATURE, V479, P278, DOI 10.1038/479278a; Lehner T, 2010, ACAD PSYCHIATR, V34, P87, DOI 10.1176/appi.ap.34.2.87; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Saha K, 2011, NATURE, V478, P312, DOI 10.1038/478312a; Sahakian BJ, 2010, LANCET, V375, P1854, DOI 10.1016/S0140-6736(10)60817-3; Sankaran VG, 2008, SCIENCE, V322, P1839, DOI 10.1126/science.1165409	10	52	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					269	269		10.1038/483269a	http://dx.doi.org/10.1038/483269a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22422245	Bronze			2022-12-28	WOS:000301481800023
J	Krishnan, AS; Barrett, T				Krishnan, Anant Subramanian; Barrett, Tristan			Westermark Sign in Pulmonary Embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Krishnan, Anant Subramanian; Barrett, Tristan] Addenbrookes Hosp, Cambridge, England	Addenbrooke's Hospital; University of Cambridge	Krishnan, AS (corresponding author), Addenbrookes Hosp, Cambridge, England.			Barrett, Tristan/0000-0002-1180-1474					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					E16	E16		10.1056/NEJMicm1107936	http://dx.doi.org/10.1056/NEJMicm1107936			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908HZ	22417276				2022-12-28	WOS:000301482800008
J	Jha, AK; Joynt, KE; Orav, EJ; Epstein, AM				Jha, Ashish K.; Joynt, Karen E.; Orav, E. John; Epstein, Arnold M.			The Long-Term Effect of Premier Pay for Performance on Patient Outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DUTY HOUR REFORM; QUALITY-OF-CARE; FOR-PERFORMANCE; ADMINISTRATIVE DATA; MORTALITY-RATES; RISK ADJUSTMENT; HEALTH-CARE; MEDICARE; HOSPITALS; IMPROVEMENT	Background Pay for performance has become a central strategy in the drive to improve health care. We assessed the long-term effect of the Medicare Premier Hospital Quality Incentive Demonstration (HQID) on patient outcomes. Methods We used Medicare data to compare outcomes between the 252 hospitals participating in the Premier HQID and 3363 control hospitals participating in public reporting alone. We examined 30-day mortality among more than 6 million patients who had acute myocardial infarction, congestive heart failure, or pneumonia or who underwent coronary-artery bypass grafting (CABG) between 2003 and 2009. Results At baseline, the composite 30-day mortality was similar for Premier and non-Premier hospitals (12.33% and 12.40%, respectively; difference, -0.07 percentage points; 95% confidence interval [CI], -0.40 to 0.26). The rates of decline in mortality per quarter at the two types of hospitals were also similar (0.04% and 0.04%, respectively; difference, -0.01 percentage points; 95% CI, -0.02 to 0.01), and mortality remained similar after 6 years under the pay-for-performance system (11.82% for Premier hospitals and 11.74% for non-Premier hospitals; difference, 0.08 percentage points; 95% CI, -0.30 to 0.46). We found that the effects of pay for performance on mortality did not differ significantly among conditions for which outcomes were explicitly linked to incentives (acute myocardial infarction and CABG) and among conditions not linked to incentives (congestive heart failure and pneumonia) (P=0.36 for interaction). Among hospitals that were poor performers at baseline, mortality was similar in the two groups of hospitals at the start of the study (15.12% and 14.73%; difference, 0.39 percentage points; 95% CI, -0.36 to 1.15), with similar rates of improvement per quarter (0.10% and 0.07%; difference, -0.03 percentage points; 95% CI, -0.08 to 0.02) and similar mortality rates at the end of the study (13.37% and 13.21%; difference, 0.15 percentage points; 95% CI, -0.70 to 1.01). Conclusions We found no evidence that the largest hospital-based pay-for-performance program led to a decrease in 30-day mortality. Expectations of improved outcomes for programs modeled after Premier HQID should therefore remain modest.	[Jha, Ashish K.; Joynt, Karen E.; Epstein, Arnold M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Jha, Ashish K.; Orav, E. John; Epstein, Arnold M.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	ajha@hsph.harvard.edu	Callahan, Charles D/L-1641-2013		Robert Wood Johnson Foundation	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	Supported by a grant from the Robert Wood Johnson Foundation.	[Anonymous], 2010, FED REG; Berwick DM, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.6.8; Centers for Medicare and Medicaid Services, 2011, ROADM IMPL VAL DRIV; Centers for Medicare and Medicaid Services, CMS PREM HOSP QUAL I; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Glickman SW, 2007, JAMA-J AM MED ASSOC, V297, P2373, DOI 10.1001/jama.297.21.2373; Greenberg JO, 2010, NEW ENGL J MED, V362, P1558, DOI 10.1056/NEJMp1000650; Healthcare Cost and Utilization Project, 2010, HCUP COM SOFTW VERS; Jha AK, 2007, HEALTH AFFAIR, V26, P1104, DOI 10.1377/hlthaff.26.4.1104; Jha AK, 2010, ANN INTERN MED, V153, P299, DOI 10.7326/0003-4819-153-5-201009070-00004; Lee PV, 2010, NEW ENGL J MED, V362, P3, DOI 10.1056/NEJMp0910459; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Ly DP, 2011, J GEN INTERN MED, V26, P1291, DOI 10.1007/s11606-011-1815-5; Petersen LA, 2006, ANN INTERN MED, V145, P265, DOI 10.7326/0003-4819-145-4-200608150-00006; Pine M, 2007, JAMA-J AM MED ASSOC, V297, P71, DOI 10.1001/jama.297.1.71; Rosenthal MB, 2006, MED CARE RES REV, V63, P135, DOI 10.1177/1077558705285291; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Rosenthal MB, 2006, NEW ENGL J MED, V355, P1895, DOI 10.1056/NEJMsa063682; Ryan AM, 2009, HEALTH SERV RES, V44, P821, DOI 10.1111/j.1475-6773.2009.00956.x; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975; Weller WE, 2007, J AM COLL SURGEONS, V204, P383, DOI 10.1016/j.jamcollsurg.2006.12.031; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Werner RM, 2011, HEALTH AFFAIR, V30, P690, DOI 10.1377/hlthaff.2010.1277; Werner RM, 2007, JAMA-J AM MED ASSOC, V297, P700	27	228	233	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 26	2012	366	17					1606	1615		10.1056/NEJMsa1112351	http://dx.doi.org/10.1056/NEJMsa1112351			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931FC	22455751	Bronze			2022-12-28	WOS:000303200100009
J	Levin, AM; Bates, DL; Ring, AM; Krieg, C; Lin, JT; Su, L; Moraga, I; Raeber, ME; Bowman, GR; Novick, P; Pande, VS; Fathman, CG; Boyman, O; Garcia, KC				Levin, Aron M.; Bates, Darren L.; Ring, Aaron M.; Krieg, Carsten; Lin, Jack T.; Su, Leon; Moraga, Ignacio; Raeber, Miro E.; Bowman, Gregory R.; Novick, Paul; Pande, Vijay S.; Fathman, C. Garrison; Boyman, Onur; Garcia, K. Christopher			Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'	NATURE			English	Article							SELECTIVE STIMULATION; MOLECULAR-CLONING; ALPHA-RECEPTOR; EXPRESSION; COMPLEXES; PROTEINS; DYNAMICS; KINETICS; CHAIN	The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of leukocytes, including T cells and natural killer (NK) cells(1-3). Considerable effort has been invested in using IL-2 as a therapeutic agent for a variety of immune disorders ranging from AIDS to cancer. However, adverse effects have limited its use in the clinic. On activated T cells, IL-2 signals through a quaternary 'high affinity' receptor complex consisting of IL-2, IL-2R alpha (termed CD25), IL-2R beta and IL-2R gamma(4-8). Naive T cells express only a low density of IL-2R beta and IL-2R gamma, and are therefore relatively insensitive to IL-2, but acquire sensitivity after CD25 expression, which captures the cytokine and presents it to IL-2R beta and IL-2R gamma. Here, using in vitro evolution, we eliminated the functional requirement of IL-2 for CD25 expression by engineering an IL-2 'superkine' (also called super-2) with increased binding affinity for IL-2R beta. Crystal structures of the IL-2 superkine in free and receptor-bound forms showed that the evolved mutations are principally in the core of the cytokine, and molecular dynamics simulations indicated that the evolved mutations stabilized IL-2, reducing the flexibility of a helix in the IL-2R beta binding site, into an optimized receptor-binding conformation resembling that when bound to CD25. The evolved mutations in the IL-2 superkine recapitulated the functional role of CD25 by eliciting potent phosphorylation of STAT5 and vigorous proliferation of T cells irrespective of CD25 expression. Compared to IL-2, the IL-2 superkine induced superior expansion of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionally less expansion of T regulatory cells and reduced pulmonary oedema. Collectively, we show that in vitro evolution has mimicked the functional role of CD25 in enhancing IL-2 potency and regulating target cell specificity, which has implications for immunotherapy.	[Levin, Aron M.; Garcia, K. Christopher] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; [Bates, Darren L.; Ring, Aaron M.; Moraga, Ignacio; Garcia, K. Christopher] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA; [Bates, Darren L.; Ring, Aaron M.; Moraga, Ignacio; Garcia, K. Christopher] Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA; [Krieg, Carsten; Raeber, Miro E.; Boyman, Onur] Univ Zurich, Lab Appl Immunobiol, CH-8006 Zurich, Switzerland; [Krieg, Carsten; Raeber, Miro E.; Boyman, Onur] Univ Zurich Hosp, Allergy Unit, Dept Dermatol, CH-8091 Zurich, Switzerland; [Lin, Jack T.; Su, Leon; Fathman, C. Garrison] Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Bowman, Gregory R.; Novick, Paul; Pande, Vijay S.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; University of Zurich; University of Zurich; University Zurich Hospital; Stanford University; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.	onur.boyman@uzh.ch; kcgarcia@stanford.edu	Raeber, Miro E/J-7626-2012; Pande, Vijay/ABE-8145-2020; Krieg, Carsten/ABA-6734-2020	Raeber, Miro E/0000-0003-2609-0246; Krieg, Carsten/0000-0002-5145-7591; Ring, Aaron/0000-0003-3699-2446; Moraga, Ignacio/0000-0001-9909-0701; Boyman, Onur/0000-0001-8279-5545; Su, Leon/0000-0001-7654-9997	Swiss National Science Foundation [NIH-RO1AI51321, PP00P3-128421]; Swiss Cancer League [KFS-02672-08-2010]; NIH [R01-GM062868, U01 DK078123, U19 AI 082719]; MRI-R2; American Recovery and Reinvestment Act [NIH-AR050942]; Stanford Medical Scientist Training Program [NIH-GM07365]; NATIONAL CANCER INSTITUTE [R01CA065237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI051321, U19AI082719, R01AI051321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR050942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK078123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062868, T32GM007365] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRI-R2; American Recovery and Reinvestment Act; Stanford Medical Scientist Training Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge W. Leonard, R. Levy and R. Schwendener for reagents and discussion. This work was supported by NIH-RO1AI51321 (to K. C. G.), PP00P3-128421 from the Swiss National Science Foundation and KFS-02672-08-2010 from the Swiss Cancer League (both to O.B.), NIH R01-GM062868 (to V. S. P.), MRI-R2 (this award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5)) (to V.S.P.), NIH-AR050942 (to J.T.L.), NIH U01 DK078123 (to C. G. F.), and NIH U19 AI 082719 (to C. G. F.). A. M. R. was supported by the Stanford Medical Scientist Training Program (NIH-GM07365). K. C. G. is an Investigator of the Howard Hughes Medical Institute.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Arkin MR, 2003, P NATL ACAD SCI USA, V100, P1603, DOI 10.1073/pnas.252756299; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Bowman GR, 2010, CELL RES, V20, P622, DOI 10.1038/cr.2010.57; Bowman GR, 2009, METHODS, V49, P197, DOI 10.1016/j.ymeth.2009.04.013; Bowman GR, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3216567; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W.L, PYMOL MOL GRAPHICS S; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Krieg C, 2010, P NATL ACAD SCI USA, V107, P11906, DOI 10.1073/pnas.1002569107; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Letourneau S, 2010, P NATL ACAD SCI USA, V107, P2171, DOI 10.1073/pnas.0909384107; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MOTT HR, 1995, J MOL BIOL, V247, P979, DOI 10.1006/jmbi.1994.0194; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; Noe F, 2008, CURR OPIN STRUC BIOL, V18, P154, DOI 10.1016/j.sbi.2008.01.008; Rao BM, 2004, MOL PHARMACOL, V66, P864, DOI 10.1124/mol.66.4.864; Rickert M, 2004, J MOL BIOL, V339, P1115, DOI 10.1016/j.jmb.2004.04.038; Rickert M, 2005, SCIENCE, V308, P1477, DOI 10.1126/science.1109745; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Thanos CD, 2006, P NATL ACAD SCI USA, V103, P15422, DOI 10.1073/pnas.0607058103; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Eswar Narayanan, 2007, Curr Protoc Protein Sci, VChapter 2, DOI [10.1002/cpbi.3, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/0471140864.ps0209s50]	39	315	356	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 26	2012	484	7395					529	U159		10.1038/nature10975	http://dx.doi.org/10.1038/nature10975			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931FF	22446627	Green Accepted			2022-12-28	WOS:000303200400054
J	Close, P; East, P; Dirac-Svejstrup, AB; Hartmann, H; Heron, M; Maslen, S; Chariot, A; Soding, J; Skehel, M; Svejstrup, JQ				Close, Pierre; East, Philip; Dirac-Svejstrup, A. Barbara; Hartmann, Holger; Heron, Mark; Maslen, Sarah; Chariot, Alain; Soeding, Johannes; Skehel, Mark; Svejstrup, Jesper Q.			DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation	NATURE			English	Article							PROTEOMIC ANALYSIS; BINDING-PROTEINS; IN-VIVO; CLEAVAGE; CELLS	Alternative messenger RNA splicing is the main reason that vast mammalian proteomic complexity can be achieved with a limited number of genes. Splicing is physically and functionally coupled to transcription, and is greatly affected by the rate of transcript elongation(1-3). As the nascent pre-mRNA emerges from transcribing RNA polymerase II (RNAPII), it is assembled into a messenger ribonucleoprotein (mRNP) particle; this is the functional form of the nascent pre-mRNA and determines the fate of the mature transcript(4). However, factors that connect the transcribing polymerase with the mRNP particle and help to integrate transcript elongation with mRNA splicing remain unclear. Here we characterize the human interactome of chromatin-associated mRNP particles. This led us to identify deleted in breast cancer 1 (DBC1) and ZNF326 (which we call ZNF-protein interacting with nuclear mRNPs and DBC1 (ZIRD)) as subunits of a novel protein complex-named DBIRD-that binds directly to RNAPII. DBIRD regulates alternative splicing of a large set of exons embedded in (A + T)-rich DNA, and is present at the affected exons. RNA-interference-mediated DBIRD depletion results in region-specific decreases in transcript elongation, particularly across areas encompassing affected exons. Together, these data indicate that the DBIRD complex acts at the interface between mRNP particles and RNAPII, integrating transcript elongation with the regulation of alternative splicing.	[Close, Pierre; Dirac-Svejstrup, A. Barbara; Svejstrup, Jesper Q.] Canc Res UK London Res Inst, Mech Transcript Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; [Close, Pierre; Chariot, Alain] Univ Liege, Unit Med Chem, GIGA Signal Transduct, GIGA R,CHU, B-4000 Liege, Belgium; [East, Philip] Canc Res UK London Res Inst, Bioinformat & Biostat Grp, London WC2A 3LY, England; [Hartmann, Holger; Heron, Mark; Soeding, Johannes] Univ Munich, Gene Ctr, D-81377 Munich, Germany; [Hartmann, Holger; Heron, Mark; Soeding, Johannes] Univ Munich, Ctr Integrated Prot Sci Munich, D-81377 Munich, Germany; [Maslen, Sarah; Skehel, Mark] Canc Res UK London Res Inst, London Res Inst, Prot Anal & Prote Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK; University of Liege; Cancer Research UK; University of Munich; University of Munich; Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK London Res Inst, Mech Transcript Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk	Söding, Johannes/A-3341-2013	Söding, Johannes/0000-0001-9642-8244; CLOSE, PIERRE/0000-0002-8844-9616; Chariot, Alain/0000-0002-1691-4347; East, Philip/0000-0001-5801-5713; Svejstrup, Jesper/0000-0003-4964-6147	Cancer Research UK; European Research council (ERC); European Molecular Biology Organization (EMBO); Fonds Leon Fredericq foundation; Cancer Research UK [11567] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); European Research council (ERC)(European Research Council (ERC)); European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); Fonds Leon Fredericq foundation; Cancer Research UK(Cancer Research UK)	This work was supported by grants from Cancer Research UK and the European Research council (ERC) (to J.Q.S.), by an European Molecular Biology Organization (EMBO) long-term fellowship and by the Fonds Leon Fredericq foundation (to P. C.). We thank the Molecular Biology Core Facility at the Paterson Institute (Manchester) and Cell Services at London Research Insitute for analysis and help. We thank B. Chabot for CB3 cells, and members of the Svejstrup laboratory, P. Verrijjzer and T. H. Jensen for comments on the manuscript. P. C. is a senior research assistant at the Belgian National Foundation for Scientific Research (FNRS).	Aygun O, 2008, P NATL ACAD SCI USA, V105, P8580, DOI 10.1073/pnas.0804424105; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Chen YIG, 2007, NUCLEIC ACIDS RES, V35, P3928, DOI 10.1093/nar/gkm347; Close P, 2006, MOL CELL, V22, P521, DOI 10.1016/j.molcel.2006.04.017; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Dye MJ, 2006, MOL CELL, V21, P849, DOI 10.1016/j.molcel.2006.01.032; Fong N, 2009, NAT STRUCT MOL BIOL, V16, P916, DOI 10.1038/nsmb.1652; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gilbert C, 2006, CURR PROTOC MOL BIOL, V75; Hu X, 2006, P NATL ACAD SCI USA, V103, P9506, DOI 10.1073/pnas.0603702103; Kiledjian Megerditch, 1994, P127; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JE, 2009, CELL CYCLE, V8, P2932; Kornblihtt AR, 2007, ADV EXP MED BIOL, V623, P175, DOI 10.1007/978-0-387-77374-2_11; Lee JY, 2000, DNA CELL BIOL, V19, P227, DOI 10.1089/104454900314492; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Saeki H, 2009, MOL CELL, V35, P191, DOI 10.1016/j.molcel.2009.06.009; Selth LA, 2011, METHODS MOL BIOL, V791, P253, DOI 10.1007/978-1-61779-316-5_19; Sigurdsson S, 2010, MOL CELL, V38, P202, DOI 10.1016/j.molcel.2010.02.026; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	24	86	90	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					386	389		10.1038/nature10925	http://dx.doi.org/10.1038/nature10925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22446626	Green Accepted			2022-12-28	WOS:000302946500035
J	Smith, DE; Zuber, MT; Phillips, RJ; Solomon, SC; Hauck, SA; Lemoine, FG; Mazarico, E; Neumann, GA; Peale, SJ; Margot, JL; Johnson, CL; Torrence, MH; Perry, ME; Rowlands, DD; Goossens, S; Head, JW; Taylor, AH				Smith, David E.; Zuber, Maria T.; Phillips, Roger J.; Solomon, Sean C.; Hauck, Steven A., II; Lemoine, Frank G.; Mazarico, Erwan; Neumann, Gregory A.; Peale, Stanton J.; Margot, Jean-Luc; Johnson, Catherine L.; Torrence, Mark H.; Perry, Mark E.; Rowlands, David D.; Goossens, Sander; Head, James W.; Taylor, Anthony H.			Gravity Field and Internal Structure of Mercury from MESSENGER	SCIENCE			English	Article							MOLTEN CORE; EVOLUTION; TOPOGRAPHY; MARS	Radio tracking of the MESSENGER spacecraft has provided a model of Mercury's gravity field. In the northern hemisphere, several large gravity anomalies, including candidate mass concentrations (mascons), exceed 100 milli-Galileos (mgal). Mercury's northern hemisphere crust is thicker at low latitudes and thinner in the polar region and shows evidence for thinning beneath some impact basins. The low-degree gravity field, combined with planetary spin parameters, yields the moment of inertia C/MR2 = 0.353 +/- 0.017, where M and R are Mercury's mass and radius, and a ratio of the moment of inertia of Mercury's solid outer shell to that of the planet of C-m/C = 0.452 +/- 0.035. A model for Mercury's radial density distribution consistent with these results includes a solid silicate crust and mantle overlying a solid iron-sulfide layer and an iron-rich liquid outer core and perhaps a solid inner core.	[Smith, David E.; Zuber, Maria T.; Mazarico, Erwan] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [Phillips, Roger J.] SW Res Inst, Planetary Sci Directorate, Boulder, CO 80302 USA; [Solomon, Sean C.] Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; [Hauck, Steven A., II] Case Western Reserve Univ, Dept Earth Environm & Planetary Sci, Cleveland, OH 44106 USA; [Lemoine, Frank G.; Mazarico, Erwan; Neumann, Gregory A.; Torrence, Mark H.; Rowlands, David D.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Peale, Stanton J.] Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; [Margot, Jean-Luc] Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; [Johnson, Catherine L.] Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; [Johnson, Catherine L.] Planetary Sci Inst, Tucson, AZ 85719 USA; [Torrence, Mark H.] Stinger Ghaffarian Technol Inc, Greenbelt, MD 20770 USA; [Perry, Mark E.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; [Goossens, Sander] Univ Maryland Baltimore Cty, Baltimore, MD 21250 USA; [Head, James W.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Taylor, Anthony H.] KinetX Inc, Tempe, AZ 85284 USA	Massachusetts Institute of Technology (MIT); Carnegie Institution for Science; Case Western Reserve University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles; University of British Columbia; Stinger Ghaffarian Technologies, Inc. (SGT); Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University System of Maryland; University of Maryland Baltimore County; Brown University	Zuber, MT (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	zuber@mit.edu	Lemoine, Frank/D-1215-2013; Goossens, Sander J/K-2526-2015; Rowlands, David/D-2751-2012; Hauck, Steven A/A-7865-2008; Mazarico, Erwan/N-6034-2014; Perry, Mark E./B-8870-2016; Johnson, Catherine L./AAZ-7295-2020; Margot, Jean-Luc/A-6154-2012; Neumann, Gregory A/I-5591-2013	Goossens, Sander J/0000-0002-7707-1128; Hauck, Steven A/0000-0001-8245-146X; Mazarico, Erwan/0000-0003-3456-427X; Perry, Mark E./0000-0003-1600-6856; Margot, Jean-Luc/0000-0001-9798-1797; Neumann, Gregory A/0000-0003-0644-9944; Lemoine, Frank G./0000-0002-3051-1456	NASA [NAS5-97271, NASW-00002]	NASA(National Aeronautics & Space Administration (NASA))	The MESSENGER project is supported by the NASA Discovery Program under contracts NAS5-97271 to The Johns Hopkins University Applied Physics Laboratory and NASW-00002 to the Carnegie Institution of Washington. We acknowledge the contributions of the MESSENGER spacecraft team and the radio science and MLA instrument teams in acquiring the observations used herein. We are also grateful to three anonymous reviewers for comments that improved the manuscript.	Anderson J. D., 2011, AM GEOPH UN FALL M S; Charlier B., 2012, LUNAR PLANET SCI, V43; Christensen UR, 2006, NATURE, V444, P1056, DOI 10.1038/nature05342; Hauck SA, 2004, EARTH PLANET SC LETT, V222, P713, DOI 10.1016/j.epsl.2004.03.037; Hauck SA, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030793; Head JW, 2011, SCIENCE, V333, P1853, DOI 10.1126/science.1211997; Kaula W.M., 1966, THEORY SATELLITE GEO; Malavergne V, 2010, ICARUS, V206, P199, DOI 10.1016/j.icarus.2009.09.001; Margot JL, 2007, SCIENCE, V316, P710, DOI 10.1126/science.1140514; Margot J.L., 2011, AM GEOPH UN FALL M S; McGovern PJ, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002286; Morard G, 2010, GEOCHIM COSMOCHIM AC, V74, P3659, DOI 10.1016/j.gca.2010.03.025; MULLER PM, 1968, SCIENCE, V161, P680, DOI 10.1126/science.161.3842.680; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; Nimmo F, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018847; Nittler LR, 2011, SCIENCE, V333, P1847, DOI 10.1126/science.1211567; Nittler LR., 2011, INTERACTIVE PROCESSI; Peale SJ, 2002, METEORIT PLANET SCI, V37, P1269, DOI 10.1111/j.1945-5100.2002.tb00895.x; PEALE SJ, 1976, NATURE, V262, P765, DOI 10.1038/262765a0; Smith DE, 2010, ICARUS, V209, P88, DOI 10.1016/j.icarus.2010.04.007; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Solomon SC, 2007, SPACE SCI REV, V131, P3, DOI 10.1007/s11214-007-9247-6; Strom R. G., 1988, MERCURY, P363; Yseboodt M, 2006, ICARUS, V181, P327, DOI 10.1016/j.icarus.2005.11.024; Zuber MT, 2008, SCIENCE, V321, P77, DOI 10.1126/science.1159086; Zuber MT, 2012, SCIENCE, V336, P217, DOI 10.1126/science.1218805; Zuber MT, 2000, SCIENCE, V287, P1788, DOI 10.1126/science.287.5459.1788	27	198	200	8	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 13	2012	336	6078					214	217		10.1126/science.1218809	http://dx.doi.org/10.1126/science.1218809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924PN	22438509				2022-12-28	WOS:000302703900046
J	Demeshkina, N; Jenner, L; Westhof, E; Yusupov, M; Yusupova, G				Demeshkina, Natalia; Jenner, Lasse; Westhof, Eric; Yusupov, Marat; Yusupova, Gulnara			A new understanding of the decoding principle on the ribosome	NATURE			English	Article							AMINOACYL-TRANSFER-RNA; EF-TU; MESSENGER-RNA; SELECTION; RECOGNITION; FIDELITY; ACTIVATION; MECHANISM	During protein synthesis, the ribosome accurately selects transfer RNAs (tRNAs) in accordance with the messenger RNA (mRNA) triplet in the decoding centre. tRNA selection is initiated by elongation factor Tu, which delivers tRNA to the aminoacyl tRNA-binding site (A site) and hydrolyses GTP upon establishing codon-anticodon interactions in the decoding centre(1-9). At the following proofreading step the ribosome re-examines the tRNA and rejects it if it does not match the A codon(2,3,10-14). It was suggested that universally conserved G530, A1492 and A1493 of 16S ribosomal RNA, critical for tRNA binding in the Asite(15-17), actively monitor cognate tRNA(18), and that recognition of the correct codon-anticodon duplex induces an overall ribosome conformational change (domain closure)(19). Here we propose an integrated mechanism for decoding based on six X-ray structures of the 70S ribosome determined at 3.1-3.4A resolution, modelling cognate or near-cognate states of the decoding centre at the proofreading step. We show that the 30S subunit undergoes an identical domain closure upon binding of either cognate or near-cognate tRNA. This conformational change of the 30S subunit forms a decoding centre that constrains the mRNA in such a way that the first two nucleotides of the A codon are limited to form Watson-Crick base pairs. When U center dot G and G center dot U mismatches, generally considered to form wobble base pairs, are at the first or second codon-anticodon position, the decoding centre forces this pair to adopt the geometry close to that of a canonical C center dot G pair. This by itself, or with distortions in the codon-anticodon mini-helix and the anticodon loop, causes the near-cognate tRNA to dissociate from the ribosome.	[Demeshkina, Natalia; Jenner, Lasse; Yusupov, Marat; Yusupova, Gulnara] Inst Genet & Biol Mol & Cellulaire, Dept Biol & Genom Struct, F-67400 Illkirch Graffenstaden, France; [Demeshkina, Natalia; Jenner, Lasse; Yusupov, Marat; Yusupova, Gulnara] CNRS, UMR7104, F-67400 Illkirch Graffenstaden, France; [Demeshkina, Natalia; Jenner, Lasse; Yusupov, Marat; Yusupova, Gulnara] INSERM, U964, F-67400 Illkirch Graffenstaden, France; [Demeshkina, Natalia; Jenner, Lasse; Yusupov, Marat; Yusupova, Gulnara] Univ Strasbourg, F-67000 Strasbourg, France; [Westhof, Eric] Univ Strasbourg, CNRS, Inst Biol Mol & Cellulaire, Architecture & Reactivite ARN, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Yusupov, M (corresponding author), Inst Genet & Biol Mol & Cellulaire, Dept Biol & Genom Struct, F-67400 Illkirch Graffenstaden, France.	marat@igbmc.fr; gula@igbmc.fr	Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013; Jenner, Lasse/H-1584-2017	Yusupov, Marat/0000-0001-5544-0597; Jenner, Lasse/0000-0003-3917-8853	ANR [BLAN07-3_190451, ANR-07-PCVI-0015-01]; Fondation pour la Recherche Medicale en France; European Commission SPINE2	ANR(French National Research Agency (ANR)); Fondation pour la Recherche Medicale en France(Fondation pour la Recherche Medicale); European Commission SPINE2(European CommissionEuropean Commission Joint Research Centre)	We are grateful to C. Schulze-Briese and the staff at the Swiss Light Source (Switzerland) for help during synchrotron X-ray data collection. We thank S. Duclaud for ribosome preparation and the staff of the Structural Biology Department core facility at Institut de Genetique et de Biologie Moleculaire et Cellulaire, Universite de Strasbourg. This work was supported by ANR BLAN07-3_190451 (to M.Y.), ANR-07-PCVI-0015-01 (to G.Y.), Fondation pour la Recherche Medicale en France (to N.D.) and by the European Commission SPINE2.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; [Anonymous], 2008, BPS DATABASE RNA BAS; Auffinger P, 2001, RNA, V7, P334, DOI 10.1017/S1355838201002382; Bebenek K, 2011, P NATL ACAD SCI USA, V108, P1862, DOI 10.1073/pnas.1012825108; Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; Dale T, 2005, TRENDS BIOCHEM SCI, V30, P659, DOI 10.1016/j.tibs.2005.10.006; EHRENBERG M, 1986, BIOCHIMIE, V68, P261, DOI 10.1016/S0300-9084(86)80023-2; Geggier P, 2010, J MOL BIOL, V399, P576, DOI 10.1016/j.jmb.2010.04.038; Gromadski KB, 2006, MOL CELL, V21, P369, DOI 10.1016/j.molcel.2005.12.018; Jenner L, 2010, NAT STRUCT MOL BIOL, V17, P1072, DOI 10.1038/nsmb.1880; Jenner LB, 2010, NAT STRUCT MOL BIOL, V17, P555, DOI 10.1038/nsmb.1790; Lee TH, 2007, P NATL ACAD SCI USA, V104, P13661, DOI 10.1073/pnas.0705988104; Li W, 2008, EMBO J, V27, P3322, DOI 10.1038/emboj.2008.243; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Mueller M, 2012, ACTA CRYSTALLOGR D, V68, P42, DOI 10.1107/S0907444911049833; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 2000, NAT STRUCT BIOL, V7, P104; POWERS T, 1994, J MOL BIOL, V235, P156, DOI 10.1016/S0022-2836(05)80023-3; Praznikar J, 2009, ACTA CRYSTALLOGR D, V65, P921, DOI 10.1107/S0907444909021933; Rodnina MV, 2005, FEBS LETT, V579, P938, DOI 10.1016/j.febslet.2004.11.048; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; Schmeing TM, 2011, NAT STRUCT MOL BIOL, V18, P432, DOI 10.1038/nsmb.2003; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Schuette JC, 2009, EMBO J, V28, P755, DOI 10.1038/emboj.2009.26; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Voorhees RM, 2010, SCIENCE, V330, P835, DOI 10.1126/science.1194460; Voorhees RM, 2009, NAT STRUCT MOL BIOL, V16, P528, DOI 10.1038/nsmb.1577; Whitford PC, 2010, RNA, V16, P1196, DOI 10.1261/rna.2035410; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722; Zaher HS, 2009, CELL, V136, P746, DOI 10.1016/j.cell.2009.01.036	31	232	237	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					256	U146		10.1038/nature10913	http://dx.doi.org/10.1038/nature10913			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22437501				2022-12-28	WOS:000303149900038
J	Morrow, DA; Braunwald, E; Bonaca, MP; Ameriso, SF; Dalby, AJ; Fish, MP; Fox, KAA; Lipka, LJ; Liu, X; Nicolau, JC; Ophuis, AJO; Paolasso, E; Scirica, BM; Spinar, J; Theroux, P; Wiviott, SD; Strony, J; Murphy, SA				Morrow, David A.; Braunwald, Eugene; Bonaca, Marc P.; Ameriso, Sebastian F.; Dalby, Anthony J.; Fish, Mary Polly; Fox, Keith A. A.; Lipka, Leslie J.; Liu, Xuan; Nicolau, Jose Carlos; Ophuis, A. J. Oude; Paolasso, Ernesto; Scirica, Benjamin M.; Spinar, Jindrich; Theroux, Pierre; Wiviott, Stephen D.; Strony, John; Murphy, Sabina A.		TRA 2P-TIMI 50 Steering Comm Inves	Vorapaxar in the Secondary Prevention of Atherothrombotic Events	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; CLOPIDOGREL; SAFETY; ASPIRIN; TOLERABILITY; ANTAGONISTS; PRASUGREL; ATOPAXAR; EFFICACY; LESSONS	BACKGROUND Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)	[Morrow, David A.; Braunwald, Eugene; Bonaca, Marc P.; Fish, Mary Polly; Scirica, Benjamin M.; Wiviott, Stephen D.; Murphy, Sabina A.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Dept Med, Boston, MA 02115 USA; [Ameriso, Sebastian F.] FLENI, Neurol Res Inst, Buenos Aires, DF, Argentina; [Dalby, Anthony J.] Milpark Hosp, Johannesburg, South Africa; [Fox, Keith A. A.] Univ Edinburgh, Div Cardiovasc Res, Edinburgh, Midlothian, Scotland; [Lipka, Leslie J.; Liu, Xuan; Strony, John] Merck Res Labs, Rahway, NJ USA; [Nicolau, Jose Carlos] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil; [Ophuis, A. J. Oude] Canisius Wilhelmina Hosp, Nijmegen, Netherlands; [Paolasso, Ernesto] Inst Invest Clin Rosario, Rosario, Santa Fe, Argentina; [Spinar, Jindrich] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic; [Theroux, Pierre] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Theroux, Pierre] Univ Montreal, Montreal, PQ, Canada	Harvard University; Brigham & Women's Hospital; University of Edinburgh; Merck & Company; Universidade de Sao Paulo; Canisius-Wilhelmina Hospital; Masaryk University Brno; University Hospital Brno; Universite de Montreal; Universite de Montreal	Morrow, DA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	dmorrow@partners.org	Reverté Villarroya, Silvia/AAX-7360-2020; corrada, elena/GZK-5818-2022; Spratt, James/AAH-3589-2020; Danzi, Gian Battista/P-2244-2016; Scrutinio, Domenico/E-8074-2019; Kubica, Jacek/D-6906-2014; WORNER, FERNANDO/A-6821-2010; Macleod, Malcolm Robert/B-2052-2010; Ponikowski, Piotr/O-6454-2015; Sobiczewski, Wojciech T/E-9256-2012; Tanne, David/F-2560-2010; ameriso, sebastian/AAV-2296-2020; Tauil, Carlos Bernardo/T-3095-2019; De Caterina, Raffaele/K-3857-2016; Urina-Triana, Miguel A/H-2605-2016; Bonaca, Marc/AAJ-2397-2021; Chaves, Marcia L F/K-8353-2014; Bar, Michal/I-4516-2017; Aladro, Yolanda/GSE-3319-2022; Neto, Jose R Faria/G-7559-2012; FERNANDEZ-VAZQUEZ, FELIPE FFV/R-8969-2018; Nicolau, Jose C/E-1487-2012; Quere, Isabelle/AAB-8519-2020; Vanhooren, Geert/H-4433-2011; Fox, keith A A/I-3742-2013; Aroney, Con/A-7672-2013; Linhart, Ales/O-2375-2017; Řiháček, Ivan/F-7871-2017; Hamann, Gerhard F./J-6300-2014; Miranda, Fausto/N-9780-2018; Esposito, Giovanni/F-2880-2010; Wiviott, Stephen/HIK-2534-2022; Hankey, Graeme J/H-4968-2014; marcheselli, simona/L-2972-2013; Ayo-Martin, Oscar/Q-8541-2017; Herzig, Roman/O-8901-2017; Bath, Philip/F-9020-2011	Reverté Villarroya, Silvia/0000-0002-2052-9978; corrada, elena/0000-0002-6200-5152; Spratt, James/0000-0001-8719-4538; Danzi, Gian Battista/0000-0003-0897-8006; Scrutinio, Domenico/0000-0002-8535-3264; Kubica, Jacek/0000-0001-8250-754X; Macleod, Malcolm Robert/0000-0001-9187-9839; Ponikowski, Piotr/0000-0002-3391-7064; Sobiczewski, Wojciech T/0000-0001-6583-9147; Tanne, David/0000-0002-6699-2220; Tauil, Carlos Bernardo/0000-0003-1137-2398; De Caterina, Raffaele/0000-0003-1637-574X; Urina-Triana, Miguel A/0000-0001-6003-4622; Bonaca, Marc/0000-0002-9860-3584; Chaves, Marcia L F/0000-0002-1940-4043; Bar, Michal/0000-0002-5049-5844; Aladro, Yolanda/0000-0001-9459-5452; Neto, Jose R Faria/0000-0002-1397-0634; FERNANDEZ-VAZQUEZ, FELIPE FFV/0000-0001-7187-1290; Nicolau, Jose C/0000-0002-9680-3689; Quere, Isabelle/0000-0002-1492-9764; Vanhooren, Geert/0000-0001-6818-9346; Aroney, Con/0000-0002-0908-7179; Linhart, Ales/0000-0002-3372-7850; Řiháček, Ivan/0000-0003-2434-5807; Miranda, Fausto/0000-0003-2954-8638; Esposito, Giovanni/0000-0003-0565-7127; Hankey, Graeme J/0000-0002-6044-7328; Isasti, Guillermo/0000-0001-7262-8620; REY, RAUL CARLOS/0000-0002-8057-2169; Sinnaeve, Peter/0000-0003-4716-5892; CARUGO, STEFANO/0000-0002-5166-0899; Marenzi, Giancarlo/0000-0003-4410-4461; Ramotowski, Bogumil/0000-0001-7267-2621; GALINIER, Michel/0000-0003-1735-3390; TRITTO, Isabella/0000-0003-0026-7154; Csanyi, Attila/0000-0002-2368-3751; Timsit, Serge/0000-0003-0346-8576; Jensen, Majken Karoline/0000-0003-4729-7545; Marin-Neto, Jose Antonio/0000-0002-8651-8833; marcheselli, simona/0000-0002-7238-4088; Jaramillo, Monica/0000-0003-0100-5682; Wuttig, Helge/0000-0003-1877-8905; Rynkiewicz, Andrzej/0000-0002-5284-9511; Gorog, Diana/0000-0002-9286-1451; Fox, Keith/0000-0002-0140-2752; Ayo-Martin, Oscar/0000-0002-3632-1696; Stanislav, Afanasiev/0000-0001-6497-1795; Roik, Marek/0000-0003-0761-426X; SUISSA, LAURENT/0000-0003-2345-8711; Morrow, David/0000-0002-9589-5382; Stramba-Badiale, Marco/0000-0001-5900-811X; Iversen, Helle Klingenberg/0000-0002-5880-6352; Moulin, thierry/0000-0002-6639-8117; Coetsee, Elizabeth/0000-0002-9214-4647; A. Samad, Bassem/0000-0001-9440-5073; samson, yves/0000-0002-8080-1427; McDonough, Caitrin/0000-0001-6393-7288; Katz, Amos/0000-0003-0422-934X; Mansouri, Vahid/0000-0001-8472-9058; Simal, Patricia/0000-0002-5555-5308; Herzig, Roman/0000-0001-7238-7724; Fiszer, Urszula/0000-0002-9286-2454; solinas, emilia/0000-0003-3532-1317; Mikulik, Robert/0000-0002-7458-5166; Welsh, Robert/0000-0003-2613-9142; Chew, Derek/0000-0003-3593-296X; HERNANDEZ-TRIANA, ERIC/0000-0002-9233-3448; Garcia-Moll, Xavier/0000-0001-7837-8378; Manzur, Fernando/0000-0001-6679-5609; Van de Werf, Frans/0000-0001-9479-7767; Aylward, Philip/0000-0002-5358-8552; ELBAZ, Meyer/0000-0002-3520-7883; Konstantinides, Stavros/0000-0001-6359-7279; Vatrano, Marco/0000-0003-1469-1714; Christensen, Hanne/0000-0002-7472-3194; Bath, Philip/0000-0003-2734-5132; Theurl, Markus/0000-0002-3609-9730; Wahlgren, Carl Magnus/0000-0002-9619-3577; Airaksinen, Juhani/0000-0002-0193-568X	Merck	Merck(Merck & Company)	Supported by Merck.	Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Bhatt DL, 2007, J AM COLL CARDIOL, V49, P1982, DOI 10.1016/j.jacc.2007.03.025; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Chackalamannil S, 2005, J MED CHEM, V48, P5884, DOI 10.1021/jm0502236; Chackalamannil S, 2006, J MED CHEM, V49, P5389, DOI 10.1021/jm0603670; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Goto S, 2010, J ATHEROSCLER THROMB, V17, P156, DOI 10.5551/jat.3038; Leger AJ, 2006, CIRCULATION, V114, P1070, DOI 10.1161/CIRCULATIONAHA.105.574830; Morrow DA, 2009, AM HEART J, V158, P335, DOI 10.1016/j.ahj.2009.06.027; O'Donoghue ML, 2011, CIRCULATION, V123, P1843, DOI 10.1161/CIRCULATIONAHA.110.000786; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Wiviott SD, 2011, AM J CARDIOL, V108, P905, DOI 10.1016/j.amjcard.2011.05.020; Wiviott SD, 2011, CIRCULATION, V123, P1854, DOI 10.1161/CIRCULATIONAHA.110.001404; Yusuf S, 2001, NEW ENGL J MED, V345, P1716	18	690	714	3	131	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1404	1413		10.1056/NEJMoa1200933	http://dx.doi.org/10.1056/NEJMoa1200933			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923GV	22443427	Green Published, Bronze			2022-12-28	WOS:000302608600004
J	Shibata, Y; Kumar, P; Layer, R; Willcox, S; Gagan, JR; Griffith, JD; Dutta, A				Shibata, Yoshiyuki; Kumar, Pankaj; Layer, Ryan; Willcox, Smaranda; Gagan, Jeffrey R.; Griffith, Jack D.; Dutta, Anindya			Extrachromosomal MicroDNAs and Chromosomal Microdeletions in Normal Tissues	SCIENCE			English	Article							MULTIPLE DISPLACEMENT AMPLIFICATION; CIRCULAR DNA; HUMAN GENOME; CHROMATIN; VARIANTS; TRAITS	We have identified tens of thousands of short extrachromosomal circular DNAs (microDNA) in mouse tissues as well as mouse and human cell lines. These microDNAs are 200 to 400 base pairs long, are derived from unique nonrepetitive sequence, and are enriched in the 5'-untranslated regions of genes, exons, and CpG islands. Chromosomal loci that are enriched sources of microDNA in the adult brain are somatically mosaic for microdeletions that appear to arise from the excision of microDNAs. Germline microdeletions identified by the "Thousand Genomes" project may also arise from the excision of microDNAs in the germline lineage. We have thus identified a previously unknown DNA entity in mammalian cells and provide evidence that their generation leaves behind deletions in different genomic loci.	[Shibata, Yoshiyuki; Kumar, Pankaj; Layer, Ryan; Gagan, Jeffrey R.; Dutta, Anindya] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Willcox, Smaranda; Griffith, Jack D.] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA	University of Virginia; University of North Carolina; University of North Carolina Chapel Hill	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Kumar, Pankaj/0000-0002-8702-8879; Gagan, Jeffrey/0000-0003-4676-9969; Dutta, Anindya/0000-0002-4319-0073	 [R01 CA60499];  [GM84465];  [GM31819];  [ESO13773]; NATIONAL CANCER INSTITUTE [R01CA060499, P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084465, R01GM031819, T32GM007267, T32GM008136] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by R01 CA60499 and GM84465 (to A. D.), and GM31819 and ESO13773 (to J.D.G.). We thank all members of the Dutta Lab for helpful discussions and A. Prorock for assistance with DNA sequencing. Accession number for the sequence data submitted to Gene Expression Omnibus: GSE36088.	Beckmann JS, 2007, NAT REV GENET, V8, P639, DOI 10.1038/nrg2149; Changolkar LN, 2010, MOL CELL BIOL, V30, P5473, DOI 10.1128/MCB.00518-10; Cohen S, 2009, CYTOGENET GENOME RES, V124, P327, DOI 10.1159/000218136; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Flores M, 2007, P NATL ACAD SCI USA, V104, P6099, DOI 10.1073/pnas.0701631104; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hideo Y., 1983, GENE, V26, P317; Lolle SJ, 2005, NATURE, V434, P505, DOI 10.1038/nature03380; Lovmar L, 2006, HUM MUTAT, V27, P603, DOI 10.1002/humu.20341; Lupski JR, 2010, NAT GENET, V42, P1036, DOI 10.1038/ng1210-1036; Maeda T, 2004, BIOCHEM BIOPH RES CO, V319, P1117, DOI 10.1016/j.bbrc.2004.05.093; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002; Shibata Y, 2010, GENOME MED, V2, DOI 10.1186/gm191; SMITH CA, 1972, J MOL BIOL, V69, P163, DOI 10.1016/0022-2836(72)90222-7; Stankiewicz P, 2010, ANNU REV MED, V61, P437, DOI 10.1146/annurev-med-100708-204735; THRESHER R, 1992, METHOD ENZYMOL, V211, P481	19	141	146	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 6	2012	336	6077					82	86		10.1126/science.1213307	http://dx.doi.org/10.1126/science.1213307			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920LG	22403181	Green Accepted, Green Submitted			2022-12-28	WOS:000302405400056
J	Machan, M; Tonkovic-Capin, V				Machan, Mac; Tonkovic-Capin, Viseslav			Fordyce's Angiokeratomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Machan, Mac; Tonkovic-Capin, Viseslav] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Machan, M (corresponding author), Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.	mmachan@kumc.edu							0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1240	1240		10.1056/NEJMicm1104749	http://dx.doi.org/10.1056/NEJMicm1104749			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455418				2022-12-28	WOS:000302005100012
J	Checkley, AM; Smith, A; Smith, V; Blaze, M; Bradley, D; Chiodini, PL; Whitty, CJM				Checkley, Anna M.; Smith, Adrian; Smith, Valerie; Blaze, Marie; Bradley, David; Chiodini, Peter L.; Whitty, Christopher J. M.			Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMODIUM-FALCIPARUM; SURVEILLANCE DATA; TRAVELERS; IMMUNITY; IMMIGRANTS; GUIDELINES; CHRISTMAS; TANZANIA; DISEASES; DEATHS	Objectives To determine which travellers with malaria are at greatest risk of dying, highlighting factors which can be used to target health messages to travellers. Design Observational study based on 20 years of UK national data. Setting National register of malaria cases. Participants 25 054 patients notified with Plasmodium falciparum malaria, of whom 184 died, between 1987 and 2006. Main outcome measures Comparison between those with falciparum malaria who died and non-fatal cases, including age, reason for travel, country of birth, time of year diagnosed, malaria prophylaxis used. Results Mortality increased steadily with age, with a case fatality of 25/548 (4.6%) in people aged >65 years, adjusted odds ratio 10.68 (95% confidence interval 6.4 to 17.8), P < 0.001 compared with 18-35 year olds. There were no deaths in the <= 5 year age group. Case fatality was 3.0% (81/2740 cases) in tourists compared with 0.32% (26/8077) in travellers visiting friends and relatives (adjusted odds ratio 8.2 (5.1 to 13.3), P < 0.001). Those born in African countries with endemic malaria had a case fatality of 0.4% (36/8937) compared with 2.4% (142/5849) in others (adjusted odds ratio 4.6 (3.1 to 9.9), P < 0.001). Case fatality was particularly high from the Gambia. There was an inverse correlation in mortality between region of presentation and number of cases seen in the region (R-2 = 0.72, P < 0.001). Most delay in fatal cases was in seeking care. Conclusions Most travellers acquiring malaria are of African heritage visiting friends and relatives. In contrast the risks of dying from malaria once acquired are highest in the elderly, tourists, and those presenting in areas in which malaria is seldom seen. Doctors often do not think of these as high risk groups for malaria; for this reason they are important groups to target in pre-travel advice.	[Checkley, Anna M.; Smith, Valerie; Blaze, Marie; Bradley, David; Chiodini, Peter L.; Whitty, Christopher J. M.] HPA Malaria Reference Lab, London WC1B 3DP, England; [Checkley, Anna M.; Smith, Valerie; Blaze, Marie; Bradley, David; Chiodini, Peter L.; Whitty, Christopher J. M.] Univ London London Sch Hyg & Trop Med, London WC1B 3DP, England; [Smith, Adrian] Univ Oxford, Oxford OX1 2JD, England; [Chiodini, Peter L.] Hosp Trop Dis London, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; University College London Hospitals NHS Foundation Trust	Whitty, CJM (corresponding author), HPA Malaria Reference Lab, London WC1B 3DP, England.	Christopher.whitty@lshtm.ac.uk	Whitty, Christopher/C-7740-2012	Chiodini, Peter/0000-0003-0317-7090; Whitty, Christopher/0000-0002-6076-5027; Smith, Adrian/0000-0003-0036-1490	UK Health Protection Agency; UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme; Malaria Reference Laboratory	UK Health Protection Agency; UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme; Malaria Reference Laboratory	The Malaria Reference Laboratory is funded by the UK Health Protection Agency. AC has an Academic Clinical Lectureship. PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: PLC had support from the Malaria Reference Laboratory for the submitted work; PLC has received an honorarium from GlaxoSmithKline for a lecture on malaria in the previous 3 years. No other financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.	Angell SY, 2005, ANN INTERN MED, V142, P67, DOI 10.7326/0003-4819-142-1-200501040-00013; Ansah EK, 2010, BMJ-BRIT MED J, V340, P930; Baird JK, 1998, J INFECT DIS, V178, P592, DOI 10.1086/517482; Bouchaud O, 2005, AM J TROP MED HYG, V72, P21, DOI 10.4269/ajtmh.2005.72.21; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Bunn A, 2004, QJM-INT J MED, V97, P645, DOI 10.1093/qjmed/hch113; Cathcart SJ, 2010, EPIDEMIOL INFECT, V138, P1052, DOI 10.1017/S0950268809991130; Chandler CIR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-53; Christen D, 2006, AM J TROP MED HYG, V75, P1188, DOI 10.4269/ajtmh.2006.75.1188; de Savigny D, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-27; DELORON P, 1992, PARASITOL TODAY, V8, P375, DOI 10.1016/0169-4758(92)90174-Z; Dubos F, 2010, DIAGN MICR INFEC DIS, V66, P169, DOI 10.1016/j.diagmicrobio.2009.08.018; Fhogartaigh CN, 2008, QJM-INT J MED, V101, P649, DOI 10.1093/qjmed/hcn072; Gill CA, 1936, T ROY SOC TROP MED H, V29, P429; Gjorup IE, 2002, J TRAVEL MED, V9, P91, DOI 10.2310/7060.2002.21494; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; Jelinek T, 2002, CLIN INFECT DIS, V34, P572, DOI 10.1086/338235; Jelinek T, 2008, EUROSURVEILLANCE, V13, pii; Jensenius M, 1999, SCAND J INFECT DIS, V31, P73, DOI 10.1080/00365549950161925; Ladhani S, 2010, PEDIATR INFECT DIS J, V29, P434, DOI 10.1097/INF.0b013e3181c4d97c; Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003; Legros F, 2007, EMERG INFECT DIS, V13, P883, DOI 10.3201/eid1305.060955; Mascarello M, 2009, J TRAVEL MED, V16, P317, DOI 10.1111/j.1708-8305.2009.00321.x; Milne EMG, 2005, EUR J EPIDEMIOL, V20, P849, DOI 10.1007/s10654-005-2147-8; Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556; Moore DAJ, 2004, T ROY SOC TROP MED H, V98, P55, DOI 10.1016/S0035-9203(03)00007-5; Muhlberger N, 2003, CLIN INFECT DIS, V36, P990, DOI 10.1086/374224; Newman RD, 2004, ANN INTERN MED, V141, P547, DOI 10.7326/0003-4819-141-7-200410050-00012; Office for National Statistics, 2011, REG FORM GORS; Millet JP, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-56; Phillips DP, 2004, CIRCULATION, V110, P3781, DOI 10.1161/01.CIR.0000151424.02045.F7; Rogerson SJ, 2010, LANCET INFECT DIS, V10, P51, DOI 10.1016/S1473-3099(09)70322-6; Sabatinelli G, 2001, Euro Surveill, V6, P61; Smith AD, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a120; SOME ES, 1994, E AFR MED J, V71, P2; Soni PN, 1996, S AFR MED J, V86, P653; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744	38	75	76	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2012	344								e2116	10.1136/bmj.e2116	http://dx.doi.org/10.1136/bmj.e2116			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923EV	22454091	Green Published, Green Accepted, Green Submitted, hybrid			2022-12-28	WOS:000302603100003
J	Gulland, A				Gulland, Anne			Joined-up working: introducing the best teams of the year	BRITISH MEDICAL JOURNAL			English	Editorial Material												annecgulland@yahoo.co.uk							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 27	2012	344								e2328	10.1136/bmj.e2328	http://dx.doi.org/10.1136/bmj.e2328			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923EV	22453186				2022-12-28	WOS:000302603100022
J	Lewinsohn, TM; Cagnolo, L				Lewinsohn, Thomas M.; Cagnolo, Luciano			Keystones in a Tangled Bank	SCIENCE			English	Editorial Material							FOOD WEBS; NETWORKS		[Lewinsohn, Thomas M.] State Univ Campinas UNICAMP, Dept Anim Biol, BR-13083970 Campinas, SP, Brazil; [Cagnolo, Luciano] Univ Nacl Cordoba, Inst Multidisciplinario Biol Vegetal, RA-5000 Cordoba, Argentina	Universidade Estadual de Campinas; National University of Cordoba	Lewinsohn, TM (corresponding author), State Univ Campinas UNICAMP, Dept Anim Biol, BR-13083970 Campinas, SP, Brazil.	thomasl@unicamp.br; lcagnolo@efn.uncor.edu	Lewinsohn, Thomas M/D-5880-2012	Lewinsohn, Thomas M/0000-0001-5950-5343				Aizen MA, 2012, SCIENCE, V335, P1486, DOI 10.1126/science.1215320; Buchanan M., 2002, NEXUS SMALL WORLDS G; Kaartinen R, 2011, J ANIM ECOL, V80, P622, DOI 10.1111/j.1365-2656.2011.01811.x; Lewinsohn TM, 2006, OIKOS, V113, P174, DOI 10.1111/j.0030-1299.2006.14583.x; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Novotny V, 2010, J ANIM ECOL, V79, P1193, DOI 10.1111/j.1365-2656.2010.01728.x; PAINE RT, 1969, AM NAT, V103, P91, DOI 10.1086/282586; PASCUAL M, 2006, ECOLOGICAL NETWORKS; Pocock MJO, 2012, SCIENCE, V335, P973, DOI 10.1126/science.1214915; Sabatino M, 2010, ECOL APPL, V20, P1491, DOI 10.1890/09-1626.1; Stouffer DB, 2012, SCIENCE, V335, P1489, DOI 10.1126/science.1216556; Stouffer DB, 2010, ECOL LETT, V13, P154, DOI 10.1111/j.1461-0248.2009.01407.x; Waser NM., 2006, PLANT POLLINATOR INT; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	14	15	15	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1449	1451		10.1126/science.1220138	http://dx.doi.org/10.1126/science.1220138			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442469	Green Published			2022-12-28	WOS:000301837000030
J	Zhang, X; Zhang, HJ; Wang, J; Felser, C; Zhang, SC				Zhang, Xiao; Zhang, Haijun; Wang, Jing; Felser, Claudia; Zhang, Shou-Cheng			Actinide Topological Insulator Materials with Strong Interaction	SCIENCE			English	Article							SEMICONDUCTORS; TRANSITION; SURFACE; STATES	Topological band insulators have recently been discovered in spin-orbit coupled two-and three-dimensional systems. We theoretically predict a class of topological insulators where interaction effects play a dominant role. In actinide elements, simple rocksalt compounds formed by Pu and Am lie on the boundary between metals and insulators. We show that interaction drives a quantum phase transition to a topological insulator phase with a single Dirac cone on the surface. These putative topological insulators may provide a setting for both applied and fundamental investigation.	[Zhang, Xiao; Zhang, Haijun; Wang, Jing; Zhang, Shou-Cheng] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Felser, Claudia] Johannes Gutenberg Univ Mainz, Inst Inorgan & Analyt Chem, D-55099 Mainz, Germany; [Felser, Claudia] Max Planck Inst Chem Phys Solids, Dresden, Germany	Stanford University; Johannes Gutenberg University of Mainz; Max Planck Society	Zhang, SC (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	sczhang@stanford.edu	Zhang, Haijun/E-5098-2013; Zhang, Xiao/D-9996-2018; Felser, Claudia/A-5779-2009; Zhang, Shou-Cheng/B-2794-2010; Wang, Jing/E-5925-2012	Felser, Claudia/0000-0002-8200-2063; Wang, Jing/0000-0002-4674-9485; Zhang, Haijun/0000-0002-9958-1102	U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering [DE-AC02-76SF00515]; Army Research Office [W911NF-09-1-0508]	U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering(United States Department of Energy (DOE)); Army Research Office	We thank S. Raghu for useful discussions. This work is supported by the U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering, under contract DE-AC02-76SF00515 and in part by the Army Research Office under the grant number W911NF-09-1-0508.	ANISIMOV VI, 1991, PHYS REV B, V44, P943, DOI 10.1103/PhysRevB.44.943; ANISIMOV VI, 1993, PHYS REV B, V48, P16929, DOI 10.1103/PhysRevB.48.16929; Bernevig BA, 2006, SCIENCE, V314, P1757, DOI 10.1126/science.1133734; BROOKS MSS, 1987, J MAGN MAGN MATER, V63-4, P649, DOI 10.1016/0304-8853(87)90693-7; Dzero M, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.045130; Fang Z, 2002, J PHYS-CONDENS MAT, V14, P3001, DOI 10.1088/0953-8984/14/11/312; Fu L, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.045302; Fu L, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.096407; Ghosh DB, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115123; Gouder T, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115122; Hasan MZ, 2010, REV MOD PHYS, V82, P3045, DOI 10.1103/RevModPhys.82.3045; Ichas V, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.045109; Kanellakopulos B., 1976, TRANSPLUTONIUM 1975; Li RD, 2010, NAT PHYS, V6, P284, DOI 10.1038/NPHYS1534; LUTTINGER JM, 1956, PHYS REV, V102, P1030, DOI 10.1103/PhysRev.102.1030; Marzari N, 1997, PHYS REV B, V56, P12847, DOI 10.1103/PhysRevB.56.12847; Moore KT, 2009, REV MOD PHYS, V81, P235, DOI 10.1103/RevModPhys.81.235; Qi XL, 2011, REV MOD PHYS, V83, DOI 10.1103/RevModPhys.83.1057; Qi XL, 2010, PHYS TODAY, V63, P33, DOI 10.1063/1.3293411; Qi XL, 2009, SCIENCE, V323, P1184, DOI 10.1126/science.1167747; Raghu S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.156401; Souza I, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.035109; Suzuki MT, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.161103; Suzuki S, 2007, J PHYS SOC JPN, V76, DOI 10.1143/JPSJ.76.024707; VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892; WASTIN F, 1995, J ALLOY COMPD, V219, P232, DOI 10.1016/0925-8388(94)05016-3; Zhang HJ, 2009, NAT PHYS, V5, P438, DOI 10.1038/NPHYS1270	28	83	83	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1464	1466		10.1126/science.1216184	http://dx.doi.org/10.1126/science.1216184			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442476	Green Submitted			2022-12-28	WOS:000301837000038
J	Amole, C; Ashkezari, MD; Baquero-Ruiz, M; Bertsche, W; Bowe, PD; Butler, E; Capra, A; Cesar, CL; Charlton, M; Deller, A; Donnan, PH; Eriksson, S; Fajans, J; Friesen, T; Fujiwara, MC; Gill, DR; Gutierrez, A; Hangst, JS; Hardy, WN; Hayden, ME; Humphries, AJ; Isaac, CA; Jonsell, S; Kurchaninov, L; Little, A; Madsen, N; McKenna, JTK; Menary, S; Napoli, SC; Nolan, P; Olchanski, K; Olin, A; Pusa, P; Rasmussen, CO; Robicheaux, F; Sarid, E; Shields, CR; Silveira, DM; Stracka, S; So, C; Thompson, RI; van der Werf, DP; Wurtele, JS				Amole, C.; Ashkezari, M. D.; Baquero-Ruiz, M.; Bertsche, W.; Bowe, P. D.; Butler, E.; Capra, A.; Cesar, C. L.; Charlton, M.; Deller, A.; Donnan, P. H.; Eriksson, S.; Fajans, J.; Friesen, T.; Fujiwara, M. C.; Gill, D. R.; Gutierrez, A.; Hangst, J. S.; Hardy, W. N.; Hayden, M. E.; Humphries, A. J.; Isaac, C. A.; Jonsell, S.; Kurchaninov, L.; Little, A.; Madsen, N.; McKenna, J. T. K.; Menary, S.; Napoli, S. C.; Nolan, P.; Olchanski, K.; Olin, A.; Pusa, P.; Rasmussen, C. O.; Robicheaux, F.; Sarid, E.; Shields, C. R.; Silveira, D. M.; Stracka, S.; So, C.; Thompson, R. I.; van der Werf, D. P.; Wurtele, J. S.			Resonant quantum transitions in trapped antihydrogen atoms	NATURE			English	Article							MAGNETIC TRAP; CONFINEMENT	The hydrogen atom is one of the most important and influential model systems in modern physics. Attempts to understand its spectrum are inextricably linked to the early history and development of quantum mechanics. The hydrogen atom's stature lies in its simplicity and in the accuracy with which its spectrum can be measured(1) and compared to theory. Today its spectrum remains a valuable tool for determining the values of fundamental constants and for challenging the limits of modern physics, including the validity of quantum electrodynamics and-by comparison with measurements on its antimatter counterpart, antihydrogen-the validity of CPT (charge conjugation, parity and time reversal) symmetry. Here we report spectroscopy of a pure antimatter atom, demonstrating resonant quantum transitions in antihydrogen. We have manipulated the internal spin state(2,3) of antihydrogen atoms so as to induce magnetic resonance transitions between hyperfine levels of the positronic ground state. We used resonant microwave radiation to flip the spin of the positron in antihydrogen atoms that were magnetically trapped(4-6) in the ALPHA apparatus. The spin flip causes trapped anti-atoms to be ejected from the trap. We look for evidence of resonant interaction by comparing the survival rate of trapped atoms irradiated with microwaves on-resonance to that of atoms subjected to microwaves that are off-resonance. In one variant of the experiment, we detect 23 atoms that survive in 110 trapping attempts with microwaves off-resonance (0.21 per attempt), and only two atoms that survive in 103 attempts with microwaves on-resonance (0.02 per attempt). We also describe the direct detection of the annihilation of antihydrogen atoms ejected by the microwaves.	[Bowe, P. D.; Hangst, J. S.; Rasmussen, C. O.] Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; [Amole, C.; Capra, A.; Menary, S.] York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada; [Ashkezari, M. D.; Hayden, M. E.] Simon Fraser Univ, Dept Phys, Burnaby, BC V5A 1S6, Canada; [Baquero-Ruiz, M.; Fajans, J.; Little, A.; So, C.; Wurtele, J. S.] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Bertsche, W.; Charlton, M.; Deller, A.; Eriksson, S.; Humphries, A. J.; Isaac, C. A.; Madsen, N.; Napoli, S. C.; Shields, C. R.; van der Werf, D. P.] Swansea Univ, Dept Phys, Swansea SA2 8PP, W Glam, Wales; [Bertsche, W.] Univ Manchester, Sch Phys & Astron, Manchester M13 9PL, Lancs, England; [Bertsche, W.] Cockcroft Inst, Warrington WA4 4AD, Cheshire, England; [Butler, E.] CERN, Dept PH, CH-1211 Geneva 23, Switzerland; [Cesar, C. L.] Univ Fed Rio de Janeiro, Inst Fis, BR-21941972 Rio De Janeiro, Brazil; [Donnan, P. H.; Robicheaux, F.] Auburn Univ, Dept Phys, Auburn, AL 36849 USA; [Fajans, J.; Wurtele, J. S.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Friesen, T.; Fujiwara, M. C.; Thompson, R. I.] Univ Calgary, Dept Phys & Astron, Calgary, AB T2N 1N4, Canada; [Fujiwara, M. C.; Gill, D. R.; Kurchaninov, L.; Olchanski, K.; Olin, A.; Stracka, S.] TRIUMF, Vancouver, BC V6T 2A3, Canada; [Gutierrez, A.; Hardy, W. N.] Univ British Columbia, Dept Geophys & Astron, Vancouver, BC V6T 1Z1, Canada; [Hardy, W. N.] Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada; [Jonsell, S.] Stockholm Univ, Dept Phys, SE-10691 Stockholm, Sweden; [McKenna, J. T. K.; Nolan, P.; Pusa, P.] Univ Liverpool, Dept Phys, Liverpool L69 7ZE, Merseyside, England; [Olin, A.] Univ Victoria, Dept Phys & Astron, Victoria, BC V8W 3P6, Canada; [Sarid, E.] Nucl Res Ctr Negev, Dept Phys, IL-84190 Beer Sheva, Israel; [Silveira, D. M.] RIKEN, Atom Phys Lab, Wako, Saitama 3510198, Japan	Aarhus University; York University - Canada; Simon Fraser University; University of California System; University of California Berkeley; Swansea University; University of Manchester; STFC Daresbury Laboratory; European Organization for Nuclear Research (CERN); Universidade Federal do Rio de Janeiro; Auburn University System; Auburn University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Calgary; University of British Columbia; University of British Columbia; Canadian Institute for Advanced Research (CIFAR); Stockholm University; University of Liverpool; University of Victoria; RIKEN	Hangst, JS (corresponding author), Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark.	hangst@phys.au.dk; mhayden@sfu.ca	quantica, Inct Informacao/H-9493-2013; Stracka, Simone/M-3931-2015; Donnan, Patrick/C-4481-2013; Fajans, Joel/J-6597-2016; Cesar, Claudio/AAH-4612-2021; Madsen, Niels/G-3548-2013; Hardy, Walter Newbold/AAN-7827-2020; Madsen, Niels/I-2314-2019; Bertsche, William/A-3678-2012; Little, Anthony/W-2732-2019; Wurtele, Jonathan S/J-6278-2016; Jonsell, Svante/J-2251-2016; Robicheaux, Francis/F-4343-2014	Stracka, Simone/0000-0003-0013-4714; Fajans, Joel/0000-0002-4403-6027; Madsen, Niels/0000-0002-7372-0784; Madsen, Niels/0000-0002-7372-0784; Bertsche, William/0000-0002-6565-9282; Little, Anthony/0000-0001-9100-1903; Wurtele, Jonathan S/0000-0001-8401-0297; Jonsell, Svante/0000-0003-4969-1714; McKenna, Joseph/0000-0002-7838-4230; Deller, Adam/0000-0002-3430-1501; Cesar, Claudio/0000-0003-2638-0032; Eriksson, Stefan/0000-0002-5390-1879; Isaac, Aled/0000-0002-7813-1903; Friesen, Timothy/0000-0002-7017-9662; Butler, Eoin/0000-0003-0947-7166; Capra, Andrea/0000-0001-9499-0380; Rasmussen, Chris Orum/0000-0002-6029-1730; Donnan, Patrick H./0000-0002-8076-2683; van der Werf, Dirk/0000-0001-5436-5214; Kurchaninov, Leonid/0000-0001-9392-3936; Robicheaux, Francis/0000-0002-8054-6040	CNPq (Brazil); FINEP/RENAFAE (Brazil); ISF (Israel); MEXT (Japan); FNU (Denmark); VR (Sweden); NSERC (Canada); NRC/TRIUMF (Canada); AITF (Canada); FQRNT (Canada); DOE (USA); NSF (USA); EPSRC (UK); Royal Society (UK); Leverhulme Trust (UK); CERN; Engineering and Physical Sciences Research Council [EP/H02431X/1, EP/E048951/1, EP/F019785/1, EP/H026932/1] Funding Source: researchfish; Science and Technology Facilities Council [ST/G008248/1] Funding Source: researchfish; EPSRC [EP/H026932/1, EP/F019785/1, EP/E048951/1, EP/H02431X/1] Funding Source: UKRI; STFC [ST/G008248/1] Funding Source: UKRI	CNPq (Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FINEP/RENAFAE (Brazil)(Financiadora de Inovacao e Pesquisa (Finep)); ISF (Israel)(Israel Science Foundation); MEXT (Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); FNU (Denmark)(Danish Natural Science Research Council); VR (Sweden)(Swedish Research Council); NSERC (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NRC/TRIUMF (Canada); AITF (Canada); FQRNT (Canada)(FQRNT); DOE (USA)(United States Department of Energy (DOE)); NSF (USA)(National Science Foundation (NSF)); EPSRC (UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society (UK)(Royal Society of London); Leverhulme Trust (UK)(Leverhulme Trust); CERN; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	This work was supported by CNPq, FINEP/RENAFAE (Brazil), ISF (Israel), MEXT (Japan), FNU (Denmark), VR (Sweden), NSERC, NRC/TRIUMF, AITF, FQRNT (Canada), DOE, NSF (USA), EPSRC, the Royal Society and the Leverhulme Trust (UK). We thank them for their generous support. We are grateful to the AD team (T. Eriksson, P. Belochitskii, B. Dupuy, L. Bojtar, C. Oliveira, B. Lefort and G. Tranquille) for the delivery of a high-quality antiproton beam. We thank the following individuals for help: M. Harrison, J. Escallier, A. Marone, M. Anerella, A. Ghosh, B. Parker, G. Ganetis, J. Thornhill, D. Wells, D. Seddon, F. Butin, H. Brueker, K. Dahlerup-Pedersen, J. Mourao, T. Fowler, S. Russenschuck, R. De Oliveira, N. Wauquier, J. Hansen, M. Polini, J. M. Geisser, L. Deparis, P. Frichot, J. M. Malzacker, A. Briswalter, P. Moyret, S. Mathot, G. Favre, J. P. Brachet, P. Mesenge, S. Sgobba, A. Cherif, J. Bremer, J. Casas-Cubillos, N. Vauthier, G. Perinic, O. Pirotte, A. Perin, G. Perinic, B. Vullierme, D. Delkaris, N. Veillet, K. Barth, R. Consentino, S. Guido, L. Stewart, M. Malabaila, A. Mongelluzzo, P. Chiggiato, G. Willering, E. Mahner, A. Froton, C. Lasseur, F. Hahn, E. Sondergaard, F. Mikkelsen, W. Carlisle, A. Charman, J. Keller, P. Amaudruz, D. Bishop, R. Bula, K. Langton, P. Vincent, S. Chan, D. Rowbotham, P. Bennet, B. Evans, J.-P. Martin, P. Kowalski, A. Read, T. Willis, J. Kivell, H. Thomas, W. Lai, L. Wasilenko, C. Kolbeck, H. Malik, P. Genoa, L. Posada, R. Funakoshi, M. Okeane, S. Carey and N. Evetts. We thank former collaborators M. J. Jenkins, G. B. Andresen, R. Hydomako, S. Chapman, A. Povilus, R. Hayano, L. V. Jorgensen and Y. Yamazaki. We are grateful to the CERN Summer Student Program for funding the participation of undergraduate students (C. O. R. and S. C. N.) in our experiment.	Andresen GB, 2012, J INSTRUM, V7, DOI 10.1088/1748-0221/7/01/C01051; Andresen GB, 2011, NAT PHYS, V7, P558, DOI [10.1038/NPHYS2025, 10.1038/nphys2025]; Andresen GB, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.025002; Andresen GB, 2011, PHYS LETT B, V695, P95, DOI 10.1016/j.physletb.2010.11.004; Andresen GB, 2010, NATURE, V468, P673, DOI 10.1038/nature09610; Andresen GB, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.013003; Andresen G. B., NUCL INSTRUM A UNPUB; [Anonymous], 2005, STATPATTERNRECOGNITI; Bertsche W, 2006, NUCL INSTRUM METH A, V566, P746, DOI 10.1016/j.nima.2006.07.012; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; DEHMELT H, 1990, REV MOD PHYS, V62, P525, DOI 10.1103/RevModPhys.62.525; Fujiwara MC, 2006, HYPERFINE INTERACT, V172, P81, DOI 10.1007/s10751-007-9527-2; Hansch TW, 2006, REV MOD PHYS, V78, P1297, DOI 10.1103/RevModPhys.78.1297; HARDY WN, 1979, PHYS REV LETT, V42, P1042, DOI 10.1103/PhysRevLett.42.1042; MARTIN AG, 1988, PHYS REV LETT, V61, P2431, DOI 10.1103/PhysRevLett.61.2431; Maury S, 1997, HYPERFINE INTERACT, V109, P43, DOI 10.1023/A:1012632812327; Narsky I., 2005, OPTIMIZATION SIGNAL; PRITCHARD DE, 1983, PHYS REV LETT, V51, P1336, DOI 10.1103/PhysRevLett.51.1336; Przyborowski J, 1940, BIOMETRIKA, V31, P313, DOI 10.2307/2332612; Punzi G., 2003, ECONF; TINKLE MD, 1994, PHYS REV LETT, V72, P352, DOI 10.1103/PhysRevLett.72.352	21	117	117	0	59	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					439	U86		10.1038/nature10942	http://dx.doi.org/10.1038/nature10942			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22398451	Green Submitted, Green Accepted			2022-12-28	WOS:000301771200037
J	Kay, JN; Chu, MW; Sanes, JR				Kay, Jeremy N.; Chu, Monica W.; Sanes, Joshua R.			MEGF10 and MEGF11 mediate homotypic interactions required for mosaic spacing of retinal neurons	NATURE			English	Article							CHOLINERGIC AMACRINE CELLS; MOUSE RETINA; ENGULFMENT RECEPTOR; HORIZONTAL CELLS; RODENT RETINA; RESOURCE; MODELS; DSCAM	In many parts of the nervous system, neuronal somata display orderly spatial arrangements(1). In the retina, neurons of numerous individual subtypes form regular arrays called mosaics: they are less likely to be near neighbours of the same subtype than would occur by chance, resulting in 'exclusion zones' that separate them(1-4). Mosaic arrangements provide a mechanism to distribute each cell type evenly across the retina, ensuring that all parts of the visual field have access to a full set of processing elements(2). Remarkably, mosaics are independent of each other: although a neuron of one subtype is unlikely to be adjacent to another of the same subtype, there is no restriction on its spatial relationship to neighbouring neurons of other subtypes(5). This independence has led to the hypothesis that molecular cues expressed by specific subtypes pattern mosaics by mediating homotypic (within-subtype) short-range repulsive interactions(1,4-9). So far, however, no molecules have been identified that show such activity, so this hypothesis remains untested. Here we demonstrate in mouse that two related transmembrane proteins, MEGF10 and MEGF11, have critical roles in the formation of mosaics by two retinal interneuron subtypes, starburst amacrine cells and horizontal cells. MEGF10 and 11 and their invertebrate relatives Caenorhabditis elegans CED-1 and Drosophila Draper have hitherto been studied primarily as receptors necessary for engulfment of debris following apoptosis or axonal injury(10-14). Our results demonstrate that members of this gene family can also serve as subtype-specific ligands that pattern neuronal arrays.	[Kay, Jeremy N.; Chu, Monica W.; Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA; [Kay, Jeremy N.; Chu, Monica W.; Sanes, Joshua R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University	Sanes, JR (corresponding author), Harvard Univ, Ctr Brain Sci, 52 Oxford St, Cambridge, MA 02138 USA.	sanesj@mcb.harvard.edu			National Institutes of Health [NS029169, EY022073]; Life Sciences Research Foundation; NATIONAL EYE INSTITUTE [R01EY022073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029169, R37NS029169] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Life Sciences Research Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank B. Tilton, P. Rogers, J. Couget, and the Harvard Genome Modification Facility for technical assistance; S. Sarin and M. Yamagata for critical discussions; the National Institutes of Health (NS029169 and EY022073 to J. R. S.) and Life Sciences Research Foundation (J.N.K.) for funding.	Budry L, 2011, P NATL ACAD SCI USA, V108, P12515, DOI 10.1073/pnas.1105929108; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Cook JE, 2000, TRENDS NEUROSCI, V23, P26, DOI 10.1016/S0166-2236(99)01487-3; Demb JB, 2007, NEURON, V55, P179, DOI 10.1016/j.neuron.2007.07.001; Eglen SJ, 2006, MATH MED BIOL, V23, P79, DOI 10.1093/imammb/dql003; Elshatory Y, 2007, J NEUROSCI, V27, P12707, DOI 10.1523/JNEUROSCI.3951-07.2007; Fuerst PG, 2008, NATURE, V451, P470, DOI 10.1038/nature06514; Fuerst PG, 2009, NEURON, V64, P484, DOI 10.1016/j.neuron.2009.09.027; Galli-Resta L, 2000, DEVELOPMENT, V127, P1509; GalliResta L, 1997, J NEUROSCI, V17, P7831; GRAY GE, 1992, DEVELOPMENT, V114, P271; Hamon Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000120; Haverkamp S, 2000, J COMP NEUROL, V424, P1; Hong YK, 2011, J COMP NEUROL, V519, P1691, DOI 10.1002/cne.22595; Huberman AD, 2009, NEURON, V62, P327, DOI 10.1016/j.neuron.2009.04.014; Huckfeldt RM, 2009, NAT NEUROSCI, V12, P35, DOI 10.1038/nn.2236; Kay JN, 2011, NAT NEUROSCI, V14, P965, DOI 10.1038/nn.2859; Kay JN, 2011, J NEUROSCI, V31, P7753, DOI 10.1523/JNEUROSCI.0907-11.2011; Keeley PW, 2007, J COMP NEUROL, V505, P539, DOI 10.1002/cne.21518; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Poche RA, 2008, EUR J NEUROSCI, V27, P1607, DOI 10.1111/j.1460-9568.2008.06132.x; Raven MA, 2003, J COMP NEUROL, V461, P123, DOI 10.1002/cne.10693; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; Reese BE, 2002, PROG RETIN EYE RES, V21, P153, DOI 10.1016/S1350-9462(01)00024-6; Rockhill RL, 2000, P NATL ACAD SCI USA, V97, P2303, DOI 10.1073/pnas.030413497; RODIECK RW, 1991, VISUAL NEUROSCI, V6, P95, DOI 10.1017/S095252380001049X; Sanes JR, 2010, NEURON, V66, P15, DOI 10.1016/j.neuron.2010.01.018; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Solecki DJ, 2004, NAT NEUROSCI, V7, P1195, DOI 10.1038/nn1332; Suzuki E, 2007, EXP CELL RES, V313, P3729, DOI 10.1016/j.yexcr.2007.06.015; WASSLE H, 1978, PROC R SOC SER B-BIO, V200, P441, DOI 10.1098/rspb.1978.0026; Whitney IE, 2008, J COMP NEUROL, V508, P1, DOI 10.1002/cne.21630; Wiegand T, 2004, OIKOS, V104, P209, DOI 10.1111/j.0030-1299.2004.12497.x; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446	35	120	122	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					465	U117		10.1038/nature10877	http://dx.doi.org/10.1038/nature10877			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22407321	Green Accepted			2022-12-28	WOS:000301771200043
J	Verma, IM				Verma, Inder M.			Renato Dulbecco (1914-2012) OBITUARY	NATURE			English	Biographical-Item									Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, La Jolla, CA 92037 USA.	verma@salk.edu						DULBECCO R, PUBLICATION LIST	1	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					408	408		10.1038/483408a	http://dx.doi.org/10.1038/483408a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437605	Bronze			2022-12-28	WOS:000301771200026
J	Greysen, SR; Chretien, KC; Kind, T; Young, A; Gross, CP				Greysen, S. Ryan; Chretien, Katherine C.; Kind, Terry; Young, Aaron; Gross, Cary P.			Physician Violations of Online Professionalism and Disciplinary Actions: A National Survey of State Medical Boards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SOCIAL MEDIA		[Greysen, S. Ryan] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA; [Chretien, Katherine C.] Washington DC VA Med Ctr, Med Serv, Washington, DC USA; [Kind, Terry] Childrens Natl Med Ctr, Dept Med Educ, Washington, DC 20010 USA; [Young, Aaron] Federat State Med Boards, Washington, DC USA; [Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA	University of California System; University of California San Francisco; Children's National Health System; Robert Wood Johnson Foundation (RWJF); Yale University	Greysen, SR (corresponding author), Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA.	ryan.greysen@ucsf.edu		Kind, Terry/0000-0002-3017-5683				Chretien KC, 2011, JAMA-J AM MED ASSOC, V305, P566, DOI 10.1001/jama.2011.68; Greysen SR, 2010, J GEN INTERN MED, V25, P1227, DOI 10.1007/s11606-010-1447-1; Lagu T, 2008, J GEN INTERN MED, V23, P1642, DOI 10.1007/s11606-008-0726-6; Lagu T, 2011, J CLIN ETHIC, V22, P187; Morrison J, 1998, JAMA-J AM MED ASSOC, V279, P1889, DOI 10.1001/jama.279.23.1889; Shore R, 2011, J CLIN ETHIC, V22, P165	6	104	108	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1141	1142		10.1001/jama.2012.330	http://dx.doi.org/10.1001/jama.2012.330			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436951	Bronze			2022-12-28	WOS:000301708000017
J	Biermann, F; Abbott, K; Andresen, S; Backstrand, K; Bernstein, S; Betsill, MM; Bulkeley, H; Cashore, B; Clapp, J; Folke, C; Gupta, A; Gupta, J; Haas, PM; Jordan, A; Kanie, N; Kluvankova-Oravska, T; Lebel, L; Liverman, D; Meadowcroft, J; Mitchell, RB; Newell, P; Oberthur, S; Olsson, L; Pattberg, P; Sanchez-Rodriguez, R; Schroeder, H; Underdal, A; Vieira, SC; Vogel, C; Young, OR; Brock, A; Zondervan, R				Biermann, F.; Abbott, K.; Andresen, S.; Backstrand, K.; Bernstein, S.; Betsill, M. M.; Bulkeley, H.; Cashore, B.; Clapp, J.; Folke, C.; Gupta, A.; Gupta, J.; Haas, P. M.; Jordan, A.; Kanie, N.; Kluvankova-Oravska, T.; Lebel, L.; Liverman, D.; Meadowcroft, J.; Mitchell, R. B.; Newell, P.; Oberthur, S.; Olsson, L.; Pattberg, P.; Sanchez-Rodriguez, R.; Schroeder, H.; Underdal, A.; Camargo Vieira, S.; Vogel, C.; Young, O. R.; Brock, A.; Zondervan, R.			Navigating the Anthropocene: Improving Earth System Governance	SCIENCE			English	Editorial Material									[Biermann, F.; Gupta, J.; Pattberg, P.; Brock, A.] Vrije Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands; [Biermann, F.; Backstrand, K.; Olsson, L.; Zondervan, R.] Lund Univ, S-22100 Lund, Sweden; [Abbott, K.] Arizona State Univ, Tempe, AZ 85287 USA; [Andresen, S.] Fridtjof Nansen Inst Polhogda, N-1326 Lysaker, Norway; [Bernstein, S.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Betsill, M. M.] Colorado State Univ, Ft Collins, CO 80523 USA; [Bulkeley, H.] Univ Durham, Durham DH1 3LE, England; [Cashore, B.] Yale Univ, New Haven, CT 06511 USA; [Clapp, J.] Univ Waterloo, Waterloo, ON N2L 3G1, Canada; [Folke, C.] Stockholm Univ, Stockholm Resilience Ctr, S-10691 Stockholm, Sweden; [Folke, C.] Royal Swedish Acad Sci, Beijer Inst, S-10405 Stockholm, Sweden; [Gupta, A.] Univ Wageningen & Res Ctr, NL-6706 KN Wageningen, Netherlands; [Gupta, J.] UNESCO IHE Inst Water Educ, NL-2611 AX Delft, Netherlands; [Haas, P. M.] Univ Massachusetts, Amherst, MA 01003 USA; [Jordan, A.; Schroeder, H.] Univ E Anglia, Tyndall Ctr, Norwich NR4 7TJ, Norfolk, England; [Kanie, N.] Tokyo Inst Technol, Tokyo 1528552, Japan; [Kanie, N.] United Nations Univ, Inst Adv Studies, Yokohama, Kanagawa 2208502, Japan; [Kluvankova-Oravska, T.] Slovak Acad Sci, CETIP, Bratislava 81438, Slovakia; [Lebel, L.] Chiang Mai Univ, Chiang Mai 50200, Thailand; [Liverman, D.] Univ Arizona, Tucson, AZ 85721 USA; [Liverman, D.] Univ Oxford, Oxford OX1 2JD, England; [Meadowcroft, J.] Carleton Univ, Ottawa, ON K1S 5B6, Canada; [Mitchell, R. B.] Univ Oregon, Eugene, OR 97403 USA; [Newell, P.] Univ Sussex, Brighton BN1 9SN, E Sussex, England; [Oberthur, S.] Vrije Univ Brussel, B-1050 Brussels, Belgium; [Sanchez-Rodriguez, R.] Colegio Frontera Norte, Tijuana 22560, Mexico; [Sanchez-Rodriguez, R.] Univ Calif Riverside, Riverside, CA 92521 USA; [Underdal, A.] Univ Oslo, N-0317 Oslo, Norway; [Camargo Vieira, S.] Univ Itauna, BR-35680054 Itauna, MG, Brazil; [Young, O. R.] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA	Vrije Universiteit Amsterdam; Lund University; Arizona State University; Arizona State University-Tempe; University of Toronto; Colorado State University; Durham University; Yale University; University of Waterloo; Stockholm University; Royal Swedish Academy of Sciences; Beijer Institute of Ecological Economics; Wageningen University & Research; IHE Delft Institute for Water Education; University of Massachusetts System; University of Massachusetts Amherst; University of East Anglia; Tokyo Institute of Technology; United Nations University; Slovak Academy of Sciences; Chiang Mai University; University of Arizona; University of Oxford; Carleton University; University of Oregon; University of Sussex; Vrije Universiteit Brussel; Colegio Frontera Norte; University of California System; University of California Riverside; University of Oslo; Universidade de Itauna; University of California System; University of California Santa Barbara	Biermann, F (corresponding author), Vrije Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands.	frank.biermann@vu.nl	Betsill, Michele/GQY-4502-2022; Betsill, Michele/ABD-5548-2020; Gupta, Joyeeta/L-8672-2013; Clapp, Jennifer/GRO-3628-2022; Mitchell, Ronald/A-6997-2009; Folke, Carl/Z-1545-2019; Bulkeley, Harriet/Y-3348-2019; Biermann, Frank/D-4175-2013; Pattberg, Philipp/J-4141-2012; Lebel, Louis/D-4130-2014	Betsill, Michele/0000-0001-7090-904X; Mitchell, Ronald/0000-0002-7281-1035; Biermann, Frank/0000-0002-0292-0703; Abbott, Kenneth W./0000-0002-5540-1683; Schroeder, Heike/0000-0003-2342-2030; Pattberg, Philipp/0000-0003-1136-7791; Gupta, Aarti/0000-0003-4908-7453; Folke, Carl/0000-0002-4050-3281; Clapp, Jennifer/0000-0002-1871-8067; Lebel, Louis/0000-0001-6187-6418; Olsson, Lennart/0000-0001-8353-1074; Jordan, Andrew/0000-0001-7678-1024; Gupta, Joyeeta/0000-0003-1424-2660; Oberthur, Sebastian/0000-0001-8626-5082; Brock, Andrea/0000-0001-5771-5603	ESRC [ES/F037163/1] Funding Source: UKRI; Division Of Behavioral and Cognitive Sci [1134890] Funding Source: National Science Foundation; Economic and Social Research Council [ES/F037163/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Abbott K. W., 2006, ENVIRON LAW REP, V36, P10931; Abbott Kenneth W, 2006, RETHINKING DEV CARBO, V36, P10931; Bernstein S., 2005, J INT LAW INT RELATI, V1, P139, DOI DOI 10.1080/09692290903173087; Biermann F, 2000, ENVIRONMENT, V42, P22, DOI 10.1080/00139150009605762; Biermann F, 2007, GLOBAL ENVIRON CHANG, V17, P326, DOI 10.1016/j.gloenvcha.2006.11.010; Charnovitz S., 2002, GLOBAL ENV GOVERNANC, V27, P323; CHARNOVITZ S, 2002, COLUMBIA J ENV LAW, V27, P323; Earth System Governance Project, 2011, CHART MOM HAK VIS GO; Gupta A, 2010, GLOBAL ENVIRON POLIT, V10, P1, DOI 10.1162/GLEP_e_00011; Gupta J., 2010, MAINSTREAMING CLIMAT; Hovi J, 2006, GLOBAL ENVIRON POLIT, V6, P28, DOI 10.1162/glep.2006.6.3.28; Muller B, 2008, INT ADAPTATION FINAN; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Schellnhuber H. J., 2004, EARTH SYSTEM ANAL SU; Schellnhuber H.J., 2004, GLOBAL CHANGE EARTH; Science and Implementation Plan of the Earth System Governance Project, 2009, SCI IMPL PLAN EARTH; World Bank, 2009, WORLD DEV REP 2010 D; Young OR, 2008, INSTITUTIONS AND ENVIRONMENTAL CHANGE: PRINCIPAL FINDINGS, APPLICATIONS, AND RESEARCH FRONTIERS, P1	18	288	295	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074					1306	1307		10.1126/science.1217255	http://dx.doi.org/10.1126/science.1217255			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908ZM	22422966				2022-12-28	WOS:000301531600030
J	Gagnon, MG; Seetharaman, SV; Bulkley, D; Steitz, TA				Gagnon, Matthieu G.; Seetharaman, Sai V.; Bulkley, David; Steitz, Thomas A.			Structural Basis for the Rescue of Stalled Ribosomes: Structure of YaeJ Bound to the Ribosome	SCIENCE			English	Article							PEPTIDYL-TRANSFER-RNA; TRANS-TRANSLATION; ESCHERICHIA-COLI; MESSENGER-RNA; CRYSTAL-STRUCTURE; GGQ MOTIF; TMRNA; SMPB; RELEASE; PROTEIN	In bacteria, the hybrid transfer-messenger RNA (tmRNA) rescues ribosomes stalled on defective messenger RNAs (mRNAs). However, certain gram-negative bacteria have evolved proteins that are capable of rescuing stalled ribosomes in a tmRNA-independent manner. Here, we report a 3.2 angstrom-resolution crystal structure of the rescue factor YaeJ bound to the Thermus thermophilus 70S ribosome in complex with the initiator tRNA(i)(fMet) and a short mRNA. The structure reveals that the C-terminal tail of YaeJ functions as a sensor to discriminate between stalled and actively translating ribosomes by binding in the mRNA entry channel downstream of the A site between the head and shoulder of the 30S subunit. This allows the N-terminal globular domain to sample different conformations, so that its conserved GGQ motif is optimally positioned to catalyze the hydrolysis of peptidyl-tRNA. This structure gives insights into the mechanism of YaeJ function and provides a basis for understanding how it rescues stalled ribosomes.	[Gagnon, Matthieu G.; Seetharaman, Sai V.; Steitz, Thomas A.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Bulkley, David; Steitz, Thomas A.] Yale Univ, Dept Chem, New Haven, CT 06520 USA; [Gagnon, Matthieu G.; Seetharaman, Sai V.; Steitz, Thomas A.] Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	thomas.steitz@yale.edu		Gagnon, Matthieu/0000-0003-4516-604X; Bulkley, David/0000-0002-2535-904X	NIH [GM022778]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM022778] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are thankful to the members of the Steitz lab for useful suggestions and discussions. We thank R. Grodzicki for providing the tRNA<INF>i</INF><SUP>fMet</SUP> and the staffs of the Advanced Photon Source beamline 24-ID and the National Synchrotron Light Source beamline X29 for help during data collection and the Center for Structural Biology facility at Yale University for computational support. Special thanks to Y. Polikanov, J. Wang, and W. Meng for advice with crystallographic software. This work was supported by NIH grant GM022778 (to T. A. S.). Coordinates and structure factors have been deposited in the Protein Data Bank with accession codes 4DH9, 4DHA, 4DHB, and 4DHC. T. A. S. owns stock in and is on the advisory board of Rib-X Pharmaceuticals, which does structure-based design of drugs that target the ribosome.	Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Burakovsky DE, 2010, RNA, V16, P1848, DOI 10.1261/rna.2185710; Chadani Y, 2011, MOL MICROBIOL, V80, P772, DOI 10.1111/j.1365-2958.2011.07607.x; Chadani Y, 2010, MOL MICROBIOL, V78, P796, DOI 10.1111/j.1365-2958.2010.07375.x; Felden B, 2011, RNA BIOL, V8, P440, DOI 10.4161/rna.8.3.15387; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Garza-Sanchez F, 2011, MOL MICROBIOL, V80, P1204, DOI 10.1111/j.1365-2958.2011.07638.x; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Handa Y, 2011, NUCLEIC ACIDS RES, V39, P1739, DOI 10.1093/nar/gkq1097; Handa Y, 2010, J MOL BIOL, V404, P260, DOI 10.1016/j.jmb.2010.09.033; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kurita D, 2007, NUCLEIC ACIDS RES, V35, P7248, DOI 10.1093/nar/gkm677; Kurita D, 2010, RNA, V16, P980, DOI 10.1261/rna.1916610; Laurberg M, 2008, NATURE, V454, P852, DOI 10.1038/nature07115; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Rabl J, 2011, SCIENCE, V331, P730, DOI 10.1126/science.1198308; Richter R, 2010, EMBO J, V29, P1116, DOI 10.1038/emboj.2010.14; Savelsbergh A, 2009, RNA, V15, P772, DOI 10.1261/rna.1592509; Schmeing TM, 2005, NATURE, V438, P520, DOI 10.1038/nature04152; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Weis F, 2010, RNA, V16, P299, DOI 10.1261/rna.1757410; Weixlbaumer A, 2008, SCIENCE, V322, P953, DOI 10.1126/science.1164840; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803; Youngman EA, 2008, ANNU REV MICROBIOL, V62, P353, DOI 10.1146/annurev.micro.61.080706.093323	27	78	80	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074					1370	1372		10.1126/science.1217443	http://dx.doi.org/10.1126/science.1217443			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422986	Green Accepted			2022-12-28	WOS:000301531600053
J	Braun, M; Young, J; Reiner, CS; Poster, D; Wuthrich, RP; Serra, AL				Braun, Matthias; Young, James; Reiner, Caecilia S.; Poster, Diane; Wuethrich, Rudolf P.; Serra, Andreas L.			Ovarian Toxicity from Sirolimus	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							POLYCYSTIC KIDNEY-DISEASE		[Braun, Matthias; Reiner, Caecilia S.; Poster, Diane; Wuethrich, Rudolf P.; Serra, Andreas L.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Young, James] Biometr Practice BIOP, Basel, Switzerland	University of Zurich; University Zurich Hospital	Braun, M (corresponding author), Univ Zurich Hosp, CH-8091 Zurich, Switzerland.	andreas.serra@usz.ch		Young, Jim/0000-0002-4314-3007				Alam H, 2004, J BIOL CHEM, V279, P19431, DOI 10.1074/jbc.M401235200; Cure P, 2004, TRANSPLANTATION, V78, P1576, DOI 10.1097/01.TP.0000147301.41864.C0; Heinonen PK, 2002, AM J KIDNEY DIS, V40, P504, DOI 10.1053/ajkd.2002.34902; Serra AL, 2010, NEW ENGL J MED, V363, P820, DOI 10.1056/NEJMoa0907419; Stamm ER, 1999, AM J KIDNEY DIS, V34, P120, DOI 10.1016/S0272-6386(99)70117-4	5	25	30	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1062	1064		10.1056/NEJMc1113145	http://dx.doi.org/10.1056/NEJMc1113145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417271	Green Published			2022-12-28	WOS:000301482800025
J	Li, PL; Banjade, S; Cheng, HC; Kim, S; Chen, B; Guo, L; Llaguno, M; Hollingsworth, JV; King, DS; Banani, SF; Russo, PS; Jiang, QX; Nixon, BT; Rosen, MK				Li, Pilong; Banjade, Sudeep; Cheng, Hui-Chun; Kim, Soyeon; Chen, Baoyu; Guo, Liang; Llaguno, Marc; Hollingsworth, Javoris V.; King, David S.; Banani, Salman F.; Russo, Paul S.; Jiang, Qiu-Xing; Nixon, B. Tracy; Rosen, Michael K.			Phase transitions in the assembly of multivalent signalling proteins	NATURE			English	Article							NUCLEAR-BODIES; NCK; MECHANISMS; RNA; POLYMERIZATION; TRANSLATION; POLYMERS; GRANULES; DOMAINS; MOTIFS	Cells are organized on length scales ranging from angstrom to micrometres. However, the mechanisms by which angstrom-scale molecular properties are translated to micrometre-scale macroscopic properties are not well understood. Here we show that interactions between diverse synthetic, multivalent macromolecules (including multi-domain proteins and RNA) produce sharp liquid-liquid demixing phase separations, generating micrometre-sized liquid droplets in aqueous solution. This macroscopic transition corresponds to a molecular transition between small complexes and large, dynamic supramolecular polymers. The concentrations needed for phase transition are directly related to the valency of the interacting species. In the case of the actin-regulatory protein called neural Wiskott-Aldrich syndrome protein (N-WASP) interacting with its established biological partners NCK and phosphorylated nephrin(1), the phase transition corresponds to a sharp increase in activity towards an actin nucleation factor, the Arp2/3 complex. The transition is governed by the degree of phosphorylation of nephrin, explaining how this property of the system can be controlled to regulatory effect by kinases. The widespread occurrence of multivalent systems suggests that phase transitions may be used to spatially organize and biochemically regulate information throughout biology.	[Li, Pilong; Banjade, Sudeep; Cheng, Hui-Chun; Kim, Soyeon; Chen, Baoyu; Banani, Salman F.; Rosen, Michael K.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Li, Pilong; Banjade, Sudeep; Cheng, Hui-Chun; Kim, Soyeon; Chen, Baoyu; Banani, Salman F.; Rosen, Michael K.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Guo, Liang] Argonne Natl Lab, BioCAT IIT Adv Photon Source, Argonne, IL 60439 USA; [Llaguno, Marc; Jiang, Qiu-Xing] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Hollingsworth, Javoris V.; Russo, Paul S.] Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; [Hollingsworth, Javoris V.; Russo, Paul S.] Louisiana State Univ, Macromol Studies Grp, Baton Rouge, LA 70803 USA; [King, David S.] Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Berkeley, CA 94720 USA; [King, David S.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Nixon, B. Tracy] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Argonne National Laboratory; University of Texas System; University of Texas Southwestern Medical Center Dallas; Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Rosen, MK (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.	Michael.Rosen@utsouthwestern.edu	Russo, Paul Stephen/ABC-6584-2020; Russo, Paul S/G-6473-2012; Jiang, Qiu-Xing/AAI-8579-2020; Chen, Baoyu/A-7072-2011; Jiang, Qiu-Xing/ABF-1143-2021	Russo, Paul Stephen/0000-0001-6009-2742; Chen, Baoyu/0000-0002-6366-159X; Llaguno, Marc/0000-0001-9568-9565	Howard Hughes Medical Institute; National Institutes of Health (NIH) [R01-GM56322, RR-08630]; Welch Foundation [I-1544]; Chilton Foundation; NIH EUREKA [R01-GM088745]; National Science Foundation [DMR-1005707]; Gates Millennium Fund; US Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-ENG-38]; NATIONAL CANCER INSTITUTE [P30CA142543] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056322, R01GM088745, P41GM103622] Funding Source: NIH RePORTER; Direct For Mathematical & Physical Scien [1005707] Funding Source: National Science Foundation	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); Chilton Foundation; NIH EUREKA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Gates Millennium Fund; US Department of Energy, Basic Energy Sciences, Office of Science(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We thank J. Onuchic and S. Padrick for discussion of the theoretical aspects of this study, L. Rice for sharing his fluorescence microscope, M. Socolich for a gift of purified eGFP, K. Luby-Phelps and A. Bugde for advice on FRAP experiments, S. Padrick and L. Doolittle for help in purifying actin and the Arp2/3 complex and for sharing reagents, N. Grishin and S. Shi for help withdatabase searches, K. Lynch for providing the PTB expression construct, D. Billadeau and T. Gomez for providing antibodies, A. Ramesh, W. Winkler and P.-L. Tsai for advice on RNA experiments, K. Roybal and C. Wulfing for sharing unpublished data, and J. Liu for help with cryo-electron tomography. This work was supported by the following: the Howard Hughes Medical Institute and grants from the National Institutes of Health (NIH) (R01-GM56322) and Welch Foundation (I-1544) to M. K. R., a Chilton Foundation Fellowship to H.-C. C., an NIH EUREKA award (R01-GM088745) to Q.-X. J., an NIH Cancer Biology T32 Training Grant to M. L., a National Science Foundation award (DMR-1005707) to P. S. R. and a Gates Millennium Fund award to J. V. H. Use of the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under contract number W-31-109-ENG-38. BioCAT is NIH-supported Research Center RR-08630.	Asherie N, 1998, BIOPHYS CHEM, V75, P213, DOI 10.1016/S0301-4622(98)00208-7; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Blasutig IM, 2008, MOL CELL BIOL, V28, P2035, DOI 10.1128/MCB.01770-07; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; Chen BY, 2007, STRUCTURE, V15, P429, DOI 10.1016/j.str.2007.02.007; COHEN RJ, 1982, J PHYS CHEM-US, V86, P3696, DOI 10.1021/j100216a005; Dam TK, 2005, J BIOL CHEM, V280, P8640, DOI 10.1074/jbc.M412827200; Fischer H, 2010, J APPL CRYSTALLOGR, V43, P101, DOI 10.1107/S0021889809043076; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; GOLDBERG RJ, 1952, J AM CHEM SOC, V74, P5715, DOI 10.1021/ja01142a045; Jin J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000546; Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662; Lehn JM, 2002, POLYM INT, V51, P825, DOI 10.1002/pi.852; Lettau M, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-1; Li JF, 2010, POLYM J, V42, P609, DOI 10.1038/pj.2010.59; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Matera AG, 2009, DEV CELL, V17, P639, DOI 10.1016/j.devcel.2009.10.017; Matera AG, 2006, CURR OPIN CELL BIOL, V18, P317, DOI 10.1016/j.ceb.2006.03.005; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Padrick SB, 2008, MOL CELL, V32, P426, DOI 10.1016/j.molcel.2008.10.012; Padrick SB, 2010, ANNU REV BIOCHEM, V79, P707, DOI 10.1146/annurev.biochem.77.060407.135452; Parker R, 2007, MOL CELL, V25, P635, DOI 10.1016/j.molcel.2007.02.011; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Semenov A, 2007, RHEOL ACTA, V46, P541, DOI 10.1007/s00397-006-0149-4; Semenov AN, 1998, MACROMOLECULES, V31, P1373, DOI 10.1021/ma970616h; Sisu C, 2009, CHEMBIOCHEM, V10, P329, DOI 10.1002/cbic.200800550; STOCKMAYER WH, 1952, J POLYM SCI, V9, P69, DOI 10.1002/pol.1952.120090106; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tanaka F., 2011, POLYM PHYS APPL MOL	34	1218	1243	22	502	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					336	U129		10.1038/nature10879	http://dx.doi.org/10.1038/nature10879			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22398450	Green Accepted			2022-12-28	WOS:000301481800050
J	Cuijpers, P; Beekman, ATF; Reynolds, CF				Cuijpers, Pim; Beekman, Aartjan T. F.; Reynolds, Charles F., III			Preventing Depression A Global Priority	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COST-EFFECTIVENESS; DISORDERS		[Cuijpers, Pim; Beekman, Aartjan T. F.; Reynolds, Charles F., III] UPMC, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	Reynolds, CF (corresponding author), UPMC, Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	reynoldscf@upmc.edu	Sanders, Matthew R/C-1941-2013; Christensen, Helen/F-5053-2012; Sanders, Matthew/O-6900-2019; Cuijpers, Pim/G-1703-2013	Sanders, Matthew R/0000-0003-3479-6337; Christensen, Helen/0000-0003-0435-2065; Sanders, Matthew/0000-0003-3479-6337; Cuijpers, Pim/0000-0001-5497-2743	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH090333, R01MH083660] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NCRR NIH HHS [UL1 RR024153] Funding Source: Medline; NIMH NIH HHS [R01 MH083660, P30 MH090333] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andrews G, 2004, BRIT J PSYCHIAT, V184, P526, DOI 10.1192/bjp.184.6.526; Institute of Medicine Committee on Prevention of Mental Disorders Division of Biobehavorial Science and Mental Disorders, 1994, RED RISKS MENT DIS F; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Munoz RF, 2010, ANNU REV CLIN PSYCHO, V6, P181, DOI 10.1146/annurev-clinpsy-033109-132040; Patel V, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000160; Smit F, 2006, BRIT J PSYCHIAT, V188, P330, DOI 10.1192/bjp.188.4.330; Therapeutics Initiative University of British Columbia, 2003, THERAPEUTICS LETT; Waraich P, 2004, CAN J PSYCHIAT, V49, P124, DOI 10.1177/070674370404900208	8	221	224	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1033	1034		10.1001/jama.2012.271	http://dx.doi.org/10.1001/jama.2012.271			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416097	Green Published, Green Accepted			2022-12-28	WOS:000301479700022
J	Howard, R; McShane, R; Lindesay, J; Ritchie, C; Baldwin, A; Barber, R; Burns, A; Dening, T; Findlay, D; Holmes, C; Hughes, A; Jacoby, R; Jones, R; Jones, R; McKeith, I; Macharouthu, A; O'Brien, J; Passmore, P; Sheehan, B; Juszczak, E; Katona, C; Hills, R; Knapp, M; Ballard, C; Brown, R; Banerjee, S; Onions, C; Griffin, M; Adams, J; Gray, R; Johnson, T; Bentham, P; Phillips, P				Howard, Robert; McShane, Rupert; Lindesay, James; Ritchie, Craig; Baldwin, Ashley; Barber, Robert; Burns, Alistair; Dening, Tom; Findlay, David; Holmes, Clive; Hughes, Alan; Jacoby, Robin; Jones, Rob; Jones, Roy; McKeith, Ian; Macharouthu, Ajay; O'Brien, John; Passmore, Peter; Sheehan, Bart; Juszczak, Edmund; Katona, Cornelius; Hills, Robert; Knapp, Martin; Ballard, Clive; Brown, Richard; Banerjee, Sube; Onions, Caroline; Griffin, Mary; Adams, Jessica; Gray, Richard; Johnson, Tony; Bentham, Peter; Phillips, Patrick			Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; RECEIVING DONEPEZIL; DEMENTIA; POPULATION; EFFICACY; 24-WEEK; SAFETY	BACKGROUND Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U. K. Medical Research Council and the U. K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.)	[Howard, Robert] Kings Coll London, Inst Psychiat, Dept Old Age Psychiat, London SE5 8AF, England; [Ballard, Clive] Kings Coll London, Wolfson Ctr Age Related Dis, London SE5 8AF, England; [Ritchie, Craig] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, London, England; [Katona, Cornelius] UCL, Dept Mental Hlth Sci, London, England; [Johnson, Tony; Phillips, Patrick] MRC, Clin Trials Unit, London, England; [McShane, Rupert] Univ Oxford, Churchill Hosp, Fulbrook Ctr, Oxford, England; [Jacoby, Robin] Univ Oxford, Dept Psychiat, Oxford, England; [Juszczak, Edmund] Univ Oxford, Ctr Stat Med, Oxford, England; [Gray, Richard] Univ Oxford, Clin Trial Serv Unit, Oxford, England; [Lindesay, James] Univ Leicester, Leicester, Leics, England; [Baldwin, Ashley] Whiston Hosp, Knowlsey Resource & Recovery Ctr, Prescot, England; [Barber, Robert; McKeith, Ian; O'Brien, John] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Burns, Alistair] Wythenshawe Hosp, Sch Psychiat & Behav Sci, Manchester M23 9LT, Lancs, England; [Dening, Tom] Fulbourn Hosp, Older Peoples Mental Hlth Serv, Cambridge, England; [Johnson, Tony] Univ Cambridge, MRC, Biostat Unit, Cambridge, England; [Findlay, David] Royal Dundee Liff Hosp, Dundee, Scotland; [Holmes, Clive] Univ Southampton, Memory Assessment & Res Ctr, Southampton, Hants, England; [Hughes, Alan] Inverclyde Royal Hosp, Dept Geriatr Psychiat, Inverclyde, England; [Jones, Rob] Univ Nottingham, Old Age Psychiat Sect, Nottingham NG7 2RD, England; [Onions, Caroline] Univ Nottingham, Fac Med & Hlth Sci, Nottingham NG7 2RD, England; [Jones, Roy] Res Inst Care Older People, Bath, Avon, England; [Macharouthu, Ajay] Crichton Royal Hosp, Mental Hlth Directorate, Dumfries, Scotland; [Passmore, Peter] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland; [Sheehan, Bart] Univ Warwick, Hlth Sci Res Inst, Coventry CV4 7AL, W Midlands, England; [Hills, Robert] Univ Wales Coll Cardiff, Dept Haematol, Cardiff CF1 3NS, S Glam, Wales; [Griffin, Mary] Avon & Wiltshire Mental Hlth Partnership, SW Dementias & Neurodegenerat Dis Res Network, Chippenham, England; [Bentham, Peter] Queen Elizabeth Psychiat Hosp, Birmingham, W Midlands, England	University of London; King's College London; University of London; King's College London; Imperial College London; University of London; University College London; Medical Research Council Clinical Trials Unit; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Leicester; Whiston Hospital; Newcastle University - UK; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; MRC Biostatistics Unit; University of Cambridge; University of Southampton; University of Nottingham; University of Nottingham; Queens University Belfast; University of Warwick; Cardiff University; University of Birmingham	Howard, R (corresponding author), Kings Coll London, Inst Psychiat, Dept Old Age Psychiat, Box PO70,16 DeCrespigny Pk, London SE5 8AF, England.	robert.j.howard@kcl.ac.uk	Dening, Tom/E-1335-2013; Brown, Richard G/A-9599-2010; Banerjee, Sube/E-3757-2010; McKeith, Ian/AAH-3382-2021; Phillips, Patrick/B-6347-2008	Dening, Tom/0000-0003-3387-4241; Brown, Richard G/0000-0001-9021-0172; Phillips, Patrick/0000-0002-6336-7024; Gray, Richard/0000-0003-4440-574X; Katona, Cornelius/0000-0001-7451-0167; Hills, Robert/0000-0003-0166-0062; Knapp, Martin/0000-0003-1427-0215; Ballard, Clive/0000-0003-0022-5632; Holmes, Clive/0000-0003-1999-6912; Howard, Robert/0000-0002-3071-2338; Banerjee, Sube/0000-0002-8083-7649; O'Brien, John/0000-0002-0837-5080; Burns, Alistair/0000-0002-9837-0645; McKeith, Ian/0000-0002-9250-0568	U.K. Medical Research Council; Alzheimer's Society; Novartis NEURONET; Janssen; Novartis; Eisai; Pfizer; Lundbeck; Merz Pharmaceuticals; GE Healthcare; Bayer Healthcare; Servier; Eli Lilly; Shire; Johnson Johnson; Bristol-Myers Squibb; Acadia; UCB Pharma; Solvay; TauRx Therapeutics; MRC [G0600989, MC_U122888466, MC_U137686861] Funding Source: UKRI; Medical Research Council [MC_U137686861, G0600989, MC_U122888466] Funding Source: researchfish; Alzheimer&quot;s Society [86] Funding Source: researchfish	U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimer's Society; Novartis NEURONET; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Novartis(Novartis); Eisai(Eisai Co Ltd); Pfizer(Pfizer); Lundbeck(Lundbeck Corporation); Merz Pharmaceuticals; GE Healthcare(General ElectricGE Healthcare); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Servier(Servier); Eli Lilly(Eli Lilly); Shire; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Bristol-Myers Squibb(Bristol-Myers Squibb); Acadia; UCB Pharma(UCB Pharma SA); Solvay(Solvay SA); TauRx Therapeutics; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Alzheimer&quot;s Society	Supported by the U.K. Medical Research Council and Alzheimer's Society.; Dr. McShane reports receiving payment for work as the local principal investigator for commercial trials from Abbott, Novartis, i3 Innovus, and Medivation; Dr. Lindesay, receiving consulting fees from Novartis NEURONET and lecture fees from Janssen, Novartis, Eisai, and Pfizer; Dr. Ritchie, receiving consulting and lecture fees from Pfizer and Eisai and grant support and reimbursement for travel expenses from Eisai; Dr. Barber, receiving royalties from Arnold Press; Dr. Burns, receiving royalties from John Wiley; Dr. Findlay, receiving lecture fees and reimbursement for meeting expenses from Eisai, Pfizer, and Lundbeck; Dr. Jones, receiving consulting fees from Merz Pharmaceuticals and Janssen, grant support from Eisai, Lundbeck, and Merz Pharmaceuticals, and lecture fees from Lundbeck, Merz Pharmaceuticals, Eisai, Pfizer, and Novartis and being a board member of Merz Pharmaceuticals, Lundbeck, Eisai, Pfizer, and Lilly; Dr. McKeith, receiving lecture fees from Novartis; Dr. O'Brien, receiving consulting fees from GE Healthcare, Bayer Healthcare, and Servier and lecture fees from Pfizer, Eisai, Novartis, Lundbeck, Eli Lilly, Shire, and GE Healthcare; Dr. Passmore, receiving consulting fees from Pfizer, Lundbeck, Novartis, Shire, and Johnson & Johnson and lecture fees and reimbursement for travel expenses from Lundbeck and Pfizer; Dr. Katona, receiving consulting fees from Lundbeck and Eli Lilly, grant support from Lundbeck, lecture fees from Lundbeck, Lilly, Shire, and Pfizer, payment for development of educational presentations from Lundbeck, and reimbursement for travel expenses from Pfizer and being a board member of Lundbeck; Dr. Ballard, receiving consulting and lecture fees from Lundbeck, Eisai, Bristol-Myers Squibb, Janssen, Acadia, and Novartis and grant support from Lundbeck and Acadia; Dr. Brown, receiving lecture fees from UCB Pharma, GlaxoSmithKline, Solvay, and Lundbeck; Dr. Banerjee, receiving grant support from Pfizer, lecture fees from Lundbeck, and reimbursement for travel expenses from Pfizer and Eisai; and Dr. Bentham, receiving consulting fees from TauRx Therapeutics. No other potential conflict of interest relevant to this article was reported.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Areosa SA, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003154.PUB4; Armitage P., 2002, STAT METHODS MED RES; Bentham P, 2004, LANCET, V363, P2105; Black SE, 2007, NEUROLOGY, V69, P459, DOI 10.1212/01.wnl.0000266627.96040.5a; Bucks RS, 1996, AGE AGEING, V25, P113, DOI 10.1093/ageing/25.2.113; Burback D, 1999, DEMENT GERIATR COGN, V10, P534, DOI 10.1159/000017201; Cook RJ, 1996, J ROY STAT SOC A STA, V159, P93, DOI 10.2307/2983471; Cummings JL, 2006, NEUROLOGY, V67, P57, DOI 10.1212/01.wnl.0000223333.42368.f1; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Feldman H, 2005, INT J GERIATR PSYCH, V20, P559, DOI 10.1002/gps.1325; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Feldman H, 2001, NEUROLOGY, V57, P2153; Food and Drug Administration, 1989, PER CENTR NERV SYST, P227; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Homma A, 2008, DEMENT GERIATR COGN, V25, P399, DOI 10.1159/000122961; Howard R, 2011, INT J GERIATR PSYCH, V26, P812, DOI 10.1002/gps.2607; Jones R, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-57; Kaduszkiewicz H, 2005, BMJ-BRIT MED J, V331, P321, DOI 10.1136/bmj.331.7512.321; McEntegart DJ, 2003, DRUG INF J, V37, P293, DOI 10.1177/009286150303700305; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Molloy D W, 1997, Int Psychogeriatr, V9 Suppl 1, P87, DOI 10.1017/S1041610297004754; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Porsteinsson AP, 2008, CURR ALZHEIMER RES, V5, P83, DOI 10.2174/156720508783884576; Singh S, 2003, INT J GERIATR PSYCH, V18, P282, DOI 10.1002/gps.811; Smith SC, 2005, HEALTH TECHNOL ASSES, V9, P1; StataCorp, 2021, STATA STAT SOFTWARE; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tariot PN, 2001, J AM GERIATR SOC, V49, P1590, DOI 10.1046/j.1532-5415.2001.t01-1-49266.x; The technologies, 2011, DON GAL RIV MEM TREA; Winblad B, 2006, LANCET, V368, P1650; Winblad B, 2006, LANCET, V367, P1057, DOI 10.1016/S0140-6736(06)68350-5; Winblad B, 2006, LANCET, V367, P1980	34	407	420	11	144	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					893	903		10.1056/NEJMoa1106668	http://dx.doi.org/10.1056/NEJMoa1106668			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397651	Green Published			2022-12-28	WOS:000301172500006
J	Liu, X; Ramirez, S; Pang, PT; Puryear, CB; Govindarajan, A; Deisseroth, K; Tonegawa, S				Liu, Xu; Ramirez, Steve; Pang, Petti T.; Puryear, Corey B.; Govindarajan, Arvind; Deisseroth, Karl; Tonegawa, Susumu			Optogenetic stimulation of a hippocampal engram activates fear memory recall	NATURE			English	Article							DENTATE GYRUS; PATTERN SEPARATION; AMYGDALA; EXPRESSION; RETRIEVAL; PLASTICITY; STRATEGIES; ALLOCATION; CA3	A specific memory is thought to be encoded by a sparse population of neurons(1,2). These neurons can be tagged during learning for subsequent identification(3) and manipulation(4-6). Moreover, their ablation or inactivation results in reduced memory expression, suggesting their necessity in mnemonic processes. However, the question of sufficiency remains: it is unclear whether it is possible to elicit the behavioural output of a specific memory by directly activating a population of neurons that was active during learning. Here we show in mice that optogenetic reactivation of hippocampal neurons activated during fear conditioning is sufficient to induce freezing behaviour. We labelled a population of hippocampal dentate gyrus neurons activated during fear learning with channelrhodopsin-2 (ChR2)(7,8) and later optically reactivated these neurons in a different context. The mice showed increased freezing only upon light stimulation, indicating light-induced fear memory recall. This freezing was not detected in non-fear-conditioned mice expressing ChR2 in a similar proportion of cells, nor in fear-conditioned mice with cells labelled by enhanced yellow fluorescent protein instead of ChR2. Finally, activation of cells labelled in a context not associated with fear did not evoke freezing in mice that were previously fear-conditioned in a different context, suggesting that light-induced fear memory recall is context-specific. Together, our findings indicate that activating a sparse but specific ensemble of hippocampal neurons that contribute to a memory engram is sufficient for the recall of that memory. Moreover, our experimental approach offers a general method of mapping cellular populations bearing memory engrams.	[Liu, Xu; Ramirez, Steve; Pang, Petti T.; Puryear, Corey B.; Govindarajan, Arvind; Tonegawa, Susumu] MIT, RIKEN MIT Ctr Neural Circuit Genet, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; [Liu, Xu; Ramirez, Steve; Pang, Petti T.; Puryear, Corey B.; Govindarajan, Arvind; Tonegawa, Susumu] MIT, RIKEN MIT Ctr Neural Circuit Genet, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Deisseroth, Karl] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Massachusetts Institute of Technology (MIT); Northwell Health; RIKEN; Massachusetts Institute of Technology (MIT); Northwell Health; RIKEN; Stanford University; Stanford University	Tonegawa, S (corresponding author), MIT, RIKEN MIT Ctr Neural Circuit Genet, Picower Inst Learning & Memory, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tonegawa@mit.edu			Tonegawa laboratory; National Institutes of Health [R01-MH078821, P50-MH58880]; RIKEN Brain Science Institute; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH078821, P50MH058880] Funding Source: NIH RePORTER	Tonegawa laboratory; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RIKEN Brain Science Institute; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank S. Huang, G. Lin, M. Ragion and X. Zhou for help with the experiments, T. Ryan, A. Rivest, J. Young, R. Redondo and G. Dragoi for comments and discussions on the manuscript, and all the members of the Tonegawa laboratory for their support. This work is supported by National Institutes of Health grants R01-MH078821, P50-MH58880 to S. T. and RIKEN Brain Science Institute.	Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Chawla MK, 2005, HIPPOCAMPUS, V15, P579, DOI 10.1002/hipo.20091; Gerber B, 2004, CURR OPIN NEUROBIOL, V14, P737, DOI 10.1016/j.conb.2004.10.014; Goshen I, 2011, CELL, V147, P678, DOI 10.1016/j.cell.2011.09.033; Han JH, 2007, SCIENCE, V316, P457, DOI [10.1126/science.1139438, 10.1126/science.1134697]; Han JH, 2009, SCIENCE, V323, P1492, DOI 10.1126/science.1164139; Josselyn SA, 2010, J PSYCHIATR NEUROSCI, V35, P221, DOI 10.1503/jpn.100015; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kubik S, 2007, LEARN MEMORY, V14, P758, DOI 10.1101/lm.698107; Lee I, 2004, HIPPOCAMPUS, V14, P301, DOI 10.1002/hipo.10177; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lever C, 2002, NATURE, V416, P90, DOI 10.1038/416090a; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Nakashiba T., 2012, CELL            0223, DOI [10.1016/j.cell.2012.01.046, DOI 10.1016/J.CELL.2012.01.046]; Paxinos G., 2001, MOUSE BRAIN STEREOTA; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Ramamoorthi K, 2011, SCIENCE, V334, P1669, DOI 10.1126/science.1208049; Rasband W.S., 1997, IMAGE J; Reijmers LG, 2007, SCIENCE, V317, P1230, DOI 10.1126/science.1143839; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Satvat E, 2011, J NEUROSCI, V31, P7163, DOI 10.1523/JNEUROSCI.0094-11.2011; Schafe GE, 2005, J NEUROSCI, V25, P10010, DOI 10.1523/JNEUROSCI.3307-05.2005; Schmidt B, 2012, BEHAV BRAIN RES, V226, P56, DOI 10.1016/j.bbr.2011.08.039; Seidenbecher T, 2003, SCIENCE, V301, P846, DOI 10.1126/science.1085818; Shockett PE, 1996, P NATL ACAD SCI USA, V93, P5173, DOI 10.1073/pnas.93.11.5173; Silva AJ, 2009, SCIENCE, V326, P391, DOI 10.1126/science.1174519; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; Tye KM, 2011, NATURE, V471, P358, DOI 10.1038/nature09820; Zhou Y, 2009, NAT NEUROSCI, V12, P1438, DOI 10.1038/nn.2405	30	864	889	10	420	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 19	2012	484	7394					381	U415		10.1038/nature11028	http://dx.doi.org/10.1038/nature11028			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22441246	Green Accepted, Green Submitted			2022-12-28	WOS:000302946500034
J	Vervaeke, K; Lorincz, A; Nusser, Z; Silver, RA				Vervaeke, Koen; Loerincz, Andrea; Nusser, Zoltan; Silver, R. Angus			Gap Junctions Compensate for Sublinear Dendritic Integration in an Inhibitory Network	SCIENCE			English	Article							ELECTRICAL SYNAPSES; RAT; INTERNEURONS; POTENTIALS; MECHANISMS; LOCATION; EFFICACY; NEURONS; INPUTS; CELLS	Electrically coupled inhibitory interneurons dynamically control network excitability, yet little is known about how chemical and electrical synapses regulate their activity. Using two-photon glutamate uncaging and dendritic patch-clamp recordings, we found that the dendrites of cerebellar Golgi interneurons acted as passive cables. They conferred distance-dependent sublinear synaptic integration and weakened distal excitatory inputs. Gap junctions were present at a higher density on distal dendrites and contributed substantially to membrane conductance. Depolarization of one Golgi cell increased firing in its neighbors, and inclusion of dendritic gap junctions in interneuron network models enabled distal excitatory synapses to drive network activity more effectively. Our results suggest that dendritic gap junctions counteract sublinear dendritic integration by enabling excitatory synaptic charge to spread into the dendrites of neighboring inhibitory interneurons.	[Vervaeke, Koen; Silver, R. Angus] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England; [Loerincz, Andrea; Nusser, Zoltan] Hungarian Acad Sci, Inst Expt Med, Lab Cellular Neurophysiol, H-1083 Budapest, Hungary	University of London; University College London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Silver, RA (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Mortimer St, London WC1E 6BT, England.	nusser.zoltan@koki.hu; a.silver@ucl.ac.uk	Nusser, Zoltan/K-8587-2014	Nusser, Zoltan/0000-0001-7004-4111; Silver, Robin/0000-0002-5480-6638	U.K. Biotechnology and Biological Sciences Research Council (BBSRC) [F005490]; Medical Research Council [G0400598]; Wellcome Trust [064413, 095667]; European Research Council (ERC); Janos Bolyai Scholarship; BBSRC [BB/F005490/1] Funding Source: UKRI; MRC [G0400598] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F005490/1] Funding Source: researchfish	U.K. Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); European Research Council (ERC)(European Research Council (ERC)European Commission); Janos Bolyai Scholarship(Hungarian Academy of Sciences); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funded by U.K. Biotechnology and Biological Sciences Research Council (BBSRC) (F005490), Medical Research Council (G0400598), and Wellcome Trust (064413). R.A.S. holds a Wellcome Trust Principal Research Fellowship (095667) and a European Research Council (ERC) Advanced Grant, Z.N. a Wellcome Trust Project Grant and an ERC Advanced Grant, and A.L. a Janos Bolyai Scholarship. We thank D. Paul for the Cx36<SUP>-/-</SUP> mice; E. Chaigneau, T. Branco, and P. Gleeson for help; D. Attwell, M. Farrant, H. Hu, D. Kullmann, J. Rothman, and D. Ward for comments on the manuscript; and T. Fernandez-Alfonso, H. Hu, and D. Ruedt for discussions.	Bloomfield SA, 2009, NAT REV NEUROSCI, V10, P495, DOI 10.1038/nrn2636; Cash S, 1999, NEURON, V22, P383, DOI 10.1016/S0896-6273(00)81098-3; Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128; Cruikshank SJ, 2004, P NATL ACAD SCI USA, V101, P12364, DOI 10.1073/pnas.0402044101; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Dieudonne S, 1998, J PHYSIOL-LONDON, V510, P845, DOI 10.1111/j.1469-7793.1998.845bj.x; Dugue GP, 2009, NEURON, V61, P126, DOI 10.1016/j.neuron.2008.11.028; Forti L, 2006, J PHYSIOL-LONDON, V574, P711, DOI 10.1113/jphysiol.2006.110858; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Gleeson P, 2007, NEURON, V54, P219, DOI 10.1016/j.neuron.2007.03.025; Hu H, 2010, SCIENCE, V327, P52, DOI 10.1126/science.1177876; Jonas P, 2004, TRENDS NEUROSCI, V27, P30, DOI 10.1016/j.tins.2003.10.010; Kanichay RT, 2008, J NEUROSCI, V28, P8955, DOI 10.1523/JNEUROSCI.5469-07.2008; Kerlin AM, 2010, NEURON, V67, P858, DOI 10.1016/j.neuron.2010.08.002; Losonczy A, 2006, NEURON, V50, P291, DOI 10.1016/j.neuron.2006.03.016; Magee JC, 2000, NAT NEUROSCI, V3, P895, DOI 10.1038/78800; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Martina M, 2000, SCIENCE, V287, P295, DOI 10.1126/science.287.5451.295; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; Nevian T, 2007, NAT NEUROSCI, V10, P206, DOI 10.1038/nn1826; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; RALL W, 1967, J NEUROPHYSIOL, V30, P1138, DOI 10.1152/jn.1967.30.5.1138; Solinas S, 2007, FRONT CELL NEUROSCI, V1, DOI 10.3389/neuro.03.002.2007; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P74, DOI 10.1152/jn.1993.69.1.74; Vervaeke K, 2010, NEURON, V67, P435, DOI 10.1016/j.neuron.2010.06.028; Vos BP, 1999, EUR J NEUROSCI, V11, P2621, DOI 10.1046/j.1460-9568.1999.00678.x; Williams SR, 2002, SCIENCE, V295, P1907, DOI 10.1126/science.1067903; Yaksi E, 2010, NEURON, V67, P1034, DOI 10.1016/j.neuron.2010.08.041	29	81	83	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 30	2012	335	6076					1624	1628		10.1126/science.1215101	http://dx.doi.org/10.1126/science.1215101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915YD	22403180	Green Accepted			2022-12-28	WOS:000302062600045
J	Wei, W; Ba, ZQ; Gao, M; Wu, Y; Ma, YT; Amiard, S; White, CI; Danielsen, JMR; Yang, YG; Qi, YJ				Wei, Wei; Ba, Zhaoqing; Gao, Min; Wu, Yang; Ma, Yanting; Amiard, Simon; White, Charles I.; Danielsen, Jannie Michaela Rendtlew; Yang, Yun-Gui; Qi, Yijun			A Role for Small RNAs in DNA Double-Strand Break Repair	CELL			English	Article							TRANS-ACTING SIRNAS; HOMOLOGOUS RECOMBINATION; DAMAGE RESPONSE; DIFFERENT PATHWAYS; STRUCTURAL BASIS; ATR; RECOGNITION; METHYLATION; GAMMA-H2AX; MECHANISMS	Eukaryotes have evolved complex mechanisms to repair DNA double-strand breaks (DSBs) through coordinated actions of protein sensors, transducers, and effectors. Here we show that similar to 21-nucleotide small RNAs are produced from the sequences in the vicinity of DSB sites in Arabidopsis and in human cells. We refer to these as diRNAs for DSB-induced small RNAs. In Arabidopsis, the biogenesis of diRNAs requires the PI3 kinase ATR, RNA polymerase IV (Pol IV), and Dicer-like proteins. Mutations in these proteins as well as in Pol V cause significant reduction in DSB repair efficiency. In Arabidopsis, diRNAs are recruited by Argonaute 2 (AGO2) to mediate DSB repair. Knock down of Dicer or Ago2 in human cells reduces DSB repair. Our findings reveal a conserved function for small RNAs in the DSB repair pathway. We propose that diRNAs may function as guide molecules directing chromatin modifications or the recruitment of protein complexes to DSB sites to facilitate repair.	[Wei, Wei; Ba, Zhaoqing; Wu, Yang; Ma, Yanting; Qi, Yijun] Nat Inst Biol Sci, Beijing 102206, Peoples R China; [Wei, Wei] Chinese Acad Med Sci, Grad Program, Beijing 100730, Peoples R China; [Wei, Wei] Peking Union Med Coll, Beijing 100730, Peoples R China; [Ba, Zhaoqing] Beijing Normal Univ, Coll Life Sci, Beijing 100875, Peoples R China; [Gao, Min; Danielsen, Jannie Michaela Rendtlew; Yang, Yun-Gui] Chinese Acad Sci, Beijing Inst Genom, Dis Genom & Individualized Med Lab, Genome Struct & Stabil Grp, Beijing 100029, Peoples R China; [Amiard, Simon; White, Charles I.] Clermont Univ, Inst Natl Sante & Rech Med U931, Ctr Natl Rech Sci, Unite Mixte Rech 6247, F-63177 Aubiere, France; [Danielsen, Jannie Michaela Rendtlew] Novo Nordisk Fdn Ctr Prot Res, Fac Hlth Sci, Ubiquitin Signalling Grp, DK-2200 Copenhagen, Denmark; [Qi, Yijun] Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China; [Qi, Yijun] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Beijing Normal University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Tsinghua University; Tsinghua University	Qi, YJ (corresponding author), Nat Inst Biol Sci, 7 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China.	qiyijun@nibs.ac.cn	amiard, simon/J-6951-2015; Yang, Yungui/ABF-2507-2021; Qi, Yijun/AAE-8797-2019; White, Charles I/F-1001-2011	amiard, simon/0000-0002-0427-1647; White, Charles I/0000-0001-8152-5797; /0000-0002-5592-9349; Ba, Zhaoqing/0000-0002-8431-5469	National Basic Research Program of China (973 program) [2012CB910900, 2011CB100700, 2011CB812600, 2011CB510103]	National Basic Research Program of China (973 program)(National Basic Research Program of China)	We thank Drs. A. Britt, L. Du, M. Carmell, and B. Ding for critical reading of the manuscript and stimulating discussions. We are grateful to Dr. H. Puchta for DGU.US, DU.GUS and I-SceI trigger lines and Dr. M. Jasin for DR-GFP/U2OS cell line and PCBASce plasmid. This work was supported by National Basic Research Program of China (973 program 2012CB910900, 2011CB100700, and 2011CB812600 to Y.Q. and 2011CB510103 to Y.G.Y.).	Amiard S, 2010, PLANT CELL, V22, P3020, DOI 10.1105/tpc.110.078527; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Culligan K, 2004, PLANT CELL, V16, P1091, DOI 10.1105/tpc.018903; Culligan KM, 2008, PLANT J, V55, P629, DOI 10.1111/j.1365-313X.2008.03530.x; Culligan KM, 2006, PLANT J, V48, P947, DOI 10.1111/j.1365-313X.2006.02931.x; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Fillingham J, 2006, BIOCHEM CELL BIOL, V84, P568, DOI 10.1139/O06-072; Friesner JD, 2005, MOL BIOL CELL, V16, P2566, DOI 10.1091/mbc.E04-10-0890; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Hartlerode AJ, 2009, BIOCHEM J, V423, P157, DOI 10.1042/BJ20090942; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Huen MS, 2008, CELL RES, V18, P8, DOI 10.1038/cr.2007.109; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kanno T, 2005, NAT GENET, V37, P761, DOI 10.1038/ng1580; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Kapranov P, 2010, NATURE, V466, P642, DOI 10.1038/nature09190; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Klattenhoff C, 2007, DEV CELL, V12, P45, DOI 10.1016/j.devcel.2006.12.001; Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719; Lee HC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000496; Lee HC, 2009, NATURE, V459, P274, DOI 10.1038/nature08041; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045; Mannuss A, 2010, PLANT CELL, V22, P3318, DOI 10.1105/tpc.110.078568; Matzke M, 2009, CURR OPIN CELL BIOL, V21, P367, DOI 10.1016/j.ceb.2009.01.025; Mi SJ, 2008, CELL, V133, P116, DOI 10.1016/j.cell.2008.02.034; Mochizuki K, 2004, GENE DEV, V18, P2068, DOI 10.1101/gad.1219904; Montgomery TA, 2008, CELL, V133, P128, DOI 10.1016/j.cell.2008.02.033; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Orel N, 2003, PLANT J, V35, P604, DOI 10.1046/j.1365-313X.2003.01832.x; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peragine A, 2004, GENE DEV, V18, P2368, DOI 10.1101/gad.1231804; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Podhorecka M, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/920161; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Puchta H, 2005, J EXP BOT, V56, P1, DOI 10.1093/jxb/eri025; Qi Y, 2005, MOL CELL, V19, P421, DOI 10.1016/j.molcel.2005.06.014; Qi YJ, 2006, NATURE, V443, P1008, DOI 10.1038/nature05198; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Sasaki M, 2010, NAT REV MOL CELL BIO, V11, P182, DOI 10.1038/nrm2849; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Taft RJ, 2009, NAT GENET, V41, P572, DOI 10.1038/ng.312; Tolia NH, 2007, NAT CHEM BIOL, V3, P36, DOI 10.1038/nchembio848; Vazquez F, 2004, MOL CELL, V16, P69, DOI 10.1016/j.molcel.2004.09.028; Wierzbicki AT, 2008, CELL, V135, P635, DOI 10.1016/j.cell.2008.09.035; Wu L, 2010, MOL CELL, V38, P465, DOI 10.1016/j.molcel.2010.03.008; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Yao MC, 2005, ANNU REV GENET, V39, P537, DOI 10.1146/annurev.genet.39.073003.095906; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	56	418	439	4	149	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 30	2012	149	1					101	112		10.1016/j.cell.2012.03.002	http://dx.doi.org/10.1016/j.cell.2012.03.002			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	918FT	22445173	Bronze			2022-12-28	WOS:000302235400013
J	Joensuu, H; Eriksson, M; Hall, KS; Hartmann, JT; Pink, D; Schutte, J; Ramadori, G; Hohenberger, P; Duyster, J; Al-Batran, SE; Schlemmer, M; Bauer, S; Wardelmann, E; Sarlomo-Rikala, M; Nilsson, B; Sihto, H; Monge, OR; Bono, P; Kallio, R; Vehtari, A; Leinonen, M; Alvegard, T; Reichardt, P				Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Hartmann, Joerg T.; Pink, Daniel; Schuette, Jochen; Ramadori, Giuliano; Hohenberger, Peter; Duyster, Justus; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Sarlomo-Rikala, Maarit; Nilsson, Bengt; Sihto, Harri; Monge, Odd R.; Bono, Petri; Kallio, Raija; Vehtari, Aki; Leinonen, Mika; Alvegard, Thor; Reichardt, Peter			One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KIT MUTATIONS; DOSE IMATINIB; RISK; RECURRENCE; RESECTION; MESYLATE; PROGNOSTICATION; STRATIFICATION; CRITERIA	Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo. Objective To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery. Design, Setting, and Patients Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria. Intervention Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery. Main Outcome Measures The primary end point was RFS; the secondary end points included overall survival and treatment safety. Results Two hundred patients were allocated to each group. The median follow-up time after randomization was 54 months in December 2010. Diagnosis of GIST was confirmed in 382 of 397 patients (96%) in the intention-to-treat population at a central pathology review. KIT or PDGFRA mutation was detected in 333 of 366 tumors (91%) available for testing. Patients assigned for 36 months of imatinib had longer RFS compared with those assigned for 12 months (hazard ratio [HR], 0.46; 95% CI, 0.32-0.65; P = .001; 5-year RFS, 65.6% vs 47.9%, respectively) and longer overall survival (HR, 0.45; 95% CI, 0.22-0.89; P=. 02; 5-year survival, 92.0% vs 81.7%). Imatinib was generally well tolerated, but 12.6% and 25.8% of patients assigned to the 12-and 36-month groups, respectively, discontinued imatinib for a reason other than GIST recurrence. Conclusion Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence.	[Joensuu, Heikki; Bono, Petri] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; [Sarlomo-Rikala, Maarit] Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00029 Helsinki, Finland; [Eriksson, Mikael] Skane Univ Hosp, Dept Oncol, Lund, Sweden; [Alvegard, Thor] Lund Univ, Dept Canc Epidemiol, Lund, Sweden; [Hall, Kirsten Sundby] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; [Hartmann, Joerg T.] Univ Tubingen, Med Ctr, Dept Med Oncol Hematol Immunol Rheumatol & Pulmon, Tubingen, Germany; [Pink, Daniel; Reichardt, Peter] HELIOS Klinikum Berlin Buch, Sarkomzentrum Berlin Brandenburg, Berlin, Germany; [Schuette, Jochen] Marien Hosp, Dept Hematol Oncol, Dusseldorf, Germany; [Ramadori, Giuliano] Univ Gottingen, Dept Gastroenterol Endocrinol, Gottingen, Germany; [Hohenberger, Peter] Univ Mannheim, Med Ctr, Div Surg Oncol & Thorac Surg, Mannheim, Germany; [Duyster, Justus] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-8000 Munich, Germany; [Al-Batran, Salah-Eddin] Krankenhaus NW Frankfurt, Klin Onkol & Hamatol, Frankfurt, Germany; [Schlemmer, Marcus] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; [Bauer, Sebastian] W German Canc Ctr, Sarcoma Ctr, Essen, Germany; [Wardelmann, Eva] Univ Cologne, Dept Pathol, Cologne, Germany; [Nilsson, Bengt] Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden; [Sihto, Harri] Univ Helsinki, Biomedicum, Mol Oncol Lab, Helsinki, Finland; [Monge, Odd R.] Haukeland Hosp, Dept Radiotherapy & Oncol, N-5021 Bergen, Norway; [Kallio, Raija] Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland; [Vehtari, Aki] Aalto Univ, Dept Biomed Engn & Computat Sci, Espoo, Finland; [Leinonen, Mika] 4Pharma, Turku, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Lund University; Skane University Hospital; Lund University; University of Oslo; Eberhard Karls University of Tubingen; Helios Kliniken; Marien Hospital Dusseldorf; St. Marien Hospital; University of Gottingen; University of Mannheim; Technical University of Munich; Krankenhaus Nordwest; University of Munich; University of Cologne; Sahlgrenska University Hospital; University of Helsinki; University of Bergen; Haukeland University Hospital; University of Oulu; Aalto University	Joensuu, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Oncol, Haartmaninkatu 4,POB 180, FIN-00029 Helsinki, Finland.	heikki.joensuu@hus.fi	Bauer, Sebastian/HHR-9319-2022; Hartmann, Joerg Thomas/E-3369-2010; Bauer, Sebastian/D-8120-2012; Sihto, Harri J/B-3432-2015; Pink, Daniel/A-1084-2014; Vehtari, Aki/A-7584-2008	Bauer, Sebastian/0000-0001-5949-8120; Sihto, Harri J/0000-0001-5265-5509; Pink, Daniel/0000-0001-7243-7373; Vehtari, Aki/0000-0003-2164-9469; Joensuu, Heikki/0000-0003-0281-2507	Scandinavian Sarcoma Group; Novartis Oncology; Academy of Finland [218068, 131449]; Cancer Society of Finland; Sigrid Juselius Foundation, Finland; Helsinki University [TYH7206]; Cancer Foundation Finland sr [110071, 120084] Funding Source: researchfish	Scandinavian Sarcoma Group; Novartis Oncology; Academy of Finland(Academy of Finland); Cancer Society of Finland; Sigrid Juselius Foundation, Finland(Sigrid Juselius Foundation); Helsinki University; Cancer Foundation Finland sr	This study was sponsored by the Scandinavian Sarcoma Group and funded by Novartis Oncology; Academy of Finland (grants 218068 and 131449); Cancer Society of Finland; Sigrid Juselius Foundation, Finland; and Helsinki University Research Funds (grant TYH7206). Novartis Oncology provided the study drug.	Agaimy A, 2007, AM J SURG PATHOL, V31, P113, DOI 10.1097/01.pas.0000213307.05811.f0; Andersson J, 2006, GASTROENTEROLOGY, V130, P1573, DOI 10.1053/j.gastro.2006.01.043; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183; Debiec-Rychter M, 2006, EUR J CANCER, V42, P1093, DOI 10.1016/j.ejca.2006.01.030; DeMatteo RP, 2008, CANCER-AM CANCER SOC, V112, P608, DOI 10.1002/cncr.23199; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Gal R, 2005, INT J SURG PATHOL, V13, P161, DOI 10.1177/106689690501300206; Gold JS, 2009, LANCET ONCOL, V10, P1045, DOI 10.1016/S1470-2045(09)70242-6; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hohenberger P, 2010, BRIT J SURG, V97, P1854, DOI 10.1002/bjs.7222; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Joensuu H, 2012, LANCET ONCOL, V13, P265, DOI 10.1016/S1470-2045(11)70299-6; Kawanowa K, 2006, HUM PATHOL, V37, P1527, DOI 10.1016/j.humpath.2006.07.002; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Mucciarini C, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-230; Nilsson B, 2005, CANCER-AM CANCER SOC, V103, P821, DOI 10.1002/cncr.20862; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Reichardt P, 2011, EUR J CANCER, V47, P15, DOI 10.1016/S0959-8049(11)70130-7; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Rutkowski P, 2007, ANN SURG ONCOL, V14, P2018, DOI 10.1245/s10434-007-9377-9; Takahashi T, 2007, INT J CLIN ONCOL, V12, P369, DOI 10.1007/s10147-007-0705-7; Trent JC, 2010, CANCER-AM CANCER SOC, V116, P184, DOI 10.1002/cncr.24683; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Woodall CE, 2009, ARCH SURG-CHICAGO, V144, P670, DOI 10.1001/archsurg.2009.108	28	634	706	0	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1265	1272		10.1001/jama.2012.347	http://dx.doi.org/10.1001/jama.2012.347			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453568	Bronze			2022-12-28	WOS:000301978400022
J	Messerschmidt, DM; de Vries, W; Ito, M; Solter, D; Ferguson-Smith, A; Knowles, BB				Messerschmidt, Daniel M.; de Vries, Wilhelmine; Ito, Mitsuteru; Solter, Davor; Ferguson-Smith, Anne; Knowles, Barbara B.			Trim28 Is Required for Epigenetic Stability During Mouse Oocyte to Embryo Transition	SCIENCE			English	Article							IMPRINTED EXPRESSION; H19 GENE; METHYLATION; IGF2; GENOME; TUMOR; 11P15	Phenotypic variability in genetic disease is usually attributed to genetic background variation or environmental influence. Here, we show that deletion of a single gene, Trim28 (Kap1 or Tif1 beta), from the maternal germ line alone, on an otherwise identical genetic background, results in severe phenotypic and epigenetic variability that leads to embryonic lethality. We identify early and minute epigenetic variations in blastomeres of the preimplantation embryo of these animals, suggesting that the embryonic lethality may result from the misregulation of genomic imprinting in mice lacking maternal Trim28. Our results reveal the long-range effects of a maternal gene deletion on epigenetic memory and illustrate the delicate equilibrium of maternal and zygotic factors during nuclear reprogramming.	[Messerschmidt, Daniel M.; Solter, Davor; Knowles, Barbara B.] Inst Med Biol, Mammalian Dev Grp, Singapore 138648, Singapore; [de Vries, Wilhelmine] Jackson Lab, Bar Harbor, ME 04609 USA; [Ito, Mitsuteru; Ferguson-Smith, Anne] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Solter, Davor] Duke NUS, Grad Sch Med, Singapore 169857, Singapore; [Ferguson-Smith, Anne] Singapore Inst Clin Sci, Singapore 117609, Singapore; [Knowles, Barbara B.] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Jackson Laboratory; University of Cambridge; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); National University of Singapore	Messerschmidt, DM (corresponding author), Inst Med Biol, Mammalian Dev Grp, Singapore 138648, Singapore.	daniel.m@imb.a-star.edu.sg	Solter, Davor/Q-5476-2019; Messerschmidt, Daniel Martin/W-7193-2019	Messerschmidt, Daniel Martin/0000-0003-2022-4696; Knowles, Barbara B./0000-0002-2597-5619; Ferguson-Smith, Anne/0000-0002-7608-5894	A*STAR, Singapore; Wellcome Trust; UK Technology Strategy Board; MRC [MR/J001597/1] Funding Source: UKRI; Medical Research Council [MR/J001597/1] Funding Source: researchfish	A*STAR, Singapore(Agency for Science Technology & Research (A*STAR)); Wellcome Trust(Wellcome Trust); UK Technology Strategy Board; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This research was financed by A*STAR, Singapore and by grants from the Wellcome Trust and UK Technology Strategy Board. We thank H. Wollmann, S. Balu, D. Tham, and K. Yamazawa for their help. Microarray data and accession nos. can be found in the Supporting Online Material.	BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Cammas F, 2000, DEVELOPMENT, V127, P2955; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Engel N, 2004, NAT GENET, V36, P883, DOI 10.1038/ng1399; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Ferguson-Smith AC, 2011, NAT REV GENET, V12, P565, DOI 10.1038/nrg3032; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959; Li XJ, 2008, DEV CELL, V15, P547, DOI 10.1016/j.devcel.2008.08.014; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Nakamura T, 2007, NAT CELL BIOL, V9, P64, DOI 10.1038/ncb1519; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; Smallwood SA, 2011, NAT GENET, V43, P811, DOI 10.1038/ng.864; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Whitelaw NC, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-11-r111; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240	26	241	255	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1499	1502		10.1126/science.1216154	http://dx.doi.org/10.1126/science.1216154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442485				2022-12-28	WOS:000301837000050
J	Koch, C; Reid, RC				Koch, Christof; Reid, R. Clay			Observatories of the mind	NATURE			English	Editorial Material									[Koch, Christof] Allen Inst Brain Sci, Seattle, WA 98103 USA; [Koch, Christof] CALTECH, Pasadena, CA 91125 USA; [Reid, R. Clay] Harvard Univ, Sch Med, Boston, MA 02115 USA	Allen Institute for Brain Science; California Institute of Technology; Harvard University; Harvard Medical School	Koch, C (corresponding author), Allen Inst Brain Sci, Seattle, WA 98103 USA.	christofk@alleninstitute.org		Koch, Christof/0000-0001-6482-8067				[Anonymous], 2011, NAT METHODS, V8, P1, DOI 10.1038/NMETH.F.321; Herculano-Houzel S, 2006, P NATL ACAD SCI USA, V103, P12138, DOI 10.1073/pnas.0604911103; Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009; Waldrop MM, 2012, NATURE, V482, P456, DOI 10.1038/482456a; Wang QX, 2007, J COMP NEUROL, V502, P339, DOI 10.1002/cne.21286	5	61	64	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					397	398		10.1038/483397a	http://dx.doi.org/10.1038/483397a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	912CC	22437592	Bronze			2022-12-28	WOS:000301771200014
J	Alexander, A; Ladd, P; Powell, S				Alexander, Andrew; Ladd, Paddy; Powell, Steve			Deafness might damage your health	LANCET			English	Editorial Material									[Alexander, Andrew] Royal United Hosp, Resp Unit, Bath BA1 3NG, Avon, England; [Ladd, Paddy] Univ Bristol, Ctr Deaf Studies, Bristol BS8 1TH, Avon, England; [Powell, Steve] SignHlth, Beaconsfield, England	University of Bristol	Alexander, A (corresponding author), Royal United Hosp, Resp Unit, Combe Pk, Bath BA1 3NG, Avon, England.	andrew.alexander@nhs.net						[Anonymous], 2009, LANCET, V374, P1793, DOI 10.1016/S0140-6736(09)62043-2; Barnett S, 2011, PREV CHRONIC DIS, V8; Department of Health, 2011, GP PAT SURV; Department of Health, 2005, MENT HLTH DEAFN EQ A; Disability Rights Commission, 2006, EQ TREATM CLOS GAP F; Fellinger J, 2012, LANCET, V379, P1037, DOI 10.1016/S0140-6736(11)61143-4; Kyle J, 1996, DEAF HLTH SCOTLAND I; Ladd Paddy., 2003, UNDERSTING DEAF C; LAKHANI M, 2008, NO PATIENT LEFT CAN; Marmot M, STRATEGIC REV HLTH I; Middleton A, 2010, BMJ-BRIT MED J, V341, P726; National Health Service Practice Management Network, 2009, IMPR ACC RESP PAT; Reeves D, 2004, ACCESS PRIMARY CARE; Royal National Institute for the Deaf, 2004, SIMPL CUR NAT REP DE SIMPL CUR NAT REP DE; Royal National Institute for the Deaf, 1999, CAN YOU HEAR US DEAF; Woodroffe T, 1998, AIDS CARE, V10, P377, DOI 10.1080/09540129850124154	16	45	46	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					979	981		10.1016/S0140-6736(11)61670-X	http://dx.doi.org/10.1016/S0140-6736(11)61670-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22423872				2022-12-28	WOS:000301712300008
J	Falub, CV; von Kanel, H; Isa, F; Bergamaschini, R; Marzegalli, A; Chrastina, D; Isella, G; Muller, E; Niedermann, P; Miglio, L				Falub, Claudiu V.; von Kaenel, Hans; Isa, Fabio; Bergamaschini, Roberto; Marzegalli, Anna; Chrastina, Daniel; Isella, Giovanni; Mueller, Elisabeth; Niedermann, Philippe; Miglio, Leo			Scaling Hetero-Epitaxy from Layers to Three-Dimensional Crystals	SCIENCE			English	Article							HIGH-QUALITY GE; THREADING-DISLOCATION DENSITIES; EPITAXIAL NECKING; GROWTH; SI; SILICON; SUBSTRATE; EPILAYERS; MISFIT; STRAIN	Quantum structures made from epitaxial semiconductor layers have revolutionized our understanding of low-dimensional systems and are used for ultrafast transistors, semiconductor lasers, and detectors. Strain induced by different lattice parameters and thermal properties offers additional degrees of freedom for tailoring materials, but often at the expense of dislocation generation, wafer bowing, and cracks. We eliminated these drawbacks by fast, low-temperature epitaxial growth of Ge and SiGe crystals onto micrometer-scale tall pillars etched into Si(001) substrates. Faceted crystals were shown to be strain-and defect-free by x-ray diffraction, electron microscopy, and defect etching. They formed space-filling arrays up to tens of micrometers in height by a mechanism of self-limited lateral growth. The mechanism is explained by reduced surface diffusion and flux shielding by nearest-neighbor crystals.	[Falub, Claudiu V.; von Kaenel, Hans] ETH, Lab Solid State Phys, CH-8093 Zurich, Switzerland; [Isa, Fabio; Chrastina, Daniel; Isella, Giovanni] Politecn Milan, Dept Phys, L NESS, I-22100 Como, Italy; [Bergamaschini, Roberto; Marzegalli, Anna; Miglio, Leo] Univ Milano Bicocca, Dept Mat Sci, L NESS, I-20126 Milan, Italy; [Mueller, Elisabeth] ETH, Electron Microscopy Ctr, CH-8093 Zurich, Switzerland; [Niedermann, Philippe] Ctr Suisse Elect & Microtech SA, CH-2002 Neuchatel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Polytechnic University of Milan; University of Milano-Bicocca; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Center for Electronics & Microtechnology (CSEM)	Falub, CV (corresponding author), ETH, Lab Solid State Phys, Schafmattstr 16, CH-8093 Zurich, Switzerland.	cfalub@phys.ethz.ch	Falub, Claudiu/J-9687-2015; Bergamaschini, Roberto/AAC-8373-2022; Chrastina, Daniel/B-6361-2008; Chrastina, Daniel/I-7815-2015; Isella, Giovanni/A-7305-2008	Falub, Claudiu/0000-0003-1735-4908; Bergamaschini, Roberto/0000-0002-3686-2273; Chrastina, Daniel/0000-0002-1054-3717; Chrastina, Daniel/0000-0002-1054-3717; Isella, Giovanni/0000-0001-5951-7440; Marzegalli, Anna/0000-0003-3109-3353; MIGLIO, LEONIDA/0000-0002-1329-527X; Muller, Elisabeth/0000-0001-8239-7109; Isa, Fabio/0000-0002-1517-7242	Swiss federal program funding Nano-Tera through NEXRAY; Fondazione CARIPLO within the MANDIS	Swiss federal program funding Nano-Tera through NEXRAY; Fondazione CARIPLO within the MANDIS	Supported by the Swiss federal program funding Nano-Tera through project NEXRAY. Partial support from Fondazione CARIPLO within the MANDIS Project is gratefully acknowledged. We thank Centre Suisse d'Electronique et Microtechnique, Neuchatel, for providing most of the patterned Si substrates used in this work; D. Colombo for preparing the patterned substrates with the submicrometer-wide Si pillars and trenches by means of cryogenic deep reactive ion etching; M. Meduna for his help in performing and analyzing the synchrotron submicrometer diffraction experiments; B. Batlogg, A. Dommann, A. Neels, R. Kaufmann, A. Pezous, F. Montalenti, F. Pezzoli, E. Bonera, R. Gatti, A. G. Taboada, and T. Kreiliger for valuable discussions; A. Fedorov and K. Mattenberger for technical support; the FIRST Center for Micro- and Nanoscience of ETH Zurich for making available its infrastructure; and the scientific personnel at the ID01 beamline of the European Synchrotron Radiation Facility, Grenoble, in providing user support for the submicrometer diffraction experiments. International patent application WO 2011/135432 has been filed.	Bai J, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2711276; BOOKER GR, 1978, J CRYST GROWTH, V45, P407, DOI 10.1016/0022-0248(78)90470-0; Feltin E, 2001, APPL PHYS LETT, V79, P3230, DOI 10.1063/1.1415043; FITZGERALD EA, 1991, APPL PHYS LETT, V59, P811, DOI 10.1063/1.105351; FITZGERALD EA, 1991, J ELECTRON MATER, V20, P839, DOI 10.1007/BF02665973; GOULDING MR, 1993, MAT SCI ENG B-SOLID, V17, P47, DOI 10.1016/0921-5107(93)90080-7; HODSON PD, 1988, SEMICOND SCI TECH, V3, P715, DOI 10.1088/0268-1242/3/7/013; Hu S, 2009, NAT NANOTECHNOL, V4, P649, DOI 10.1038/nnano.2009.233; JONES SH, 1991, J CRYST GROWTH, V108, P73, DOI 10.1016/0022-0248(91)90355-9; Klapper H, 2000, MATER CHEM PHYS, V66, P101, DOI 10.1016/S0254-0584(00)00342-4; KVAM EP, 1990, J MATER RES, V5, P1900, DOI 10.1557/JMR.1990.1900; Langdo TA, 2000, APPL PHYS LETT, V76, P3700, DOI 10.1063/1.126754; Li SZ, 1995, J CRYST GROWTH, V157, P185, DOI 10.1016/0022-0248(95)00406-8; Luan HC, 1999, APPL PHYS LETT, V75, P2909, DOI 10.1063/1.125187; MADHUKAR A, 1993, THIN SOLID FILMS, V231, P8, DOI 10.1016/0040-6090(93)90701-P; MATTHEWS JW, 1976, THIN SOLID FILMS, V33, P253, DOI 10.1016/0040-6090(76)90085-7; MATTHEWS JW, 1970, J APPL PHYS, V41, P3800, DOI 10.1063/1.1659510; MO YW, 1990, PHYS REV LETT, V65, P1020, DOI 10.1142/S0217984990001732; OHTSUKA M, 1988, J APPL PHYS, V64, P3522, DOI 10.1063/1.341490; Park JS, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2435603; Rondanini M, 2008, J APPL PHYS, V104, DOI 10.1063/1.2948927; Rosenblad C, 1998, J VAC SCI TECHNOL A, V16, P2785, DOI 10.1116/1.581422; Sakai M, 2004, JPN J APPL PHYS 1, V43, P8019, DOI 10.1143/JJAP.43.8019; SLACK GA, 1975, J APPL PHYS, V46, P89, DOI 10.1063/1.321373; STORMER HL, 1983, SCIENCE, V220, P1241, DOI 10.1126/science.220.4603.1241; Thompson SE, 2004, IEEE ELECTR DEVICE L, V25, P191, DOI 10.1109/LED.2004.825195; Umansky V, 2009, J CRYST GROWTH, V311, P1658, DOI 10.1016/j.jcrysgro.2008.09.151; VANDERMERWE JH, 1963, J APPL PHYS, V34, P123, DOI 10.1063/1.1729051; Wang G, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3360231	29	135	142	5	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1330	1334		10.1126/science.1217666	http://dx.doi.org/10.1126/science.1217666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422978				2022-12-28	WOS:000301531600042
J	Sparks, RSJ; Biggs, J; Neuberg, JW				Sparks, R. S. J.; Biggs, J.; Neuberg, J. W.			Monitoring Volcanoes	SCIENCE			English	Editorial Material							DEFORMATION; ERUPTION		[Sparks, R. S. J.; Biggs, J.] Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; [Neuberg, J. W.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England	University of Bristol; University of Leeds	Sparks, RSJ (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.	steve.sparks@bristol.ac.uk	Biggs, Juliet/D-4599-2011; NCEO, COMET+`/A-3443-2013	Biggs, Juliet/0000-0002-4855-039X; Neuberg, Jurgen/0000-0001-7866-0736	NERC [come20001, NE/J02483X/1, NE/I015760/1] Funding Source: UKRI; Natural Environment Research Council [come20001, NE/J02483X/1, earth010007, NE/I015760/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aspinall W, 2011, 20100806 NGI, P3; Biggs J, 2009, GEOLOGY, V37, P979, DOI 10.1130/G30133A.1; Dzurisin D, 2003, REV GEOPHYS, V41, DOI 10.1029/2001RG000107; Edmonds M, 2008, PHILOS T R SOC A, V366, P4559, DOI 10.1098/rsta.2008.0185; Hautmann S, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006909; Iverson RM, 2006, NATURE, V444, P439, DOI 10.1038/nature05322; LINDE AT, 1993, NATURE, V365, P737, DOI 10.1038/365737a0; McCormick BT, 2012, GEOCHEM GEOPHY GEOSY, V13, DOI 10.1029/2011GC003945; Nadeau PA, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL045820; Neuberg J. W., 2011, ENCY SOLID EARTH GEO, V1, P261; Pritchard ME, 2002, NATURE, V418, P167, DOI 10.1038/nature00872; Rix M., 2009, SEL TOPICS APPL EART, V2, P196; Sparks RSJ, 2003, EARTH PLANET SC LETT, V210, P1, DOI 10.1016/S0012-821X(03)00124-9	14	135	135	2	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1310	1311		10.1126/science.1219485	http://dx.doi.org/10.1126/science.1219485			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422969				2022-12-28	WOS:000301531600033
J	Van Noorden, R				Van Noorden, Richard			PRODUCTION Beyond sticky tape	NATURE			English	Editorial Material							GRAPHENE NANORIBBONS; GROWTH; FILMS											Bae S, 2010, NAT NANOTECHNOL, V5, P574, DOI [10.1038/nnano.2010.132, 10.1038/NNANO.2010.132]; Cai JM, 2010, NATURE, V466, P470, DOI 10.1038/nature09211; Kwak J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1650; Li XS, 2011, J AM CHEM SOC, V133, P2816, DOI 10.1021/ja109793s; Peng ZW, 2011, ACS NANO, V5, P8241, DOI 10.1021/nn202923y; Sprinkle M, 2010, NAT NANOTECHNOL, V5, P727, DOI 10.1038/nnano.2010.192; Xu Z, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1583	7	43	43	2	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S32	S33		10.1038/483S32a	http://dx.doi.org/10.1038/483S32a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419208	Bronze			2022-12-28	WOS:000301481800002
J	Day, C; Michelson, D; Thomson, S; Penney, C; Draper, L				Day, Crispin; Michelson, Daniel; Thomson, Stacey; Penney, Caroline; Draper, Lucy			Evaluation of a peer led parenting intervention for disruptive behaviour problems in children: community based randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTISOCIAL-BEHAVIOR; CONDUCT DISORDER; CHILDHOOD; HEALTH; RISK	Objective To evaluate the effectiveness of a peer led parenting intervention delivered to socially disadvantaged families. Design Randomised controlled trial. Setting Schools and children's centres in a socially deprived borough of inner London. Participants Parental caregivers seeking help with managing the problem behaviours of 116 index children, aged 2-11 years; 59 families were randomised to the intervention and 57 to a waitlist control condition. Intervention Empowering parents, empowering communities is an eight week (two hours each week), manualised programme delivered to groups of parents by trained peer facilitators from the local community. Main outcome measures Child problems (number and severity), parental stress, and parenting competencies were assessed before and after the intervention using standardised parent reported measures. Results Significantly greater improvements in positive parenting practices and child problems were observed in the intervention group compared with the waitlist group, with no difference in parental stress between the groups. An intention to treat analysis for the primary outcome measure, the intensity subscale of the Eyberg child behaviour inventory, showed an intervention effect size of 0.38 (95% confidence interval 0.01 to 0.75, P=0.01). The intervention group had high rates of treatment retention (91.5%) and user satisfaction. Conclusion The peer led parenting intervention significantly reduced child behaviour problems and improved parenting competencies. This is a promising method for providing effective and acceptable parenting support to families considered hard to reach by mainstream services.	[Day, Crispin; Michelson, Daniel; Thomson, Stacey] Kings Coll London, Inst Psychiat, Dept Psychol, Child & Adolescent Mental Hlth Serv Res Unit, London SE5 8AF, England; [Day, Crispin; Penney, Caroline; Draper, Lucy] S London & Maudsley NHS Fdn Trust, Michael Rutter Ctr, Ctr Parent & Child Support, London, England	University of London; King's College London; South London & Maudsley NHS Trust	Michelson, D (corresponding author), Kings Coll London, Inst Psychiat, Dept Psychol, Child & Adolescent Mental Hlth Serv Res Unit, London SE5 8AF, England.	daniel.m.d.michelson@kcl.ac.uk		Day, Crispin/0000-0002-7655-7839; Michelson, Daniel/0000-0001-7370-8788	Guy's and St Thomas' Charity; London Borough of Southwark; Institute of Psychiatry, King's College London	Guy's and St Thomas' Charity; London Borough of Southwark; Institute of Psychiatry, King's College London(General Electric)	This study was supported by Guy's and St Thomas' Charity and the London Borough of Southwark.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: all authors have support from the Institute of Psychiatry, King's College London for the submitted work; all authors have no relationships with any organisations that might have an interest in the submitted work in the previous three years; and all authors have no non-financial interests that may be relevant to the submitted work.	Abidin RR., 1995, PSYCHOL ASSESSMENT R; Arnold D.S., 1993, PSYCHOL ASSESSMENT, V9, P137, DOI [10.1037/1040-3590.5.2.137, DOI 10.1037/1040-3590.5.2.137]; Barlow J, 2005, J R SOC PROMO HEALTH, V125, P64, DOI 10.1177/146642400512500209; Barlow J, 2002, BRIT J GEN PRACT, V52, P223; Burke JD, 2002, J AM ACAD CHILD PSY, V41, P1275, DOI 10.1097/00004583-200211000-00009; Cupples ME, 2011, ARCH DIS CHILD, V96, P252, DOI 10.1136/adc.2009.167387; Davis H, 2000, CLIN CHILD PSYCHOL P, V5, P168; Day C, 2012, CHILD ADOL MENT H-UK, V17, P52, DOI 10.1111/j.1475-3588.2011.00619.x; Dretzke J, 2009, CHILD ADOLESCENT PSY, V3, P289; Eyberg S.M., 1999, EYBERG CHILD BEHAV I; EYBERG SM, 1978, J CLIN CHILD PSYCHOL, V7, P113, DOI 10.1080/15374417809532835; Fergusson DM, 2005, J CHILD PSYCHOL PSYC, V46, P837, DOI 10.1111/j.1469-7610.2004.00387.x; Forehand R, 1996, BEHAV THER, V27, P187, DOI 10.1016/S0005-7894(96)80014-1; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hutchings J, 2007, BMJ-BRIT MED J, V334, P678, DOI 10.1136/bmj.39126.620799.55; Kazdin AE, 1997, J CONSULT CLIN PSYCH, V65, P453, DOI 10.1037/0022-006X.65.3.453; Konrad SC, 2007, OMEGA-J DEATH DYING, V55, P117, DOI 10.2190/OM.55.2.b; Loeber R, 2000, DEV PSYCHOPATHOL, V12, P737, DOI 10.1017/S0954579400004107; McKay M. M., 2004, BRIEF TREATMENT CRIS, V4, P177, DOI [10.1093/brief-treatment/mhh014, DOI 10.1093/BRIEF-TREATMENT/MHH014]; National Institute for Health and Clinical Excellence, 2006, PAR TRAIN ED PROGR M; Nock MK, 2005, CLIN CHILD FAM PSYCH, V8, P149, DOI 10.1007/s10567-005-4753-0; Penney C, 2010, BEING PARENT MANUAL; Rawana EP, 1989, BEHAV RESIDENTIAL TR, V4, P32; Rich B.A., 2001, AMBULATORY CHILD HLT, V7, P249, DOI [DOI 10.1046/J.1467-0658.2001.00141.X, https://doi.org/10.1046/j.1467-0658.2001.00141.x]; Schulz KF, 2010, BMC MED, V8, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; Scott S, 2001, BRIT MED J, V323, P194, DOI 10.1136/bmj.323.7306.194; Serketich WJ, 1996, BEHAV THER, V27, P171, DOI 10.1016/S0005-7894(96)80013-X; Southwark Analytical Hub, 2008, ENGL IND DEPR 2007; Southwark Analytical Hub, 2009, SOUTHW VIT STAT 2008; Webel AR, 2010, AM J PUBLIC HEALTH, V100, P247, DOI 10.2105/AJPH.2008.149419	30	35	35	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2012	344								e1107	10.1136/bmj.e1107	http://dx.doi.org/10.1136/bmj.e1107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BR	22416059	Green Submitted, hybrid, Green Accepted			2022-12-28	WOS:000301846900002
J	Badylak, SF; Weiss, DJ; Caplan, A; Macchiarini, P				Badylak, Stephen F.; Weiss, Daniel J.; Caplan, Arthur; Macchiarini, Paolo			RETRACTED: Engineered whole organs and complex tissues (Retracted article. See vol. 392, pg. 11, 2018)	LANCET			English	Article; Retracted Publication							EXTRACELLULAR-MATRIX SCAFFOLDS; REGENERATIVE MEDICINE APPROACH; SMALL-INTESTINAL SUBMUCOSA; MESENCHYMAL STEM-CELLS; PROGENITOR CELLS; LUNG-TISSUE; 3-DIMENSIONAL CULTURE; CLINICAL-APPLICATION; BIOLOGIC SCAFFOLD; GENE-EXPRESSION	End-stage organ failure is a key challenge for the medical community because of the ageing population and the severe shortage of suitable donor organs available. Equally, injuries to or congenital absence of complex tissues such as the trachea, oesophagus, or skeletal muscle have few therapeutic options. A new approach to treatment involves the use of three-dimensional biological scaffolds made of allogeneic or xenogeneic extracellular matrix derived from non-autologous sources. These scaffolds can act as an inductive template for functional tissue and organ reconstruction after recellularisation with autologous stem cells or differentiated cells. Such an approach has been used successfully for the repair and reconstruction of several complex tissues such as trachea, oesophagus, and skeletal muscle in animal models and human beings, and, guided by appropriate scientific and ethical oversight, could serve as a platform for the engineering of whole organs and other tissues.	[Badylak, Stephen F.] Univ Pittsburgh, Dept Surg, McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Weiss, Daniel J.] Univ Vermont, Coll Med, Vermont Lung Ctr, Burlington, VT USA; [Caplan, Arthur] Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA; [Macchiarini, Paolo] Adv Ctr Translat Regenerat Med, Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Vermont; University of Pennsylvania; Pennsylvania Medicine	Macchiarini, P (corresponding author), Karolinska Inst, Adv Ctr Translat Regenerat Med ACTREM, Div Ear Nose & Throat, Dept Clin Sci Intervent & Technol CLINTEC, Alfred Nobel Alle 8, S-14186 Stockholm, Sweden.	paolo.macchiarini@ki.se	Macchiarini, Paolo/E-6878-2013; Phatak, Sai/C-5725-2012	Badylak, Stephen/0000-0003-3555-0689	Wallenberg Institute for Regenerative Medicine; Karolinska Institutet/SLL (Stockholm, Sweden); US National Institutes of Health [RC4HL106625]; National Heart, Lung, and Blood Institute [R21HL094611]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL094611, RC4HL106625] Funding Source: NIH RePORTER	Wallenberg Institute for Regenerative Medicine; Karolinska Institutet/SLL (Stockholm, Sweden); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This review was supported by the Wallenberg Institute for Regenerative Medicine and Karolinska Institutet/SLL grants (Stockholm, Sweden) and grants from the US National Institutes of Health (RC4HL106625) and National Heart, Lung, and Blood Institute (R21HL094611). We thank Eve A Simpson, Philipp Jungebluth, and Silvia Baiguera for their excellent technical assistance with this report.	Agrawal V, 2011, TISSUE ENG PT A, V17, P2435, DOI [10.1089/ten.TEA.2011.0036, 10.1089/ten.tea.2011.0036]; Agrawal V, 2010, P NATL ACAD SCI USA, V107, P3351, DOI 10.1073/pnas.0905851106; Andrade CF, 2007, AM J PHYSIOL-LUNG C, V292, pL510, DOI 10.1152/ajplung.00175.2006; Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112531; Asnaghi MA, 2009, BIOMATERIALS, V30, P5260, DOI 10.1016/j.biomaterials.2009.07.018; Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9; Auger FA, 2009, SKIN PHARMACOL PHYS, V22, P94, DOI 10.1159/000178868; Bader A, 1998, EUR J CARDIO-THORAC, V14, P279, DOI 10.1016/S1010-7940(98)00171-7; Badylak SF, 2007, BIOMATERIALS, V28, P3587, DOI 10.1016/j.biomaterials.2007.04.043; Badylak SF, 2011, TISSUE ENG PT A, V17, P1643, DOI 10.1089/ten.tea.2010.0739; Baiguera S, BIOMATERIAL IN PRESS; Baiguera S, 2011, BIOMATERIALS, V32, P4433, DOI 10.1016/j.biomaterials.2011.02.055; Baiguera S, 2010, BIOMATERIALS, V31, P8931, DOI 10.1016/j.biomaterials.2010.08.005; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Beattie AJ, 2009, TISSUE ENG PT A, V15, P1119, DOI 10.1089/ten.tea.2008.0162; Biancosino C, 2006, CYTOTHERAPY, V8, P178, DOI 10.1080/14653240600621166; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Borschel GH, 2004, PLAST RECONSTR SURG, V113, P595, DOI 10.1097/01.PRS.0000101064.62289.2F; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Brewer MB, 2011, HERNIA, V15, P141, DOI 10.1007/s10029-010-0748-y; Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040; Brown D. W., 2008, Morbidity and Mortality Weekly Report, V57, P1229; Calve S, 2010, DEV BIOL, V344, P259, DOI 10.1016/j.ydbio.2010.05.007; Caplan A, 2004, AM J BIOETHICS, V4, P18, DOI 10.1080/15265160490496930; Caplan A, 2010, AM J BIOETHICS, V10, P24, DOI 10.1080/15265161.2010.481980; Cebotari S, 2006, CIRCULATION, V114, pI132, DOI 10.1161/CIRCULATIONAHA.105.001065; Chen F, 1999, UROLOGY, V54, P407, DOI 10.1016/S0090-4295(99)00179-X; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Cortiella J, 2006, TISSUE ENG, V12, P1213, DOI 10.1089/ten.2006.12.1213; Cortiella J, 2010, TISSUE ENG PT A, V16, P2565, DOI 10.1089/ten.tea.2009.0730; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Curcio E, 2010, BIOMATERIALS, V31, P5131, DOI 10.1016/j.biomaterials.2010.03.013; Dahl SLM, 2003, CELL TRANSPLANT, V12, P659, DOI 10.3727/000000003108747136; Daly AB, 2012, TISSUE ENG PT A, V18, P1, DOI [10.1089/ten.tea.2011.0301, 10.1089/ten.TEA.2011.0301]; Daly KA, 2009, TISSUE ENG PT A, V15, P3877, DOI [10.1089/ten.tea.2009.0089, 10.1089/ten.TEA.2009.0089]; Draheim KM, 2011, METHODS MOL BIOL, V750, P261, DOI 10.1007/978-1-61779-145-1_18; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941; El Nahas AM, 2005, LANCET, V365, P331, DOI 10.1016/S0140-6736(05)17789-7; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; Gassmann P, 2004, ONKOLOGIE, V27, P577, DOI 10.1159/000081343; Gilbert TW, 2007, J BONE JOINT SURG AM, V89A, P621, DOI 10.2106/JBJS.F.00742; Grillo HC, 2002, ANN THORAC SURG, V73, P1995, DOI 10.1016/S0003-4975(02)03564-6; Guenou H, 2009, LANCET, V374, P1745, DOI 10.1016/S0140-6736(09)61496-3; Heron Melonie, 2009, Natl Vital Stat Rep, V57, P1; Hodde J P, 2005, J Wound Care, V14, P23; Hoppo T, 2011, GASTROENTEROLOGY, V140, P656, DOI 10.1053/j.gastro.2010.11.006; Houghton AM, 2006, CANCER RES, V66, P6149, DOI 10.1158/0008-5472.CAN-04-0297; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Jungebluth P, 2011, LANCET, V378, P1997, DOI 10.1016/S0140-6736(11)61715-7; Laurance J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1633; Lin YM, 2006, J BIOMATER APPL, V21, P109, DOI 10.1177/0885328206057952; Lineen E, 2008, J CRANIOFAC SURG, V19, P923, DOI 10.1097/SCS.0b013e318175b5ab; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6; Mase Vincent J Jr, 2010, Orthopedics, V33, P511, DOI 10.3928/01477447-20100526-24; Mondrinos MJ, 2007, AM J PHYSIOL-LUNG C, V293, pL639, DOI 10.1152/ajplung.00403.2006; Morigi M, 2008, STEM CELLS, V26, P2075, DOI 10.1634/stemcells.2007-0795; Morigi M, 2010, STEM CELLS, V28, P513, DOI 10.1002/stem.293; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nakayama KH, 2010, TISSUE ENG PT A, V16, P2207, DOI [10.1089/ten.tea.2009.0602, 10.1089/ten.TEA.2009.0602]; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Nieponice A, 2006, ANN THORAC SURG, V82, P2050, DOI 10.1016/j.athoracsur.2006.06.036; Omori K, 2008, ANN OTO RHINOL LARYN, V117, P673, DOI 10.1177/000348940811700908; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orens Jonathan B, 2009, Proc Am Thorac Soc, V6, P13, DOI 10.1513/pats.200807-072GO; Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684; Ott HC, 2010, NAT MED, V16, P927, DOI 10.1038/nm.2193; Ott HC, 2005, CIRCULATION, V112, pU105; Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345; Price AP, 2010, TISSUE ENG PT A, V16, P2581, DOI [10.1089/ten.tea.2009.0659, 10.1089/ten.TEA.2009.0659]; Priya SG, 2008, TISSUE ENG PART B-RE, V14, P105, DOI 10.1089/teb.2007.0318; Reynolds Teri A, 2008, Ann Emerg Med, V52, P561, DOI 10.1016/j.annemergmed.2008.09.013; Roomans Godfried M, 2010, Eur Cell Mater, V19, P284; Ross EA, 2009, J AM SOC NEPHROL, V20, P2338, DOI 10.1681/ASN.2008111196; Roy M, 2009, J CELL BIOCHEM, V106, P200, DOI 10.1002/jcb.22005; Sellaro TL, 2010, TISSUE ENG PT A, V16, P1075, DOI [10.1089/ten.tea.2008.0587, 10.1089/ten.TEA.2008.0587]; Shigemura N, 2006, AM J RESP CRIT CARE, V174, P1199, DOI 10.1164/rccm.200603-406OC; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Soto-Gutierrez A, 2011, TISSUE ENG PART C-ME, V17, P677, DOI 10.1089/ten.tec.2010.0698; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tottey S, 2011, TISSUE ENG PT A, V17, P37, DOI [10.1089/ten.tea.2010.0188, 10.1089/ten.TEA.2010.0188]; United States Renal Data System (USRDS), 2009, REN DIS DAT; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; Valentin JE, 2010, BIOMATERIALS, V31, P7475, DOI 10.1016/j.biomaterials.2010.06.039; Valentin JE, 2009, TISSUE ENG PT A, V15, P1687, DOI 10.1089/ten.tea.2008.0419; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; VRACKO R, 1974, AM J PATHOL, V77, P314; Wilson JM, 2009, SCIENCE, V324, P727, DOI 10.1126/science.1174935; Zehr KJ, 2005, J THORAC CARDIOV SUR, V130, P1010, DOI 10.1016/j.jtcvs.2005.03.044	90	320	336	3	172	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					943	952		10.1016/S0140-6736(12)60073-7	http://dx.doi.org/10.1016/S0140-6736(12)60073-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22405797				2022-12-28	WOS:000301353700035
J	Herink, G; Solli, DR; Gulde, M; Ropers, C				Herink, G.; Solli, D. R.; Gulde, M.; Ropers, C.			Field-driven photoemission from nanostructures quenches the quiver motion	NATURE			English	Article							IONIZATION; ACCELERATION; LIMIT	Strong-field physics, an extreme limit of light-matter interaction(1-3), is expanding into the realm of surfaces(4,5) and nanostructures(6-11) from its origin in atomic and molecular science(12-15). The attraction of nanostructures lies in two intimately connected features: local intensity enhancement and sub-wavelength confinement of optical fields. Local intensity enhancement facilitates access to the strong-field regime and has already sparked various applications, whereas spatial localization has the potential to generate strong-field dynamics exclusive to nanostructures. However, the observation of features unattainable in gaseous media is challenged by many-body effects and material damage, which arise under intense illumination of dense systems(16-19). Here, we non-destructively access this regime in the solid state by employing single plasmonic nanotips and few-cycle mid-infrared pulses, making use of the wavelength-dependence of the interaction, that is, the ponderomotive energy. We investigate strong-field photoelectron emission and acceleration from single nanostructures over a broad spectral range, and find kinetic energies of hundreds of electronvolts. We observe the transition to a new regime in strong-field dynamics, in which the electrons escape the nanolocalized field within a fraction of an optical half-cycle. The transition into this regime, characterized by a spatial adiabaticity parameter, would require relativistic electrons in the absence of nanostructures. These results establish new degrees of freedom for the manipulation and control of electron dynamics on femtosecond and attosecond timescales, combining optical near-fields and nanoscopic sources.	[Herink, G.; Solli, D. R.; Gulde, M.; Ropers, C.] Univ Gottingen, Courant Res Ctr Nanospect & Xray Imaging, D-37077 Gottingen, Germany	University of Gottingen	Ropers, C (corresponding author), Univ Gottingen, Courant Res Ctr Nanospect & Xray Imaging, D-37077 Gottingen, Germany.	cropers@gwdg.de	Herink, Georg/AAQ-8136-2020; Ropers, Claus/D-4843-2015	Herink, Georg/0000-0001-6649-534X; Ropers, Claus/0000-0002-9539-3817	Deutsche Forschungsgemeinschaft [DFG-ZUK 45/1, SPP 1391]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank R. Bormann, F. Schenk, M. Sivis and S. V. Yalunin for discussions. Financial support by the Deutsche Forschungsgemeinschaft (DFG-ZUK 45/1 and SPP 1391) is gratefully acknowledged.	AESCHLIMANN M, 1995, J CHEM PHYS, V102, P8606, DOI 10.1063/1.468962; Bormann R, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.147601; Bouhelier A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.013903; Colosimo P, 2008, NAT PHYS, V4, P386, DOI 10.1038/nphys914; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; Einstein A, 1905, ANN PHYS-BERLIN, V17, P132; GILTON TL, 1990, J APPL PHYS, V68, P4802, DOI 10.1063/1.346137; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Hommelhoff P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.077401; Hommelhoff P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.247402; Huber AJ, 2008, NANO LETT, V8, P3766, DOI 10.1021/nl802086x; Irvine SE, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.184801; KELDYSH LV, 1965, SOV PHYS JETP-USSR, V20, P1307; Kim S, 2008, NATURE, V453, P757, DOI 10.1038/nature07012; Krausz F, 2009, REV MOD PHYS, V81, P163, DOI 10.1103/RevModPhys.81.163; Kruger M, 2011, NATURE, V475, P78, DOI 10.1038/nature10196; Lenard P, 1902, ANN PHYS-BERLIN, V8, P149; Meckel M, 2008, SCIENCE, V320, P1478, DOI 10.1126/science.1157980; Passlack S, 2006, J APPL PHYS, V100, DOI 10.1063/1.2217985; PAULUS GG, 1995, PHYS REV A, V52, P4043, DOI 10.1103/PhysRevA.52.4043; PETITE G, 1992, PHYS REV B, V45, P12210, DOI 10.1103/PhysRevB.45.12210; Racz P, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3567941; Ropers C, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.043907; Sansone G, 2006, SCIENCE, V314, P443, DOI 10.1126/science.1132838; Schenk M, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.257601; Sivis M., NATURE IN PRESS; Stockman MI, 2007, NAT PHOTONICS, V1, P539, DOI 10.1038/nphoton.2007.169; Sussmann F, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.121406; Yalunin SV, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.195426; Zherebtsov S, 2011, NAT PHYS, V7, P656, DOI [10.1038/nphys1983, 10.1038/NPHYS1983]	30	333	337	4	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					190	193		10.1038/nature10878	http://dx.doi.org/10.1038/nature10878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904DT	22398557				2022-12-28	WOS:000301174900033
J	Smith, ZD; Chan, MM; Mikkelsen, TS; Gu, HC; Gnirke, A; Regev, A; Meissner, A				Smith, Zachary D.; Chan, Michelle M.; Mikkelsen, Tarjei S.; Gu, Hongcang; Gnirke, Andreas; Regev, Aviv; Meissner, Alexander			A unique regulatory phase of DNA methylation in the early mammalian embryo	NATURE			English	Article							NON-CPG METHYLATION; GENE-EXPRESSION; PATERNAL GENOME; MOUSE EMBRYO; WIDE; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; CELLS; PLURIPOTENT; PATTERNS	DNA methylation is highly dynamic during mammalian embryogenesis. It is broadly accepted that the paternal genome is actively depleted of 5-methylcytosine at fertilization, followed by passive loss that reaches a minimum at the blastocyst stage. However, this model is based on limited data, and so far no base-resolution maps exist to support and refine it. Here we generate genome-scale DNA methylation maps in mouse gametes and from the zygote through post-implantation. We find that the oocyte already exhibits global hypomethylation, particularly at specific families of long interspersed element 1 and long terminal repeat retroelements, which are disparately methylated between gametes and have lower methylation values in the zygote than in sperm. Surprisingly, the oocyte contributes a unique set of differentially methylated regions (DMRs)-including many CpG island promoters-that are maintained in the early embryo but are lost upon specification and absent from somatic cells. In contrast, sperm-contributed DMRs are largely intergenic and become hypermethylated after the blastocyst stage. Our data provide a genome-scale, base-resolution timeline of DNA methylation in the pre-specified embryo, when this epigenetic modification is most dynamic, before returning to the canonical somatic pattern.	[Smith, Zachary D.; Chan, Michelle M.; Mikkelsen, Tarjei S.; Gu, Hongcang; Gnirke, Andreas; Regev, Aviv; Meissner, Alexander] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Smith, Zachary D.; Mikkelsen, Tarjei S.; Meissner, Alexander] Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Smith, Zachary D.; Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Chan, Michelle M.] MIT, Computat & Syst Biol Program, Cambridge, MA 02139 USA; [Regev, Aviv] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Meissner, A (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	alexander_meissner@harvard.edu	Mikkelsen, Tarjei S/A-1306-2007	Mikkelsen, Tarjei S/0000-0002-8133-3135; Gu, Hongcang/0000-0002-1439-7606	NIH [5DP1OD003958, 5RC1AA019317, U01ES017155, P01GM099117]; HHMI; Harvard Stem Cell Institute; Massachusetts Life Science Center; Pew Charitable Trusts; Center for Excellence in Genome Science from the NHGRI [1P50HG006193-01]; Burroughs Wellcome Career Award at the Scientific Interface; NATIONAL CANCER INSTITUTE [DP1CA174427] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG006193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES017155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM099117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [RC1AA019317] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003958] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); Harvard Stem Cell Institute; Massachusetts Life Science Center; Pew Charitable Trusts; Center for Excellence in Genome Science from the NHGRI; Burroughs Wellcome Career Award at the Scientific Interface(Burroughs Wellcome Fund); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank all members of the Meissner and Regev laboratories. M. Garber, N. Yosef, J. Ye, R. Koche, C. Bock, R. Maehr and D. Egli for technical advice and discussion. We thank all members of the Broad Sequencing Platform, in particular F. Kelly and J. Meldrim, T. Fennel, K. Tibbetts and J. Fostel. We also thank S. Levine, M. Gravina and K. Thai from the MIT BioMicro Center. A.R. is an investigator of the Merkin Foundation for Stem Cell Research at the Broad Institute. This work was supported by the NIH Pioneer Award (5DP1OD003958), the Burroughs Wellcome Career Award at the Scientific Interface and HHMI (to A.R.), the Harvard Stem Cell Institute (to T.S.M.) and the NIH (5RC1AA019317, U01ES017155 and P01GM099117), the Massachusetts Life Science Center and the Pew Charitable Trusts (to A.M.) and a Center for Excellence in Genome Science from the NHGRI (1P50HG006193-01, to A.R. and A.M.).	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blake JA, 2011, NUCLEIC ACIDS RES, V39, pD842, DOI 10.1093/nar/gkq1008; Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Davis T, 2011, JOVE-J VIS EXP, DOI 10.3791/2661; Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013; Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190; Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414; Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443; Haines TR, 2001, DEV BIOL, V240, P585, DOI 10.1006/dbio.2001.0504; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682; Hirasawa R, 2008, GENE DEV, V22, P1607, DOI 10.1101/gad.1667008; Ichiyanagi K, 2011, GENOME RES, V21, P2058, DOI 10.1101/gr.123679.111; Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kigami D, 2003, BIOL REPROD, V68, P651, DOI 10.1095/biolreprod.102.007906; Kim SH, 2004, BIOCHEM BIOPH RES CO, V324, P58, DOI 10.1016/j.bbrc.2004.09.023; Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168; Lucifero D, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-36; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684; MONK M, 1987, DEVELOPMENT, V99, P371; Nagy A., 2003, MANIPULATING MOUSE E; Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Smallwood SA, 2011, NAT GENET, V43, P811, DOI 10.1038/ng.864; Smith ZD, 2009, METHODS, V48, P226, DOI 10.1016/j.ymeth.2009.05.003; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Szulwach KE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002154; Tomizawa S, 2011, DEVELOPMENT, V138, P811, DOI 10.1242/dev.061416; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240; Wossidlo M, 2010, EMBO J, V29, P1877, DOI 10.1038/emboj.2010.80; Wu H, 2011, GENE DEV, V25, P679, DOI 10.1101/gad.2036011; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Ziller MJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002389	55	693	719	7	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					339	U74		10.1038/nature10960	http://dx.doi.org/10.1038/nature10960			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22456710	Green Accepted, Green Submitted			2022-12-28	WOS:000302946500025
J	Franklyn, JA; Boelaert, K				Franklyn, Jayne A.; Boelaert, Kristien			Thyrotoxicosis	LANCET			English	Article							SUBCLINICAL THYROID-DYSFUNCTION; AMIODARONE-INDUCED THYROTOXICOSIS; ENVIRONMENTAL IODINE INTAKE; PEDIATRIC GRAVES-DISEASE; LIFE FOLLOW-UP; RADIOIODINE TREATMENT; ANTITHYROID DRUGS; ATRIAL-FIBRILLATION; RADIOACTIVE IODINE; CLINICAL-FEATURES	Thyrotoxicosis is a common disorder, especially in women. The most frequent cause is Graves' disease (autoimmune hyperthyroidism). Other important causes include toxic nodular hyperthyroidism, due to the presence of one or more autonomously functioning thyroid nodules, and thyroiditis caused by inflammation, which results in release of stored hormones. Antithyroid drugs are the usual initial treatment (thionamides such as carbimazole or its active metabolite methimazole are the drugs of choice). A prolonged course leads to remission of Graves' hyperthyroidism in about a third of cases. Because of the low remission rate in Graves' disease and the inability to cure toxic nodular hyperthyroidism with antithyroid drugs alone, radioiodine is increasingly used as first line therapy, and is the preferred choice for relapsed Graves' hyperthyroidism. Total thyroidectomy is an option in selected cases. Future efforts are likely to concentrate on novel and safe ways to modulate the underlying disease process rather than stopping excess thyroid hormone production.	[Franklyn, Jayne A.; Boelaert, Kristien] Univ Birmingham, Ctr Diabet Endocrinol & Metab, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Franklyn, JA (corresponding author), Univ Birmingham, Sch Med, 2nd Floor IBR, Birmingham B15 2TT, W Midlands, England.	j.a.franklyn@bham.ac.uk	Sahay, Rakesh Kumar/I-1336-2013	Sahay, Rakesh Kumar/0000-0002-5471-0695	Medical Research Council [G0601811] Funding Source: Medline; MRC [G0601811] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abalovich M, 2007, J CLIN ENDOCR METAB, V92, pS1, DOI 10.1210/jc.2007-0141; Abraham P, 2005, EUR J ENDOCRINOL, V153, P489, DOI 10.1530/eje.1.01993; Abraham-Nordling M, 2005, THYROID, V15, P1279, DOI 10.1089/thy.2005.15.1279; Abraham-Nordling M, 2010, EUR J ENDOCRINOL, V163, P651, DOI 10.1530/EJE-10-0475; Acharya SH, 2008, CLIN ENDOCRINOL, V69, P943, DOI 10.1111/j.1365-2265.2008.03279.x; Allahabadia A, 2000, J CLIN ENDOCR METAB, V85, P1038, DOI 10.1210/jc.85.3.1038; Amino N, 1999, THYROID, V9, P705, DOI 10.1089/thy.1999.9.705; Asvold BO, 2007, ARCH INTERN MED, V167, P1428, DOI 10.1001/archinte.167.13.1428; Bahn RS, 2011, THYROID, V21, P593, DOI 10.1089/thy.2010.0417; Bahn Rebecca S, 2009, Thyroid, V19, P673, DOI 10.1089/thy.2009.0169; Bartalena L, 2005, J CLIN ENDOCR METAB, V90, P5497, DOI 10.1210/jc.2005-1553; Bartalena L, 2008, EUR J ENDOCRINOL, V158, P273, DOI 10.1530/EJE-07-0666; Basaria S, 2005, AM J MED, V118, P706, DOI 10.1016/j.amjmed.2004.11.028; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; Bauer DC, 2007, AM J MED, V120, P343, DOI 10.1016/j.amjmed.2006.04.034; Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043; Biondi B, 2010, NAT REV ENDOCRINOL, V6, P431, DOI 10.1038/nrendo.2010.105; Bjorndal MM, 2008, J ENDOCRINOL INVEST, V31, P856, DOI 10.1007/BF03346431; Boelaert K, 2010, J CLIN ENDOCR METAB, V95, P2715, DOI 10.1210/jc.2009-2495; Boelaert K, 2009, CLIN ENDOCRINOL, V70, P129, DOI 10.1111/j.1365-2265.2008.03291.x; Boelaert K, 2010, AM J MED, V123, DOI 10.1016/j.amjmed.2009.06.030; Bogazzi F, 2010, J CLIN ENDOCR METAB, V95, P2529, DOI 10.1210/jc.2010-0180; Bogazzi F, 2010, J CLIN ENDOCR METAB, V95, P201, DOI 10.1210/jc.2009-1655; Boice JD, 2006, JAMA-J AM MED ASSOC, V295, P1060, DOI 10.1001/jama.295.9.1060; Bonnema SJ, 1999, J CLIN ENDOCR METAB, V84, P3636, DOI 10.1210/jc.84.10.3636; Bonnema SJ, 2003, EUR J ENDOCRINOL, V149, P485, DOI 10.1530/eje.0.1490485; Bonnema SJ, 2006, J CLIN ENDOCR METAB, V91, P2946, DOI 10.1210/jc.2006-0226; Brand OJ, 2010, MOL CELL ENDOCRINOL, V322, P135, DOI 10.1016/j.mce.2010.01.013; Brand OJ, 2009, HUM MOL GENET, V18, P1704, DOI 10.1093/hmg/ddp087; Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033; Carani C, 2005, J CLIN ENDOCR METAB, V90, P6472, DOI 10.1210/jc.2005-1135; Cerqueira C, 2009, J CLIN ENDOCR METAB, V94, P2400, DOI 10.1210/jc.2009-0123; Clementi M, 2010, J CLIN ENDOCR METAB, V95, pE337, DOI 10.1210/jc.2010-0652; Cohen-Lehman J, 2010, NAT REV ENDOCRINOL, V6, P34, DOI 10.1038/nrendo.2009.225; Conen D, 2007, J AM COLL CARDIOL, V49, P2350, DOI 10.1016/j.jacc.2007.02.054; Cooper DS, 2003, J CLIN ENDOCR METAB, V88, P3474, DOI 10.1210/jc.2003-030185; de Rooij A, 2009, EUR J ENDOCRINOL, V161, P771, DOI 10.1530/EJE-09-0286; El Fassi D, 2007, J CLIN ENDOCR METAB, V92, P1769, DOI 10.1210/jc.2006-2388; Emiliano AB, 2010, J CLIN ENDOCR METAB, V95, P2227, DOI 10.1210/jc.2009-2752; Erbil Y, 2007, J CLIN ENDOCR METAB, V92, P2182, DOI 10.1210/jc.2007-0229; Erickson D, 1998, THYROID, V8, P277, DOI 10.1089/thy.1998.8.277; Faber J, 1998, CLIN ENDOCRINOL, V48, P285; Fatourechi V, 2003, J CLIN ENDOCR METAB, V88, P2100, DOI 10.1210/jc.2002-021799; Flynn RWV, 2004, J CLIN ENDOCR METAB, V89, P3879, DOI 10.1210/jc.2003-032089; Franklyn JA, 1999, LANCET, V353, P2111, DOI 10.1016/S0140-6736(98)12295-X; Franklyn JA, 2005, JAMA-J AM MED ASSOC, V294, P71, DOI 10.1001/jama.294.1.71; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; Franklyn JA, 2010, CLIN ENDOCRINOL, V72, P11, DOI 10.1111/j.1365-2265.2009.03633.x; Frost L, 2004, ARCH INTERN MED, V164, P1993, DOI 10.1001/archinte.164.18.1993; Gammage MD, 2007, ARCH INTERN MED, V167, P928, DOI 10.1001/archinte.167.9.928; Gianoukakis AG, 2009, CLIN ENDOCRINOL, V70, P781, DOI 10.1111/j.1365-2265.2008.03382.x; Golden SH, 2009, J CLIN ENDOCR METAB, V94, P1853, DOI 10.1210/jc.2008-2291; Greenlund Laura J S, 2008, Endocr Pract, V14, P973; Grodski S, 2007, THYROID, V17, P157, DOI 10.1089/thy.2006.0141; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Haentjens P, 2008, EUR J ENDOCRINOL, V159, P329, DOI 10.1530/EJE-08-0110; Harper L, 2004, CLIN ENDOCRINOL, V60, P671, DOI 10.1111/j.1365-2265.2004.02029.x; Helfand M, 2004, ANN INTERN MED, V140, P128, DOI 10.7326/0003-4819-140-2-200401200-00015; Hernandez-Jimenez S, 2007, ARCH MED RES, V38, P185, DOI 10.1016/j.arcmed.2006.09.007; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; Houghton SG, 2004, WORLD J SURG, V28, P1083, DOI 10.1007/s00268-004-7599-6; Iervasi G, 2007, ARCH INTERN MED, V167, P1526, DOI 10.1001/archinte.167.14.1526; Iglesias P, 2010, CLIN ENDOCRINOL, V72, P551, DOI 10.1111/j.1365-2265.2009.03682.x; In H, 2009, J AM COLL SURGEONS, V209, P170, DOI 10.1016/j.jamcollsurg.2009.03.025; Kaguelidou F, 2008, J CLIN ENDOCR METAB, V93, P3817, DOI 10.1210/jc.2008-0842; Kuijpens JL, 1998, EUR J ENDOCRINOL, V139, P36, DOI 10.1530/eje.0.1390036; Kung AWC, 2006, J CLIN ENDOCR METAB, V91, P2490, DOI 10.1210/jc.2006-0356; Kuy S, 2009, ARCH SURG-CHICAGO, V144, P399, DOI 10.1001/archsurg.2009.48; Lai A, 2010, J CLIN ENDOCR METAB, V95, P1333, DOI 10.1210/jc.2009-2130; Laurberg P, 2001, THYROID, V11, P457, DOI 10.1089/105072501300176417; Laurberg P, 2009, EUR J ENDOCRINOL, V160, P1, DOI 10.1530/EJE-08-0663; Lazarus JH, 2011, J CLIN ENDOCR METAB, V96, P614, DOI 10.1210/jc.2011-0091; Lee JA, 2007, J CLIN ENDOCR METAB, V92, P801, DOI 10.1210/jc.2006-1238; Li AM, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.10.045; Ma C, 2008, COCHRANE DB SYST REV, V16; Manji N, 2006, J CLIN ENDOCR METAB, V91, P4873, DOI 10.1210/jc.2006-1402; MARTINO E, 1984, ANN INTERN MED, V101, P28, DOI 10.7326/0003-4819-101-1-28; Masiukiewicz US, 1999, THYROID, V9, P647, DOI 10.1089/thy.1999.9.647; Mazza E, 2008, J ENDOCRINOL INVEST, V31, P866, DOI 10.1007/BF03346433; Metso S, 2007, J CLIN ENDOCR METAB, V92, P2190, DOI 10.1210/jc.2006-2321; Metso S, 2007, CANCER, V109, P1972, DOI 10.1002/cncr.22635; Meyerovitch J, 2007, ARCH INTERN MED, V167, P1533, DOI 10.1001/archinte.167.14.1533; MILLAR LK, 1994, OBSTET GYNECOL, V84, P946; Momotani N, 1997, J CLIN ENDOCR METAB, V82, P3633, DOI 10.1210/jc.82.11.3633; Murphy E, 2010, J CLIN ENDOCR METAB, V95, P3173, DOI 10.1210/jc.2009-2630; Nakamura H, 2007, J CLIN ENDOCR METAB, V92, P2157, DOI 10.1210/jc.2006-2135; Nedrebo BG, 2002, EUR J ENDOCRINOL, V147, P583, DOI 10.1530/eje.0.1470583; Noh JY, 2009, J CLIN ENDOCR METAB, V94, P2806, DOI 10.1210/jc.2008-2700; Norrelund H, 1999, CLIN ENDOCRINOL, V51, P693, DOI 10.1046/j.1365-2265.1999.00861.x; Nygaard B, 1999, ARCH INTERN MED, V159, P1364, DOI 10.1001/archinte.159.12.1364; O'Sullivan AJ, 2006, EUR J ENDOCRINOL, V154, P533, DOI 10.1530/eje.1.02122; Ochs N, 2008, ANN INTERN MED, V148, P832, DOI 10.7326/0003-4819-148-11-200806030-00225; Okosieme OE, 2010, CLIN ENDOCRINOL, V72, P122, DOI 10.1111/j.1365-2265.2009.03623.x; Osman F, 2002, CIRCULATION, V105, P1275, DOI 10.1161/circ.105.11.1275; Osman F, 2007, J AM COLL CARDIOL, V49, P71, DOI 10.1016/j.jacc.2006.08.042; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Patel NN, 2006, THYROID, V16, P593, DOI 10.1089/thy.2006.16.593; Pearce EN, 2006, BMJ-BRIT MED J, V332, P1369, DOI 10.1136/bmj.332.7554.1369; Porterfield JR, 2008, WORLD J SURG, V32, P1278, DOI 10.1007/s00268-008-9566-0; Prummel MF, 2003, EUR J ENDOCRINOL, V148, P491, DOI 10.1530/eje.0.1480491; Razvi S, 2006, EUR J ENDOCRINOL, V154, P783, DOI 10.1530/eje.1.02169; Read CH, 2004, J CLIN ENDOCR METAB, V89, P4229, DOI 10.1210/jc.2003-031223; Rivkees SA, 1998, J CLIN ENDOCR METAB, V83, P3767, DOI 10.1210/jc.83.11.3767; Rivkees SA, 2007, J CLIN ENDOCR METAB, V92, P797, DOI 10.1210/jc.2006-1239; Rivkees SA, 2010, J CLIN ENDOCR METAB, V95, P3260, DOI 10.1210/jc.2009-2546; Rivkees SA, 2009, NEW ENGL J MED, V360, P1574, DOI 10.1056/NEJMc0809750; Roberts LM, 2006, ANN INTERN MED, V145, P573, DOI 10.7326/0003-4819-145-8-200610170-00006; Rochester DB, 2005, THYROID, V15, P1287, DOI 10.1089/thy.2005.15.1287; Roher HD, 1999, CHIRURG, V70, P999, DOI 10.1007/s001040050757; Rosario PW, 2010, CLIN ENDOCRINOL, V72, P685, DOI 10.1111/j.1365-2265.2009.03696.x; Rotondi M, 2008, J CLIN ENDOCR METAB, V93, P3985, DOI 10.1210/jc.2008-0966; Rotondi M, 2008, EUR J ENDOCRINOL, V159, P161, DOI 10.1530/EJE-08-0236; Royal College of Physicians, 2007, REP WORK PART; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Schott M, 2009, CLIN ENDOCRINOL, V71, P566, DOI 10.1111/j.1365-2265.2008.03512.x; Sgarbi JA, 2003, J CLIN ENDOCR METAB, V88, P1672, DOI 10.1210/jc.2002-021046; Sheffield JS, 2004, AM J OBSTET GYNECOL, V190, P211, DOI 10.1016/S0002-9378(03)00944-X; Siu CW, 2007, HEART, V93, P483, DOI 10.1136/hrt.2006.100628; Sosa JA, 2008, J CLIN ENDOCR METAB, V93, P3058, DOI 10.1210/jc.2008-0660; Sosa JA, 2008, J AM COLL SURGEONS, V206, P1097, DOI 10.1016/j.jamcollsurg.2007.11.023; Stagnaro-Green A, 2002, J CLIN ENDOCR METAB, V87, P4042, DOI 10.1210/jc.2002-020524; Stan MN, 2010, THYROID, V20, P777, DOI 10.1089/thy.2010.1634; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Takata K, 2010, CLIN ENDOCRINOL, V72, P845, DOI 10.1111/j.1365-2265.2009.03745.x; Takata K, 2009, THYROID, V19, P559, DOI 10.1089/thy.2008.0364; Torring O, 1996, J CLIN ENDOCR METAB, V81, P2986, DOI 10.1210/jc.81.8.2986; Traisk F, 2009, J CLIN ENDOCR METAB, V94, P3700, DOI 10.1210/jc.2009-0747; Tsai WC, 2005, CLIN ENDOCRINOL, V62, P521, DOI 10.1111/j.1365-2265.2005.02249.x; Tuggle CT, 2008, SURGERY, V144, P869, DOI 10.1016/j.surg.2008.08.033; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Vadiveloo T, 2011, J CLIN ENDOCR METAB, V96, pE1, DOI 10.1210/jc.2010-0854; Vitti P, 1997, THYROID, V7, P369, DOI 10.1089/thy.1997.7.369; Walter MA, 2007, BRIT MED J, V334, P514, DOI 10.1136/bmj.39114.670150.BE; Wang Z, 2010, J CLIN ENDOCR METAB, V95, P4012, DOI 10.1210/jc.2009-2184; Wartofsky L, 1991, Thyroid, V1, P129, DOI 10.1089/thy.1991.1.129; Wilhelm SM, 2010, WORLD J SURG, V34, P1261, DOI 10.1007/s00268-009-0337-3; Williams M, 2002, THYROID, V12, P523, DOI 10.1089/105072502760143926; Williamson S, 2010, CLIN ENDOCRINOL, V72, P358, DOI 10.1111/j.1365-2265.2009.03717.x; Wilson S, 2006, J CLIN ENDOCR METAB, V91, P4809, DOI 10.1210/jc.2006-1557; Wustmann K, 2008, J CLIN ENDOCR METAB, V93, P2104, DOI 10.1210/jc.2008-0092; Yiu KH, 2009, J CLIN ENDOCR METAB, V94, P109, DOI 10.1210/jc.2008-1907	141	153	160	0	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2012	379	9821					1155	1166		10.1016/S0140-6736(11)60782-4	http://dx.doi.org/10.1016/S0140-6736(11)60782-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22394559				2022-12-28	WOS:000302131800037
J	McGlone, M				McGlone, Matt			The Hunters Did It	SCIENCE			English	Editorial Material							MEGAFAUNAL EXTINCTION; PLEISTOCENE EXTINCTIONS; AUSTRALIA; TRANSFORMATION; COLLAPSE; CLIMATE		Landcare Res, Lincoln 7640, New Zealand	Landcare Research - New Zealand	McGlone, M (corresponding author), Landcare Res, Lincoln 7640, New Zealand.	mcglonem@landcareresearch.co.nz						Burney DA, 2005, TRENDS ECOL EVOL, V20, P395, DOI 10.1016/j.tree.2005.04.022; Feranec RS, 2011, QUATERN INT, V245, P333, DOI 10.1016/j.quaint.2011.06.004; FLANNERY T F, 1990, Archaeology in Oceania, V25, P45; Flannery T. F., 1994, FUTURE EATERS; Gill JL, 2009, SCIENCE, V326, P1100, DOI 10.1126/science.1179504; Grayson DK, 2007, J ANTHROPOL RES, V63, P185, DOI 10.3998/jar.0521004.0063.205; Johnson C, 2006, AUSTR MAMMAL EXTINCT; Keppel G, 2007, NEW ZEAL J BOT, V45, P545, DOI 10.1080/00288250709509738; Kershaw AP, 2007, PALAEOGEOGR PALAEOCL, V251, P23, DOI 10.1016/j.palaeo.2007.02.015; Lorenzen ED, 2011, NATURE, V479, P359, DOI 10.1038/nature10574; Martin P. S., 1967, P75; McWethy DB, 2010, P NATL ACAD SCI USA, V107, P21343, DOI 10.1073/pnas.1011801107; Miller GH, 2005, SCIENCE, V309, P287, DOI 10.1126/science.1111288; OWENSMITH N, 1987, PALEOBIOLOGY, V13, P351; Prescott GW, 2012, P NATL ACAD SCI USA, V109, P4527, DOI 10.1073/pnas.1113875109; Robinson GS, 2005, ECOL MONOGR, V75, P295, DOI 10.1890/03-4064; Rule S, 2012, SCIENCE, V335, P1483, DOI 10.1126/science.1214261; Wroe S, 2006, QUATERNARY SCI REV, V25, P2692, DOI 10.1016/j.quascirev.2006.03.005	18	15	15	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1452	1453		10.1126/science.1220176	http://dx.doi.org/10.1126/science.1220176			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	912YG	22442471				2022-12-28	WOS:000301837000032
J	Patel, JP; Gonen, M; Figueroa, ME; Fernandez, H; Sun, ZX; Racevskis, J; Van Vlierberghe, P; Dolgalev, I; Thomas, S; Aminova, O; Huberman, K; Cheng, J; Viale, A; Socci, ND; Heguy, A; Cherry, A; Vance, G; Higgins, RR; Ketterling, RP; Gallagher, RE; Litzow, M; van den Brink, MRM; Lazarus, HM; Rowe, JM; Luger, S; Ferrando, A; Paietta, E; Tallman, MS; Melnick, A; Abdel-Wahab, O; Levine, RL				Patel, Jay P.; Goenen, Mithat; Figueroa, Maria E.; Fernandez, Hugo; Sun, Zhuoxin; Racevskis, Janis; Van Vlierberghe, Pieter; Dolgalev, Igor; Thomas, Sabrena; Aminova, Olga; Huberman, Kety; Cheng, Janice; Viale, Agnes; Socci, Nicholas D.; Heguy, Adriana; Cherry, Athena; Vance, Gail; Higgins, Rodney R.; Ketterling, Rhett P.; Gallagher, Robert E.; Litzow, Mark; van den Brink, Marcel R. M.; Lazarus, Hillard M.; Rowe, Jacob M.; Luger, Selina; Ferrando, Adolfo; Paietta, Elisabeth; Tallman, Martin S.; Melnick, Ari; Abdel-Wahab, Omar; Levine, Ross L.			Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL CYTOGENETICS; YOUNGER ADULTS; OLDER PATIENTS; MUTATIONS; TET2; IDENTIFY; DNMT3A; AML	BACKGROUND Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML. METHODS We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients. RESULTS We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P = 0.001 for FLT3-ITD, P = 0.009 for MLL-PTD, P = 0.05 for ASXL1, and P = 0.006 for PHF6); CEBPA and IDH2 mutations were associated with improved overall survival (P = 0.05 for CEBPA and P = 0.01 for IDH2). The favorable effect of NPM1 mutations was restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations. We identified genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, and validated the significance of these predictors in an independent cohort. High-dose daunorubicin, as compared with standarddose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P = 0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P = 0.67). CONCLUSIONS We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.)	[Abdel-Wahab, Omar; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, Leukemia Serv, Dept Med, New York, NY 10065 USA; [Goenen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Cheng, Janice; Viale, Agnes] Mem Sloan Kettering Canc Ctr, Genom Core Lab, New York, NY 10065 USA; [Figueroa, Maria E.; Melnick, Ari] Weill Cornell Med Coll, Dept Med, Div Hematol Oncol, New York, NY USA; [Racevskis, Janis; Gallagher, Robert E.; Paietta, Elisabeth] Montefiore Med Ctr, New York, NY USA; [Van Vlierberghe, Pieter; Ferrando, Adolfo] Columbia Univ, Inst Canc Genet, New York, NY USA; [Van Vlierberghe, Pieter; Ferrando, Adolfo] Columbia Univ, Dept Pediat, New York, NY 10027 USA; [Van Vlierberghe, Pieter; Ferrando, Adolfo] Columbia Univ, Dept Pathol, New York, NY USA; [van den Brink, Marcel R. M.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA; [Fernandez, Hugo] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Blood & Bone Marrow Transplantat, Tampa, FL 33682 USA; [Sun, Zhuoxin] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; [Cherry, Athena] Stanford Hosp & Clin, Dept Pathol, Palo Alto, CA USA; [Vance, Gail] Indiana Univ Sch Med, Dept Med & Mol Genet, Bloomington, IN USA; [Higgins, Rodney R.] Abbott NW Hosp, Allina Cytogenet Lab, Minneapolis, MN 55407 USA; [Ketterling, Rhett P.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA; [Litzow, Mark] Mayo Clin, Coll Med, Dept Hematol & Oncol, Rochester, MN USA; [Lazarus, Hillard M.] Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; [Rowe, Jacob M.] Technion Israel Inst Technol, Jerusalem, Israel; [Rowe, Jacob M.] Shaare Zedek Med Ctr, Jerusalem, Israel; [Luger, Selina] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Montefiore Medical Center; Columbia University; Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Dana-Farber Cancer Institute; Stanford University; Indiana University System; Indiana University Bloomington; Mayo Clinic; Mayo Clinic; Case Western Reserve University; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Shaare Zedek Medical Center; University of Pennsylvania	Levine, RL (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, Leukemia Serv, Dept Med, 1275 York Ave,Box 20, New York, NY 10065 USA.	leviner@mskcc.org	Patel, Jay/HDM-6251-2022; van den Brink, Marcel R. M./HGB-9434-2022; Heguy, Adriana/GPP-3907-2022; Van Vlierberghe, Pieter/G-8894-2013; Melnick, Ari/AAA-5763-2020; levine, ross/AAE-7658-2019; Figueroa, Maria/AAE-8662-2019; Gonen, Mithat/E-4826-2012; Dolgalev, Igor/AAY-6406-2020	Van Vlierberghe, Pieter/0000-0001-9063-7205; Gonen, Mithat/0000-0001-8683-8477; Dolgalev, Igor/0000-0003-4451-126X; Figueroa, Maria Eugenia/0000-0003-4887-4981; Ketterling, Rhett/0000-0001-6479-7897; Abdel-Wahab, Omar/0000-0002-3907-6171	National Cancer Institute (NCI) Physical Sciences Oncology Center [U54CA143798-01]; Gabrielle's Angel Fund; Starr Cancer Consortium; Memorial Sloan-Kettering Cancer Center; American Society; Leukemia and Lymphoma Society; Fund for Scientific Research (FWO) Flanders; Leukemia and Lymphoma Society Specialized Center; Sackler Center for Biomedical and Physical Sciences; Howard Hughes Medical Institute; NCI [CA21115, CA56771, CA114737]; NATIONAL CANCER INSTITUTE [U10CA021115, U10CA023318, U54CA143798, U24CA114737, R01CA056771, R01CA155743, P30CA008748] Funding Source: NIH RePORTER	National Cancer Institute (NCI) Physical Sciences Oncology Center; Gabrielle's Angel Fund; Starr Cancer Consortium; Memorial Sloan-Kettering Cancer Center; American Society(American Cancer Society); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Fund for Scientific Research (FWO) Flanders(FWO); Leukemia and Lymphoma Society Specialized Center(Leukemia and Lymphoma Society); Sackler Center for Biomedical and Physical Sciences; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (NCI) Physical Sciences Oncology Center (U54CA143798-01, to Dr. Levine), the Gabrielle's Angel Fund (to Dr. Levine), and the Starr Cancer Consortium (to Drs. Levine and Melnick) and funding from the Peter Solomon Fund at Memorial Sloan-Kettering Cancer Center. Mr. Patel is supported by an American Society of Hematology Trainee Research Award; Dr. Figueroa is funded by a Leukemia and Lymphoma Society Special Fellow Award; Drs. Van Vlierberghe and Abdel-Wahab are American Society of Hematology Basic Research Fellows; Dr. Van Vlierberghe is supported by the Fund for Scientific Research (FWO) Flanders; Dr. Melnick is funded by a Leukemia and Lymphoma Society Specialized Center of Research Award and Translational Research Program Award and is a Burroughs Wellcome Clinical Translational Scholar and a Scholar of the Leukemia and Lymphoma Society; Drs. Figueroa and Melnick are also supported by the Sackler Center for Biomedical and Physical Sciences; Dr. Levine is the recipient of an Early Career Award from the Howard Hughes Medical Institute; Dr. Paietta is supported by NCI grants CA21115 and CA114737; Dr. Gallagher is supported by NCI grant CA56771; and Dr. Ferrando is funded by a Leukemia and Lymphoma Society Scholar Award.	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Caligiuri MA, 1998, CANCER RES, V58, P55; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409; Marcucci G., 2011, J CLIN ONCOL, V29, P1798; Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Metzeler KH, 2011, BLOOD, V118, P6920, DOI 10.1182/blood-2011-08-368225; Metzeler KH, 2011, J CLIN ONCOL, V29, P1373, DOI 10.1200/JCO.2010.32.7742; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Van Vlierberghe P, 2011, LEUKEMIA, V25, P130, DOI 10.1038/leu.2010.247; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Westfall P.H., 1993, RESAMPLING BASED MUL; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788	24	1352	1410	10	146	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1079	1089		10.1056/NEJMoa1112304	http://dx.doi.org/10.1056/NEJMoa1112304			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22417203	Green Accepted			2022-12-28	WOS:000301769700007
J	Proudfoot, LE; Morris-Jones, R				Proudfoot, Laura Erin; Morris-Jones, Rachael			Kerion Celsi	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Proudfoot, Laura Erin; Morris-Jones, Rachael] Kings Coll Hosp, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Proudfoot, LE (corresponding author), Kings Coll Hosp, London, England.	laura.proudfoot@kcl.ac.uk							0	9	11	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1142	1142		10.1056/NEJMicm1104889	http://dx.doi.org/10.1056/NEJMicm1104889			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435373				2022-12-28	WOS:000301769700013
J	Weaver, P; Johnson, D				Weaver, Phil; Johnson, David			Think big for marine conservation	NATURE			English	Editorial Material									[Weaver, Phil] Global Ocean Biodivers Initiat, Southampton, Hants, England; [Weaver, Phil] Natl Oceanog Ctr, Southampton, Hants, England; [Johnson, David] Convent Protect Marine Environm NE Atlantic OSPAR, London, England	NERC National Oceanography Centre	Weaver, P (corresponding author), Global Ocean Biodivers Initiat, Southampton, Hants, England.	ppew@noc.ac.uk		Weaver, Philip/0000-0002-9541-3830	NERC [noc010011] Funding Source: UKRI; Natural Environment Research Council [noc010011] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))			0	24	25	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					399	399		10.1038/483399a	http://dx.doi.org/10.1038/483399a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	912CC	22437593				2022-12-28	WOS:000301771200015
J	Gulland, A				Gulland, Anne			Patient safety: where nothing is unavoidable	BRITISH MEDICAL JOURNAL			English	Editorial Material												annecgulland@yahoo.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2160	10.1136/bmj.e2160	http://dx.doi.org/10.1136/bmj.e2160			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438381				2022-12-28	WOS:000301849200022
J	Palmer, SC; Di Micco, L; Razavian, M; Craig, JC; Perkovic, V; Pellegrini, F; Copetti, M; Graziano, G; Tognoni, G; Jardine, M; Webster, A; Nicolucci, A; Zoungas, S; Strippoli, GFM				Palmer, Suetonia C.; Di Micco, Lucia; Razavian, Mona; Craig, Jonathan C.; Perkovic, Vlado; Pellegrini, Fabio; Copetti, Massimiliano; Graziano, Giusi; Tognoni, Gianni; Jardine, Meg; Webster, Angela; Nicolucci, Antonio; Zoungas, Sophia; Strippoli, Giovanni F. M.			Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-DOSE ASPIRIN; ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROME; ARTERIOVENOUS-FISTULAS; CONTROLLED-TRIAL; RENAL-FUNCTION; SHORT-TERM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PLUS ASPIRIN; HEMODIALYSIS	Background: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effects may differ in persons with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleeding hazards may be increased in this population. Purpose: To summarize the effects of antiplatelet treatment on cardiovascular events, mortality, and bleeding in persons with CKD. Data Sources: Embase and Cochrane databases through November 2011 without language restriction. Study Selection: Randomized trials that included adults with CKD and compared antiplatelet agents with standard care, placebo, or no treatment. Data Extraction: Data for populations, interventions, outcomes, and risk for bias were extracted. Quality of evidence for treatment effects on myocardial infarction, death, and bleeding was summarized by using Grading of Recommendations Assessment, Development, and Evaluation guidelines. Data Synthesis: Nine trials (all post hoc subgroup analyses for CKD) involving 9969 persons who had acute coronary syndromes or were undergoing percutaneous coronary intervention and 31 trials involving 11 701 persons with stable or no cardiovascular disease were identified. Low-quality evidence has found that in persons with acute coronary syndromes, glycoprotein IIb/IIIa inhibitors or clopidogrel plus standard care compared with standard care alone had little or no effect on all-cause or cardiovascular mortality or on myocardial infarction but increased serious bleeding. Compared with placebo or no treatment in persons with stable or no cardiovascular disease, antiplatelet agents prevented myocardial infarction but had uncertain effects on mortality and increased minor bleeding according to generally low-quality evidence. Limitations: Data for antiplatelet agents in persons with CKD are frequently derived from post hoc analyses of trials of broader populations. Definitions for bleeding outcomes and trial duration were heterogeneous. Conclusion: Benefits for antiplatelet therapy among persons with CKD are uncertain and are potentially outweighed by bleeding hazards.	[Strippoli, Giovanni F. M.] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, I-66030 Santa Maria Imbaro, Italy; Univ Otago, Christchurch, New Zealand; Univ Naples Federico II, Naples, Italy; Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; IRCCS Casa Sollievo Sofferenza, Foggia, Italy; Concord Repatriat Gen Hosp, Concord, Australia; Univ Bari, Bari, Italy; Diaverum Med Sci Off, Lund, Sweden	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Otago; University of Naples Federico II; George Institute for Global Health; University of Sydney; University of Sydney; IRCCS Casa Sollievo Della Sofferenza; Concord Repatriation General Hospital; Universita degli Studi di Bari Aldo Moro; Diaverum	Strippoli, GFM (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, Via Nazl 8-A, I-66030 Santa Maria Imbaro, Italy.	strippoli@negrisud.it	Craig, Jonathan/E-2813-2013; COPETTI, MASSIMILIANO/AAG-1473-2021; Jardine, Meg/AAS-1864-2020; Copetti, Massimiliano/K-3186-2016; Jardine, Meg/AFR-1699-2022; Graziano, Giusi/J-9083-2016; Webster, Angela/J-2186-2012; Perkovic, Vlado/AAY-1933-2021	Craig, Jonathan/0000-0002-2548-4035; COPETTI, MASSIMILIANO/0000-0002-7960-5947; Jardine, Meg/0000-0002-0160-2375; Copetti, Massimiliano/0000-0002-7960-5947; Jardine, Meg/0000-0002-0160-2375; Graziano, Giusi/0000-0002-3347-8049; Webster, Angela/0000-0001-7509-0512; Perkovic, Vlado/0000-0002-4257-7620; Zoungas, Sophia/0000-0003-2672-0949	Amgen Dompe; Amgen; Heart Foundation of Australia; Johnson Johnson; Servier; Oxford University; Royal Australasian College of Physicians; Merck Sharp Dohme; Novo Nordisk; Sanofi Aventis; Eli Lilly; Roche; Bristol-Myers Squibb/AstraZeneca; Novartis; MediMark Australia	Amgen Dompe; Amgen(Amgen); Heart Foundation of Australia(National Heart Foundation of Australia); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Servier(Servier); Oxford University; Royal Australasian College of Physicians(General Electric); Merck Sharp Dohme(Merck & Company); Novo Nordisk(Novo Nordisk); Sanofi Aventis(Sanofi-Aventis); Eli Lilly(Eli Lilly); Roche(Roche Holding); Bristol-Myers Squibb/AstraZeneca(Bristol-Myers SquibbAstraZeneca); Novartis(Novartis); MediMark Australia	Dr. Palmer: Grant: Amgen Dompe. Dr. Razavian: Grant: Amgen. Dr. Perkovic: Grants/grants pending (money to institution): Heart Foundation of Australia, Johnson & Johnson, Servier, Oxford University; Board membership: Baxter; Board membership (money to institution): Boehringer Ingelheim, Vitae, Abbott, Reata and Abbott; Payment for lectures including service on speakers bureaus (money to institution): Roche. Dr. Jardine: Grant (money to institution): Royal Australasian College of Physicians. Dr. Nicolucci: Board membership: Merck Sharp & Dohme; Grants/grants pending (money to institution): Merck Sharp & Dohme, Novo Nordisk, Sanofi Aventis, Eli Lilly, Johnson & Johnson. Dr. Zoungas: Board membership: Merck Sharp & Dohme, Novo Nordisk, Boehringer Ingelheim, Sanofi Aventis, Bristol-Myers Squibb/AstraZeneca; Payment for lectures including service on speakers bureaus (money to institution): Merck Sharp & Dohme, Novo Nordisk, Sanofi Aventis, Bristol-Myers Squibb/AstraZeneca, Novartis, Servier; Payment for development of educational presentations: MediMark Australia. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2512.	Abdul-Rahman IS, 2007, HONG KONG J NEPHROL, V9, P23, DOI DOI 10.1016/S1561-5413(07)60005-2; Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; ANDERSON M, 1974, CLIN NEPHROL, V2, P93; ANDRASSY K, 1974, KLIN WOCHENSCHR, V52, P348, DOI 10.1007/BF01468835; Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 32 ANN REP 2009 REP; Baigent C, 2005, AM J KIDNEY DIS, V45, P473, DOI 10.1053/j.ajkd.2004.11.015; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Best PJM, 2008, AM HEART J, V155, P687, DOI 10.1016/j.ahj.2007.10.046; Boutron I, 2010, JAMA-J AM MED ASSOC, V303, P2058, DOI 10.1001/jama.2010.651; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cheng IKP, 1998, NEPHROLOGY, V4, P19, DOI 10.1046/j.1440-1797.1998.d01-12.x; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Creek R, 1990, TICLOPIDINE PATENCY; Dasgupta A, 2009, AM J CARDIOL, V103, P1359, DOI 10.1016/j.amjcard.2009.01.342; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Dember LM, 2008, JAMA-J AM MED ASSOC, V299, P2164, DOI 10.1001/jama.299.18.2164; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; DIPALO FQ, 1991, TRANSPL P, V23, P969; Dixon BS, 2009, NEW ENGL J MED, V360, P2191, DOI 10.1056/NEJMoa0805840; Dodd NJ, 1980, P 6 INT C MED LEAG T; DONADIO JV, 1984, NEW ENGL J MED, V310, P1421, DOI 10.1056/NEJM198405313102203; ELL S, 1982, HAEMOSTASIS, V12, P180; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FISKERSTRAND CE, 1985, ARTIF ORGANS, V9, P61, DOI 10.1111/j.1525-1594.1985.tb04349.x; Fox CS, 2010, CIRCULATION, V121, P357, DOI 10.1161/CIRCULATIONAHA.109.865352; Frasca GM, 1997, CLIN DRUG INVEST, V13, P185, DOI 10.2165/00044011-199713040-00002; Ghorbani A, 2009, Indian J Nephrol, V19, P57, DOI 10.4103/0971-4065.53323; Giustina A, 1998, DIABETES, V47, P423, DOI 10.2337/diabetes.47.3.423; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gonzalez MT, 1995, 13 INT C NEPHR MADR; Greenland S, 2006, INT J EPIDEMIOL, V35, P765, DOI 10.1093/ije/dyi312; Grontoft KC, 1998, SCAND J UROL NEPHROL, V32, P276; GRONTOFT KC, 1985, SCAND J UROL NEPHROL, V19, P55, DOI 10.3109/00365598509180223; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; HARTER HR, 1979, NEW ENGL J MED, V301, P577, DOI 10.1056/NEJM197909133011103; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Higgins J.P., 2011, COCHRANE HDB SYSTEMA, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holden RM, 2008, CLIN J AM SOC NEPHRO, V3, P105, DOI 10.2215/CJN.01810407; Hunsicker LG, 2004, J AM SOC NEPHROL, V15, P1363, DOI 10.1097/01.ASN.0000126069.68755.99; James S, 2010, CIRCULATION, V122, P1056, DOI 10.1161/CIRCULATIONAHA.109.933796; Januzzi JL, 2002, CIRCULATION, V105, P2361, DOI 10.1161/01.CIR.0000016359.94919.16; Jardine MJ, 2010, J AM COLL CARDIOL, V56, P956, DOI 10.1016/j.jacc.2010.02.068; KAEGI A, 1974, NEW ENGL J MED, V290, P304, DOI 10.1056/NEJM197402072900604; Kasiske BL, 2006, J AM SOC NEPHROL, V17, P900, DOI 10.1681/ASN.2005090984; Kaufman JS, 2003, J AM SOC NEPHROL, V14, P2313, DOI 10.1097/01.ASN.0000081661.10246.33; Keltai M, 2007, EUR J CARDIOV PREV R, V14, P312, DOI 10.1097/01.hjr.0000220582.19516.a6; Khajehdehi P, 2002, SCAND J UROL NEPHROL, V36, P145, DOI 10.1080/003655902753679454; KOBAYASHI K, 1980, THROMB RES, V20, P255, DOI 10.1016/0049-3848(80)90390-4; KOOISTRA MP, 1994, NEPHROL DIAL TRANSPL, V9, P1115, DOI 10.1093/ndt/9.8.1115; MICHIE DD, 1977, CURR THER RES CLIN E, V22, P196; Middleton DA, 1992, PROPHYLAXIS THROMBOS; MILETI M, 1995, J NEPHROL, V8, P167; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Murray MA, 2009, PATIENT EDUC COUNS, V76, P149, DOI 10.1016/j.pec.2008.12.010; Razavian M, 2010, COCHRANE DB SYST REV; REMUZZI G, 1988, LANCET, V1, P1205; Rucker G, 2009, STAT MED, V28, P721, DOI 10.1002/sim.3511; Saito Y, 2011, DIABETES CARE, V34, P280, DOI 10.2337/dc10-1615; SCHULZE R, 1990, Z UROL NEPHROL, V83, P255; Smith DH, 2004, J AM SOC NEPHROL, V15, P1300, DOI 10.1097/01.ASN.0000125670.64996.BB; Smith KA, 2011, J AM SOC NEPHROL, V22, P225, DOI 10.1681/ASN.2010111152; SREEDHARA R, 1994, KIDNEY INT, V45, P1477, DOI 10.1038/ki.1994.192; Stijnen T, 2010, STAT MED, V29, P3046, DOI 10.1002/sim.4040; Strippoli GFM, 2008, BMJ-BRIT MED J, V336, P645, DOI 10.1136/bmj.39472.580984.AE; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; TABER T, 1992, Journal of the American Society of Nephrology, V3, P397; Tcheng JE, 1997, LANCET, V349, P1422; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Trivedi H, 2009, NEPHROL DIAL TRANSPL, V24, P258, DOI 10.1093/ndt/gfn426; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Weiner DE, 2006, AM J KIDNEY DIS, V48, P392, DOI 10.1053/j.ajkd.2006.05.021; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; ZAUNER I, 1994, NEPHROL DIAL TRANSPL, V9, P619	79	146	151	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					445	U116		10.7326/0003-4819-156-6-201203200-00007	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00007			28	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431677				2022-12-28	WOS:000303150900017
J	Neubauer, C; Gillet, R; Kelley, AC; Ramakrishnan, V				Neubauer, Cajetan; Gillet, Reynald; Kelley, Ann C.; Ramakrishnan, V.			Decoding in the Absence of a Codon by tmRNA and SmpB in the Ribosome	SCIENCE			English	Article							TRANSFER-MESSENGER-RNA; AMINOACYL-TRANSFER-RNA; SMALL PROTEIN-B; TRANS-TRANSLATION; STALLED RIBOSOMES; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TAGGING ACTIVITY; BINDING PROTEIN	In bacteria, ribosomes stalled at the end of truncated messages are rescued by transfer-messenger RNA (tmRNA), a bifunctional molecule that acts as both a transfer RNA (tRNA) and a messenger RNA (mRNA), and SmpB, a small protein that works in concert with tmRNA. Here, we present the crystal structure of a tmRNA fragment, SmpB and elongation factor Tu bound to the ribosome at 3.2 angstroms resolution. The structure shows how SmpB plays the role of both the anticodon loop of tRNA and portions of mRNA to facilitate decoding in the absence of an mRNA codon in the A site of the ribosome and explains why the tmRNA-SmpB system does not interfere with normal translation.	[Neubauer, Cajetan; Kelley, Ann C.; Ramakrishnan, V.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Gillet, Reynald] Univ Rennes 1, F-35042 Rennes, France; [Gillet, Reynald] CNRS, IGDR, UMR 6290, Translat & Folding Grp,Inst Univ France, F-35042 Rennes, France	MRC Laboratory Molecular Biology; Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Universitaire de France	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.	ramak@mrc-lmb.cam.ac.uk	Neubauer, Cajetan/B-8935-2016	Neubauer, Cajetan/0000-0002-5348-5609; Ramakrishnan, V/0000-0002-4699-2194	MRC [U105184332]; Wellcome Trust; Agouron Institute; Louis-Jeantet Foundation; Boehringer Ingelheim Fonds;  [ANR-08JCJC-0027-01];  [ANR-09-MIE]; Medical Research Council [MC_U105184332] Funding Source: researchfish; MRC [MC_U105184332] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Agouron Institute(Pfizer); Louis-Jeantet Foundation; Boehringer Ingelheim Fonds(Boehringer Ingelheim); ; ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T. Tomizaki at Swiss Light Source and L. Ng and I. Sanchez for help with data collection. This work was supported by the MRC (grant U105184332), the Wellcome Trust, the Agouron Institute, and the Louis-Jeantet Foundation. C.N. was supported by a Boehringer Ingelheim Fonds scholarship and R. G. by grants ANR-08JCJC-0027-01 and ANR-09-MIE. Coordinates and structure factors have been deposited at the PDB with accession codes 4abr and 4abs. The strain Thermus thermophilus HB8-MRC-MSAW1 is available subject to a Material Transfer Agreement with the MRC.	Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bessho Y, 2007, P NATL ACAD SCI USA, V104, P8293, DOI 10.1073/pnas.0700402104; Cheng K, 2010, J STRUCT BIOL, V169, P342, DOI 10.1016/j.jsb.2009.10.015; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Dong G, 2002, EMBO J, V21, P1845, DOI 10.1093/emboj/21.7.1845; Fu J, 2010, EMBO J, V29, P3819, DOI 10.1038/emboj.2010.255; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hayes CS, 2010, FEBS LETT, V584, P413, DOI 10.1016/j.febslet.2009.11.023; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; Jacob Y, 2005, J BIOL CHEM, V280, P5503, DOI 10.1074/jbc.M409277200; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Kaur S, 2006, P NATL ACAD SCI USA, V103, P16484, DOI 10.1073/pnas.0607438103; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Kurita D, 2007, NUCLEIC ACIDS RES, V35, P7248, DOI 10.1093/nar/gkm677; Kurita D, 2010, RNA, V16, P980, DOI 10.1261/rna.1916610; Martin A, 2008, MOL CELL, V29, P441, DOI 10.1016/j.molcel.2008.02.002; Miller MR, 2011, RNA, V17, P1727, DOI 10.1261/rna.2821711; Moore SD, 2005, MOL MICROBIOL, V58, P456, DOI 10.1111/j.1365-2958.2005.04832.x; Moore SD, 2007, ANNU REV BIOCHEM, V76, P101, DOI 10.1146/annurev.biochem.75.103004.142733; Neubauer C, 2009, CELL, V139, P1084, DOI 10.1016/j.cell.2009.11.015; Nonin-Lecomte S, 2009, EMBO REP, V10, P160, DOI 10.1038/embor.2008.243; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; Schmeing TM, 2011, NAT STRUCT MOL BIOL, V18, P432, DOI 10.1038/nsmb.2003; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Shimizu Y, 2006, J BIOL CHEM, V281, P15987, DOI 10.1074/jbc.M512165200; Someya T, 2003, FEBS LETT, V535, P94, DOI 10.1016/S0014-5793(02)03880-2; Sundermeier TR, 2005, P NATL ACAD SCI USA, V102, P2316, DOI 10.1073/pnas.0409694102; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Voorhees RM, 2010, SCIENCE, V330, P835, DOI 10.1126/science.1194460; Weis F, 2010, EMBO J, V29, P3810, DOI 10.1038/emboj.2010.252; Weis F, 2010, RNA, V16, P299, DOI 10.1261/rna.1757410; Yusupova G, 2006, NATURE, V444, P391, DOI 10.1038/nature05281	36	81	84	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1366	1369		10.1126/science.1217039	http://dx.doi.org/10.1126/science.1217039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422985	Green Accepted			2022-12-28	WOS:000301531600052
J	Harjunmaa, E; Kallonen, A; Voutilainen, M; Hamalainen, K; Mikkola, ML; Jernvall, J				Harjunmaa, Enni; Kallonen, Aki; Voutilainen, Maria; Hamalainen, Keijo; Mikkola, Marja L.; Jernvall, Jukka			On the difficulty of increasing dental complexity	NATURE			English	Article							GENE-EXPRESSION; MAMMALIAN TEETH; TOOTH; EVOLUTION; INHIBITION; CYCLOPAMINE; DENTITION; PATTERNS; FEEDBACK; ACTIVIN	One of the fascinating aspects of the history of life is the apparent increase in morphological complexity through time(1), a well known example being mammalian cheek tooth evolution(2-4). In contrast, experimental studies of development more readily show a decrease in complexity, again well exemplified by mammalian teeth, in which tooth crown features called cusps are frequently lost in mutant and transgenic mice(5-7). Here we report that mouse tooth complexity can be increased substantially by adjusting multiple signalling pathways simultaneously. We cultured teeth in vitro and adjusted ectodysplasin (EDA), activin A and sonic hedgehog (SHH) pathways, all of which are individually required for normal tooth development. We quantified tooth complexity using the number of cusps and a topographic measure of surface complexity(8). The results show that whereas activation of EDA and activin A signalling, and inhibition of SHH signalling, individually cause subtle to moderate increases in complexity, cusp number is doubled when all three pathways are adjusted in unison. Furthermore, the increase in cusp number does not result from an increase in tooth size, but from an altered primary patterning phase of development. The combination of a lack of complex mutants(5-7), the paucity of natural variants with complex phenotypes(9), and our results of greatly increased dental complexity using multiple pathways, suggests that an increase may be inherently different from a decrease in phenotypic complexity.	[Harjunmaa, Enni; Voutilainen, Maria; Mikkola, Marja L.; Jernvall, Jukka] Univ Helsinki, Dev Biol Program, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Kallonen, Aki; Hamalainen, Keijo] Univ Helsinki, Dept Phys, Div Mat Phys, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Jernvall, J (corresponding author), Univ Helsinki, Dev Biol Program, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	jernvall@fastmail.fm	Hamalainen, Keijo J/A-3986-2010	Hamalainen, Keijo J/0000-0002-9234-9810	Academy of Finland; Sigrid Juselius Foundation; Finnish Cultural Foundation; graduate school GSBM	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); graduate school GSBM	We thank I. Thesleff, P. Munne, A. R. Evans, I. Corfe, J. Moustakas, M. Murtoniemi, I. Salazar-Ciudad, S. Sova, J.-P. Suuronen and S. Zohdy for discussions or help; R. Santalahti, R. Savolainen and M. Makinen for technical assistance; M. Hyvonen for the activin A protein; P. Schneider for the Fc-EDA-A1-protein; and C. Tabin and A. Gritli-Linde for the ShhGFP mice. This study was funded by the Academy of Finland, the Sigrid Juselius Foundation, the Finnish Cultural Foundation, and the graduate school GSBM.	Ahn Y, 2010, DEVELOPMENT, V137, P3221, DOI 10.1242/dev.054668; Bei M, 2009, CURR OPIN GENET DEV, V19, P504, DOI 10.1016/j.gde.2009.09.002; Cai JL, 2007, DEV BIOL, V304, P499, DOI 10.1016/j.ydbio.2007.01.002; Carroll SB, 2001, NATURE, V409, P1102, DOI 10.1038/35059227; Charles C, 2009, P NATL ACAD SCI USA, V106, P22364, DOI 10.1073/pnas.0910086106; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Cho SW, 2011, DEVELOPMENT, V138, P1807, DOI 10.1242/dev.056051; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Evans AR, 2007, NATURE, V445, P78, DOI 10.1038/nature05433; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Gabris K, 2006, COMMUNITY DENT HLTH, V23, P80; Gaide O, 2003, NAT MED, V9, P614, DOI 10.1038/nm861; GRUNEBERG H, 1965, J EMBRYOL EXP MORPH, V14, P137; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; HUNTER JP, 1995, P NATL ACAD SCI USA, V92, P10718, DOI 10.1073/pnas.92.23.10718; Ishida K, 2011, BIOCHEM BIOPH RES CO, V405, P455, DOI 10.1016/j.bbrc.2011.01.052; Jernvall J, 2000, P NATL ACAD SCI USA, V97, P14444, DOI 10.1073/pnas.97.26.14444; Kangas AT, 2004, NATURE, V432, P211, DOI 10.1038/nature02927; Kavanagh KD, 2007, NATURE, V449, P427, DOI 10.1038/nature06153; KAY RF, 1994, AM J PHYS ANTHROPOL, V95, P333, DOI 10.1002/ajpa.1330950305; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Luo ZX, 2007, NATURE, V450, P1011, DOI 10.1038/nature06277; Metscher BD, 2009, DEV DYNAM, V238, P632, DOI 10.1002/dvdy.21857; Mikkola ML, 2008, CYTOKINE GROWTH F R, V19, P219, DOI 10.1016/j.cytogfr.2008.04.008; Miles AEW., 2003, COLYERS VARIATIONS D; Narhi K, 2010, METHODS MOL BIOL, V666, P253, DOI 10.1007/978-1-60761-820-1_16; Nieminen P, 2009, J EXP ZOOL PART B, V312B, P320, DOI 10.1002/jez.b.21277; Pispa J, 2004, DEV DYNAM, V231, P432, DOI 10.1002/dvdy.20138; Salazar-Ciudad I, 2010, NATURE, V464, P583, DOI 10.1038/nature08838; Santana SE, 2011, FUNCT ECOL, V25, P839, DOI 10.1111/j.1365-2435.2011.01832.x; Skinner MM, 2010, AM J PHYS ANTHROPOL, V142, P157, DOI 10.1002/ajpa.21248; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Uhen MD, 2007, ANAT REC, V290, P514, DOI 10.1002/ar.20545	34	75	76	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					324	+		10.1038/nature10876	http://dx.doi.org/10.1038/nature10876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22398444				2022-12-28	WOS:000301481800047
J	Sun, X; Briel, M; Busse, JW; You, JJ; Akl, EA; Mejza, F; Bala, MM; Bassler, D; Mertz, D; Diaz-Granados, N; Vandvik, PO; Malaga, G; Srinathan, SK; Dahm, P; Johnston, BC; Alonso-Coello, P; Hassouneh, B; Walter, SD; Heels-Ansdell, D; Bhatnagar, N; Altman, DG; Guyatt, GH				Sun, Xin; Briel, Matthias; Busse, Jason W.; You, John J.; Akl, Elie A.; Mejza, Filip; Bala, Malgorzata M.; Bassler, Dirk; Mertz, Dominik; Diaz-Granados, Natalia; Vandvik, Per Olav; Malaga, German; Srinathan, Sadeesh K.; Dahm, Philipp; Johnston, Bradley C.; Alonso-Coello, Pablo; Hassouneh, Basil; Walter, Stephen D.; Heels-Ansdell, Diane; Bhatnagar, Neera; Altman, Douglas G.; Guyatt, Gordon H.			Credibility of claims of subgroup effects in randomised controlled trials: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; CANCER	Objective To investigate the credibility of authors' claims of subgroup effects using a representative sample of recently published randomised controlled trials. Design Systematic review. Data source Core clinical journals, as defined by the National Library of Medicine, in Medline. Study selection Randomised controlled trials published in 2007. Using prespecified criteria, teams of trained reviewers independently judged whether authors claimed subgroup effects and the strength of their claims. Reviewers assessed each of these claims against 10 predefined criteria, developed through a search of existing criteria and a consensus process. Results Of 207 randomised controlled trials reporting subgroup analyses, 64 (31%) made claims for the primary outcome. Of those, 20 were strong claims and 28 claims of a likely effect. Authors included subgroup variables measured at baseline in 60 (94%) trials, used subgroup variable as a stratification factor at randomisation in 13 (20%), clearly prespecified their hypotheses in 26 (41%), correctly prespecified direction in 4 (6%), tested a small number of hypotheses in 28 (44%), carried out a test of interaction that proved statistically significant in 6 (9%), documented replication of a subgroup effect with previous related studies in 21 (33%), identified consistency of a subgroup effect across related outcomes in 19 (30%), and provided a compelling indirect evidence for the effect in 14 (22%). In the 19 trials making more than one claim, only one (5%) checked the independence of the interaction. Of the 64 claims, 54 (84%) met four or fewer of the 10 criteria. For strong claims, more than 50% failed each of the individual criteria, and only three (15%) met more than five criteria. Conclusion Authors often claim subgroup effects in their trial report. However, the credibility of subgroup effects, even when claims are strong, is usually low. Users of the information should treat claims that fail to meet most criteria with scepticism. Trial researchers should report the conduct of subgroup analyses and provide sufficient evidence when claiming a subgroup effect or suggesting a possible effect.	[Sun, Xin; Briel, Matthias; Busse, Jason W.; You, John J.; Akl, Elie A.; Mertz, Dominik; Diaz-Granados, Natalia; Johnston, Bradley C.; Hassouneh, Basil; Walter, Stephen D.; Heels-Ansdell, Diane; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada; [Sun, Xin] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA; [Briel, Matthias] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland; [Busse, Jason W.] Inst Work & Hlth, Toronto, ON, Canada; [You, John J.; Mertz, Dominik] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA; [Akl, Elie A.] SUNY Buffalo, Dept Family Med, Buffalo, NY 14260 USA; [Mejza, Filip] Jagiellonian Univ, Sch Med, Dept Pulm Dis, Krakow, Poland; [Bala, Malgorzata M.] Jagiellonian Univ, Sch Med, Dept Internal Med 2, Krakow, Poland; [Bassler, Dirk] Univ Childrens Hosp Tuebingen, Dept Neonatol, Tubingen, Germany; [Bassler, Dirk] Univ Childrens Hosp Tuebingen, Ctr Pediat Clin Studies, Tubingen, Germany; [Mertz, Dominik] McMaster Univ, Michael G DeGroote Inst Infect Dis Res, Hamilton, ON, Canada; [Vandvik, Per Olav] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway; [Vandvik, Per Olav] Innlandet Hosp Trust, Dept Med, Gjovik, Norway; [Malaga, German] Univ Peruana Cayetano Heredia, Dept Med, Lima, Peru; [Srinathan, Sadeesh K.] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Dahm, Philipp] Univ Florida, Coll Med, Dept Urol, Gainesville, FL USA; [Johnston, Bradley C.] Hosp Sick Children, Dept Anaesthesiol & Pain Med, Toronto, ON M5G 1X8, Canada; [Alonso-Coello, Pablo] Biomed Res Inst CIBER Epidemiol & Publ Hlth, IberoAmer Cochrane Ctr, Barcelona, Spain; [Bhatnagar, Neera] McMaster Univ, Hlth Sci Lib, Hamilton, ON, Canada; [Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford, England	McMaster University; Kaiser Permanente; University of Basel; Institute for Work & Health; McMaster University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Jagiellonian University; Jagiellonian University; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; McMaster University; Norwegian Knowledge Centre for Health Services; Innlandet Hospital Trust; Universidad Peruana Cayetano Heredia; University of Manitoba; State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; McMaster University; University of Oxford	Guyatt, GH (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	guyatt@mcmaster.ca	Briel, Matthias/AAT-9284-2021; Dahm, Philipp/I-1614-2019; Akl, Elie A/R-2079-2016; Busse, Jason/CAH-3696-2022; Akl, Elie/K-5269-2019; Walter, Stephen/AAB-5548-2022; Bhatnagar, Neera/B-8004-2013	Dahm, Philipp/0000-0003-2819-2553; Akl, Elie A/0000-0002-3444-8618; Busse, Jason/0000-0002-0178-8712; Walter, Stephen/0000-0003-4157-8928; Bhatnagar, Neera/0000-0002-5060-5257; Alonso-Coello, Pablo/0000-0002-8001-8504; Bassler, Dirk/0000-0003-2358-4419; Malaga, German/0000-0002-7828-300X; Briel, Matthias/0000-0002-2070-5230	National Natural Science Foundation of China [70703025]; Santesuisse; Gottfried and Julia Bangerter-Rhyner Foundation; Canadian Institutes of Health Research; Canadian Chiropractic Research Foundation; European Union [health-F5-2009-223060]; Swiss National Science Foundation [PBBSP3-124436, PASMP3-132571]; Lichtenstein-Stiftung, Basel, Switzerland; American Geriatrics Society; SickKids Foundation; Instituto de Salud Carlos III [CP09/00137]; Ontario Ministry of Health and Long-Term Care; Cancer Research UK [C5529]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Santesuisse; Gottfried and Julia Bangerter-Rhyner Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Chiropractic Research Foundation; European Union(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Lichtenstein-Stiftung, Basel, Switzerland; American Geriatrics Society; SickKids Foundation; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Cancer Research UK(Cancer Research UK)	This study was supported by the National Natural Science Foundation of China (project No: 70703025). The funder had no role in the study design, writing of the manuscript, or decision to submit this or future manuscripts for publication. MB is supported by Santesuisse and the Gottfried and Julia Bangerter-Rhyner Foundation. JWB is funded by a new investigator award from the Canadian Institutes of Health Research and the Canadian Chiropractic Research Foundation. DB is supported by the European Union (grant award health-F5-2009-223060). DM is supported by a research scholarship from the Swiss National Science Foundation (PBBSP3-124436 and PASMP3-132571) and the Lichtenstein-Stiftung, Basel, Switzerland. PD is supported by a Dennis W Jahnigan Career Development Award by the American Geriatrics Society. BCJ holds a SickKids Foundation postdoctoral fellowship. PA-C is funded by a Miguel Servet contract by the Instituto de Salud Carlos III (CP09/00137). JJY is supported by a career scientist award from the Ontario Ministry of Health and Long-Term Care. DGA is supported by Cancer Research UK (grant No C5529).	Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Bender R, 2010, J CLIN EPIDEMIOL, V63, P1305, DOI 10.1016/j.jclinepi.2010.06.003; Bhandari M, 2006, CLIN ORTHOP RELAT R, P247, DOI 10.1097/01.blo.0000218736.23506.fe; Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x; Cui Lu, 2002, J Biopharm Stat, V12, P347, DOI 10.1081/BIP-120014565; Fletcher J, 2007, BRIT MED J, V335, P96, DOI 10.1136/bmj.39265.596262.AD; Gabler NB, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-43; Guyatt G, 2008, USERS GUIDES MED LIT; Hernandez AV, 2006, AM HEART J, V151, P257, DOI 10.1016/j.ahj.2005.04.020; Itoi E, 2007, J BONE JOINT SURG AM, V89A, P2124, DOI 10.2106/JBJS.F.00654; National Library of Medicine, 2012, ABR IND MED AIM COR; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Pocock SJ, 2008, NEW ENGL J MED, V358, P2076, DOI 10.1056/NEJMc0800616; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Schulz KF, 2010, BMC MED, V8, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Spiegel D, 2007, CANCER-AM CANCER SOC, V110, P1130, DOI 10.1002/cncr.22890; Sun X, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1569; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; Sun X, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-101; Thomson Reuters, 2012, ISI WEB KNOWL; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	27	218	220	3	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2012	344								e1553	10.1136/bmj.e1553	http://dx.doi.org/10.1136/bmj.e1553			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CD	22422832	Green Submitted, hybrid			2022-12-28	WOS:000301848100006
J	Luther, V; Townell, J; Rahman, H; Loong, CY				Luther, Vishal; Townell, Jennifer; Rahman, Haseeb; Loong, Chee Yee			CASE REPORT Fever and haemoptysis in an injecting drug user	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ENDOCARDITIS; PNEUMONIA		[Luther, Vishal; Rahman, Haseeb; Loong, Chee Yee] Whittington Hosp, London N19 5NF, England; [Townell, Jennifer] Watford Dist Gen Hosp, Watford, England	University of London; University College London; Watford General Hospital	Luther, V (corresponding author), Whittington Hosp, London N19 5NF, England.	vishal_luther@yahoo.co.uk						Brusselle GG, 2007, ACTA CLIN BELG, V62, P88, DOI 10.1179/acb.2007.016; CHERRY JD, 1993, CLIN INFECT DIS, V17, pS47, DOI 10.1093/clinids/17.Supplement_1.S47; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; Darke S, 2001, DRUG ALCOHOL DEPEN, V62, P77, DOI 10.1016/S0376-8716(00)00161-7; File TM, 2010, AM J MED, V123, pS4, DOI 10.1016/j.amjmed.2010.02.002; Fowler VG, 2005, JAMA-J AM MED ASSOC, V293, P3012, DOI 10.1001/jama.293.24.3012; Fraeyman A, 2010, ACTA CLIN BELG, V65, P192, DOI 10.1179/acb.2010.040; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Macalino GE, 1998, J ACQ IMMUN DEF SYND, V18, pS111, DOI 10.1097/00042560-199802001-00019; McColl MD, 2001, BRIT J HAEMATOL, V112, P641, DOI 10.1046/j.1365-2141.2001.02633.x; Morokuma H, 2010, ANN THORAC CARDIOVAS, V16, P134; National Institute for Health and Clinical Excellence, 2007, DRUG MIS METH BUPR M; National Treatment Agency for Substance Misuse, 2007, DRUG MIS DEP UK GUID; O'Grady J, 2011, CURR OPIN PULM MED, V17, P134, DOI 10.1097/MCP.0b013e3283452346; Olmstead TA, 2009, DRUG ALCOHOL DEPEN, V102, P108, DOI 10.1016/j.drugalcdep.2009.02.005; Samad Z, 2011, HEART, V97, P221, DOI 10.1136/hrt.2010.202432; WILLIAMS I, 1999, AM J MED S, V107, P2, DOI DOI 10.1016/S0002-9343(99)00373-3; Working Party of the British Society for Antimicrobial Chemotherapy, 2011, GUID ANT TREATM END; Yung D, 2007, J ANTIMICROB CHEMOTH, V60, P921, DOI 10.1093/jac/dkm324; Zarogoulidis P, 2011, INT J GEN MED, V4, P15, DOI 10.2147/IJGM.S15654	20	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2012	344								e1568	10.1136/bmj.e1568	http://dx.doi.org/10.1136/bmj.e1568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913BR	22415952				2022-12-28	WOS:000301846900004
J	Laganowsky, A; Liu, C; Sawaya, MR; Whitelegge, JP; Park, J; Zhao, ML; Pensalfini, A; Soriaga, AB; Landau, M; Teng, PK; Cascio, D; Glabe, C; Eisenberg, D				Laganowsky, Arthur; Liu, Cong; Sawaya, Michael R.; Whitelegge, Julian P.; Park, Jiyong; Zhao, Minglei; Pensalfini, Anna; Soriaga, Angela B.; Landau, Meytal; Teng, Poh K.; Cascio, Duilio; Glabe, Charles; Eisenberg, David			Atomic View of a Toxic Amyloid Small Oligomer	SCIENCE			English	Article							BETA-SHEET; GEOMETRICAL PROPERTIES; FIBRILLAR OLIGOMERS; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURES; PROTEINS; POLYPEPTIDE; MEMBRANE; FRAGMENT; PROVIDES	Amyloid diseases, including Alzheimer's, Parkinson's, and the prion conditions, are each associated with a particular protein in fibrillar form. These amyloid fibrils were long suspected to be the disease agents, but evidence suggests that smaller, often transient and polymorphic oligomers are the toxic entities. Here, we identify a segment of the amyloid-forming protein alpha B crystallin, which forms an oligomeric complex exhibiting properties of other amyloid oligomers: beta-sheet-rich structure, cytotoxicity, and recognition by an oligomer-specific antibody. The x-ray-derived atomic structure of the oligomer reveals a cylindrical barrel, formed from six antiparallel protein strands, that we term a cylindrin. The cylindrin structure is compatible with a sequence segment from the beta-amyloid protein of Alzheimer's disease. Cylindrins offer models for the hitherto elusive structures of amyloid oligomers.	[Laganowsky, Arthur; Liu, Cong; Sawaya, Michael R.; Park, Jiyong; Zhao, Minglei; Soriaga, Angela B.; Landau, Meytal; Teng, Poh K.; Cascio, Duilio; Eisenberg, David] Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Prote, Dept Biol Chem, Los Angeles, CA 90095 USA; [Laganowsky, Arthur; Liu, Cong; Sawaya, Michael R.; Park, Jiyong; Zhao, Minglei; Soriaga, Angela B.; Landau, Meytal; Teng, Poh K.; Cascio, Duilio; Eisenberg, David] Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Prote, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Whitelegge, Julian P.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Neuropsychiat Inst NPI, Los Angeles, CA 90024 USA; [Pensalfini, Anna; Glabe, Charles] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles; Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Irvine	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Prote, Dept Biol Chem, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu	Landau, Meytal/AAF-3479-2021; liu, cong/H-1103-2011; Park, Jiyong/AAK-9684-2020; Landau, Meytal/J-3075-2012; Pensalfini, Anna/X-5563-2019; Zhao, Minglei/J-4446-2015	Landau, Meytal/0000-0002-1743-3430; Park, Jiyong/0000-0002-3225-4510; Landau, Meytal/0000-0002-1743-3430; Zhao, Minglei/0000-0001-5832-6060; Laganowsky, Arthur/0000-0001-5012-5547	National Center for Research Resources of the NIH [RR-15301]; U.S. DOE [DE-AC02-06CH11357]; NIH [5T32GM008496, 1R01-AG029430]; UCLA; NSF [MCB-0445429]; Alzheimer's Disease Research at UCLA [NIH-016570]; HHMI; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG016570, R01AG029430, R01AG033069] Funding Source: NIH RePORTER	National Center for Research Resources of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); U.S. DOE(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA(University of California System); NSF(National Science Foundation (NSF)); Alzheimer's Disease Research at UCLA; HHMI(Howard Hughes Medical Institute); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank L. Goldschmidt for the 3D profile scan of ABC; J.-P. Colletier, D. Anderson, G. Fujii, J. Stroud, H. Chang, S. Sievers, J. Weissman, J. L. P. Benesch, G. Hochberg, and C. V. Robinson for useful discussion; J. Navarro at the UCLA Crystallization Facility; A. Berk and D. Guo for help with tissue culture experiments; and C. Ralston at the Advanced Light Source (ALS) 8.2.2 and K. Rajashankar and beamline staff at Argonne Photon Source (APS), Northeastern Collaborative Access Team beamlines 24-ID-E/C, for data collection. The last is supported by award RR-15301 from the National Center for Research Resources of the NIH. Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under contract no. DE-AC02-06CH11357. We thank the NIH Chemistry Biology Interface Training program (award 5T32GM008496) sponsorship for A.L., UCLA Dissertation Year fellowships awarded to A.L. and M.Z., NSF award MCB-0445429, NIH award 1R01-AG029430, award NIH-016570 from Alzheimer's Disease Research at UCLA, and HHMI for support. Atomic coordinates and structure factors have been deposited in the PDB with the following accession codes: K11V (3SGO), K11V-Br2 (3SGM), K11V-Br8 (3SGN), K11V<SUP>V2L</SUP> (3SGP), K11V-TR (3SGR), and GDVIEV (3SGS). A11 is available under a uniform biological material transfer agreement with the University of California, Irvine. UCLA has filed a provisional patent on cylindrin as the possible generic etiologic agent of amyloid diseases.	Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799; Austen BM, 2008, BIOCHEMISTRY-US, V47, P1984, DOI 10.1021/bi701415b; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Bernstein SL, 2009, NAT CHEM, V1, P326, DOI [10.1038/NCHEM.247, 10.1038/nchem.247]; Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chimon S, 2007, NAT STRUCT MOL BIOL, V14, P1157, DOI 10.1038/nsmb1345; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Chiti F, 2009, NAT CHEM BIOL, V5, P15, DOI 10.1038/nchembio.131; Conway J. D., 1986, THESIS UCLA; Dehle FC, 2010, CELL STRESS CHAPERON, V15, P1013, DOI 10.1007/s12192-010-0212-z; Ecroyd H, 2009, CELL MOL LIFE SCI, V66, P62, DOI 10.1007/s00018-008-8327-4; Engel MFM, 2008, P NATL ACAD SCI USA, V105, P6033, DOI 10.1073/pnas.0708354105; Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200; Goldschmidt L, 2010, P NATL ACAD SCI USA, V107, P3487, DOI 10.1073/pnas.0915166107; Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Jang H, 2010, J MOL BIOL, V404, P917, DOI 10.1016/j.jmb.2010.10.025; Jehle S, 2011, P NATL ACAD SCI USA, V108, P6409, DOI 10.1073/pnas.1014656108; Kajava AV, 2010, FASEB J, V24, P1311, DOI 10.1096/fj.09-145979; Kar K, 2011, NAT STRUCT MOL BIOL, V18, P328, DOI 10.1038/nsmb.1992; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Khemtemourian L, 2010, BBA-BIOMEMBRANES, V1798, P1805, DOI 10.1016/j.bbamem.2010.05.022; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Kodali R, 2007, CURR OPIN STRUC BIOL, V17, P48, DOI 10.1016/j.sbi.2007.01.007; Laganowsky A, 2010, PROTEIN SCI, V19, P1031, DOI 10.1002/pro.380; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Last NB, 2011, P NATL ACAD SCI USA, V108, P9460, DOI 10.1073/pnas.1102356108; Liu C, 2011, J AM CHEM SOC, V133, P6736, DOI 10.1021/ja200222n; Meehan S, 2007, J MOL BIOL, V372, P470, DOI 10.1016/j.jmb.2007.06.060; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106; Picone P, 2009, BIOPHYS J, V96, P4200, DOI 10.1016/j.bpj.2008.11.056; Pryciak P. M., 1986, PROTEIN STRUCTURE FO, V39, P243; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SALEMME FR, 1981, J MOL BIOL, V146, P119, DOI 10.1016/0022-2836(81)90369-7; SALEMME FR, 1981, J MOL BIOL, V146, P101, DOI 10.1016/0022-2836(81)90368-5; Sarsoza F, 2009, ACTA NEUROPATHOL, V118, P505, DOI 10.1007/s00401-009-0530-3; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Shafrir Y, 2010, PROTEINS, V78, P3473, DOI 10.1002/prot.22853; Streltsov VA, 2011, J NEUROSCI, V31, P1419, DOI 10.1523/JNEUROSCI.4259-10.2011; Thompson MJ, 2006, P NATL ACAD SCI USA, V103, P4074, DOI 10.1073/pnas.0511295103; Tomic JL, 2009, NEUROBIOL DIS, V35, P352, DOI 10.1016/j.nbd.2009.05.024; Tycko R, 2011, ANNU REV PHYS CHEM, V62, P279, DOI 10.1146/annurev-physchem-032210-103539; Wu JW, 2010, J BIOL CHEM, V285, P6071, DOI 10.1074/jbc.M109.069542; Xue WF, 2009, J BIOL CHEM, V284, P34272, DOI 10.1074/jbc.M109.049809; Yoshiike Y, 2007, NEUROMOL MED, V9, P270, DOI 10.1007/s12017-007-0003-6	50	440	446	5	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1228	1231		10.1126/science.1213151	http://dx.doi.org/10.1126/science.1213151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403391	Green Accepted			2022-12-28	WOS:000301225100046
J	Lu, JL; Fu, BS; Kung, MC; Xiao, GM; Elam, JW; Kung, HH; Stair, PC				Lu, Junling; Fu, Baosong; Kung, Mayfair C.; Xiao, Guomin; Elam, Jeffrey W.; Kung, Harold H.; Stair, Peter C.			Coking- and Sintering-Resistant Palladium Catalysts Achieved Through Atomic Layer Deposition	SCIENCE			English	Article							OXIDATIVE DEHYDROGENATION; REFORMING CATALYSTS; DEACTIVATION; ETHANE; CONVERSION; VANADIUM; PROPANE; ALKANES; OXIDES	We showed that alumina (Al2O3) overcoating of supported metal nanoparticles (NPs) effectively reduced deactivation by coking and sintering in high-temperature applications of heterogeneous catalysts. We overcoated palladium NPs with 45 layers of alumina through an atomic layer deposition (ALD) process that alternated exposures of the catalysts to trimethylaluminum and water at 200 degrees C. When these catalysts were used for 1 hour in oxidative dehydrogenation of ethane to ethylene at 650 degrees C, they were found by thermogravimetric analysis to contain less than 6% of the coke formed on the uncoated catalysts. Scanning transmission electron microscopy showed no visible morphology changes after reaction at 675 degrees C for 28 hours. The yield of ethylene was improved on all ALD Al2O3 overcoated Pd catalysts.	[Stair, Peter C.] Northwestern Univ, Dept Chem, Evanston, IL 60201 USA; [Lu, Junling; Elam, Jeffrey W.] Argonne Natl Lab, Div Energy Syst, Argonne, IL 60439 USA; [Fu, Baosong; Xiao, Guomin] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Peoples R China; [Kung, Mayfair C.; Kung, Harold H.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA; [Stair, Peter C.] Argonne Natl Lab, Chem Sci & Engn Div, Argonne, IL 60439 USA	Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory; Southeast University - China; Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory	Stair, PC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60201 USA.	pstair@northwestern.edu	Lu, Junling/F-3791-2010; Lu, Junling/D-7644-2018; Kung, Harold H/B-7647-2009; Kung, Mayfair/B-7648-2009	Lu, Junling/0000-0002-7371-8414; Lu, Junling/0000-0002-2607-6869; 	Dow Chemical Company; U.S. Department of Energy, Office of Basic Energy Sciences, Hydrogen Fuel Initiative, Chemical Sciences [DE-AC-02-06CH11357]; China Scholarship Council	Dow Chemical Company; U.S. Department of Energy, Office of Basic Energy Sciences, Hydrogen Fuel Initiative, Chemical Sciences; China Scholarship Council(China Scholarship Council)	The work was financially supported by The Dow Chemical Company under the Dow Methane Challenge Award and by the U.S. Department of Energy, Office of Basic Energy Sciences, Hydrogen Fuel Initiative, Chemical Sciences, under contract DE-AC-02-06CH11357. Applications for U.S. and international patents with the title "Metal Catlayst Composition" have been filed. All data and images are available in the body of the paper or as supporting online material. We thank J. T. Miller for providing the Pd/Al2O3 sample, F. A. Rabuffetti and K. R. Poeppelmeier for technical assistance on TGA measurements, M. M. Schwartz and C. L. Marshall for technical assistance on BET measurements, F. H. Ribeiro and F. Sollberger for particle dispersion measurements, and N. M. Schweitzer and D. Barton for helpful discussions. B.F. acknowledges financial support in part by the China Scholarship Council.	Arnal PM, 2006, ANGEW CHEM INT EDIT, V45, P8224, DOI 10.1002/anie.200603507; BARBIER J, 1986, APPL CATAL, V23, P225, DOI 10.1016/S0166-9834(00)81294-4; BHARADWAJ SS, 1995, J CATAL, V155, P403, DOI 10.1006/jcat.1995.1222; BILOEN P, 1980, J CATAL, V63, P112, DOI 10.1016/0021-9517(80)90064-0; Cargnello M, 2010, DALTON T, V39, P2122, DOI 10.1039/b916035c; Cavani F, 2007, CATAL TODAY, V127, P113, DOI 10.1016/j.cattod.2007.05.009; Chao ZS, 2004, J CATAL, V222, P17, DOI 10.1016/j.jcat.2003.11.004; Chen KD, 2000, J PHYS CHEM B, V104, P1292, DOI 10.1021/jp9933875; Concepcion P, 2004, CATAL TODAY, V96, P179, DOI 10.1016/j.cattod.2004.06.151; Farrauto R.J., 1997, FUNDAMENTALS IND CAT; Feng H, 2011, CATAL LETT, V141, P512, DOI 10.1007/s10562-011-0548-8; Ferguson JD, 2000, THIN SOLID FILMS, V371, P95, DOI 10.1016/S0040-6090(00)00973-1; George SM, 2010, CHEM REV, V110, P111, DOI 10.1021/cr900056b; GHOSH KK, 1988, IND ENG CHEM RES, V27, P559, DOI 10.1021/ie00076a005; Helveg S, 2004, NATURE, V427, P426, DOI 10.1038/nature02278; Horiuchi T, 1996, APPL CATAL A-GEN, V144, P111, DOI 10.1016/0926-860X(96)00100-7; HUFF M, 1993, J PHYS CHEM-US, V97, P11815, DOI 10.1021/j100147a040; Joo SH, 2009, NAT MATER, V8, P126, DOI 10.1038/NMAT2329; Lear T, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2101487; Lim BS, 2003, NAT MATER, V2, P749, DOI 10.1038/nmat1000; Liu ZP, 2003, J AM CHEM SOC, V125, P1958, DOI 10.1021/ja0207551; Macleod N, 1998, CATAL TODAY, V46, P37, DOI 10.1016/S0920-5861(98)00349-6; Moulijn JA, 2001, APPL CATAL A-GEN, V212, P3, DOI 10.1016/S0926-860X(00)00842-5; Nakagawa K, 2003, CATAL TODAY, V84, P149, DOI 10.1016/S0920-5861(03)00268-2; Puurunen RL, 2005, J APPL PHYS, V97, DOI 10.1063/1.1940727; Radnik J, 2005, ANGEW CHEM INT EDIT, V44, P6771, DOI 10.1002/anie.200501650; Rostrup-Nielsen JR, 1999, CATAL TODAY, V53, P311, DOI 10.1016/S0920-5861(99)00125-X; Rovik AK, 2009, APPL CATAL A-GEN, V358, P269, DOI 10.1016/j.apcata.2009.02.020; Seipenbusch M, 2009, J PHYS CHEM C, V113, P20606, DOI 10.1021/jp9063998; Trimm DL, 1999, CATAL TODAY, V49, P3, DOI 10.1016/S0920-5861(98)00401-5; Wickham D. T., 2002, U.S. Patent, Patent No. [6482311, 6,482,311B1]; WOLF EE, 1982, CATAL REV, V24, P329, DOI 10.1080/03602458208079657; Yu K, 2008, J PHYS CHEM C, V112, P2244, DOI 10.1021/jp711880e	33	602	629	61	1162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1205	1208		10.1126/science.1212906	http://dx.doi.org/10.1126/science.1212906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403386				2022-12-28	WOS:000301225100039
J	Garner, AR; Rowland, DC; Hwang, SY; Baumgaertel, K; Roth, BL; Kentros, C; Mayford, M				Garner, Aleena R.; Rowland, David C.; Hwang, Sang Youl; Baumgaertel, Karsten; Roth, Bryan L.; Kentros, Cliff; Mayford, Mark			Generation of a Synthetic Memory Trace	SCIENCE			English	Article							MICROSTIMULATION; DISCRIMINATION; STIMULATION; HIPPOCAMPUS; RECEPTORS; DYNAMICS; NEURONS; MICE	We investigated the effect of activating a competing, artificially generated, neural representation on encoding of contextual fear memory in mice. We used a c-fos-based transgenic approach to introduce the hM(3)D(q) DREADD receptor (designer receptor exclusively activated by designer drug) into neurons naturally activated by sensory experience. Neural activity could then be specifically and inducibly increased in the hM(3)D(q)-expressing neurons by an exogenous ligand. When an ensemble of neurons for one context (ctxA) was artificially activated during conditioning in a distinct second context (ctxB), mice formed a hybrid memory representation. Reactivation of the artificially stimulated network within the conditioning context was required for retrieval of the memory, and the memory was specific for the spatial pattern of neurons artificially activated during learning. Similar stimulation impaired recall when not part of the initial conditioning.	[Garner, Aleena R.; Hwang, Sang Youl; Baumgaertel, Karsten; Mayford, Mark] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Garner, Aleena R.; Hwang, Sang Youl; Baumgaertel, Karsten; Mayford, Mark] Scripps Res Inst, Dorris Neurosci Ctr, La Jolla, CA 92037 USA; [Garner, Aleena R.; Mayford, Mark] Univ Calif San Diego, Grad Program Neurosci, La Jolla, CA 92037 USA; [Rowland, David C.; Kentros, Cliff] Univ Oregon, Inst Neurosci, Dept Psychol, Eugene, OR 97403 USA; [Roth, Bryan L.] Univ N Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Roth, Bryan L.] Univ N Carolina Chapel Hill, Sch Med, Dept Biol Chem, Chapel Hill, NC 27599 USA; [Roth, Bryan L.] Univ N Carolina Chapel Hill, Sch Med, Dept Med Chem, Chapel Hill, NC 27599 USA; [Roth, Bryan L.] Univ N Carolina Chapel Hill, Sch Med, Program Neurosci, Chapel Hill, NC 27599 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; University of Oregon; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mayford, M (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mmayford@scripps.edu	Roth, Bryan L/F-3928-2010; Roth, Bryan/ABE-7032-2020	Roth, Bryan/0000-0002-0561-6520; Garner, Aleena/0000-0002-3488-2959; Mayford, Mark/0000-0002-9001-5024; Kentros, Clifford/0000-0003-3850-3829	National Institute of Mental Health (NIMH) [R01MH057368, U19MH82441]; National Institute on Drug Abuse [R01DA028300]; Michael Hooker Distinguished Chair in Pharmacology; California Institute for Regenerative Medicine; NATIONAL INSTITUTE OF MENTAL HEALTH [U19MH082441, R01MH057368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA028300] Funding Source: NIH RePORTER	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Michael Hooker Distinguished Chair in Pharmacology; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank K. Cowansage for helpful discussions. Supported by National Institute of Mental Health (NIMH) grant R01MH057368 and National Institute on Drug Abuse grant R01DA028300 (M. M.), NIMH grant U19MH82441 and the Michael Hooker Distinguished Chair in Pharmacology (B. L. R.), and a graduate fellowship from the California Institute for Regenerative Medicine (A.R.G.).	Alexander GM, 2009, NEURON, V63, P27, DOI 10.1016/j.neuron.2009.06.014; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Choi GB, 2011, CELL, V146, P1003, DOI 10.1016/j.cell.2011.07.041; Doty R W, 1969, Annu Rev Psychol, V20, P289, DOI 10.1146/annurev.ps.20.020169.001445; Fiser J, 2004, NATURE, V431, P573, DOI 10.1038/nature02907; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Girardeau G, 2009, NAT NEUROSCI, V12, P1222, DOI 10.1038/nn.2384; Han JH, 2007, SCIENCE, V316, P457, DOI [10.1126/science.1139438, 10.1126/science.1134697]; Han JH, 2009, SCIENCE, V323, P1492, DOI 10.1126/science.1164139; Huber D, 2008, NATURE, V451, P61, DOI 10.1038/nature06445; Jasper H., 1954, EPILEPSY FUNCTIONAL; Kenet T, 2003, NATURE, V425, P954, DOI 10.1038/nature02078; Luo L, 2008, NEURON, V57, P634, DOI 10.1016/j.neuron.2008.01.002; MacLean JN, 2005, NEURON, V48, P811, DOI 10.1016/j.neuron.2005.09.035; Matsuo N, 2008, SCIENCE, V319, P1104, DOI 10.1126/science.1149967; Reijmers LG, 2007, SCIENCE, V317, P1230, DOI 10.1126/science.1143839; Ringach DL, 2009, CURR OPIN NEUROBIOL, V19, P439, DOI 10.1016/j.conb.2009.07.005; Romo R, 1998, NATURE, V392, P387, DOI 10.1038/32891; Shinkman PG, 1996, BEHAV NEUROSCI, V110, P914, DOI 10.1037/0735-7044.110.5.914; Tse D, 2007, SCIENCE, V316, P76, DOI 10.1126/science.1135935; Tse D, 2011, SCIENCE, V333, P891, DOI 10.1126/science.1205274; Zhou Y, 2009, NAT NEUROSCI, V12, P1438, DOI 10.1038/nn.2405	22	254	263	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1513	1516		10.1126/science.1214985	http://dx.doi.org/10.1126/science.1214985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442487	Green Accepted, Green Submitted			2022-12-28	WOS:000301837000054
J	Walter, MJ; Shen, D; Ding, L; Shao, J; Koboldt, DC; Chen, K; Larson, DE; McLellan, MD; Dooling, D; Abbott, R; Fulton, R; Magrini, V; Schmidt, H; Kalicki-Veizer, J; O'Laughlin, M; Fan, X; Grillot, M; Witowski, S; Heath, S; Frater, JL; Eades, W; Tomasson, M; Westervelt, P; DiPersio, JF; Link, DC; Mardis, ER; Ley, TJ; Wilson, RK; Graubert, TA				Walter, Matthew J.; Shen, Dong; Ding, Li; Shao, Jin; Koboldt, Daniel C.; Chen, Ken; Larson, David E.; McLellan, Michael D.; Dooling, David; Abbott, Rachel; Fulton, Robert; Magrini, Vincent; Schmidt, Heather; Kalicki-Veizer, Joelle; O'Laughlin, Michelle; Fan, Xian; Grillot, Marcus; Witowski, Sarah; Heath, Sharon; Frater, John L.; Eades, William; Tomasson, Michael; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Mardis, Elaine R.; Ley, Timothy J.; Wilson, Richard K.; Graubert, Timothy A.			Clonal Architecture of Secondary Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELODYSPLASTIC SYNDROMES; POINT MUTATIONS; CANCER; PROGRESSION; EVOLUTION; NUMBER; MODEL; DELETION; RUNX1	BACKGROUND The myelodysplastic syndromes are a group of hematologic disorders that often evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie progression from the myelodysplastic syndromes to secondary AML are not well understood. METHODS We performed whole-genome sequencing of seven paired samples of skin and bone marrow in seven subjects with secondary AML to identify somatic mutations specific to secondary AML. We then genotyped a bone marrow sample obtained during the antecedent myelodysplastic-syndrome stage from each subject to determine the presence or absence of the specific somatic mutations. We identified recurrent mutations in coding genes and defined the clonal architecture of each pair of samples from the myelodysplastic-syndrome stage and the secondary-AML stage, using the allele burden of hundreds of mutations. RESULTS Approximately 85% of bone marrow cells were clonal in the myelodysplastic-syndrome and secondary-AML samples, regardless of the myeloblast count. The secondary-AML samples contained mutations in 11 recurrently mutated genes, including 4 genes that have not been previously implicated in the myelodysplastic syndromes or AML. In every case, progression to acute leukemia was defined by the persistence of an antecedent founding clone containing 182 to 660 somatic mutations and the outgrowth or emergence of at least one subclone, harboring dozens to hundreds of new mutations. All founding clones and subclones contained at least one mutation in a coding gene. CONCLUSIONS Nearly all the bone marrow cells in patients with myelodysplastic syndromes and secondary AML are clonally derived. Genetic evolution of secondary AML is a dynamic process shaped by multiple cycles of mutation acquisition and clonal selection. Recurrent gene mutations are found in both founding clones and daughter subclones. (Funded by the National Institutes of Health and others.)	[Graubert, Timothy A.] Washington Univ, Sch Med, Div Oncol, Stem Cell Biol Sect,Dept Internal Med, St Louis, MO 63110 USA; [Walter, Matthew J.; Ding, Li; Mardis, Elaine R.; Ley, Timothy J.; Wilson, Richard K.] Washington Univ, Dept Genet, St Louis, MO 63110 USA; [Frater, John L.; Graubert, Timothy A.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Walter, Matthew J.; Eades, William; Tomasson, Michael; Westervelt, Peter; DiPersio, John F.; Link, Daniel C.; Mardis, Elaine R.; Ley, Timothy J.; Wilson, Richard K.; Graubert, Timothy A.] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA; [Shen, Dong; Ding, Li; Koboldt, Daniel C.; Chen, Ken; Larson, David E.; McLellan, Michael D.; Dooling, David; Abbott, Rachel; Fulton, Robert; Magrini, Vincent; Schmidt, Heather; Kalicki-Veizer, Joelle; O'Laughlin, Michelle; Fan, Xian; Mardis, Elaine R.; Ley, Timothy J.; Wilson, Richard K.] Washington Univ, Genome Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Graubert, TA (corresponding author), Washington Univ, Sch Med, Div Oncol, Stem Cell Biol Sect,Dept Internal Med, Campus Box 8007,660 S Euclid Ave, St Louis, MO 63110 USA.	graubert@wustl.edu	Chen, Ken/AAU-1432-2021; Walter, Matthew J/S-7758-2018; Mardis, Elaine/W-2202-2019; Magrini, Vincent/AAT-5830-2020; Wilson, Richard K./AAF-4139-2019	Chen, Ken/0000-0003-4013-5279; Magrini, Vincent/0000-0002-2019-4872; Wilson, Richard K./0000-0002-1992-1358; Larson, David/0000-0001-7934-5906; Graubert, Timothy/0000-0002-7710-1171; Mallory, Xian/0000-0003-0365-0909; Tomasson, Michael/0000-0003-4518-7123; MCLELLAN, MICHAEL/0000-0002-2703-8784	National Institutes of Health [R01HL082973, RC2HL102927, U54HG003079, P01CA101937]; Howard Hughes Medical Institute; National Center for Research Resources [UL1RR024992]; NATIONAL CANCER INSTITUTE [P01CA101937] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082973, RC2HL102927] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported by grants from the National Institutes of Health (R01HL082973 and RC2HL102927, to Dr. Graubert; U54HG003079, to Dr. Wilson; and P01CA101937, to Dr. Ley); a Howard Hughes Medical Institute Physician-Scientist Early Career Award (to Dr. Walter); and a grant from the National Center for Research Resources (UL1RR024992).	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Bacher U, 2007, HAEMATOLOGICA, V92, P744, DOI 10.3324/haematol.10869; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bello C, 2011, CANCER-AM CANCER SOC, V117, P1463, DOI 10.1002/cncr.25598; Califano J, 1996, CANCER RES, V56, P2488; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen CY, 2007, BRIT J HAEMATOL, V139, P405, DOI 10.1111/j.1365-2141.2007.06811.x; Cogle CR, 2011, BLOOD, V117, P7121, DOI 10.1182/blood-2011-02-337964; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Di Schiavi E, 2005, EUR J NEUROSCI, V21, P3291, DOI 10.1111/j.1460-9568.2005.04164.x; Dicker F, 2010, LEUKEMIA, V24, P1528, DOI 10.1038/leu.2010.124; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Graubert TA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004583; Greenberg, 1998, BLOOD, V91, P1100; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinrichs S, 2009, LEUKEMIA, V23, P1605, DOI 10.1038/leu.2009.82; HORIIKE S, 1994, LEUKEMIA, V8, P1331; Jasek M, 2010, LEUKEMIA, V24, P216, DOI 10.1038/leu.2009.189; LAI JL, 1995, LEUKEMIA, V9, P370; Larson RA, 2007, BEST PRACT RES CL HA, V20, P29, DOI 10.1016/j.beha.2006.10.006; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Notta F, 2011, NATURE, V471, DOI 10.1038/nature09877; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Schnittger S, 2011, LEUKEMIA, V25, P615, DOI 10.1038/leu.2010.299; Shih LY, 2004, LEUKEMIA, V18, P466, DOI 10.1038/sj.leu.2403274; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Steensma DP, 2006, LEUKEMIA RES, V30, P1227, DOI 10.1016/j.leukres.2005.12.001; VANKAMP H, 1992, BLOOD, V79, P1266, DOI 10.1182/blood.V79.5.1266.bloodjournal7951266; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Walter MJ, 2009, P NATL ACAD SCI USA, V106, P12950, DOI 10.1073/pnas.0903091106	39	566	585	3	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1090	1098		10.1056/NEJMoa1106968	http://dx.doi.org/10.1056/NEJMoa1106968			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22417201	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000301769700008
J	O'Flynn, N; Staniszewska, S				O'Flynn, Norma; Staniszewska, Sophie		Guideline Dev Grp	Improving the experience of care for people using NHS services: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[O'Flynn, Norma] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England; [Staniszewska, Sophie] Univ Warwick, Royal Coll, Nursing Res Inst, Warwick, England	Royal College of Physicians; University of Warwick	O'Flynn, N (corresponding author), Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England.	norma.oflynn@rcplondon.ac.uk						Darzi A., 2008, HIGH QUALITY CARE AL; Goodrich J, 2008, SEEING PERSON PATIEN; National Institute for Health and Clinical Excellence (Great Britain) National Clinical Guideline Centre for Acute and Chronic Conditions, 2012, PAT EXP AD NHS SERV; National Quality Board, 2012, NHS PAT EXP FRAM; Staniszewska S, 2011, PATIENT EXPERIENCES; The NHS Confederation, 2010, FEEL BETT IMPR PAT E	6	8	8	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	2012	344								d6422	10.1136/bmj.d6422	http://dx.doi.org/10.1136/bmj.d6422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CE	22427271				2022-12-28	WOS:000301848200001
J	Gee, H				Gee, Henry			DEVELOPMENTAL BIOLOGY A brainy background	NATURE			English	Editorial Material														Gee, Henry/0000-0002-9363-7654					0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					280	280		10.1038/483280a	http://dx.doi.org/10.1038/483280a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422257				2022-12-28	WOS:000301481800034
J	Bergh, S; Selbaek, G; Engedal, K				Bergh, Sverre; Selbaek, Geir; Engedal, Knut			Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NURSING-HOMES; CORNELL SCALE; PSYCHOTIC SYMPTOMS; ALZHEIMER-DISEASE; DEPRESSION; SERTRALINE; CITALOPRAM; EFFICACY; DISTURBANCES; RELIABILITY	Objective To determine the effect of discontinuing antidepressant treatment in people with dementia and neuropsychiatric symptoms. Design Double blind, randomised, parallel group, placebo controlled trial. Setting Norwegian nursing homes; residents recruited by 16 study centres in Norway from August 2008 to June 2010. Participants 128 patients with Alzheimer's disease, dementia or vascular dementia, and neuropsychiatric symptoms (but no depressive disorder), who had been prescribed escitalopram, citalopram, sertraline, or paroxetine for three months or more. We excluded patients with severe somatic disease or terminal illness, or who were unable to take tablets or capsules as prescribed. Interventions Antidepressant treatment was discontinued over one week in 63 patients, and continued in 68 patients. We assessed patients at baseline, four, seven, 13, and 25 weeks. Main outcome measures Primary outcomes were score differences between study groups in the Cornell scale of depression in dementia and the neuropsychiatric inventory (10 item version) after 25 weeks. Secondary outcomes were score differences in the clinical dementia rating scale, unified Parkinson's disease rating scale, quality of life-Alzheimer's disease scale, Lawton and Brody's physical self maintenance scale, and severe impairment battery. Results Using a linear multilevel model analysis, we found that the discontinued group had significantly higher scores on the Cornell scale after 25 weeks than the continuation group (difference -2.89 (95% confidence interval -4.76 to -1.02); P=0.003). We saw a similar result in the mean total score for the neuropsychiatric inventory after 25 weeks, but this difference was non-significant (-5.96 (-12.35 to 0.44); P=0.068). We confirmed these results by non-response analysis (>30% worsening on the Cornell scale)-significantly more patients worsened in the discontinuation group than in the continuation group (32 (54%) v 17 (29%); P=0.006). We found no significant differences between the groups for secondary outcomes. Forty seven (37%) patients withdrew from the study early. Conclusions Discontinuation of antidepressant treatment in patients with dementia and neuropsychiatric symptoms leads to an increase in depressive symptoms, compared with those patients who continue with treatment.	[Bergh, Sverre; Selbaek, Geir; Engedal, Knut] Innlandet Hosp Trust, Ctr Old Age Psychiat Res, N-2312 Ottestad, Norway; [Selbaek, Geir; Engedal, Knut] Oslo Univ Hosp, Norwegian Ctr Dementia Res, Oslo, Norway; [Engedal, Knut] Univ Oslo, Oslo, Norway	Innlandet Hospital Trust; University of Oslo; University of Oslo	Bergh, S (corresponding author), Innlandet Hosp Trust, Ctr Old Age Psychiat Res, N-2312 Ottestad, Norway.	sverre.bergh@sykehuset-innlandet.no		Selbaek, Geir/0000-0001-6511-8219	Innlandet Hospital Trust; Research Council of Norway; South-Eastern Norway Regional Health Authority	Innlandet Hospital Trust; Research Council of Norway(Research Council of Norway); South-Eastern Norway Regional Health Authority	The study was funded by unrestricted grants from the Innlandet Hospital Trust, the Research Council of Norway, and the South-Eastern Norway Regional Health Authority.	ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Bains J, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003944; Ballard C, 1997, ACTA NEUROL SCAND, V96, P366; Ballard C, 2010, CNS DRUGS, V24, P729, DOI 10.2165/11319240-000000000-00000; Banerjee S, 2011, LANCET, V378, P403, DOI 10.1016/S0140-6736(11)60830-1; Barca ML, 2008, INT J GERIATR PSYCH, V23, P1058, DOI 10.1002/gps.2033; Barca ML, 2010, DEMENT GERIATR COGN, V29, P438, DOI 10.1159/000313533; Barca ML, 2009, INT J GERIATR PSYCH, V24, P417, DOI 10.1002/gps.2139; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Bergh S, 2008, INT J GERIATR PSYCH, V23, P877, DOI 10.1002/gps.2008; Coupland C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4551; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Gaber S, 2001, ARCH GERONTOL GERIAT, P159; Henry G, 2011, AM J ALZHEIMERS DIS, V26, P169, DOI 10.1177/1533317511402051; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lyketsos CG, 2003, ARCH GEN PSYCHIAT, V60, P737, DOI 10.1001/archpsyc.60.7.737; Nelson JC, 2011, J AM GERIATR SOC, V59, P577, DOI 10.1111/j.1532-5415.2011.03355.x; NYTH AL, 1990, BRIT J PSYCHIAT, V157, P894, DOI 10.1192/bjp.157.6.894; PANISSET M, 1994, ARCH NEUROL-CHICAGO, V51, P41, DOI 10.1001/archneur.1994.00540130067012; Pollock BG, 2002, AM J PSYCHIAT, V159, P460, DOI 10.1176/appi.ajp.159.3.460; Pollock BG, 2007, AM J GERIAT PSYCHIAT, V15, P942, DOI 10.1097/JGP.0b013e3180cc1ff5; Rosenberg PB, 2010, AM J GERIAT PSYCHIAT, V18, P136, DOI 10.1097/JGP.0b013e3181c796eb; Seitz DP, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008191.pub2; Selbaek G, 2008, AM J GERIAT PSYCHIAT, V16, P528, DOI 10.1097/JGP.0b013e318167ae76; Selbaek G, 2007, INT J GERIATR PSYCH, V22, P843, DOI 10.1002/gps.1749; Selbaek G, 2012, INT PSYCHOGERIATR, V24, P62, DOI 10.1017/S104161021100086X; Siddique H, 2009, J CLIN PSYCHIAT, V70, P915, DOI 10.4088/JCP.08m04828; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; Steinberg M, 2004, INT J GERIATR PSYCH, V19, P19, DOI 10.1002/gps.1025; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; Weintraub D, 2010, AM J GERIAT PSYCHIAT, V18, P332, DOI 10.1097/JGP.0b013e3181cc0333; Wetzels R, 2010, INT PSYCHOGERIATR, V22, P1040, DOI 10.1017/S1041610210000918; Wetzels RB, 2010, AM J GERIAT PSYCHIAT, V18, P1054, DOI 10.1097/JGP.0b013e3181f60fa1	33	80	80	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2012	344								e1566	10.1136/bmj.e1566	http://dx.doi.org/10.1136/bmj.e1566			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908HS	22408266	hybrid			2022-12-28	WOS:000301482100001
J	Xiao, SH; Knoll, AH; Schiffbauer, JD; Zhou, CM; Yuan, XL				Xiao, Shuhai; Knoll, Andrew H.; Schiffbauer, James D.; Zhou, Chuanming; Yuan, Xunlai			Comment on "Fossilized Nuclei and Germination Structures Identify Ediacaran 'Animal Embryos' as Encysting Protists"	SCIENCE			English	Editorial Material							NEOPROTEROZOIC DOUSHANTUO FORMATION; SOUTH CHINA; ICHTHYOSPOREA; MICROFOSSILS; EVOLUTION; ALGAE		[Xiao, Shuhai; Schiffbauer, James D.] Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA; [Knoll, Andrew H.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Schiffbauer, James D.] Virginia Polytech Inst & State Univ, Inst Crit Technol & Appl Sci, Nanoscale Characterizat & Fabricat Lab, Blacksburg, VA 24061 USA; [Zhou, Chuanming; Yuan, Xunlai] Chinese Acad Sci, Nanjing Inst Geol & Paleontol, State Key Lab Paleobiol & Stratig, Nanjing 210008, Peoples R China	Virginia Polytechnic Institute & State University; Harvard University; Virginia Polytechnic Institute & State University; Chinese Academy of Sciences; Nanjing Institute of Geology & Paleontology, CAS	Xiao, SH (corresponding author), Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA.	xiao@vt.edu	Zhou, Chuanming/E-5313-2010; Xiao, Shuhai/A-2190-2009	Xiao, Shuhai/0000-0003-4655-2663; Schiffbauer, James/0000-0003-4726-0355				Belk D, 1998, J CRUSTACEAN BIOL, V18, P147, DOI 10.2307/1549529; Cohen PA, 2009, P NATL ACAD SCI USA, V106, P6519, DOI 10.1073/pnas.0902322106; Dong Xi-ping, 2009, Acta Palaeontologica Sinica, V48, P390; Dong XP, 2009, ACTA GEOL SIN-ENGL, V83, P429, DOI 10.1111/j.1755-6724.2009.00066.x; Eitel M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019639; Fan XP, 2011, INT J SYST EVOL MICR, V61, P1476, DOI 10.1099/ijs.0.024794-0; Hagadorn JW, 2006, SCIENCE, V314, P291, DOI 10.1126/science.1133129; Huldtgren T, 2011, SCIENCE, V334, P1696, DOI 10.1126/science.1209537; Knoll AH, 2011, ANNU REV EARTH PL SC, V39, P217, DOI 10.1146/annurev.earth.031208.100209; Laflamme M, 2009, P NATL ACAD SCI USA, V106, P14438, DOI 10.1073/pnas.0904836106; Lohr JN, 2010, J EUKARYOT MICROBIOL, V57, P328, DOI 10.1111/j.1550-7408.2010.00479.x; Marshall CR, 2010, EVOLUTION, V64, P1189, DOI 10.1111/j.1558-5646.2009.00908.x; Marshall WL, 2010, MOL BIOL EVOL, V27, P2014, DOI 10.1093/molbev/msq078; Mendoza L, 1999, MYCOPATHOLOGIA, V148, P9, DOI 10.1023/A:1007108910025; Mendoza L, 2002, ANNU REV MICROBIOL, V56, P315, DOI 10.1146/annurev.micro.56.012302.160950; Mikhailov KV, 2009, BIOESSAYS, V31, P758, DOI 10.1002/bies.200800214; Petryshyn VA, 2013, PRECAMBRIAN RES, V225, P58, DOI 10.1016/j.precamres.2011.08.003; Raff EC, 2006, P NATL ACAD SCI USA, V103, P5846, DOI 10.1073/pnas.0601536103; Schiffbauer JD, 2012, GEOLOGY, V40, P223, DOI 10.1130/G32546.1; Sergeev VN, 2011, J PALEONTOL, V85, P987, DOI 10.1666/11-022.1; Sperling EA, 2010, EVOL DEV, V12, P201, DOI 10.1111/j.1525-142X.2010.00404.x; Xiao S., 2008, FOSSILS ASTROBIOLOGY, P89; Xiao SH, 2000, J PALEONTOL, V74, P767, DOI 10.1666/0022-3360(2000)074<0767:PAEFTN>2.0.CO;2; Xiao SH, 2000, P NATL ACAD SCI USA, V97, P13684, DOI 10.1073/pnas.250491697; Xiao SH, 2004, AM J BOT, V91, P214, DOI 10.3732/ajb.91.2.214; Xiao SH, 2002, PALEOBIOLOGY, V28, P244, DOI 10.1666/0094-8373(2002)028<0244:MTAMON>2.0.CO;2	26	27	31	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073								10.1126/science.1218814	http://dx.doi.org/10.1126/science.1218814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403373				2022-12-28	WOS:000301225100024
J	Seal, KH; Shi, Y; Cohen, G; Cohen, BE; Maguen, S; Krebs, EE; Neylan, TC				Seal, Karen H.; Shi, Ying; Cohen, Gregory; Cohen, Beth E.; Maguen, Shira; Krebs, Erin E.; Neylan, Thomas C.			Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; VIETNAM COMBAT VETERANS; CHRONIC NONCANCER PAIN; PRIMARY-CARE PATIENTS; MEDICATION USE; WAR; PREVALENCE; SYMPTOMS; PTSD	Context Record numbers of Iraq and Afghanistan veterans survive their war injuries and yet continue to experience pain and mental health problems, particularly post-traumatic stress disorder (PTSD). Little is known about the association of mental health disorders and prescription opioid use. Objective To investigate the effect of mental health disorders, particularly PTSD, on risks and adverse clinical outcomes associated with prescription opioid use. Design Retrospective cohort study involving 141 029 Iraq and Afghanistan veterans who received at least 1 non-cancer-related pain diagnosis within 1 year of entering the Department of Veterans Affairs (VA) health care system from October 1, 2005, through December 31, 2010. Main Outcome Measures Independent association of mental health disorders and the prescription of opioids, higher risk opioid use, and adverse clinical outcomes (eg, accidents and overdose) within 1 year of receiving a pain-related diagnosis. Results A total of 15 676 veterans were prescribed opioids within 1 year of their initial pain diagnosis. Compared with 6.5% of veterans without mental health disorders, 17.8% (adjusted relative risk [RR], 2.58; 95% CI, 2.49-2.67) of veterans with PTSD and 11.7% (adjusted RR, 1.74; 95% CI, 1.67-1.82) with other mental health diagnoses but without PTSD were significantly more likely to receive opioids for pain diagnoses. Of those who were prescribed pain medication, veterans with PTSD were more likely than those without mental health disorders to receive higher-dose opioids (22.7% vs 15.9%, adjusted RR, 1.42; 95% CI, 1.31-1.54), receive 2 or more opioids concurrently (19.8% vs 10.7%, adjusted RR, 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted RR, 5.46; 95% CI, 4.91-6.07), or obtain early opioid refills (33.8% vs 20.4%; adjusted RR, 1.64; 95% CI, 1.531.75). Receiving prescription opioids (vs not) was associated with an increased risk of adverse clinical outcomes for all veterans (9.5% vs 4.1%; RR, 2.33; 95% CI, 2.20-2.46), which was most pronounced in veterans with PTSD. Conclusion Among US veterans of Iraq and Afghanistan, mental health diagnoses, especially PTSD, were associated with an increased risk of receiving opioids for pain, high-risk opioid use, and adverse clinical outcomes. JAMA. 2012;307(9):940-947 www.jama.com	[Seal, Karen H.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA; [Krebs, Erin E.] Indiana Univ Sch Med, Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA; [Krebs, Erin E.] Regenstrief Inst Inc, Indianapolis, IN USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, 4150 Clement St,POB 111A-1, San Francisco, CA 94121 USA.	karen.seal@ucsf.edu		Krebs, Erin/0000-0003-0843-7410	Department of Veterans Affairs (VA), Health Services Research and Development (HSRD) at the San Francisco VA Medical Center; VA HSRD [RCD 06-042, CD2 07-215]; National Institutes of Health, National Heart, Lung, and Blood Institute [K23 HL 094765-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL094765] Funding Source: NIH RePORTER	Department of Veterans Affairs (VA), Health Services Research and Development (HSRD) at the San Francisco VA Medical Center(US Department of Veterans Affairs); VA HSRD; National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was financially supported by the Department of Veterans Affairs (VA), Health Services Research and Development (HSRD) Research Enhancement Award Program at the San Francisco VA Medical Center (Dr Seal), by VA HSRD Career Development Awards RCD 06-042 (Dr Maguen), and CD2 07-215 (Dr Krebs), and grant K23 HL 094765-01 from the National Institutes of Health, National Heart, Lung, and Blood Institute (Dr Cohen).	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andersen J, 2010, PSYCHOSOM MED, V72, P498, DOI 10.1097/PSY.0b013e3181d969a1; Becker WC, 2007, DRUG ALCOHOL DEPEN, V90, P280, DOI 10.1016/j.drugalcdep.2007.04.009; Beckham JC, 1998, AM J PSYCHIAT, V155, P1565, DOI 10.1176/ajp.155.11.1565; Braden JB, 2010, ARCH INTERN MED, V170, P1425, DOI 10.1001/archinternmed.2010.273; BRAUN P, 1990, J CLIN PSYCHIAT, V51, P236; Bremner JD, 1996, AM J PSYCHIAT, V153, P369; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Dao J, 2011, NY TIMES        0212; Department of Veterans Affairs; Department of Defense, 2003, VA DOD CLIN PRACT GU; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Friedman MJ, 2000, J CLIN PSYCHIAT, V61, P44; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Harris KM, 2005, HEALTH SERV RES, V40, P117, DOI 10.1111/j.1475-6773.2005.00345.x; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2011, JAMA-J AM MED ASSOC, V306, P549, DOI 10.1001/jama.2011.1096; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2009, JAMA-J AM MED ASSOC, V301, P2099, DOI 10.1001/jama.2009.723; Levinson L, 2011, HUFFINGTON POST 0221; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mills KL, 2005, PSYCHIAT SERV, V56, P940, DOI 10.1176/appi.ps.56.8.940; Morasco BJ, 2008, GEN HOSP PSYCHIAT, V30, P93, DOI 10.1016/j.genhosppsych.2007.12.004; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Phifer J, 2011, PAIN, V152, P2233, DOI 10.1016/j.pain.2011.04.019; Sansone RA, 2004, GEN HOSP PSYCHIAT, V26, P415, DOI 10.1016/j.genhosppsych.2004.07.003; Sayer NA, 2009, PSYCHIATRY, V72, P238, DOI 10.1521/psyc.2009.72.3.238; Schwartz AC, 2006, PSYCHOSOMATICS, V47, P136, DOI 10.1176/appi.psy.47.2.136; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Skurtveit S, 2010, PAIN MED, V11, P805, DOI 10.1111/j.1526-4637.2010.00870.x; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; Stecker T, 2010, PSYCHOSOMATICS, V51, P503, DOI 10.1176/appi.psy.51.6.503; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2010, PAIN, V151, P567, DOI 10.1016/j.pain.2010.08.036; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Warner Margaret, 2009, NCHS Data Brief, P1; Wu Phipson C, 2010, J Opioid Manag, V6, P133	52	359	360	3	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					940	947		10.1001/jama.2012.234	http://dx.doi.org/10.1001/jama.2012.234			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396516				2022-12-28	WOS:000301172100022
J	Chao, WCH; Kulkarni, K; Zhang, ZG; Kong, EH; Barford, D				Chao, William C. H.; Kulkarni, Kiran; Zhang, Ziguo; Kong, Eric H.; Barford, David			Structure of the mitotic checkpoint complex	NATURE			English	Article							ANAPHASE-PROMOTING COMPLEX; SPINDLE-ASSEMBLY CHECKPOINT; KEN BOX; PSEUDOSUBSTRATE INHIBITION; MAD2 ACTIVATION; PROTEIN MAD2; CDC20; BINDING; BUBR1; APC/C	In mitosis, the spindle assembly checkpoint (SAC) ensures genome stability by delaying chromosome segregation until all sister chromatids have achieved bipolar attachment to the mitotic spindle. The SAC is imposed by the mitotic checkpoint complex (MCC), whose assembly is catalysed by unattached chromosomes and which binds and inhibits the anaphase-promoting complex/cyclosome (APC/C), the E3 ubiquitin ligase that initiates chromosome segregation. Here, using the crystal structure of Schizosaccharomyces pombe MCC(a complex of mitotic spindle assembly checkpoint proteins Mad2, Mad3 and APC/C co-activator protein Cdc20), we reveal the molecular basis of MCC-mediated APC/C inhibition and the regulation of MCC assembly. The MCC inhibits the APC/C by obstructing degron recognition sites on Cdc20 (the substrate recruitment subunit of the APC/C) and displacing Cdc20 to disrupt formation of a bipartite D-box receptor with the APC/C subunit Apc10. Mad2, in the closed conformation (C-Mad2), stabilizes the complex by optimally positioning the Mad3 KEN-box degron to bind Cdc20. Mad3 and p31(comet) (also known as MAD2L1-binding protein) compete for the same C-Mad2 interface, which explains how p31(comet) disrupts MCC assembly to antagonize the SAC. This study shows how APC/C inhibition is coupled to degron recognition by co-activators.	[Chao, William C. H.; Kulkarni, Kiran; Zhang, Ziguo; Kong, Eric H.; Barford, David] Inst Canc Res, Chester Beatty Labs, Div Struct Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Barford, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Div Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	david.barford@icr.ac.uk		Zhang, Ziguo/0000-0002-7268-9631; Barford, David/0000-0001-8810-950X	Cancer Research UK; ICR; Cancer Research UK [14109] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); ICR; Cancer Research UK(Cancer Research UK)	work was funded by a Cancer Research UK grant to D.B. and an ICR studentship to W.C.H.C. We thank J. Yang and J. He for advice, and staff at the Diamond Light Source beamline I02 for help with data collection.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Barford D, 2011, Q REV BIOPHYS, V44, P153, DOI 10.1017/S0033583510000259; Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Carroll CW, 2005, CURR BIOL, V15, P11, DOI 10.1016/j.cub.2004.12.066; Choi E, 2008, J BIOL CHEM, V283, P23701, DOI 10.1074/jbc.M803695200; D'Arcy S, 2010, J BIOL CHEM, V285, P14764, DOI 10.1074/jbc.M109.082016; da Fonseca PCA, 2011, NATURE, V470, P274, DOI 10.1038/nature09625; Davenport J, 2006, EXP CELL RES, V312, P1831, DOI 10.1016/j.yexcr.2006.02.018; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Herzog F, 2009, SCIENCE, V323, P1477, DOI 10.1126/science.1163300; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kim S., 2011, SEMIN CELL DEV BIOL; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Kimata Y, 2008, DEV CELL, V14, P446, DOI 10.1016/j.devcel.2007.12.010; Kimata Y, 2008, MOL CELL, V32, P576, DOI 10.1016/j.molcel.2008.09.023; King EMJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000342; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kulukian A, 2009, DEV CELL, V16, P105, DOI 10.1016/j.devcel.2008.11.005; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Luo XL, 2008, STRUCTURE, V16, P1616, DOI 10.1016/j.str.2008.10.002; Malureanu LA, 2009, DEV CELL, V16, P118, DOI 10.1016/j.devcel.2008.11.004; Mapelli M, 2007, CELL, V131, P730, DOI 10.1016/j.cell.2007.08.049; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Ostapenko D, 2008, MOL CELL BIOL, V28, P4653, DOI 10.1128/MCB.00055-08; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Pan J, 2004, GENE DEV, V18, P1439, DOI 10.1101/gad.1184204; Passmore LA, 2005, METHOD ENZYMOL, V398, P195, DOI 10.1016/S0076-6879(05)98017-8; Pfleger CM, 2000, GENE DEV, V14, P655; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Schreiber A, 2011, NATURE, V470, P227, DOI 10.1038/nature09756; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Sczaniecka M, 2008, J BIOL CHEM, V283, P23039, DOI 10.1074/jbc.M803594200; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Song JJ, 2008, J BIOL CHEM, V283, P35258, DOI 10.1074/jbc.M806900200; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Tipton AR, 2011, J BIOL CHEM, V286, P21173, DOI 10.1074/jbc.M111.238543; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Westhorpe FG, 2011, J CELL SCI, V124, P3905, DOI 10.1242/jcs.093286; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Yang MJ, 2008, PLOS BIOL, V6, P643, DOI 10.1371/journal.pbio.0060050; Yang MJ, 2007, CELL, V131, P744, DOI 10.1016/j.cell.2007.08.048; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	61	215	223	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					208	U89		10.1038/nature10896	http://dx.doi.org/10.1038/nature10896			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22437499				2022-12-28	WOS:000303149900028
J	Antonetti, DA; Klein, R; Gardner, TW				Antonetti, David A.; Klein, Ronald; Gardner, Thomas W.			Mechanisms of Disease Diabetic Retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; RETINAL INSULIN-RECEPTOR; BLOOD-BRAIN-BARRIER; OCCLUDIN PHOSPHORYLATION; VASCULAR-PERMEABILITY; GLYCEMIC CONTROL; LAYER THICKNESS; MACULAR EDEMA; RISK-FACTORS; PROGRESSION		[Antonetti, David A.; Gardner, Thomas W.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA; [Antonetti, David A.; Gardner, Thomas W.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA; [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Gardner, TW (corresponding author), Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.	tomwgard@umich.edu		antonetti, david/0000-0003-1130-6577; Gardner, Thomas/0000-0002-5112-5810; Klein, Ronald/0000-0002-4428-6237	Apogee Biotechnology; Alcon; AstraZeneca; Novartis; Eli Lilly; Merck; Sanofi Aventis; GlaxoSmithKline; Pfizer; Genentech; Takeda; Comentis; Allegan; Clarus	Apogee Biotechnology; Alcon(Novartis); AstraZeneca(AstraZeneca); Novartis(Novartis); Eli Lilly(Eli Lilly); Merck(Merck & Company); Sanofi Aventis(Sanofi-Aventis); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Genentech(Roche HoldingGenentech); Takeda(Takeda Pharmaceutical Company Ltd); Comentis; Allegan; Clarus	Dr. Antonetti reports receiving consulting fees from Apogee Biotechnology and Alcon and is a co-inventor of a protein kinase C zeta inhibitor, for which Penn State University holds patent rights; Dr. Klein, consulting fees from AstraZeneca, Novartis, Eli Lilly, Merck, Sanofi Aventis, GlaxoSmithKline, Pfizer, Genentech, Takeda, Comentis, and Allegan; and Dr. Gardner, consulting fees from Genentech, GlaxoSmithKline, Apogee Biotechnology, and Merck and payment for the development of educational presentations from Clarus, and he holds a patent regarding periocular drug delivery for diabetic retinopathy. No other potential conflict of interest relevant to this article was reported.	Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032; ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Aiello LP, 2007, ARCH OPHTHALMOL-CHIC, V125, P318; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Al-Rubeaan K., 2010, INT J DIABETES MELLI, V2, P71, DOI [10.1016/j.ijdm.2009.12.009, DOI 10.1016/J.IJDM.2009.12.009, 10.1016/j.ijdm.2010.06.001]; [Anonymous], 1978, Ophthalmology, V85, P82; Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x; Arnold E, 2010, DIABETES, V59, P3192, DOI 10.2337/db10-0873; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P3259, DOI 10.1167/iovs.04-0308; Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008; Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052; Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P626, DOI 10.1016/j.ophtha.2010.12.028; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9; Chew EY, 2011, NEW ENGL J MED, V364, P190; Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288; Clermont A, 2011, DIABETES, V60, P1590, DOI 10.2337/db10-1260; del Zoppo GJ, 2010, J INTERN MED, V267, P156, DOI 10.1111/j.1365-2796.2009.02199.x; Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138; Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647; Diabetic Retinopathy Clinical Research Network, 2010, OPHTHALMOLOGY, V117; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Felinski EA, 2008, EXP EYE RES, V86, P867, DOI 10.1016/j.exer.2008.01.002; Field MG, 2008, ARCH OPHTHALMOL-CHIC, V126, P934, DOI 10.1001/archopht.126.7.934; Fort PE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026498; Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534; Gardner TW, 2009, ACTA OPHTHALMOL, V87, P709, DOI 10.1111/j.1755-3768.2009.01545.x; Gastinger MJ, 2008, INVEST OPHTH VIS SCI, V49, P2635, DOI 10.1167/iovs.07-0683; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Gowda K, 2011, J NEUROCHEM, V117, P309, DOI 10.1111/j.1471-4159.2011.07206.x; Harhaj NS, 2006, INVEST OPHTH VIS SCI, V47, P5106, DOI 10.1167/iovs.06-0322; Harrison WW, 2011, INVEST OPHTH VIS SCI, V52, P6825, DOI 10.1167/iovs.11-7533; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hirsch IB, 2010, JAMA-J AM MED ASSOC, V303, P2291, DOI 10.1001/jama.2010.785; Holfort SK, 2011, DIABETOLOGIA, V54, P1853, DOI 10.1007/s00125-011-2149-x; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9; Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9; Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552; Klein R, 2010, DIABETES, V59, P1853, DOI 10.2337/db09-1904; Klein R, 2010, OPHTHALMOLOGY, V117, P63, DOI 10.1016/j.ophtha.2009.06.051; Klein R, 2008, CONTEMP DIABETES, P67, DOI 10.1007/978-1-59745-563-3_3; Kondo T, 2004, J BIOL CHEM, V279, P37997, DOI 10.1074/jbc.M401339200; Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675; Mann DM, 2009, ARCH INTERN MED, V169, P1718, DOI 10.1001/archinternmed.2009.296; Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631; Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400; Michaelides M, 2010, OPHTHALMOLOGY, V117; Murakami T, DIABETES IN PRESS; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nathan DM, 2009, ARCH INTERN MED, V169, P1307, DOI 10.1001/archinternmed.2009.193; Navaratna D, 2007, DIABETES, V56, P2380, DOI 10.2337/db06-1694; Nguyen TT, 2009, DIABETES CARE, V32, P1704, DOI 10.2337/dc09-0102; Nordwall M, 2004, DIABETOLOGIA, V47, P1266, DOI 10.1007/s00125-004-1431-6; Parravano M, 2008, BRIT J OPHTHALMOL, V92, P1656, DOI 10.1136/bjo.2008.143057; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; Pearson PA, 2011, OPHTHALMOLOGY, V118, P1580, DOI 10.1016/j.ophtha.2011.02.048; Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002; Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016; Rajala RVS, 2009, INVEST OPHTH VIS SCI, V50, P1033, DOI 10.1167/iovs.08-2851; Reiter CEN, 2006, DIABETES, V55, P1148, DOI 10.2337/diabetes.55.04.06.db05-0744; Rema M, 2005, INVEST OPHTH VIS SCI, V46, P2328, DOI 10.1167/iovs.05-0019; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335; Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JC133361, 10.1172/JCI33361]; Schram MT, 2005, DIABETOLOGIA, V48, P370, DOI 10.1007/s00125-004-1628-8; Scott IU, 2011, BR J OPHTHALMOL 1215; Seki M, 2004, DIABETES, V53, P2412, DOI 10.2337/diabetes.53.9.2412; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7; Sloan FA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1548, DOI 10.1001/archopht.126.11.1548; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594; Su EJ, 2009, J THROMB HAEMOST, V7, P155, DOI 10.1111/j.1538-7836.2009.03402.x; Suh Dong-Churl, 2009, J Hypertens, V27, P1908, DOI 10.1097/HJH.0b013e32832d4aee; Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045; Targher G, 2010, DIABETOLOGIA, V53, P1341, DOI 10.1007/s00125-010-1720-1; Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; van Dijk HW, 2010, INVEST OPHTH VIS SCI, V51, P3660, DOI 10.1167/iovs.09-5041; van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143; VanGuilder HD, 2008, EUR J NEUROSCI, V28, P1, DOI 10.1111/j.1460-9568.2008.06322.x; Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773; West SD, 2010, DIABETIC MED, V27, P423, DOI 10.1111/j.1464-5491.2010.02962.x; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Wright AD, 2011, EYE, V25, P842, DOI 10.1038/eye.2011.62; Yang JL, 2010, INVEST OPHTH VIS SCI, V51, P3273, DOI 10.1167/iovs.08-2878; Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65; Zietz B, 2008, EXP CLIN ENDOCR DIAB, V116, P532, DOI 10.1055/s-2008-1058086; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	97	1083	1141	18	117	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1227	1239		10.1056/NEJMra1005073	http://dx.doi.org/10.1056/NEJMra1005073			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455417				2022-12-28	WOS:000302005100011
J	Sessions, SY; Detsky, AS				Sessions, Samuel Y.; Detsky, Allan S.			The Severability of the Individual Mandate	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sessions, Samuel Y.] Harbor UCLA Med Ctr, Dept Psychiat & LA Biomed, Torrance, CA 90509 USA; [Sessions, Samuel Y.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA; [Sessions, Samuel Y.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA; [Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Sessions, SY (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat & LA Biomed, Torrance, CA 90509 USA.							Rosenbaum S, 2010, NEW ENGL J MED, V363, P1881, DOI 10.1056/NEJMp1010850; Sheils JF, 2011, HEALTH AFFAIR, V30, P2177, DOI 10.1377/hlthaff.2011.0708	2	0	0	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13								10.1056/NEJMp1201951	http://dx.doi.org/10.1056/NEJMp1201951			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915DW	22417202				2022-12-28	WOS:000302005100005
J	Glynn, J				Glynn, Jenifer			The art of medicine Remembering my sister Rosalind Franklin	LANCET			English	Biographical-Item									The Lancet, London NW7 1BY, England		Glynn, J (corresponding author), The Lancet, London NW7 1BY, England.							FRANKLIN R, PUBLICATION LIST	1	2	2	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1094	1095		10.1016/S0140-6736(12)60452-8	http://dx.doi.org/10.1016/S0140-6736(12)60452-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22451966				2022-12-28	WOS:000302131800019
J	Raviglione, M; Zumla, A; Marais, B; Horton, R; Motsoaledi, A				Raviglione, Mario; Zumla, Alimuddin; Marais, Ben; Horton, Richard; Motsoaledi, Aaron			A sustainable agenda for tuberculosis control and research	LANCET			English	Editorial Material									[Raviglione, Mario] WHO, STOP TB Dept, CH-1211 Geneva, Switzerland; [Zumla, Alimuddin] UCL, Dept Infect, Div Infect & Immun, London, England; [Marais, Ben] Univ Sydney, Sydney Inst Emerging Infect Dis & Biosecur, Sydney, NSW 2006, Australia; [Marais, Ben] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia; [Horton, Richard] The Lancet, London NW1 7BY, England; [Motsoaledi, Aaron] Govt S Africa, Minist Hlth, Pretoria, South Africa	World Health Organization; University of London; University College London; University of Sydney; University of Sydney	Raviglione, M (corresponding author), WHO, STOP TB Dept, CH-1211 Geneva, Switzerland.	raviglionem@who.int	ZUMLA, Alimuddin/ABA-8208-2020; Marais, Ben/AAX-2626-2021	ZUMLA, Alimuddin/0000-0002-5111-5735; RAVIGLIONE, Mario/0000-0002-9331-2067				[Anonymous], 2012, LANCET, V379, P193, DOI 10.1016/S0140-6736(12)60081-6; [Anonymous], 2011, LANCET, V378, P1198, DOI 10.1016/S0140-6736(11)61526-2; [Anonymous], 2012, RIO 20 UN C SUST DEV; Blas E, 2010, EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES, P261; Dye C, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P289; Lonnroth K, 2010, LANCET, V375, P1814, DOI 10.1016/S0140-6736(10)60483-7; Marais BJ, 2010, LANCET, V375, P2179, DOI 10.1016/S0140-6736(10)60554-5; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2011, POL STAT AUT REAL TI	9	16	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2012	379	9821					1077	1078		10.1016/S0140-6736(12)60373-0	http://dx.doi.org/10.1016/S0140-6736(12)60373-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22444391				2022-12-28	WOS:000302131800007
J	Gomory, F; Solovyov, M; Souc, J; Navau, C; Prat-Camps, J; Sanchez, A				Goemoery, Fedor; Solovyov, Mykola; Souc, Jan; Navau, Carles; Prat-Camps, Jordi; Sanchez, Alvaro			Experimental Realization of a Magnetic Cloak	SCIENCE			English	Article							GROUND-PLANE CLOAK; METAMATERIALS; INVISIBILITY	Invisibility to electromagnetic fields has become an exciting theoretical possibility. However, the experimental realization of electromagnetic cloaks has only been achieved starting from simplified approaches (for instance, based on ray approximation, canceling only some terms of the scattering fields, or hiding a bulge in a plane instead of an object in free space). Here, we demonstrate, directly from Maxwell equations, that a specially designed cylindrical superconductor-ferromagnetic bilayer can exactly cloak uniform static magnetic fields, and we experimentally confirmed this effect in an actual setup.	[Goemoery, Fedor; Solovyov, Mykola; Souc, Jan] Slovak Acad Sci, Inst Elect Engn, Bratislava 84104, Slovakia; [Navau, Carles; Prat-Camps, Jordi; Sanchez, Alvaro] Univ Autonoma Barcelona, Dept Fis, Grp Electromagnetisme, E-08193 Barcelona, Catalonia, Spain	Slovak Academy of Sciences; Institute of Electrical Engineering, SAS; Autonomous University of Barcelona	Sanchez, A (corresponding author), Univ Autonoma Barcelona, Dept Fis, Grp Electromagnetisme, E-08193 Barcelona, Catalonia, Spain.	alvar.sanchez@uab.cat	Prat-Camps, Jordi/Q-3911-2018; Navau, Carles/O-9936-2015; Solovyov, Mykola/J-5180-2018; Gömöry, Fedor/AAY-9694-2021; Prat-Camps, Jordi/M-1095-2016; Sanchez, Alvaro/C-7041-2008	Prat-Camps, Jordi/0000-0003-4306-0874; Navau, Carles/0000-0003-4763-5305; Solovyov, Mykola/0000-0002-1014-5938; Gömöry, Fedor/0000-0002-2278-5123; Sanchez, Alvaro/0000-0002-2988-0289	Consolider Project NANOSELECT [CSD2007-00041]; VEGA [2/0172/09]	Consolider Project NANOSELECT; VEGA(Vedecka grantova agentura MSVVaS SR a SAV (VEGA)European Commission)	We thank D.-X. Chen for valuable comments and Consolider Project NANOSELECT (CSD2007-00041) and VEGA 2/0172/09 for financial support.	Alitalo P, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3068749; Alu A, 2008, J OPT A-PURE APPL OP, V10, DOI 10.1088/1464-4258/10/9/093002; Chen HY, 2010, NAT MATER, V9, P387, DOI [10.1038/nmat2743, 10.1038/NMAT2743]; Chen XZ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1176; Edwards B, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.153901; Ergin T, 2010, SCIENCE, V328, P337, DOI 10.1126/science.1186351; Greenleaf A, 2003, PHYSIOL MEAS, V24, P413, DOI 10.1088/0967-3334/24/2/353; Leonhardt U, 2006, SCIENCE, V312, P1777, DOI 10.1126/science.1126493; Leonhardt U, 2011, NATURE, V471, P292, DOI 10.1038/471292a; Li JS, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.203901; Liu R, 2009, SCIENCE, V323, P366, DOI 10.1126/science.1166949; Ma HF, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1023; Magnus F, 2008, NAT MATER, V7, P295, DOI 10.1038/nmat2126; Navau C, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3154555; Pendry JB, 2006, SCIENCE, V312, P1780, DOI 10.1126/science.1125907; Perczel J, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/8/083007; Rabbers JJ, 2010, SUPERCOND SCI TECH, V23, DOI 10.1088/0953-2048/23/12/125003; Sanchez A, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/9/093034; Schurig D, 2006, SCIENCE, V314, P977, DOI 10.1126/science.1133628; Shalaev VM, 2008, SCIENCE, V322, P384, DOI 10.1126/science.1166079; Solovyov M, 2011, IEEE T APPL SUPERCON, V21, P3277, DOI 10.1109/TASC.2010.2086998; Vrba J, 2001, METHODS, V25, P249, DOI 10.1006/meth.2001.1238; Wood B, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/7/076208; Xie YY, 2007, IEEE T APPL SUPERCON, V17, P1981, DOI 10.1109/TASC.2007.898186; Zhang BL, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.033901	25	280	289	10	140	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1466	1468		10.1126/science.1218316	http://dx.doi.org/10.1126/science.1218316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442477				2022-12-28	WOS:000301837000039
J	Bhandari, N; Mazumder, S; Taneja, S; Sommerfelt, H; Strand, TA				Bhandari, Nita; Mazumder, Sarmila; Taneja, Sunita; Sommerfelt, Halvor; Strand, Tor A.		IMNCI Evaluation Study Grp	Effect of implementation of Integrated Management of Neonatal and Childhood Illness (IMNCI) programme on neonatal and infant mortality: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; BANGLADESH; NUTRITION; SURVIVAL; COST	Objective To evaluate the Indian Integrated Management of Neonatal and Childhood Illness (IMNCI) programme, which integrates improved treatment of illness for children with home visits for newborn care, to inform its scale-up. Design Cluster randomised trial. Setting 18 clusters (population 1.1 million) in Haryana, India. Participants 29 667 births in intervention clusters and 30 813 in control clusters. Intervention Community health workers were trained to conduct postnatal home visits and women's group meetings; physicians, nurses, and community health workers were trained to treat or refer sick newborns and children; supply of drugs and supervision were strengthened. Main outcome measures Neonatal and infant mortality; newborn care practices. Results The infant mortality rate (adjusted hazard ratio 0.85, 95% confidence interval 0.77 to 0.94) and the neonatal mortality rate beyond the first 24 hours (adjusted hazard ratio 0.86, 0.79 to 0.95) were significantly lower in the intervention clusters than in control clusters. The adjusted hazard ratio for neonatal mortality rate was 0.91 (0.80 to 1.03). A significant interaction was found between the place of birth and the effect of the intervention for all mortality outcomes except post-neonatal mortality rate. The neonatal mortality rate was significantly lower in the intervention clusters in the subgroup born at home (adjusted hazard ratio 0.80, 0.68 to 0.93) but not in the subgroup born in a health facility (1.06, 0.91 to1.23) (P value for interaction=0.001). Optimal newborn care practices were significantly more common in the intervention clusters. Conclusions Implementation of the IMNCI resulted in substantial improvement in infant survival and in neonatal survival in those born at home. The IMNCI should be a part of India's strategy to achieve the millennium development goal on child survival.	[Bhandari, Nita; Mazumder, Sarmila; Taneja, Sunita] Ctr Hlth Res & Dev, Soc Appl Studies, New Delhi 110016, India; [Sommerfelt, Halvor; Strand, Tor A.] Univ Bergen, Ctr Int Hlth, N-5020 Bergen, Norway; [Sommerfelt, Halvor; Strand, Tor A.] Norwegian Inst Publ Hlth, Oslo, Norway	University of Bergen; Norwegian Institute of Public Health (NIPH)	Bhandari, N (corresponding author), Ctr Hlth Res & Dev, Soc Appl Studies, 45 Kalu Sarai, New Delhi 110016, India.	CHRD@sas.org.in	Sommerfelt, Halvor/ABD-3552-2020; Mazumder, Sarmila/AAD-8952-2020; Strand, Tor/D-9836-2016	Sommerfelt, Halvor/0000-0002-5670-9786; Mazumder, Sarmila/0000-0003-4200-6112; Strand, Tor/0000-0002-4038-151X	World Health Organization, Geneva (through USAID); United Nations Children's Fund, New Delhi; Research Council of Norway [183722]	World Health Organization, Geneva (through USAID)(United States Agency for International Development (USAID)World Health Organization); United Nations Children's Fund, New Delhi; Research Council of Norway(Research Council of Norway)	The study was funded by the World Health Organization, Geneva (through an umbrella grant from USAID); the United Nations Children's Fund, New Delhi; and the GLOBVAC Program of the Research Council of Norway through grant No 183722. Individual scientists at WHO and Unicef contributed importantly to the planning, analysis, and reporting of this study. However, the central bodies of these agencies and the Research Council of Norway had no influence on how the data was collected, analysed, or presented. The corresponding author had full access to all data that were analysed and had final responsibility for the decision to submit the manuscript for publication.	Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Bang Abhay T, 2005, J Perinatol, V25 Suppl 1, pS108, DOI 10.1038/sj.jp.7211278; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Baqui AH, 2008, B WORLD HEALTH ORGAN, V86, P796, DOI 10.2471/BLT.07.042226; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Baqui AH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2826; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bhandari N, 2008, PEDIATRICS, V121, pE1279, DOI 10.1542/peds.2007-1939; Bhutta ZA, 2008, B WORLD HEALTH ORGAN, V86, P452, DOI 10.2471/BLT.07.045849; Bhutta ZA, 2011, LANCET, V377, P403, DOI 10.1016/S0140-6736(10)62274-X; Carlo WA, 2010, NEW ENGL J MED, V362, P614, DOI 10.1056/NEJMsa0806033; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Government of India Ministry of Health and Family Welfare, 2003, IMNCI TRAIN MOD PHYS; Government of India Ministry of Health and Family Welfare, 2003, INT MAN NEON CHILDH; Government of India Ministry of Health and Family Welfare, 2005, INT MAN NEON CHILDH; Government of India Ministry of Health and Family Welfare, 2003, IMNCI TRAIN MOD WORK; Government of India Ministry of Health and Family Welfare, 2005, NAT PROGR IMPL PLAN; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X; United Nations Children's Fund, 2010, LEV TRENDS CHILD MOR; World Health Organization, 1996, ESS NEWB CAR REP TEC; World Health Organization, 1998, IMCI AD GUID VERS 5; World Health Organization, 2003, INT MAN NEON CHILDH; World Health Organization, 2006, PREGN CHILDB POSTP N; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 1999, STAND VERB AUT METH	28	81	82	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2012	344								e1634	10.1136/bmj.e1634	http://dx.doi.org/10.1136/bmj.e1634			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CO	22438367	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000301849200001
J	Hickam, DH				Hickam, David H.			Ibuprofen plus acetaminophen reduced knee pain in the short-term more than acetaminophen but not ibuprofen	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									VA Med Ctr, Portland, OR USA		Hickam, DH (corresponding author), VA Med Ctr, Portland, OR USA.			Hickman, Heather/0000-0003-4168-4894				[Anonymous], 2007, TREATM PRIM 2 OST KN	1	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-12	10.7326/0003-4819-156-6-201203200-02012	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431698				2022-12-28	WOS:000303150900011
J	McNally, EM				McNally, Elizabeth M.			GENETICS Broken giant linked to heart failure	NATURE			English	Editorial Material							DILATED CARDIOMYOPATHY; TITIN		[McNally, Elizabeth M.] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; [McNally, Elizabeth M.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA.	emcnally@uchicago.edu	McNally, Elizabeth/W-4909-2019	McNally, Elizabeth/0000-0002-1221-719X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061322] Funding Source: Medline; NIAMS NIH HHS [U54 AR052646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Dellefave L, 2010, CURR OPIN CARDIOL, V25, P198, DOI 10.1097/HCO.0b013e328337ba52; Gautel M, 2011, PFLUG ARCH EUR J PHY, V462, P119, DOI 10.1007/s00424-011-0946-1; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Herman DS, 2012, NEW ENGL J MED, V366, P619, DOI 10.1056/NEJMoa1110186; Miller MK, 2004, TRENDS CELL BIOL, V14, P119, DOI 10.1016/j.tcb.2004.01.003; Nagueh SF, 2004, CIRCULATION, V110, P155, DOI 10.1161/01.CIR.0000135591.37759.AF; van Rijsingen IAW, 2012, J AM COLL CARDIOL, V59, P493, DOI 10.1016/j.jacc.2011.08.078	8	10	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					281	282		10.1038/483281a	http://dx.doi.org/10.1038/483281a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422258	Green Accepted			2022-12-28	WOS:000301481800035
J	Sharon, E				Sharon, Eran			Swell Approaches for Changing Polymer Shapes	SCIENCE			English	Editorial Material									Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Sharon, E (corresponding author), Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel.	erans@vms.huji.ac.il						Efrati E, 2009, J MECH PHYS SOLIDS, V57, P762, DOI 10.1016/j.jmps.2008.12.004; Kim J, 2012, SCIENCE, V335, P1201, DOI 10.1126/science.1215309; Nath U, 2003, SCIENCE, V299, P1404, DOI 10.1126/science.1079354; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820	4	9	14	4	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1179	1180		10.1126/science.1219020	http://dx.doi.org/10.1126/science.1219020			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403378				2022-12-28	WOS:000301225100030
J	Naylor, CD; Naylor, KT				Naylor, C. David; Naylor, Karline Treurnicht			Seven Provocative Principles for Health Care Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							11 COUNTRIES; MEDICAL-CARE; COSTS; PHYSICIANS		[Naylor, C. David] Univ Toronto, Dept Med, Toronto, ON M5S 1A5, Canada; [Naylor, Karline Treurnicht] Columbia Univ, MPH Program, New York, NY USA; [Naylor, Karline Treurnicht] Univ Western Ontario, London, ON N6A 3K7, Canada	University of Toronto; Columbia University; Western University (University of Western Ontario)	Naylor, CD (corresponding author), Univ Toronto, Dept Med, 27 Kings Coll Cir,Ste 206, Toronto, ON M5S 1A5, Canada.	david.naylor@utoronto.ca						Brook RH, 2011, JAMA-J AM MED ASSOC, V306, P650, DOI 10.1001/jama.2011.1136; FUCHS VR, 2004, HLTH AFF MILLWOOD S; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; MECHANIC D, 1978, NEW ENGL J MED, V298, P249, DOI 10.1056/NEJM197802022980505; Schoen C, 2011, HEALTH AFFAIR, V30, P2437, DOI 10.1377/hlthaff.2011.0923; Schoen C, 2010, HEALTH AFFAIR, V29, P2323, DOI 10.1377/hlthaff.2010.0862; Schoen C, 2009, HEALTH AFFAIR, V28, pW1171, DOI 10.1377/hlthaff.28.6.w1171	7	4	4	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					919	920		10.1001/jama.2012.252	http://dx.doi.org/10.1001/jama.2012.252			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904CU	22396512				2022-12-28	WOS:000301172100018
J	Son, MBF; Newburger, JW				Son, Mary Beth F.; Newburger, Jane W.			Management of Kawasaki disease: corticosteroids revisited	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; GAMMA-GLOBULIN; THERAPY		[Newburger, Jane W.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; [Son, Mary Beth F.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Newburger, JW (corresponding author), Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.	jane.newburger@cardio.chboston.org		Son, Mary Beth/0000-0002-7394-2862				Athappan G, 2009, CARDIOVASC J AFR, V20, P233; Burns JC, 2005, J PEDIATR-US, V146, P662, DOI 10.1016/j.jpeds.2004.12.022; Inoue Y, 2006, J PEDIATR-US, V149, P336, DOI 10.1016/j.jpeds.2006.05.025; KATO H, 1979, PEDIATRICS, V63, P175; Kawasaki T, 1967, Arerugi, V16, P178; Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865; Kobayashi T, 2012, LANCET, V379, P1613, DOI 10.1016/S0140-6736(11)61930-2; Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235; Newburger JW, 2004, CIRCULATION, V110, P2747, DOI 10.1161/01.CIR.0000145143.19711.78; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; Shinohara M, 1999, J PEDIATR-US, V135, P465, DOI 10.1016/S0022-3476(99)70169-1; Sleeper LA, 2011, J PEDIATR-US, V158, P831, DOI 10.1016/j.jpeds.2010.10.031; Sundel RP, 2003, J PEDIATR-US, V142, P611, DOI 10.1067/mpd.2003.191; Wallace CA, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e78; Wright DA, 1996, J PEDIATR-US, V128, P146, DOI 10.1016/S0022-3476(96)70447-X	15	13	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 28	2012	379	9826					1571	1572		10.1016/S0140-6736(12)60196-2	http://dx.doi.org/10.1016/S0140-6736(12)60196-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	934OB	22405252				2022-12-28	WOS:000303452600008
J	Li, GW; Oh, E; Weissman, JS				Li, Gene-Wei; Oh, Eugene; Weissman, Jonathan S.			The anti-Shine-Dalgarno sequence drives translational pausing and codon choice in bacteria	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBOSOMAL-RNA; IN-VIVO; ELONGATION; GENES; USAGE; TRANSCRIPTION; ABUNDANCE; REVEALS	Protein synthesis by ribosomes takes place on a linear substrate but at non-uniform speeds. Transient pausing of ribosomes can affect a variety of co-translational processes, including protein targeting and folding(1). These pauses are influenced by the sequence of the messenger RNA(2). Thus, redundancy in the genetic code allows the same protein to be translated at different rates. However, our knowledge of both the position and the mechanism of translational pausing in vivo is highly limited. Here we present a genome-wide analysis of translational pausing in bacteria by ribosome profiling-deep sequencing of ribosome-protected mRNA fragments(3-5). This approach enables the high-resolution measurement of ribosome density profiles along most transcripts at unperturbed, endogenous expression levels. Unexpectedly, we found that codons decoded by rare transfer RNAs do not lead to slow translation under nutrient-rich conditions. Instead, Shine-Dalgarno-(SD) 6-like features within coding sequences cause pervasive translational pausing. Using an orthogonal ribosome(7,8) possessing an altered anti-SD sequence, we show that pausing is due to hybridization between the mRNA and 16S ribosomal RNA of the translating ribosome. In protein-coding sequences, internal SD sequences are disfavoured, which leads to biased usage, avoiding codons and codon pairs that resemble canonical SD sites. Our results indicate that internal SD-like sequences are a major determinant of translation rates and a global driving force for the coding of bacterial genomes.	[Li, Gene-Wei; Oh, Eugene; Weissman, Jonathan S.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.	weissman@cmp.ucsf.edu		Oh, Eugene/0000-0003-1970-8423; Li, Gene-Wei/0000-0001-7036-8511; Weissman, Jonathan/0000-0003-2445-670X	Helen Hay Whitney Foundation; Howard Hughes Medical Institute	Helen Hay Whitney Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute)	We thank E. Reuman, D. Burkhardt, C. Jan, C. Gross, J. Elf and members of the Weissman laboratory for discussions; J. Dunn for ribosome profiling data on S. cerevisiae; C. Chu for help with sequencing; and J. Chin for orthogonal ribosome reagents and advice. This research was supported by the Helen Hay Whitney Foundation (to G. W. L.) and by the Howard Hughes Medical Institute (to J.S.W.).	ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; Baranov PV, 2002, EMBO REP, V3, P373, DOI 10.1093/embo-reports/kvf065; Burmann BM, 2010, SCIENCE, V328, P501, DOI 10.1126/science.1184953; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; Chiba S, 2011, P NATL ACAD SCI USA, V108, P6073, DOI 10.1073/pnas.1018343108; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; Elf J, 2005, PLOS COMPUT BIOL, V1, P14, DOI 10.1371/journal.pcbi.0010002; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; GUTMAN GA, 1989, P NATL ACAD SCI USA, V86, P3699, DOI 10.1073/pnas.86.10.3699; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; Ingolia NT, 2011, CELL, V147, P789, DOI 10.1016/j.cell.2011.10.002; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kanaya S, 1999, GENE, V238, P143, DOI 10.1016/S0378-1119(99)00225-5; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; Kramer G, 2009, NAT STRUCT MOL BIOL, V16, P589, DOI 10.1038/nsmb.1614; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; Li WZ, 2001, BIOINFORMATICS, V17, P282, DOI 10.1093/bioinformatics/17.3.282; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Oh E, 2011, CELL, V147, P1295, DOI 10.1016/j.cell.2011.10.044; PEDERSEN S, 1984, EMBO J, V3, P2895, DOI 10.1002/j.1460-2075.1984.tb02227.x; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Proshkin S, 2010, SCIENCE, V328, P504, DOI 10.1126/science.1184939; PRUSS BM, 1994, J BACTERIOL, V176, P2143; Rackham O, 2005, NAT CHEM BIOL, V1, P159, DOI 10.1038/nchembio719; Sezonov G, 2007, J BACTERIOL, V189, P8746, DOI 10.1128/JB.01368-07; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; SORENSEN MA, 1991, J MOL BIOL, V222, P265, DOI 10.1016/0022-2836(91)90211-N; VARENNE S, 1984, J MOL BIOL, V180, P549, DOI 10.1016/0022-2836(84)90027-5; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; Wen JD, 2008, NATURE, V452, P598, DOI 10.1038/nature06716; Wu M, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r151	37	435	449	5	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 26	2012	484	7395					538	U172		10.1038/nature10965	http://dx.doi.org/10.1038/nature10965			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931FF	22456704	Green Accepted, Green Submitted			2022-12-28	WOS:000303200400056
J	Schulz, C; Perdiguero, EG; Chorro, L; Szabo-Rogers, H; Cagnard, N; Kierdorf, K; Prinz, M; Wu, BS; Jacobsen, SEW; Pollard, JW; Frampton, J; Liu, KJ; Geissmann, F				Schulz, Christian; Perdiguero, Elisa Gomez; Chorro, Laurent; Szabo-Rogers, Heather; Cagnard, Nicolas; Kierdorf, Katrin; Prinz, Marco; Wu, Bishan; Jacobsen, Sten Eirik W.; Pollard, Jeffrey W.; Frampton, Jon; Liu, Karen J.; Geissmann, Frederic			A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells	SCIENCE			English	Article							MONONUCLEAR PHAGOCYTE SYSTEM; IMMUNOHISTOCHEMICAL LOCALIZATION; SELF-RENEWAL; AORTIC ENDOTHELIUM; LANGERHANS CELLS; MICROGLIA DERIVE; FLT3 EXPRESSION; ANTIGEN F4/80; YOLK-SAC; MACROPHAGES	Macrophages and dendritic cells (DCs) are key components of cellular immunity and are thought to originate and renew from hematopoietic stem cells (HSCs). However, some macrophages develop in the embryo before the appearance of definitive HSCs. We thus reinvestigated macrophage development. We found that the transcription factor Myb was required for development of HSCs and all CD11b(high) monocytes and macrophages, but was dispensable for yolk sac (YS) macrophages and for the development of YS-derived F4/80(bright) macrophages in several tissues, such as liver Kupffer cells, epidermal Langerhans cells, and microglia-cell populations that all can persist in adult mice independently of HSCs. These results define a lineage of tissue macrophages that derive from the YS and are genetically distinct from HSC progeny.	[Schulz, Christian; Perdiguero, Elisa Gomez; Chorro, Laurent; Geissmann, Frederic] Kings Coll London, CMCBI, London SE1 1UL, England; [Schulz, Christian; Perdiguero, Elisa Gomez; Chorro, Laurent; Geissmann, Frederic] Kings Coll London, Peter Gorer Dept Immunobiol, London SE1 9RT, England; [Szabo-Rogers, Heather; Liu, Karen J.] Kings Coll London, Dept Craniofacial Dev, London SE1 9RT, England; [Cagnard, Nicolas] Univ Paris 05, Plateforme Bioinformat, INSERM IRNEM IFR94, F-75015 Paris, France; [Kierdorf, Katrin; Prinz, Marco] Univ Freiburg, Dept Neuropathol, D-79106 Freiburg, Germany; [Kierdorf, Katrin; Prinz, Marco] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Wu, Bishan; Jacobsen, Sten Eirik W.] Univ Oxford, Haematopoiet Stem Cell Biol Lab, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England; [Pollard, Jeffrey W.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Ctr Study Reprod Biol & Womens Hlth, New York, NY 10461 USA; [Frampton, Jon] Univ Birmingham, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; University of Freiburg; University of Oxford; Yeshiva University; University of Birmingham	Geissmann, F (corresponding author), Kings Coll London, CMCBI, New Hunts House, London SE1 1UL, England.	frederic.geissmann@kcl.ac.uk	Kierdorf, Katrin/AAO-6288-2021; Schulz, Christian/J-8545-2012; Perdiguero, Elisa Gomez/U-2120-2018; Jacobsen, Sten Eirik W/D-3974-2018; Liu, Karen/F-2870-2010; Cagnard, Nicolas/K-2754-2014	Schulz, Christian/0000-0003-3878-7833; Perdiguero, Elisa Gomez/0000-0002-7717-7897; Jacobsen, Sten Eirik W/0000-0002-1362-3659; Liu, Karen/0000-0002-2483-2165; geissmann, frederic/0000-0001-5029-2468; Kierdorf, Katrin/0000-0002-9272-4780; Cagnard, Nicolas/0000-0002-9051-1896	German National Academy of Sciences Leopoldina [LPDS 2009-31]; Wellcome Trust [WT081880AIA]; U.K. Biotechnology and Biological Sciences Research Council [BB/E013872]; U.K. Medical Research Council [MRC G0900867]; European Research Council [ERC-2010-StG-261299 MPS2010]; Biotechnology and Biological Sciences Research Council [BB/I021922/1, BB/E013872/1] Funding Source: researchfish; Medical Research Council [G0900867, MC_UU_12009/5, G1002033, G0501838, G0801073] Funding Source: researchfish; BBSRC [BB/I021922/1, BB/E013872/1] Funding Source: UKRI; MRC [G1002033, G0801073, G0501838, MC_UU_12009/5, G0900867] Funding Source: UKRI	German National Academy of Sciences Leopoldina; Wellcome Trust(Wellcome TrustEuropean Commission); U.K. Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors are indebted to S. McKercher, Sanford-Burnham Medical Research Institute La Jolla, California, USA, for providing Pu.1<SUP>+/-</SUP> mice and to T. Boehm and C. Bleul, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany, for providing Flt3-Cre mice. We also thank P. Saha for help with surgical procedures; C. Trouillet for help with flow cytometry and general organization of the lab; A. McGuigan and the staff of the Biological Service Unit at King's College London (KCL), Guy's Campus, for support with mouse husbandry; and S. Heck and the Flow facility of the Biomedical Research Centre (BRC) at King's Health Partners. The data presented in this manuscript are tabulated in the main paper and the supplementary materials. MIAME data are available at www.ebi.ac.uk/ arrayexpress: GomezElisa_AgilentMouse, ArrayExpress accession: E-MEXP-3510. C. S. is supported by a fellowship program of the German National Academy of Sciences Leopoldina (LPDS 2009-31). K.J.L. is supported by the Wellcome Trust (WT081880AIA) and U.K. Biotechnology and Biological Sciences Research Council (BB/E013872). F. G. is the Arthritis Research U.K. Chair of Inflammation Biology, at KCL. This work was funded by grants MRC G0900867, from the U.K. Medical Research Council, and ERC-2010-StG-261299 MPS2010 from the European Research Council to F.G.	Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3; Aziz A, 2009, SCIENCE, V326, P867, DOI 10.1126/science.1176056; Bertrand JY, 2010, NATURE, V464, P108, DOI 10.1038/nature08738; Bertrand JY, 2005, BLOOD, V106, P3004, DOI 10.1182/blood-2005-02-0461; Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Buza-Vidas N, 2011, BLOOD, V118, P1544, DOI 10.1182/blood-2010-10-316232; Chorro L, 2009, J EXP MED, V206, P3089, DOI 10.1084/jem.20091586; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Cumano A, 2007, ANNU REV IMMUNOL, V25, P745, DOI 10.1146/annurev.immunol.25.022106.141538; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; HUME DA, 1984, ANAT REC, V210, P503, DOI 10.1002/ar.1092100311; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; HUME DA, 1984, P NATL ACAD SCI-BIOL, V81, P4174, DOI 10.1073/pnas.81.13.4174; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Klein I, 2007, BLOOD, V110, P4077, DOI 10.1182/blood-2007-02-073841; Liu K, 2009, SCIENCE, V324, P392, DOI 10.1126/science.1170540; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; MORRIS L, 1991, DEVELOPMENT, V112, P517; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Nakamura E, 2006, DEV DYNAM, V235, P2603, DOI 10.1002/dvdy.20892; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; REAMS WM, 1973, DEV BIOL, V31, P114, DOI 10.1016/0012-1606(73)90323-0; Samokhvalov IM, 2007, NATURE, V446, P1056, DOI 10.1038/nature05725; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; VANFURTH R, 1984, J EXP MED, V160, P1273, DOI 10.1084/jem.160.5.1273	40	1632	1685	7	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 6	2012	336	6077					86	90		10.1126/science.1219179	http://dx.doi.org/10.1126/science.1219179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920LG	22442384				2022-12-28	WOS:000302405400057
J	Reinhardt, C; Bergentall, M; Greiner, TU; Schaffner, F; Ostergren-Lunden, G; Petersen, LC; Ruf, W; Backhed, F				Reinhardt, Christoph; Bergentall, Mattias; Greiner, Thomas U.; Schaffner, Florence; Ostergren-Lunden, Gunnel; Petersen, Lars C.; Ruf, Wolfram; Backhed, Fredrik			Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling	NATURE			English	Article							FACTOR CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; FACTOR EXPRESSION; ANGIOGENESIS; HEMOSTASIS; MICE	The gut microbiota is a complex ecosystem that has coevolved with host physiology. Colonization of germ-free (GF) mice with a microbiota promotes increased vessel density in the small intestine(1), but little is known about the mechanisms involved. Tissue factor (TF) is themembrane receptor that initiates the extrinsic coagulation pathway(2), and it promotes developmental and tumour angiogenesis(3,4). Here we show that the gut microbiota promotes TF glycosylation associated with localization of TF on the cell surface, the activation of coagulation proteases, and phosphorylation of theTFcytoplasmic domain in the small intestine. Anti-TF treatment of colonized GF mice decreased microbiota-induced vascular remodelling and expression of the proangiogenic factor angiopoietin-1 (Ang-1) in the small intestine. Mice with a genetic deletion of theTFcytoplasmic domain or with hypomorphic TF (F3) alleles had a decreased intestinal vessel density. Coagulation proteases downstream of TF activate protease-activated receptor (PAR) signalling implicated in angiogenesis(5). Vesseldensity and phosphorylation of the cytoplasmic domain of TF were decreased in small intestine fromPAR1-deficient (F2r(-/-)) but not PAR2-deficient (F2rl1(-/-)) mice, and inhibition of thrombin showed that thrombin-PAR1 signalling was upstream of TF phosphorylation. Thus, the microbiota-induced extravascular TF-PAR1 signalling loop is a novel pathway thatmay bemodulated to influence vascular remodelling in the small intestine.	[Reinhardt, Christoph; Bergentall, Mattias; Greiner, Thomas U.; Ostergren-Lunden, Gunnel; Backhed, Fredrik] Univ Gothenburg, Sahlgrenska Ctr Cardiovasc & Metab Res, Wallenberg Lab, S-41345 Gothenburg, Sweden; [Reinhardt, Christoph; Bergentall, Mattias; Greiner, Thomas U.; Ostergren-Lunden, Gunnel; Backhed, Fredrik] Univ Gothenburg, Dept Mol & Clin Med, S-41345 Gothenburg, Sweden; [Reinhardt, Christoph] Univ Med Ctr Mainz, CTH, D-55131 Mainz, Germany; [Schaffner, Florence; Ruf, Wolfram] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Petersen, Lars C.] Novo Nordisk AS, Haemostasis Biol, DK-2760 Malov, Denmark; [Backhed, Fredrik] Univ Copenhagen, Fac Hlth Sci, Sect Metab Receptol & Enteroendocrinol, Novo Nordisk Fdn Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark	University of Gothenburg; University of Gothenburg; Johannes Gutenberg University of Mainz; Scripps Research Institute; Novo Nordisk; Novo Nordisk Foundation; University of Copenhagen	Backhed, F (corresponding author), Univ Gothenburg, Sahlgrenska Ctr Cardiovasc & Metab Res, Wallenberg Lab, S-41345 Gothenburg, Sweden.	fredrik.backhed@wlab.gu.se	Backhed, Fredrik/ABE-6613-2020	Backhed, Fredrik/0000-0002-4871-8818	Swedish Foundation for Strategic Research; Swedish Research Council; Torsten and Ragnar Soderberg's foundation; Petrus and Augusta Hedlund's foundation; Swedish federal government under LUA/ALF; National Institutes of Health [HL-60742, HL-77753]; European Union; German Federal Ministry of Education and Research [BMBF 01EO1003]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077753, R01HL060742] Funding Source: NIH RePORTER	Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council(Swedish Research CouncilEuropean Commission); Torsten and Ragnar Soderberg's foundation; Petrus and Augusta Hedlund's foundation; Swedish federal government under LUA/ALF; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank R. Perkins for editing the manuscript; C. Arvidsson, A. Hallen, S. Wagoner, M. Karlsson, D. O'Donell, S. Islam, N. Hormann and A. Mohammadzadeh for technical assistance; A. Hallen for providing Supplementary Fig. 16; and P. Lindahl, J. Gordon, C. Betsholtz, M. Bergo, A. Wichmann, V. Tremaroli, M. Levin and S. Massberg for comments and suggestions. We are grateful to D. Kirchhofer for the gift of 1H1 monoclonal anti-mouse TF antibody, J. Nichols at Amgen for mL4-3, N. Mackman for the low-TF mice, M. Anderson for the human TF knock-in mice, and J. Gordon for providing CR2-tox176 mice. This study was supported by the Swedish Foundation for Strategic Research, the Swedish Research Council, Torsten and Ragnar Soderberg's foundation, Petrus and Augusta Hedlund's foundation, and the Swedish federal government under the LUA/ALF agreement to F. B., National Institutes of Health grants HL-60742 and HL-77753 to W. R., and a Marie Curie Fellowship, a Marie Curie Reintegration Grant from the European Union and the German Federal Ministry of Education and Research (BMBF 01EO1003) to C.R.	Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037; Blackburn JS, 2008, AM J PATHOL, V173, P1736, DOI 10.2353/ajpath.2008.080512; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Camerer E, 1996, BLOOD, V88, P1339, DOI 10.1182/blood.V88.4.1339.bloodjournal8841339; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Dorfleutner A, 2003, BLOOD, V102, P3998, DOI 10.1182/blood-2003-04-1149; Falcon BL, 2009, AM J PATHOL, V175, P2159, DOI 10.2353/ajpath.2009.090391; Furlan-Freguia C, 2011, J CLIN INVEST, V121, P2932, DOI 10.1172/JCI46129; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; Kirchhofer D, 2005, J THROMB HAEMOST, V3, P1098, DOI 10.1111/j.1538-7836.2005.01253.x; Krudysz-Amblo J, 2010, J BIOL CHEM, V285, P3371, DOI 10.1074/jbc.M109.055178; Luther T, 1996, AM J PATHOL, V149, P101; Melis E, 2001, BIOCHEM BIOPH RES CO, V286, P580, DOI 10.1006/bbrc.2001.5425; MORE L, 1993, J CLIN PATHOL, V46, P703, DOI 10.1136/jcp.46.8.703; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Petersen LC, 2005, THROMB RES, V116, P75, DOI 10.1016/j.thromres.2004.11.003; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaffner F, 2010, BLOOD, V116, P6106, DOI 10.1182/blood-2010-06-289314; Snyder LA, 2008, J THROMB HAEMOST, V6, P306, DOI 10.1111/j.1538-7836.2007.02833.x; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; van den Berg YW, 2009, P NATL ACAD SCI USA, V106, P19497, DOI 10.1073/pnas.0905325106; ZIONCHECK TF, 1992, J BIOL CHEM, V267, P3561	34	172	182	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 29	2012	483	7391					627	U155		10.1038/nature10893	http://dx.doi.org/10.1038/nature10893			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22407318	Green Accepted			2022-12-28	WOS:000302006100045
J	Ferguson, J; Docherty, G; Bauld, L; Lewis, S; Lorgelly, P; Boyd, KA; McEwen, A; Coleman, T				Ferguson, Janet; Docherty, Graeme; Bauld, Linda; Lewis, Sarah; Lorgelly, Paula; Boyd, Kathleen Anne; McEwen, Andy; Coleman, Tim			Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING-CESSATION; CIGARETTE; SMOKERS	Objective To compare the effects of free nicotine replacement therapy or proactive telephone counselling in addition to standard smoking cessation support offered through a telephone quitline. Design Parallel group, 2x2 factorial, randomised controlled trial. Setting National quitline, England. Participants 2591 non-pregnant smokers aged 16 or more residing in England who called the quitline between February 2009 and February 2010 and agreed to set a quit date: 648 were each randomised to standard support, proactive support, or proactive support with nicotine replacement therapy, and 647 were randomised to standard support with nicotine replacement therapy. Interventions Two interventions were offered in addition to standard support: six weeks' nicotine replacement therapy, provided free, and proactive counselling sessions (repeat telephone calls from, and interaction with, cessation advisors). Main outcome measures The primary outcome was self reported smoking cessation for six or more months after the quit date. The secondary outcome was cessation validated by exhaled carbon monoxide measured at six or more months. Results At six months, 17.7% (n=229) of those offered nicotine replacement therapy reported smoking cessation compared with 20.1% (n=261) not offered such therapy (odds ratio 0.85, 95% confidence interval 0.70 to 1.04), and 18.2% (n=236) offered proactive counselling reported smoking cessation compared with 19.6% (n=254) offered standard support (0.91, 0.75 to 1.11). Data validated by carbon monoxide readings changed the findings for nicotine replacement therapy only, with smoking cessation validated in 6.6% (85/1295) of those offered nicotine replacement therapy compared with 9.4% (122/1296) not offered such therapy (0.67, 0.50 to 0.90). Conclusions Offering free nicotine replacement therapy or additional (proactive) counselling to standard helpline support had no additional effect on smoking cessation.	[Coleman, Tim] Univ Nottingham, Sch Med, Queens Med Ctr, UK Ctr Tobacco Control Studies,Div Primary Care, Nottingham NG7 2RD, England; [Coleman, Tim] Univ Nottingham, Sch Med, Queens Med Ctr, NIHR Sch Primary Care Res, Nottingham NG7 2RD, England; [Docherty, Graeme; Lewis, Sarah] Univ Nottingham, City Hosp Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Docherty, Graeme; Lewis, Sarah] Univ Nottingham, City Hosp Nottingham, UK Ctr Tobacco Control Studies, Nottingham NG7 2RD, England; [McEwen, Andy] UCL, UCL Epidemiol & Publ Hlth, London WC1E 6BT, England; [McEwen, Andy] UCL, UK Ctr Tobacco Control Studies, London WC1E 6BT, England; [Lorgelly, Paula] Monash Univ, Ctr Hlth Econ, Clayton, Vic 3800, Australia; [Ferguson, Janet; Boyd, Kathleen Anne] Univ Glasgow, Ctr Populat & Hlth Sci, Glasgow G12 8QQ, Lanark, Scotland; [Bauld, Linda] Univ Stirling, Stirling Management Sch, Stirling FK9 4LA, Scotland; [Bauld, Linda] Univ Stirling, UK Ctr Tobacco Control Studies, Stirling FK9 4LA, Scotland	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of London; University College London; University of London; University College London; Monash University; University of Glasgow; University of Stirling; University of Stirling	Coleman, T (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, UK Ctr Tobacco Control Studies,Div Primary Care, Nottingham NG7 2RD, England.	tim.coleman@nottingham.ac.uk		Docherty, Graeme/0000-0002-4996-5554; Lorgelly, Paula/0000-0002-8990-9514; Coleman, Tim/0000-0002-7303-4805; Boyd, Kathleen/0000-0002-9764-0113	English Department of Health; UK Centre for Tobacco Control Studies The Department of Health; Cancer Research UK [14135] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish	English Department of Health; UK Centre for Tobacco Control Studies The Department of Health; Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This study was funded by the English Department of Health, with additional funding from the UK Centre for Tobacco Control Studies The Department of Health paid for the nicotine replacement therapy. Views expressed in this publication are those of the authors and not necessarily those of the Department of Health. No third party (including funder) has reviewed or influenced the writing of this manuscript.	An LC, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.014555; Carlin-Menter S, 2011, J PUBLIC HEALTH MAN, V17, pE9, DOI 10.1097/PHH.0b013e318208e730; EQ-5D, 2011, EQ5D; Ferguson J, 2005, ADDICTION, V100, P59, DOI 10.1111/j.1360-0443.2005.01028.x; Fidler JA, 2011, ADDICTION, V106, P631, DOI 10.1111/j.1360-0443.2010.03226.x; Gilbert H, 2006, ADDICTION, V101, P590, DOI 10.1111/j.1360-0443.2006.01398.x; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Hollis JF, 2007, TOB CONTROL, V16, pI53, DOI 10.1136/tc.2006.019794; Hughes J., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000031.PUB2; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub4, 10.1002/14651858.CD000031.pub3]; Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; McAfee TA, 2008, AM J PREV MED, V35, P103, DOI 10.1016/j.amepre.2008.04.017; McNeill A, 2005, ADDICTION, V100, P1, DOI 10.1111/j.1360-0443.2005.01022.x; Murray RL, 2009, ADDICTION, V104, P1901, DOI 10.1111/j.1360-0443.2009.02647.x; Ossip DJ, 2009, NICOTINE TOB RES, V11, P408, DOI 10.1093/ntr/ntp005; Platt S, 1997, BRIT MED J, V314, P1371; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001007.PUB2; Stead LF, 2007, TOB CONTROL, V16, pI3, DOI 10.1136/tc.2006.019737; Tobacco Advisory Group of the Royal College of Physicians, 2005, GOING SMOK FREE CAS; Tobacco Advisory Group of the Royal College of Physicians, 2000, NIC ADD BRIT; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64; UK Statistics Authority, IND MULT DEPR IMD 20; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660	27	38	38	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2012	344								e1696	10.1136/bmj.e1696	http://dx.doi.org/10.1136/bmj.e1696			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	962YP	22446739	hybrid, Green Submitted, Green Accepted, Green Published			2022-12-28	WOS:000305587600001
J	Rapley, C				Rapley, Chris			The health impacts of climate change	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Earth Sci, London WC1E 6BT, England	University of London; University College London	Rapley, C (corresponding author), UCL, Dept Earth Sci, Gower St, London WC1E 6BT, England.	christopher.rapley@ucl.ac.uk						Allison I, 2009, COPENHAGEN DIAGNOSIS; Crutzen P.J., 2000, INT GEOSPHERE BIOSPH; Dawson RJ, 2005, INT J WATER RESOUR D, V21, P577, DOI 10.1080/07900620500258380; International Energy Agency, 2010, WORLD EN OUTL 2010 E; Lovelock J., 2000, GAIA NEW LOOK LIFE E; Luthi D, 2008, NATURE, V453, P379, DOI 10.1038/nature06949; Showstack R, 2009, EOS T AGU, V90, P216; Solomon S., 2007, PHYS SCI BASIS WORKI; Stern N. H., 2006, STERN REV EC CLIMATE	9	2	2	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2012	344								e1026	10.1136/bmj.e1026	http://dx.doi.org/10.1136/bmj.e1026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431657	Bronze			2022-12-28	WOS:000301848400003
J	El-Kady, MF; Strong, V; Dubin, S; Kaner, RB				El-Kady, Maher F.; Strong, Veronica; Dubin, Sergey; Kaner, Richard B.			Laser Scribing of High-Performance and Flexible Graphene-Based Electrochemical Capacitors	SCIENCE			English	Article							DOUBLE-LAYER CAPACITOR; ENERGY-STORAGE; ELECTROPHORETIC DEPOSITION; MICRO-SUPERCAPACITORS; MATERIALS SCIENCE; GRAPHITE OXIDE; CARBON; FILMS; ELECTRODES; DENSITY	Although electrochemical capacitors (ECs), also known as supercapacitors or ultracapacitors, charge and discharge faster than batteries, they are still limited by low energy densities and slow rate capabilities. We used a standard LightScribe DVD optical drive to do the direct laser reduction of graphite oxide films to graphene. The produced films are mechanically robust, show high electrical conductivity (1738 siemens per meter) and specific surface area (1520 square meters per gram), and can thus be used directly as EC electrodes without the need for binders or current collectors, as is the case for conventional ECs. Devices made with these electrodes exhibit ultrahigh energy density values in different electrolytes while maintaining the high power density and excellent cycle stability of ECs. Moreover, these ECs maintain excellent electrochemical attributes under high mechanical stress and thus hold promise for high-power, flexible electronics.	[El-Kady, Maher F.; Strong, Veronica; Dubin, Sergey; Kaner, Richard B.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [El-Kady, Maher F.; Strong, Veronica; Dubin, Sergey; Kaner, Richard B.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA; [El-Kady, Maher F.] Cairo Univ, Fac Sci, Dept Chem, Giza 12613, Egypt; [Kaner, Richard B.] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Egyptian Knowledge Bank (EKB); Cairo University; University of California System; University of California Los Angeles	Kaner, RB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	kaner@chem.ucla.edu	Kaner, Richard B./K-1594-2019; El-Kady, Maher/Q-1663-2019	Kaner, Richard B./0000-0003-0345-4924; 	UCLA-based Focused Center; Ministry of Higher Education of Egypt	UCLA-based Focused Center; Ministry of Higher Education of Egypt(Ministry of Higher Education & Scientific Research (MHESR))	The authors thank the UCLA-based Focused Center Research Program in Functional Engineered NanoArchitectonics (R. B. K.) and the Ministry of Higher Education of Egypt (M.F.E.-K) for financial support, G. Gruner for valuable discussions, and B. Dunn, D. Membreno, and V. Augustyn for help with impedance and capacitance measurements.	Andrea D., 2016, BATTERY MANAGEMENT S; Chandrasekaran R, 2008, J SOLID STATE ELECTR, V12, P1349, DOI 10.1007/s10008-008-0559-6; Chmiola J, 2010, SCIENCE, V328, P480, DOI 10.1126/science.1184126; Du CS, 2006, NANOTECHNOLOGY, V17, P5314, DOI 10.1088/0957-4484/17/21/005; Du CS, 2006, J POWER SOURCES, V160, P1487, DOI 10.1016/j.jpowsour.2006.02.092; Gao W, 2011, NAT NANOTECHNOL, V6, P496, DOI [10.1038/NNANO.2011.110, 10.1038/nnano.2011.110]; Lee SW, 2011, ENERG ENVIRON SCI, V4, P1972, DOI 10.1039/c0ee00642d; Liu C, 2010, ADV MATER, V22, pE28, DOI 10.1002/adma.200903328; Liu CG, 2010, NANO LETT, V10, P4863, DOI 10.1021/nl102661q; Miller JR, 2008, SCIENCE, V321, P651, DOI 10.1126/science.1158736; Miller JR, 2011, ELECTROCHIM ACTA, V56, P10443, DOI 10.1016/j.electacta.2011.05.122; Miller JR, 2010, SCIENCE, V329, P1637, DOI 10.1126/science.1194372; Nishide H, 2008, SCIENCE, V319, P737, DOI 10.1126/science.1151831; Pech D, 2010, NAT NANOTECHNOL, V5, P651, DOI [10.1038/nnano.2010.162, 10.1038/NNANO.2010.162]; Segal M, 2009, NAT NANOTECHNOL, V4, P611, DOI 10.1038/nnano.2009.279; Shim Y, 2011, J PHYS CHEM C, V115, P23574, DOI 10.1021/jp203458b; Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297; Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y; Strong V., 2012, ACS NANO; Su DS, 2010, CHEMSUSCHEM, V3, P136, DOI 10.1002/cssc.200900182; Taberna PL, 2003, J ELECTROCHEM SOC, V150, pA292, DOI 10.1149/1.1543948; Wang DW, 2008, ANGEW CHEM INT EDIT, V47, P373, DOI 10.1002/anie.200702721; Wang Y, 2009, J PHYS CHEM C, V113, P13103, DOI 10.1021/jp902214f; Weng Z, 2011, ADV ENERGY MATER, V1, P917, DOI 10.1002/aenm.201100312; Wishart JF, 2009, ENERG ENVIRON SCI, V2, P956, DOI 10.1039/b906273d; Xia JL, 2009, NAT NANOTECHNOL, V4, P505, DOI [10.1038/NNANO.2009.177, 10.1038/nnano.2009.177]; Yang XW, 2011, ADV MATER, V23, P2833, DOI 10.1002/adma.201100261; Zhang HG, 2011, NAT NANOTECHNOL, V6, P277, DOI [10.1038/NNANO.2011.38, 10.1038/nnano.2011.38]; Zhang LL, 2009, CHEM SOC REV, V38, P2520, DOI 10.1039/b813846j; Zhao X, 2009, J POWER SOURCES, V194, P1208, DOI 10.1016/j.jpowsour.2009.06.004; Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770; Zhu YW, 2010, ACS NANO, V4, P1227, DOI 10.1021/nn901689k	32	3195	3280	77	2974	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1326	1330		10.1126/science.1216744	http://dx.doi.org/10.1126/science.1216744			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422977				2022-12-28	WOS:000301531600041
J	Marijon, E; Mirabel, M; Celermajer, DS; Jouven, X				Marijon, Eloi; Mirabel, Mariana; Celermajer, David S.; Jouven, Xavier			Rheumatic heart disease	LANCET			English	Article							GROUP-A STREPTOCOCCUS; PERCUTANEOUS MITRAL COMMISSUROTOMY; TERM-FOLLOW-UP; SCHOOL-CHILDREN; INFECTIVE ENDOCARDITIS; HIGH PREVALENCE; INITIAL ATTACK; VALVE DISEASE; NORTH-INDIA; NEW-ZEALAND	Rheumatic heart disease, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250 000 deaths per year worldwide. The disease results from an abnormal autoimmune response to a group A streptococcal infection in a genetically susceptible host. Acute rheumatic fever-the precursor to rheumatic heart disease-can affect different organs and lead to irreversible valve damage and heart failure. Although penicillin is effective in the prevention of the disease, treatment of advanced stages uses up a vast amount of resources, which makes disease management especially challenging in emerging nations. Guidelines have therefore emphasised antibiotic prophylaxis against recurrent episodes of acute rheumatic fever, which seems feasible and cost effective. Early detection and targeted treatment might be possible if populations at risk for rheumatic heart disease in endemic areas are screened. In this setting, active surveillance with echocardiography-based screening might become very important.	[Marijon, Eloi; Mirabel, Mariana; Jouven, Xavier] Hop Europeen Georges Pompidou, Cardiovasc Res Ctr, INSERM, U970, F-75737 Georges Pompidou 15, France; [Marijon, Eloi; Jouven, Xavier] Hop Europeen Georges Pompidou, Dept Cardiol, F-75737 Georges Pompidou 15, France; [Marijon, Eloi; Mirabel, Mariana; Jouven, Xavier] Paris Descartes Univ, Paris, France; [Marijon, Eloi; Jouven, Xavier] Maputo Heart Inst ICOR, Maputo, Mozambique; [Mirabel, Mariana] UCL, London, England; [Celermajer, David S.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University of Sydney	Marijon, E (corresponding author), Hop Europeen Georges Pompidou, Cardiovasc Res Ctr, INSERM, U970, F-75737 Georges Pompidou 15, France.	eloi_marijon@yahoo.fr		Celermajer, David/0000-0001-7640-0439				Anabwani GM, 1996, E AFR MED J, V73, P215; [Anonymous], 1999, WHO GLOB PROGR PREV; ARGUEDAS A, 1992, J PEDIATR-US, V121, P569, DOI 10.1016/S0022-3476(05)81146-1; Bach JF, 1996, LANCET, V347, P644, DOI 10.1016/S0140-6736(96)91202-7; BARLOW JB, 1990, S AFR MED J, V78, P181; Bhaya M, 2010, ECHOCARDIOGR-J CARD, V27, P448, DOI 10.1111/j.1540-8175.2009.01055.x; Biancaniello T, 2005, CIRCULATION, V111, pE20, DOI 10.1161/01.CIR.0000153388.41229.CB; Bisno AL, 2005, CLIN INFECT DIS, V41, P1150, DOI 10.1086/444505; Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; Bisno AL, 2002, CLIN INFECT DIS, V35, P113, DOI 10.1086/340949; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748; Bryant PA, 2009, CIRCULATION, V119, P742, DOI 10.1161/CIRCULATIONAHA.108.792135; Caldas AM, 2008, PEDIATR CARDIOL, V29, P1048, DOI 10.1007/s00246-008-9242-z; Carapetis J. R., 2006, STANDARDIZATION EPID; Carapetis JR, 2008, NAT CLIN PRACT CARD, V5, P411, DOI 10.1038/ncpcardio1185; Carapetis JR, 2008, CIRCULATION, V118, P2748, DOI 10.1161/CIRCULATIONAHA.108.774307; Carapetis JR, 1996, LANCET, V347, P1271, DOI 10.1016/S0140-6736(96)90797-7; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; Carapetis JR, 1999, AUST NZ J PUBL HEAL, V23, P159, DOI 10.1111/j.1467-842X.1999.tb01227.x; Carapetis JR, 1999, ARCH DIS CHILD, V80, P353, DOI 10.1136/adc.80.4.353; Carapetis JR, 2006, DIAGNOSIS MANAGEMENT; Chauvaud S, 2001, CIRCULATION, V104, pI12; Cheadle WB, 1889, LANCET, V133, P821, DOI [10.1016/S0140-6736(01)90541-0, DOI 10.1016/S0140-6736(01)90541-0]; Chesler E, 1983, CLIN CARDIOLOGY; Cilliers AM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003176; Council of Europe Committee of Ministers, 1994, R9411 COUNC EUR COMM; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036; Diao M, 2011, ARCH CARDIOVASC DIS, V104, P370, DOI 10.1016/j.acvd.2011.04.001; Dobson J, 2012, PEDIATR CARDIOL, V33, P332, DOI 10.1007/s00246-011-0139-x; DORFMAN A, 1961, PEDIATRICS, V27, P692; Eissa S, 2005, AUST NZ J PUBL HEAL, V29, P521, DOI 10.1111/j.1467-842X.2005.tb00243.x; Engel ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025326; Enriquez-Sarano M, 2009, LANCET, V373, P1382, DOI 10.1016/S0140-6736(09)60692-9; Essawy MAE, 2010, J EGYPT PUBLIC HEAL, V85, P205; Essop MR, 2005, CIRCULATION, V112, P3584, DOI 10.1161/CIRCULATIONAHA.105.539775; ESSOP MR, 1991, CIRCULATION, V84, P1669, DOI 10.1161/01.CIR.84.4.1669; Fae KC, 2005, J AUTOIMMUN, V24, P101, DOI 10.1016/j.jaut.2005.01.007; Figueroa FE, 2001, HEART, V85, P407, DOI 10.1136/heart.85.4.407; Gerber MA, 2009, CIRCULATION, V119, P1541, DOI 10.1161/CIRCULATIONAHA.109.191959; GOLDSTEIN I, 1968, NATURE, V219, P866, DOI 10.1038/219866a0; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; Grayson Sarah, 2006, N Z Med J, V119, pU2255; Guilherme L, 2007, ANN NY ACAD SCI, V1107, P426, DOI 10.1196/annals.1381.045; Guilherme L, 2010, J CLIN IMMUNOL, V30, P17, DOI 10.1007/s10875-009-9332-6; Gunther G, 2006, LANCET, V367, P391, DOI 10.1016/S0140-6736(06)68128-2; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Iung B, 2003, EUR HEART J, V24, P1231, DOI 10.1016/S0195-668X(03)00201-X; Iung B, 1999, CIRCULATION, V99, P3272, DOI 10.1161/01.CIR.99.25.3272; Iung B, 2011, ARCH CARDIOVASC DIS, V104, P367, DOI 10.1016/j.acvd.2011.06.001; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; JAIYESIMI F, 1981, TROP GEOGR MED, V33, P14; Kamblock J, 2003, EUR HEART J, V24, P855, DOI 10.1016/S0195-668X(02)00825-4; KAPLAN EL, 1993, CIRCULATION, V88, P1964, DOI 10.1161/01.CIR.88.4.1964; KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301; KAPLAN MH, 1964, J EXP MED, V119, P643, DOI 10.1084/jem.119.4.643; Karthikeyan G, 2009, CIRCULATION, V120, P709, DOI 10.1161/CIRCULATIONAHA.108.836510; Kearns TM, 2010, RURAL REMOTE HEALTH, V10; KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225; Lennon D, 2009, PEDIATR INFECT DIS J, V28, P787, DOI 10.1097/INF.0b013e3181a282be; Lennon Diana, 2009, Pediatr Infect Dis J, V28, pe259, DOI 10.1097/INF.0b013e3181a8e12a; Longo-Mbenza B, 1998, INT J CARDIOL, V63, P287, DOI 10.1016/S0167-5273(97)00311-2; Lung B, 2004, EUR HEART J, V25, P701, DOI 10.1016/j.ehj.2004.02.026; MAJEED HA, 1986, J CHRON DIS, V39, P361, DOI 10.1016/0021-9681(86)90122-0; Manyemba J., 2002, COCHRANE DB SYST REV, V2002, pCD002227, DOI [10.1002/14651858.CD002227, DOI 10.1002/14651858.CD002227, 10.1002/14651858.CD00222712137650]; MARCUS RH, 1994, ANN INTERN MED, V120, P177, DOI 10.7326/0003-4819-120-3-199402010-00001; Marijon E, 2008, NAT CLIN PRACT CARD, V5, DOI 10.1038/ncpcardio1300; Marijon E, 2008, B WORLD HEALTH ORGAN, V86, P84, DOI 10.2471/BLT.07.046680; Marijon E, 2007, NEW ENGL J MED, V357, P470, DOI 10.1056/NEJMoa065085; Marijon Eloi, 2007, Cardiol Rev, V15, P42, DOI 10.1097/01.crd.0000214187.79296.3c; Marijon E, 2009, CIRCULATION, V120, P663, DOI 10.1161/CIRCULATIONAHA.109.849190; Marijon E, 2009, INT J CARDIOL, V134, P295, DOI 10.1016/j.ijcard.2008.12.110; Marijon E, 2008, ARCH CARDIOVASC DIS, V101, P611, DOI 10.1016/j.acvd.2008.09.012; MARKOWITZ M, 1991, LANCET, V337, P1308; MARTIN DR, 1994, PEDIATR INFECT DIS J, V13, P264, DOI 10.1097/00006454-199404000-00004; Mathur K S, 1982, Indian Heart J, V34, P367; Mayosi B, 2006, SAMJ S AFR MED J, V96, P246; McDonald M, 2005, HEART, V91, P1131, DOI 10.1136/hrt.2004.057570; McDonald M, 2004, LANCET INFECT DIS, V4, P240, DOI 10.1016/S1473-3099(04)00975-2; McDonald MI, 2006, CLIN INFECT DIS, V43, P683, DOI 10.1086/506938; McDonald R, 2007, AUST J RURAL HEALTH, V15, P234, DOI 10.1111/j.1440-1584.2007.00896.x; McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458; Meira ZMA, 2005, HEART, V91, P1019, DOI 10.1136/hrt.2004.042762; Michaud CRR, 1999, RHEUMATIC FEVER, P485; Minich LD, 1997, CLIN CARDIOL, V20, P924, DOI 10.1002/clc.4960201105; Mishra S, 2008, INDIAN PEDIATR, V45, P565; Monya-Tambi I, 2005, LANCET, V366, P1355, DOI 10.1016/S0140-6736(05)67559-9; MORTIMER EA, 1959, NEW ENGL J MED, V260, P101, DOI 10.1056/NEJM195901152600301; Nkgudi B, 2006, S Afr Med J, V96, P206; Nkomo VT, 2007, HEART, V93, P1510, DOI 10.1136/hrt.2007.118810; NORDET P, 1992, B WORLD HEALTH ORGAN, V70, P213; Nordet P, 2008, CARDIOVASC J AFR, V19, P135; NORTH DA, 1993, NEW ZEAL MED J, V106, P400; North RA, 1999, CIRCULATION, V99, P2669, DOI 10.1161/01.CIR.99.20.2669; Paar JA, 2010, AM J CARDIOL, V105, P1809, DOI 10.1016/j.amjcard.2010.01.364; Parnaby MG, 2010, J PAEDIATR CHILD H, V46, P527, DOI 10.1111/j.1440-1754.2010.01841.x; Pastore S, 2011, RHEUMATOLOGY, V50, P396, DOI 10.1093/rheumatology/keq290; Periwal K L, 2006, J Assoc Physicians India, V54, P279; Population Reference Bureau, 2008 WORLD POP DAT S; Pruksakorn S, 2000, J CLIN MICROBIOL, V38, P1250, DOI 10.1128/JCM.38.3.1250-1254.2000; Rahimtoola SH, 2010, J AM COLL CARDIOL, V55, P2413, DOI 10.1016/j.jacc.2009.10.085; Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001; Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296; Reeves BM, 2011, J PAEDIATR CHILD H, V47, P473, DOI 10.1111/j.1440-1754.2010.01997.x; Remenyi B, 2012, NAT REV CARDIOL, V9, P297, DOI 10.1038/nrcardio.2012.7; Rizvi SF, 2004, HEART, V90, P394, DOI 10.1136/hrt.2003.025981; Robertson KA, 2006, SAMJ S AFR MED J, V96, P241; Robertson Katharine A, 2005, BMC Cardiovasc Disord, V5, P11, DOI 10.1186/1471-2261-5-11; ROY SB, 1963, LANCET, V2, P1193, DOI 10.1016/S0140-6736(63)92922-2; Sadiq M, 2009, HEART, V95, P353, DOI 10.1136/hrt.2008.143982; SANYAL SK, 1982, CIRCULATION, V65, P375, DOI 10.1161/01.CIR.65.2.375; SANYAL SK, 1974, CIRCULATION, V49, P7, DOI 10.1161/01.CIR.49.1.7; Saxena A, 2011, HEART, V97, P2018, DOI 10.1136/heartjnl-2011-300792; SKOULARIGIS J, 1994, CIRCULATION, V90, P167; Sliwa K, 2010, EUR HEART J, V31, P719, DOI 10.1093/eurheartj/ehp530; Soma-Pillay P, 2008, SAMJ S AFR MED J, V98, P553; Steer AC, 2009, NAT REV CARDIOL, V6, P689, DOI 10.1038/nrcardio.2009.162; Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1; Steer AC, 2009, J HEART VALVE DIS, V18, P327; STRASSER T, 1985, HEALTH POLICY, V5, P159, DOI 10.1016/0168-8510(85)90030-2; STRASSER T, 1981, B WORLD HEALTH ORGAN, V59, P285; TALBOT RG, 1984, NEW ZEAL MED J, V97, P630; Terreri MT, 2001, J RHEUMATOL, V28, P1394; Tibazarwa KB, 2008, HEART, V94, P1534, DOI 10.1136/hrt.2007.141309; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; VARDI P, 1983, PEDIATRICS, V71, P830; Vasan RS, 1996, CIRCULATION, V94, P73, DOI 10.1161/01.CIR.94.1.73; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; Voss LM, 2001, CIRCULATION, V103, P401; Webb R, 2011, 18 LANC INT S PAL IT; Webb RH, 2011, CARDIOL YOUNG, V21, P436, DOI 10.1017/S1047951111000266; White H, 2010, HEART LUNG CIRC, V19, P273, DOI 10.1016/j.hlc.2010.02.019; Wilson N, 2010, HEART LUNG CIRC, V19, P282, DOI 10.1016/j.hlc.2010.02.021; Wilson W, 2007, J AM DENT ASSOC, V138, P739, DOI 10.1161/CIRCULATIONAHA.106.183095; WISENBAUGH T, 1994, CIRCULATION, V89, P191, DOI 10.1161/01.CIR.89.1.191; World Health Organization, 2004, WHO TECHN REP SER, V923; World Health Organization, 2004, GLOB BURD DIS 2004 U	140	392	407	3	75	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					953	964		10.1016/S0140-6736(11)61171-9	http://dx.doi.org/10.1016/S0140-6736(11)61171-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22405798				2022-12-28	WOS:000301353700036
J	Berwick, DM; Hackbarth, AD				Berwick, Donald M.; Hackbarth, Andrew D.			Eliminating Waste in US Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; COSTS; CANADA; GROWTH	The need is urgent to bring US health care costs into a sustainable range for both public and private payers. Commonly, programs to contain costs use cuts, such as reductions in payment levels, benefit structures, and eligibility. A less harmful strategy would reduce waste, not value-added care. The opportunity is immense. In just 6 categories of waste-overtreatment, failures of care coordination, failures in execution of care processes, administrative complexity, pricing failures, and fraud and abuse-the sum of the lowest available estimates exceeds 20% of total health care expenditures. The actual total may be far greater. The savings potentially achievable from systematic, comprehensive, and cooperative pursuit of even a fractional reduction in waste are far higher than from more direct and blunter cuts in care and coverage. The potential economic dislocations, however, are severe and require mitigation through careful transition strategies. JAMA. 2012;307(14):1513-1516 Published online March 14, 2012. doi:10.1001/jama.2012.362	[Hackbarth, Andrew D.] RAND Corp, Santa Monica, CA USA; [Hackbarth, Andrew D.] Pardee RAND Grad Sch, Santa Monica, CA USA	RAND Corporation; RAND Corporation; Pardee RAND Graduate School		donberwick1@gmail.com						Agrawal S, 2012, JAMA-J AM MED ASSOC, V307, P459, DOI 10.1001/jama.2012.78; [Anonymous], 2010, ADVERSE EVENTS HOSP; [Anonymous], 2007, MPA COMMITTEE REPORT; Berenson RA, 2009, WE CAN PAY HLTH CARE; Bernard D. M., 2004, ADVERSE PATIENT SAFE; Bradford JW, 2011, ACCOUNTING COST US H; Centers for Medicare and Medicaid Services, 2010, EST FIN EFF PAT PROT; Centers for Medicare & Medicaid Services Office of the Actuary, 2011, NAT HLTH EXP WEB TAB; Committee on Oversight and Government Reform, 2008, MED D; Cutler DM, 2011, J ECON PERSPECT, V25, P3, DOI 10.1257/jep.25.2.3; Delaune J, 2008, WASTE INEFFICIENCY U; Eibner C, 2009, CONTROLLING HLTH CAR; Farrell D, 2008, ACCOUNTING COST US H; Federal Bureau of Investigation, 2009, 2009 FIN CRIM REP; International Federation of Health Plans, 2010 COMP PRIC REP M; Jha AK, 2009, HEALTH AFFAIR, V28, P897, DOI 10.1377/hlthaff.28.3.897; Keehan SP, 2011, HEALTH AFFAIR, V30, P1594, DOI 10.1377/hlthaff.2011.0662; KELLEY R, 2009, CAN 700 BILLION WAST, P43990; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Matthews M, 2006, MEDICARES HIDDEN ADM; National Primary Health Care Development Agency. National Primary Health Care Development Agency, 2008, NATL EMERG PLAN POL NATL EMERG PLAN POL, P10; Pacala S, 2004, SCIENCE, V305, P968, DOI 10.1126/science.1100103; Pozen A, 2010, INQUIRY-J HEALTH CAR, V47, P124, DOI 10.5034/inquiryjrnl_47.02.124; PriceWaterhouseCoopers, 2010, PRIC EXC ID WAST HEA; Reinhardt U, 2012, HEALTH ECON, V21, P41, DOI 10.1002/hec.1813; Schoen C, 2007, BENDING CURVE OPTION; Shatto J. D., 2018, PROJECTED MED EXPEND; Thorpe KE, 2010, HEALTH AFFAIR, V29, P1183, DOI 10.1377/hlthaff.2010.0415; Waters HR, 2011, AM J MED QUAL, V26, P333, DOI 10.1177/1062860611410685; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; Yong PL, 2010, HEALTHCARE IMPERATIV	31	1055	1063	4	124	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 11	2012	307	14					1513	1516		10.1001/jama.2012.362	http://dx.doi.org/10.1001/jama.2012.362			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	922HN	22419800				2022-12-28	WOS:000302538100025
J	Carr, AJ; Robertsson, O; Graves, S; Price, AJ; Arden, NK; Judge, A; Beard, DJ				Carr, Andrew J.; Robertsson, Otto; Graves, Stephen; Price, Andrew J.; Arden, Nigel K.; Judge, Andrew; Beard, David J.			Knee replacement	LANCET			English	Article							TOTAL JOINT REPLACEMENT; QUALITY-OF-LIFE; TOTAL HIP; FOLLOW-UP; ARTHROPLASTY REGISTER; RHEUMATOID-ARTHRITIS; PATIENT SATISFACTION; OXFORD HIP; SURVIVORSHIP ANALYSIS; OUTCOME MEASURES	Knee-replacement surgery is frequently done and highly successful. It relieves pain and improves knee function in people with advanced arthritis of the joint. The most common indication for the procedure is osteoarthritis. We review the epidemiology of and risk factors for knee replacement. Because replacement is increasingly considered for patients younger than 55 years, improved decision making about whether a patient should undergo the procedure is needed. We discuss assessment of surgery outcomes based on data for revision surgery from national joint-replacement registries and on patient-reported outcome measures. Widespread surveillance of existing implants is urgently needed alongside the carefully monitored introduction of new implant designs. Developments for the future are improved delivery of care and training for surgeons and clinical teams. In an increasingly ageing society, the demand for knee-replacement surgery will probably rise further, and we predict future trends. We also emphasise the need for new strategies to treat early-stage osteoarthritis, which will ultimately reduce the demand for joint-replacement surgery.	[Carr, Andrew J.] Univ Oxford, Botnar Res Ctr, NIHR Biomed Res Unit, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England; [Robertsson, Otto] Lund Univ, Dept Orthopaed & Clin Sci, Lund, Sweden; [Graves, Stephen] Univ Adelaide, Dept Orthopaed Surg, Adelaide, SA, Australia	University of Oxford; Lund University; University of Adelaide	Carr, AJ (corresponding author), Univ Oxford, Botnar Res Ctr, NIHR Biomed Res Unit, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.	andrew.carr@ndorms.ox.ac.uk	Graves, Stephen E/A-9463-2016	Graves, Stephen E/0000-0002-1629-319X; Beard, David/0000-0001-7884-6389	Stryker; Genzyme	Stryker; Genzyme(Sanofi-AventisGenzyme Corporation)	SG is paid by the Australian Orthopaedic Association as Director of the National Joint Registry. AP has received honoraria and support for travel from Biomet. DB has received consultancy fees from Stryker and institutional research grants from Genzyme. AC, AJ, NA, and OR declare that they have no conflicts of interest.	Acheson SD, 1998, INDEPENDENT INQUIRY; Ackerman IN, 2009, ARTHRIT RHEUM-ARTHR, V61, P166, DOI 10.1002/art.24215; Adam JA, 2008, ANN ROY COLL SURG, V90, P198, DOI 10.1308/003588408X285748; Agency for Healthcare Research and Quality, HCUPNET 2008 OUTC PA; Amendola A, 2010, INT ORTHOP, V34, P155, DOI 10.1007/s00264-009-0889-8; Amin AK, 2006, J BONE JOINT SURG BR, V88B, P1321, DOI 10.1302/0301-620X.88B10.17697; [Anonymous], 2003, NIH Consens State Sci Statements, V20, P1; [Anonymous], 2008, GUID METH TECHN APPR; [Anonymous], 1999, KNEE REPL GUID GOOD; [Anonymous], 2010, HIP KNEE ARTHR ANN R; Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007; Arden NK, 2011, OSTEOARTHR CARTILAGE, V19, P155, DOI 10.1016/j.joca.2010.10.004; Ayers DC, 2005, CLIN ORTHOP RELAT R, P157, DOI 10.1097/01.blo.0000185447.43622.93; Becher C, 2008, Z ORTHOP UNFALLCHIR, V146, P773, DOI 10.1055/s-2008-1039000; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; BOHANNON RW, 1995, PERCEPT MOTOR SKILL, V80, P163, DOI 10.2466/pms.1995.80.1.163; Borus T, 2008, J AM ACAD ORTHOP SUR, V16, P9, DOI 10.5435/00124635-200801000-00003; Bourne RB, 2010, CLIN ORTHOP RELAT R, V468, P57, DOI 10.1007/s11999-009-1119-9; Brander VA, 2003, CLIN ORTHOP RELAT R, P27, DOI 10.1097/01.blo.0000092983.12414.e9; Callaghan JJ, 2004, J ARTHROPLASTY, V19, P31, DOI 10.1016/j.arth.2004.02.015; Canale ST, 2008, CAMPBELLS OPERATIVE, V11th, P1580; Cobos R, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-249; Culliford DJ, 2010, J BONE JOINT SURG BR, V92B, P130, DOI 10.1302/0301-620X.92B1.22654; Dawson J, 1998, J BONE JOINT SURG BR, V80B, P63, DOI 10.1302/0301-620X.80B1.7859; *DEP HLTH, 2000, NHS PLAN; Department of Health, 2006, JOINT DOCTRINE INTER; Department of Health, 2002, TACKL HLTH IN 2002 C; Department of Health, 1999, SAV LIV OUR HLTH NAT; Department of Health, 2003, DEL INV GEN PRACT IM; Department of Health, 2010, EQ EXC LIB NHS; Diduch DR, 1997, J BONE JOINT SURG AM, V79A, P575, DOI 10.2106/00004623-199704000-00015; Dillon CF, 2006, J RHEUMATOL, V33, P2271; DOREY F, 1989, J BONE JOINT SURG AM, V71A, P544, DOI 10.2106/00004623-198971040-00010; Dreyer NA, 2009, JAMA-J AM MED ASSOC, V302, P790, DOI 10.1001/jama.2009.1092; Ethgen O, 2004, J BONE JOINT SURG AM, V86A, P963, DOI 10.2106/00004623-200405000-00012; FARO LMC, 1992, ACTA ORTHOP SCAND, V63, P1, DOI 10.3109/17453679209155045; Feldman-Stewart D, 2007, HEALTH EXPECT, V10, P46, DOI 10.1111/j.1369-7625.2006.00420.x; Furnes O, 2007, J BONE JOINT SURG AM, V89A, P519, DOI 10.2106/JBJS.F.00210; Gillespie GN, 2007, KNEE, V14, P81, DOI 10.1016/j.knee.2006.11.004; Goodfellow JW, 2010, J BONE JOINT SURG BR, V92B, P1628, DOI 10.1302/0301-620X.92B12.25193; Gossec L, 2011, OSTEOARTHR CARTILAGE, V19, P147, DOI 10.1016/j.joca.2010.10.025; Graves SE, 2010, ACTA ORTHOP, V81, P8, DOI 10.3109/17453671003667184; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hadorn DC, 1997, BRIT MED J, V314, P135, DOI 10.1136/bmj.314.7074.135; Hang JR, 2010, ACTA ORTHOP, V81, P95, DOI 10.3109/17453671003628731; Harry LE, 2000, ANN ROY COLL SURG, V82, P186; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163, DOI 10.2106/00004623-199802000-00003; Hawker GA, 2002, ARTHRITIS RHEUM-US, V46, P3331, DOI 10.1002/art.10682; Hawker GA, 2001, MED CARE, V39, P206, DOI 10.1097/00005650-200103000-00002; Hawker GA, 2009, MED CARE, V47, P732, DOI 10.1097/MLR.0b013e3181934553; Healy WL, 2007, CLIN ORTHOP RELAT R, P57, DOI 10.1097/BLO.0b013e31803372e0; Heyse TJ, 2010, ARCH ORTHOP TRAUM SU, V130, P1539, DOI 10.1007/s00402-010-1137-9; Hurst NP, 1997, BRIT J RHEUMATOL, V36, P551; INSALL JN, 1989, CLIN ORTHOP RELAT R, P13; Jamsen E, 2009, J BONE JOINT SURG AM, V91A, P38, DOI 10.2106/JBJS.G.01686; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Judge A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4092; Judge A, 2009, ARTHRIT RHEUM-ARTHR, V61, P1657, DOI 10.1002/art.24892; Judge A, 2009, ARTHRIT RHEUM-ARTHR, V61, P1667, DOI 10.1002/art.24732; Judge A, 2009, J PUBLIC HEALTH-UK, V31, P413, DOI 10.1093/pubmed/fdp061; Julin J, 2010, ACTA ORTHOP, V81, P413, DOI 10.3109/17453674.2010.501747; Juni P, 2003, RHEUMATOLOGY, V42, P516, DOI 10.1093/rheumatology/keg196; Kalairajah Y, 2005, J ARTHROPLASTY, V20, P1037, DOI 10.1016/j.arth.2005.04.017; Katz JN, 2006, BEST PRACT RES CL RH, V20, P145, DOI 10.1016/j.berh.2005.09.003; Kendell K, 2001, BRIT J HEALTH PSYCH, V6, P41, DOI 10.1348/135910701169043; Kim HA, 2008, RHEUMATOLOGY, V47, P88, DOI 10.1093/rheumatology/kem308; Kmietowicz Z, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1520; KNUTSON K, 1994, ACTA ORTHOP SCAND, V65, P375, DOI 10.3109/17453679408995475; Knutson K, 2010, ACTA ORTHOP, V81, P5, DOI 10.3109/17453671003667267; KOZINN SC, 1989, J BONE JOINT SURG AM, V71A, P145, DOI 10.2106/00004623-198971010-00023; Kurd MF, 2010, CLIN ORTHOP RELAT R, V468, P2060, DOI 10.1007/s11999-010-1296-6; Kurtz SM, 2010, CLIN ORTHOP RELAT R, V468, P52, DOI 10.1007/s11999-009-1013-5; Labek G, 2010, J BONE JOINT SURG S4, V92, P496; Laskin RS, 2001, CLIN ORTHOP RELAT R, P267; LAURENCIN CT, 1991, CLIN ORTHOP RELAT R, P151; LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85; Leung F, 2011, CLIN ORTHOP RELAT R, V469, P1009, DOI 10.1007/s11999-010-1725-6; Lewold S, 1998, ACTA ORTHOP SCAND, V69, P469, DOI 10.3109/17453679808997780; Lingard EA, 2001, J BONE JOINT SURG AM, V83A, P1149, DOI 10.2106/00004623-200108000-00003; Lingard EA, 2007, J BONE JOINT SURG AM, V89A, P1161, DOI 10.2106/JBJS.F.00914; Llewellyn-Thomas H A, 1998, J Eval Clin Pract, V4, P63, DOI 10.1046/j.1365-2753.1998.t01-1-00006.x; Lohmander LS, 2009, ANN RHEUM DIS, V68, P490, DOI 10.1136/ard.2008.089748; Lonner JH, 2000, CLIN ORTHOP RELAT R, P85; Louie GH, 2010, ANN RHEUM DIS, V69, P868, DOI 10.1136/ard.2009.112474; Lutzner J, 2009, NAT REV RHEUMATOL, V5, P309, DOI 10.1038/nrrheum.2009.88; Mancuso CA, 1996, J ARTHROPLASTY, V11, P34, DOI 10.1016/S0883-5403(96)80159-8; Mulhall KJ, 2006, CLIN ORTHOP RELAT R, P45, DOI 10.1097/01.blo.0000214421.21712.62; Murray DW, 2007, J BONE JOINT SURG BR, V89B, P1010, DOI 10.1302/0301-620X.89B8; National Joint Registry, 2010, NAT JOINT REG ENGL W; Naudie DDR, 2007, J AM ACAD ORTHOP SUR, V15, P53, DOI 10.5435/00124635-200701000-00006; Newman J, 2009, J BONE JOINT SURG BR, V91B, P52, DOI 10.1302/0301-620X.91B1.20899; Noble PC, 2005, CLIN ORTHOP RELAT R, P157, DOI 10.1097/01.blo.0000150130.03519.fb; Noble PC, 2006, CLIN ORTHOP RELAT R, P35, DOI 10.1097/011.blo.0000238825.63648.1e; O'Rourke MR, 2005, CLIN ORTHOP RELAT R, P27, DOI 10.1097/01.blo.0000185451.96987.aa; Odumenya M, 2010, J BONE JOINT SURG BR, V92B, P56, DOI 10.1302/0301-620X.92B1.23135; Pearse AJ, 2010, J BONE JOINT SURG BR, V92B, P508, DOI 10.1302/0301-620X.92B4.22659; Price AJ, 2010, KNEE, V17, P196, DOI 10.1016/j.knee.2009.09.003; Price A, 2010, ANN ROY COLL SURG, V92, P459, DOI 10.1308/003588410X12771863936567; RAND JA, 1991, J BONE JOINT SURG AM, V73A, P397, DOI 10.2106/00004623-199173030-00011; Rand JA, 2003, J BONE JOINT SURG AM, V85A, P259, DOI 10.2106/00004623-200302000-00012; Rankin EA, 2004, J BONE JOINT SURG AM, V86A, P1328; Razmjou H, 2006, J BONE JOINT SURG AM, V88A, P2590, DOI 10.2106/JBJS.F.00283; Rees JL, 2010, J BONE JOINT SURG BR, V92B, P1107, DOI 10.1302/0301-620X.92B8.22860; Ritter MA, 2003, J BONE JOINT SURG AM, V85A, P1532, DOI 10.2106/00004623-200308000-00015; Roberts VI, 2007, J BONE JOINT SURG BR, V89B, P1452, DOI 10.1302/0301-620X.89B11.19783; Robertsson O, 2000, ACTA ORTHOP SCAND, V71, P262, DOI 10.1080/000164700317411852; Robertsson O, 2000, ACTA ORTHOP SCAND, V71, P7, DOI 10.1080/00016470052943829; Robertsson O, 2007, J BONE JOINT SURG BR, V89B, P1, DOI 10.1302/0301-620X.89B1.18327; Robertsson O, 2001, J ARTHROPLASTY, V16, P476, DOI 10.1054/arth.2001.22395a; Robertsson O, 2008, J ARTHROPLASTY, V23, P801, DOI 10.1016/j.arth.2007.07.011; Robertsson O, 2010, ACTA ORTHOP, V81, P82, DOI 10.3109/17453671003685442; Roos EM, 1998, J ORTHOP SPORT PHYS, V28, P88, DOI 10.2519/jospt.1998.28.2.88; Rothwell AG, 2010, J BONE JOINT SURG BR, V92B, P413, DOI 10.1302/0301-620X.92B3.22913; ROUGRAFF BT, 1991, CLIN ORTHOP RELAT R, P157; Saccomanni B, 2010, CLIN RHEUMATOL, V29, P339, DOI 10.1007/s10067-009-1354-1; Samson AJ, 2010, ANZ J SURG, V80, P595, DOI 10.1111/j.1445-2197.2010.05396.x; Schrama JC, 2010, ARTHRIT CARE RES, V62, P473, DOI 10.1002/acr.20036; Singh JA, 2010, MAYO CLIN PROC, V85, P898, DOI 10.4065/mcp.2010.0115; Sokka T, 2007, ANN RHEUM DIS, V66, P341, DOI 10.1136/ard.2006.057067; Steel N, 2006, RHEUMATOLOGY, V45, P1437, DOI 10.1093/rheumatology/kel131; Stefansdottir A, 2010, THESIS LUND U; Steffen TM, 2002, PHYS THER, V82, P128, DOI 10.1093/ptj/82.2.128; Suarez-Almazor ME, 2010, JCR-J CLIN RHEUMATOL, V16, P158, DOI 10.1097/RHU.0b013e3181df4de4; Swedish Knee Arthroplasty Register, 2010, ANN REP 2010; TENNANT A, 1995, BMJ-BRIT MED J, V310, P1291, DOI 10.1136/bmj.310.6990.1291; The Information Centre for Health and Social Care, 2010, PROV MONTHL PAT REP; Valle DC, 2003, ADULT KNEE, P1047; Vessely MB, 2006, CLIN ORTHOP RELAT R, P28, DOI 10.1097/01.blo.0000229356.81749.11; Wang YY, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2636; Willis-Owen CA, 2009, KNEE, V16, P473, DOI 10.1016/j.knee.2009.04.006; Xie F, 2011, INT J RHEUM DIS, V14, P206, DOI 10.1111/j.1756-185X.2010.01580.x; Yong PFK, 2004, ANN RHEUM DIS, V63, P1483, DOI 10.1136/ard.2003.013938; Zahiri CA, 1998, J ARTHROPLASTY, V13, P890, DOI 10.1016/S0883-5403(98)90195-4; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014	135	640	666	9	155	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2012	379	9823					1331	1340		10.1016/S0140-6736(11)60752-6	http://dx.doi.org/10.1016/S0140-6736(11)60752-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922FB	22398175				2022-12-28	WOS:000302531100031
J	Kuo, AJ; Song, JK; Cheung, P; Ishibe-Murakami, S; Yamazoe, S; Chen, JK; Patel, DJ; Gozani, O				Kuo, Alex J.; Song, Jikui; Cheung, Peggie; Ishibe-Murakami, Satoko; Yamazoe, Sayumi; Chen, James K.; Patel, Dinshaw J.; Gozani, Or			The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; 20 METHYLTRANSFERASE PR-SET7; HBO1 HISTONE ACETYLASE; STRUCTURAL BASIS; CHROMATIN MODIFICATIONS; PRIMORDIAL DWARFISM; PHD FINGER; METHYLATION; MUTATIONS; H3	The recognition of distinctly modified histones by specialized 'effector' proteins constitutes a key mechanism for transducing molecular events at chromatin to biological outcomes(1). Effector proteins influence DNA-templated processes, including transcription, DNA recombination and DNA repair; however, no effector functions have yet been identified within the mammalian machinery that regulate DNA replication. Here we show that ORC1-a component of ORC (origin of replication complex), which mediates pre-DNA replication licensing(2)-contains a bromo adjacent homology (BAH) domain that specifically recognizes histone H4 dimethylated at lysine 20 (H4K20me2). Recognition of H4K20me2 is a property common to BAH domains present within diverse metazoan ORC1 proteins. Structural studies reveal that the specificity of the BAH domain for H4K20me2 is mediated by a dynamic aromatic dimethyl-lysine-binding cage and multiple intermolecular contacts involving the bound peptide. H4K20me2 is enriched at replication origins, and abrogating ORC1 recognition of H4K20me2 in cells impairs ORC1 occupancy at replication origins, ORC chromatin loading and cell-cycle progression. Mutation of the ORC1 BAH domain has been implicated in the aetiology of Meier-Gorlin syndrome (MGS)(3,4), a form of primordial dwarfism(5), and ORC1 depletion in zebrafish results in an MGS-like phenotype(4). We find that wild-type human ORC1, but not ORC1-H4K20me2-binding mutants, rescues the growth retardation of orc1 morphants. Moreover, zebrafish depleted of H4K20me2 have diminished body size, mirroring the phenotype of orc1 morphants. Together, our results identify the BAH domain as a novel methyl-lysine-binding module, thereby establishing the first direct link between histone methylation and the metazoan DNA replication machinery, and defining a pivotal aetiological role for the canonical H4K20me2 mark, via ORC1, in primordial dwarfism.	[Song, Jikui; Ishibe-Murakami, Satoko; Patel, Dinshaw J.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA; [Kuo, Alex J.; Cheung, Peggie; Gozani, Or] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Yamazoe, Sayumi; Chen, James K.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA	Memorial Sloan Kettering Cancer Center; Stanford University; Stanford University	Patel, DJ (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA.	pateld@mskcc.org; ogozani@stanford.edu	Chen, James/G-9972-2011; Kuo, Alex/AAL-2845-2020; Gozani, Or P/I-6157-2013	Chen, James/0000-0002-9220-8436; Gozani, Or/0000-0002-1365-4463	Abby Rockefeller Mauze Foundation; STARR Foundation; Maloris Foundation; Genentech Foundation; Ellison Senior Scholar in Aging Award;  [R01 GM079641];  [DP1 OD003792]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [DP1HD075622] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079641] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003792] Funding Source: NIH RePORTER	Abby Rockefeller Mauze Foundation; STARR Foundation; Maloris Foundation; Genentech Foundation(Roche HoldingGenentech); Ellison Senior Scholar in Aging Award; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank R. Tennen for critical reading of the manuscript. This work was supported in part by grants to O.G. (R01 GM079641), D.J.P. (Abby Rockefeller Mauze, STARR and Maloris Foundations) and J.K.C. (DP1 OD003792), and a predoctoral fellowship to A.J.K. (Genentech Foundation). O.G. is a recipient of an Ellison Senior Scholar in Aging Award.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Armache KJ, 2011, SCIENCE, V334, P977, DOI 10.1126/science.1210915; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Bicknell LS, 2011, NAT GENET, V43, P356, DOI 10.1038/ng.775; Bicknell LS, 2011, NAT GENET, V43, P350, DOI 10.1038/ng.776; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Brustel J, 2011, TRENDS CELL BIOL, V21, P452, DOI 10.1016/j.tcb.2011.04.006; Bua DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006789; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Costas C, 2011, NAT STRUCT MOL BIOL, V18, P395, DOI 10.1038/nsmb.1988; Dorn ES, 2011, EPIGENETICS-US, V6, P552, DOI 10.4161/epi.6.5.15082; Duncker BP, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-214; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Guernsey DL, 2011, NAT GENET, V43, P360, DOI 10.1038/ng.777; Jacob Y, 2010, NATURE, V466, P987, DOI 10.1038/nature09290; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Klingseisen A, 2011, GENE DEV, V25, P2011, DOI 10.1101/gad.169037; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Li H, 2007, MOL CELL, V28, P677, DOI 10.1016/j.molcel.2007.10.023; Matthews AGW, 2007, NATURE, V450, P1106, DOI 10.1038/nature06431; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Miotto B, 2008, GENE DEV, V22, P2633, DOI 10.1101/gad.1674108; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Noguchi K, 2006, EMBO J, V25, P5372, DOI 10.1038/sj.emboj.7601396; Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08; Onishi M, 2007, MOL CELL, V28, P1015, DOI 10.1016/j.molcel.2007.12.004; Sampath V, 2009, MOL CELL BIOL, V29, P2532, DOI 10.1128/MCB.01682-08; Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sun XJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001499; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Tardat M, 2010, NAT CELL BIOL, V12, P1086, DOI 10.1038/ncb2113; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Zhang ZG, 2002, EMBO J, V21, P4600, DOI 10.1093/emboj/cdf468	37	225	234	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					115	+		10.1038/nature10956	http://dx.doi.org/10.1038/nature10956			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22398447	Green Accepted, Green Submitted			2022-12-28	WOS:000302343400045
J	Sarwar, N; Butterworth, AS; Freitag, DF; Gregson, J; Willeit, P; Gorman, DN; Gao, P; Saleheen, D; Rendon, A; Nelson, CP; Braund, PS; Hall, AS; Chasman, DI; Tybjaerg-Hansen, A; Chambers, JC; Benjamin, EJ; Franks, PW; Clarke, R; Wilde, AAM; Trip, MD; Steri, M; Witteman, JCM; Qi, L; van der Schoot, CE; de Faire, U; Erdmann, J; Stringham, HM; Koenig, W; Rader, DJ; Melzer, D; Reich, D; Psaty, BM; Kleber, ME; Panagiotakos, DB; Willeit, J; Wennberg, P; Woodward, M; Adamovic, S; Rimm, EB; Meade, TW; Gillum, RF; Shaffer, JA; Hofman, A; Onat, A; Sundstrom, J; Wassertheil-Smoller, S; Mellstrom, D; Gallacher, J; Cushman, M; Tracy, RP; Kauhanen, J; Karlsson, M; Salonen, JT; Wilhelmsen, L; Amouyel, P; Cantin, B; Best, LG; Ben-Shlomo, Y; Manson, JE; Davey-Smith, G; de Bakker, PIW; O'Donnell, CJ; Wilson, JF; Wilson, AG; Assimes, TL; Jansson, JO; Ohlsson, C; Tivesten, A; Ljunggren, O; Reilly, MP; Hamsten, A; Ingelsson, E; Cambien, F; Hung, J; Thomas, GN; Boehnke, M; Schunkert, H; Asselbergs, FW; Kastelein, JJP; Gudnason, V; Salomaa, V; Harris, TB; Kooner, JS; Allin, KH; Nordestgaard, BG; Hopewell, JC; Goodall, AH; Ridker, PM; Holm, H; Watkins, H; Ouwehand, WH; Samani, NJ; Kaptoge, S; Di Angelantonio, E; Harari, O; Danesh, J				Sarwar, Nadeem; Butterworth, Adam S.; Freitag, Daniel F.; Gregson, John; Willeit, Peter; Gorman, Donal N.; Gao, Pei; Saleheen, Danish; Rendon, Augusto; Nelson, Christopher P.; Braund, Peter S.; Hall, Alistair S.; Chasman, Daniel I.; Tybjaerg-Hansen, Anne; Chambers, John C.; Benjamin, Emelia J.; Franks, Paul W.; Clarke, Robert; Wilde, Arthur A. M.; Trip, Mieke D.; Steri, Maristella; Witteman, Jacqueline C. M.; Qi, Lu; van der Schoot, C. Ellen; de Faire, Ulf; Erdmann, Jeanette; Stringham, Heather M.; Koenig, Wolfgang; Rader, Daniel J.; Melzer, David; Reich, David; Psaty, Bruce M.; Kleber, Marcus E.; Panagiotakos, Demosthenes B.; Willeit, Johann; Wennberg, Patrik; Woodward, Mark; Adamovic, Svetlana; Rimm, Eric B.; Meade, Tom W.; Gillum, Richard F.; Shaffer, Jonathan A.; Hofman, Albert; Onat, Altan; Sundstrom, Johan; Wassertheil-Smoller, Sylvia; Mellstrom, Dan; Gallacher, John; Cushman, Mary; Tracy, Russell P.; Kauhanen, Jussi; Karlsson, Magnus; Salonen, Jukka T.; Wilhelmsen, Lars; Amouyel, Philippe; Cantin, Bernard; Best, Lyle G.; Ben-Shlomo, Yoav; Manson, JoAnn E.; Davey-Smith, George; de Bakker, Paul I. W.; O'Donnell, Christopher J.; Wilson, James F.; Wilson, Anthony G.; Assimes, Themistocles L.; Jansson, John-Olov; Ohlsson, Claes; Tivesten, Asa; Ljunggren, Osten; Reilly, Muredach P.; Hamsten, Anders; Ingelsson, Erik; Cambien, Francois; Hung, Joseph; Thomas, G. Neil; Boehnke, Michael; Schunkert, Heribert; Asselbergs, Folkert W.; Kastelein, John J. P.; Gudnason, Vilmundur; Salomaa, Veikko; Harris, Tamara B.; Kooner, Jaspal S.; Allin, Kristine H.; Nordestgaard, Borge G.; Hopewell, Jemma C.; Goodall, Alison H.; Ridker, Paul M.; Holm, Hilma; Watkins, Hugh; Ouwehand, Willem H.; Samani, Nilesh J.; Kaptoge, Stephen; Di Angelantonio, Emanuele; Harari, Olivier; Danesh, John		IL6R Genetics Consortium Emerging	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies	LANCET			English	Article							C-REACTIVE PROTEIN; RHEUMATOID-ARTHRITIS; RISK; LOCI; ASSOCIATION; TOCILIZUMAB; FIBRINOGEN; INFLAMMATION; INHIBITION; REDUCTION	Background Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades. To assess whether this pathway is causally relevant to coronary heart disease, we studied a functional genetic variant known to affect IL6R signalling. Methods In a collaborative meta-analysis, we studied Asp358Ala (rs2228145) in IL6R in relation to a panel of conventional risk factors and inflammation biomarkers in 125 222 participants. We also compared the frequency of Asp358Ala in 51 441 patients with coronary heart disease and in 136 226 controls. To gain insight into possible mechanisms, we assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6. Findings The minor allele frequency of Asp358Ala was 39%. Asp358Ala was not associated with lipid concentrations, blood pressure, adiposity, dysglycaemia, or smoking (p value for association per minor allele >= 0.04 for each). By contrast, for every copy of 358Ala inherited, mean concentration of IL6R increased by 34.3% (95% CI 30.4-38.2) and of interleukin 6 by 14.6% (10.7-18.4), and mean concentration of C-reactive protein was reduced by 7.5% (5.9-9.1) and of fibrinogen by 1.0% (0.7-1.3). For every copy of 358Ala inherited, risk of coronary heart disease was reduced by 3.4% (1.8-5.0). Asp358Ala was not related to IL6R mRNA levels or interleukin-6 production in monocytes. Interpretation Large-scale human genetic and biomarker data are consistent with a causal association between IL6R-related pathways and coronary heart disease.	[Sarwar, Nadeem] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England; [Nelson, Christopher P.; Braund, Peter S.; Goodall, Alison H.; Samani, Nilesh J.] Univ Leicester, Leicester LE1 7RH, Leics, England; [Hall, Alistair S.] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England; [Chasman, Daniel I.; Ridker, Paul M.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Chasman, Daniel I.; Reich, David; Manson, JoAnn E.; O'Donnell, Christopher J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Tybjaerg-Hansen, Anne; Allin, Kristine H.; Nordestgaard, Borge G.] Univ Copenhagen, Copenhagen Univ Hosp, DK-1168 Copenhagen, Denmark; [Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Benjamin, Emelia J.] Boston Univ, Sch Med & Publ Hlth, Boston, MA 02215 USA; [Benjamin, Emelia J.] NHLBI, Framingham Heart Study, Framingham, MA USA; [Franks, Paul W.] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden; [Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Med Sect, Umea, Sweden; [Clarke, Robert; Hopewell, Jemma C.; Watkins, Hugh] Univ Oxford, Oxford OX1 2JD, England; [Wilde, Arthur A. M.; Trip, Mieke D.; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands; [Steri, Maristella] CNR, IRGB, I-00185 Rome, Italy; [Witteman, Jacqueline C. M.; Hofman, Albert] Erasmus MC, Rotterdam, Netherlands; [Qi, Lu] Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, Cambridge, MA 02138 USA; [de Faire, Ulf] Karolinska Inst, S-10401 Stockholm, Sweden; [Erdmann, Jeanette; Schunkert, Heribert] Univ Lubeck, Lubeck, Germany; [Stringham, Heather M.; Boehnke, Michael] Univ Michigan, Ann Arbor, MI 48109 USA; [Koenig, Wolfgang] Univ Ulm, D-89069 Ulm, Germany; [Rader, Daniel J.; Reilly, Muredach P.] Univ Penn, Philadelphia, PA 19104 USA; [Melzer, David] Univ Exeter, Peninsula Coll Med & Dent, Exeter EX4 4QJ, Devon, England; [Psaty, Bruce M.] Univ Washington, Seattle, WA 98195 USA; [Kleber, Marcus E.] LURIC Study Nonprofit LLC, Freiburg, Germany; [Panagiotakos, Demosthenes B.] Harokopio Univ Athens, Athens, Greece; [Willeit, Johann] Med Univ Innsbruck, Innsbruck, Austria; [Woodward, Mark] Univ Sydney, Sydney, NSW 2006, Australia; [Adamovic, Svetlana; Mellstrom, Dan; Ohlsson, Claes; Tivesten, Asa] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Meade, Tom W.] London Sch Hyg & Trop Med, London, England; [Gillum, Richard F.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Shaffer, Jonathan A.] Columbia Univ, Med Ctr, New York, NY 10027 USA; [Onat, Altan] Istanbul Univ, Istanbul, Turkey; [Sundstrom, Johan] Uppsala Univ, Uppsala, Sweden; [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Bronx, NY USA; [Gallacher, John] Cardiff Univ, Cardiff, Wales; [Cushman, Mary; Tracy, Russell P.] Univ Vermont, Burlington, VT 05405 USA; [Kauhanen, Jussi] Univ Eastern Finland, Kuopio, Finland; [Karlsson, Magnus] Lund Univ, S-22100 Lund, Sweden; [Wilhelmsen, Lars] Univ Gothenburg, Gothenburg, Sweden; [Amouyel, Philippe] Inst Pasteur, Lille, France; [Cantin, Bernard] Hop Laval, Laval, PQ, Canada; [Best, Lyle G.] Missouri Breaks Ind Res Inc, Timber Lake, MO USA; [Ben-Shlomo, Yoav; Davey-Smith, George] Univ Bristol, Bristol BS8 1TH, Avon, England; [Wilson, James F.] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; [Wilson, Anthony G.] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England; [Assimes, Themistocles L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Jansson, John-Olov] Gothenburg Univ, S-41124 Gothenburg, Sweden; [Ljunggren, Osten] Uppsala Univ, S-75105 Uppsala, Sweden; [Hamsten, Anders; Ingelsson, Erik] Karolinska Inst, Stockholm, Sweden; [Cambien, Francois] INSERM, F-75654 Paris 13, France; [Hung, Joseph] Univ Western Australia, Nedlands, WA 6009, Australia; [Thomas, G. Neil] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Gudnason, Vilmundur] Univ Iceland, IS-101 Reykjavik, Iceland; [Salomaa, Veikko] Natl Inst Hlth & Welf, Helsinki, Finland; [Holm, Hilma] deCODE Genet, Reykjavik, Iceland	University of Cambridge; University of Leicester; University of Leeds; Harvard University; Brigham & Women's Hospital; Harvard University; University of Copenhagen; Imperial College London; Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lund University; Skane University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Umea University; University of Oxford; University of Amsterdam; Academic Medical Center Amsterdam; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Erasmus University Rotterdam; Erasmus MC; Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; Karolinska Institutet; University of Lubeck; University of Michigan System; University of Michigan; Ulm University; University of Pennsylvania; University of Exeter; University of Plymouth; University of Washington; University of Washington Seattle; Harokopio University Athens; Medical University of Innsbruck; University of Sydney; Sahlgrenska University Hospital; University of London; London School of Hygiene & Tropical Medicine; Centers for Disease Control & Prevention - USA; Columbia University; Istanbul University; Uppsala University; Yeshiva University; Albert Einstein College of Medicine; Cardiff University; University of Vermont; University of Eastern Finland; Lund University; University of Gothenburg; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Laval University; University of Bristol; University of Edinburgh; University of Sheffield; Stanford University; University of Gothenburg; Uppsala University; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia; University of Birmingham; Utrecht University; Utrecht University Medical Center; University of Iceland; Finland National Institute for Health & Welfare	Sarwar, N (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England.	erfc@phpc.cam.ac.uk	Willeit, Peter/HCI-7091-2022; Sundstrom, Johan/R-2139-2019; Willenborg, Christina/D-2668-2012; Wilson, James F/A-5704-2009; Sundström, Johan/A-6286-2009; Gao, Pei/AAF-3065-2019; Panagiotakos, Demosthenes/M-9167-2019; Gudnason, Vilmundur/K-6885-2015; Nordestgaard, Borge Gronne/ABF-1310-2020; Davey Smith, George/A-7407-2013; Kastelein, John/AAF-7950-2020; Panagiotakos, Demosthenes/K-8294-2019; Woodward, Mark/L-6817-2017; Thompson, Peter L/P-1071-2014; Franks, Paul/AAA-3300-2020; Uda, Manuela/AAC-2645-2019; Erdmann, Jeanette/P-7513-2014; Cheng, Kar/AAL-8899-2021; Panagiotakos, Demosthenes/C-9776-2013; Onland-Moret, N. Charlotte/G-9185-2011; Meisinger, Christine/B-5358-2014; Erdmann, Jeanette/A-4417-2009; Shaffer, Jonathan A/B-2783-2013; DiAngelantonio, Emanuele/ABE-6852-2020; Gao, Pei/R-4794-2018; Singleton, Andrew B/C-3010-2009; Hall, Alistair/K-1953-2019; Thorand, Barbara/B-5349-2014; McQuillan, Brendan/B-8271-2013; Allin, Kristine Højgaard/ABG-3463-2021; Ben-Shlomo, Yoav/ABD-2004-2021; Asselbergs, Folkert W./ABD-6752-2021; Assimes, Themistocles Leonard/D-9696-2015; Woodward, Mark/D-8492-2015; Cambien, Francois/AAP-9751-2020; de Bakker, Paul IW/B-8730-2009; Ohlsson, Claes/AGP-3544-2022; Gudnason, Vilmundur/AAE-7126-2019; Kauhanen, Jussi/ABC-4064-2021; Steri, Maristella/AAX-8760-2020; Stefanadis, Christodoulos/ABH-2232-2020; Ohlsson, Claes/HIR-6959-2022; Cushman, Mary/K-1157-2019; Ripatti, Samuli/H-9446-2014; Lleal, Maria Sabater/I-5832-2013; Thomas, G. Neil/A-1879-2013; Smith, Albert Vernon/K-5150-2015; Benjamin, Emelia/E-7103-2011	Willeit, Peter/0000-0002-1866-7159; Sundstrom, Johan/0000-0003-2247-8454; Willenborg, Christina/0000-0001-5217-6882; Wilson, James F/0000-0001-5751-9178; Sundström, Johan/0000-0003-2247-8454; Gao, Pei/0000-0001-8649-1290; Panagiotakos, Demosthenes/0000-0001-8583-153X; Gudnason, Vilmundur/0000-0001-5696-0084; Davey Smith, George/0000-0002-1407-8314; Uda, Manuela/0000-0002-4890-6456; Erdmann, Jeanette/0000-0002-4486-6231; Cheng, Kar/0000-0002-1516-1857; Panagiotakos, Demosthenes/0000-0001-8583-153X; Onland-Moret, N. Charlotte/0000-0002-2360-913X; Gao, Pei/0000-0001-8649-1290; Thorand, Barbara/0000-0002-8416-6440; McQuillan, Brendan/0000-0002-2130-8114; Ben-Shlomo, Yoav/0000-0001-6648-3007; Asselbergs, Folkert W./0000-0002-1692-8669; Assimes, Themistocles Leonard/0000-0003-2349-0009; de Bakker, Paul IW/0000-0001-7735-7858; Ohlsson, Claes/0000-0002-9633-2805; Gudnason, Vilmundur/0000-0001-5696-0084; Steri, Maristella/0000-0001-5869-3872; Stefanadis, Christodoulos/0000-0001-5974-6454; Ohlsson, Claes/0000-0002-9633-2805; Cushman, Mary/0000-0002-7871-6143; Ripatti, Samuli/0000-0002-0504-1202; Lleal, Maria Sabater/0000-0002-0128-379X; Thomas, G. Neil/0000-0002-2777-1847; s, hema/0000-0002-3440-9475; Gigante, Bruna/0000-0003-4508-7990; Rendon, Augusto/0000-0001-8994-0039; Butterworth, Adam/0000-0002-6915-9015; Nordestgaard, Borge/0000-0002-1954-7220; Mannisto, Satu/0000-0002-8668-3046; Hopewell, Jemma/0000-0002-3870-8018; Reilly, Muredach/0000-0002-3035-9386; Fontes, Joao Daniel/0000-0001-5011-0855; Kleber, Marcus/0000-0003-0663-7275; Allin, Kristine Hojgaard/0000-0002-6880-5759; Morris, Richard/0000-0001-7240-4563; Preuss, Michael/0000-0001-5266-8465; Wilson, Anthony Gerard/0000-0003-4855-3926; Bezzina, Connie/0000-0002-0633-3514; Whincup, Peter/0000-0002-5589-4107; Di Angelantonio, Emanuele/0000-0001-8776-6719; Smith, Albert Vernon/0000-0003-1942-5845; Hall, Alistair/0000-0003-0306-7887; Fraser, Ross/0000-0003-0488-2592; Harari, Olivier/0000-0001-8214-489X; Tanck, Michael/0000-0001-9828-4459; Koenig, Wolfgang/0000-0002-2064-9603; Van Duijn, Cornelia/0000-0002-2374-9204; Nelson, Christopher/0000-0001-8025-2897; Melzer, David/0000-0002-0170-3838; Amouyel, Philippe/0000-0001-9088-234X; Shungin, Dmitry/0000-0001-7900-5856; CUCCA, Francesco/0000-0002-7414-1995; Davidson, Karina/0000-0002-9162-477X; Goodall, Alison/0000-0002-7883-9645; Ouwehand, Willem/0000-0002-7744-1790; Watkins, Hugh/0000-0002-5287-9016; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Benjamin, Emelia/0000-0003-4076-2336; Franks, Paul/0000-0002-0520-7604	British Heart Foundation [RG/08/014)]; UK Medical Research Council; UK National Institute of Health Research, Cambridge Biomedical Research Centre; BUPA Foundation; Zoll; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL084034, ZIAHL006175, ZIAHL006173, R01HL091099, ZIAHL006002, R01HL087647, P01HL088117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG001050, ZIAAG000675] Funding Source: NIH RePORTER; MRC [MC_U137686857, G0600705, G0601966, G0700931, MC_U105260799] Funding Source: UKRI; British Heart Foundation [PG/09/002/26056, RG/09/012/28096, RG/08/014/24067] Funding Source: researchfish; Medical Research Council [G0801056B, G0600705, G0700931, MC_U137686857, G0601966, MC_U105260799] Funding Source: researchfish; Chief Scientist Office [CZB/4/710] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute of Health Research, Cambridge Biomedical Research Centre; BUPA Foundation; Zoll; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office	Since April, 2011, Nadeem Sarwar has been a full-time employee of Pfizer Inc. Olivier Harari is an employee of Roche Products. Hilma Holm is an employee of deCODE genetics. Bruce Psaty serves on a data safety and monitoring board for a clinical trial of a device funded by the manufacturer Zoll. JoAnn Manson is listed as a co-inventor on a pending patent held by Brigham and Women's Hospital, Harvard Medical School, that relates to inflammatory markers in diabetes prediction. Paul M Ridker is listed as a co-inventor on patents held by Brigham and Women's Hospital that relate to the use of inflammatory markers in cardiovascular disease, and that have been licensed to AstraZeneca and Siemens. John Danesh has received research funding from the British Heart Foundation, BUPA Foundation, Denka, diaDexus, European Union, European Research Council, Evelyn Trust, Fogarty International Centre, GlaxoSmithKline, Medical Research Council, Merck Sharp and Dohme, National Heart, Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, National Institute for Health Research, Novartis, Pfizer, Roche, Wellcome Trust, and UK Biobank, and has served on advisory boards for Merck, Pfizer, and Novartis, for which he has received compensation. All other members of the writing committee declare that they have no conflicts of interest.; The coordinating centre was supported by the British Heart Foundation (RG/08/014), the UK Medical Research Council, the UK National Institute of Health Research, Cambridge Biomedical Research Centre, and a specific grant from the BUPA Foundation. Various sources have supported recruitment, follow-up, and laboratory measurements in the studies contributing to this report. Investigators of several of these studies have contributed to a list naming some of these funding sources. Sekar Kathiresan, Kenneth G C Smith, and John Todd commented helpfully on an earlier version of this report.	Abeywardena MY, 2009, CURR PHARM DESIGN, V15, P1809, DOI 10.2174/138161209788186290; Bannwarth B, 2011, EXPERT OPIN DRUG SAF, V10, P123, DOI 10.1517/14740338.2011.537256; Butterworth AS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002260; Choy E, 2009, ANN RHEUM DIS, V68, P460, DOI 10.1136/ard.2008.101964; Danesh J, 2005, JAMA-J AM MED ASSOC, V294, P1799, DOI 10.1001/jama.294.14.1799; Danesh J, 2008, PLOS MED, V5, P600, DOI 10.1371/journal.pmed.0050078; Danik JS, 2009, CIRC-CARDIOVASC GENE, V2, P134, DOI 10.1161/CIRCGENETICS.108.825273; Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570; Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148; Eleftherohorinou H, 2011, HUM MOL GENET, V20, P3494, DOI 10.1093/hmg/ddr248; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Furst DE, 2012, ANN RHEUM DIS, V71, P2, DOI 10.1136/annrheumdis-2011-201036; Genovese MC, 2009, RHEUMATOLOGY, V48, pI81; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kanoni S, 2011, ICHG ASHG SCI M MONT; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Keavney B, 2006, INT J EPIDEMIOL, V35, P935, DOI 10.1093/ije/dyl114; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Linsel-Nitschke P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002986; Marinou I, 2010, ANN RHEUM DIS, V69, P1191, DOI 10.1136/ard.2008.100644; McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948; Melzer D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000072; MULLBERG J, 1994, J IMMUNOL, V152, P4958; Nica AC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002003; Nurmohamed MT, 2007, VASC HEALTH RISK MAN, V3, P845; Protogerou AD, 2011, ATHEROSCLEROSIS, V219, P734, DOI 10.1016/j.atherosclerosis.2011.09.015; Lamas JR, 2011, ARTHRITIS RHEUM-US, V63, pS143; Reich D, 2007, AM J HUM GENET, V80, P716, DOI 10.1086/513206; Reilly MP, 2011, LANCET, V377, P383, DOI 10.1016/S0140-6736(10)61996-4; Ridker PM, 2008, AM J HUM GENET, V82, P1185, DOI 10.1016/j.ajhg.2008.03.015; Ridker PM, 2011, AM HEART J, V162, P597, DOI 10.1016/j.ahj.2011.06.012; Ridker PM, 2009, J THROMB HAEMOST, V7, P332, DOI 10.1111/j.1538-7836.2009.03404.x; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Sarwar N, 2010, LANCET, V375, P1634, DOI 10.1016/S0140-6736(10)60545-4; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schmitt C, 2011, CLIN PHARMACOL THER, V89, P735, DOI 10.1038/clpt.2011.35; Schuett H, 2012, ARTERIOSCL THROM VAS, V32, P281, DOI 10.1161/ATVBAHA.111.229435; Schuett H, 2009, THROMB HAEMOSTASIS, V102, P215, DOI 10.1160/TH09-05-0297; Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Stephens OW, 2012, BLOOD, V119, P503, DOI 10.1182/blood-2011-07-367052; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Thompson A, 2010, LANCET, V375, P1536, DOI 10.1016/S0140-6736(10)60319-4; US Food and Drug Administration, 2011, FDA APPR NEW DRUG RH; Wassel CL, 2011, BLOOD, V117, P268, DOI 10.1182/blood-2010-06-289546; Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	49	541	560	3	95	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2012	379	9822					1205	1213		10.1016/S0140-6736(11)61931-4	http://dx.doi.org/10.1016/S0140-6736(11)61931-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918DV	22421339	Green Published, Green Submitted			2022-12-28	WOS:000302230400033
J	Shetty, P				Shetty, Priya			Beate Kampmann: research advocate for children with tuberculosis	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1093	1093		10.1016/S0140-6736(12)60451-6	http://dx.doi.org/10.1016/S0140-6736(12)60451-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22444393	Bronze			2022-12-28	WOS:000302131800018
J	Gardner, KH; Correa, F				Gardner, Kevin H.; Correa, Fernando			How Plants See the Invisible	SCIENCE			English	Editorial Material							UV-B; PROTEIN; ARABIDOPSIS; PHOTORECEPTORS		[Gardner, Kevin H.; Correa, Fernando] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Gardner, KH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.	kevin.gardner@utsouthwestern.edu	Gardner, Kevin/K-5493-2019; Gardner, Kevin H./K-7802-2012	Gardner, Kevin H./0000-0002-8671-2556; Correa, Fernando/0000-0001-5349-1104	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081875] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM081875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown BA, 2005, P NATL ACAD SCI USA, V102, P18225, DOI 10.1073/pnas.0507187102; Christie JM, 2012, SCIENCE, V335, P1492, DOI 10.1126/science.1218091; Favory JJ, 2009, EMBO J, V28, P591, DOI 10.1038/emboj.2009.4; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; Moglich A, 2010, ANNU REV PLANT BIOL, V61, P21, DOI 10.1146/annurev-arplant-042809-112259; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Rizzini L, 2011, SCIENCE, V332, P103, DOI 10.1126/science.1200660; Scholes GD, 2011, NAT CHEM, V3, P763, DOI [10.1038/NCHEM.1145, 10.1038/nchem.1145]; Toettcher JE, 2011, NAT METHODS, V8, P35, DOI [10.1038/nmeth.f.326, 10.1038/NMETH.F.326]; Ulm R, 2004, P NATL ACAD SCI USA, V101, P1397, DOI 10.1073/pnas.0308044100; Vallurupalli P, 2008, J AM CHEM SOC, V130, P2734, DOI 10.1021/ja710817g; Wu D., 2012, NATURE          0229, DOI [10.1038/nature10931, DOI 10.1038/NATURE10931]; Zoltowski BD, 2011, BIOCHEMISTRY-US, V50, P4, DOI 10.1021/bi101665s	14	6	6	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1451	1452		10.1126/science.1220248	http://dx.doi.org/10.1126/science.1220248			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442470				2022-12-28	WOS:000301837000031
J	Cutler, DM; Ghosh, K				Cutler, David M.; Ghosh, Kaushik			The Potential for Cost Savings through Bundled Episode Payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SURGERY		[Cutler, David M.] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA; [Cutler, David M.; Ghosh, Kaushik] Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; National Bureau of Economic Research	Cutler, DM (corresponding author), Harvard Univ, Dept Econ, Cambridge, MA 02138 USA.			Cutler, David/0000-0002-4949-8917	NATIONAL INSTITUTE ON AGING [P01AG031098] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG031098, P01 AG031098-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cromwell J, 1997, HEALTH CARE FINANC R, V19, P41; Miller DC, 2011, HEALTH AFFAIR, V30, P2107, DOI 10.1377/hlthaff.2011.0783; Nelson L, 2012, LESSONS MED DEMONSTR; Skinner JS, 2011, NEW SERIES MED EXPEN; Sood N, 2011, HEALTH AFFAIR, V30, P1708, DOI 10.1377/hlthaff.2010.0394	5	204	205	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1075	1077		10.1056/NEJMp1113361	http://dx.doi.org/10.1056/NEJMp1113361			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912BO	22435368	Green Accepted, Green Published			2022-12-28	WOS:000301769700006
J	Wilensky, GR				Wilensky, Gail R.			Directions for Bipartisan Medicare Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Project HOPE, Bethesda, MD USA		Wilensky, GR (corresponding author), Project HOPE, Bethesda, MD USA.							[Anonymous], 2010, CHANG PROJ MED SPEND; Debt Reduction Task Force, REST AM FUT; House of Representatives Committee on the Budget, PATH PROSP REST AM P; Wyden Ron, GUARANTEED CHOICES S	4	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1071	1073		10.1056/NEJMp1200914	http://dx.doi.org/10.1056/NEJMp1200914			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912BO	22397632				2022-12-28	WOS:000301769700004
J	Sokol, DK				Sokol, Daniel K.			No laughing matter One doctor's "banter" is another's offensive remark	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Sokol, DK (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	daniel.sokol@talk21.com						General Medical Council, GOOD MED PRACT RESP; General Medical Council, DEC; Hadfield S., 1958, LAW ETHICS DOCTORS; Osler W, 1985, COLLECTED ESSAYS W O, P413; Percival T., 1985, MED ETHICS	5	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2119	10.1136/bmj.e2119	http://dx.doi.org/10.1136/bmj.e2119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438391				2022-12-28	WOS:000301849200006
J	Spence, D				Spence, Des			Baby boomers go bust	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], SMOK STAT; Cowie I, TELEGRAPH; Office for National Statistics, 1993, TRENDS AV MORT ENGL	3	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2191	10.1136/bmj.e2191	http://dx.doi.org/10.1136/bmj.e2191			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438382				2022-12-28	WOS:000301849200024
J	Glickman, MS; Sawyers, CL				Glickman, Michael S.; Sawyers, Charles L.			Converting Cancer Therapies into Cures: Lessons from Infectious Diseases	CELL			English	Review							IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANT PROSTATE-CANCER; TYROSINE KINASE INHIBITOR; CATALASE-PEROXIDASE GENE; ESCHERICHIA-COLI K-12; CHRONIC-PHASE; LUNG-CANCER; ACQUIRED-RESISTANCE; CONTROLLED-TRIAL; DRUG-RESISTANCE	During the past decade, cancer drug development has shifted from a focus on cytotoxic chemotherapies to drugs that target specific molecular alterations in tumors. Although these drugs dramatically shrink tumors, the responses are temporary. Research is now focused on overcoming drug resistance, a frequent cause of treatment failure. Here we reflect on analogous challenges faced by researchers in infectious diseases. We compare and contrast the resistance mechanisms arising in cancer and infectious diseases and discuss how approaches for overcoming viral and bacterial infections, such as HIV and tuberculosis, are instructive for developing a more rational approach for cancer therapy. In particular, maximizing the effect of the initial treatment response, which often requires synergistic combination therapy, is foremost among these approaches. A remaining challenge in both fields is identifying drugs that eliminate drug-tolerant "persister'' cells (infectious disease) or tumor-initiating/stem cells (cancer) to prevent late relapse and shorten treatment duration.	[Glickman, Michael S.] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY 10065 USA; [Glickman, Michael S.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA; [Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Sawyers, Charles L.] Howard Hughes Med Inst, Chevy Chase, MD USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Glickman, MS (corresponding author), Mem Sloan Kettering Canc Ctr, Infect Dis Serv, 1275 York Ave, New York, NY 10065 USA.	glickmam@mskcc.org; sawyersc@mskcc.org	Sawyers, Charles/G-5327-2016	Glickman, Michael S/0000-0001-7918-5164	Howard Hughes Medical Institute; NCI; Stand Up to Cancer; Geoffrey Beene Cancer Research Center; Starr Cancer Consortium; NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053417] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stand Up to Cancer; Geoffrey Beene Cancer Research Center; Starr Cancer Consortium; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors apologize to those whose work could not be cited due to space limitations. Work in the Sawyers laboratory is supported by the Howard Hughes Medical Institute and grants from NCI and Stand Up to Cancer. Work in the Glickman laboratory is supported by the Geoffrey Beene Cancer Research Center, the Starr Cancer Consortium, and NIAID.	Adams KN, 2011, CELL, V145, P39, DOI 10.1016/j.cell.2011.02.022; Allan EJ, 2009, ADV APPL MICROBIOL, V68, P1, DOI 10.1016/S0065-2164(09)01201-5; ALTAMIRANO M, 1994, J INFECT DIS, V169, P1162, DOI 10.1093/infdis/169.5.1162; [Anonymous], 1950, Br Med J, V2, P1073; [Anonymous], 1952, Br Med J, V2, P735; [Anonymous], 1947, Am Rev Tuberc, V56, P485; [Anonymous], 1948, Br Med J, V2, P769; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Blanco JL, 2011, J INFECT DIS, V203, P1204, DOI 10.1093/infdis/jir025; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Borges S, 2006, CLIN PHARMACOL THER, V80, P61, DOI 10.1016/j.clpt.2006.03.013; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Casadevall A, 2009, EXPERT OPIN PHARMACO, V10, P1699, DOI 10.1517/14656560903066837; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Clatworthy AE, 2007, NAT CHEM BIOL, V3, P541, DOI 10.1038/nchembio.2007.24; Connolly LE, 2007, PLOS MED, V4, P435, DOI 10.1371/journal.pmed.0040120; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cornaglia G, 2011, LANCET INFECT DIS, V11, P381, DOI 10.1016/S1473-3099(11)70056-1; Critical Path Institute, 2010, CRIT PATH TB DRUG RE; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Del Favero A, 2001, CLIN INFECT DIS, V33, P1295, DOI 10.1086/322646; DiPersio JF, 2009, J CLIN ONCOL, V27, P4767, DOI 10.1200/JCO.2008.20.7209; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Food and Drug Administration [FDA], 2010, GUID IND COD 2 MOR U; Fox W, 1999, INT J TUBERC LUNG D, V3, pS231; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hughes TP, 2010, BLOOD, V116, P3758, DOI 10.1182/blood-2010-03-273979; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kantarjian HM, 2007, BLOOD, V110, P3540, DOI 10.1182/blood-2007-03-080689; Lander AD, 2011, CELL, V144, P955, DOI 10.1016/j.cell.2011.03.009; Leary RJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000702; LEHMANN J, 1946, LANCET, V250, P15; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; Mackinnon S, 1997, BAILLIERE CLIN HAEM, V10, P357, DOI 10.1016/S0950-3536(97)80012-1; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Maisonneuve E, 2011, P NATL ACAD SCI USA, V108, P13206, DOI 10.1073/pnas.1100186108; Marcellin P, 2008, NEW ENGL J MED, V359, P2442, DOI 10.1056/NEJMoa0802878; Martinez-Picado J, 2008, VIRUS RES, V134, P104, DOI 10.1016/j.virusres.2007.12.021; MASKELL R, 1978, J MED MICROBIOL, V11, P33, DOI 10.1099/00222615-11-1-33; MOYED HS, 1983, J BACTERIOL, V155, P768, DOI 10.1128/JB.155.2.768-775.1983; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Skaggs BJ, 2006, P NATL ACAD SCI USA, V103, P19466, DOI 10.1073/pnas.0609239103; STEEN R, 1985, ANTIMICROB AGENTS CH, V27, P933, DOI 10.1128/AAC.27.6.933; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; WOLFSON JS, 1990, ANTIMICROB AGENTS CH, V34, P1938, DOI 10.1128/AAC.34.10.1938; Zapun A, 2008, FEMS MICROBIOL REV, V32, P361, DOI 10.1111/j.1574-6976.2007.00095.x; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	84	132	135	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1089	1098		10.1016/j.cell.2012.02.015	http://dx.doi.org/10.1016/j.cell.2012.02.015			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424221	Green Accepted, Bronze			2022-12-28	WOS:000301889500008
J	Vaidyanathan, G				Vaidyanathan, Gayathri			Redefining Clinical Trials: The Age of Personalized Medicine	CELL			English	Editorial Material								The triumph of personalized cancer therapeutics in recent years is prompting some oncologists to rethink clinical trial design; other researchers have different priorities for trial reform.											0	20	21	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 16	2012	148	6					1079	1080		10.1016/j.cell.2012.02.041	http://dx.doi.org/10.1016/j.cell.2012.02.041			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424218	Bronze			2022-12-28	WOS:000301889500005
J	Christy, MR; Shridharani, SM				Christy, Michael R.; Shridharani, Sachin M.			Appearance of a Rapidly Expanding Facial Eschar in a Severely Injured Trauma Patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MUCORMYCOSIS		[Christy, Michael R.] R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Div Plast Reconstruct & Maxillofacial Surg, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Christy, MR (corresponding author), R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.	mchristy@umm.edu	Shridharani, Sachin/AAH-2846-2019					Ashkenazi-Hoffnung L, 2010, TRANSPLANTATION, V90, P1133, DOI 10.1097/TP.0b013e3181f86916; Ketenci I, 2011, J LARYNGOL OTOL, V125, DOI 10.1017/S0022215111000843; Lin CT, 2011, Z GASTROENTEROL, V49, P449, DOI 10.1055/s-0029-1245694; Losee JE, 2002, ANN PLAS SURG, V49, P385, DOI 10.1097/00000637-200210000-00009; Prabhu RM, 2004, CLIN MICROBIOL INFEC, V10, P31, DOI 10.1111/j.1470-9465.2004.00843.x; Van Sickels N, 2011, J TRAUMA, V70, P507, DOI 10.1097/TA.0b013e31820784ff; VELIATH AJ, 1976, ARCH DERMATOL, V112, P509, DOI 10.1001/archderm.112.4.509	7	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1080	1081		10.1001/jama.2012.288	http://dx.doi.org/10.1001/jama.2012.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416104				2022-12-28	WOS:000301479700029
J	Piastra, M; Pietrini, D; Conti, G; De Rosa, G; Rigante, D				Piastra, Marco; Pietrini, Domenico; Conti, Giorgio; De Rosa, Gabriella; Rigante, Donato			Sudden shock from capillary leak	LANCET			English	Editorial Material							COMPARTMENT SYNDROME		[Piastra, Marco; Pietrini, Domenico; Conti, Giorgio] Univ Cattolica Sacro Cuore, Paediat Intens Care Unit, I-00168 Rome, Italy; [De Rosa, Gabriella; Rigante, Donato] Univ Cattolica Sacro Cuore, Dept Paediat Sci, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Piastra, M (corresponding author), Univ Cattolica Sacro Cuore, Paediat Intens Care Unit, Largo A Gemelli 8, I-00168 Rome, Italy.	marco_piastra@yahoo.it	Rigante, Donato/Q-1044-2019; Rigante, Donato/AAE-2660-2019; Conti, Giorgio/AAB-9546-2022	Rigante, Donato/0000-0001-7032-7779; Conti, Giorgio/0000-0002-8566-9365; DE ROSA, Gabriella/0000-0002-8780-5105				CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; Gousseff M, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00004; Karatzios C, 2006, PEDIATR CRIT CARE ME, V7, P377, DOI 10.1097/01.PCC.0000227120.61949.FB; Matsumura M, 2007, INTERNAL MED, V46, P1585, DOI 10.2169/internalmedicine.46.0254; Sanghavi R, 2006, ANAESTH INTENS CARE, V34, P388, DOI 10.1177/0310057X0603400308	5	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 10	2012	379	9819					976	976		10.1016/S0140-6736(11)61819-9	http://dx.doi.org/10.1016/S0140-6736(11)61819-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22405799				2022-12-28	WOS:000301353700038
J	Davidson, EH				Davidson, Eric H.			Roy J. Britten (1919-2012)	SCIENCE			English	Biographical-Item									CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Davidson, EH (corresponding author), CALTECH, Pasadena, CA 91125 USA.	davidson@caltech.edu						BRITTEN RJ, PUBLICATION LIST	1	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1183	1183		10.1126/science.1220828	http://dx.doi.org/10.1126/science.1220828			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403381				2022-12-28	WOS:000301225100033
J	Benedito, R; Rocha, SF; Woeste, M; Zamykal, M; Radtke, F; Casanovas, O; Duarte, A; Pytowski, B; Adams, RH				Benedito, Rui; Rocha, Susana F.; Woeste, Marina; Zamykal, Martin; Radtke, Freddy; Casanovas, Oriol; Duarte, Antonio; Pytowski, Bronislaw; Adams, Ralf H.			Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling	NATURE			English	Article							TIP CELL-FORMATION; DLL4; ACTIVATION; GROWTH; BEVACIZUMAB; PATHWAYS; INHIBIT; LIGAND; MOUSE; D114	Developing tissues and growing tumours produce vascular endothelial growth factors (VEGFs), leading to the activation of the corresponding receptors in endothelial cells. The resultant angiogenic expansion of the local vasculature can promote physiological and pathological growth processes(1). Previous work has uncovered that the VEGF and Notch pathways are tightly linked. Signalling triggered by VEGF-A (also known as VEGF) has been shown to induce expression of the Notch ligand DLL4 in angiogenic vessels and, most prominently, in the tip of endothelial sprouts(2,3). DLL4 activates Notch in adjacent cells, which suppresses the expression of VEGF receptors and thereby restrains endothelial sprouting and proliferation(2,4-6). Here we show, by using inducible loss-of-function genetics in combination with inhibitors in vivo, that DLL4 protein expression in retinal tip cells is only weakly modulated by VEGFR2 signalling. Surprisingly, Notch inhibition also had no significant impact on VEGFR2 expression and induced deregulated endothelial sprouting and proliferation even in the absence of VEGFR2, which is the most important VEGF-A receptor and is considered to be indispensable for these processes. By contrast, VEGFR3, the main receptor for VEGF-C, was strongly modulated by Notch. VEGFR3 kinase-activity inhibitors but not ligand-blocking antibodies suppressed the sprouting of endothelial cells that had low Notch signalling activity. Our results establish that VEGFR2 and VEGFR3 are regulated in a highly differential manner by Notch. We propose that successful anti-angiogenic targeting of these receptors and their ligands will strongly depend on the status of endothelial Notch signalling.	[Benedito, Rui; Rocha, Susana F.; Woeste, Marina; Zamykal, Martin; Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D-48149 Munster, Germany; [Benedito, Rui; Rocha, Susana F.; Woeste, Marina; Zamykal, Martin; Adams, Ralf H.] Univ Munster, Fac Med, D-48149 Munster, Germany; [Radtke, Freddy] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, CH-1015 Lausanne, Switzerland; [Casanovas, Oriol] IDIBELL, Catalan Inst Oncol, Translat Res Lab, Lhospitalet De Llobregat 08907, Spain; [Duarte, Antonio] Univ Tecn Lisboa, Fac Vet Med, Interdisciplinary Ctr Res Anim Hlth CIISA, P-1300474 Lisbon, Portugal; [Pytowski, Bronislaw] ImClone Syst, New York, NY 10014 USA	Max Planck Society; University of Munster; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade de Lisboa; Eli Lilly	Adams, RH (corresponding author), Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D-48149 Munster, Germany.	rui.benedito@mpi-muenster.mpg.de; ralf.adams@mpi-muenster.mpg.de	Radtke, Freddy/Q-3198-2017; Benedito, Rui/AAQ-8096-2020; Benedito, Rui/G-8295-2012; Adams, Ralf H/AAE-9274-2019; Duarte, Antonio/V-1178-2018; Casanovas, Oriol/L-5210-2014	Radtke, Freddy/0000-0003-4315-4045; Benedito, Rui/0000-0003-2458-3055; Benedito, Rui/0000-0003-2458-3055; Duarte, Antonio/0000-0002-9255-3635; Casanovas, Oriol/0000-0002-4298-3995	Max Planck Society; University of Munster; German Research Foundation [SFB 629, SPP 1190]	Max Planck Society(Max Planck Society); University of Munster; German Research Foundation(German Research Foundation (DFG))	We thank M. Schiller, M. Ehling, M. Pitulescu and M. Nakayama for the help with experiments and discussions, and G. Breier and T. Honjo for floxed Vegfr2 and Rbpj mutant mice, respectively. Funding was provided by the Max Planck Society, the University of Munster and the German Research Foundation (programmes SFB 629 and SPP 1190).	Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Claxton S, 2008, GENESIS, V46, P74, DOI 10.1002/dvg.20367; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Estrach S, 2011, CIRC RES, V109, P172, DOI 10.1161/CIRCRESAHA.111.240622; Galvagni F, 2010, CIRC RES, V106, P1839, DOI 10.1161/CIRCRESAHA.109.206326; Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Harrington LS, 2008, MICROVASC RES, V75, P144, DOI 10.1016/j.mvr.2007.06.006; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hogan BM, 2009, DEVELOPMENT, V136, P4001, DOI 10.1242/dev.039990; Jubb AM, 2010, LANCET ONCOL, V11, P1172, DOI 10.1016/S1470-2045(10)70232-1; Kirkin V, 2001, EUR J BIOCHEM, V268, P5530, DOI 10.1046/j.1432-1033.2001.02476.x; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902; Manley PW, 2002, J MED CHEM, V45, P5687, DOI 10.1021/jm020899q; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Prewett M, 1999, CANCER RES, V59, P5209; Pytowski B, 2005, JNCI-J NATL CANCER I, V97, P14, DOI 10.1093/jnci/dji003; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Sainson RCA, 2005, FASEB J, V19, P1027, DOI 10.1096/fj.04-3172fje; Siekmann AF, 2008, BIOESSAYS, V30, P303, DOI 10.1002/bies.20736; Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577; Stenzel D, 2011, EMBO REP, V12, P1135, DOI 10.1038/embor.2011.194; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Tammela T, 2011, NAT CELL BIOL, V13, P1202, DOI 10.1038/ncb2331; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Zhang LQ, 2010, CELL RES, V20, P1319, DOI 10.1038/cr.2010.116	36	258	276	2	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					110	+		10.1038/nature10908	http://dx.doi.org/10.1038/nature10908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22426001				2022-12-28	WOS:000302343400044
J	Harvey, CD; Coen, P; Tank, DW				Harvey, Christopher D.; Coen, Philip; Tank, David W.			Choice-specific sequences in parietal cortex during a virtual-navigation decision task	NATURE			English	Article							HIPPOCAMPAL PLACE CELLS; PREFRONTAL CORTEX; WORKING-MEMORY; CELLULAR RESOLUTION; PERCEPTUAL DECISIONS; SPATIAL INFORMATION; ACTIVITY PATTERNS; NEURAL ACTIVITY; VISUAL-CORTEX; DYNAMICS	The posterior parietal cortex (PPC) has an important role in many cognitive behaviours; however, the neural circuit dynamics underlying PPC function are not well understood. Here we optically imaged the spatial and temporal activity patterns of neuronal populations in mice performing a PPC-dependent task that combined a perceptual decision and memory-guided navigation in a virtual environment. Individual neurons had transient activation staggered relative to one another in time, forming a sequence of neuronal activation spanning the entire length of a task trial. Distinct sequences of neurons were triggered on trials with opposite behavioural choices and defined divergent, choice-specific trajectories through a state space of neuronal population activity. Cells participating in the different sequences and at distinct time points in the task were anatomically intermixed over microcircuit length scales (<100 micrometres). During working memory decision tasks, the PPC may therefore perform computations through sequence-based circuit dynamics, rather than long-lived stable states, implemented using anatomically intermingled microcircuits.	[Harvey, Christopher D.; Coen, Philip; Tank, David W.] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Tank, David W.] Princeton Univ, Bezos Ctr Neural Circuit Dynam, Princeton, NJ 08544 USA; [Harvey, Christopher D.; Tank, David W.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Harvey, Christopher D.; Coen, Philip; Tank, David W.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University; Princeton University	Harvey, CD (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	christopher_harvey@hms.harvard.edu; dwtank@princeton.edu	Fernandez-Revelles, Andres B/A-4391-2012	Fernandez-Revelles, Andres B/0000-0002-8089-650X; COEN, PHILIP/0000-0003-1495-1061	NIH [R01-MH083686, RC1-NS068148]; Helen Hay Whitney Foundation; Burroughs Wellcome Fund Career Award at the Scientific Interface; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH083686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [RC1NS068148] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helen Hay Whitney Foundation; Burroughs Wellcome Fund Career Award at the Scientific Interface(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank D. Dombeck for assistance with imaging methods and analysis; C. Domnisoru, M. de Bettencourt, C. Brody and A. Miri for discussions; and M. Goldman, J. Hopfield, D. Aronov, B. Scott and T. Hanks for comments on the manuscript. This work was supported by the NIH (R01-MH083686; RC1-NS068148), a fellowship from the Helen Hay Whitney Foundation (C.D.H.), and a Burroughs Wellcome Fund Career Award at the Scientific Interface (C.D.H.)	Andersen RA, 2009, NEURON, V63, P568, DOI 10.1016/j.neuron.2009.08.028; Baeg EH, 2003, NEURON, V40, P177, DOI 10.1016/S0896-6273(03)00597-X; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BATUEV AS, 1994, ACTA NEUROBIOL EXP, V54, P335; Binzegger T, 2004, J NEUROSCI, V24, P8441, DOI 10.1523/JNEUROSCI.1400-04.2004; Bisley JW, 2010, ANNU REV NEUROSCI, V33, P1, DOI 10.1146/annurev-neuro-060909-152823; Braitenberg V, 1991, ANATOMY CORTEX STAT; Briggman KL, 2005, SCIENCE, V307, P896, DOI 10.1126/science.1103736; Burke SN, 2005, NEURON, V45, P667, DOI 10.1016/j.neuron.2005.01.042; Calton JL, 2009, NEUROBIOL LEARN MEM, V91, P186, DOI 10.1016/j.nlm.2008.09.015; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Churchland MM, 2007, CURR OPIN NEUROBIOL, V17, P609, DOI 10.1016/j.conb.2007.11.001; Corwin JV, 1998, PSYCHOBIOLOGY, V26, P87; Crowe DA, 2010, J NEUROSCI, V30, P11640, DOI 10.1523/JNEUROSCI.0954-10.2010; Curtis CE, 2010, TRENDS COGN SCI, V14, P216, DOI 10.1016/j.tics.2010.03.006; Dombeck DA, 2007, NEURON, V56, P43, DOI 10.1016/j.neuron.2007.08.003; Dombeck DA, 2010, NAT NEUROSCI, V13, P1433, DOI 10.1038/nn.2648; Erlich JC, 2011, NEURON, V72, P330, DOI 10.1016/j.neuron.2011.07.010; Freedman DJ, 2011, NAT NEUROSCI, V14, P143, DOI 10.1038/nn.2740; Fujisawa S, 2008, NAT NEUROSCI, V11, P823, DOI 10.1038/nn.2134; Ganguli S, 2008, NEURON, V58, P15, DOI 10.1016/j.neuron.2008.01.038; Ganguli S, 2008, P NATL ACAD SCI USA, V105, P18970, DOI 10.1073/pnas.0804451105; Gold JI, 2007, ANNU REV NEUROSCI, V30, P535, DOI 10.1146/annurev.neuro.29.051605.113038; Goldman MS, 2009, NEURON, V61, P621, DOI 10.1016/j.neuron.2008.12.012; Harvey CD, 2009, NATURE, V461, P941, DOI 10.1038/nature08499; Jun JK, 2010, J NEUROSCI, V30, P916, DOI 10.1523/JNEUROSCI.2062-09.2010; Ko H, 2011, NATURE, V473, P87, DOI 10.1038/nature09880; Komiyama T, 2010, NATURE, V464, P1182, DOI 10.1038/nature08897; Leon MI, 2003, NEURON, V38, P317, DOI 10.1016/S0896-6273(03)00185-5; Maass W, 2007, PLOS COMPUT BIOL, V3, P15, DOI 10.1371/journal.pcbi.0020165; Machens CK, 2010, J NEUROSCI, V30, P350, DOI 10.1523/JNEUROSCI.3276-09.2010; Machens CK, 2005, SCIENCE, V307, P1121, DOI 10.1126/science.1104171; Mazor O, 2005, NEURON, V48, P661, DOI 10.1016/j.neuron.2005.09.032; Mazurek ME, 2003, CEREB CORTEX, V13, P1257, DOI 10.1093/cercor/bhg097; MCNAUGHTON BL, 1994, CEREB CORTEX, V4, P27, DOI 10.1093/cercor/4.1.27; Miller P, 2003, CEREB CORTEX, V13, P1208, DOI 10.1093/cercor/bhg101; Nitz DA, 2006, NEURON, V49, P747, DOI 10.1016/j.neuron.2006.01.037; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Pastalkova E, 2008, SCIENCE, V321, P1322, DOI 10.1126/science.1159775; Seidemann E, 1996, J NEUROSCI, V16, P752; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Singh R, 2006, J NEUROSCI, V26, P3667, DOI 10.1523/JNEUROSCI.4864-05.2006; Song S, 2005, PLOS BIOL, V3, P507, DOI 10.1371/journal.pbio.0030068; Sussillo D, 2009, NEURON, V63, P544, DOI 10.1016/j.neuron.2009.07.018; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Wang XJ, 2008, NEURON, V60, P215, DOI 10.1016/j.neuron.2008.09.034; Whitlock JR, 2008, P NATL ACAD SCI USA, V105, P14755, DOI 10.1073/pnas.0804216105; Wong KF, 2006, J NEUROSCI, V26, P1314, DOI 10.1523/JNEUROSCI.3733-05.2006; Wood ER, 2000, NEURON, V27, P623, DOI 10.1016/S0896-6273(00)00071-4; Yoshimura Y, 2005, NATURE, V433, P868, DOI 10.1038/nature03252	50	531	535	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					62	68		10.1038/nature10918	http://dx.doi.org/10.1038/nature10918			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22419153	Green Accepted			2022-12-28	WOS:000302343400034
J	Mehari, A; Gladwin, MT; Tian, X; Machado, RF; Kato, GJ				Mehari, Alem; Gladwin, Mark T.; Tian, Xin; Machado, Roberto F.; Kato, Gregory J.			Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Mehari, Alem] Howard Univ, Coll Med, Washington, DC 20059 USA; [Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; [Tian, Xin; Kato, Gregory J.] NHLBI, Bethesda, MD 20892 USA; [Machado, Roberto F.] Univ Illinois, Sect Pulm Crit Care Med Sleep & Allergy, Chicago, IL USA	Howard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehari, A (corresponding author), Howard Univ, Coll Med, Washington, DC 20059 USA.	gkato@mail.nih.gov	Kato, Gregory J/I-7615-2014	Kato, Gregory J/0000-0003-4465-3217; Machado, Roberto/0000-0002-3722-5954	Intramural NIH HHS [ZIA HL006015-04, ZIA HL006012-02, ZIA HL006015, ZIA HL006011, ZIA HL006011-04, ZIA HL006012] Funding Source: Medline; NHLBI NIH HHS [R01HL098032, R01HL096973, R01 HL098032, P01HL103455, K23 HL098454, R01 HL096973, P01 HL103455, K23HL098454] Funding Source: Medline; NIDDK NIH HHS [RC1DK085852, RC1 DK085852] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006015, R01HL096973, P01HL103455, ZIAHL006014, K23HL098454, ZIAHL005116, ZIAHL006012, R01HL098032, ZIAHL006011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [RC1DK085852] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ataga KI, 2006, BRIT J HAEMATOL, V134, P109, DOI 10.1111/j.1365-2141.2006.06110.x; Bunn HF, 2010, BLOOD, V116, P687, DOI 10.1182/blood-2010-02-268193; Fonseca GHH, 2012, EUR RESPIR J, V39, P112, DOI 10.1183/09031936.00134410; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Parent F, 2011, NEW ENGL J MED, V365, P44, DOI 10.1056/NEJMoa1005565	5	141	145	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1254	1256		10.1001/jama.2012.358	http://dx.doi.org/10.1001/jama.2012.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453563	Green Accepted, Bronze			2022-12-28	WOS:000301978400017
J	Wellbery, C				Wellbery, Caroline			Our Ubiquitous Technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA	Georgetown University	Wellbery, C (corresponding author), Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA.	wellberc@georgetown.edu						Levy D, 2011, ASS CONT MIND HIGH E; Masson V., 2007, CLIN GUIDE SOUL	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1263	1264		10.1001/jama.2012.343	http://dx.doi.org/10.1001/jama.2012.343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453567				2022-12-28	WOS:000301978400021
J	Scott, MC; Chen, CC; Mecklenburg, M; Zhu, C; Xu, R; Ercius, P; Dahmen, U; Regan, BC; Miao, JW				Scott, M. C.; Chen, Chien-Chun; Mecklenburg, Matthew; Zhu, Chun; Xu, Rui; Ercius, Peter; Dahmen, Ulrich; Regan, B. C.; Miao, Jianwei			Electron tomography at 2.4-angstrom resolution	NATURE			English	Article							ATOMIC-SCALE; MICROSCOPY; CONTRAST; CELLS	Transmission electron microscopy is a powerful imaging tool that has found broad application in materials science, nanoscience and biology(1-3). With the introduction of aberration-corrected electron lenses, both the spatial resolution and the image quality in transmission electron microscopy have been significantly improved(4,5) and resolution below 0.5 angstroms has been demonstrated(6). To reveal the three-dimensional (3D) structure of thin samples, electron tomography is the method of choice(7-11), with cubic-nanometre resolution currently achievable(10,11). Discrete tomography has recently been used to generate a 3D atomic reconstruction of a silver nanoparticle two to three nanometres in diameter(12), but this statistical method assumes prior knowledge of the particle's lattice structure and requires that the atoms fit rigidly on that lattice. Here we report the experimental demonstration of a general electron tomography method that achieves atomic-scale resolution without initial assumptions about the sample structure. By combining a novel projection alignment and tomographic reconstruction method with scanning transmission electron microscopy, we have determined the 3D structure of an approximately ten-nanometre gold nanoparticle at 2.4-angstrom resolution. Although we cannot definitively locate all of the atoms inside the nanoparticle, individual atoms are observed in some regions of the particle and several grains are identified in three dimensions. The 3D surface morphology and internal lattice structure revealed are consistent with a distorted icosahedral multiply twinned particle. We anticipate that this general method can be applied not only to determine the 3D structure of nanomaterials at atomic-scale resolution(13-15), but also to improve the spatial resolution and image quality in other tomography fields(7,9,16-20).	[Scott, M. C.; Chen, Chien-Chun; Mecklenburg, Matthew; Zhu, Chun; Xu, Rui; Regan, B. C.; Miao, Jianwei] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Scott, M. C.; Chen, Chien-Chun; Mecklenburg, Matthew; Zhu, Chun; Xu, Rui; Regan, B. C.; Miao, Jianwei] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA; [Ercius, Peter; Dahmen, Ulrich] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Natl Ctr Electron Microscopy, Berkeley, CA 94720 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Miao, JW (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.	miao@physics.ucla.edu	Ercius, Peter/AAN-2870-2020	Ercius, Peter/0000-0002-6762-9976; Regan, B. C./0000-0003-3923-2688	UC Discovery/TomoSoft Technologies [IT107-10166]	UC Discovery/TomoSoft Technologies(University of California System)	We thank E. J. Kirkland for help with multislice STEM calculations, R. F. Egerton, Z. H. Zhou and J. A. Rodriguez for discussions and I. Atanasov for assistance in data acquisition. The tomographic tilt series were acquired at the Electron Imaging Center for NanoMachines of the California NanoSystems Institute. This work was partially supported by UC Discovery/TomoSoft Technologies (IT107-10166).	Arslan I, 2005, SCIENCE, V309, P2195, DOI 10.1126/science.1116745; Arslan I, 2008, ULTRAMICROSCOPY, V108, P1579, DOI 10.1016/j.ultramic.2008.05.008; Averbuch A, 2008, SIAM J SCI COMPUT, V30, P785, DOI 10.1137/060650301; BAILEY DH, 1991, SIAM REV, V33, P389, DOI 10.1137/1033097; Bar Sadan M, 2008, NANO LETT, V8, P891, DOI 10.1021/nl073149i; Barnard AS, 2009, ACS NANO, V3, P1431, DOI 10.1021/nn900220k; Batson PE, 2002, NATURE, V418, P617, DOI 10.1038/nature00972; Billinge SJL, 2007, SCIENCE, V316, P561, DOI 10.1126/science.1135080; BOVIN JO, 1985, NATURE, V317, P47, DOI 10.1038/317047a0; Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; Erni R, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.096101; Fahimian BP, 2010, PHYS MED BIOL, V55, P5383, DOI 10.1088/0031-9155/55/18/008; Frank J, 1992, ELECT TOMOGRAPHY; Frank J, 2006, 3 DIMENSIONAL ELECT; Haider M, 1998, NATURE, V392, P768, DOI 10.1038/33823; HOWIE A, 1966, PHILOS MAG, V14, P223, DOI 10.1080/14786436608219008; Jiang HD, 2010, P NATL ACAD SCI USA, V107, P11234, DOI 10.1073/pnas.1000156107; Kak A. C., 2001, PRINCIPLES COMPUTERI; Kirkland E.J., 2010, ADV COMPUTING ELECT, V2nd; Lee E, 2008, J STRUCT BIOL, V164, P221, DOI 10.1016/j.jsb.2008.07.011; Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112; Mao Y, 2010, IEEE T IMAGE PROCESS, V19, P1259, DOI 10.1109/TIP.2009.2039660; MARKS LD, 1994, REP PROG PHYS, V57, P603, DOI 10.1088/0034-4885/57/6/002; Miao J, 1998, J OPT SOC AM A, V15, P1662, DOI 10.1364/JOSAA.15.001662; Miao J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.155502; Miao JW, 1999, NATURE, V400, P342, DOI 10.1038/22498; Miao JW, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.052103; Midgley PA, 2003, ULTRAMICROSCOPY, V96, P413, DOI 10.1016/S0304-3991(03)00105-0; Midgley PA, 2009, NAT MATER, V8, P271, DOI 10.1038/nmat2406; Muller DA, 2009, NAT MATER, V8, P263, DOI [10.1038/nmat2380, 10.1038/NMAT2380]; Pennycook S. J., 2011, SCANNING TRANSMISSIO; SAXTON WO, 1984, ULTRAMICROSCOPY, V13, P57, DOI 10.1016/0304-3991(84)90057-3; SPENCE JCH, 2003, EXPT HIGH RESOLUTION; Van Aert S, 2011, NATURE, V470, P374, DOI 10.1038/nature09741; Williams DB, 2009, SPRINGER, P407, DOI DOI 10.1295/KOBUNSHI.43.94; Yacaman MJ, 2001, J VAC SCI TECHNOL B, V19, P1091, DOI 10.1116/1.1387089; Zuo JM, 2003, SCIENCE, V300, P1419, DOI 10.1126/science.1083887	37	281	285	9	274	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					444	U91		10.1038/nature10934	http://dx.doi.org/10.1038/nature10934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437612	Green Submitted			2022-12-28	WOS:000301771200038
J	Tholken, H				Thoelken, Hinrich			Politics and policies: making change happen	BRITISH MEDICAL JOURNAL			English	Article									German Foreign Minist, D-10117 Berlin, Germany		Tholken, H (corresponding author), German Foreign Minist, Werderscher Markt 1, D-10117 Berlin, Germany.	404-rl@auswaertiges-amt.de							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1356	10.1136/bmj.e1356	http://dx.doi.org/10.1136/bmj.e1356			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431659	Bronze			2022-12-28	WOS:000301848400005
J	Shi, L; Shen, QT; Kiel, A; Wang, J; Wang, HW; Melia, TJ; Rothman, JE; Pincet, F				Shi, Lei; Shen, Qing-Tao; Kiel, Alexander; Wang, Jing; Wang, Hong-Wei; Melia, Thomas J.; Rothman, James E.; Pincet, Frederic			SNARE Proteins: One to Fuse and Three to Keep the Nascent Fusion Pore Open	SCIENCE			English	Article							MEDIATED MEMBRANE-FUSION; DOPAMINE NEURONS; VESICLE FUSION; SPEED LIMIT; COMPLEX; EXOCYTOSIS; CELLS; TRANSMITTER; NANODISCS; SYNAPSES	Neurotransmitters are released through nascent fusion pores, which ordinarily dilate after bilayer fusion, preventing consistent biochemical studies. We used lipid bilayer nanodiscs as fusion partners; their rigid protein framework prevents dilation and reveals properties of the fusion pore induced by SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor). We found that although only one SNARE per nanodisc is required for maximum rates of bilayer fusion, efficient release of content on the physiologically relevant time scale of synaptic transmission apparently requires three or more SNARE complexes (SNAREpins) and the native transmembrane domain of vesicle-associated membrane protein 2 (VAMP2). We suggest that several SNAREpins simultaneously zippering their SNARE transmembrane helices within the freshly fused bilayers provide a radial force that prevents the nascent pore from resealing during synchronous neurotransmitter release.	[Shi, Lei; Kiel, Alexander; Wang, Jing; Melia, Thomas J.; Rothman, James E.; Pincet, Frederic] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; [Shen, Qing-Tao; Wang, Hong-Wei] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Pincet, Frederic] Univ Paris 06, UMR CNRS 8550, Lab Phys Stat, F-75005 Paris, France; [Pincet, Frederic] Univ Paris 07, Ecole Normale Super, F-75005 Paris, France	Yale University; Yale University; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite	Rothman, JE (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	james.rothman@yale.edu; pincet@lps.ens.fr	Shi, Lei/AAX-9455-2021	PINCET, FREDERIC/0000-0002-4243-2157	Agence Nationale de la Recherche [09-Blanc-0129]; NIH; Partner University; Yale Normale Superieure laboratory; Ecole Normale Superieure laboratory; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044, R37DK027044] Funding Source: NIH RePORTER	Agence Nationale de la Recherche(French National Research Agency (ANR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Partner University; Yale Normale Superieure laboratory; Ecole Normale Superieure laboratory; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Agence Nationale de la Recherche grant 09-Blanc-0129 (F. P.), NIH grants (J.E.R.), and a Partner University Funds exchange grant between the Yale and Ecole Normale Superieure laboratories. We thank J. Shen (University of Colorado, Boulder) for providing the PDGFR-VAMP2 expressing vector; R. Beck, E. Rhoades, E. Karatekin, and A. Nath for many helpful discussions; and W. Xu and J. Coleman for their kind help.	Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; Brewer KD, 2011, P NATL ACAD SCI USA, V108, P12723, DOI 10.1073/pnas.1105128108; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Dill KA, 2007, CURR OPIN STRUC BIOL, V17, P342, DOI 10.1016/j.sbi.2007.06.001; Fang QH, 2008, P NATL ACAD SCI USA, V105, P15388, DOI 10.1073/pnas.0805377105; Fdez E, 2010, J CELL SCI, V123, P2473, DOI 10.1242/jcs.061325; Li F, 2007, NAT STRUCT MOL BIOL, V14, P890, DOI 10.1038/nsmb1310; Frauenfeld J, 2011, NAT STRUCT MOL BIOL, V18, P614, DOI 10.1038/nsmb.2026; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Hu YM, 2008, SYNAPSE, V62, P953, DOI 10.1002/syn.20567; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Karatekin E, 2003, POLYM INT, V52, P486, DOI 10.1002/pi.1007; Katayama H, 2010, P NATL ACAD SCI USA, V107, P3453, DOI 10.1073/pnas.1000100107; KHANIN R, 1994, BIOPHYS J, V67, P966, DOI 10.1016/S0006-3495(94)80562-4; Kubelka J, 2004, CURR OPIN STRUC BIOL, V14, P76, DOI 10.1016/j.sbi.2004.01.013; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Mohrmann R, 2010, SCIENCE, V330, P502, DOI 10.1126/science.1193134; Montecucco C, 2005, TRENDS BIOCHEM SCI, V30, P367, DOI 10.1016/j.tibs.2005.05.002; Pothos EN, 1998, J NEUROSCI, V18, P4106; Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076-6879(09)64011-8; Smith EA, 2011, BIOPHYS J, V100, P2141, DOI 10.1016/j.bpj.2011.03.015; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Staal RGW, 2004, NAT NEUROSCI, V7, P341, DOI 10.1038/nn1205; Stein A, 2009, NATURE, V460, P525, DOI 10.1038/nature08156; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; van den Bogaart G, 2010, NAT STRUCT MOL BIOL, V17, P358, DOI 10.1038/nsmb.1748; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Yang WY, 2003, NATURE, V423, P193, DOI 10.1038/nature01609	34	185	189	1	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1355	1359		10.1126/science.1214984	http://dx.doi.org/10.1126/science.1214984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422984	Green Accepted			2022-12-28	WOS:000301531600049
J	Bourzac, K				Bourzac, Katherine			ELECTRONICS Back to analogue	NATURE			English	Editorial Material																			0	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S34	S36		10.1038/483S34a	http://dx.doi.org/10.1038/483S34a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419209	Bronze			2022-12-28	WOS:000301481800003
J	Wu, HX; Wacker, D; Mileni, M; Katritch, V; Han, GW; Vardy, E; Liu, W; Thompson, AA; Huang, XP; Carroll, FI; Mascarella, SW; Westkaemper, RB; Mosier, PD; Roth, BL; Cherezov, V; Stevens, RC				Wu, Huixian; Wacker, Daniel; Mileni, Mauro; Katritch, Vsevolod; Han, Gye Won; Vardy, Eyal; Liu, Wei; Thompson, Aaron A.; Huang, Xi-Ping; Carroll, F. Ivy; Mascarella, S. Wayne; Westkaemper, Richard B.; Mosier, Philip D.; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.			Structure of the human kappa-opioid receptor in complex with JDTic	NATURE			English	Article							PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; TRANSMEMBRANE DOMAIN; MEMBRANE-PROTEINS; OPIATE RECEPTOR; SALVINORIN-A; IN-VITRO; DOCKING; AGONIST; ANALOGS	Opioid receptors mediate the actions of endogenous and exogenous opioids on many physiological processes, including the regulation of pain, respiratory drive, mood, and-in the case of kappa-opioid receptor (kappa-OR)-dysphoria and psychotomimesis. Here we report the crystal structure of the human kappa-OR in complex with the selective antagonist JDTic, arranged in parallel dimers, at 2.9 angstrom resolution. The structure reveals important features of the ligand-binding pocket that contribute to the high affinity and subtype selectivity of JDTic for the human kappa-OR. Modelling of other important kappa-OR-selective ligands, including the morphinan-derived antagonists norbinaltorphimine and 5'-guanidinonaltrindole, and the diterpene agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes. Analysis of site-directed mutagenesis and ligand structure-activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for kappa-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human kappa-OR.	[Wu, Huixian; Wacker, Daniel; Mileni, Mauro; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Thompson, Aaron A.; Cherezov, Vadim; Stevens, Raymond C.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Vardy, Eyal; Huang, Xi-Ping; Roth, Bryan L.] Univ N Carolina, Chapel Hill Med Sch, Natl Inst Mental Hlth Psychoact Drug Screening Pr, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Vardy, Eyal; Huang, Xi-Ping; Roth, Bryan L.] Univ N Carolina, Chapel Hill Med Sch, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA; [Carroll, F. Ivy; Mascarella, S. Wayne] Res Triangle Inst, Ctr Organ & Med Chem, Res Triangle Pk, NC 27709 USA; [Westkaemper, Richard B.; Mosier, Philip D.] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Virginia Commonwealth University	Stevens, RC (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevens@scripps.edu	Cherezov, Vadim/L-9812-2013; Han, Gye Won/GLQ-8673-2022; Katritch, Vsevolod/Y-2721-2019; Roth, Bryan L/F-3928-2010; Han, Gye Won/GLT-1531-2022; Stevens, Raymond/K-7272-2015; Han, Gye Won/GLQ-8724-2022; Katritch, Vsevolod/Q-8357-2016; Wu, Huixian/N-6353-2014; Roth, Bryan/ABE-7032-2020	Cherezov, Vadim/0000-0002-5265-3914; Stevens, Raymond/0000-0002-4522-8725; Han, Gye Won/0000-0003-4107-835X; Katritch, Vsevolod/0000-0003-3883-4505; Wu, Huixian/0000-0003-1357-9747; Roth, Bryan/0000-0002-0561-6520; Thompson, Aaron/0000-0003-4314-4242; Mascarella, Wayne/0000-0003-0092-8178; Huang, Xi-Ping/0000-0002-2585-653X	PSI:Biology [U54 GM094618]; NIH [P50 GM073197, R01 DA017624, R01 DA027170, R01 DA009045]; NIMH; Michael Hooker Distinguished Chair of Pharmacology; Boehringer Ingelheim Fonds; National Cancer Institute [Y1-CO-1020]; National Institute of General Medical Sciences [Y1-GM-1104]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM073197, U54GM094618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027170, R01DA017204, R01DA009045] Funding Source: NIH RePORTER	PSI:Biology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Michael Hooker Distinguished Chair of Pharmacology; Boehringer Ingelheim Fonds(Boehringer Ingelheim); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by PSI:Biology grant U54 GM094618 (V. K., V. C., R. C. S.) for biological studies and structure production, NIH Roadmap grant P50 GM073197 (V. C., R. C. S.) for technology development and R01 DA017624 (B. L. R., E. V., R. B. M., P. D. M.), R01 DA027170 (B. L. R.), the NIMH Psychoactive Drug Screening Program Contract (B. L. R., X.-P. H.), the Michael Hooker Distinguished Chair of Pharmacology (B. L. R.), and the NIH grant R01 DA009045 (F. I. C.). D. W. is supported by a Boehringer Ingelheim Fonds PhD Fellowship. The JDTic X-ray structure was determined by C. George at the Laboratory for the Structure of Matter, Naval Research Laboratory. We thank J. Velasquez for help on molecular biology; T. Trinh, K. Allin and M. Chu for help on baculovirus expression; V. Setola for help with functional activity assays; J. Evans for help acquiring compounds; the National Institute of Drug Abuse Drug Supply Program for supplying JDTic and other opioid ligands used in these studies; K. Kadyshevskaya for assistance with figure preparation; E. Abola for assistance with manuscript preparation; A. Walker for assistance with manuscript preparation; J. Smith, R. Fischetti and N. Sanishvili for assistance in the development and use of the minibeam and beamtime at GM/CA-CAT beamline 23-ID at the Advanced Photon Source, which is supported by National Cancer Institute grant Y1-CO-1020 and National Institute of General Medical Sciences grant Y1-GM-1104.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Befort K, 1996, MOL PHARMACOL, V49, P216; Bricogne G, 2009, BUSTER V 2 8 0; Caffrey M, 2009, NAT PROTOC, V4, P706, DOI 10.1038/nprot.2009.31; Cai TB, 2008, J MED CHEM, V51, P1849, DOI 10.1021/jm701344b; Carlezon WA, 2009, PHARMACOL THERAPEUT, V123, P334, DOI 10.1016/j.pharmthera.2009.05.008; Carroll I, 2004, EUR J PHARMACOL, V501, P111, DOI 10.1016/j.ejphar.2004.08.028; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; Chen SH, 2002, BIOCHEMISTRY-US, V41, P6045, DOI 10.1021/bi012189c; Cherezov V, 2004, ACTA CRYSTALLOGR D, V60, P1795, DOI 10.1107/S0907444904019109; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Cherezov V, 2009, J R SOC INTERFACE, V6, pS587, DOI 10.1098/rsif.2009.0142.focus; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Congreve M, 2011, J MED CHEM, V54, P4283, DOI 10.1021/jm200371q; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Jackson KJ, 2010, PSYCHOPHARMACOLOGY, V210, P285, DOI 10.1007/s00213-010-1803-1; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Kufareva I, 2011, STRUCTURE, V19, P1108, DOI 10.1016/j.str.2011.05.012; Mancia F, 2008, EMBO REP, V9, P363, DOI 10.1038/embor.2008.27; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Metzger TG, 1996, NEUROCHEM RES, V21, P1287, DOI 10.1007/BF02532369; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Runyon SP, 2010, J MED CHEM, V53, P5290, DOI 10.1021/jm1004978; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236; Standfuss J, 2011, NATURE, V471, P656, DOI 10.1038/nature09795; Subramanian G, 1998, J MED CHEM, V41, P4777, DOI 10.1021/jm9803166; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Thomas JB, 2004, J MED CHEM, V47, P1070, DOI 10.1021/jm030467v; Thomas JB, 2001, J MED CHEM, V44, P2687, DOI 10.1021/jm015521r; Totrov M, 1997, PROTEINS, P215; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Vortherms TA, 2007, J BIOL CHEM, V282, P3146, DOI 10.1074/jbc.M609264200; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walsh SL, 2001, PSYCHOPHARMACOLOGY, V157, P151, DOI 10.1007/s002130100788; WANG JB, 1994, J BIOL CHEM, V269, P25966; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Yan F, 2009, BIOCHEMISTRY-US, V48, P6898, DOI 10.1021/bi900605n; ZIMMERMAN DM, 1978, NATURE, V275, P332, DOI 10.1038/275332a0	50	668	683	1	165	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 17	2012	485	7398					327	U69		10.1038/nature10939	http://dx.doi.org/10.1038/nature10939			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	943CW	22437504	Green Accepted, Green Submitted			2022-12-28	WOS:000304099100033
J	Chan, AT; Cook, NR				Chan, Andrew T.; Cook, Nancy R.			Are we ready to recommend aspirin for cancer prevention?	LANCET			English	Editorial Material							COLORECTAL-CANCER; FOLLOW-UP; CHEMOPREVENTION; MORTALITY; RISK		[Cook, Nancy R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; [Chan, Andrew T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02215 USA; [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Cook, NR (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.	ncook@rics.bwh.harvard.edu	Chan, Andrew T/P-8293-2014	Chan, Andrew T/0000-0001-7284-6767	NCI NIH HHS [R01 CA047988, R01 CA137178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA137178, R01CA047988] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Burn J, 2011, CANCER PREV RES, V4, P655, DOI 10.1158/1940-6207.CAPR-11-0106; Calonge N, 2009, ANN INTERN MED, V150, P396; Chan AT, 2007, ARCH INTERN MED, V167, P562, DOI 10.1001/archinte.167.6.562; Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; Huang ES, 2011, AM J MED, V124, P426, DOI 10.1016/j.amjmed.2010.12.022; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; US Preventive Services Task Force, 2007, ANN INTERN MED, V146, P361, DOI 10.7326/0003-4819-146-5-200703060-00008	16	27	27	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2012	379	9826					1569	1571		10.1016/S0140-6736(11)61654-1	http://dx.doi.org/10.1016/S0140-6736(11)61654-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	934OB	22440945	Green Accepted			2022-12-28	WOS:000303452600007
J	Rothwell, PM; Price, JF; Fowkes, FGR; Zanchetti, A; Roncaglioni, MC; Tognoni, G; Lee, R; Belch, JFF; Wilson, M; Mehta, Z; Meade, TW				Rothwell, Peter M.; Price, Jacqueline F.; Fowkes, F. Gerald R.; Zanchetti, Alberto; Roncaglioni, Maria Carla; Tognoni, Gianni; Lee, Robert; Belch, Jill F. F.; Wilson, Michelle; Mehta, Ziyah; Meade, Tom W.			Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials	LANCET			English	Article							LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PERIPHERAL ARTERIAL-DISEASE; TRANSIENT ISCHEMIC ATTACK; DOUBLE-BLIND TRIAL; COLORECTAL-CANCER; PRIMARY PREVENTION; COLLABORATIVE METAANALYSIS; MYOCARDIAL-INFARCTION; PHYSICIANS HEALTH	Background Daily aspirin reduces the long-term risk of death due to cancer. However, the short-term effect is less certain, especially in women, effects on cancer incidence are largely unknown, and the time course of risk and benefit in primary prevention is unclear. We studied cancer deaths in all trials of daily aspirin versus control and the time course of effects of low-dose aspirin on cancer incidence and other outcomes in trials in primary prevention. Methods We studied individual patient data from randomised trials of daily aspirin versus no aspirin in prevention of vascular events. Death due to cancer, all non-vascular death, vascular death, and all deaths were assessed in all eligible trials. In trials of low-dose aspirin in primary prevention, we also established the time course of effects on incident cancer, major vascular events, and major extracranial bleeds, with stratification by age, sex, and smoking status. Results Allocation to aspirin reduced cancer deaths (562 vs 664 deaths; odds ratio [OR] 0.85, 95% CI 0.76-0.96, p=0.008; 34 trials, 69 224 participants), particularly from 5 years onwards (92 vs 145; OR 0.63, 95% CI 0.49-0.82, p=0.0005), resulting in fewer non-vascular deaths overall (1021 vs 1173; OR 0.88, 95% CI 0.78-0.96, p=0.003; 51 trials, 77 549 participants). In trials in primary prevention, the reduction in non-vascular deaths accounted for 87 (91%) of 96 deaths prevented. In six trials of daily low-dose aspirin in primary prevention (35 535 participants), aspirin reduced cancer incidence from 3 years onwards (324 vs 421 cases; OR 0.76, 95% CI 0.66-0.88, p=0.0003) in women (132 vs 176; OR 0.75, 95% CI 0.59-0.94, p=0.01) and in men (192 vs 245; OR 0.77, 95% CI 0.63-0.93, p=0.008). The reduced risk of major vascular events on aspirin was initially off set by an increased risk of major bleeding, but effects on both outcomes diminished with increasing follow-up, leaving only the reduced risk of cancer (absolute reduction 3.13 [95% CI 1.44-4.82] per 1000 patients per year) from 3 years onwards. Case-fatality from major extracranial bleeds was also lower on aspirin than on control (8/203 vs 15/132; OR 0.32, 95% CI 0.12-0.83, p=0.009). Interpretation Alongside the previously reported reduction by aspirin of the long-term risk of cancer death, the short-term reductions in cancer incidence and mortality and the decrease in risk of major extracranial bleeds with extended use, and their low case-fatality, add to the case for daily aspirin in prevention of cancer.	[Rothwell, Peter M.; Wilson, Michelle; Mehta, Ziyah] Univ Oxford, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England; [Price, Jacqueline F.; Fowkes, F. Gerald R.; Lee, Robert] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Zanchetti, Alberto] Univ Milan, Ist Auxol Italiano, Milan, Italy; [Roncaglioni, Maria Carla; Tognoni, Gianni] Ist Ric Farmacol Mario Negri, Milan, Italy; [Belch, Jill F. F.] Univ Dundee, Ninewells Hosp & Med Sch, Univ Div Med & Therapeut, Vasc & Inflammatory Dis Res Unit,Inst Cardiovasc, Dundee DD1 9SY, Scotland; [Meade, Tom W.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Oxford; University of Edinburgh; IRCCS Istituto Auxologico Italiano; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Dundee; University of London; London School of Hygiene & Tropical Medicine	Rothwell, PM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Belch, Jill/AAE-9189-2019; Rothwell, Peter/ABE-5913-2020; roncaglioni, maria carla/AAB-1875-2020	Belch, Jill/0000-0001-8280-6689; Rothwell, Peter/0000-0001-9739-9211; roncaglioni, maria carla/0000-0002-2029-7847; Price, Jackie/0000-0003-3251-3970; zanchetti, alberto/0000-0003-4796-7959	AstraZeneca; Bayer; Sanofi-Aventis/Bristol-Myers Squibb; Wellcome Trust; NIHR; NIHR Biomedical Research centre, Oxford; MRC [G9534799] Funding Source: UKRI; Medical Research Council [G9534799] Funding Source: researchfish	AstraZeneca(AstraZeneca); Bayer(Bayer AG); Sanofi-Aventis/Bristol-Myers Squibb(Sanofi-AventisBristol-Myers Squibb); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR(National Institute for Health Research (NIHR)); NIHR Biomedical Research centre, Oxford(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was completely independent of any pharmaceutical company or other commercial interest. However, PMR has received honoraria for talks, advisory boards, and clinical trial committees from several pharmaceutical companies with an interest in antiplatelet agents, including AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis/Bristol-Myers Squibb and Servier, and is on the executive committee of the ARRIVE Trial. FGRF has received research support and honoraria from AstraZeneca, Bayer, and Sanofi-Aventis/Bristol-Myers Squibb.; Funding of the original trials was as reported previously. The ongoing NOVA collaboration will be funded by the Wellcome Trust, but the work reported here preceded that funding. PMR is in receipt of an NIHR Senior Investigator Award, a Wellcome Trust Senior Investigator Award, and is also supported by the NIHR Biomedical Research centre, Oxford.	Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; [Anonymous], 2010, LANCET, V375, P1665, DOI 10.1016/S0140-6736(10)60718-0; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barbui T, 1997, BRIT J HAEMATOL, V97, P453; BAUDOIN C, 1989, DIABETES, V38, P491; Belch J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1840; Bosetti C, 2009, RECENT RESULTS CANC, V181, P231; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Chan FKL, 2005, NEW ENGL J MED, V352, P238, DOI 10.1056/NEJMoa042087; Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010; Coghill AE, 2011, GUT, V60, P491, DOI 10.1136/gut.2010.221143; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Cook NR, 2002, AM J EPIDEMIOL, V155, P1045, DOI 10.1093/aje/155.11.1045; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; COTE R, 1995, ANN INTERN MED, V123, P649, DOI 10.7326/0003-4819-123-9-199511010-00002; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Dannenberg AJ, 2003, PROGR EXPT TUMOUR RE, V37; Doria-Rose VP, 2009, LUNG CANCER, V63, P295, DOI 10.1016/j.lungcan.2008.05.019; Ederer F, 1999, J CLIN EPIDEMIOL, V52, P447, DOI 10.1016/S0895-4356(99)00016-5; Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fowkes FGR, 2010, JAMA-J AM MED ASSOC, V303, P841, DOI 10.1001/jama.2010.221; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Holmes MD, 2010, J CLIN ONCOL, V28, P1467, DOI 10.1200/JCO.2009.22.7918; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; Lai KC, 2002, NEW ENGL J MED, V346, P2033, DOI 10.1056/NEJMoa012877; Lanas A, 2002, ALIMENT PHARM THER, V16, P779, DOI 10.1046/j.1365-2036.2002.01230.x; Landolfi R, 2004, NEW ENGL J MED, V350, P114, DOI 10.1056/NEJMoa035572; LEBEAU B, 1993, CANCER, V71, P1741, DOI 10.1002/1097-0142(19930301)71:5<1741::AID-CNCR2820710507>3.0.CO;2-Q; Meade TW, 1998, LANCET, V351, P233; Ogawa H, 2008, JAMA-J AM MED ASSOC, V300, P2134, DOI 10.1001/jama.2008.623; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Pilger E, 2007, J INTERN MED, V261, P276, DOI 10.1111/j.1365-2796.2006.01763.x; Robinson MH, 2000, J MED SCREEN, V7, P97, DOI 10.1136/jms.7.2.97; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Seshasai SRK, 2012, ARCH INTERN MED, V172, P209, DOI 10.1001/archinternmed.2011.628; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801	46	612	632	0	78	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2012	379	9826					1602	1612		10.1016/S0140-6736(11)61720-0	http://dx.doi.org/10.1016/S0140-6736(11)61720-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934OB	22440946				2022-12-28	WOS:000303452600034
J	Som, SM; Catling, DC; Harnmeijer, JP; Polivka, PM; Buick, R				Som, Sanjoy M.; Catling, David C.; Harnmeijer, Jelte P.; Polivka, Peter M.; Buick, Roger			Air density 2.7 billion years ago limited to less than twice modern levels by fossil raindrop imprints	NATURE			English	Article							GREENHOUSE; OXYGEN; TEMPERATURE; SUPERGROUP; ATMOSPHERE; CLIMATE; DROPS; CYCLE; RISE	According to the 'Faint Young Sun' paradox, during the late Archaean eon a Sun approximately 20% dimmer warmed the early Earth such that it had liquid water and a clement climate(1). Explanations for this phenomenon have invoked a denser atmosphere that provided warmth by nitrogen pressure broadening(1) or enhanced greenhouse gas concentrations(2). Such solutions are allowed by geochemical studies and numerical investigations that place approximate concentration limits on Archaean atmospheric gases, including methane, carbon dioxide and oxygen(2-7). But no field data constraining ground-level air density and barometric pressure have been reported, leaving the plausibility of these various hypotheses in doubt. Here we show that raindrop imprints in tuffs of the Ventersdorp Supergroup, South Africa, constrain surface air density 2.7 billion years ago to less than twice modern levels. We interpret the raindrop fossils using experiments in which water droplets of known size fall at terminal velocity into fresh and weathered volcanic ash, thus defining a relationship between imprint size and raindrop impact momentum. Fragmentation following raindrop flattening limits raindrop size to a maximum value independent of air density, whereas raindrop terminal velocity varies as the inverse of the square root of air density. If the Archaean raindrops reached the modern maximum measured size, air density must have been less than 2.3 kg m(-3), compared to today's 1.2 kg m(-3), but because such drops rarely occur, air density was more probably below 1.3 kg m(-3). The upper estimate for air density renders the pressure broadening explanation(1) possible, but it is improbable under the likely lower estimates. Our results also disallow the extreme CO2 levels required for hot Archaean climates(8).	[Som, Sanjoy M.; Catling, David C.; Harnmeijer, Jelte P.; Polivka, Peter M.; Buick, Roger] Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; [Som, Sanjoy M.; Catling, David C.; Harnmeijer, Jelte P.; Polivka, Peter M.; Buick, Roger] Univ Washington, Astrobiol Program, Seattle, WA 98195 USA; [Som, Sanjoy M.] Blue Marble Space Inst Sci, Seattle, WA 98145 USA; [Harnmeijer, Jelte P.] Edinburgh Ctr Low Carbon Innovat, Sustainable Community Energy Network, Edinburgh EH8 9AA, Midlothian, Scotland; [Polivka, Peter M.] Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Som, SM (corresponding author), NASA, Exobiol Branch, Ames Res Ctr, Moffett Field, CA 94035 USA.	sanjoy.m.som@nasa.gov		Buick, Roger/0000-0003-0139-1659; Catling, David/0000-0001-5646-120X	NASA [NNX08AP56G, NNX10AQ90G]; Coordination Action for Research Activities on life in Extreme Environments (CAREX); European Commission; University of Washington Department of Earth and Space Sciences, and its Geoclub; Directorate For Geosciences [0921580] Funding Source: National Science Foundation	NASA(National Aeronautics & Space Administration (NASA)); Coordination Action for Research Activities on life in Extreme Environments (CAREX); European Commission(European CommissionEuropean Commission Joint Research Centre); University of Washington Department of Earth and Space Sciences, and its Geoclub; Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	This work was supported by NASA Exobiology/Astrobiology grant NNX08AP56G. We thank W. Van der Westhuizen of the University of the Free State in South Africa, and E. and D. Jackson of Omdraaivlei for their assistance when sampling in the field. We also thank E. Stueken, A. Chen and K. Huntington at the University of Washington for laboratory assistance, and the staff at Metron Corporation for data acquisition. XRF measurements were performed by the Washington State University Geoanalytical Laboratory. Funding and field logistics for the Iceland fieldwork was supported by the Coordination Action for Research Activities on life in Extreme Environments (CAREX), a project supported by the European Commission Seventh Framework Programme. Funding and field logistics for the Hawaiian fieldwork was supported by the University of Washington Department of Earth and Space Sciences, and its Geoclub. D. C. C. was also supported by NASA Exobiology/Astrobiology grant NNX10AQ90G.	BEARD KV, 1976, J ATMOS SCI, V33, P851, DOI 10.1175/1520-0469(1976)033<0851:TVASOC>2.0.CO;2; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Claire M., 2006, GEOBIOLOGY, V4, P239, DOI [10.1111/j.1472-4669.2006.00084.x, DOI 10.1111/J.1472-4669.2006.00084.X]; Clift R., 1978, BUBBLES DROPS PARTIC; DODD KN, 1960, J FLUID MECH, V9, P175, DOI 10.1017/S002211206000102X; Domagal-Goldman SD, 2008, EARTH PLANET SC LETT, V269, P29, DOI 10.1016/j.epsl.2008.01.040; Driese SG, 2011, PRECAMBRIAN RES, V189, P1, DOI 10.1016/j.precamres.2011.04.003; Easton R. M., 1987, 75 ANNIVERSARY VOLUM, V1, P243; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Foote G. B., 1969, J APPL METEOROL, V8, P249, DOI [DOI 10.1175/1520-0450(1969)008<0249:TVORA>2.0.CO;2, 10.1175/1520-0450(1969)008<0249:TVORA>2.0.CO;2, DOI 10.1175/1520-0450(1969)008<0249:TV0RA>2.0.00;2]; Garvin J, 2009, SCIENCE, V323, P1045, DOI 10.1126/science.1165675; Goldblatt C, 2009, NAT GEOSCI, V2, P891, DOI 10.1038/NGEO692; Haqq-Misra JD, 2008, ASTROBIOLOGY, V8, P1127, DOI 10.1089/ast.2007.0197; Holland HD, 2006, PHILOS T R SOC B, V361, P903, DOI 10.1098/rstb.2006.1838; Hren MT, 2009, NATURE, V462, P205, DOI 10.1038/nature08518; HUANG C, 1983, SOIL SCI SOC AM J, V47, P855, DOI 10.2136/sssaj1983.03615995004700050003x; Kasting JF, 2006, PHILOS T R SOC B, V361, P1733, DOI 10.1098/rstb.2006.1902; KASTING JF, 1987, PRECAMBRIAN RES, V34, P205, DOI 10.1016/0301-9268(87)90001-5; Knauth LP, 2003, GEOL SOC AM BULL, V115, P566, DOI 10.1130/0016-7606(2003)115<0566:HACTIF>2.0.CO;2; Knauth LP, 2005, PALAEOGEOGR PALAEOCL, V219, P53, DOI 10.1016/j.palaeo.2004.10.014; LORENZ RD, 1993, PLANET SPACE SCI, V41, P647, DOI 10.1016/0032-0633(93)90048-7; Lyell, 1851, Q J GEOL SOC LOND, V7, P238; MAGONO C, 1954, J METEOROL, V11, P77, DOI 10.1175/1520-0469(1954)011<0077:OTSOWD>2.0.CO;2; MATTHEWS JB, 1964, Q J ROY METEOR SOC, V90, P274; Ohmoto H, 2004, NATURE, V429, P395, DOI 10.1038/nature02573; Pruppacher HR, 1997, MICROPHYSICS CLOUDS; Reineck H., 1980, DEPOSITIONAL SEDIMEN, V61; SPILHAUS AF, 1948, J METEOROL, V5, P108, DOI 10.1175/1520-0469(1948)005<0108:RSSAFS>2.0.CO;2; VANDERWESTHUIZEN WA, 1989, SEDIMENT GEOL, V61, P303, DOI 10.1016/0037-0738(89)90064-X; WILLIS PT, 1989, J APPL METEOROL, V28, P3, DOI 10.1175/1520-0450(1989)028&lt;0003:DSDAWI&gt;2.0.CO;2; Zachos JC, 2008, NATURE, V451, P279, DOI 10.1038/nature06588	31	124	128	1	61	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					359	362		10.1038/nature10890	http://dx.doi.org/10.1038/nature10890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22456703				2022-12-28	WOS:000302946500029
J	Papp, KA; Leonardi, C; Menter, A; Ortonne, JP; Krueger, JG; Kricorian, G; Aras, G; Li, J; Russell, CB; Thompson, EHZ; Baumgartner, S				Papp, Kim A.; Leonardi, Craig; Menter, Alan; Ortonne, Jean-Paul; Krueger, James G.; Kricorian, Gregory; Aras, Girish; Li, Juan; Russell, Chris B.; Thompson, Elizabeth H. Z.; Baumgartner, Scott			Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMG 827 LEADS; T-CELLS; HISTOPATHOLOGIC ABNORMALITIES; GENE-EXPRESSION; IL-17 RECEPTOR; RAPID REVERSAL; TH17; SKIN; INTERLEUKIN-17; INHIBITION	Background In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. Methods We randomly assigned patients with a score of 12 or higher on the psoriasis area-and-severity index (PASI, on which scores range from 0 to 72, with higher scores indicating more severe disease) and with 10% or more of their body-surface area affected by psoriasis to receive brodalumab (70 mg, 140 mg, or 210 mg at day 1 and weeks 1, 2, 4, 6, 8, and 10 or 280 mg monthly) or placebo. The primary end point was the percentage improvement from baseline in the PASI score at week 12. Secondary end points included improvement of at least 75% and at least 90% in the PASI score and the score on the static physician's global assessment at week 12. Results A total of 198 patients underwent randomization. At week 12, the mean percentage improvements in the PASI score were 45.0% among patients receiving 70 mg of brodalumab, 85.9% among those receiving 140 mg, 86.3% among those receiving 210 mg, 76.0% among those receiving 280 mg, and 16.0% among those receiving placebo (P<0.001 for all comparisons with placebo). An improvement of at least 75% and at least 90% in the PASI score at week 12 was seen in 77% and 72%, respectively, of the patients in the 140-mg brodalumab group and in 82% and 75%, respectively, of the patients in the 210-mg group, as compared with 0% in the placebo group (P<0.001 for all comparisons). The percentage of patients with a static physician's global assessment of clear or minimal disease was 26%, 85%, 80%, and 69% with the 70-mg, 140-mg, 210-mg, and 280-mg doses, respectively, of brodalumab, as compared with 3% with placebo (P<0.01 for all comparisons with placebo). Two cases of grade 3 neutropenia were reported in the 210-mg brodalumab group. The most commonly reported adverse events in the combined brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-site erythema (6%). Conclusions Brodalumab significantly improved plaque psoriasis in this 12-week, phase 2 study. (Funded by Amgen; ClinicalTrials.gov number, NCT00975637.)	[Papp, Kim A.] Prob Med Res, Waterloo, ON, Canada; [Leonardi, Craig] St Louis Univ, St Louis, MO 63103 USA; [Menter, Alan] Baylor Univ Med Ctr, Dallas, TX USA; [Ortonne, Jean-Paul] Hop Archet, Nice, France; [Krueger, James G.] Rockefeller Univ, New York, NY 10021 USA; [Kricorian, Gregory; Aras, Girish; Li, Juan; Thompson, Elizabeth H. Z.; Baumgartner, Scott] Amgen Inc, Thousand Oaks, CA USA; [Russell, Chris B.] Amgen Inc, Seattle, WA USA	Saint Louis University; Baylor University Medical Center; CHU Nice; Rockefeller University; Amgen; Amgen	Papp, KA (corresponding author), Prob Med Res, 135 Union St, E Waterloo, ON N2J 1C4, Canada.	kapapp@probitymedical.com		Russell, Chris/0000-0002-0240-1815; Papp, Kim A./0000-0001-9557-3642	Amgen; Abbott; Astellas; Celgene; Centocor; Eli Lilly; Galderma; Graceway Pharmaceuticals; Janssen; Johnson Johnson; Merck; Norvartis; Pfizer; UCB; LEO Pharma; LEO Pharma, Merck, Novartis; Stiefel; GlaxoSmithKline; Medimmune; Wyeth	Amgen(Amgen); Abbott(Abbott Laboratories); Astellas(Astellas Pharmaceuticals); Celgene(Bristol-Myers SquibbCelgene Corporation); Centocor; Eli Lilly(Eli Lilly); Galderma; Graceway Pharmaceuticals; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Merck(Merck & Company); Norvartis; Pfizer(Pfizer); UCB(UCB Pharma SA); LEO Pharma(LEO Pharma); LEO Pharma, Merck, Novartis(LEO Pharma); Stiefel; GlaxoSmithKline(GlaxoSmithKline); Medimmune(AstraZenecaMedimmune); Wyeth(Wyeth)	Funded by Amgen; ClinicalTrials.gov number, NCT00975637.; Dr. Papp reports receiving consulting fees from Abbott, Amgen, Astellas, Celgene, Centocor, Eli Lilly, Galderma, Graceway Pharmaceuticals, Janssen, Johnson & Johnson, Merck, Norvartis, Pfizer, and UCB, lecture fees from Abbott, Amgen, Astellas, Celgene, Centocor, Galderma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and Stiefel, and grant support from Abbott, Amgen, Astellas, Celgene, Centocor, Eli Lilly, Galderma, GlaxoSmithKline, Graceway Pharmaceuticals, Janssen, Johnson & Johnson, Medimmune, Merck, Novartis, Pfizer, Stiefel, and UCB; Dr. Leonardi, receiving consulting fees from Abbott, Amgen, Centocor, Eli Lilly, and Pfizer, lecture fees from Abbott and Amgen, and investigator fees from Abbott, Amgen, Celgene, Centocor, Galderma, GlaxoSmithKline, Incyte, Maruho, Novartis, Novo Nordisk, Pfizer, Schering-Plough (now Merck), Sirtris, Stiefel, Vascular Biogenics, and Wyeth (now Pfizer); Dr. Menter, receiving consulting fees from Abbott, Amgen, Astellas, Centocor, Galderma, Genentech, and Wyeth, lecture fees from Abbott, Amgen, Centocor, Galderma, and Wyeth, and fees for expert testimony from Galderma; Dr. Krueger, receiving consulting fees from Centocor, Eli Lilly, and Pfizer and grant support from Amgen, Centocor, Eli Lilly, Merck, and Pfizer; and Drs. Krikorian, Aras, Li, Russell, Thompson, and Baumgartner being full-time employees of Amgen. No other potential conflict of interest was relevant to this article was reported.	[Anonymous], 2011, COMMON TERMINOLOGY C; Chandran V, 2010, J AUTOIMMUN, V34, pJ314, DOI 10.1016/j.jaut.2009.12.001; Feldman SR, 2005, ANN RHEUM DIS, V64, P65, DOI 10.1136/ard.2004.031237; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Genovese MC, 2010, ARTHRITIS RHEUM-US, V62, P929, DOI 10.1002/art.27334; Ghoreschi K, 2007, CLIN DERMATOL, V25, P574, DOI 10.1016/j.clindermatol.2007.08.012; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Kurd SK, 2009, J AM ACAD DERMATOL, V61, P507; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; Russell CB, 2011, J INVEST DERMATOL, V131, pS11; Russell CB, 2010, J INVEST DERMATOL, V130, pS46; Smith E, 2008, J IMMUNOL, V181, P1357, DOI 10.4049/jimmunol.181.2.1357; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; von Vietinghoff S, 2008, J IMMUNOL, V181, P5183, DOI 10.4049/jimmunol.181.8.5183; Ware JE, 2001, SF 36 PHYS MENTAL HL; Wright JF, 2008, J IMMUNOL, V181, P2799, DOI 10.4049/jimmunol.181.4.2799; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zhang L, 2010, CLIN IMMUNOL, V135, P108, DOI 10.1016/j.clim.2009.11.008	32	740	829	1	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1181	1189		10.1056/NEJMoa1109017	http://dx.doi.org/10.1056/NEJMoa1109017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455412				2022-12-28	WOS:000302005100006
J	Morris, RGM; Takeuchi, T				Morris, Richard G. M.; Takeuchi, Tomonori			The Imaginary Mind of a Mouse	SCIENCE			English	Editorial Material									[Morris, Richard G. M.; Takeuchi, Tomonori] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh	Morris, RGM (corresponding author), Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH8 9JZ, Midlothian, Scotland.	r.g.m.morris@ed.ac.uk; tomonori.takeuchi@ed.ac.uk	Morris, Richard G M/C-9982-2013; Takeuchi, Tomonori/P-5988-2016	Takeuchi, Tomonori/0000-0002-9981-4260; MORRIS, Richard G M/0000-0001-8661-1520	MRC [G0700447] Funding Source: UKRI; Medical Research Council [G0700447] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alexander GM, 2009, NEURON, V63, P27, DOI 10.1016/j.neuron.2009.06.014; BOWER GH, 1978, J VERB LEARN VERB BE, V17, P573, DOI 10.1016/S0022-5371(78)90348-1; Bransford J., 1979, HUMAN COGNITION LEAR; Fenno L, 2011, ANNU REV NEUROSCI, V34, P389, DOI 10.1146/annurev-neuro-061010-113817; Garner AR, 2012, SCIENCE, V335, P1513, DOI 10.1126/science.1214985; Jezek K, 2011, NATURE, V478, P246, DOI 10.1038/nature10439; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Tse D, 2011, SCIENCE, V333, P891, DOI 10.1126/science.1205274	8	1	1	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1455	1456		10.1126/science.1220824	http://dx.doi.org/10.1126/science.1220824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442473				2022-12-28	WOS:000301837000034
J	Quadir, IZ				Quadir, Iqbal Z.			Entrepreneurship Training for the Developing World	SCIENCE			English	Editorial Material									MIT, Legatum Ctr Dev & Entrepreneurship, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Quadir, IZ (corresponding author), MIT, Legatum Ctr Dev & Entrepreneurship, Cambridge, MA 02142 USA.	iqbalquadir@mit.edu						[Anonymous], 2011, ECONOMIST       0406; [Anonymous], 2009, ECONOMIST       0926; Basu A., 2006, OXFORD HDB ENTREPREN; Baumol W., 2004, 10578 NBER; Easterly William, 2001, ELUSIVE QUEST GROWTH, P74; EC (European Commission), 2008, ENTR HIGH ED ESP NON; Guest R., 2011, BORDERLESS EC; Huang Y, 2008, CAPITALISM WITH CHINESE CHARACTERISTICS: ENTREPRENEURSHIP AND THE STATE, P1; IMF, 2011, WORLD EC OUTL SEPT 2; Immelt JR, 2009, HARVARD BUS REV, V87, P56; KRUEGER AO, 1974, AM ECON REV, V64, P291; Lacy S., 2011, BRILLIANT CRAZY COCK, P8; Leff N., 1979, J ECON LIT, V17, P51; Remmer KL, 2004, AM J POLIT SCI, V48, P77, DOI 10.1111/j.0092-5853.2004.00057.x; Schramm C. J., 2006, ENTREPRENEURIAL IMPE, P174; Schumpeter Joseph A., 1951, THEORY EC DEV; The Economist, 2010, ECONOMIST       0417; United Nations, 2004, UNL ENTR MAK BUS WOR; Volkmann C., 2011, ED NEXT WAVE ENTREPR; Wadhwa V., 2011, SSRN ELECT J, V5, P141, DOI [10.2139/ssrn.1127248, DOI 10.2139/SSRN.1127248]	20	1	1	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1445	1446		10.1126/science.1217790	http://dx.doi.org/10.1126/science.1217790			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	912YG	22442466				2022-12-28	WOS:000301837000027
J	Pacala, JT; Yueh, B				Pacala, James T.; Yueh, Bevan			Hearing Deficits in the Older Patient "I Didn't Notice Anything"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; AID USE; ELDERLY-PEOPLE; LOSS PREVALENCE; IMPAIRMENT; ADULTS; HEALTH; REHABILITATION; BENEFIT; DETERMINANTS	Hearing loss is common in older adults. Patients, clinicians, and health care staff often do not recognize hearing loss, particularly in its early stages, and it is undertreated. Age-related hearing loss or presbycusis, the most common type of hearing loss in older adults, is a multifactorial sensorineural loss that frequently includes a component of impaired speech discrimination. Simple office-based screening and evaluation procedures can identify potential hearing disorders, which should prompt audiologic referral to confirm the diagnosis with audiometric testing. The mainstay of treatment is amplification. For many older adults, accepting the need for amplification, selecting and purchasing a hearing aid, and getting accustomed to its use is a daunting and often frustrating process. There are numerous barriers to hearing aid use, the most common of which is dissatisfaction with its performance across a range of sonic environments. Newer digital hearing aids have many features that improve performance, making them potentially more acceptable to users, but they are expensive and are not covered by Medicare. Hearing aids have been demonstrated to improve hearing function and hearing-related quality of life (QOL), but evidence is less robust for improving overall QOL. Depending upon the etiology of the hearing loss, other medical and surgical procedures, including cochlear implantation, may benefit older adults. Older adults with multiple morbidities and who are frail pose specific challenges for the management of hearing loss. These patients may require integration of hearing assessment and treatment as part of functional assessment in an interdisciplinary, team-based approach to care. JAMA. 2012;307(11):1185-1194	[Pacala, James T.] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA; [Yueh, Bevan] Univ Minnesota, Sch Med, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Pacala, JT (corresponding author), Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, A682 Mayo Mem Bldg,MMC 381,420 Delaware St SE, Minneapolis, MN 55455 USA.	pacal001@umn.edu		Yueh, Bevan/0000-0003-1380-1053	American Head Neck Society; American Academy of Otolaryngology/Head Neck Surgery; National Institutes of Health; SCAN Foundation	American Head Neck Society; American Academy of Otolaryngology/Head Neck Surgery; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SCAN Foundation	Dr Yueh reports receipt of research support from the American Head & Neck Society, the American Academy of Otolaryngology/Head & Neck Surgery, and the National Institutes of Health. The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	American Association of Retired Persons (AARP), 2007, CONS GUID HEAR AIDS; American Speech-Language-Hearing Association, GUID AUD SCREEN; [Anonymous], QUICK REF INF ABCS P; [Anonymous], MED BEN ONL DAT; [Anonymous], SCREEN HEAR LOSS OLD; [Anonymous], CLIN PREV SERV HEAR; [Anonymous], AUD; [Anonymous], FDA APPR 1 TOT IMPL; Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89; Bagai A, 2006, JAMA-J AM MED ASSOC, V295, P416, DOI 10.1001/jama.295.4.416; Bertoli S, 2010, INT J AUDIOL, V49, P333, DOI 10.3109/14992020903473431; Bertoli S, 2009, INT J AUDIOL, V48, P183, DOI 10.1080/14992020802572627; BINGEA R L, 1982, Journal of Auditory Research, V22, P275; Boatman DF, 2007, NEUROLOGY, V68, P1311, DOI 10.1212/01.wnl.0000259524.08148.16; Bogardus ST, 2003, JAMA-J AM MED ASSOC, V289, P1986, DOI 10.1001/jama.289.15.1986; Boothroyd Arthur, 2007, Trends Amplif, V11, P63, DOI 10.1177/1084713807301073; Boymans M, 2008, EAR HEARING, V29, P930, DOI 10.1097/AUD.0b013e31818713a8; Cacciatore F, 1999, GERONTOLOGY, V45, P323, DOI 10.1159/000022113; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; Chang HP, 2009, EAR HEARING, V30, P576, DOI 10.1097/AUD.0b013e3181ac127a; Chia EM, 2007, EAR HEARING, V28, P187, DOI 10.1097/AUD.0b013e31803126b6; Chou R, 2011, ANN INTERN MED, V154, P347, DOI 10.7326/0003-4819-154-5-201103010-00009; Clark J G, 1981, ASHA, V23, P493; CLARK K, 1991, AM J EPIDEMIOL, V134, P704, DOI 10.1093/oxfordjournals.aje.a116147; Cohen-Mansfield Jiska, 2004, J Am Med Dir Assoc, V5, P289, DOI 10.1016/S1525-8610(04)70018-3; Collins MP, 2007, J REHABIL RES DEV, V44, P739, DOI 10.1682/JRRD.2007.02.0029; Corna LM, 2009, GERONTOLOGY, V55, P468, DOI 10.1159/000219589; Dalton DS, 2003, GERONTOLOGIST, V43, P661, DOI 10.1093/geront/43.5.661; Desjardins JL, 2009, AM J AUDIOL, V18, P69, DOI 10.1044/1059-0889(2009/08-0022); Dillon Charles F, 2010, NCHS Data Brief, P1; Duijvestijn JA, 2003, ACTA OTO-LARYNGOL, V123, P846, DOI 10.1080/0001648031000719; Erber NP, 2003, INT J AUDIOL, V42, pS21; Fischer ME, 2011, AM J PUBLIC HEALTH, V101, P1449, DOI 10.2105/AJPH.2010.300078; GARAHAN MB, 1992, J AM GERIATR SOC, V40, P130, DOI 10.1111/j.1532-5415.1992.tb01932.x; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; Gnewikow D., 2006, HEAR J, V59, P66, DOI [DOI 10.1097/01.HJ.0000286220.14835.13, 10.1097/01.HJ.0000286220.14835.13]; Gopinath B, 2011, ANN EPIDEMIOL, V21, P497, DOI 10.1016/j.annepidem.2011.03.005; Gopinath B, 2009, J AM GERIATR SOC, V57, P1306, DOI 10.1111/j.1532-5415.2009.02317.x; Guidance on the 2010 ADA Standards for Accessible Design US Department of Justice, GUID 2010 ADA STAND; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hartley D, 2010, J AM ACAD AUDIOL, V21, P642, DOI 10.3766/jaaa.21.10.4; Helzner EP, 2005, J AM GERIATR SOC, V53, P2119, DOI 10.1111/j.1532-5415.2005.00525.x; Hickson L, 2007, EAR HEARING, V28, P212, DOI 10.1097/AUD.0b013e31803126c8; Hickson L, 2010, INT J AUDIOL, V49, P586, DOI 10.3109/14992021003777259; Hogan A, 2009, J AGING HEALTH, V21, P1098, DOI 10.1177/0898264309347821; Holmes AE, 2003, INT J AUDIOL, V42, pS63; Iezzoni LI, 2004, ANN INTERN MED, V140, P356, DOI 10.7326/0003-4819-140-5-200403020-00011; Kobler S, 2002, INT J AUDIOL, V41, P395, DOI 10.3109/14992020209090416; Koehnke Janet, 2001, Seminars in Hearing, V22, P241, DOI 10.1055/s-2001-15629; Laplante-Levesque A, 2010, INT J AUDIOL, V49, P497, DOI 10.3109/14992021003645902; Lin FR, 2011, J GERONTOL A-BIOL, V66, P582, DOI 10.1093/gerona/glr002; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; Lockey K, 2010, INT J AUDIOL, V49, P542, DOI 10.3109/14992021003685817; Hidalgo JLT, 2009, ARCH GERONTOL GERIAT, V49, P88, DOI 10.1016/j.archger.2008.05.006; Lunner T, 2003, INT J AUDIOL, V42, pS49; Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689; Martin JS, 2005, J REHABIL RES DEV, V42, P25, DOI 10.1682/JRRD.2004.12.0164; Mazelova J, 2003, EXP GERONTOL, V38, P87, DOI 10.1016/S0531-5565(02)00155-9; Metselaar M, 2009, EUR ARCH OTO-RHINO-L, V266, P907, DOI 10.1007/s00405-008-0847-x; Naidoo S V, 1997, J Am Acad Audiol, V8, P188; Natalizia A, 2010, EUR REV MED PHARMACO, V14, P223; Noble W, 2006, INT J AUDIOL, V45, pS63, DOI 10.1080/14992020600782873; Nondahl DM, 1998, AUDIOLOGY, V37, P295; Popelka MM, 1998, J AM GERIATR SOC, V46, P1075, DOI 10.1111/j.1532-5415.1998.tb06643.x; Preminger JE, 2010, AM J AUDIOL, V19, P109, DOI 10.1044/1059-0889(2010/09-0027); Raman G, EFFECTIVENESS COCHLE; Rauch SD, 2008, NEW ENGL J MED, V359, P833, DOI 10.1056/NEJMcp0802129; Rauch SD, 2011, JAMA-J AM MED ASSOC, V305, P2071, DOI 10.1001/jama.2011.679; Reuben DB, 1998, J AM GERIATR SOC, V46, P1008, DOI 10.1111/j.1532-5415.1998.tb02758.x; SCHREURS KK, 1985, EAR HEARING, V6, P198, DOI 10.1097/00003446-198507000-00005; Simon HJ, 2005, J REHABIL RES DEV, V42, P117, DOI 10.1682/JRRD.2005.01.0021; Sindhusake D, 2001, INT J EPIDEMIOL, V30, P1371, DOI 10.1093/ije/30.6.1371; Stach B A, 1990, J Am Acad Audiol, V1, P109; Stark P, 2004, INT J AUDIOL, V43, P390, DOI 10.1080/14992020400050050; Stephens S D, 1990, Acta Otolaryngol Suppl, V476, P281; Stevens G, 2013, EUR J PUBLIC HEALTH, V23, P146, DOI 10.1093/eurpub/ckr176; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; Sweetow Robert, 2005, J Am Acad Audiol, V16, P494, DOI 10.3766/jaaa.16.7.9; Takahashi G, 2007, J AM ACAD AUDIOL, V18, P323, DOI 10.3766/jaaa.18.4.6; Ventry I M, 1983, ASHA, V25, P37; Walden Therese C, 2005, J Am Acad Audiol, V16, P574; Wiley T L, 2000, J Am Acad Audiol, V11, P67; Yueh B, 2010, J AM GERIATR SOC, V58, P427, DOI 10.1111/j.1532-5415.2010.02738.x	83	72	88	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1185	1194		10.1001/jama.2012.305	http://dx.doi.org/10.1001/jama.2012.305			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911HN	22436959				2022-12-28	WOS:000301708000027
J	Long, JA; Jahnle, EC; Richardson, DM; Loewenstein, G; Volpp, KG				Long, Judith A.; Jahnle, Erica C.; Richardson, Diane M.; Loewenstein, George; Volpp, Kevin G.			Peer Mentoring and Financial Incentives to Improve Glucose Control in African American Veterans A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							GLYCEMIC CONTROL; SELF-MANAGEMENT; SOCIAL SUPPORT; WEIGHT-LOSS; CLINICAL-OUTCOMES; CARE MANAGEMENT; GROUP VISITS; HEALTH-CARE; TYPE-2; BEHAVIORS	Background: Compared with white persons, African Americans have a greater incidence of diabetes, decreased control, and higher rates of microvascular complications. A peer mentorship model could be a scalable approach to improving control in this population and reducing disparities in diabetic outcomes. Objective: To determine whether peer mentors or financial incentives are superior to usual care in helping African American veterans decrease their hemoglobin A(1c) (HbA(1c)) levels. Design: A 6-month randomized, controlled trial. (ClinicalTrials.gov registration number: NCT01125956) Setting: Philadelphia Veterans Affairs Medical Center. Patients: African American veterans aged 50 to 70 years with persistently poor diabetes control. Intervention: 118 patients were randomly assigned to 1 of 3 groups: usual care, a peer mentoring group, and a financial incentives group. Usual care patients were notified of their starting HbA(1c) level and recommended goals for HbA(1c). Those in the peer mentoring group were assigned a mentor who formerly had poor glycemic control but now had good control (HbA(1c) level <= 7.5%). The mentor was asked to talk with the patient at least once per week. Peer mentors were matched by race, sex, and age. Patients in the financial incentive group could earn $100 by decreasing their HbA(1c) level by 1% and $200 by decreasing it by 2% or to an HbA(1c) level of 6.5%. Measurements: Change in HbA(1c) level at 6 months. Results: Mentors and mentees talked the most in the first month (mean calls, 4; range, 0 to 30), but calls decreased to a mean of 2 calls (range, 0 to 10) by the sixth month. Levels of HbA(1c) decreased from 9.9% to 9.8% in the control group, from 9.8% to 8.7% in the peer mentor group, and from 9.5% to 9.1% in the financial incentive group. Mean change in HbA(1c) level from baseline to 6 months relative to control was -1.07% (95% CI, -1.84% to -0.31%) in the peer mentor group and -0.45% (CI, -1.23% to 0.32%) in the financial incentive group. Limitation: The study included only veterans and lasted only 6 months. Conclusion: Peer mentorship improved glucose control in a cohort of African American veterans with diabetes.	Philadelphia Vet Affairs Ctr Hlth Equ Research &, Philadelphia, PA USA; Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA; Carnegie Mellon Univ, Pittsburgh, PA 15213 USA	University of Pennsylvania; Carnegie Mellon University	Long, JA (corresponding author), 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	jalong@mail.med.upenn.edu	Loewenstein, George/G-7616-2014	Loewenstein, George/0000-0003-2790-0474; Volpp, Kevin/0000-0003-1423-4599	National Institute on Aging Roybal Center [1P30AG034546]; NATIONAL INSTITUTE ON AGING [P30AG034546] Funding Source: NIH RePORTER	National Institute on Aging Roybal Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: By the National Institute on Aging Roybal Center (grant 1P30AG034546 to Dr. Volpp).	American Diabetes Association, 2002, DIABETES CARE, V25, pS28, DOI [10.2337/diacare.25.2007.S28, DOI 10.2337/DIACARE.25.2007.S28]; Armstrong K, 2008, J GEN INTERN MED, V23, P827, DOI 10.1007/s11606-008-0561-9; Bishop G, 2006, NEW ENGL J MED, V355, P756, DOI 10.1056/NEJMp068170; [Centers for Disease Control and Prevention National Institutes of Health American Diabetes Association], 2007, NAT DIAB FACT SHEET; Clancy DE, 2003, DIABETES CARE, V26, P2032, DOI 10.2337/diacare.26.7.2032; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Emanuele N, 2005, DIABETES CARE, V28, P1954, DOI 10.2337/diacare.28.8.1954; Gallant MP, 2003, HEALTH EDUC BEHAV, V30, P170, DOI 10.1177/1090198102251030; Gamble VN, 1997, AM J PUBLIC HEALTH, V87, P1773, DOI 10.2105/AJPH.87.11.1773; Gary TL, 2003, DIABETES EDUCATOR, V29, P488, DOI 10.1177/014572170302900313; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; GLASGOW RE, 1988, DIABETES CARE, V11, P377, DOI 10.2337/diacare.11.5.377; Haisley E, 2012, AM J HEALTH PROMOT, V26, P184, DOI 10.4278/ajhp.100729-ARB-257; Halpern SD, 2009, CIRC-CARDIOVASC QUAL, V2, P514, DOI 10.1161/CIRCOUTCOMES.109.871855; Heisler M, 2010, ANN INTERN MED, V153, P507, DOI 10.7326/0003-4819-153-8-201010190-00007; Heisler M, 2010, FAM PRACT, V27, pI23, DOI 10.1093/fampra/cmp003; Jaber R, 2006, J AM BOARD FAM MED, V19, P276, DOI 10.3122/jabfm.19.3.276; Joseph DH, 2001, DIABETES EDUCATOR, V27, P703, DOI 10.1177/014572170102700511; Keyserling TC, 2000, DIABETES EDUCATOR, V26, P796, DOI 10.1177/014572170002600508; Keyserling TC, 2002, DIABETES CARE, V25, P1576, DOI 10.2337/diacare.25.9.1576; Kirsh S, 2007, QUAL SAF HEALTH CARE, V16, P349, DOI 10.1136/qshc.2006.019158; KULIK JA, 1993, J BEHAV MED, V16, P45, DOI 10.1007/BF00844754; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Little R.J.A., 2002, STAT ANAL MISSING DA; LLOYD CE, 1993, DIABETES RES CLIN PR, V21, P187, DOI 10.1016/0168-8227(93)90068-G; Loewenstein G, 2007, JAMA-J AM MED ASSOC, V298, P2415, DOI 10.1001/jama.298.20.2415; Matthews BA, 2002, PSYCHO-ONCOLOGY, V11, P199, DOI 10.1002/pon.550; Mitnick S, 2010, ETHICAL CONSIDERATIO; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; O'Donoghue T, 1999, AM ECON REV, V89, P103, DOI 10.1257/aer.89.1.103; Pearson SD, 2009, HEALTH AFFAIR, V28, P845, DOI 10.1377/hlthaff.28.3.845; Peek ME, 2007, MED CARE RES REV, V64, p101S, DOI 10.1177/1077558707305409; Pleis John R, 2009, Vital Health Stat 10, P1; Rollnick S, 1995, BEHAV COGN PSYCHOTH, V23, P325, DOI DOI 10.1017/S135246580001643X; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; RUGGIERO L, 1990, DIABETES CARE, V13, P441, DOI 10.2337/diacare.13.4.441; Schwartz CE, 1999, SOC SCI MED, V48, P1563, DOI 10.1016/S0277-9536(99)00049-0; Shacter HE, 2009, ETHNIC DIS, V19, P121; Shaw Joanne, 2007, BMJ, V335, P233, DOI 10.1136/bmj.39286.422639.BE; Stone RA, 2010, DIABETES CARE, V33, P478, DOI 10.2337/dc09-1012; Sunstein CR, 2003, U CHICAGO LAW REV, V70, P1159, DOI 10.2307/1600573; Tillotson LM, 1996, DIABETES EDUCATOR, V22, P133, DOI 10.1177/014572179602200206; Trento M, 2002, DIABETOLOGIA, V45, P1231, DOI 10.1007/s00125-002-0904-8; Trivedi AN, 2011, HEALTH AFFAIR, V30, P707, DOI 10.1377/hlthaff.2011.0074; Volpp KG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-272; Volpp KG, 2009, HEALTH AFFAIR, V28, P206, DOI 10.1377/hlthaff.28.1.206; Volpp KG, 2009, NEW ENGL J MED, V360, P699, DOI 10.1056/NEJMsa0806819; Volpp KG, 2008, JAMA-J AM MED ASSOC, V300, P2631, DOI 10.1001/jama.2008.804; Webel AR, 2010, AM J PUBLIC HEALTH, V100, P247, DOI 10.2105/AJPH.2008.149419; WILSON W, 1987, AM J PUBLIC HEALTH, V77, P634, DOI 10.2105/AJPH.77.5.634; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; Young BA, 2003, DIABETES CARE, V26, P2392, DOI 10.2337/diacare.26.8.2392	53	212	214	1	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					416	U60		10.7326/0003-4819-156-6-201203200-00004	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	930PF	22431674	Green Accepted			2022-12-28	WOS:000303150900014
J	Stott, R				Stott, Robin			Contraction and convergence: the best possible solution to the twin problems of climate change and inequity	BRITISH MEDICAL JOURNAL			English	Article									BMJ Publishing Grp, Climate & Hlth Council, London WC1 H9JR, England	BMJ Publishing Group Ltd	Stott, R (corresponding author), BMJ Publishing Grp, Climate & Hlth Council, London WC1 H9JR, England.	stott@dircon.co.uk						[Anonymous], 2008, CLOS GAP GEN HLTH EQ; Bunting M, 2009, GUARDIAN        0527; Center for Environmental Economic Development (CEED) Tobin Tax Initiative, TOB TAX IN FACT SHEE; European Commission Joint Research Centre (JRC), 2011, STEEP INCR GLOB CO2; Farrington J., 2005, GER TECH COOP, P1; Fox M, 2009, ANTIDEPRESSANT USE D; Global Commons Institute, CONTR CONV; Hanlon J., 2010, JUST GIVE MONEY POOR; IPCC Climate Change, 2022, CLIMATE CHANGE 2022; Millennium Villages, OV; Organization WH, 2016, GLOBAL STATUS REPORT; Sachs J, 2005, SCI AM          0822; Sandbu M, 2011, FINANCIAL TIMES 0928; Trading Economics, WORLD BANK DAT FERT; UCL Institute of Health Equity, 2010, STRAT REV HLTH IN EN; Wenzel B, 2006, WHAT ELECT RENEWABLE; World Health Organization, 2010, CLIM CHANG HLTH; World Health Organization, 2021, LANCET	18	8	9	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1765	10.1136/bmj.e1765	http://dx.doi.org/10.1136/bmj.e1765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431663	Bronze			2022-12-28	WOS:000301848400009
J	Miller, JR				Miller, John R.			Valuing Reversible Energy Storage	SCIENCE			English	Editorial Material							PERFORMANCE; GRAPHENE		[Miller, John R.] JME Inc, Beachwood, OH 44122 USA; [Miller, John R.] Case Western Reserve Univ, Great Lakes Energy Inst, Cleveland, OH 44106 USA	Case Western Reserve University	Miller, JR (corresponding author), JME Inc, 23500 Mercantile Rd,Suite L, Beachwood, OH 44122 USA.	jmecapacitor@att.net	Miller, John J/GZG-5663-2022					El-Kady MF, 2012, SCIENCE, V335, P1326, DOI 10.1126/science.1216744; Gogotsi Y, 2011, SCIENCE, V334, P917, DOI 10.1126/science.1213003; Le LT, 2011, ELECTROCHEM COMMUN, V13, P355, DOI 10.1016/j.elecom.2011.01.023; Miller J. R., 2012, BATTERIES ENERGY STO, V35, P115; Miller JR, 2008, ELECTROCHEM SOC INTE, V17, P53; Miller JR, 2010, SCIENCE, V329, P1637, DOI 10.1126/science.1194372; Shao X., 2009, J POWER SOURCES, V194, P1208; Strong V, 2012, ACS NANO, V6, P1395, DOI 10.1021/nn204200w	8	159	163	4	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1312	1313		10.1126/science.1219134	http://dx.doi.org/10.1126/science.1219134			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422970				2022-12-28	WOS:000301531600034
J	Gomes, KK; Mar, W; Ko, W; Guinea, F; Manoharan, HC				Gomes, Kenjiro K.; Mar, Warren; Ko, Wonhee; Guinea, Francisco; Manoharan, Hari C.			Designer Dirac fermions and topological phases in molecular graphene	NATURE			English	Article								The observation of massless Dirac fermions in monolayer graphene has generated a new area of science and technology seeking to harness charge carriers that behave relativistically within solid-state materials(1). Both massless and massive Dirac fermions have been studied and proposed in a growing class of Dirac materials that includes bilayer graphene, surface states of topological insulators and iron-based high-temperature superconductors. Because the accessibility of this physics is predicated on the synthesis of new materials, the quest for Dirac quasi-particles has expanded to artificial systems such as lattices comprising ultracold atoms(2-4). Here we report the emergence of Dirac fermions in a fully tunable condensed-matter system-molecular graphene-assembled by atomic manipulation of carbon monoxide molecules over a conventional two-dimensional electron system at a copper surface(5). Using low-temperature scanning tunnelling microscopy and spectroscopy, we embed the symmetries underlying the two-dimensional Dirac equation into electron lattices, and then visualize and shape the resulting ground states. These experiments show the existence within the system of linearly dispersing, massless quasi-particles accompanied by a density of states characteristic of graphene. We then tune the quantum tunnelling between lattice sites locally to adjust the phase accrual of propagating electrons. Spatial texturing of lattice distortions produces atomically sharp p-n and p-n-p junction devices with two-dimensional control of Dirac fermion density and the power to endow Dirac particles with mass(6-8). Moreover, we apply scalar and vector potentials locally and globally to engender topologically distinct ground states and, ultimately, embedded gauge fields(9-12), wherein Dirac electrons react to 'pseudo' electric and magnetic fields present in their reference frame but absent from the laboratory frame. We demonstrate that Landau levels created by these gauge fields can be taken to the relativistic magnetic quantum limit, which has so far been inaccessible in natural graphene. Molecular graphene provides a versatile means of synthesizing exotic topological electronic phases in condensed matter using tailored nanostructures.	[Gomes, Kenjiro K.; Manoharan, Hari C.] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Gomes, Kenjiro K.; Mar, Warren; Ko, Wonhee; Manoharan, Hari C.] SLAC Natl Accelerator Lab, Stanford Inst Mat & Energy Sci, Menlo Pk, CA 94025 USA; [Mar, Warren] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; [Ko, Wonhee] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Guinea, Francisco] CSIC, Inst Ciencia Mat Madrid, E-28049 Madrid, Spain	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University; Stanford University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Madrid (ICMM)	Manoharan, HC (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	manoharan@stanford.edu	Ko, Wonhee/ABG-1509-2020; Guinea, Francisco/A-7122-2008	Guinea, Francisco/0000-0001-5915-5427; Ko, Wonhee/0000-0002-6155-1485	US Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering [DE-AC02-76SF00515]; MICINN (Spain) [FIS2008-00124, CSD2007-00010]; US National Science Foundation	US Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering(United States Department of Energy (DOE)); MICINN (Spain)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); US National Science Foundation(National Science Foundation (NSF))	This work was supported by the US Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering, under contract DE-AC02-76SF00515. F. G. acknowledges financial support from MICINN (Spain) through grants FIS2008-00124 and CONSOLIDER CSD2007-00010, and calculations supported by the US National Science Foundation. We thank C.-H. Park, I. Martin, A. Balatsky, T. Wehling, A. Akhmerov, E. Heller and A. Fetter for discussions.	Bena C, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.125432; Bloch I, 2005, NAT PHYS, V1, P23, DOI 10.1038/nphys138; Cahangirov S, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.236804; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Cheianov VV, 2007, SCIENCE, V315, P1252, DOI 10.1126/science.1138020; Guinea F, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.075422; Guinea F, 2010, NAT PHYS, V6, P30, DOI 10.1038/NPHYS1420; Herbut IF, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.205433; Hou CY, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.186809; Jackiw R, 2007, AIP CONF PROC, V939, P341, DOI 10.1063/1.2803825; Kailasvuori J, 2009, EPL-EUROPHYS LETT, V87, DOI 10.1209/0295-5075/87/47008; Katsnelson MI, 2006, NAT PHYS, V2, P620, DOI 10.1038/nphys384; Levy N, 2010, SCIENCE, V329, P544, DOI 10.1126/science.1191700; Lobo-Checa J, 2009, SCIENCE, V325, P300, DOI 10.1126/science.1175141; Martin I, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.036804; Moon CR, 2008, NAT PHYS, V4, P454, DOI 10.1038/nphys930; Moon CR, 2008, SCIENCE, V319, P782, DOI 10.1126/science.1151490; Moon CR, 2009, NAT NANOTECHNOL, V4, P167, DOI [10.1038/NNANO.2008.415, 10.1038/nnano.2008.415]; Nomura K, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.146806; Park CH, 2009, NANO LETT, V9, P1793, DOI 10.1021/nl803706c; Roy B, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.035429; Ryu S, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.205319; Seradjeh B, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.033104; Seradjeh B, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.146401; Singha A, 2011, SCIENCE, V332, P1176, DOI 10.1126/science.1204333; Wehling TO, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.125425; Wehling TO, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.085413; Wunsch B, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/10/103027; Zhu SL, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.260402	30	516	517	9	426	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					306	310		10.1038/nature10941	http://dx.doi.org/10.1038/nature10941			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422264				2022-12-28	WOS:000301481800043
J	Hohmann, EL; Kim, J				Hohmann, Elizabeth L.; Kim, JiYeon			Case 8-2012: A 53-Year-Old Man with Crohn's Disease, Diarrhea, Fever, and Bacteremia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LISTERIA-MONOCYTOGENES; GASTROENTERITIS		[Hohmann, Elizabeth L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Kim, JiYeon] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Hohmann, Elizabeth L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Kim, JiYeon] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hohmann, EL (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.							Amaya-Villar R, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-324; Buchholz U, 2011, NEW ENGL J MED, V365, P1763, DOI 10.1056/NEJMoa1106482; dos Reis CMF, 2011, REV SOC BRAS MED TRO, V44, P173, DOI 10.1590/S0037-86822011005000019; Mitja O, 2009, J ANTIMICROB CHEMOTH, V64, P416, DOI 10.1093/jac/dkp180; Morvan A, 2010, ANTIMICROB AGENTS CH, V54, P2728, DOI 10.1128/AAC.01557-09; Ooi ST, 2005, CLIN INFECT DIS, V40, P1327, DOI 10.1086/429324; Schlech WF, 2005, CLIN INFECT DIS, V41, P778, DOI 10.1086/432724	7	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1039	1045		10.1056/NEJMcpc1110054	http://dx.doi.org/10.1056/NEJMcpc1110054			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417258				2022-12-28	WOS:000301482800009
J	Karagiannis, T; Paschos, P; Paletas, K; Matthews, DR; Tsapas, A				Karagiannis, Thomas; Paschos, Paschalis; Paletas, Konstantinos; Matthews, David R.; Tsapas, Apostolos			Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INITIAL COMBINATION THERAPY; DRUG-NAIVE PATIENTS; GLYCEMIC CONTROL; DOUBLE-BLIND; WEIGHT-GAIN; COST-EFFECTIVENESS; METFORMIN THERAPY; EFFICACY; SAFETY; SITAGLIPTIN	Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, Embase, the Cochrane Library, conference proceedings, trial registers, and drug manufacturers' websites. Eligibility criteria Randomised controlled trials of adults with type 2 diabetes mellitus that compared a DPP-4 with metformin as monotherapy or with a sulfonylurea, pioglitazone, a glucagon-like peptide-1 (GLP-1) agonist, or basal insulin combined with metformin on the change from baseline in glycated haemoglobin (HbA(1c)). Data extraction The primary outcome was the change in HbA(1c). Secondary outcomes included the proportion of patients achieving the goal of HbA(1c) <7%, the change in body weight, discontinuation rate because of any adverse event, occurrence of any serious adverse event, all cause mortality, and incidence of hypoglycaemia, nasopharyngitis, urinary tract infection, upper respiratory infection, nausea, vomiting, and diarrhoea. Results 27 reports of 19 studies including 7136 patients randomised to a DPP-4 inhibitor and 6745 patients randomised to another hypoglycaemic drug were eligible for the systematic review and meta-analysis. Overall risk of bias for the primary outcome was low in three reports, unclear in nine, and high in 14. Compared with metformin as monotherapy, DPP-4 inhibitors were associated with a smaller decline in HbA(1c) (weighted mean difference 0.20, 95% confidence interval 0.08 to 0.32) and in body weight (1.5, 0.9 to 2.11). As a second line treatment, DPP-4 inhibitors were inferior to GLP-1 agonists (0.49, 0.31 to 0.67) and similar to pioglitazone (0.09, -0.07 to 0.24) in reducing HbA(1c) and had no advantage over sulfonylureas in the attainment of the HbA(1c) goal (risk ratio in favour of sulfonylureas 1.06, 0.98 to 1.14). DPP-4 inhibitors had a favourable weight profile compared with sulfonylureas (weighted mean difference -1.92, -2.34 to -1.49) or pioglitazone (-2.96, -4.13 to -1.78), but not compared with GLP-1 agonists (1.56, 0.94 to 2.18). Only a minimal number of hypoglycaemias were observed in any treatment arm in trials comparing a DPP-4 inhibitor with metformin as monotherapy or with pioglitazone or a GLP-1 agonist as second line treatment. In most trials comparing a DPP-4 inhibitor with sulfonylureas combined with metformin, the risk for hypoglycaemia was higher in the group treated with a sulfonylurea. Incidence of any serious adverse event was lower with DPP-4 inhibitors than with pioglitazone. Incidence of nausea, diarrhoea, and vomiting was higher in patients receiving metformin or a GLP-1 agonist than in those receiving a DPP-4 inhibitor. Risk for nasopharyngitis, upper respiratory tract infection, or urinary tract infection did not differ between DPP-4 inhibitors and any of the active comparators. Conclusion In patients with type 2 diabetes who do not achieve the glycaemic targets with metformin alone, DPP-4 inhibitors can lower HbA(1c), in a similar way to sulfonylureas or pioglitazone, with neutral effects on body weight. Increased unit cost, which largely exceeds that of the older drugs, and uncertainty about their long term safety, however, should also be considered.	[Karagiannis, Thomas; Paschos, Paschalis; Paletas, Konstantinos; Tsapas, Apostolos] Aristotle Univ Thessaloniki, Dept Med 2, Metab Dis Unit, Thessaloniki 54642, Greece; [Matthews, David R.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England; [Tsapas, Apostolos] Univ Oxford, Harris Manchester Coll, Oxford OX1 3TD, England	Aristotle University of Thessaloniki; University of Oxford; University of Oxford	Tsapas, A (corresponding author), Aristotle Univ Thessaloniki, Dept Med 2, Metab Dis Unit, Konstantinupoleos 49, Thessaloniki 54642, Greece.	atsapas@auth.gr	Tsapas, Apostolos/P-5593-2019; Karagiannis, Thomas/H-9476-2019	Tsapas, Apostolos/0000-0003-0221-4072; Karagiannis, Thomas/0000-0001-5242-0574	Novartis; Novo Nordisk; GlaxoSmithKline; Merck; Eli Lilly; Boehringer Ingelheim; AstraZeneca; Johnson and Johnson; Janssen Global Services; National Institute for Health Research [NF-SI-0508-10272] Funding Source: researchfish	Novartis(Novartis); Novo Nordisk(Novo Nordisk); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Eli Lilly(Eli Lilly); Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Janssen Global Services; National Institute for Health Research(National Institute for Health Research (NIHR))	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: DRM has been a member of an advisory board for vildagliptin (Novartis) and has received consulting fees from Novartis, Novo Nordisk, GlaxoSmithKline, Merck, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Johnson and Johnson, and Janssen Global Services; AT has been a member of an advisory board for liraglutide (Novo Nordisk), has received lecture fees and a research grant from Novartis, and has received support with an educational grant from Novo Nordisk.	Alexander GC, 2008, ARCH INTERN MED, V168, P2088, DOI 10.1001/archinte.168.19.2088; Amori RE, 2007, JAMA-J AM MED ASSOC, V298, P194, DOI 10.1001/jama.298.2.194; Arechavaleta R, 2011, DIABETES OBES METAB, V13, P160, DOI 10.1111/j.1463-1326.2010.01334.x; Aschner P, 2010, DIABETES OBES METAB, V12, P252, DOI 10.1111/j.1463-1326.2009.01187.x; Bergenstal RM, 2010, LANCET, V376, P431, DOI 10.1016/S0140-6736(10)60590-9; Bolli G, 2008, DIABETES OBES METAB, V10, P82, DOI 10.1111/j.1463-1326.2007.00820.x; Bolli G, 2009, DIABETES OBES METAB, V11, P589, DOI 10.1111/j.1463-1326.2008.01023.x; Bosi E, 2009, DIABETES OBES METAB, V11, P506, DOI 10.1111/j.1463-1326.2009.01040.x; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Esposito K, 2011, DIABETES OBES METAB, V13, P594, DOI 10.1111/j.1463-1326.2011.01380.x; Fakhoury WKH, 2010, PHARMACOLOGY, V86, P44, DOI 10.1159/000314690; Ferrannini E, 2009, DIABETES OBES METAB, V11, P157, DOI 10.1111/j.1463-1326.2008.00994.x; Filozof C, 2010, DIABETIC MED, V27, P318, DOI 10.1111/j.1464-5491.2010.02938.x; Forst T, 2010, DIABETIC MED, V27, P1409, DOI 10.1111/j.1464-5491.2010.03131.x; Goke B, 2008, HORM METAB RES, V40, P892, DOI 10.1055/s-0028-1082334; Goke B, 2010, INT J CLIN PRACT, V64, P1619, DOI 10.1111/j.1742-1241.2010.02510.x; Goldstein BJ, 2007, DIABETES CARE, V30, P1979, DOI 10.2337/dc07-0627; Granstrom O, 2011, PRIM CARE DIABE 1014; Gross JL, 2011, ANN INTERN MED, V154, P672, DOI 10.7326/0003-4819-154-10-201105170-00007; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Halpern SD, 2002, J GEN INTERN MED, V17, P689, DOI 10.1046/j.1525-1497.2002.11024.x; Handayani O, 2010, EFFECTS PIOGLITAZINE; Hanefeld M, 2007, CURR MED RES OPIN, V23, P1329, DOI 10.1185/030079907X188152; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Jadzinsky M, 2009, DIABETES OBES METAB, V11, P611, DOI 10.1111/j.1463-1326.2009.01056.x; Klarenbach S, 2011, CAN MED ASSOC J, V183, pE1213, DOI 10.1503/cmaj.110178; Lefebvre C., 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184.CH6; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Matthews DR, 2010, DIABETES OBES METAB, V12, P780, DOI 10.1111/j.1463-1326.2010.01233.x; McIntosh Brendan, 2011, Open Med, V5, pe35; Monami M, 2010, NUTR METAB CARDIOVAS, V20, P224, DOI 10.1016/j.numecd.2009.03.015; Montori VM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1354; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; National Institute for Health and Clinical Excellence, 2009, TYP 2 DIAB NEW AG; Nauck MA, 2007, DIABETES OBES METAB, V9, P194, DOI 10.1111/j.1463-1326.2006.00704.x; Pfutzner A, 2011, DIABETES OBES METAB, V13, P567, DOI 10.1111/j.1463-1326.2011.01385.x; Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Pratley R, 2011, INT J CLIN PRACT, V65, P397, DOI 10.1111/j.1742-1241.2011.02656.x; Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8; Richter B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006739.pub2; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Rosenstock J, 2009, CURR MED RES OPIN, V25, P2401, DOI 10.1185/03007990903178735; Scheen AJ, 2010, DIABETES-METAB RES, V26, P540, DOI 10.1002/dmrr.1114; Schwarz B, 2008, DIABETES OBES METAB, V10, P43, DOI 10.1111/j.1463-1326.2008.00886.x; Schweizer A, 2007, DIABETIC MED, V24, P955, DOI 10.1111/j.1464-5491.2007.02191.x; Schweizer A, 2009, DIABETES OBES METAB, V11, P804, DOI 10.1111/j.1463-1326.2009.01051.x; Scottish Intercollegiate Guidelines Network (SIGN), 2011, IMPL GRADE; Seck T, 2010, INT J CLIN PRACT, V64, P562, DOI 10.1111/j.1742-1241.2010.02353.x; Sherifali D, 2010, DIABETES CARE, V33, P1859, DOI 10.2337/dc09-1727; Sinha A, 2010, DIABETES CARE, V33, P695, DOI 10.2337/dc09-1488; Squibb Bristol-Myers, 2010, SHORT TERM LONG TERM; Waugh N, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14360; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Williams-Herman D, 2010, DIABETES OBES METAB, V12, P442, DOI 10.1111/j.1463-1326.2010.01204.x; Williams-Herman D, 2009, CURR MED RES OPIN, V25, P569, DOI 10.1185/03007990802705679 	57	244	257	0	67	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2012	344								e1369	10.1136/bmj.e1369	http://dx.doi.org/10.1136/bmj.e1369			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913BO	22411919	hybrid, Green Submitted			2022-12-28	WOS:000301846500003
J	Lay, T				Lay, Thorne			Why giant earthquakes keep catching us out	NATURE			English	Editorial Material									Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Lay, T (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA.	tlay@ucsc.edu	Lay, Thorne/ABE-6272-2021						0	9	9	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					149	150		10.1038/483149a	http://dx.doi.org/10.1038/483149a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904DT	22398538				2022-12-28	WOS:000301174900014
J	Spence, D				Spence, Des			FROM THE FRONTLINE Medicine's Leveson	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1671	10.1136/bmj.e1671	http://dx.doi.org/10.1136/bmj.e1671			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399709				2022-12-28	WOS:000301479800010
J	Auton, A; Fledel-Alon, A; Pfeifer, S; Venn, O; Segurel, L; Street, T; Leffler, EM; Bowden, R; Aneas, I; Broxholme, J; Humburg, P; Iqbal, Z; Lunter, G; Maller, J; Hernandez, RD; Melton, C; Venkat, A; Nobrega, MA; Bontrop, R; Myers, S; Donnelly, P; Przeworski, M; McVean, G				Auton, Adam; Fledel-Alon, Adi; Pfeifer, Susanne; Venn, Oliver; Segurel, Laure; Street, Teresa; Leffler, Ellen M.; Bowden, Rory; Aneas, Ivy; Broxholme, John; Humburg, Peter; Iqbal, Zamin; Lunter, Gerton; Maller, Julian; Hernandez, Ryan D.; Melton, Cord; Venkat, Aarti; Nobrega, Marcelo A.; Bontrop, Ronald; Myers, Simon; Donnelly, Peter; Przeworski, Molly; McVean, Gil			A Fine-Scale Chimpanzee Genetic Map from Population Sequencing	SCIENCE			English	Article							RECOMBINATION HOT-SPOTS; MEIOTIC RECOMBINATION; HUMAN GENOME; PRDM9; HOTSPOTS; HUMANS; RATES; INSTABILITY; LANDSCAPE; EVOLUTION	To study the evolution of recombination rates in apes, we developed methodology to construct a fine-scale genetic map from high-throughput sequence data from 10 Western chimpanzees, Pan troglodytes verus. Compared to the human genetic map, broad-scale recombination rates tend to be conserved, but with exceptions, particularly in regions of chromosomal rearrangements and around the site of ancestral fusion in human chromosome 2. At fine scales, chimpanzee recombination is dominated by hotspots, which show no overlap with those of humans even though rates are similarly elevated around CpG islands and decreased within genes. The hotspot-specifying protein PRDM9 shows extensive variation among Western chimpanzees, and there is little evidence that any sequence motifs are enriched in hotspots. The contrasting locations of hotspots provide a natural experiment, which demonstrates the impact of recombination on base composition.	[Auton, Adam; Venn, Oliver; Bowden, Rory; Broxholme, John; Humburg, Peter; Iqbal, Zamin; Lunter, Gerton; Maller, Julian; Myers, Simon; Donnelly, Peter; McVean, Gil] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Auton, Adam] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Fledel-Alon, Adi; Segurel, Laure; Leffler, Ellen M.; Aneas, Ivy; Melton, Cord; Venkat, Aarti; Nobrega, Marcelo A.; Przeworski, Molly] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Pfeifer, Susanne; Street, Teresa; Bowden, Rory; Maller, Julian; Myers, Simon; Donnelly, Peter; McVean, Gil] Univ Oxford, Dept Stat, Oxford OX1 3TG, England; [Segurel, Laure; Venkat, Aarti; Przeworski, Molly] Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; [Bowden, Rory] Univ Oxford, Nuffield Dept Med, Oxford Biomed Res Ctr, Oxford OX3 9DU, England; [Hernandez, Ryan D.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Bontrop, Ronald] Biomed Primate Res Ctr, Dept Comparat Genet & Refinement, NL-2288 GJ Rijswijk, Netherlands; [Przeworski, Molly] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Oxford; Wellcome Centre for Human Genetics; Yeshiva University; Albert Einstein College of Medicine; University of Chicago; University of Oxford; Howard Hughes Medical Institute; University of Chicago; University of Oxford; University of California System; University of California San Francisco; University of Chicago	McVean, G (corresponding author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	mcvean@well.ox.ac.uk	Bontrop, Ronald E/J-3628-2012; Myers, Simon R/A-6792-2015; Lunter, Gerton/H-4939-2016; Leffler, Ellen/I-3010-2019; Humburg, Peter/A-4191-2009	Bontrop, Ronald E/0000-0003-0874-6467; Myers, Simon R/0000-0002-2585-9626; Leffler, Ellen/0000-0002-1614-9366; Humburg, Peter/0000-0002-3331-6496; Iqbal, Zamin/0000-0001-8466-7547; Pfeifer, Susanne/0000-0003-1378-2913; Maller, Julian/0000-0002-1565-9559; McVean, Gil/0000-0002-5012-4162; Donnelly, Peter/0000-0001-9495-3408; Lunter, Gerton/0000-0002-3798-2058; Segurel, Laure/0000-0001-7339-0976	NIH [R01 GM83098, T32 GM007197]; Wellcome Trust [076113/E/04/Z, 086084/Z/08/Z, 090532/Z/09/Z, 086786/Z/08/Z]; Wolfson-Royal Society; Howard Hughes Medical Institute; EUPRIM-Net under the European Union [RII3-026155]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007197, R01GM083098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); Wolfson-Royal Society(Royal Society of London); Howard Hughes Medical Institute(Howard Hughes Medical Institute); EUPRIM-Net under the European Union; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded by NIH grants R01 GM83098 (to M. P.) and T32 GM007197 (to E. M. L.) and by Wellcome Trust grants 076113/E/04/Z (to P. D.), 086084/Z/08/Z (to G. M.), and 090532/Z/09/Z contribution to Core Facility. P. D. was supported in part by a Wolfson-Royal Society Merit Award. M. P. is supported by the Howard Hughes Medical Institute. O.V. is funded by a Wellcome Trust studentship (086786/Z/08/Z). We thank G. Sella, G. McVicker, members of the PPS labs, and reviewers for their comments and H. Thorogood and W. Czyz for assistance with PRDM9 sequencing. Part of this work has been supported by EUPRIM-Net under the European Union contract RII3-026155 of the 6th Framework Programme. Data are available from http://panmap.uchicago.edu. Some primate samples used in this study are under a Material Transfer Agreement from the San Diego Zoo.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Axelsson E, 2012, GENOME RES, V22, P51, DOI 10.1101/gr.124123.111; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; Berg IL, 2011, P NATL ACAD SCI USA, V108, P12378, DOI 10.1073/pnas.1109531108; Berg IL, 2010, NAT GENET, V42, P859, DOI 10.1038/ng.658; Caswell JL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000057; Coop G, 2007, NAT REV GENET, V8, P23, DOI 10.1038/nrg1947; Dreszer TR, 2007, GENOME RES, V17, P1420, DOI 10.1101/gr.6395807; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Grey C, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001176; Hinch AG, 2011, NATURE, V476, P170, DOI 10.1038/nature10336; IJDO JW, 1991, P NATL ACAD SCI USA, V88, P9051, DOI 10.1073/pnas.88.20.9051; Katzman S, 2011, GENOME BIOL EVOL, V3, P614, DOI 10.1093/gbe/evr058; Kong A, 2010, NATURE, V467, P1099, DOI 10.1038/nature09525; Mancera E, 2008, NATURE, V454, P479, DOI 10.1038/nature07135; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Myers S, 2008, NAT GENET, V40, P1124, DOI 10.1038/ng.213; Myers S, 2010, SCIENCE, V327, P876, DOI 10.1126/science.1182363; Oliver PL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000753; Paigen K, 2010, NAT REV GENET, V11, P221, DOI 10.1038/nrg2712; Pan J, 2011, CELL, V144, P719, DOI 10.1016/j.cell.2011.02.009; Parvanov ED, 2010, SCIENCE, V327, P835, DOI 10.1126/science.1181495; Persikov AV, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/3/035010; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Ptak SE, 2004, PLOS BIOL, V2, P849, DOI 10.1371/journal.pbio.0020155; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Smagulova F, 2011, NATURE, V472, P375, DOI 10.1038/nature09869; Spencer CCA, 2006, PLOS GENET, V2, P1375, DOI 10.1371/journal.pgen.0020148; Stumpf MPH, 2003, NAT REV GENET, V4, P959, DOI 10.1038/nrg1227; Wall JD, 2003, AM J HUM GENET, V73, P1330, DOI 10.1086/380311; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322	33	197	198	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 13	2012	336	6078					193	198		10.1126/science.1216872	http://dx.doi.org/10.1126/science.1216872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924PN	22422862	Green Submitted, Green Accepted			2022-12-28	WOS:000302703900041
J	Richter, J; Gobels, S; Gobel, T; Westenfeld, R; Muller-Stover, I; Haussinger, D				Richter, Joachim; Goebels, Stefanie; Goebel, Thomas; Westenfeld, Ralf; Mueller-Stoever, Irmela; Haeussinger, Dieter			PICTURE QUIZ A returning traveller with fever, facial swelling, and skin lesions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRYPANOSOMIASIS		[Richter, Joachim; Goebels, Stefanie; Goebel, Thomas; Mueller-Stoever, Irmela; Haeussinger, Dieter] Univ Dusseldorf, Univ Hosp Gastroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany; [Westenfeld, Ralf] Univ Dusseldorf, Univ Hosp Cardiol Pneumol & Angiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Richter, J (corresponding author), Univ Dusseldorf, Univ Hosp Gastroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany.	joachim.richter@med.uni-duesseldorf.de						Aden Abdi Y, 1995, HDB DRUGS TROPICAL P, p[60, 109, 117, 160, 89]; [Anonymous], 2006, Wkly Epidemiol Rec, V81, P71; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Burri C., 2009, MANSONS TROPICAL DIS, P1307; Checkley AM, 2007, T ROY SOC TROP MED H, V101, P523, DOI 10.1016/j.trstmh.2006.12.001; Faust SN, 2004, PEDIATR INFECT DIS J, V23, P879, DOI 10.1097/01.inf.0000137587.80399.3b; Gautret P, 2009, EUROSURVEILLANCE, V14, P4; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Seixas J, 2010, COCHRANE DB SYST REV, V8; SEMENOVITCH I, 2006, TROPICAL DERMATOLOGY, P29; Stich A, 2002, BRIT MED J, V323, P2031; WHO, HUM AFR TRYP ANN NUM	13	6	6	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2012	344								e2092	10.1136/bmj.e2092	http://dx.doi.org/10.1136/bmj.e2092			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CP	22442353				2022-12-28	WOS:000301849300002
J	Smith, DJ; Whitehouse, I				Smith, Duncan J.; Whitehouse, Iestyn			Intrinsic coupling of lagging-strand synthesis to chromatin assembly	NATURE			English	Article							DNA-POLYMERASE-DELTA; OKAZAKI FRAGMENT MATURATION; SACCHAROMYCES-CEREVISIAE; REPLICATION FORK; SIMIAN VIRUS-40; FLAP ENDONUCLEASE-1; IN-VIVO; NUCLEOSOME; YEAST; TRANSCRIPTION	Fifty per cent of the genome is discontinuously replicated on the lagging strand as Okazaki fragments. Eukaryotic Okazaki fragments remain poorly characterized and, because nucleosomes are rapidly deposited on nascent DNA, Okazaki fragment processing and nucleosome assembly potentially affect one another. Here we show that ligation-competent Okazaki fragments in Saccharomyces cerevisiae are sized according to the nucleosome repeat. Using deep sequencing, we demonstrate that ligation junctions preferentially occur near nucleosome midpoints rather than in internucleosomal linker regions. Disrupting chromatin assembly or lagging-strand polymerase processivity affects both the size and the distribution of Okazaki fragments, suggesting a role for nascent chromatin, assembled immediately after the passage of the replication fork, in the termination of Okazaki fragment synthesis. Our studies represent the first high-resolution analysis-to our knowledge-of eukaryotic Okazaki fragments in vivo, and reveal the interconnection between lagging-strand synthesis and chromatin assembly.	[Smith, Duncan J.; Whitehouse, Iestyn] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Whitehouse, I (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10065 USA.	whitehoi@mskcc.org		Smith, Duncan/0000-0002-0898-8629; Whitehouse, Iestyn/0000-0003-0385-3116	Louis V. Gerstner Jr Young Investigator Award; Alfred Bressler Scholars Endowment Award; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102253] Funding Source: NIH RePORTER	Louis V. Gerstner Jr Young Investigator Award; Alfred Bressler Scholars Endowment Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. McGuffee for assistance with data processing; S. Keeney, K. Marians, D. Remus, T. Tsukiyama, members of the Molecular Biology Program and Whitehouse laboratory for discussions and comments on the manuscript. This work was supported by a Louis V. Gerstner Jr Young Investigator Award and an Alfred Bressler Scholars Endowment Award to I. W. D.J.S. is an HHMI fellow of the Damon Runyon Cancer Research Foundation (DRG-#2046-10).	ANDERSON S, 1979, J BIOL CHEM, V254, P1495; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Badis G, 2008, MOL CELL, V32, P878, DOI 10.1016/j.molcel.2008.11.020; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bai L, 2011, MOL CELL, V42, P465, DOI 10.1016/j.molcel.2011.03.028; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; Bondarenko VA, 2006, MOL CELL, V24, P469, DOI 10.1016/j.molcel.2006.09.009; Burgers PMJ, 2009, J BIOL CHEM, V284, P4041, DOI 10.1074/jbc.R800062200; Chafin DR, 2000, EMBO J, V19, P5492, DOI 10.1093/emboj/19.20.5492; Churchman LS, 2011, NATURE, V469, P368, DOI 10.1038/nature09652; Corpet A, 2009, TRENDS CELL BIOL, V19, P29, DOI 10.1016/j.tcb.2008.10.002; Dohmen RJ, 2005, METHOD ENZYMOL, V399, P799, DOI 10.1016/S0076-6879(05)99052-6; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; Eaton ML, 2010, GENE DEV, V24, P748, DOI 10.1101/gad.1913210; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Groth A, 2007, SCIENCE, V318, P1928, DOI 10.1126/science.1148992; Hall MA, 2009, NAT STRUCT MOL BIOL, V16, P124, DOI 10.1038/nsmb.1526; Hartley PD, 2009, CELL, V137, P445, DOI 10.1016/j.cell.2009.02.043; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Huggins CF, 2002, MOL CELL, V10, P1201, DOI 10.1016/S1097-2765(02)00736-0; Jiang CZ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-r109; Johansson E, 2004, J BIOL CHEM, V279, P1907, DOI 10.1074/jbc.M310362200; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667; KAUFMANN G, 1982, NUCLEIC ACIDS RES, V10, P2309, DOI 10.1093/nar/10.7.2309; MacIsaac KD, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-113; Murakami H, 2009, METHODS MOL BIOL, V557, P117, DOI 10.1007/978-1-59745-527-5_9; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Nieduszynski CA, 2007, NUCLEIC ACIDS RES, V35, pD40, DOI 10.1093/nar/gkl758; Pavlov YI, 2006, CURR BIOL, V16, P202, DOI 10.1016/j.cub.2005.12.002; Ray-Gallet D, 2011, MOL CELL, V44, P928, DOI 10.1016/j.molcel.2011.12.006; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Stith CM, 2008, J BIOL CHEM, V283, P34129, DOI 10.1074/jbc.M806668200; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Whitehouse I, 2007, NATURE, V450, P1031, DOI 10.1038/nature06391; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	42	190	193	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					434	U80		10.1038/nature10895	http://dx.doi.org/10.1038/nature10895			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22419157	Green Accepted			2022-12-28	WOS:000301771200036
J	Seggev, JS				Seggev, Joram S.			Review: Long-term use of inhaled corticosteroids increases fracture risk in COPD	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; FLUTICASONE; SALMETEROL		Touro Univ, Coll Osteopath Med, Las Vegas, NV USA		Seggev, JS (corresponding author), Touro Univ, Coll Osteopath Med, Las Vegas, NV USA.							Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; de Vries F, 2005, EUR RESPIR J, V25, P879, DOI 10.1183/09031936.05.00058204; Gonnelli S, 2010, CALCIFIED TISSUE INT, V87, P137, DOI 10.1007/s00223-010-9392-x; Nuti R, 2009, OSTEOPOROSIS INT, V20, P989, DOI 10.1007/s00198-008-0770-4	5	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-7	10.7326/0003-4819-156-6-201203200-02007	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431693				2022-12-28	WOS:000303150900006
J	Wilding, JPH; Woo, V; Soler, NG; Pahor, A; Sugg, J; Rohwedder, K; Parikh, S				Wilding, John P. H.; Woo, Vincent; Soler, Norman G.; Pahor, Andrea; Sugg, Jennifer; Rohwedder, Katja; Parikh, Shamik		Dapagliflozin 006 Study Grp	Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							INADEQUATE GLYCEMIC CONTROL; SELECTIVE SGLT2 INHIBITOR; DOUBLE-BLIND; THERAPY; GLIMEPIRIDE; RISK	Background: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin. Objective: To evaluate the efficacy and safety of adding dapagliflozin therapy in patients whose type 2 diabetes mellitus is inadequately controlled with insulin with or without oral antidiabetic drugs. Design: A 24-week, randomized, placebo-controlled, multicenter trial followed by a 24-week extension period. An additional 56-week extension period is ongoing. (ClinicalTrials.gov registration number: NCT00673231) Setting: 126 centers in Europe and North America from 30 April 2008 to 19 November 2009. Patients: 808 patients with inadequately controlled type 2 diabetes mellitus receiving at least 30 U of insulin daily, with or without up to 2 oral antidiabetic drugs. Intervention: Patients were randomly assigned in a 1: 1: 1: 1 ratio and allocated with a computer-generated scheme to receive placebo or 2.5, 5, or 10 mg of dapagliflozin, once daily, for 48 weeks. Measurements: The primary outcome was change in hemoglobin A(1c) from baseline to 24 weeks. Secondary outcomes included changes in body weight, insulin dose, and fasting plasma glucose level at 24 weeks and during the 24-week extension period. Adverse events were evaluated throughout both 24-week periods. Results: 800 patients were analyzed. After 24 weeks, mean hemoglobin A(1c) decreased by 0.79% to 0.96% with dapagliflozin compared with 0.39% with placebo (mean difference, -0.40% [95% CI, -0.54% to -0.25%] in the 2.5-mg group, -0.49% [CI, -0.65% to -0.34%] in the 5-mg group, and -0.57% [CI, -0.72% to -0.42%] in the 10-mg group). Daily insulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean difference, -7.60 U [CI, -10.32 to -4.87 U] in the 2.5-mg group, -6.28 U [CI, -8.99 to -3.58 U] in the 5-mg group, and -6.82 U [CI, -9.56 to -4.09 U] in the 10-mg group). Body weight decreased by 0.92 to 1.61 kg with dapagliflozin and increased by 0.43 kg with placebo (mean differences, -1.35 kg [CI, -1.90 to -0.80 kg] in the 2.5-mg group, -1.42 kg [CI, -1.97 to -0.88 kg] in the 5-mg group, and -2.04 kg [CI, -2.59 to -1.48 kg] in the 10-mg group). These effects were maintained at 48 weeks. Compared with the placebo group, patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes (56.6% vs. 51.8%), events suggesting genital infection (9.0% vs. 2.5%), and events suggesting urinary tract infection (9.7% vs. 5.1%). Limitation: Insulin doses were not titrated to target, and the study was not designed to evaluate long-term safety. Conclusion: Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major hypoglycemic episodes in patients with inadequately controlled type 2 diabetes mellitus.	[Wilding, John P. H.] Aintree Univ Hosp NHS Fdn Trust, Ctr Clin Sci, Dept Obes & Endocrinol, Diabet & Endocrinol Res Grp, Liverpool L9 7AL, Merseyside, England; Univ Manitoba, Winnipeg, MB, Canada; Springfield Diabet & Endocrine Ctr, Springfield, IL USA; AstraZeneca, Wedel, Germany; AstraZeneca, Wilmington, DE USA	Aintree University Hospitals NHS Foundation Trust; University of Liverpool; University of Manitoba; AstraZeneca; AstraZeneca	Wilding, JPH (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Ctr Clin Sci, Dept Obes & Endocrinol, Diabet & Endocrinol Res Grp, Longmoor Lane, Liverpool L9 7AL, Merseyside, England.	j.p.h.wilding@liverpool.ac.uk	Wilding, John/ABB-6443-2020; Roden, Michael/AAD-3843-2019; Wilding, John PH/A-7106-2008	Wilding, John/0000-0003-2839-8404; Wilding, John PH/0000-0003-2839-8404	AstraZeneca; Bristol-Myers Squibb	AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb)	Grant Support: By AstraZeneca. Medical writing assistance for this manuscript was provided by Julian Martins, MA, MBBS, of inScience Communications, and this assistance was funded by Bristol-Myers Squibb and AstraZeneca.	Bailey CJ, 2010, LANCET, V375, P2223, DOI 10.1016/S0140-6736(10)60407-2; Bohannon NJV, 1998, DIABETES CARE, V21, P451, DOI 10.2337/diacare.21.3.451; Buse John, 2000, American Journal of Medicine, V108, p23S; Charbonnel B, 2010, J CLIN ENDOCR METAB, V95, P2163, DOI 10.1210/jc.2009-1974; Ferrannini E, 2010, DIABETES CARE, V33, P2217, DOI 10.2337/dc10-0612; Foxman B, 2003, DM-DIS MON, V49, P53, DOI 10.1067/mda.2003.7; Han SP, 2008, DIABETES, V57, P1723, DOI 10.2337/db07-1472; Hermansen K, 2007, DIABETES OBES METAB, V9, P733, DOI 10.1111/j.1463-1326.2007.00744.x; Hoerger TJ, 2008, DIABETES CARE, V31, P81, DOI 10.2337/dc07-1572; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Holman RR, 2009, NEW ENGL J MED, V361, P1736, DOI 10.1056/NEJMoa0905479; Hsu WC, 2009, SOUTH MED J, V102, P67, DOI 10.1097/SMJ.0b013e318182d8a2; Komoroski B, 2009, CLIN PHARMACOL THER, V85, P520, DOI 10.1038/clpt.2008.251; Komoroski B, 2009, CLIN PHARMACOL THER, V85, P513, DOI 10.1038/clpt.2008.250; Larsson SC, 2006, DIABETOLOGIA, V49, P2819, DOI 10.1007/s00125-006-0468-0; List JF, 2009, DIABETES CARE, V32, P650, DOI 10.2337/dc08-1863; Meng W, 2008, J MED CHEM, V51, P1145, DOI 10.1021/jm701272q; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Pi-Sunyer FX, 2009, POSTGRAD MED, V121, P94, DOI 10.3810/pgm.2009.09.2056; Ratitch B., 2011, IMPLEMENTATION PATTE; Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510; Squibb Bristol-Myers, 2011, BMS512148 US FOOD DR; Strojek K, 2011, DIABETES OBES METAB, V13, P928, DOI 10.1111/j.1463-1326.2011.01434.x; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Verbeke G, 2000, LINEAR MIXED MODELS; Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087; Wilding JPH, 2009, DIABETES CARE, V32, P1656, DOI 10.2337/dc09-0517; Wright EM, 2007, J INTERN MED, V261, P32, DOI 10.1111/j.1365-2796.2006.01746.x; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758; Zhang M, 2008, BIOMETRICS, V64, P707, DOI 10.1111/j.1541-0420.2007.00976.x	30	342	365	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					405	U50		10.7326/0003-4819-156-6-201203200-00003	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00003			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431673				2022-12-28	WOS:000303150900013
J	McMichael, T; Montgomery, H; Costello, A				McMichael, Tony; Montgomery, Hugh; Costello, Anthony			Health risks, present and future, from global climate change	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EAST-AFRICAN HIGHLANDS; IMPACT; TEMPERATURE; MALARIA; TRENDS; YIELDS		[Costello, Anthony] UCL, UCL Inst Global Hlth, London WC1N 1EH, England; [McMichael, Tony] Australian Natl Univ, Coll Med Biol & Environm, Canberra, ACT, Australia; [Montgomery, Hugh] UCL, UCL Inst Human Hlth & Performance, London WC1E 6BT, England	University of London; University College London; Australian National University; University of London; University College London	Costello, A (corresponding author), UCL, UCL Inst Global Hlth, London WC1N 1EH, England.	A.costello@ucl.ac.uk	Montgomery, Hugh/L-1229-2019; Montgomery, Hugh/C-2592-2008	Montgomery, Hugh/0000-0001-8797-5019				Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; Burke MB, 2009, P NATL ACAD SCI USA, V106, P20670, DOI 10.1073/pnas.0907998106; Climate Institute, 2011, CLIM SUFF REAL COST; Costello A, 2009, LANCET, V373, P1693, DOI [10.1016/S0140-6736(09)60935-1, 10.1016/S0140-6736(09)60929-6]; Delpla I, 2009, ENVIRON INT, V35, P1225, DOI 10.1016/j.envint.2009.07.001; Dole R, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046582; Friedlingstein P, 2011, NAT CLIM CHANGE, V1, P457, DOI 10.1038/NCLIMATE1302; Gage KL, 2008, AM J PREV MED, V35, P436, DOI 10.1016/j.amepre.2008.08.030; Gilbert N, 2010, NATURE NEWS     0812; Haines A, 2009, LANCET, V374, P2104, DOI 10.1016/S0140-6736(09)61759-1; Hajat S, 2006, EPIDEMIOLOGY, V17, P632, DOI 10.1097/01.ede.0000239688.70829.63; Hsiang SM, 2011, NATURE, V476, P438, DOI 10.1038/nature10311; International Energy Agency, WORLD EN OUTL NOV 20; IPCC, 2011, MAN RISKS EXTR EV DI; Kjellstrom T, 2009, GLOBAL HLTH ACTION, P2; Lake IR, 2009, EPIDEMIOL INFECT, V137, P1538, DOI 10.1017/S0950268809002477; Lindsay SW, 2000, LANCET, V355, P989, DOI 10.1016/S0140-6736(00)90022-9; Lloyd SJ, 2011, ENVIRON HEALTH PERSP, V119, P1817, DOI 10.1289/ehp.1003311; Lobell DB, 2007, ENVIRON RES LETT, V2, DOI 10.1088/1748-9326/2/1/014002; Lobell DB, 2011, SCIENCE, V333, P616, DOI [10.1126/science.1204531, 10.1126/science.1206376]; McMichael A., 2004, COMP QUANTIFICATION, V2, P1543; McMichael AJ, 2008, BRIT MED J, V336, P191, DOI 10.1136/bmj.39392.473727.AD; McMichael AJ, 2011, J INTERN MED, V270, P401, DOI 10.1111/j.1365-2796.2011.02415.x; Meinshausen M, 2009, NATURE, V458, P1158, DOI 10.1038/nature08017; Min SK, 2011, NATURE, V470, P378, DOI 10.1038/nature09763; Ogden NH, 2006, INT J PARASITOL, V36, P63, DOI 10.1016/j.ijpara.2005.08.016; Omumbo JA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-12; Pall P, 2011, NATURE, V470, P382, DOI 10.1038/nature09762; Parry M, 2005, PHILOS T R SOC B, V360, P2125, DOI 10.1098/rstb.2005.1751; Parry M. L., 2007, CLIMATE CHANGE 2007; Pascual M, 2006, P NATL ACAD SCI USA, V103, P5829, DOI 10.1073/pnas.0508929103; Pencheon D, 2009, J HEALTH SERV RES PO, V14, P2, DOI 10.1258/jhsrp.2008.008147; Peng SB, 2004, P NATL ACAD SCI USA, V101, P9971, DOI 10.1073/pnas.0403720101; Peters GP, 2012, NAT CLIM CHANGE, V2, P2, DOI 10.1038/nclimate1332; Rahmstorf S., 2010, NAT CLIM CHANGE, V1, P44, DOI [10.1038/climate.2010.29, DOI 10.1038/CLIMATE.2010.29]; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Schiermeier Q, 2011, NATURE, V477, P148, DOI 10.1038/477148a; Smit C.S., 2008, 9 INT NAV ENG C EXHI; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Stott PA, 2004, NATURE, V432, P610, DOI 10.1038/nature03089; Strazdins L, 2011, INT J PUBLIC HEALTH, V2, P493; Sumaila UR, 2011, NAT CLIM CHANGE, V1, P449, DOI 10.1038/NCLIMATE1301; Sutherst RW, 2004, CLIN MICROBIOL REV, V17, P136, DOI 10.1128/CMR.17.1.136-173.2004; Terazono E, 2011, FINANCIAL TIMES 1010; World Health Organization, 1998, Weekly Epidemiological Record, V73, P148; Zhang DD, 2011, P NATL ACAD SCI USA, V108, P17296, DOI 10.1073/pnas.1104268108; Zhou XN, 2008, AM J TROP MED HYG, V78, P188, DOI 10.4269/ajtmh.2008.78.188; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	48	59	59	2	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2012	344								e1359	10.1136/bmj.e1359	http://dx.doi.org/10.1136/bmj.e1359			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431661	Bronze, Green Submitted			2022-12-28	WOS:000301848400007
J	Ashton, JR				Ashton, John R.			The art of medicine Defending democracy and the National Health Service	LANCET			English	Editorial Material									Penrith Hosp, NHS Cumbria, Offi Director Publ Hlth, Penrith CA11 8HX, Cumbria, England		Ashton, JR (corresponding author), Penrith Hosp, NHS Cumbria, Offi Director Publ Hlth, Penrith CA11 8HX, Cumbria, England.	john.ashton@cumbriapct.nhs.uk						Abel-Smith Brian, 1964, HOSP 1800 1948; [Anonymous], 1988, NEW PUBLIC HLTH; McKee M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7973; Neumann S, 1847, ENTLICHES GESUNDEHEI; Oakley Ann, 2004, PRIVATE COMPLAINTS P; Titmuss RM, SOCIAL POLICY INTRO	6	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					997	998		10.1016/S0140-6736(12)60287-6	http://dx.doi.org/10.1016/S0140-6736(12)60287-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22432153				2022-12-28	WOS:000301712300017
J	DeBerardinis, RJ; Thompson, CB				DeBerardinis, Ralph J.; Thompson, Craig B.			Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?	CELL			English	Review							FUMARATE-HYDRATASE; IDH2 MUTATIONS; ALPHA-KETOGLUTARATE; RENAL-CANCER; DEHYDROGENASE; GROWTH; GENE; GLUTAMINE; PATHWAY; PROTEIN	An understanding of metabolic pathways based solely on biochemistry textbooks would underestimate the pervasive role of metabolism in essentially every aspect of biology. It is evident from recent work that many human diseases involve abnormal metabolic states-often genetically programmed-that perturb normal physiology and lead to severe tissue dysfunction. Understanding these metabolic outliers is now a crucial frontier in disease-oriented research. This Review discusses the broad impact of metabolism in cellular function and how modern concepts of metabolism can inform our understanding of common diseases like cancer and also considers the prospects of developing new metabolic approaches to disease treatment.	[DeBerardinis, Ralph J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Childrens Res Inst, Dallas, TX 75390 USA; [DeBerardinis, Ralph J.] Univ Texas SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; [Thompson, Craig B.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Memorial Sloan Kettering Cancer Center	DeBerardinis, RJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Childrens Res Inst, Dallas, TX 75390 USA.	ralph.deberardinis@utsouthwestern.edu; craig@mskcc.org			NIH [1R01 CA157996]; Cancer Prevention and Research Institute of Texas [HIRP100437, RP101243]; Robert A. Welch Foundation [I-1733]; Damon-Runyon Cancer Research Foundation; SU2C; NCI; NATIONAL CANCER INSTITUTE [R01CA105463, R01CA157996] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Robert A. Welch Foundation(The Welch Foundation); Damon-Runyon Cancer Research Foundation; SU2C; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to colleagues whose work could not be cited owing to space limitations. We thank members of the DeBerardinis laboratory for reading the manuscript critically. R.J.D. is supported by grants from the NIH (1R01 CA157996), the Cancer Prevention and Research Institute of Texas (HIRP100437 and RP101243), the Robert A. Welch Foundation (I-1733), and the Damon-Runyon Cancer Research Foundation. C.B.T. is supported by grants from SU2C, NIH, and NCI. C.B.T. is a founder and consultant to Agios Pharmaceuticals and is a member of the Board of Directors of Merck.	Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Alfardan J, 2010, MOL GENET METAB, V100, P333, DOI 10.1016/j.ymgme.2010.04.014; Baysal BE, 2008, J MED GENET, V45, P689, DOI 10.1136/jmg.2008.058560; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Chace DH, 2002, ANNU REV GENOM HUM G, V3, P17, DOI 10.1146/annurev.genom.3.022502.103213; Childs B., 2001, METABOLIC MOL BASES, P155; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Choi C, 2011, MAGN RESON MED, V66, P609, DOI 10.1002/mrm.22857; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Eichhorst J, 2010, MOL GENET METAB, V101, P84, DOI 10.1016/j.ymgme.2010.05.002; Erez A, 2011, AM J HUM GENET, V88, P402, DOI 10.1016/j.ajhg.2011.03.005; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garrod AE, 1902, LANCET, V2, P1616; Gibbons JJ, 2009, SEMIN ONCOL       S3, V36, pS3, DOI 10.1053/j.seminoncol.2009.10.011; Gieger C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000282; Glunde K, 2011, SEMIN ONCOL, V38, P26, DOI 10.1053/j.seminoncol.2010.11.001; Guarente L, 2011, NEW ENGL J MED, V364, P2235, DOI 10.1056/NEJMra1100831; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Hu S, 2011, CELL METAB, V14, P131, DOI 10.1016/j.cmet.2011.04.012; Illig T, 2010, NAT GENET, V42, P137, DOI 10.1038/ng.507; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jonathan C, 2005, NAT GENET, V37, P161, DOI 10.1038/ng1509; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Koglin N, 2011, CLIN CANCER RES, V17, P6000, DOI 10.1158/1078-0432.CCR-11-0687; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kranendijk M, 2010, SCIENCE, V330, P336, DOI 10.1126/science.1192632; Krebs H A, 1972, Adv Enzyme Regul, V10, P397, DOI 10.1016/0065-2571(72)90025-8; Kurhanewicz J, 2011, NEOPLASIA, V13, P81, DOI 10.1593/neo.101102; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McKnight SL, 2010, SCIENCE, V330, P1338, DOI 10.1126/science.1199908; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Moroni I, 2004, NEUROLOGY, V62, P1882, DOI 10.1212/01.WNL.0000125335.21381.87; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Pietrak B., 2011, BIOCHEMISTRY-US, V50, P4804; Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Qu WC, 2011, J AM CHEM SOC, V133, P1122, DOI 10.1021/ja109203d; Robinson BH, 1996, J INHERIT METAB DIS, V19, P452, DOI 10.1007/BF01799106; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Tong WH, 2011, CANCER CELL, V20, P315, DOI 10.1016/j.ccr.2011.07.018; Trowell H C, 1982, Br Med J (Clin Res Ed), V285, P217; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yudkoff M, 2010, MOL GENET METAB, V100, pS37, DOI 10.1016/j.ymgme.2010.02.017; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	97	496	511	3	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1132	1144		10.1016/j.cell.2012.02.032	http://dx.doi.org/10.1016/j.cell.2012.02.032			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424225	Green Accepted, Bronze			2022-12-28	WOS:000301889500012
J	Schmidt, C				Schmidt, Charles			BIOELECTRONICS The bionic material	NATURE			English	Editorial Material																			0	22	22	5	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S37	S37		10.1038/483S37a	http://dx.doi.org/10.1038/483S37a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419210	Bronze			2022-12-28	WOS:000301481800004
J	Hunter, DJ; Williams, GH				Hunter, David J.; Williams, Gareth H.			NHS "reform" in England: where is the public interest?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hunter, David J.] Univ Durham, Wolfson Res Inst, Sch Med & Hlth, Durham DH1 3HP, England; [Williams, Gareth H.] Cardiff Univ, Sch Social Sci, Cardiff Inst Soc & Hlth, Cardiff, S Glam, Wales	Durham University; Cardiff University	Hunter, DJ (corresponding author), Univ Durham, Wolfson Res Inst, Sch Med & Hlth, Durham DH1 3HP, England.	d.j.hunter@durham.ac.uk			Economic and Social Research Council [ES/G007543/1, ES/G007470/1] Funding Source: researchfish; ESRC [ES/G007470/1, ES/G007543/1] Funding Source: UKRI	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Bevan A., 1978, PLACE FEAR; Bevan Commission, 2011, NHS WAL FORG BETT FU; Brindley M, 2011, W MAIL          0623; Cooper Z, 2012, 1125 CEP LOND SCH EC; Gaynor M, 2010, J HEALTH SERV RES PO, V17, P49; Humphreys K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1316; Ingleby D, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1079; Judt T., 2010, ILL FARES LAND; Kettl D. F, 1993, SHARING POWER PUBLIC; Lansley A, 2012, HSJ, P18; Le Grand J, 2012, FINANCIAL TIMES 0221; Office of Health Economics, 2012, REP OHE COMM COMP NH; Pollock A, 2011, LANCET, V378, P2057, DOI 10.1016/S0140-6736(11)61553-5; Reynolds L, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3760; SANDEL M, 2010, JUSTICE WHATS RIGHT	15	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e2014	10.1136/bmj.e2014	http://dx.doi.org/10.1136/bmj.e2014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418422				2022-12-28	WOS:000301847600022
J	Srygley, FD; Gerardo, CJ; Tran, T; Fisher, DA				Srygley, F. Douglas; Gerardo, Charles J.; Tran, Tony; Fisher, Deborah A.			Does This Patient Have a Severe Upper Gastrointestinal Bleed?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTIFICIAL NEURAL-NETWORK; BLOOD UREA NITROGEN; NASOGASTRIC ASPIRATION; TRACT HEMORRHAGE; CREATININE RATIO; ENDOSCOPY; MANAGEMENT; LAVAGE; NEED; COLONOSCOPY	Context Emergency physicians must determine both the location and the severity of acute gastrointestinal bleeding (GIB) to optimize the diagnostic and therapeutic approaches. Objectives To identify the historical features, symptoms, signs, bedside maneuvers, and basic laboratory test results that distinguish acute upper GIB (UGIB) from acute lower GIB (LGIB) and to risk stratify those patients with a UGIB least likely to have severe bleeding that necessitates an urgent intervention. Data Sources A structured search of MEDLINE (1966-September 2011) and reference lists from retrieved articles, review articles, and physical examination textbooks. Study Selection High-quality studies were included of adult patients who were either admitted with GIB or evaluated in emergency departments with bedside evaluations and/or routine laboratory tests, and studies that did not include endoscopic findings in prediction models. The initial search yielded 2628 citations, of which 8 were retained that tested methods of identifying a UGIB and 18 that identified methods of determining the severity of UGIB. Data Extraction One author abstracted the data (prevalence, sensitivity, specificity, and likelihood ratios [LRs]) and assessed methodological quality, with confirmation by another author. Data were combined using random effects measures. Data Synthesis The majority of patients (N=1776) had an acute UGIB (prevalence, 63%; 95% CI, 51%-73%). Several clinical factors increase the likelihood that a patient has a UGIB, including a patient-reported history of melena (LR range, 5.15.9), melenic stool on examination (LR, 25; 95% CI, 4-174), a nasogastric lavage with blood or coffee grounds (LR, 9.6; 95% CI, 4.0-23.0), and a serum urea nitrogen: creatinine ratio of more than 30 (summary LR, 7.5; 95% CI, 2.8-12.0). Conversely, the presence of blood clots in stool (LR, 0.05; 95% CI, 0.01-0.38) decreases the likelihood of a UGIB. Of the patients clinically diagnosed with acute UGIB, 36% (95% CI, 29%-44%) had severe bleeding. A nasogastric lavage with red blood (summary LR, 3.1; 95% CI, 1.2-14.0), tachycardia (LR, 4.9; 95% CI, 3.2-7.6), or a hemoglobin level of less than 8 g/dL (LR range, 4.5-6.2) increase the likelihood of a severe UGIB requiring urgent intervention. A Blatchford score of 0 (summary LR, 0.02; 95% CI, 0-0.05) decreases the likelihood that a UGIB requires urgent intervention. Conclusions Melena, nasogastric lavage with blood or coffee grounds, or serum urea nitrogen: creatinine ratio of more than 30 increase the likelihood of a UGIB. Blood clots in the stool make a UGIB much less likely. The Blatchford clinical prediction score, which does not require nasogastric lavage, is very efficient for identifying patients who do not require urgent intervention. JAMA. 2012;307(10):1072-1079 www.jama.com	[Srygley, F. Douglas; Tran, Tony; Fisher, Deborah A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Gerardo, Charles J.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Fisher, Deborah A.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Srygley, FD (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3913, Durham, NC 27710 USA.	srygl001@mc.duke.edu			Veterans Affairs Health Services [RCD 03-174]	Veterans Affairs Health Services	Dr Fisher is supported in part by a Veterans Affairs Health Services Research and Development Career Development Transition Award (RCD 03-174).	Adamopoulos AB, 2003, EUR J GASTROEN HEPAT, V15, P381, DOI 10.1097/00042737-200304000-00008; Aljebreen AM, 2004, GASTROINTEST ENDOSC, V59, P172, DOI 10.1016/S0016-5107(03)02543-4; Barkun AN, 2010, ANN INTERN MED, V152, P101, DOI 10.7326/0003-4819-152-2-201001190-00009; Best Carolyn, 2007, Nurs Stand, V21, P39; Blatchford O, 1997, BMJ-BRIT MED J, V315, P510, DOI 10.1136/bmj.315.7107.510; Blatchford O, 2000, LANCET, V356, P1318, DOI 10.1016/S0140-6736(00)02816-6; Borenstein M., 2009, INTRO METAANALYSIS; Chalasani N, 1997, AM J GASTROENTEROL, V92, P1796; CHAMPION MC, 1982, ANN SURG, V195, P314, DOI 10.1097/00000658-198203000-00011; Chandra S, 2011, AM J EMERG MED; Chen GC, 2007, AM J EMERG MED, V25, P774, DOI 10.1016/j.ajem.2006.12.024; CUELLAR RE, 1990, ARCH INTERN MED, V150, P1381, DOI 10.1001/archinte.150.7.1381; Das A, 2003, LANCET, V362, P1261, DOI 10.1016/S0140-6736(03)14568-0; Das A, 2008, GASTROENTEROLOGY, V134, P65, DOI 10.1053/j.gastro.2007.10.037; Esrailian E, 2008, ALIMENT PHARM THER, V28, P1199, DOI 10.1111/j.1365-2036.2008.03838.x; Farooq FT, 2012, AM J EMERG MED, V30, P129, DOI 10.1016/j.ajem.2010.11.007; Feldman M, 2009, SLEISINGER FORDTRANS, P211; Garcia-Tsao G, 2007, AM J GASTROENTEROL, V102, P2086, DOI 10.1111/j.1572-0241.2007.01481.x; Green BT, 2005, AM J GASTROENTEROL, V100, P2395, DOI 10.1111/j.1572-0241.2005.00306.x; Healthcare Cost and Utilization Project (HCUP), 2011, HCUP CLIN CLASS SOFT; HILSMAN J H, 1950, J Med Assoc Ga, V39, P402; Huang ES, 2011, GASTROINTEST ENDOSC, V74, P971, DOI 10.1016/j.gie.2011.04.045; Lanas A, 2009, AM J GASTROENTEROL, V104, P1633, DOI 10.1038/ajg.2009.164; LeBlond RF, 2009, DEGOWINS DIAGNOSTIC; Lee SD, 2004, J CLIN GASTROENTEROL, V38, P861, DOI 10.1097/00004836-200411000-00005; LUKE RG, 1964, GUT, V5, P77, DOI 10.1136/gut.5.1.77; Marmo R, 2008, AM J GASTROENTEROL, V103, P1639, DOI 10.1111/j.1572-0241.2008.01865.x; Masaoka T, 2007, J GASTROEN HEPATOL, V22, P1404, DOI 10.1111/j.1440-1746.2006.04762.x; Menke J, 2010, METHOD INFORM MED, V49, P54, DOI 10.3414/ME09-01-0001; MORTENSEN PB, 1994, DAN MED BULL, V41, P237; OLSEN LH, 1991, BRIT J SURG, V78, P71, DOI 10.1002/bjs.1800780122; Palamidessi N, 2010, ACAD EMERG MED, V17, P126, DOI 10.1111/j.1553-2712.2009.00609.x; Pallin DJ, 2011, GASTROINTEST ENDOSC, V74, P981, DOI 10.1016/j.gie.2011.07.007; Pang SH, 2010, GASTROINTEST ENDOSC, V71, P1134, DOI 10.1016/j.gie.2010.01.028; Pillai Jain Bhaskara, 2005, Interact Cardiovasc Thorac Surg, V4, P429, DOI 10.1510/icvts.2005.109488; RICHARDS RJ, 1990, J CLIN GASTROENTEROL, V12, P500, DOI 10.1097/00004836-199010000-00004; Romagnuolo J, 2007, ARCH INTERN MED, V167, P265, DOI 10.1001/archinte.167.3.265; Schiff L, 1942, AM J MED SCI, V203, P409, DOI 10.1097/00000441-194203000-00016; Schmulewitz N, 2003, GASTROINTEST ENDOSC, V58, P841, DOI 10.1016/S0016-5107(03)02304-6; Simel DL, 2009, J CLIN EPIDEMIOL, V62, P1292, DOI 10.1016/j.jclinepi.2009.02.007; Singer AJ, 1999, ANN EMERG MED, V33, P652, DOI 10.1016/S0196-0644(99)70194-0; SNOOK JA, 1986, LANCET, V1, P1064; Spiegel BMR, 2009, GASTROINTEST ENDOSC, V70, P236, DOI 10.1016/j.gie.2008.12.053; Srirajaskanthan R, 2010, INT J CLIN PRACT, V64, P868, DOI 10.1111/j.1742-1241.2009.02267.x; Stanley AJ, 2009, LANCET, V373, P42, DOI 10.1016/S0140-6736(08)61769-9; STOLZING H, 1991, HEPATO-GASTROENTEROL, V38, P224; Sung JJY, 2011, GUT, V60, P1170, DOI 10.1136/gut.2010.230292; Targownik LE, 2007, CAN J GASTROENTEROL, V21, P425, DOI 10.1155/2007/636032; Thomsen TW, 2006, NEW ENGL J MED, V354, DOI 10.1056/NEJMvcm050183; Witting MD, 2006, AM J EMERG MED, V24, P280, DOI 10.1016/j.ajem.2005.11.005; Witting MD, 2004, ANN EMERG MED, V43, P525, DOI 10.1016/j.annemergmed.2003.09.002; ZUCKERMAN GR, 1995, DIGEST DIS SCI, V40, P1614, DOI 10.1007/BF02212679	52	101	119	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1072	1079		10.1001/jama.2012.253	http://dx.doi.org/10.1001/jama.2012.253			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416103				2022-12-28	WOS:000301479700028
J	McColl, K				McColl, Karen			HIV Mentor mothers to prevent mother-to-child transmission of HIV	BRITISH MEDICAL JOURNAL			English	Editorial Material												karenmccoll@gmail.com						Baek C., 2007, KEY FINDINGS EVALUAT; SHISANA O, 2010, S AFRICAN NATL HIV P; UNAIDS, 2011, COUNTD ZER GLOB PLAN; UNICEF, 2010, CHILDR AIDS 5 STOCKT	4	11	11	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 12	2012	344								e1590	10.1136/bmj.e1590	http://dx.doi.org/10.1136/bmj.e1590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BO	22411931				2022-12-28	WOS:000301846500005
J	Bucknall, CE; Miller, G; Lloyd, SM; Cleland, J; McCluskey, S; Cotton, M; Stevenson, RD; Cotton, P; McConnachie, A				Bucknall, C. E.; Miller, G.; Lloyd, S. M.; Cleland, J.; McCluskey, S.; Cotton, M.; Stevenson, R. D.; Cotton, P.; McConnachie, A.			Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATIONS; DEPRESSION; THERAPY; ANXIETY	Objective To determine whether supported self management in chronic obstructive pulmonary disease (COPD) can reduce hospital readmissions in the United Kingdom. Design Randomised controlled trial. Setting Community based intervention in the west of Scotland. Participants Patients admitted to hospital with acute exacerbation of COPD. Intervention Participants in the intervention group were trained to detect and treat exacerbations promptly, with ongoing support for 12 months. Main outcome measures The primary outcome was hospital readmissions and deaths due to COPD assessed by record linkage of Scottish Morbidity Records; health related quality of life measures were secondary outcomes. Results 464 patients were randomised, stratified by age, sex, per cent predicted forced expiratory volume in 1 second, recent pulmonary rehabilitation attendance, smoking status, deprivation category of area of residence, and previous COPD admissions. No difference was found in COPD admissions or death (111/232 (48%) v 108/232 (47%); hazard ratio 1.05, 95% confidence interval 0.80 to 1.38). Return of health related quality of life questionnaires was poor (n=265; 57%), so that no useful conclusions could be made from these data. Pre-planned subgroup analysis showed no differential benefit in the primary outcome relating to disease severity or demographic variables. In an exploratory analysis, 42% (75/150) of patients in the intervention group were classified as successful self managers at study exit, from review of use of self management therapy. Predictors of successful self management on stepwise regression were younger age (P=0.012) and living with others (P=0.010). COPD readmissions/deaths were reduced in successful self managers compared with unsuccessful self managers (20/75 (27%) v 51/105 (49%); hazard ratio 0.44, 0.25 to 0.76; P=0.003). Conclusion Supported self management had no effect on time to first readmission or death with COPD. Exploratory subgroup analysis identified a minority of participants who learnt to self manage; this group had a significantly reduced risk of COPD readmission, were younger, and were more likely to be living with others.	[Bucknall, C. E.; Miller, G.; McCluskey, S.; Cotton, M.; Stevenson, R. D.] Glasgow Royal Infirm, Dept Resp Med, Glasgow G4 0SF, Lanark, Scotland; [Lloyd, S. M.; McConnachie, A.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Cleland, J.] Univ Aberdeen, Sch Med, Div Med & Dent Educ, Aberdeen AB9 2ZD, Scotland; [Cotton, P.] Univ Glasgow, Undergrad Med Sch, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Aberdeen; University of Glasgow	Bucknall, CE (corresponding author), Glasgow Royal Infirm, Dept Resp Med, Glasgow G4 0SF, Lanark, Scotland.	christine.bucknall@ggc.scot.nhs.uk	Lloyd, Suzanne/H-7424-2013; Cleland, Jennifer/AAI-9412-2020	Cleland, Jennifer/0000-0003-1433-9323	Chief Scientist Office, Scottish Health Department [CZH/4/246]; Boehringer Ingelheim; GlaxoSmithKline; Astra Zeneca; Chief Scientist Office [CZH/4/246] Funding Source: researchfish	Chief Scientist Office, Scottish Health Department; Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Astra Zeneca(AstraZeneca); Chief Scientist Office	In addition to funding from the Chief Scientist Office, Scottish Health Department (CZH/4/246), this study was supported by educational grants from Boehringer Ingelheim, GlaxoSmithKline, and Astra Zeneca. The commercial sponsors played no part in the design, implementation, or analysis of results from this trial or in the preparation of this paper.	ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Bischoff EWMA, 2011, THORAX, V66, P26, DOI 10.1136/thx.2009.127621; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; British Thoracic Society, 2006, BURD LUNG DIS; Clark NM, 2001, HEALTH EDUC BEHAV, V28, P769, DOI 10.1177/109019810102800608; Effing T, 2009, COCHRANE LIB; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; Gonzalez AV, 2011, THORAX, V66, P38, DOI 10.1136/thx.2010.141978; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Kind P, 1996, QUALITY LIFE PHARMAC; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; McLoone P., 2004, CARSTAIRS SCORES SCO; Monninkhof E, 2003, THORAX, V58, P394, DOI 10.1136/thorax.58.5.394; National Clinical Guideline Centre, 2010, CHRON HEART FAIL NAT; Purdy S., 2010, AVOIDING HOSP ADMISS; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Royal College of Physicians British Thoracic Society British Lung Foundation, 2008, REP NAT CHRON OBSTR; Silverman J., 1996, ED GEN PRACT, V7, P288; Silverman J, 1997, ED GEN PRACTICE, V8, P16; Walters JA., 2010, COCHRANE DB SYST REV, V5; WIGAL JK, 1991, CHEST, V99, P1193, DOI 10.1378/chest.99.5.1193; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC; Wong AWM, 2008, CAN RESPIR J, V15, P361, DOI 10.1155/2008/569496; Woolhouse IS, 2001, THORAX, V56, P947, DOI 10.1136/thorax.56.12.947; Xu WN, 2008, AM J RESP CRIT CARE, V178, P913, DOI 10.1164/rccm.200804-619OC; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	153	156	2	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2012	344								e1060	10.1136/bmj.e1060	http://dx.doi.org/10.1136/bmj.e1060			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GM	22395923	hybrid, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000301478900001
J	Henderson, M; Walker, D				Henderson, Michael; Walker, Don			The art of medicine Smoking may seriously affect your skeleton	LANCET			English	Editorial Material									[Henderson, Michael; Walker, Don] Museum London Archaeol, London N1 7ED, England		Henderson, M (corresponding author), Museum London Archaeol, Mortimer Wheeler House, London N1 7ED, England.	mhenderson@museumoflondon.org.uk						[Anonymous], 1833, TIMES           0909; Brodie BO, 1860, TIMES           0831; Garwood John, 1853, MILLION PEOPLED CITY; Hilton M., 2000, SMOKING BRIT POPULAR; Lin HH, 2008, LANCET, V372, P1473, DOI 10.1016/S0140-6736(08)61345-8; Solly S, 1857, LANCET, V69, P175; Walker D, 2010, POST-MEDIEV ARCHAEOL, V44, P209, DOI 10.1179/174581310X12662382629373	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 3	2012	379	9818					796	797		10.1016/S0140-6736(12)60336-5	http://dx.doi.org/10.1016/S0140-6736(12)60336-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	901RB	22393574				2022-12-28	WOS:000300983400015
J	Rothwell, PM; Wilson, M; Price, JF; Belch, JFF; Meade, TW; Mehta, Z				Rothwell, Peter M.; Wilson, Michelle; Price, Jacqueline F.; Belch, Jill F. F.; Meade, Tom W.; Mehta, Ziyah			Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LOW-DOSE ASPIRIN; COLORECTAL-CANCER; BREAST-CANCER; PREVENTION; PLATELET; SURVIVAL; DISEASE; PROGRESSION; CARCINOMA	Background Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis. We established the frequency of distant metastasis in patients who developed cancer during trials of daily aspirin versus control. Methods Our analysis included all five large randomised trials of daily aspirin (>= 75 mg daily) versus control for the prevention of vascular events in the UK. Electronic and paper records were reviewed for all patients with incident cancer. The effect of aspirin on risk of metastases at presentation or on subsequent follow-up (including post-trial follow-up of in-trial cancers) was stratified by tumour histology (adenocarcinoma vs other) and clinical characteristics. Findings Of 17 285 trial participants, 987 had a new solid cancer diagnosed during mean in-trial follow-up of 6.5 years (SD 2.0). Allocation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0.64, 95% CI 0.48-0.84, p=0.001; adenocarcinoma, HR 0.54, 95% CI 0.38-0.77, p=0.0007; other solid cancers, HR 0.82, 95% CI 0.53-1.28, p=0.39), due mainly to a reduction in proportion of adenocarcinomas that had metastatic versus local disease (odds ratio 0.52, 95% CI 0.35-0.75, p=0.0006). Aspirin reduced risk of adenocarcinoma with metastasis at initial diagnosis (HR 0.69, 95% CI 0.50-0.95, p=0.02) and risk of metastasis on subsequent follow-up in patients without metastasis initially (HR 0.45, 95% CI 0.28-0.72, p=0.0009), particularly in patients with colorectal cancer (HR 0.26, 95% CI 0.11-0.57, p=0.0008) and in patients who remained on trial treatment up to or after diagnosis (HR 0.31, 95% CI 0.15-0.62, p=0.0009). Allocation to aspirin reduced death due to cancer in patients who developed adenocarcinoma, particularly in those without metastasis at diagnosis (HR 0.50, 95% CI 0.34-0.74, p=0.0006). Consequently, aspirin reduced the overall risk of fatal adenocarcinoma in the trial populations (HR 0.65, 95% CI 0.53-0.82, p=0.0002), but not the risk of other fatal cancers (HR 1.06, 95% CI 0.84-1.32, p=0.64; difference, p=0.003). Effects were independent of age and sex, but absolute benefit was greatest in smokers. A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses. Interpretation That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily aspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides proof of principle for pharmacological intervention specifically to prevent distant metastasis.	[Rothwell, Peter M.; Wilson, Michelle; Mehta, Ziyah] Univ Oxford, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England; [Price, Jacqueline F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Belch, Jill F. F.] Univ Dundee, Ninewells Hosp & Med Sch, Univ Div Med & Therapeut, Vasc & Inflammatory Dis Res Unit,Inst Cardiovasc, Dundee DD1 9SY, Scotland; [Meade, Tom W.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Oxford; University of Edinburgh; University of Dundee; University of London; London School of Hygiene & Tropical Medicine	Rothwell, PM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020; Belch, Jill/AAE-9189-2019	Rothwell, Peter/0000-0001-9739-9211; Belch, Jill/0000-0001-8280-6689; Price, Jackie/0000-0003-3251-3970	NIHR; Wellcome Trust; NIHR Biomedical Research centre, Oxford; MRC [G0701113, G9534799] Funding Source: UKRI; Medical Research Council [G9534799, G0701113] Funding Source: researchfish	NIHR(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Biomedical Research centre, Oxford(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	PMR is in receipt of an NIHR Senior Investigator Award, a Wellcome Trust Senior Investigator Award, and is also supported by the NIHR Biomedical Research centre, Oxford.	Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; [Anonymous], 2010, LANCET, V375, P1665, DOI 10.1016/S0140-6736(10)60718-0; Bambace NM, 2011, J THROMB HAEMOST, V9, P237, DOI 10.1111/j.1538-7836.2010.04131.x; Belch J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1840; Bosetti C, 2009, RECENT RESULTS CANC, V181, P231; Chan AT, 2008, GASTROENTEROLOGY, V134, P21, DOI 10.1053/j.gastro.2007.09.035; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Chan AT, 2005, JAMA-J AM MED ASSOC, V294, P914, DOI 10.1001/jama.294.8.914; CHARMAN WN, 1993, BRIT J CLIN PHARMACO, V36, P470, DOI 10.1111/j.1365-2125.1993.tb00399.x; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Dannenberg AJ, 2003, PROGR EXPT TUMOUR RE, V37; Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fontaine E, 2010, EUR J CARDIO-THORAC, V38, P21, DOI 10.1016/j.ejcts.2010.01.015; Fowkes FGR, 2010, JAMA-J AM MED ASSOC, V303, P841, DOI 10.1001/jama.2010.221; Futakuchi M, 2002, JPN J CANCER RES, V93, P1175, DOI 10.1111/j.1349-7006.2002.tb01220.x; GASIC GJ, 1973, INT J CANCER, V11, P704, DOI 10.1002/ijc.2910110322; GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46; GASIC GJ, 1972, LANCET, V2, P932; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Henschke U K, 1977, J Natl Med Assoc, V69, P581; Holmes MD, 2010, J CLIN ONCOL, V28, P1467, DOI 10.1200/JCO.2009.22.7918; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; LEBEAU B, 1993, CANCER, V71, P1741, DOI 10.1002/1097-0142(19930301)71:5<1741::AID-CNCR2820710507>3.0.CO;2-Q; Leitzmann MF, 2002, CANCER EPIDEM BIOMAR, V11, P1108; LIPTON A, 1982, J MED, V13, P419; Liu JF, 2009, ANN SURG ONCOL, V16, P1397, DOI 10.1245/s10434-009-0382-z; Meade TW, 1998, LANCET, V351, P233; Murin S, 2001, CHEST, V119, P1635, DOI 10.1378/chest.119.6.1635; Pantarotto J, 2007, BJU INT, V99, P564, DOI 10.1111/j.1464-410X.2006.06656.x; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Sansbury LB, 2005, AM J EPIDEMIOL, V162, P548, DOI 10.1093/aje/kwi248; Sharpe CR, 2000, BRIT J CANCER, V83, P112; Slatore CG, 2009, CANCER EPIDEM BIOMAR, V18, P1203, DOI 10.1158/1055-9965.EPI-08-1110; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Zhang SM, 2008, BRIT J CANCER, V98, P989, DOI 10.1038/sj.bjc.6604240	41	692	710	5	112	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2012	379	9826					1591	1601		10.1016/S0140-6736(12)60209-8	http://dx.doi.org/10.1016/S0140-6736(12)60209-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934OB	22440947				2022-12-28	WOS:000303452600033
J	Charo, RA				Charo, R. Alta			Warning: Contraceptive Drugs May Cause Political Headaches	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Charo, R. Alta] Univ Wisconsin, Sch Law, Madison, WI 53706 USA; [Charo, R. Alta] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Charo, RA (corresponding author), Univ Wisconsin, Sch Law, Madison, WI 53706 USA.			Charo, Robin Alta/0000-0003-3710-1043				Abelson Reed, 2012, NY TIMES, p[A1, A3]; Bolstad E, 2012, MCCLATCHY NEWSP 0205; Charo R. Alta, 2007, HLTH CARE PROVIDER R; Equal Employment Opportunity Commission, DEC CONTR; Uttley LJ, 2002, NO STRINGS ATTACHED	5	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1361	1364		10.1056/NEJMp1202701	http://dx.doi.org/10.1056/NEJMp1202701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22417204				2022-12-28	WOS:000302608600011
J	Kumar, SV; Lucyshyn, D; Jaeger, KE; Alos, E; Alvey, E; Harberd, NP; Wigge, PA				Kumar, S. Vinod; Lucyshyn, Doris; Jaeger, Katja E.; Alos, Enriqueta; Alvey, Elizabeth; Harberd, Nicholas P.; Wigge, Philip A.			Transcription factor PIF4 controls the thermosensory activation of flowering	NATURE			English	Article							ARABIDOPSIS-THALIANA; LOCUS-T; HIGH-TEMPERATURE; GIBBERELLIN; GROWTH; TIME; CONSTANS; LIGHT; EXPRESSION; PLANTS	Plant growth and development are strongly affected by small differences in temperature(1). Current climate change has already altered global plant phenology and distribution(2,3), and projected increases in temperature pose a significant challenge to agriculture(4). Despite the important role of temperature on plant development, the underlying pathways are unknown. It has previously been shown that thermal acceleration of flowering is dependent on the florigen, FLOWERING LOCUS T (FT)(5,6). How this occurs is, however, not understood, because the major pathway known to upregulate FT, the photoperiod pathway, is not required for thermal acceleration of flowering(6). Here we demonstrate a direct mechanism by which increasing temperature causes the bHLH transcription factor PHYTOCHROME INTERACTING FACTOR4 (PIF4) to activate FT. Our findings provide a new understanding of how plants control their timing of reproduction in response to temperature. Flowering time is an important trait in crops as well as affecting the life cycles of pollinator species. A molecular understanding of how temperature affects flowering will be important for mitigating the effects of climate change.	[Kumar, S. Vinod; Lucyshyn, Doris; Jaeger, Katja E.; Alos, Enriqueta; Alvey, Elizabeth; Harberd, Nicholas P.; Wigge, Philip A.] John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; [Harberd, Nicholas P.] Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Oxford	Wigge, PA (corresponding author), Univ Cambridge, Sainsbury Lab, Bateman St, Cambridge CB2 1LR, England.	philip.wigge@slcu.cam.ac.uk	Wigge, Philip Anthony/ABD-5113-2021; Alos, Enriqueta/E-7674-2012	Wigge, Philip Anthony/0000-0003-4822-361X; Alos, Enriqueta/0000-0003-2878-2617; Kumar, S Vinod/0000-0001-9265-4906; Lucyshyn, Doris/0000-0001-8558-1219	King Abdullah University of Science and Technology [KUK-I1-002-03]; Biotechnology and Biological Sciences Research Council (BBSRC) [BB/I019022/1, BB/D0100470/1]; Erwin Schroedinger Fellowship from the Austrian Science Fund FWF; John Innes Centre; European Research Council (ERC) [243140]; Biotechnology and Biological Sciences Research Council [BBS/E/J/000C0636, BBS/E/J/00000583, BBS/E/J/000CA402, BBS/E/J/00000610, BBS/E/J/000C0656, BB/I019022/1, P19972, BBS/E/J/000CA346] Funding Source: researchfish; BBSRC [BB/I019022/1, BBS/E/J/000CA346, BBS/E/J/000C0656, BBS/E/J/000CA402] Funding Source: UKRI	King Abdullah University of Science and Technology(King Abdullah University of Science & Technology); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Erwin Schroedinger Fellowship from the Austrian Science Fund FWF(Austrian Science Fund (FWF)); John Innes Centre; European Research Council (ERC)(European Research Council (ERC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank S. Prat, C. Fankhauser, K. Franklin, K. Goto, G. Coupland and D. Weigel for seeds. We are grateful to members of the Wigge laboratory for discussions. This work was supported in part by award No. KUK-I1-002-03 (to N.P.H.) made by King Abdullah University of Science and Technology and a Biotechnology and Biological Sciences Research Council (BBSRC) grant BB/I019022/1 (to S.V.K.). D.L. was supported by an Erwin Schroedinger Fellowship from the Austrian Science Fund FWF. P.A.W. was supported by start-up funds from the John Innes Centre and BBSRC, a BBSRC grant (BB/D0100470/1) and a European Research Council Starting Grant (ERC 243140).	Adrian J, 2010, PLANT CELL, V22, P1425, DOI 10.1105/tpc.110.074682; Angel A, 2011, NATURE, V476, P105, DOI 10.1038/nature10241; Balasubramanian S, 2006, PLOS GENET, V2, P980, DOI 10.1371/journal.pgen.0020106; Battisti DS, 2009, SCIENCE, V323, P240, DOI 10.1126/science.1164363; Blazquez MA, 2003, NAT GENET, V33, P168, DOI 10.1038/ng1085; BRIAN PW, 1958, NATURE, V181, P1122, DOI 10.1038/1811122a0; Brock MT, 2010, MOL ECOL, V19, P1187, DOI 10.1111/j.1365-294X.2010.04538.x; de Lucas M, 2008, NATURE, V451, P480, DOI 10.1038/nature06520; Feng SH, 2008, NATURE, V451, P475, DOI 10.1038/nature06448; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Foreman J, 2011, PLANT J, V65, P441, DOI 10.1111/j.1365-313X.2010.04434.x; Franklin KA, 2011, P NATL ACAD SCI USA, V108, P20231, DOI 10.1073/pnas.1110682108; Halliday KJ, 2003, PLANT J, V33, P875, DOI 10.1046/j.1365-313X.2003.01674.x; Hisamatsu T, 2008, J EXP BOT, V59, P3821, DOI 10.1093/jxb/ern232; Koini MA, 2009, CURR BIOL, V19, P408, DOI 10.1016/j.cub.2009.01.046; Kumar SV, 2010, CELL, V140, P136, DOI 10.1016/j.cell.2009.11.006; Liu HT, 2008, SCIENCE, V322, P1535, DOI 10.1126/science.1163927; Lorrain S, 2008, PLANT J, V53, P312, DOI 10.1111/j.1365-313X.2007.03341.x; Mutasa-Gottgens E, 2009, J EXP BOT, V60, P1979, DOI 10.1093/jxb/erp040; Nozue K, 2007, NATURE, V448, P358, DOI 10.1038/nature05946; Samach A, 2005, CURR OPIN PLANT BIOL, V8, P483, DOI 10.1016/j.pbi.2005.07.011; Stavang JA, 2009, PLANT J, V60, P589, DOI 10.1111/j.1365-313X.2009.03983.x; Takada S, 2003, PLANT CELL, V15, P2856, DOI 10.1105/tpc.016345; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Wenkel S, 2006, PLANT CELL, V18, P2971, DOI 10.1105/tpc.106.043299; Willis CG, 2008, P NATL ACAD SCI USA, V105, P17029, DOI 10.1073/pnas.0806446105	26	446	492	16	359	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					242	U127		10.1038/nature10928	http://dx.doi.org/10.1038/nature10928			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22437497	Green Accepted			2022-12-28	WOS:000303149900035
J	Smith, AJ; Dieppe, P; Vernon, K; Porter, M; Blom, AW				Smith, Alison J.; Dieppe, Paul; Vernon, Kelly; Porter, Martyn; Blom, Ashley W.		Natl Joint Registry England Wales	Failure rates of stemmed metal-on-metal hip replacements: analysis of data from the National Joint Registry of England and Wales	LANCET			English	Article							DIFFERENT BEARING SURFACES; ARTHROPLASTY; OSTEOARTHRITIS; DIAMETER; IMPLANTS; SURVIVAL; THA	Background Total hip replacement (THR) is extremely common. Some prostheses fail, particularly in younger patients, and need to be revised, most commonly for loosening secondary to wear or dislocation. Surgeons have tried to address these problems by implanting large diameter metal-on-metal bearing surfaces. Our aim was to assess if metal-on-metal bearing surfaces lead to increased implant survival compared with other bearing surfaces in stemmed THR and, additionally, if larger head sizes result in improved implant survival. Methods We analysed the National Joint Registry of England and Wales for primary hip replacements (402 051, of which 31 171 were stemmed metal-on-metal) undertaken between 2003 and 2011. Our analysis was with a multivariable flexible parametric survival model to estimate the covariate-adjusted cumulative incidence of revision adjusting for the competing risk of death. Findings Metal-on-metal THR failed at high rates. Failure was related to head size, with larger heads failing earlier (3.2% cumulative incidence of revision [95% CI 2.5-4.1] for 28 mm and 5.1% [4.2-6.2] for 52 mm head at 5 years in men aged 60 years). 5 year revision rates in younger women were 6.1% (5.2-7.2) for 46 mm metal-on-metal compared with 1.6% (1.3-2.1) for 28 mm metal-on-polyethylene. By contrast, for ceramic-on-ceramic articulations larger head sizes were associated with improved survival (5 year revision rate of 3.3% [2.6-4.1] with 28 mm and 2.0% [1.5-2.7] with 40 mm for men aged 60 years). Interpretation Metal-on-metal stemmed articulations give poor implant survival compared with other options and should not be implanted. All patients with these bearings should be carefully monitored, particularly young women implanted with large diameter heads. Since large diameter ceramic-on-ceramic bearings seem to do well we support their continued use.	[Smith, Alison J.; Vernon, Kelly; Blom, Ashley W.] Univ Bristol, Sch Clin Sci, Musculoskeletal Res Unit, Bristol BS10 5NB, Avon, England; [Dieppe, Paul] Univ Plymouth, Peninsula Med Sch, Plymouth PL4 8AA, Devon, England; [Dieppe, Paul] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England	University of Bristol; University of Plymouth; University of Exeter	Smith, AJ (corresponding author), Univ Bristol, Southmead Hosp, Avon Orthopaed Ctr Lower Level, Musculoskeletal Res Unit,Sch Clin Sci, Bristol BS10 5NB, Avon, England.	alison.smith@bristol.ac.uk		Blom, Ashley/0000-0002-9940-1095	National Joint Registry of England and Wales	National Joint Registry of England and Wales	National Joint Registry of England and Wales.	Aldrian S, 2009, HIP INT, V19, P36, DOI 10.1177/112070000901900107; Australian Orthopaedic Association, 2010, ANN REP 2010 AUSTR O; Blom AW, 2008, ANN ROY COLL SURG, V90, P658, DOI 10.1308/003588408X318156; Bolland BJRF, 2011, J BONE JOINT SURG BR, V93B, P608, DOI 10.1302/0301-620X.93B5.26309; Bozic KJ, 2010, CLIN ORTHOP RELAT R, V468, P2357, DOI 10.1007/s11999-010-1262-3; CASE CP, 1994, J BONE JOINT SURG BR, V76B, P701, DOI 10.1302/0301-620X.76B5.8083255; Choi IY, 2010, CLIN ORTHOP RELAT R, V468, P3234, DOI 10.1007/s11999-010-1394-5; Coviello E, STCOMPADJ STATA MODU; Davies AP, 2005, J BONE JOINT SURG AM, V87A, P18, DOI 10.2106/JBJS.C.00949; Dowson D, 2004, J ARTHROPLASTY, V19, P124, DOI 10.1016/j.arth.2004.09.016; Guillemin F, 2011, OSTEOARTHR CARTILAGE, V19, P1314, DOI 10.1016/j.joca.2011.08.004; Haddad FS, 2011, J BONE JOINT SURG BR, V93B, P572, DOI 10.1302/0301-620X.93B4.26429; Howard JL, 2011, J BONE JOINT SURG AM, V93A, P1597, DOI 10.2106/JBJS.J.00195; Keegan GM, 2008, CRIT REV TOXICOL, V38, P645, DOI [10.1080/10408440701845534, 10.1080/10408440701845534 ]; Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222; Ladon D, 2004, J ARTHROPLASTY, V19, P78, DOI 10.1016/j.arth.2004.09.010; Langton DJ, 2011, J BONE JOINT SURG BR, V93B, P1011, DOI 10.1302/0301-620X.93B8.26040; Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140-6736(07)60457-7; Makela KT, 2011, ACTA ORTHOP, V82, P521, DOI 10.3109/17453674.2011.618908; Medicines and healthcare products regulatory agency, MED DEV AL ALL MET O; National Joint Registry for England and Wales, 2011, 8 ANN REP 2011; Neuerburg C, 2012, ARCH ORTHOP TRAUM SU, V132, P527, DOI 10.1007/s00402-011-1427-x; Parry MC, 2010, BIOMATERIALS, V31, P4477, DOI 10.1016/j.biomaterials.2010.02.038; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Sedrakyan A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7434; Shetty V, 2011, INT ORTHOP, V35, P1281, DOI 10.1007/s00264-010-1104-7; Smith SL, 2001, P I MECH ENG H, V215, P161, DOI 10.1243/0954411011533724; Wylde V, 2011, J BONE JOINT SURG BR, V93B, P569, DOI 10.1302/0301-620X.93B5.26687; Zywiel MG, 2011, CLIN ORTHOP RELAT R, V469, P1536, DOI 10.1007/s11999-010-1658-0	29	381	390	2	85	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 31	2012	379	9822					1199	1204		10.1016/S0140-6736(12)60353-5	http://dx.doi.org/10.1016/S0140-6736(12)60353-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918DV	22417410				2022-12-28	WOS:000302230400032
J	High, AA; Leonard, JR; Hammack, AT; Fogler, MM; Butov, LV; Kavokin, AV; Campman, KL; Gossard, AC				High, A. A.; Leonard, J. R.; Hammack, A. T.; Fogler, M. M.; Butov, L. V.; Kavokin, A. V.; Campman, K. L.; Gossard, A. C.			Spontaneous coherence in a cold exciton gas	NATURE			English	Article							BOSE-EINSTEIN CONDENSATION; COUPLED QUANTUM-WELLS; NOBEL LECTURE; SEMICONDUCTORS; TRANSPORT; VORTICES; LIQUID	If bosonic particles are cooled down below the temperature of quantum degeneracy, they can spontaneously form a coherent state in which individual matter waves synchronize and combine. Spontaneous coherence of matter waves forms the basis of a number of fundamental phenomena in physics, including superconductivity, superfluidity and Bose-Einstein condensation(1,2). Spontaneous coherence is the key characteristic of condensation in momentum space(3). Excitons-bound pairs of electrons and holes-form amodel system to explore the quantum physics of cold bosons in solids(4,5). Cold exciton gases can be realized in a system of indirect excitons, which can cool down below the temperature of quantum degeneracy owing to their long lifetimes(6). Here we report measurements of spontaneous coherence in a gas of indirect excitons. We found that spontaneous coherence of excitons emerges in the region of the macroscopically ordered exciton state(7) and in the region of vortices of linear polarization. The coherence length in these regions is much larger than in a classical gas, indicating a coherent state with a much narrower than classical exciton distribution in momentum space, characteristic of a condensate. A pattern of extended spontaneous coherence is correlated with a pattern of spontaneous polarization, revealing the properties of a multicomponent coherent state. We also observed phase singularities in the coherent exciton gas. All these phenomena emerge when the exciton gas is cooled below a few kelvin.	[High, A. A.; Leonard, J. R.; Hammack, A. T.; Fogler, M. M.; Butov, L. V.] Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; [Kavokin, A. V.] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Kavokin, A. V.] St Petersburg State Univ, Spin Opt Lab, St Petersburg 198504, Russia; [Campman, K. L.; Gossard, A. C.] Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	University of California System; University of California San Diego; University of Southampton; Saint Petersburg State University; University of California System; University of California Santa Barbara	High, AA (corresponding author), Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA.	alex.high@gmail.com	High, Alexander A/U-1307-2018; Hammack, Aaron/A-4843-2011; KAVOKINE, ALEXIS/C-3601-2016; Fogler, Michael M/O-4610-2017	Hammack, Aaron/0000-0002-8966-5978; KAVOKINE, ALEXIS/0000-0003-2713-1062; Fogler, Michael M/0000-0001-8239-7221; Leonard, Jason/0000-0001-5368-2293	DOE Office of Basic Energy Sciences [DE-FG02-07ER46449]; UCOP; Royal Society (UK); Division Of Materials Research [0907349] Funding Source: National Science Foundation	DOE Office of Basic Energy Sciences(United States Department of Energy (DOE)); UCOP; Royal Society (UK)(Royal Society of London); Division Of Materials Research(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We thank L. Levitov, T. Ostatnicky, L. Sham, B. Simons and C. Wu for discussions. This work was supported by the DOE Office of Basic Energy Sciences (DE-FG02-07ER46449). The development of spectroscopy in a dilution refrigerator was supported by ARO and NSF. M. M. F. was supported by the UCOP. A. V. K. was supported by the Royal Society (UK).	Butov LV, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117404; Butov LV, 1998, PHYS REV B, V58, P1980, DOI 10.1103/PhysRevB.58.1980; Butov LV, 2002, NATURE, V418, P751, DOI 10.1038/nature00943; Butov LV, 2001, PHYS REV LETT, V86, P5608, DOI 10.1103/PhysRevLett.86.5608; BUTOV LV, 1994, PHYS REV LETT, V73, P304, DOI 10.1103/PhysRevLett.73.304; CHEN XM, 1991, PHYS REV LETT, V67, P895, DOI 10.1103/PhysRevLett.67.895; Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; Eisenstein JP, 2004, NATURE, V432, P691, DOI 10.1038/nature03081; Fogler MM, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.035411; FUKUZAWA T, 1990, SURF SCI, V228, P482, DOI 10.1016/0039-6028(90)90358-F; Hadzibabic Z, 2006, NATURE, V441, P1118, DOI 10.1038/nature04851; Jang JI, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.045211; Karmakar B, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.036802; KELDYSH LV, 1968, SOV PHYS JETP-USSR, V27, P521; KELDYSH LV, 1965, FIZ TVERD TELA+, V6, P2219; KELDYSH LV, 1986, CONTEMP PHYS, V27, P395, DOI 10.1080/00107518608211022; Ketterle W, 2002, REV MOD PHYS, V74, P1131, DOI [10.1103/RevModPhys.74.1131, 10.1142/S0217979202014668]; Lagoudakis KG, 2008, NAT PHYS, V4, P706, DOI 10.1038/nphys1051; Lozovik Y. E., 1976, SOV PHYS JETP, V44, P389; MAIALLE MZ, 1993, PHYS REV B, V47, P15776, DOI 10.1103/PhysRevB.47.15776; PENROSE O, 1956, PHYS REV, V104, P576, DOI 10.1103/PhysRev.104.576; Rapaport R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117405; Read D, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.195309; Scheuer J, 1999, SCIENCE, V285, P230, DOI 10.1126/science.285.5425.230; Sen Y., 2006, PHYS REV LETT, V97; Spielman IB, 2000, PHYS REV LETT, V84, P5808, DOI 10.1103/PhysRevLett.84.5808; Tiemann L, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.033306; Tikhodeev SG, 1998, PHYS STATUS SOLIDI B, V206, P45, DOI 10.1002/(SICI)1521-3951(199803)206:1<45::AID-PSSB45>3.0.CO;2-5; Tutuc E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.036802; Wu C., 2008, EXCITON CONDENSATION	30	225	228	3	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 29	2012	483	7391					584	588		10.1038/nature10903	http://dx.doi.org/10.1038/nature10903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22437498	Green Submitted			2022-12-28	WOS:000302006100036
J	Wu, Q; Clark, MS; Palmiter, RD				Wu, Qi; Clark, Michael S.; Palmiter, Richard D.			Deciphering a neuronal circuit that mediates appetite	NATURE			English	Article							FOOD-INTAKE; PARABRACHIAL NUCLEUS; ENERGY HOMEOSTASIS; SEROTONIN; BRAIN; RAT; ANOREXIA; TASTE; FOS; STARVATION	Hypothalamic neurons that co-express agouti-related protein (AgRP), neuropeptide Y and gamma-aminobutyric acid (GABA) are known to promote feeding and weight gain by integration of various nutritional, hormonal, and neuronal signals(1,2). Ablation of these neurons in mice leads to cessation of feeding that is accompanied by activation of Fos in most regions where they project(3-6). Previous experiments have indicated that the ensuing starvation is due to aberrant activation of the parabrachial nucleus (PBN) and it could be prevented by facilitating GABA(A) receptor signalling in the PBN within a critical adaptation period(5). We speculated that loss of GABA signalling from AgRP-expressing neurons (AgRP neurons) within the PBN results in unopposed excitation of the PBN, which in turn inhibits feeding. However, the source of the excitatory inputs to the PBN was unknown. Here we show that glutamatergic neurons in the nucleus tractus solitarius (NTS) and caudal serotonergic neurons control the excitability of PBN neurons and inhibit feeding. Blockade of serotonin (5-HT3) receptor signalling in the NTS by either the chronic administration of ondansetron or the genetic inactivation of Tph2 in caudal serotonergic neurons that project to the NTS protects against starvation when AgRP neurons are ablated. Likewise, genetic inactivation of glutamatergic signalling by the NTS onto N-methyl D-aspartate-type glutamate receptors in the PBN prevents starvation. We also show that suppressing glutamatergic output of the PBN reinstates normal appetite after AgRP neuron ablation, whereas it promotes weight gain without AgRP neuron ablation. Thus we identify the PBN as a hub that integrates signals from several brain regions to bidirectionally modulate feeding and body weight.	[Wu, Qi; Palmiter, Richard D.] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; [Wu, Qi; Palmiter, Richard D.] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; [Clark, Michael S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.	palmiter@uw.edu			National Institutes of Health [DA024908]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA024908] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank G. Froelick, J. Wang and K. Battani for help with histology; A. Rainwater for help with mouse breeding; A. Quintana for propagating CAV2-Cre virus and preparing AAV1-CreGFP virus; and A. Guler and M. Carter for helpful comments on the manuscript. This work was supported in part by National Institutes of Health grant DA024908 to R.D.P.	Abizaid A, 2008, REGUL PEPTIDES, V149, P3, DOI 10.1016/j.regpep.2007.10.006; Barnes NM, 2009, NEUROPHARMACOLOGY, V56, P273, DOI 10.1016/j.neuropharm.2008.08.003; BERRIDGE KC, 1995, NEUROSCI BIOBEHAV R, V19, P121, DOI 10.1016/0149-7634(94)00026-W; Berthoud HR, 2008, ANNU REV PSYCHOL, V59, P55, DOI 10.1146/annurev.psych.59.103006.093551; Fulwiler CE, 1984, BRAIN RES, V319, P229; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Grill HJ, 2006, OBESITY, V14, P216, DOI 10.1038/oby.2006.312; Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548; Heisler LK, 2006, NEURON, V51, P239, DOI 10.1016/j.neuron.2006.06.004; HERBERT H, 1990, J COMP NEUROL, V293, P540, DOI 10.1002/cne.902930404; Hnasko TS, 2010, NEURON, V65, P643, DOI 10.1016/j.neuron.2010.02.012; JHAMANDAS JH, 1992, AM J PHYSIOL, V263, pR324, DOI 10.1152/ajpregu.1992.263.2.R324; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026; Rask-Andersen M, 2010, BRAIN RES REV, V62, P147, DOI 10.1016/j.brainresrev.2009.10.007; SWANK MW, 1994, BRAIN RES, V636, P202, DOI 10.1016/0006-8993(94)91018-9; Takase LF, 2008, BRAIN RES, V1200, P10, DOI 10.1016/j.brainres.2008.01.036; THOR KB, 1987, J COMP NEUROL, V265, P275, DOI 10.1002/cne.902650210; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006-2952(03)00556-2; Wu Q, 2008, J NEUROSCI, V28, P9218, DOI 10.1523/JNEUROSCI.2449-08.2008; Wu Q, 2008, P NATL ACAD SCI USA, V105, P2687, DOI 10.1073/pnas.0712062105; Wu Q, 2011, EUR J PHARMACOL, V660, P21, DOI 10.1016/j.ejphar.2010.10.110; Wu Q, 2009, CELL, V137, P1225, DOI 10.1016/j.cell.2009.04.022; Xu Y, 2010, J NEUROSCI, V30, P14630, DOI 10.1523/JNEUROSCI.5412-09.2010; Xu Y, 2008, NEURON, V60, P582, DOI 10.1016/j.neuron.2008.09.033; Yamamoto T, 2006, ARCH HISTOL CYTOL, V69, P243, DOI 10.1679/aohc.69.243	30	230	240	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 29	2012	483	7391					594	U112		10.1038/nature10899	http://dx.doi.org/10.1038/nature10899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22419158	Green Accepted			2022-12-28	WOS:000302006100038
J	Czyzewski, BK; Wang, DN				Czyzewski, Bryan K.; Wang, Da-Neng			Identification and characterization of a bacterial hydrosulphide ion channel	NATURE			English	Article							ESCHERICHIA-COLI; SULFIDE ACQUISITION; CHLORIDE CHANNEL; MEMBRANE; TRANSPORTER; PURIFICATION; BIOCHEMISTRY; BINDING; PROTEIN; NIRC	The hydrosulphide ion (HS-) and its undissociated form, hydrogen sulphide (H2S), which are believed to have been critical to the origin of life on Earth(1), remain important in physiology and cellular signalling(2). As a major metabolite in anaerobic bacterial growth, hydrogen sulphide is a product of both assimilatory and dissimilatory sulphate reduction(2-4). These pathways can reduce various oxidized sulphur compounds including sulphate, sulphite and thiosulphate. The dissimilatory sulphate reduction pathway uses this molecule as the terminal electron acceptor for anaerobic respiration, in which process it produces excess amounts of H2S (ref. 4). The reduction of sulphite is a key intermediate step in all sulphate reduction pathways. In Clostridium and Salmonella, an inducible sulphite reductase is directly linked to the regeneration of NAD(+), which has been suggested to have a role in energy production and growth, as well as in the detoxification of sulphite(3). Above a certain concentration threshold, both H2S and HS- inhibit cell growth by binding the metal centres of enzymes and cytochrome oxidase(5), necessitating a release mechanism for the export of this toxic metabolite from the cell(5-9). Here we report the identification of a hydrosulphide ion channel in the pathogen Clostridium difficile through a combination of genetic, biochemical and functional approaches. The HS- channel is a member of the formate/nitrite transport family, in which about 50 hydrosulphide ion channels form a third subfamily alongside those for formate(10,11) (FocA) and for nitrite(12) (NirC). The hydrosulphide ion channel is permeable to formate and nitrite as well as to HS- ions. Such polyspecificity can be explained by the conserved ion selectivity filter observed in the channel's crystal structure. The channel has a low open probability and is tightly regulated, to avoid decoupling of the membrane proton gradient.	[Czyzewski, Bryan K.; Wang, Da-Neng] NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med, New York, NY 10016 USA; [Czyzewski, Bryan K.] NYU, Sch Med, Mol Biophys Grad Program, New York, NY 10016 USA; [Wang, Da-Neng] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University; New York University	Wang, DN (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Helen L & Martin S Kimmel Ctr Biol & Med, 540 1st Ave, New York, NY 10016 USA.	wang@saturn.med.nyu.edu		Wang, Da-Neng/0000-0002-6496-4699	NIH [R01-GM093825, R01-DK073973, R01-MH083840, U54-GM075026, R01-DK053973-08A1S1, F31-AI086072]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073973, R01DK053973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093825, U54GM075026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH083840] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We are grateful the staff at beamlines X25 and X29 of the National Synchrotron Light Source at Brookhaven National Laboratory and at beamline 23ID of the Advanced Photon Source at Argonne National Laboratory for assistance in X-ray diffraction experiments. We thank A. B. Waight for suggesting the project; J. J. Marden for assistance with cloning of mutants; T. Neubert and S. Blais for mass spectrometry measurements; the 2010 CCP4 Workshop for assistance in processing diffraction data; and A. David, H. Jackson, N. K. Karpowich, J. J. Marden, R. L. Mancusso, Y. Pan and M. Zhou for discussions. This work was financially supported by the NIH (R01-GM093825, R01-DK073973, R01-MH083840 and U54-GM075026). B. K. C. was partly supported by an NIH Supplement Grant to Promote Diversity in Health-Related Research (R01-DK053973-08A1S1) and an NIH pre-doctoral fellowship (F31-AI086072).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Auer M, 2001, BIOCHEMISTRY-US, V40, P6628, DOI 10.1021/bi010138+; Benson DA, 2014, NUCLEIC ACIDS RES, V42, pD32, DOI [10.1093/nar/gkp1024, 10.1093/nar/gkt1030, 10.1093/nar/gks1195, 10.1093/nar/gkw1070, 10.1093/nar/gkq1079, 10.1093/nar/gkn723, 10.1093/nar/gkr1202, 10.1093/nar/gkx1094]; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Crane BR, 1996, CURR OPIN STRUC BIOL, V6, P744, DOI 10.1016/S0959-440X(96)80003-0; Das P, 2009, MICROBIOL-SGM, V155, P2476, DOI 10.1099/mic.0.029611-0; DeLano W.L, PYMOL MOL GRAPHICS S; Dhillon A, 2005, ASTROBIOLOGY, V5, P18, DOI 10.1089/ast.2005.5.18; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FETH S, 1993, J PHYS CHEM-US, V97, P11445, DOI 10.1021/j100146a017; Freytag JK, 2001, P NATL ACAD SCI USA, V98, P13408, DOI 10.1073/pnas.231589498; Goffredi SK, 1997, J EXP BIOL, V200, P2609; HALLENBECK PC, 1989, J BACTERIOL, V171, P3008, DOI 10.1128/jb.171.6.3008-3015.1989; Han MV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-356; Hille B, 1992, IONIC CHANNELS EXCIT, P362; Hirshfield Irvin N., 2003, Science Progress, V86, P245, DOI 10.3184/003685003783238626; Hughes MN, 2009, FREE RADICAL BIO MED, V47, P1346, DOI 10.1016/j.freeradbiomed.2009.09.018; Jacques AG, 1936, J GEN PHYSIOL, V19, P0397, DOI 10.1085/jgp.19.3.397; Jia WJ, 2009, BIOCHEM J, V417, P297, DOI 10.1042/BJ20080746; Kabil O, 2010, J BIOL CHEM, V285, P21903, DOI 10.1074/jbc.R110.128363; Lee JK, 2005, P NATL ACAD SCI USA, V102, P18932, DOI 10.1073/pnas.0509469102; Li XD, 2001, FEBS LETT, V494, P165, DOI 10.1016/S0014-5793(01)02334-1; Lu W, 2011, SCIENCE, V332, P352, DOI 10.1126/science.1199098; Mathai JC, 2009, P NATL ACAD SCI USA, V106, P16633, DOI 10.1073/pnas.0902952106; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penel S, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S6-S3; Rabus R, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 2, THIRD EDITION, P659, DOI 10.1007/0-387-30742-7_22; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; Safferling M, 2003, BIOCHEMISTRY-US, V42, P13969, DOI 10.1021/bi035173q; Savage DF, 2010, P NATL ACAD SCI USA, V107, P17164, DOI 10.1073/pnas.1009864107; SIMONS J, 1987, CHEM REV, V87, P535, DOI 10.1021/cr00079a004; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; SUPPMANN B, 1994, MOL MICROBIOL, V11, P965, DOI 10.1111/j.1365-2958.1994.tb00375.x; Tai CH, 2001, BIOCHEMISTRY-US, V40, P7446, DOI 10.1021/bi015511s; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Waight AB, 2010, NAT STRUCT MOL BIOL, V17, P31, DOI 10.1038/nsmb.1740; Wang DN, 2003, BBA-BIOMEMBRANES, V1610, P23, DOI 10.1016/S0005-2736(02)00709-5; Wang Y, 2009, NATURE, V462, P467, DOI 10.1038/nature08610; WILSON W. JAMES, 1926, JOUR PATH BACT, V29, P310, DOI 10.1002/path.1700290312; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045	43	95	96	3	78	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					494	U155		10.1038/nature10881	http://dx.doi.org/10.1038/nature10881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22407320	Green Accepted			2022-12-28	WOS:000301771200049
J	Steinman, MA; Landefeld, CS; Baron, RB				Steinman, Michael A.; Landefeld, C. Seth; Baron, Robert B.			Industry Support of CME - Are We at the Tipping Point?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Steinman, Michael A.; Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; [Steinman, Michael A.; Landefeld, C. Seth; Baron, Robert B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Steinman, Michael A.; Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA; [Baron, Robert B.] Univ Calif San Francisco, Off Associate Dean Grad & Continuing Med Educ, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Steinman, MA (corresponding author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.							Accreditation Council for Continuing Medical Education, 2011, ACCME 2010 ANN REP D; Accreditation Council for Continuing Medical Education, 2010, ACCME 2010 ANN REP D; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Committee on Conflict of Interest in Medical Research Education and Practice Institute of Medicine, 2009, CONFL INT MED RES ED; Fletcher Suzanne W., 2008, CONTINUING ED HLTH P, P13	5	34	36	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1069	1071		10.1056/NEJMp1114776	http://dx.doi.org/10.1056/NEJMp1114776			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912BO	22435367				2022-12-28	WOS:000301769700003
J	White, C; Ginsburg, PB				White, Chapin; Ginsburg, Paul B.			Slower Growth in Medicare Spending - Is This the New Normal?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[White, Chapin; Ginsburg, Paul B.] Ctr Studying Hlth Syst, Washington, DC USA		White, C (corresponding author), Ctr Studying Hlth Syst, Washington, DC USA.							Hadley J, 2009, INQUIRY-J HEALTH CAR, V46, P372, DOI 10.5034/inquiryjrnl_46.4.372; Martin AB, 2012, HEALTH AFFAIR, V31, P208, DOI 10.1377/hlthaff.2011.1135; White C, 2008, HEALTH AFFAIR, V27, P793, DOI 10.1377/hlthaff.27.3.793	3	12	12	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1073	1075		10.1056/NEJMp1201853	http://dx.doi.org/10.1056/NEJMp1201853			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912BO	22397631				2022-12-28	WOS:000301769700005
J	Opal, SM				Opal, Steven M.			Review: Short-course antibiotics in hospital-acquired pneumonia do not affect mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Brown Univ, Alpert Med Sch, Providence, RI 02912 USA	Brown University	Opal, SM (corresponding author), Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.							Livermore DM, 2005, LANCET INFECT DIS, V5, P450, DOI 10.1016/S1473-3099(05)70166-3; Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997	2	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-13	10.7326/0003-4819-156-6-201203200-02013	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431699				2022-12-28	WOS:000303150900012
J	Prabakar, I; Webb, A				Prabakar, I.; Webb, A.			Emergency contraception	BRITISH MEDICAL JOURNAL			English	Editorial Material							ULIPRISTAL ACETATE; LEVONORGESTREL; PREGNANCY; OVULATION; TRIALS; MG		[Prabakar, I.; Webb, A.] Liverpool Community Hlth, Abacus Serv Sexual & Reprod Healthcare, Liverpool L2 5SF, Merseyside, England		Prabakar, I (corresponding author), Liverpool Community Hlth, Abacus Serv Sexual & Reprod Healthcare, Liverpool L2 5SF, Merseyside, England.	iprabakar@nhs.net						[Anonymous], 2004, SEL PRACT REC CONTR; Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157; Cheng L, 2008, COCHRANE DB SYST REV, V2; Creinin MD, 2006, OBSTET GYNECOL, V108, P1089, DOI 10.1097/01.AOG.0000239440.02284.45; Croxatto HB, 2004, CONTRACEPTION, V70, P442, DOI 10.1016/j.contraception.2004.05.007; Espinos JJ, 1999, CONTRACEPTION, V60, P243, DOI 10.1016/S0010-7824(99)00090-6; *FAC SEX REPR HEAL, 2010, QUICK START CONTR; Faculty of Sexual and Reproductive Healthcare, 2007, FSRH CLIN GUID INTR; Faculty of Sexual and Reproductive Healthcare, 2011, CLIN GUID; Glasier A, 2011, CONTRACEPTION, V84, P363, DOI 10.1016/j.contraception.2011.02.009; Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8; HRA Pharma UK, 2011, ELLAONE SUMM PROD CH; Lader D., 2008, REPORT RES USING NAT; Noe G, 2010, CONTRACEPTION, V81, P414, DOI 10.1016/j.contraception.2009.12.015; Piaggio G, 2011, CONTRACEPTION, V84, P35, DOI 10.1016/j.contraception.2010.11.010; Raymond EG, 2007, OBSTET GYNECOL, V109, P181, DOI 10.1097/01.AOG.0000250904.06923.4a; Stirling A, 2002, CONTRACEPTION, V66, P19, DOI 10.1016/S0010-7824(02)00310-4; Thomas CM, 2010, J FAM PLAN REPROD H, V36, P197, DOI 10.1783/147118910793048656; Trussell J, 2012, EMERGENCY CONTRACEPTION: THE STORY OF A GLOBAL REPRODUCTIVE HEALTH TECHNOLOGY, P19; WHO, 2015, MED EL CRIT CONTR US, V5th; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301	21	4	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1492	10.1136/bmj.e1492	http://dx.doi.org/10.1136/bmj.e1492			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431662				2022-12-28	WOS:000301848400008
J	Petitpierre, B; Kueffer, C; Broennimann, O; Randin, C; Daehler, C; Guisan, A				Petitpierre, Blaise; Kueffer, Christoph; Broennimann, Olivier; Randin, Christophe; Daehler, Curtis; Guisan, Antoine			Climatic Niche Shifts Are Rare Among Terrestrial Plant Invaders	SCIENCE			English	Article							NORTH-AMERICA; INVASIVE PLANTS; MULTIPLE INTRODUCTIONS; GLOBAL-SCALE; EVOLUTION; RANGE; CONSERVATISM; HOME; COMMUNITIES; PREDICTIONS	The assumption that climatic niche requirements of invasive species are conserved between their native and invaded ranges is key to predicting the risk of invasion. However, this assumption has been challenged recently by evidence of niche shifts in some species. Here, we report the first large-scale test of niche conservatism for 50 terrestrial plant invaders between Eurasia, North America, and Australia. We show that when analog climates are compared between regions, fewer than 15% of species have more than 10% of their invaded distribution outside their native climatic niche. These findings reveal that substantial niche shifts are rare in terrestrial plant invaders, providing support for an appropriate use of ecological niche models for the prediction of both biological invasions and responses to climate change.	[Petitpierre, Blaise; Broennimann, Olivier; Guisan, Antoine] Univ Lausanne, Dept Ecol & Evolut, CH-1015 Lausanne, Switzerland; [Kueffer, Christoph] ETH, Inst Integrat Biol, CH-8092 Zurich, Switzerland; [Kueffer, Christoph; Daehler, Curtis] Univ Hawaii Manoa, Dept Bot, Honolulu, HI 96822 USA; [Randin, Christophe] Univ Basel, Inst Bot, CH-4056 Basel, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Hawaii System; University of Hawaii Manoa; University of Basel	Guisan, A (corresponding author), Univ Lausanne, Dept Ecol & Evolut, Biophore Bldg, CH-1015 Lausanne, Switzerland.	antoine.guisan@unil.ch	Kueffer, Christoph/H-6091-2013; Randin, Christophe F/K-6969-2016; Broennimann, Olivier/D-3495-2011; Guisan, Antoine/A-1057-2011	Kueffer, Christoph/0000-0001-6701-0703; Randin, Christophe F/0000-0002-4171-0178; Broennimann, Olivier/0000-0001-9913-3695; Guisan, Antoine/0000-0002-3998-4815; Bronnimann, Olivier/0000-0001-5394-4564	National Center for Competence in Research (Plant Survival); USDA National Institute of Food and Agriculture [2006-35320-17360]	National Center for Competence in Research (Plant Survival); USDA National Institute of Food and Agriculture(United States Department of Agriculture (USDA))	We thank R. Engler, E. Schumacher, and C. Angelo for contributing to the compilation of the data and J. Alexander, H. Possingham, L. Pellissier, and S. M. Gray for comments on the manuscript. A. G., O.B., and B. P. received main support from the National Center for Competence in Research (Plant Survival). C. D. and C. K. received support from the USDA National Institute of Food and Agriculture, Biology of Weedy and Invasive Species Program grant no. 2006-35320-17360. The climatic data used in this study are available online, and the species data used in this study were assembled from multiple sources with various release politics. All data sources are described in the SOM.	Alexander JM, 2010, OIKOS, V119, P1377, DOI 10.1111/j.1600-0706.2009.17977.x; Blair AC, 2010, EVOL APPL, V3, P40, DOI 10.1111/j.1752-4571.2009.00097.x; Broennimann O, 2007, ECOL LETT, V10, P701, DOI 10.1111/j.1461-0248.2007.01060.x; Broennimann O, 2012, GLOBAL ECOL BIOGEOGR, V21, P481, DOI 10.1111/j.1466-8238.2011.00698.x; Callaway RM, 2011, ECOLOGY, V92, P2208, DOI 10.1890/11-0518.1; Crisp MD, 2009, NATURE, V458, P754, DOI 10.1038/nature07764; Crosby Alfred W., 1986, STUDIES ENV HIST; Durka W, 2005, MOL ECOL, V14, P1697, DOI 10.1111/j.1365-294X.2005.02521.x; Firn J, 2011, ECOL LETT, V14, P274, DOI 10.1111/j.1461-0248.2010.01584.x; Fitzpatrick MC, 2007, GLOBAL ECOL BIOGEOGR, V16, P24, DOI 10.1111/j.1466-8238.2006.00258.x; FORNO IW, 1983, AQUAT BOT, V17, P71, DOI 10.1016/0304-3770(83)90019-0; Gallagher RV, 2010, J ECOL, V98, P790, DOI 10.1111/j.1365-2745.2010.01677.x; Guisan A, 2005, ECOL LETT, V8, P993, DOI 10.1111/j.1461-0248.2005.00792.x; Hierro JL, 2006, AM NAT, V168, P144, DOI 10.1086/505767; Klironomos JN, 2002, NATURE, V417, P67, DOI 10.1038/417067a; Lauzeral C, 2011, GLOBAL ECOL BIOGEOGR, V20, P407, DOI 10.1111/j.1466-8238.2010.00611.x; Lavergne S, 2007, P NATL ACAD SCI USA, V104, P3883, DOI 10.1073/pnas.0607324104; Leung B, 2002, P ROY SOC B-BIOL SCI, V269, P2407, DOI 10.1098/rspb.2002.2179; Mandle L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015297; Medley KA, 2010, GLOBAL ECOL BIOGEOGR, V19, P122, DOI 10.1111/j.1466-8238.2009.00497.x; Muller-Scharer H, 2004, TRENDS ECOL EVOL, V19, P417, DOI 10.1016/j.tree.2004.05.010; Novak SJ, 2001, BIOSCIENCE, V51, P114, DOI 10.1641/0006-3568(2001)051[0114:TPIASG]2.0.CO;2; Pairon M, 2010, ANN BOT-LONDON, V105, P881, DOI 10.1093/aob/mcq065; Pearman PB, 2008, TRENDS ECOL EVOL, V23, P149, DOI 10.1016/j.tree.2007.11.005; Rejmanek M, 2000, AUSTRAL ECOL, V25, P497, DOI 10.1046/j.1442-9993.2000.01080.x; Seastedt TR, 2011, ANNU REV ECOL EVOL S, V42, P133, DOI 10.1146/annurev-ecolsys-102710-145057; Seipel T, 2012, GLOBAL ECOL BIOGEOGR, V21, P236, DOI 10.1111/j.1466-8238.2011.00664.x; Thuiller W, 2005, GLOBAL CHANGE BIOL, V11, P2234, DOI 10.1111/j.1365-2486.2005.001018.x; Treier UA, 2009, ECOLOGY, V90, P1366, DOI 10.1890/08-0420.1; Vila M, 2010, FRONT ECOL ENVIRON, V8, P135, DOI 10.1890/080083; Warren DL, 2008, EVOLUTION, V62, P2868, DOI 10.1111/j.1558-5646.2008.00482.x; Welk E, 2004, ECOL MODEL, V179, P551, DOI 10.1016/j.ecolmodel.2004.04.020; Wiens JJ, 2005, ANNU REV ECOL EVOL S, V36, P519, DOI 10.1146/annurev.ecolsys.36.102803.095431; Woodward F.I., 1987, CLIMATE PLANT DISTRI; Xu CY, 2010, ECOL LETT, V13, P32, DOI 10.1111/j.1461-0248.2009.01395.x	35	531	551	15	407	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1344	1348		10.1126/science.1215933	http://dx.doi.org/10.1126/science.1215933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422981	Green Accepted, Green Submitted			2022-12-28	WOS:000301531600046
J	Lebwohl, M; Swanson, N; Anderson, LL; Melgaard, A; Xu, ZY; Berman, B				Lebwohl, Mark; Swanson, Neil; Anderson, Lawrence L.; Melgaard, Anita; Xu, Zhenyi; Berman, Brian			Ingenol Mebutate Gel for Actinic Keratosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2.5-PERCENT HYALURONAN GEL; CREAM; 5-FLUOROURACIL; 0.5-PERCENT; TRIALS	BACKGROUND Actinic keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical and subclinical actinic keratoses. Topical field therapy currently requires weeks or months of treatment. We investigated the efficacy and safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk and extremities). METHODS In four multicenter, randomized, double-blind studies, we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extremities to receive ingenol mebutate or placebo (vehicle), self-applied to a 25-cm(2) contiguous field once daily for 3 consecutive days for lesions on the face or scalp or for 2 consecutive days for the trunk or extremities. Complete clearance (primary outcome) was assessed at 57 days, and local reactions were quantitatively measured. RESULTS In a pooled analysis of the two trials involving the face and scalp, the rate of complete clearance was higher with ingenol mebutate than with placebo (42.2% vs. 3.7%, P<0.001). Local reactions peaked at day 4, with a mean maximum composite score of 9.1 on the local-skin-response scale (which ranges from 0 to 4 for six types of reaction, yielding a composite score of 0 to 24, with higher numbers indicating more severe reactions), rapidly decreased by day 8, and continued to decrease, approaching baseline scores by day 29. In a pooled analysis of the two trials involving the trunk and extremities, the rate of complete clearance was also higher with ingenol mebutate than with placebo (34.1% vs. 4.7%, P<0.001). Local skin reactions peaked between days 3 and 8 and declined rapidly, approaching baseline by day 29, with a mean maximum score of 6.8. Adverse events were generally mild to moderate in intensity and resolved without sequelae. CONCLUSIONS Ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses. (Funded by LEO Pharma; ClinicalTrials.gov numbers, NCT00742391, NCT00916006, NCT00915551, and NCT00942604.)	[Swanson, Neil] Oregon Hlth & Sci Univ, Dept Dermatol, Ctr Hlth & Healing, Portland, OR 97239 USA; [Lebwohl, Mark] Mt Sinai Sch Med, Dept Dermatol, New York, NY USA; [Anderson, Lawrence L.] Dermatol Associates Tyler, Tyler, TX USA; [Melgaard, Anita] LEO Pharma, Dept Biostat & Data Management, Ballerup, Denmark; [Xu, Zhenyi] LEO Pharma, Dept Med, Ballerup, Denmark; [Berman, Brian] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA	Oregon Health & Science University; Icahn School of Medicine at Mount Sinai; LEO Pharma; LEO Pharma; University of Miami	Swanson, N (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, Ctr Hlth & Healing, 3303 SW Bond Ave,Mail Code CH5D, Portland, OR 97239 USA.	swansonn@ohsu.edu			LEO Pharma [NCT00742391, NCT00916006, NCT00915551, NCT00942604]	LEO Pharma(LEO Pharma)	Funded by LEO Pharma; ClinicalTrials.gov numbers, NCT00742391, NCT00916006, NCT00915551, and NCT00942604.); Supported by LEO Pharma.	Challacombe JM, 2006, J IMMUNOL, V177, P8123, DOI 10.4049/jimmunol.177.11.8123; Drake Lynn A., 1995, Journal of the American Academy of Dermatology, V32, P95; Green A C, 1988, Australas J Dermatol, V29, P127, DOI 10.1111/j.1440-0960.1988.tb00383.x; Krawtchenko N, 2007, BRIT J DERMATOL, V157, P34, DOI 10.1111/j.1365-2133.2007.08271.x; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P714, DOI 10.1016/j.jaad.2003.12.010; Ogbourne SM, 2004, CANCER RES, V64, P2833, DOI 10.1158/0008-5472.CAN-03-2837; Ramsay JR, 2011, BRIT J DERMATOL, V164, P633, DOI 10.1111/j.1365-2133.2010.10184.x; Rivers JK, 2002, BRIT J DERMATOL, V146, P94, DOI 10.1046/j.1365-2133.2002.04561.x; Rosen RH, 2011, J AM ACAD DERMA 1104; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; Stockfleth E, 2008, EUR J DERMATOL, V18, P651, DOI 10.1684/ejd.2008.0514; Swanson N, 2011, PROGR ABSTR 2011 FAL; Swanson N, 2010, J AM ACAD DERMATOL, V62, P582, DOI 10.1016/j.jaad.2009.07.004; Weiss J, 2002, CUTIS, V70, P22; Wolf JE, 2001, INT J DERMATOL, V40, P709, DOI 10.1046/j.1365-4362.2001.01324.x; Yentzer B, 2009, ARCH DERMATOL, V145, P203, DOI 10.1001/archdermatol.2008.562	16	337	347	2	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1010	1019		10.1056/NEJMoa1111170	http://dx.doi.org/10.1056/NEJMoa1111170			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417254				2022-12-28	WOS:000301482800004
J	Dupont, L				Dupont, Lydie			The Human Factor	SCIENCE			English	Editorial Material							VEGETATION; CAMEROON; CLIMATE; AFRICA; BP; EVOLUTION; POLLEN		Univ Bremen, MARUM Ctr Marine Environm Sci, D-28334 Bremen, Germany	University of Bremen	Dupont, L (corresponding author), Univ Bremen, MARUM Ctr Marine Environm Sci, POB 330440, D-28334 Bremen, Germany.	dupont@uni-bremen.de		Dupont, Lydie/0000-0001-9531-6793				A Land Cover Map of Africa. European Commission, 2003, LAND COV MAP AFR; Assi-Kaudjhis C., 2010, GEO-ECO-TROP, V34, P1; Bayon G, 2012, SCIENCE, V335, P1219, DOI 10.1126/science.1215400; Bostoen K, 2007, J AFR HIST, V48, P173, DOI 10.1017/S002185370700254X; Hoelzmann P, 2004, DEV PALEOENVIRON RES, V6, P219; Lebamba J, 2012, CLIM PAST, V8, P59, DOI 10.5194/cp-8-59-2012; LEZINE AM, 1989, QUATERNARY RES, V32, P317, DOI 10.1016/0033-5894(89)90098-7; Ngomanda A, 2009, QUATERNARY RES, V71, P307, DOI 10.1016/j.yqres.2008.12.002; Vincens A, 2010, CLIM PAST, V6, P281, DOI 10.5194/cp-6-281-2010; Vincens A, 1999, J BIOGEOGR, V26, P879, DOI 10.1046/j.1365-2699.1999.00333.x; Weijers JWH, 2007, SCIENCE, V315, P1701, DOI 10.1126/science.1138131; Wotzka H.P., 1995, STUDIEN ARCHAOLOGIE, V6	12	1	1	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1180	1181		10.1126/science.1219903	http://dx.doi.org/10.1126/science.1219903			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904VB	22403379				2022-12-28	WOS:000301225100031
J	Kanamori, H				Kanamori, Hiroo			Putting seismic research to most effective use	NATURE			English	Editorial Material									CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Kanamori, H (corresponding author), CALTECH, Pasadena, CA 91125 USA.	hiroo@gps.caltech.edu						Hayes GP, 2011, SEISMOL RES LETT, V82, P481, DOI 10.1785/gssrl.82.4.481; Heki K, 2011, SCIENCE, V332, P1390, DOI 10.1126/science.1206643	2	7	9	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					147	148		10.1038/483147a	http://dx.doi.org/10.1038/483147a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904DT	22398537	Bronze			2022-12-28	WOS:000301174900013
J	Mascarelli, A				Mascarelli, Amanda			Run To Failure: BP and the Making of the Deepwater Horizon Disaster	NATURE			English	Book Review												amanda.mascarelli@gmail.com						Lustgarten A., 2012, RUN FAILURE BP MAKIN	1	6	8	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					154	155		10.1038/483154a	http://dx.doi.org/10.1038/483154a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904DT	22432121	Bronze			2022-12-28	WOS:000301174900016
J	Sommers, BD; Kronick, R				Sommers, Benjamin D.; Kronick, Richard			The Affordable Care Act and Insurance Coverage for Young Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sommers, Benjamin D.; Kronick, Richard] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA		Sommers, BD (corresponding author), US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA.	ben.sommers@hhs.gov						Cohen RA, 2008, HLTH INSURANCE COVER; DeNavas-Walt C., INCOME POVERTY HLTH; Kaiser Family Foundation; Health Research & Educational Trust, EMPL HLTH BEN 2011 A; Mendes E., US SIGNIFICANTLY FEW; US Census Bureau; US Department of Labor, 66 US DEP LAB US CEN; US Government Accountability Office, PREEX COND INS PLANS	6	108	108	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					913	914		10.1001/jama.307.9.913	http://dx.doi.org/10.1001/jama.307.9.913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396509	Bronze			2022-12-28	WOS:000301172100015
J	Selker, HP; Beshansky, JR; Sheehan, PR; Massaro, JM; Griffith, JL; D'Agostino, RB; Ruthazer, R; Atkins, JM; Sayah, AJ; Levy, MK; Richards, ME; Aufderheide, TP; Braude, DA; Pirrallo, RG; Doyle, DD; Frascone, RJ; Kosiak, DJ; Leaming, JM; Van Gelder, CM; Walter, GP; Wayne, MA; Woolard, RH; Opie, LH; Rackley, CE; Apstein, CS; Udelson, JE				Selker, Harry P.; Beshansky, Joni R.; Sheehan, Patricia R.; Massaro, Joseph M.; Griffith, John L.; D'Agostino, Ralph B.; Ruthazer, Robin; Atkins, James M.; Sayah, Assaad J.; Levy, Michael K.; Richards, Michael E.; Aufderheide, Tom P.; Braude, Darren A.; Pirrallo, Ronald G.; Doyle, Delanor D.; Frascone, Ralph J.; Kosiak, Donald J.; Leaming, James M.; Van Gelder, Carin M.; Walter, Gert-Paul; Wayne, Marvin A.; Woolard, Robert H.; Opie, Lionel H.; Rackley, Charles E.; Apstein, Carl S.; Udelson, James E.			Out-of-Hospital Administration of Intravenous Glucose-Insulin-Potassium in Patients With Suspected Acute Coronary Syndromes The IMMEDIATE Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PREDICTIVE INSTRUMENT; FATTY-ACIDS; INFUSION; MORTALITY; THERAPY; MULTICENTER; ARRHYTHMIAS; ISCHEMIA; ASSIST	Context Laboratory studies suggest that in the setting of cardiac ischemia, immediate intravenous glucose-insulin-potassium (GIK) reduces ischemia-related arrhythmias and myocardial injury. Clinical trials have not consistently shown these benefits, possibly due to delayed administration. Objective To test out-of hospital emergency medical service (EMS) administration of GIK in the first hours of suspected acute coronary syndromes (ACS). Design, Setting, and Participants Randomized, placebo-controlled, double-blind effectiveness trial in 13 US cities (36 EMS agencies), from December 2006 through July 31, 2011, in which paramedics, aided by electrocardiograph (ECG)-based decision support, randomized 911 (871 enrolled) patients (mean age, 63.6 years; 71.0% men) with high probability of ACS. Intervention Intravenous GIK solution (n=411) or identical-appearing 5% glucose placebo (n=460) administered by paramedics in the out-of-hospital setting and continued for 12 hours. Main Outcome Measures The prespecified primary end point was progression of ACS to myocardial infarction (MI) within 24 hours, as assessed by biomarkers and ECG evidence. Prespecified secondary end points included survival at 30 days and a composite of prehospital or in-hospital cardiac arrest or in-hospital mortality, analyzed by intent-to-treat and by presentation with ST-segment elevation. Results There was no significant difference in the rate of progression to MI among patients who received GIK (n=200; 48.7%) vs those who received placebo (n=242; 52.6%) (odds ratio [OR], 0.88; 95% CI, 0.66-1.13; P=.28). Thirty-day mortality was 4.4% with GIK vs 6.1% with placebo (hazard ratio [HR], 0.72; 95% CI, 0.40-1.29; P=.27). The composite of cardiac arrest or in-hospital mortality occurred in 4.4% with GIK vs 8.7% with placebo (OR, 0.48; 95% CI, 0.27-0.85; P=.01). Among patients with ST-segment elevation (163 with GIK and 194 with placebo), progression to MI was 85.3% with GIK vs 88.7% with placebo (OR, 0.74; 95% CI, 0.40-1.38; P=.34); 30-day mortality was 4.9% with GIK vs 7.7% with placebo (HR, 0.63; 95% CI, 0.27-1.49; P=.29). The composite outcome of cardiac arrest or in-hospital mortality was 6.1% with GIK vs 14.4% with placebo (OR, 0.39; 95% CI, 0.18-0.82; P=.01). Serious adverse events occurred in 6.8% (n=28) with GIK vs 8.9% (n=41) with placebo (P=.26). Conclusions Among patients with suspected ACS, out-of-hospital administration of intravenous GIK, compared with glucose placebo, did not reduce progression to MI. Compared with placebo, GIK administration was not associated with improvement in 30-day survival but was associated with lower rates of the composite outcome of cardiac arrest or in-hospital mortality.	[Selker, Harry P.; Beshansky, Joni R.; Sheehan, Patricia R.; Griffith, John L.; Ruthazer, Robin] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Cardiovasc Hlth Serv Res, Boston, MA 02111 USA; [Udelson, James E.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Massaro, Joseph M.] Boston Univ, Dept Biostat, Boston, MA 02215 USA; [D'Agostino, Ralph B.] Boston Univ, Dept Math, Boston, MA 02215 USA; [Atkins, James M.] Univ Texas SW Med Sch, Dept Med, Dallas, TX USA; [Sayah, Assaad J.] Cambridge Hlth Alliance, Dept Emergency Med, Cambridge, MA USA; [Levy, Michael K.] Alaska Reg Hosp, Anchorage, AK USA; [Richards, Michael E.; Braude, Darren A.] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Braude, Darren A.] Univ New Mexico, Sch Med, Dept Anesthesia, Albuquerque, NM 87131 USA; [Aufderheide, Tom P.; Pirrallo, Ronald G.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Doyle, Delanor D.] Med Ctr Cent Georgia, Dept Emergency Med, Macon, GA USA; [Frascone, Ralph J.] Reg Hosp EMS, St Paul, MN USA; [Kosiak, Donald J.] Avera Med Grp, Sioux Falls, SD USA; [Leaming, James M.] Penn State Hershey Med Ctr, Dept Emergency Med, Hershey, PA USA; [Van Gelder, Carin M.] Johnson Mem Hosp, Dept Emergency Med, Stafford, CT USA; [Van Gelder, Carin M.] Windham Community Mem Hosp, Willimantic, CT USA; [Walter, Gert-Paul] Emerson Hosp, Dept Emergency Med, Concord, MA USA; [Wayne, Marvin A.] St Joseph Med Ctr, Dept Emergency Med, Bellingham, WA USA; [Woolard, Robert H.] Texas Tech Univ Hlth Sci Ctr, Dept Emergency Med, El Paso, TX USA; [Opie, Lionel H.] Univ Cape Town, Dept Med, Hatter Cardiovasc Res Inst Africa, ZA-7925 Cape Town, South Africa; [Rackley, Charles E.] Georgetown Med Ctr, Lipid Disorders Ctr, Washington, DC USA; [Udelson, James E.] Tufts Med Ctr, Div Cardiol, Ctr Cardiovasc, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Boston University; Boston University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Cambridge Health Alliance; University of New Mexico; University of New Mexico; Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Texas Tech University System; Texas Tech University Health Science Center; University of Cape Town; Georgetown University; Tufts Medical Center	Selker, HP (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Cardiovasc Hlth Serv Res, 800 Washington St,63, Boston, MA 02111 USA.	hselker@tuftsmedicalcenter.org		Massaro, Joseph/0000-0002-2682-4812; Pirrallo, Ronald/0000-0002-8321-3866	NIH, NHLBI; IMMEDIATE Trial scientific advisory committee; NIH from the National Heart, Lung, and Blood Institute [U01HL077821, U01HL077826, U01HL077823]; National Center for Advancing Translational Sciences [UL1RR025752]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077823, U01HL077826, U01HL077821] Funding Source: NIH RePORTER	NIH, NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); IMMEDIATE Trial scientific advisory committee; NIH from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Selker, principal investigator, reported institutional receipt of grant funds and indirect payment for his work and travel expenses; the institution's grant paid for honoraria to members of the scientific advisory committee, DSMB, and Harvard Clinical Research Institute for event adjudication and statistical analysis, Curlin Inc for intravenous pumps, and Philips Healthcare for ECG decision support software. Dr Selker also reported an expired patent for the TPI ECG software, but no royalties are received. Ms Beshansky, co-principal investigator, reported institutional and indirect receipt of grant support and support for travel expenses. Dr Massaro reported grant support provided to his institution and direct receipt of funds, in addition to support for travel. Drs D'Agostino and Atkins reported institutional grant support and support for travel expenses. Drs Braude, Doyle, Frascone, Griffith, Leaming, Richards, Udelson, and Woolard, Ms Ruthazer, and Ms Sheehan reported grant support (NIH, NHLBI) provided to their institution. Dr Kosiak reported institutional and direct receipt of funds in support for travel expenses and fees for data review and training. Dr Rackley reported direct receipt of funds for fees for participating on the IMMEDIATE Trial scientific advisory committee. Dr Opie reported consulting fees, support for travel, and fees for scientific advisory committee participation; direct payment for employment (salary) and grants pending (Medical Research Council); and institutional payment for travel (European Society of Cardiology Task Force) outside of the submitted work. Dr Pirrallo reported institutional grant support and support for travel expenses; and relevant but outside of the submitted work he reported direct payment for board membership in National Association of EMS Physicians. Dr Sayah reported institutional receipt of grant support and fees for participating in review activities. Dr Van Gelder reported institutional and direct receipt of grant funds and institutional receipt of funds for provision of equipment and administrative support. Dr Aufderheide reported institutional grant support, support for travel expenses, and provision for software and equipment; also reported as relevant but outside of the submitted work: board membership (volunteer at Citizen CPR Foundation and Take Heart America), consultant (funds to institution, Medtronic Inc), 5 pending emergency research grants (funds to institution, NHLBI, NINDS, Leducq Foundation, Medtronic Foundation); and volunteer member (BLS Subcommittee and Research Working Group, AHA). Dr Wayne reported grant support provided to his institution and direct receipt of funds; also reported, as relevant but outside of the submitted work: direct payment for employment as emergency medicine physician, EMS director, expert testimony, royalties (chest tube by Cook Critical Care), payment for development of educational presentations, and travel expenses for a nonprofit foundation administration. Dr Walter reported institutional receipt of funds for equipment, administrative support, paramedic training, and investigator effort; also reported, relevant but outside the submitted work: receipt of funds for employment as the medical director for the paramedic service at Emerson Hospital. Drs Levy and Apstein reported no conflicts of interest.; This work was funded by an NIH cooperative agreement from the National Heart, Lung, and Blood Institute (grants U01HL077821, U01HL077826, U01HL077823). National Center for Research Resources (grant UL1RR025752), now at the National Center for Advancing Translational Sciences, provided laboratory testing. Insulin was donated by Eli Lilly and Company. ECG-based decision support software was donated by Physio-Control and Zoll Medical.	Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; Apstein CS, 2005, JAMA-J AM MED ASSOC, V293, P2596, DOI 10.1001/jama.293.21.2596; Apstein CS, 1999, CARDIOVASC DRUG THER, V13, P185, DOI 10.1023/A:1007757407246; Beshansky JR, 2010, CLIN TRIALS, V7, P428; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; KURIEN VA, 1969, LANCET, V2, P185; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; Oliver MF, 2002, EUR HEART J, V23, P1797, DOI 10.1053/euhj.2002.3373; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE LH, 1975, CIRCULATION, V52, P49, DOI 10.1161/01.CIR.52.1.49; RACKLEY CE, 1981, AM HEART J, V102, P1038, DOI 10.1016/0002-8703(81)90488-9; Selker HP, 2012, AM HEART J, V163, P315, DOI 10.1016/j.ahj.2012.02.002; Selker HP, 2011, PREHOSP EMERG CARE, V15, P139, DOI 10.3109/10903127.2010.545478; Selker HP, 2003, AM J CARDIOL, V91, P280, DOI 10.1016/S0002-9149(02)03155-7; Selker HP, 2002, ANN INTERN MED, V137, P87, DOI 10.7326/0003-4819-137-2-200207160-00006; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Timmer JR, 2006, J AM COLL CARDIOL, V47, P1730, DOI 10.1016/j.jacc.2006.01.040; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1	21	164	173	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 9	2012	307	18					1925	1933		10.1001/jama.2012.426	http://dx.doi.org/10.1001/jama.2012.426			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938OD	22452807	Bronze, Green Accepted			2022-12-28	WOS:000303741900026
J	Huang, W; Perez-Garcia, P; Pokhilko, A; Millar, AJ; Antoshechkin, I; Riechmann, JL; Mas, P				Huang, W.; Perez-Garcia, P.; Pokhilko, A.; Millar, A. J.; Antoshechkin, I.; Riechmann, J. L.; Mas, P.			Mapping the Core of the Arabidopsis Circadian Clock Defines the Network Structure of the Oscillator	SCIENCE			English	Article							PSEUDO-RESPONSE REGULATORS; TOC1; RHYTHMS; TIME; EXPRESSION; THALIANA; GIGANTEA; GENE	In many organisms, the circadian clock is composed of functionally coupled morning and evening oscillators. In Arabidopsis, oscillator coupling relies on a core loop in which the evening oscillator component TIMING OF CAB EXPRESSION 1 (TOC1) was proposed to activate a subset of morning-expressed oscillator genes. Here, we show that TOC1 does not function as an activator but rather as a general repressor of oscillator gene expression. Repression occurs through TOC1 rhythmic association to the promoters of the oscillator genes. Hormone-dependent induction of TOC1 and analysis of RNA interference plants show that TOC1 prevents the activation of morning-expressed genes at night. Our study overturns the prevailing model of the Arabidopsis circadian clock, showing that the morning and evening oscillator loops are connected through the repressing activity of TOC1.	[Huang, W.; Perez-Garcia, P.; Riechmann, J. L.; Mas, P.] Ctr Res Agr Genom, Barcelona 08193, Spain; [Pokhilko, A.; Millar, A. J.] Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JH, Midlothian, Scotland; [Millar, A. J.] Ctr Syst Biol Edinburgh, Edinburgh EH9 3JD, Midlothian, Scotland; [Antoshechkin, I.; Riechmann, J. L.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Antoshechkin, I.; Riechmann, J. L.] Inst Catalana Rec & Estudis Avancats, Barcelona 08010, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Centre de Recerca en Agrigenomica (CRAG); University of Edinburgh; California Institute of Technology; ICREA	Mas, P (corresponding author), Ctr Res Agr Genom, Barcelona 08193, Spain.	paloma.mas@cragenomica.es	Mas, Paloma/B-8215-2016; Riechmann, José Luis/M-7005-2018; Perez-Garcia, Pablo/O-6860-2017; Millar, Andrew J/G-2423-2012	Mas, Paloma/0000-0002-3780-8041; Riechmann, José Luis/0000-0003-1108-1945; Perez-Garcia, Pablo/0000-0001-8595-8530; Millar, Andrew J/0000-0003-1756-3654	Ramon Areces Foundation; Spanish Ministry of Science and Innovation (MICINN); European Molecular Biology Organization (EMBO); European Heads of Research Councils; European Science Foundation; European Comission (EC); MICINN; Biotechnology and Biological Sciences Research Council; Engineering and Physical Sciences Research Council [D019621]; BBSRC [BB/D019621/1] Funding Source: UKRI; ICREA Funding Source: Custom; Biotechnology and Biological Sciences Research Council [BB/D019621/1] Funding Source: researchfish	Ramon Areces Foundation; Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); European Heads of Research Councils; European Science Foundation(European Science Foundation (ESF)European Commission); European Comission (EC); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); ICREA(ICREA); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank E. Meyerowitz for comments on the manuscript, E. Centeno for help with ChIP-Seq analysis, O. Casagran for help with the microfluidic arrays, M. Perales for help with the ChIP, L. Rico for help with the inducible constructs, and L. Schaeffer and D. Trout (Jacobs Genetics and Genomics Laboratory at Caltech) for the primary sequence data processing. This work was supported by grants to P. M. from the Ramon Areces Foundation, the Spanish Ministry of Science and Innovation (MICINN), the European Molecular Biology Organization (EMBO) Young Investigators Program, and from the European Heads of Research Councils and the European Science Foundation through the European Young Investigator Award; to J.L.R. from the European Comission (EC) Marie Curie program and MICINN; and to A.J.M. and others from the EC FP7 Collaborative Project TiMet. The Centre for Systems Biology at Edinburgh is a Centre for Integrative and Systems Biology supported by the Biotechnology and Biological Sciences Research Council and the Engineering and Physical Sciences Research Council award D019621. W. H. is supported by a Juan de la Cierva contract (MICINN) and P. P.-G. by a Formacion de Personal Investigador fellowship (MICINN). Sequencing data have been deposited with the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE35952.	Alabadi D, 2001, SCIENCE, V293, P880, DOI 10.1126/science.1061320; Baudry A, 2010, PLANT CELL, V22, P606, DOI 10.1105/tpc.109.072843; Covington MF, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-r130; Fowler S, 1999, EMBO J, V18, P4679, DOI 10.1093/emboj/18.17.4679; Hazen SP, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r17; Herrero E., 2012, PLANT CELL; Legnaioli T, 2009, EMBO J, V28, P3745, DOI 10.1038/emboj.2009.297; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; Locke JCW, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100018; Mas P, 2003, NATURE, V426, P567, DOI 10.1038/nature02163; Mas P, 2003, PLANT CELL, V15, P223, DOI 10.1105/tpc.006734; Mas P, 2008, TRENDS CELL BIOL, V18, P273, DOI 10.1016/j.tcb.2008.03.005; Matsushika A, 2000, PLANT CELL PHYSIOL, V41, P1002, DOI 10.1093/pcp/pcd043; McClung CR, 2010, CURR OPIN GENET DEV, V20, P588, DOI 10.1016/j.gde.2010.08.010; Michael TP, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040014; Nakamichi N, 2010, PLANT CELL, V22, P594, DOI 10.1105/tpc.109.072892; Nusinow DA, 2011, NATURE, V475, P398, DOI 10.1038/nature10182; Park DH, 1999, SCIENCE, V285, P1579, DOI 10.1126/science.285.5433.1579; Perales M, 2007, PLANT CELL, V19, P2111, DOI 10.1105/tpc.107.050807; Pokhilko A, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.69; Pruneda-Paz JL, 2009, SCIENCE, V323, P1481, DOI 10.1126/science.1167206; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Somers DE, 1998, DEVELOPMENT, V125, P485; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wijnen H, 2006, ANNU REV GENET, V40, P409, DOI 10.1146/annurev.genet.40.110405.090603; Zeilinger MN, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100101	27	343	358	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 6	2012	336	6077					75	79		10.1126/science.1219075	http://dx.doi.org/10.1126/science.1219075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920LG	22403178	Green Submitted			2022-12-28	WOS:000302405400054
J	Molyneux, DH				Molyneux, David H.			Tropical Lymphedemas - Control and Prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Liverpool, Liverpool Sch Trop Med, Ctr Neglected Trop Dis, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Molyneux, DH (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Ctr Neglected Trop Dis, Liverpool L3 5QA, Merseyside, England.							[Anonymous], 2011, Wkly Epidemiol Rec, V86, P377; [Anonymous], 2012, WKLY EPIDEMIOL REC, V87, P17; Davey G, 2007, LANCET, V369, P888, DOI 10.1016/S0140-6736(07)60425-5; Ottesen EA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000317	4	20	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1169	1171		10.1056/NEJMp1202011	http://dx.doi.org/10.1056/NEJMp1202011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455411	Green Accepted			2022-12-28	WOS:000302005100001
J	Munoz, J; Hanbali, A				Munoz, Javier; Hanbali, Amr			Blue Sclerae	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OSTEOGENESIS IMPERFECTA		[Munoz, Javier; Hanbali, Amr] Henry Ford Hosp, Dept Hematol Oncol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Munoz, J (corresponding author), Henry Ford Hosp, Dept Hematol Oncol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	javier.munoz@me.com						Adam MP, 2005, AM J MED GENET A, V137A, P117, DOI 10.1002/ajmg.a.30580; Drera B, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-24; Kivuva EC, 2008, CLIN DYSMORPHOL, V17, P99, DOI 10.1097/MCD.0b013e3282f4a964; Kosho T, 2010, AM J MED GENET A, V152A, P1333, DOI 10.1002/ajmg.a.33498; Michou L, 2011, JOINT BONE SPINE, V78, P252, DOI 10.1016/j.jbspin.2010.07.010; Regier D.S., GENEREVIEWS; Wilcox RA, 2007, MAYO CLIN PROC, V82, P265; Yancovitz Molly, 2010, Dermatol Online J, V16, P6	8	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1310	1311		10.1001/jama.2012.363	http://dx.doi.org/10.1001/jama.2012.363			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453572				2022-12-28	WOS:000301978400027
J	Nishtar, S				Nishtar, Sania			Pakistan's deadly cocktail of substandard drugs	LANCET			English	Editorial Material									Heartfile, Chak Shahzad, Islamabad, Pakistan		Nishtar, S (corresponding author), Heartfile, Chak Shahzad, Islamabad, Pakistan.	sania@heartfile.org						[Anonymous], 2016, NATL POLICY PROGRAM; McGinnis N., 2011, MEDIA REPORTS MED QU; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Nishtar S, 2010, CHOKED PIPES REFORMI; Nishtar S, 2011, LANCET, V378, P648, DOI 10.1016/S0140-6736(11)60606-5; Pak Tribune, 2006, PAK TRIBUNE     0515; Sengaloundeth S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-172; World Health Organization, 2012, DRUG SAF AL	8	14	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1084	1085		10.1016/S0140-6736(12)60277-3	http://dx.doi.org/10.1016/S0140-6736(12)60277-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22394558				2022-12-28	WOS:000302131800012
J	Milczarek, G; Inganas, O				Milczarek, Grzegorz; Inganas, Olle			Renewable Cathode Materials from Biopolymer/Conjugated Polymer Interpenetrating Networks	SCIENCE			English	Article							ELECTROCHEMICALLY ACTIVE POLYMERS; MODIFIED ELECTRODE; POLYPYRROLE; BATTERIES; LIGNOSULFONATE; OXIDATION; CHARGE	Renewable and cheap materials in electrodes could meet the need for low-cost, intermittent electrical energy storage in a renewable energy system if sufficient charge density is obtained. Brown liquor, the waste product from paper processing, contains lignin derivatives. Polymer cathodes can be prepared by electrochemical oxidation of pyrrole to polypyrrole in solutions of lignin derivatives. The quinone group in lignin is used for electron and proton storage and exchange during redox cycling, thus combining charge storage in lignin and polypyrrole in an interpenetrating polypyrrole/lignin composite.	[Inganas, Olle] Linkoping Univ, Dept Phys Chem & Biol, S-58183 Linkoping, Sweden; [Milczarek, Grzegorz] Poznan Tech Univ, Inst Chem & Tech Electrochem, PL-60965 Poznan, Poland	Linkoping University; Poznan University of Technology	Inganas, O (corresponding author), Linkoping Univ, Dept Phys Chem & Biol, S-58183 Linkoping, Sweden.	ois@ifm.liu.se	Milczarek, Grzegorz/N-2080-2014	Milczarek, Grzegorz/0000-0002-0984-7916; Inganas, Olle/0000-0002-6243-1450	Knut and Alice Wallenberg Foundation	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation)	This work was supported by the Knut and Alice Wallenberg Foundation, and O.I. is a Wallenberg Scholar. We thank R. Gabrielsson, N. Solin, A. Elfving, and V. Andersson for experimental support and discussion. The kind donation of lignosulfonate samples from Borregaard LignoTech AS is gratefully acknowledged. The authors have applied for a Swedish patent on the class of materials reported here.	Agarwal U.P., 2010, LIGNIN LIGNANS ADV C, P104, DOI 10.1201/EBK1574444865; Armand M, 2008, NATURE, V451, P652, DOI 10.1038/451652a; BJORKLUND RB, 1986, J CHEM SOC CHEM COMM, P1293, DOI 10.1039/c39860001293; Haringer D, 1999, J ELECTROCHEM SOC, V146, P2393, DOI 10.1149/1.1391947; Hashmi SA, 2004, J POWER SOURCES, V137, P145, DOI 10.1016/j.jpowsour.2004.05.007; Huang YH, 2008, CHEM MATER, V20, P7237, DOI 10.1021/cm8012304; INGANAS O, 1984, J PHYS CHEM SOLIDS, V45, P427, DOI 10.1016/0022-3697(84)90150-1; Meyer TJ, 2007, ANGEW CHEM INT EDIT, V46, P5284, DOI 10.1002/anie.200600917; Milczarek G, 2008, ELECTROANAL, V20, P211, DOI 10.1002/elan.200704071; Milczarek G, 2007, ELECTROANAL, V19, P1411, DOI 10.1002/elan.200703870; Milczarek G, 2009, LANGMUIR, V25, P10345, DOI 10.1021/la9008575; Naoi K, 2000, J ELECTROCHEM SOC, V147, P420, DOI 10.1149/1.1393212; NOVAK P, 1987, J ELECTROCHEM SOC, V134, P1341, DOI 10.1149/1.2100670; Novak P, 1997, CHEM REV, V97, P207, DOI 10.1021/cr941181o; Nyholm L, 2011, ADV MATER, V23, P3751, DOI 10.1002/adma.201004134; Nystrom G, 2009, NANO LETT, V9, P3635, DOI 10.1021/nl901852h; PEI Q, 1991, SYNTHETIC MET, V45, P35, DOI 10.1016/0379-6779(91)91845-2; Piro B, 1998, J CHIM PHYS PCB, V95, P1522, DOI 10.1051/jcp:1998320; Sasso C, 2008, BIORESOURCES, V3, P1187; Song HK, 2006, ADV MATER, V18, P1764, DOI 10.1002/adma.200600375; Yang C, 2009, IND ENG CHEM RES, V48, P9498, DOI 10.1021/ie900189j; YONEYAMA H, 1992, J ELECTROCHEM SOC, V139, P28, DOI 10.1149/1.2069187; ZINGER B, 1989, SYNTHETIC MET, V30, P209, DOI 10.1016/0379-6779(89)90791-1	23	394	405	29	685	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1468	1471		10.1126/science.1215159	http://dx.doi.org/10.1126/science.1215159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442478				2022-12-28	WOS:000301837000040
J	Ryan, D; Price, D; Musgrave, SD; Malhotra, S; Lee, AJ; Ayansina, D; Sheikh, A; Tarassenko, L; Pagliari, C; Pinnock, H				Ryan, Dermot; Price, David; Musgrave, Stan D.; Malhotra, Shweta; Lee, Amanda J.; Ayansina, Dolapo; Sheikh, Aziz; Tarassenko, Lionel; Pagliari, Claudia; Pinnock, Hilary			Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; PRIMARY-CARE; LONG-TERM; MANAGEMENT; QUALITY; QUESTIONNAIRE; TECHNOLOGY; VALIDATION; OUTCOMES; SYSTEM	Objective To determine whether mobile phone based monitoring improves asthma control compared with standard paper based monitoring strategies. Design Multicentre randomised controlled trial with cost effectiveness analysis. Setting UK primary care. Participants 288 adolescents and adults with poorly controlled asthma (asthma control questionnaire (ACQ) score >= 1.5) from 32 practices. Intervention Participants were centrally randomised to twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback prompting action according to an agreed plan or paper based monitoring. Main outcome measures Changes in scores on asthma control questionnaire and self efficacy (knowledge, attitude, and self efficacy asthma questionnaire (KASE-AQ)) at six months after randomisation. Assessment of outcomes was blinded. Analysis was on an intention to treat basis. Results There was no significant difference in the change in asthma control or self efficacy between the two groups (ACQ: mean change 0.75 in mobile group v 0.73 in paper group, mean difference in change -0.02 (95% confidence interval -0.23 to 0.19); KASE-AQ score: mean change -4.4 v -2.4, mean difference 2.0 (-0.3 to 4.2)). The numbers of patients who had acute exacerbations, steroid courses, and unscheduled consultations were similar in both groups, with similar healthcare costs. Overall, the mobile phone service was more expensive because of the expenses of telemonitoring. Conclusions Mobile technology does not improve asthma control or increase self efficacy compared with paper based monitoring when both groups received clinical care to guidelines standards. The mobile technology was not cost effective.	[Ryan, Dermot; Price, David; Musgrave, Stan D.; Malhotra, Shweta] Univ Aberdeen, Acad Ctr Primary Care, Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Lee, Amanda J.; Ayansina, Dolapo] Univ Aberdeen, Med Stat Team, Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Sheikh, Aziz; Pinnock, Hilary] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; [Tarassenko, Lionel] Univ Oxford, Inst Biomed Engn, Oxford OX3 7DQ, England; [Pagliari, Claudia] Univ Edinburgh, eHth Res Grp, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland	University of Aberdeen; University of Aberdeen; University of Edinburgh; University of Oxford; University of Edinburgh	Ryan, D (corresponding author), Woodbrook Med Ctr, 28 Bridge St, Loughborough LE11 1NH, Leics, England.	dermotryan@doctors.org.uk	Pagliari, Claudia C/P-6412-2018; Price, David/H-2837-2019; Ryan, Dermot/AAJ-2329-2021; Sheikh, Aziz/D-2818-2009; Ayansina, Dolapo/AAP-1663-2020	Pagliari, Claudia C/0000-0001-5791-7723; Price, David/0000-0002-9728-9992; Ryan, Dermot/0000-0002-4115-7376; Sheikh, Aziz/0000-0001-7022-3056; Ayansina, Dolapo/0000-0001-7684-8620	Asthma UK [07/047]; chief scientist's office of the Scottish Government; UK National Health Service; Aerocrine; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; Mundipharma; Novartis; Nycomed; Pfizer; Teva; Merck and Co; AKL Technologies; Chiesi; Mundipharma AS; Napp; NIHR Biomedical Research Centre; Chief Scientist Office [PCRCA/08/01] Funding Source: researchfish	Asthma UK; chief scientist's office of the Scottish Government; UK National Health Service; Aerocrine; AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Mundipharma; Novartis(Novartis); Nycomed; Pfizer(Pfizer); Teva(Teva Pharmaceutical Industries); Merck and Co(Merck & Company); AKL Technologies; Chiesi(Chiesi Pharmaceuticals Inc); Mundipharma AS; Napp; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Chief Scientist Office	This study was funded by Asthma UK (project ID 07/047). Piko peak flow meters were donated by nSpire Health. HP is supported by a primary care research career award from the chief scientist's office of the Scottish Government.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: DR has spoken on behalf of AstraZeneca, Nycomed, MSD, AlkAbello, Chiesi, Novartis, Pfizer and BoehringerIingelheim. He has undertaken advisory work for Astra Zeneca, MSD, Novartis, Uriach, Mundipharma, Orion, and Napp. DP has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, and Teva. In the past five years, he or his research team have received grants and support for research in respiratory disease from UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer, and Teva. He has spoken for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Pfizer, and Teva. He has shares in AKL, which produces phytopharmaceuticals. He is the sole owner of Research in Real Life. SDM has received institutional grant support from Merck and Co, AKL Technologies, Chiesi, and Mundipharma AS serves on WHO's mHealth and Information Technology for Patient Safety Expert Working Groups and is an adviser to NHS Connecting for Health's Evaluation Programme. He is a consultant to ALK and Phadia and has received support from Napp, Pfizer, and Chiesi for research advice. LT is a cofounder of, advisor to, and holds shares in OBS Medical. He contributed to the design of t+ asthma and of the trial, but had no role in the day-to-day conduct of the study or statistical analysis. His work on telehealthcare is funded by the NIHR Biomedical Research Centre Programme. HP has spoken for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer, and Teva and undertaken advisory group work for Chiesi.	British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387; British Medical Association and Royal Pharmaceutical Society, 2008, BRIT NAT FORM SEPT 2; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Catwell L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000126; Clatworthy Jane, 2009, Prim Care Respir J, V18, P300, DOI 10.4104/pcrj.2009.00037; Cleland J, 2007, J TELEMED TELECARE, V13, P85, DOI 10.1258/135763307780096230; Cobern W, ASTHMA SELF MANAGEME; Craig P., 2008, DEV EVALUATING COMPL; Curtis L., UNIT COSTS HLTH SOCI; Department of Health, NAT SCHED REF COSTS; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; GINA, 2010, GLOB STRAT ASTHM MAN; Glasziou P, 2005, BMJ-BRIT MED J, V330, P644, DOI 10.1136/bmj.330.7492.644; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; International Telecommunication Union, 2010, KEY GLOB TEL IND WOR; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 2001, AM J RESP CRIT CARE, V163, P642; Lemaigre V, 2005, CHEST, V128, P3133, DOI 10.1378/chest.128.5.3133; Liu WT, 2011, EUR RESPIR J, V37, P310, DOI 10.1183/09031936.00000810; Masoli M, 2003, GLOBAL BURDEN ASTHMA; McIvor RA, 2008, LANCET, V372, P1021, DOI 10.1016/S0140-6736(08)61423-3; McLean S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007717.pub2; McLean S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d120; Ostojic V, 2005, TELEMED J E-HEALTH, V11, P28, DOI 10.1089/tmj.2005.11.28; Pinnock H, 2007, CLIN EXP ALLERGY, V37, P794, DOI 10.1111/j.1365-2222.2007.02708.x; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010; Pinnock H, 2010, PRIM CARE RESP J, V19, P75, DOI 10.4104/pcrj.2010.00006; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Ryan D, 2005, J TELEMED TELECARE, V11, P43, DOI 10.1258/1357633054461714; Ryan Dermot, 2009, Prim Care Respir J, V18, P343, DOI 10.4104/pcrj.2009.00064; van der Meer V, 2007, CHEST, V132, P112, DOI 10.1378/chest.06-2787; van der Meer V, 2009, ANN INTERN MED, V151, P110, DOI 10.7326/0003-4819-151-2-200907210-00008; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144; Yoos HL, 2002, ANN ALLERG ASTHMA IM, V88, P283, DOI 10.1016/S1081-1206(10)62010-8	46	128	131	2	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2012	344								e1756	10.1136/bmj.e1756	http://dx.doi.org/10.1136/bmj.e1756			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CQ	22446569	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000301849400002
J	Scholl, JA; Koh, AL; Dionne, JA				Scholl, Jonathan A.; Koh, Ai Leen; Dionne, Jennifer A.			Quantum plasmon resonances of individual metallic nanoparticles	NATURE			English	Article							DIELECTRIC FUNCTIONS; OPTICAL-ABSORPTION; GOLD; EXCITATIONS; GENERATION; RESOLUTION; SPECTRA; CLUSTER	The plasmon resonances of metallic nanoparticles have received considerable attention for their applications in nanophotonics, biology, sensing, spectroscopy and solar energy harvesting. Although thoroughly characterized for spheres larger than ten nanometres in diameter, the plasmonic properties of particles in the quantum size regime have been historically difficult to describe owing to weak optical scattering, metal-ligand interactions, and inhomogeneity in ensemble measurements. Such difficulties have precluded probing and controlling the plasmonic properties of quantum-sized particles in many natural and engineered processes, notably catalysis. Here we investigate the plasmon resonances of individual ligand-free silver nanoparticles using aberration-corrected transmission electron microscope (TEM) imaging and monochromated scanning TEM electron energy-loss spectroscopy (EELS). This technique allows direct correlation between a particle's geometry and its plasmon resonance. As the nanoparticle diameter decreases from 20 nanometres to less than two nanometres, the plasmon resonance shifts to higher energy by 0.5 electronvolts, a substantial deviation from classical predictions. We present an analytical quantum mechanical model that describes this shift due to a change in particle permittivity. Our results highlight the quantum plasmonic properties of small metallic nanospheres, with direct application to understanding and exploiting catalytically active and biologically relevant nanoparticles.	[Scholl, Jonathan A.; Dionne, Jennifer A.] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA; [Koh, Ai Leen] Stanford Univ, Stanford Nanocharacterizat Lab, Stanford, CA 94305 USA	Stanford University; Stanford University	Dionne, JA (corresponding author), Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA.	jscholl@stanford.edu; jdionne@stanford.edu		Dionne, Jennifer/0000-0001-5287-4357	National Science Foundation; Stanford Terman Fellowship; Robert N. Noyce Family Faculty Fellowship	National Science Foundation(National Science Foundation (NSF)); Stanford Terman Fellowship; Robert N. Noyce Family Faculty Fellowship	We thank S. Sheikholeslami, A. Atre, A. Garcia-Etxarri and A. Baldi for discussions. This research was supported by the National Science Foundation Graduate Research Fellowship Program. J.A.D. acknowledges support from a Stanford Terman Fellowship and a Robert N. Noyce Family Faculty Fellowship.	Akimov AV, 2007, NATURE, V450, P402, DOI 10.1038/nature06230; Alvarez MM, 1997, J PHYS CHEM B, V101, P3706, DOI 10.1021/jp962922n; Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162; Bakr OM, 2009, ANGEW CHEM INT EDIT, V48, P5921, DOI 10.1002/anie.200900298; Berciaud S, 2005, NANO LETT, V5, P515, DOI 10.1021/nl050062t; Bingham JM, 2010, J AM CHEM SOC, V132, P17358, DOI 10.1021/ja1074272; Bohren C., 2008, ABSORPTION SCATTERIN; Catchpole KR, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3021072; Cognet L, 2003, P NATL ACAD SCI USA, V100, P11350, DOI 10.1073/pnas.1534635100; David C, 2011, J PHYS CHEM C, V115, P19470, DOI 10.1021/jp204261u; Egerton RF, 2009, REP PROG PHYS, V72, DOI 10.1088/0034-4885/72/1/016502; FERRELL TL, 1985, PHYS REV LETT, V55, P1526, DOI 10.1103/PhysRevLett.55.1526; de Abajo FJG, 2010, REV MOD PHYS, V82, P209, DOI 10.1103/RevModPhys.82.209; de Abajo FJG, 2008, J PHYS CHEM C, V112, P17983, DOI 10.1021/jp807345h; GENZEL L, 1975, Z PHYS B CON MAT, V21, P339, DOI 10.1007/BF01325393; Gloter A, 2003, ULTRAMICROSCOPY, V96, P385, DOI 10.1016/S0304-3991(03)00103-7; He Y, 2010, J PHYS CHEM C, V114, P18023, DOI 10.1021/jp101598j; Hirakawa T, 2005, J AM CHEM SOC, V127, P3928, DOI 10.1021/ja042925a; HOVEL H, 1993, PHYS REV B, V48, P18178, DOI 10.1103/PhysRevB.48.18178; Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h; Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804; JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6; JOHNSON PB, 1972, PHYS REV B, V6, P4370, DOI 10.1103/PhysRevB.6.4370; Juluri BK, 2008, J PHYS CHEM C, V112, P7309, DOI 10.1021/jp077346h; Koh AL, 2009, ACS NANO, V3, P3015, DOI 10.1021/nn900922z; KRAUS WA, 1983, J CHEM PHYS, V79, P6130, DOI 10.1063/1.445794; KREIBIG U, 1969, Z PHYS, V224, P307, DOI 10.1007/BF01393059; KREIBIG U, 1985, SURF SCI, V156, P678, DOI 10.1016/0039-6028(85)90239-0; Kreibig U., 1995, OPTICAL PROPERTIES M, P1, DOI [10.1007/978-3-662-09109-8_1, DOI 10.1007/978-3-662-09109-8_1]; Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g; Larsson EM, 2009, SCIENCE, V326, P1091, DOI 10.1126/science.1176593; Lindfors K, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.037401; Link S, 1999, J PHYS CHEM B, V103, P8410, DOI 10.1021/jp9917648; Liu N, 2011, NAT MATER, V10, P631, DOI [10.1038/NMAT3029, 10.1038/nmat3029]; Luther JM, 2011, NAT MATER, V10, P361, DOI [10.1038/nmat3004, 10.1038/NMAT3004]; McMahon JM, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.097403; Mie G, 1908, ANN PHYS-BERLIN, V25, P377, DOI 10.1002/andp.19083300302; Nelayah J, 2007, NAT PHYS, V3, P348, DOI 10.1038/nphys575; Novo C, 2008, NAT NANOTECHNOL, V3, P598, DOI 10.1038/nnano.2008.246; OUYANG F, 1992, PHYS REV B, V46, P15421, DOI 10.1103/PhysRevB.46.15421; Palik E, 1998, HDB OPTICAL CONSTANT, V2; Peng S, 2010, P NATL ACAD SCI USA, V107, P14530, DOI 10.1073/pnas.1007524107; RITCHIE RH, 1957, PHYS REV, V106, P874, DOI 10.1103/PhysRev.106.874; Solomon SD, 2007, J CHEM EDUC, V84, P322; Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a; Stiles PL, 2008, ANNU REV ANAL CHEM, V1, P601, DOI 10.1146/annurev.anchem.1.031207.112814; Templeton AC, 2000, J PHYS CHEM B, V104, P564, DOI 10.1021/jp991889c; Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607; Zhu M, 2008, J AM CHEM SOC, V130, P5883, DOI 10.1021/ja801173r	50	863	877	28	1077	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					421	U68		10.1038/nature10904	http://dx.doi.org/10.1038/nature10904			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437611				2022-12-28	WOS:000301771200034
J	Schwartz, LM; Woloshin, S				Schwartz, Lisa M.; Woloshin, Steven			NOT SO STORIES How the FDA forgot the evidence: the case of donepezil 23 mg	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Schwartz, Lisa M.; Woloshin, Steven] Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; [Schwartz, Lisa M.; Woloshin, Steven] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med & Media, Lebanon, NH USA	VA Outcomes Group; Dartmouth College	Schwartz, LM (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA.	Steven.Woloshin@dartmouth.edu						Eisai, 2011, 3Q FY2010 FISC YEAR; Farlow MR, 2010, CLIN THER, V32, P1234, DOI 10.1016/j.clinthera.2010.06.019; FDA Center for Drug Evaluation and Research, AR LAB; FDA Center for Drug Evauation and Research, APPL 022568 STAT REV; FDA Center for Drug Evauation and Research, APPL 022568 SUMM REV; FDA Center for Drug Evauation and Research, 2010, APPL 022568 MED REV; Memorandum of meeting minutes, 2007, M MIN MARCH 19 SUSTT; Schwartz LM, 2009, NEW ENGL J MED, V361, P1717, DOI 10.1056/NEJMp0907708	8	19	19	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2012	344								e1086	10.1136/bmj.e1086	http://dx.doi.org/10.1136/bmj.e1086			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CP	22442352				2022-12-28	WOS:000301849300001
J	Sumino, Y; Nagai, KH; Shitaka, Y; Tanaka, D; Yoshikawa, K; Chate, H; Oiwa, K				Sumino, Yutaka; Nagai, Ken H.; Shitaka, Yuji; Tanaka, Dan; Yoshikawa, Kenichi; Chate, Hugues; Oiwa, Kazuhiro			Large-scale vortex lattice emerging from collectively moving microtubules	NATURE			English	Article							CORTICAL MICROTUBULES; SELF-ORGANIZATION; TRANSLOCATION; MOTORS; ARRAY	Spontaneous collective motion, as in some flocks of bird and schools of fish, is an example of an emergent phenomenon. Such phenomena are at present of great interest(1-5) and physicists have put forward a number of theoretical results that so far lack experimental verification(6-8). In animal behaviour studies, large-scale data collection is now technologically possible, but data are still scarce and arise from observations rather than controlled experiments. Multicellular biological systems, such as bacterial colonies or tissues(9,10), allow more control, but may have many hidden variables and interactions, hindering proper tests of theoretical ideas. However, in systems on the subcellular scale such tests may be possible, particularly in in vitro experiments with only few purified components(11-13). Motility assays, in which protein filaments are driven by molecular motors grafted to a substrate in the presence of ATP, can show collective motion for high densities of motors and attached filaments. This was demonstrated recently for the actomyosin system(14,15), but a complete understanding of the mechanisms at work is still lacking. Here we report experiments in which microtubules are propelled by surface-bound dyneins. In this system it is possible to study the local interaction: we find that colliding microtubules align with each other with high probability. At high densities, this alignment results in self-organization of the microtubules, which are on average 15 mu m long, into vortices with diameters of around 400 mu m. Inside the vortices, the microtubules circulate both clockwise and anticlockwise. On longer timescales, the vortices form a lattice structure. The emergence of these structures, as verified by a mathematical model, is the result of the smooth, reptation-like motion of single microtubules in combination with local interactions (the nematic alignment due to collisions)-there is no need for long-range interactions. Apart from its potential relevance to cortical arrays in plant cells(16,17) and other biological situations, our study provides evidence for the existence of previously unsuspected universality classes of collective motion phenomena.	[Shitaka, Yuji; Oiwa, Kazuhiro] Natl Inst Informat & Communicat Technol, Adv ICT Res Inst, Kobe, Hyogo 6512492, Japan; [Nagai, Ken H.] Univ Tokyo, Grad Sch Sci, Dept Phys, Tokyo 1130033, Japan; [Tanaka, Dan] Nagoya Univ, Grad Sch Informat Sci, Dept Complex Syst Sci, Nagoya, Aichi 4648601, Japan; [Yoshikawa, Kenichi] Kyoto Univ, Grad Sch Sci, Dept Phys, Kyoto 6068502, Japan; [Yoshikawa, Kenichi] JST, ICORP, Kyoto 6068502, Japan; [Chate, Hugues] CEA Saclay, Serv Phys Etat Condense, F-91191 Gif Sur Yvette, France; [Oiwa, Kazuhiro] Univ Hyogo, Grad Sch Life Sci, Harima, Hyogo 6781297, Japan	National Institute of Information & Communications Technology (NICT) - Japan; University of Tokyo; Nagoya University; Kyoto University; Japan Science & Technology Agency (JST); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Hyogo	Oiwa, K (corresponding author), Natl Inst Informat & Communicat Technol, Adv ICT Res Inst, Kobe, Hyogo 6512492, Japan.	oiwa@nict.go.jp	Chaté, Hugues/D-2156-2015; Sumino, Yutaka/W-2657-2017; Yoshikawa, Kenichi/N-1867-2019; Oiwa, Kazuhiro/D-7721-2011	Chaté, Hugues/0000-0002-6098-4094; Sumino, Yutaka/0000-0002-0724-7650; Yoshikawa, Kenichi/0000-0002-2751-7136; Oiwa, Kazuhiro/0000-0002-1281-113X; Nagai, Ken/0000-0002-8286-3111	JSPS [23-1819];  [23840019];  [21340023];  [20244067]; Grants-in-Aid for Scientific Research [21340023] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ; ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H. Sakakibara, Y. Uchida and R. Nakamori for the preparation of the material and observations. They as well as H. Kitahata are also thanked for discussions. Y. Sumino is supported by a Grant-in-Aid for Research Activity Start-up (no. 23840019), Grant-in-Aid for Scientific Research (B) (no. 21340023) and Grant-in-Aid for Scientific Research (A) (no. 20244067). K.H.N. would like to acknowledge the support of a fellowship from the JSPS (no. 23-1819).	Allard JF, 2010, BIOPHYS J, V99, P1082, DOI 10.1016/j.bpj.2010.05.037; Ballerini M, 2008, P NATL ACAD SCI USA, V105, P1232, DOI 10.1073/pnas.0711437105; Buhl J, 2006, SCIENCE, V312, P1402, DOI 10.1126/science.1125142; Butt T, 2010, J BIOL CHEM, V285, P4964, DOI 10.1074/jbc.M109.044792; Dixit R, 2004, PLANT CELL, V16, P3274, DOI 10.1105/tpc.104.026930; Ginelli F, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.184502; Hess H, 2005, NANO LETT, V5, P629, DOI 10.1021/nl0478427; KAGAMI O, 1992, J CELL SCI, V103, P653; Katz Y, 2011, P NATL ACAD SCI USA, V108, P18720, DOI 10.1073/pnas.1107583108; Kikushima K, 2008, BIOPHYS J, V94, P4014, DOI 10.1529/biophysj.107.123083; Kudrolli A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.058001; Loose M, 2008, SCIENCE, V320, P789, DOI 10.1126/science.1154413; Lukeman R, 2010, P NATL ACAD SCI USA, V107, P12576, DOI 10.1073/pnas.1001763107; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Peruani F, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.030904; Poujade M, 2007, P NATL ACAD SCI USA, V104, P15988, DOI 10.1073/pnas.0705062104; Ramaswamy S, 2010, ANNU REV CONDEN MA P, V1, P323, DOI 10.1146/annurev-conmatphys-070909-104101; Riedel IH, 2005, SCIENCE, V309, P300, DOI 10.1126/science.1110329; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; Schaller V, 2011, P NATL ACAD SCI USA, V108, P19183, DOI 10.1073/pnas.1107540108; Schaller V, 2010, NATURE, V467, P73, DOI 10.1038/nature09312; Sumpter D. J., 2010, COLLECTIVE ANIMAL BE, DOI [10.1515/9781400837106, DOI 10.1515/9781400837106]; Surrey T, 2001, SCIENCE, V292, P1167, DOI 10.1126/science.1059758; Tindemans SH, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.058103; Toner J, 2005, ANN PHYS-NEW YORK, V318, P170, DOI 10.1016/j.aop.2005.04.011; VICSEK T, 1995, PHYS REV LETT, V75, P1226, DOI 10.1103/PhysRevLett.75.1226; Wasteneys GO, 2009, TRENDS CELL BIOL, V19, P62, DOI 10.1016/j.tcb.2008.11.004; YUAN M, 1994, P NATL ACAD SCI USA, V91, P6050, DOI 10.1073/pnas.91.13.6050; Zhang HP, 2010, P NATL ACAD SCI USA, V107, P13626, DOI 10.1073/pnas.1001651107	29	431	433	2	145	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					448	452		10.1038/nature10874	http://dx.doi.org/10.1038/nature10874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437613	Green Published			2022-12-28	WOS:000301771200039
J	Ashcroft, FM; Rorsman, P				Ashcroft, Frances M.; Rorsman, Patrik			Diabetes Mellitus and the beta Cell: The Last Ten Years	CELL			English	Review							K-ATP CHANNEL; GLUCAGON-LIKE PEPTIDE-1; GASTRIC BYPASS-SURGERY; SUBUNITS KIR6.2 KCNJ11; GLUCOSE-HOMEOSTASIS; INSULIN-SECRETION; ACTIVATING MUTATIONS; BARIATRIC SURGERY; PANCREATIC-ISLETS; CA2+ CHANNELS	Diabetes is a major global problem. During the past decade, the genetic basis of various monogenic forms of the disease, and their underlying molecular mechanisms, have been elucidated. Many genes that increase type 2 diabetes (T2DM) risk have also been identified, but how they do so remains enigmatic. Nevertheless, defective insulin secretion emerges as the main culprit in both monogenic and polygenic diabetes, with environmental and lifestyle factors, via obesity, accounting for the current dramatic increase in T2DM. There also have been significant advances in therapy, particularly for some monogenic disorders. We review here what ails the beta cell and how its function may be restored.	[Ashcroft, Frances M.] Univ Oxford, Henry Wellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Ashcroft, Frances M.; Rorsman, Patrik] Univ Oxford, OXION Ctr Ion Channel Studies, Oxford OX1 3PT, England; [Rorsman, Patrik] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England; [Rorsman, Patrik] Churchill Hosp, Oxford NIHR Biomed Ctr, Oxford OX3 7LJ, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Ashcroft, FM (corresponding author), Univ Oxford, Henry Wellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Sherrington Bldg,Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@dpag.ox.ac.uk	Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767	Wellcome Trust; MRC; Royal Society; Diabetes UK; Medical Research Council [G0801995] Funding Source: researchfish; Wellcome Trust [095531/Z/11/Z] Funding Source: researchfish; MRC [G0801995] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Royal Society(Royal Society of London); Diabetes UK(Diabetes UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We apologize to colleagues whose work we may have overlooked or were unable to include due to space reasons. This is also, by necessity, a highly personal perspective. We thank Drs. Anne Clark and Fiona Gribble and our many other colleagues and students for stimulating discussion and reviewing the manuscript. We acknowledge the Wellcome Trust, the MRC, the Royal Society, and Diabetes UK for financial support.	Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bergman RN, 2005, HORM RES, V64, P8, DOI 10.1159/000089312; Bonnefond A, 2010, TRENDS MOL MED, V16, P407, DOI 10.1016/j.molmed.2010.06.004; Braun M, 2008, DIABETES, V57, P1618, DOI 10.2337/db07-0991; Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Clark A, 2004, DIABETOLOGIA, V47, P157, DOI 10.1007/s00125-003-1304-4; Clark RH, 2010, SCIENCE, V329, P458, DOI 10.1126/science.1186146; Cnop M, 2010, DIABETOLOGIA, V53, P321, DOI 10.1007/s00125-009-1562-x; Collins SC, 2010, DIABETES, V59, P1192, DOI 10.2337/db09-0791; Deacon CF, 2008, FRONT BIOSCI-LANDMRK, V13, P1780, DOI 10.2741/2799; Del Guerra S, 2005, DIABETES, V54, P727, DOI 10.2337/diabetes.54.3.727; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Ellard S, 2007, AM J HUM GENET, V81, P375, DOI 10.1086/519174; Falken Y, 2011, J CLIN ENDOCR METAB, V96, P2227, DOI 10.1210/jc.2010-2876; Flanagan SE, 2007, DIABETES, V56, P1930, DOI 10.2337/db07-0043; Flanagan SE, 2009, HUM MUTAT, V30, P170, DOI 10.1002/humu.20838; Garin I, 2010, P NATL ACAD SCI USA, V107, P3105, DOI 10.1073/pnas.0910533107; Girard CA, 2009, J CLIN INVEST, V119, P80, DOI 10.1172/JCI35772; Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Hattersley AT, 2005, DIABETES, V54, P2503, DOI 10.2337/diabetes.54.9.2503; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; Hoppa MB, 2009, CELL METAB, V10, P455, DOI 10.1016/j.cmet.2009.09.011; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; Iafusco D, 2011, DIABETOLOGIA, V54, P2736, DOI 10.1007/s00125-011-2273-7; Isbell JM, 2010, DIABETES CARE, V33, P1438, DOI 10.2337/dc09-2107; Karra E, 2010, TRENDS ENDOCRIN MET, V21, P337, DOI 10.1016/j.tem.2010.01.006; Kashyap S, 2003, DIABETES, V52, P2461, DOI 10.2337/diabetes.52.10.2461; Kebede MA, 2009, DIABETES OBES METAB, V11, P10, DOI 10.1111/j.1463-1326.2009.01114.x; Kirkpatrick CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011053; Kohler CU, 2011, AM J PHYSIOL-ENDOC M, V300, pE221, DOI 10.1152/ajpendo.00496.2010; Kulenovic I., 1996, EUR J PUBLIC HEALTH, V6, P252; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Leech CA, 2011, PROG BIOPHYS MOL BIO, V107, P236, DOI 10.1016/j.pbiomolbio.2011.07.005; Lemaire K, 2009, P NATL ACAD SCI USA, V106, P14872, DOI 10.1073/pnas.0906587106; Lim EL, 2011, DIABETOLOGIA, V54, P2506, DOI 10.1007/s00125-011-2204-7; Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JCI30706; Ma D, 2004, J CLIN INVEST, V114, P339, DOI 10.1172/jci200419876; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Mandrup-Poulsen T, 2010, NAT REV ENDOCRINOL, V6, P158, DOI 10.1038/nrendo.2009.271; Matschinsky FM, 2009, NAT REV DRUG DISCOV, V8, P399, DOI 10.1038/nrd2850; McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948; McTaggart JS, 2010, J PHYSIOL-LONDON, V588, P3201, DOI 10.1113/jphysiol.2010.191767; Menge BA, 2008, DIABETES, V57, P142, DOI 10.2337/db07-1294; Mlynarski WC, 2007, NAT CLIN PRACT NEURO, V3, P640, DOI 10.1038/ncpneuro0640; Murphy R, 2008, NAT CLIN PRACT ENDOC, V4, P200, DOI 10.1038/ncpendmet0778; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Osbak KK, 2009, HUM MUTAT, V30, P1512, DOI 10.1002/humu.21110; Parnaud G, 2008, DIABETOLOGIA, V51, P91, DOI 10.1007/s00125-007-0855-1; Pearson ER, 2003, LANCET, V362, P1275, DOI 10.1016/S0140-6736(03)14571-0; Pearson ER, 2006, NEW ENGL J MED, V355, P467, DOI 10.1056/NEJMoa061759; Pinnick KE, 2008, OBESITY, V16, P522, DOI 10.1038/oby.2007.110; Poitout V, 2008, ENDOCR REV, V29, P351, DOI 10.1210/er.2007-0023; Rahier J, 2008, DIABETES OBES METAB, V10, P32, DOI 10.1111/j.1463-1326.2008.00969.x; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rosengren AH, 2010, SCIENCE, V327, P217, DOI 10.1126/science.1176827; Rubio-Cabezas O., 2011, PEDIAT DIABETES; Sellick GS, 2004, NAT GENET, V36, P1301, DOI 10.1038/ng1475; Senee V, 2006, NAT GENET, V38, P682, DOI 10.1038/ng1802; Servitja JM, 2004, DIABETOLOGIA, V47, P597, DOI 10.1007/s00125-004-1368-9; Shu L, 2008, DIABETES, V57, P645, DOI 10.2337/db07-0847; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Slingerland AS, 2006, DIABETOLOGIA, V49, P2559, DOI 10.1007/s00125-006-0407-0; Smith SB, 2010, NATURE, V463, P775, DOI 10.1038/nature08748; Stefanovski D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018134; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoy J, 2010, REV ENDOCR METAB DIS, V11, P205, DOI 10.1007/s11154-010-9151-3; Takahashi N, 2010, CELL METAB, V12, P19, DOI 10.1016/j.cmet.2010.05.013; Temple IK, 2010, REV ENDOCR METAB DIS, V11, P199, DOI 10.1007/s11154-010-9150-4; Turkkahraman D, 2008, J PEDIATR-US, V153, P122, DOI 10.1016/j.jpeds.2007.12.037; Tushuizen ME, 2007, DIABETES CARE, V30, P2916, DOI 10.2337/dc07-0326; Walker JN, 2011, DIABETES OBES METAB, V13, P95, DOI 10.1111/j.1463-1326.2011.01450.x; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16; WESTLUND K, 1966, BRIT J PREV SOC MED, V20, P105; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Yasuda K, 2008, NAT GENET, V40, P1092, DOI 10.1038/ng.207; Yoo HW, 2002, EUR J PEDIATR, V161, P351, DOI 10.1007/s00431-002-0931-y; Zhang CL, 2009, SCIENCE, V325, P607, DOI 10.1126/science.1172256; Zung A, 2004, J CLIN ENDOCR METAB, V89, P5504, DOI 10.1210/jc.2004-1241	85	621	649	8	232	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1160	1171		10.1016/j.cell.2012.02.010	http://dx.doi.org/10.1016/j.cell.2012.02.010			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424227	Green Accepted, Bronze			2022-12-28	WOS:000301889500014
J	Hu, EA; Pan, A; Malik, V; Sun, Q				Hu, Emily A.; Pan, An; Malik, Vasanti; Sun, Qi			White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC INDEX; DIETARY FIBER; JAPANESE MEN; BROWN RICE; LOAD; PREVALENCE; MAGNESIUM; MELLITUS; OVERWEIGHT; DISEASE	Objectives To summarise evidence on the association between white rice consumption and risk of type 2 diabetes and to quantify the potential dose-response relation. Design Meta-analysis of prospective cohort studies. Data sources Searches of Medline and Embase databases for articles published up to January 2012 using keywords that included both rice intake and diabetes; further searches of references of included original studies. Study selection Included studies were prospective cohort studies that reported risk estimates for type 2 diabetes by rice intake levels. Data synthesis Relative risks were pooled using a random effects model; dose-response relations were evaluated using data from all rice intake categories in each study. Results Four articles were identified that included seven distinct prospective cohort analyses in Asian and Western populations for this study. A total of 13 284 incident cases of type 2 diabetes were ascertained among 352 384 participants with follow-up periods ranging from 4 to 22 years. Asian (Chinese and Japanese) populations had much higher white rice consumption levels than did Western populations (average intake levels were three to four servings/day versus one to two servings/week). The pooled relative risk was 1.55 (95% confidence interval 1.20 to 2.01) comparing the highest with the lowest category of white rice intake in Asian populations, whereas the corresponding relative risk was 1.12 (0.94 to 1.33) in Western populations (P for interaction=0.038). In the total population, the dose-response meta-analysis indicated that for each serving per day increment of white rice intake, the relative risk of type 2 diabetes was 1.11 (1.08 to 1.14) (P for linear trend<0.001). Conclusion Higher consumption of white rice is associated with a significantly increased risk of type 2 diabetes, especially in Asian (Chinese and Japanese) populations.	[Hu, Emily A.; Pan, An; Malik, Vasanti; Sun, Qi] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Sun, Qi] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Sun, Qi] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sun, Q (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA.	qisun@hsph.harvard.edu	Pan, An/C-5572-2011; Henry, Christiani Jeyakumar/AHB-2632-2022	Pan, An/0000-0002-1089-7945; Henry, Christiani Jeyakumar/0000-0002-1602-0140	US National Heart, Lung, and Blood Institute [K99HL098459]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL098459] Funding Source: NIH RePORTER	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	QS was supported by career development award K99HL098459 from the US National Heart, Lung, and Blood Institute. The funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors are not affiliated with the funding institutions.	Agardh E, 2011, INT J EPIDEMIOL, V40, P804, DOI 10.1093/ije/dyr029; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627; Batres-Marquez SP, 2009, J AM DIET ASSOC, V109, P1719, DOI 10.1016/j.jada.2009.07.010; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; Fuller DQ, 2010, ARCHAEOL ANTHROP SCI, V2, P115, DOI 10.1007/s12520-010-0035-y; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; Gu DF, 2005, LANCET, V365, P1398, DOI 10.1016/S0140-6736(05)66375-1; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Hayashino Y, 2010, ARCH ENVIRON OCCUP H, V65, P224, DOI 10.1080/19338244.2010.486423; Higham C, 1998, ANTIQUITY, V72, P867, DOI 10.1017/S0003598X00087500; Hodge AM, 2004, DIABETES CARE, V27, P2701, DOI 10.2337/diacare.27.11.2701; Jang Y, 2001, ARTERIOSCL THROM VAS, V21, P2065, DOI 10.1161/hq1201.100258; Larsen HN, 1996, EUR J CLIN NUTR, V50, P22; Larsen HN, 2000, EUR J CLIN NUTR, V54, P380, DOI 10.1038/sj.ejcn.1600969; Liu L, 2007, HOLOCENE, V17, P1059, DOI 10.1177/0959683607085121; Meyer KA, 2000, AM J CLIN NUTR, V71, P921; Miller G, 2002, WHOLE GRAIN FOODS HL; MILLER JB, 1992, AM J CLIN NUTR, V56, P1034, DOI 10.1093/ajcn/56.6.1034; Murakami K, 2006, AM J CLIN NUTR, V83, P1161, DOI 10.1093/ajcn/83.5.1161; Nanri A, 2008, DIABETES CARE, V31, P1568, DOI 10.2337/dc08-0297; Nanri A, 2010, AM J CLIN NUTR, V92, P1468, DOI 10.3945/ajcn.2010.29512; POPKIN BM, 1994, NUTR REV, V52, P285, DOI 10.1111/j.1753-4887.1994.tb01460.x; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Schulze MB, 2007, ARCH INTERN MED, V167, P956, DOI 10.1001/archinte.167.9.956; Schulze MB, 2004, AM J CLIN NUTR, V80, P348, DOI 10.1093/ajcn/80.2.348; Slavin JL, 1999, AM J CLIN NUTR, V70, p459S, DOI 10.1093/ajcn/70.3.459s; Song Y, 2006, DIABETIC MED, V23, P1050, DOI 10.1111/j.1464-5491.2006.01852.x; Sun Q, 2010, ARCH INTERN MED, V170, P961, DOI 10.1001/archinternmed.2010.109; US Centers for Disease Control and Prevention, 2012, INC DIAGN DIAB PER 1; US Department of Agriculture Economic Research Service, 2010, DAT SETS; van Dam RM, 2006, DIABETES CARE, V29, P2238, DOI 10.2337/dc06-1014; Villegas R, 2007, ARCH INTERN MED, V167, P2310, DOI 10.1001/archinte.167.21.2310; Weickert MO, 2006, DIABETES CARE, V29, P775, DOI 10.2337/diacare.29.04.06.dc05-2374; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Yu R, 2011, PUBLIC HEALTH NUTR, P1; Zhang G, 2011, J NUTR, V141, P1685, DOI 10.3945/jn.111.142224	39	367	379	8	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2012	344								e1454	10.1136/bmj.e1454	http://dx.doi.org/10.1136/bmj.e1454			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CD	22422870	Green Submitted, Green Published			2022-12-28	WOS:000301848100004
J	Lister, J				Lister, John			Will Liberal Democrats take the chance to kill the Health Bill?	LANCET			English	Editorial Material									Coventry Univ, Sch Art & Design, Coventry CV1 5FB, W Midlands, England	Coventry University	Lister, J (corresponding author), Coventry Univ, Sch Art & Design, Coventry CV1 5FB, W Midlands, England.	J.Lister@coventry.ac.uk						Broad M, 2011, HOSP DR         0914; Davie E, 2011, PULSE           0810; Ford Steve, 2009, Health Serv J, V119, P7; Institute of Healthcare Management, IHM MEMB UN OPP BILL; Lansley Andrew, 2012, Health Serv J, V122, P18; Lister J., 2008, NHS 60 PATIENTS PROF; Manning K, 2010, LIBERATING NHS NEXT; Pollock AM, 2012, LANCET, V379, P387, DOI 10.1016/S0140-6736(12)60119-6; Timmins N, 2007, FINANCIAL TIMES 0312; TIMMINS N, 1995, 5 GIANTS; West D, 2012, HLTH SERV J, V122, P7	11	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 10	2012	379	9819					869	870		10.1016/S0140-6736(12)60362-6	http://dx.doi.org/10.1016/S0140-6736(12)60362-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	906NY	22405783				2022-12-28	WOS:000301353700006
J	Ptaszek, LM; Mansour, M; Ruskin, JN; Chien, KR				Ptaszek, Leon M.; Mansour, Moussa; Ruskin, Jeremy N.; Chien, Kenneth R.			Towards regenerative therapy for cardiac disease	LANCET			English	Article							BONE-MARROW-CELLS; HEMATOPOIETIC STEM-CELLS; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; INTRACORONARY INJECTION; SMOOTH-MUSCLE; ADULT HEART; CARDIOMYOCYTES; DIFFERENTIATION; TRANSPLANTATION	Development of regenerative therapeutic strategies to reverse the progression of advanced heart failure is one of the most urgent clinical needs of this century. Insights gained from clinical trials of adult stem cells, together with fundamental scientific advances in cardiac stem cell and regenerative biology, are beginning to yield potential new targets and strategies for regenerative therapies. Of particular importance are new scientific discoveries related to intrinsic cardiac regeneration, renewal factors that can trigger regeneration, and tissue-engineering technology, which are beginning to change the way investigators view the scientific and clinical position of cardiovascular regenerative therapy.	[Ptaszek, Leon M.; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Ptaszek, Leon M.; Mansour, Moussa; Ruskin, Jeremy N.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Ctr Heart, Boston, MA 02114 USA; [Ptaszek, Leon M.; Mansour, Moussa; Ruskin, Jeremy N.] Harvard Univ, Sch Med, Boston, MA USA; [Ptaszek, Leon M.; Chien, Kenneth R.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University	Chien, KR (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St,CPZN 3250, Boston, MA 02114 USA.	kchien@harvard.edu			de Gunzburg Family Foundation; Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at the Massachusetts General Hospital (Boston, MA, USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100408] Funding Source: NIH RePORTER	de Gunzburg Family Foundation; Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at the Massachusetts General Hospital (Boston, MA, USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We apologise to those of our colleagues whose work could not be cited because of constraints on space. LMP thanks the de Gunzburg Family Foundation and the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at the Massachusetts General Hospital (Boston, MA, USA) for their support.	Andersen DC, 2009, STEM CELLS, V27, P1571, DOI 10.1002/stem.72; Assmus B, 2010, CIRC-HEART FAIL, V3, P89, DOI 10.1161/CIRCHEARTFAILURE.108.843243; Bai XW, 2010, EUR HEART J, V31, P489, DOI 10.1093/eurheartj/ehp568; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bergmann O, 2011, EXP CELL RES, V317, P188, DOI 10.1016/j.yexcr.2010.08.017; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0; Bu L, 2009, NATURE, V460, P113, DOI 10.1038/nature08191; Buckingham M, 2005, NAT REV GENET, V6, P826, DOI 10.1038/nrg1710; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Chien KR, 2008, SCIENCE, V322, P1494, DOI 10.1126/science.1163267; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164; Frederick JR, 2010, CIRCULATION, V122, pS107, DOI 10.1161/CIRCULATIONAHA.109.930404; Gaziano TA, 2007, HEALTH AFFAIR, V26, P13, DOI 10.1377/hlthaff.26.1.13; Gersh BJ, 2009, MAYO CLIN PROC, V84, P876, DOI 10.1016/S0025-6196(11)60505-3; Hou DM, 2005, CIRCULATION, V112, pI150, DOI 10.1161/CIRCULATIONAHA.104.526749; Hsieh PCH, 2007, NAT MED, V13, P970, DOI 10.1038/nm1618; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864; Kimura T, 2011, J THORAC CARDIOV SUR, V142, P181, DOI 10.1016/j.jtcvs.2010.09.050; Kraehenbuehl TP, 2011, BIOMATERIALS, V32, P1102, DOI 10.1016/j.biomaterials.2010.10.005; Kubo H, 2008, CIRCULATION, V118, P649, DOI 10.1161/CIRCULATIONAHA.107.761031; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Laflamme MA, 2011, NATURE, V473, P326, DOI 10.1038/nature10147; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leor J, 2009, J AM COLL CARDIOL, V54, P1014, DOI 10.1016/j.jacc.2009.06.010; Loffredo FS, 2011, CELL STEM CELL, V8, P389, DOI 10.1016/j.stem.2011.02.002; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Menasche P, 2008, CIRCULATION, V117, P1189, DOI 10.1161/CIRCULATIONAHA.107.734103; Mirotsou M, 2011, J MOL CELL CARDIOL, V50, P280, DOI 10.1016/j.yjmcc.2010.08.005; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Neff AW, 1996, INT J DEV BIOL, V40, P719; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040; Pompilio G, 2008, THORAC CARDIOV SURG, V56, P71, DOI 10.1055/s-2007-989351; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Qyang Y, 2007, CELL STEM CELL, V1, P165, DOI 10.1016/j.stem.2007.05.018; Raake P, 2004, J AM COLL CARDIOL, V44, P1124, DOI 10.1016/j.jacc.2004.05.074; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Segers VFM, 2010, J CARDIOVASC TRANSL, V3, P469, DOI 10.1007/s12265-010-9207-5; Siu CW, 2012, LANCET, V379, P870, DOI 10.1016/S0140-6736(12)60236-0; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Smart N, 2011, NATURE, V474, P640, DOI 10.1038/nature10188; Solomon SD, 2005, CIRCULATION, V111, P3411, DOI 10.1161/CIRCULATIONAHA.104.508093; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Stehlik J, 2011, J HEART LUNG TRANSPL, V30, P1078, DOI 10.1016/j.healun.2011.08.003; Stevens KR, 2009, P NATL ACAD SCI USA, V106, P16568, DOI 10.1073/pnas.0908381106; Stoller JZ, 2005, SEMIN CELL DEV BIOL, V16, P704, DOI 10.1016/j.semcdb.2005.06.004; Strauer BE, 2010, EUR J HEART FAIL, V12, P721, DOI 10.1093/eurjhf/hfq095; Sun Y, 2010, J MOL CELL CARDIOL, V48, P483, DOI 10.1016/j.yjmcc.2009.08.002; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; van Laake LW, 2007, STEM CELL RES, V1, P9, DOI 10.1016/j.scr.2007.06.001; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Xu HS, 2012, CELL RES, V22, P142, DOI 10.1038/cr.2011.171; Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135; Zhou B, 2008, NATURE, V454, P109, DOI 10.1038/nature07060; Zhou B, 2011, J CLIN INVEST, V121, P1894, DOI 10.1172/JCI45529; Zimmet H, 2012, EUR J HEART FAIL, V14, P91, DOI 10.1093/eurjhf/hfr148	82	176	181	0	62	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					933	942		10.1016/S0140-6736(12)60075-0	http://dx.doi.org/10.1016/S0140-6736(12)60075-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22405796				2022-12-28	WOS:000301353700034
J	Liang, ZZS; Nguyen, T; Mattila, HR; Rodriguez-Zas, SL; Seeley, TD; Robinson, GE				Liang, Zhengzheng S.; Trang Nguyen; Mattila, Heather R.; Rodriguez-Zas, Sandra L.; Seeley, Thomas D.; Robinson, Gene E.			Molecular Determinants of Scouting Behavior in Honey Bees	SCIENCE			English	Article							DOPAMINE; IMMUNOREACTIVITY; POLYMORPHISMS; DIVISION; RECRUITS; LABOR; GENE	Little is known about the molecular basis of differences in behavior among individuals. Here we report consistent novelty-seeking behavior, across different contexts, among honey bees in their tendency to scout for food sources and nest sites, and we reveal some of the molecular underpinnings of this behavior relative to foragers that do not scout. Food scouts showed extensive differences in brain gene expression relative to other foragers, including differences related to catecholamine, glutamate, and gamma-aminobutyric acid signaling. Octopamine and glutamate treatments increased the likelihood of scouting, whereas dopamine antagonist treatment decreased it. These findings demonstrate intriguing similarities in human and insect novelty seeking and suggest that this trait, which presumably evolved independently in these two lineages, may be subserved by conserved molecular components.	[Liang, Zhengzheng S.; Rodriguez-Zas, Sandra L.; Robinson, Gene E.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA; [Trang Nguyen; Robinson, Gene E.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Mattila, Heather R.] Wellesley Coll, Dept Biol Sci, Wellesley, MA 02181 USA; [Rodriguez-Zas, Sandra L.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; [Seeley, Thomas D.] Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA; [Robinson, Gene E.] Univ Illinois, Dept Entomol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Wellesley College; University of Illinois System; University of Illinois Urbana-Champaign; Cornell University; University of Illinois System; University of Illinois Urbana-Champaign	Robinson, GE (corresponding author), Univ Illinois, Neurosci Program, Urbana, IL 61801 USA.	generobi@illinois.edu		Liang, Zhengzheng/0000-0002-3969-4199	NSF [EF 0425852]; NIH [1DP1OD006416]; Illinois Sociogenomics Initiative; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA027548] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006416] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Illinois Sociogenomics Initiative; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Special thanks to M. K. Carr-Markell and J. Recchia-Rife for extensive help in the field. We also thank the following: C. Nye and K. Pruiett (bee management); A. Brockmann, P. Date, J. Dotterer, L. Felley, M. Girard, S. Kantarovich, H. S. Pollock, and M. Wray (field assistance); T. Newman (molecular studies); S. Aref and A. Toth (statistics); E. Hadley (graphics); and A. M. Bell, D. F. Clayton, R. C. Fuller, J. S. Rhodes, C. W. Whitfield, and members of the Robinson laboratory (review of the manuscript). Supported by NSF Frontiers in Biological Research grant EF 0425852 (B. L. Schatz, PI, BeeSpace Project); NIH Director's Pioneer Award 1DP1OD006416 (G.E.R); and the Illinois Sociogenomics Initiative (G.E.R). Microarray data meet Minimum Information About Microarray Experiment (MIAME) standards and are available at ArrayExpress (www.ebi.ac.uk/arrayexpress, #E-MTAB-491). Z.S.L. and G.E.R. conceived the project, designed the experiments and wrote the paper; Z.S.L. performed sample collection, molecular and field experiments, and analyses; T.N. and S.L.R.-Z. performed microarray experiments and statistical analyses, respectively; and H.R.M. and T.D.S. contributed to protocol development and sample collection and co-wrote the paper.	Bardo MT, 1996, BEHAV BRAIN RES, V77, P23, DOI 10.1016/0166-4328(95)00203-0; Becker J. B., 2007, HDB NEUROCHEMISTRY M; Bendesky A, 2011, NATURE, V472, P313, DOI 10.1038/nature09821; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BICKER G, 1988, J NEUROSCI, V8, P2108; Dreller C, 1998, BEHAV ECOL SOCIOBIOL, V43, P191, DOI 10.1007/s002650050480; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Evans Peter D., 2005, Invertebrate Neuroscience, V5, P111, DOI 10.1007/s10158-005-0001-z; Fidler AE, 2007, P ROY SOC B-BIOL SCI, V274, P1685, DOI 10.1098/rspb.2007.0337; Kucharski R, 2000, GENE, V242, P399, DOI 10.1016/S0378-1119(99)00503-X; Kurshan PT, 2003, J COMP NEUROL, V466, P91, DOI 10.1002/cne.10864; LINDAUER M, 1952, Z VERGL PHYSIOL, V34, P299, DOI 10.1007/BF00298048; Mustard JA, 2003, MOL BRAIN RES, V113, P67, DOI 10.1016/S0169-328X(03)00091-3; OETTINGENSPIELBERG TZ, 1949, Z VERGL PHYSIOL, V31, P454, DOI 10.1007/BF00338037; SCHURMANN FW, 1989, CELL TISSUE RES, V256, P399, DOI 10.1007/BF00218898; Seeley T.D., 2010, HONEYBEE DEMOCRACY; SEELEY TD, 1983, BEHAV ECOL SOCIOBIOL, V12, P253, DOI 10.1007/BF00290778; Viggiano D, 2002, BEHAV GENET, V32, P315, DOI 10.1023/A:1020210221156	18	93	93	5	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1225	1228		10.1126/science.1213962	http://dx.doi.org/10.1126/science.1213962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403390				2022-12-28	WOS:000301225100045
J	Razzell, W; Martin, P				Razzell, William; Martin, Paul			Embryonic Clutch Control	SCIENCE			English	Editorial Material							CELL-SHAPE CHANGE; APICAL CONSTRICTION; GASTRULATION; FORCES		[Razzell, William; Martin, Paul] Univ Bristol, Sch Biochem, Fac Med & Vet Sci, Bristol BS8 1TD, Avon, England; [Martin, Paul] Univ Bristol, Sch Physiol & Pharmacol, Fac Med & Vet Sci, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Razzell, W (corresponding author), Univ Bristol, Sch Biochem, Fac Med & Vet Sci, Bristol BS8 1TD, Avon, England.	william.razzell@bristol.ac.uk; paul.martin@bristol.ac.uk		Razzell, William/0000-0002-1262-0501; Martin, Paul/0000-0002-2665-5086				Bard L, 2008, J NEUROSCI, V28, P5879, DOI 10.1523/JNEUROSCI.5331-07.2008; Dawes-Hoang RE, 2005, DEVELOPMENT, V132, P4165, DOI 10.1242/dev.01938; Haigo SL, 2003, CURR BIOL, V13, P2125, DOI 10.1016/j.cub.2003.11.054; Kolsch V, 2007, SCIENCE, V315, P384, DOI 10.1126/science.1134833; Leptin M, 2005, DEV CELL, V8, P305, DOI 10.1016/j.devcel.2005.02.007; Martin AC, 2010, J CELL BIOL, V188, P735, DOI 10.1083/jcb.200910099; Martin AC, 2009, NATURE, V457, P495, DOI 10.1038/nature07522; Neisch AL, 2011, CURR OPIN CELL BIOL, V23, P377, DOI 10.1016/j.ceb.2011.04.011; Pouille PA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000098; Roh-Johnson M, 2012, SCIENCE, V335, P1232, DOI 10.1126/science.1217869; Sawyer JM, 2010, DEV BIOL, V341, P5, DOI 10.1016/j.ydbio.2009.09.009; Solon J, 2009, CELL, V137, P1331, DOI 10.1016/j.cell.2009.03.050; Yamaguchi Y, 2011, J CELL BIOL, V195, P1047, DOI 10.1083/jcb.201104057	13	2	2	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1181	1182		10.1126/science.1220388	http://dx.doi.org/10.1126/science.1220388			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403380				2022-12-28	WOS:000301225100032
J	Whyte, MP; Greenberg, CR; Salman, NJ; Bober, MB; McAlister, WH; Wenkert, D; Van Sickle, BJ; Simmons, JH; Edgar, TS; Bauer, ML; Hamdan, MA; Bishop, N; Lutz, RE; McGinn, M; Craig, S; Moore, JN; Taylor, JW; Cleveland, RH; Cranley, WR; Lim, R; Thacher, TD; Mayhew, JE; Downs, M; Millan, JL; Skrinar, AM; Crine, P; Landy, H				Whyte, Michael P.; Greenberg, Cheryl R.; Salman, Nada J.; Bober, Michael B.; McAlister, William H.; Wenkert, Deborah; Van Sickle, Bradley J.; Simmons, Jill H.; Edgar, Terence S.; Bauer, Martin L.; Hamdan, Mohamed A.; Bishop, Nick; Lutz, Richard E.; McGinn, Mairead; Craig, Stanley; Moore, Jean N.; Taylor, John W.; Cleveland, Robert H.; Cranley, William R.; Lim, Ruth; Thacher, Tom D.; Mayhew, Jill E.; Downs, Matthew; Millan, Jose Luis; Skrinar, Alison M.; Crine, Philippe; Landy, Hal			Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSPECIFIC ALKALINE-PHOSPHATASE; INFANTILE HYPOPHOSPHATASIA; MURINE HYPOPHOSPHATASIA; INTRAVENOUS-INFUSION; BONE; DISEASE; GENE; PYRIDOXAL-5'-PHOSPHATE; TRANSPLANTATION; MINERALIZATION	BACKGROUND Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice. METHODS We enrolled infants and young children with life-threatening or debilitating perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-0040. The primary objective was the healing of rickets, as assessed by means of radiographic scales. Motor and cognitive development, respiratory function, and safety were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040. RESULTS Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. Healing of rickets at 6 months in 9 patients was accompanied by improvement in developmental milestones and pulmonary function. Elevated plasma levels of the TNSALP substrates inorganic pyrophosphate and pyridoxal 5'-phosphate diminished. Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia, ectopic calcification, or definite drug-related serious adverse events. Low titers of anti-ENB-0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment. CONCLUSIONS ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.)	[Whyte, Michael P.; Wenkert, Deborah] Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA; [Whyte, Michael P.] Washington Univ, Sch Med, Div Bone & Mineral Dis, Barnes Jewish Hosp, St Louis, MO 63130 USA; [McAlister, William H.] Washington Univ, Sch Med, St Louis Childrens Hosp, Mallinckrodt Inst Radiol, St Louis, MO 63130 USA; [Greenberg, Cheryl R.] Univ Manitoba, Winnipeg, MB, Canada; [Greenberg, Cheryl R.] Winnipeg Reg Hlth Author, Winnipeg, MB, Canada; [Salman, Nada J.; Hamdan, Mohamed A.] Tawam Hosp, Al Ain, U Arab Emirates; [Bober, Michael B.] Alfred I Dupont Hosp Children, Wilmington, DE USA; [Van Sickle, Bradley J.; Simmons, Jill H.] Vanderbilt Childrens Hosp, Nashville, TN USA; [Edgar, Terence S.; Taylor, John W.] Prevea Hlth Clin, Green Bay, WI USA; [Taylor, John W.] St Vincents Hosp, Green Bay, WI USA; [Bauer, Martin L.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA; [Bishop, Nick] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [McGinn, Mairead; Craig, Stanley] Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland; [Lutz, Richard E.] Univ Nebraska Med Ctr, Omaha, NE USA; [Moore, Jean N.] St Johns Hosp, Springfield, MO USA; [Cleveland, Robert H.] Childrens Hosp, Boston, MA 02115 USA; [Cranley, William R.] Boston Med Ctr, Boston, MA USA; [Lim, Ruth] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Thacher, Tom D.] Mayo Clin, Rochester, MN USA; [Mayhew, Jill E.; Skrinar, Alison M.; Crine, Philippe; Landy, Hal] Enobia Pharma, Montreal, PQ, Canada; [Downs, Matthew] Stat Collaborat, Washington, DC USA; [Millan, Jose Luis] Sanford Burnham Med Res Inst, La Jolla, CA USA	Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of Manitoba; Nemours Alfred I. duPont Hospital for Children; Vanderbilt University; University of Arkansas System; University of Arkansas Medical Sciences; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; Saint Johns Mercy Medical Center; Harvard University; Boston Children's Hospital; Boston Medical Center; Harvard University; Massachusetts General Hospital; Mayo Clinic; Sanford Burnham Prebys Medical Discovery Institute	Whyte, MP (corresponding author), Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.	mwhyte@shrinenet.org	Bober, Michael/AAH-4553-2021; Downs, Matt/S-7646-2019; Thacher, Tom/B-3356-2009	Thacher, Tom/0000-0002-7644-8173; Bober, Michael/0000-0002-6178-1264; Simmons, Jill/0000-0002-4189-6718	Enobia Pharma Hospital for Children; Shriners Hospital for Children; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012889] Funding Source: NIH RePORTER	Enobia Pharma Hospital for Children; Shriners Hospital for Children; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Supported by Enobia Pharma and Shriners Hospitals for Children.	Anderson HC, 1997, AM J PATHOL, V151, P1555; [Anonymous], 2005, BAYL SCAL INF TODDL; Baumgartner-Sigl S, 2007, BONE, V40, P1655, DOI 10.1016/j.bone.2007.01.020; Beal S, 1989, NONMEM USERS GUIDE 1; Cahill RA, 2007, J CLIN ENDOCR METAB, V92, P2923, DOI 10.1210/jc.2006-2131; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Collmann H, 2009, CHILD NERV SYST, V25, P217, DOI 10.1007/s00381-008-0708-3; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0; Fleisch H, 1995, BISPHOSPHONATES BONE, P149; FRASER D, 1957, AM J MED, V22, P730, DOI 10.1016/0002-9343(57)90124-9; Greenberg CR, 2009, 16 ANN CLIN GEN M AM; Ish-Shalom S, 1986, 8 ANN SCI M AM SOC B; McKee MD, 2011, J DENT RES, V90, P470, DOI 10.1177/0022034510393517; Millan J.L., 2006, MAMMALIAN ALKALINE P; Millan JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213; MORNET E, 2006, TISSUE NONSPECIFIC A; Mumm S, 2002, MOL GENET METAB, V75, P143, DOI 10.1006/mgme.2001.3283; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; PRESTON CJ, 1986, BRIT MED J, V292, P79, DOI 10.1136/bmj.292.6513.79; RATHBUN JC, 1948, AM J DIS CHILD, V75, P822, DOI 10.1001/archpedi.1948.02030020840003; RUSSELL RGG, 1965, LANCET, V2, P461; Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221; SESHIA SS, 1990, ARCH DIS CHILD, V65, P130, DOI 10.1136/adc.65.1.130; Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132; van den Bos T, 2005, J DENT RES, V84, P1021, DOI 10.1177/154405910508401110; WEISS MJ, 1988, P NATL ACAD SCI USA, V85, P7666, DOI 10.1073/pnas.85.20.7666; Wenkert D, 2011, J BONE MINER RES, V26, P2389, DOI 10.1002/jbmr.454; Whyte MP, 2007, J CLIN ENDOCR METAB, V92, P1203, DOI 10.1210/jc.2006-1902; Whyte MP, 2012, PEDIATRIC BONE: BIOLOGY & DISEASES, 2ND EDITION, P771, DOI 10.1016/B978-0-12-382040-2.10028-0; Whyte MP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1573, DOI 10.1016/B978-0-12-373884-4.00080-X; Whyte MP, 2000, J BONE MINER RES, V15, pS483; WHYTE MP, 1988, J CLIN INVEST, V81, P1234, DOI 10.1172/JCI113440; WHYTE MP, 1984, J PEDIATR-US, V105, P926, DOI 10.1016/S0022-3476(84)80079-7; Whyte MP, 2003, J BONE MINER RES, V18, P624, DOI 10.1359/jbmr.2003.18.4.624; WHYTE MP, 1992, J BONE MINER RES, V7, pS155; WHYTE MP, 1982, J PEDIATR-US, V101, P379, DOI 10.1016/S0022-3476(82)80061-9; WHYTE MP, 1985, J CLIN INVEST, V76, P752, DOI 10.1172/JCI112031; Wilcoxon F., 1945, BIOMETRICS B, V6, P80; Yadav MC, 2011, BONE, V49, P250, DOI 10.1016/j.bone.2011.03.770	40	344	376	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					904	913		10.1056/NEJMoa1106173	http://dx.doi.org/10.1056/NEJMoa1106173			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397652	Green Published, Bronze			2022-12-28	WOS:000301172500007
J	Frank, J				Frank, Jennifer			The Before	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Theda Care, Neenah, WI 54956 USA		Frank, J (corresponding author), Theda Care, Neenah, WI 54956 USA.	drjenfrank@gmail.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					921	921		10.1001/jama.2012.200	http://dx.doi.org/10.1001/jama.2012.200			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396513				2022-12-28	WOS:000301172100019
J	Sedgwick, P				Sedgwick, Philip			Incidence rates	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London, Ctr Med & Healthcare Educ, London, England	St Georges University London; University of London	Sedgwick, P (corresponding author), Univ London, Ctr Med & Healthcare Educ, London, England.	p.sedgwick@sgul.ac.uk	Sedgwick, Philip/C-6997-2019	Sedgwick, Philip/0000-0001-8859-2175					0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1589	10.1136/bmj.e1589	http://dx.doi.org/10.1136/bmj.e1589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399704				2022-12-28	WOS:000301479800012
J	Gulmezoglu, AM; Lumbiganon, P; Landoulsi, S; Widmer, M; Abdel-Aleem, H; Festin, M; Carroli, G; Qureshi, Z; Souza, JP; Bergel, E; Piaggio, G; Goudar, SS; Yeh, J; Armbruster, D; Singata, M; Pelaez-Crisologo, C; Althabe, F; Sekweyama, P; Hofmeyr, J; Stanton, ME; Derman, R; Elbourne, D				Guelmezoglu, A. Metin; Lumbiganon, Pisake; Landoulsi, Sihem; Widmer, Mariana; Abdel-Aleem, Hany; Festin, Mario; Carroli, Guillermo; Qureshi, Zahida; Souza, Joao Paulo; Bergel, Eduardo; Piaggio, Gilda; Goudar, Shivaprasad S.; Yeh, John; Armbruster, Deborah; Singata, Mandisa; Pelaez-Crisologo, Cristina; Althabe, Fernando; Sekweyama, Peter; Hofmeyr, Justus; Stanton, Mary-Ellen; Derman, Richard; Elbourne, Diana			Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial	LANCET			English	Article							EQUIVALENCE	Background Active management of the third stage of labour reduces the risk of post-partum haemorrhage. We aimed to assess whether controlled cord traction can be omitted from active management of this stage without increasing the risk of severe haemorrhage. Methods We did a multicentre, non-inferiority, randomised controlled trial in 16 hospitals and two primary healthcare centres in Argentina, Egypt, India, Kenya, the Philippines, South Africa, Thailand, and Uganda. Women expecting to deliver singleton babies vaginally (ie, not planned caesarean section) were randomly assigned (in a 1: 1 ratio) with a centrally generated allocation sequence, stratified by country, to placental delivery with gravity and maternal effort (simplified package) or controlled cord traction applied immediately after uterine contraction and cord clamping (full package). After randomisation, allocation could not be concealed from investigators, participants, or assessors. Oxytocin 10 IU was administered immediately after birth with cord clamping after 1-3 min. Uterine massage was done after placental delivery according to local policy. The primary (non-inferiority) outcome was blood loss of 1000 mL or more (severe haemorrhage). The non-inferiority margin for the risk ratio was 1.3. Analysis was by modified intention-to-treat, excluding women who had emergency caesarean sections. This trial is registered with the Australian and New Zealand Clinical Trials Registry, ACTRN 12608000434392. Findings Between June 1, 2009, and Oct 30, 2010, 12 227 women were randomly assigned to the simplified package group and 12 163 to the full package group. After exclusion of women who had emergency caesarean sections, 11 861 were in the simplified package group and 11 820 were in the full package group. The primary outcome of blood loss of 1000 mL or more had a risk ratio of 1.09 (95% CI 0.91-1.31) and the upper 95% CI limit crossed the pre-stated non-inferiority margin. One case of uterine inversion occurred in the full package group. Other adverse events were haemorrhage-related. Interpretation Although the hypothesis of non-inferiority was not met, omission of controlled cord traction has very little effect on the risk of severe haemorrhage. Scaling up of haemorrhage prevention programmes for non-hospital settings can safely focus on use of oxytocin.	[Guelmezoglu, A. Metin] WHO, Dept Reprod Hlth & Res, UNDP UNFPA WHO World Bank Special Programme Res D, CH-1211 Geneva, Switzerland; [Lumbiganon, Pisake] Khon Kaen Univ, Fac Med, Dept Obstet & Gynaecol, Khon Kaen, Thailand; [Abdel-Aleem, Hany] Assiut Univ, Fac Med, Dept Obstet & Gynaecol, Assiut, Egypt; [Festin, Mario; Pelaez-Crisologo, Cristina] Univ Philippines, Philippine Gen Hosp, Dept Obstet & Gynaecol, Manila, Philippines; [Carroli, Guillermo] Ctr Rosarino Estudios Perinatales, Rosario, Argentina; [Qureshi, Zahida] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya; [Goudar, Shivaprasad S.] Jawaharlal Nehru Med Coll, Womens & Childrens Hlth Res Unit, Belgaum, Karnataka, India; [Yeh, John] Harvard Univ, Sch Med, Boston, MA USA; [Armbruster, Deborah; Stanton, Mary-Ellen] US Agcy Int Dev, Washington, DC 20523 USA; [Singata, Mandisa; Hofmeyr, Justus] Univ Witwatersrand, Eastern Cape Dept Hlth, Effect Care Res Unit, E London, South Africa; [Singata, Mandisa; Hofmeyr, Justus] Univ Ft Hare, Eastern Cape Dept Hlth, Effect Care Res Unit, E London, South Africa; [Althabe, Fernando] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina; [Sekweyama, Peter] San Raphael St Francis Hosp, Nsambya, Uganda; [Derman, Richard] Christiana Care Hlth Syst, Ctr Womens & Childrens Hlth Res, Dept Obstet & Gynaecol, Newark, DE USA; [Elbourne, Diana] London Sch Hyg & Trop Med, London WC1, England	United Nations Population Fund; World Health Organization; Khon Kaen University; Egyptian Knowledge Bank (EKB); Assiut University; University of the Philippines System; University of the Philippines Manila; University of Nairobi; K.L.E. Academy of Higher Education & Research; Jawaharlal Nehru Medical College, Belgaum; Harvard University; Harvard Medical School; United States Agency for International Development (USAID); University of Witwatersrand; University of Fort Hare; Christiana Care Health System; University of London; London School of Hygiene & Tropical Medicine	Gulmezoglu, AM (corresponding author), WHO, Dept Reprod Hlth & Res, UNDP UNFPA WHO World Bank Special Programme Res D, CH-1211 Geneva, Switzerland.	gulmezoglum@who.int	Lumbiganon, Pisake/E-8634-2010; GOUDAR, SHIVAPRASAD S/S-1217-2019; Souza, João Paulo/G-1982-2010; Festin, Mario Philip/GQQ-9749-2022	Lumbiganon, Pisake/0000-0001-9372-0071; GOUDAR, SHIVAPRASAD S/0000-0002-8680-7053; Souza, João Paulo/0000-0002-2288-4244; Derman, Richard/0000-0003-1148-1594	United States Agency for International Development; UN Development Programme/UN Population Fund/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research; UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction of WHO	United States Agency for International Development(United States Agency for International Development (USAID)); UN Development Programme/UN Population Fund/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research; UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction of WHO	United States Agency for International Development and UN Development Programme/UN Population Fund/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research.; We thank the women who took part in the trial and the doctors, nurses, and midwives in the participating hospitals for making the project possible. We also thank Matthews Mathai and Kathy Herschderfer for participating in trial meetings and Neal Brandes and Lily Kak for support throughout the project and comments on the report. We thank Novartis for donating the oxytocin ampoules used in the trial. This trial was supported by the United States Agency for International Development (USAID) and UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction of WHO. Some of the authors are staff of the sponsor organisations. The interpretation and conclusions are those of the individual authors and not necessarily those of the sponsors.	Althabe F, 2009, INT J GYNECOL OBSTET, V107, P4, DOI 10.1016/j.ijgo.2009.05.021; [Anonymous], 2010, INT J GYNECOL OBSTET, V108, P258, DOI 10.1016/j.ijgo.2009.11.002; [Anonymous], 2007, MAN COMPL PREGN CHIL; Begley CM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007412.pub2; COTTER A, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001808, DOI 10.1002/14651858.CD001808]; Festin MR, 2003, B WORLD HEALTH ORGAN, V81, P286; Garrett AD, 2003, STAT MED, V22, P741, DOI 10.1002/sim.1360; Gulmezoglu AM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000494.pub3; Gulmezoglu A Metin, 2009, Reprod Health, V6, P2, DOI 10.1186/1742-4755-6-2; Hofmeyr GJ, 2008, COCHRANE DB SYST REV, V3; ICH Steering Committee, INT C HARM TECHN REQ; Keirse MJNC, 1998, LANCET, V351, P690, DOI 10.1016/S0140-6736(05)78490-7; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; McDonald SJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004074.pub2; Mshweshwe NT, 2009, COCHRANE DB SYST REV, V4; Patel A, 2006, INT J GYNECOL OBSTET, V93, P220, DOI 10.1016/j.ijgo.2006.02.014; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; SPENCER P M, 1962, Br Med J, V1, P1728; Widmer M, 2010, LANCET, V375, P1808, DOI 10.1016/S0140-6736(10)60348-0; World Health Organization (WHO), 2007, WHO REC PREV POSTP H	21	99	107	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2012	379	9827					1721	1727		10.1016/S0140-6736(12)60206-2	http://dx.doi.org/10.1016/S0140-6736(12)60206-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937KX	22398174	Green Submitted			2022-12-28	WOS:000303658500032
J	Schreiber, A; Gabris, A; Rohde, PP; Laiho, K; Stefanak, M; Potocek, V; Hamilton, C; Jex, I; Silberhorn, C				Schreiber, Andreas; Gabris, Aurel; Rohde, Peter P.; Laiho, Kaisa; Stefanak, Martin; Potocek, Vaclav; Hamilton, Craig; Jex, Igor; Silberhorn, Christine			A 2D Quantum Walk Simulation of Two-Particle Dynamics	SCIENCE			English	Article								Multidimensional quantum walks can exhibit highly nontrivial topological structure, providing a powerful tool for simulating quantum information and transport systems. We present a flexible implementation of a two-dimensional (2D) optical quantum walk on a lattice, demonstrating a scalable quantum walk on a nontrivial graph structure. We realized a coherent quantum walk over 12 steps and 169 positions by using an optical fiber network. With our broad spectrum of quantum coins, we were able to simulate the creation of entanglement in bipartite systems with conditioned interactions. Introducing dynamic control allowed for the investigation of effects such as strong nonlinearities or two-particle scattering. Our results illustrate the potential of quantum walks as a route for simulating and understanding complex quantum systems.	[Schreiber, Andreas; Rohde, Peter P.; Laiho, Kaisa; Silberhorn, Christine] Univ Paderborn, D-33098 Paderborn, Germany; [Schreiber, Andreas; Laiho, Kaisa; Silberhorn, Christine] Max Planck Inst Sci Light, D-91058 Erlangen, Germany; [Gabris, Aurel; Stefanak, Martin; Potocek, Vaclav; Hamilton, Craig; Jex, Igor] Czech Tech Univ, Dept Phys, Fac Nucl Sci & Phys Engn, Prague 11519, Czech Republic; [Gabris, Aurel] Hungarian Acad Sci, Wigner Res Ctr Phys, H-1525 Budapest, Hungary; [Rohde, Peter P.] Macquarie Univ, Ctr Engn Quantum Syst, Dept Phys & Astron, Sydney, NSW 2113, Australia	University of Paderborn; Max Planck Society; Czech Technical University Prague; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Wigner Research Centre for Physics; Macquarie University	Schreiber, A (corresponding author), Univ Paderborn, Warburger Str 100, D-33098 Paderborn, Germany.	andreas.schreiber@uni-paderborn.de	Gábris, Aurél/A-7615-2008; Stefanak, Martin/G-5239-2012; Silberhorn, Christine/J-4919-2013; Rohde, Peter/M-8244-2019; Potoček, Václav/GOE-4856-2022	Gábris, Aurél/0000-0002-2671-6328; Stefanak, Martin/0000-0002-0433-7765; Silberhorn, Christine/0000-0002-2349-5443; Rohde, Peter/0000-0002-5814-7289; Potocek, Vaclav/0000-0002-6415-598X	German Israel Foundation [970/2007]; Australian Research Council Centre of Excellence for Engineered Quantum Systems [CE110001013];  [MSM6840770039];  [MSMT LC06002];  [SGS10/294/OHK4/3T/14];  [GA CR 202/08/H078];  [OTKA T83858]	German Israel Foundation(German-Israeli Foundation for Scientific Research and Development); Australian Research Council Centre of Excellence for Engineered Quantum Systems(Australian Research Council); ; ; ; ; 	We acknowledge financial support from the German Israel Foundation (project no. 970/2007). A.G., M.S., V.P., C.H., and I.J. acknowledge grant support from MSM6840770039 and MSMT LC06002, SGS10/294/OHK4/3T/14, GA CR 202/08/H078, and OTKA T83858. P.P.R. acknowledges support from the Australian Research Council Centre of Excellence for Engineered Quantum Systems (project no. CE110001013).	Aharonov D., 2001, PROC 33 ANN ACM S TH, ppp 50; AHARONOV Y, 1993, PHYS REV A, V48, P1687, DOI 10.1103/PhysRevA.48.1687; Ambainis A, 2005, PROCEEDINGS OF THE SIXTEENTH ANNUAL ACM-SIAM SYMPOSIUM ON DISCRETE ALGORITHMS, P1099; Berry SD, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.042317; Bhattacharya N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.137901; Bouwmeester D, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.013410; Broome MA, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.153602; Cerf NJ, 1998, PHYS REV A, V57, pR1477, DOI 10.1103/PhysRevA.57.R1477; Childs AM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.180501; Hamilton CS, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/1/013015; Hillery M, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.062324; Inui N, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.052323; Karski M, 2009, SCIENCE, V325, P174, DOI 10.1126/science.1174436; Kitagawa T, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.033429; Lovett NB, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.042330; Mackay TD, 2002, J PHYS A-MATH GEN, V35, P2745, DOI 10.1088/0305-4470/35/12/304; Mohseni M, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3002335; Peruzzo A, 2010, SCIENCE, V329, P1500, DOI 10.1126/science.1193515; Plenio MB, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/11/113019; Roldan E, 2005, J MOD OPTIC, V52, P2649, DOI 10.1080/09500340500309873; Sansoni L, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.010502; Schmitz H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.090504; Schreiber A, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.180403; Schreiber A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.050502; Shenvi N, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.052307; Spreeuw RJC, 1998, FOUND PHYS, V28, P361, DOI 10.1023/A:1018703709245; Zahringer F, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.100503	27	298	300	11	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 6	2012	336	6077					55	58		10.1126/science.1218448	http://dx.doi.org/10.1126/science.1218448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920LG	22403179	Green Submitted			2022-12-28	WOS:000302405400048
J	Nunns, D; Murphy, R				Nunns, David; Murphy, Ruth			Assessment and management of vulval pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELECTROMYOGRAPHIC BIOFEEDBACK; DIAGNOSTIC-CRITERIA; VULVODYNIA; VESTIBULITIS; VESTIBULECTOMY; GUIDELINES; THERAPY		[Nunns, David; Murphy, Ruth] Univ Nottingham Hosp, Nottingham NG5 1PB, England	University of Nottingham	Nunns, D (corresponding author), Univ Nottingham Hosp, Nottingham NG5 1PB, England.	david.nunns@nuh.nhs.uk						Bergeron S, 2001, PAIN, V91, P297, DOI 10.1016/S0304-3959(00)00449-8; Bergeron S, 2001, OBSTET GYNECOL, V98, P45, DOI 10.1016/S0029-7844(01)01389-8; Bornstein J, 1999, OBSTET GYNECOL, V93, P876, DOI 10.1016/S0029-7844(98)00535-3; Bowen AR, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.004; Eanes A, 2011, INT J GYNECOL OBSTET, V113, P225, DOI 10.1016/j.ijgo.2010.12.018; Farmer K., 2010, EFFECT VOLUNATARY EX; Foster DC, 2010, OBSTET GYNECOL, V116, P583, DOI 10.1097/AOG.0b013e3181e9e0ab; Harlow Bernard L, 2003, J Am Med Womens Assoc (1972), V58, P82; Harris G, 2007, J REPROD MED, V52, P103; JADRESIC D, 1993, INT J STD AIDS, V4, P237, DOI 10.1177/095646249300400413; Kehoe S, 1996, ACTA OBSTET GYN SCAN, V75, P676, DOI 10.3109/00016349609054697; Labat JJ, 2008, NEUROUROL URODYNAM, V27, P306, DOI 10.1002/nau.20505; Lehman JS, 2009, INT J DERMATOL, V48, P682, DOI 10.1111/j.1365-4632.2009.04062.x; Lewis FM, 1997, J REPROD MED, V42, P169; Mandal D, 2010, BRIT J DERMATOL, V162, P1180, DOI 10.1111/j.1365-2133.2010.09684.x; McKay E, 2001, J REPROD MED, V46, P337; Moyal-Barracco M, 2004, J REPROD MED, V49, P772; Munday P E, 2001, J Obstet Gynaecol, V21, P610; Munday P, 2007, J REPROD MED, V52, P19; Murphy R, 2008, J REPROD MED, V53, P124; Neill SM, 2010, BRIT J DERMATOL, V163, P672, DOI 10.1111/j.1365-2133.2010.09997.x; Nunns D, 1997, CONTACT DERMATITIS, V37, P87, DOI 10.1111/j.1600-0536.1997.tb00045.x; Reed Barbara D, 2006, J Low Genit Tract Dis, V10, P245, DOI 10.1097/01.lgt.0000225899.75207.0a; Royal College of Obstetricians & Gynecologists, 2011, MAN VULV SKIN DIS; SCHOVER LR, 1992, AM J OBSTET GYNECOL, V167, P630, DOI 10.1016/S0002-9378(11)91562-2; Schultz WCMW, 1996, J PSYCHOSOM OBST GYN, V17, P143, DOI 10.3109/01674829609025675; Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114; STEWART DE, 1994, OBSTET GYNECOL, V84, P587; Ventolini G, 2009, J OBSTET GYNAECOL, V29, P648, DOI 10.1080/01443610903095882; Wylie K, 2004, J PSYCHOSOM OBST GYN, V25, P257, DOI 10.1080/01674820400024463	30	10	10	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2012	344								e1723	10.1136/bmj.e1723	http://dx.doi.org/10.1136/bmj.e1723			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923FF	22457438				2022-12-28	WOS:000302604100007
J	Robinson, D; Cardozo, L				Robinson, Dudley; Cardozo, Linda			Antimuscarinic drugs to treat overactive bladder	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; EXTENDED-RELEASE; ANTICHOLINERGIC DRUGS; DOUBLE-BLIND; TOLTERODINE; TOLERABILITY; EFFICACY; SOLIFENACIN; OXYBUTYNIN; DETRUSOR		[Robinson, Dudley; Cardozo, Linda] Kings Coll Hosp London, Dept Urogynaecol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Robinson, D (corresponding author), Kings Coll Hosp London, Dept Urogynaecol, Denmark Hill, London SE5 9RS, England.	dudley.robinson@nhs.net						Alhasso AA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003193.pub3; Andersson KE, 2009, INCONTINENCE, P631; Appell RA, 2001, MAYO CLIN PROC, V76, P358; Brading AF, 1997, UROLOGY, V50, P57, DOI 10.1016/S0090-4295(97)00591-8; Cardozo L, 2010, BJU INT, V106, P506, DOI 10.1111/j.1464-410X.2009.09160.x; Chapple CR, 2008, EUR UROL SUPPL, V7, P239; Chapple CR, 2008, EUR UROL, V54, P543, DOI 10.1016/j.eururo.2008.06.047; Chapple CR, 2006, EUR UROL, V49, P879, DOI 10.1016/j.eururo.2006.01.037; Chapple CR, 2005, EUR UROL, V48, P464, DOI 10.1016/j.eururo.2005.05.015; Colli E, 2007, EXPERT OPIN INV DRUG, V16, P999, DOI 10.1517/13543784.16.7.999; Diokno AC, 2003, MAYO CLIN PROC, V78, P687, DOI 10.4065/78.6.687; Green SA, 2006, J UROLOGY, V176, P2535, DOI 10.1016/j.juro.2006.08.018; Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Hashim H, 2004, NEUROUROL URODYNAM, V23, P484; Haylen BT, 2010, INT UROGYNECOL J, V21, P5, DOI [10.1007/s00192-009-0976-9, 10.1590/S1677-55382010000100032]; Herbison P, 2003, BMJ-BRIT MED J, V326, P841, DOI 10.1136/bmj.326.7394.841; Herschorn S, 2010, BJU INT, V105, P58, DOI 10.1111/j.1464-410X.2009.09086.x; Herzog AR., 2001, INT UROGYNAECOL J, V12, pS66; Kay GG, 2008, INT J CLIN PRACT, V62, P1792, DOI 10.1111/j.1742-1241.2008.01849.x; LAVAL KU, 1980, UROL INT, V35, P182, DOI 10.1159/000280321; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; Nabi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003781.pub2; Oefelein MG, 2011, DRUG SAFETY, V34, P733, DOI 10.2165/11592790-000000000-00000; Paquette A, 2011, J AM GERIATR SOC, V59, P1332, DOI 10.1111/j.1532-5415.2011.03473.x; Sexton CC, 2011, INT J CLIN PRACT, V65, P567, DOI 10.1111/j.1742-1241.2010.02626.x; Sibley GNA, 1997, BRIT J UROL, V80, P54; Speakman M, 2008, CURR MED RES OPIN, V24, P2173, DOI 10.1185/03007990802234829; Staskin D, 2010, INT J CLIN PRACT, V64, P1294, DOI 10.1111/j.1742-1241.2010.02433.x; Van Kerrebroeck P, 2001, UROLOGY, V57, P414, DOI 10.1016/S0090-4295(00)01113-4; Wesnes KA, 2009, EXPERT OPIN DRUG SAF, V8, P615, DOI 10.1517/14740330903260790	31	14	15	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2012	344								e2130	10.1136/bmj.e2130	http://dx.doi.org/10.1136/bmj.e2130			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923EV	22453185				2022-12-28	WOS:000302603100008
J	Delamothe, T				Delamothe, Tony			SPOTLIGHT: CLIMATE CHANGE The world on tilt	BRITISH MEDICAL JOURNAL			English	Article												tdelamothe@bmj.com							0	0	0	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2207	10.1136/bmj.e2207	http://dx.doi.org/10.1136/bmj.e2207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CO	22438387				2022-12-28	WOS:000301849200031
J	Wilmshurst, P				Wilmshurst, Peter			PERSONAL VIEW CLOSURE 1 seen through the MIST	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Shrewsbury Hosp, Shrewsbury, Shrops, England		Wilmshurst, P (corresponding author), Royal Shrewsbury Hosp, Shrewsbury, Shrops, England.	peter.wilmshurst@tiscali.co.uk							0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2226	10.1136/bmj.e2226	http://dx.doi.org/10.1136/bmj.e2226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438388				2022-12-28	WOS:000301849200032
J	Morisetti, N				Morisetti, Neil			Climate change and resource security	BRITISH MEDICAL JOURNAL			English	Article											Morisetti, N (corresponding author), Desk 6 G 20,Minist Def Main Bldg, London SW1A 2HB, England.	DBR-MOD-FCOCESE@mod.uk							0	6	6	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1352	10.1136/bmj.e1352	http://dx.doi.org/10.1136/bmj.e1352			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431658	Bronze			2022-12-28	WOS:000301848400004
J	Ruoff, R				Ruoff, Rodney			A means to an end	NATURE			English	Editorial Material							GRAPHENE		Univ Texas Austin, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Ruoff, R (corresponding author), Univ Texas Austin, Austin, TX 78712 USA.	r.ruoff@mail.utexas.edu	Ruoff, Rodney/ABE-6532-2020; Ruoff, Rodney S/B-7605-2009	Ruoff, Rodney/0000-0002-6599-6764; Ruoff, Rodney S/0000-0002-6599-6764				Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016; Luo JY, 2011, ACS NANO, V5, P8943, DOI 10.1021/nn203115u; Srivastava D, 1999, J PHYS CHEM B, V103, P4330, DOI 10.1021/jp990882s; Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969; Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770	5	44	46	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S42	S42		10.1038/483S42a	http://dx.doi.org/10.1038/483S42a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419213	Bronze			2022-12-28	WOS:000301481800007
J	Savage, N				Savage, Neil			OPTOELECTRONICS Come into the light	NATURE			English	Editorial Material																			0	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S38	S39		10.1038/483S38a	http://dx.doi.org/10.1038/483S38a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419211	Bronze			2022-12-28	WOS:000301481800005
J	Stone, GW; Maehara, A; Witzenbichler, B; Godlewski, J; Parise, H; Dambrink, JHE; Ochala, A; Carlton, TW; Cristea, E; Wolff, SD; Brener, SJ; Chowdhary, S; El-Omar, M; Neunteufl, T; Metzger, DC; Karwoski, T; Dizon, JM; Mehran, R; Gibson, CM				Stone, Gregg W.; Maehara, Akiko; Witzenbichler, Bernhard; Godlewski, Jacek; Parise, Helen; Dambrink, Jan-Henk E.; Ochala, Andrzej; Carlton, Trevor W.; Cristea, Ecaterina; Wolff, Steven D.; Brener, Sorin J.; Chowdhary, Saqib; El-Omar, Magdi; Neunteufl, Thomas; Metzger, D. Christopher; Karwoski, Theodore; Dizon, Jose M.; Mehran, Roxana; Gibson, C. Michael		INFUSE-AMI Investigators	Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction The INFUSE-AMI Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS CORONARY INTERVENTION; MAGNETIC-RESONANCE; THROMBUS ASPIRATION; DISTAL EMBOLIZATION; PRIMARY ANGIOPLASTY; BIVALIRUDIN; SIZE; MULTICENTER; OUTCOMES; DEVICES	Context Thrombus embolization during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is common and results in suboptimal myocardial perfusion and increased infarct size. Two strategies proposed to reduce distal embolization and improve outcomes after primary PCI are bolus intracoronary abciximab and manual aspiration thrombectomy. Objective To determine whether bolus intracoronary abciximab, manual aspiration thrombectomy, or both reduce infarct size in high-risk patients with STEMI. Design, Setting, and Patients Between November 28, 2009, and December 2, 2011, 452 patients presenting at 37 sites in 6 countries within 4 hours of STEMI due to proximal or mid left anterior descending artery occlusion undergoing primary PCI with bivalirudin anticoagulation were randomized in an open-label, 2 x 2 factorial design to bolus intracoronary abciximab delivered locally at the infarct lesion site vs no abciximab and to manual aspiration thrombectomy vs no thrombectomy. Interventions A 0.25-mg/kg bolus of abciximab was administered at the site of the infarct lesion via a local drug delivery catheter. Manual aspiration thrombectomy was performed with a 6 F aspiration catheter. Main Outcome Measures Primary end point: infarct size (percentage of total left ventricular mass) at 30 days assessed by cardiac magnetic resonance imaging (cMRI) in the abciximab vs no abciximab groups (pooled across the aspiration randomization); major secondary end point: 30-day infarct size in the aspiration vs no aspiration groups (pooled across the abciximab randomization). Results Evaluable cMRI results at 30 days were present in 181 and 172 patients randomized to intracoronary abciximab vs no abciximab, respectively, and in 174 and 179 patients randomized to manual aspiration vs no aspiration, respectively. Patients randomized to intracoronary abciximab compared with no abciximab had a significant reduction in 30-day infarct size (median, 15.1%; interquartile range [IQR], 6.8%-22.7%; n=181, vs 17.9% [IQR, 10.3%-25.4%]; n=172; P=.03). Patients randomized to intracoronary abciximab also had a significant reduction in absolute infarct mass (median, 18.7 g [IQR, 7.4-31.3 g]; n=184, vs 24.0 g [IQR, 12.1-34.2 g]; n=175; P=.03) but not abnormal wall motion score (median, 7.0 [IQR, 2.0-10.0]; n=188, vs 8.0 [IQR, 3.0-10.0]; n=184; P=. 08). Patients randomized to aspiration thrombectomy vs no aspiration had no significant difference in infarct size at 30 days (median, 17.0% [IQR, 9.0%-22.8%]; n=174, vs 17.3% [IQR, 7.1%-25.5%]; n=179; P=.51), absolute infarct mass (median, 20.3 g [IQR, 9.7-31.7 g]; n=178, vs 21.0 g [IQR, 9.1-34.1 g]; n=181; P=. 36), or abnormal wall motion score (median, 7.5 [IQR, 2.0-10.0]; n=186, vs 7.5 [IQR, 2.0-10.0]; n=186; P=.89). Conclusion In patients with large anterior STEMI presenting early after symptom onset and undergoing primary PCI with bivalirudin anticoagulation, infarct size at 30 days was significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion site but not by manual aspiration thrombectomy.	[Stone, Gregg W.; Maehara, Akiko; Parise, Helen; Dizon, Jose M.] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY 10022 USA; [Stone, Gregg W.; Maehara, Akiko; Parise, Helen; Dizon, Jose M.] New York Presbyterian Hosp, New York, NY USA; [Witzenbichler, Bernhard] Charite Campus Benjamin Franklin, Berlin, Germany; [Godlewski, Jacek] Jagiellonian Univ, Sch Med, Krakow, Poland; [Dambrink, Jan-Henk E.] Isala Klin, Zwolle, Netherlands; [Ochala, Andrzej] Med Univ Silesia, Katowice, Poland; [Carlton, Trevor W.; Karwoski, Theodore] Atrium Med, Hudson, NH USA; [Chowdhary, Saqib] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; [El-Omar, Magdi] Manchester Heart Ctr, Manchester, Lancs, England; [Neunteufl, Thomas] Univ Vienna, Sch Med, Vienna, Austria; [Metzger, D. Christopher] Wellmont CVA Heart Inst, Kingsport, TN USA; [Gibson, C. Michael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; [Brener, Sorin J.] New York Methodist Hosp, Brooklyn, NY USA; [Mehran, Roxana] Mt Sinai Med Ctr, New York, NY 10029 USA	Cardiovascular Research Foundation (CRF); Columbia University; NewYork-Presbyterian Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Jagiellonian University; Isala Clinics; Medical University Silesia; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Vienna; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai	Stone, GW (corresponding author), Columbia Univ, Med Ctr, Cardiovasc Res Fdn, 111 E 59th St,11th Floor, New York, NY 10022 USA.	gs2184@columbia.edu	Gibson, C. Michael/AAE-8212-2019; Ochala, Andrzej/AAH-3855-2020; Mehran, Roxana/ABF-4160-2021; Witzenbichler, Bernhard/ABC-2525-2021	Parise, Helen/0000-0001-7761-4973; Baumbach, Andreas/0000-0001-7707-2254; Witzenbichler, Bernhard/0000-0001-9322-1926; Ochala, Andrzej/0000-0002-2484-967X; Curzen, Nick/0000-0001-9651-7829	Abbott Vascular; AstraZeneca; Atrium; Boston Scientific; Edwards Life Sciences; Eli Lilly-Daiichi Sankyo; BMS/sanofi-aventis; IDEV; Pathway; Alpha Medical; Medicines Company; Daiichi Sankyo; Eli Lilly; Atrium Medical	Abbott Vascular(Abbott Laboratories); AstraZeneca(AstraZeneca); Atrium; Boston Scientific(Boston Scientific); Edwards Life Sciences; Eli Lilly-Daiichi Sankyo(Daiichi Sankyo Company LimitedEli Lilly); BMS/sanofi-aventis(Sanofi-Aventis); IDEV; Pathway; Alpha Medical; Medicines Company; Daiichi Sankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Atrium Medical	Dr Stone reports having served as a consultant for Medtronic, Osprey, Reva, Merck, Abbott Vascular, Boston Scientific, Evalve, AstraZeneca, Eli Lilly-Daiichi Sankyo partnership, Bristol-Meyers Squibb-Sanofi partnership, Otsuka, The Medicines Company, Ortho-McNeil, Atrium, Gilead, InspireMD, TherOx, Volcano, InfraReDx, Genentech, GlaxoSmithKline, Miracor, MPP Group, and Lutonix; having received honoraria from Edwards and Vascular Solutions; and holding stock or options from CoreValve, Savacor, Biostar I and II funds, MedFocus I, II, and Accelerator funds, Caliber, Flowcardia, Mediguide, Guided Delivery Systems, Ovalum, Arstasis, Micardia, Access Closure, Embrella and VNT. Dr Witzenbichler reports having served on advisory boards for Boston Scientific and Biotronik and receiving lecture honoraria from Boston Scientific, Biotronik, Medtronic, and The Medicines Company. Mr Carlton and Mr Karwoski report being employed by Atrium Medical. Dr Wolff reports receiving honoraria and royalties from GE Healthcare and is the founder of NeoSoft and NeoCoil. Dr Brener reports having served as a consultant for Medtronic and receiving lecture honoraria for Eli Lilly. Dr Neunteufl reports having served on advisory boards for AstraZeneca, Bayer, Biotronik, Boston Scientific, Eli Lilly-Daiichi Sankyo, and St Jude and having received lecture fees from Abbott Vascular, AstraZeneca, Atrium, Boston Scientific, Edwards Life Sciences, Eli Lilly-Daiichi Sankyo and BMS/sanofi-aventis. Dr Metzger reports serving as a consultant for Abbott Vascular, Medtronic, Lutonix, IDEV, Cook Medical, and Cordis Endovascular and has received lecture fees from IDEV, Pathway, and Alpha Medical. Dr Mehran reports serving as a consultant for Abbott Vascular, AstraZeneca, Ortho McNeil, and Regado Biosciences and receiving grants from BMS/sanofi-aventis and The Medicines Company. Dr Gibson reports having served as a consultant for Biogen IDEC, Bristol Meyer Squibb, Daiichi-Sankyo, CSL Behring, Cytori Therapeutics, Eli Lilly, GlaxoSmithKline, Genentech, Ischemix, Bayer, Johnson and Johnson, Ortho McNeil, Merck, Portola Pharmaceuticals, Regado Biosciences, sanofi-aventis, St Jude, The Medicines Company, Medicure, Archemix, and Boeringer Ingelheim; having received lecture fees from Daiichi Sankyo, Eli Lilly, and The Medicines Company; receiving royalties from UpToDate in CV Medicine; and having received payments for development of educational presentations from Daiichi Sankyo and Eli Lilly. The other authors report no disclosures.; This study was sponsored and funded by Atrium Medical. Atrium supplied the local drug delivery catheter. Aspiration catheters were provided at a discount by Medtronic. Bivalirudin was provided at no charge by The Medicines Company. All other study devices and drugs were commercially purchased.	Abdel-Aty H, 2009, J AM COLL CARDIOL, V53, P1194, DOI 10.1016/j.jacc.2008.10.065; Alexander W, TCTMD; Bartorelli AL, 1999, CATHETER CARDIO INTE, V48, P211, DOI 10.1002/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V; Brener SJ, 2011, AM HEART J, V162, P1044, DOI 10.1016/j.ahj.2011.08.022; Cheong BYC, 2009, CIRCULATION, V120, P2069, DOI 10.1161/CIRCULATIONAHA.109.852517; De Luca G, 2008, EUR HEART J, V29, P3002, DOI 10.1093/eurheartj/ehn389; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; Gibson CM, 2011, AM HEART J, V161, P478, DOI 10.1016/j.ahj.2010.10.006; Gu YL, 2010, CIRCULATION, V122, P2709, DOI 10.1161/CIRCULATIONAHA.110.002741; Henriques JPS, 2002, EUR HEART J, V23, P1112, DOI 10.1053/euhj.2001.3035; Inaba Y, 2009, EUROINTERVENTION, V5, P375, DOI 10.4244/V5I3A59; Kaltoft A, 2006, CIRCULATION, V114, P40, DOI 10.1161/CIRCULATIONAHA.105.595660; Marciniak SJ, 2002, THROMB HAEMOSTASIS, V87, P1020; McLaughlin MG, 2004, J AM COLL CARDIOL, V44, P1215, DOI 10.1016/j.jacc.2004.06.053; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Moser M, 2003, J CARDIOVASC PHARM, V41, P586, DOI 10.1097/00005344-200304000-00011; Navarese EP, 2012, PLATELETS, V23, P274, DOI 10.3109/09537104.2011.619602; Patel MR, 2011, JAMA-J AM MED ASSOC, V306, P1329, DOI 10.1001/jama.2011.1280; Rassen JA, 2010, EUR HEART J, V31, P561, DOI 10.1093/eurheartj/ehp437; Ripa RS, 2007, AM HEART J, V154, P929, DOI 10.1016/j.ahj.2007.06.038; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Stone GW, 2007, AM J CARDIOL, V100, P1370, DOI 10.1016/j.amjcard.2007.06.027; Stone GW, 2011, LANCET, V377, P2193, DOI 10.1016/S0140-6736(11)60764-2; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Svilaas T, 2008, NEW ENGL J MED, V358, P557, DOI 10.1056/NEJMoa0706416; Thiele H, 2008, CIRCULATION, V118, P49, DOI 10.1161/CIRCULATIONAHA.107.747642; Vlaar PJ, 2008, LANCET, V371, P1915, DOI 10.1016/S0140-6736(08)60833-8; Vlaar PJ, 2008, JACC-CARDIOVASC INTE, V1, P258, DOI 10.1016/j.jcin.2008.03.014; Wu E, 2008, HEART, V94, P730, DOI 10.1136/hrt.2007.122622; Wu KC, 1998, CIRCULATION, V97, P765, DOI 10.1161/01.CIR.97.8.765	30	366	381	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2012	307	17					1817	1826		10.1001/jama.2012.421	http://dx.doi.org/10.1001/jama.2012.421			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TV	22447888	Bronze			2022-12-28	WOS:000303386800021
J	Kobayashi, T; Saji, T; Otani, T; Takeuchi, K; Nakamura, T; Arakawa, H; Kato, T; Hara, T; Hamaoka, K; Ogawa, S; Miura, M; Nomura, Y; Fuse, S; Ichida, F; Seki, M; Fukazawa, R; Ogawa, C; Furuno, K; Tokunaga, H; Takatsuki, S; Hara, S; Morikawa, A				Kobayashi, Tohru; Saji, Tsutomu; Otani, Tetsuya; Takeuchi, Kazuo; Nakamura, Tetsuya; Arakawa, Hirokazu; Kato, Taichi; Hara, Toshiro; Hamaoka, Kenji; Ogawa, Shunichi; Miura, Masaru; Nomura, Yuichi; Fuse, Shigeto; Ichida, Fukiko; Seki, Mitsuru; Fukazawa, Ryuji; Ogawa, Chitose; Furuno, Kenji; Tokunaga, Hirohide; Takatsuki, Shinichi; Hara, Shinya; Morikawa, Akihiro		RAISE Study Grp Investigators	Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial	LANCET			English	Article							INTRAVENOUS GAMMA-GLOBULIN; CORTICOSTEROID-THERAPY; ANEURYSM FORMATION; INITIAL TREATMENT; PULSE THERAPY; ACUTE-PHASE; METHYLPREDNISOLONE; RETREATMENT; CHILDREN; JAPAN	Background Evidence indicates that corticosteroid therapy might be beneficial for the primary treatment of severe Kawasaki disease. We assessed whether addition of prednisolone to intravenous immunoglobulin with aspirin would reduce the incidence of coronary artery abnormalities in patients with severe Kawasaki disease. Methods We did a multicentre, prospective, randomised, open-label, blinded-endpoints trial at 74 hospitals in Japan between Sept 29, 2008, and Dec 2, 2010. Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised). Patients and treating physicians were unmasked to group allocation. The primary endpoint was incidence of coronary artery abnormalities during the study period. Analysis was by intention to treat. This trial is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000000940. Findings We randomly assigned 125 patients to the intravenous immunoglobulin plus prednisolone group and 123 to the intravenous immunoglobulin group. Incidence of coronary artery abnormalities was significantly lower in the intravenous immunoglobulin plus prednisolone group than in the intravenous immunoglobulin group during the study period (four patients [3%] vs 28 patients [23%]; risk difference 0.20, 95% CI 0.12-0.28, p<0.0001). Serious adverse events were similar between both groups: two patients had high total cholesterol and one neutropenia in the intravenous immunoglobulin plus prednisolone group, and one had high total cholesterol and another non-occlusive thrombus in the intravenous immunoglobulin group. Interpretation Addition of prednisolone to the standard regimen of intravenous immunoglobulin improves coronary artery outcomes in patients with severe Kawasaki disease in Japan. Further study of intensified primary treatment for this disease in a mixed ethnic population is warranted.	[Kobayashi, Tohru; Arakawa, Hirokazu; Morikawa, Akihiro] Gunma Univ, Grad Sch Med, Dept Pediat, Gunma 3718511, Japan; [Saji, Tsutomu; Takatsuki, Shinichi] Toho Univ, Omori Med Ctr, Dept Pediat 1, Tokyo, Japan; [Otani, Tetsuya] Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan; [Takeuchi, Kazuo] Saitama Univ, Fac Educ, Saitama 3388570, Japan; [Nakamura, Tetsuya] Gunma Univ Hosp, Clin Invest & Res Unit, Gunma, Japan; [Kato, Taichi] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi 4648601, Japan; [Hara, Toshiro] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Japan; [Hamaoka, Kenji] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat Cardiol & Nephrol, Kyoto, Japan; [Ogawa, Shunichi; Fukazawa, Ryuji] Nippon Med Sch, Dept Pediat, Tokyo 113, Japan; [Miura, Masaru] Tokyo Metropolitan Childrens Med Ctr, Dept Cardiol, Tokyo, Japan; [Nomura, Yuichi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pediat, Kagoshima 890, Japan; [Fuse, Shigeto] NTT E Japan Sapporo Hosp, Dept Pediat, Sapporo, Hokkaido, Japan; [Ichida, Fukiko] Toyama Univ, Dept Pediat, Toyama 930, Japan; [Seki, Mitsuru] Gunma Childrens Med Ctr, Dept Cardiol, Gunma, Japan; [Fukazawa, Ryuji] Tama Nagayama Hosp, Nippon Med Sch, Dept Pediat, Tokyo, Japan; [Ogawa, Chitose] St Lukes Int Hosp, Dept Pediat, Tokyo, Japan; [Furuno, Kenji] Fukuoka Higashi Med Ctr, Dept Pediat, Fukuoka, Japan; [Tokunaga, Hirohide] Nagoya Mem Hosp, Dept Pediat, Nagoya, Aichi, Japan; [Hara, Shinya] Toyota Mem Hosp, Dept Pediat, Toyota, Japan	Gunma University; Toho University; National Center for Child Health & Development - Japan; Saitama University; Gunma University; Nagoya University; Kyushu University; Kyoto Prefectural University of Medicine; Nippon Medical School; Tokyo Metropolitan Children's Medical Center; Kagoshima University; University of Toyama; Gunma Children's Medical Centre; Nippon Medical School; St. Luke's International Hospital	Kobayashi, T (corresponding author), Gunma Univ, Grad Sch Med, Dept Pediat, Gunma 3718511, Japan.	torukoba@nifty.com	Yamagishi, Hiroyuki/A-6345-2017; Furuno, Kenji/ABD-6491-2020; Kato, Taichi/I-7386-2014	Furuno, Kenji/0000-0003-3991-8348	Japanese Ministry of Health, Labour and Welfare; Health and Labour Sciences Research Grants; Grants-in-Aid for Scientific Research [24591578] Funding Source: KAKEN	Japanese Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Health and Labour Sciences Research Grants(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by Japanese Ministry of Health, Labour and Welfare, Health and Labour Sciences Research Grants for the Comprehensive Research on Practical Application of Medical Technology: Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE study). We thank all our patients, their families, and the site investigators, and David Kipler for editing of the article.	Ayusawa M, 2005, PEDIATR INT, V47, P232, DOI 10.1111/j.1442-200x.2005.02033.x; Brown TJ, 2001, J INFECT DIS, V184, P940, DOI 10.1086/323155; Burns JC, 2006, J PEDIATR-US, V149, P291, DOI 10.1016/j.jpeds.2006.07.016; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Burns JC, 1998, PEDIATR INFECT DIS J, V17, P1144, DOI 10.1097/00006454-199812000-00009; Durongpisitkul K, 2003, PEDIATR CARDIOL, V24, P145, DOI 10.1007/s00246-002-0216-2; FURUSHO K, 1984, LANCET, V2, P1055; Fuse S MM, 2009, J JAPAN PEDIAT SOC, V113, P928; Inoue Y, 2006, J PEDIATR-US, V149, P336, DOI 10.1016/j.jpeds.2006.05.025; KATO H, 1979, PEDIATRICS, V63, P175; KIJIMA Y, 1982, JPN CIRC J, V46, P1239, DOI 10.1253/jcj.46.1239; Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865; Kobayashi T, 2009, PEDIATR INFECT DIS J, V28, P498, DOI 10.1097/INF.0b013e3181950b64; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Miura M, 2005, ARCH DIS CHILD, V90, P1096, DOI 10.1136/adc.2004.062299; Nakamura Y, 2010, J EPIDEMIOL, V20, P302, DOI 10.2188/jea.JE20090180; Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Okada K, 2009, EUR J PEDIATR, V168, P181, DOI 10.1007/s00431-008-0727-9; Okada Y, 2003, J PEDIATR-US, V143, P363, DOI 10.1067/S0022-3476(03)00387-1; Pyne D, 2002, RHEUMATOLOGY, V41, P367, DOI 10.1093/rheumatology/41.4.367; Research Committee on Kawasaki Disease, 1984, REP SUBC STAND DIAGN; Rowley AH, 1997, J IMMUNOL, V159, P5946; SAJI T, 2003, J JAPAN PEDIAT SOC, V107, P1713; Seki M, 2011, PEDIATR INFECT DIS J, V30, P145, DOI 10.1097/INF.0b013e3181f386db; Shinohara M, 1999, J PEDIATR-US, V135, P465, DOI 10.1016/S0022-3476(99)70169-1; Sinha A, 2008, INDIAN J PEDIATR, V75, P1057, DOI 10.1007/s12098-008-0210-7; Sleeper LA, 2011, J PEDIATR-US, V158, P831, DOI 10.1016/j.jpeds.2010.10.031; Sundel RP, 2003, J PEDIATR-US, V142, P611, DOI 10.1067/mpd.2003.191; Uehara R, 2008, PEDIATR INFECT DIS J, V27, P155, DOI 10.1097/INF.0b013e31815922b5; Wooditch AC, 2005, PEDIATRICS, V116, P989, DOI 10.1542/peds.2005-0504; Zhu BH, 2012, EUR J PEDIATR, V171, P571, DOI 10.1007/s00431-011-1585-4	33	362	384	4	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 28	2012	379	9826					1613	1620		10.1016/S0140-6736(11)61930-2	http://dx.doi.org/10.1016/S0140-6736(11)61930-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934OB	22405251				2022-12-28	WOS:000303452600035
J	Chen, Z; Cheng, K; Walton, Z; Wang, YC; Ebi, H; Shimamura, T; Liu, Y; Tupper, T; Ouyang, J; Li, J; Gao, P; Woo, MS; Xu, CX; Yanagita, M; Altabef, A; Wang, SM; Lee, C; Nakada, Y; Pena, CG; Sun, YP; Franchetti, Y; Yao, C; Saur, A; Cameron, MD; Nishino, M; Hayes, DN; Wilkerson, MD; Roberts, PJ; Lee, CB; Bardeesy, N; Butaney, M; Chirieac, LR; Costa, DB; Jackman, D; Sharpless, NE; Castrillon, DH; Demetri, GD; Janne, PA; Pandolfi, PP; Cantley, LC; Kung, AL; Engelman, JA; Wong, KK				Chen, Zhao; Cheng, Katherine; Walton, Zandra; Wang, Yuchuan; Ebi, Hiromichi; Shimamura, Takeshi; Liu, Yan; Tupper, Tanya; Ouyang, Jing; Li, Jie; Gao, Peng; Woo, Michele S.; Xu, Chunxiao; Yanagita, Masahiko; Altabef, Abigail; Wang, Shumei; Lee, Charles; Nakada, Yuji; Pena, Christopher G.; Sun, Yanping; Franchetti, Yoko; Yao, Catherine; Saur, Amy; Cameron, Michael D.; Nishino, Mizuki; Hayes, D. Neil; Wilkerson, Matthew D.; Roberts, Patrick J.; Lee, Carrie B.; Bardeesy, Nabeel; Butaney, Mohit; Chirieac, Lucian R.; Costa, Daniel B.; Jackman, David; Sharpless, Norman E.; Castrillon, Diego H.; Demetri, George D.; Jaenne, Pasi A.; Pandolfi, Pier Paolo; Cantley, Lewis C.; Kung, Andrew L.; Engelman, Jeffrey A.; Wong, Kwok-Kin			A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response	NATURE			English	Article							STANDARDIZED UPTAKE VALUE; VOLUME MEASUREMENT; MOUSE MODELS; SURVIVAL; METAANALYSIS; GEFITINIB; DOCETAXEL; ADENOCARCINOMA; ARRY-142886; ACTIVATION	Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers(1-4). Although most patients with lung cancer are stratified according to a single oncogenic driver, cancers harbouring identical activating genetic mutations show large variations in their responses to the same targeted therapy(1,3). The biology underlying this heterogeneity is not well understood, and the impact of co-existing genetic mutations, especially the loss of tumour suppressors(5-) (9), has not been fully explored. Here we use genetically engineeredmousemodels to conduct a ` co-clinical' trial that mirrors an ongoing human clinical trial in patients with KRAS-mutant lung cancers. This trial aims to determine if the MEK inhibitor selumetinib (AZD6244)(10) increases the efficacy of docetaxel, a standard of care chemotherapy. Our studies demonstrate that concomitant loss of either p53 (also known as Tp53) or Lkb1 (also known as Stk11), two clinically relevant tumour suppressors(6,9,11,12), markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy. We observed that the addition of selumetinib provided substantial benefit for mice with lung cancer caused by Kras and Kras and p53 mutations, but mice with Kras and Lkb1 mutations had primary resistance to this combination therapy. Pharmacodynamic studies, including positron-emission tomography (PET) and computed tomography (CT), identified biological markers in mice and patients that provide a rationale for the differential efficacy of these therapies in the different genotypes. These co-clinical results identify predictive genetic biomarkers that should be validated by interrogating samples from patients enrolled on the concurrent clinical trial. These studies also highlight the rationale for synchronous co-clinical trials, not only to anticipate the results of ongoing human clinical trials, but also to generate clinically relevant hypotheses that can inform the analysis and design of human studies.	[Chen, Zhao; Ebi, Hiromichi; Liu, Yan; Xu, Chunxiao; Jaenne, Pasi A.; Engelman, Jeffrey A.; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Chen, Zhao; Cheng, Katherine; Walton, Zandra; Liu, Yan; Ouyang, Jing; Gao, Peng; Woo, Michele S.; Xu, Chunxiao; Yanagita, Masahiko; Altabef, Abigail; Yao, Catherine; Butaney, Mohit; Jackman, David; Jaenne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, Zhao; Cheng, Katherine; Walton, Zandra; Liu, Yan; Gao, Peng; Xu, Chunxiao; Demetri, George D.; Wong, Kwok-Kin] Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr Dana Farber, Boston, MA 02115 USA; [Wang, Yuchuan; Tupper, Tanya; Sun, Yanping; Saur, Amy; Kung, Andrew L.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA; [Wang, Yuchuan; Sun, Yanping; Nishino, Mizuki] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA; [Wang, Yuchuan; Nishino, Mizuki] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Ebi, Hiromichi; Bardeesy, Nabeel; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Dept Med Oncol, Boston, MA 02114 USA; [Shimamura, Takeshi] Loyola Univ Chicago, Stritch Sch Med, Inst Oncol, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA; [Li, Jie] Iowa State Univ, Dept Stat & Stat Lab, Ctr Survey Stat & Methodol, Ames, IA 50010 USA; [Wang, Shumei; Lee, Charles; Chirieac, Lucian R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Nakada, Yuji; Pena, Christopher G.; Castrillon, Diego H.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Nakada, Yuji; Pena, Christopher G.; Castrillon, Diego H.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Franchetti, Yoko] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst,Dept Biostat, Boston, MA 02115 USA; [Cameron, Michael D.] Scripps Res Inst, Translat Res Inst, Jupiter, FL 33458 USA; [Hayes, D. Neil; Wilkerson, Matthew D.; Roberts, Patrick J.; Lee, Carrie B.; Sharpless, Norman E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Costa, Daniel B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; [Jaenne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program,Dept Med & Pathol, Boston, MA 02115 USA; [Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; [Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Kung, Andrew L.] Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Loyola University Chicago; Iowa State University; Harvard University; Brigham & Women's Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Wong, KK (corresponding author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.	andrew_kung@dfci.harvard.edu; jengelman@partners.org; kwong1@partners.org	Butaney, Mohit/O-5511-2019; Cantley, Lewis C/D-1800-2014; Kung, Andrew/AAL-2384-2020; Lee, Carrie/AAT-6939-2021; Kung, Andrew L/AEU-0826-2022; Chirieac, Lucian R./AAD-2030-2019; Ebi, Hiromichi/AAA-7358-2019	Butaney, Mohit/0000-0002-4760-4026; Cantley, Lewis C/0000-0002-1298-7653; Lee, Carrie/0000-0003-4786-3834; Kung, Andrew L/0000-0002-9091-488X; Ebi, Hiromichi/0000-0003-3155-7576; Cameron, Michael/0000-0003-3154-4775; Costa, Daniel/0000-0002-0689-395X; Hayes, D. Neil/0000-0001-6203-7771; Wang, Yuchuan/0000-0001-5111-6562; Pandolfi, Pier Paolo/0000-0002-5352-5295; wong, kwok kin/0000-0001-6323-235X; Walton, Zandra/0000-0002-0465-0153; Sharpless, Norman/0000-0001-7078-9455	National Institutes of Health [CA122794, CA140594, CA137181, CA137008, CA147940, CA137008-01, 1U01CA141576, Lung SPORE P50CA090578]; United against Lung Cancer Foundation; American Lung Association; Susan Spooner Research Fund; NATIONAL CANCER INSTITUTE [P50CA090578, U01CA141576, P01CA120964, R01CA166480, R01CA163896, P30CA016086, R01CA140594, R01CA137181, K23CA157631, RC2CA147940, R01CA137008, R01CA122794] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United against Lung Cancer Foundation; American Lung Association; Susan Spooner Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the National Institutes of Health (CA122794, CA140594, CA137181, CA137008, CA147940, CA137008-01, 1U01CA141576, Lung SPORE P50CA090578), United against Lung Cancer Foundation, American Lung Association and Susan Spooner Research Fund.	Ahrendt SA, 2003, J NATL CANCER I, V95, P961, DOI 10.1093/jnci/95.13.961; Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Douillard JY, 2010, J CLIN ONCOL, V28, P744, DOI 10.1200/JCO.2009.24.3030; DYKES DJ, 1995, INVEST NEW DRUG, V13, P1, DOI 10.1007/BF02614214; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Erasmus Jeremy J, 2009, Proc Am Thorac Soc, V6, P171, DOI 10.1513/pats.200806-059LC; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Hainsworth JD, 2010, J THORAC ONCOL, V5, P1630, DOI 10.1097/JTO.0b013e3181e8b3a3; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; LoRusso PM, 2008, J CLIN ONCOL, V26, P3051, DOI 10.1200/JCO.2007.14.9633; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nishino M, 2011, ACAD RADIOL, V18, P54, DOI 10.1016/j.acra.2010.08.021; Politi K, 2011, J CLIN ONCOL, V29, P2273, DOI 10.1200/JCO.2010.30.8304; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Vansteenkiste JF, 1999, J CLIN ONCOL, V17, P3201, DOI 10.1200/JCO.1999.17.10.3201; Verhoeven D, 2009, VIROLOGY, V390, P151, DOI 10.1016/j.virol.2009.05.004; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zhao BS, 2010, CLIN CANCER RES, V16, P4647, DOI 10.1158/1078-0432.CCR-10-0125	30	353	364	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 29	2012	483	7391					613	617		10.1038/nature10937	http://dx.doi.org/10.1038/nature10937			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22425996	Green Published, Green Accepted			2022-12-28	WOS:000302006100042
J	Ma, D; Lu, PL; Yan, CY; Fan, C; Yin, P; Wang, JW; Shi, YG				Ma, Dan; Lu, Peilong; Yan, Chuangye; Fan, Chao; Yin, Ping; Wang, Jiawei; Shi, Yigong			Structure and mechanism of a glutamate-GABA antiporter	NATURE			English	Article							AMINO-ACID ANTIPORTER; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; SUBSTRATE RECOGNITION; AGMATINE ANTIPORTER; BINDING-SITE; RESISTANCE; TRANSPORTER; ARGININE	Food-borne hemorrhagic Escherichia coli, exemplified by the strains O157:H7 and O104:H4 (refs 1, 2), require elaborate acid-resistance systems (ARs)(3) to survive the extremely acidic environment such as the stomach (pH approximate to 2). AR2 expels intracellular protons through the decarboxylation of L-glutamate (Glu) in the cytoplasm and exchange of the reaction product c-aminobutyric acid (GABA) with extracellular Glu. The latter process is mediated by the Glu-GABA antiporter GadC(4,5), a representative member of theamino-acid-polyamine-organocation superfamily of membrane transporters. The functional mechanism of GadC remains largely unknown. Here we show, with the use of anin vitro proteoliposome-based assay, that GadC transports GABA/Glu only under acidic conditions, with no detectable activity at pH values higher than 6.5. We determined the crystal structure of E. coli GadC at 3.1 angstrom resolution under basic conditions. GadC, comprising 12 transmembrane segments (TMs), exists in a closed state, with its carboxy-terminal domain serving as a plug to block an otherwise inward-open conformation. Structural and biochemical analyses reveal the essential transport residues, identify the transport path and suggest a conserved transport mechanism involving the rigid-body rotation of a helical bundle for GadC and other amino acid antiporters.	[Ma, Dan; Lu, Peilong; Fan, Chao; Shi, Yigong] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, Prot Sci Lab,Minist Educ, Beijing 100084, Peoples R China; [Ma, Dan; Lu, Peilong; Yan, Chuangye; Fan, Chao; Yin, Ping; Wang, Jiawei; Shi, Yigong] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China; [Yan, Chuangye; Yin, Ping; Wang, Jiawei] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; [Ma, Dan; Lu, Peilong; Yan, Chuangye; Shi, Yigong] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, Tsinghua Peking Joint Ctr Life Sci, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University	Shi, YG (corresponding author), Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, Prot Sci Lab,Minist Educ, Beijing 100084, Peoples R China.	shi-lab@tsinghua.edu.cn	Wang, Jiawei/D-1144-2010; Yan, Chuangye/AAJ-5832-2021	Wang, Jiawei/0000-0001-9893-8539; Lu, Peilong/0000-0001-5894-9268; Shi, Yigong/0000-0003-2030-168X; Yan, Chuangye/0000-0001-9338-8048	Ministry of Science and Technology [2009CB918801]; National Natural Science Foundation; Beijing Municipal Commissions of Education and Science and Technology	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Municipal Commissions of Education and Science and Technology	We thank S. Huang and J. He (at SSRF beamline BL17U) and N. Shimizu, T. Kumasaka and S. Baba at the Spring-8 beamline BL41XU for on-site assistance, and N. Yan for discussion and comments on the manuscript. This work was supported by funds from the Ministry of Science and Technology (grant 2009CB918801), National Natural Science Foundation, and Beijing Municipal Commissions of Education and Science and Technology.	Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; Cowtan K., 1994, CRYSTALLOGRAPHY, V31, P34; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faham S, 2008, SCIENCE, V321, P810, DOI 10.1126/science.1160406; Fang YL, 2007, J BIOL CHEM, V282, P176, DOI 10.1074/jbc.M610075200; Fang YL, 2009, NATURE, V460, P1040, DOI 10.1038/nature08201; Foster JW, 2004, NAT REV MICROBIOL, V2, P898, DOI 10.1038/nrmicro1021; Gao X, 2010, NATURE, V463, P828, DOI 10.1038/nature08741; Gao X, 2009, SCIENCE, V324, P1565, DOI 10.1126/science.1173654; Gong S, 2003, J BACTERIOL, V185, P4402, DOI 10.1128/JB.185.15.4402-4409.2003; Hersh BM, 1996, J BACTERIOL, V178, P3978, DOI 10.1128/jb.178.13.3978-3981.1996; Iyer R, 2003, J BACTERIOL, V185, P6556, DOI 10.1128/JB.185.22.6556-6561.2003; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; Kowalczyk L, 2011, P NATL ACAD SCI USA, V108, P3935, DOI 10.1073/pnas.1018081108; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ressl S, 2009, NATURE, V458, P47, DOI 10.1038/nature07819; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Robertson JL, 2010, NATURE, V468, P844, DOI 10.1038/nature09556; Rohde H, 2011, NEW ENGL J MED, V365, P718, DOI 10.1056/NEJMoa1107643; Sasahara A, 2011, J BIOL CHEM, V286, P29044, DOI 10.1074/jbc.M111.260224; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shaffer PL, 2009, SCIENCE, V325, P1010, DOI 10.1126/science.1176088; Shimamura T, 2010, SCIENCE, V328, P470, DOI 10.1126/science.1186303; Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; Watanabe A, 2010, NATURE, V468, P988, DOI 10.1038/nature09580; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; Weyand S, 2008, SCIENCE, V322, P709, DOI [10.1126/science.1164440, 10.1126/science.1160058]; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	35	137	146	4	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 29	2012	483	7391					632	U161		10.1038/nature10917	http://dx.doi.org/10.1038/nature10917			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22407317				2022-12-28	WOS:000302006100046
J	Ioannidis, JPA				Ioannidis, John P. A.			Are Medical Conferences Useful? And for Whom?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-PRACTICE GUIDELINES; CONFLICTS-OF-INTEREST		[Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Ioannidis, John P. A.] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Ioannidis, JPA (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, 1265 Welch Rd,MSOB X306, Stanford, CA 94305 USA.	jioannid@stanford.edu	Ioannidis, John P. A./G-9836-2011					Green M, 2008, BRIT MED J, V336, P1466, DOI [10.1136/bmj.a358, 10.1136/bmj.a351]; Mendelson TB, 2011, ARCH INTERN MED, V171, P577, DOI 10.1001/archinternmed.2011.96; Moynihan R, 2008, BRIT MED J, V336, P1402, DOI 10.1136/bmj.39575.675787.651; Neuman J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5621; Ross JS, 2006, JAMA-J AM MED ASSOC, V295, P1675, DOI 10.1001/jama.295.14.1675; Scherer RW, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000005.pub3, 10.1002/14651858.MR000005.pub4]; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Toma M, 2006, JAMA-J AM MED ASSOC, V295, P1281, DOI 10.1001/jama.295.11.1281	8	76	75	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1257	1258		10.1001/jama.2012.360	http://dx.doi.org/10.1001/jama.2012.360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453564				2022-12-28	WOS:000301978400018
J	Kawakatsu, H				Kawakatsu, Hitoshi			At the Bottom of the Oceanic Plate	SCIENCE			English	Editorial Material									Univ Tokyo, Earthquake Res Inst, Tokyo 1130032, Japan	University of Tokyo	Kawakatsu, H (corresponding author), Univ Tokyo, Earthquake Res Inst, Tokyo 1130032, Japan.	hitosi@eri.u-tokyo.ac.jp						Anderson D.L., 1970, PHYS EARTH PLANET IN, V3, P41, DOI DOI 10.1016/0031-9201(70)90042-7; Bagley B, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2008JB005692; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; Kawakatsu H, 2009, SCIENCE, V324, P499, DOI 10.1126/science.1169499; Maggi A, 2006, EARTH PLANET SC LETT, V250, P53, DOI 10.1016/j.epsl.2006.07.010; Nettles M, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2006JB004819; Richards MA, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000115; Rychert CA, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB008070; Schmerr N, 2012, SCIENCE, V335, P1480, DOI 10.1126/science.1215433; Stixrude L, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB002965; Takei Y, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005850	11	2	2	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1448	1449		10.1126/science.1219658	http://dx.doi.org/10.1126/science.1219658			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442468				2022-12-28	WOS:000301837000029
J	Rule, S; Brook, BW; Haberle, SG; Turney, CSM; Kershaw, AP; Johnson, CN				Rule, Susan; Brook, Barry W.; Haberle, Simon G.; Turney, Chris S. M.; Kershaw, A. Peter; Johnson, Christopher N.			The Aftermath of Megafaunal Extinction: Ecosystem Transformation in Pleistocene Australia	SCIENCE			English	Article							LATE QUATERNARY EXTINCTIONS; NEW-GUINEA; SPORORMIELLA; COLLAPSE; SPORES	Giant vertebrates dominated many Pleistocene ecosystems. Many were herbivores, and their sudden extinction in prehistory could have had large ecological impacts. We used a high-resolution 130,000-year environmental record to help resolve the cause and reconstruct the ecological consequences of extinction of Australia's megafauna. Our results suggest that human arrival rather than climate caused megafaunal extinction, which then triggered replacement of mixed rainforest by sclerophyll vegetation through a combination of direct effects on vegetation of relaxed herbivore pressure and increased fire in the landscape. This ecosystem shift was as large as any effect of climate change over the last glacial cycle, and indicates the magnitude of changes that may have followed megafaunal extinction elsewhere in the world.	[Johnson, Christopher N.] Univ Tasmania, Sch Zool, Hobart, Tas 7001, Australia; [Rule, Susan; Haberle, Simon G.] Australian Natl Univ, Sch Culture Hist & Language, Canberra, ACT 0200, Australia; [Rule, Susan] James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia; [Brook, Barry W.] Univ Adelaide, Inst Environm, Adelaide, SA 5005, Australia; [Brook, Barry W.] Univ Adelaide, Sch Earth & Environm Sci, Adelaide, SA 5005, Australia; [Turney, Chris S. M.] Univ New S Wales, Climate Change Res Ctr, Sydney, NSW 2052, Australia; [Kershaw, A. Peter] Monash Univ, Sch Geog & Environm Sci, Clayton, Vic 3168, Australia	University of Tasmania; Australian National University; James Cook University; University of Adelaide; University of Adelaide; University of New South Wales Sydney; Monash University	Johnson, CN (corresponding author), Univ Tasmania, Sch Zool, Hobart, Tas 7001, Australia.	c.n.johnson@utas.edu.au	Turney, Chris S M/P-8701-2018; Johnson, Christopher/J-7894-2014; Haberle, Simon/U-4118-2019; Johnson, Chris N/A-7275-2008; Brook, Barry W./G-2686-2011	Turney, Chris S M/0000-0001-6733-0993; Johnson, Christopher/0000-0002-9719-3771; Brook, Barry W./0000-0002-2491-1517; Haberle, Simon/0000-0001-5802-6535; Kershaw, Peter/0000-0002-9478-0567	Australian Research Council; National Geographic Society; Monash Univ.; Royal Society; Australian Institute of Nuclear Science and Engineering; Natural Environment Research Council	Australian Research Council(Australian Research Council); National Geographic Society(National Geographic Society); Monash Univ.; Royal Society(Royal Society of London); Australian Institute of Nuclear Science and Engineering; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by the Australian Research Council, the National Geographic Society, Monash Univ., The Royal Society, Australian Institute of Nuclear Science and Engineering, and Natural Environment Research Council. We thank D. Bowman and E. Cameron for comments on the manuscript. The study was initiated by C.N.J. and B.W.B. and was designed by all authors. S.R. was responsible for data collection; B.W.B., C.N.J., S.R., and A.P.K. analyzed the data; C.S.M.T. developed the age model; C.N.J. led the writing; and all authors contributed to interpretation of results. The authors declare no competing interests. Original data will be provided by the corresponding author on request.	Brook B. W., 2006, ALCHERINGA, V1, P39; Burney DA, 2003, P NATL ACAD SCI USA, V100, P10800, DOI 10.1073/pnas.1534700100; Danell K., 2006, LARGE HERBIVORE ECOL; David B, 1997, ANTIQUITY, V71, P183, DOI 10.1017/S0003598X00084672; DAVIS OK, 1987, QUATERNARY RES, V28, P290, DOI 10.1016/0033-5894(87)90067-6; Davis OK, 2006, PALAEOGEOGR PALAEOCL, V237, P40, DOI 10.1016/j.palaeo.2005.11.028; Field J, 2008, EARTH-SCI REV, V89, P97, DOI 10.1016/j.earscirev.2008.04.006; Flannery T. F., 1994, FUTURE EATERS; Gill JL, 2009, SCIENCE, V326, P1100, DOI 10.1126/science.1179504; Gillespie R., 2006, ALCHERINGA, V30, P163, DOI DOI 10.1080/03115510608619580; Grun R, 2008, AUST J EARTH SCI, V55, P917, DOI 10.1080/08120090802097419; Hiscock P., 2008, ARCHAEOLOGY ANCIENT; Johnson C, 2006, AUSTR MAMMAL EXTINCT; Johnson CN, 2009, P ROY SOC B-BIOL SCI, V276, P2509, DOI 10.1098/rspb.2008.1921; KERSHAW AP, 1986, NATURE, V322, P47, DOI 10.1038/322047a0; Koch PL, 2006, ANNU REV ECOL EVOL S, V37, P215, DOI 10.1146/annurev.ecolsys.34.011802.132415; Leavesley MG., 2002, AUST ARCHAEOL, V54, P55, DOI [10.1080/03122417.2002.11682070, DOI 10.1080/03122417.2002.11682070]; Miller GH, 2005, SCIENCE, V309, P287, DOI 10.1126/science.1111288; Murphy BP, 2012, GLOBAL ECOL BIOGEOGR, V21, P142, DOI 10.1111/j.1466-8238.2011.00668.x; Roberts RG, 2001, SCIENCE, V292, P1888, DOI 10.1126/science.1060264; Robinson GS, 2005, ECOL MONOGR, V75, P295, DOI 10.1890/03-4064; Summerhayes GR, 2010, SCIENCE, V330, P78, DOI 10.1126/science.1193130; Turney CSM, 2004, NATURE, V428, P306, DOI 10.1038/nature02386; Turney CSM, 2001, J QUATERNARY SCI, V16, P767, DOI 10.1002/jqs.643; Wood JR, 2011, QUATERNARY SCI REV, V30, P915, DOI 10.1016/j.quascirev.2011.01.007	25	218	222	3	248	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1483	1486		10.1126/science.1214261	http://dx.doi.org/10.1126/science.1214261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442481				2022-12-28	WOS:000301837000045
J	Frieden, TR; De Cock, KM				Frieden, Thomas R.; De Cock, Kevin M.			The CDC's Center for Global Health	LANCET			English	Editorial Material							PROGRESS; TRANSMISSION; MORTALITY		[Frieden, Thomas R.; De Cock, Kevin M.] Ctr Dis Control & Prevent, US Dept HHS, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Frieden, TR (corresponding author), Ctr Dis Control & Prevent, US Dept HHS, Atlanta, GA 30333 USA.	tfrieden@cdc.gov		Frieden, Thomas/0000-0002-4759-2256				Centers for Disease Control and Prevention, 2011, GLOB DIS DET PROGR 2; De Cock Kevin M, 2011, MMWR Suppl, V60, P104; Dooyema CA, 2011, ENV HLTH PERSPECT, DOI [10.1289/eph.1103965., DOI 10.1289/EPH.1103965]; Gass K, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001479; Hopkins Donald R., 2011, Morbidity and Mortality Weekly Report, V60, P1450; Horton R, 2012, LANCET, V379, P504, DOI 10.1016/S0140-6736(12)60201-3; Lindblade KA, 2007, AM J TROP MED HYG, V77, P334, DOI 10.4269/ajtmh.2007.77.334; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Menzies NA, 2011, AIDS, V25, P1753, DOI 10.1097/QAD.0b013e3283463eec; Moloney G. M., 2011, Morbidity and Mortality Weekly Report, V60, P1026; Odhiambo FO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010016; Ogbuanu Ikechukwu U., 2011, Morbidity and Mortality Weekly Report, V60, P582; Schneider D, 2011, PUBLIC HEALTH REV, V33, P190, DOI 10.1007/BF03391627; Tappero JW, 2011, EMERG INFECT DIS, V17, P2087, DOI 10.3201/eid1711.110827; Tauxe RV, 2011, EMERG INFECT DIS, V17, P2094, DOI 10.3201/eid1711.110857; The United States President's Emergency Plan for AIDS Relief, 2012, 7 US DEP STAT; The United States President's Emergency Plan for AIDS Relief, 2012, US PRES EM PLAN AIDS; US Agency for International Development, 2011, 5 US AG INT DEV; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E	19	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					986	988		10.1016/S0140-6736(12)60370-5	http://dx.doi.org/10.1016/S0140-6736(12)60370-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22417407				2022-12-28	WOS:000301712300012
J	Gunawardana, NP; Keenan, NG; Moon, JC; Rakhit, R				Gunawardana, Nushan P.; Keenan, Niall G.; Moon, James C.; Rakhit, Roby			Cardiac arrest and myocardial pseudoinfarction	LANCET			English	Editorial Material							SARCOIDOSIS		[Gunawardana, Nushan P.; Keenan, Niall G.; Rakhit, Roby] Royal Free Hosp, Dept Cardiol, London NW3 2QG, England; [Moon, James C.] UCL, Heart Hosp, Dept Cardiovasc Med, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Gunawardana, NP (corresponding author), Royal Free Hosp, Dept Cardiol, Pond St, London NW3 2QG, England.	nushan.gunawardana@nhs.net	Keenan, Niall/AAG-3376-2020; Moon, James/AAA-9905-2020; Moon, James C/F-1031-2014	Moon, James/0000-0001-8071-1491; Moon, James C/0000-0001-8071-1491; Keenan, Niall/0000-0002-0841-6989				Doughan AR, 2006, HEART, V92, P282, DOI 10.1136/hrt.2005.080481; Kim JS, 2009, AM HEART J, V157, P9, DOI 10.1016/j.ahj.2008.09.009; Patel MR, 2009, CIRCULATION, V120, P1969, DOI 10.1161/CIRCULATIONAHA.109.851352; Soejima K, 2009, J CARDIOVASC ELECTR, V20, P578, DOI 10.1111/j.1540-8167.2008.01417.x; Yazaki Y, 2001, AM J CARDIOL, V88, P1006, DOI 10.1016/S0002-9149(01)01978-6	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					1074	1074		10.1016/S0140-6736(11)61818-7	http://dx.doi.org/10.1016/S0140-6736(11)61818-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22423885				2022-12-28	WOS:000301712300036
J	Pani, AM; Mullarkey, EE; Aronowicz, J; Assimacopoulos, S; Grove, EA; Lowe, CJ				Pani, Ariel M.; Mullarkey, Erin E.; Aronowicz, Jochanan; Assimacopoulos, Stavroula; Grove, Elizabeth A.; Lowe, Christopher J.			Ancient deuterostome origins of vertebrate brain signalling centres	NATURE			English	Article							HEMICHORDATE SACCOGLOSSUS-KOWALEVSKII; NERVOUS-SYSTEM; FOREBRAIN DEVELOPMENT; TRANSCRIPTION FACTORS; CELL FATE; FGF8; AMPHIOXUS; HEDGEHOG; EVOLUTIONARY; EXPRESSION	Neuroectodermal signalling centres induce and pattern many novel vertebrate brain structures but are absent, or divergent, in invertebrate chordates. This has led to the idea that signalling-centre genetic programs were first assembled in stem vertebrates and potentially drove morphological innovations of the brain. However, this scenario presumes that extant cephalochordates accurately represent ancestral chordate characters, which has not been tested using close chordate outgroups. Here we report that genetic programs homologous to three vertebrate signalling centres-the anterior neural ridge, zona limitans intrathalamica and isthmic organizer-are present in the hemichordate Saccoglossus kowalevskii. Fgf8/17/18 (a single gene homologous to vertebrate Fgf8, Fgf17 and Fgf18), sfrp1/5, hh and wnt1 are expressed in vertebrate-like arrangements in hemichordate ectoderm, and homologous genetic mechanisms regulate ectodermal patterning in both animals. We propose that these genetic programs were components of an unexpectedly complex, ancient genetic regulatory scaffold for deuterostome body patterning that degenerated in amphioxus and ascidians, but was retained to pattern divergent structures in hemichordates and vertebrates.	[Pani, Ariel M.; Lowe, Christopher J.] Univ Chicago, Comm Evolut Biol, Chicago, IL 60637 USA; [Pani, Ariel M.; Lowe, Christopher J.] Stanford Univ, Hopkins Marine Stn, Dept Biol, Pacific Grove, CA 93950 USA; [Mullarkey, Erin E.; Grove, Elizabeth A.] Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; [Aronowicz, Jochanan; Grove, Elizabeth A.; Lowe, Christopher J.] Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; [Assimacopoulos, Stavroula; Grove, Elizabeth A.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA	University of Chicago; Stanford University; University of Chicago; University of Chicago; University of Chicago	Lowe, CJ (corresponding author), Univ Chicago, Comm Evolut Biol, 1025 E 57th St, Chicago, IL 60637 USA.	clowe@stanford.edu		Lowe, Christopher/0000-0002-7789-8643	Searle Kinship Foundation; Brain Research Foundation; National Science Foundation [1049106]; National Institutes of Health [R01 HD42330]; University of Chicago; Marine Biological Laboratory Frank R. Lillie Fellowship; National Institute of Child Health and Development [1T32HD055164-01A1]; National Institute of Neurological Disorders and Stroke [1F31NS074738-01A1]; National Science and Engineering Research Council of Canada; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007009, T32HD055164] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS074738] Funding Source: NIH RePORTER; Direct For Biological Sciences [1049106] Funding Source: National Science Foundation	Searle Kinship Foundation; Brain Research Foundation; National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago(University of Chicago); Marine Biological Laboratory Frank R. Lillie Fellowship; National Institute of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We thank J. Gerhart and M. Kirschner for assistance and support, R. Freeman for bioinformatics assistance, E. Farrelly, M. Terasaki and S. Darras for technical guidance, the members of the Lowe laboratory for discussions, and G. Wray and J. Gerhart for comments on drafts of the manuscript. We also thank the staff of the Marine Biological Laboratory, the Waquoit Bay National Estuarine Research Reserve, Carl ZeissandNikonfor assistance duringour field season. This work was funded by the Searle Kinship Foundation, Brain Research Foundation and National Science Foundation grant 1049106 (C. J. L.), National Institutes of Health grant R01 HD42330 (E. A. G.) and the University of Chicago Hinds Fund (A. M. P). A. M. P. was supported by a Marine Biological Laboratory Frank R. Lillie Fellowship, National Institute of Child Health and Development institutional training grant 1T32HD055164-01A1, and National Institute of Neurological Disorders and Stroke pre-doctoral fellowship 1F31NS074738-01A1. J. A. was supported by a National Science and Engineering Research Council of Canada pre-doctoral grant.	Bertrand S, 2011, P NATL ACAD SCI USA, V108, P9160, DOI 10.1073/pnas.1014235108; Bourlat SJ, 2006, NATURE, V444, P85, DOI 10.1038/nature05241; Campo-Paysaa F, 2008, GENESIS, V46, P640, DOI 10.1002/dvg.20444; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 2001, NEUROSCIENCE, V108, P183, DOI 10.1016/S0306-4522(01)00411-0; Darras S, 2011, DEVELOPMENT, V138, P959, DOI 10.1242/dev.059493; Echevarria D, 2003, BRAIN RES REV, V43, P179, DOI 10.1016/j.brainresrev.2003.08.002; Freeman RM, 2008, BIOL BULL-US, V214, P284, DOI 10.2307/25470670; Fukuchi-Shimogori T, 2001, SCIENCE, V294, P1071, DOI 10.1126/science.1064252; Garel S, 2003, DEVELOPMENT, V130, P1903, DOI 10.1242/dev.00416; Gavino MA, 2011, CURR BIOL, V21, P294, DOI 10.1016/j.cub.2011.01.017; Gillis JA, 2012, P ROY SOC B-BIOL SCI, V279, P237, DOI 10.1098/rspb.2011.0599; Grande C, 2009, NATURE, V457, P1007, DOI 10.1038/nature07603; Hebert JM, 2008, NAT REV NEUROSCI, V9, P678, DOI 10.1038/nrn2463; Holland L. Z., 2008, BRAIN BEHAV EVOL, V72; Holland LZ, 2009, NAT REV NEUROSCI, V10, P736, DOI 10.1038/nrn2703; Holland LZ, 2000, DEV GENES EVOL, V210, P522, DOI 10.1007/s004270000089; Houart C, 2002, NEURON, V35, P255, DOI 10.1016/S0896-6273(02)00751-1; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Imai KS, 2009, DEVELOPMENT, V136, P285, DOI 10.1242/dev.026419; Irimia M, 2010, EVODEVO, V1, DOI 10.1186/2041-9139-1-7; Kiecker C, 2004, NAT NEUROSCI, V7, P1242, DOI 10.1038/nn1338; Lacalli TC, 2006, INT J BIOL SCI, V2, P104; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lowe CJ, 2006, PLOS BIOL, V4, P1603, DOI 10.1371/journal.pbio.0040291; Lowe CJ, 2003, CELL, V113, P853, DOI 10.1016/S0092-8674(03)00469-0; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Meinertzhagen IA, 2004, ANNU REV NEUROSCI, V27, P453, DOI 10.1146/annurev.neuro.27.070203.144255; Meulemans D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000787; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nomaksteinsky M, 2009, CURR BIOL, V19, P1264, DOI 10.1016/j.cub.2009.05.063; Paek H, 2009, DEVELOPMENT, V136, P2457, DOI 10.1242/dev.032656; Reifers F, 1998, DEVELOPMENT, V125, P2381; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Scholpp S, 2006, DEVELOPMENT, V133, P855, DOI 10.1242/dev.02248; Scholpp S, 2007, DEVELOPMENT, V134, P3167, DOI 10.1242/dev.001461; Scholpp S, 2010, TRENDS NEUROSCI, V33, P373, DOI 10.1016/j.tins.2010.05.003; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimeld SM, 1999, DEV GENES EVOL, V209, P40, DOI 10.1007/s004270050225; Simon HH, 2004, CELL TISSUE RES, V318, P53, DOI 10.1007/s00441-004-0973-8; Takatori N, 2002, MECH DEVELOP, V116, P235, DOI 10.1016/S0925-4773(02)00150-8; Tomer R, 2010, CELL, V142, P800, DOI 10.1016/j.cell.2010.07.043; Urbach R, 2007, NEURAL DEV, V2, DOI 10.1186/1749-8104-2-23; Walshe J, 2003, DEVELOPMENT, V130, P4337, DOI 10.1242/dev.00660; Wicht H, 2005, CAN J ZOOL, V83, P122, DOI 10.1139/Z04-163; Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Zeltser LM, 2001, NAT NEUROSCI, V4, P683, DOI 10.1038/89455	50	164	167	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					289	U79		10.1038/nature10838	http://dx.doi.org/10.1038/nature10838			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422262	Green Accepted			2022-12-28	WOS:000301481800040
J	Schwab, M; Buchli, A				Schwab, Martin; Buchli, Anita			Plug the real brain drain	NATURE			English	Editorial Material									[Schwab, Martin; Buchli, Anita] Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; [Schwab, Martin; Buchli, Anita] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schwab, M (corresponding author), Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland.	schwab@hifo.uzh.ch						Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Baker M, 2011, NATURE, V479, P459, DOI 10.1038/479459a; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Sobocki P, 2006, EUR J NEUROSCI, V24, P2691, DOI 10.1111/j.1460-9568.2006.05116.x; Zoerner B., 2010, ANN NY ACAD SCI, V1198, pE22	7	5	6	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					267	268		10.1038/483267a	http://dx.doi.org/10.1038/483267a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22422244	Bronze			2022-12-28	WOS:000301481800022
J	Cheung, NKV; Zhang, JH; Lu, C; Parker, M; Bahrami, A; Tickoo, SK; Heguy, A; Pappo, AS; Federico, S; Dalton, J; Cheung, IY; Ding, L; Fulton, R; Wang, JW; Chen, X; Becksfort, J; Wu, JR; Billups, CA; Ellison, D; Mardis, ER; Wilson, RK; Downing, JR; Dyer, MA				Cheung, Nai-Kong V.; Zhang, Jinghui; Lu, Charles; Parker, Matthew; Bahrami, Armita; Tickoo, Satish K.; Heguy, Adriana; Pappo, Alberto S.; Federico, Sara; Dalton, James; Cheung, Irene Y.; Ding, Li; Fulton, Robert; Wang, Jianwin; Chen, Xiang; Becksfort, Jared; Wu, Jianrong; Billups, Catherine A.; Ellison, David; Mardis, Elaine R.; Wilson, Richard K.; Downing, James R.; Dyer, Michael A.		St Jude Children's Res Hosp Washin	Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HISTONE CHAPERONE; QUANTITATIVE PCR; TELOMERE LENGTH; COPY NUMBER; ADOLESCENTS; EXPERIENCE; SURVIVAL; TUMORS; RISK; DAXX	Context Neuroblastoma is diagnosed over a wide age range from birth through young adulthood, and older age at diagnosis is associated with a decline in survivability. Objective To identify genetic mutations that are associated with age at diagnosis in patients with metastatic neuroblastoma. Design, Setting, and Patients Whole genome sequencing was performed on DNA from diagnostic tumors and their matched germlines from 40 patients with metastatic neuroblastoma obtained between 1987 and 2009. Age groups at diagnosis included infants (0-<18 months), children (18 months-<12 years), and adolescents and young adults (>= 12 years). To confirm the findings from this discovery cohort, validation testing using tumors from an additional 64 patients obtained between 1985 and 2009 also was performed. Formalin-fixed, paraffin-embedded tumor tissue was used for immunohistochemistry and fluorescence in situ hybridization. Telomere lengths were analyzed using whole genome sequencing data, quantitative polymerase chain reaction, and fluorescent in situ hybridization. Main Outcome Measure Somatic recurrent mutations in tumors from patients with neuroblastoma correlated with the age at diagnosis and telomere length. Results In the discovery cohort (n=40), mutations in the ATRX gene were identified in 100% (95% CI, 50%-100%) of tumors from patients in the adolescent and young adult group (5 of 5), in 17% (95% CI, 7%-36%) of tumors from children (5 of 29), and 0% (95% CI, 0%-40%) of tumors from infants (0 of 6). In the validation cohort (n=64), mutations in the ATRX gene were identified in 33% (95% CI, 17%-54%) of tumors from patients in the adolescent and young adult group (9 of 27), in 16% (95% CI, 6%-35%) of tumors from children (4 of 25), and in 0% (95% CI, 0%-24%) of tumors from infants (0 of 12). In both cohorts (N=104), mutations in the ATRX gene were identified in 44% (95% CI, 28%-62%) of tumors from patients in the adolescent and young adult group (14 of 32), in 17% (95% CI, 9%-29%) of tumors from children (9 of 54), and in 0% (95% CI, 0%-17%) of tumors from infants (0 of 18). ATRX mutations were associated with an absence of the ATRX protein in the nucleus and with long telomeres. Conclusion ATRX mutations were associated with age at diagnosis in children and young adults with stage 4 neuroblastoma.	[Dyer, Michael A.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Cheung, Nai-Kong V.; Cheung, Irene Y.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Heguy, Adriana] Mem Sloan Kettering Canc Ctr, Dept Human Oncol & Pathogenesis, New York, NY 10021 USA; [Zhang, Jinghui; Parker, Matthew; Chen, Xiang] St Jude Childrens Res Hosp, Dept Computat Biol, Memphis, TN 38105 USA; [Bahrami, Armita; Dalton, James; Ellison, David; Downing, James R.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Pappo, Alberto S.; Federico, Sara] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Wu, Jianrong; Billups, Catherine A.] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Wang, Jianwin; Becksfort, Jared] St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; [Lu, Charles; Ding, Li; Fulton, Robert; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO USA; [Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; [Dyer, Michael A.] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN USA; [Dyer, Michael A.] Howard Hughes Med Inst, Chevy Chase, MD USA	St Jude Children's Research Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute	Dyer, MA (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, MS 323,262 Danny Thomas Pl, Memphis, TN 38105 USA.	michael.dyer@stjude.org	Heguy, Adriana/GPP-3907-2022; Downing, James R./N-8102-2018; Mardis, Elaine/W-2202-2019; Zhang, Jing/GWZ-7332-2022; Bahrami, Armita/N-3262-2018; Chen, Xiang/N-2524-2018; Wilson, Richard K./AAF-4139-2019; Dyer, Michael/N-8134-2018	Bahrami, Armita/0000-0002-8515-2649; Chen, Xiang/0000-0002-2499-8261; Wilson, Richard K./0000-0002-1992-1358; Parker, Matthew/0000-0003-2999-3870	National Cancer Institute [CA21765]; National Institutes of Health [EY014867, EY018599]; American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital; Catie Hoch Foundation; Robert Steel Foundation; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018599, R01EY014867] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); Catie Hoch Foundation; Robert Steel Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The whole genome sequencing was supported as part of the St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. This work was supported in part by Cancer Center Support grant CA21765 from the National Cancer Institute; grants EY014867 and EY018599 from the National Institutes of Health (awarded to Dr Dyer); and the American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital. Dr Dyer is a Howard Hughes Medical Institute Early Career Scientist. This work also was supported by the Catie Hoch Foundation and the Robert Steel Foundation.	Anderson J, 2006, PEDIATR BLOOD CANCER, V46, P820, DOI 10.1002/pbc.20311; BOWMAN LC, 1991, J CLIN ONCOL, V9, P1599, DOI 10.1200/JCO.1991.9.9.1599; Castle JC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-244; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Conte M, 2006, CANCER, V106, P1409, DOI 10.1002/cncr.21751; Cotterill SJ, 2000, EUR J CANCER, V36, P901, DOI 10.1016/S0959-8049(00)00058-7; Deyell RJ, 2011, CANCER GENET-NY, V204, P113, DOI 10.1016/j.cancergen.2011.03.001; Drane P, 2010, GENE DEV, V24, P1253, DOI 10.1101/gad.566910; Franks LM, 1997, CANCER, V79, P2028, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V; Garaventa A, 2009, EUR J CANCER, V45, P2835, DOI 10.1016/j.ejca.2009.06.010; Gibbons R, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-15; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Hampton T, 2011, JAMA-J AM MED ASSOC, V305, P2278, DOI 10.1001/jama.2011.772; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kushner BH, 2003, MED PEDIATR ONCOL, V41, P508, DOI 10.1002/mpo.10273; Kushner BH, 2002, CANCER-AM CANCER SOC, V95, P1366, DOI 10.1002/cncr.10800; LADENSTEIN R, 1993, J CLIN ONCOL, V11, P2330, DOI 10.1200/JCO.1993.11.12.2330; Law MJ, 2010, CELL, V143, P367, DOI 10.1016/j.cell.2010.09.023; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; London WB, 2011, J CLIN ONCOL, V29, P3286, DOI 10.1200/JCO.2010.34.3392; Moroz V, 2011, EUR J CANCER, V47, P561, DOI 10.1016/j.ejca.2010.10.022; O'Callaghan NJ, 2008, BIOTECHNIQUES, V44, P807, DOI 10.2144/000112761; Pickett H, 2009, TELOMERES TELOMERASE; POLLOCK BH, 1991, J PEDIATR-US, V119, P725, DOI 10.1016/S0022-3476(05)80287-2; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/nmeth.1628, 10.1038/NMETH.1628]; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	31	272	284	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1062	1071		10.1001/jama.2012.228	http://dx.doi.org/10.1001/jama.2012.228			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416102	Green Accepted, Bronze			2022-12-28	WOS:000301479700027
J	Wilson, RM; Michel, P; Olsen, S; Gibberd, RW; Vincent, C; El-Assady, R; Rasslan, O; Qsous, S; Macharia, WM; Sahel, A; Whittaker, S; Abdo-Ali, M; Letaief, M; Ahmed, NA; Abdellatif, A; Larizgoitia, I				Wilson, R. M.; Michel, P.; Olsen, S.; Gibberd, R. W.; Vincent, C.; El-Assady, R.; Rasslan, O.; Qsous, S.; Macharia, W. M.; Sahel, A.; Whittaker, S.; Abdo-Ali, M.; Letaief, M.; Ahmed, N. A.; Abdellatif, A.; Larizgoitia, I.		WHO Patient Safety EMRO AFRO Worki	Patient safety in developing countries: retrospective estimation of scale and nature of harm to patients in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE EVENTS; HEALTH-CARE	Objective To assess the frequency and nature of adverse events to patients in selected hospitals in developing or transitional economies. Design Retrospective medical record review of hospital admissions during 2005 in eight countries. Setting Ministries of Health of Egypt, Jordan, Kenya, Morocco, Tunisia, Sudan, South Africa and Yemen; the World Health Organisation (WHO) Eastern Mediterranean and African Regions (EMRO and AFRO), and WHO Patient Safety. Participants Convenience sample of 26 hospitals from which 15 548 patient records were randomly sampled. Main outcome measures Two stage screening. Initial screening based on 18 explicit criteria. Records that screened positive were then reviewed by a senior physician for determination of adverse event, its preventability, and the resulting disability. Results Of the 15 548 records reviewed, 8.2% showed at least one adverse event, with a range of 2.5% to 18.4% per country. Of these events, 83% were judged to be preventable, while about 30% were associated with death of the patient. About 34% adverse events were from therapeutic errors in relatively non-complex clinical situations. Inadequate training and supervision of clinical staff or the failure to follow policies or protocols contributed to most events. Conclusions Unsafe patient care represents a serious and considerable danger to patients in the hospitals that were studied, and hence should be a high priority public health problem. Many other developing and transitional economies will probably share similar rates of harm and similar contributory factors. The convenience sampling of hospitals might limit the interpretation of results, but the identified adverse event rates show an estimate that should stimulate and facilitate the urgent institution of appropriate remedial action and also to trigger more research. Prevention of these adverse events will be complex and involves improving basic clinical processes and does not simply depend on the provision of more resources.	[Wilson, R. M.] New York City Hlth & Hosp Corp, New York, NY 10013 USA; [Michel, P.] Bordeaux Univ Hosp, Aquitaine Reg Ctr Qual & Safety, Bordeaux, France; [Olsen, S.; Vincent, C.] Univ London Imperial Coll Sci Technol & Med, Dept Biosurg & Technol, Imperial Ctr Patient Safety & Serv Qual, London, England; [Gibberd, R. W.] Univ Newcastle, Callaghan, NSW 2308, Australia; [El-Assady, R.] WHO Eastern Mediterranean Reg, Cairo, Egypt; [Rasslan, O.; Abdellatif, A.] Ain Shams Univ, Fac Med, Egyptian Patient Safety Assoc, Cairo, Egypt; [Qsous, S.] Minist Hlth, Amman, Jordan; [Macharia, W. M.] Aga Khan Univ, Dept Paediat, Nairobi, Kenya; [Whittaker, S.] Council Hlth Serv Accreditat So Africa, Cape Town, South Africa; [Abdo-Ali, M.] Natl Ribat Univ, Khartoum, Sudan; [Letaief, M.] Univ Hosp Monastir, Tunis, Tunisia; [Ahmed, N. A.] Minist Publ Hlth & Populat, Sanaa, Yemen; [Larizgoitia, I.] WHO, Patient Safety Programme, CH-1211 Geneva, Switzerland	CHU Bordeaux; Imperial College London; University of Newcastle; Egyptian Knowledge Bank (EKB); World Health Organization Egypt; Egyptian Knowledge Bank (EKB); Ain Shams University; Aga Khan University; Universite de Monastir; World Health Organization	Wilson, RM (corresponding author), New York City Hlth & Hosp Corp, 125 Worth St, New York, NY 10013 USA.	ross.wilson@nychhc.org	macharia, william/Q-6042-2018; Vincent, Charles A/D-1134-2010; michel, philippe/J-9443-2017	macharia, william/0000-0002-4428-862X; Vincent, Charles A/0000-0003-0270-0222; michel, philippe/0000-0001-8455-8332; Mohammed, Nasr/0000-0003-0486-5290	WHO	WHO(World Health Organization)	This study was sponsored and funded by WHO. The Northern Centre for Healthcare Improvement of NSW Health was contracted by WHO to conduct the study. RW was the director of the centre, and RG was subcontracted for advice on statistical methods and analysis. Most other authors received support for travel related expenses for the study. The authors employed by WHO received salaries from WHO and travel expenses related to the study.	Aranaz-Andres JM, 2008, J EPIDEMIOL COMMUN H, V62, P1022, DOI 10.1136/jech.2007.065227; Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Davis P, 2004, CAN MED ASSOC J, V170, P1688, DOI 10.1503/cmaj.1040690; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; Michel P, 2007, QUAL SAF HEALTH CARE, V16, P369, DOI 10.1136/qshc.2005.016964; Scheffler RM, 2009, HEALTH AFFAIR, V28, pW849, DOI 10.1377/hlthaff.28.5.w849; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; Thomas EJ, 2003, J GEN INTERN MED, V18, P61, DOI 10.1046/j.1525-1497.2003.20147.x; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; World Health Organization, 2011, E MED REG HLTH SYST; World Health Organization, 2010, WHO PAT SAF; Zegers M, 2010, J CLIN EPIDEMIOL, V63, P94, DOI 10.1016/j.jclinepi.2009.03.004	14	162	168	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2012	344								e832	10.1136/bmj.e832	http://dx.doi.org/10.1136/bmj.e832			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BR	22416061	hybrid, Green Submitted			2022-12-28	WOS:000301846900001
J	Li, QG; Gao, KQ; Meng, QJ; Clarke, JA; Shawkey, MD; D'Alba, L; Pei, R; Ellison, M; Norell, MA; Vinther, J				Li, Quanguo; Gao, Ke-Qin; Meng, Qingjin; Clarke, Julia A.; Shawkey, Matthew D.; D'Alba, Liliana; Pei, Rui; Ellison, Mick; Norell, Mark A.; Vinther, Jakob			Reconstruction of Microraptor and the Evolution of Iridescent Plumage	SCIENCE			English	Article							COLOR; DINOSAURS; CHINA; ARCHAEOPTERYX; FLIGHT; MODEL; SIZE	Iridescent feather colors involved in displays of many extant birds are produced by nanoscale arrays of melanin-containing organelles (melanosomes). Data relevant to the evolution of these colors and the properties of melanosomes involved in their generation have been limited. A data set sampling variables of extant avian melanosomes reveals that those forming most iridescent arrays are distinctly narrow. Quantitative comparison of these data with melanosome imprints densely sampled from a previously unknown specimen of the Early Cretaceous feathered Microraptor predicts that its plumage was predominantly iridescent. The capacity for simple iridescent arrays is thus minimally inferred in paravian dinosaurs. This finding and estimation of Microraptor feathering consistent with an ornamental function for the tail suggest a centrality for signaling in early evolution of plumage and feather color.	[Shawkey, Matthew D.; D'Alba, Liliana] Univ Akron, Dept Biol, Akron, OH 44325 USA; [Shawkey, Matthew D.; D'Alba, Liliana] Univ Akron, Integrated Biosci Program, Akron, OH 44325 USA; [Li, Quanguo; Meng, Qingjin] Beijing Museum Nat Hist, Beijing 100050, Peoples R China; [Gao, Ke-Qin] Peking Univ, Sch Earth & Space Sci, Beijing 100871, Peoples R China; [Clarke, Julia A.; Vinther, Jakob] Univ Texas Austin, Dept Geol Sci, Austin, TX 78712 USA; [Pei, Rui; Ellison, Mick; Norell, Mark A.] Amer Museum Nat Hist, Dept Paleontol, New York, NY 10024 USA; [Vinther, Jakob] Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	University System of Ohio; University of Akron; University System of Ohio; University of Akron; Peking University; University of Texas System; University of Texas Austin; American Museum of Natural History (AMNH); Yale University	Shawkey, MD (corresponding author), Univ Akron, Dept Biol, Akron, OH 44325 USA.	shawkey@uakron.edu	D'Alba, Liliana/AAC-4969-2022; Vinther, Jakob/GZG-4679-2022; Meng, Q./GSI-6185-2022; Li, Quanguo/ABE-9756-2021	D'Alba, Liliana/0000-0002-2478-3455; Shawkey, Matthew/0000-0002-5131-8209; Vinther, Jakob/0000-0002-3584-9616	NSF EAR [0938199]; Air Force Office of Scientific Research [FA9550-09-1-0159]; National Natural Science Foundation of China [40532008]; Beijing Municipal Bureau of Human Resources; Beijing Academy of Science and Technology (BJAST); University of Texas at Austin; American Museum of Natural History	NSF EAR(National Science Foundation (NSF)); Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Bureau of Human Resources; Beijing Academy of Science and Technology (BJAST); University of Texas at Austin; American Museum of Natural History	The research was funded by NSF EAR 0938199, Air Force Office of Scientific Research FA9550-09-1-0159, National Natural Science Foundation of China 40532008, Beijing Municipal Bureau of Human Resources, Beijing Academy of Science and Technology (BJAST) Innovation Team Fund, University of Texas at Austin, and the American Museum of Natural History. The Copenhagen Museum of Natural History (J. Fjeldsaa) and the Yale University Peabody Museum (R. O. Prum and K. Zyskowski) provided extant feather samples. The fossil specimen is accessioned to the Beijing Museum of Natural History (BMNHC). Data are presented in the supporting online material.	Alexander DE, 2010, P NATL ACAD SCI USA, V107, P2972, DOI 10.1073/pnas.0911852107; Andersson Malte, 1994; Bennett ATD, 1997, P NATL ACAD SCI USA, V94, P8618, DOI 10.1073/pnas.94.16.8618; Chatterjee S, 2007, P NATL ACAD SCI USA, V104, P1576, DOI 10.1073/pnas.0609975104; Chiappe Luis M, 2008, Biol Lett, V4, P719, DOI 10.1098/rsbl.2008.0409; Clarke JA, 2006, J ANAT, V208, P287, DOI 10.1111/j.1469-7580.2006.00534.x; Clarke JA, 2010, SCIENCE, V330, P954, DOI 10.1126/science.1193604; Doucet SM, 2002, CONDOR, V104, P30, DOI 10.1650/0010-5422(2002)104[0030:SPCMBS]2.0.CO;2; Doucet SM, 2009, J R SOC INTERFACE, V6, pS115, DOI 10.1098/rsif.2008.0395.focus; DURRER H, 1986, BIOL INTEGUMENT, V2, P239; Elliott A., 1992, HDB BIRDS WORLD ALIV; Fisher, 1958, GENETICAL THEORY NAT; Gatesy SM, 1996, EVOLUTION, V50, P2037, DOI 10.1111/j.1558-5646.1996.tb03590.x; Li QG, 2010, SCIENCE, V327, P1369, DOI 10.1126/science.1186290; Maia R, 2012, J R SOC INTERFACE, V9, P734, DOI 10.1098/rsif.2011.0456; Maia R, 2011, P ROY SOC B-BIOL SCI, V278, P1973, DOI 10.1098/rspb.2010.1637; McGraw KJ, 2002, J EXP BIOL, V205, P3747; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P167; Prum RO, 2010, EVOLUTION, V64, P3085, DOI 10.1111/j.1558-5646.2010.01054.x; Prum RO, 2006, BIRD COLORATION, V1, P295; Schmitz L, 2011, SCIENCE, V332, P705, DOI 10.1126/science.1200043; Scholes E, 2006, AUK, V123, P967, DOI 10.1642/0004-8038(2006)123[967:CEOCPP]2.0.CO;2; Shawkey MD, 2006, J R SOC INTERFACE, V3, P777, DOI 10.1098/rsif.2006.0131; Stoddard MC, 2011, BEHAV ECOL, V22, P1042, DOI 10.1093/beheco/arr088; Thomas ALR, 1997, BIOSCIENCE, V47, P215, DOI 10.2307/1313075; Toomey MB, 2010, BEHAV ECOL SOCIOBIOL, V64, P1047, DOI 10.1007/s00265-010-0926-z; Turner AH, 2007, SCIENCE, V317, P1378, DOI 10.1126/science.1144066; Vinther J, 2010, BIOL LETTERS, V6, P128, DOI 10.1098/rsbl.2009.0524; Xu X, 2003, NATURE, V421, P335, DOI 10.1038/nature01342; Xu X, 2011, NATURE, V475, P465, DOI 10.1038/nature10288; Zhang FC, 2008, NATURE, V455, P1105, DOI 10.1038/nature07447; Zhang FC, 2010, NATURE, V463, P1075, DOI 10.1038/nature08740	32	129	131	4	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1215	1219		10.1126/science.1213780	http://dx.doi.org/10.1126/science.1213780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403389				2022-12-28	WOS:000301225100042
J	Colao, A; Petersenn, S; Newell-Price, J; Findling, JW; Gu, F; Maldonado, M; Schoenherr, U; Mills, D; Salgado, LR; Biller, BMK				Colao, Annamaria; Petersenn, Stephan; Newell-Price, John; Findling, James W.; Gu, Feng; Maldonado, Mario; Schoenherr, Ulrike; Mills, David; Salgado, Luiz Roberto; Biller, Beverly M. K.		Pasireotide B2305 Study Grp	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSENSUS STATEMENT; CABERGOLINE; SOM230; SECRETION; ADENOMAS; RELEASE	BACKGROUND Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 mu g (82 patients) or 900 mu g (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 mu g twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS Twelve of the 82 patients in the 600-mu g group and 21 of the 80 patients in the 900-mu g group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose- lowering medication was initiated in 74 of 162 patients. CONCLUSIONS The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropinsecreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.)	[Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Neuroendocrine Clin Ctr, Boston, MA 02459 USA; [Colao, Annamaria] Univ Naples Federico 2, Endocrinol Sect, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy; [Petersenn, Stephan] ENDOC Ctr Endocrine Tumors, Hamburg, Germany; [Petersenn, Stephan] Univ Duisburg Essen, Fac Med, Essen, Germany; [Newell-Price, John] Univ Sheffield, Dept Human Metab, Sheffield, S Yorkshire, England; [Findling, James W.] Med Coll Wisconsin, Div Endocrinol Metab & Clin Nutr, Milwaukee, WI 53226 USA; [Gu, Feng] Beijing Union Med Coll Hosp, Minist Hlth, Key Lab Endocrinol, Dept Endocrinol, Beijing, Peoples R China; [Maldonado, Mario; Schoenherr, Ulrike; Mills, David] Novartis Pharmaceut, Oncol Business Unit, Clin Dev, Basel, Switzerland; [Salgado, Luiz Roberto] Univ Sao Paulo, Sch Med, Hosp Clin, Div Gen Internal Med, Sao Paulo, Brazil	Harvard University; Massachusetts General Hospital; University of Naples Federico II; University of Duisburg Essen; University of Sheffield; Medical College of Wisconsin; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Novartis; Universidade de Sao Paulo	Biller, BMK (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Neuroendocrine Clin Ctr, 55 Fruit St,Bulfinch 457B, Boston, MA 02459 USA.	bbiller@partners.org	Mills, David/GXF-1821-2022; Petersenn, Stephan/AHC-4344-2022; Czepielewski, Mauro/H-4972-2015; Brue, Thierry/AAI-2328-2019; Webb, Susan SM/C-7294-2008; Boguszewski, Cesar Luiz/V-5661-2019; Brue, Thierry/P-6571-2019	Czepielewski, Mauro/0000-0001-5083-5776; Brue, Thierry/0000-0001-8482-6691; Webb, Susan SM/0000-0001-7052-6436; Boguszewski, Cesar Luiz/0000-0001-7285-7941; Brue, Thierry/0000-0001-8482-6691; BERTHERAT, Jerome/0000-0003-2551-3008; CHABRE, Olivier/0000-0001-8756-7218	Novartis Pharma	Novartis Pharma	Supported by Novartis Pharma.	Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003-030871; Batista DL, 2006, J CLIN ENDOCR METAB, V91, P4482, DOI 10.1210/jc.2006-1245; Biller BMK, 2008, J CLIN ENDOCR METAB, V93, P2454, DOI 10.1210/jc.2007-2734; Boscaro M, 2009, J CLIN ENDOCR METAB, V94, P115, DOI 10.1210/jc.2008-1008; Bruns C, 2002, EUR J ENDOCRINOL, V146, P707, DOI 10.1530/eje.0.1460707; Cavagnini F, 2001, ANN ENDOCRINOL-PARIS, V62, P168; ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x; Feelders RA, 2010, NEW ENGL J MED, V362, P1846, DOI 10.1056/NEJMc1000094; Godbout A, 2010, EUR J ENDOCRINOL, V163, P709, DOI 10.1530/EJE-10-0382; Henry RR, 2011, 13 EUR C END ROTT NE; Hofland LJ, 2003, ENDOCR REV, V24, P28, DOI 10.1210/er.2000-0001; Hofland LJ, 2005, EUR J ENDOCRINOL, V152, P645, DOI 10.1530/eje.1.01876; Lila AR, 2010, ENDOCR PRACT, V16, P968, DOI 10.4158/EP10031.OR; Lindholm J, 2001, J CLIN ENDOCR METAB, V86, P117, DOI 10.1210/jc.86.1.117; National Cancer Institute, 2006, COMM TERM CRIT ADV E; Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6; Pivonello R, 2009, J CLIN ENDOCR METAB, V94, P223, DOI 10.1210/jc.2008-1533; van der Hoek J, 2005, AM J PHYSIOL-ENDOC M, V289, pE278, DOI 10.1152/ajpendo.00004.2005; Vilar L, 2010, PITUITARY, V13, P123, DOI 10.1007/s11102-009-0209-8; Webb SM, 2008, EUR J ENDOCRINOL, V158, P623, DOI 10.1530/EJE-07-0762	20	398	415	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					914	924		10.1056/NEJMoa1105743	http://dx.doi.org/10.1056/NEJMoa1105743			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397653	Bronze			2022-12-28	WOS:000301172500008
J	McGauran, A; Hawkes, N				McGauran, Ann; Hawkes, Nigel			PUBLIC HEALTH Is there a role for acute hospitals in tackling public health?	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com						[Anonymous], NAT HLTH PROM HOSP A; Cook G, 2010, MAKING EVERY HLTH CA	2	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1325	10.1136/bmj.e1325	http://dx.doi.org/10.1136/bmj.e1325			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399702				2022-12-28	WOS:000301479800018
J	Sarrazin, AF; Peel, AD; Averof, M				Sarrazin, Andres F.; Peel, Andrew D.; Averof, Michalis			A Segmentation Clock with Two-Segment Periodicity in Insects	SCIENCE			English	Article							VERTEBRATE SEGMENTATION; GRYLLUS-BIMACULATUS; ANNELID PLATYNEREIS; NOTCH; INVOLVEMENT; EVOLUTION; AXIS; GENERATION; NETWORKS; GENES	Vertebrate segmentation relies on a mechanism characterized by oscillating gene expression. Whether this mechanism is used by other segmented animals has been controversial. Rigorous proof of cyclic expression during arthropod segmentation has been lacking. We find that the segmentation gene odd-skipped (Tc-odd) oscillates with a two-segment periodicity in the beetle Tribolium castaneum. By bisecting embryos and culturing the two halves over different time intervals, we demonstrate that Tc-odd cycles with a period of about 95 minutes at 30 degrees C. Using live imaging and cell tracking in green fluorescent protein-expressing embryos, we can exclude that cell movements explain this dynamic expression. Our results show that molecular oscillators represent a common feature of segmentation in divergent animals and help reconcile the contrasting paradigms of insect and vertebrate segmentation.	[Sarrazin, Andres F.; Peel, Andrew D.; Averof, Michalis] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol IMBB, GR-70013 Iraklion, Crete, Greece		Averof, M (corresponding author), Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol IMBB, Nikolaou Plastira 100, GR-70013 Iraklion, Crete, Greece.	averof@imbb.forth.gr	Sarrazin, Andres/A-1218-2013	Sarrazin, Andres/0000-0002-4307-1744; Averof, Michalis/0000-0002-6803-7251	CELLIMAGE and ZOONET (European Union)	CELLIMAGE and ZOONET (European Union)	We thank J. Schinko and G. Bucher for teaching us how to handle Tribolium and for help in generating the GFP-expressing transgenic line; J. P. Couso and S. Bishop for advice on embryo culture; D. Kosman, W. McGinnis, and C. Delidakis for advice on fluorescence in situ; and M. Strigini for critical comments on the manuscript. Our work was funded by the Marie Curie programs CELLIMAGE and ZOONET (FP6, European Union).	Brown S. J., 2009, COLD SPRING HARBOR P, P126; Chipman AD, 2004, CURR BIOL, V14, P1250, DOI 10.1016/j.cub.2004.07.026; Chipman AD, 2008, DEV BIOL, V319, P160, DOI 10.1016/j.ydbio.2008.02.038; Chipman AD, 2010, BIOESSAYS, V32, P60, DOI 10.1002/bies.200900130; Choe CP, 2006, P NATL ACAD SCI USA, V103, P6560, DOI 10.1073/pnas.0510440103; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Copf T, 2004, P NATL ACAD SCI USA, V101, P17711, DOI 10.1073/pnas.0407327102; de Rosa R, 2005, EVOL DEV, V7, P574; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Dray N, 2010, SCIENCE, V329, P339, DOI 10.1126/science.1188913; Kainz F, 2011, DEVELOPMENT, V138, P5015, DOI 10.1242/dev.073395; Krol AJ, 2011, DEVELOPMENT, V138, P2783, DOI 10.1242/dev.063834; Martin BL, 2009, CURR BIOL, V19, pR215, DOI 10.1016/j.cub.2009.01.052; Masamizu Y, 2006, P NATL ACAD SCI USA, V103, P1313, DOI 10.1073/pnas.0508658103; Mito T, 2011, DEVELOPMENT, V138, P3823, DOI 10.1242/dev.060681; Oates AC, 2012, DEVELOPMENT, V139, P625, DOI 10.1242/dev.063735; Oda H, 2007, DEVELOPMENT, V134, P2195, DOI 10.1242/dev.004598; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Peel A, 2003, CURR BIOL, V13, pR708, DOI 10.1016/j.cub.2003.08.045; Pueyo JI, 2008, P NATL ACAD SCI USA, V105, P16614, DOI 10.1073/pnas.0804093105; Schoppmeier M, 2005, DEV BIOL, V280, P211, DOI 10.1016/j.ydbio.2005.01.024; Stollewerk A, 2003, NATURE, V423, P863, DOI 10.1038/nature01682; Wilson V, 2009, DEVELOPMENT, V136, P1591, DOI 10.1242/dev.021246	23	145	146	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 20	2012	336	6079					338	341		10.1126/science.1218256	http://dx.doi.org/10.1126/science.1218256			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928PO	22403177				2022-12-28	WOS:000302995400043
J	Dimaras, H; Kimani, K; Dimba, EAO; Gronsdahl, P; White, A; Chan, HSL; Gallie, BL				Dimaras, Helen; Kimani, Kahaki; Dimba, Elizabeth A. O.; Gronsdahl, Peggy; White, Abby; Chan, Helen S. L.; Gallie, Brenda L.			Retinoblastoma	LANCET			English	Article							OPHTHALMIC ARTERY CHEMOTHERAPY; LONG-TERM SURVIVORS; INTRAOCULAR RETINOBLASTOMA; TRILATERAL RETINOBLASTOMA; METASTATIC RETINOBLASTOMA; HEREDITARY RETINOBLASTOMA; PRESENTING SIGNS; GENE-MUTATIONS; RB1 MUTATIONS; PHASE-I/II	Retinoblastoma is an aggressive eye cancer of infancy and childhood. Survival and the chance of saving vision depend on severity of disease at presentation. Retino blastoma was the first tumour to draw attention to the genetic aetiology of cancer. Despite good under standing of its aetiology, mortality from retinoblastoma is about 70% in countries of low and middle income, where most affected children live. Poor public and medical awareness, and an absence of rigorous clinical trials to assess innovative treatments impede progress. Worldwide, most of the estimated 9000 newly diagnosed patients every year will die. However, global digital communications present opportunities to optimise standards of care for children and families affected by this rare and often devastating cancer. Parents are now leading the effort for widespread awareness of the danger of leucocoria. Genome-level technologies could make genetic testing a reality for every family affected by retinoblastoma. Best-practice guidelines, online sharing of pathological images, point-of-care data entry, multi disciplinary research, and clinical trials can reduce mortality. Most importantly, active participation of survivors and families will ensure that the whole wellbeing of the child is prioritised in any treatment plan.	[Dimaras, Helen; Chan, Helen S. L.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Gallie, Brenda L.] Hosp Sick Children, Dept Ophthalmol & Visual Sci, Toronto, ON M5G 1X8, Canada; [Chan, Helen S. L.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Kimani, Kahaki] Kenyatta Natl Hosp, Dept Ophthalmol, Nairobi, Kenya; [Dimba, Elizabeth A. O.] Univ Nairobi, Dept Maxillofacial Pathol, Nairobi, Kenya; [Gronsdahl, Peggy] Canadian Retinoblastoma Soc, Toronto, ON, Canada; [Dimaras, Helen; White, Abby; Chan, Helen S. L.; Gallie, Brenda L.] Daisys Eye Canc Fund, Oxford, England; [Chan, Helen S. L.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Dimaras, Helen; Gallie, Brenda L.] Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; [Gallie, Brenda L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Gallie, Brenda L.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Kenyatta National Hospital; University of Nairobi; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Gallie, BL (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Canc Res, Ontario Canc Inst, Room 8-415,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	brenda@gallie.ca	kimani, kahaki/AAC-9898-2020	Dimaras, Helen/0000-0003-1164-2001; Gallie, Brenda/0000-0002-9697-9211	Campbell Family Institute for Cancer Research; Ontario Institute for Cancer Research; Terry Fox Research Institute; Canadian Retinoblastoma Society; Royal Arch Masons of Canada; Ontario Ministry of Health and Long Term Care (OMOHLTC)	Campbell Family Institute for Cancer Research; Ontario Institute for Cancer Research; Terry Fox Research Institute; Canadian Retinoblastoma Society; Royal Arch Masons of Canada; Ontario Ministry of Health and Long Term Care (OMOHLTC)(Ministry of Health and Long-Term Care, Ontario)	We were supported by the Campbell Family Institute for Cancer Research, Ontario Institute for Cancer Research, Terry Fox Research Institute, Canadian Retinoblastoma Society, Royal Arch Masons of Canada, and Ontario Ministry of Health and Long Term Care (OMOHLTC). The views expressed in this report do not necessarily represent those of the OMOHLTC.	Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014; Abramson DH, 2010, OPHTHALMOLOGY, V117, P1623, DOI 10.1016/j.ophtha.2009.12.030; Abramson DH, 2010, ARCH OPHTHALMOL-CHIC, V128, P370, DOI 10.1001/archophthalmol.2010.7; Abramson DH, 1999, OPHTHALMOLOGY, V106, P1947, DOI 10.1016/S0161-6420(99)90406-2; Abramson DH, 2003, PEDIATRICS, V112, P1248, DOI 10.1542/peds.112.6.1248; Abramson DH, 1998, J PEDIATR-US, V132, P505, DOI 10.1016/S0022-3476(98)70028-9; Albrecht P, 2005, HUM MUTAT, V26, P437, DOI 10.1002/humu.20234; Aziz Hassan A, 2010, Retina, V30, pS63, DOI 10.1097/IAE.0b013e3181cbda0f; Baud O, 1999, CLIN GENET, V55, P478, DOI 10.1034/j.1399-0004.1999.550614.x; Bhasker S, 2008, SINGAP MED J, V49, P998; Boubacar T, 2010, BRIT J OPHTHALMOL, V94, P467, DOI 10.1136/bjo.2009.159699; Bowles E, 2007, GENE CHROMOSOME CANC, V46, P118, DOI 10.1002/gcc.20383; Bowman RJC, 2008, PEDIATR BLOOD CANCER, V50, P160, DOI 10.1002/pbc.21080; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Canadian Retinoblastoma Society, 2009, Can J Ophthalmol, V44 Suppl 2, pS1, DOI 10.3129/i09-194; Canturk S, 2010, BRIT J OPHTHALMOL, V94, P1432, DOI 10.1136/bjo.2009.168062; Chan Helen S L, 2005, Ophthalmol Clin North Am, V18, P55, DOI 10.1016/j.ohc.2004.11.002; CHAN HSL, 1989, ANTICANCER RES, V9, P469; Chan HSL, 1996, CLIN CANCER RES, V2, P1499; CHAN HSL, 1991, OPHTHALMOLOGY, V98, P1425; Chantada GL, 2009, INVEST OPHTH VIS SCI, V50, P1492, DOI 10.1167/iovs.08-2737; Chuka-Okosa C M, 2008, West Afr J Med, V27, P144; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; Dai S, 2008, OPHTHALMIC GENET, V29, P120, DOI 10.1080/13816810802043678; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Dimaras H, 2008, KENYAN NATL RETINOBL; Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024; Dimaras H, 2011, ARCH OPHTHALMOL-CHIC, V129, P362, DOI 10.1001/archophthalmol.2011.17; Dimaras H, 2010, TRANSL RES, V156, P91, DOI 10.1016/j.trsl.2010.05.009; Dimaras H, 2009, OPHTHALMIC GENET, V30, P121, DOI 10.1080/13816810902988780; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; DRYJA TP, 1989, NATURE, V339, P556, DOI 10.1038/339556a0; Duffner PK, 2004, NEUROLOGIST, V10, P293, DOI 10.1097/01.nrl.0000144287.35993.96; Dunkel IJ, 2000, CANCER, V89, P2117, DOI 10.1002/1097-0142(20001115)89:10<2117::AID-CNCR12>3.0.CO;2-9; Dunkel IJ, 2010, PEDIATR BLOOD CANCER, V54, P384, DOI 10.1002/pbc.22336; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Finger P., 2010, AJCC CANC STAGING MA, V7th, P561; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; Goddard AG, 1999, BRIT J OPHTHALMOL, V83, P1320, DOI 10.1136/bjo.83.12.1320; Houdayer C, 2004, HUM MUTAT, V23, P193, DOI 10.1002/humu.10303; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Isaac CE, 2006, MOL CELL BIOL, V26, P3659, DOI 10.1128/MCB.26.9.3659-3671.2006; Kao LY, 2002, JPN J OPHTHALMOL, V46, P577, DOI 10.1016/S0021-5155(02)00546-4; Kimani K, 2009, RATIS CHALLENGE VISI; Kivela T, 2011, INFORM AUTHORS PROJE; Kivela T, 2009, BRIT J OPHTHALMOL, V93, P1129, DOI 10.1136/bjo.2008.150292; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Kleinerman RA, 2007, JNCI-J NATL CANCER I, V99, P24, DOI 10.1093/jnci/djk002; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Leal-Leal C, 2004, BRIT J OPHTHALMOL, V88, P1074, DOI 10.1136/bjo.2003.035642; Leander C, 2007, PEDIATR BLOOD CANCER, V49, P817, DOI 10.1002/pbc.21052; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; LOHMANN DR, 1994, HUM GENET, V94, P349; Longworth MS, 2010, CHROMOSOMA, V119, P1, DOI 10.1007/s00412-009-0238-0; MacCarthy A, 2006, EUR J CANCER, V42, P2092, DOI 10.1016/j.ejca.2006.06.003; Mallipatna AC, 2011, ARCH OPHTHALMOL-CHIC, V129, P738, DOI 10.1001/archophthalmol.2011.130; Mallipatna AC, 2009, J AAPOS, V13, P546, DOI 10.1016/j.jaapos.2009.09.004; Mallipatna CA, 2009, EVIDENCE BASED OPHTH, V10, P183; Marchong MN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000923; McDaid C, 2005, HEALTH TECHNOL ASSES, V9, P1; Menon BS, 2009, PEDIATR BLOOD CANCER, V52, P215, DOI 10.1002/pbc.21791; Mulvihill A, 2003, ARCH OPHTHALMOL-CHIC, V121, P1120, DOI 10.1001/archopht.121.8.1120; Novetsky DE, 2009, OPHTHALMIC GENET, V30, P40, DOI 10.1080/13816810802452168; Nyamori JM, BR J OPHTHA IN PRESS; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Owoeye Joshua F A, 2006, Afr J Health Sci, V13, P117; Panton RL, 2009, PSYCHO-ONCOLOGY, V18, P300, DOI 10.1002/pon.1397; Paulino AC, 1999, CANCER-AM CANCER SOC, V86, P135, DOI 10.1002/(SICI)1097-0142(19990701)86:1<135::AID-CNCR19>3.0.CO;2-0; Pezzente M, 2009, PERSONAL STORY; REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Rodrigues Karla E. S., 2004, J. Pediatr. (Rio J.), V80, P511, DOI 10.2223/1266; Rodriguez-Galindo C, 2003, OPHTHALMOLOGY, V110, P1237, DOI 10.1016/S0161-6420(03)00258-6; Rushlow D, 2009, HUM MUTAT, V30, P842, DOI 10.1002/humu.20940; Sahgal A, 2006, CLIN ONCOL-UK, V18, P628, DOI 10.1016/j.clon.2006.06.013; Samaila Modupeola Omotara, 2009, Afr J Paediatr Surg, V6, P19, DOI 10.4103/0189-6725.48570; Schmack I, 2006, AM J OPHTHALMOL, V142, P310, DOI 10.1016/j.ajo.2006.02.044; Shields CL, 2009, RETINA-J RET VIT DIS, V29, P1207, DOI 10.1097/IAE.0b013e3181b4ce39; Shome D, 2010, OPHTHALMOLOGY, V117, P1638, DOI 10.1016/j.ophtha.2009.12.035; STALLARD HB, 1952, LANCET, V262, P1046; Suzuki S, 2011, OPHTHALMOLOGY, V118, P2081, DOI 10.1016/j.ophtha.2011.03.013; Talluri S, 2010, MOL CELL BIOL, V30, P948, DOI 10.1128/MCB.01168-09; Yamane Takashi, 2004, Int J Clin Oncol, V9, P69, DOI 10.1007/s10147-004-0392-6; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012; Zeschnigk M, 1999, J MED GENET, V36, P793, DOI 10.1136/jmg.36.10.793; Zhao JY, 2011, J CLIN ONCOL, V29, P845, DOI 10.1200/JCO.2010.32.5332; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	92	392	427	3	70	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2012	379	9824					1436	1446		10.1016/S0140-6736(11)61137-9	http://dx.doi.org/10.1016/S0140-6736(11)61137-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926BR	22414599				2022-12-28	WOS:000302806800032
J	Pavlidis, N; Pentheroudakis, G				Pavlidis, Nicholas; Pentheroudakis, George			Cancer of unknown primary site	LANCET			English	Article							POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASES; NEUROENDOCRINE CARCINOMA; PRIMARY TUMOR; MANAGEMENT; DIAGNOSIS; PROGNOSIS; PET	Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5% of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. Diagnostic approaches to identify the primary site include detailed histopathological examination with specific immunohistochemistry and radiological assessment. Gene-profiling microarray diagnosis has high sensitivity, but further prospective study is necessary to establish whether patients' outcomes are improved by its clinical use. Metastatic adenocarcinoma is the most common CUP histopathology (80%). CUP patients are divided into subsets of favourable (20%) and unfavourable (80%) prognosis. Favourable subsets are mostly given locoregional treatment or systemic platinum-based chemotherapy. Responses and survival are similar to those of patients with relevant known primary tumours. Patients in unfavourable subsets are treated with empirical chemotherapy based on combination regimens of platinum or taxane, but responses and survival are generally poor.	[Pavlidis, Nicholas; Pentheroudakis, George] Univ Ioannina, Sch Med, Dept Med Oncol, GR-45110 Ioannina, Greece	University of Ioannina	Pavlidis, N (corresponding author), Univ Hosp Ioannina, Dept Oncol, Ioannina 45110, Greece.	npavlid@uoi.gr						ABBRUZZESE JL, 1995, J CLIN ONCOL, V13, P2094, DOI 10.1200/JCO.1995.13.8.2094; Bender RA, 2009, SEMIN ONCOL, V36, P38, DOI 10.1053/j.seminoncol.2008.10.002; Bridgewater J, 2008, BRIT J CANCER, V98, P1425, DOI 10.1038/sj.bjc.6604315; Chen AM, 2011, INT J RADIAT ONCOL, V81, P346, DOI 10.1016/j.ijrobp.2010.06.031; Culine S, 2009, SEMIN ONCOL, V36, P60, DOI 10.1053/j.seminoncol.2008.10.004; Delgado-Bolton RC, 2003, J NUCL MED, V44, P1301; Fernandez JA, 1998, CLIN OTOLARYNGOL, V23, P158; Golfinopoulos V, 2009, CANCER TREAT REV, V35, P570, DOI 10.1016/j.ctrv.2009.05.005; Greco FA, 2010, ONCOLOGIST, V15, P500, DOI 10.1634/theoncologist.2009-0328; Greco FA, 2009, SEMIN ONCOL, V36, P65, DOI 10.1053/j.seminoncol.2008.10.005; GUARISCHI A, 1987, CANCER-AM CANCER SOC, V59, P572, DOI 10.1002/1097-0142(19870201)59:3<572::AID-CNCR2820590336>3.0.CO;2-3; Hainsworth JD, 2007, J CLIN ONCOL, V25, P1747, DOI 10.1200/JCO.2006.09.3047; Hainsworth JD, 2009, ONCOLOGIST, V14, P1189, DOI 10.1634/theoncologist.2009-0112; Hainsworth JD, 2009, SEMIN ONCOL, V36, P44, DOI 10.1053/j.seminoncol.2008.10.006; HEDLEY DW, 1985, EUR J CANCER CLIN ON, V21, P185, DOI 10.1016/0277-5379(85)90171-3; Horlings HM, 2008, J CLIN ONCOL, V26, P4435, DOI 10.1200/JCO.2007.14.6969; Jereczek-Fossa BA, 2004, CANCER TREAT REV, V30, P153, DOI 10.1016/j.ctrv.2003.10.001; Keller F, 2011, HEAD NECK-J SCI SPEC, V33, P1569, DOI 10.1002/hed.21635; Kwee TC, 2009, EUR RADIOL, V19, P731, DOI 10.1007/s00330-008-1194-4; Lazaridis G, 2008, CANCER TREAT REV, V34, P693, DOI 10.1016/j.ctrv.2008.05.005; Lesimple T., 2006, CARCINOMA UNKNOWN PR, P133; Monzon FA, 2010, ARCH PATHOL LAB MED, V134, P216, DOI 10.1043/1543-2165-134.2.216; Oien KA, 2009, SEMIN ONCOL, V36, P8, DOI 10.1053/j.seminoncol.2008.10.009; Orel SG, 1999, RADIOLOGY, V212, P543, DOI 10.1148/radiology.212.2.r99au40543; Pavlidis N, 2003, EUR J CANCER, V39, P1990, DOI 10.1016/S0959-8049(03)00547-1; Pavlidis N, 2008, METASTATIC CARCINOMA, P225; Pavlidis N, 2007, ACTA ONCOL, V46, P592, DOI 10.1080/02841860701243095; Pavlidis N, 2009, CLIN TRANSL ONCOL, V11, P340, DOI 10.1007/s12094-009-0367-1; Pavlidis N, 2009, CRIT REV ONCOL HEMAT, V69, P271, DOI 10.1016/j.critrevonc.2008.09.005; Pentheroudakis G, 2008, METASTATIC CARCINOMA, P165; Pentheroudakis G, 2010, ANN ONCOL S8, V21, P865; Pentheroudakis G, 2007, EUR J CANCER, V43, P2026, DOI 10.1016/j.ejca.2007.06.023; Pentheroudakis G, 2007, ONCOLOGIST, V12, P418, DOI 10.1634/theoncologist.12-4-418; Pentheroudakis G, 2011, CANCER TREAT REV, V37, P120, DOI 10.1016/j.ctrv.2010.06.003; Pentheroudakis G, 2010, CRIT REV ONCOL HEMAT, V75, P27, DOI 10.1016/j.critrevonc.2009.10.003; Pentheroudakis G, 2010, BREAST CANCER RES TR, V119, P1, DOI 10.1007/s10549-009-0554-3; Pilarsky CP, 1999, CURR OPIN MOL THER, V1, P727; Polyzoidis KS, 2005, CANCER TREAT REV, V31, P247, DOI 10.1016/j.ctrv.2005.03.006; Prasad V, 2010, EUR J NUCL MED MOL I, V37, P67, DOI 10.1007/s00259-009-1205-y; Rusthoven KE, 2004, CANCER-AM CANCER SOC, V101, P2641, DOI 10.1002/cncr.20687; Seve P, 2007, CANCER-AM CANCER SOC, V109, P292, DOI 10.1002/cncr.22410; Sher DJ, 2011, INT J RADIAT ONCOL, V80, P1405, DOI 10.1016/j.ijrobp.2010.04.029; Spigel DR, 2009, SEMIN ONCOL, V36, P52, DOI 10.1053/j.seminoncol.2008.10.003; Stella GM, 2011, HUM MUTAT, V32, P44, DOI 10.1002/humu.21374; Stoyianni A, 2011, CANCER TREAT REV, V37, P358, DOI 10.1016/j.ctrv.2011.03.002; Varadhachary GR, 2008, J CLIN ONCOL, V26, P4442, DOI 10.1200/JCO.2007.14.4378; Varadhachary GR, 2009, SEMIN ONCOL, V36, P75, DOI 10.1053/j.seminoncol.2008.10.008; Varadhachary GR, 2008, LANCET ONCOL, V9, P596, DOI 10.1016/S1470-2045(08)70151-7	48	312	324	2	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2012	379	9824					1428	1435		10.1016/S0140-6736(11)61178-1	http://dx.doi.org/10.1016/S0140-6736(11)61178-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926BR	22414598				2022-12-28	WOS:000302806800031
J	Tang, W; Kannan, R; Blanchette, M; Baumann, P				Tang, Wen; Kannan, Ram; Blanchette, Marco; Baumann, Peter			Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SCHIZOSACCHAROMYCES-POMBE; IN-VITRO; YEAST TELOMERASE; U6 SNRNA; PROTEIN; HYPERMETHYLATION; IDENTIFICATION; ASSOCIATION; LENGTH	In most eukaryotes, the progressive loss of chromosome-terminal DNA sequences is counteracted by the enzyme telomerase, a reverse transcriptase that uses part of an RNA subunit as template to synthesize telomeric repeats. Many cancer cells express high telomerase activity, and mutations in telomerase subunits are associated with degenerative syndromes including dyskeratosis congenita and aplastic anaemia. The therapeutic value of altering telomerase activity thus provides ample impetus to study the biogenesis and regulation of this enzyme in human cells and model systems. We have previously identified a precursor of the fission yeast telomerase RNA subunit (TER1)(1) and demonstrated that the mature 3'-end is generated by the spliceosome in a single cleavage reaction akin to the first step of splicing(2). Directly upstream and partly overlapping with the spliceosomal cleavage site is a putative binding site for Sm proteins. Sm and like-Sm (LSm) proteins belong to an ancient family of RNA-binding proteins represented in all three domains of life(3). Members of this family form ring complexes on specific sets of target RNAs and have critical roles in their biogenesis, function and turnover. Here we demonstrate that the canonical Sm ring and the Lsm2-8 complex sequentially associate with fission yeast TER1. The Sm ring binds to the TER1 precursor, stimulates spliceosomal cleavage and promotes the hypermethylation of the 5'-cap by Tgs1. Sm proteins are then replaced by the Lsm2-8 complex, which promotes the association with the catalytic subunit and protects the mature 3'-end of TER1 from exonucleolytic degradation. Our findings define the sequence of events that occur during telomerase biogenesis and characterize roles for Sm and Lsm complexes as well as for the methylase Tgs1.	[Tang, Wen; Kannan, Ram; Baumann, Peter] Howard Hughes Med Inst, Kansas City, MO 64110 USA; [Tang, Wen; Kannan, Ram; Blanchette, Marco; Baumann, Peter] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Tang, Wen; Kannan, Ram; Baumann, Peter] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Blanchette, Marco] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Howard Hughes Medical Institute; Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Baumann, P (corresponding author), Howard Hughes Med Inst, Kansas City, MO 64110 USA.	peb@stowers.org		Baumann, Peter/0000-0003-4892-1485	Stowers Institute for Medical Research; American Heart Association	Stowers Institute for Medical Research; American Heart Association(American Heart Association)	We thank S. Shuman for the tgs1 Delta strain, J. A. Box, J. T. Bunch, S. Hartnett and R. M. Helston for technical assistance, the Molecular Biology Core Facility for site-directed mutagenesis and sequencing, D. P. Baumann and R. M. Helston for proofreading the manuscript, and all members of the Baumann laboratory for discussions. This work was funded in part by the Stowers Institute for Medical Research. R. K. is supported by an award from the American Heart Association, and P. B. is an Early Career Scientist with the Howard Hughes Medical Institute.	Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Berman AJ, 2010, MOL CELL BIOL, V30, P4965, DOI 10.1128/MCB.00827-10; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Box JA, 2008, NATURE, V456, P910, DOI 10.1038/nature07584; Bunch JT, 2005, MOL CELL BIOL, V25, P5567, DOI 10.1128/mcb.25.13.5567-5578.2005; Dandjinou AT, 2004, CURR BIOL, V14, P1148, DOI 10.1016/j.cub.2004.05.054; Franke J, 2008, J CELL SCI, V121, P3553, DOI 10.1242/jcs.033308; Fu D, 2006, GENE DEV, V20, P531, DOI 10.1101/gad.1390306; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Gunisova S, 2009, RNA, V15, P546, DOI 10.1261/rna.1194009; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 2005, CHROMOSOME RES, V13, P493, DOI 10.1007/s10577-005-0994-5; Hausmann S, 2007, NUCLEIC ACIDS RES, V35, P1411, DOI 10.1093/nar/gkl1150; Jady BE, 2004, J CELL BIOL, V164, P647, DOI 10.1083/jcb.200310138; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; Leonardi J, 2008, NAT STRUCT MOL BIOL, V15, P26, DOI 10.1038/nsmb1343; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; Mozdy AD, 2006, RNA, V12, P1721, DOI 10.1261/rna.134706; O'Connor CM, 2006, MOL CELL BIOL, V26, P2029, DOI 10.1128/MCB.26.6.2029-2036.2006; Patel SB, 2008, NUCLEIC ACIDS RES, V36, P6482, DOI 10.1093/nar/gkn658; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Stone MD, 2007, NATURE, V446, P458, DOI 10.1038/nature05600; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Webb CJ, 2008, NAT STRUCT MOL BIOL, V15, P34, DOI 10.1038/nsmb1354; Wilusz CJ, 2005, NAT STRUCT MOL BIOL, V12, P1031, DOI 10.1038/nsmb1037; Yong J, 2010, MOL CELL, V38, P551, DOI 10.1016/j.molcel.2010.03.014	33	63	64	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					260	U152		10.1038/nature10924	http://dx.doi.org/10.1038/nature10924			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22446625	Green Accepted			2022-12-28	WOS:000303149900039
J	Derecki, NC; Cronk, JC; Lu, ZJ; Xu, E; Abbott, SBG; Guyenet, PG; Kipnis, J				Derecki, Noel C.; Cronk, James C.; Lu, Zhenjie; Xu, Eric; Abbott, Stephen B. G.; Guyenet, Patrice G.; Kipnis, Jonathan			Wild-type microglia arrest pathology in a mouse model of Rett syndrome	NATURE			English	Article							CPG-BINDING PROTEIN-2; ALZHEIMERS-DISEASE; MUTANT MICE; MECP2; DEFICIENCY; MUTATIONS; SYMPTOMS; REVERSAL; DEATH; CELLS	Rett syndrome is an X-linked autism spectrum disorder. The disease is characterized inmost cases by mutation of the MECP2 gene, which encodes a methyl-CpG-binding protein(1-5). Although MECP2 is expressed in many tissues, the disease is generally attributed to a primary neuronal dysfunction(6). However, as shown recently, glia, specifically astrocytes, also contribute to Rett pathophysiology. Here we examine the role of another form of glia, microglia, in a murine model of Rett syndrome. Transplantation of wild-type bone marrow into irradiation-conditioned Mecp2-null hosts resulted in engraftment of brain parenchyma by bone-marrow-derived myeloid cells of microglial phenotype, and arrest of disease development. However, when cranial irradiation was blocked by lead shield, and microglial engraftment was prevented, disease was not arrested. Similarly, targeted expression of MECP2 in myeloid cells, driven by Lysm(cre) on an Mecp2-null background, markedly attenuated disease symptoms. Thus, through multiple approaches, wild-type Mecp2-expressing microglia within the context of an Mecp2-null male mouse arrested numerous facets of disease pathology: lifespan was increased, breathing patterns were normalized, apnoeas were reduced, body weight was increased to near that of wild type, and locomotor activity was improved. Mecp2(+/-) females also showed significant improvements as a result of wild-type microglial engraftment. These benefits mediated by wild-type microglia, however, were diminished when phagocytic activity was inhibited pharmacologically by using annexin V to block phosphatydilserine residues on apoptotic targets, thus preventing recognition and engulfment by tissue-resident phagocytes. These results suggest the importance of microglial phagocytic activity in Rett syndrome. Our data implicate microglia as major players in the pathophysiology of this devastating disorder, and suggest that bone marrow transplantation might offer a feasible therapeutic approach for it.	[Derecki, Noel C.; Cronk, James C.; Lu, Zhenjie; Xu, Eric; Kipnis, Jonathan] Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA; [Derecki, Noel C.; Cronk, James C.; Kipnis, Jonathan] Univ Virginia, Sch Med, Grad Program Neurosci, Charlottesville, VA 22908 USA; [Cronk, James C.; Kipnis, Jonathan] Univ Virginia, Sch Med, Med Scientist Training Program, Charlottesville, VA 22908 USA; [Xu, Eric] Univ Virginia, Undergrad Sch Arts & Sci, Charlottesville, VA 22908 USA; [Abbott, Stephen B. G.; Guyenet, Patrice G.] Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Kipnis, J (corresponding author), Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA.	kipnis@virginia.edu	Kipnis, Jonathan/AGG-9735-2022	Kipnis, Jonathan/0000-0002-3714-517X; Abbott, Stephen BG/0000-0003-1244-3637	Hartwell Foundation; Rett Syndrome Research Trust;  [HD056293];  [AG034113]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD056293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS081026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034113] Funding Source: NIH RePORTER	Hartwell Foundation; Rett Syndrome Research Trust; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank S. Smith for editing the manuscript. We thank the members of the Kipnis laboratory as well as the members of the University of Virginia Neuroscience Department for their comments during multiple discussions of this work. We also thank S. Feldman for injection of neonatal mice, I. Smirnov for tail vein injections, and B. Tomlin and J. Jones for their animal care. N.C.D. is a recipient of a Hartwell Foundation post-doctoral fellowship. This work was primarily supported by a grant from the Rett Syndrome Research Trust (to J.K.) and in part by HD056293 and AG034113 (to J.K).	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballas N, 2009, NAT NEUROSCI, V12, P311, DOI 10.1038/nn.2275; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Cho IH, 2008, BRAIN, V131, P3019, DOI 10.1093/brain/awn230; DRORBAUGH JE, 1955, PEDIATRICS, V16, P81; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; Lioy DT, 2011, NATURE, V475, P497, DOI 10.1038/nature10214; Lu ZJ, 2011, NAT CELL BIOL, V13, P1076, DOI 10.1038/ncb2299; Luikenhuis S, 2004, P NATL ACAD SCI USA, V101, P6033, DOI 10.1073/pnas.0401626101; Maezawa I, 2010, J NEUROSCI, V30, P5346, DOI 10.1523/JNEUROSCI.5966-09.2010; Maezawa I, 2009, J NEUROSCI, V29, P5051, DOI 10.1523/JNEUROSCI.0324-09.2009; McGraw CM, 2011, SCIENCE, V333, P186, DOI 10.1126/science.1206593; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Nan XH, 2001, BRAIN DEV-JPN, V23, pS32, DOI 10.1016/S0387-7604(01)00333-3; Nijboer CH, 2010, BRAIN BEHAV IMMUN, V24, P420, DOI 10.1016/j.bbi.2009.11.009; OLDFORS A, 1990, PEDIATR NEUROL, V6, P310, DOI 10.1016/0887-8994(90)90022-S; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Tropea D, 2009, P NATL ACAD SCI USA, V106, P2029, DOI 10.1073/pnas.0812394106; Van den Veyver IB, 2001, BRAIN DEV-JPN, V23, pS147, DOI 10.1016/S0387-7604(01)00376-X; Van den Veyver IB, 2002, MENT RETARD DEV D R, V8, P82, DOI 10.1002/mrdd.10025; Willemen HLDM, 2010, PAIN, V150, P550, DOI 10.1016/j.pain.2010.06.015; Zhang X, 2009, TOXICOL SCI, V111, P355, DOI 10.1093/toxsci/kfp167	30	428	441	4	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					105	+		10.1038/nature10907	http://dx.doi.org/10.1038/nature10907			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22425995	Green Accepted			2022-12-28	WOS:000302343400043
J	Sedrakyan, A				Sedrakyan, Art			Metal-on-metal failures-in science, regulation, and policy	LANCET			English	Editorial Material							MEDICAL DEVICES; HIP; TRIALS		Weill Cornell Med Coll, New York, NY 10065 USA	Cornell University	Sedrakyan, A (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	ars2013@med.cornell.edu						Cohen D, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1410; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; de Steiger RN, 2011, J BONE JOINT SURG AM, V93A, P2287, DOI [10.2106/JBJS.J.01727, 10.2106/JBJSJ.01727]; House Energy and Commerce Committee, 2012, REAUTH MDUFA WHAT IT; ICOR Collaborators, 2011, J BONE JOINT S A S3E, V93-A, P1; ICOR Collaborators, 2011, J BONE JOINT S A S3E, V93-A, P43; Kramer DB, 2012, NEW ENGL J MED, V366, P848, DOI 10.1056/NEJMhle1113918; Kurtz SM, 2007, J BONE JOINT SURG AM, V89A, P144, DOI 10.2106/JBJS.G.00587; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Meier B, 2011, HIGH COST FAILING AR; MHRA, 2012, MED DEV AL ALL MET O; Mullan F, 2004, HEALTH AFFAIR, V23, pVAR73, DOI 10.1377/hlthaff.var.73; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Sedrakyan A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7434; Sedrakyan A, 2010, MED CARE, V48, pS121, DOI 10.1097/MLR.0b013e3181d991c4; Smith AJ, 2012, LANCET, V379, P1199, DOI 10.1016/S0140-6736(12)60353-5	16	37	37	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2012	379	9822					1174	1176		10.1016/S0140-6736(12)60372-9	http://dx.doi.org/10.1016/S0140-6736(12)60372-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	918DV	22417409				2022-12-28	WOS:000302230400009
J	Ayele, FT; Adeyemo, A; Finan, C; Hailu, E; Sinnott, P; Burlinson, ND; Aseffa, A; Rotimi, CN; Newport, MJ; Davey, G				Ayele, Fasil Tekola; Adeyemo, Adebowale; Finan, Chris; Hailu, Elena; Sinnott, Paul; Burlinson, Natalia Diaz; Aseffa, Abraham; Rotimi, Charles N.; Newport, Melanie J.; Davey, Gail			HLA Class II Locus and Susceptibility to Podoconiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-FILARIAL ELEPHANTIASIS; ENDEMIC ELEPHANTIASIS; SOUTHERN ETHIOPIA; GENETIC-ANALYSIS; COMPLEX DISEASE; LOWER LEGS; ASSOCIATION; SILICOSIS; CONSENT; STIGMA	BACKGROUND Podoconiosis is a tropical lymphedema resulting from long-term barefoot exposure to red-clay soil derived from volcanic rock. The World Health Organization recently designated it as a neglected tropical disease. Podoconiosis develops in only a subgroup of exposed people, and studies have shown familial clustering with high heritability (63%). METHODS We conducted a genomewide association study of 194 case patients and 203 controls from southern Ethiopia. Findings were validated by means of family-based association testing in 202 family trios and HLA typing in 94 case patients and 94 controls. RESULTS We found a genomewide significant association of podoconiosis with the single-nucleotide polymorphism (SNP) rs17612858, located 5.8 kb from the HLA-DQA1 locus (in the allelic model: odds ratio, 2.44; 95% confidence interval [CI], 1.82 to 3.26; P = 1.42x10(-9); and in the additive model: odds ratio, 2.19; 95% CI, 1.66 to 2.90; P = 3.44x10(-8)), and suggestive associations (P<1.0x10(-5)) with seven other SNPs in or near HLA-DQB1, HLA-DQA1, and HLA-DRB1. We confirmed these associations using family-based association testing. HLA typing showed the alleles HLA-DRB1*0701 (odds ratio, 2.00), DQA1*0201 (odds ratio, 1.91), and DQB1*0202 (odds ratio, 1.79) and the HLA-DRB1*0701-DQB1*0202 haplotype (odds ratio, 1.92) were risk variants for podoconiosis. CONCLUSIONS Association between variants in HLA class II loci with podoconiosis (a noncommunicable disease) suggests that the condition may be a T-cell-mediated inflammatory disease and is a model for gene-environment interactions that may be relevant to other complex genetic disorders. (Funded by the Wellcome Trust and others.)	[Ayele, Fasil Tekola; Adeyemo, Adebowale; Rotimi, Charles N.] NHGRI, Ctr Res Genom & Global Hlth, NIH, Bethesda, MD 20892 USA; [Ayele, Fasil Tekola; Finan, Chris; Newport, Melanie J.; Davey, Gail] Brighton & Sussex Med Sch, Brighton, E Sussex, England; [Ayele, Fasil Tekola; Hailu, Elena; Aseffa, Abraham] Armauer Hansen Res Inst, Addis Ababa, Ethiopia; [Sinnott, Paul; Burlinson, Natalia Diaz] Royal London Hosp, Clin Transplantat Lab, London E1 1BB, England	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Brighton; University of Sussex; Barts Health NHS Trust; Royal London Hospital	Ayele, FT (corresponding author), NHGRI, Ctr Res Genom & Global Hlth, NIH, Bldg 12A,Rm 4044,12 South Dr,MSC 5635, Bethesda, MD 20892 USA.	ayeleft@mail.nih.gov	Aseffa, Abraham/J-3248-2016	Aseffa, Abraham/0000-0002-8028-1150; Tekola-Ayele, Fasil/0000-0003-4194-9370; Newport, Melanie/0000-0002-8946-7525; Adeyemo, Adebowale/0000-0002-3105-3231; Davey, Gail/0000-0003-2796-7468	Wellcome Trust [079791]; Association of Physicians of Great Britain and Ireland; Center for Research on Genomics and Global Health (CRGGH); National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Center for Information Technology; Office of the Director at the National Institutes of Health [Z01HG200362]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200362, ZIAHG200362] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Association of Physicians of Great Britain and Ireland; Center for Research on Genomics and Global Health (CRGGH); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Information Technology(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); Office of the Director at the National Institutes of Health; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Funded by the Wellcome Trust and others.; Supported in part by grants from the Wellcome Trust (079791) and the Association of Physicians of Great Britain and Ireland's Links with Developing Country Scheme, as well as the Intramural Research Program of the Center for Research on Genomics and Global Health (CRGGH). The CRGGH is supported by a grant from the National Human Genome Research Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Center for Information Technology, and the Office of the Director at the National Institutes of Health (Z01HG200362).	Campbell MC, 2008, ANNU REV GENOM HUM G, V9, P403, DOI 10.1146/annurev.genom.9.081307.164258; Caruso C, 2000, HUM IMMUNOL, V61, P942, DOI 10.1016/S0198-8859(00)00168-3; Cesbron-Gautier A, 2004, ANN BIOL CLIN-PARIS, V62, P93; Davey G, 2007, T ROY SOC TROP MED H, V101, P91, DOI 10.1016/j.trstmh.2006.05.002; de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885; Destas K, 2003, TROP DOCT, V33, P217, DOI 10.1177/004947550303300410; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Lapolla W, 2011, NEW ENGL J MED, V364, pE23, DOI 10.1056/NEJMicm1008802; Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; NEWMAN LS, 1993, SCIENCE, V262, P197, DOI 10.1126/science.8105535; Pearson TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335; Price E W, 1972, Ethiop Med J, V10, P87; PRICE EW, 1981, ANN OCCUP HYG, V24, P1, DOI 10.1093/annhyg/24.1.1; PRICE EW, 1978, T ROY SOC TROP MED H, V72, P132, DOI 10.1016/0035-9203(78)90048-2; Price EW, 1990, PODOCONIOSIS NONFILA; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; Saltini C, 2001, EUR RESPIR J, V18, P677, DOI 10.1183/09031936.01.00106201; Spencer CCA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000477; Tekola F, 2006, TROP MED INT HEALTH, V11, P1136, DOI 10.1111/j.1365-3156.2006.01658.x; Tekola F, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-13; Tekola F, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000482; Teo YY, 2007, BIOINFORMATICS, V23, P2741, DOI 10.1093/bioinformatics/btm443; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; Ueki A, 2005, J OCCUP HEALTH, V47, P61, DOI 10.1539/joh.47.61; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WOLDEGABRIEL G, 1990, GEOL SOC AM BULL, V102, P439, DOI 10.1130/0016-7606(1990)102<0439:GGARBD>2.3.CO;2; Yakob B, 2008, T ROY SOC TROP MED H, V102, P439, DOI 10.1016/j.trstmh.2008.01.023	28	101	102	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1200	1208		10.1056/NEJMoa1108448	http://dx.doi.org/10.1056/NEJMoa1108448			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455414	Green Accepted, Bronze			2022-12-28	WOS:000302005100008
J	Orrow, G; Kinmonth, AL; Sanderson, S; Sutton, S				Orrow, Gillian; Kinmonth, Ann-Louise; Sanderson, Simon; Sutton, Stephen			Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXERCISE-REFERRAL SCHEMES; ACTIVITY INTERVENTIONS; IMPROVE FITNESS; RISK; PRESCRIPTION; ADVICE; PEOPLE; ADULTS	Objectives To determine whether trials of physical activity promotion based in primary care show sustained effects on physical activity or fitness in sedentary adults, and whether exercise referral interventions are more effective than other interventions. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, CINAHL, PsycINFO, EMBASE, SPORTDiscus, Centre for Reviews and Dissemination, the Cochrane Library, and article reference lists. Review methods Review of randomised controlled trials of physical activity promotion in sedentary adults recruited in primary care, with minimum follow-up of 12 months, reporting physical activity or fitness (or both) as outcomes, and using intention to treat analyses. Two reviewers independently assessed studies for inclusion, appraised risk of bias, and extracted data. Pooled effect sizes were calculated using a random effects model. Results We included 15 trials (n=8745). Most interventions took place in primary care, included health professionals in delivery, and involved advice or counselling given face to face or by phone (or both) on multiple occasions. Only three trials investigated exercise referral. In 13 trials presenting self reported physical activity, we saw small to medium positive intervention effects at 12 months (odds ratio 1.42, 95% confidence interval 1.17 to 1.73; standardised mean difference 0.25, 0.11 to 0.38). The number needed to treat with an intervention for one additional sedentary adult to meet internationally recommended levels of activity at 12 months was 12 (7 to 33). In four trials reporting cardiorespiratory fitness, a medium positive effect at 12 months was non-significant (standardised mean difference 0.51, -0.18 to 1.20). Three trials of exercise referral found small non-significant effects on self reported physical activity at 12 months (odds ratio 1.38; 0.98 to 1.95; standardised mean difference 0.20, -0.21 to 0.61). Conclusions Promotion of physical activity to sedentary adults recruited in primary care significantly increases physical activity levels at 12 months, as measured by self report. We found insufficient evidence to recommend exercise referral schemes over advice or counselling interventions. Primary care commissioners should consider these findings while awaiting further trial evaluation of exercise referral schemes and other primary care interventions, with longer follow-up and use of objective measures of outcome.	[Orrow, Gillian; Kinmonth, Ann-Louise; Sanderson, Simon; Sutton, Stephen] Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England	University of Cambridge	Orrow, G (corresponding author), Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England.	ghlo2@medschl.cam.ac.uk		Sutton, Stephen/0000-0003-1610-0404	National Institute for Health Research (NIHR) at the UK Department of Health; University of Cambridge; NIHR [RP-PG-0608-10079]; NIHR School for Primary Care Research; MRC [G0200391] Funding Source: UKRI; Medical Research Council [G0200391] Funding Source: researchfish; National Institute for Health Research [PB-PG-0110-20199, RP-PG-0608-10079, ACF-2008-14-008, NF-SI-0507-10182] Funding Source: researchfish	National Institute for Health Research (NIHR) at the UK Department of Health(National Institute for Health Research (NIHR)); University of Cambridge(University of Cambridge); NIHR(National Institute for Health Research (NIHR)); NIHR School for Primary Care Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	GO is funded by an academic clinical fellowship from the National Institute for Health Research (NIHR) at the UK Department of Health. ALK is funded by the University of Cambridge and is an NIHR senior investigator. SSu's contribution to the study was funded by an NIHR Programme Grant for Applied Research (RP-PG-0608-10079). SSa's contribution was funded by the NIHR School for Primary Care Research.	Abraham C, 2008, HEALTH PSYCHOL, V27, P379, DOI 10.1037/0278-6133.27.3.379; Cardone A, 2011, EQUIPP EUROPE QUITTI; Chambers R., 2000, HEALTH EDUC J, V59, P90, DOI [10.1177/001789690005900108, DOI 10.1177/001789690005900108]; Chartered Society of Physiotherapists, 2008, REC MIND BOD; Chief medical officers of England Scotland Wales and Northern Island, 2011, START ACT STAY ACT R; Craig A, 2001, NATL QUALITY ASSURAN; Department of Health, 2010, DIR SECR STAT PRIM M; Eakin EG, 2000, J FAM PRACTICE, V49, P158; Eaton CB, 1998, BRIT J SPORT MED, V32, P11, DOI 10.1136/bjsm.32.1.11; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Foster C., 2005, COCHRANE DB SYST REV, V1, P1, DOI 10.1002/14651858.cd003180.pub2; Garrett S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X561249; Halbert JA, 2000, MED J AUSTRALIA, V173, P84, DOI 10.5694/j.1326-5377.2000.tb139250.x; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Harrison RA, 2004, J PUBLIC HLTH, V271, P25; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins J.P.T, 2009, COCHRANE HDB SYSTEMA, P187; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hillsdon M, 2002, INT J EPIDEMIOL, V31, P808, DOI 10.1093/ije/31.4.808; Jimmy G, 2005, PATIENT EDUC COUNS, V56, P323, DOI 10.1016/j.pec.2004.03.006; Joint Health Surveys Unit, 2009, HLTH SURV ENGL 2008; Kaner EFS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004148.pub4; Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7; Kolt GS, 2007, J AM GERIATR SOC, V55, P986, DOI 10.1111/j.1532-5415.2007.01203.x; Lamb SE, 2002, J EPIDEMIOL COMMUN H, V56, P246, DOI 10.1136/jech.56.4.246; Lawlor DA, 2001, J PUBLIC HEALTH MED, V23, P219, DOI 10.1093/pubmed/23.3.219; Lawton BA, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2509; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Morey MC, 2009, J AM GERIATR SOC, V57, P1166, DOI 10.1111/j.1532-5415.2009.02301.x; Muller-Riemenschneider F, 2008, PREV MED, V47, P354, DOI 10.1016/j.ypmed.2008.07.006; National Institute for Health & Clinical Excellence, 2006, 4 COMM US METH INCR; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pavey TG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6462; Petrella RJ, 2003, AM J PREV MED, V24, P316, DOI 10.1016/S0749-3797(03)00022-9; Riddoch C, 1998, EFFECTIVENESS PHYS A; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; Smith B J, 2004, J Sci Med Sport, V7, P67, DOI 10.1016/S1440-2440(04)80280-9; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub3; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; van Doorslaer E, 2006, CAN MED ASSOC J, V174, P177, DOI 10.1503/cmaj.050584; van Sluijs EMF, 2005, AM J PUBLIC HEALTH, V95, P1825, DOI 10.2105/AJPH.2004.044537; Williams NH, 2009, BRIT J SPORT MED, V43, P106, DOI 10.1136/bjsm.2008.051458; Williams NH, 2007, BRIT J GEN PRACT, V57, P979, DOI 10.3399/096016407782604866; Woodcock J, 2011, INT J EPIDEMIOL, V40, P121, DOI 10.1093/ije/dyq104	44	375	377	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2012	344								e1389	10.1136/bmj.e1389	http://dx.doi.org/10.1136/bmj.e1389			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923DY	22451477	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000302600700001
J	Din, IU; Mumtaz, Z; Ataullahjan, A				Din, Iftikhar Ud; Mumtaz, Zubia; Ataullahjan, Anushka			How the Taliban undermined community healthcare in Swat, Pakistan	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Mumtaz, Zubia; Ataullahjan, Anushka] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2T4, Canada; [Din, Iftikhar Ud] EDO Hlth Off, Dassu Kohistan, Khyber Pakhtunk, Pakistan	University of Alberta	Mumtaz, Z (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2T4, Canada.	zubia.mumtaz@ualberta.ca	Ataullahjan, Anushka/AAV-8082-2021	Ataullahjan, Anushka/0000-0001-5261-5523				[Anonymous], 2008, BBC NEWS        0819; [Anonymous], 2009, BBC NEWS 0216; Asian Development Bank and World Bank, 2009, PREL DAM NEEDS ASS I; Henckaerts Jean-Marie, 2005, CUSTOMARY INT HUMANI; HONGORO C, 2006, HLTH WORKERS BUILDIN, P1309; International Committee of the Red Cross, 2010, GEN CONV 1949 THEIR; Jafar A, 2007, SOC PROBL, V54, P256, DOI 10.1525/sp.2007.54.3.256; Khankhel E, 2008, NATION          0726; Kivlahan C, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c3270; Othman N, 2006, WOMEN STUD INT FORUM, V29, P339, DOI 10.1016/j.wsif.2006.05.008; Rehmat K, 2009, ALJAZEERA       0127; Wilkinson I, 2009, TELEGRAPH       0524; World Health Organization Global Health Workforce Alliance, 2008, PAK LAD HLTH WORK PR	13	17	17	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2093	10.1136/bmj.e2093	http://dx.doi.org/10.1136/bmj.e2093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438368				2022-12-28	WOS:000301849200002
J	Levitz, SM; Golenbock, DT				Levitz, Stuart M.; Golenbock, Douglas T.			Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research	CELL			English	Review							MONOPHOSPHORYL-LIPID-A; YELLOW-FEVER VACCINE; DENDRITIC CELLS; ANTIGEN PRESENTATION; NALP3 INFLAMMASOME; PATHOGEN RECOGNITION; ALUMINUM-HYDROXIDE; NLRP3 INFLAMMASOME; ANTIBODY-RESPONSES; EXPANDED-PROGRAM	Although a great public heath success, vaccines provide suboptimal protection in some patient populations and are not available to protect against many infectious diseases. Insights from innate immunity research have led to a better understanding of how existing vaccines work and have informed vaccine development. New adjuvants and delivery systems are being designed based upon their capacity to stimulate innate immune sensors and target antigens to dendritic cells, the cells responsible for initiating adaptive immune responses. Incorporating these adjuvants and delivery systems in vaccines can beneficially alter the quantitative and qualitative nature of the adaptive immune response, resulting in enhanced protection.	[Levitz, Stuart M.; Golenbock, Douglas T.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Levitz, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.	stuart.levitz@umassmed.edu			National Institutes of Health [AI025780, AI093302];  [AI052455];  [AI07293];  [GM54060]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052455, R01AI025780, F32AI007293, R56AI052455, R01AI079293, R21AI093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	S.M.L. is supported by National Institutes of Health grants AI025780 and AI093302 and D.T.G. is supported by AI052455, AI07293, and GM54060. The authors thank George Deepe for his critical reading of the manuscript.	Abbott A, 2006, NATURE, V439, P524, DOI 10.1038/439524a; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Ahmed SS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002302; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1; Barry M, 2007, EXPERT OPIN BIOL TH, V7, P1731, DOI 10.1517/14712598.7.11.1731; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Brereton CF, 2011, J LEUKOCYTE BIOL, V89, P565, DOI 10.1189/jlb.0710421; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Bueter CL, 2011, J BIOL CHEM, V286, P35447, DOI 10.1074/jbc.M111.274936; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Burke JM, 2007, J IMMUNOL, V179, P3222, DOI 10.4049/jimmunol.179.5.3222; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Chen WX, 2010, VACCINE, V28, P3080, DOI 10.1016/j.vaccine.2010.02.081; Clapp T, 2011, J PHARM SCI-US, V100, P388, DOI 10.1002/jps.22284; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333; Demento SL, 2011, TRENDS BIOTECHNOL, V29, P294, DOI 10.1016/j.tibtech.2011.02.004; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Duewell P, 2011, J IMMUNOL, V187, P55, DOI 10.4049/jimmunol.1004114; Dupuis M, 1998, CELL IMMUNOL, V186, P18, DOI 10.1006/cimm.1998.1283; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Elinav E, 2011, IMMUNITY, V34, P665, DOI 10.1016/j.immuni.2011.05.007; Ferrer PE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002083; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Garcon N, 2011, VACCINE, V29, P4453, DOI 10.1016/j.vaccine.2011.04.046; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005; Gowthaman U, 2011, J INFECT DIS, V204, P1328, DOI 10.1093/infdis/jir548; Gunzer M, 2005, BLOOD, V106, P2424, DOI 10.1182/blood-2005-01-0342; Hajishengallis G, 2011, NAT REV IMMUNOL, V11, P187, DOI 10.1038/nri2918; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Hinchey J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015857; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hornung V, 2010, NAT REV IMMUNOL, V10, P123, DOI 10.1038/nri2690; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Huang HB, 2010, MBIO, V1, DOI 10.1128/mBio.00164-10; Ichinohe T, 2007, J INFECT DIS, V196, P1313, DOI 10.1086/521304; Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Kaufmann SHE, 2010, IMMUNITY, V33, P567, DOI 10.1016/j.immuni.2010.09.015; Kong QK, 2011, J IMMUNOL, V187, P412, DOI 10.4049/jimmunol.1100339; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019; Lam JS, 2005, J IMMUNOL, V175, P7496, DOI 10.4049/jimmunol.175.11.7496; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Luke JM, 2011, J VIROL, V85, P1370, DOI 10.1128/JVI.01250-10; MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; O'Neill LAJ, 2010, CURR BIOL, V20, pR328, DOI 10.1016/j.cub.2010.01.044; Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001; Ovsyannikova IG, 2010, J INFECT DIS, V201, P207, DOI 10.1086/649588; Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rajagopal D, 2010, BLOOD, V115, P1949, DOI 10.1182/blood-2009-08-238543; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Scarselli M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002234; Schoenen H, 2010, J IMMUNOL, V184, P2756, DOI 10.4049/jimmunol.0904013; Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017; Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108; Shann F, 2011, J INFECT DIS, V204, P182, DOI 10.1093/infdis/jir244; Sharma S, 2011, IMMUNITY, V35, P194, DOI 10.1016/j.immuni.2011.05.016; Song XT, 2008, NAT MED, V14, P258, DOI 10.1038/nm1721; Song XT, 2006, PLOS MED, V3, P76, DOI 10.1371/journal.pmed.0030011; Stubbs AC, 2001, NAT MED, V7, P625, DOI 10.1038/87974; Tacken PJ, 2011, SEMIN IMMUNOL, V23, P12, DOI 10.1016/j.smim.2011.01.001; Taylor DN, 2011, VACCINE, V29, P4897, DOI 10.1016/j.vaccine.2011.05.001; Warren SE, 2011, EUR J IMMUNOL, V41, P1934, DOI 10.1002/eji.201041214; Wuthrich M, 2003, J EXP MED, V197, P1405, DOI 10.1084/jem.20030109; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510; Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105	91	108	109	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1284	1292		10.1016/j.cell.2012.02.012	http://dx.doi.org/10.1016/j.cell.2012.02.012			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424235	Green Accepted, Bronze			2022-12-28	WOS:000301889500022
J	Tracey, I; Dickenson, A				Tracey, Irene; Dickenson, Anthony			SnapShot: Pain Perception	CELL			English	Editorial Material							NEUROPATHIC PAIN; MECHANISMS; MODULATION; HUMANS		[Tracey, Irene] Univ Oxford, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England; [Dickenson, Anthony] UCL, London WC1E 6BT, England	University of Oxford; University of London; University College London	Tracey, I (corresponding author), Univ Oxford, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England.			Tracey, Irene/0000-0003-4134-6115	MRC [G0700399] Funding Source: UKRI; Medical Research Council [G0700399] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bannister K, 2009, NEUROTHERAPEUTICS, V6, P703, DOI 10.1016/j.nurt.2009.07.009; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; D'Mello R, 2008, BRIT J ANAESTH, V101, P8, DOI 10.1093/bja/aen088; De Felice M, 2011, PAIN, V152, P2701, DOI 10.1016/j.pain.2011.06.008; Dickenson AH, 2002, EUR J PAIN, V6, P51, DOI 10.1053/eujp.2001.0323; Fields HL, 2000, PROG BRAIN RES, V122, P245; Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947; Tracey I, 2011, NAT REV NEUROL, V7, P173, DOI 10.1038/nrneurol.2011.4; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229	9	26	27	1	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 16	2012	148	6					1308	U242		10.1016/j.cell.2012.03.004	http://dx.doi.org/10.1016/j.cell.2012.03.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424237	Bronze			2022-12-28	WOS:000301889500024
J	Truepenny, P; Kaushik, V; Lempp, H				Truepenny, Paul; Kaushik, Viswanath; Lempp, Heidi			A PATIENT'S JOURNEY Polymyositis	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Kaushik, Viswanath] Lincoln Cty Hosp, Dept Rheumatol, Lincoln LN2 5QY, England; [Lempp, Heidi] Kings Coll London, Sch Med, Dept Acad Rheumatol, London WC2R 2LS, England	University of London; King's College London	Kaushik, V (corresponding author), Lincoln Cty Hosp, Dept Rheumatol, Lincoln LN2 5QY, England.	Viswanath.Kaushik@ulh.nhs.uk	Lempp, Heidi/T-2914-2017	Lempp, Heidi/0000-0003-2509-3656				ODDIS CV, 1990, J RHEUMATOL, V17, P1329	1	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2012	344								e1181	10.1136/bmj.e1181	http://dx.doi.org/10.1136/bmj.e1181			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CD	22422831	Bronze			2022-12-28	WOS:000301848100001
J	Detsky, AS				Detsky, Allan S.			Underestimating the Value of Reassurance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROSTATE-CANCER; MORTALITY		[Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto	Detsky, AS (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.	adetsky@mtsinai.on.ca						Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; [Anonymous], CTV NEWS; Bill-Axelson A, 2011, NEW ENGL J MED, V364, P1708, DOI 10.1056/NEJMoa1011967; Chou R, 2011, JAMA-J AM MED ASSOC, V306, P2721, DOI 10.1001/jama.2011.1891; Detsky AS, 2001, NEW ENGL J MED, V345, P607, DOI 10.1056/NEJM200108233450809; Kim J, 2011, JAMA-J AM MED ASSOC, V306, P2717, DOI 10.1001/jama.2011.1881; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; Miller DC, 2011, JAMA-J AM MED ASSOC, V306, P2719, DOI 10.1001/jama.2011.1879; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Smith MR, 2011, NEW ENGL J MED, V364, P1770, DOI 10.1056/NEJMe1100787; Sullivan PW, 2011, MED DECIS MAKING, V31, P787, DOI 10.1177/0272989X11400755; Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918; *US PREV SERV TASK, SCREEN PROST CANC; Volk RJ, 2011, JAMA-J AM MED ASSOC, V306, P2715, DOI 10.1001/jama.2011.1893; Welch HG, 2011, JAMA-J AM MED ASSOC, V306, P2649, DOI 10.1001/jama.2011.1898	15	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1035	1036		10.1001/jama.2012.235	http://dx.doi.org/10.1001/jama.2012.235			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416098				2022-12-28	WOS:000301479700023
J	Kmietowicz, Z				Kmietowicz, Zosia			BMJ GROUP IMPROVING HEALTH AWARDS Sports and exercise doctors: the unsung heroes of champions	BRITISH MEDICAL JOURNAL			English	Editorial Material												zkmietowicz@bmj.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e1787	10.1136/bmj.e1787	http://dx.doi.org/10.1136/bmj.e1787			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418414				2022-12-28	WOS:000301847600014
J	Aalaa, M; Mohajeri-Tehrani, MR				Aalaa, Maryam; Mohajeri-Tehrani, Mohammad Reza			Ectopic Thyroid Gland	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Aalaa, Maryam; Mohajeri-Tehrani, Mohammad Reza] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran	Tehran University of Medical Sciences	Aalaa, M (corresponding author), Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran.			Aalaa, Maryam/0000-0001-8664-3733					0	5	5	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					943	943		10.1056/NEJMicm1106077	http://dx.doi.org/10.1056/NEJMicm1106077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397656				2022-12-28	WOS:000301172500011
J	Gerlinger, M; Rowan, AJ; Horswell, S; Larkin, J; Endesfelder, D; Gronroos, E; Martinez, P; Matthews, N; Stewart, A; Tarpey, P; Varela, I; Phillimore, B; Begum, S; McDonald, NQ; Butler, A; Jones, D; Raine, K; Latimer, C; Santos, CR; Nohadani, M; Eklund, AC; Spencer-Dene, B; Clark, G; Pickering, L; Stamp, G; Gore, M; Szallasi, Z; Downward, J; Futreal, PA; Swanton, C				Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Downward, Julian; Futreal, P. Andrew; Swanton, Charles			Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; PANCREATIC-CANCER; GENOMIC ANALYSIS; LUNG-CANCER; MUTATIONS; NEPHRECTOMY; GENE; INSTABILITY; METASTASIS	BACKGROUND Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. METHODS To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. RESULTS Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. CONCLUSIONS Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.)	[Swanton, Charles] Canc Res UK London Res Inst, Translat Canc Therapeut Lab, London WC2A 3LY, England; [Larkin, James; Nohadani, Mahrokh; Pickering, Lisa; Stamp, Gordon; Gore, Martin] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England; [Tarpey, Patrick; Varela, Ignacio; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Futreal, P. Andrew] Wellcome Trust Sanger Inst, London, England; [Gerlinger, Marco] Barts & London Queen Marys Sch Med & Dent, Barts Canc Inst, London, England; [Swanton, Charles] UCL, Inst Canc, London, England; [Eklund, Aron C.; Szallasi, Zoltan] Tech Univ Denmark, DK-2800 Lyngby, Denmark; [Szallasi, Zoltan] Harvard Univ, Sch Med, Boston, MA USA	Cancer Research UK; Royal Marsden NHS Foundation Trust; Wellcome Trust Sanger Institute; University of London; Queen Mary University London; University of London; University College London; Technical University of Denmark; Harvard University; Harvard Medical School	Swanton, C (corresponding author), Canc Res UK London Res Inst, Translat Canc Therapeut Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	charles.swanton@cancer.org.uk	Varela, Ignacio/G-1699-2016; Gronroos, Eva/P-6951-2015; Jang, JaJune/F-6647-2011; wang, edwin/G-5372-2010; Gronroos, Eva/E-9351-2013; Varela, Ignacio/AAA-7680-2021	Varela, Ignacio/0000-0002-0969-506X; Varela, Ignacio/0000-0002-0969-506X; Eklund, Aron Charles/0000-0003-0861-1001; Gronroos, Eva/0000-0001-8303-5409; Larkin, James/0000-0001-5569-9523; Swanton, Charles/0000-0002-4299-3018; Szallasi, Zoltan/0000-0001-5395-7509; Martinez, Pierre/0000-0001-7069-4413; Santos, Claudio/0000-0002-8766-2247; Horswell, Stuart/0000-0003-2787-1933; Gerlinger, Marco/0000-0003-2719-299X; Downward, Julian/0000-0002-2331-4729; Raine, Keiran/0000-0002-5634-1539	Medical Research Council, Cancer Research UK; Royal Marsden Hospital; Novartis; EU; Wellcome Trust; MRC [G0701935, G0902275] Funding Source: UKRI; Cancer Research UK [10747, 15680] Funding Source: researchfish; Medical Research Council [G0701935, G0902275] Funding Source: researchfish	Medical Research Council, Cancer Research UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Cancer Research UK); Royal Marsden Hospital(Royal Society of New ZealandMarsden Fund (NZ)); Novartis(Novartis); EU(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from the Medical Research Council, Cancer Research UK, the Royal Marsden Hospital Renal Research Fund, Novartis, EU Framework 7 Personalized RNA Interference to Enhance the Delivery of Individualized Cytotoxic and Targeted Therapeutics (PREDICT), and the Wellcome Trust (to Dr. Futreal).	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Brannon A Rose, 2010, Genes Cancer, V1, P152; Campbell PJ, 2008, P NATL ACAD SCI USA, V105, P13081, DOI 10.1073/pnas.0801523105; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cho D, 2007, CLIN GENITOURIN CANC, V5, P379, DOI 10.3816/CGC.2007.n.020; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013; Flanigan RC, 2004, J UROLOGY, V171, P1071, DOI 10.1097/01.ju.0000110610.61545.ae; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140-6736(01)06103-7; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Poste G, 2011, NATURE, V469, P156, DOI 10.1038/469156a; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tao Y, 2011, P NATL ACAD SCI USA, V108, P12042, DOI 10.1073/pnas.1108715108; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	30	5377	5558	17	859	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					883	892		10.1056/NEJMoa1113205	http://dx.doi.org/10.1056/NEJMoa1113205			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397650	Green Accepted			2022-12-28	WOS:000301172500005
J	Blinderman, CD; Krakauer, EL; Solomon, MZ				Blinderman, Craig D.; Krakauer, Eric L.; Solomon, Mildred Z.			Time to Revise the Approach to Determining Cardiopulmonary Resuscitation Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Blinderman, Craig D.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA; [Solomon, Mildred Z.] Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; [Krakauer, Eric L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Krakauer, Eric L.; Solomon, Mildred Z.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Optimum Care Comm, Boston, MA 02114 USA; [Solomon, Mildred Z.] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA	Columbia University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Blinderman, CD (corresponding author), Columbia Univ, Med Ctr, Dept Anesthesiol, 622 W 168th St,PH5-530B, New York, NY 10032 USA.	cdb21@columbia.edu						Billings JA, 2011, ARCH INTERN MED, V171, P849, DOI 10.1001/archinternmed.2011.180; Brett AS, 2012, JAMA-J AM MED ASSOC, V307, P149, DOI 10.1001/jama.2011.1999; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Halpern SD, 2007, NEW ENGL J MED, V357, P1340, DOI 10.1056/NEJMsb071595; Kane RS, 1997, J AM GERIATR SOC, V45, P154, DOI 10.1111/j.1532-5415.1997.tb04500.x; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; [Standards for cardiopulmonary resuscitation (CPR) emergency cardiac care (ECC)], 1974, JAMA, V227, P837	7	51	51	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					917	918		10.1001/jama.2012.236	http://dx.doi.org/10.1001/jama.2012.236			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396511				2022-12-28	WOS:000301172100017
J	Iglehart, JK				Iglehart, John K.			Financing Graduate Medical Education - Mounting Pressure for Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Cooke M, 2010, ED PHYS CALL REFORM; GME Commission, 2010, REP C AL INC MED, P103; Iglehart JK, 2011, NEW ENGL J MED, V365, P1340, DOI 10.1056/NEJMhpr1107519; Josiah Macy Jr. Foundation, 2010, ENS EFF PHYS WORKF A; Nasca TJ, 2012, NEW ENGL J MED, V366, P1051, DOI 10.1056/NEJMsr1200117	5	20	20	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2012	366	17					1562	1563		10.1056/NEJMp1114236	http://dx.doi.org/10.1056/NEJMp1114236			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931FC	22436049				2022-12-28	WOS:000303200100003
J	Mingrone, G; Panunzi, S; De Gaetano, A; Guidone, C; Iaconelli, A; Leccesi, L; Nanni, G; Pomp, A; Castagneto, M; Ghirlanda, G; Rubino, F				Mingrone, Geltrude; Panunzi, Simona; De Gaetano, Andrea; Guidone, Caterina; Iaconelli, Amerigo; Leccesi, Laura; Nanni, Giuseppe; Pomp, Alfons; Castagneto, Marco; Ghirlanda, Giovanni; Rubino, Francesco			Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; GASTRIC BYPASS; WEIGHT-LOSS; GLUCOSE; OBESE; LIFE	Background Roux-en-Y gastric bypass and biliopancreatic diversion can markedly ameliorate diabetes in morbidly obese patients, often resulting in disease remission. Prospective, randomized trials comparing these procedures with medical therapy for the treatment of diabetes are needed. Methods In this single-center, nonblinded, randomized, controlled trial, 60 patients between the ages of 30 and 60 years with a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 35 or more, a history of at least 5 years of diabetes, and a glycated hemoglobin level of 7.0% or more were randomly assigned to receive conventional medical therapy or undergo either gastric bypass or biliopancreatic diversion. The primary end point was the rate of diabetes remission at 2 years (defined as a fasting glucose level of <100 mg per deciliter [5.6 mmol per liter] and a glycated hemoglobin level of <6.5% in the absence of pharmacologic therapy). Results At 2 years, diabetes remission had occurred in no patients in the medical-therapy group versus 75% in the gastric-bypass group and 95% in the biliopancreatic-diversion group (P<0.001 for both comparisons). Age, sex, baseline BMI, duration of diabetes, and weight changes were not significant predictors of diabetes remission at 2 years or of improvement in glycemia at 1 and 3 months. At 2 years, the average baseline glycated hemoglobin level (8.65 +/- 1.45%) had decreased in all groups, but patients in the two surgical groups had the greatest degree of improvement (average glycated hemoglobin levels, 7.69 +/- 0.57% in the medical-therapy group, 6.35 +/- 1.42% in the gastric-bypass group, and 4.95 +/- 0.49% in the biliopancreatic-diversion group). Conclusions In severely obese patients with type 2 diabetes, bariatric surgery resulted in better glucose control than did medical therapy. Preoperative BMI and weight loss did not predict the improvement in hyperglycemia after these procedures. (Funded by Catholic University of Rome; ClinicalTrials.gov number, NCT00888836.)	[Mingrone, Geltrude; Guidone, Caterina; Iaconelli, Amerigo; Leccesi, Laura; Ghirlanda, Giovanni] Univ Cattolica Sacro Cuore, Dept Internal Med, I-00168 Rome, Italy; [Nanni, Giuseppe; Castagneto, Marco; Rubino, Francesco] Univ Cattolica Sacro Cuore, Dept Surg, I-00168 Rome, Italy; [Panunzi, Simona; De Gaetano, Andrea] Inst Syst Anal & Comp Sci IASI, Natl Res Council Italy, BioMatLab, Rome, Italy; [Pomp, Alfons; Rubino, Francesco] Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Sect Gastrointestinal Metab Surg, New York, NY 10021 USA	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Analisi dei Sistemi ed Informatica "Antonio Ruberti" (IASI-CNR); Cornell University; NewYork-Presbyterian Hospital	Mingrone, G (corresponding author), Univ Cattolica Sacro Cuore, Dept Internal Med, Largo A Gemelli 8, I-00168 Rome, Italy.	gmingrone@rm.unicatt.it	Mingrone, Geltrude/AAB-9681-2019; De Gaetano, Andrea/AAC-4805-2021; Guidone, Caterina/ABG-6508-2021; Panunzi, Simona/AAK-9337-2020	Guidone, Caterina/0000-0002-0241-7083; Mingrone, Geltrude/0000-0003-2021-528X; De Gaetano, Andrea/0000-0001-7712-056X; Panunzi, Simona/0000-0003-0956-8578	Catholic University of Rome	Catholic University of Rome	Supported by the Catholic University of Rome.	Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041; Buse JB, 2009, DIABETES CARE, V32, P2133, DOI 10.2337/dc09-9036; DiGiorgi M, 2010, SURG OBES RELAT DIS, V6, P249, DOI 10.1016/j.soard.2009.09.019; Dixon JB, 2011, DIABETIC MED, V28, P628, DOI 10.1111/j.1464-5491.2011.03306.x; Dixon JB, 2008, JAMA-J AM MED ASSOC, V299, P316, DOI 10.1001/jama.299.3.316; Guidone C, 2006, DIABETES, V55, P2025, DOI 10.2337/db06-0068; Hofso D, 2010, OBES SURG, V20, P302, DOI 10.1007/s11695-009-0022-5; Iaconelli A, 2011, DIABETES CARE, V34, P561, DOI 10.2337/dc10-1761; International Diabetes Federation, 2011, IDF DIAB ATL; Laferrere B, 2008, J CLIN ENDOCR METAB, V93, P2479, DOI 10.1210/jc.2007-2851; Liebl A, 2002, DIABETOLOGIA, V45, pS23, DOI 10.1007/s00125-002-0863-0; Maggard MA, 2005, ANN INTERN MED, V142, P547, DOI 10.7326/0003-4819-142-7-200504050-00013; Mingrone G, 1999, DIABETES, V48, P1258, DOI 10.2337/diabetes.48.6.1258; Pories WJ, 2008, J CLIN ENDOCR METAB, V93, pS89, DOI 10.1210/jc.2008-1641; PORIES WJ, 1987, ANN SURG, V206, P316, DOI 10.1097/00000658-198709000-00009; Rubino F, 2002, ANN SURG, V236, P554, DOI 10.1097/00000658-200211000-00003; Rubino F, 2006, ANN SURG, V244, P741, DOI 10.1097/01.sla.0000224726.61448.1b; Rubino F, 2010, ANN SURG, V251, P399, DOI 10.1097/SLA.0b013e3181be34e7; Salinari S, 2009, DIABETES CARE, V32, P375, DOI 10.2337/dc08-1314; Scopinaro N, 1998, WORLD J SURG, V22, P936, DOI 10.1007/s002689900497; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Sjostrom L, 2012, JAMA-J AM MED ASSOC, V307, P56, DOI 10.1001/jama.2011.1914; Sovik TT, 2011, ANN INTERN MED, V155, P281, DOI 10.7326/0003-4819-155-5-201109060-00005; Zhang P, 2011, DIABETES RES CLIN PR, V92, P301, DOI 10.1016/j.diabres.2010.12.025	25	1233	1319	2	130	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2012	366	17					1577	1585		10.1056/NEJMoa1200111	http://dx.doi.org/10.1056/NEJMoa1200111			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931FC	22449317	Bronze			2022-12-28	WOS:000303200100006
J	Kon, T; Oyama, T; Shimo-Kon, R; Imamula, K; Shima, T; Sutoh, K; Kurisu, G				Kon, Takahide; Oyama, Takuji; Shimo-Kon, Rieko; Imamula, Kenji; Shima, Tomohiro; Sutoh, Kazuo; Kurisu, Genji			The 2.8 angstrom crystal structure of the dynein motor domain	NATURE			English	Article							MICROTUBULE-BINDING DOMAIN; CYTOPLASMIC DYNEIN; COILED-COIL; ATP HYDROLYSIS; AAA; MECHANISM; PROGRAM; CRYSTALLOGRAPHY; EXPRESSION; TRANSPORT	Dyneins are microtubule-based AAA(+) motor complexes that power ciliary beating, cell division, cell migration and intracellular transport. Here we report the most complete structure obtained so far, to our knowledge, of the 380-kDa motor domain of Dictyostelium discoideum cytoplasmic dynein at 2.8 angstrom resolution; the data are reliable enough to discuss the structure and mechanism at the level of individual amino acid residues. Features that can be clearly visualized at this resolution include the coordination of ADP in each of four distinct nucleotide-binding sites in the ring-shaped AAA(+) ATPase unit, a newly identified interaction interface between the ring and mechanical linker, and junctional structures between the ring and microtubule-binding stalk, all of which should be critical for the mechanism of dynein motility. We also identify a long-range allosteric communication pathway between the primary ATPase and the microtubule-binding sites. Our work provides a framework for understanding the mechanism of dynein-based motility.	[Kon, Takahide; Oyama, Takuji; Shimo-Kon, Rieko; Kurisu, Genji] Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; [Kon, Takahide; Kurisu, Genji] Osaka Univ, Dept Macromol Sci, Sch Sci, Osaka 5600043, Japan; [Imamula, Kenji] Univ Tokyo, Dept Life Sci, Sch Arts & Sci, Tokyo 1538902, Japan; [Shima, Tomohiro] Univ Tokyo, Dept Phys, Grad Sch Sci, Bunkyou Ku, Tokyo 1130033, Japan; [Sutoh, Kazuo] Waseda Univ, Res Inst Sci & Engn, Toshima Ku, Tokyo 1710033, Japan	Osaka University; Osaka University; University of Tokyo; University of Tokyo; Waseda University	Kon, T (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	takahide.kon@protein.osaka-u.ac.jp	KURISU, GENJI/AAD-7109-2022; Kon, Takahide/AAG-6975-2021; KURISU, GENJI/ABA-5960-2020	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807; Oyama, Takuji/0000-0002-3411-7608; Kon, Takahide/0000-0002-1231-7609	Ministry of Education, Culture Sports, Science, and Technology of Japan [17770126, 20687011, 23370073, 16083205, 17107003, 17053006, 18054008, 20051006]; Human Frontier Science Program; Grants-in-Aid for Scientific Research [23370073] Funding Source: KAKEN	Ministry of Education, Culture Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Human Frontier Science Program(Human Frontier Science Program); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank E. Yamashita, Y. Umena, M. Suzuki and A. Nakagawa of SPring-8 BL-44XU for their support during X-ray data collection; and T. Kikuchi and R. Ohkura for their technical support. We are grateful to C. Toyoshima for discussion of X-ray data collection; K. Kinosita Jr and T. Tsukihara for their support and encouragement. This work was supported by Grants-in-Aid for Scientific Research (17770126, 20687011 and 23370073 (T. K.), 16083205 and 17107003 (K. S.), 17053006, 18054008 and 20051006 (G. K.)) from the Ministry of Education, Culture Sports, Science, and Technology of Japan and a grant from the Human Frontier Science Program (T.K.).	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Carter AP, 2011, SCIENCE, V331, P1159, DOI 10.1126/science.1202393; Carter AP, 2008, SCIENCE, V322, P1691, DOI 10.1126/science.1164424; DiBella LM, 2001, INT REV CYTOL, V210, P227; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Enernark EJ, 2008, CURR OPIN STRUC BIOL, V18, P243, DOI 10.1016/j.sbi.2008.01.007; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Gibbons IR, 2005, J BIOL CHEM, V280, P23960, DOI 10.1074/jbc.M501636200; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hook P, 2006, J CELL SCI, V119, P4369, DOI 10.1242/jcs.03176; Imamula K, 2007, P NATL ACAD SCI USA, V104, P16134, DOI 10.1073/pnas.0702370104; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Kon T, 2005, NAT STRUCT MOL BIOL, V12, P513, DOI 10.1038/nsmb930; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; Kon T, 2011, NAT STRUCT MOL BIOL, V18, P638, DOI 10.1038/nsmb.2074; Kon T, 2009, METHOD CELL BIOL, V92, P65, DOI 10.1016/S0091-679X(08)92005-7; Kon T, 2009, NAT STRUCT MOL BIOL, V16, P325, DOI 10.1038/nsmb.1555; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mocz G, 1996, BIOCHEMISTRY-US, V35, P9204, DOI 10.1021/bi960662u; Neuwald AF, 1999, GENOME RES, V9, P27; Numata N, 2011, FEBS LETT, V585, P1185, DOI 10.1016/j.febslet.2011.03.036; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Roberts AJ, 2009, CELL, V136, P485, DOI 10.1016/j.cell.2008.11.049; Samso M, 2004, J MOL BIOL, V340, P1059, DOI 10.1016/j.jmb.2004.05.063; Scholey JM, 2008, J CELL BIOL, V180, P23, DOI 10.1083/jcb.200709133; Schrodinger L., 2020, PYMOL MOL GRAPHICS S; Schroder GF, 2010, NATURE, V464, P1218, DOI 10.1038/nature08892; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; Strelkov SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/jsbi.2002.4454; Suno R, 2006, MOL CELL, V22, P575, DOI 10.1016/j.molcel.2006.04.020; Tucker PA, 2007, CURR OPIN STRUC BIOL, V17, P641, DOI 10.1016/j.sbi.2007.09.012; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h	50	166	167	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					345	U81		10.1038/nature10955	http://dx.doi.org/10.1038/nature10955			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22398446				2022-12-28	WOS:000302946500026
J	Litt, HI; Gatsonis, C; Snyder, B; Singh, H; Miller, CD; Entrikin, DW; Leaming, JM; Gavin, LJ; Pacella, CB; Hollander, JE				Litt, Harold I.; Gatsonis, Constantine; Snyder, Brad; Singh, Harjit; Miller, Chadwick D.; Entrikin, Daniel W.; Leaming, James M.; Gavin, Laurence J.; Pacella, Charissa B.; Hollander, Judd E.			CT Angiography for Safe Discharge of Patients with Possible Acute Coronary Syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY-DEPARTMENT PATIENTS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ACUTE CHEST-PAIN; AMERICAN-HEART-ASSOCIATION; ACUTE CARDIAC ISCHEMIA; MYOCARDIAL-INFARCTION; DIAGNOSTIC-ACCURACY; RISK SCORE; TASK-FORCE; TRIAGE	BACKGROUND Admission rates among patients presenting to emergency departments with possible acute coronary syndromes are high, although for most of these patients, the symptoms are ultimately found not to have a cardiac cause. Coronary computed tomographic angiography (CCTA) has a very high negative predictive value for the detection of coronary disease, but its usefulness in determining whether discharge of patients from the emergency department is safe is not well established. METHODS We randomly assigned low-to-intermediate-risk patients presenting with possible acute coronary syndromes, in a 2: 1 ratio, to undergo CCTA or to receive traditional care. Patients were enrolled at five centers in the United States. Patients older than 30 years of age with a Thrombolysis in Myocardial Infarction risk score of 0 to 2 and signs or symptoms warranting admission or testing were eligible. The primary outcome was safety, assessed in the subgroup of patients with a negative CCTA examination, with safety defined as the absence of myocardial infarction and cardiac death during the first 30 days after presentation. RESULTS We enrolled 1370 subjects: 908 in the CCTA group and 462 in the group receiving traditional care. The baseline characteristics were similar in the two groups. Of 640 patients with a negative CCTA examination, none died or had a myocardial infarction within 30 days (0%; 95% confidence interval [CI], 0 to 0.57). As compared with patients receiving traditional care, patients in the CCTA group had a higher rate of discharge from the emergency department (49.6% vs. 22.7%; difference, 26.8 percentage points; 95% CI, 21.4 to 32.2), a shorter length of stay (median, 18.0 hours vs. 24.8 hours; P<0.001), and a higher rate of detection of coronary disease (9.0% vs. 3.5%; difference, 5.6 percentage points; 95% CI, 0 to 11.2). There was one serious adverse event in each group. CONCLUSIONS A CCTA-based strategy for low-to-intermediate-risk patients presenting with a possible acute coronary syndrome appears to allow the safe, expedited discharge from the emergency department of many patients who would otherwise be admitted. (Funded by the Commonwealth of Pennsylvania Department of Health and the American College of Radiology Imaging Network Foundation; ClinicalTrials.gov number, NCT00933400.)	[Litt, Harold I.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gavin, Laurence J.; Hollander, Judd E.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gatsonis, Constantine; Snyder, Brad] Brown Univ, Dept Biostat, Ctr Stat Sci, Providence, RI 02912 USA; [Singh, Harjit] Penn State Hershey Med Ctr, Dept Radiol, Hershey, PA USA; [Leaming, James M.] Penn State Hershey Med Ctr, Dept Emergency Med, Hershey, PA USA; [Miller, Chadwick D.] Wake Forest Sch Med, Dept Emergency Med, Winston Salem, NC USA; [Entrikin, Daniel W.] Wake Forest Sch Med, Dept Radiol, Winston Salem, NC USA; [Entrikin, Daniel W.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA; [Pacella, Charissa B.] Univ Pittsburgh, Med Ctr, Dept Emergency Med, Pittsburgh, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Wake Forest University; Wake Forest University; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Litt, HI (corresponding author), Univ Penn, Dept Radiol, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	harold.litt@uphs.upenn.edu	Pacella, Charissa/AAJ-2722-2021	Snyder, Bradley/0000-0003-2757-7195; Hollander, Judd/0000-0002-1318-2785	Commonwealth of Pennsylvania Department of Health; American College of Radiology Imaging Network Foundation; Medrad-Bayer; Siemens Medical Solutions; Wilex; Mela Sciences; Endocyte; BioMimetic Therapeutics; Radiological Society of North America; Heartscape Technologies; BreathQuant Medical; Johnson Johnson-Scios; GlaxoSmithKline; EKR Therapeutics; 3M; Dyax; Sanofi-Aventis; Society of Chest Pain Centers; Alere; Brahms; Nanosphere; Abbott Laboratories; Bristol-Myers Squibb	Commonwealth of Pennsylvania Department of Health; American College of Radiology Imaging Network Foundation; Medrad-Bayer; Siemens Medical Solutions(Siemens AG); Wilex; Mela Sciences; Endocyte(Novartis); BioMimetic Therapeutics; Radiological Society of North America; Heartscape Technologies; BreathQuant Medical; Johnson Johnson-Scios(Johnson & JohnsonJohnson & Johnson USA); GlaxoSmithKline(GlaxoSmithKline); EKR Therapeutics; 3M(3M); Dyax; Sanofi-Aventis(Sanofi-Aventis); Society of Chest Pain Centers; Alere; Brahms; Nanosphere; Abbott Laboratories(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb)	Supported by the Commonwealth of Pennsylvania Department of Health and the American College of Radiology Imaging Network Foundation.; Dr. Litt reports receiving consulting fees from Medrad-Bayer, grant funding from Siemens Medical Solutions, and reimbursement for travel expenses from Siemens Medical Solutions; Dr. Gatsonis, receiving consulting fees from Wilex, Mela Sciences, Endocyte, and BioMimetic Therapeutics, payment for the development of educational presentations from the Radiological Society of North America, and reimbursement for travel expenses from the Medical Imaging and Technology Alliance; Dr. Miller, providing medical malpractice case review for the law offices of Wade E. Byrd, Lewis & Oliver, and Hinshaw and Culbertson, receiving grant support from Heartscape Technologies, BreathQuant Medical, Johnson & Johnson-Scios, GlaxoSmithKline, EKR Therapeutics, 3M, and Dyax and lecture fees from Sanofi-Aventis and the Society of Chest Pain Centers, holding a provisional patent with the U.S. Patent and Trademark Office related to the diagnosis of chest pain, and receiving research support from Siemens Medical Solutions; and Dr. Hollander, providing expert testimony for Emergency Care Education and Consulting in a medical malpractice case, and receiving grant funding from Biosite (now Alere), Siemens Medical Solutions, Brahms, Nanosphere, and Abbott Laboratories and lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.	Baxt WG, 2002, ANN EMERG MED, V39, P366, DOI 10.1067/mem.2002.122705; Budoff MJ, 2010, CIRCULATION, V121, pE255, DOI 10.1161/CIR.0b013e3181cfcdaa; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Chase M, 2006, ANN EMERG MED, V48, P252, DOI 10.1016/j.annemergmed.2006.01.032; Chow BJW, 2010, AM J CARDIOL, V106, P463, DOI 10.1016/j.amjcard.2010.03.058; d'Othee BJ, 2008, EUR J RADIOL, V65, P449, DOI 10.1016/j.ejrad.2007.05.003; Gallagher MJ, 2007, ANN EMERG MED, V49, P125, DOI 10.1016/j.annemergmed.2006.06.043; Gerber TC, 2009, CIRCULATION, V119, P1056, DOI 10.1161/CIRCULATIONAHA.108.191650; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Goldstein JA, 2007, J AM COLL CARDIOL, V49, P863, DOI 10.1016/j.jacc.2006.08.064; Goldstein JA, 2011, J AM COLL CARDIOL, V58, P1414, DOI 10.1016/j.jacc.2011.03.068; Hess EP, 2008, CAN J EMERG MED, V10, P373; Hess EP, 2012, ANN EMERG MED, V59, P115, DOI 10.1016/j.annemergmed.2011.07.026; Hess EP, 2010, CAN MED ASSOC J, V182, P1039, DOI 10.1503/cmaj.092119; Hoffmann U, 2009, J AM COLL CARDIOL, V53, P1642, DOI 10.1016/j.jacc.2009.01.052; Hollander JE, 2004, ANN EMERG MED, V44, P589, DOI 10.1016/j.annemergmed.2004.08.009; Hollander JE, 1999, ACAD EMERG MED, V6, P979, DOI 10.1111/j.1553-2712.1999.tb01177.x; Hollander JE, 2007, ACAD EMERG MED, V14, P210, DOI 10.1197/j.aem.2006.09.053; Hollander JE, 2009, ACAD EMERG MED, V16, P693, DOI 10.1111/j.1553-2712.2009.00459.x; Hollander JE, 2009, ANN EMERG MED, V53, P295, DOI 10.1016/j.annemergmed.2008.09.025; Hulten EA, 2011, J AM COLL CARDIOL, V57, P1237, DOI 10.1016/j.jacc.2010.10.011; Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515; LaBounty TM, 2010, AM J CARDIOL, V106, P287, DOI 10.1016/j.amjcard.2010.02.038; Lyon R, 2007, RESUSCITATION, V74, P90, DOI 10.1016/j.resuscitation.2006.11.023; Miller CD, 2005, ANN EMERG MED, V46, P96, DOI 10.1016/j.annemergmed.2005.01.039; Miller CD, 2004, ANN EMERG MED, V44, P565, DOI 10.1016/j.annemergmed.2004.03.021; Min JK, 2007, J AM COLL CARDIOL, V50, P1161, DOI 10.1016/j.jacc.2007.03.067; Niska Richard, 2010, Natl Health Stat Report, P1; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; Pitts WR, 1997, AM J CARDIOL, V80, P1086, DOI 10.1016/S0002-9149(97)00610-3; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Raff Gilbert L, 2009, J Cardiovasc Comput Tomogr, V3, P122, DOI 10.1016/j.jcct.2009.01.001; Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428; Rubinshtein R, 2007, AM J CARDIOL, V100, P1522, DOI 10.1016/j.amjcard.2007.06.052; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Swap CJ, 2006, JAMA-J AM MED ASSOC, V295, P2250; Swap CJ, 2005, JAMA-J AM MED ASSOC, V294, P2623, DOI 10.1001/jama.294.20.2623; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; Taylor AJ, 2010, CIRCULATION, V122, pE525, DOI 10.1161/CIR.0b013e3181fcae66; Than M, 2011, LANCET, V377, P1077, DOI 10.1016/S0140-6736(11)60310-3; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397	41	447	458	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1393	1403		10.1056/NEJMoa1201163	http://dx.doi.org/10.1056/NEJMoa1201163			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923GV	22449295				2022-12-28	WOS:000302608600003
J	Boekholdt, SM; Stroes, ESG				Boekholdt, S. Matthijs; Stroes, Erik S. G.			The interleukin-6 pathway and atherosclerosis	LANCET			English	Editorial Material							C-REACTIVE PROTEIN; RATIONALE; DESIGN; INHIBITION; EVENTS; RISK		[Boekholdt, S. Matthijs] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; [Stroes, Erik S. G.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Boekholdt, SM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands.	s.m.boekholdt@amc.uva.nl	Boekholdt, Matthijs S.M./G-7562-2014	Boekholdt, Matthijs/0000-0002-0861-0765				deMaat MPM, 1996, ARTERIOSCL THROM VAS, V16, P1156, DOI 10.1161/01.ATV.16.9.1156; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; MULLBERG J, 1994, J IMMUNOL, V152, P4958; Nicholls SJ, 2012, CARDIOVASC DRUG THER, V26, P71, DOI 10.1007/s10557-011-6358-9; O'Donoghue ML, 2011, AM HEART J, V162, P613, DOI 10.1016/j.ahj.2011.07.018; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2011, AM HEART J, V162, P597, DOI 10.1016/j.ahj.2011.06.012; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ridker PM, 2012, J THROMB HAEMOST S1, V7, P332; Sarwar N, 2012, LANCET, V379, P1205, DOI 10.1016/S0140-6736(11)61931-4; Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140-6736(12)60110-X; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548; Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402	15	41	43	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2012	379	9822					1176	1178		10.1016/S0140-6736(12)60361-4	http://dx.doi.org/10.1016/S0140-6736(12)60361-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	918DV	22421338				2022-12-28	WOS:000302230400010
J	Swerdlow, DI; Holmes, MV; Kuchenbaecker, KB; Engmann, JEL; Shah, T; Sofat, R; Guo, YR; Chung, C; Peasey, A; Ster, RP; Mooijaart, SP; Ireland, HA; Leusink, M; Langenberg, C; Li, K; Palmen, J; Howard, P; Cooper, JA; Drenos, F; Hardy, J; Nalls, MA; Li, YR; Lowe, G; Stewart, M; Bielinski, SJ; Peto, J; Timpson, NJ; Gallacher, J; Dunlop, M; Houlston, R; Tomlinson, I; Tzoulaki, I; Luan, J; Boer, JMA; Forouhi, NG; Onland-Moret, NC; van der Schouw, YT; Schnabel, RB; Hubacek, JA; Kubinova, R; Baceviciene, M; Tamosiunas, A; Pajak, A; Topor-Madry, R; Malyutina, SA; Baldassarre, D; Sennblad, B; Tremoli, E; de Faire, U; Ferrucci, L; Bandenelli, S; Tanaka, T; Meschia, JF; Singleton, A; Navis, G; Leach, IM; Bakker, SJL; Gansevoort, RT; Ford, I; Epstein, SE; Burnett, MS; Devaney, JM; Jukema, JW; Westendorp, RGJ; de Borst, GJ; van der Graaf, Y; de Jong, PA; Maitland-van der Zee, AH; Klungel, OH; de Boer, A; Doevendans, PA; Stephens, JW; Eaton, CB; Robinson, JG; Manson, JE; Fowkes, FGR; Frayling, TM; Price, JF; Whincup, PH; Morris, RW; Lawlor, DA; Smith, GD; Ben-Shlomo, Y; Redline, S; Lange, LA; Kumari, M; Wareham, NJ; Verschuren, WMM; Benjamin, EJ; Whittaker, JC; Hamsten, A; Dudbridge, F; Delaney, JAC; Wong, A; Kuh, D; Hardy, R; Castillo, BA; Connolly, JJ; van der Harst, P; Brunner, EJ; Marmot, MG; Wassel, CL; Humphries, SE; Talmud, PJ; Kivimaki, M; Asselbergs, FW; Voevoda, M; Bobak, M; Pikhart, H; Wilson, JG; Hakonarson, H; Reiner, AP; Keating, BJ; Sattar, N; Hingorani, AD; Casas, JP				Swerdlow, Daniel I.; Holmes, Michael V.; Kuchenbaecker, Karoline B.; Engmann, Jorgen E. L.; Shah, Tina; Sofat, Reecha; Guo, Yiran; Chung, Christina; Peasey, Anne; Ster, Roman Pfi; Mooijaart, Simon P.; Ireland, Helen A.; Leusink, Maarten; Langenberg, Claudia; Li, KaWah; Palmen, Jutta; Howard, Philip; Cooper, Jackie A.; Drenos, Fotios; Hardy, John; Nalls, Michael A.; Li, Yun Rose; Lowe, Gordon; Stewart, Marlene; Bielinski, Suzette J.; Peto, Julian; Timpson, Nicholas J.; Gallacher, John; Dunlop, Malcolm; Houlston, Richard; Tomlinson, Ian; Tzoulaki, Ioanna; Luan, Jian'an; Boer, Jolanda M. A.; Forouhi, Nita G.; Onland-Moret, N. Charlotte; van der Schouw, Yvonne T.; Schnabel, Renate B.; Hubacek, Jaroslav A.; Kubinova, Ruzena; Baceviciene, Migle; Tamosiunas, Abdonas; Pajak, Andrzej; Topor-Madry, Roman; Malyutina, Sofi A.; Baldassarre, Damiano; Sennblad, Bengt; Tremoli, Elena; de Faire, Ulf; Ferrucci, Luigi; Bandenelli, Stefania; Tanaka, Toshiko; Meschia, James F.; Singleton, Andrew; Navis, Gerjan; Leach, Irene Mateo; Bakker, Stephan J. L.; Gansevoort, Ron T.; Ford, Ian; Epstein, Stephen E.; Burnett, Mary Susan; Devaney, Joe M.; Jukema, J. Wouter; Westendorp, Rudi G. J.; de Borst, Gert Jan; van der Graaf, Yolanda; de Jong, Pim A.; Maitland-van der Zee, Anke-Hilse; Klungel, Olaf H.; de Boer, Anthonius; Doevendans, Pieter A.; Stephens, Jeffrey W.; Eaton, Charles B.; Robinson, Jennifer G.; Manson, JoAnn E.; Fowkes, F. Gerry R.; Frayling, Timothy M.; Price, Jackie F.; Whincup, Peter H.; Morris, Richard W.; Lawlor, Debbie A.; Smith, George Davey; Ben-Shlomo, Yoav; Redline, Susan; Lange, Leslie A.; Kumari, Meena; Wareham, Nick J.; Verschuren, W. M. Monique; Benjamin, Emelia J.; Whittaker, John C.; Hamsten, Anders; Dudbridge, Frank; Delaney, J. A. Chris; Wong, Andrew; Kuh, Diana; Hardy, Rebecca; Castillo, Berta Almoguera; Connolly, John J.; van der Harst, Pim; Brunner, Eric J.; Marmot, Michael G.; Wassel, Christina L.; Humphries, Steve E.; Talmud, Philippa J.; Kivimaki, Mika; Asselbergs, Folkert W.; Voevoda, Mikhail; Bobak, Martin; Pikhart, Hynek; Wilson, James G.; Hakonarson, Hakon; Reiner, Alex P.; Keating, Brendan J.; Sattar, Naveed; Hingorani, Aroon D.; Casas, Juan Pablo		Interleukin-6 Receptor Mendelian R	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis	LANCET			English	Article							GENOME-WIDE ASSOCIATION; C-REACTIVE PROTEIN; INDIVIDUAL PARTICIPANTS DATA; RHEUMATOID-ARTHRITIS; IL-6 RECEPTOR; DOUBLE-BLIND; JOINT ANALYSIS; SOLUBLE IL-6; TOCILIZUMAB; MECHANISMS	Background A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. Methods Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. Findings In 40 studies including up to 133 449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9.45%, 95% CI 8.34-10.57) as well as reduced C-reactive protein (decrease per allele 8.35%, 95% CI 7.31-9.38) and fibrinogen concentrations (decrease per allele 0.85%, 95% CI 0.60-1.10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25 458 coronary heart disease cases and 100 740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0.95, 95% CI 0.93-0.97, p=1.53x10(-5)). Interpretation On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.	[Swerdlow, Daniel I.] UCL, UCL Inst Epidemiol & Hlth Care, Res Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London WC1E 6BT, England	University of London; University College London	Swerdlow, DI (corresponding author), UCL, UCL Inst Epidemiol & Hlth Care, Res Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, Mortimer St, London WC1E 6BT, England.	d.swerdlow@ucl.ac.uk	Holmes, Michael/AAA-2208-2021; Pikhart, Hynek/E-3074-2010; Fox, Laura J/C-6249-2016; Hubacek, Jaroslav Alois/AAN-6134-2021; Hardy, John/C-2451-2009; Whittaker, John C/B-8609-2012; Wong, Andrew/M-8899-2016; Ford, Ian/ABE-6145-2020; Asselbergs, Folkert W./ABD-6752-2021; Wong, Andrew/AAE-6995-2019; Mooijaart, Simon P./A-5306-2008; Brunner, Eric/H-2114-2011; Swerdlow, Daniel/A-3497-2009; Voevoda, Mikhail/N-6713-2015; Langenberg, Claudia/ABG-9067-2021; Timpson, Nicholas John/O-7548-2015; Onland-Moret, N. Charlotte/G-9185-2011; Kuh, Diana/L-6019-2014; Schnabel, Renate B/ABE-6668-2021; Singleton, Andrew B/C-3010-2009; Kivimaki, Mika/B-3607-2012; Delaney, Joseph A/J-8204-2019; Benjamin, Emelia/E-7103-2011; van der Schouw, Yvonne T./F-8327-2014; Topor-Madry, Roman/ABF-5449-2020; Marmot, M G/Y-3920-2019; Hardy, Rebecca/AFR-1989-2022; de Jong, Pim A/G-7220-2014; Dunlop, Malcolm G/F-1973-2011; Jukema, J. Wouter/ABD-6503-2021; Tzoulaki, Ioanna/ABE-6269-2020; Baceviciene, Migle/AAG-1246-2020; Guo, Yiran/H-4120-2011; Malyutina, Sofia/J-1651-2018; Davey Smith, George/A-7407-2013; Ben-Shlomo, Yoav/ABD-2004-2021; Bielinski, Suzette/A-2238-2009; , Jennifer/AAD-8336-2019; Bakker, Stephan J. L./J-4023-2015; Attrill, Lauren/V-1688-2018; Meschia, James/GPP-1636-2022; Tamosiunas, Abdonas/AAD-4274-2021; Maitland-van der Zee, Anke/I-9572-2016; TREMOLI, ELENA/I-8126-2018; Baldassarre, Damiano/J-3295-2016	Pikhart, Hynek/0000-0001-5277-4049; Hubacek, Jaroslav Alois/0000-0001-6537-1353; Hardy, John/0000-0002-3122-0423; Whittaker, John C/0000-0002-3529-2379; Wong, Andrew/0000-0003-2079-4779; Asselbergs, Folkert W./0000-0002-1692-8669; Wong, Andrew/0000-0003-2079-4779; Mooijaart, Simon P./0000-0003-3106-3568; Brunner, Eric/0000-0002-0595-4474; Swerdlow, Daniel/0000-0002-7946-3459; Voevoda, Mikhail/0000-0001-9425-413X; Langenberg, Claudia/0000-0002-5017-7344; Timpson, Nicholas John/0000-0002-7141-9189; Onland-Moret, N. Charlotte/0000-0002-2360-913X; Kuh, Diana/0000-0001-7386-2857; Schnabel, Renate B/0000-0001-7170-9509; Kivimaki, Mika/0000-0002-4699-5627; Delaney, Joseph A/0000-0003-1771-1776; Benjamin, Emelia/0000-0003-4076-2336; van der Schouw, Yvonne T./0000-0002-4605-435X; Marmot, M G/0000-0002-2431-6419; de Jong, Pim A/0000-0003-4840-6854; Dunlop, Malcolm G/0000-0002-3033-5851; Jukema, J. Wouter/0000-0002-3246-8359; Tzoulaki, Ioanna/0000-0002-4275-9328; Baceviciene, Migle/0000-0002-9819-2316; Malyutina, Sofia/0000-0001-6539-0466; Davey Smith, George/0000-0002-1407-8314; Ben-Shlomo, Yoav/0000-0001-6648-3007; Bielinski, Suzette/0000-0002-2905-5430; Bakker, Stephan J. L./0000-0003-3356-6791; Meschia, James/0000-0002-4475-8142; Lawlor, Debbie A/0000-0002-6793-2262; Morris, Richard/0000-0001-7240-4563; Maitland-van der Zee, Anke/0000-0002-0414-3442; TREMOLI, ELENA/0000-0002-0929-6106; Baldassarre, Damiano/0000-0002-2766-8882; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Connolly, John/0000-0003-4396-1226; Sofat, Reecha/0000-0002-0242-6115; Forouhi, Nita/0000-0002-5041-248X; Price, Jackie/0000-0003-3251-3970; Hardy, Rebecca/0000-0001-9949-0799; Stewart, Marlene/0000-0001-7939-7001; Shah, Tina/0000-0001-7724-7210; Engmann, Jorgen/0000-0001-7015-7773; Li, Yun Rose/0000-0002-8077-4975; Whincup, Peter/0000-0002-5589-4107; Kumari, Meena/0000-0001-9716-1035; s, hema/0000-0002-3440-9475; Bobak, Martin/0000-0002-2633-6851; Hingorani, Aroon/0000-0001-8365-0081; Drenos, Fotios/0000-0003-2469-5516; Humphries, Stephen E/0000-0002-8221-6547; Peasey, Anne/0000-0001-7434-2079	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095163, N01HC095159, N01HC095166, N01HC095169, N01HC095168, N01HC095167, N01HC095165, N01HC095162, N01HC095161, N01HC095164, N01HC095160] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065226, R43HL095160, R21HL095165, R01HL095163, R43HL095167, R44HL095169, R43HL095161, R13HL095166, R43HL095169, R01HL036310] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG005152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F30AR066486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039987, R01NS042733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196, Z01AG000015, R01AG017644, R01AG023522, R37AG013196, Z01AG000954] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM010098] Funding Source: NIH RePORTER; MRC [G0701075, G0902037, MC_U127527198, MC_PC_U127527198, MC_U123092720, G1000718, MC_UP_A100_1003, G0500877, G0802432, G0600705, MC_U123092721] Funding Source: UKRI; Alzheimers Research UK [ART-PPG2011A-14, ART-PG2010-1] Funding Source: researchfish; British Heart Foundation [RG/07/008/23674, PG/09/022/26739, RG/08/008/25291, RG/10/12/28456, RG/08/013/25942] Funding Source: researchfish; Cancer Research UK [12076] Funding Source: researchfish; Medical Research Council [G0802432, G8802774, G0902037, G1000718, G0701075, MC_U106179471, MC_U127527198, G19/35, G0600705, MC_PC_U127527198, MC_U123092720, MC_UP_A100_1003, G0500877, MC_U123092721, G0100222] Funding Source: researchfish	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Casas JP, 2006, INT J EPIDEMIOL, V35, P922, DOI 10.1093/ije/dyl041; Chalaris A, 2010, BBA-MOL CELL RES, V1803, P234, DOI 10.1016/j.bbamcr.2009.12.001; Choy E, 2009, ANN RHEUM DIS, V68, P460, DOI 10.1136/ard.2008.101964; Danesh J, 2008, PLOS MED, V5, P600, DOI 10.1371/journal.pmed.0050078; Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932; European Medicines Agency, 2010, EUR PUBL ASS REP ROA; FDA, 2008, BRIEF DOC ARTHR ADV; Galicia JC, 2004, GENES IMMUN, V5, P513, DOI 10.1038/sj.gene.6364120; Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2968, DOI 10.1002/art.23940; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hingorani A, 2005, LANCET, V366, P1906, DOI 10.1016/S0140-6736(05)67767-7; Huth C, 2006, DIABETES, V55, P2915, DOI 10.2337/db06-0600; Huth C, 2009, ANN MED, V41, P128, DOI 10.1080/07853890802337037; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kawashiri SY, 2011, RHEUMATOL INT, V31, P451, DOI 10.1007/s00296-009-1303-y; Keating BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003583; Keavney B, 2006, INT J EPIDEMIOL, V35, P935, DOI 10.1093/ije/dyl114; Kivimaki M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003013; Kivimaki M, 2007, ARTERIOSCL THROM VAS, V27, P978, DOI 10.1161/01.ATV.0000258869.48076.14; Kremer JM, 2011, ARTHRITIS RHEUM-US, V63, P609, DOI 10.1002/art.30158; Liuzzo G, 2001, Rays, V26, P221; Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033; Melton L, 2008, NAT BIOTECHNOL, V26, P957, DOI 10.1038/nbt0908-957; Mihara M, 2005, INT IMMUNOPHARMACOL, V5, P1731, DOI 10.1016/j.intimp.2005.05.010; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565; NICE, 2010, TOC TREATM RHEUM ART; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846; Nishimoto N, 2010, MOD RHEUMATOL, V20, P222, DOI 10.1007/s10165-010-0279-5; Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Rafiq S, 2007, GENES IMMUN, V8, P552, DOI 10.1038/sj.gene.6364414; Rantala A, 2011, HUM IMMUNOL, V72, P63, DOI 10.1016/j.humimm.2010.10.010; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Sattar N, 2005, CURR OPIN RHEUMATOL, V17, P286, DOI 10.1097/01.bor.0000158150.57154.f9; Sattar N, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000099; Singh JA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008331.pub2; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; Sofat R, 2010, CIRCULATION, V121, P52, DOI 10.1161/CIRCULATIONAHA.109.865444; Steiner G, 2009, SEMIN ARTHRITIS RHEU, V38, P372, DOI 10.1016/j.semarthrit.2008.01.015; Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639; Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548	49	675	695	7	94	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2012	379	9822					1214	1224		10.1016/S0140-6736(12)60110-X	http://dx.doi.org/10.1016/S0140-6736(12)60110-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	918DV	22421340	hybrid, Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000302230400034
J	Bazinsky, KR; Herrera, L; Sharfstein, JM				Bazinsky, Katharine R.; Herrera, Laura; Sharfstein, Joshua M.			Toward Innovative Models of Health Care and Financing Matchmaking in Maryland	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bazinsky, Katharine R.; Herrera, Laura; Sharfstein, Joshua M.] Dept Hlth & Mental Hyg, Baltimore, MD 21202 USA	Maryland Department of Health & Mental Hygiene	Sharfstein, JM (corresponding author), Dept Hlth & Mental Hyg, 201 W Preston St, Baltimore, MD 21202 USA.	jsharfstein@dhmh.state.md.us						Flexner A., 1910, MED ED US CANADA REP, P68; Maryland Department of Health and Mental Hygiene, HLTH CAR INN MAR; Rinke ML, 2012, AM J EMERG MED, V30, P352, DOI 10.1016/j.ajem.2010.12.012	3	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1261	1262		10.1001/jama.2012.364	http://dx.doi.org/10.1001/jama.2012.364			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453566				2022-12-28	WOS:000301978400020
J	Emanuel, EJ; Fuchs, VR				Emanuel, Ezekiel J.; Fuchs, Victor R.			Shortening Medical Training by 30%	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EDUCATION		[Emanuel, Ezekiel J.] Univ Penn, Off Provost, Philadelphia, PA 19104 USA; [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Emanuel, Ezekiel J.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA; [Fuchs, Victor R.] Stanford Univ, Dept Econ, Palo Alto, CA 94304 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Stanford University	Emanuel, EJ (corresponding author), Univ Penn, Off Provost, 1 Coll Hall,Room 122, Philadelphia, PA 19104 USA.	zemanuel@upenn.edu						Duke University School of Medicine Admissions website, YOUR ED YEAR ON BAS; Farrell D, ACCOUNTING COST US H; Flexner A, 1924, J AMER MED ASSOC, V82, P833, DOI 10.1001/jama.1924.02650370001001; Grochowski CO, 2007, ACAD MED, V82, P375, DOI 10.1097/ACM.0b013e3180333575; Harvard Medical School website, PROGR MED ED NEW PAT; Loftus LS, 1997, TEACH LEARN MED, V9, P248, DOI 10.1207/s15328015tlm0904_1; Sachdeva AK, 2007, ACAD MED, V82, P1200, DOI 10.1097/ACM.0b013e318159e052	7	104	105	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1143	1144		10.1001/jama.2012.292	http://dx.doi.org/10.1001/jama.2012.292			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436952				2022-12-28	WOS:000301708000019
J	Haines, A; Dora, C				Haines, Andy; Dora, Carlos			How the low carbon economy can improve health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; MORTALITY		[Haines, Andy] Univ London London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1E 7HT, England; [Haines, Andy] Univ London London Sch Hyg & Trop Med, Dept Nutr & Publ Hlth Intervent Res, London WC1E 7HT, England; [Dora, Carlos] WHO, Dept Publ Hlth & Environm, Intervent Hlth Environm Unit, CH-1211 Geneva, Switzerland	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; World Health Organization	Haines, A (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, Keppel St, London WC1E 7HT, England.	andy.haines@lshtm.ac.uk		Haines, Andy/0000-0002-8053-4605				Andersen LB, 2000, ARCH INTERN MED, V160, P1621, DOI 10.1001/archinte.160.11.1621; Anderson K, 2011, PHILOS T R SOC A, V369, P20, DOI 10.1098/rsta.2010.0290; [Anonymous], 2006, EVALUATION COSTS BEN; [Anonymous], URBAN TRANSPORT HLTH; Atkinson J, 2009, NATURAL VENTILATION FOR INFECTION CONTROL IN HEALTH-CARE SETTINGS, P1; Cavill N, 2008, TRANSPORT POLICY, V15, P291, DOI 10.1016/j.tranpol.2008.11.001; Committee on Climate Change, 2008, BUILD LOW CARB EC UK; Dora C, 2000, EUROPEAN SERIES; European Environment Agency, 2010, TRANSP EM AIR POLL T; [FAO] Food and Agriculture Organisation, 2006, LIV LONG SHAD; Friel S, 2009, LANCET, V374, P2016, DOI 10.1016/S0140-6736(09)61753-0; Haines A, 2009, LANCET, V374, P2104, DOI 10.1016/S0140-6736(09)61759-1; IPCC Apndice, 2007, AR4 CLIMATE CHANGE 2; Keiser J, 2005, LANCET INFECT DIS, V5, P695, DOI 10.1016/S1473-3099(05)70268-1; Markandya A, 2009, LANCET, V374, P2006, DOI 10.1016/S0140-6736(09)61715-3; Matthews CE, 2007, AM J EPIDEMIOL, V165, P1343, DOI 10.1093/aje/kwm088; McMichael A J, 1993, PLANETARY OVERLOAD G; Meyer A, 2001, CONTRACTION CONVERGE; OECD, 2008, RIS FOOD PRIC CAUS C; Organization WH, 2009, GLOB HLTH RISKS MORT; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Stern Nicholas, 2006, STERN REV EC CLIMATE; Stieglitz J, 2010, FREEFALL FREE MARKET, P361; United Nations General Assembly, 2011, POL DECL HIGH LEV M; WHO, 2012, HLTH GREEN EC; WHO, 2011, HLTH GREEN EC HLTH C; Wilkinson P, 2009, LANCET, V374, P1917, DOI 10.1016/S0140-6736(09)61713-X; Woodcock J, 2009, LANCET, V374, P1930, DOI 10.1016/S0140-6736(09)61714-1; Woodfine L, 2011, BRIT J GEN PRACT, V61, P674, DOI 10.3399/bjgp11X606636; World Health Organization, 2009, INT DIET PHYS ACT WH; World Health Organization Global Health Observatory, 2012, GLOB HLTH OBS OUTD A	31	29	29	3	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2012	344								e1018	10.1136/bmj.e1018	http://dx.doi.org/10.1136/bmj.e1018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431656	Bronze, Green Submitted			2022-12-28	WOS:000301848400002
J	Eisenberg, D; Jucker, M				Eisenberg, David; Jucker, Mathias			The Amyloid State of Proteins in Human Diseases	CELL			English	Review							A-BETA PEPTIDE; FAMILIAL DANISH DEMENTIA; HUMAN PRION DISEASE; X-RAY-DIFFRACTION; AGE-OF-ONSET; ALZHEIMERS-DISEASE; MOLECULAR-BASIS; FIBRIL FORMATION; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISORDERS	Amyloid fibers and oligomers are associated with a great variety of human diseases including Alzheimer's disease and the prion conditions. Here we attempt to connect recent discoveries on the molecular properties of proteins in the amyloid state with observations about pathological tissues and disease states. We summarize studies of structure and nucleation of amyloid and relate these to observations on amyloid polymorphism, prion strains, coaggregation of pathogenic proteins in tissues, and mechanisms of toxicity and transmissibility. Molecular studies have also led to numerous strategies for biological and chemical interventions against amyloid diseases.	[Eisenberg, David] Univ Calif Los Angeles, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; [Jucker, Mathias] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Cellular Neurol, D-72076 Tubingen, Germany; [Jucker, Mathias] German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu; mathias.jucker@uni-tuebingen.de		Jucker, Mathias/0000-0001-9045-1072	Howard Hughes Medical Institute Funding Source: Medline; NIA NIH HHS [R01 AG029430] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG029430] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguzzi A, 2007, NAT REV MOL CELL BIO, V8, P552, DOI 10.1038/nrm2204; Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050; Aguzzi A, 2009, NEURON, V64, P783, DOI 10.1016/j.neuron.2009.12.016; Andreetto E, 2010, ANGEW CHEM INT EDIT, V49, P3081, DOI 10.1002/anie.200904902; Apostol MI, 2010, J BIOL CHEM, V285, P29671, DOI 10.1074/jbc.C110.158303; ASTBURY WILLIAM THOMAS, 1935, BIOCHEM JOUR, V29, P2351; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Bergstrom J, 2005, J PATHOL, V206, P224, DOI 10.1002/path.1759; Bodin K, 2010, NATURE, V468, P93, DOI 10.1038/nature09494; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Buxbaum JN, 2009, FEBS LETT, V583, P2663, DOI 10.1016/j.febslet.2009.07.031; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Campioni S, 2010, NAT CHEM BIOL, V6, P140, DOI [10.1038/NCHEMBIO.283, 10.1038/nchembio.283]; Chai XY, 2011, J BIOL CHEM, V286, P34457, DOI 10.1074/jbc.M111.229633; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chen J, 2010, J AM CHEM SOC, V132, P17015, DOI 10.1021/ja107552s; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; COHEN AS, 1959, NATURE, V183, P1202, DOI 10.1038/1831202a0; Colby DW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a006833; Colletier JP, 2011, P NATL ACAD SCI USA, V108, P16938, DOI 10.1073/pnas.1112600108; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Coomaraswamy J, 2010, P NATL ACAD SCI USA, V107, P7969, DOI 10.1073/pnas.1001056107; De Strooper B, 2010, PHYSIOL REV, V90, P465, DOI 10.1152/physrev.00023.2009; Dierksen GA, 2010, ANN NEUROL, V68, P545, DOI 10.1002/ana.22099; Duering M, 2005, NEUROBIOL AGING, V26, P785, DOI 10.1016/j.neurobiolaging.2004.08.002; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Fandrich M, 2003, P NATL ACAD SCI USA, V100, P15463, DOI 10.1073/pnas.0303758100; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Frost B, 2009, J BIOL CHEM, V284, P3546, DOI 10.1074/jbc.M805627200; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200; Goedert M, 2010, TRENDS NEUROSCI, V33, P317, DOI 10.1016/j.tins.2010.04.003; Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; Goldsbury C, 2005, J MOL BIOL, V352, P282, DOI 10.1016/j.jmb.2005.07.029; Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009; Gruys Erik, 2004, J Zhejiang Univ Sci, V5, P1226, DOI 10.1631/jzus.2004.1226; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hamaguchi T, 2012, ACTA NEUROPATHOL, V123, P31, DOI 10.1007/s00401-011-0912-1; Hebda JA, 2009, ANNU REV BIOPHYS, V38, P125, DOI 10.1146/annurev.biophys.050708.133622; Hedden T, 2009, J NEUROSCI, V29, P12686, DOI 10.1523/JNEUROSCI.3189-09.2009; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Herzig MC, 2006, BRAIN PATHOL, V16, P40, DOI 10.1111/j.1750-3639.2006.tb00560.x; HIGUCHI K, 1993, FEBS LETT, V317, P207, DOI 10.1016/0014-5793(93)81277-7; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Ihse E, 2008, J PATHOL, V216, P253, DOI 10.1002/path.2411; Ihse E, 2011, J MOL MED, V89, P171, DOI 10.1007/s00109-010-0695-1; Ivanova MI, 2009, P NATL ACAD SCI USA, V106, P18990, DOI 10.1073/pnas.0910080106; Jan A, 2011, J BIOL CHEM, V286, P8585, DOI 10.1074/jbc.M110.172411; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Johnson SM, 2012, J MOL BIOL, V421, P185, DOI 10.1016/j.jmb.2011.12.060; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; Kaeser SA, 2007, NAT GENET, V39, P1437, DOI 10.1038/ng.2007.23; Kajava AV, 2010, FASEB J, V24, P1311, DOI 10.1096/fj.09-145979; Kelly JW, 2001, PHILOS T ROY SOC B, V356, P210; Keshet B, 2010, BIOTECHNOL BIOENG, V106, P333, DOI 10.1002/bit.22691; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Knowles TPJ, 2009, SCIENCE, V326, P1533, DOI 10.1126/science.1178250; Korenaga T, 2006, AM J PATHOL, V168, P898, DOI 10.2353/ajpath.2006.050350; KUHNS IE, 1968, PROC R SOC LON SER-A, V302, P437, DOI 10.1098/rspa.1968.0028; Kumar S, 2011, EMBO J, V30, P2255, DOI 10.1038/emboj.2011.138; Kumar-Singh S, 2006, HUM MUTAT, V27, P686, DOI 10.1002/humu.20336; Kummer MP, 2011, NEURON, V71, P833, DOI 10.1016/j.neuron.2011.07.001; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Kuperstein I, 2010, EMBO J, V29, P3408, DOI 10.1038/emboj.2010.211; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Langer F, 2011, J NEUROSCI, V31, P14488, DOI 10.1523/JNEUROSCI.3088-11.2011; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Lee J, 2011, NAT CHEM BIOL, V7, P602, DOI [10.1038/nchembio.624, 10.1038/NCHEMBIO.624]; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LeVine H, 2010, NEUROBIOL AGING, V31, P542, DOI 10.1016/j.neurobiolaging.2008.05.026; Lewandowski JR, 2011, J AM CHEM SOC, V133, P14686, DOI 10.1021/ja203736z; Liao MC, 2010, J BIOL CHEM, V285, P35590, DOI 10.1074/jbc.M110.169599; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Lundmark K, 2005, P NATL ACAD SCI USA, V102, P6098, DOI 10.1073/pnas.0501814102; Maarouf CL, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-20; Mackenzie IRA, 2010, LANCET NEUROL, V9, P995, DOI 10.1016/S1474-4422(10)70195-2; MAEDA A, 1993, STROKE, V24, P1857, DOI 10.1161/01.STR.24.12.1857; Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155; Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102; Martins IC, 2008, EMBO J, V27, P224, DOI 10.1038/sj.emboj.7601953; Masliah E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019338; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Miravalle L, 2005, BIOCHEMISTRY-US, V44, P10810, DOI 10.1021/bi0508237; MIYAZONO M, 1992, ACTA NEUROPATHOL, V83, P333, DOI 10.1007/BF00713522; Morales R, 2010, J NEUROSCI, V30, P4528, DOI 10.1523/JNEUROSCI.5924-09.2010; Mougenot A.L., 2011, NEUROBIOL AGING 0801; Necula M, 2007, J BIOL CHEM, V282, P10311, DOI 10.1074/jbc.M608207200; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Nilsson KPR, 2007, ACS CHEM BIOL, V2, P553, DOI 10.1021/cb700116u; Nilsson KPR, 2010, J NEUROSCI, V30, P12094, DOI 10.1523/JNEUROSCI.2417-10.2010; Olzscha H, 2011, CELL, V144, P67, DOI 10.1016/j.cell.2010.11.050; Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106; Page LJ, 2009, P NATL ACAD SCI USA, V106, P11125, DOI 10.1073/pnas.0811753106; Paravastu AK, 2009, P NATL ACAD SCI USA, V106, P7443, DOI 10.1073/pnas.0812033106; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Piccini A, 2005, J BIOL CHEM, V280, P34186, DOI 10.1074/jbc.M501694200; Pickhardt Marcus, 2005, Current Alzheimer Research, V2, P219, DOI 10.2174/1567205053585891; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Revesz T, 2009, ACTA NEUROPATHOL, V118, P115, DOI 10.1007/s00401-009-0501-8; Roychaudhuri R, 2009, J BIOL CHEM, V284, P4749, DOI 10.1074/jbc.R800036200; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Schilling S, 2008, NAT MED, V14, P1106, DOI 10.1038/nm.1872; Schmidt M, 2009, P NATL ACAD SCI USA, V106, P19813, DOI 10.1073/pnas.0905007106; Sciarretta KL, 2006, METHOD ENZYMOL, V413, P273, DOI 10.1016/S0076-6879(06)13015-3; Selkoe DJ, 2011, NAT MED, V17, P1060, DOI 10.1038/nm.2460; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Sievers SA, 2011, NATURE, V475, P96, DOI 10.1038/nature10154; Sigurdson CJ, 2007, NAT METHODS, V4, P1023, DOI 10.1038/nmeth1131; Singleton A, 2004, HUM MOL GENET, V13, pR123, DOI 10.1093/hmg/ddh093; Sipe JD, 2010, AMYLOID, V17, P101, DOI 10.3109/13506129.2010.526812; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Spires-Jones TL, 2011, J MOL NEUROSCI, V45, P438, DOI 10.1007/s12031-011-9566-7; Stefani M, 2010, FEBS J, V277, P4602, DOI 10.1111/j.1742-4658.2010.07889.x; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tanaka M, 2006, NATURE, V442, P585, DOI 10.1038/nature04922; Tekirian TL, 1998, J NEUROPATH EXP NEUR, V57, P76, DOI 10.1097/00005072-199801000-00009; Thal Dietmar R, 2006, Sci Aging Knowledge Environ, V2006, pre1, DOI 10.1126/sageke.2006.6.re1; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomidokoro Y, 2005, J BIOL CHEM, V280, P36883, DOI 10.1074/jbc.M504038200; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Tsemekhman K, 2007, PROTEIN SCI, V16, P761, DOI 10.1110/ps.062609607; Tycko R, 2011, ANNU REV PHYS CHEM, V62, P279, DOI 10.1146/annurev-physchem-032210-103539; Ueda M., 2011, LAB INVEST      1219; Wadsworth JDF, 2010, NEUROPATH APPL NEURO, V36, P576, DOI 10.1111/j.1365-2990.2010.01129.x; Walker L, 2006, ACTA NEUROPATHOL, V112, P1, DOI 10.1007/s00401-006-0072-x; Wang L, 2008, PLOS BIOL, V6, P1791, DOI 10.1371/journal.pbio.0060195; Wasmer C, 2008, SCIENCE, V319, P1523, DOI 10.1126/science.1151839; Watt B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002286; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; WESTERMARK GT, 1989, SCAND J IMMUNOL, V30, P605, DOI 10.1111/j.1365-3083.1989.tb02468.x; Westermark GT, 2010, TRENDS MOL MED, V16, P501, DOI 10.1016/j.molmed.2010.08.004; Westermark P, 2005, FEBS J, V272, P5942, DOI 10.1111/j.1742-4658.2005.05024.x; White HE, 2009, J MOL BIOL, V389, P48, DOI 10.1016/j.jmb.2009.03.066; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Wiltzius JJW, 2009, NAT STRUCT MOL BIOL, V16, P973, DOI 10.1038/nsmb.1643; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001; Winner B, 2011, P NATL ACAD SCI USA, V108, P4194, DOI 10.1073/pnas.1100976108; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; YAMADA M, 1987, J NEUROL, V234, P371, DOI 10.1007/BF00314080; Yan JM, 2007, AM J PATHOL, V171, P172, DOI 10.2353/ajpath.2007.060576; Yankner BA, 2009, J BIOL CHEM, V284, P4754, DOI 10.1074/jbc.R800018200; Zhang BR, 2008, P NATL ACAD SCI USA, V105, P7263, DOI 10.1073/pnas.0800367105	165	1172	1189	13	508	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1188	1203		10.1016/j.cell.2012.02.022	http://dx.doi.org/10.1016/j.cell.2012.02.022			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424229	Green Accepted, Bronze			2022-12-28	WOS:000301889500016
J	Lodish, H; Fedoroff, N				Lodish, Harvey; Fedoroff, Nina			Norton Zinder (1928-2012)	SCIENCE			English	Biographical-Item									[Lodish, Harvey] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Lodish, Harvey] MIT, Cambridge, MA 02142 USA; [Fedoroff, Nina] Penn State Univ, University Pk, PA 16802 USA; [Fedoroff, Nina] King Abdullah Univ Sci & Technol KAUST, Thuwal, Saudi Arabia	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; King Abdullah University of Science & Technology	Lodish, H (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu; nvf1@psu.edu							0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1316	1316		10.1126/science.1220682	http://dx.doi.org/10.1126/science.1220682			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422973				2022-12-28	WOS:000301531600037
J	Silvius, J				Silvius, John			Membrane Bending Tug of War	SCIENCE			English	Editorial Material							ANCHORED PROTEINS; YEAST		McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Silvius, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	john.silvius@mcgill.ca						Bhagatji P, 2009, J CELL BIOL, V186, P615, DOI 10.1083/jcb.200903102; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; Castillon GA, 2011, MOL BIOL CELL, V22, P2924, DOI 10.1091/mbc.E11-04-0294; Castillon GA, 2009, TRAFFIC, V10, P186, DOI 10.1111/j.1600-0854.2008.00857.x; Copic A, 2012, SCIENCE, V335, P1359, DOI 10.1126/science.1215909; Dancourt J, 2010, ANNU REV BIOCHEM, V79, P777, DOI 10.1146/annurev-biochem-061608-091319; Dupuy AD, 2008, P NATL ACAD SCI USA, V105, P2848, DOI 10.1073/pnas.0712379105; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fath S, 2007, CELL, V129, P1325, DOI 10.1016/j.cell.2007.05.036; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030	13	5	5	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074					1308	1309		10.1126/science.1220221	http://dx.doi.org/10.1126/science.1220221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422967				2022-12-28	WOS:000301531600031
J	Bakker, OJ; van Santvoort, HC; van Brunschot, S; Geskus, RB; Besselink, MG; Bollen, TL; van Eijck, CH; Fockens, P; Hazebroek, EJ; Nijmeijer, RM; Poley, JW; van Ramshorst, B; Vleggaar, FP; Boermeester, MA; Gooszen, HG; Weusten, BL; Timmer, R				Bakker, Olaf J.; van Santvoort, Hjalmar C.; van Brunschot, Sandra; Geskus, Ronald B.; Besselink, Marc G.; Bollen, Thomas L.; van Eijck, Casper H.; Fockens, Paul; Hazebroek, Eric J.; Nijmeijer, Rian M.; Poley, Jan-Werner; van Ramshorst, Bert; Vleggaar, Frank P.; Boermeester, Marja A.; Gooszen, Hein G.; Weusten, Bas L.; Timmer, Robin		Dutch Pancreatitis Study Grp	Endoscopic Transgastric vs Surgical Necrosectomy for Infected Necrotizing Pancreatitis A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONVENTIONAL COLORECTAL RESECTIONS; INFLAMMATORY RESPONSE; ORGAN FAILURE; NECROSIS; DEBRIDEMENT; THERAPY; MANAGEMENT; MORTALITY; SURGERY	Context Most patients with infected necrotizing pancreatitis require necrosectomy. Surgical necrosectomy induces a proinflammatory response and is associated with a high complication rate. Endoscopic transgastric necrosectomy, a form of natural orifice transluminal endoscopic surgery, may reduce the proinflammatory response and reduce complications. Objective To compare the proinflammatory response and clinical outcome of endoscopic transgastric and surgical necrosectomy. Design, Setting, and Patients Randomized controlled assessor-blinded clinical trial in 3 academic hospitals and 1 regional teaching hospital in the Netherlands between August 20, 2008, and March 3, 2010. Patients had signs of infected necrotizing pancreatitis and an indication for intervention. Interventions Random allocation to endoscopic transgastric or surgical necrosectomy. Endoscopic necrosectomy consisted of transgastric puncture, balloon dilatation, retroperitoneal drainage, and necrosectomy. Surgical necrosectomy consisted of video-assisted retroperitoneal debridement or, if not feasible, laparotomy. Main Outcome Measures The primary end point was the postprocedural proinflammatory response as measured by serum interleukin 6 (IL-6) levels. Secondary clinical end points included a predefined composite end point of major complications (new-onset multiple organ failure, intra-abdominal bleeding, enterocutaneous fistula, or pancreatic fistula) or death. Results We randomized 22 patients, 2 of whom did not undergo necrosectomy following percutaneous catheter drainage and could not be analyzed for the primary end point. Endoscopic transgastric necrosectomy reduced the postprocedural IL-6 levels compared with surgical necrosectomy (P=.004). The composite clinical end point occurred less often after endoscopic necrosectomy (20% vs 80%; risk difference [RD], 0.60; 95% CI, 0.16-0.80; P=.03). Endoscopic necrosectomy did not cause new-onset multiple organ failure (0% vs 50%, RD, 0.50; 95% CI, 0.12-0.76; P=.03) and reduced the number of pancreatic fistulas (10% vs 70%; RD, 0.60; 95% CI, 0.17-0.81; P=.02). Conclusion In patients with infected necrotizing pancreatitis, endoscopic necrosectomy reduced the proinflammatory response as well as the composite clinical end point compared with surgical necrosectomy.	[Bakker, Olaf J.; van Santvoort, Hjalmar C.; Besselink, Marc G.; Hazebroek, Eric J.; Nijmeijer, Rian M.] Univ Med Ctr Utrecht, Dept Surg, Dutch Pancreatitis Study Grp, NL-3508 GA Utrecht, Netherlands; [Vleggaar, Frank P.] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, NL-3508 GA Utrecht, Netherlands; [van Brunschot, Sandra; Gooszen, Hein G.] Radboud Univ Nijmegen, Med Ctr, Dept Operat Room & Evidence Based Surg, NL-6525 ED Nijmegen, Netherlands; [Geskus, Ronald B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands; [Boermeester, Marja A.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [Fockens, Paul] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Bollen, Thomas L.] St Antonius Hosp, Dept Radiol, Nieuwegein, Netherlands; [van Ramshorst, Bert] St Antonius Hosp, Dept Surg, Nieuwegein, Netherlands; [Weusten, Bas L.; Timmer, Robin] St Antonius Hosp, Dept Gastroenterol, Nieuwegein, Netherlands; [van Eijck, Casper H.] Univ Med Ctr, Erasmus MC, Dept Surg, Rotterdam, Netherlands; [Poley, Jan-Werner] Univ Med Ctr, Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Bakker, OJ (corresponding author), Univ Med Ctr Utrecht, Dept Surg, Dutch Pancreatitis Study Grp, POB 85500,HP G04-228, NL-3508 GA Utrecht, Netherlands.	o.j.bakker@umcutrecht.nl	van Goor, H./H-8035-2014; Gooszen, H.G./H-8036-2014; Besselink, Marc/H-3294-2019; Besselink, Marc G/R-4268-2019; van Eijck, casper/K-5983-2019; Geskus, Ronald B/H-3684-2019; Van Eijck, Casper/ABD-1655-2020	van Goor, H./0000-0003-0323-4876; Besselink, Marc G/0000-0003-2650-9350; Geskus, Ronald B/0000-0002-2740-3155; Voermans, Rogier/0000-0002-9969-019X	Abbott Netherlands	Abbott Netherlands	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fockens reported serving as a consultant for Boston Scientific, Cook Endoscopy, and Torax Medical and receiving royalties from Elsevier. Dr Poley reported receiving support for himself and his institution from Cook Endoscopy and travel support for meetings from MI Tech. Dr Boermeester reported pending grant support from Abbott Netherlands. No other conflicts were disclosed.	Barkun JS, 2009, LANCET, V374, P1089, DOI 10.1016/S0140-6736(09)61083-7; Baron TH, 1996, GASTROENTEROLOGY, V111, P755, DOI 10.1053/gast.1996.v111.pm8780582; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; BEGER HG, 1988, WORLD J SURG, V12, P255, DOI 10.1007/BF01658069; Besselink MGH, 2007, ARCH SURG-CHICAGO, V142, P1194, DOI 10.1001/archsurg.142.12.1194; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; Buchler MW, 2000, ANN SURG, V232, P619; Charnley RM, 2006, ENDOSCOPY, V38, P925, DOI 10.1055/s-2006-944731; Escourrou J, 2008, ANN SURG, V248, P1074, DOI 10.1097/SLA.0b013e31818b728b; Fagenholz PJ, 2007, ANN EPIDEMIOL, V17, P491, DOI 10.1016/j.annepidem.2007.02.002; Forsmark CE, 2007, GASTROENTEROLOGY, V132, P2022, DOI 10.1053/j.gastro.2007.03.065; Frossard JL, 2008, LANCET, V371, P143, DOI 10.1016/S0140-6736(08)60107-5; Gardner TB, 2011, GASTROINTEST ENDOSC, V73, P718, DOI 10.1016/j.gie.2010.10.053; Haghshenasskashani A, 2011, SURG ENDOSC, V25, P3724, DOI 10.1007/s00464-011-1795-x; Johnson CD, 2005, GUT, V54, P1, DOI 10.1136/gut.200A.057026; Johnson CD, 2004, GUT, V53, P1340, DOI 10.1136/gut.2004.039883; LEVINE DW, 1991, NEW ENGL J MED, V325, P967; Makhija Rohit, 2002, J Hepatobiliary Pancreat Surg, V9, P401, DOI 10.1007/s005340200049; Mathew A, 2008, GASTROINTEST ENDOSC, V68, P776, DOI 10.1016/j.gie.2008.05.010; McGee MF, 2008, SURGERY, V143, P318, DOI 10.1016/j.surg.2007.09.032; Meining A, 2011, ENDOSCOPY, V43, P140, DOI 10.1055/s-0030-1256128; Ordemann J, 2001, SURG ENDOSC, V15, P600, DOI 10.1007/s004640090032; Papachristou GI, 2007, ANN SURG, V245, P943, DOI 10.1097/01.sla.0000254366.19366.69; Petrov MS, 2010, GASTROENTEROLOGY, V139, P813, DOI 10.1053/j.gastro.2010.06.010; Pradhan AD, 2009, JAMA-J AM MED ASSOC, V302, P1186, DOI 10.1001/jama.2009.1347; Raraty MGT, 2010, ANN SURG, V251, P787, DOI 10.1097/SLA.0b013e3181d96c53; Rattner DW, 2011, SURG ENDOSC, V25, P2441, DOI 10.1007/s00464-011-1605-5; Rodriguez JR, 2008, ANN SURG, V247, P294, DOI 10.1097/SLA.0b013e31815b6976; Schrover IM, 2008, PANCREATOLOGY, V8, P271, DOI 10.1159/000134275; Schwenk W, 2000, LANGENBECK ARCH SURG, V385, P2, DOI 10.1007/s004230050002; Seewald S, 2005, GASTROINTEST ENDOSC, V62, P92, DOI 10.1016/S0016-5107(05)00541-9; Seifert H, 2000, LANCET, V356, P653, DOI 10.1016/S0140-6736(00)02611-8; Seifert H, 2009, GUT, V58, P1260, DOI 10.1136/gut.2008.163733; Singla A, 2009, GASTROENTEROLOGY, V137, P1995, DOI 10.1053/j.gastro.2009.08.056; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Uhl W, 2003, PANCREATOLOGY, V3, DOI 10.1159/000067684; van Santvoort HC, 2010, NEW ENGL J MED, V362, P1491, DOI 10.1056/NEJMoa0908821; Voermans RP, 2007, GASTROINTEST ENDOSC, V66, P909, DOI 10.1016/j.gie.2007.05.043; Werner J, 2005, SCAND J SURG, V94, P130, DOI 10.1177/145749690509400209; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995	41	411	463	1	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1053	1061		10.1001/jama.2012.276	http://dx.doi.org/10.1001/jama.2012.276			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416101	Bronze			2022-12-28	WOS:000301479700026
J	Stukel, TA; Fisher, ES; Alter, DA; Guttmann, A; Ko, DT; Fung, K; Wodchis, WP; Baxter, NN; Earle, CC; Lee, DS				Stukel, Therese A.; Fisher, Elliott S.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Fung, Kinwah; Wodchis, Walter P.; Baxter, Nancy N.; Earle, Craig C.; Lee, Douglas S.			Association of Hospital Spending Intensity With Mortality and Readmission Rates in Ontario Hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; QUALITY-OF-CARE; SURGICAL OUTCOMES; 30-DAY MORTALITY; HIP FRACTURE; REGIONAL-VARIATIONS; CARDIAC MANAGEMENT; HEALTH OUTCOMES; UNITED-STATES	Context The extent to which better spending produces higher-quality care and better patient outcomes in a universal health care system with selective access to medical technology is unknown. Objective To assess whether acute care patients admitted to higher-spending hospitals have lower mortality and readmissions. Design, Setting, and Patients The study population comprised adults (>18 years) in Ontario, Canada, with a first admission for acute myocardial infarction (AMI) (n=179 139), congestive heart failure (CHF) (n=92 377), hip fracture (n=90 046), or colon cancer (n=26 195) during 1998-2008, with follow-up to 1 year. The exposure measure was the index hospital's end-of-life expenditure index for hospital, physician, and emergency department services. Main Outcome Measures The primary outcomes were 30-day and 1-year mortality and readmissions and major cardiac events (readmissions for AMI, angina, CHF, or death) for AMI and CHF. Results Patients' baseline health status was similar across hospital expenditure groups. Patients admitted to hospitals in the highest-vs lowest-spending intensity terciles had lower rates of all adverse outcomes. In the highest-vs lowest-spending hospitals, respectively, the age-and sex-adjusted 30-day mortality rate was 12.7% vs 12.8% for AMI, 10.2% vs 12.4% for CHF, 7.7% vs 9.7% for hip fracture, and 3.3% vs 3.9% for CHF; fully adjusted relative 30-day mortality rates were 0.93 (95% CI, 0.89-0.98) for AMI, 0.81 (95% CI, 0.76-0.86) for CHF, 0.74 (95% CI, 0.68-0.80) for hip fracture, and 0.78 (95% CI, 0.66-0.91) for colon cancer. Results for 1-year mortality, readmissions, and major cardiac events were similar. Higher-spending hospitals had higher nursing staff ratios, and their patients received more inpatient medical specialist visits, interventional (AMI cohort) and medical (AMI and CHF cohorts) cardiac therapies, preoperative specialty care (colon cancer cohort), and postdischarge collaborative care with a cardiologist and primary care physician (AMI and CHF cohorts). Conclusion Among Ontario hospitals, higher spending intensity was associated with lower mortality, readmissions, and cardiac event rates. JAMA. 2012;307(10):1037-1045 www.jama.com	[Stukel, Therese A.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Fung, Kinwah; Wodchis, Walter P.; Baxter, Nancy N.; Earle, Craig C.; Lee, Douglas S.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; [Stukel, Therese A.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Wodchis, Walter P.; Baxter, Nancy N.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Stukel, Therese A.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada; [Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada; [Stukel, Therese A.; Fisher, Elliott S.] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Populat Hlth, Lebanon, NH USA; [Stukel, Therese A.; Fisher, Elliott S.] Dartmouth Med Sch, Lebanon, NH USA; [Alter, David A.; Baxter, Nancy N.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Alter, David A.; Wodchis, Walter P.] Toronto Rehabil Inst, Toronto, ON, Canada; [Lee, Douglas S.] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dartmouth College; Dartmouth College; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Stukel, TA (corresponding author), Inst Clin Evaluat Sci, G106-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	stukel@ices.on.ca	Baxter, Nancy N/E-7020-2015; Greiver, Michelle/N-8764-2015	Baxter, Nancy N/0000-0003-4793-4620; Greiver, Michelle/0000-0001-8957-0285; wodchis, walter/0000-0003-2494-7031; Ko, Dennis/0000-0001-6840-8051; Lee, Douglas/0000-0001-7078-745X; Stukel, Therese/0000-0002-2951-1360	Canadian Institutes of Health Research [ETG92248]; US National Institute on Aging [1PO1-AG19783-01]; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding was provided by an Emerging Team Grant (ETG92248) in Applied Health Services and Policy Research from the Canadian Institutes of Health Research, by a grant from the US National Institute on Aging (1PO1-AG19783-01), and by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care.	Alter DA, 2006, CIRCULATION, V113, P380, DOI 10.1161/CIRCULATIONAHA.105.560466; Austin PC, 2006, J ROY STAT SOC A STA, V169, P115, DOI 10.1111/j.1467-985X.2005.00380.x; Ayanian JZ, 2006, CIRCULATION, V113, P333, DOI 10.1161/CIRCULATIONAHA.105.598789; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; Bach PB, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp0909947; Barnato AE, 2010, MED CARE, V48, P125, DOI 10.1097/MLR.0b013e3181c161e4; Birkmeyer NJO, 2005, CANCER-AM CANCER SOC, V103, P435, DOI 10.1002/cncr.20785; Chen LM, 2010, ARCH INTERN MED, V170, P340, DOI 10.1001/archinternmed.2009.511; Fisher E, 2010, HLTH SERV RES 2, V45, P1908; Fisher E, 2010, HEALTH SERV RES, V45, P1893, DOI 10.1111/j.1475-6773.2010.01186.x; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Juurlink D, 2006, CANADIAN I HLTH INFO; Krumholz HM, 2008, CIRCULATION, V118, P2596, DOI 10.1161/CIRCULATIONAHA.108.191099; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Landrum MB, 2008, HEALTH AFFAIR, V27, P159, DOI 10.1377/hlthaff.27.1.159; Lee DS, 2010, CIRCULATION, V122, P1806, DOI 10.1161/CIRCULATIONAHA.110.940262; Lee DS, 2003, CAN J CARDIOL, V19, P357; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; Lucas FL, 2006, CIRCULATION, V113, P374, DOI 10.1161/CIRCULATIONAHA.105.560433; Martin S, 2008, J HEALTH ECON, V27, P826, DOI 10.1016/j.jhealeco.2007.12.002; Meyerhardt JA, 2003, ANN INTERN MED, V139, P649, DOI 10.7326/0003-4819-139-8-200310210-00008; Morrison RS, 1998, ANN INTERN MED, V128, P1010, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00010; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025; Neuman MD, 2009, J AM GERIATR SOC, V57, P2046, DOI 10.1111/j.1532-5415.2009.02492.x; OECD, 2011, OECD HLTH DAT 2011; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Richards J, 2012, DATA QUALITY STUDY C; Romley JA, 2011, ANN INTERN MED, V154, P160, DOI 10.7326/0003-4819-154-3-201102010-00005; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Rothberg MB, 2010, HEALTH AFFAIR, V29, P1523, DOI 10.1377/hlthaff.2009.0287; Shortell SM, 2008, JAMA-J AM MED ASSOC, V300, P95, DOI 10.1001/jama.300.1.95; Silber JH, 2010, HEALTH SERV RES, V45, P1872, DOI 10.1111/j.1475-6773.2010.01180.x; Skinner J., 2012, HDB HLTH EC, V2, P45; Skinner J, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp1000448; Skinner JS, 2006, HEALTH AFFAIR, V25, pW34, DOI 10.1377/hlthaff.25.w34; StataCorp, 2009, STAT STAT SOFTW SE R; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Stukel TA, 2010, MED CARE, V48, P157, DOI 10.1097/MLR.0b013e3181bd4da7; Tourangeau AE, 2007, J ADV NURS, V57, P32, DOI 10.1111/j.1365-2648.2006.04084.x; Tu JV, 2008, CAN MED ASSOC J, V179, P909, DOI 10.1503/cmaj.080749; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Tu JV, 2001, JAMA-J AM MED ASSOC, V285, P3116, DOI 10.1001/jama.285.24.3116; Weinstein MC, 2010, NEW ENGL J MED, V362, P460, DOI 10.1056/NEJMsb0911104; Weller I, 2005, J BONE JOINT SURG BR, V87B, P361, DOI 10.1302/0301-620X.87B3.15300; World Health Organization, COUNTR; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566	52	104	105	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1037	1045		10.1001/jama.2012.265	http://dx.doi.org/10.1001/jama.2012.265			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GU	22416099	Green Accepted			2022-12-28	WOS:000301479700024
J	Druckman, JN; Lupia, A				Druckman, James N.; Lupia, Arthur			Experimenting with Politics	SCIENCE			English	Editorial Material							VOTER TURNOUT		[Druckman, James N.] Northwestern Univ, Dept Polit Sci, Evanston, IL 60208 USA; [Druckman, James N.] Northwestern Univ, Inst Policy Res, Evanston, IL 60208 USA; [Lupia, Arthur] Univ Michigan, Dept Polit Sci, Ann Arbor, MI 48104 USA; [Lupia, Arthur] Univ Michigan, Inst Social Res, Ann Arbor, MI 48104 USA	Northwestern University; Northwestern University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Druckman, JN (corresponding author), Northwestern Univ, Dept Polit Sci, Evanston, IL 60208 USA.	druckman@northwestern.edu; lupia@isr.umich.edu	Lupia, Arthur/A-8617-2009					Carpini MXD., 1997, WHAT AM KNOW POLITIC; Gerber AS, 2008, AM POLIT SCI REV, V102, P33, DOI 10.1017/S000305540808009X; Gerber AS, 2000, AM POLIT SCI REV, V94, P653, DOI 10.2307/2585837; Green D.P., 2008, GET OUT VOTE INCREAS, V2nd ed.; Guan M, 2006, COMP POLIT STUD, V39, P1175, DOI 10.1177/0010414005284377; Kuklinski JH, 1997, AM J POLIT SCI, V41, P402, DOI 10.2307/2111770; LODGE M, 1995, AM POLIT SCI REV, V89, P309, DOI 10.2307/2082427; Lowell AL, 1910, AM POLIT SCI REV, V4, P1, DOI 10.2307/1944407; Olken BA, 2010, AM POLIT SCI REV, V104, P243, DOI 10.1017/S0003055410000079; OSTROM E, 1992, AM POLIT SCI REV, V86, P404, DOI 10.2307/1964229; Ostrom E., 2011, CAMBRIDGE HDB EXPT P, P339; Prior M, 2008, AM J POLIT SCI, V52, P169, DOI 10.1111/j.1540-5907.2007.00306.x; Schuldt JP, 2011, PUBLIC OPIN QUART, V75, P115, DOI 10.1093/poq/nfq073; Sniderman P.M., 1991, REASONING CHOICE EXP; Sondheimer RachelMilstein., 2011, CAMBRIDGE HDB EXPT P, P494, DOI 10.1017/CBO9780511921452.034	15	19	19	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1177	1179		10.1126/science.1207808	http://dx.doi.org/10.1126/science.1207808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904VB	22403377				2022-12-28	WOS:000301225100029
J	Lalonde, K; Mucci, A; Ouellet, A; Gelinas, Y				Lalonde, Karine; Mucci, Alfonso; Ouellet, Alexandre; Gelinas, Yves			Preservation of organic matter in sediments promoted by iron	NATURE			English	Article							MARINE-SEDIMENTS; MINERAL SURFACES; SORPTION; METAL; SOIL	The biogeochemical cycles of iron and organic carbon are strongly interlinked. In oceanic waters, organic ligands have been shown to control the concentration of dissolved iron(1). In soils, solid iron phases shelter and preserve organic carbon(2), but the role of iron in the preservation of organic matter in sediments has not been clearly established. Here we use an iron reduction method previously applied to soils(3) to determine the amount of organic carbon associated with reactive iron phases in sediments of various mineralogies collected from a wide range of depositional environments. Our findings suggest that 21.5 +/- 8.6 per cent of the organic carbon in sediments is directly bound to reactive iron phases. We further estimate that a global mass of (19-45) x 10(15) grams of organic carbon is preserved in surface marine sediments as a result of its association with iron(4). We propose that these associations between organic carbon and iron, which are formed primarily through co-precipitation and/or direct chelation, promote the preservation of organic carbon in sediments. Because reactive iron phases are metastable over geological timescales, we suggest that they serve as an efficient 'rusty sink' for organic carbon, acting as a key factor in the long-term storage of organic carbon and thus contributing to the global cycles of carbon, oxygen and sulphur(5).	[Lalonde, Karine; Ouellet, Alexandre; Gelinas, Yves] Concordia Univ, GEOTOP, Montreal, PQ H4B 1R6, Canada; [Lalonde, Karine; Ouellet, Alexandre; Gelinas, Yves] Concordia Univ, Dept Chem & Biochem, Montreal, PQ H4B 1R6, Canada; [Mucci, Alfonso] McGill Univ, GEOTOP, Montreal, PQ H3A 2A7, Canada	Concordia University - Canada; Concordia University - Canada; McGill University	Gelinas, Y (corresponding author), Concordia Univ, GEOTOP, 7141 Sherbrooke St W, Montreal, PQ H4B 1R6, Canada.	ygelinas@alcor.concordia.ca	Gélinas, Yves/K-4019-2013	Gélinas, Yves/0000-0001-5751-8378; Mucci, Alfonso/0000-0001-9155-6319	NSERC; CFI; FQRNT	NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); CFI(Canada Foundation for Innovation); FQRNT(FQRNT)	This work is dedicated to the memory of J.I. Hedges; in addition to being an inspiration to Y.G., he provided several sediment samples used in this work. We thank H. T. Yan for surface area measurements and the captains and crews of RV Coriolis II for their help during sampling missions on the St Lawrence estuary. L. N. Barazzuol is also acknowledged for her work during the first phase of the project. This work was supported by grants (Y.G. and A.M.) and scholarships (K.L.) from NSERC, CFI and FQRNT. This is GEOTOP contribution no. 2012-0001.	Arnarson TS, 2007, GEOCHIM COSMOCHIM AC, V71, P3545, DOI 10.1016/j.gca.2007.04.027; BAAS BECKING L. G. M., 1959, Journal of Sedimentary Petrology, V29, P454; BERNER RA, 1970, AM J SCI, V268, P1, DOI 10.2475/ajs.268.1.1; Berner RA, 2003, NATURE, V426, P323, DOI 10.1038/nature02131; BOUDOT JP, 1989, SOIL BIOL BIOCHEM, V21, P961, DOI 10.1016/0038-0717(89)90088-6; Burdige D. J., 2006, GEOCHEMISTRY MARINE, V107, P108; Canfield DE, 1997, GEOCHIM COSMOCHIM AC, V61, P3349, DOI 10.1016/S0016-7037(97)00172-5; Deflandre B, 2002, GEOCHIM COSMOCHIM AC, V66, P2547, DOI 10.1016/S0016-7037(02)00861-X; Guggenberger G, 2003, GEODERMA, V113, P293, DOI 10.1016/S0016-7061(02)00366-X; Haese RR, 1997, GEOCHIM COSMOCHIM AC, V61, P63, DOI 10.1016/S0016-7037(96)00312-2; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; Hedges JI, 1997, ORG GEOCHEM, V27, P195, DOI 10.1016/S0146-6380(97)00066-1; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; Jones DL, 1998, SOIL BIOL BIOCHEM, V30, P1895, DOI 10.1016/S0038-0717(98)00060-1; Kaiser K, 2000, ORG GEOCHEM, V31, P711, DOI 10.1016/S0146-6380(00)00046-2; Kraemer SM, 2004, AQUAT SCI, V66, P3, DOI 10.1007/s00027-003-0690-5; MACKEY DJ, 1994, ANAL CHIM ACTA, V284, P635, DOI 10.1016/0003-2670(94)85068-2; Mayer LM, 1999, GEOCHIM COSMOCHIM AC, V63, P207, DOI 10.1016/S0016-7037(99)00028-9; MAYER LM, 1994, GEOCHIM COSMOCHIM AC, V58, P1271, DOI 10.1016/0016-7037(94)90381-6; MAYER LM, 1995, MAR CHEM, V49, P123, DOI 10.1016/0304-4203(95)00011-F; MEHRA O. P., 1960, Proceedings 7th nat. Conf. Clays, V5, P317; Poulton SW, 2005, CHEM GEOL, V218, P203, DOI 10.1016/j.chemgeo.2005.01.007; Ransom B, 1997, MAR GEOL, V138, P1, DOI 10.1016/S0025-3227(97)00012-1; RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L; SCHWERTMANN U, 1966, NATURE, V212, P645, DOI 10.1038/212645b0; van der Zee C, 2003, GEOLOGY, V31, P993, DOI 10.1130/G19924.1; Wagai R, 2007, GEOCHIM COSMOCHIM AC, V71, P25, DOI 10.1016/j.gca.2006.08.047; Wang XC, 1998, GEOCHIM COSMOCHIM AC, V62, P1365, DOI 10.1016/S0016-7037(98)00074-X	28	633	674	145	1105	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 8	2012	483	7388					198	200		10.1038/nature10855	http://dx.doi.org/10.1038/nature10855			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904DT	22398559	Green Accepted			2022-12-28	WOS:000301174900035
J	McCool, FD; Tzelepis, GE				McCool, F. Dennis; Tzelepis, George E.			Dysfunction of the Diaphragm	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY MUSCLE STRENGTH; VOLUME REDUCTION SURGERY; GUILLAIN-BARRE-SYNDROME; TERM-FOLLOW-UP; PHRENIC-NERVE; NEURALGIC AMYOTROPHY; INSPIRATORY MUSCLES; CLINICAL-FEATURES; CARDIAC-SURGERY		[McCool, F. Dennis] Brown Univ, Mem Hosp Rhode Isl, Dept Pulm Crit Care & Sleep Med, Pawtucket, RI 02860 USA; [McCool, F. Dennis] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Tzelepis, George E.] Univ Athens, Sch Med, Dept Physiol, GR-10679 Athens, Greece	Brown University; Brown University; Athens Medical School; National & Kapodistrian University of Athens	McCool, FD (corresponding author), Brown Univ, Mem Hosp Rhode Isl, Dept Pulm Crit Care & Sleep Med, 111 Brewster St, Pawtucket, RI 02860 USA.	f_mccool@brown.edu						Al-Bilbeisi F, 2000, AM J RESP CRIT CARE, V162, P456, DOI 10.1164/ajrccm.162.2.9908059; Alexander C, 1966, Clin Radiol, V17, P79, DOI 10.1016/S0009-9260(66)80128-9; AMBLER R, 1985, ARCH DIS CHILD, V60, P170, DOI 10.1136/adc.60.2.170; [Anonymous], 1999, CHEST, V116, P521; Bourke SC, 2002, EUR RESPIR J, V19, P1194, DOI 10.1183/09031936.02.01302001a; CHAN CK, 1988, ARCH PHYS MED REHAB, V69, P976; Chawla J, 2010, NEUROL CLIN, V28, P961, DOI 10.1016/j.ncl.2010.03.027; Chetta A, 2005, RESP MED, V99, P39, DOI 10.1016/j.rmed.2004.04.016; CICCOLELLA DE, 1992, AM REV RESPIR DIS, V146, P797, DOI 10.1164/ajrccm/146.3.797; Clausen MR, 1996, QJM-MON J ASSOC PHYS, V89, P631; Cohn D, 1997, J APPL PHYSIOL, V83, P291, DOI 10.1152/jappl.1997.83.1.291; Cosi V, 2006, NEUROL SCI, V27, pS47, DOI 10.1007/s10072-006-0548-4; Dahan V, 2006, ARCH PHYS MED REHAB, V87, P1352, DOI 10.1016/j.apmr.2006.07.256; DAVIS JN, 1976, Q J MED, V45, P87; DAVISON A, 1992, BMJ-BRIT MED J, V304, P492, DOI 10.1136/bmj.304.6825.492; DECRAMER M, 1989, EUR RESPIR J, V2, P299; DIEHL JL, 1994, J THORAC CARDIOV SUR, V107, P487, DOI 10.1016/S0022-5223(94)70094-X; DiMarco AF, 2009, J APPL PHYSIOL, V107, P662, DOI 10.1152/japplphysiol.00252.2009; EFTHIMIOU J, 1991, ANN THORAC SURG, V52, P1005, DOI 10.1016/0003-4975(91)91268-Z; Estenne M, 2009, J APPL PHYSIOL, V107, P977, DOI 10.1152/japplphysiol.91620.2008; Freeman RK, 2009, ANN THORAC SURG, V88, P1112, DOI 10.1016/j.athoracsur.2009.05.027; Gayan-Ramirez G, 2008, RESP MED, V102, P690, DOI 10.1016/j.rmed.2008.01.001; GIBSON GJ, 1989, THORAX, V44, P960, DOI 10.1136/thx.44.11.960; Gottesman E, 1997, AM J RESP CRIT CARE, V155, P1570, DOI 10.1164/ajrccm.155.5.9154859; Groth SS, 2010, ANN THORAC SURG, V89, pS2146, DOI 10.1016/j.athoracsur.2010.03.021; Hart N, 2002, AM J RESP CRIT CARE, V165, P1265, DOI 10.1164/rccm.2110016; HOUSTON JG, 1995, CLIN RADIOL, V50, P95, DOI 10.1016/S0009-9260(05)82987-3; HOWARD RS, 1992, BRAIN, V115, P479, DOI 10.1093/brain/115.2.479; Hughes PD, 1999, EUR RESPIR J, V13, P379, DOI 10.1183/09031936.99.13237999; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; KNOCHEL JP, 1982, AM J MED, V72, P521, DOI 10.1016/0002-9343(82)90522-8; Kumar N, 2004, MAYO CLIN PROC, V79, P1563, DOI 10.4065/79.12.1563; Laghi F, 2003, AM J RESP CRIT CARE, V168, P10, DOI 10.1164/rccm.2206020; Lahrmann H, 1999, MUSCLE NERVE, V22, P437, DOI 10.1002/(SICI)1097-4598(199904)22:4<437::AID-MUS2>3.3.CO;2-6; Lando Y, 1999, AM J RESP CRIT CARE, V159, P796, DOI 10.1164/ajrccm.159.3.9804055; LAROCHE CM, 1988, THORAX, V43, P170, DOI 10.1136/thx.43.3.170; LAROCHE CM, 1988, THORAX, V43, P583; LAROCHE CM, 1988, AM REV RESPIR DIS, V138, P862, DOI 10.1164/ajrccm/138.4.862; LAROCHE CM, 1989, THORAX, V44, P913, DOI 10.1136/thx.44.11.913; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Levine S, 2011, CRIT CARE MED, V39, P1844, DOI 10.1097/CCM.0b013e31821e85ca; LISBOA C, 1986, AM REV RESPIR DIS, V134, P488; LORING SH, 1982, J APPL PHYSIOL, V53, P756, DOI 10.1152/jappl.1982.53.3.756; MCCAULEY RGK, 1984, RADIOLOGY, V153, P33, DOI 10.1148/radiology.153.1.6473801; MCCOOL FD, 1989, AM REV RESPIR DIS, V139, P275, DOI 10.1164/ajrccm/139.1.275; MCPARLAND C, 1995, AM J RESP CRIT CARE, V151, P1101; Merino-Ramirez MA, 2006, J THORAC CARDIOV SUR, V132, P530, DOI 10.1016/j.jtcvs.2006.05.011; MIER A, 1989, THORAX, V44, P990, DOI 10.1136/thx.44.12.990; MIER AK, 1986, BRIT MED J, V292, P1495, DOI 10.1136/bmj.292.6534.1495; MIERJEDRZEJOWICZ A, 1988, AM REV RESPIR DIS, V137, P877, DOI 10.1164/ajrccm/137.4.877; Mills GH, 1997, AM J RESP CRIT CARE, V155, P1565, DOI 10.1164/ajrccm.155.5.9154858; Mouroux J, 2005, ANN THORAC SURG, V79, P308, DOI 10.1016/j.athoracsur.2004.06.050; O'Donnell Denis E, 2006, Proc Am Thorac Soc, V3, P180, DOI 10.1513/pats.200508-093DO; Onders RP, 2009, SURG ENDOSC, V23, P1433, DOI 10.1007/s00464-008-0223-3; Oo T, 1999, SPINAL CORD, V37, P117, DOI 10.1038/sj.sc.3100775; PIEHLER JM, 1982, J THORAC CARDIOV SUR, V84, P861; POLKEY MI, 1995, THORAX, V50, P1131, DOI 10.1136/thx.50.11.1131; SAADEH PB, 1993, MUSCLE NERVE, V16, P15, DOI 10.1002/mus.880160105; Salati M, 2010, J THORAC CARDIOV SUR, V139, pE77, DOI 10.1016/j.jtcvs.2008.06.051; SKATRUD J, 1980, AM REV RESPIR DIS, V121, P587, DOI 10.1164/arrd.1980.121.3.587; Steier J, 2008, EUR RESPIR J, V32, P1479, DOI 10.1183/09031936.00018808; Steier J, 2007, THORAX, V62, P975, DOI 10.1136/thx.2006.072884; STRADLING JR, 1988, THORAX, V43, P75, DOI 10.1136/thx.43.1.75; Summerhill EM, 2008, CHEST, V133, P737, DOI 10.1378/chest.07-2200; TSAIRIS P, 1972, ARCH NEUROL-CHICAGO, V27, P109, DOI 10.1001/archneur.1972.00490140013004; TZELEPIS G, 1988, J APPL PHYSIOL, V64, P1796, DOI 10.1152/jappl.1988.64.5.1796; van Doorn PA, 2008, LANCET NEUROL, V7, P939, DOI 10.1016/S1474-4422(08)70215-1; WHEELER WE, 1985, CHEST, V88, P680, DOI 10.1378/chest.88.5.680; WICKS AB, 1986, CHEST, V90, P406, DOI 10.1378/chest.90.3.406; WILCOX PG, 1989, LUNG, V167, P323, DOI 10.1007/BF02714961; Witoonpanich R, 2010, CLIN TOXICOL, V48, P177, DOI 10.3109/15563651003596113	71	230	258	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					932	942		10.1056/NEJMra1007236	http://dx.doi.org/10.1056/NEJMra1007236			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397655				2022-12-28	WOS:000301172500010
J	Bhasin, S; Travison, TG; Storer, TW; Lakshman, K; Kaushik, M; Mazer, NA; Ngyuen, AH; Davda, MN; Jara, H; Aakil, A; Anderson, S; Knapp, PE; Hanka, S; Mohammed, N; Daou, P; Miciek, R; Ulloor, J; Zhang, AQ; Brooks, B; Orwoll, K; Hede-Brierley, L; Eder, R; Elmi, A; Bhasin, G; Collins, L; Singh, R; Basaria, S				Bhasin, Shalender; Travison, Thomas G.; Storer, Thomas W.; Lakshman, Kishore; Kaushik, Manas; Mazer, Norman A.; Ngyuen, Ahn-Hoa; Davda, Maithili N.; Jara, Hernan; Aakil, Adam; Anderson, Stephan; Knapp, Philip E.; Hanka, Samson; Mohammed, Nurahmed; Daou, Pierre; Miciek, Renee; Ulloor, Jagadish; Zhang, Anqi; Brooks, Brad; Orwoll, Katie; Hede-Brierley, Leife; Eder, Richard; Elmi, Ayan; Bhasin, Geeta; Collins, Lauren; Singh, Ravinder; Basaria, Shehzad			Effect of Testosterone Supplementation With and Without a Dual 5 alpha-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENIGN PROSTATIC HYPERPLASIA; BONE-MINERAL DENSITY; PLACEBO-CONTROLLED TRIAL; HEALTHY-YOUNG MEN; STEROID 5-ALPHA-REDUCTASE; OLDER MEN; SERUM TESTOSTERONE; SKELETAL-MUSCLE; TRANSDERMAL DIHYDROTESTOSTERONE; MALE PSEUDOHERMAPHRODITISM	Context Steroid 5 alpha-reductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the role of 5 alpha-dihydrotestosterone (DHT) in mediating testosterone's effects on muscle, sexual function, erythropoiesis, and other androgen-dependent processes remains poorly understood. Objective To determine whether testosterone's effects on muscle mass, strength, sexual function, hematocrit level, prostate volume, sebum production, and lipid levels are attenuated when its conversion to DHT is blocked by dutasteride (an inhibitor of 5 alpha-reductase type 1 and 2). Design, Setting, and Patients The 5 alpha-Reductase Trial was a randomized controlled trial of healthy men aged 18 to 50 years comparing placebo plus testosterone enthanate with dutasteride plus testosterone enanthate from May 2005 through June 2010. Interventions Eight treatment groups received 50, 125, 300, or 600 mg/wk of testosterone enanthate for 20 weeks plus placebo (4 groups) or 2.5 mg/d of dutasteride (4 groups). Main Outcome Measures The primary outcome was change in fat-free mass; secondary outcomes: changes in fat mass, muscle strength, sexual function, prostate volume, sebum production, and hematocrit and lipid levels. Results A total of 139 men were randomized; 102 completed the 20-week intervention. Men assigned to dutasteride were similar at baseline to those assigned to placebo. The mean fat-free mass gained by the dutasteride groups was 0.6 kg (95% CI, -0.1 to 1.2 kg) when receiving 50 mg/wk of testosterone enanthate, 2.6 kg (95% CI, 0.9 to 4.3 kg) for 125 mg/wk, 5.8 kg (95% CI, 4.8 to 6.9 kg) for 300 mg/wk, and 7.1 kg (95% CI, 6.0 to 8.2 kg) for 600 mg/wk. The mean fat-free mass gained by the placebo groups was 0.8 kg (95% CI, -0.1 to 1.7 kg) when receiving 50 mg/wk of testosterone enanthate, 3.5 kg (95% CI, 2.1 to 4.8 kg) for 125 mg/wk, 5.7 kg (95% CI, 4.8 to 6.5 kg) for 300 mg/wk, and 8.1 kg (95% CI, 6.7 to 9.5 kg) for 600 mg/wk. The dose-adjusted differences between the dutasteride and placebo groups for fat-free mass were not significant (P=.18). Changes in fat mass, muscle strength, sexual function, prostate volume, sebum production, and hematocrit and lipid levels did not differ between groups. Conclusion Changes in fat-free mass in response to graded testosterone doses did not differ in men in whom DHT was suppressed by dutasteride from those treated with placebo, indicating that conversion of testosterone to DHT is not essential for mediating its anabolic effects on muscle.	[Bhasin, Shalender; Travison, Thomas G.; Storer, Thomas W.; Lakshman, Kishore; Kaushik, Manas; Mazer, Norman A.; Ngyuen, Ahn-Hoa; Davda, Maithili N.; Knapp, Philip E.; Hanka, Samson; Mohammed, Nurahmed; Daou, Pierre; Miciek, Renee; Ulloor, Jagadish; Zhang, Anqi; Brooks, Brad; Orwoll, Katie; Hede-Brierley, Leife; Eder, Richard; Elmi, Ayan; Bhasin, Geeta; Collins, Lauren; Basaria, Shehzad] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA; [Jara, Hernan; Aakil, Adam; Anderson, Stephan] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA; [Travison, Thomas G.] Boston Univ, Sch Publ Hlth, Boston Med Ctr, Boston, MA 02118 USA; [Travison, Thomas G.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Singh, Ravinder] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Clin Biochem & Immunol, Rochester, MN USA	Boston University; Boston University; Boston Medical Center; Boston University; Boston University; Mayo Clinic	Bhasin, S (corresponding author), Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, 670 Albany St, Boston, MA 02118 USA.	bhasin@bu.edu	Mazer, Norman A/HGU-8266-2022	Zhang, Anqi/0000-0003-3723-8293; Knapp, Philip/0000-0002-5290-6125; Jara, Hernan/0000-0001-6395-3819; Basaria, Shehzad/0000-0002-8533-2383; Daou, Pierre/0000-0002-2713-5381; Basaria, Shehzad/0000-0003-1749-8549	Solvay Pharmaceuticals; Merck Co; Ligand Pharmaceuticals Inc; GlaxoSmithKline; Novartis; Lilly and Co; Ligand Pharmaceuticals; National Institute of Child Health and Human Development [1RO1HD043348]; Boston University Clinical and Translational Science Institute [1UL1RR025771]; Boston Claude D. Pepper Older Americans Independence Center; National Institute on Aging [5P30AG031679]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043348] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679] Funding Source: NIH RePORTER	Solvay Pharmaceuticals(Solvay SA); Merck Co(Merck & Company); Ligand Pharmaceuticals Inc; GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Lilly and Co; Ligand Pharmaceuticals; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Boston University Clinical and Translational Science Institute; Boston Claude D. Pepper Older Americans Independence Center; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr S. Bhasin reported board membership for Novartis, working as a consultant to GlaxoSmithKline, having grants pending with Solvay Pharmaceuticals, Merck & Co, and Ligand Pharmaceuticals Inc, receiving reimbursement for travel expenses from GlaxoSmithKline, Novartis, Lilly and Co, and Ligand Pharmaceuticals, and receiving compensation for serving as the chair for 2 Endocrine Society expert panels. No other author reported disclosures.; This study was supported by grant 1RO1HD043348 from the National Institute of Child Health and Human Development. Additional support was provided by Boston University Clinical and Translational Science Institute grant 1UL1RR025771, by the Boston Claude D. Pepper Older Americans Independence Center, and by grant 5P30AG031679 from the National Institute on Aging. GlaxoSmithKline Inc provided dutasteride and placebo and ENDO Pharmaceuticals provided testosterone enanthate.	Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003-031110; Amory JK, 2008, J UROLOGY, V179, P2333, DOI 10.1016/j.juro.2008.01.145; Anderson RA, 1999, J CLIN ENDOCR METAB, V84, P3556, DOI 10.1210/jc.84.10.3556; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; BARTSCH W, 1980, J STEROID BIOCHEM, V13, P259, DOI 10.1016/0022-4731(80)90003-5; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004-1184; Bhasin S, 2006, NAT CLIN PRACT ENDOC, V2, P146, DOI 10.1038/ncpendmet0120; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Bhasin S, 2011, J CLIN ENDOCR METAB, V96, P2430, DOI 10.1210/jc.2010-3012; Borst SE, 2007, AM J PHYSIOL-ENDOC M, V293, pE507, DOI 10.1152/ajpendo.00130.2007; Canguven O, 2008, J ANDROL, V29, P514, DOI 10.2164/jandrol.108.005025; Clark RV, 2004, J CLIN ENDOCR METAB, V89, P2179, DOI 10.1210/jc.2003-030330; CUNNINGHAM GR, 1995, J CLIN ENDOCR METAB, V80, P1934, DOI 10.1210/jc.80.6.1934; DIANI AR, 1992, J CLIN ENDOCR METAB, V74, P345, DOI 10.1210/jc.74.2.345; Farraher SW, 2005, RADIOLOGY, V237, P322, DOI 10.1148/radiol.2371041416; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; Idan A, 2010, ANN INTERN MED, V153, P621, DOI 10.7326/0003-4819-153-10-201011160-00004; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLEY J, 1985, ENDOCRINOLOGY, V116, P807, DOI 10.1210/endo-116-2-807; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; Kim J, 2002, AM J CLIN NUTR, V76, P378, DOI 10.1093/ajcn/76.2.378; Kunelius P, 2002, J CLIN ENDOCR METAB, V87, P1467, DOI 10.1210/jc.87.4.1467; LUGG JA, 1995, ENDOCRINOLOGY, V136, P1495, DOI 10.1210/en.136.4.1495; Ly LP, 2001, J CLIN ENDOCR METAB, V86, P4078, DOI 10.1210/jc.86.9.4078; Mahendroo MS, 2001, ENDOCRINOLOGY, V142, P4652, DOI 10.1210/en.142.11.4652; Marberger M, 2006, J CLIN ENDOCR METAB, V91, P1323, DOI 10.1210/jc.2005-1947; Marks LS, 2006, JAMA-J AM MED ASSOC, V296, P2351, DOI 10.1001/jama.296.19.2351; Matsumoto AM, 2002, J UROLOGY, V167, P2105, DOI 10.1016/S0022-5347(05)65095-1; Mazer NA, 2009, STEROIDS, V74, P512, DOI 10.1016/j.steroids.2009.01.008; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; PALATSI R, 1984, ACTA DERM-VENEREOL, V64, P517; Pierard G, 1992, Eur J Med, V1, P109; Rittmaster R, 2008, UROLOGY, V72, P808, DOI 10.1016/j.urology.2008.06.032; Roehrborn CG, 2002, UROLOGY, V60, P434, DOI 10.1016/S0090-4295(02)01905-2; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rosen RC, 2004, UROLOGY, V64, P777, DOI 10.1016/j.urology.2004.04.056; Shaw G, 2006, ENDOCRINOLOGY, V147, P2368, DOI 10.1210/en.2005-1251; Shiraishi S, 2008, CLIN CHEM, V54, P1855, DOI 10.1373/clinchem.2008.103846; Sobel V, 2006, J CLIN ENDOCR METAB, V91, P3017, DOI 10.1210/jc.2005-2809; Storer TW, 2003, J CLIN ENDOCR METAB, V88, P1478, DOI 10.1210/jc.2002-021231; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; Wilson JD, 2009, REPROD FERT DEVELOP, V21, P649, DOI 10.1071/RD08253; Wilton L, 1996, BRIT J UROL, V78, P379, DOI 10.1046/j.1464-410X.1996.00091.x; Wurzel R, 2007, PROSTATE CANCER P D, V10, P149, DOI 10.1038/sj.pcan.4500931	48	107	110	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					931	939		10.1001/jama.2012.227	http://dx.doi.org/10.1001/jama.2012.227			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396515	Green Accepted, Bronze			2022-12-28	WOS:000301172100021
J	Coombes, R				Coombes, Rebecca			ROUND TABLE After the bill, what next?	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmj.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1661	10.1136/bmj.e1661	http://dx.doi.org/10.1136/bmj.e1661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399708				2022-12-28	WOS:000301479800019
J	Ormiston, JA; Webster, MWI				Ormiston, John A.; Webster, Mark W. I.			Stent thrombosis: has the firestorm been extinguished?	LANCET			English	Editorial Material							DRUG-ELUTING STENTS; BARE-METAL STENTS; TRIALS; SAFETY		[Ormiston, John A.] Mercy Angiog Mercy Hosp, Auckland, New Zealand; [Webster, Mark W. I.] Auckland City Hosp, Auckland, New Zealand	Auckland City Hospital	Ormiston, JA (corresponding author), Mercy Angiog Mercy Hosp, POB 9911, Auckland, New Zealand.	johno@mercyangiography.co.nz						Camenzind E, 2007, CIRCULATION, V115, P1440, DOI 10.1161/CIRCULATIONAHA.106.666800; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6; James SK, 2009, NEW ENGL J MED, V360, P1933, DOI 10.1056/NEJMoa0809902; Kolandaivelu K, 2011, CIRCULATION, V123, P1400, DOI 10.1161/CIRCULATIONAHA.110.003210; Lagerqvist B, 2007, NEW ENGL J MED, V356, P1009, DOI 10.1056/NEJMoa067722; Nakazawa G, 2011, J AM COLL CARDIOL, V57, P1314, DOI 10.1016/j.jacc.2011.01.011; Nordmann AJ, 2006, EUR HEART J, V27, P2784, DOI 10.1093/eurheartj/ehl282; Palmerini T, 2012, LANCET, V379, P1393, DOI 10.1016/S0140-6736(12)60324-9; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; Pocock SJ, 2007, LANCET, V370, P2099, DOI 10.1016/S0140-6736(07)61898-4; Spaulding C, 2007, NEW ENGL J MED, V356, P989, DOI 10.1056/NEJMoa066633	12	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2012	379	9824					1368	1369		10.1016/S0140-6736(12)60440-1	http://dx.doi.org/10.1016/S0140-6736(12)60440-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926BR	22445240				2022-12-28	WOS:000302806800006
J	Konstantinopoulos, PA; Awtrey, CS				Konstantinopoulos, Panagiotis A.; Awtrey, Christopher S.			Management of Ovarian Cancer A 75-Year-Old Woman Who Has Completed Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED PHASE-III; CARBOPLATIN PLUS PACLITAXEL; GERMLINE MUTATIONS; 1ST-LINE TREATMENT; STAGE-III; SURGICAL CYTOREDUCTION; INTRAPERITONEAL CISPLATIN; NEOADJUVANT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; PROGNOSTIC-FACTORS	Ovarian cancer includes primary tumors of epithelial, sex cord-stromal, or germ cell origin as well as metastatic tumors that frequently originate in the gastrointestinal tract. Approximately 90% of ovarian cancer is epithelial in origin and constitutes a major therapeutic challenge because of its advanced stage of presentation in most patients. Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States, with approximately 1 in 70 women developing this disease in their lifetime. Several important advances in surgical and medical management of this disease have led to prolongation of survival and improvement of quality of life of patients with ovarian cancer. Using the case of Ms W, we discuss the signs, symptoms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgical and postoperative medical management; and present the current recommendations for screening and follow-up. JAMA. 2012;307(13):1420-1429	[Konstantinopoulos, Panagiotis A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Gynecol Med Oncol, Boston, MA 02215 USA; [Awtrey, Christopher S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Obstet, Boston, MA 02215 USA; [Awtrey, Christopher S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Gynecol, Boston, MA 02215 USA; [Awtrey, Christopher S.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Konstantinopoulos, PA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Gynecol Med Oncol, 227 Feldberg,East Campus, Boston, MA 02215 USA.	pkonstan@bidmc.harvard.edu						Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bankhead CR, 2008, BJOG-INT J OBSTET GY, V115, P1008, DOI 10.1111/j.1471-0528.2008.01772.x; Basen-Engquist K, 2001, J CLIN ONCOL, V19, P1809, DOI 10.1200/JCO.2001.19.6.1809; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; Bell J, 2006, GYNECOL ONCOL, V102, P432, DOI 10.1016/j.ygyno.2006.06.013; Berek J, 2009, J CLIN ONCOL, V27, P418, DOI 10.1200/JCO.2008.17.8400; Bonadona V, 2011, JAMA-J AM MED ASSOC, V305, P2304, DOI 10.1001/jama.2011.743; Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Cannistra SA, 2006, NEW ENGL J MED, V354, P77, DOI 10.1056/NEJMe058308; Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814; Chan JK, 2008, CANCER-AM CANCER SOC, V112, P2202, DOI 10.1002/cncr.23390; Chi DS, 2008, GYNECOL ONCOL, V108, P191, DOI 10.1016/j.ygyno.2007.09.020; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; Cohn DE, 2011, J CLIN ONCOL, V29, P1247, DOI 10.1200/JCO.2010.32.1075; De Placido S, 2004, J CLIN ONCOL, V22, P2635, DOI 10.1200/JCO.2004.09.088; du Bois A, 2006, J CLIN ONCOL, V24, P1127, DOI 10.1200/JCO.2005.03.2938; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; du Bois A, 2010, J CLIN ONCOL, V28, P4162, DOI 10.1200/JCO.2009.27.4696; Earle CC, 2006, J NATL CANCER I, V98, P172, DOI 10.1093/jnci/djj019; Edge SB, 2009, AJCC CANC STAGING MA, V7; Eisenhauer EL, 2008, GYNECOL ONCOL, V108, P276, DOI 10.1016/j.ygyno.2007.10.022; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Giede KC, 2005, GYNECOL ONCOL, V99, P447, DOI 10.1016/j.ygyno.2005.07.008; Goff BA, 2004, JAMA-J AM MED ASSOC, V291, P2705, DOI 10.1001/jama.291.22.2705; GRANBERG S, 1989, GYNECOL ONCOL, V35, P139, DOI 10.1016/0090-8258(89)90031-0; Grzankowski KS, 2011, CANCER CONTROL, V18, P52; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoskins P, 2010, J NATL CANCER I, V102, P1547, DOI 10.1093/jnci/djq362; Hou JY, 2007, GYNECOL ONCOL, V105, P211, DOI 10.1016/j.ygyno.2006.11.025; HOWELL SB, 1983, CANCER RES, V43, P1426; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Ketabi Z, 2011, GYNECOL ONCOL, V121, P462, DOI 10.1016/j.ygyno.2011.02.010; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; KING ME, 1984, J CLIN ONCOL, V2, P662, DOI 10.1200/JCO.1984.2.6.662; Kinkel K, 2000, RADIOLOGY, V217, P803, DOI 10.1148/radiology.217.3.r00dc20803; Kinkel K, 2005, RADIOLOGY, V236, P85, DOI 10.1148/radiol.2361041618; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; LAVIN PT, 1987, OBSTET GYNECOL, V69, P223; Liu JZ, 2007, EUR J RADIOL, V62, P328, DOI 10.1016/j.ejrad.2007.02.040; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Markman M, 2003, J CLIN ONCOL, V21, P2460, DOI 10.1200/JCO.2003.07.013; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Medeiros LR, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.031; Medeiros LR, 2009, INT J GYNECOL CANCER, V19, P230, DOI 10.1111/IGC.0b013e31819c1369; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Meinhold-Heerlein I, 2005, ONCOGENE, V24, P1053, DOI 10.1038/sj.onc.1208298; Menon U, 2009, LANCET ONCOL, V10, P327, DOI 10.1016/S1470-2045(09)70026-9; Moore RG, 2008, GYNECOL ONCOL, V108, P402, DOI 10.1016/j.ygyno.2007.10.017; Morgan RJ, 2011, J NATL COMPR CANC NE, V9, P82, DOI 10.6004/jnccn.2011.0008; Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pfisterer J, 2011, J CLIN ONCOL S, V29, plba5002; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Piccart MJ, 2003, INT J GYNECOL CANCER, V13, P196, DOI 10.1111/j.1525-1438.2003.13360.x; Pignata S, 2011, J CLIN ONCOL, V29, P3628, DOI 10.1200/JCO.2010.33.8566; Riedinger JM, 2006, ANN ONCOL, V17, P1234, DOI 10.1093/annonc/mdl120; Rose PG, 2004, NEW ENGL J MED, V351, P2489, DOI 10.1056/NEJMoa041125; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8; Schindler AE, 2011, GYNECOL ENDOCRINOL, V27, P1043, DOI 10.3109/09513590.2011.569788; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THIGPEN JT, 1989, SEMIN ONCOL, V16, P58; THIGPEN JT, 1994, J CLIN ONCOL, V12, P1748, DOI 10.1200/JCO.1994.12.9.1748; Thrall MM, 2011, OBSTET GYNECOL, V118, P537, DOI 10.1097/AOG.0b013e31822a6d56; Trimbos JB, 2003, JNCI-J NATL CANCER I, V95, P105; Tsilidis KK, 2011, BRIT J CANCER, V105, P1436, DOI 10.1038/bjc.2011.371; US Preventive Services Task Force, GRADE DEF; van Nagell JR, 1999, CURR OPIN OBSTET GYN, V11, P45, DOI 10.1097/00001703-199901000-00009; VANDERBURG MEL, 1995, NEW ENGL J MED, V332, P629, DOI 10.1056/NEJM199503093321002; Varia MA, 2003, J CLIN ONCOL, V21, P2849, DOI 10.1200/JCO.2003.11.018; Vasey PA, 2004, JNCI-J NATL CANCER I, V96, P1682, DOI 10.1093/jnci/djh323; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; WHITTEMORE AS, 1994, GYNECOL ONCOL, V55, pS15, DOI 10.1006/gyno.1994.1334; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Winter WE, 2008, J CLIN ONCOL, V26, P83, DOI 10.1200/JCO.2007.13.1953; Winter WE, 2007, J CLIN ONCOL, V25, P3621, DOI 10.1200/JCO.2006.10.2517; Young RC, 2003, J CLIN ONCOL, V21, P4350, DOI 10.1200/JCO.2003.02.154; Young RC, 2003, JNCI-J NATL CANCER I, V95, P94, DOI 10.1093/jnci/95.2.94; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; Zhang SY, 2011, GYNECOL ONCOL, V121, P353, DOI 10.1016/j.ygyno.2011.01.020	91	8	8	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2012	307	13					1420	1429		10.1001/jama.2012.269	http://dx.doi.org/10.1001/jama.2012.269			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919AY	22396438				2022-12-28	WOS:000302294200029
J	Sanada, T; Kim, M; Mimuro, H; Suzuki, M; Ogawa, M; Oyama, A; Ashida, H; Kobayashi, T; Koyama, T; Nagai, S; Shibata, Y; Gohda, J; Inoue, J; Mizushima, T; Sasakawa, C				Sanada, Takahito; Kim, Minsoo; Mimuro, Hitomi; Suzuki, Masato; Ogawa, Michinaga; Oyama, Akiho; Ashida, Hiroshi; Kobayashi, Taira; Koyama, Tomohiro; Nagai, Shinya; Shibata, Yuri; Gohda, Jin; Inoue, Jun-ichiro; Mizushima, Tsunehiro; Sasakawa, Chihiro			The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response	NATURE			English	Article							NF-KAPPA-B; CRYSTAL-STRUCTURES; PROTEIN; KINASE; ACTIVATION; HOST; TRAF6; INVASION; BACTERIA; DOMAIN	Many bacterial pathogens can enter various host cells and then survive intracellularly, transiently evade humoral immunity, and further disseminate to other cells and tissues. When bacteria enter host cells and replicate intracellularly, the host cells sense the invading bacteria as damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) by way of various pattern recognition receptors. As a result, the host cells induce alarm signals that activate the innate immune system(1). Therefore, bacteria must modulate host inflammatory signalling and dampen these alarm signals(2-4.) How pathogens do this after invading epithelial cells remainsunclear, however. Herewe showthat OspI, a Shigella flexneri effector encoded by ORF169b on the large plasmid and delivered by the type III secretion system, dampens acute inflammatory responses during bacterial invasion by suppressing the tumour-necrosis factor (TNF)-receptor-associated factor 6 (TRAF6)-mediated signalling pathway. OspI is a glutamine deamidase that selectively deamidates the glutamine residue at position 100 in UBC13 to a glutamic acid residue. Consequently, the E2 ubiquitin-conjugating activity required for TRAF6 activation is inhibited, allowing S. flexneri OspI to modulate the diacylglycerolCBM (CARD-BCL10-MALT1) complex-TRAF6-nuclear-factorkB signalling pathway. We determined the 2.0 angstrom crystal structure of OspI, which contains a putative cysteine-histidine-aspartic acid catalytic triad. A mutational analysis showed this catalytic triad to be essential for the deamidation of UBC13. Our results suggest that S. flexneri inhibits acute inflammatory responses in the initial stage of infection by targeting the UBC13-TRAF6 complex.	[Sanada, Takahito; Kim, Minsoo; Sasakawa, Chihiro] Univ Tokyo, Dept Infect Dis Control, Int Res Ctr Infect Dis, Minato Ku, Tokyo 1088639, Japan; [Mimuro, Hitomi] Univ Tokyo, Int Res Ctr Infect Dis, Dept Infect Dis Control, Div Bacteriol,Minato Ku, Tokyo 1088639, Japan; [Suzuki, Masato; Ogawa, Michinaga; Oyama, Akiho; Ashida, Hiroshi; Kobayashi, Taira; Sasakawa, Chihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Bacterial Infect,Minato Ku, Tokyo 1088639, Japan; [Koyama, Tomohiro; Nagai, Shinya; Sasakawa, Chihiro] Nippon Inst Biol Sci, Tokyo 1980024, Japan; [Shibata, Yuri; Gohda, Jin; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; [Mizushima, Tsunehiro] Univ Hyogo, Grad Sch Life Sci, Dept Life Sci, Picobiol Inst, Akoh, Hyogo 6781297, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Hyogo	Sasakawa, C (corresponding author), Univ Tokyo, Dept Infect Dis Control, Int Res Ctr Infect Dis, Minato Ku, Tokyo 1088639, Japan.	mizushi@sci.u-hyogo.ac.jp; sasakawa@ims.u-tokyo.ac.jp	Kobayashi, Taira/GQA-7087-2022; Suzuki, Masato/B-7568-2013; Kobayashi, Taira/B-1149-2014; Kobayashi, Taira/AAH-5580-2020	Suzuki, Masato/0000-0001-8975-2193; Kobayashi, Taira/0000-0001-7297-8524; Ashida, Hiroshi/0000-0003-1408-6864; Kim, Minsoo/0000-0001-8536-8653; Mizushima, Tsunehiro/0000-0002-6631-2889	Japan Initiative for Global Research Network on Infectious Diseases; Naito Foundation; Waksman Foundation of Japan; Yakult Bio-Science Foundation; Yakult Central Institute; Hayashi Memorial Foundation for Female Natural Scientists;  [23121525];  [23000012];  [23689027];  [23790471];  [23790472];  [22790403];  [23390102];  [23659220];  [18073003]; Grants-in-Aid for Scientific Research [22117002] Funding Source: KAKEN	Japan Initiative for Global Research Network on Infectious Diseases(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Waksman Foundation of Japan(Waksman Foundation of Japan Inc.); Yakult Bio-Science Foundation; Yakult Central Institute; Hayashi Memorial Foundation for Female Natural Scientists(Hayashi Memorial Foundation for Female Natural Scientists); ; ; ; ; ; ; ; ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H. Fukuda for matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) analysis. We thank the members of the Sasakawa laboratory for their advice. We are grateful to R. Whittier for critical reading of the manuscript. Diffraction data were collected at the Osaka University beamline BL44XU at SPring-8. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas (23121525 (T. M.)), a Grant-in-Aid for Specially Promoted Research (23000012 (C. S.)), a Grant-in Aid for Young Scientists (A) (23689027 (M. K.)), several Grants-in-Aid for Young Scientists (B) (23790471 (M.O.), 23790472 (H. A.) and 22790403 (T. S.)), a Grant-in-Aid for Scientific Research (B) (23390102 (H. M.)), a Grant-in-Aid for Challenging Exploratory Research (23659220 (H. M.)), a Grant-in-Aid for Scientific Research on Priority Areas (18073003 (C. S.)) and the Japan Initiative for Global Research Network on Infectious Diseases (C. S.). Part of this work was supported by grants from the Naito Foundation (M. K. and H. M.), the Waksman Foundation of Japan (M.O.), the Yakult Bio-Science Foundation (M.O.), the Yakult Central Institute (C. S.) and The Hayashi Memorial Foundation for Female Natural Scientists (M. K.).	Ashida H, 2012, NAT CHEM BIOL, V8, P36, DOI 10.1038/nchembio.741; Ashida H, 2011, J CELL BIOL, V195, P931, DOI 10.1083/jcb.201108081; Ashida H, 2010, NAT CELL BIOL, V12, P66, DOI 10.1038/ncb2006; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Buetow L, 2001, NAT STRUCT BIOL, V8, P584, DOI 10.1038/89610; Crow A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005582; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dupont N, 2009, CELL HOST MICROBE, V6, P137, DOI 10.1016/j.chom.2009.07.005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fukushima T, 2007, P NATL ACAD SCI USA, V104, P6371, DOI 10.1073/pnas.0700548104; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Hilbi H, 2009, CELL HOST MICROBE, V6, P102, DOI 10.1016/j.chom.2009.08.001; Holden NS, 2008, CELL SIGNAL, V20, P1338, DOI 10.1016/j.cellsig.2008.03.001; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kim M, 2010, CELL HOST MICROBE, V8, P20, DOI 10.1016/j.chom.2010.06.006; Kim M, 2009, NATURE, V459, P578, DOI 10.1038/nature07952; Kitadokoro K, 2007, P NATL ACAD SCI USA, V104, P5139, DOI 10.1073/pnas.0608197104; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Mattoo S, 2007, CURR OPIN IMMUNOL, V19, P392, DOI 10.1016/j.coi.2007.06.005; McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281; Morikawa H, 2010, BIOCHEM BIOPH RES CO, V401, P268, DOI 10.1016/j.bbrc.2010.09.048; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; Rahman MM, 2011, NAT REV MICROBIOL, V9, P291, DOI 10.1038/nrmicro2539; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; SASAKAWA C, 1986, INFECT IMMUN, V54, P32, DOI 10.1128/IAI.54.1.32-36.1986; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shahnazari S, 2010, CELL HOST MICROBE, V8, P137, DOI 10.1016/j.chom.2010.07.002; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Taxman DJ, 2010, CELL HOST MICROBE, V8, P7, DOI 10.1016/j.chom.2010.06.005; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YL, 2007, NUCLEIC ACIDS RES, V35, pD298, DOI 10.1093/nar/gkl952; Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605; Zhu MF, 2004, P NATL ACAD SCI USA, V101, P302, DOI 10.1073/pnas.2036536100	45	120	124	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 29	2012	483	7391					623	U149		10.1038/nature10894	http://dx.doi.org/10.1038/nature10894			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915EF	22407319				2022-12-28	WOS:000302006100044
J	Stouffer, DB; Sales-Pardo, M; Sirer, MI; Bascompte, J				Stouffer, Daniel B.; Sales-Pardo, Marta; Sirer, M. Irmak; Bascompte, Jordi			Evolutionary Conservation of Species' Roles in Food Webs	SCIENCE			English	Article							TROPHIC MODULES; NETWORKS; STABILITY; ARCHITECTURE; PERSISTENCE; COMPLEXITY; LIFE	Studies of ecological networks (the web of interactions between species in a community) demonstrate an intricate link between a community's structure and its long-term viability. It remains unclear, however, how much a community's persistence depends on the identities of the species present, or how much the role played by each species varies as a function of the community in which it is found. We measured species' roles by studying how species are embedded within the overall network and the subsequent dynamic implications. Using data from 32 empirical food webs, we find that species' roles and dynamic importance are inherent species attributes and can be extrapolated across communities on the basis of taxonomic classification alone. Our results illustrate the variability of roles across species and communities and the relative importance of distinct species groups when attempting to conserve ecological communities.	[Stouffer, Daniel B.; Bascompte, Jordi] EBD CSIC, Integrat Ecol Grp, Seville 41092, Spain; [Stouffer, Daniel B.] Univ Canterbury, Sch Biol Sci, Christchurch 8140, New Zealand; [Sales-Pardo, Marta] Univ Rovira & Virgili, Dept Engn Quim, Tarragona 43007, Spain; [Sirer, M. Irmak] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); University of Canterbury; Universitat Rovira i Virgili; Northwestern University	Stouffer, DB (corresponding author), EBD CSIC, Integrat Ecol Grp, Seville 41092, Spain.		Sales-Pardo, Marta/O-9797-2019; Sales-Pardo, Marta/C-1725-2008; Bascompte, Jordi/B-7596-2008; Sirer, Mehmet Irmak/E-1072-2013; Stouffer, Daniel/C-2223-2008	Sales-Pardo, Marta/0000-0002-8140-6525; Sales-Pardo, Marta/0000-0002-8140-6525; Bascompte, Jordi/0000-0002-0108-6411; Sirer, Mehmet Irmak/0000-0002-0300-5582; Stouffer, Daniel/0000-0001-9436-9674	Ministerio de Ciencia e Innovacion (MICINN), Spain [FIS2010-18639]; James S. McDonnell Foundation; European Union [PIRG-GA-2010-268342]; W. M. Keck Foundation; European Research Council under the European Community [FP7/2007-2013, 268543]	Ministerio de Ciencia e Innovacion (MICINN), Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); James S. McDonnell Foundation; European Union(European Commission); W. M. Keck Foundation(W.M. Keck Foundation); European Research Council under the European Community(European Research Council (ERC))	D.B.S. acknowledges the support of a Consejo Superior de Investigaciones Cientificas-Junta para la Ampliacion de Estudios Postdoctoral Fellowship and a Juan de la Cierva Fellowship from the Ministerio de Ciencia e Innovacion (MICINN), Spain. M. S. P. acknowledges the support of grant FIS2010-18639 from the MICINN, Spain; a Research Award from the James S. McDonnell Foundation; and grant PIRG-GA-2010-268342 from the European Union. M. I. S. acknowledges the support of a W. M. Keck Foundation grant. J.B. acknowledges the support of the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013) through an Advanced Grant (grant agreement 268543). A list of references from which the food web data can be obtained is found in table S1. All figures were generated with PyGrace (http://pygrace.sourceforge.net).	Allesina S, 2008, THEOR ECOL-NETH, V1, P55, DOI 10.1007/s12080-007-0007-8; Allesina S, 2009, ECOL LETT, V12, P652, DOI 10.1111/j.1461-0248.2009.01321.x; Bascompte J, 2005, ECOLOGY, V86, P2868, DOI 10.1890/05-0101; Bascompte J, 2009, SCIENCE, V325, P416, DOI 10.1126/science.1170749; Eklof A, 2012, P ROY SOC B-BIOL SCI, V279, P1588, DOI 10.1098/rspb.2011.2149; Garcia-Domingo JL, 2008, OIKOS, V117, P336, DOI 10.1111/j.2007.0030-1299.16261.x; Gomez JM, 2010, NATURE, V465, P918, DOI 10.1038/nature09113; Guimera R, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.036102; Kondoh M, 2008, P NATL ACAD SCI USA, V105, P16631, DOI 10.1073/pnas.0805870105; Luczkovich JJ, 2003, J THEOR BIOL, V220, P303, DOI 10.1006/jtbi.2003.3147; MILLS LS, 1993, BIOSCIENCE, V43, P219, DOI 10.2307/1312122; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Neutel AM, 2002, SCIENCE, V296, P1120, DOI 10.1126/science.1068326; Olesen JM, 2007, P NATL ACAD SCI USA, V104, P19891, DOI 10.1073/pnas.0706375104; PAINE RT, 1969, AM NAT, V103, P91, DOI 10.1086/282586; PASCUAL M, 2006, ECOLOGICAL NETWORKS; POWER ME, 1992, ECOLOGY, V73, P733, DOI 10.2307/1940153; Rezende EL, 2007, NATURE, V448, P925, DOI 10.1038/nature05956; Sales-Pardo M, 2007, P NATL ACAD SCI USA, V104, P15224, DOI 10.1073/pnas.0703740104; Stouffer DB, 2007, P ROY SOC B-BIOL SCI, V274, P1931, DOI 10.1098/rspb.2007.0571; Stouffer DB, 2011, P NATL ACAD SCI USA, V108, P3648, DOI 10.1073/pnas.1014353108; Stouffer DB, 2010, ECOL LETT, V13, P154, DOI 10.1111/j.1461-0248.2009.01407.x; Stouffer DB, 2010, FUNCT ECOL, V24, P44, DOI 10.1111/j.1365-2435.2009.01644.x; Thebault E, 2010, SCIENCE, V329, P853, DOI 10.1126/science.1188321; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Townsend CR, 1998, ECOL LETT, V1, P200; Tylianakis JM, 2010, BIOL CONSERV, V143, P2270, DOI 10.1016/j.biocon.2009.12.004	27	129	131	1	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1489	1492		10.1126/science.1216556	http://dx.doi.org/10.1126/science.1216556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442483	Green Submitted			2022-12-28	WOS:000301837000047
J	Fitch, MT; Nicks, BA; Pariyadath, M; McGinnis, HD; Manthey, DE				Fitch, Michael T.; Nicks, Bret A.; Pariyadath, Manoj; McGinnis, Henderson D.; Manthey, David E.			Emergency Pericardiocentesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIAC-TAMPONADE; GUIDED PERICARDIOCENTESIS; PERICARDIAL-EFFUSION; MANAGEMENT		[Fitch, Michael T.] Wake Forest Sch Med, Dept Emergency Med, Winston Salem, NC 27157 USA	Wake Forest University	Fitch, MT (corresponding author), Wake Forest Sch Med, Dept Emergency Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mfitch@wakehealth.edu	Manthey, David/C-9936-2013					Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; COOPER JP, 1995, BRIT HEART J, V73, P351; Gandhi S, 2008, ECHOCARDIOGR-J CARD, V25, P237, DOI 10.1111/j.1540-8175.2007.00592.x; Garth AP, 2009, ACAD EMERG MED, V16, P811, DOI 10.1111/j.1553-2712.2009.00473.x; Harper RJ, 2010, CLIN PROCEDURES EMER, P287; Heller K, 2007, ACAD EMERG MED, V14, P1157, DOI 10.1197/j.aem.2007.08.010; Kennedy UM, 2006, EUR J EMERG MED, V13, P254, DOI 10.1097/00063110-200610000-00002; Pepi M, 2006, J CARDIOVASC MED, V7, P533, DOI 10.2459/01.JCM.0000234772.73454.57; Roy CL, 2007, JAMA-J AM MED ASSOC, V297, P1810, DOI 10.1001/jama.297.16.1810; Salem K, 1999, CAN J CARDIOL, V15, P1251; Spodick DH, 2003, NEW ENGL J MED, V349, P684, DOI 10.1056/NEJMra022643	11	17	17	2	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					E17	U9		10.1056/NEJMvcm0907841	http://dx.doi.org/10.1056/NEJMvcm0907841			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435385				2022-12-28	WOS:000301769700001
J	Liu, HS; Waxman, DA; Main, R; Mattke, S				Liu, Hangsheng; Waxman, Daniel A.; Main, Regan; Mattke, Soeren			Utilization of Anesthesia Services During Outpatient Endoscopies and Colonoscopies and Associated Spending in 2003-2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE REFORM; GI ENDOSCOPY; SEDATION	Context The frequency with which anesthesiologists or nurse anesthetists provide sedation for gastrointestinal endoscopies, especially for low-risk patients, is poorly understood and controversial. Objective To quantify temporal comparisons and regional variation in the use of and payment for gastroenterology anesthesia services. Design, Setting, and Patients A retrospective analysis of claims data for a 5% representative sample of Medicare fee-for-service patients (1.1 million adults) and a sample of 5.5 million commercially insured patients between 2003 and 2009. Main Outcome Measures Total number of upper gastrointestinal endoscopies and colonoscopies, proportion of gastroenterology procedures with associated anesthesia claims, payments for gastroenterology anesthesia services, and proportion of services and spending for gastroenterology anesthesia delivered to low-risk patients (American Society of Anesthesiologists physical status class 1 or 2). Results The number of gastroenterology procedures per million enrollees remained largely unchanged in Medicare patients (mean, 136 718 procedures), but increased more than 50% in commercially insured patients (from 33 599 in 2003 to 50 816 in 2009). In both populations, the proportion of procedures using anesthesia services increased from approximately 14% in 2003 to more than 30% in 2009, and more than two-thirds of anesthesia services were delivered to low-risk patients. There was substantial regional variation in the proportion of procedures using anesthesia services in both populations (ranging from 13% in the West to 59% in the Northeast). Payments for gastroenterology anesthesia services doubled in Medicare patients and quadrupled in commercially insured patients. Conclusions Between 2003 and 2009, utilization of anesthesia services during gastroenterology procedures increased substantially. Anesthesia services are predominantly used in low-risk patients and show considerable regional variation. JAMA. 2012;307(11):1178-1184	[Liu, Hangsheng; Mattke, Soeren] RAND Corp, Boston, MA 02116 USA; [Main, Regan] RAND Corp, Pittsburgh, PA USA; [Waxman, Daniel A.] RAND Corp, Santa Monica, CA USA	RAND Corporation; RAND Corporation; RAND Corporation	Mattke, S (corresponding author), RAND Corp, 20 Pk Plaza,Ste 920, Boston, MA 02116 USA.	mattke@rand.org			Ethicon Endo-Surgery Inc, Cincinnati, Ohio	Ethicon Endo-Surgery Inc, Cincinnati, Ohio	This study was financially supported by Ethicon Endo-Surgery Inc, Cincinnati, Ohio.	Aetna, 2007, CLIN POL MON AN CAR; Aisenberg J, 2005, AM J GASTROENTEROL, V100, P996, DOI 10.1111/j.1572-0241.2005.50034.x; [Anonymous], CONS PRIC IND HIST T; Centers for Medicare & Medicaid Services, DUAL EL ENR JUL 1 20; Centers for Medicare & Medicaid Services, 2010 ANN REP BOARDS; Centers for Medicare & Medicaid Services, WELC MED COV DAT; Chung SA, 2008, ANESTH ANALG, V107, P1543, DOI 10.1213/ane.0b013e318187c83a; Cohen LB, 2009, GASTROENTEROLOGY HEP, V5, P565; Cohen LB, POLITICS SCI ENDOSCO; *CTR MED MED SERV, NAT SUMM MED MAN CAR; Hansen LG, HLTH RES DATA REAL W; Healthcare Cost and Utilization Project, CLIN CLASS SOFTW CCS; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Medicare Payment Advisory Commission, REP C MED PAYM POL; Mitka M, 2008, JAMA-J AM MED ASSOC, V299, P622, DOI 10.1001/jama.299.6.622; Orkin FK, 2009, ANESTHESIOLOGY, V111, P697, DOI 10.1097/ALN.0b013e3181b78713; Poincloux L, 2011, DIGEST LIVER DIS, V43, P553, DOI 10.1016/j.dld.2011.02.007; Porter ME, 2009, NEW ENGL J MED, V361, P109, DOI 10.1056/NEJMp0904131; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Sisko AM, 2010, HEALTH AFFAIR, V29, P1933, DOI 10.1377/hlthaff.2010.0788; The Henry J. Kaiser Family Foundation, DISTR MED ENR ENR GR; The Henry J Kaiser Family Foundation, SUMM NEW HLTH REF LA; US Census Bureau, 2009 POP EST SEX SEL; Vargo JJ, 2009, AM J GASTROENTEROL, V104, P2886, DOI 10.1038/ajg.2009.607; Wellpoint, AN SERV GASTR END PR	27	138	141	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1178	1184		10.1001/jama.2012.270	http://dx.doi.org/10.1001/jama.2012.270			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436958	Bronze			2022-12-28	WOS:000301708000026
J	Kiely, B; Stockler, M				Kiely, Belinda; Stockler, Martin			Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kiely, Belinda] Univ Sydney, Campbelltown Hosp, Sydney Canc Ctr, Sydney, NSW 2006, Australia; Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Kiely, B (corresponding author), Univ Sydney, Campbelltown Hosp, Sydney Canc Ctr, Sydney, NSW 2006, Australia.		Stockler, Martin R/N-3859-2016	Stockler, Martin R/0000-0003-3793-8724				Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082	1	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-4	10.7326/0003-4819-156-6-201203200-02004	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431690				2022-12-28	WOS:000303150900003
J	Holmes, D				Holmes, David			Profile Gail Davey: raising the profile of "podo ... what?"	LANCET			English	Biographical-Item																			0	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					996	996		10.1016/S0140-6736(12)60418-8	http://dx.doi.org/10.1016/S0140-6736(12)60418-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22423874				2022-12-28	WOS:000301712300016
J	Nunnari, J; Suomalainen, A				Nunnari, Jodi; Suomalainen, Anu			Mitochondria: In Sickness and in Health	CELL			English	Review							ACTIVATED PROTEIN-KINASE; DYNAMIN-RELATED PROTEIN; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY; SUBSTANTIA-NIGRA NEURONS; BROWN ADIPOSE-TISSUE; CYTOCHROME-C RELEASE; INNER MEMBRANE; SKELETAL-MUSCLE; DNA POLYMERASE	Mitochondria perform diverse yet interconnected functions, producing ATP and many biosynthetic intermediates while also contributing to cellular stress responses such as autophagy and apoptosis. Mitochondria form a dynamic, interconnected network that is intimately integrated with other cellular compartments. In addition, mitochondrial functions extend beyond the boundaries of the cell and influence an organism's physiology by regulating communication between cells and tissues. It is therefore not surprising that mitochondrial dysfunction has emerged as a key factor in a myriad of diseases, including neurodegenerative and metabolic disorders. We provide a current view of how mitochondrial functions impinge on health and disease.	[Nunnari, Jodi] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; [Suomalainen, Anu] Univ Helsinki, Biomedicum Helsinki, Res Programs Unit, FIN-00290 Helsinki, Finland; [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland	University of California System; University of California Davis; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Nunnari, J (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.	jmnunnari@ucdavis.edu; anu.wartiovaara@helsinki.fi		Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195	Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Academy of Finland; European Research Council; University of Helsinki; Helsinki University Central Hospital; National Institutes of Health [R01GM062942, R01GM097432]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062942, R01GM097432] Funding Source: NIH RePORTER	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jane and Aatos Erkko Foundation; Academy of Finland(Academy of Finland); European Research Council(European Research Council (ERC)European Commission); University of Helsinki; Helsinki University Central Hospital; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors would like to express thanks to members of the Nunnari lab for discussions and manuscript editing. J.N. is supported by National Institutes of Health grants R01GM062942 and R01GM097432. A.S. is supported by the Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Academy of Finland, European Research Council, University of Helsinki, and Helsinki University Central Hospital. The authors wish to thank Helena Schmidt for figure art.	Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012; Ahola-Erkkila S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076; Al Rawi S, 2011, SCIENCE, V334, P1144, DOI 10.1126/science.1211878; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Anton F, 2011, J CELL SCI, V124, P1126, DOI 10.1242/jcs.073080; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Ashrafian H, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001000; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007; Battersby BJ, 2005, HUM MOL GENET, V14, P2587, DOI 10.1093/hmg/ddi293; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Bogner C, 2010, CURR OPIN CELL BIOL, V22, P845, DOI 10.1016/j.ceb.2010.08.002; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Braschi E, 2009, EMBO REP, V10, P748, DOI 10.1038/embor.2009.86; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829; Brown TA, 2011, MOL CELL BIOL, V31, P4994, DOI 10.1128/MCB.05694-11; Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/nchembio.610, 10.1038/NCHEMBIO.610]; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Chen ML, 2009, BLOOD, V114, P4045, DOI 10.1182/blood-2008-08-169474; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Cho DH, 2010, CELL MOL LIFE SCI, V67, P3435, DOI 10.1007/s00018-010-0435-2; Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Claypool SM, 2008, J CELL BIOL, V182, P937, DOI 10.1083/jcb.200801152; Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Costa V, 2010, EMBO MOL MED, V2, P490, DOI 10.1002/emmm.201000102; Cui M, 2010, J BIOL CHEM, V285, P11740, DOI 10.1074/jbc.M109.066662; Davey KM, 2006, J MED GENET, V43, P385, DOI 10.1136/jmg.2005.036657; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; DeVay RM, 2009, J CELL BIOL, V186, P793, DOI 10.1083/jcb.200906098; Diaz F, 2011, SEMIN FETAL NEONAT M, V16, P197, DOI 10.1016/j.siny.2011.05.004; Dickey AS, 2011, J NEUROSCI, V31, P15716, DOI 10.1523/JNEUROSCI.3159-11.2011; Durr M, 2006, MOL BIOL CELL, V17, P3745, DOI 10.1091/mbc.E06-01-0053; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Efremov RG, 2011, CURR OPIN STRUC BIOL, V21, P532, DOI 10.1016/j.sbi.2011.07.002; Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084; Euro L, 2011, NUCLEIC ACIDS RES, V39, P9072, DOI 10.1093/nar/gkr618; Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Friedman JR, 2011, SCIENCE, V334, P358, DOI 10.1126/science.1207385; Gabaldon T, 2004, CELL MOL LIFE SCI, V61, P930, DOI 10.1007/s00018-003-3387-y; Garcia-Perez C, 2011, AM J PHYSIOL-HEART C, V301, pH1907, DOI 10.1152/ajpheart.00397.2011; Gaston D, 2009, METHOD ENZYMOL, V457, P21, DOI 10.1016/S0076-6879(09)05002-2; Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; Golubitzky A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026883; Gomes LC, 2011, CELL CYCLE, V10, P2635, DOI 10.4161/cc.10.16.17002; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Gotz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Griffin EE, 2006, J BIOL CHEM, V281, P16599, DOI 10.1074/jbc.M601847200; Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Hardie DG, 2011, TRENDS BIOCHEM SCI, V36, P470, DOI 10.1016/j.tibs.2011.06.004; Harner M, 2011, EMBO J, V30, P4356, DOI 10.1038/emboj.2011.379; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016; Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119; Head B, 2009, J CELL BIOL, V187, P959, DOI 10.1083/jcb.200906083; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heo JM, 2010, MOL CELL, V40, P465, DOI 10.1016/j.molcel.2010.10.021; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1097/00005768-200301000-00016; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Hoppins S, 2011, J CELL BIOL, V195, P323, DOI 10.1083/jcb.201107053; Hoppins S, 2011, MOL CELL, V41, P150, DOI 10.1016/j.molcel.2010.11.030; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Ishikawa K, 2010, J EXP MED, V207, P2297, DOI 10.1084/jem.20092296; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Iwasawa R, 2011, EMBO J, V30, P556, DOI 10.1038/emboj.2010.346; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, pC698, DOI 10.1152/ajpcell.00109.2006; Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, pC689, DOI 10.1152/ajpcell.00108.2006; Jokinen R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001161; Kang JS, 2008, CELL, V132, P137, DOI 10.1016/j.cell.2007.11.024; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kim KY, 2011, J CLIN INVEST, V121, P3701, DOI 10.1172/JCI44736; Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koivunen P., 2012, NATURE          0215; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lackner LL, 2010, CHEM BIOL, V17, P578, DOI 10.1016/j.chembiol.2010.05.016; Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lill R, 2008, ANNU REV BIOCHEM, V77, P669, DOI 10.1146/annurev.biochem.76.052705.162653; Lin W, 2008, J NEUROCHEM, V106, P464, DOI 10.1111/j.1471-4159.2008.05398.x; Liu XG, 2009, INT J BIOCHEM CELL B, V41, P1972, DOI 10.1016/j.biocel.2009.05.013; Lu C., 2012, NATURE          0215; Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3; Lutz AK, 2009, J BIOL CHEM, V284, P22938, DOI 10.1074/jbc.M109.035774; MacAskill AF, 2009, NEURON, V61, P541, DOI 10.1016/j.neuron.2009.01.030; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mayr JA, 2011, AM J HUM GENET, V89, P792, DOI 10.1016/j.ajhg.2011.11.011; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Montessuit S, 2010, CELL, V142, P889, DOI 10.1016/j.cell.2010.08.017; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790; Narasimhaiah R, 2005, CEREB CORTEX, V15, P696, DOI 10.1093/cercor/bhh171; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Neutzner Albert, 2007, Novartis Found Symp, V287, P4; Neutzner A, 2008, ANN NY ACAD SCI, V1147, P242, DOI 10.1196/annals.1427.012; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Norddahl GL, 2011, CELL STEM CELL, V8, P499, DOI 10.1016/j.stem.2011.03.009; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okuno D, 2011, J BIOCHEM, V149, P655, DOI 10.1093/jb/mvr049; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257; Patsi J, 2008, BIOCHEM J, V409, P129, DOI 10.1042/BJ20070866; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Perkins GA, 2000, MICRON, V31, P97, DOI 10.1016/S0968-4328(99)00065-7; PERRY TL, 1985, J INHERIT METAB DIS, V8, P63, DOI 10.1007/BF01801666; Pierce SB, 2011, P NATL ACAD SCI USA, V108, P6543, DOI 10.1073/pnas.1103471108; Pietilainen KH, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050051; Polianskyte Z, 2009, P NATL ACAD SCI USA, V106, P18960, DOI 10.1073/pnas.0906734106; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Reichert AS, 2002, BBA-MOL CELL RES, V1592, P41, DOI 10.1016/S0167-4889(02)00263-X; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Rolland SG, 2009, J CELL BIOL, V186, P525, DOI 10.1083/jcb.200905070; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Saotome M, 2008, P NATL ACAD SCI USA, V105, P20728, DOI 10.1073/pnas.0808953105; Sato M, 2011, SCIENCE, V334, P1141, DOI 10.1126/science.1210333; Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013; Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959; Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Shirendeb UP, 2012, HUM MOL GENET, V21, P406, DOI 10.1093/hmg/ddr475; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Song WJ, 2011, NAT MED, V17, P377, DOI 10.1038/nm.2313; Soubannier V, 2012, CURR BIOL, V22, P135, DOI 10.1016/j.cub.2011.11.057; Sterky FH, 2011, P NATL ACAD SCI USA, V108, P12937, DOI 10.1073/pnas.1103295108; Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Strack S, 2012, J BIOL CHEM; Strauss M, 2008, EMBO J, V27, P1154, DOI 10.1038/emboj.2008.35; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7; Suomalainen A, 2011, SEMIN FETAL NEONAT M, V16, P236, DOI 10.1016/j.siny.2011.05.003; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Tang FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021208; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Turcan S., 2012, NATURE          0215; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; VANDENBOGERT C, 1981, BIOCHEM PHARMACOL, V30, P1706, DOI 10.1016/0006-2952(81)90403-2; Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Voelker DR, 2009, ANNU REV BIOCHEM, V78, P827, DOI 10.1146/annurev.biochem.78.081307.112144; von der Malsburg K, 2011, DEV CELL, V21, P694, DOI 10.1016/j.devcel.2011.08.026; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; Waagepetersen HS, 2001, J NEUROSCI RES, V63, P347, DOI 10.1002/1097-4547(20010215)63:4<347::AID-JNR1029>3.0.CO;2-G; Wakabayashi J, 2009, J CELL BIOL, V186, P805, DOI 10.1083/jcb.200903065; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wang C, 2011, EXPERT OPIN THER TAR, V15, P647, DOI 10.1517/14728222.2011.561321; Wang XL, 2009, J NEUROSCI, V29, P9090, DOI 10.1523/JNEUROSCI.1357-09.2009; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Warburg O, 1923, BIOCHEM Z, V142, P317; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436; Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wurm CA, 2011, P NATL ACAD SCI USA, V108, P13546, DOI 10.1073/pnas.1107553108; Xu S, 2011, MOL BIOL CELL, V22, P291, DOI 10.1091/mbc.E10-09-0748; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang YL, 2011, CELL, V146, P991, DOI 10.1016/j.cell.2011.07.039; Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482; Ylikallio E, 2012, ANN MED, V44, P41, DOI 10.3109/07853890.2011.598547; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Ziviani E, 2010, P NATL ACAD SCI USA, V107, P5018, DOI 10.1073/pnas.0913485107; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	241	1732	1785	22	443	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1145	1159		10.1016/j.cell.2012.02.035	http://dx.doi.org/10.1016/j.cell.2012.02.035			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424226	Bronze, Green Accepted			2022-12-28	WOS:000301889500013
J	Spitali, P; Aartsma-Rus, A				Spitali, Pietro; Aartsma-Rus, Annemieke			Splice Modulating Therapies for Human Disease	CELL			English	Review							DYSTROPHIN RESTORATION; RNA; REPEAT; REVERSAL; RESCUE; BRAIN	Dysregulation of splicing and alternative splicing underlies many genetic and acquired diseases. We present an overview of recent strategies and successes in modulating splicing therapeutically in clinical and preclinical contexts. Effective approaches include restoring open reading frames, influencing alternative splicing, and inducing exon inclusion to generate beneficial proteins and remove deleterious ones.	[Spitali, Pietro; Aartsma-Rus, Annemieke] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Aartsma-Rus, A (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands.	a.m.rus@lumc.nl	Spitali, Pietro/Y-2948-2018	Spitali, Pietro/0000-0003-2783-688X; Aartsma-Rus, Annemieke/0000-0003-1565-654X	Duchenne Parent Project (the Netherlands); ZonMw (the Netherlands); Prinses Beatrix Foundation; FP7 BIO-NMD project [HEALTH-F2-2009-241665]	Duchenne Parent Project (the Netherlands)(Netherlands Government); ZonMw (the Netherlands)(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Prinses Beatrix Foundation; FP7 BIO-NMD project	A.A.-R. and P.S. receive funding from the Duchenne Parent Project (the Netherlands), ZonMw (the Netherlands), the Prinses Beatrix Foundation, and the FP7 BIO-NMD project (HEALTH-F2-2009-241665) and utilize the infrastructure of the Center for Medical System Biology (CMSB) and the Center for Biomedical Genetics (CBG). A.A.-R. reports being coinventor on patents on exon shipping, licensed to Prosensa Therapeutics, and being entitled to a share of royalties.	Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Du LT, 2011, HUM MOL GENET, V20, P3151, DOI 10.1093/hmg/ddr217; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Hammond SM, 2011, TRENDS GENET, V27, P196, DOI 10.1016/j.tig.2011.02.004; Hua YM, 2008, AM J HUM GENET, V82, P834, DOI 10.1016/j.ajhg.2008.01.014; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Kinali M, 2009, LANCET NEUROL, V8, P918, DOI 10.1016/S1474-4422(09)70211-X; Mulders SAM, 2009, P NATL ACAD SCI USA, V106, P13915, DOI 10.1073/pnas.0905780106; Mykowska A, 2011, NUCLEIC ACIDS RES, V39, P8938, DOI 10.1093/nar/gkr608; Osman EY, 2012, MOL THER, V20, P119, DOI 10.1038/mt.2011.232; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Pros E, 2010, EUR J HUM GENET, V18, P614, DOI 10.1038/ejhg.2009.212; Shetty RS, 2011, HUM MOL GENET, V20, P4093, DOI 10.1093/hmg/ddr333; Taniguchi-Ikeda M, 2011, NATURE, V478, P127, DOI 10.1038/nature10456; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Wheeler TM, 2009, SCIENCE, V325, P336, DOI 10.1126/science.1173110; Zammarchi F, 2011, P NATL ACAD SCI USA, V108, P17779, DOI 10.1073/pnas.1108482108	18	99	102	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1085	1088		10.1016/j.cell.2012.02.014	http://dx.doi.org/10.1016/j.cell.2012.02.014			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424220	Bronze			2022-12-28	WOS:000301889500007
J	Brody, H				Brody, Herb			GRAPHENE	NATURE			English	Editorial Material																			0	20	20	1	253	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S29	S29		10.1038/483S29a	http://dx.doi.org/10.1038/483S29a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22419206	Bronze			2022-12-28	WOS:000301481800057
J	Burns, NZ; Jacobsen, EN				Burns, Noah Z.; Jacobsen, Eric N.			ORGANIC CHEMISTRY Catalysis in tight spaces	NATURE			English	Editorial Material									[Burns, Noah Z.; Jacobsen, Eric N.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University	Burns, NZ (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	jacobsen@chemistry.harvard.edu	Burns, Noah/AFA-8975-2022	Burns, Noah/0000-0003-1064-4507				Akiyama T, 2007, CHEM REV, V107, P5744, DOI 10.1021/cr068374j; Coric I, 2012, NATURE, V483, P315, DOI 10.1038/nature10932; Hamilton GL, 2007, SCIENCE, V317, P496, DOI 10.1126/science.1145229; HANIOTAKIS G, 1986, J CHEM ECOL, V12, P1559, DOI 10.1007/BF01012372; Knowles RR, 2010, P NATL ACAD SCI USA, V107, P20678, DOI 10.1073/pnas.1006402107; Mayer S, 2006, ANGEW CHEM INT EDIT, V45, P4193, DOI 10.1002/anie.200600512; Reisman SE, 2008, J AM CHEM SOC, V130, P7198, DOI 10.1021/ja801514m; Singh SB, 2002, ORG LETT, V4, P1123, DOI 10.1021/ol025539b; Zhang ZG, 2009, CHEM SOC REV, V38, P1187, DOI 10.1039/b801793j	9	5	6	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					278	279		10.1038/483278a	http://dx.doi.org/10.1038/483278a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422255				2022-12-28	WOS:000301481800032
J	Kuzyk, A; Schreiber, R; Fan, ZY; Pardatscher, G; Roller, EM; Hogele, A; Simmel, FC; Govorov, AO; Liedl, T				Kuzyk, Anton; Schreiber, Robert; Fan, Zhiyuan; Pardatscher, Guenther; Roller, Eva-Maria; Hoegele, Alexander; Simmel, Friedrich C.; Govorov, Alexander O.; Liedl, Tim			DNA-based self-assembly of chiral plasmonic nanostructures with tailored optical response	NATURE			English	Article							METAL NANOPARTICLE ASSEMBLIES; CIRCULAR-DICHROISM; SHAPES; SUPERSTRUCTURES; ORIGAMI	Matter structured on a length scale comparable to or smaller than the wavelength of light can exhibit unusual optical properties(1). Particularly promising components for such materials are metal nanostructures, where structural alterations provide a straightforward means of tailoring their surface plasmon resonances and hence their interaction with light(2,3). But the top-down fabrication of plasmonic materials with controlled optical responses in the visible spectral range remains challenging, because lithographic methods are limited in resolution and in their ability to generate genuinely three-dimensional architectures(4,5). Molecular self-assembly(6,7) provides an alternative bottom-up fabrication route not restricted by these limitations, and DNA-and peptide-directed assembly have proved to be viable methods for the controlled arrangement of metal nanoparticles in complex and also chiral geometries(8-14). Here we show that DNA origami(15,16) enables the high-yield production of plasmonic structures that contain nanoparticles arranged in nanometre-scale helices. We find, in agreement with theoretical predictions(17), that the structures in solution exhibit defined circular dichroism and optical rotatory dispersion effects at visible wavelengths that originate from the collective plasmon-plasmon interactions of the nanoparticles positioned with an accuracy better than two nanometres. Circular dichroism effects in the visible part of the spectrum have been achieved by exploiting the chiral morphology of organic molecules and the plasmonic properties of nanoparticles(18-20), or even without precise control over the spatial configuration of the nanoparticles(12,21,22). In contrast, the optical response of our nanoparticle assemblies is rationally designed and tunable in handedness, colour and intensity-in accordance with our theoretical model.	[Schreiber, Robert; Roller, Eva-Maria; Hoegele, Alexander; Liedl, Tim] Univ Munich, Fak Phys, D-80539 Munich, Germany; [Schreiber, Robert; Roller, Eva-Maria; Hoegele, Alexander; Liedl, Tim] Univ Munich, Ctr Nanosci, D-80539 Munich, Germany; [Kuzyk, Anton; Pardatscher, Guenther; Simmel, Friedrich C.] Tech Univ Munich, Phys Dept, D-85748 Garching, Germany; [Kuzyk, Anton; Pardatscher, Guenther; Simmel, Friedrich C.] Tech Univ Munich, ZNN WSI, D-85748 Garching, Germany; [Fan, Zhiyuan; Govorov, Alexander O.] Ohio Univ, Dept Phys & Astron, Athens, OH 45701 USA	University of Munich; University of Munich; Technical University of Munich; Technical University of Munich; University System of Ohio; Ohio University	Liedl, T (corresponding author), Univ Munich, Fak Phys, Geschwister Scholl Pl 1, D-80539 Munich, Germany.	tim.liedl@lmu.de	Kuzyk, Anton/D-7317-2011; Fan, Zhiyuan/C-2504-2015; Liedl, Tim/O-7539-2014; Simmel, Friedrich/G-3281-2010; Fan, Zhiyuan/AAY-1080-2021; Hogele, Alexander/C-1080-2016	Kuzyk, Anton/0000-0001-8060-6122; Fan, Zhiyuan/0000-0002-9312-2271; Liedl, Tim/0000-0002-0040-0173; Simmel, Friedrich/0000-0003-3829-3446; Fan, Zhiyuan/0000-0002-9312-2271; Hogele, Alexander/0000-0002-0178-9117	Volkswagen Foundation; DFG Cluster of Excellence NIM (Nanosystems Initiative Munich); NSF (USA)	Volkswagen Foundation(Volkswagen); DFG Cluster of Excellence NIM (Nanosystems Initiative Munich); NSF (USA)(National Science Foundation (NSF))	We thank H. Dietz and G. Acuna for experimental advice and B. Yurke, E. Graugnard, J. O. Radler and J. P. Kotthaus for discussions. We acknowledge J. Buchner and M. Rief for giving us access to their CD spectrometers, E. Herold for help with the CD measurements, and T. Martin and S. Kempter for assistance. We also thank D. M. Smith for carefully reading the manuscript. This work was funded by the Volkswagen Foundation, the DFG Cluster of Excellence NIM (Nanosystems Initiative Munich) and the NSF (USA).	Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Berova N., 2000, CIRCULAR DICHROISM P, DOI DOI 10.1038/natrevmats.2016.21; Chen CL, 2010, J AM CHEM SOC, V132, P6902, DOI 10.1021/ja102000g; Chen W, 2009, NANO LETT, V9, P2153, DOI 10.1021/nl900726s; Ding BQ, 2010, J AM CHEM SOC, V132, P3248, DOI 10.1021/ja9101198; Douglas SM, 2009, NATURE, V459, P414, DOI 10.1038/nature08016; Fan JA, 2010, SCIENCE, V328, P1135, DOI 10.1126/science.1187949; Fan ZY, 2011, J PHYS CHEM C, V115, P13254, DOI 10.1021/jp204265x; Fan ZY, 2010, NANO LETT, V10, P2580, DOI 10.1021/nl101231b; Gansel JK, 2009, SCIENCE, V325, P1513, DOI 10.1126/science.1177031; George J, 2010, J AM CHEM SOC, V132, P2502, DOI 10.1021/ja908574j; Guerrero-Martinez A, 2011, NANO TODAY, V6, P381, DOI 10.1016/j.nantod.2011.06.003; Guerrero-Martinez A, 2011, ANGEW CHEM INT EDIT, V50, P5499, DOI 10.1002/anie.201007536; Halas NJ, 2011, CHEM REV, V111, P3913, DOI 10.1021/cr200061k; Jones MR, 2011, CHEM REV, V111, P3736, DOI 10.1021/cr1004452; Liu YM, 2011, CHEM SOC REV, V40, P2494, DOI 10.1039/c0cs00184h; Mastroianni AJ, 2009, J AM CHEM SOC, V131, P8455, DOI 10.1021/ja808570g; Pendry JB, 2004, SCIENCE, V306, P1353, DOI 10.1126/science.1104467; Pilo-Pais M, 2011, NANO LETT, V11, P3489, DOI 10.1021/nl202066c; Polman A, 2008, SCIENCE, V322, P868, DOI 10.1126/science.1163959; Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586; Schaaff TG, 2000, J PHYS CHEM B, V104, P2630, DOI 10.1021/jp993691y; Schreiber R, 2011, SMALL, V7, P1795, DOI 10.1002/smll.201100465; Seeman NC, 2010, ANNU REV BIOCHEM, V79, P65, DOI 10.1146/annurev-biochem-060308-102244; Sharma J, 2009, SCIENCE, V323, P112, DOI 10.1126/science.1165831; Shemer G, 2006, J AM CHEM SOC, V128, P11006, DOI 10.1021/ja063702i; Soukoulis CM, 2011, NAT PHOTONICS, V5, P523, DOI [10.1038/NPHOTON.2011.154, 10.1038/nphoton.2011.154]; Tan SJ, 2011, NAT NANOTECHNOL, V6, P268, DOI [10.1038/nnano.2011.49, 10.1038/NNANO.2011.49]; Torring T, 2011, CHEM SOC REV, V40, P5636, DOI 10.1039/c1cs15057j; Urzhumov YA, 2007, OPT EXPRESS, V15, P14129, DOI 10.1364/OE.15.014129	30	1524	1552	76	1865	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					311	314		10.1038/nature10889	http://dx.doi.org/10.1038/nature10889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422265	Green Submitted			2022-12-28	WOS:000301481800044
J	Yu, TY; Chang, TC				Yu, Tse-Ya; Chang, Tien-Chun			Lingual Thyroid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Yu, Tse-Ya; Chang, Tien-Chun] Natl Taiwan Univ Hosp, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital	Yu, TY (corresponding author), Natl Taiwan Univ Hosp, Taipei, Taiwan.	tienchunchang@ntu.edu.tw		Chang, Tien-Chun/0000-0003-3385-2026					0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					E15	E15		10.1056/NEJMicm1112306	http://dx.doi.org/10.1056/NEJMicm1112306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397674				2022-12-28	WOS:000301172500012
J	Engel, J; McDermott, MP; Wiebe, S; Langfitt, JT; Stern, JM; Dewar, S; Sperling, MR; Gardiner, I; Erba, G; Fried, I; Jacobs, M; Vinters, HV; Mintzer, S; Kieburtz, K				Engel, Jerome, Jr.; McDermott, Michael P.; Wiebe, Samuel; Langfitt, John T.; Stern, John M.; Dewar, Sandra; Sperling, Michael R.; Gardiner, Irenita; Erba, Giuseppe; Fried, Itzhak; Jacobs, Margaret; Vinters, Harry V.; Mintzer, Scott; Kieburtz, Karl		Early Randomized Surgical Epilepsy	Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; INTRACTABLE EPILEPSY; SURGERY; MULTICENTER; INVENTORY; LOBECTOMY; DIAGNOSIS; SEIZURES; OUTCOMES; LONG	Context Despite reported success, surgery for pharmacoresistant seizures is often seen as a last resort. Patients are typically referred for surgery after 20 years of seizures, often too late to avoid significant disability and premature death. Objective We sought to determine whether surgery soon after failure of 2 antiepileptic drug (AED) trials is superior to continued medical management in controlling seizures and improving quality of life (QOL). Design, Setting, and Participants The Early Randomized Surgical Epilepsy Trial (ERSET) is a multicenter, controlled, parallel-group clinical trial performed at 16 US epilepsy surgery centers. The 38 participants (18 men and 20 women; aged >= 12 years) had mesial temporal lobe epilepsy (MTLE) and disabling seizues for no more than 2 consecutive years following adequate trials of 2 brand-name AEDs. Eligibility for anteromesial temporal resection (AMTR) was based on a standardized presurgical evaluation protocol. Participants were randomized to continued AED treatment or AMTR 2003-2007, and observed for 2 years. Planned enrollment was 200, but the trial was halted prematurely due to slow accrual. Intervention Receipt of continued AED treatment (n=23) or a standardized AMTR plus AED treatment (n=15). In the medical group, 7 participants underwent AMTR prior to the end of follow-up and 1 participant in the surgical group never received surgery. Main Outcome Measures The primary outcome variable was freedom from disabling seizures during year 2 of follow-up. Secondary outcome variables were health-related QOL (measured primarily by the 2-year change in the Quality of Life in Epilepsy 89 [QOLIE-89] overall T-score), cognitive function, and social adaptation. Results Zero of 23 participants in the medical group and 11 of 15 in the surgical group were seizure free during year 2 of follow-up (odds ratio=infinity; 95% CI, 11.8 to infinity; P<.001). In an intention-to-treat analysis, the mean improvement in QOLIE-89 overall T-score was higher in the surgical group than in the medical group but this difference was not statistically significant (12.6 vs 4.0 points; treatment effect=8.5; 95% CI, -1.0 to 18.1; P=.08). When data obtained after surgery from participants in the medical group were excluded, the effect of surgery on QOL was significant (12.8 vs 2.8 points; treatment effect=9.9; 95% CI, 2.2 to 17.7; P=.01). Memory decline (assessed using the Rey Auditory Verbal Learning Test) occurred in 4 participants (36%) after surgery, consistent with rates seen in the literature; but the sample was too small to permit definitive conclusions about treatment group differences in cognitive outcomes. Adverse events included a transient neurologic deficit attributed to a magnetic resonance imaging-identified postoperative stroke in a participant who had surgery and 3 cases of status epilepticus in the medical group. Conclusions Among patients with newly intractable disabling MTLE, resective surgery plus AED treatment resulted in a lower probability of seizures during year 2 of follow-up than continued AED treatment alone. Given the premature termination of the trial, the results should be interpreted with appropriate caution.	[Engel, Jerome, Jr.; Stern, John M.; Dewar, Sandra] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [McDermott, Michael P.] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA; [Wiebe, Samuel] Univ Calgary, Calgary, AB, Canada; [Wiebe, Samuel] Foothills Med Ctr, Div Neurol, Calgary, AB, Canada; [Langfitt, John T.; Erba, Giuseppe] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Gardiner, Irenita; Kieburtz, Karl] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA; [Fried, Itzhak; Mintzer, Scott] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA; [Sperling, Michael R.; Mintzer, Scott] Thomas Jefferson Univ, Jefferson Comprehens Epilepsy Ctr, Philadelphia, PA 19107 USA; [Fried, Itzhak] Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA USA; [Vinters, Harry V.] Ronald Reagan UCLA Med Ctr, Dept Anat & Clin Pathol, Los Angeles, CA USA; [Jacobs, Margaret] Amer Epilepsy Soc, Hartford, CT USA; [Jacobs, Margaret] Natl Inst Neurol Disorders & Stroke, NIH, Rockville, MD USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Rochester; University of Calgary; University of Calgary; University of Rochester; University of Rochester; Jefferson University; Jefferson University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Engel, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	engel@ucla.edu	Rodríguez, Fernando López/A-7557-2016; McDermott, Michael Francis/GZM-5330-2022; French, Jacqueline A/G-6795-2013	Rodríguez, Fernando López/0000-0002-0519-9624; French, Jacqueline A/0000-0003-2242-8027; Fisher, Robert/0000-0003-0287-613X; Vossler, David/0000-0003-4823-0537; Stern, John/0000-0002-3549-1642	National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS); Medtronics; Valeant; Acorda; US Food and Drug Administration; Esai; Johnson Johnson; Novartis; Lippincott [WO2009/123734A1, WO2009/123735A1]; UCB Pharmaceuticals; Teva Pharmaceutical Industries; Smith and Nephew; Synosia; Impax Pharmaceuticals; Medivation; NeuroSearch Sweden AB; Boehringer-Ingelheim; Pfizer; Canadian Institutes of Health Research; International League Against Epilepsy; UCSF/Elekta; Northern Illinois University; University of Cincinnatti; NIH CSR (Center for Scientific Review); NINDS; Agency for Healthcare Research and Quality; UCB; Vertex; Sunovion; Eisai; Neuropace; SK Life Sciences; Neuronex; Epilepsia; National Institutes of Health [R21 NS37897, U01 NS42372]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS037897, U01NS042372] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Medtronics; Valeant; Acorda; US Food and Drug Administration; Esai; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Novartis(Novartis); Lippincott; UCB Pharmaceuticals(UCB Pharma SA); Teva Pharmaceutical Industries(Teva Pharmaceutical Industries); Smith and Nephew; Synosia; Impax Pharmaceuticals; Medivation; NeuroSearch Sweden AB; Boehringer-Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); International League Against Epilepsy; UCSF/Elekta; Northern Illinois University; University of Cincinnatti; NIH CSR (Center for Scientific Review); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); UCB(UCB Pharma SA); Vertex(Vertex Pharmaceuticals); Sunovion; Eisai(Eisai Co Ltd); Neuropace; SK Life Sciences; Neuronex; Epilepsia; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Engel, Stern, Sperling, and Mintzer and Mss Gardiner and Jacobs report receipt of an institutional grant from the National Institutes of Health (NIH); and Drs McDermott, Langfitt, and Fried report receipt of an institutional grant from the National Institute of Neurological Disorders and Stroke (NINDS). Dr Engel reports receipt of consultancy fees from Medtronics, Valeant, Acorda, the US Food and Drug Administration, Best Doctors; receipt of fees to the institution for expert testimony; receipt of lecture/speakers bureau fees from Esai, Johnson & Johnson, Novartis, Lippincott; receipt of patent fees (WO2009/123734A1 and WO2009/123735A1); receipt of royalties from Wolters Kluwer, Wiley Blackwell, Elsevier, MedLink; and receipt of fees for travel accommodations/meeting expenses from UCB Pharmaceuticals. Dr McDermott reports receipt of fees to the institution for travel accommodations/meeting expenses for this study from NINDS, fees to the institution for consultancy from BoehringerIngelheim and Pfizer; receipt of consultancy fees from Teva Pharmaceutical Industries, Smith and Nephew, Synosia, Impax Pharmaceuticals; grant support or pending grant support to the institution from Medivation, NeuroSearch Sweden AB, Boehringer-Ingelheim, Pfizer. Dr Wiebe reports grant support from NINDS, fees for travel accommodations/meeting expenses from NINDS; employment with the University of Calgary; grant support or pending grant support from the Canadian Institutes of Health Research; fees for travel accommodations/meeting expenses from the International League Against Epilepsy. Dr Langfitt reports receipt of fees for travel accommodations/meeting expenses from NIH; consultancy fees from NINDS, UCSF/Elekta, Northern Illinois University, University of Cincinnatti, NIH CSR (Center for Scientific Review); grant support or pending grant support from NINDS and the Agency for Healthcare Research and Quality; fees to the institution for development of educational presentations from NIH. Dr Stern reports receipt of fees for travel accommodations/meeting expenses from NIH. Dr Sperling reports receipt of consultancy fees from UCB, Vertex, Sunovion; grant support or pending grant support from NIH, UCP, Vertex, Eisai, Sunovion, Medtronics, Neuropace, SK Life Sciences, Novartis, Neuronex; lecture/speakers bureau fees from UCB; other fees as associate editor from Epilepsia. Mss Gardiner and Dewar and Dr Erba report no disclosures.; This study was supported by the National Institutes of Health (grant numbers R21 NS37897 and U01 NS42372).	Alarcon G, 2006, J NEUROL NEUROSUR PS, V77, P474, DOI 10.1136/jnnp.2005.077289; Begley CE, 2000, EPILEPSIA, V41, P342, DOI 10.1111/j.1528-1157.2000.tb00166.x; Berg AT, 1999, EPILEPSIA, V40, P445, DOI 10.1111/j.1528-1157.1999.tb00739.x; Berg AT, 2004, CNS SPECTRUMS, V9, P136, DOI 10.1017/S109285290000849X; Berg AT, 2003, EPILEPSIA, V44, P1425, DOI 10.1046/j.1528-1157.2003.24203.x; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Choi H, 2008, JAMA-J AM MED ASSOC, V300, P2497, DOI 10.1001/jama.2008.771; Cramer JA, 1999, EPILEPSIA, V40, P1114, DOI 10.1111/j.1528-1157.1999.tb00828.x; DEVINSKY O, 1995, EPILEPSIA, V36, P1089, DOI 10.1111/j.1528-1157.1995.tb00467.x; Engel J, 2004, CNS SPECTRUMS, V9, P95, DOI 10.1017/S1092852900008452; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; Engel J, 2001, NEW ENGL J MED, V345, P365, DOI 10.1056/NEJM200108023450510; Engel J, 1998, NEUROLOGY, V51, P1243, DOI 10.1212/WNL.51.5.1243; Engel J, 2008, EPILEPSY COMPREHENSI, P2479; Engel J, 2008, JAMA-J AM MED ASSOC, V300, P2548, DOI 10.1001/jama.2008.756; Engel J, 2010, EPILEPSIA, V51, P1978, DOI 10.1111/j.1528-1167.2010.02641.x; Engel Jerome Jr., 1993, P23; Engel Jr J, 2008, EPILEPSY COMPREHENSI, P1791; Gilliam FG, 2011, EPILEPSY BEHAV, V20, P156, DOI 10.1016/j.yebeh.2010.12.022; Haneef Z, 2010, NEUROLOGY, V75, P699, DOI 10.1212/WNL.0b013e3181eee457; Immonen A, 2010, EPILEPSIA, V51, P2260, DOI 10.1111/j.1528-1167.2010.02720.x; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; Jallon P, 2001, EPILEPSIA, V42, P464, DOI 10.1046/j.1528-1157.2001.31400.x; Jokeit H, 2002, PROG BRAIN RES, V135, P455; Kaplan E, 2001, BOSTON NAMING TEST; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Murray G, 1994, GLOBAL COMP ASSESSME; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Reeves AL, 1997, EPILEPSIA, V38, P689, DOI 10.1111/j.1528-1157.1997.tb01238.x; Schmidt M., 1996, W PSYCHOL SERVICES; Seidenberg M, 1998, NEUROPSYCHOLOGY, V12, P303, DOI 10.1037/0894-4105.12.2.303; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sherman EMS, 2011, EPILEPSIA, V52, P857, DOI 10.1111/j.1528-1167.2011.03022.x; SPENCER DD, 1984, NEUROSURGERY, V15, P667, DOI 10.1227/00006123-198411000-00005; Spencer SS, 2007, ANN NEUROL, V62, P327, DOI 10.1002/ana.21131; Sperling MR, 2004, CNS SPECTRUMS, V9, P98, DOI 10.1017/S1092852900008464; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Sperling MR, 2004, CNS SPECTRUMS, V9, P106, DOI DOI 10.1017/S1092852900008464; Swarztrauber K, 2003, EPILEPSY BEHAV, V4, P19, DOI 10.1016/S1525-5050(02)00687-X; Walczak TS, 2001, EPILEPSIA, V42, P804; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501; Wieser HG, 2004, EPILEPSIA, V45, P32	44	706	730	3	84	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					922	930		10.1001/jama.2012.220	http://dx.doi.org/10.1001/jama.2012.220			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396514	Green Accepted			2022-12-28	WOS:000301172100020
J	Jabbour, S				Jabbour, Samer			PERSONAL VIEW Syria: tales of life, death, and dignity	BRITISH MEDICAL JOURNAL			English	Editorial Material									Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon	American University of Beirut	Jabbour, S (corresponding author), Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon.	sjabbour@aub.edu.lb	Jabbour, Samer/Y-6860-2018	Jabbour, Samer/0000-0002-7150-6856					0	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1691	10.1136/bmj.e1691	http://dx.doi.org/10.1136/bmj.e1691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399711	Green Submitted			2022-12-28	WOS:000301479800011
J	Kodali, SK; Williams, MR; Smith, CR; Svensson, LG; Webb, JG; Makkar, RR; Fontana, GP; Dewey, TM; Thourani, VH; Pichard, AD; Fischbein, M; Szeto, WY; Lim, S; Greason, KL; Teirstein, PS; Malaisrie, SC; Douglas, PS; Hahn, RT; Whisenant, B; Zajarias, A; Wang, DL; Akin, JJ; Anderson, WN; Leon, MB				Kodali, Susheel K.; Williams, Mathew R.; Smith, Craig R.; Svensson, Lars G.; Webb, John G.; Makkar, Raj R.; Fontana, Gregory P.; Dewey, Todd M.; Thourani, Vinod H.; Pichard, Augusto D.; Fischbein, Michael; Szeto, Wilson Y.; Lim, Scott; Greason, Kevin L.; Teirstein, Paul S.; Malaisrie, S. Chris; Douglas, Pamela S.; Hahn, Rebecca T.; Whisenant, Brian; Zajarias, Alan; Wang, Duolao; Akin, Jodi J.; Anderson, William N.; Leon, Martin B.		PARTNER Trial Investigators	Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTISLICE COMPUTED-TOMOGRAPHY; LONG-TERM OUTCOMES; HIGH-RISK PATIENTS; IMPLANTATION IMPACT; STENOSIS; REGURGITATION; CALCIFICATION; REGISTRY; ANNULUS; DEVICE	Background The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that among high-risk patients with aortic stenosis, the 1-year survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical replacement. However, longer-term follow-up is necessary to determine whether TAVR has prolonged benefits. Methods At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis to undergo either surgical aortic-valve replacement or TAVR. All patients were followed for at least 2 years, with assessment of clinical outcomes and echocardiographic evaluation. Results The rates of death from any cause were similar in the TAVR and surgery groups (hazard ratio with TAVR, 0.90; 95% confidence interval [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan-Meier analysis) were 33.9% in the TAVR group and 35.0% in the surgery group (P=0.78). The frequency of all strokes during follow-up did not differ significantly between the two groups (hazard ratio, 1.22; 95% CI, 0.67 to 2.23; P=0.52). At 30 days, strokes were more frequent with TAVR than with surgical replacement (4.6% vs. 2.4%, P=0.12); subsequently, there were 8 additional strokes in the TAVR group and 12 in the surgery group. Improvement in valve areas was similar with TAVR and surgical replacement and was maintained for 2 years. Paravalvular regurgitation was more frequent after TAVR (P<0.001), and even mild paravalvular regurgitation was associated with increased late mortality (P<0.001). Conclusions A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients. The two treatments were similar with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.)	[Kodali, Susheel K.; Williams, Mathew R.; Smith, Craig R.; Hahn, Rebecca T.; Leon, Martin B.] Columbia Univ, Med Ctr, New York, NY 10032 USA; [Fontana, Gregory P.] Lenox Hill Hosp, New York, NY 10021 USA; [Svensson, Lars G.] Cleveland Clin Fdn, Cleveland, OH USA; [Webb, John G.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Webb, John G.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Makkar, Raj R.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Dewey, Todd M.] Med City Dallas, Dallas, TX USA; [Thourani, Vinod H.] Emory Univ, Sch Med, Atlanta, GA USA; [Pichard, Augusto D.] Washington Hosp Ctr, Washington, DC 20010 USA; [Fischbein, Michael] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Teirstein, Paul S.] Scripps Clin, La Jolla, CA 92037 USA; [Akin, Jodi J.; Anderson, William N.] Edwards Lifesci, Irvine, CA USA; [Szeto, Wilson Y.] Hosp Univ Penn, Philadelphia, PA 19104 USA; [Lim, Scott] Univ Virginia, Charlottesville, VA USA; [Greason, Kevin L.] Mayo Clin, Rochester, MN USA; [Malaisrie, S. Chris] Northwestern Univ, Chicago, IL 60611 USA; [Douglas, Pamela S.] Duke Univ, Med Ctr, Durham, NC USA; [Whisenant, Brian] Intermt Med Ctr, Salt Lake City, UT USA; [Zajarias, Alan] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Zajarias, Alan] Barnes Jewish Hosp, St Louis, MO USA; [Wang, Duolao] London Sch Hyg & Trop Med, London, England; [Kodali, Susheel K.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY 10032 USA	Columbia University; Northwell Health; Cleveland Clinic Foundation; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; Cedars Sinai Medical Center; Medical City Dallas Hospital; Emory University; MedStar Washington Hospital Center; Stanford University; Scripps Research Institute; Edwards Lifesciences; University of Pennsylvania; Pennsylvania Medicine; University of Virginia; Mayo Clinic; Northwestern University; Duke University; Intermountain Healthcare; Intermountain Medical Center; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); University of London; London School of Hygiene & Tropical Medicine; Columbia University; NewYork-Presbyterian Hospital	Kodali, SK (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, 161 Ft Washington Ave,6th Fl, New York, NY 10032 USA.	sk2427@columbia.edu	Doğan, Ali/AAN-5331-2020; Hahn, Rebecca/ABE-6221-2020; thourani, vinod/AAP-5968-2020; Asch, Federico/AAS-7653-2021	Asch, Federico/0000-0002-1744-5271; Williams, Mathew/0000-0003-2055-8741; Douglas, Pamela/0000-0001-9876-4049; Miller, D. Craig/0000-0001-7619-0080	Edwards Lifesciences; Agency for Healthcare Research and Quality; Atritech; Ikaria; Viacor; National Marfan Foundation; Entourage Medical Technologies; Medtronic; Sorin; St. Jude Medical; Abbott; Abiomed; Cordis	Edwards Lifesciences; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Atritech; Ikaria; Viacor; National Marfan Foundation; Entourage Medical Technologies; Medtronic(Medtronic); Sorin; St. Jude Medical(St. Jude Medical); Abbott(Abbott Laboratories); Abiomed; Cordis	Ms. Akin reports being an employee of Edwards Lifesciences; Dr. Anderson, receiving consulting fees and fees for manuscript preparation and owning stock in Edwards Lifesciences; Dr. Dewey, receiving consulting fees and lecture fees from Edwards Lifesciences; Dr. Douglas, being a board member of Translational Research in Oncology and CardioDx and receiving grant funding from the Agency for Healthcare Research and Quality, Atritech, Ikaria, and Viacor on behalf of her institution; Dr. Fisch-bein, receiving consulting fees from Edwards Lifesciences and grant funding from the National Marfan Foundation on behalf of his institution; Dr. Fontana, receiving consulting fees and lecture fees from Edwards Lifesciences, receiving consulting fees from and owning stock or stock options in Entourage Medical Technologies, receiving consulting fees and lecture fees from Medtronic, receiving consulting fees and lecture fees from Sorin, and receiving consulting fees and lecture fees from St. Jude Medical; Dr. Kodali, being a medical advisory board member of Paieon Medical, receiving consulting fees from Edwards Lifesciences, Medtronic, and St. Jude Medical, and owning stock options in Thubrikar Aortic Valve; Dr. Makkar, receiving consulting fees from and owning stock or stock options in Entourage Medical Technologies, receiving consulting fees from Abbott, Abiomed, Cordis, and Medtronic, providing expert testimony for the law office of Pivo, Halbreich, Martin, Wilson & Amo, receiving grant funding from Edwards Lifesciences on behalf of his institution and reimbursement for travel expenses from Edwards Lifesciences on behalf of his institution, receiving lecture fees from Eli Lilly, and receiving reimbursement for travel expenses from St. Jude Medical on behalf of his institution and compensation from St. Jude Medical for being the national principal investigator of its valve trial; Dr. Malaisrie, receiving consulting fees from Baxter, Edwards Lifesciences, and Medtronic; Dr. Teirstein, receiving grant funding and payment for manuscript preparation from Edwards Lifesciences and Medtronic on behalf of his institution; Dr. Thourani, being an advisory board member of Edwards Lifesciences; Dr. Webb, receiving consulting fees and lecture fees from Edwards Lifesciences on behalf of himself and grant funding from Edwards Lifesciences on behalf of his institution; and Dr. Williams, receiving consulting fees from Edwards Lifesciences. No other potential conflicts of interest were reported. Disclosure forms provided by	Abdel-Wahab M, 2011, HEART, V97, P899, DOI 10.1136/hrt.2010.217158; Alli OO, 2012, JACC-CARDIOVASC INTE, V5, P72, DOI 10.1016/j.jcin.2011.09.014; Bach DS, 2009, CIRC-CARDIOVASC QUAL, V2, P533, DOI 10.1161/CIRCOUTCOMES.109.848259; Bleiziffer S, 2012, J THORAC CARDIOV SUR, V143, P310, DOI 10.1016/j.jtcvs.2011.10.060; Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748; Colli A, 2011, J THORAC CARDIOV SUR, V142, P1229, DOI 10.1016/j.jtcvs.2011.04.026; Cribier A, 2002, CIRCULATION, V106, P3006, DOI 10.1161/01.CIR.0000047200.36165.B8; Detaint D, 2009, JACC-CARDIOVASC INTE, V2, P821, DOI 10.1016/j.jcin.2009.07.003; Gotzmann M, 2011, AM HEART J, V162, P238, DOI 10.1016/j.ahj.2011.05.011; Gotzmann M, 2011, AM J CARDIOL, V107, P1687, DOI 10.1016/j.amjcard.2011.01.058; Gurvitch R, 2010, CIRCULATION, V122, P1319, DOI 10.1161/CIRCULATIONAHA.110.948877; Gurvitch R, 2011, CATHETER CARDIO INTE, V78, P977, DOI 10.1002/ccd.22961; Haensig M, 2012, EUR J CARDIOTHO 0112; HERAS M, 1995, J AM COLL CARDIOL, V25, P1111, DOI 10.1016/0735-1097(94)00563-6; Iung B, 2003, EUR HEART J, V24, P1231, DOI 10.1016/S0195-668X(03)00201-X; Jabbour A, 2011, J AM COLL CARDIOL, V58, P2165, DOI 10.1016/j.jacc.2011.09.010; Kempfert J, 2011, CIRCULATION, V124, pS124, DOI 10.1161/CIRCULATIONAHA.110.013425; Koos R, 2011, INT J CARDIOL   0209; Koos R, 2011, INT J CARDIOL, V150, P142, DOI 10.1016/j.ijcard.2010.03.004; Leipsic J, 2011, JACC-CARDIOVASC IMAG, V4, P416, DOI 10.1016/j.jcmg.2011.01.014; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; Moat NE, 2011, J AM COLL CARDIOL, V58, P2130, DOI 10.1016/j.jacc.2011.08.050; Nietlispach F, 2010, JACC-CARDIOVASC INTE, V3, P1133, DOI 10.1016/j.jcin.2010.05.022; Pellikka PA, 2005, CIRCULATION, V111, P3290, DOI 10.1161/CIRCULATIONAHA.104.495903; Piazza N, 2008, CIRCULATION, V118, pS807; Ruel M, 2005, EUR J CARDIO-THORAC, V27, P425, DOI 10.1016/j.ejcts.2004.12.002; Schoen FJ, 2005, ANN THORAC SURG, V79, P1072, DOI 10.1016/j.athoracsur.2004.06.033; Shroyer ALW, 2003, ANN THORAC SURG, V75, P1856, DOI 10.1016/S0003-4975(03)00179-6; Smith CR, 2011, NEW ENGL J MED, V364, P2187, DOI 10.1056/NEJMoa1103510; Tamburino C, 2011, CIRCULATION, V123, P299, DOI 10.1161/CIRCULATIONAHA.110.946533; Thomas M, 2010, CIRCULATION, V122, P62, DOI 10.1161/CIRCULATIONAHA.109.907402; Tops LF, 2008, JACC-CARDIOVASC IMAG, V1, P321, DOI 10.1016/j.jcmg.2007.12.006; Tzikas A, 2011, CATHETER CARDIO INTE, V77, P868, DOI 10.1002/ccd.22761; Ussia GP, 2011, AM J CARDIOL, V108, P1772, DOI 10.1016/j.amjcard.2011.07.049; Ussia GP, 2012, EUR HEART J     0112; Varadarajan P, 2006, ANN THORAC SURG, V82, P2111, DOI 10.1016/j.athoracsur.2006.07.048; Walther T, 2011, EUR J CARDIO-THORAC, V39, P532, DOI 10.1016/j.ejcts.2010.06.002; Webb JG, 2007, CIRCULATION, V116, P755, DOI 10.1161/CIRCULATIONAHA.107.698258; Webb JG, 2009, CIRCULATION, V119, P3009, DOI 10.1161/CIRCULATIONAHA.108.837807; Ye J, 2009, J THORAC CARDIOV SUR, V137, P167, DOI 10.1016/j.jtcvs.2008.08.028	40	1735	1782	4	108	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 3	2012	366	18					1686	1695		10.1056/NEJMoa1200384	http://dx.doi.org/10.1056/NEJMoa1200384			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934HH	22443479	Bronze, Green Accepted			2022-12-28	WOS:000303434300008
J	Joynt, KE; Jha, AK				Joynt, Karen E.; Jha, Ashish K.			Thirty-Day Readmissions - Truth and Consequences	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HOSPITAL READMISSIONS; CARE		[Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.							Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	5	372	374	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1366	1369		10.1056/NEJMp1201598	http://dx.doi.org/10.1056/NEJMp1201598			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22455752				2022-12-28	WOS:000302608600013
J	Wright, JD; Medel, NIB; Sehouli, J; Fujiwara, K; Herzog, TJ				Wright, Jason D.; Medel, Nicanor I. Barrena; Sehouli, Jalid; Fujiwara, Keiichi; Herzog, Thomas J.			Contemporary management of endometrial cancer	LANCET			English	Review							PHASE-III TRIAL; DOXORUBICIN PLUS CISPLATIN; STAGE-I; RADIATION-THERAPY; ADJUVANT CHEMOTHERAPY; INTERMEDIATE-RISK; ONCOLOGY-GROUP; CORPUS CANCER; MEDROXYPROGESTERONE ACETATE; POSTOPERATIVE RADIOTHERAPY	The treatment of endometrial cancer has changed substantially in the past decade with the introduction of a new staging system and surgical approaches accompanied by novel adjuvant therapies. Primary surgical treatment is the mainstay of therapy but the effectiveness and extent of lymphadenectomy has been challenged, and its acceptance as a routine procedure varies by country. The role of radiation has evolved and chemotherapy has been incorporated, either alone or combined with radiation, to treat the many patients in whom cancer recurs because of a tumour outside the originally radiated pelvic and lower abdominal area. Use of traditional adjuvant chemotherapeutics has been challenged in clinical trials of new agents with improved side-effect profiles. Novel agents and targeted therapies are being investigated. Research into genetic susceptibility to endometrial cancer and the potential genetic aberrations that might translate into therapeutic interventions continues to increase. Substantial global variability in the treatment of endometrial cancer has led to examination of long-accepted norms, which has resulted in rapidly changing standards. International cooperation in clinical trials will hasten progress in treatment of this ubiquitous cancer.	[Wright, Jason D.; Medel, Nicanor I. Barrena; Herzog, Thomas J.] Columbia Univ Coll Phys & Surg, New York Presbyterian Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, New York, NY 10032 USA; [Sehouli, Jalid] Univ Berlin, Dept Gynecol, Charite Campus Virchow Klinikum, Berlin, Germany; [Fujiwara, Keiichi] Saitama Med Univ, Int Med Ctr, Saitama, Japan	Columbia University; NewYork-Presbyterian Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saitama Medical University	Herzog, TJ (corresponding author), Columbia Univ Coll Phys & Surg, New York Presbyterian Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, New York, NY 10032 USA.	th2135@columbia.edu			Genentech; Merck	Genentech(Roche HoldingGenentech); Merck(Merck & Company)	JDW has received research funding from Genentech and Merck, and payment for lectures from Precision Therapeutics. TJH has been a consultant for Genentech, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche, Bayer, Sanofi-Aventis, and Precision Therapeutics, and has received payment for lectures from Amgen, GlaxoSmithKline, Johnson & Johnson, Lilly, and Merck. NIBM, KF, and JS declare that they have no conflicts of interest.	AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Aapro MS, 2003, ANN ONCOL, V14, P441, DOI 10.1093/annonc/mdg112; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Asbury RF, 2002, AM J CLIN ONCOL-CANC, V25, P557, DOI 10.1097/00000421-200212000-00004; Ben-Shachar I, 2005, OBSTET GYNECOL, V105, P487, DOI 10.1097/01.AOG.0000149151.74863.c4; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; Boggess JF, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.08.012; BOKHMAN JV, 1981, GYNECOL ONCOL, V11, P371, DOI 10.1016/0090-8258(81)90051-2; BORONOW RC, 1984, OBSTET GYNECOL, V63, P825; Bray F, 2005, INT J CANCER, V117, P123, DOI 10.1002/ijc.21099; Bristow RE, 2006, GYNECOL ONCOL, V103, P281, DOI 10.1016/j.ygyno.2006.03.011; Bruzzone M, 2004, GYNECOL ONCOL, V93, P345, DOI 10.1016/j.ygyno.2004.02.008; Carey MS, 2006, GYNECOL ONCOL, V101, P158, DOI 10.1016/j.ygyno.2005.11.019; Case AS, 2006, OBSTET GYNECOL, V108, P1375, DOI 10.1097/01.AOG.0000245444.14015.00; Chan JK, 2006, CANCER, V107, P1823, DOI 10.1002/cncr.22185; CHILDERS JM, 1993, GYNECOL ONCOL, V51, P33, DOI 10.1006/gyno.1993.1242; Colombo N, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.11.1005; Cragun JM, 2005, J CLIN ONCOL, V23, P3668, DOI 10.1200/JCO.2005.04.144; Creasman WT, 2010, GYNECOL ONCOL, V116, P293, DOI 10.1016/j.ygyno.2009.10.065; CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8; Creutzberg CL, 2004, J CLIN ONCOL, V22, P1234, DOI 10.1200/JCO.2004.08.159; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Creutzberg CL, 2003, GYNECOL ONCOL, V89, P201, DOI 10.1016/S0090-8258(03)00126-4; Decruze SB, 2007, INT J GYNECOL CANCER, V17, P964, DOI 10.1111/j.1525-1438.2007.00897.x; Dimopoulos MA, 2000, GYNECOL ONCOL, V78, P52, DOI 10.1006/gyno.2000.5827; DISAIA PJ, 1985, AM J OBSTET GYNECOL, V151, P1009, DOI 10.1016/0002-9378(85)90371-0; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; ELLIOTT P, 1994, INT J GYNECOL CANCER, V4, P84, DOI 10.1046/j.1525-1438.1994.04020084.x; Fiorica JV, 2004, GYNECOL ONCOL, V92, P10, DOI 10.1016/j.ygyno.2003.11.008; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184; Fleming GF, 2004, ANN ONCOL, V15, P1173, DOI 10.1093/annonc/mdh316; Fleming GF, 2010, GYNECOL ONCOL, V116, P15, DOI 10.1016/j.ygyno.2009.09.025; Fotopoulou C, 2010, EUR J OBSTET GYN R B, V149, P199, DOI 10.1016/j.ejogrb.2009.12.021; Gallion HH, 2003, J CLIN ONCOL, V21, P3808, DOI 10.1200/JCO.2003.10.083; GOFF BA, 1990, GYNECOL ONCOL, V38, P46, DOI 10.1016/0090-8258(90)90009-A; Goudge C, 2004, GYNECOL ONCOL, V93, P536, DOI 10.1016/j.ygyno.2004.02.020; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Greven K, 2006, GYNECOL ONCOL, V103, P155, DOI 10.1016/j.ygyno.2006.02.007; GREVEN KM, 1993, CANCER-AM CANCER SOC, V71, P3697, DOI 10.1002/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U; Grushko TA, 2008, GYNECOL ONCOL, V108, P3, DOI 10.1016/j.ygyno.2007.09.007; Hogberg T, 2010, EUR J CANCER, V46, P2422, DOI 10.1016/j.ejca.2010.06.002; Holtz DO, 2010, J MINIM INVAS GYN, V17, P500, DOI 10.1016/j.jmig.2010.03.012; Homesley HD, 2009, GYNECOL ONCOL, V112, P543, DOI 10.1016/j.ygyno.2008.11.014; Huh WK, 2007, INT J GYNECOL CANCER, V17, P886, DOI 10.1111/j.1525-1438.2007.00858.x; Janda M, 2010, LANCET ONCOL, V11, P772, DOI 10.1016/S1470-2045(10)70145-5; Johnson N, 2007, BJOG-INT J OBSTET GY, V114, P1313, DOI 10.1111/j.1471-0528.2007.01332.x; Kamat AA, 2007, CLIN CANCER RES, V13, P7487, DOI 10.1158/1078-0432.CCR-07-1017; Karolewski K, 2006, EUR J GYNAECOL ONCOL, V27, P579; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; KHALIFA MA, 1994, GYNECOL ONCOL, V53, P84, DOI 10.1006/gyno.1994.1092; Khoury-Collado F, 2009, GYNECOL ONCOL, V115, P453, DOI 10.1016/j.ygyno.2009.08.026; Kitchener H, 2009, LANCET, V373, P125, DOI 10.1016/S0140-6736(08)61766-3; Kong A, 2007, COCHRANE DB SYST REV, V18; Kornblith AB, 2009, J CLIN ONCOL, V27, P5337, DOI 10.1200/JCO.2009.22.3529; Lee CM, 2006, JAMA-J AM MED ASSOC, V295, P389, DOI 10.1001/jama.295.4.389; Lee TS, 2009, GYNECOL ONCOL, V115, P26, DOI 10.1016/j.ygyno.2009.06.041; Lindor NM, 2006, JAMA-J AM MED ASSOC, V296, P1507, DOI 10.1001/jama.296.12.1507; Lu KH, 2007, J CLIN ONCOL, V25, P5158, DOI 10.1200/JCO.2007.10.8597; Ma BBY, 2004, INT J GYNECOL CANCER, V14, P650, DOI 10.1111/j.1048-891X.2004.14419.x; Maggi R, 2006, BRIT J CANCER, V95, P266, DOI 10.1038/sj.bjc.6603279; Mariani A, 2002, GYNECOL ONCOL, V87, P274, DOI 10.1006/gyno.2002.6836; Mariani A, 2002, GYNECOL ONCOL, V87, P112, DOI 10.1006/gyno.2002.6789; Mariani A, 2001, GYNECOL ONCOL, V80, P113, DOI 10.1006/gyno.2000.6050; Mariani A, 2000, AM J OBSTET GYNECOL, V182, P1506, DOI 10.1067/mob.2000.107335; MORROW CP, 1990, GYNECOL ONCOL, V36, P166, DOI 10.1016/0090-8258(90)90166-I; Mourits MJE, 2010, LANCET ONCOL, V11, P763, DOI 10.1016/S1470-2045(10)70143-1; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; National Comprehensive Cancer Network, 2011, NCCN PHYS CLIN PRACT; Nimeiri HS, 2010, GYNECOL ONCOL, V117, P37, DOI 10.1016/j.ygyno.2010.01.013; Nomura H, 2011, ANN ONCOL, V22, P636, DOI 10.1093/annonc/mdq401; Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2; OZA AM, 2006, J CLIN ONCOL, V24, P3003; Oza AM, 2008, J CLIN ONCOL, V26, P4319, DOI 10.1200/JCO.2007.15.8808; Oza AM, 2011, J CLIN ONCOL, V29, P3278, DOI 10.1200/JCO.2010.34.1578; Pandya KJ, 2001, AM J CLIN ONCOL-CANC, V24, P43, DOI 10.1097/00000421-200102000-00007; Panici PB, 2008, JNCI-J NATL CANCER I, V100, P1707, DOI 10.1093/jnci/djn397; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Ramirez PT, 2004, GYNECOL ONCOL, V95, P133, DOI 10.1016/j.ygyno.2004.06.045; Randall ME, 2006, J CLIN ONCOL, V24, P36, DOI 10.1200/JCO.2004.00.7617; RENDINA GM, 1984, EUR J OBSTET GYN R B, V17, P285, DOI 10.1016/0028-2243(84)90071-6; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Richter CE, 2009, GYNECOL ONCOL, V114, P99, DOI 10.1016/j.ygyno.2009.03.032; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808; Seamon LG, 2009, OBSTET GYNECOL, V114, P16, DOI 10.1097/AOG.0b013e3181aa96c7; Secord AA, 2007, GYNECOL ONCOL, V107, P285, DOI 10.1016/j.ygyno.2007.06.014; Sorbe B, 2009, INT J GYNECOL CANCER, V19, P873, DOI 10.1111/IGC.0b013e3181a6c9df; Sovak MA, 2006, GYNECOL ONCOL, V103, P451, DOI 10.1016/j.ygyno.2006.03.019; Straughn JM, 2002, GYNECOL ONCOL, V84, P194, DOI 10.1006/gyno.2001.6494; Susumu N, 2008, GYNECOL ONCOL, V108, P226, DOI 10.1016/j.ygyno.2007.09.029; Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736; THIGPEN JT, 1994, J CLIN ONCOL, V12, P1408, DOI 10.1200/JCO.1994.12.7.1408; Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088; Thigpen T, 2001, J CLIN ONCOL, V19, P364, DOI 10.1200/JCO.2001.19.2.364; Tierney Ryan M, 2007, Radiat Med, V25, P439, DOI 10.1007/s11604-007-0163-1; Todo Y, 2010, LANCET, V375, P1165, DOI 10.1016/S0140-6736(09)62002-X; Touboul E, 2001, INT J RADIAT ONCOL, V50, P81, DOI 10.1016/S0360-3016(00)01571-6; van Wijk FH, 2009, INT J GYNECOL CANCER, V19, P314, DOI 10.1111/IGC.0b013e3181a7f71e; Walker JL, 2009, J CLIN ONCOL, V27, P5331, DOI 10.1200/JCO.2009.22.3248; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; Whitney CW, 2004, GYNECOL ONCOL, V92, P4, DOI 10.1016/j.ygyno.2003.09.018; Wright JD, 2007, ANTICANCER RES, V27, P3525; Wright JD, 2009, J CLIN ONCOL, V27, P1214, DOI 10.1200/JCO.2008.19.8150	105	208	215	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2012	379	9823					1352	1360		10.1016/S0140-6736(12)60442-5	http://dx.doi.org/10.1016/S0140-6736(12)60442-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922FB	22444602				2022-12-28	WOS:000302531100033
J	Aizen, MA; Sabatino, M; Tylianakis, JM				Aizen, Marcelo A.; Sabatino, Malena; Tylianakis, Jason M.			Specialization and Rarity Predict Nonrandom Loss of Interactions from Mutualist Networks	SCIENCE			English	Article							POLLINATION NETWORKS; PLANT; STABILITY; CONSERVATION; ARCHITECTURE; DISRUPTION; IMPACT	The loss of interactions from mutualistic networks could foreshadow both plant and animal species extinctions. Yet, the characteristics of interactions that predispose them to disruption are largely unknown. We analyzed 12 pollination webs from isolated hills ("sierras"), in Argentina, ranging from tens to thousands of hectares. We found evidence of nonrandom loss of interactions with decreasing sierra size. Low interaction frequency and high specialization between interacting partners contributed additively to increase the vulnerability of interactions to disruption. Interactions between generalists in the largest sierras were ubiquitous across sierras, but many of them lost their central structural role in the smallest sierras. Thus, particular configurations of interaction networks, along with unique ecological relations and evolutionary pathways, could be lost forever after habitat reduction.	[Aizen, Marcelo A.; Sabatino, Malena] Univ Nacl Comahue, Lab Ecotono, CRUB, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina; [Aizen, Marcelo A.] Inst Invest Biodiversidad Medioambiente INIBIOMA, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina; [Aizen, Marcelo A.] Museo Argentino Ciencias Nat Bernardino Rivadavia, Dept Bot, RA-1405 Buenos Aires, DF, Argentina; [Tylianakis, Jason M.] Univ Canterbury, Sch Biol Sci, Christchurch 1, New Zealand	Universidad Nacional del Comahue; Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN); University of Canterbury	Aizen, MA (corresponding author), Univ Nacl Comahue, Lab Ecotono, CRUB, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina.	maizen@comahue-conicet.gob.ar	Tylianakis, Jason/B-6634-2011	Tylianakis, Jason/0000-0001-7402-5620; Aizen, Marcelo/0000-0001-9079-9749	National Institute of Agricultural Technology (INTA), Balcarce [PNECO1302]; Argentina National Research Council (CONICET) [PIP 01623]; National Fund for Research [PICT 01300]; National University of Comahue [B152/04]; Rutherford Discovery Fellowship	National Institute of Agricultural Technology (INTA), Balcarce; Argentina National Research Council (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); National Fund for Research; National University of Comahue; Rutherford Discovery Fellowship	The authors thank J. M. Gomez, L. D. Harder, D. P. Vazquez, M. Verdu, N. M. Waser, and two anonymous referees for useful comments and suggestions; A. Saez and D. Porrini for field assistance; V. Izpizua and M. Nuciari for help in plant identification; and J. Farina and A. Roig-Alsina for help in identifying insects. Partial funding by the National Institute of Agricultural Technology (INTA), Balcarce (PNECO1302), the Argentina National Research Council (CONICET) (PIP 01623), the National Fund for Research (PICT 01300), and the National University of Comahue (B152/04) is acknowledged. M.A.A. is a career researcher and M. S. a fellow of CONICET. J.M.T. is funded by a Rutherford Discovery Fellowship administered by the Royal Society of New Zealand. Data used in the analyses are available in the Supporting Online Material.	Aizen MA, 2008, PLOS BIOL, V6, P396, DOI 10.1371/journal.pbio.0060031; Almeida-Neto M, 2008, OIKOS, V117, P1227, DOI 10.1111/j.0030-1299.2008.16644.x; Anderson B, 2008, EVOLUTION, V62, P220, DOI 10.1111/j.1558-5646.2007.00275.x; Bascompte J, 2006, SCIENCE, V312, P431, DOI 10.1126/science.1123412; Bascompte J, 2003, P NATL ACAD SCI USA, V100, P9383, DOI 10.1073/pnas.1633576100; Bastolla U, 2009, NATURE, V458, P1018, DOI 10.1038/nature07950; BOND WJ, 1994, PHILOS T R SOC B, V344, P83, DOI 10.1098/rstb.1994.0055; Crisci-V. Jorge, 2001, Caldasia, V23, P21; Fontaine C, 2006, PLOS BIOL, V4, P129, DOI 10.1371/journal.pbio.0040001; Guimaraes PR, 2007, CURR BIOL, V17, P1797, DOI 10.1016/j.cub.2007.09.059; Kaiser-Bunbury CN, 2010, ECOL LETT, V13, P442, DOI 10.1111/j.1461-0248.2009.01437.x; Koh LP, 2004, SCIENCE, V305, P1632, DOI 10.1126/science.1101101; Lavorel S, 1997, TRENDS ECOL EVOL, V12, P474, DOI 10.1016/S0169-5347(97)01219-6; Memmott J, 2004, P ROY SOC B-BIOL SCI, V271, P2605, DOI 10.1098/rspb.2004.2909; Memmott J, 2007, ECOL LETT, V10, P710, DOI 10.1111/j.1461-0248.2007.01061.x; Muller A, 2006, BIOL CONSERV, V130, P604, DOI 10.1016/j.biocon.2006.01.023; Okuyama T, 2008, ECOL LETT, V11, P208, DOI 10.1111/j.1461-0248.2007.01137.x; Olesen JM, 2002, DIVERS DISTRIB, V8, P181, DOI 10.1046/j.1472-4642.2002.00148.x; Padron B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006275; Pauw A, 2007, ECOLOGY, V88, P1759, DOI 10.1890/06-1383.1; Pauw A, 2011, OIKOS, V120, P344, DOI 10.1111/j.1600-0706.2010.19039.x; Rooney N, 2006, NATURE, V442, P265, DOI 10.1038/nature04887; Sabatino M, 2010, ECOL APPL, V20, P1491, DOI 10.1890/09-1626.1; STEINER KE, 1990, EVOLUTION, V44, P1701, DOI [10.2307/2409348, 10.1111/j.1558-5646.1990.tb03857.x]; Thebault E, 2010, SCIENCE, V329, P853, DOI 10.1126/science.1188321; Thompson JD., 1994, COEVOLUTIONARY PROCE; TILMAN D, 1994, NATURE, V371, P65, DOI 10.1038/371065a0; Tylianakis JM, 2008, ECOL LETT, V11, P1351, DOI 10.1111/j.1461-0248.2008.01250.x; Tylianakis JM, 2010, BIOL CONSERV, V143, P2270, DOI 10.1016/j.biocon.2009.12.004; Vazquez DP, 2005, J ANIM ECOL, V74, P946, DOI 10.1111/j.1365-2656.2005.00992.x; Vazquez DP, 2004, ECOLOGY, V85, P1251, DOI 10.1890/03-3112; Vazquez DP, 2003, ECOLOGY, V84, P2493, DOI 10.1890/02-0587; Williams NM, 2007, ECOL APPL, V17, P910, DOI 10.1890/06-0269; Williams NM, 2010, BIOL CONSERV, V143, P2280, DOI 10.1016/j.biocon.2010.03.024	34	181	186	4	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1486	1489		10.1126/science.1215320	http://dx.doi.org/10.1126/science.1215320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442482	Green Submitted			2022-12-28	WOS:000301837000046
J	Weiner, LM; Lotze, MT				Weiner, Louis M.; Lotze, Michael T.			Tumor-Cell Death, Autophagy, and Immunity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Weiner, Louis M.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA; [Lotze, Michael T.] Univ Pittsburgh, Dept Surg, Inst Canc, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Dept Immunol, Inst Canc, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Dept Bioengn, Inst Canc, Pittsburgh, PA USA	Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiner, LM (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA.				NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NCI NIH HHS [P30 CA051008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744	5	48	51	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1156	1158		10.1056/NEJMcibr1114526	http://dx.doi.org/10.1056/NEJMcibr1114526			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435376	Green Accepted			2022-12-28	WOS:000301769700017
J	Tan, JM; Wu, WZ; Xu, XM; Liao, LM; Zheng, F; Messinger, S; Sun, XH; Chen, J; Yang, SL; Cai, JQ; Gao, X; Pileggi, A; Ricordi, C				Tan, Jianming; Wu, Weizhen; Xu, Xiumin; Liao, Lianming; Zheng, Feng; Messinger, Shari; Sun, Xinhui; Chen, Jin; Yang, Shunliang; Cai, Jinquan; Gao, Xia; Pileggi, Antonello; Ricordi, Camillo			Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SOLID-ORGAN TRANSPLANTATION; VERSUS-HOST-DISEASE; STROMAL CELLS; RENAL-TRANSPLANTATION; GRAFT FUNCTION; IN-VITRO; PHASE-I; DONOR; SURVIVAL	Context Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging. Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease. Objective To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor. Design, Setting, and Patients One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed. Intervention Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later. Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs. Main Outcome Measures The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events. Results Patient and graft survival at 13 to 30 months was similar in all groups. After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P=.04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P=.046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection. None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control showing increased eGFR levels during the first month postsurgery group did (95% CI, 0.6%-15.1%; overall P=.02). Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group. Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002). Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02) Conclusion Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.	[Tan, Jianming; Wu, Weizhen; Liao, Lianming; Zheng, Feng; Sun, Xinhui; Chen, Jin; Yang, Shunliang; Cai, Jinquan; Gao, Xia] Xiamen Univ, Fuzhou Gen Hosp, Organ Transplant Inst, Fuzhou 350025, Fujian, Peoples R China; [Tan, Jianming; Wu, Weizhen; Liao, Lianming; Zheng, Feng; Chen, Jin] Fujian Key Lab Transplant Biol, Fuzhou, Peoples R China; [Xu, Xiumin; Messinger, Shari; Pileggi, Antonello; Ricordi, Camillo] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA; [Messinger, Shari] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA	Xiamen University; University of Miami; University of Miami	Tan, JM (corresponding author), Xiamen Univ, Fuzhou Gen Hosp, Organ Transplant Inst, 156 Xi Er Huang Rd, Fuzhou 350025, Fujian, Peoples R China.	tanjm156@yahoo.com.cn; cricordi@med.miami.edu	Pileggi, Antonello/A-2394-2008; RICORDI, CAMILLO/AAA-4740-2019; Tan, Ming-Jen/A-3862-2011	Pileggi, Antonello/0000-0001-7819-2813; Chen, Jin/0000-0003-0794-3995; Tan, Ming-Jen/0000-0002-3583-1723; Ricordi, Camillo/0000-0001-8092-7153; Liao, Lianming/0000-0003-0248-0821	Key Science Research Project of Fujian Province, China [2009Y4001]; Key Laboratory of Fujian Province, China [2008J1006]	Key Science Research Project of Fujian Province, China; Key Laboratory of Fujian Province, China	This study was supported in part by grants 2009Y4001 from the Key Science Research Project and 2008J1006 from the Key Laboratory, both of Fujian Province, China.	[Anonymous], 2007, 171 EX M STAT COUNC; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Casiraghi F, 2010, CURR OPIN ORGAN TRAN, DOI [10.1097/MOT.0b013e328340172c, DOI 10.1097/MOT.OB013E328340172C]; Centeno CJ, 2011, CURR STEM CELL RES T, V6, P368; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; Ciancio G, 2002, TRANSPLANTATION, V74, P488, DOI 10.1097/00007890-200208270-00010; Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841; Crop M, 2009, TRANSPL INT, V22, P365, DOI 10.1111/j.1432-2277.2008.00786.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Delmonico FL, 2005, TRANSPLANTATION, V79, pS53; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; Ekberg H, 2007, NEW ENGL J MED, V357, P2562, DOI 10.1056/NEJMoa067411; Hanaway MJ, 2011, NEW ENGL J MED, V364, P1909, DOI 10.1056/NEJMoa1009546; Hariharan S, 2002, KIDNEY INT, V62, P311, DOI 10.1046/j.1523-1755.2002.00424.x; Herrera MB, 2004, INT J MOL MED, V14, P1035; Hoogduijn MJ, 2010, TRANSPLANTATION, V90, P124, DOI 10.1097/TP.0b013e3181ea4240; Kahan BD, 1998, TRANSPLANTATION, V66, P1040, DOI 10.1097/00007890-199810270-00013; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kyllonen LEJ, 2000, TRANSPLANT INT, V13, P122, DOI 10.1111/j.1432-2277.2000.tb01051.x; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lebranchu Y, 2002, AM J TRANSPLANT, V2, P48, DOI 10.1034/j.1600-6143.2002.020109.x; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Momin EN, 2010, CURR STEM CELL RES T, V5, P326; Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Perico N, 2011, CLIN J AM SOC NEPHRO, V6, P412, DOI 10.2215/CJN.04950610; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Roodnat JI, 2003, TRANSPLANTATION, V75, P799, DOI 10.1097/01.TP.0000056632.00848.8D; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Schnuelle P, 2009, JAMA-J AM MED ASSOC, V302, P1067, DOI 10.1001/jama.2009.1310; Tan Jianming, 2005, Clin Transpl, P203; Wynn JJ, 2004, AM J TRANSPLANT, V4, P72, DOI 10.1111/j.1600-6135.2004.00399.x; Zhao WY, 2010, CLIN TRANSPLANT, V24, pE158, DOI 10.1111/j.1399-0012.2010.01229.x; Zhuo WL, 2011, UROL INT, V86, P191, DOI 10.1159/000319366	40	388	408	0	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1169	1177		10.1001/jama.2012.316	http://dx.doi.org/10.1001/jama.2012.316			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436957	Bronze			2022-12-28	WOS:000301708000025
J	Alberts, MJ				Alberts, Mark J.			Targeting management of fever, hyperglycemia, and swallowing improved outcomes in acute stroke	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Alberts, MJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.							Baker L, 2011, CURR TREAT OPTION NE, V13, P616, DOI 10.1007/s11940-011-0143-8; Broessner G, 2009, STROKE, V40, pE657, DOI 10.1161/STROKEAHA.109.557652	2	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-9	10.7326/0003-4819-156-6-201203200-02009	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431695				2022-12-28	WOS:000303150900008
J	Lacasse, Y				Lacasse, Yves			Screening with chest radiography did not reduce lung cancer mortality in older patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Ste Foy, PQ G1K 7P4, Canada	Laval University	Lacasse, Y (corresponding author), Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Ste Foy, PQ G1K 7P4, Canada.							Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6	2	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-8	10.7326/0003-4819-156-6-201203200-02008	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431694				2022-12-28	WOS:000303150900007
J	Chen, R; Mias, GI; Li-Pook-Than, J; Jiang, LH; Lam, HYK; Chen, R; Miriami, E; Karczewski, KJ; Hariharan, M; Dewey, FE; Cheng, Y; Clark, MJ; Im, H; Habegger, L; Balasubramanian, S; O'Huallachain, M; Dudley, JT; Hillenmeyer, S; Haraksingh, R; Sharon, D; Euskirchen, G; Lacroute, P; Bettinger, K; Boyle, AP; Kasowski, M; Grubert, F; Seki, S; Garcia, M; Whirl-Carrillo, M; Gallardo, M; Blasco, MA; Greenberg, PL; Snyder, P; Klein, TE; Altman, RB; Butte, AJ; Ashley, EA; Gerstein, M; Nadeau, KC; Tang, H; Snyder, M				Chen, Rui; Mias, George I.; Li-Pook-Than, Jennifer; Jiang, Lihua; Lam, Hugo Y. K.; Chen, Rong; Miriami, Elana; Karczewski, Konrad J.; Hariharan, Manoj; Dewey, Frederick E.; Cheng, Yong; Clark, Michael J.; Im, Hogune; Habegger, Lukas; Balasubramanian, Suganthi; O'Huallachain, Maeve; Dudley, Joel T.; Hillenmeyer, Sara; Haraksingh, Rajini; Sharon, Donald; Euskirchen, Ghia; Lacroute, Phil; Bettinger, Keith; Boyle, Alan P.; Kasowski, Maya; Grubert, Fabian; Seki, Scott; Garcia, Marco; Whirl-Carrillo, Michelle; Gallardo, Mercedes; Blasco, Maria A.; Greenberg, Peter L.; Snyder, Phyllis; Klein, Teri E.; Altman, Russ B.; Butte, Atul J.; Ashley, Euan A.; Gerstein, Mark; Nadeau, Kari C.; Tang, Hua; Snyder, Michael			Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes	CELL			English	Article							TIME-SERIES ANALYSIS; PERIODICITY DETECTION; GENE ONTOLOGY; RNA; EXPRESSION; IDENTIFICATION; TRANSCRIPT; MUTATIONS; ALGORITHM; DATABASE	Personalized medicine is expected to benefit from combining genomic information with regular monitoring of physiological states by multiple high-throughput methods. Here, we present an integrative personal omics profile (iPOP), an analysis that combines genomic, transcriptomic, proteomic, metabolomic, and autoantibody profiles from a single individual over a 14 month period. Our iPOP analysis revealed various medical risks, including type 2 diabetes. It also uncovered extensive, dynamic changes in diverse molecular components and biological pathways across healthy and diseased conditions. Extremely high-coverage genomic and transcriptomic data, which provide the basis of our iPOP, revealed extensive heteroallelic changes during healthy and diseased states and an unexpected RNA editing mechanism. This study demonstrates that longitudinal iPOP can be used to interpret healthy and diseased states by connecting genomic information with additional dynamic omics activity.	[Chen, Rui; Mias, George I.; Li-Pook-Than, Jennifer; Jiang, Lihua; Lam, Hugo Y. K.; Miriami, Elana; Karczewski, Konrad J.; Hariharan, Manoj; Cheng, Yong; Clark, Michael J.; Im, Hogune; O'Huallachain, Maeve; Hillenmeyer, Sara; Haraksingh, Rajini; Sharon, Donald; Euskirchen, Ghia; Lacroute, Phil; Bettinger, Keith; Boyle, Alan P.; Kasowski, Maya; Grubert, Fabian; Whirl-Carrillo, Michelle; Snyder, Phyllis; Klein, Teri E.; Altman, Russ B.; Tang, Hua; Snyder, Michael] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Chen, Rong; Dudley, Joel T.; Seki, Scott; Garcia, Marco; Butte, Atul J.; Nadeau, Kari C.] Stanford Univ, Dept Pediat, Div Syst Med, Stanford, CA 94305 USA; [Chen, Rong; Dudley, Joel T.; Seki, Scott; Butte, Atul J.; Nadeau, Kari C.] Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; [Dewey, Frederick E.; Ashley, Euan A.] Stanford Univ, Sch Med, Div Cardiovasc Med, Ctr Inherited Cardiovasc Dis, Stanford, CA 94305 USA; [Greenberg, Peter L.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Altman, Russ B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Habegger, Lukas; Balasubramanian, Suganthi; Gerstein, Mark] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Habegger, Lukas; Balasubramanian, Suganthi; Gerstein, Mark] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Gerstein, Mark] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA; [Gallardo, Mercedes; Blasco, Maria A.] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain; [Gallardo, Mercedes] Life Length, E-28003 Madrid, Spain	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Yale University; Yale University; Yale University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Snyder, M (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	mpsnyder@stanford.edu	Mias, George/J-1138-2019; Boyle, Alan/I-1848-2014; Im, Hogune/ABG-3002-2021; Blasco, Maria A./M-1694-2014; cheng, yong/I-4270-2012; Hariharan, Manoj/N-2855-2015; O'Huallachain, Maeve/AAO-4312-2020; Karczewski, Jakub/L-7326-2018	Mias, George/0000-0002-9083-1216; Boyle, Alan/0000-0002-2081-1105; Im, Hogune/0000-0002-2812-4617; Blasco, Maria A./0000-0002-4211-233X; Hariharan, Manoj/0000-0002-1006-5372; O'Huallachain, Maeve/0000-0002-0618-6032; Balasubramanian, Suganthi/0000-0003-2243-5948; Karczewski, Jakub/0000-0001-9322-7842; Haraksingh, Rajini/0000-0002-6644-8874; Whirl-Carrillo, Michelle/0000-0003-2414-9312; Klein, Teri/0000-0001-5527-6475; Karczewski, Konrad/0000-0003-2878-4671; Snyder, Michael/0000-0003-0784-7987	Stanford University; NIH [OD004613]; NIH/NLM [T15-LM007033]; NIH/NIGMS [R24-GM61374]; Spanish Ministry of Science and Innovation [SAF2008-05384, CSD2007-00017]; European Union [2007-A-201630, 2007-A-200950]; European Research Council [GA232854]; Korber Foundation; Fundacion Marcelino Botin; Fundacion Lilly (Espana); NIH/NHLBI [T32 HL094274, KO8 HL083914]; Breetwor Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094274, K08HL083914] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044, P50HG002357, U54HG004558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM061374, T32GM007205] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007033] Funding Source: NIH RePORTER	Stanford University(Stanford University); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NLM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Union(European Commission); European Research Council(European Research Council (ERC)European Commission); Korber Foundation; Fundacion Marcelino Botin; Fundacion Lilly (Espana); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Breetwor Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	M. S. is funded by grants from Stanford University and the NIH. M.G. is funded by grants from the NIH. G.I.M. is funded by NIH training grant. K.J.K., J.T.D., and S.H. are supported by the NIH/NLM training grant T15-LM007033. T.E.K. and R.B.A are funded by NIH/NIGMS R24-GM61374. M.A.B.'s laboratory is funded by the Spanish Ministry of Science and Innovation Projects SAF2008-05384 and CSD2007-00017, European Union FP7 Projects 2007-A-201630 (GENICA) and 2007-A-200950 (TELOMARKER), European Research Council Advanced Grant GA232854, the Korber Foundation, the Fundacion Marcelino Botin, and Fundacion Lilly (Espana). F.E.D. was supported by NIH/NHLBI training grant T32 HL094274. E.A.A. was supported by NIH/NHLBI KO8 HL083914, NIH New Investigator DP2 Award OD004613, and a grant from the Breetwor Family Foundation. We dedicate this manuscript to Dr. Tara A. Gianoulis, an enthusiastic advocate for genomic science. R.B.A., E.A.A., A.B., and M.S. serve as founders and consultants for Personalis. R.B.A. is a consultant to 23andMe. M.S. is a member of the scientific advisory board of GenapSys and a consultant for Illumina. M.A.B. acts as consultant and holds stock in Life Length.	Abyzov A, 2011, GENOME RES, V21, P974, DOI 10.1101/gr.114876.110; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ahdesmaki M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-233; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Cox J, 2011, ANNU REV BIOCHEM, V80, P273, DOI 10.1146/annurev-biochem-061308-093216; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Dewey FE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002280; Erlich HA, 2009, GENES IMMUN, V10, pS54, DOI 10.1038/gene.2009.92; Galeano F, 2010, INT J CANCER, V127, P127, DOI 10.1002/ijc.25022; Glynn EF, 2006, BIOINFORMATICS, V22, P310, DOI 10.1093/bioinformatics/bti789; Gommans WM, 2008, RNA, V14, P2074, DOI 10.1261/rna.816908; Grayson BL, 2011, GENES IMMUN, V12, P341, DOI 10.1038/gene.2011.13; Hani EH, 1998, DIABETOLOGIA, V41, P1511, DOI 10.1007/s001250051098; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Hocke K, 2009, ATMOS CHEM PHYS, V9, P4197, DOI 10.5194/acp-9-4197-2009; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jima DD, 2010, BLOOD, V116, pE118, DOI 10.1182/blood-2010-05-285403; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kusunoki Masataka, 2007, J Med Invest, V54, P243, DOI 10.2152/jmi.54.243; Lam HYK, 2010, NAT BIOTECHNOL, V28, P47, DOI 10.1038/nbt.1600; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Levanon EY, 2005, NUCLEIC ACIDS RES, V33, P1162, DOI 10.1093/nar/gki239; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018; Li RQ, 2010, NAT BIOTECHNOL, V28, P57, DOI 10.1038/nbt.1596; LOMB NR, 1976, ASTROPHYS SPACE SCI, V39, P447, DOI 10.1007/BF00648343; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596; Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813; Rozowsky J, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.54; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; SCARGLE JD, 1989, ASTROPHYS J, V343, P874, DOI 10.1086/167757; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Snyder M, 2010, GENE DEV, V24, P423, DOI 10.1101/gad.1864110; Snyder M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.32; Stewart C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002236; Sun JC, 2010, WORLD J GASTROENTERO, V16, P4611, DOI 10.3748/wjg.v16.i36.4611; Theodoridis G, 2011, MASS SPECTROM REV, V30, P884, DOI 10.1002/mas.20306; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van der Werf N, 2007, DIABETES-METAB RES, V23, P169, DOI 10.1002/dmrr.695; van Dongen HPA, 1999, BIOL RHYTHM RES, V30, P149, DOI 10.1076/brhm.30.2.149.1424; Vaxillaire M, 2008, DIABETES, V57, P2253, DOI 10.2337/db07-1807; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wu JQ, 2010, P NATL ACAD SCI USA, V107, P5254, DOI 10.1073/pnas.0914114107; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Yang RD, 2011, BIOINFORMATICS, V27, P1023, DOI 10.1093/bioinformatics/btr041; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zhao W., 2008, EURASIP J BIOINFORM, V2008	60	810	837	18	302	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1293	1307		10.1016/j.cell.2012.02.009	http://dx.doi.org/10.1016/j.cell.2012.02.009			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424236	Green Accepted, Bronze			2022-12-28	WOS:000301889500023
J	Weiner, LM; Murray, JC; Shuptrine, CW				Weiner, Louis M.; Murray, Joseph C.; Shuptrine, Casey W.			Antibody-Based Immunotherapy of Cancer	CELL			English	Review							CELLS; GENERATION; INDUCTION; EGFR	By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy.	[Weiner, Louis M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Murray, Joseph C.; Shuptrine, Casey W.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Tumor Biol Training Program, Washington, DC 20007 USA	Georgetown University; Georgetown University	Weiner, LM (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	weinerl@georgetown.edu	Murray, Joseph C/J-8916-2014	Murray, Joseph C/0000-0001-6159-7814	National Cancer Institute [CA51008, CA50633, T32-CA009686]; NATIONAL CANCER INSTITUTE [T32CA009686, P30CA051008, F30CA165474, R01CA050633] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants CA51008 and CA50633 from the National Cancer Institute (L.M.W.) and by T32-CA009686 (C.W.S.) from the National Cancer Institute.	Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Doppalapudi VR, 2010, P NATL ACAD SCI USA, V107, P22611, DOI 10.1073/pnas.1016478108; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Guo K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002296; Hilchey SP, 2009, BLOOD, V113, P3809, DOI 10.1182/blood-2008-10-185280; Jiang XR, 2011, NAT REV DRUG DISCOV, V10, P101, DOI 10.1038/nrd3365; Kreitman RJ, 2009, J CLIN ONCOL, V27, P2983, DOI 10.1200/JCO.2008.20.2630; Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954; Lutterbuese R, 2010, P NATL ACAD SCI USA, V107, P12605, DOI 10.1073/pnas.1000976107; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Ruf P, 2001, BLOOD, V98, P2526, DOI 10.1182/blood.V98.8.2526; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Steiner M, 2011, CLIN CANCER RES, V17, P6406, DOI 10.1158/1078-0432.CCR-11-0483; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Wilson NS, 2011, CANCER CELL, V19, P101, DOI 10.1016/j.ccr.2010.11.012	20	184	207	1	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1081	1084		10.1016/j.cell.2012.02.034	http://dx.doi.org/10.1016/j.cell.2012.02.034			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424219	Bronze, Green Accepted			2022-12-28	WOS:000301889500006
J	Bostock, S; Steptoe, A				Bostock, Sophie; Steptoe, Andrew			Association between low functional health literacy and mortality in older adults: longitudinal cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT LITERACY; OUTCOMES; INDIVIDUALS; KNOWLEDGE; COGNITION; BEHAVIOR; SKILLS	Objective To investigate the association between low functional health literacy (ability to read and understand basic health related information) and mortality in older adults. Design Population based longitudinal cohort study based on a stratified random sample of households. Setting England. Participants 7857 adults aged 52 or more who participated in the second wave (2004-5) of the English Longitudinal Study of Ageing and survived more than 12 months after interview. Participants completed a brief four item test of functional health literacy, which assessed understanding of written instructions for taking an aspirin tablet. Main outcome measure Time to death, based on all cause mortality through October 2009. Results Health literacy was categorised as high (maximum score, 67.2%), medium (one error, 20.3%), or low (more than one error, 12.5%). During follow-up (mean 5.3 years) 621 deaths occurred: 321 (6.1%) in the high health literacy category, 143 (9.0%) in the medium category, and 157 (16.0%) in the low category. After adjusting for personal characteristics, socioeconomic position, baseline health, and health behaviours, the hazard ratio for all cause mortality for participants with low health literacy was 1.40 (95% confidence interval 1.15 to 1.72) and with medium health literacy was 1.15 (0.94 to 1.41) compared with participants with high health literacy. Further adjustment for cognitive ability reduced the hazard ratio for low health literacy to 1.26 (1.02 to 1.55). Conclusions A third of older adults in England have difficulties reading and understanding basic health related written information. Poorer understanding is associated with higher mortality. The limited health literacy capabilities within this population have implications for the design and delivery of health related services for older adults in England.	[Bostock, Sophie; Steptoe, Andrew] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Bostock, S (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	sophie.bostock.09@ucl.ac.uk	Steptoe, Andrew/Y-2440-2019	Steptoe, Andrew/0000-0001-7808-4943; Bostock, Sophie/0000-0001-9008-5180	National Institute of Aging in the United States; consortium of UK government departments; British Heart Foundation	National Institute of Aging in the United States(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); consortium of UK government departments; British Heart Foundation(British Heart Foundation)	The English Longitudinal Study of Ageing was developed by a team of researchers based at the University College London, National Centre for Social Research, and the Institute for Fiscal Studies. The data were collected by the National Centre for Social Research. The funding is provided by the National Institute of Aging in the United States, and a consortium of UK government departments coordinated by the Office for National Statistics. The developers and funders of the English Longitudinal Study of Ageing and the UK Data Archive do not bear any responsibility for the analyses or interpretations presented here. SB is supported by a PhD Studentship from the British Heart Foundation. AS holds the British Heart Foundation chair of psychology.	[Anonymous], 2000, ORG EC COOP DEV STAT; [Anonymous], 2005, LEARN LIV 1 RES AD L; Baker DW, 2008, J GEN INTERN MED, V23, P723, DOI 10.1007/s11606-008-0566-4; Baker DW, 2007, ARCH INTERN MED, V167, P1503, DOI 10.1001/archinte.167.14.1503; Baker DW, 2006, J GEN INTERN MED, V21, P878, DOI 10.1111/j.1525-1497.2006.00540.x; Baker DW, 2004, J GEN INTERN MED, V19, P215, DOI 10.1111/j.1525-1497.2004.21130.x; Banks J., 2006, RETIREMENT HLTH RELA; Bankson HL, 2009, J MED LIBR ASSOC, V97, P148, DOI 10.3163/1536-5050.97.2.016; Baumeister H, 2010, J CLIN EPIDEMIOL, V63, P558, DOI 10.1016/j.jclinepi.2009.08.009; Bennett I, 2009, ANN FAM MED, V7, P3; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Canada, 2011, CHIEF DEF STAFF DEP; Cavanaugh KL, 2010, J AM SOC NEPHROL, V21, P1979, DOI 10.1681/ASN.2009111163; Chinn D, 2011, SOC SCI MED, V73, P60, DOI 10.1016/j.socscimed.2011.04.004; Davis T C, 1991, Fam Med, V23, P433; Department of Health, 2010, EQ EXC LIB NHS; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; Federman AD, 2009, J AM GERIATR SOC, V57, P1475, DOI 10.1111/j.1532-5415.2009.02347.x; Feinstein L, 2003, ECONOMICA, V70, P73, DOI 10.1111/1468-0335.t01-1-00272; Gazmararian JA, 2003, PATIENT EDUC COUNS, V51, P267, DOI 10.1016/S0738-3991(02)00239-2; Greenhalgh T., 2010, BMJ-BRIT MED J, V341, pc5814; Health and Retirement Study, 2000, QUEST; Healthy People 2020, 2010, FDN HLTH MEAS REP HE; Jordan JE, 2011, J CLIN EPIDEMIOL, V64, P366, DOI 10.1016/j.jclinepi.2010.04.005; Kelly PA, 2007, PATIENT EDUC COUNS, V66, P119, DOI 10.1016/j.pec.2006.10.007; Kirsch I, 2001, INT ADULT LITERACY S; Kondilis BK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002519; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0; Levinthal BR, 2008, J GEN INTERN MED, V23, P1172, DOI 10.1007/s11606-008-0612-2; Macabasco-O'Connell A, 2011, J GEN INTERN MED, V26, P979, DOI 10.1007/s11606-011-1668-y; Machtinger EL, 2007, JT COMM J QUAL PATIE, V33, P625, DOI 10.1016/S1553-7250(07)33072-9; Manning DL, 2006, EUR J CANCER CARE, V15, P448, DOI 10.1111/j.1365-2354.2006.00687.x; Marmot M, 2003, HLTH WEALTH LIFESTYL; Moscovitch M, 1982, AGING COGNITIVE PROC; Murray C, 2011, INTELLIGENCE, V39, P178, DOI 10.1016/j.intell.2011.04.001; Nielsen-Bohlman L, 2004, HLTH LITERACY PRESCR; Nutbeam D, 2008, SOC SCI MED, V67, P2072, DOI 10.1016/j.socscimed.2008.09.050; Osborn CY, 2010, DIABETES TECHNOL THE, V12, P913, DOI 10.1089/dia.2010.0058; Osborn CY, 2011, AM J HEALTH BEHAV, V35, P118; Paasche-Orlow MK, 2007, AM J HEALTH BEHAV, V31, pS19; Parikh NS, 1996, PATIENT EDUC COUNS, V27, P33, DOI 10.1016/0738-3991(95)00787-3; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; Peterson PN, 2011, JAMA-J AM MED ASSOC, V305, P1695, DOI 10.1001/jama.2011.512; Protheroe J, 2009, BRIT J GEN PRACT, V59, P721, DOI 10.3399/bjgp09X472584; RATZAN SC, 2000, NATL LIB MED CURRENT; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rothman RL, 2004, JAMA-J AM MED ASSOC, V292, P1711, DOI 10.1001/jama.292.14.1711; Rudd RE, 2007, AM J HEALTH BEHAV, V31, pS8; Schillinger D, 2006, PUBLIC HEALTH REP, V121, P245, DOI 10.1177/003335490612100305; Shaw A, 2009, PATIENT EDUC COUNS, V75, P114, DOI 10.1016/j.pec.2008.09.026; Sheridan SL, 2011, J HEALTH COMMUN, V16, P30, DOI 10.1080/10810730.2011.604391; Smith SK, 2009, SOC SCI MED, V69, P1805, DOI 10.1016/j.socscimed.2009.09.056; Steffick D. E., 2000, DR005 HRSAHEAD; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Sudore RL, 2006, J GEN INTERN MED, V21, P806, DOI 10.1111/j.1525-1497.2006.00539.x; Sudore Rebecca L, 2009, J Clin Outcomes Manag, V16, P20; U.S. Department of Health and Human Services, 2010, HLTH PEOPL 2020; von Wagner C, 2007, J EPIDEMIOL COMMUN H, V61, P1086, DOI 10.1136/jech.2006.053967; von Wagner C, 2009, HEALTH EDUC BEHAV, V36, P860, DOI 10.1177/1090198108322819; von Wagner C, 2009, PATIENT EDUC COUNS, V75, P352, DOI 10.1016/j.pec.2009.03.015; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Wilson RS, 2007, PSYCHOSOM MED, V69, P131, DOI 10.1097/PSY.0b013e31803130ae; Wolf MS, 2010, SOC SCI MED, V70, P1335, DOI 10.1016/j.socscimed.2009.12.013; Wolf MS, 2009, PEDIATRICS, V124, pS275, DOI DOI 10.1542/PEDS.2009-1162C; World Health Organisation, 2011, HLTH LIT HLTH BEH	66	285	288	10	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2012	344								e1602	10.1136/bmj.e1602	http://dx.doi.org/10.1136/bmj.e1602			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CD	22422872	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000301848100007
J	Fuchs, VR				Fuchs, Victor R.			Major Trends in the US Health Economy since 1950	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Fuchs, VR (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Fuchs VR., 2000, FUTURE MANAGED CARE; NEWHOUSE JOSEPH P., 1993, LESSONS RAND HLTH IN, V40, P162; Pauly MV, 2005, HEALTH AFFAIR, V24, P1523, DOI 10.1377/hlthaff.24.6.1523; Stranges E, 2011, ANN M AM ASS MED COL; WEISBROD BA, 1991, J ECON LIT, V29, P523	5	40	40	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					973	977		10.1056/NEJMp1200478	http://dx.doi.org/10.1056/NEJMp1200478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908HZ	22417250				2022-12-28	WOS:000301482800013
J	Delamothe, T				Delamothe, Tony			ON THE CONTRARY Deaths from smoking: the avoidable holocaust	BRITISH MEDICAL JOURNAL			English	Editorial Material												tdelamothe@bmj.com						2012, BRIT MED J, V344, pE1617, DOI DOI 10.1136/BMJ.E1617; 2011, BRIT MED J, V343, pD6491, DOI DOI 10.1136/BMJ.D6491; 2012, BRIT MED J, V344, pC1676, DOI DOI 10.1136/BMJ.E1676; 2012, TOB CONTROL, V21, P87, DOI DOI 10.1136/TOBACCOCONTROL-2011-050338; 2012, BRIT MED J, V344, pE1269, DOI DOI 10.1136/BMJ.E1269	5	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e2029	10.1136/bmj.e2029	http://dx.doi.org/10.1136/bmj.e2029			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418424				2022-12-28	WOS:000301847600024
J	Nitschke, M; Sayk, F; Hartel, C; Roseland, RT; Hauswaldt, S; Steinhoff, J; Fellermann, K; Derad, I; Wellhoner, P; Buning, J; Tiemer, B; Katalinic, A; Rupp, J; Lehnert, H; Solbach, W; Knobloch, JKM				Nitschke, Martin; Sayk, Friedhelm; Haertel, Christoph; Roseland, Rahel Tabea; Hauswaldt, Susanne; Steinhoff, Juergen; Fellermann, Klaus; Derad, Inge; Wellhoener, Peter; Buening, Juergen; Tiemer, Bettina; Katalinic, Alexander; Rupp, Jan; Lehnert, Hendrik; Solbach, Werner; Knobloch, Johannes K. -M.			Association Between Azithromycin Therapy and Duration of Bacterial Shedding Among Patients With Shiga Toxin-Producing Enteroaggregative Escherichia coli O104:H4	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; ANTIBIOTIC-TREATMENT; TRAVELERS DIARRHEA; EPIDEMIOLOGY; OUTBREAK; RISK	Context An outbreak of Shiga toxin-producing enteroaggregative Escherichia coli (STEC O104:H4) infection with a high incidence of hemolytic uremic syndrome (HUS) occurred in Germany in May 2011. Antibiotic treatment of STEC infection is discouraged because it might increase the risk of HUS development. However, antibiotic therapy is widely used to treat enteroaggregative E coli infection. In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab. Objective To analyze the duration of bacterial shedding in patients with STEC infection who did and did not receive oral azithromycin therapy. Design, Setting, and Patients At a single center in Lubeck, Germany, 65 patients with STEC infection, including patients with HUS as well as STEC-infected outpatients without manifestation of HUS, were investigated between May 15 and July 26, 2011, and were monitored for a mean of 39.3 days after onset of clinical symptoms. Main Outcome Measure Carriage of STEC after azithromycin therapy. Results Twenty-two patients received oral azithromycin and 43 patients did not receive antibiotic treatment. Among antibiotic-treated patients, long-term STEC carriage (>28 days) was observed in 1 of 22 patients (4.5%; 95% CI, 0%-13.3%) compared with 35 of 43 patients (81.4%; 95% CI, 69.8%-93.0%) who were not treated with antibiotics (P<.001). All 22 patients receiving azithromycin treatment had at least 3 STEC-negative stool specimens after the completion of treatment, and no recurrence of STEC was observed in these patients. As proof of principle, 15 patients who initially were not treated with antibiotics and were long-term STEC carriers were treated with oral azithromycin given for 3 days and subsequently had negative stool specimens. Conclusion Treatment with azithromycin was associated with a lower frequency of long-term STEC O104: H4 carriage. JAMA. 2012;307(10):1046-1052 www.jama.com	[Roseland, Rahel Tabea; Hauswaldt, Susanne; Rupp, Jan; Solbach, Werner; Knobloch, Johannes K. -M.] Univ Hosp Schleswig Holstein, Dept Med Microbiol & Hyg, D-23538 Lubeck, Germany; [Nitschke, Martin; Sayk, Friedhelm; Steinhoff, Juergen; Fellermann, Klaus; Derad, Inge; Wellhoener, Peter; Buening, Juergen; Lehnert, Hendrik] Univ Hosp Schleswig Holstein, Dept Internal Med 1, D-23538 Lubeck, Germany; [Haertel, Christoph] Univ Hosp Schleswig Holstein, Dept Pediat, D-23538 Lubeck, Germany; [Rupp, Jan] Univ Hosp Schleswig Holstein, Dept Internal Med Infect Dis 3, D-23538 Lubeck, Germany; [Tiemer, Bettina] Lab Gemeinschaftspraxis Lubeck, Lubeck, Germany; [Katalinic, Alexander] Med Univ Lubeck, Inst Clin Epidemiol, D-23538 Lubeck, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck	Knobloch, JKM (corresponding author), Univ Hosp Schleswig Holstein, Dept Med Microbiol & Hyg, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Johannes.Knobloch@uksh.de	Härtel, Christoph/ABD-8841-2020; Katalinic, Alexander/D-2512-2010; Rupp, Jan/C-8794-2011; Solbach, Werner/F-9217-2012; Solbach, Werner/O-8582-2015; Knobloch, Johannes K./D-6456-2011; Nitschke, Martin/ABA-9388-2021	Katalinic, Alexander/0000-0003-0490-1554; Rupp, Jan/0000-0001-8722-1233; Solbach, Werner/0000-0002-3608-8652; Knobloch, Johannes K./0000-0002-2591-6387; Nitschke, Martin/0000-0002-2716-7527	Novartis; Genzyme; Roche; German Research Foundation [SFB 654]; Bayer Healthcare; Gilead; Janssen-Cilag; German Ministry of Educationand Research; bioMerieux; Bayer Vital; Alere; Alexion Pharma	Novartis(Novartis); Genzyme(Sanofi-AventisGenzyme Corporation); Roche(Roche Holding); German Research Foundation(German Research Foundation (DFG)); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Gilead(Gilead Sciences); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); German Ministry of Educationand Research(Federal Ministry of Education & Research (BMBF)); bioMerieux; Bayer Vital(Bayer AG); Alere; Alexion Pharma	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Nitschke reported receiving research and travel grants from Novartis, Genzyme, and Roche. Dr Sayk reported receiving funding from a grant of the German Research Foundation (SFB 654, Project B4). Dr Hartel reported serving on a consultant/advisory board for Drager Medical. Dr Rupp reported receiving research and travel grants from Bayer Healthcare, Gilead, and Janssen-Cilag and serving as consultant or speaker for Merck Sharpe & Dohme, Bayer Healthcare, Gilead, and Abbott. Dr Lehnert reported receiving funding from grants of the German Research Foundation and the German Ministry of Educationand Research. Dr Knobloch reported receiving research and travel grants from Novartis, bioMerieux, Bayer Vital, and Alere and serving as consultant or speaker for bioMerieux, Novartis, and Pfizer. No further disclosures were reported.; This study was not funded by any third party. Some of the patients in this are enrolled in a separate multicenter study funded by Alexion Pharma (clinicaltrials.gov identifier: NCT01410916).	Bielaszewska M, 2011, LANCET INFECT DIS, V11, P671, DOI 10.1016/S1473-3099(11)70165-7; de la Cabada Bauche Javier, 2011, Gastroenterol Hepatol (N Y), V7, P88; Ericsson CD, 2007, J TRAVEL MED, V14, P312, DOI 10.1111/j.1708-8305.2007.00144.x; Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483; Hill DR, 2010, CURR OPIN INFECT DIS, V23, P481, DOI 10.1097/QCO.0b013e32833dfca5; Huang DB, 2006, J MED MICROBIOL, V55, P1303, DOI 10.1099/jmm.0.46674-0; Huang David B, 2004, Semin Pediatr Infect Dis, V15, P266, DOI 10.1053/j.spid.2004.07.008; Kimmitt PT, 2000, EMERG INFECT DIS, V6, P458, DOI 10.3201/eid0605.000503; Lapeyraque AL, 2011, NEW ENGL J MED, V364, P2561, DOI 10.1056/NEJMc1100859; McGannon CM, 2010, ANTIMICROB AGENTS CH, V54, P3790, DOI 10.1128/AAC.01783-09; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; Mellmann A, 2008, EMERG INFECT DIS, V14, P1287, DOI 10.3201/eid1408.071082; Ohara T, 2002, ANTIMICROB AGENTS CH, V46, P3478, DOI 10.1128/AAC.46.11.3478-3483.2002; Okeke I N, 2001, Lancet Infect Dis, V1, P304, DOI 10.1016/S1473-3099(01)00144-X; Okhuysen PC, 2010, J INFECT DIS, V202, P503, DOI 10.1086/654895; Okhuysen PC, 2005, CURR OPIN INFECT DIS, V18, P522, DOI 10.1097/01.qco.0000185987.02878.6e; Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5; Pedersen MG, 2008, J CLIN MICROBIOL, V46, P2987, DOI 10.1128/JCM.00871-08; Rasko DA, 2011, NEW ENGL J MED, V365, P709, DOI 10.1056/NEJMoa1106920; Robert Koch Institute, 2011, AUSBR FALLD EHEC HUS; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; Scheutz F, 2011, EUROSURVEILLANCE, V16, P5; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Weintraub A, 2007, J MED MICROBIOL, V56, P4, DOI 10.1099/jmm.0.46930-0; Wilson JB, 1996, J INFECT DIS, V174, P1021, DOI 10.1093/infdis/174.5.1021; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601	26	107	109	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1046	1052		10.1001/jama.2012.264	http://dx.doi.org/10.1001/jama.2012.264			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416100				2022-12-28	WOS:000301479700025
J	Little, MP; Rajaraman, P; Curtis, RE; Devesa, SS; Inskip, PD; Check, DP; Linet, MS				Little, M. P.; Rajaraman, P.; Curtis, R. E.; Devesa, S. S.; Inskip, P. D.; Check, D. P.; Linet, M. S.			Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELLULAR-TELEPHONE USE; MALIGNANT BRAIN-TUMORS; CORDLESS PHONES; INCIDENCE RATES; TIME TRENDS; CANCER; CLONALITY; RADIATION; UPDATE; CELLS	Objective In view of mobile phone exposure being classified as a possible human carcinogen by the International Agency for Research on Cancer (IARC), we determined the compatibility of two recent reports of glioma risk (forming the basis of the IARC's classification) with observed incidence trends in the United States. Design Comparison of observed rates with projected rates of glioma incidence for 1997-2008. We estimated projected rates by combining relative risks reported in the 2010 Interphone study and a 2011 Swedish study by Hardell and colleagues with rates adjusted for age, registry, and sex; data for mobile phone use; and various latency periods. Setting US population based data for glioma incidence in 1992-2008, from 12 registries in the Surveillance, Epidemiology, and End Results (SEER) programme (Atlanta, Detroit, Los Angeles, San Francisco, San Jose-Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New Mexico, and Utah). Participants Data for 24 813 non-Hispanic white people diagnosed with glioma at age 18 years or older. Results Age specific incidence rates of glioma remained generally constant in 1992-2008 (-0.02% change per year, 95% confidence interval -0.28% to 0.25%), a period coinciding with a substantial increase in mobile phone use from close to 0% to almost 100% of the US population. If phone use was associated with glioma risk, we expected glioma incidence rates to be higher than those observed, even with a latency period of 10 years and low relative risks (1.5). Based on relative risks of glioma by tumour latency and cumulative hours of phone use in the Swedish study, predicted rates should have been at least 40% higher than observed rates in 2008. However, predicted glioma rates based on the small proportion of highly exposed people in the Interphone study could be consistent with the observed data. Results remained valid if we used either non-regular users or low users of mobile phones as the baseline category, and if we constrained relative risks to be more than 1. Conclusions Raised risks of glioma with mobile phone use, as reported by one (Swedish) study forming the basis of the IARC's re-evaluation of mobile phone exposure, are not consistent with observed incidence trends in US population data, although the US data could be consistent with the modest excess risks in the Interphone study.	[Little, M. P.; Rajaraman, P.; Curtis, R. E.; Inskip, P. D.; Linet, M. S.] NCI, Radiat Epidemiol Branch, Rockville, MD 20852 USA; [Devesa, S. S.; Check, D. P.] NCI, Biostat Branch, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Little, MP (corresponding author), NCI, Radiat Epidemiol Branch, Rockville, MD 20852 USA.	mark.little@nih.gov	Check, David P/J-7184-2015	Check, David P/0000-0003-3887-0493; Little, Mark/0000-0003-0980-7567	National Institutes of Health; National Cancer Institute, Division of Cancer Epidemiology and Genetics; NATIONAL CANCER INSTITUTE [ZIACP010135] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Division of Cancer Epidemiology and Genetics(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Intramural Research Program of the National Institutes of Health, and the National Cancer Institute, Division of Cancer Epidemiology and Genetics.	Advisory Group on Non-ionising Radiation, 2003, HLTH EFF RAD EL FIEL; Ahlbom A, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6605; Auvinen A, 2002, EPIDEMIOLOGY, V13, P356, DOI 10.1097/00001648-200205000-00018; Baan R, 2011, LANCET ONCOL, V12, P624, DOI 10.1016/S1470-2045(11)70147-4; BUSQUE L, 1994, NUCLEIC ACIDS RES, V22, P697, DOI 10.1093/nar/22.4.697; Cardis E, 2010, INT J EPIDEMIOL, V39, P675, DOI 10.1093/ije/dyq079; [CBTRUS C.B.T.R.o.t.U. States], 2010, CBTRUS STAT REP PRIM; Cellular Telephone Industry Association (CTIA), 2011, CTIA SEM WIR IND SUR; Claus EB, 2006, CANCER-AM CANCER SOC, V106, P1358, DOI 10.1002/cncr.21733; de Vocht F, 2011, BIOELECTROMAGNETICS, V32, P675, DOI 10.1002/bem.20678; de Vocht F, 2011, BIOELECTROMAGNETICS, V32, P334, DOI 10.1002/bem.20648; Deltour I, 2009, J NATL CANCER I, V101, P1721, DOI 10.1093/jnci/djp415; Frei P, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6387; Fritz AG., 2000, INT CLASSIFICATION D, V3rd; Hardell L, 2006, ENVIRON RES, V100, P232, DOI 10.1016/j.envres.2005.04.006; Hardell L, 2002, INT J RADIAT BIOL, V78, P931, DOI 10.1080/09553000210158038; Hardell L, 2011, INT J EPIDEMIOL, V40, P1126, DOI 10.1093/ije/dyq246; Hardell L, 2011, INT J ONCOL, V38, P1465, DOI 10.3892/ijo.2011.947; Hardell L, 2009, INT J ONCOL, V35, P5, DOI 10.3892/ijo_00000307; Howlader N, 2011, SEER CANC STAT REV 1; Inskip PD, 2001, NEW ENGL J MED, V344, P79, DOI 10.1056/NEJM200101113440201; Inskip PD, 2010, NEURO-ONCOLOGY, V12, P1147, DOI 10.1093/neuonc/noq077; Johansen C, 2001, JNCI-J NATL CANCER I, V93, P203, DOI 10.1093/jnci/93.3.203; La Regina M, 2003, RADIAT RES, V160, P143, DOI 10.1667/RR3028; Little MP, 2009, RADIOLOGY, V251, P6, DOI [10.1148/radiol.2511081686, 10.1148/radiol.1.2511081686]; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Muscat JE, 2000, JAMA-J AM MED ASSOC, V284, P3001, DOI 10.1001/jama.284.23.3001; National Research Council (US) Committee on the Biological Effects of Ionizing Radiation, 2006, HLTH RISKS EXP LOW L; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; Preston DL, 1998, EPICURE RELEASE 2 10; Ries LAG, 2007, PUBLICATION SEER; Sato Y, 2011, BIOELECTROMAGNETICS, V32, P85, DOI 10.1002/bem.20616; Schuz J, 2006, JNCI-J NATL CANCER I, V98, P1707, DOI 10.1093/jnci/djj464; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Surveillance Epidemiology and End Results (SEER) Program, 2011, SEER STAT DAT INC SE; Tada M, 1996, INT J CANCER, V67, P447, DOI 10.1002/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3; United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 2008, UNSCEAR 2006 REP ANN; US Census Bureau, 2011, POP EST; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Zhu JJG, 1999, NEUROSURGERY, V45, P409, DOI 10.1097/00006123-199908000-00049	40	83	86	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 8	2012	344								e1147	10.1136/bmj.e1147	http://dx.doi.org/10.1136/bmj.e1147			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HL	22403263	hybrid, Green Published			2022-12-28	WOS:000301481400001
J	Greenhalgh, T				Greenhalgh, Trisha			OUTSIDE THE BOX The medium and the message	BRITISH MEDICAL JOURNAL			English	Editorial Material									Barts & London Queen Marys Sch Med & Dent, London, England	University of London; Queen Mary University London	Greenhalgh, T (corresponding author), Barts & London Queen Marys Sch Med & Dent, London, England.	p.greenhalgh@qmul.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	2012	344								e1620	10.1136/bmj.e1620	http://dx.doi.org/10.1136/bmj.e1620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GV	22399707				2022-12-28	WOS:000301479800008
J	Meirik, O; Nguyen, TMH; Piaggio, G; Bergel, E; von Hertzen, H				Meirik, Olav; Nguyen Thi My Huong; Piaggio, Gilda; Bergel, Eduardo; von Hertzen, Helena		WHO Res Grp Postovulatory Methods	Complications of first-trimester abortion by vacuum aspiration after cervical preparation with and without misoprostol: a multicentre randomised trial	LANCET			English	Article								Background Little information is available about the incidence of complications from vacuum aspiration for first-trimester abortion after cervical preparation with prostaglandin analogues. We compared incidence of complications from vacuum aspiration in women who had had cervical preparation with misoprostol and those who had not. Methods We did a randomised parallel-group trial at 14 centres in nine countries between Oct 22, 2002, and Sept 24, 2005. Healthy women seeking first-trimester abortion were randomly assigned via a computer-generated randomisation sequence stratified by centre, to receive vaginal administration of either two 200 mu g tablets of misoprostol or two placebo tablets 3 h before abortion by vacuum aspiration. Participants and health-care personnel other than staff administering the treatment were masked to group assignment. Follow-up was up to 2 weeks. The primary outcome was one or more complications of vacuum aspiration (cervical tear, uterine perforation, incomplete abortion, uterine re-evacuation, pelvic inflammatory disease, or any other serious adverse event). We included women under going treatment and vacuum aspiration in the analysis of immediate complications; whereas, in the analysis of delayed complications, we included only those followed-up. In the analysis of any immediate or delayed complication, we excluded women lost to follow-up. This trial is registered, number ISRCTN85366519. Findings We randomly assigned 2485 women to the misoprostol group and 2487 to the placebo group. Two women in the misoprostol group did not have vacuum aspiration. 56 women in each group were lost to follow-up. 50 (2%) of 2427 women in the misoprostol group and 74 (3%) of 2431 in the placebo group had one or more complication of vacuum aspiration (relative risk [RR] 0.68, 95% CI 0.47-0.96). No women in the misoprostol group had cervical tears and three had uterine perforations compared with two women in the placebo group who had cervical tears and one who had perforation. 19 (<1%) women given misoprostol and 55 (2%) on placebo had incomplete abortions (0.35, 0.21-0.58), of whom 14 (<1%) versus 48 (2%) needed uterine re-evacuation (0.29, 0.16-0.53). We noted no difference between groups in incidence of pelvic inflammatory disease (30 [1%] vs 25 [1%]; RR 1.20, 0.71-2.04) or other serious adverse events. The main side-effects of misoprostol during the 3 h treatment were abdominal pain (1355 [55%] of 2484 women vs 545 [22%] of 2487 women in the placebo group) and vaginal bleeding (909 [37%] vs 167 [7%]). Interpretation Cervical preparation with 400 mu g of vaginal misoprostol can reduce incidence of complications from vacuum aspiration for first trimester abortion.	[Bergel, Eduardo] WHO, Dept Reprod Hlth & Res, World Bank Special Programme Res Dev & Res Traini, CH-1211 Geneva 27, Switzerland; [Meirik, Olav; Nguyen Thi My Huong; Bergel, Eduardo; von Hertzen, Helena] WHO, UN Dev Programme, UN Populat Fund, CH-1211 Geneva 27, Switzerland; [Piaggio, Gilda] Stat Consultoria, Divonne Les Bains, France; [Piaggio, Gilda] Stat Consultoria, Sao Paulo, Brazil; [von Hertzen, Helena] Concept Fdn, Geneva, Switzerland	The World Bank; World Health Organization; United Nations Population Fund; World Health Organization	Bergel, E (corresponding author), WHO, Dept Reprod Hlth & Res, World Bank Special Programme Res Dev & Res Traini, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	bergele@who.int			WHO/World Bank; Department of Reproductive Health and Research; WHO; Packard Foundation; UNDP/UNFPA/WHO/World Bank	WHO/World Bank; Department of Reproductive Health and Research; WHO(World Health Organization); Packard Foundation(The David & Lucile Packard Foundation); UNDP/UNFPA/WHO/World Bank(World Health Organization)	UN Development Programme/UN Population Fund/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO, and the Packard Foundation.; This study was supported by UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO, and the Packard Foundation. The investigators alone are responsible for the views expressed in this publication and these views do not necessarily represent the decisions, policy, or views of WHO. We thank the members of the Data and Safety Monitoring Board for their contribution to interim analyses and advice on final analysis, Nathalie Kapp for comments on the paper, and Wallada Im-amornphong for checking of data.	[Anonymous], 1981, CONTRACEPTION, V23, P251; Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Chambers DG, 2009, INT J GYNECOL OBSTET, V107, P211, DOI 10.1016/j.ijgo.2009.07.034; Child TJ, 2001, HUM REPROD, V16, P875, DOI 10.1093/humrep/16.5.875; Fiala C, 2007, INT J GYNECOL OBSTET, V99, pS168, DOI 10.1016/j.ijgo.2007.09.005; Grimes D A, 1979, Obstet Gynecol Surv, V34, P177, DOI 10.1097/00006254-197903000-00001; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; HULKA JF, 1974, AM J OBSTET GYNECOL, V120, P166, DOI 10.1016/0002-9378(74)90358-5; JOHNSTONE FD, 1974, J OBSTET GYN BR COMM, V81, P558; Kapp N, 2010, COCHRANE DB SYST REV, V17; Luk J, 2007, CONTRACEPTION, V76, P331, DOI 10.1016/j.contraception.2007.06.001; Machin D., 1997, STAT TABLES DESIGN C, V2nd; Mittal S, 2011, INT J GYNECOL OBSTET, V112, P34, DOI 10.1016/j.ijgo.2010.07.035; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Pazol Karen, 2009, Morbidity and Mortality Weekly Report, V58, P1; Royal College of Obstetricians and Gynaecologists, 2004, CAR WOM REQ IND AB E; Sawaya GF, 1996, OBSTET GYNECOL, V87, P884; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Sedgh G, 2007, LANCET, V370, P1338, DOI 10.1016/S0140-6736(07)61575-X; Thonneau P, 1998, EUR J OBSTET GYN R B, V81, P59, DOI 10.1016/S0301-2115(98)00147-X; Warriner IK, 2006, LANCET, V368, P1965, DOI 10.1016/S0140-6736(06)69742-0; WHO, 1997, WHO TECHN REP SER; World Health Organization, 2003, SAF AB TECHN POL GUI	23	36	40	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 12	2012	379	9828					1817	1824		10.1016/S0140-6736(11)61937-5	http://dx.doi.org/10.1016/S0140-6736(11)61937-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	941BR	22405255				2022-12-28	WOS:000303937700036
J	Chong, YS; Arulkumaran, S				Chong, Yap-Seng; Arulkumaran, Sabaratnam			Keep things simple for safer childbirth and better medicine	LANCET			English	Editorial Material									[Chong, Yap-Seng] Natl Univ Hlth Syst, Dept Obstet & Gynaecol, Yong Loo Lin Sch Med, Natl Univ Singapore, Singapore 119228, Singapore; [Arulkumaran, Sabaratnam] St George Hosp, Sch Med, Div Obstet & Gynaecol, London, England	National University of Singapore; St Georges University London	Chong, YS (corresponding author), Natl Univ Hlth Syst, Dept Obstet & Gynaecol, Yong Loo Lin Sch Med, Natl Univ Singapore, Singapore 119228, Singapore.	obgcys@nus.edu.sg		Chong, Yap Seng/0000-0002-7232-8473				[Anonymous], 2010, INT J GYNECOL OBSTET, V108, P258, DOI 10.1016/j.ijgo.2009.11.002; Chong YS, 2011, LANCET, V377, P1127, DOI 10.1016/S0140-6736(11)60166-9; Chong YS, 2010, LANCET, V375, P440, DOI 10.1016/S0140-6736(10)60055-4; Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6; Figo Safe Motherhood And Newborn H, 2009, INT J GYNECOL OBSTET, V105, P74, DOI 10.1016/j.ijgo.2008.11.007; Gulmezoglu AM, 2012, LANCET, V379, P1721, DOI 10.1016/S0140-6736(12)60206-2; Heffernan Margaret, 2011, WILLFUL BLINDNESS; Hussain Munawar, 2004, J Coll Physicians Surg Pak, V14, P215; Landon MB, 2006, OBSTET GYNECOL, V108, P12, DOI 10.1097/01.AOG.0000224694.32531.f3; Liker J. K., 2004, TOYOTA WAY 14 MANAGE; Rouse DJ, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.08.003; UNDP/UNFPA/WHO/World Bank Special Programme of Research Development and Research Training in Human Reproduction (HRP), 2008, WHORHRHRP0804 UNDPUN	12	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2012	379	9827					1684	1685		10.1016/S0140-6736(12)60354-7	http://dx.doi.org/10.1016/S0140-6736(12)60354-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	937KX	22398173				2022-12-28	WOS:000303658500008
J	Fiskerstrand, T; Arshad, N; Haukanes, BI; Tronstad, RR; Pham, KDC; Johansson, S; Havik, B; Tonder, SL; Levy, SE; Brackman, D; Boman, H; Biswas, KH; Apold, J; Hovdenak, N; Visweswariah, SS; Knappskog, PM				Fiskerstrand, Torunn; Arshad, Najla; Haukanes, Bjorn Ivar; Tronstad, Rune Rose; Pham, Khanh Do-Cong; Johansson, Stefan; Havik, Bjarte; Tonder, Siv L.; Levy, Shawn E.; Brackman, Damien; Boman, Helge; Biswas, Kabir Hassan; Apold, Jaran; Hovdenak, Nils; Visweswariah, Sandhya S.; Knappskog, Per M.			Familial Diarrhea Syndrome Caused by an Activating GUCY2C Mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; FUNCTIONAL ABDOMINAL-PAIN; IRRITABLE-BOWEL-SYNDROME; CROHNS-DISEASE; CLINICAL MANAGEMENT; NITRIC-OXIDE; CYCLASE-C; INFLAMMATION; DYSFUNCTION; MICE	BACKGROUND Familial diarrhea disorders are, in most cases, severe and caused by recessive mutations. We describe the cause of a novel dominant disease in 32 members of a Norwegian family. The affected members have chronic diarrhea that is of early onset, is relatively mild, and is associated with increased susceptibility to inflammatory bowel disease, small-bowel obstruction, and esophagitis. METHODS We used linkage analysis, based on arrays with single-nucleotide polymorphisms, to identify a candidate region on chromosome 12 and then sequenced GUCY2C, encoding guanylate cyclase C (GC-C), an intestinal receptor for bacterial heat-stable enterotoxins. We performed exome sequencing of the entire candidate region from three affected family members, to exclude the possibility that mutations in genes other than GUCY2C could cause or contribute to susceptibility to the disease. We carried out functional studies of mutant GC-C using HEK293T cells. RESULTS We identified a heterozygous missense mutation (c.2519G -> T) in GUCY2C in all affected family members and observed no other rare variants in the exons of genes in the candidate region. Exposure of the mutant receptor to its ligands resulted in markedly increased production of cyclic guanosine monophosphate (cGMP). This may cause hyperactivation of the cystic fibrosis transmembrane regulator (CFTR), leading to increased chloride and water secretion from the enterocytes, and may thus explain the chronic diarrhea in the affected family members. CONCLUSIONS Increased GC-C signaling disturbs normal bowel function and appears to have a proinflammatory effect, either through increased chloride secretion or additional effects of elevated cellular cGMP. Further investigation of the relevance of genetic variants affecting the GC-C-CFTR pathway to conditions such as Crohn's disease is warranted. (Funded by Helse Vest [Western Norway Regional Health Authority] and the Department of Science and Technology, Government of India.)	[Fiskerstrand, Torunn; Haukanes, Bjorn Ivar; Johansson, Stefan; Havik, Bjarte; Tonder, Siv L.; Boman, Helge; Apold, Jaran; Knappskog, Per M.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway; [Pham, Khanh Do-Cong; Hovdenak, Nils] Haukeland Hosp, Dept Internal Med, N-5021 Bergen, Norway; [Tronstad, Rune Rose; Brackman, Damien] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway; [Fiskerstrand, Torunn; Havik, Bjarte; Knappskog, Per M.] Univ Bergen, Dept Clin Med, Bergen, Norway; [Johansson, Stefan] Univ Bergen, Dept Biomed, Bergen, Norway; [Arshad, Najla; Biswas, Kabir Hassan; Visweswariah, Sandhya S.] Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; [Levy, Shawn E.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Indian Institute of Science (IISC) - Bangalore; HudsonAlpha Institute for Biotechnology	Fiskerstrand, T (corresponding author), Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.	torunn.fiskerstrand@helse-bergen.no; sandhya@mrdg.iisc.ernet.in	Biswas, Kabir H/AAG-9156-2019; Arshad, Najla/H-9453-2019; Johansson, Stefan/C-4394-2011; Visweswariah, Sandhya/Q-7500-2019	Biswas, Kabir H/0000-0001-9194-4127; Arshad, Najla/0000-0001-5553-311X; Johansson, Stefan/0000-0002-2298-7008; Visweswariah, Sandhya/0000-0003-2786-7344; Levy, Shawn/0000-0002-1369-5740; Haukanes, Bjorn Ivar/0000-0003-1559-3366; Pham, Khanh Do-Cong/0000-0002-6476-1680	Helse Vest (Western Norway Regional Health Authority) [911308]; Department of Science and Technology, Government of India; Indian Institute of Science; Council of Scientific and Industrial Research, Government of India	Helse Vest (Western Norway Regional Health Authority); Department of Science and Technology, Government of India(Department of Science & Technology (India)); Indian Institute of Science; Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India)	Supported by grants from Helse Vest (Western Norway Regional Health Authority) (911308, to Drs. Fiskerstrand, Haukanes, Johansson, Boman, and Knappskog) and the Department of Science and Technology, Government of India (to Dr. Visweswariah). Dr. Arshad was supported by a fellowship from the Indian Institute of Science, and Dr. Biswas was supported by a Senior Research Fellowship from the Council of Scientific and Industrial Research, Government of India.	Basu N, 2010, MOL CELL BIOCHEM, V334, P67, DOI 10.1007/s11010-009-0324-x; Biswas KH, 2009, J MOL EVOL, V68, P587, DOI 10.1007/s00239-009-9242-5; Canani RB, 2010, J PEDIATR GASTR NUTR, V50, P360, DOI 10.1097/MPG.0b013e3181d135ef; Caprilli R, 2008, J CROHNS COLITIS, V2, P352, DOI 10.1016/j.crohns.2008.06.001; COHEN MB, 1988, GASTROENTEROLOGY, V94, P367, DOI 10.1016/0016-5085(88)90423-4; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Francis SH, 2010, PHARMACOL REV, V62, P525, DOI 10.1124/pr.110.002907; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fries W, 2005, AM J GASTROENTEROL, V100, P2730, DOI 10.1111/j.1572-0241.2005.00325.x; Gong R, 2011, SCIENCE, V333, P1642, DOI 10.1126/science.1207675; Habre Jihad, 2008, Am J Surg, V196, pe48, DOI 10.1016/j.amjsurg.2007.11.029; Han XN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016139; Kuhn Michaela, 2009, V191, P47, DOI 10.1007/978-3-540-68964-5_4; Kurjak M, 2001, J PHYSIOL-LONDON, V534, P827, DOI 10.1111/j.1469-7793.2001.00827.x; Laubitz D, 2008, AM J PHYSIOL-GASTR L, V295, pG63, DOI 10.1152/ajpgi.90207.2008; Lelievre V, 2007, PEPTIDES, V28, P1688, DOI 10.1016/j.peptides.2007.05.006; Lembo AJ, 2011, NEW ENGL J MED, V365, P527, DOI 10.1056/NEJMoa1010863; Li CY, 2010, INTEGR BIOL-UK, V2, P161, DOI [10.1039/B924455G, 10.1039/b924455g]; McGuckin MA, 2009, INFLAMM BOWEL DIS, V15, P100, DOI 10.1002/ibd.20539; Mourad FH, 2000, GUT, V47, P382, DOI 10.1136/gut.47.3.382; Murek M, 2010, EXP PHYSIOL, V95, P471, DOI 10.1113/expphysiol.2009.049445; Navaneethan U, 2008, NAT CLIN PRACT GASTR, V5, P637, DOI 10.1038/ncpgasthep1264; Ochiai T, 1997, LIFE SCI, V61, P1479, DOI 10.1016/S0024-3205(97)00707-8; Ohman L, 2010, NAT REV GASTRO HEPAT, V7, P163, DOI 10.1038/nrgastro.2010.4; Qian X, 2008, ENDOCRINOLOGY, V149, P4499, DOI 10.1210/en.2007-1724; Saha S, 2009, J BIOL CHEM, V284, P27135, DOI 10.1074/jbc.M109.020032; Saito YA, 2011, GASTROENTEROL CLIN N, V40, P45, DOI 10.1016/j.gtc.2010.12.011; Saito YA, 2010, AM J GASTROENTEROL, V105, P833, DOI 10.1038/ajg.2010.116; Shen L, 2009, DIGEST DIS, V27, P443, DOI 10.1159/000233282; Shulman RJ, 2008, J PEDIATR-US, V153, P646, DOI 10.1016/j.jpeds.2008.04.062; Steinbrecher KA, 2011, J IMMUNOL, V186, P7205, DOI 10.4049/jimmunol.1002469; Steinbrecher KA, 2011, CURR OPIN GASTROEN, V27, P139, DOI 10.1097/MOG.0b013e328341ead5; Thompson WG, 1999, GUT, V45, P43; Valentino MA, 2011, J CLIN INVEST, V121, P3578, DOI 10.1172/JCI57925; Wedenoja S, 2010, ALIMENT PHARM THER, V31, P477, DOI 10.1111/j.1365-2036.2009.04197.x	35	133	139	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2012	366	17					1586	1595		10.1056/NEJMoa1110132	http://dx.doi.org/10.1056/NEJMoa1110132			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931FC	22436048				2022-12-28	WOS:000303200100007
J	Lamy, A; Devereaux, PJ; Prabhakaran, D; Taggart, DP; Hu, SS; Paolasso, E; Straka, Z; Piegas, LS; Akar, AR; Jain, AR; Noiseux, N; Padmanabhan, C; Bahamondes, JC; Novick, RJ; Vaijyanath, P; Reddy, S; Tao, L; Olavegogeascoechea, PA; Airan, B; Sulling, TA; Whitlock, RP; Ou, YN; Ng, J; Chrolavicius, S; Yusuf, S				Lamy, Andre; Devereaux, P. J.; Prabhakaran, Dorairaj; Taggart, David P.; Hu, Shengshou; Paolasso, Ernesto; Straka, Zbynek; Piegas, Leopoldo S.; Akar, Ahmet Ruchan; Jain, Anil R.; Noiseux, Nicolas; Padmanabhan, Chandrasekar; Bahamondes, Juan-Carlos; Novick, Richard J.; Vaijyanath, Prashant; Reddy, Sukesh; Tao, Liang; Olavegogeascoechea, Pablo A.; Airan, Balram; Sulling, Toomas-Andres; Whitlock, Richard P.; Ou, Yongning; Ng, Jennifer; Chrolavicius, Susan; Yusuf, Salim		CORONARY Investigators	Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE KIDNEY INJURY; RANDOMIZED-TRIALS; CARDIAC-SURGERY; OUTCOMES; MORBIDITY; COLLABORATION; METAANALYSIS; DESIGN	Background The relative benefits and risks of performing coronary-artery bypass grafting (CABG) with a beating-heart technique (off-pump CABG), as compared with cardiopulmonary bypass (on-pump CABG), are not clearly established. Methods At 79 centers in 19 countries, we randomly assigned 4752 patients in whom CABG was planned to undergo the procedure off-pump or on-pump. The first coprimary outcome was a composite of death, nonfatal stroke, nonfatal myocardial infarction, or new renal failure requiring dialysis at 30 days after randomization. Results There was no significant difference in the rate of the primary composite outcome between off-pump and on-pump CABG (9.8% vs. 10.3%; hazard ratio for the off-pump group, 0.95; 95% confidence interval [CI], 0.79 to 1.14; P = 0.59) or in any of its individual components. The use of off-pump CABG, as compared with on-pump CABG, significantly reduced the rates of blood-product transfusion (50.7% vs. 63.3%; relative risk, 0.80; 95% CI, 0.75 to 0.85; P<0.001), reoperation for perioperative bleeding (1.4% vs. 2.4%; relative risk, 0.61; 95% CI, 0.40 to 0.93; P = 0.02), acute kidney injury (28.0% vs. 32.1%; relative risk, 0.87; 95% CI, 0.80 to 0.96; P = 0.01), and respiratory complications (5.9% vs. 7.5%; relative risk, 0.79; 95% CI, 0.63 to 0.98; P = 0.03) but increased the rate of early repeat revascularizations (0.7% vs. 0.2%; hazard ratio, 4.01; 95% CI, 1.34 to 12.0; P = 0.01). Conclusions There was no significant difference between off-pump and on-pump CABG with respect to the 30-day rate of death, myocardial infarction, stroke, or renal failure requiring dialysis. The use of off-pump CABG resulted in reduced rates of transfusion, reoperation for perioperative bleeding, respiratory complications, and acute kidney injury but also resulted in an increased risk of early revascularization. (Funded by the Canadian Institutes of Health Research; CORONARY ClinicalTrials.gov number, NCT00463294.)	[Lamy, Andre; Devereaux, P. J.; Whitlock, Richard P.; Ou, Yongning; Ng, Jennifer; Chrolavicius, Susan; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Novick, Richard J.] London Hlth Sci Ctr, London, ON, Canada; [Taggart, David P.] Ctr Chron Dis Control, New Delhi, India; [Airan, Balram] All India Inst Med Sci, New Delhi, India; [Jain, Anil R.] SAL Hosp & Med Inst, Ahmadabad, Gujarat, India; [Padmanabhan, Chandrasekar] G Kuppuswamy Naidu Mem Hosp, Coimbatore, Tamil Nadu, India; [Vaijyanath, Prashant] Dr KM Cherian Heart Fdn, Madras, Tamil Nadu, India; [Reddy, Sukesh] Mediciti Hosp, Hyderabad, Andhra Pradesh, India; [Taggart, David P.] Univ Oxford, Oxford, England; [Hu, Shengshou] Fu Wai Cardiovasc Hosp, Beijing, Peoples R China; [Paolasso, Ernesto] Inst Invest Clin Rosario, Rosario, Argentina; [Straka, Zbynek] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Piegas, Leopoldo S.] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; Ankara Univ, Sch Med, TR-06100 Ankara, Turkey; [Noiseux, Nicolas] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada; [Bahamondes, Juan-Carlos] Hosp Reg Temuco, Temuco, Chile; [Tao, Liang] Wuhan Asia Heart Hosp, Wuhan, Peoples R China; [Olavegogeascoechea, Pablo A.] Fdn Med Rio Negro & Neuguen, Rio Negro, Argentina; [Sulling, Toomas-Andres] N Estonia Med Ctr, Tallinn, Estonia	McMaster University; Population Health Research Institute; London Health Sciences Centre; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Oxford; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Charles University Prague; Instituto Dante Pazzanese de Cardiologia; Ankara University; Universite de Montreal; Universidad de Chile	Lamy, A (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	lamya@mcmaster.ca	Buse, Giovanna Lurati/ABE-6008-2020; Akar, Ahmet Ruchan/C-9905-2009; Zamvar, Vipin/J-3430-2013; Hueb, Alexandre/E-6804-2013; Rösler, Álvaro/AAM-4460-2021; Baran, Cagdas/AAM-3369-2020; LAMY, ANDRE/AAS-3855-2021; Brat, Radim/G-7925-2019; Devereaux, PJ/AAF-2862-2019; Harrer, Jan/M-3637-2017; Airan, Balram/ABH-1465-2020; Kahraman, Doğan/H-6800-2018; Buffolo, Enio/A-2126-2013; Devereaux, PJ/AAY-1757-2021; Prabhakaran, Dorairaj/B-4147-2011; Whitlock, Richard/AAQ-1593-2021; Olavegogeascoechea, Pablo/Q-2834-2018; Stevens, Louis-Mathieu/E-6453-2016; Gogayeva, Olena/B-8386-2017; Vanek, Tomas/I-7078-2017; Stocco Guilhen, Jose Cicero/F-2714-2015	Buse, Giovanna Lurati/0000-0002-8076-5737; Akar, Ahmet Ruchan/0000-0002-5191-5505; Zamvar, Vipin/0000-0003-2447-828X; Rösler, Álvaro/0000-0003-4727-3367; Brat, Radim/0000-0001-9381-9135; Harrer, Jan/0000-0001-7072-2760; Kahraman, Doğan/0000-0002-5367-2340; Prabhakaran, Dorairaj/0000-0002-3172-834X; Whitlock, Richard/0000-0002-6863-5884; Olavegogeascoechea, Pablo/0000-0002-2625-2922; Stevens, Louis-Mathieu/0000-0003-3372-3419; Gogayeva, Olena/0000-0002-7338-475X; Yusuf, Salim/0000-0003-4776-5601; Bannon, Paul/0000-0002-3117-7250; Devereaux, PJ/0000-0003-2935-637X; Lanas, Fernando/0000-0003-3595-9759; Vanek, Tomas/0000-0002-7412-6912; Stocco Guilhen, Jose Cicero/0000-0001-7502-5585; Morillo, Carlos/0000-0002-8739-2099; Piegas, Leopoldo/0000-0003-1021-817X; Botto, Fernando/0000-0002-0572-8493	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institutes of Health Research.; Funded by the Canadian Institutes of Health Research; CORONARY ClinicalTrials.gov number, NCT00463294.	Afilalo J, 2011, EUR HEART J     1010; [Anonymous], STS AD CARD SURG DAT; Brown PP, 2001, ANN THORAC SURG, V72, pS1009, DOI 10.1016/S0003-4975(01)02937-X; Cheng DC, 2005, ANESTHESIOLOGY, V102, P188, DOI 10.1097/00000542-200501000-00028; deGuzman BJ, 2004, NEW ENGL J MED, V350, P1791; Devereaux PJ, 2005, BMJ-BRIT MED J, V330, P88, DOI 10.1136/bmj.330.7482.88; Karkouti K, 2009, CIRCULATION, V119, P495, DOI 10.1161/CIRCULATIONAHA.108.786913; Lamy A, 2012, AM HEART J, V163, P1, DOI 10.1016/j.ahj.2011.10.007; Legare JF, 2004, CIRCULATION, V109, P887, DOI 10.1161/01.CIR.0000115943.41814.7D; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Nathoe HM, 2003, NEW ENGL J MED, V348, P394, DOI 10.1056/NEJMoa021775; Novitzky D, 2007, CLIN TRIALS, V4, P81, DOI 10.1177/1740774506075859; Puskas JD, 2004, JAMA-J AM MED ASSOC, V291, P1841, DOI 10.1001/jama.291.15.1841; Roques F, 2003, EUR HEART J, V24, P881, DOI 10.1016/S0195-668X(02)00799-6; Sedrakyan A, 2006, STROKE, V37, P2759, DOI 10.1161/01.STR.0000245081.52877.f2; Sellke FW, 2005, CIRCULATION, V111, P2858, DOI 10.1161/CIRCULATIONAHA.105.165030; Shroyer AL, 2009, NEW ENGL J MED, V361, P1827, DOI 10.1056/NEJMoa0902905; Song HK, 2003, EUR J CARDIO-THORAC, V24, P947, DOI 10.1016/S1010-7940(03)00616-X; Spiess Bruce D, 2004, Semin Cardiothorac Vasc Anesth, V8, P267, DOI 10.1177/108925320400800402; Straka Z, 2004, ANN THORAC SURG, V77, P789, DOI 10.1016/j.athoracsur.2003.08.039; VANDERLINDEN W, 1980, SURGERY, V87, P258; Venkataraman Ramesh, 2007, J Intensive Care Med, V22, P187, DOI 10.1177/0885066607299510; Yusuf, 1994, LANCET, V344, P1446; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	24	478	520	2	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 19	2012	366	16					1489	1497		10.1056/NEJMoa1200388	http://dx.doi.org/10.1056/NEJMoa1200388			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927UE	22449296				2022-12-28	WOS:000302934800006
J	Lin, SM; Tsai, JY; Hsiao, CD; Huang, YT; Chiu, CL; Liu, MH; Tung, JY; Liu, TH; Pan, RL; Sun, YJ				Lin, Shih-Ming; Tsai, Jia-Yin; Hsiao, Chwan-Deng; Huang, Yun-Tzu; Chiu, Chen-Liang; Liu, Mu-Hsuan; Tung, Jung-Yu; Liu, Tseng-Huang; Pan, Rong-Long; Sun, Yuh-Ju			Crystal structure of a membrane-embedded H+-translocating pyrophosphatase	NATURE			English	Article							SUBSTRATE-BINDING SUBUNIT; INORGANIC PYROPHOSPHATASE; MOLECULAR-CLONING; PURIFICATION; RESIDUES; ORGANIZATION; INHIBITION; STRATEGY; SEQUENCE; DOMAINS	H+-translocating pyrophosphatases (H+-PPases) are active proton transporters that establish a proton gradient across the endomembrane by means of pyrophosphate (PPi) hydrolysis(1,2). H+-PPases are found primarily as homodimers in the vacuolar membrane of plants and the plasma membrane of several protozoa and prokaryotes(2,3). The three-dimensional structure and detailed mechanisms underlying the enzymatic and proton translocation reactions of H+-PPases are unclear. Here we report the crystal structure of a Vigna radiata H+-PPase (VrH(+)-PPase) in complex with a non-hydrolysable substrate analogue, imidodiphosphate (IDP), at 2.35 angstrom resolution. Each VrH(+)-PPase subunit consists of an integral membrane domain formed by 16 transmembrane helices. IDP is bound in the cytosolic region of each subunit and trapped by numerous charged residues and five Mg2+ ions. A previously undescribed proton translocation pathway is formed by six core transmembrane helices. Proton pumping can be initialized by PPi hydrolysis, and H+ is then transported into the vacuolar lumen through a pathway consisting of Arg 242, Asp 294, Lys 742 and Glu 301. We propose a working model of the mechanism for the coupling between proton pumping and PPi hydrolysis by H+-PPases.	[Lin, Shih-Ming; Huang, Yun-Tzu; Chiu, Chen-Liang; Liu, Mu-Hsuan; Tung, Jung-Yu; Liu, Tseng-Huang; Pan, Rong-Long; Sun, Yuh-Ju] Natl Tsing Hua Univ, Dept Life Sci, Coll Life Sci, Hsinchu 30013, Taiwan; [Lin, Shih-Ming; Huang, Yun-Tzu; Chiu, Chen-Liang; Liu, Mu-Hsuan; Tung, Jung-Yu; Liu, Tseng-Huang; Pan, Rong-Long; Sun, Yuh-Ju] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Coll Life Sci, Hsinchu 30013, Taiwan; [Tsai, Jia-Yin; Hsiao, Chwan-Deng] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	National Tsing Hua University; National Tsing Hua University; Academia Sinica - Taiwan	Sun, YJ (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Coll Life Sci, Hsinchu 30013, Taiwan.	rlpan@life.nthu.edu.tw; yjsun@life.nthu.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021	Hsiao, Chwan-Deng/0000-0002-7012-1532	National Science Council of Taiwan [NSC 99-2311-B-007-007-MY3, NSC 100-2311-B-007-001-MY3, NSC 100-2627-M-007-012]; National Tsing Hua University, Taiwan [99N82416E1]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Tsing Hua University, Taiwan	We thank M. F. Tam, P. C. Huang and H. J. Kung for their critical reading of the manuscript and for useful comments. The X-ray diffraction data were collected from the in-house X-ray facility at National Tsing Hua University and from beamlines BL13B1/BL13C1 at the National Synchrotron Radiation Research Center, Taiwan, and BL44XU/BL12B2 at SPring-8, Japan. This work was supported by grants from the National Science Council of Taiwan (NSC 99-2311-B-007-007-MY3 to Y.-J.S.; NSC 100-2311-B-007-001-MY3 and NSC 100-2627-M-007-012 to R.-L.P.) and National Tsing Hua University, Taiwan (99N82416E1 to Y.-J.S.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; Buch-Pedersen MJ, 2009, PFLUG ARCH EUR J PHY, V457, P573, DOI 10.1007/s00424-008-0503-8; CHANSON A, 1985, PLANT PHYSIOL, V79, P159, DOI 10.1104/pp.79.1.159; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Ferjani A, 2011, PLANT CELL, V23, P2895, DOI 10.1105/tpc.111.085415; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; Guo SL, 2006, PLANT MOL BIOL, V60, P41, DOI 10.1007/s11103-005-2417-6; Hirono M, 2007, BBA-BIOENERGETICS, V1767, P930, DOI 10.1016/j.bbabio.2007.03.014; Ho BK, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-49; Hsu SH, 2009, BOT STUD, V50, P291; Huang YT, 2010, J BIOL CHEM, V285, P23655, DOI 10.1074/jbc.M110.134916; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.190215; Li JS, 2005, SCIENCE, V310, P121, DOI 10.1126/science.1115711; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YJ, 2011, BBA-BIOENERGETICS, V1807, P59, DOI 10.1016/j.bbabio.2010.10.006; Park S, 2005, P NATL ACAD SCI USA, V102, P18830, DOI 10.1073/pnas.0509512102; Pedersen BP, 2007, NATURE, V450, P1111, DOI 10.1038/nature06417; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; REA PA, 1985, PLANT PHYSIOL, V77, P46, DOI 10.1104/pp.77.1.46; Samygina VR, 2007, J MOL BIOL, V366, P1305, DOI 10.1016/j.jmb.2006.11.082; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; Serrano A, 2004, J BIOENERG BIOMEMBR, V36, P127, DOI 10.1023/B:JOBB.0000019604.49875.b3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tzeng CM, 1996, BIOCHEM J, V316, P143, DOI 10.1042/bj3160143; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Van RC, 2005, BBA-BIOENERGETICS, V1709, P84, DOI 10.1016/j.bbabio.2005.05.011; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	43	112	122	4	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					399	403		10.1038/nature10963	http://dx.doi.org/10.1038/nature10963			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22456709				2022-12-28	WOS:000302946500038
J	Cui, YJ; Wang, W; Dong, NZ; Lou, JL; Srinivasan, DK; Cheng, WW; Huang, XY; Liu, M; Fang, CD; Peng, JH; Chen, SH; Wu, SN; Liu, ZZ; Dong, L; Zhou, YQ; Wu, QY				Cui, Yujie; Wang, Wei; Dong, Ningzheng; Lou, Jinglei; Srinivasan, Dinesh Kumar; Cheng, Weiwei; Huang, Xiaoyi; Liu, Meng; Fang, Chaodong; Peng, Jianhao; Chen, Shenghan; Wu, Shannon; Liu, Zhenzhen; Dong, Liang; Zhou, Yiqing; Wu, Qingyu			Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy	NATURE			English	Article							PROATRIAL NATRIURETIC PEPTIDE; PLASMA SOLUBLE CORIN; SERINE-PROTEASE; PATHOGENESIS; PREECLAMPSIA; IMPLANTATION; HYPERTENSION	In pregnancy, trophoblast invasion and uterine spiral artery remodelling are important for lowering maternal vascular resistance and increasing uteroplacental blood flow. Impaired spiral artery remodelling has been implicated in pre-eclampsia, a major complication of pregnancy, for a long time but the underlying mechanisms remain unclear(1,2). Corin (also known as atrial natriuretic peptide-converting enzyme) is a cardiac protease that activates atrial natriuretic peptide (ANP), a cardiac hormone that is important in regulating blood pressure(3). Unexpectedly, corin expression was detected in the pregnant uterus(4). Here we identify a new function of corin and ANP in promoting trophoblast invasion and spiral artery remodelling. We show that pregnant corin-or ANP-deficient mice developed high blood pressure and proteinuria, characteristics of pre-eclampsia. In these mice, trophoblast invasion and uterine spiral artery remodelling were markedly impaired. Consistent with this, the ANP potently stimulated human trophoblasts in invading Matrigels. In patients with pre-eclampsia, uterine Corin messenger RNA and protein levels were significantly lower than that in normal pregnancies. Moreover, we have identified Corin gene mutations inpre-eclamptic patients, which decreased corin activity in processing pro-ANP. These results indicate that corin and ANP are essential for physiological changes at the maternal-fetal interface, suggesting that defects in corin and ANP function may contribute to pre-eclampsia.	[Cui, Yujie; Wang, Wei; Lou, Jinglei; Srinivasan, Dinesh Kumar; Peng, Jianhao; Chen, Shenghan; Wu, Shannon; Wu, Qingyu] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA; [Dong, Ningzheng; Liu, Meng; Fang, Chaodong; Liu, Zhenzhen; Dong, Liang; Zhou, Yiqing; Wu, Qingyu] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China; [Dong, Ningzheng] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis, Suzhou 215006, Peoples R China; [Cheng, Weiwei; Huang, Xiaoyi] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Child Hlth Hosp, Shanghai 200030, Peoples R China	Cleveland Clinic Foundation; Soochow University - China; Soochow University - China; Shanghai Jiao Tong University	Wu, QY (corresponding author), Cleveland Clin, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	wuq@ccf.org	Srinivasan, Dinesh Kumar/A-9872-2008; Srinivasan, Dinesh Kumar/P-6528-2019; Srinivasan, Dinesh Kumar/E-6383-2017	Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Wu, Qingyu/0000-0003-0561-9315	Ralph Wilson Medical Foundation; Bakken Heart-Brain Institute; National Institutes of Health [HL089298, HD064634]; National Natural Science Foundation of China [31070716, 81170247, 31161130356]; Priority Academic Program Development of Jiangsu Higher Education Institutions; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD064634] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089298] Funding Source: NIH RePORTER	Ralph Wilson Medical Foundation; Bakken Heart-Brain Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank J. Robbins for the alpha-myosin heavy chain promoter construct and L. Zhang for help with statistical analysis. This work was partly supported by grants from the Ralph Wilson Medical Foundation, the Bakken Heart-Brain Institute and the National Institutes of Health (HL089298, HD064634), and by grants from the National Natural Science Foundation of China (31070716, 81170247 and 31161130356) and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Brosens I A, 1972, Obstet Gynecol Annu, V1, P177; Chan JCY, 2005, P NATL ACAD SCI USA, V102, P785, DOI 10.1073/pnas.0407234102; Chen SH, 2010, AM J PHYSIOL-HEART C, V299, pH1687, DOI 10.1152/ajpheart.00399.2010; Davisson RL, 2002, HYPERTENSION, V39, P337, DOI 10.1161/hy02t2.102904; Dong NZ, 2010, CLIN CHIM ACTA, V411, P1998, DOI 10.1016/j.cca.2010.08.021; Dong NZ, 2010, CIRC-HEART FAIL, V3, P207, DOI 10.1161/CIRCHEARTFAILURE.109.903849; Dries DL, 2005, CIRCULATION, V112, P2403, DOI 10.1161/CIRCULATIONAHA.105.568881; Irons DW, 1997, AM J PHYSIOL-RENAL, V273, pF483, DOI 10.1152/ajprenal.1997.273.3.F483; Jiang JJ, 2011, J BIOL CHEM, V286, P10066, DOI 10.1074/jbc.M110.185082; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kanasaki K, 2008, NATURE, V453, P1117, DOI 10.1038/nature06951; Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977; Knappe S, 2004, J BIOL CHEM, V279, P34464, DOI 10.1074/jbc.M405041200; Kuhn M, 2009, J CLIN INVEST, V119, P2019, DOI 10.1172/JCI37430; Lain KY, 2002, JAMA-J AM MED ASSOC, V287, P3183, DOI 10.1001/jama.287.24.3183; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Liao X, 2007, J BIOL CHEM, V282, P27728, DOI 10.1074/jbc.M703687200; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Pan JL, 2002, J BIOL CHEM, V277, P38390, DOI 10.1074/jbc.M205686200; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; Qi XF, 2011, J BIOL CHEM, V286, P20963, DOI 10.1074/jbc.M110.217570; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; Tihtonen KM, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.11.033; Tokudome T, 2009, ARTERIOSCL THROM VAS, V29, P1516, DOI 10.1161/ATVBAHA.109.187526; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Wang W, 2008, CIRC RES, V103, P502, DOI 10.1161/CIRCRESAHA.108.177352; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Wu QY, 2009, KIDNEY INT, V75, P142, DOI 10.1038/ki.2008.418; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zhou CC, 2008, NAT MED, V14, P855, DOI 10.1038/nm.1856	33	209	228	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					246	U134		10.1038/nature10897	http://dx.doi.org/10.1038/nature10897			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22437503	Green Accepted			2022-12-28	WOS:000303149900036
J	Boissier, F; Khalil, A; Chalumeau-Lemoine, L; Lescure, FX; Parrot, A				Boissier, Florence; Khalil, Antoine; Chalumeau-Lemoine, Ludivine; Lescure, Francois-Xavier; Parrot, Antoine			Rash diagnosis of blood expectoration	LANCET			English	Editorial Material									[Boissier, Florence; Chalumeau-Lemoine, Ludivine; Parrot, Antoine] Hop Tenon, AP HP, Serv Pneumol & Reanimat, F-75020 Paris, France; [Khalil, Antoine] Hop Tenon, AP HP, Serv Radiol, F-75020 Paris, France; [Lescure, Francois-Xavier] Hop Tenon, AP HP, Serv Malad Infect, F-75020 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Boissier, F (corresponding author), Hop Tenon, AP HP, Serv Pneumol & Reanimat, 4 Rue Chine, F-75020 Paris, France.	florence.boissier@hmn.aphp.fr	Lescure, Xavier/AAM-5261-2020					DiLeo M D, 1995, Ear Nose Throat J, V74, P822; JOHN DG, 1988, J LARYNGOL OTOL, V102, P64, DOI 10.1017/S0022215100104001; Mal H, 1999, CHEST, V115, P996, DOI 10.1378/chest.115.4.996; Muscat M, 2009, LANCET, V373, P383, DOI 10.1016/S0140-6736(08)61849-8; Parrot A, 2008, HEMOPTYSIS	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1170	1170		10.1016/S0140-6736(11)61645-0	http://dx.doi.org/10.1016/S0140-6736(11)61645-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22444400				2022-12-28	WOS:000302131800039
J	Stein, EA; Mellis, S; Yancopoulos, GD; Stahl, N; Logan, D; Smith, WB; Lisbon, E; Gutierrez, M; Webb, C; Wu, R; Du, YL; Kranz, T; Gasparino, E; Swergold, GD				Stein, Evan A.; Mellis, Scott; Yancopoulos, George D.; Stahl, Neil; Logan, Douglas; Smith, William B.; Lisbon, Eleanor; Gutierrez, Maria; Webb, Cheryle; Wu, Richard; Du, Yunling; Kranz, Therese; Gasparino, Evelyn; Swergold, Gary D.			Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MICE; MUTATIONS; POPULATION; STATIN	BACKGROUND Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials. gov numbers, NCT01026597, NCT01074372, and NCT01161082.)	[Stein, Evan A.; Webb, Cheryle; Kranz, Therese] Metab & Atherosclerosis Res Ctr, Cincinnati, OH 45212 USA; [Logan, Douglas] Medpace Clin Pharmacol Unit, Cincinnati, OH USA; [Mellis, Scott; Yancopoulos, George D.; Stahl, Neil; Wu, Richard; Du, Yunling; Gasparino, Evelyn; Swergold, Gary D.] Regeneron Pharmaceut, Tarrytown, NY USA; [Smith, William B.] Univ Tennessee, Med Ctr, New Orleans Ctr Clin Res, Knoxville, TN USA; [Lisbon, Eleanor] Quintiles, Overland Pk, KS USA	Regeneron; University of Tennessee System; University of Tennessee Health Science Center; IQVIA	Stein, EA (corresponding author), Metab & Atherosclerosis Res Ctr, 4685 Forest Ave, Cincinnati, OH 45212 USA.	esteinmrl@aol.com			Regeneron Pharmaceuticals; Sanofi	Regeneron Pharmaceuticals(Regeneron); Sanofi	Supported by Regeneron Pharmaceuticals and Sanofi.	Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Berge KE, 2006, ARTERIOSCL THROM VAS, V26, P1094, DOI 10.1161/01.ATV.0000204337.81286.1c; Chan JCY, 2009, P NATL ACAD SCI USA, V106, P9820, DOI 10.1073/pnas.0903849106; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Demant T, 2001, ATHEROSCLEROSIS, V157, P325, DOI 10.1016/S0021-9150(00)00732-2; Department of Health and Human Services, 1982, DEP HLTH HUM SERV PU; Hooper AJ, 2007, ATHEROSCLEROSIS, V193, P445, DOI 10.1016/j.atherosclerosis.2006.08.039; Jonathan C, 2005, NAT GENET, V37, P161, DOI 10.1038/ng1509; Kotowski IK, 2006, AM J HUM GENET, V78, P410, DOI 10.1086/500615; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Olsson AG, 2001, CLIN CARDIOL, V24, P18; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Yue P, 2006, HUM MUTAT, V27, P460, DOI 10.1002/humu.20316; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	17	533	608	3	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1108	1118		10.1056/NEJMoa1105803	http://dx.doi.org/10.1056/NEJMoa1105803			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435370	Bronze			2022-12-28	WOS:000301769700010
J	Smellie, WSA				Smellie, W. S. A.		Assoc Clinical Biochem Clinical Pr	Time to harmonise common laboratory test profiles	BRITISH MEDICAL JOURNAL			English	Editorial Material							PRIMARY-CARE PATHOLOGY		[Smellie, W. S. A.] Bishop Auckland Hosp, Clin Lab, Auckland DL14 6AD, New Zealand		Smellie, WSA (corresponding author), Bishop Auckland Hosp, Clin Lab, Auckland DL14 6AD, New Zealand.	stuart.smellie@cddft.nhs.uk						[Anonymous], 2008, LORD CARTER COLES RE; Association for Clinical Biochemistry, UK GUID US THYR FUNC; BROUGHTON PMG, 1989, ANN CLIN BIOCHEM, V26, P119, DOI 10.1177/000456328902600204; Cook S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1281; Gama R, 1990, J MANAGMT MED, V4, P226; *ROYAL COLL PHYS R, CHRON KIDN DIS AD UK; Smellie WSA, 2007, J CLIN PATHOL, V60, P1195, DOI 10.1136/jcp.2007.048512; Smellie WSA, 2006, J CLIN PATHOL, V59, P1229, DOI 10.1136/jcp.2006.037754	8	21	21	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2012	344								e1169	10.1136/bmj.e1169	http://dx.doi.org/10.1136/bmj.e1169			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CJ	22434088				2022-12-28	WOS:000301848700001
J	Mendell, JT; Olson, EN				Mendell, Joshua T.; Olson, Eric N.			MicroRNAs in Stress Signaling and Human Disease	CELL			English	Review							SMALL RNAS; GENE-EXPRESSION; MIR-17-SIMILAR-TO-92 CLUSTER; CARDIAC-HYPERTROPHY; CELL-PROLIFERATION; SLITRK1 GENE; TARGET SITE; LUNG-CANCER; IN-VIVO; FAMILY	Disease is often the result of an aberrant or inadequate response to physiologic and pathophysiologic stress. Studies over the last 10 years have uncovered a recurring paradigm in which microRNAs (miRNAs) regulate cellular behavior under these conditions, suggesting an especially significant role for these small RNAs in pathologic settings. Here, we review emerging principles of miRNA regulation of stress signaling pathways and apply these concepts to our understanding of the roles of miRNAs in disease. These discussions further highlight the unique challenges and opportunities associated with the mechanistic dissection of miRNA functions and the development of miRNA-based therapeutics.	[Mendell, Joshua T.; Olson, Eric N.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Mendell, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.	joshua.mendell@utsouthwestern.edu			Cancer Prevention and Research Institute of Texas (CPRIT); National Institutes of Health (NIH) [R01CA120185, P01CA134292, R01HL77439, R01HL093039, U01HL100401]; Robert A. Welch Foundation; American Heart Association-Jon Holden DeHaan Foundation; D.W. Reynolds Center for Clinical Cardiovascular Research; Leducq Transatlantic Network of Excellence in Cardiovascular Research; NATIONAL CANCER INSTITUTE [P01CA134292, R01CA120185] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077439, R01HL093039, U01HL100401, R01HL111665] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas (CPRIT); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); American Heart Association-Jon Holden DeHaan Foundation(American Heart Association); D.W. Reynolds Center for Clinical Cardiovascular Research; Leducq Transatlantic Network of Excellence in Cardiovascular Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Kathryn O'Donnell and members of the Mendell and Olson laboratories for helpful comments on the manuscript. J.T.M. is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health (NIH) (R01CA120185 and P01CA134292). E.N.O. is supported by grants from the NIH (R01HL77439, R01HL093039, and U01HL100401), the Robert A. Welch Foundation, the American Heart Association-Jon Holden DeHaan Foundation, the D.W. Reynolds Center for Clinical Cardiovascular Research, the Leducq Transatlantic Network of Excellence in Cardiovascular Research Program, and CPRIT. E.N.O. is a cofounder and member of the Scientific Advisory Board of miRagen Therapeutics and holds equity in the company.	Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Alexiou P, 2009, BIOINFORMATICS, V25, P3049, DOI 10.1093/bioinformatics/btp565; Alvarez-Saavedra E, 2010, CURR BIOL, V20, P367, DOI 10.1016/j.cub.2009.12.051; Ameres SL, 2010, SCIENCE, V328, P1534, DOI 10.1126/science.1187058; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bao L, 2007, NUCLEIC ACIDS RES, V35, pD51, DOI 10.1093/nar/gkl797; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Boon RA, 2011, CIRC RES, V109, P1115, DOI 10.1161/CIRCRESAHA.111.255737; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brenner JL, 2010, CURR BIOL, V20, P1321, DOI 10.1016/j.cub.2010.05.062; Bui Thi V, 2010, Genes Cancer, V1, P568; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517; Chiang HR, 2010, GENE DEV, V24, P992, DOI 10.1101/gad.1884710; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Chou IC, 2007, PEDIATR NEUROL, V37, P404, DOI 10.1016/j.pediatrneurol.2007.06.017; Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Cohen SM, 2006, GENE DEV, V20, P2769, DOI 10.1101/gad.1484606; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC; de Pontual L, 2011, NAT GENET, V43, P1026, DOI 10.1038/ng.915; Deng H, 2006, ACTA NEUROL SCAND, V114, P400, DOI 10.1111/j.1600-0404.2006.00706.x; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Di Stefano V, 2011, VASC PHARMACOL, V55, P111, DOI 10.1016/j.vph.2011.08.001; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Farazi TA, 2008, DEVELOPMENT, V135, P1201, DOI 10.1242/dev.005629; Feingold M, 1997, AM J MED GENET, V69, P245, DOI 10.1002/(SICI)1096-8628(19970331)69:3<245::AID-AJMG7>3.3.CO;2-U; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Georges M, 2006, COLD SPRING HARB SYM, V71, P343, DOI 10.1101/sqb.2006.71.056; Hartge P, 2009, NAT GENET, V41, P637, DOI 10.1038/ng0609-637; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hill JA, 2008, NEW ENGL J MED, V358, P1370, DOI 10.1056/NEJMra072139; Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236; Hullinger TG, 2012, CIRC RES, V110, P71, DOI 10.1161/CIRCRESAHA.111.244442; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kuhn S, 2011, P NATL ACAD SCI USA, V108, P2355, DOI 10.1073/pnas.1016646108; Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lewis MA, 2009, NAT GENET, V41, P614, DOI 10.1038/ng.369; Li HQ, 2010, J NEUROSCI, V30, P3254, DOI 10.1523/JNEUROSCI.4948-09.2010; Li XD, 2010, PATHOLOGY, V42, P669, DOI 10.3109/00313025.2010.522175; Lin ZQ, 2009, P NATL ACAD SCI USA, V106, P12103, DOI 10.1073/pnas.0811371106; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu N, 2011, J CLIN INVEST, V121, P3258, DOI 10.1172/JCI46267; Liu N, 2008, GENE DEV, V22, P3242, DOI 10.1101/gad.1738708; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Martins PAD, 2010, NAT CELL BIOL, V12, P1220, DOI 10.1038/ncb2126; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Mencia A, 2009, NAT GENET, V41, P609, DOI 10.1038/ng.355; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montgomery RL, 2011, CIRCULATION, V124, P1537, DOI 10.1161/CIRCULATIONAHA.111.030932; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Patrick DM, 2010, J CLIN INVEST, V120, P3912, DOI 10.1172/JCI43604; Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x; Porrello ER, 2011, CIRC RES, V109, P670, DOI 10.1161/CIRCRESAHA.111.248880; Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106; Pramanik D, 2011, MOL CANCER THER, V10, P1470, DOI 10.1158/1535-7163.MCT-11-0152; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004; Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783; Stenvang J, 2008, SEMIN CANCER BIOL, V18, P89, DOI 10.1016/j.semcancer.2008.01.004; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tian T, 2009, CANCER EPIDEM BIOMAR, V18, P1183, DOI 10.1158/1055-9965.EPI-08-0814; Tijsen AJ, 2010, CIRC RES, V106, P1035, DOI 10.1161/CIRCRESAHA.110.218297; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; van Bokhoven H, 2005, NAT GENET, V37, P465, DOI 10.1038/ng1546; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; van Rooij E, 2009, DEV CELL, V17, P662, DOI 10.1016/j.devcel.2009.10.013; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Weston MD, 2006, BRAIN RES, V1111, P95, DOI 10.1016/j.brainres.2006.07.006; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108; Zhu H, 2010, NAT GENET, V42, P626, DOI 10.1038/ng.593; Zimprich A, 2008, PSYCHIAT GENET, V18, P308, DOI 10.1097/YPG.0b013e3283060f6f	126	1264	1330	4	234	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1172	1187		10.1016/j.cell.2012.02.005	http://dx.doi.org/10.1016/j.cell.2012.02.005			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424228	Bronze, Green Accepted			2022-12-28	WOS:000301889500015
J	Wood, AM; Pasupathy, D; Pell, JP; Fleming, M; Smith, GCS				Wood, Angela M.; Pasupathy, Dharmintra; Pell, Jill P.; Fleming, Michael; Smith, Gordon C. S.			Trends in socioeconomic inequalities in risk of sudden infant death syndrome, other causes of infant mortality, and stillbirth in Scotland: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; DEPRIVATION	Objectives To compare changes in inequalities in sudden infant death syndrome with other causes of infant mortality and stillbirth in Scotland, 1985-2008. Design Retrospective cohort study. Setting Scotland 1985-2008, analysed by four epochs of six years. Participants Singleton births of infants with birth weight >500 g born at 28-43 weeks' gestation. Main outcome measures Sudden infant death syndrome, other causes of postneonatal infant death, neonatal death, and stillbirth. Odds ratios expressed as the association across the range of seven categories of Carstairs deprivation score. Results The association between deprivation and the risk of all cause stillbirth and infant death varied between the four epochs (P=0.04). This was wholly explained by variation in the risk of sudden infant death syndrome (P<0.001 for interaction). Among women living in areas of low deprivation, there was a sharp decline in the rate of sudden infant death syndrome from 1990 to 1993. Among women living in areas of high deprivation, there was a slower decline in sudden infant death syndrome rates between 1992 and 2004. Consequently, the odds ratio for the association between socioeconomic deprivation and sudden infant death syndrome increased from 2.04 (95% confidence interval 1.53 to 2.72) in 1985-90, to 7.52 (4.62 to 12.25) in 1991-6, and 9.50 (5.46 to 16.53) in 1997-2002 but fell to 1.78 (0.87 to 3.65) in 2002-8. The interaction remained significant after adjustment for maternal characteristics. Conclusion The rate of sudden infant death syndrome declined throughout Scotland in the early 1990s. The decline had a later onset and was slower among women living in areas of high deprivation, probably because of slower uptake of recommended changes in infant sleeping position. The effect was to create a strong independent association between deprivation and sudden infant death syndrome where one did not exist before.	[Smith, Gordon C. S.] Univ Cambridge, Dept Obstet & Gynaecol, NIHR Biomed Res Ctr, Cambridge CB2 0SW, England; [Wood, Angela M.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; [Pasupathy, Dharmintra] Kings Coll London, Womens Hlth Acad Ctr, London SE1 7EH, England; [Pell, Jill P.] Univ Glasgow, Publ Hlth Unit, Glasgow G12 8RZ, Lanark, Scotland; [Fleming, Michael] NHS Natl Serv Scotland, Infect Serv Div, Edinburgh EH12 9EB, Midlothian, Scotland	University of Cambridge; University of Cambridge; University of London; King's College London; University of Glasgow; NHS National Services Scotland	Smith, GCS (corresponding author), Univ Cambridge, Dept Obstet & Gynaecol, NIHR Biomed Res Ctr, Cambridge CB2 0SW, England.	gcss2@cam.ac.uk	Pasupathy, Dharmintra/N-9586-2019; Wood, Angela/GZA-5762-2022; Smith, Gordon/A-8070-2008	Pasupathy, Dharmintra/0000-0002-6722-1006; Wood, Angela/0000-0002-7937-304X; Smith, Gordon/0000-0003-2124-0997; fleming, michael/0000-0002-2185-4502; Pell, Jill/0000-0002-8898-7035	NIHR Cambridge Comprehensive Biomedical Research Centre; MRC; MRC [G0600469] Funding Source: UKRI; British Heart Foundation [RG/08/014/24067] Funding Source: researchfish; Medical Research Council [G0600469] Funding Source: researchfish	NIHR Cambridge Comprehensive Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was supported by the NIHR Cambridge Comprehensive Biomedical Research Centre. DP was funded by an MRC clinical training fellowship. The funding bodies had no role in any aspect of the conduct, analysis, or presentation of this study.	BEAL S, 1988, LANCET, V2, P512; Blair PS, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3666; Blair PS, 2006, LANCET, V367, P314, DOI 10.1016/S0140-6736(06)67968-3; Brooke H, 1997, BMJ-BRIT MED J, V314, P1516, DOI 10.1136/bmj.314.7093.1516; Carpenter RG, 2004, LANCET, V363, P185, DOI 10.1016/S0140-6736(03)15323-8; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Guildea ZES, 2001, ARCH DIS CHILD, V84, P307, DOI 10.1136/adc.84.4.307; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; Information Services Division NHS Scotland, 2008, SCOTT PER INF MORT R; Kinney HC, 2009, NEW ENGL J MED, V361, P795, DOI 10.1056/NEJMra0803836; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; Little R, 2008, STAT ANAL MISSING DA; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Messer J, 2010, STAT B GESTATION SPE, P1; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; Sadler DW, 1998, J CLIN PATHOL, V51, P689, DOI 10.1136/jcp.51.9.689; Shipton D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4347; Smith GCS, 2007, LANCET, V370, P1715, DOI 10.1016/S0140-6736(07)61723-1; World Health Organization, 2008, GLOB BURD DIS 2004 U	20	33	33	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	2012	344								e1552	10.1136/bmj.e1552	http://dx.doi.org/10.1136/bmj.e1552			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CE	22427307	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000301848200002
J	Kretzschmar, T; Kohlen, W; Sasse, J; Borghi, L; Schlegel, M; Bachelier, JB; Reinhardt, D; Bours, R; Bouwmeester, HJ; Martinoia, E				Kretzschmar, Tobias; Kohlen, Wouter; Sasse, Joelle; Borghi, Lorenzo; Schlegel, Markus; Bachelier, Julien B.; Reinhardt, Didier; Bours, Ralph; Bouwmeester, Harro J.; Martinoia, Enrico			A petunia ABC protein controls strigolactone-dependent symbiotic signalling and branching	NATURE			English	Article							CASSETTE-TYPE TRANSPORTER; ARBUSCULAR MYCORRHIZA; MEDICAGO-TRUNCATULA; GENE FAMILY; PLANT; AUXIN; ARABIDOPSIS; ACID; PCR; GERMINATION	Strigolactones were originally identified as stimulators of the germination of root-parasitic weeds(1) that pose a serious threat to resource-limited agriculture(2). They are mostly exuded from roots and function as signalling compounds in the initiation of arbuscular mycorrhizae(3), which are plant-fungus symbionts with a global effect on carbon and phosphate cycling(4). Recently, strigolactones were established to be phytohormones that regulate plant shoot architecture by inhibiting the outgrowth of axillary buds(5,6). Despite their importance, it is not known how strigolactones are transported. ATP-binding cassette (ABC) transporters, however, are known to have functions in phytohormone translocation(7-9). Here we show that the Petunia hybrida ABC transporter PDR1 has a key role in regulating the development of arbuscular mycorrhizae and axillary branches, by functioning as a cellular strigolactone exporter. P. hybrida pdr1 mutants are defective in strigolactone exudation from their roots, resulting in reduced symbiotic interactions. Above ground, pdr1 mutants have an enhanced branching phenotype, which is indicative of impaired strigolactone allocation. Overexpression of Petunia axillaris PDR1 in Arabidopsis thaliana results in increased tolerance to high concentrations of a synthetic strigolactone, consistent with increased export of strigolactones from the roots. PDR1 is the first known component in strigolactone transport, providing new opportunities for investigating and manipulating strigolactone-dependent processes.	[Kretzschmar, Tobias; Sasse, Joelle; Borghi, Lorenzo; Schlegel, Markus; Bachelier, Julien B.; Martinoia, Enrico] Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; [Kohlen, Wouter; Bours, Ralph; Bouwmeester, Harro J.] Wageningen Univ, Lab Plant Physiol, NL-6700 AR Wageningen, Netherlands; [Reinhardt, Didier] Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland; [Bouwmeester, Harro J.] Ctr Biosyst Genom, NL-6700 AB Wageningen, Netherlands	University of Zurich; Wageningen University & Research; University of Fribourg; Centre for BioSystems Genomics	Kretzschmar, T (corresponding author), Univ Zurich, Inst Plant Biol, Zollikerstr 107, CH-8008 Zurich, Switzerland.	t.kretzschmar@irri.org	Kretzschmar, Tobias/M-5930-2013; Borghi, Lorenzo/AAF-4631-2019; Reinhardt, Didier/M-8508-2014; Bouwmeester, Harro J/C-1414-2008; kretzschmar, tobias/AAH-3739-2021; Martinoia, Enrico/AAH-8712-2021	Borghi, Lorenzo/0000-0002-9631-9694; Reinhardt, Didier/0000-0003-3495-6783; Schlapfer, Joelle/0000-0001-5705-9888; kretzschmar, tobias/0000-0002-8227-0746; Bouwmeester, Harro/0000-0003-0907-2732; Schlegel, Markus/0000-0003-3453-4783	Swiss National Foundation within the NCCR; Netherlands Organization for Scientific Research (NWO) [865.06.002, 834.08.001]; Centre for BioSystems Genomics (CBSG)	Swiss National Foundation within the NCCR; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Centre for BioSystems Genomics (CBSG)	We kindly thank the following: C. Gubeli for technical assistance; and T. Gerats, S. Hortensteiner, A. Osbourne, P. Schlapfer and C. Beveridge for comments. This study was funded by the Swiss National Foundation within the NCCR-Plant Survival (project 'ABC transporters involved in signaling') and by The Netherlands Organization for Scientific Research (NWO; VICI grant 865.06.002 and Equipment grant 834.08.001to H.J.B.). H.J.B. was co-financed by the Centre for BioSystems Genomics (CBSG).	Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608; Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; Badri DV, 2009, PLANT PHYSIOL, V151, P2006, DOI 10.1104/pp.109.147462; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Beveridge CA, 2010, CURR OPIN PLANT BIOL, V13, P34, DOI 10.1016/j.pbi.2009.10.003; Brewer PB, 2009, PLANT PHYSIOL, V150, P482, DOI 10.1104/pp.108.134783; Cervera M, 2005, METH MOL B, V286, P203; COOK CE, 1966, SCIENCE, V154, P1189, DOI 10.1126/science.154.3753.1189; Crawford S, 2010, DEVELOPMENT, V137, P2905, DOI 10.1242/dev.051987; Domagalska MA, 2011, NAT REV MOL CELL BIO, V12, P211, DOI 10.1038/nrm3088; Feddermann N, 2010, PLANT J, V64, P470, DOI 10.1111/j.1365-313X.2010.04341.x; Giovannetti M., 1980, New Phytologist, V84, P489, DOI 10.1111/j.1469-8137.1980.tb04556.x; Gomez-Roldan V, 2008, NATURE, V455, P189, DOI 10.1038/nature07271; Hanlon MT, 2011, NEW PHYTOL, V189, P701, DOI 10.1111/j.1469-8137.2010.03567.x; Harrison SJ, 2006, PLANT METHODS, V2, DOI 10.1186/1746-4811-2-19; Hayward A, 2009, PLANT PHYSIOL, V151, P400, DOI 10.1104/pp.109.137646; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Jasinski M, 2001, PLANT CELL, V13, P1095, DOI 10.1105/tpc.13.5.1095; Kang J, 2010, P NATL ACAD SCI USA, V107, P2355, DOI 10.1073/pnas.0909222107; KOES R, 1995, P NATL ACAD SCI USA, V92, P8149, DOI 10.1073/pnas.92.18.8149; Kohlen W, 2011, PLANT PHYSIOL, V155, P974, DOI 10.1104/pp.110.164640; Kuromori T, 2010, P NATL ACAD SCI USA, V107, P2361, DOI 10.1073/pnas.0912516107; Liu W, 2011, PLANT CELL, V23, P3853, DOI 10.1105/tpc.111.089771; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lutke W. Kevin, 2006, V344, P339; Mashiguchi K, 2009, BIOSCI BIOTECH BIOCH, V73, P2460, DOI 10.1271/bbb.90443; Matusova R, 2005, PLANT PHYSIOL, V139, P920, DOI 10.1104/pp.105.061382; Meyer A, 2006, J BIOL CHEM, V281, P7197, DOI 10.1074/jbc.M510766200; Moons A, 2008, PLANTA, V229, P53, DOI 10.1007/s00425-008-0810-5; Nagahashi G, 1999, BIOTECHNOL TECH, V13, P893, DOI 10.1023/A:1008938527757; Napoli C, 1996, PLANT PHYSIOL, V111, P27, DOI 10.1104/pp.111.1.27; Parniske M, 2008, NAT REV MICROBIOL, V6, P763, DOI 10.1038/nrmicro1987; Petrasek J, 2009, DEVELOPMENT, V136, P2675, DOI 10.1242/dev.030353; Ruyter-Spira C, 2011, PLANT PHYSIOL, V155, P721, DOI 10.1104/pp.110.166645; Sekhara RDMR, 2007, PLANT J, V51, P739, DOI 10.1111/j.1365-313X.2007.03175.x; Sharda JN, 2008, NEW PHYTOL, V180, P696, DOI 10.1111/j.1469-8137.2008.02600.x; Snowden KC, 2005, PLANT CELL, V17, P746, DOI 10.1105/tpc.104.027714; Snowden KC, 2003, FUNCT PLANT BIOL, V30, P987, DOI 10.1071/FP03081; Sugiyama A, 2008, PLANT SIGNAL BEHAV, V3, P38, DOI 10.4161/psb.3.1.4819; Umehara M, 2008, NATURE, V455, P195, DOI 10.1038/nature07272; Van den Broeck D, 1998, PLANT J, V13, P121, DOI 10.1046/j.1365-313X.1998.00004.x; Vandenbussche M, 2004, METH MOL B, V260, P115, DOI 10.1385/1-59259-755-6:115; Verrier PJ, 2008, TRENDS PLANT SCI, V13, P151, DOI 10.1016/j.tplants.2008.02.001; Vierheilig H, 1998, APPL ENVIRON MICROB, V64, P5004; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Yoder JI, 2010, CURR OPIN PLANT BIOL, V13, P478, DOI 10.1016/j.pbi.2010.04.011; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zhang Q, 2010, PLANT CELL, V22, P1483, DOI 10.1105/tpc.110.074955; Zhang XW, 2008, HORTSCIENCE, V43, P300, DOI 10.21273/HORTSCI.43.2.300	49	366	386	12	298	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					341	U135		10.1038/nature10873	http://dx.doi.org/10.1038/nature10873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22398443	Green Submitted, Green Accepted			2022-12-28	WOS:000301481800051
J	Kempermann, G				Kempermann, Gerd			Youth Culture in the Adult Brain	SCIENCE			English	Editorial Material							ENHANCED SYNAPTIC PLASTICITY; GENERATED GRANULE CELLS; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; NEURONS; MEMORY		[Kempermann, Gerd] CRTD, D-01307 Dresden, Germany; [Kempermann, Gerd] German Ctr Neurodegenerat Dis DZNE, D-01307 Dresden, Germany	Technische Universitat Dresden; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technische Universitat Dresden	Kempermann, G (corresponding author), CRTD, D-01307 Dresden, Germany.	gerd.kempermann@crt-dresden.de	Kempermann, Gerd/F-5416-2010	Kempermann, Gerd/0000-0002-5304-4061				Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; Alme CB, 2010, HIPPOCAMPUS, V20, P1109, DOI 10.1002/hipo.20810; Garthe A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005464; Ge SY, 2007, NEURON, V54, P559, DOI 10.1016/j.neuron.2007.05.002; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kempermann G., 2011, ADULT NEUROGENESIS, V2; Marin-Burgin A, 2012, SCIENCE, V335, P1238, DOI 10.1126/science.1214956; Mongiat LA, 2011, EUR J NEUROSCI, V33, P1055, DOI 10.1111/j.1460-9568.2011.07603.x; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; SCHWEGLER H, 1990, NEUROSCIENCE, V34, P293, DOI 10.1016/0306-4522(90)90139-U; SCHWEGLER H, 1981, SCIENCE, V214, P817, DOI 10.1126/science.7292015; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028	15	5	5	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1175	1176		10.1126/science.1219304	http://dx.doi.org/10.1126/science.1219304			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403375				2022-12-28	WOS:000301225100027
J	Godley, LA; Le Beau, MM				Godley, Lucy A.; Le Beau, Michelle M.			The Histone Code and Treatments for Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Godley, Lucy A.] Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA; Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA	University of Chicago; Robert H. Lurie Comprehensive Cancer Center; University of Chicago	Godley, LA (corresponding author), Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA.							Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	2	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					960	961		10.1056/NEJMcibr1113401	http://dx.doi.org/10.1056/NEJMcibr1113401			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397660				2022-12-28	WOS:000301172500016
J	Scally, A; Dutheil, JY; Hillier, LW; Jordan, GE; Goodhead, I; Herrero, J; Hobolth, A; Lappalainen, T; Mailund, T; Marques-Bonet, T; McCarthy, S; Montgomery, SH; Schwalie, PC; Tang, YA; Ward, MC; Xue, YL; Yngvadottir, B; Alkan, C; Andersen, LN; Ayub, Q; Ball, EV; Beal, K; Bradley, BJ; Chen, Y; Clee, CM; Fitzgerald, S; Graves, TA; Gu, Y; Heath, P; Heger, A; Karakoc, E; Kolb-Kokocinski, A; Laird, GK; Lunter, G; Meader, S; Mort, M; Mullikin, JC; Munch, K; O'Connor, TD; Phillips, AD; Prado-Martinez, J; Rogers, AS; Sajjadian, S; Schmidt, D; Shaw, K; Simpson, JT; Stenson, PD; Turner, DJ; Vigilant, L; Vilella, AJ; Whitener, W; Zhu, BL; Cooper, DN; de Jong, P; Dermitzakis, ET; Eichler, EE; Flicek, P; Goldman, N; Mundy, NI; Ning, ZM; Odom, DT; Ponting, CP; Quail, MA; Ryder, OA; Searle, SM; Warren, WC; Wilson, RK; Schierup, MH; Rogers, J; Tyler-Smith, C; Durbin, R				Scally, Aylwyn; Dutheil, Julien Y.; Hillier, LaDeana W.; Jordan, Gregory E.; Goodhead, Ian; Herrero, Javier; Hobolth, Asger; Lappalainen, Tuuli; Mailund, Thomas; Marques-Bonet, Tomas; McCarthy, Shane; Montgomery, Stephen H.; Schwalie, Petra C.; Tang, Y. Amy; Ward, Michelle C.; Xue, Yali; Yngvadottir, Bryndis; Alkan, Can; Andersen, Lars N.; Ayub, Qasim; Ball, Edward V.; Beal, Kathryn; Bradley, Brenda J.; Chen, Yuan; Clee, Chris M.; Fitzgerald, Stephen; Graves, Tina A.; Gu, Yong; Heath, Paul; Heger, Andreas; Karakoc, Emre; Kolb-Kokocinski, Anja; Laird, Gavin K.; Lunter, Gerton; Meader, Stephen; Mort, Matthew; Mullikin, James C.; Munch, Kasper; O'Connor, Timothy D.; Phillips, Andrew D.; Prado-Martinez, Javier; Rogers, Anthony S.; Sajjadian, Saba; Schmidt, Dominic; Shaw, Katy; Simpson, Jared T.; Stenson, Peter D.; Turner, Daniel J.; Vigilant, Linda; Vilella, Albert J.; Whitener, Weldon; Zhu, Baoli; Cooper, David N.; de Jong, Pieter; Dermitzakis, Emmanouil T.; Eichler, Evan E.; Flicek, Paul; Goldman, Nick; Mundy, Nicholas I.; Ning, Zemin; Odom, Duncan T.; Ponting, Chris P.; Quail, Michael A.; Ryder, Oliver A.; Searle, Stephen M.; Warren, Wesley C.; Wilson, Richard K.; Schierup, Mikkel H.; Rogers, Jane; Tyler-Smith, Chris; Durbin, Richard			Insights into hominid evolution from the gorilla genome sequence	NATURE			English	Article							COPY NUMBER; MUTATION; POPULATION; PRIMATES; HUMANS; CONSEQUENCES; CHIMPANZEES; PATTERNS; REVEALS; FAMILY	Gorillas are humans' closest living relatives after chimpanzees, and are of comparable importance for the study of human origins and evolution. Here we present the assembly and analysis of a genome sequence for the western lowland gorilla, and compare the whole genomes of all extant great ape genera. We propose a synthesis of genetic and fossil evidence consistent with placing the human-chimpanzee and human-chimpanzee-gorilla speciation events at approximately 6 and 10 million years ago. In 30% of the genome, gorilla is closer to human or chimpanzee than the latter are to each other; this is rarer around coding genes, indicating pervasive selection throughout great ape evolution, and has functional consequences in gene expression. A comparison of protein coding genes reveals approximately 500 genes showing accelerated evolution on each of the gorilla, human and chimpanzee lineages, and evidence for parallel acceleration, particularly of genes involved in hearing. We also compare the western and eastern gorilla species, estimating an average sequence divergence time 1.75 million years ago, but with evidence for more recent genetic exchange and a population bottleneck in the eastern species. The use of the genome sequence in these and future analyses will promote a deeper understanding of great ape biology and evolution.	[Scally, Aylwyn; Goodhead, Ian; McCarthy, Shane; Tang, Y. Amy; Xue, Yali; Yngvadottir, Bryndis; Ayub, Qasim; Chen, Yuan; Clee, Chris M.; Gu, Yong; Heath, Paul; Kolb-Kokocinski, Anja; Laird, Gavin K.; Rogers, Anthony S.; Simpson, Jared T.; Turner, Daniel J.; Whitener, Weldon; Ning, Zemin; Odom, Duncan T.; Quail, Michael A.; Searle, Stephen M.; Rogers, Jane; Tyler-Smith, Chris; Durbin, Richard] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England; [Dutheil, Julien Y.; Hobolth, Asger; Mailund, Thomas; Andersen, Lars N.; Munch, Kasper; Schierup, Mikkel H.] Aarhus Univ, Bioinformat Res Ctr, DK-8000 Aarhus C, Denmark; [Hillier, LaDeana W.; Marques-Bonet, Tomas; Alkan, Can; Karakoc, Emre; Sajjadian, Saba; Eichler, Evan E.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; [Jordan, Gregory E.; Herrero, Javier; Schwalie, Petra C.; Beal, Kathryn; Fitzgerald, Stephen; Vilella, Albert J.; Flicek, Paul; Goldman, Nick] European Bioinformat Inst, Hinxton CB10 1SD, England; [Lappalainen, Tuuli; Dermitzakis, Emmanouil T.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; [Marques-Bonet, Tomas; Prado-Martinez, Javier] Inst Biol Evolut UPF CSIC, Barcelona 08003, Catalonia, Spain; [Marques-Bonet, Tomas] ICREA, Barcelona 08010, Spain; [Montgomery, Stephen H.; Bradley, Brenda J.; O'Connor, Timothy D.; Mundy, Nicholas I.] Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; [Ward, Michelle C.; Schmidt, Dominic; Odom, Duncan T.] Univ Cambridge, Dept Oncol, Hutchison MRC Res Ctr, Cambridge CB2 0XZ, England; [Ward, Michelle C.; Schmidt, Dominic; Odom, Duncan T.] Cambridge Res Inst, Canc Res UK, Li Ka Shing Ctr, Cambridge CB2 0RE, England; [Alkan, Can; Eichler, Evan E.] Univ Washington, Howard Hughes Med Inst, Seattle, WA USA; [Ball, Edward V.; Mort, Matthew; Phillips, Andrew D.; Shaw, Katy; Stenson, Peter D.; Cooper, David N.] Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Bradley, Brenda J.] Yale Univ, Dept Anthropol, New Haven, CT 06511 USA; [Graves, Tina A.; Warren, Wesley C.; Wilson, Richard K.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA; [Heger, Andreas; Meader, Stephen; Ponting, Chris P.] Univ Oxford, Dept Physiol Anat & Genet, MRC Funct Genom Unit, Oxford OX1 3QX, England; [Lunter, Gerton] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Mullikin, James C.] NHGRI, Comparat Genom Unit, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Vigilant, Linda] Max Planck Inst Evolutionary Anthropol, Primatol Dept, D-04103 Leipzig, Germany; [Zhu, Baoli; de Jong, Pieter] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; [Ryder, Oliver A.] San Diego Zoos Inst Conservat Res, Escondido, CA 92027 USA	Wellcome Trust Sanger Institute; Aarhus University; University of Washington; University of Washington Seattle; European Molecular Biology Laboratory (EMBL); University of Geneva; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UPF - Institut de Biologia Evolutiva (IBE); ICREA; University of Cambridge; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Cardiff University; Yale University; Washington University (WUSTL); University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Max Planck Society; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Zoological Society of San Diego	Durbin, R (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	rd@sanger.ac.uk	Munch, Kasper/A-1434-2010; Dutheil, Julien Yann/K-5479-2016; Schierup, Mikkel H/F-1675-2010; Durbin, Richard/AAE-7178-2019; Ponting, Chris/AAV-2621-2021; Schierup, Mikkel Heide/AAM-4997-2020; Prado-Martinez, Javier/AAA-6341-2020; Cooper, David N/H-4384-2011; Dermitzakis, Emmanouil/B-7687-2013; Wilson, Richard K./AAF-4139-2019; Quail, michael/ABE-6131-2020; Marques-Bonet, Tomas/I-4618-2014; Alkan, Can/D-2982-2009; Lappalainen, Tuuli/AAE-6532-2020; Herrero, Javier/H-6971-2019; Ning, Zemin/D-2411-2013; Lunter, Gerton/H-4939-2016; Marques-Bonet, Tomas/ABF-3734-2020; Goodhead, Ian/ABC-9200-2020	Munch, Kasper/0000-0003-2880-6252; Dutheil, Julien Yann/0000-0001-7753-4121; Schierup, Mikkel H/0000-0002-5028-1790; Durbin, Richard/0000-0002-9130-1006; Schierup, Mikkel Heide/0000-0002-5028-1790; Prado-Martinez, Javier/0000-0001-5402-2721; Cooper, David N/0000-0002-8943-8484; Wilson, Richard K./0000-0002-1992-1358; Marques-Bonet, Tomas/0000-0002-5597-3075; Alkan, Can/0000-0002-5443-0706; Lappalainen, Tuuli/0000-0002-7746-8109; Herrero, Javier/0000-0001-7313-717X; Marques-Bonet, Tomas/0000-0002-5597-3075; Ponting, Chris/0000-0003-0202-7816; Odom, Duncan/0000-0001-6201-5599; Ayub, Qasim/0000-0003-3291-0917; Flicek, Paul/0000-0002-3897-7955; /0000-0002-5474-5695; Goldman, Nick/0000-0001-8486-2211; Goodhead, Ian/0000-0002-3110-9442; O'Connor, Timothy/0000-0002-0276-1896; McCarthy, Shane/0000-0002-2715-4187; Hobolth, Asger/0000-0003-4056-1286; Ning, Zemin/0000-0003-4359-776X; Vilella, Albert/0000-0002-2005-2516; Schwalie, Petra Catalina/0000-0002-6004-8095; Mailund, Thomas/0000-0001-6206-9239; Lunter, Gerton/0000-0002-3798-2058; Tang, Amy/0000-0003-0045-1234; Jordan, Gregory/0000-0002-7655-6000; Heger, Andreas/0000-0001-7720-0447; Andersen, Lars Norvang/0000-0001-6196-8427	Wellcome Trust [WT062023, WT089066, WT077192, WT077009, WT077198, 075491/Z/04]; EMBL; Gates Cambridge Trust; MRC; Lundbeck Foundation; Academy of Finlandand the Emil Aaltonen Foundation; Marie Curie fellowship; European Community [StG_20091118]; Spanish Ministry of Education [BES-2010-032251]; BBSRC; UK Medical Research Council; National Human Genome Research Institute, National Institutes of Health; Danish Council for Independent Research, Natural Sciences [09-062535]; Commonwealth Scholarship; Swiss National Science Foundation; Louis Jeantet Foundation; ERC; EMBO; Hutchinson Whampoa; NHGRI; BIOBASE GmbH; US National Science Foundation [DGE-0739133]; NHGRI [U54 HG003079]; NIH [HG002385]; ICREA Funding Source: Custom; MRC [G0701805, G0501331] Funding Source: UKRI; Cancer Research UK [15603] Funding Source: researchfish; Medical Research Council [G0501331, G0701805] Funding Source: researchfish; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079, ZIAHG200330, R01HG002385] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); EMBL; Gates Cambridge Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); Academy of Finlandand the Emil Aaltonen Foundation; Marie Curie fellowship(European Commission); European Community(European Commission); Spanish Ministry of Education(Spanish Government); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Human Genome Research Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Danish Council for Independent Research, Natural Sciences(Det Frie Forskningsrad (DFF)); Commonwealth Scholarship; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Louis Jeantet Foundation; ERC(European Research Council (ERC)European Commission); EMBO(European Molecular Biology Organization (EMBO)); Hutchinson Whampoa; NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); BIOBASE GmbH; US National Science Foundation(National Science Foundation (NSF)); NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ICREA(ICREA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank H. Li and E. Birney for discussions, D. Zerbino, J. Stalker, L. Wilming, D. Rajan and H. Clawson for technical assistance, J. Ahringer for comments on the manuscript, K. Leus of the Center for Research and Conservation of the Royal Zoological Society of Antwerp for sample material from Mukisi, and the Marmoset Genome Analysis Consortium for permission to use the unpublished assembly of the marmoset genome. This research was supported in part by Wellcome Trust grants WT062023 (to J.H., K.B., S.F., A.J.V., P.F.), WT089066 (to R.D.), WT077192 (to R.D., S.M., A.K.-K., J.T.S., W.W.), WT077009 (to Y.X., B.Y., Q A., Y.C., C.T.-S.), WT077198 (to G.K.L.) and 075491/Z/04 (to G.L.); EMBL grants (to P.C.S., P.F.); scholarships from the Gates Cambridge Trust (to G.E.J. and T.D.O'C.); an MRC Special Fellowship in Biomedical Informatics (to A.S.); funding from the Lundbeck Foundation (to A.H.); the Academy of Finlandand the Emil Aaltonen Foundation (to T.L.); a Marie Curie fellowship (to T.M.-B.); the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC Starting Grant (StG_20091118) (to T.M.-B.); an FPI grant from the Spanish Ministry of Education (BES-2010-032251) (to J.P.-M.); a BBSRC Doctoral Training Grant (to S.H.M.); grants from the UK Medical Research Council (to A.H., S.M., C.P.P.); the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health (to J.C.M.); the Danish Council for Independent Research, Natural Sciences, grant no. 09-062535 (to K.M., M.H.S.); a Commonwealth Scholarship (to M.C.W.); the Swiss National Science Foundation, Louis Jeantet Foundation (to E.T.D.); an ERC Starting Grant and an EMBO Young Investigator Award, Hutchinson Whampoa (to D.T.O.); NHGRI support (to W.C.W.); support from BIOBASE GmbH (to E.V.B., P.D.S., M.M., A.D.P., K.S., D.N.C.); US National Science Foundation grant DGE-0739133 (to W.W.); NHGRI U54 HG003079 (to R.K.W.); NIH grant HG002385 (to E.E.E). E.E.E. is an investigator of the Howard Hughes Medical Institute.	Alkan C, 2009, NAT GENET, V41, P1061, DOI 10.1038/ng.437; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Begun D. R., 2007, HDB PALAEOANTHROPOLO, V2, P921; Blekhman R, 2010, GENOME RES, V20, P180, DOI 10.1101/gr.099226.109; Bradley BJ, 2008, J ANAT, V212, P337, DOI 10.1111/j.1469-7580.2007.00840.x; Burgess R, 2008, MOL BIOL EVOL, V25, P1979, DOI 10.1093/molbev/msn148; Calix M., 2018, EUROPEAN RED LIST SA; CHARLESWORTH D, 1993, J HERED, V84, P321, DOI 10.1093/oxfordjournals.jhered.a111351; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Ellegren H, 2007, P ROY SOC B-BIOL SCI, V274, P1, DOI 10.1098/rspb.2006.3720; ELLIS RA, 1962, AM J PHYS ANTHROPOL, V20, P79, DOI 10.1002/ajpa.1330200210; Fleagle J.G., 1998, PRIMATE ADAPTATION E; Gazave E, 2011, GENOME RES, V21, P1626, DOI 10.1101/gr.117242.110; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Goetting-Minesky MP, 2006, J MOL EVOL, V63, P537, DOI 10.1007/s00239-005-0308-8; Green RE, 2010, SCIENCE, V328, P710, DOI 10.1126/science.1188021; Groves C.P., 2001, PRIMATE TAXONOMY; Hartwig WC, 2002, PRIMATE FOSSIL RECOR; Herculano-Houzel S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017514; Hubbard TJP, 2009, NUCLEIC ACIDS RES, V37, pD690, DOI 10.1093/nar/gkn828; Hughes JF, 2010, NATURE, V463, P536, DOI 10.1038/nature08700; Huxley T. H., 1863, EVIDENCE MANS PLACE; Jensen-Seaman MI, 2003, J MOL EVOL, V57, P261, DOI 10.1007/s00239-003-2474-x; Kamada F, 2011, J HUM GENET, V56, P34, DOI 10.1038/jhg.2010.132; Kim SH, 2006, PLOS GENET, V2, P1527, DOI 10.1371/journal.pgen.0020163; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kunarso G, 2010, NAT GENET, V42, P631, DOI 10.1038/ng.600; Lebatard AE, 2008, P NATL ACAD SCI USA, V105, P3226, DOI 10.1073/pnas.0708015105; Locke DP, 2011, NATURE, V469, P529, DOI 10.1038/nature09687; Lynch M, 2010, P NATL ACAD SCI USA, V107, P961, DOI 10.1073/pnas.0912629107; McDaniell R, 2010, SCIENCE, V328, P235, DOI 10.1126/science.1184655; McVicker G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000471; Mikkelsen TS, 2005, NATURE, V437, P69, DOI 10.1038/nature04072; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Paten B, 2008, GENOME RES, V18, P1814, DOI 10.1101/gr.076554.108; Patterson N, 2006, NATURE, V441, P1103, DOI 10.1038/nature04789; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Presgraves DC, 2009, TRENDS ECOL EVOL, V24, P533, DOI 10.1016/j.tree.2009.04.007; Roach JC, 2010, SCIENCE, V328, P636, DOI 10.1126/science.1186802; Schmidt D, 2010, SCIENCE, V328, P1036, DOI 10.1126/science.1186176; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Steiper ME, 2008, EVOL ANTHROPOL, V17, P179, DOI 10.1002/evan.20177; Stenson PD, 2009, GENOME MED, V1, DOI 10.1186/gm13; Stokes E., 2008, W LOWLAND GORILLA SU; Streeter G. L., 1922, ANAT REC, V23, P335; Thalmann OH, 2007, MOL BIOL EVOL, V24, P146, DOI 10.1093/molbev/msl160; Vicoso B, 2006, NAT REV GENET, V7, P645, DOI 10.1038/nrg1914; Wallis OC, 2001, J MOL ENDOCRINOL, V26, P249, DOI 10.1677/jme.0.0260249; Wood B, 2011, NATURE, V470, P347, DOI 10.1038/nature09709; Xue W, 2011, NATURE, V473, P544, DOI 10.1038/nature09909	51	462	472	2	200	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					169	175		10.1038/nature10842	http://dx.doi.org/10.1038/nature10842			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904DT	22398555	Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000301174900029
J	Manglik, A; Kruse, AC; Kobilka, TS; Thian, FS; Mathiesen, JM; Sunahara, RK; Pardo, L; Weis, WI; Kobilka, BK; Granier, S				Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien			Crystal structure of the mu-opioid receptor bound to a morphinan antagonist	NATURE			English	Article							BINDING; RESIDUES; OLIGOMERIZATION; DIPRENORPHINE; ETORPHINE; TOLERANCE; GPCR; LOOP	Opium is one of the world's oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnoea and dependence) by binding to and activating the G-protein-coupled mu-opioid receptor (mu-OR) in the central nervous system. Here we describe the 2.8 angstrom crystal structure of the mouse mu-OR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the mu-OR crystallizes as a two-fold symmetrical dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.	[Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; [Sunahara, Roger K.] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Pardo, Leonardo] Univ Autonoma Barcelona, Unit Bioestat, Lab Med Computac, Barcelona 08193, Spain; [Weis, William I.] Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; [Granier, Sebastien] CNRS, INSERM, U661, UMR 5203, F-34094 Montpellier, France; [Granier, Sebastien] Univ Montpellier 1 & 2, Inst Genom Fonctionnelle, F-34094 Montpellier, France	Stanford University; University of Michigan System; University of Michigan; Autonomous University of Barcelona; Stanford University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier	Granier, S (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.	kobilka@stanford.edu; granier@stanford.edu	Weis, William I/G-1437-2011; Granier, Sebastien/J-1089-2016; Sunahara, Roger/AAJ-8667-2020	Weis, William I/0000-0002-5583-6150; Pardo, Leonardo/0000-0003-1778-7420; Kobilka, Brian/0000-0001-5958-3990; Mathiesen, Jesper Mosolff/0000-0003-4251-4416	INSERM; Stanford Medical Scientist Training Program; National Science Foundation; Lundbeck Foundation; National Institutes of Health [NS028471, DA031418]; Mathers Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028471, R01NS028471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA031418] Funding Source: NIH RePORTER	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Stanford Medical Scientist Training Program; National Science Foundation(National Science Foundation (NSF)); Lundbeck Foundation(Lundbeckfonden); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mathers Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We acknowledge support from INSERM (S. G.), the Stanford Medical Scientist Training Program (A. M.), the National Science Foundation (A. C. K.), the Lundbeck Foundation (J.M.M.), the National Institutes of Health Grants NS028471 (B. K. K.) and DA031418 (B. K. K. and R. K. S.), and the Mathers Foundation (B. K. K. and W.I.W.).	Afonine PV, 2005, ACTA CRYSTALLOGR D, V61, P850, DOI 10.1107/S0907444905007894; ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bonner G, 2000, EUR J PHARMACOL, V403, P37, DOI 10.1016/S0014-2999(00)00578-1; Caffrey M, 2009, NAT PROTOC, V4, P706, DOI 10.1038/nprot.2009.31; Cassel JA, 2005, EUR J PHARMACOL, V520, P29, DOI 10.1016/j.ejphar.2005.08.008; Chen CG, 1996, J BIOL CHEM, V271, P21422, DOI 10.1074/jbc.271.35.21422; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; DISSE B, 1993, LIFE SCI, V52, P537, DOI 10.1016/0024-3205(93)90312-Q; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fanelli F, 2011, CHEM REV, V111, pPR438, DOI 10.1021/cr100437t; Fung JJ, 2009, EMBO J, V28, P3315, DOI 10.1038/emboj.2009.267; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Golebiewska U, 2011, BIOCHEMISTRY-US, V50, P2829, DOI 10.1021/bi101701x; Gomes I, 2011, MOL PHARMACOL, V79, P1044, DOI 10.1124/mol.110.070847; Granier S, 2004, J BIOL CHEM, V279, P50904, DOI 10.1074/jbc.M405089200; Haga K, 2012, NATURE, V482, P547, DOI 10.1038/nature10753; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; He SQ, 2011, NEURON, V69, P120, DOI 10.1016/j.neuron.2010.12.001; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hu JX, 2012, FASEB J, V26, P604, DOI 10.1096/fj.11-191510; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Johnston JM, 2011, BIOCHEMISTRY-US, V50, P1682, DOI 10.1021/bi101474v; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Katzung BG, 2007, BASIC CLIN PHARM; Kruse AC, 2012, NATURE, V482, P552, DOI 10.1038/nature10867; KUROWSKI M, 1982, BRAIN RES, V249, P345, DOI 10.1016/0006-8993(82)90068-3; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; Mansour A, 1997, J NEUROCHEM, V68, P344, DOI 10.1046/j.1471-4159.1997.68010344.x; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Molinari P, 2010, J BIOL CHEM, V285, P12522, DOI 10.1074/jbc.M109.059410; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; PORTOGHESE PS, 1990, J MED CHEM, V33, P1714, DOI 10.1021/jm00168a028; RAFFA RB, 1994, EUR J PHARMACOL, V258, pR5, DOI 10.1016/0014-2999(94)90073-6; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Rozenfeld R, 2011, RECEPT SER, P407, DOI 10.1007/978-1-60761-993-2_15; Schrodinger L., 2020, PYMOL MOL GRAPHICS S; Seki T, 1998, EUR J PHARMACOL, V350, P301, DOI 10.1016/S0014-2999(98)00240-4; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; Vilardaga JP, 2008, NAT CHEM BIOL, V4, P126, DOI 10.1038/nchembio.64; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	47	977	999	8	329	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 17	2012	485	7398					321	U170		10.1038/nature10954	http://dx.doi.org/10.1038/nature10954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	943CW	22437502	Green Accepted			2022-12-28	WOS:000304099100032
J	Templeton, A				Templeton, Allan			Misoprostol for all women seeking abortion?	LANCET			English	Editorial Material							CURETTAGE ABORTION		Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen Matern Hosp, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Templeton, A (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen Matern Hosp, Aberdeen AB25 2ZD, Scotland.	allan.templeton@abdn.ac.uk						[Anonymous], SAF AB TECH IN PRESS; Ashok PW, 2000, AM J OBSTET GYNECOL, V183, P998, DOI 10.1067/mob.2000.106767; GRIMES DA, 1984, JAMA-J AM MED ASSOC, V251, P2108, DOI 10.1001/jama.251.16.2108; Kapp N, 2010, COCHRANE DB SYST REV, V2; Luk J, 2007, CONTRACEPTION, V76, P331, DOI 10.1016/j.contraception.2007.06.001; Meirik O, 2012, LANCET, V379, P1817, DOI 10.1016/S0140-6736(11)61937-5; Oates M, 2011, BJOG-INT J OBSTET GY, V118, P132, DOI 10.1111/j.1471-0528.2010.02847.x; Royal College of obstetricians and gynaecologists, 2011, CAR WOM REQ IND AB E; Royal College of Obstetricians and Gynaecologists, 2004, CAR WOM REQ IND AB; SCHULZ KF, 1983, LANCET, V1, P1182; Templeton A, 2011, NEW ENGL J MED, V365, P2198, DOI 10.1056/NEJMcp1103639	11	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 12	2012	379	9828					1772	1773		10.1016/S0140-6736(12)60037-3	http://dx.doi.org/10.1016/S0140-6736(12)60037-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	941BR	22405253				2022-12-28	WOS:000303937700010
J	Olszak, T; An, DD; Zeissig, S; Vera, MP; Richter, J; Franke, A; Glickman, JN; Siebert, R; Baron, RM; Kasper, DL; Blumberg, RS				Olszak, Torsten; An, Dingding; Zeissig, Sebastian; Vera, Miguel Pinilla; Richter, Julia; Franke, Andre; Glickman, Jonathan N.; Siebert, Reiner; Baron, Rebecca M.; Kasper, Dennis L.; Blumberg, Richard S.			Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function	SCIENCE			English	Article							NKT CELLS; AIRWAY INFLAMMATION; ULCERATIVE-COLITIS; HYGIENE HYPOTHESIS; CHEMOKINE CXCL16; RECOGNITION; METHYLATION; ACTIVATION; EXPRESSION; MODELS	Exposure to microbes during early childhood is associated with protection from immune-mediated diseases such as inflammatory bowel disease (IBD) and asthma. Here, we show that in germ-free (GF) mice, invariant natural killer T (iNKT) cells accumulate in the colonic lamina propria and lung, resulting in increased morbidity in models of IBD and allergic asthma as compared with that of specific pathogen-free mice. This was associated with increased intestinal and pulmonary expression of the chemokine ligand CXCL16, which was associated with increased mucosal iNKT cells. Colonization of neonatal-but not adult-GF mice with a conventional microbiota protected the animals from mucosal iNKT accumulation and related pathology. These results indicate that age-sensitive contact with commensal microbes is critical for establishing mucosal iNKT cell tolerance to later environmental exposures.	[An, Dingding; Kasper, Dennis L.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA; [An, Dingding; Kasper, Dennis L.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Olszak, Torsten; Blumberg, Richard S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA; [Zeissig, Sebastian] Univ Med Ctr Schleswig Holstein, Dept Internal Med 1, D-24105 Kiel, Germany; [Vera, Miguel Pinilla; Baron, Rebecca M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Richter, Julia; Siebert, Reiner] Univ Kiel, Inst Human Genet, D-24105 Kiel, Germany; [Franke, Andre] Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; [Glickman, Jonathan N.] GI Pathol, Caris Diagnost, Caris Life Sci, Newton, MA 02464 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Kiel; Schleswig Holstein University Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Kiel; University of Kiel	Kasper, DL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA.	dennis_kasper@hms.harvard.edu; rblumberg@partners.org	Franke, Andre/B-2151-2010; Zeissig, Sebastian/B-6297-2012; Siebert, Reiner/A-8049-2010	Franke, Andre/0000-0003-1530-5811; Zeissig, Sebastian/0000-0001-5124-0897; Pinilla-Vera, Miguel/0000-0002-2773-1570	NIH [DK44319, DK51362, DK53056, DK88199, AI090102]; Crohn's Colitis Foundation of America; Harvard Digestive Diseases Center [DK034854]; Medizinausschuss Schleswig-Holstein, German Ministry of Education Research through the National Genome Research Network; Medical Faculty, Kiel; Deutsche Forschungsgemeinschaft (DFG) [OL 324/1-1, SZ 814/1-1, 814/4-1]; DFG Excellence Cluster "Inflammation at Interfaces"; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI090102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053056, R01DK051362, R37DK044319, R01DK044319, R01DK088199, P30DK034854, R56DK053056] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's Colitis Foundation of America; Harvard Digestive Diseases Center; Medizinausschuss Schleswig-Holstein, German Ministry of Education Research through the National Genome Research Network; Medical Faculty, Kiel; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG Excellence Cluster "Inflammation at Interfaces"(German Research Foundation (DFG)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank E. Troy and S. Edwards for handling of the GF mice, J. Cusick for technical assistance, E. Nieuwenhuis and K. Schneeberger for assistance with epigenetics studies, A. Bellacosa and K. Baker for helpful discussions and manuscript preparation, and the KinderKrebsInitiative Buchholz/Holm-Seppensen for providing pyrosequencing infrastructure. The work was supported by NIH grants DK44319, DK51362, DK53056, and DK88199 (R. S. B.) and AI090102 (D. L. K.); Crohn's Colitis Foundation of America Senior Research Award (D. L. K.) and Crohn's and Colitis Foundation of America Postdoctoral Fellowship Award (D. A. and S.Z.); the Harvard Digestive Diseases Center (DK034854); the Medizinausschuss Schleswig-Holstein, German Ministry of Education Research through the National Genome Research Network (A. F.); The Medical Faculty, Kiel (R. S.) and the Deutsche Forschungsgemeinschaft (DFG) (OL 324/1-1, SZ 814/1-1, 814/4-1); as well as DFG Excellence Cluster "Inflammation at Interfaces" (A.F. and S.Z.). The data reported in this manuscript are tabulated in the main paper and in the supplementary materials.	Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Cohen NR, 2009, ADV IMMUNOL, V102, P1, DOI 10.1016/S0065-2776(09)01201-2; Day C, 2009, EXP LUNG RES, V35, P272, DOI 10.1080/01902140802635517; Diegelmann J, 2010, INFLAMM BOWEL DIS, V16, P1871, DOI 10.1002/ibd.21306; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Germanov E, 2008, J IMMUNOL, V181, P81, DOI 10.4049/jimmunol.181.1.81; Goksor E, 2011, ACTA PAEDIATR, V100, P1561, DOI 10.1111/j.1651-2227.2011.02411.x; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Iwamura C, 2010, CURR OPIN IMMUNOL, V22, P807, DOI 10.1016/j.coi.2010.10.008; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lopez-Serrano P, 2010, SCAND J GASTROENTERO, V45, P1464, DOI 10.3109/00365521.2010.510575; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Pufulete M, 2005, GUT, V54, P648, DOI 10.1136/gut.2004.054718; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107; Roark JH, 1998, J IMMUNOL, V160, P3121; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Sullivan BA, 2007, CURR TOP MICROBIOL, V314, P165; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Wei B, 2010, J IMMUNOL, V184, P1218, DOI 10.4049/jimmunol.0902620; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Yue SC, 2005, P NATL ACAD SCI USA, V102, P11811, DOI 10.1073/pnas.0503366102	33	1073	1133	11	299	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 27	2012	336	6080					489	493		10.1126/science.1219328	http://dx.doi.org/10.1126/science.1219328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931QC	22442383	Green Accepted			2022-12-28	WOS:000303233400051
J	Everitt, AR; Clare, S; Pertel, T; John, SP; Wash, RS; Smith, SE; Chin, CR; Feeley, EM; Sims, JS; Adams, DJ; Wise, HM; Kane, L; Goulding, D; Digard, P; Anttila, V; Baillie, JK; Walsh, TS; Hume, DA; Palotie, A; Xue, YL; Colonna, V; Tyler-Smith, C; Dunning, J; Gordon, SB; Smyth, RL; Openshaw, PJ; Dougan, G; Brass, AL; Kellam, P				Everitt, Aaron R.; Clare, Simon; Pertel, Thomas; John, Sinu P.; Wash, Rachael S.; Smith, Sarah E.; Chin, Christopher R.; Feeley, Eric M.; Sims, Jennifer S.; Adams, David J.; Wise, Helen M.; Kane, Leanne; Goulding, David; Digard, Paul; Anttila, Verneri; Baillie, J. Kenneth; Walsh, Tim S.; Hume, David A.; Palotie, Aarno; Xue, Yali; Colonna, Vincenza; Tyler-Smith, Chris; Dunning, Jake; Gordon, Stephen B.; Smyth, Rosalind L.; Openshaw, Peter J.; Dougan, Gordon; Brass, Abraham L.; Kellam, Paul		GenISIS Investigators; MOSAIC Investigators	IFITM3 restricts the morbidity and mortality associated with influenza	NATURE			English	Article							WEST NILE VIRUS; PROTEINS; PATHOGENESIS; INFECTION	The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses(1-7). Both the magnitude and breadth of the IFITM proteins' in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model(8), we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 'Spanish' influenza(9,10). Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.	[Everitt, Aaron R.; Clare, Simon; Wash, Rachael S.; Smith, Sarah E.; Adams, David J.; Kane, Leanne; Goulding, David; Anttila, Verneri; Palotie, Aarno; Xue, Yali; Colonna, Vincenza; Tyler-Smith, Chris; Dougan, Gordon; Kellam, Paul] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England; [Pertel, Thomas; John, Sinu P.; Chin, Christopher R.; Feeley, Eric M.; Sims, Jennifer S.; Brass, Abraham L.] MIT, Ragon Inst Massachusetts, Gen Hosp, Charlestown, MA 02129 USA; [Pertel, Thomas; John, Sinu P.; Chin, Christopher R.; Feeley, Eric M.; Sims, Jennifer S.; Brass, Abraham L.] Harvard Univ, Charlestown, MA 02129 USA; [Wise, Helen M.; Digard, Paul] Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England; [Baillie, J. Kenneth; Hume, David A.] Univ Edinburgh, Div Genet & Genom, Roslin Inst, Roslin EH25 9RG, Midlothian, Scotland; [Baillie, J. Kenneth; Walsh, Tim S.] Univ Edinburgh, Dept Crit Care Med, Edinburgh EH16 4TJ, Midlothian, Scotland; [Colonna, Vincenza] Natl Res Council CNR, Inst Genet & Biophys A Buzzati Traverso, Naples, Italy; [Dunning, Jake; Openshaw, Peter J.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, Natl Heart & Lung Inst, London W2 1PG, England; [Gordon, Stephen B.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Smyth, Rosalind L.] Univ Liverpool, Inst Translat Med, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; [Brass, Abraham L.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02117 USA; [Kellam, Paul] UCL, UCL MRC Ctr Med Mol Virol, Dept Infect, London W1T 4JF, England	Wellcome Trust Sanger Institute; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Imperial College London; Liverpool School of Tropical Medicine; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; Harvard University; Massachusetts General Hospital; University of London; University College London	Kellam, P (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	abrass@partners.org; pk5@sanger.ac.uk	Baillie, Kenneth/AEK-6650-2022; Haley, Chris S/F-3110-2013; Hayward, Andrew C/C-3268-2013; Hume, David A/C-7695-2013; Openshaw, Peter/AAL-9442-2020; Nguyen-Van-Tam, Jonathan/I-2162-2019; John, Sinu/AAS-2054-2020; Baillie, John Kenneth/F-3124-2011; Johnston, Sebastian Lennox/I-2423-2012; Digard, Paul/B-7717-2008; Semple, Malcolm Gracie/A-8790-2008; Dunning, Jake/U-7181-2019; Aylin, Paul/A-1073-2014; Colonna, Vincenza/H-2021-2014; Hussell, Tracy/O-4630-2014	Baillie, Kenneth/0000-0001-5258-793X; Hayward, Andrew C/0000-0002-3549-6232; Openshaw, Peter/0000-0002-7220-2555; Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Baillie, John Kenneth/0000-0001-5258-793X; Johnston, Sebastian Lennox/0000-0003-3009-9200; Digard, Paul/0000-0002-0872-9440; Semple, Malcolm Gracie/0000-0001-9700-0418; Dunning, Jake/0000-0002-4035-4562; Hume, David/0000-0002-2615-1478; Anttila, Verneri/0000-0002-0073-4675; Herberg, Jethro/0000-0001-6941-6491; Colonna, Vincenza/0000-0002-3966-0474; Drumright, Lydia/0000-0002-3361-8080; Kellam, Paul/0000-0003-3166-4734; Ramsay, Pam/0000-0003-3545-4275; Ho, Ling Pei/0000-0001-8319-301X; Chin, Christopher/0000-0002-2140-3197; Aylin, Paul/0000-0003-4589-1743; Feeley, Eric/0000-0003-0910-8758; Smith, Sarah/0000-0001-8699-7670; Adamson, Walt/0000-0002-9786-2349; Gordon, Stephen/0000-0001-6576-1116; McNamara, Paul/0000-0002-7055-6034; Aston, Stephen/0000-0002-0701-8364; Pertel, Thomas/0000-0002-2286-6011; Barclay, Wendy/0000-0002-3948-0895; Murphy, Lee/0000-0001-6467-7449; Adams, David/0000-0001-9490-0306; McCulloch, Corrienne/0000-0001-5773-5217; Hussell, Tracy/0000-0001-7186-6141	Wellcome Trust [090382/Z/09/Z]; Imperial's Comprehensive Biomedical Research Centre (cBRC); Medical Research Council UK; Chief Scientist Office (Scotland); Charles H. Hood Foundation; Phillip T. and Susan M. Ragon Institute Foundation; Bill and Melinda Gates Foundation; National Institute of Allergy and Infectious Diseases [R01AI091786]; Wellcome Trust through the Edinburgh Clinical Academic Track (ECAT) [090385/Z/09/Z]; Comprehensive Local Research Networks (CLRNs); National Institute for Health Research (NIHR), UK; Biomedical Research Centre (BRC); Unit (BRU); BBSRC [BBS/E/D/20251969, BBS/E/D/20241863, BBS/E/D/20241864, BBS/E/D/20241866] Funding Source: UKRI; MRC [G0800777, MC_G1001212, G0600511, MC_U122785833, G0802752, G0901697, G0800767, G0600371] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/D/20251969, BBS/E/D/20241864, BBS/E/D/20241866, BBS/E/D/20241863] Funding Source: researchfish; Cancer Research UK [13031] Funding Source: researchfish; Medical Research Council [MC_U122785833, G0600511, G0600371, G0802752, G1000758, G1000758B, G0800777, G0800767, 975284, G0901697, MC_G1001212] Funding Source: researchfish; National Institute for Health Research [DHCS/04/G121/68, CL-2007-21-012, NF-SI-0508-10212] Funding Source: researchfish; Wellcome Trust [096964/Z/11/Z] Funding Source: researchfish; Asthma UK [S06/001, MRC-Asthma UK Centre] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Imperial's Comprehensive Biomedical Research Centre (cBRC); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office (Scotland); Charles H. Hood Foundation; Phillip T. and Susan M. Ragon Institute Foundation; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust through the Edinburgh Clinical Academic Track (ECAT); Comprehensive Local Research Networks (CLRNs); National Institute for Health Research (NIHR), UK(National Institute for Health Research (NIHR)); Biomedical Research Centre (BRC); Unit (BRU); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank C. Brandt for maintaining mouse colony health and well-being and T. Hussell for provision of A/X-31 virus. We also thank D. Gurdasani and M. Sandhu for statistical analysis of genotype frequencies. We also thank M. Hu and I. Gallego Romero for calculating genome-wide selection statistics. This work was supported by the Wellcome Trust. The MOSAIC work was supported by Imperial's Comprehensive Biomedical Research Centre (cBRC), the Wellcome Trust (090382/Z/09/Z) and Medical Research Council UK. The GenISIS work was supported by the Chief Scientist Office (Scotland). A. L. B. is the recipient of a Charles H. Hood Foundation Child Health Research Award, and is supported by grants from the Phillip T. and Susan M. Ragon Institute Foundation, the Bill and Melinda Gates Foundation's Global Health Program and the National Institute of Allergy and Infectious Diseases (R01AI091786). J.K.B. is supported by a Wellcome Trust Clinical Lectureship (090385/Z/09/Z) through the Edinburgh Clinical Academic Track (ECAT). We acknowledge the assistance of K. Alshafi, E. Bailey, A. Bermingham, M. Berry, C. Bloom, E. Brannigan, S. Bremang, J. Clark, M. C. Cox, M. Cross, L. A. Cumming, S. Dyas, J. England-Smith, J. Enstone, D. Ferreira, N. Goddard, A. Godlee, S. Gormley, M. Guiver, M. O. Hassan-Ibrahim, H. Hill, P. Holloway, K. Hoschler, G. Houghton, F. Hughes, R. R. Israel, A. Jepson, K. D. Jones, W. P. Kelleher, M. Kidd, K. Knox, A. Lackenby, G. Lloyd, H. Longworth, M. Minns, S. Mookerjee, S. Mt-Isa, D. Muir, A. Paras, V. Pascual, L. Rae, S. Rodenhurst, F. Rozakeas, E. Scott, E. Sergi, N. Shah, V. Sutton, J. Vernazza, A. W. Walker, C. Wenden, T. Wotherspoon, A. D. Wright, F. Wurie and the clinical and laboratory staff of the Alder Hey Children's NHS Foundation Trust, Brighton & Sussex University Hospitals NHS Trust, Central Manchester University Hospitals NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust, Alder Hey Children's Hospital and Liverpool School of Tropical Medicine, Health Protection Agency Microbiology Services Colindale, Imperial College Healthcare NHS Trust, Liverpool Women's NHS Foundation Trust, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Royal Brompton and Harefield NHS Foundation Trust, The Roslin Institute, Edinburgh, University Hospitals Coventry and Warwickshire NHS Trust. The MOSAIC consortium was supported by several Comprehensive Local Research Networks (CLRNs), the National Institute for Health Research (NIHR), UK, and by the Biomedical Research Centre (BRC) and Unit (BRU) funds. Finally, we thank all patients and their relatives for their generous agreement to inclusion in this study.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Belser JA, 2010, J VIROL, V84, P4194, DOI 10.1128/JVI.02742-09; Billharz R, 2009, J VIROL, V83, P10557, DOI 10.1128/JVI.00330-09; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chasman DI, 2011, NAT GENET, V43, P695, DOI 10.1038/ng.856; de Wit E, 2004, VIRUS RES, V103, P155, DOI 10.1016/j.virusres.2004.02.028; Ellis J, 2011, EUROSURVEILLANCE, V16, P2; Fay JC, 2000, GENETICS, V155, P1405; Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337; Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258; Hutchinson EC, 2008, J VIROL, V82, P11869, DOI 10.1128/JVI.01634-08; Jiang D, 2010, J VIROL, V84, P8332, DOI 10.1128/JVI.02199-09; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Lange UC, 2008, MOL CELL BIOL, V28, P4688, DOI 10.1128/MCB.00272-08; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; Maines TR, 2008, IMMUNOL REV, V225, P68, DOI 10.1111/j.1600-065X.2008.00690.x; Nielsen R, 2005, GENOME RES, V15, P1566, DOI 10.1101/gr.4252305; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; TAJIMA F, 1989, GENETICS, V123, P585; Tumpey TM, 2000, J VIROL, V74, P6105, DOI 10.1128/JVI.74.13.6105-6116.2000; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Weidner JM, 2010, J VIROL, V84, P12646, DOI 10.1128/JVI.01328-10; Yount JS, 2010, NAT CHEM BIOL, V6, P610, DOI [10.1038/NCHEMBIO.405, 10.1038/nchembio.405]; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601	33	529	560	3	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 26	2012	484	7395					519	U146		10.1038/nature10921	http://dx.doi.org/10.1038/nature10921			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931FF	22446628	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000303200400052
J	Staiger, DO; Auerbach, DI; Buerhaus, PI				Staiger, Douglas O.; Auerbach, David I.; Buerhaus, Peter I.			Registered Nurse Labor Supply and the Recession - Are We in a Bubble?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EMPLOYMENT; SURGE		[Staiger, Douglas O.] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; [Staiger, Douglas O.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Auerbach, David I.] RAND Corp, Boston, MA USA; [Buerhaus, Peter I.] Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, Nashville, TN USA	Dartmouth College; National Bureau of Economic Research; RAND Corporation; Vanderbilt University	Staiger, DO (corresponding author), Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA.							Association of American Medical Colleges, 2010, IMP HLTH CAR REF FUT; Auerbach DI, 2011, HEALTH AFFAIR, V30, P2286, DOI 10.1377/hlthaff.2011.0588; Buerhaus PI, 2009, HEALTH AFFAIR, V28, pW657, DOI 10.1377/hlthaff.28.4.w657; Buerhaus PI, 2000, JAMA-J AM MED ASSOC, V283, P2948, DOI 10.1001/jama.283.22.2948; Wood CA, 2011, MON LABOR REV, V134, P13	5	76	78	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2012	366	16					1463	1465		10.1056/NEJMp1200641	http://dx.doi.org/10.1056/NEJMp1200641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	927UE	22436050				2022-12-28	WOS:000302934800003
J	Carlton, JG; Caballe, A; Agromayor, M; Kloc, M; Martin-Serrano, J				Carlton, Jeremy G.; Caballe, Anna; Agromayor, Monica; Kloc, Magdalena; Martin-Serrano, Juan			ESCRT-III Governs the Aurora B-Mediated Abscission Checkpoint Through CHMP4C	SCIENCE			English	Article							CHROMOSOME SEGREGATION; CELL-DIVISION; CYTOKINESIS; MACHINERY; MIDBODY; PROTEIN; RECRUITMENT; CEP55; COMPLETION; DYNAMICS	The endosomal sorting complex required for transport (ESCRT) machinery plays an evolutionarily conserved role in cytokinetic abscission, the final step of cell division where daughter cells are physically separated. Here, we show that charged multivesicular body (MVB) protein 4C (CHMP4C), a human ESCRT-III subunit, is involved in abscission timing. This function correlated with its differential spatiotemporal distribution during late stages of cytokinesis. Accordingly, CHMP4C functioned in the Aurora B-dependent abscission checkpoint to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage. CHMP4C engaged the chromosomal passenger complex (CPC) via interaction with Borealin, which suggested a model whereby CHMP4C inhibits abscission upon phosphorylation by Aurora B. Thus, the ESCRT machinery may protect against genetic damage by coordinating midbody resolution with the abscission checkpoint.	[Carlton, Jeremy G.; Caballe, Anna; Agromayor, Monica; Kloc, Magdalena; Martin-Serrano, Juan] Kings Coll London, Sch Med, Dept Infect Dis, London SE1 9RT, England	University of London; King's College London	Martin-Serrano, J (corresponding author), Kings Coll London, Sch Med, Dept Infect Dis, London SE1 9RT, England.	juan.martin_serrano@kcl.ac.uk	Carlton, Jeremy/C-7702-2014; Carlton, Jeremy/X-2918-2019	Carlton, Jeremy/0000-0002-7255-1894; Caballe, Anna/0000-0002-3508-8474; Agromayor, Monica/0000-0001-6477-1750; Martin-Serrano, Juan/0000-0002-8183-3914	Medical Research Council [G0802777]; Lister Institute for Preventative Medicine; EMBO; Wellcome Trust [WT093056MA, 092429/Z/10/Z]; U.K. National Institute for Health Research Comprehensive Biomedical Research Centre at Guy's and St. Thomas's National Health Service Foundation Trust; King's College London; MRC [G0802777] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lister Institute for Preventative Medicine; EMBO(European Molecular Biology Organization (EMBO)); Wellcome Trust(Wellcome Trust); U.K. National Institute for Health Research Comprehensive Biomedical Research Centre at Guy's and St. Thomas's National Health Service Foundation Trust; King's College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank P. Bieniasz for kind gifts of GFP-CHMP4-expressing cells. J.M.-S was funded by the Medical Research Council (G0802777), the Lister Institute for Preventative Medicine and the EMBO Young Investigators Program. J.M.-S and M. A. were funded by Wellcome Trust grant (WT093056MA). J.G.C. was funded by Wellcome Trust Value in People award (092429/Z/10/Z). We acknowledge the U.K. National Institute for Health Research Comprehensive Biomedical Research Centre at Guy's and St. Thomas's National Health Service Foundation Trust and King's College London for an equipment grant.	Agromayor M, 2009, MOL BIOL CELL, V20, P1374, DOI 10.1091/mbc.E08-05-0474; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Caballe A, 2011, TRAFFIC, V12, P1318, DOI 10.1111/j.1600-0854.2011.01244.x; Carlton JG, 2008, P NATL ACAD SCI USA, V105, P10541, DOI 10.1073/pnas.0802008105; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; Connell JW, 2009, TRAFFIC, V10, P42, DOI 10.1111/j.1600-0854.2008.00847.x; Elia N, 2011, P NATL ACAD SCI USA, V108, P4846, DOI 10.1073/pnas.1102714108; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847; Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Howard TL, 2001, J CELL SCI, V114, P2395; Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207; Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042; Mackay DR, 2010, J CELL BIOL, V191, P923, DOI 10.1083/jcb.201007124; Martin-Serrano J, 2011, NAT REV MICROBIOL, V9, P519, DOI 10.1038/nrmicro2596; Mendoza M, 2009, NAT CELL BIOL, V11, P477, DOI 10.1038/ncb1855; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Samson RY, 2008, SCIENCE, V322, P1710, DOI 10.1126/science.1165322; Stauffer DR, 2001, J CELL SCI, V114, P2383; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Weiss ER, 2011, J MOL BIOL, V410, P525, DOI 10.1016/j.jmb.2011.04.055; Yang D, 2008, NAT STRUCT MOL BIOL, V15, P1278, DOI 10.1038/nsmb.1512	28	187	193	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 13	2012	336	6078					220	225		10.1126/science.1217180	http://dx.doi.org/10.1126/science.1217180			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924PN	22422861	Green Accepted			2022-12-28	WOS:000302703900048
J	Hong, WZ; Mosca, TJ; Luo, LQ				Hong, Weizhe; Mosca, Timothy J.; Luo, Liqun			Teneurins instruct synaptic partner matching in an olfactory map	NATURE			English	Article							RICH REPEAT PROTEINS; TRANSMEMBRANE PROTEINS; PAIR-RULE; RECEPTOR NEURONS; DROSOPHILA; GENE; EXPRESSION; SYSTEM; CHEMOAFFINITY; TRANSGENESIS	Neurons are interconnected with extraordinary precision to assemble a functional nervous system. Compared to axon guidance, far less is understood about how individual pre- and postsynaptic partners are matched. To ensure the proper relay of olfactory information in the fruitfly Drosophila, axons of similar to 50 classes of olfactory receptor neurons (ORNs) form one-to-one connections with dendrites of similar to 50 classes of projection neurons (PNs). Here, using genetic screens, we identified two evolutionarily conserved, epidermal growth factor (EGF)-repeat containing transmembrane Teneurin proteins, Ten-m and Ten-a, as synaptic-partner-matching molecules between PN dendrites and ORN axons. Ten-m and Ten-a are highly expressed in select PN-ORN matching pairs. Teneurin loss- and gain-of-function cause specific mismatching of select ORNs and PNs. Finally, Teneurins promote homophilic interactions in vitro, and Ten-m co-expression in non-partner PNs and ORNs promotes their ectopic connections in vivo. We propose that Teneurins instruct matching specificity between synaptic partners through homophilic attraction.	[Hong, Weizhe; Mosca, Timothy J.; Luo, Liqun] Stanford Univ, Howard Hughes Med Inst, Dept Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Luo, LQ (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biol, Stanford, CA 94305 USA.	lluo@stanford.edu	Hong, Weizhe/E-3164-2010; Hong, Weizhe/AAD-7172-2020	Hong, Weizhe/0000-0003-1523-8575; Hong, Weizhe/0000-0003-1523-8575; Luo, Liqun/0000-0001-5467-9264; Mosca, Timothy/0000-0003-3485-0719	National Institutes of Health (NIH) [R01 DC-005982, 5T32 NS007280, HD007249]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005982] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank V. Favaloro for advice on biochemistry and D. Luginbuhl for technical assistance; K. Zinn for the EP collection; H. Zhu for the initial contribution; R. Wides and S. Baumgartner for teneurin reagents; B. Zhang, Bloomington, Kyoto, Harvard and Vienna Stock Centers for fly stocks; BestGene for injection service; and K. Shen, T. Clandinin, D. Berns, V. Favaloro, X. Gao, S. Hippenmeyer, C. Liu, K. Miyamichi and X. Yu for critiques. Supported by a National Institutes of Health (NIH) grant (R01 DC-005982 to L.L.), and Epilepsy, Neonatology and Developmental Biology Training Grants (NIH 5T32 NS007280 and HD007249 to T.J.M.). L.L. is an investigator of the Howard Hughes Medical Institute.	BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Bohm RA, 2010, P NATL ACAD SCI USA, V107, P16378, DOI 10.1073/pnas.1004669107; Brochtrup A, 2011, CURR OPIN NEUROBIOL, V21, P85, DOI 10.1016/j.conb.2010.11.001; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chou YH, 2010, CELL, V142, P954, DOI 10.1016/j.cell.2010.08.015; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; de Wit J, 2011, ANNU REV CELL DEV BI, V27, P697, DOI 10.1146/annurev-cellbio-092910-154111; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Endo K, 2007, NAT NEUROSCI, V10, P153, DOI 10.1038/nn1832; Fascetti N, 2002, MECH DEVELOP, V114, P197, DOI 10.1016/S0925-4773(02)00055-2; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Hayashi S, 2002, GENESIS, V34, P58, DOI 10.1002/gene.10137; Hong WZ, 2009, NAT NEUROSCI, V12, P1542, DOI 10.1038/nn.2442; Hummel T, 2004, NEURON, V42, P77, DOI 10.1016/S0896-6273(04)00158-8; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Imai T, 2009, SCIENCE, V325, P585, DOI 10.1126/science.1173596; Jefferis GSXE, 2004, DEVELOPMENT, V131, P117, DOI 10.1242/dev.00896; Jefferis GSXE, 2001, NATURE, V414, P204, DOI 10.1038/35102574; Kinel-Tahan Y, 2007, DEV DYNAM, V236, P2541, DOI 10.1002/dvdy.21284; Komiyama T, 2007, CELL, V128, P399, DOI 10.1016/j.cell.2006.12.028; Kurtovic A, 2007, NATURE, V446, P542, DOI 10.1038/nature05672; Kurusu M, 2008, NEURON, V59, P972, DOI 10.1016/j.neuron.2008.07.037; Lattemann M, 2007, NEURON, V53, P169, DOI 10.1016/j.neuron.2006.12.024; Leamey CA, 2007, PLOS BIOL, V5, P2077, DOI 10.1371/journal.pbio.0050241; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Li H, 2006, MOL CELL NEUROSCI, V33, P136, DOI 10.1016/j.mcn.2006.06.012; Liebl FLW, 2006, J NEUROBIOL, V66, P332, DOI 10.1002/neu.20229; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Markstein M, 2008, NAT GENET, V40, P476, DOI 10.1038/ng.101; McLaughlin T, 2003, NEURON, V40, P1147, DOI 10.1016/S0896-6273(03)00790-6; Newsome TP, 2000, DEVELOPMENT, V127, P851; Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563; Pfeiffenberger C, 2006, J NEUROSCI, V26, P12873, DOI 10.1523/JNEUROSCI.3595-06.2006; Potter CJ, 2010, CELL, V141, P536, DOI 10.1016/j.cell.2010.02.025; Rakovitsky N, 2007, MECH DEVELOP, V124, P911, DOI 10.1016/j.mod.2007.08.003; Rubin BP, 2002, DEVELOPMENT, V129, P4697; Serizawa S, 2006, CELL, V127, P1057, DOI 10.1016/j.cell.2006.10.031; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Shinza-Kameda M, 2006, NEURON, V49, P205, DOI 10.1016/j.neuron.2005.11.013; Shishido E, 1998, SCIENCE, V280, P2118, DOI 10.1126/science.280.5372.2118; Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Sweeney LB, 2007, NEURON, V53, P185, DOI 10.1016/j.neuron.2006.12.022; Tea JS, 2010, J NEUROSCI, V30, P9939, DOI 10.1523/JNEUROSCI.1643-10.2010; Toba G, 1999, GENETICS, V151, P725; Tucker RP, 2007, INT J BIOCHEM CELL B, V39, P292, DOI 10.1016/j.biocel.2006.09.012; Tucker RP, 2006, DEV BIOL, V290, P237, DOI 10.1016/j.ydbio.2005.11.038; van der Goes van Naters W, 2007, CURR BIOL, V17, P606, DOI DOI 10.1016/J.CUB.2007.02.043; Venken KJT, 2006, SCIENCE, V314, P1747, DOI 10.1126/science.1134426; Venken KJT, 2009, NAT METHODS, V6, P431, DOI [10.1038/NMETH.1331, 10.1038/nmeth.1331]; Wu JS, 2006, NAT PROTOC, V1, P2110, DOI 10.1038/nprot.2006.336; Yamagata M, 2008, NATURE, V451, P465, DOI 10.1038/nature06469; Young TR, 2009, INT J BIOCHEM CELL B, V41, P990, DOI 10.1016/j.biocel.2008.06.014; Zheng LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022956; Zhu HT, 2006, NAT NEUROSCI, V9, P349, DOI 10.1038/nn1652; Zhu HT, 2004, NEURON, V42, P63, DOI 10.1016/S0896-6273(04)00142-4; Zipursky SL, 2010, CELL, V143, P343, DOI 10.1016/j.cell.2010.10.009	63	151	155	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					201	+		10.1038/nature10926	http://dx.doi.org/10.1038/nature10926			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22425994	Green Accepted			2022-12-28	WOS:000303149900027
J	Buller, HR; Prins, MH; Lensing, AWA; Decousus, H; Jacobson, BF; Minar, E; Chlumsky, J; Verhamme, P; Wells, P; Agnelli, G; Cohen, A; Berkowitz, SD; Bounameaux, H; Davidson, BL; Misselwitz, F; Gallus, AS; Raskob, GE; Schellong, S; Segers, A				Buller, Harry R.; Prins, Martin H.; Lensing, Anthonie W. A.; Decousus, Herve; Jacobson, Barry F.; Minar, Erich; Chlumsky, Jaromir; Verhamme, Peter; Wells, Phil; Agnelli, Giancarlo; Cohen, Alexander; Berkowitz, Scott D.; Bounameaux, Henri; Davidson, Bruce L.; Misselwitz, Frank; Gallus, Alex S.; Raskob, Gary E.; Schellong, Sebastian; Segers, Annelise		EINSTEIN-PE Investigators	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; XA INHIBITOR RIVAROXABAN; VENOUS THROMBOEMBOLISM; WARFARIN	BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. METHODS In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P = 0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard-therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P = 0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P = 0.003). Rates of other adverse events were similar in the two groups. CONCLUSIONS A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number,NCT00439777.)	[Buller, Harry R.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Prins, Martin H.] Maastricht Univ, Med Ctr, Dept Epidemiol, Care Res Inst, Maastricht, Netherlands; [Prins, Martin H.] Maastricht Univ, Med Ctr, Dept Epidemiol, Publ Hlth Res Inst, Maastricht, Netherlands; [Lensing, Anthonie W. A.; Misselwitz, Frank] Bayer HealthCare, Wuppertal, Germany; [Decousus, Herve] Univ St Etienne, INSERM CIE3, Ctr Hosp Univ, St Etienne, France; [Jacobson, Barry F.] Univ Witwatersrand, Johannesburg Hosp, Dept Hematol & Mol Med, Johannesburg, South Africa; [Minar, Erich] Med Univ Vienna, Dept Angiol, Vienna, Austria; [Chlumsky, Jaromir] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Verhamme, Peter] Univ Hosp Leuven, Dept Vasc Med & Hemostasis, Louvain, Belgium; [Wells, Phil] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Wells, Phil] Ottawa Hosp, Ottawa, ON, Canada; [Agnelli, Giancarlo] Univ Perugia, Osped Santa Maria della Misericordia, Sez Med Interna & Cardiovasc, I-06100 Perugia, Italy; [Cohen, Alexander] Kings Coll Hosp London, London, England; [Berkowitz, Scott D.] Bayer HealthCare, Montville, NJ USA; [Bounameaux, Henri] Univ Hosp Geneva, Div Angiol & Hemostasis, Geneva, Switzerland; [Davidson, Bruce L.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA; [Gallus, Alex S.] Flinders Med Ctr, Adelaide, SA, Australia; [Gallus, Alex S.] Flinders Univ S Australia, Adelaide, SA 5001, Australia; [Raskob, Gary E.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Schellong, Sebastian] Municipal Hosp Friedrichstadt, Dresden, Germany; [Segers, Annelise] Int Clin Trial Org, Amsterdam, Netherlands; [Segers, Annelise] Management Acad Res Org, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Maastricht University; Bayer AG; Bayer Healthcare Pharmaceuticals; CHU de St Etienne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; University of Witwatersrand; Medical University of Vienna; Motol University Hospital; KU Leuven; University Hospital Leuven; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Hospital Santa Maria della Misericordia; University of Perugia; King's College Hospital NHS Foundation Trust; King's College Hospital; Bayer AG; Bayer Healthcare Pharmaceuticals; University of Geneva; University of Washington; University of Washington Seattle; Flinders Medical Centre; Flinders University South Australia; University of Oklahoma System; University of Oklahoma Health Sciences Center	Buller, HR (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, F4-275,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	h.r.buller@amc.uva.nl	Quere, Isabelle/AAB-8519-2020; Khalafallah, Alhossain/H-9762-2019; Beyer-Westendorf, Jan/K-7569-2019; Martinelli, ida/J-2287-2015; Lazo-Langner, Alejandro/E-6993-2011; Gallus, Alexander/AAH-6204-2020; del campo, Felix/G-5716-2017; Schulman, Sam/I-7559-2019; Roig, Jordi/W-4773-2019; Berkowitz, Scott Darrell/AAS-9397-2021; Ferrari, Emile/R-2917-2016; Lodigiani, Corrado/AAW-1964-2020; Bergmann, Jean-Francois/L-6044-2017	Quere, Isabelle/0000-0002-1492-9764; Khalafallah, Alhossain/0000-0002-2399-3311; Beyer-Westendorf, Jan/0000-0002-6983-9993; Martinelli, ida/0000-0001-9218-3622; Lazo-Langner, Alejandro/0000-0001-6869-8431; del campo, Felix/0000-0002-4554-2167; Schulman, Sam/0000-0002-8512-9043; Roig, Jordi/0000-0002-5593-7090; Berkowitz, Scott Darrell/0000-0002-9428-4408; Lodigiani, Corrado/0000-0002-9152-9385; Bergmann, Jean-Francois/0000-0001-6861-9748; Borris, Lars/0000-0002-0527-1518; SANCHEZ, Olivier/0000-0003-1633-8391; LE MOIGNE, Emmanuelle/0000-0001-5103-2406; Giorgi-Pierfranceschi, Matteo/0000-0002-7988-9652; Farkas, Katalin/0000-0001-5577-6808; Couturaud, Francis/0000-0002-1855-8032; Pothirat, Chaicharn/0000-0003-0616-7066; Kolossvary, Endre/0000-0003-4507-6175; Marschang, Peter/0000-0002-8239-3447; Meijer, Karina/0000-0001-9447-0465	Bayer HealthCare; Janssen Pharmaceuticals	Bayer HealthCare(Bayer AGBayer Healthcare Pharmaceuticals); Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	Supported by Bayer HealthCare and Janssen Pharmaceuticals.	Agnelli G, 2007, CIRCULATION, V116, P180, DOI 10.1161/CIRCULATIONAHA.106.668020; BARRITT DW, 1960, LANCET, V1, P1309; Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Buller HR, 2008, BLOOD, V112, P2242, DOI 10.1182/blood-2008-05-160143; Buller HR, 2007, NEW ENGL J MED, V357, P1094; Buller HR, 2012, LANCET, V379, P123, DOI 10.1016/S0140-6736(11)61505-5; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Fiessinger JN, 2005, JAMA-J AM MED ASSOC, V293, P681, DOI 10.1001/jama.293.6.681; Kearon Clive, 2012, Chest, V141, pe419S, DOI 10.1378/chest.11-2301; Mavrakanas T, 2011, PHARMACOL THERAPEUT, V130, P46, DOI 10.1016/j.pharmthera.2010.12.007; Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277; Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Palla A, 2004, NEW ENGL J MED, V350, P423; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Turpie AGG, 2011, THROMB HAEMOSTASIS, V105, P444, DOI 10.1160/TH10-09-0601; Weitz JI, 2012, CHEST, V141, pE120S, DOI 10.1378/chest.11-2294	22	1610	1679	0	108	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 5	2012	366	14					1287	1297		10.1056/NEJMoa1113572	http://dx.doi.org/10.1056/NEJMoa1113572			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919QJ	22449293	Green Published			2022-12-28	WOS:000302343000006
J	Boekholdt, SM; Arsenault, BJ; Mora, S; Pedersen, TR; LaRosa, JC; Nestel, PJ; Simes, RJ; Durrington, P; Hitman, GA; Welch, KMA; DeMicco, DA; Zwinderman, AH; Clearfield, MB; Downs, JR; Tonkin, AM; Colhoun, HM; Gotto, AM; Ridker, PM; Kastelein, JJP				Boekholdt, S. Matthijs; Arsenault, Benoit J.; Mora, Samia; Pedersen, Terje R.; LaRosa, John C.; Nestel, Paul J.; Simes, R. John; Durrington, Paul; Hitman, Graham A.; Welch, K. M. A.; DeMicco, David A.; Zwinderman, Aeilko H.; Clearfield, Michael B.; Downs, John R.; Tonkin, Andrew M.; Colhoun, Helen M.; Gotto, Antonio M., Jr.; Ridker, Paul M.; Kastelein, John J. P.			Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DENSITY-LIPOPROTEIN CHOLESTEROL; HIGH-DOSE ATORVASTATIN; MYOCARDIAL-INFARCTION; CORONARY EVENTS; PRIMARY PREVENTION; LIPID PARAMETERS; A-I; DISEASE; ATHEROSCLEROSIS; PREDICTION	Context The associations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not been reliably documented. Objective To evaluate the relative strength of the associations of LDL-C, non-HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy. Design Meta-analysis of individual patient data from randomized controlled statin trials in which conventional lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Data Sources Relevant trials were identified by a literature search updated through December 31, 2011. Investigators were contacted and individual patient data were requested and obtained for 62154 patients enrolled in 8 trials published between 1994 and 2008. Data Extraction Hazard ratios (HRs) and corresponding 95% CIs for risk of major cardiovascular events adjusted for established risk factors by 1-SD increase in LDL-C, non-HDL-C, and apoB. Results Among 38 153 patients allocated to statin therapy, 158 fatal myocardial infarctions, 1678 nonfatal myocardial infarctions, 615 fatal events from other coronary artery disease, 2806 hospitalizations for unstable angina, and 1029 fatal or nonfatal strokes occurred during follow-up. The adjusted HRs for major cardiovascular events per 1-SD increase were 1.13 (95% CI, 1.10-1.17) for LDL-C, 1.16 (95% CI, 1.12-1.19) for non-HDL-C, and 1.14 (95% CI, 1.11-1.18) for apoB. These HRs were significantly higher for non-HDL-C than LDL-C (P=.002) and apoB (P=.02). There was no significant difference between apoB and LDL-C (P=.21). Conclusion Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non-HDL-C than for LDL-C and apoB. JAMA. 2012;307(12):1302-1309 www.jama.com	[Arsenault, Benoit J.; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Boekholdt, S. Matthijs] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; [Zwinderman, Aeilko H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; [Mora, Samia; Ridker, Paul M.] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA; [Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway; [Pedersen, Terje R.] Univ Oslo, N-0316 Oslo, Norway; [LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; [Nestel, Paul J.] Baker Heart & Diabet Res Inst, Melbourne, Vic, Australia; [Simes, R. John] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; [Durrington, Paul] Univ Manchester, Sch Biomed, Manchester, Lancs, England; [Hitman, Graham A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Diabet & Metab Med, London, England; [Welch, K. M. A.] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA; [DeMicco, David A.] Global Pharmaceut Pfizer, New York, NY USA; [Clearfield, Michael B.] Touro Univ, Mare Isl, CA USA; [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Downs, John R.] S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA; [Colhoun, Helen M.] Univ Dundee, Med Res Inst, Dundee, Scotland; [Tonkin, Andrew M.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Harvard University; Brigham & Women's Hospital; University of Oslo; University of Oslo; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Baker Heart and Diabetes Institute; University of Sydney; University of Manchester; University of London; Queen Mary University London; Rosalind Franklin University Medical & Science; Pfizer; Touro University California; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Dundee; Monash University; Cornell University	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.j.kastelein@amc.uva.nl	Simes, Robert John/P-1497-2014; Kastelein, John/AAF-7950-2020; Boekholdt, Matthijs S.M./G-7562-2014	Venkatasubramanian, Siddharth/0000-0002-5860-0768; Boekholdt, Matthijs/0000-0002-0861-0765; Colhoun, Helen/0000-0002-8345-3288	Merck Sharpe Dohme; AstraZeneca; Pfizer; Quest Diagnostics; Amgen; CSL; Boehringer-Ingelheim; EU Innovative Medicines Initiative from Roche; EU Innovative Medicines Initiative from Pfizer; EU Innovative Medicines Initiative from Eli Lilly; EU Innovative Medicines Initiative from Boehringer-Ingelheim; EU Innovative Medicines Initiative from sanofi-aventis; EU Innovative Medicines Initiative from AstraZeneca; Novartis; Eli Lilly; Kowa	Merck Sharpe Dohme(Merck & Company); AstraZeneca(AstraZeneca); Pfizer(Pfizer); Quest Diagnostics; Amgen(Amgen); CSL; Boehringer-Ingelheim(Boehringer Ingelheim); EU Innovative Medicines Initiative from Roche; EU Innovative Medicines Initiative from Pfizer; EU Innovative Medicines Initiative from Eli Lilly; EU Innovative Medicines Initiative from Boehringer-Ingelheim; EU Innovative Medicines Initiative from sanofi-aventis; EU Innovative Medicines Initiative from AstraZeneca; Novartis(Novartis); Eli Lilly(Eli Lilly); Kowa	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest Drs Boekholdt and Arsenault report receipt of consultancy fees from Pfizer. Dr Mora reports receipt of research grant support through her institution from Merck Sharpe & Dohme and AstraZeneca; consultancy fees from Pfizer and Quest Diagnostics; and lecture honoraria from AstraZeneca and Abbott. Dr LaRosa reports receipt of consultancy fees from Pfizer and Amgen, and travel expenses from Pfizer. Dr Pedersen reports receipt of research grant support and lecture fees from Pfizer. Dr Nestel reports serving as a board member for AstraZeneca and Merck Sharpe & Dohme; receipt of consultancy fees from AstraZeneca; lecture honoraria from Merck Sharpe & Dohme; and travel expenses from AstraZeneca and Merck Sharpe & Dohme. Dr DeMicco reports being a full-time employee of Pfizer. Dr Tonkin reports receipt of consultancy fees from Amgen, AstraZeneca, CSL, and Boehringer-Ingelheim; and lecture honoraria from AstraZeneca, CSL, Merck Sharpe & Dohme, and Boehringer-Ingelheim. Dr Colhoun reports receipt of research grant support through the EU Innovative Medicines Initiative from Roche, Pfizer, Eli Lilly, Boehringer-Ingelheim, sanofi-aventis, and AstraZeneca; consultancy fees from Pfizer, sanofi-aventis, Novartis, and Eli Lilly; stocks from Roche; and lecture honoraria and travel expenses from Pfizer. Dr Gotto reports serving on the board of directors for Aegerion Pharmaceuticals and Arisaph Pharmaceuticals; being a member of advisory boards for DuPont and Vatera Capital; and receiving consultancy fees from AstraZeneca, Kowa, and Merck Sharpe & Dohme. Dr Ridker reports receipt of research grant funding from Novartis and AstraZeneca; serving as a consultant to ISIS, Vascular Biogenics, Merck Sharpe & Dohme, Abbott, and Boerringer-Ingelheim; and being listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. Dr Kastelein reports receipt of lecture honoraria from Merck Sharpe & Dohme, Roche, Novartis, ISIS, Genzyme, Pfizer, Kowa, and AstraZeneca. Drs Downs, Hitman, Durrington, Simes, Welch, Clearfield, and Zwinderman reported no conflicts of interest.	Amarenco P, 2006, NEW ENGL J MED, V355, P549; Arsenault BJ, 2011, NAT REV CARDIOL, V8, P197, DOI 10.1038/nrcardio.2010.223; Charlton-Menys V, 2009, CLIN CHEM, V55, P473, DOI 10.1373/clinchem.2008.111401; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Gotto AM, 2000, CIRCULATION, V101, P477, DOI 10.1161/01.CIR.101.5.477; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Liu J, 2006, AM J CARDIOL, V98, P1363, DOI 10.1016/j.amjcard.2006.06.032; McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mora S, 2011, EUR SOC CARD C 2011; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; Pischon T, 2005, CIRCULATION, V112, P3375, DOI 10.1161/CIRCULATIONAHA.104.532499; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2005, JAMA-J AM MED ASSOC, V294, P326, DOI 10.1001/jama.294.3.326; Simes RJ, 2002, CIRCULATION, V105, P1162, DOI 10.1161/hc1002.105136; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; Sniderman AD, 2011, CIRC-CARDIOVASC QUAL, V4, P337, DOI 10.1161/CIRCOUTCOMES.110.959247; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; Warnick GR, 2001, CLIN CHEM, V47, P1579; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	31	527	561	3	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1302	1309		10.1001/jama.2012.366	http://dx.doi.org/10.1001/jama.2012.366			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453571				2022-12-28	WOS:000301978400026
J	Hagihara, A; Hasegawa, M; Abe, T; Nagata, T; Wakata, Y; Miyazaki, S				Hagihara, Akihito; Hasegawa, Manabu; Abe, Takeru; Nagata, Takashi; Wakata, Yoshifumi; Miyazaki, Shogo			Prehospital Epinephrine Use and Survival Among Patients With Out-of-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; RECOMMENDED GUIDELINES; CHEST-COMPRESSION; UTSTEIN STYLE; LIFE-SUPPORT; TASK-FORCE	Context Epinephrine is widely used in cardiopulmonary resuscitation for out-of-hospital cardiac arrest (OHCA). However, the effectiveness of epinephrine use before hospital arrival has not been established. Objective To evaluate the association between epinephrine use before hospital arrival and short-and long-term mortality in patients with cardiac arrest. Design, Setting, and Participants Prospective, nonrandomized, observational propensity analysis of data from 417 188 OHCAs occurring in 2005-2008 in Japan in which patients aged 18 years or older had an OHCA before arrival of emergency medical service (EMS) personnel, were treated by EMS personnel, and were transported to the hospital. Main Outcome Measures Return of spontaneous circulation before hospital arrival, survival at 1 month after cardiac arrest, survival with good or moderate cerebral performance (Cerebral Performance Category [CPC] 1 or 2), and survival with no, mild, or moderate neurological disability (Overall Performance Category [OPC] 1 or 2). Results Return of spontaneous circulation before hospital arrival was observed in 2786 of 15 030 patients (18.5%) in the epinephrine group and 23 042 of 402 158 patients (5.7%) in the no-epinephrine group (P<.001); it was observed in 2446 (18.3%) and 1400 (10.5%) of 13 401 propensity-matched patients, respectively (P<.001). In the total sample, the numbers of patients with 1-month survival and survival with CPC 1 or 2 and OPC 1 or 2, respectively, were 805 (5.4%), 205 (1.4%), and 211 (1.4%) with epinephrine and 18 906 (4.7%), 8903 (2.2%), and 8831 (2.2%) without epinephrine (all P<.001). Corresponding numbers in propensity-matched patients were 687 (5.1%), 173 (1.3%), and 178 (1.3%) with epinephrine and 944 (7.0%), 413 (3.1%), and 410 (3.1%) without epinephrine (all P<.001). In all patients, a positive association was observed between prehospital epinephrine and return of spontaneous circulation before hospital arrival (adjusted odds ratio [OR], 2.36; 95% CI, 2.22-2.50; P<.001). In propensity-matched patients, a positive association was also observed (adjusted OR, 2.51; 95% CI, 2.24-2.80; P<.001). In contrast, among all patients, negative associations were observed between prehospital epinephrine and long-term outcome measures (adjusted ORs: 1-month survival, 0.46 [95% CI, 0.42-0.51]; CPC 1-2, 0.31 [95% CI, 0.26-0.36]; and OPC 1-2, 0.32 [95% CI, 0.27-0.38]; all P<.001). Similar negative associations were observed among propensity-matched patients (adjusted ORs: 1-month survival, 0.54 [95% CI, 0.43-0.68]; CPC 1-2, 0.21 [95% CI, 0.10-0.44]; and OPC 1-2, 0.23 [95% CI, 0.11-0.45]; all P<.001). Conclusion Among patients with OHCA in Japan, use of prehospital epinephrine was significantly associated with increased chance of return of spontaneous circulation before hospital arrival but decreased chance of survival and good functional outcomes 1 month after the event. JAMA. 2012;307(11):1161-1168	[Hagihara, Akihito] Kyushu Univ, Grad Sch Med, Dept Hlth Serv Management & Policy, Higashi Ku, Fukuoka 8128582, Japan; [Nagata, Takashi] Kyushu Univ Hosp, Dept Emergency, Fukuoka 812, Japan; [Nagata, Takashi] Kyushu Univ Hosp, Crit Care Ctr, Fukuoka 812, Japan; [Hasegawa, Manabu] Teikyo Heisei Univ, Minist Internal Affairs & Commun, Fire & Disaster Management Agcy, Ambulance Serv,Planning Div, Tokyo, Japan; [Miyazaki, Shogo] Teikyo Heisei Univ, Fac Hlth Care, Dept Acupuncture & Moxibust, Tokyo, Japan	Kyushu University; Kyushu University; Kyushu University	Hagihara, A (corresponding author), Kyushu Univ, Grad Sch Med, Dept Hlth Serv Management & Policy, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hagihara@hsmp.med.kyushu-u.ac.jp	Abe, Takeru/J-9512-2014	Abe, Takeru/0000-0003-3496-1953; Miyazaki, Shogo/0000-0001-7270-0725				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Angelos MG, 2008, RESUSCITATION, V77, P101, DOI 10.1016/j.resuscitation.2007.10.017; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; [Anonymous], 2007, JAP GUID EM CAR CARD; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Fire and Disaster Management Agency Guidelines for Resuscitation by Emergency Life-saving Technicians, 2006, FIRE DISASTER MANAGE; Grogaard HK, 2007, J AM COLL CARDIOL, V50, P1093, DOI 10.1016/j.jacc.2007.05.028; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Holmberg M, 2002, RESUSCITATION, V54, P37, DOI 10.1016/S0300-9572(02)00048-5; Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Kitamura T, 2010, LANCET, V375, P1347, DOI 10.1016/S0140-6736(10)60064-5; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; Nishime EO, 2000, JAMA-J AM MED ASSOC, V284, P1392, DOI 10.1001/jama.284.11.1392; Ogawa T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7106; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Ong MEH, 2007, ANN EMERG MED, V50, P635, DOI 10.1016/j.annemergmed.2007.03.028; OTTO CW, 1984, ANN EMERG MED, V13, P840, DOI 10.1016/S0196-0644(84)80455-2; Parsons L, REDUCING BIAS PROPEN; PEARSON JW, 1963, AM HEART J, V66, P210, DOI 10.1016/0002-8703(63)90036-X; Ristagno G, 2007, CRIT CARE MED, V35, P2145, DOI 10.1097/01.CCM.0000280427.76175.D2; RIVERS EP, 1994, CHEST, V106, P1499, DOI 10.1378/chest.106.5.1499; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; Virkkunen I, 2008, RESUSCITATION, V77, P207, DOI 10.1016/j.resuscitation.2007.12.006; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431	31	296	321	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1161	1168		10.1001/jama.2012.294	http://dx.doi.org/10.1001/jama.2012.294			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436956				2022-12-28	WOS:000301708000024
J	Guhr, M				Guehr, Markus			Getting Molecular Electrons into Motion	SCIENCE			English	Editorial Material							HIGH HARMONIC-GENERATION; IONIZATION DYNAMICS; ATOMS		SLAC Natl Accelerator Lab, PULSE Inst, Menlo Pk, CA 94025 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Guhr, M (corresponding author), SLAC Natl Accelerator Lab, PULSE Inst, Menlo Pk, CA 94025 USA.	mguehr@slac.stanford.edu	Guehr, Markus/X-2744-2019; Guehr, Markus MG/B-7446-2015	Guehr, Markus MG/0000-0002-9111-8981				AGOSTINI P, 1979, PHYS REV LETT, V42, P1127, DOI 10.1103/PhysRevLett.42.1127; Boguslavskiy AE, 2012, SCIENCE, V335, P1336, DOI 10.1126/science.1212896; DiMauro LF, 1995, ADV ATOM MOL OPT <D>, V35, P79; Farrell JP, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.083001; Goulielmakis E, 2010, NATURE, V466, P739, DOI 10.1038/nature09212; Li W, 2008, SCIENCE, V322, P1207, DOI 10.1126/science.1163077; Loh ZH, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.143601; Lunnemann S, 2008, CHEM PHYS LETT, V450, P232, DOI 10.1016/j.cplett.2007.11.031; McFarland BK, 2008, SCIENCE, V322, P1232, DOI 10.1126/science.1162780; Remacle F, 2006, P NATL ACAD SCI USA, V103, P6793, DOI 10.1073/pnas.0601855103; Smirnova O, 2009, NATURE, V460, P972, DOI 10.1038/nature08253; Young L, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.083601	12	0	0	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1314	1315		10.1126/science.1219486	http://dx.doi.org/10.1126/science.1219486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422972				2022-12-28	WOS:000301531600036
J	Huang, YD; Mucke, L				Huang, Yadong; Mucke, Lennart			Alzheimer Mechanisms and Therapeutic Strategies	CELL			English	Review							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; HUMAN APOLIPOPROTEIN-E; HIPPOCAMPAL SYNAPTIC PLASTICITY; E/AMYLOID-BETA INTERACTION; A-BETA; TAU PHOSPHORYLATION; COGNITIVE DECLINE; RISK-FACTORS; BEHAVIORAL IMPAIRMENTS	There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but research advances over the past three decades could change this gloomy picture. Genetic studies demonstrate that the disease has multiple causes. Interdisciplinary approaches combining biochemistry, molecular and cell biology, and transgenic modeling have revealed some of its molecular mechanisms. Progress in chemistry, radiology, and systems biology is beginning to provide useful biomarkers, and the emergence of personalized medicine is poised to transform pharmaceutical development and clinical trials. However, investigative and drug development efforts should be diversified to fully address the multifactoriality of the disease.	[Huang, Yadong; Mucke, Lennart] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Huang, Yadong; Mucke, Lennart] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Mucke, L (corresponding author), Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu		Mucke, Lennart/0000-0001-6256-9559	National Institutes of Health [AG011385, AG022074]; Bristol-Myers Squibb; NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385, P01AG022074] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health grants AG011385 and AG022074 and a gift from the Stephen D. Bechtel, Jr. Foundation. We thank the authors' lab members for many stimulating discussions of these topics, John Carroll for preparation of graphics, and Monica Dela Cruz for administrative assistance. L.M. serves on the scientific advisory board of iPierian and has received research funding from Bristol-Myers Squibb for a tau-related project.	Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Ashe KH, 2010, NEURON, V66, P631, DOI 10.1016/j.neuron.2010.04.031; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BAREGGI SR, 1982, ARCH NEUROL-CHICAGO, V39, P709, DOI 10.1001/archneur.1982.00510230035010; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Berlau DJ, 2009, NEUROLOGY, V72, P829, DOI 10.1212/01.wnl.0000343853.00346.a4; Bero AW, 2011, NAT NEUROSCI, V14, P750, DOI 10.1038/nn.2801; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Bezprozvanny I, 2010, DRUG NEWS PERSPECT, V23, P518, DOI 10.1358/dnp.2010.23.8.1500435; Bien-Ly N, 2012, J NEUROSCI, V32, P4803, DOI 10.1523/JNEUROSCI.0033-12.2012; Bien-Ly N, 2011, P NATL ACAD SCI USA, V108, P4236, DOI 10.1073/pnas.1018381108; Bousquet J, 2011, GENOME MED, V3, DOI 10.1186/gm259; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Brodbeck J, 2011, J BIOL CHEM, V286, P17217, DOI 10.1074/jbc.M110.217380; Brouwers N, 2006, BRAIN, V129, P2984, DOI 10.1093/brain/awl212; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Brunden KR, 2009, NAT REV DRUG DISCOV, V8, P783, DOI 10.1038/nrd2959; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Buttini M, 2010, AM J PATHOL, V177, P563, DOI 10.2353/ajpath.2010.090973; Camandola S, 2011, BBA-MOL CELL RES, V1813, P965, DOI 10.1016/j.bbamcr.2010.10.005; Campion D, 1999, AM J HUM GENET, V65, P664, DOI 10.1086/302553; Caselli RJ, 2011, NEUROLOGY, V76, P1078, DOI 10.1212/WNL.0b013e318211c3ae; Caselli RJ, 2009, NEW ENGL J MED, V361, P255, DOI 10.1056/NEJMoa0809437; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chen HK, 2012, J BIOL CHEM, V287, P5253, DOI 10.1074/jbc.M111.276162; Chen Y, 2010, P NATL ACAD SCI USA, V107, P12011, DOI 10.1073/pnas.0914984107; Cheng JS, 2009, NAT NEUROSCI, V12, P119, DOI 10.1038/nn.2240; Chin J, 2004, J NEUROSCI, V24, P4692, DOI 10.1523/JNEUROSCI.0277-04.2004; Chin J, 2007, J NEUROSCI, V27, P2727, DOI 10.1523/JNEUROSCI.3758-06.2007; Chouliaras L, 2010, PROG NEUROBIOL, V90, P498, DOI 10.1016/j.pneurobio.2010.01.002; Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; Cohen E, 2009, CELL, V139, P1157, DOI 10.1016/j.cell.2009.11.014; Cohen TJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1255; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Cysique LA, 2009, NEUROPSYCHOL REV, V19, P169, DOI 10.1007/s11065-009-9092-3; Daviglus ML, 2010, ANN INTERN MED, V153, P176, DOI 10.7326/0003-4819-153-3-201008030-00260; Day JJ, 2011, NEURON, V70, P813, DOI 10.1016/j.neuron.2011.05.019; De Jager PL, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.033; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; Dennis NA, 2010, ALZHEIMERS DEMENT, V6, P303, DOI 10.1016/j.jalz.2009.07.003; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014; Dumanis SB, 2009, J NEUROSCI, V29, P15317, DOI 10.1523/JNEUROSCI.4026-09.2009; Durakoglugil MS, 2009, P NATL ACAD SCI USA, V106, P15938, DOI 10.1073/pnas.0908176106; Evans CG, 2011, CHEM COMMUN, V47, P529, DOI 10.1039/c0cc02253e; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Frisoni GB, 2010, NAT REV NEUROL, V6, P67, DOI 10.1038/nrneurol.2009.215; Galimberti Daniela, 2011, Front Biosci (Schol Ed), V3, P252, DOI 10.2741/s149; Gan L, 2008, NEURON, V58, P10, DOI 10.1016/j.neuron.2008.03.015; Genin E, 2011, MOL PSYCHIATR, V16, P903, DOI 10.1038/mp.2011.52; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; Gibson GE, 2000, ANN NEUROL, V48, P297, DOI 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009; Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gozes I, 2009, CURR ALZHEIMER RES, V6, P455, DOI 10.2174/156720509789207895; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Grouselle D, 1998, NEUROSCI LETT, V255, P21, DOI 10.1016/S0304-3940(98)00698-3; Gura T, 2008, NAT MED, V14, P894, DOI 10.1038/nm0908-894; Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40; Hampel H, 2010, NAT REV DRUG DISCOV, V9, P560, DOI 10.1038/nrd3115; Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200; Harris JA, 2010, J NEUROSCI, V30, P372, DOI 10.1523/JNEUROSCI.5341-09.2010; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Herrup K, 2010, J NEUROSCI, V30, P16755, DOI 10.1523/JNEUROSCI.4521-10.2010; Higashi S, 2007, BRAIN RES, V1184, P284, DOI 10.1016/j.brainres.2007.09.048; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hoover BR, 2010, NEURON, V68, P1067, DOI 10.1016/j.neuron.2010.11.030; Huang Y, 2006, CURR OPIN DRUG DISC, V9, P627; Huang YD, 2010, TRENDS MOL MED, V16, P287, DOI 10.1016/j.molmed.2010.04.004; Iqbal K, 2010, CURR ALZHEIMER RES, V7, P656, DOI 10.2174/156720510793611592; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Jones PB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014586; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kim J, 2011, J NEUROSCI, V31, P18007, DOI 10.1523/JNEUROSCI.3773-11.2011; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Kim S, 2010, CURR ALZHEIMER RES, V7, P230, DOI 10.2174/156720510791050894; Koh MT, 2010, NEUROPSYCHOPHARMACOL, V35, P1016, DOI 10.1038/npp.2009.207; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Kramer PL, 2011, NEUROBIOL AGING, V32, P2113, DOI 10.1016/j.neurobiolaging.2010.01.010; Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Lee HP, 2010, EXPERT REV NEUROTHER, V10, P1201, DOI 10.1586/ERN.10.74; Lee KJ, 2010, NEUROSCIENCE, V169, P344, DOI 10.1016/j.neuroscience.2010.04.078; Li G, 2009, CELL STEM CELL, V5, P634, DOI 10.1016/j.stem.2009.10.015; Li SM, 2011, J NEUROSCI, V31, P6627, DOI 10.1523/JNEUROSCI.0203-11.2011; Logue MW, 2011, ARCH NEUROL-CHICAGO, V68, P1569, DOI 10.1001/archneurol.2011.646; Lopez OL, 2009, J NEUROL NEUROSUR PS, V80, P600, DOI 10.1136/jnnp.2008.158964; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Marchetti C, 2011, REV NEUROSCIENCE, V22, P373, DOI 10.1515/RNS.2011.035; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; Meilandt WJ, 2008, J NEUROSCI, V28, P5007, DOI 10.1523/JNEUROSCI.0590-08.2008; Miller J, 2011, NAT CHEM BIOL, V7, P925, DOI [10.1038/nchembio.694, 10.1038/NCHEMBIO.694]; Miller JA, 2010, P NATL ACAD SCI USA, V107, P12698, DOI 10.1073/pnas.0914257107; Min SW, 2010, NEURON, V67, P953, DOI 10.1016/j.neuron.2010.08.044; Morris JC, 2009, ARCH NEUROL-CHICAGO, V66, P1469, DOI 10.1001/archneurol.2009.269; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Nixon RA, 2011, NEUROBIOL DIS, V43, P38, DOI 10.1016/j.nbd.2011.01.021; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Prasher VP, 1998, ANN NEUROL, V43, P380, DOI 10.1002/ana.410430316; Prince M., 2015, WORLD ALZHEIMER REPO, DOI [10.1111/j.0963-7214.2004.00293.x, DOI 10.1111/J.0963-7214.2004.00293.X]; Putcha D, 2011, J NEUROSCI, V31, P17680, DOI 10.1523/JNEUROSCI.4740-11.2011; Puzzo D, 2011, ANN NEUROL, V69, P819, DOI 10.1002/ana.22313; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; Reddy MM, 2011, CELL, V144, P132, DOI 10.1016/j.cell.2010.11.054; Reiman EM, 2011, J ALZHEIMERS DIS, V26, P321, DOI 10.3233/JAD-2011-0059; Remes AM, 2008, ARCH NEUROL-CHICAGO, V65, P540, DOI 10.1001/archneur.65.4.540; Renner M, 2010, NEURON, V66, P739, DOI 10.1016/j.neuron.2010.04.029; Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008; Ronicke R, 2011, NEUROBIOL AGING, V32, P2219, DOI 10.1016/j.neurobiolaging.2010.01.011; Rosendoff C, 2007, AM J GERIATR CARDIOL, V16, P143, DOI 10.1111/j.1076-7460.2007.06696.x; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103; Sahara N, 2007, J NEUROSCI RES, V85, P3098, DOI 10.1002/jnr.21417; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Salloway S, 2011, NEUROLOGY, V77, P1253, DOI 10.1212/WNL.0b013e3182309fa5; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Sanchez MM, 2012, BIOL PSYCHIAT, V71, P403, DOI 10.1016/j.biopsych.2011.08.016; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Sarantseva S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008191; Sastre M, 2011, CURR ALZHEIMER RES, V8, P132, DOI 10.2174/156720511795256062; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schirmer RH, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.12.012; Schor NF, 2011, ANN NEUROL, V69, P237, DOI 10.1002/ana.22365; Sharp ES, 2011, ALZ DIS ASSOC DIS, V25, P289, DOI 10.1097/WAD.0b013e318211c83c; Shaw P, 2007, LANCET NEUROL, V6, P494, DOI 10.1016/S1474-4422(07)70106-0; Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156; Shimada H, 2011, DEMENT GERIATR COGN, V32, P45, DOI 10.1159/000330017; Shineman DW, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt90; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Sigurdsson EM, 2009, CURR ALZHEIMER RES, V6, P446, DOI 10.2174/156720509789207930; Simon AM, 2009, NEUROBIOL DIS, V33, P369, DOI 10.1016/j.nbd.2008.11.005; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P367, DOI 10.1016/j.jalz.2011.05.2351; Sperling RA, 2010, NEUROMOL MED, V12, P27, DOI 10.1007/s12017-009-8109-7; Srikanth V, 2011, NEUROBIOL AGING, V32, P763, DOI 10.1016/j.neurobiolaging.2009.04.016; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Tomiyama T, 2010, J NEUROSCI, V30, P4845, DOI 10.1523/JNEUROSCI.5825-09.2010; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vepsalainen S, 2007, J NEUROL, V254, P1504, DOI 10.1007/s00415-007-0539-2; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Villemagne VL, 2009, ARCH NEUROL-CHICAGO, V66, P1537, DOI 10.1001/archneurol.2009.285; Vossel KA, 2013, NEUROCASE, V19, P295, DOI 10.1080/13554794.2012.667124; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Winner B, 2011, P NATL ACAD SCI USA, V108, P4194, DOI 10.1073/pnas.1100976108; Wu J, 2011, CELL, V147, P615, DOI 10.1016/j.cell.2011.09.036; Xu Q, 2008, J NEUROSCI, V28, P1452, DOI 10.1523/JNEUROSCI.3253-07.2008; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yang DS, 2011, AUTOPHAGY, V7, P788, DOI 10.4161/auto.7.7.15596; Yang J, 2011, J ALZHEIMERS DIS, V24, P269, DOI 10.3233/JAD-2011-101401; Yang L, 2009, J NEUROSCI, V29, P15660, DOI 10.1523/JNEUROSCI.4104-09.2009; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102; Zahs KR, 2010, TRENDS NEUROSCI, V33, P381, DOI 10.1016/j.tins.2010.05.004; Zempel H, 2010, J NEUROSCI, V30, P11938, DOI 10.1523/JNEUROSCI.2357-10.2010; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zhong N, 2009, J BIOL CHEM, V284, P6027, DOI 10.1074/jbc.R800009200	201	1279	1393	27	690	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1204	1222		10.1016/j.cell.2012.02.040	http://dx.doi.org/10.1016/j.cell.2012.02.040			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424230	Green Accepted, Bronze			2022-12-28	WOS:000301889500017
J	Kathiresan, S; Srivastava, D				Kathiresan, Sekar; Srivastava, Deepak			Genetics of Human Cardiovascular Disease	CELL			English	Review							GENOME-WIDE ASSOCIATION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; HEART-DISEASE; SUSCEPTIBILITY LOCUS; BARTTERS-SYNDROME; MYOCARDIAL INFARCTION; CARDIAC-ARRHYTHMIA; CHROMOSOME 9P21	Cardiovascular disease encompasses a range of conditions extending from myocardial infarction to congenital heart disease, most of which are heritable. Enormous effort has been invested in understanding the genes and specific DNA sequence variants that are responsible for this heritability. Here, we review the lessons learned for monogenic and common, complex forms of cardiovascular disease. We also discuss key challenges that remain for gene discovery and for moving from genomic localization to mechanistic insights, with an emphasis on the impact of next-generation sequencing and the use of pluripotent human cells to understand the mechanism by which genetic variation contributes to disease.	[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Kathiresan, Sekar] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Kathiresan, Sekar] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Srivastava, Deepak] Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; [Srivastava, Deepak] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Srivastava, Deepak] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kathiresan, S (corresponding author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.	skathiresan@partners.org; dsrivastava@gladstone.ucsf.edu			NHLBI/NIH; Foundation Leducq; Massachusetts General Hospital; Pfizer; Merck; Alnylam; Shire Therapeutics; California Institute for Regenerative Medicine; Younger Family Foundation; Roddenberry Foundation; Whittier Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057181, P01HL089707, U01HL100406] Funding Source: NIH RePORTER	NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Foundation Leducq(Leducq Foundation); Massachusetts General Hospital(General Electric); Pfizer(Pfizer); Merck(Merck & Company); Alnylam; Shire Therapeutics; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Younger Family Foundation; Roddenberry Foundation; Whittier Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors wish to apologize in advance to authors of outstanding work that is not acknowledged in this Review due to space constraints. The authors wish to thank Drs. Ron Do, Nathan O. Stitziel, Gina M. Peloso, and Kiran Musunuru for assistance with analyses and critical review of the manuscript. S.K. was supported by grants from NHLBI/NIH, Foundation Leducq, the Howard Goodman Fellowship from Massachusetts General Hospital, Pfizer, Merck, Alnylam, and Shire Therapeutics. D.S. was supported by grants from the NHLBI/NIH, the California Institute for Regenerative Medicine, the Younger Family Foundation, the Roddenberry Foundation, and the Whittier Foundation.	Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Boyden LM, 2012, NATURE, V482, P98, DOI 10.1038/nature10814; Braam SR, 2010, STEM CELL RES, V4, P107, DOI 10.1016/j.scr.2009.11.004; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Burkhardt R, 2010, J CLIN INVEST, V120, P4410, DOI 10.1172/JCI44213; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Butterworth AS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002260; Canadas V, 2010, NAT REV CARDIOL, V7, P256, DOI 10.1038/nrcardio.2010.30; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Choi M, 2011, SCIENCE, V331, P768, DOI 10.1126/science.1198785; Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dietz HC, 2010, NEW ENGL J MED, V363, P852, DOI 10.1056/NEJMra0907180; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Erdmann J, 2009, NAT GENET, V41, P280, DOI 10.1038/ng.307; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Faivre L, 2007, AM J HUM GENET, V81, P454, DOI 10.1086/520125; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Gelb BD, 2011, J CLIN INVEST, V121, P844, DOI 10.1172/JCI46399; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; Gieger C, 2011, NATURE, V480, P201, DOI 10.1038/nature10659; GRAY R, 1991, BONE MARROW TRANSPL, V7, P9; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harismendy O, 2011, NATURE, V470, P264, DOI 10.1038/nature09753; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; HOBBS HH, 1989, J CLIN INVEST, V84, P656, DOI 10.1172/JCI114212; Holdt LM, 2012, ARTERIOSCL THROM VAS, V32, P196, DOI 10.1161/ATVBAHA.111.232678; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Itzhaki I, 2011, NATURE, V471, P225, DOI 10.1038/nature09747; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; Ji WZ, 2008, NAT GENET, V40, P592, DOI 10.1038/ng.118; Johansen CT, 2010, NAT GENET, V42, P684, DOI 10.1038/ng.628; Kamstrup PR, 2009, JAMA-J AM MED ASSOC, V301, P2331, DOI 10.1001/jama.2009.801; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KATAN MB, 1986, LANCET, V1, P507; Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291; Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75; Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Kryukov GV, 2007, AM J HUM GENET, V80, P727, DOI 10.1086/513473; Kryukov GV, 2009, P NATL ACAD SCI USA, V106, P3871, DOI 10.1073/pnas.0812824106; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LeMaire SA, 2011, NAT GENET, V43, P996, DOI 10.1038/ng.934; Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lindsay ME, 2011, NATURE, V473, P308, DOI 10.1038/nature10145; Lloyd-Jones DM, 2004, JAMA-J AM MED ASSOC, V291, P2204, DOI 10.1001/jama.291.18.2204; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; Madsen BE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000384; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032; McNair WP, 2004, CIRCULATION, V110, P2163, DOI 10.1161/01.CIR.0000144458.58660.BB; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Menzel S, 2007, NAT GENET, V39, P1197, DOI 10.1038/ng2108; Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Musunuru K, 2010, NEW ENGL J MED, V363, P2220, DOI 10.1056/NEJMoa1002926; Musunuru K, 2010, ANNU REV GENOM HUM G, V11, P91, DOI 10.1146/annurev-genom-082509-141637; Musunuru K, 2010, NATURE, V466, P714, DOI 10.1038/nature09266; Neale BM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001322; Newton-Cheh C, 2009, NAT GENET, V41, P399, DOI 10.1038/ng.364; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Norton N, 2011, AM J HUM GENET, V88, P273, DOI 10.1016/j.ajhg.2011.01.016; O'Donnell CJ, 2011, NEW ENGL J MED, V365, P2098, DOI 10.1056/NEJMra1105239; Olson TM, 2000, J MOL CELL CARDIOL, V32, P1687, DOI 10.1006/jmcc.2000.1204; Peden JF, 2011, NAT GENET, V43, P339, DOI 10.1038/ng.782; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Pollin TI, 2008, SCIENCE, V322, P1702, DOI 10.1126/science.1161524; Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005; Raychaudhuri S, 2011, CELL, V147, P57, DOI 10.1016/j.cell.2011.09.011; Reilly MP, 2011, LANCET, V377, P383, DOI 10.1016/S0140-6736(10)61996-4; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Romeo S, 2009, J CLIN INVEST, V119, P70, DOI 10.1172/JCI37118; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Sankaran VG, 2009, NATURE, V460, P1093, DOI 10.1038/nature08243; Sankaran VG, 2008, SCIENCE, V322, P1839, DOI 10.1126/science.1165409; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Shea J, 2011, NAT GENET, V43, P801, DOI 10.1038/ng.871; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]; Stenson PD, 2009, GENOME MED, V1, DOI 10.1186/gm13; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Teupser D, 2010, CIRC-CARDIOVASC GENE, V3, P331, DOI 10.1161/CIRCGENETICS.109.907873; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Varbo A, 2011, ARTERIOSCL THROM VAS, V31, P451, DOI 10.1161/ATVBAHA.110.216333; Visel A, 2010, NATURE, V464, P409, DOI 10.1038/nature08801; Wang F, 2011, NAT GENET, V43, P345, DOI 10.1038/ng.783; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548; Wild PS, 2011, CIRC-CARDIOVASC GENE, V4, P403, DOI 10.1161/CIRCGENETICS.110.958728; Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu J, 2011, SCIENCE, V334, P993, DOI 10.1126/science.1211053; Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563; Yazawa M, 2011, NATURE, V471, P230, DOI 10.1038/nature09855; Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424; Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402	132	276	287	3	79	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1242	1257		10.1016/j.cell.2012.03.001	http://dx.doi.org/10.1016/j.cell.2012.03.001			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424232	Green Accepted, Bronze			2022-12-28	WOS:000301889500019
J	McDole, JR; Wheeler, LW; McDonald, KG; Wang, BM; Konjufca, V; Knoop, KA; Newberry, RD; Miller, MJ				McDole, Jeremiah R.; Wheeler, Leroy W.; McDonald, Keely G.; Wang, Baomei; Konjufca, Vjollca; Knoop, Kathryn A.; Newberry, Rodney D.; Miller, Mark J.			Goblet cells deliver luminal antigen to CD103(+) dendritic cells in the small intestine	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; BARRIER FUNCTION; CROHNS-DISEASE; MICE; TIGHT; COLITIS; LUMEN; MUC2	The intestinal immune system is exposed to a mixture of foreign antigens from diet, commensal flora and potential pathogens. Understanding how pathogen-specific immunity is elicited while avoiding inappropriate responses to the background of innocuous antigens is essential for understanding and treating intestinal infections and inflammatory diseases. The ingestion of protein antigen can induce oral tolerance, which is mediated in part by a subset of intestinal dendritic cells (DCs) that promote the development of regulatory T cells(1). The lamina propria (LP) underlies the expansive single-cell absorptive villous epithelium and contains a large population of DCs (CD11c(+) CD11b(+) MHCII+ cells) comprised of two predominant subsets: CD103(+) CX(3)CR1(-) DCs, which promote IgA production, imprint gut homing on lymphocytes and induce the development of regulatory T cells(2-9), and CD103(-) CX(3)CR1(+) DCs (with features of macrophages), which promote tumour necrosis factor-alpha (TNF-alpha) production, colitis, and the development of T(H)17 T cells(5-7,10). However, the mechanisms by which different intestinal LP-DC subsets capture luminal antigens in vivo remains largely unexplored. Using a minimally disruptive in vivo imaging approach we show that in the steady state, small intestine goblet cells (GCs) function as passages delivering low molecular weight soluble antigens from the intestinal lumen to underlying CD103(+) LP-DCs. The preferential delivery of antigens to DCs with tolerogenic properties implies a key role for this GC function in intestinal immune homeostasis.	[McDole, Jeremiah R.; Wang, Baomei; Miller, Mark J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Wheeler, Leroy W.; McDonald, Keely G.; Knoop, Kathryn A.; Newberry, Rodney D.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Konjufca, Vjollca] So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA	Washington University (WUSTL); Washington University (WUSTL); Southern Illinois University System; Southern Illinois University	Miller, MJ (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	rnewberry@wustl.edu; miller@pathology.wustl.edu	Knoop, Kathryn/AAM-3570-2020	Newberry, Rodney/0000-0002-4152-5191; Konjufca, Vjollca/0000-0002-7736-5097; Knoop, Kathryn/0000-0003-2007-3066; Miller, Mark/0000-0001-5676-389X	NCI Cancer Center [P30 CA91842];  [DK064798];  [AI083538];  [AI095550];  [DK085941];  [AI077600];  [P30-DK52574]; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI095550, R21AI083538, R01AI077600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064798, F32DK085941, P30DK052574] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by grants DK064798 (R.D.N.), AI083538 (R.D.N.), AI095550 (R.D.N. and M.J.M.), DK085941 (L.W.W.) and AI077600 (M.J.M.). The authors thank W. Beatty for assistance with confocal microscopy, C. Eagon for assistance with human specimens, the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis for the use of the Siteman Flow Cytometry Core, which provided high-speed flow sorting and the Washington University Digestive Disease Research Core Center (DDRCC), which provided gnotobiotic mice. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant number P30 CA91842. The Washington University DDRCC is supported by grant P30-DK52574.	Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; DVORAK AM, 1980, HUM PATHOL, V11, P561; Eri RD, 2011, MUCOSAL IMMUNOL, V4, P354, DOI 10.1038/mi.2010.74; Faust N, 2000, BLOOD, V96, P719; Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529; Hesse M, 2007, EXP CELL RES, V313, P3127, DOI 10.1016/j.yexcr.2007.05.019; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; MADARA JL, 1982, J MEMBRANE BIOL, V66, P145, DOI 10.1007/BF01868490; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; McDonald KG, 2010, AM J PATHOL, V176, P2367, DOI 10.2353/ajpath.2010.090723; Niess JH, 2010, J IMMUNOL, V184, P2026, DOI 10.4049/jimmunol.0901936; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Rescigno M, 2001, IMMUNOBIOLOGY, V204, P572, DOI 10.1078/0171-2985-00094; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Shroyer NF, 2007, GASTROENTEROLOGY, V132, P2478, DOI 10.1053/j.gastro.2007.03.047; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; TRABUCCHI E, 1986, INT J TISSUE REACT, V8, P79; Tytgat KMAJ, 1996, BIOCHEM BIOPH RES CO, V224, P397, DOI 10.1006/bbrc.1996.1039; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; Varol C, 2009, IMMUNITY, V31, P502, DOI 10.1016/j.immuni.2009.06.025; Watson AJM, 2005, GASTROENTEROLOGY, V129, P902, DOI 10.1053/j.gastro.2005.06.015; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x	32	572	597	9	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					345	U141		10.1038/nature10863	http://dx.doi.org/10.1038/nature10863			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422267	Green Accepted, Bronze			2022-12-28	WOS:000301481800052
J	Tarruell, L; Greif, D; Uehlinger, T; Jotzu, G; Esslinger, T				Tarruell, Leticia; Greif, Daniel; Uehlinger, Thomas; Jotzu, Gregor; Esslinger, Tilman			Creating, moving and merging Dirac points with a Fermi gas in a tunable honeycomb lattice	NATURE			English	Article							QUANTUM PHASE-TRANSITION; OPTICAL LATTICES; MOTT INSULATOR; ATOMS; PHYSICS	Dirac points are central to many phenomena in condensed-matter physics, from massless electrons in graphene to the emergence of conducting edge states in topological insulators(1,2). At a Dirac point, two energy bands intersect linearly and the electrons behave as relativistic Dirac fermions. In solids, the rigid structure of the material determines the mass and velocity of the electrons, as well as their interactions. A different, highly flexible means of studying condensed-matter phenomena is to create model systems using ultracold atoms trapped in the periodic potential of interfering laser beams(3,4). Here we report the creation of Dirac points with adjustable properties in a tunable honeycomb optical lattice. Using momentum-resolved interband transitions, we observe a minimum bandgap inside the Brillouin zone at the positions of the two Dirac points. We exploit the unique tunability of our lattice potential to adjust the effective mass of the Dirac fermions by breaking inversion symmetry. Moreover, changing the lattice anisotropy allows us to change the positions of the Dirac points inside the Brillouin zone. When the anisotropy exceeds a critical limit, the two Dirac points merge and annihilate each other-a situation that has recently attracted considerable theoretical interest(5-9) but that is extremely challenging to observe in solids(10). We map out this topological transition in lattice parameter space and find excellent agreement with ab initio calculations. Our results not only pave the way to model materials in which the topology of the band structure is crucial, but also provide an avenue to exploring many-body phases resulting from the interplay of complex lattice geometries with interactions(11-13).	[Tarruell, Leticia; Greif, Daniel; Uehlinger, Thomas; Jotzu, Gregor; Esslinger, Tilman] ETH, Inst Quantum Elect, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Esslinger, T (corresponding author), ETH, Inst Quantum Elect, CH-8093 Zurich, Switzerland.	esslinger@phys.ethz.ch	Esslinger, Tilman/M-9022-2016; Tarruell, Leticia/I-8152-2012; Greif, Daniel/M-4480-2017	Esslinger, Tilman/0000-0002-8333-107X; Tarruell, Leticia/0000-0002-0564-1435; Greif, Daniel/0000-0002-0721-7726; Jotzu, Gregor/0000-0003-4421-5874	SNF; NCCR-MaNEP; NCCR-QSIT; NAME-QUAM (EU, FET open); SQMS; ESF (POLATOM)	SNF; NCCR-MaNEP(Swiss National Science Foundation (SNSF)); NCCR-QSIT; NAME-QUAM (EU, FET open); SQMS; ESF (POLATOM)	We would like to thank D. Poletti for bringing our attention to honeycomb lattices without six-fold symmetry, and N. Cooper and F. Hassler for discussions. We acknowledge SNF, NCCR-MaNEP, NCCR-QSIT, NAME-QUAM (EU, FET open), SQMS (ERC advanced grant) and ESF (POLATOM) for funding.	Asano K, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.245125; Balents L, 2010, NATURE, V464, P199, DOI 10.1038/nature08917; BenDahan M, 1996, PHYS REV LETT, V76, P4508, DOI 10.1103/PhysRevLett.76.4508; Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Hasan MZ, 2010, REV MOD PHYS, V82, P3045, DOI 10.1103/RevModPhys.82.3045; Hasegawa Y, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.033413; HEMMERICH A, 1992, EUROPHYS LETT, V18, P391, DOI 10.1209/0295-5075/18/5/003; Jordens R, 2008, NATURE, V455, P204, DOI 10.1038/nature07244; Kitagawa T, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.235114; Kling S, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.215301; Kohl M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.080403; Lee KL, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.043411; Lewenstein M, 2007, ADV PHYS, V56, P243, DOI 10.1080/00018730701223200; Lin YJ, 2009, NATURE, V462, P628, DOI 10.1038/nature08609; Lubasch M, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.165301; MA LS, 1994, OPT LETT, V19, P1777, DOI 10.1364/OL.19.001777; Meng ZY, 2010, NATURE, V464, P847, DOI 10.1038/nature08942; Montambaux G, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.153412; Pereira VM, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.045401; Sachdev S, 2008, NAT PHYS, V4, P173, DOI 10.1038/nphys894; Salger T, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.190405; Schneider U, 2008, SCIENCE, V322, P1520, DOI 10.1126/science.1165449; Soltan-Panahi P, 2011, NAT PHYS, V7, P434, DOI [10.1038/nphys1916, 10.1038/NPHYS1916]; Soltan-Panahi P, 2012, NAT PHYS, V8, P71, DOI 10.1038/nphys2128; Wunsch B, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/10/103027; Zenesini A, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.065601; Zhao E, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.230404; Zhu SL, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.260402	30	710	712	6	232	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					302	+		10.1038/nature10871	http://dx.doi.org/10.1038/nature10871			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422263	Green Submitted			2022-12-28	WOS:000301481800042
J	Blaga, CI; Xu, JL; DiChiara, AD; Sistrunk, E; Zhang, KK; Agostini, P; Miller, TA; DiMauro, LF; Lin, CD				Blaga, Cosmin I.; Xu, Junliang; DiChiara, Anthony D.; Sistrunk, Emily; Zhang, Kaikai; Agostini, Pierre; Miller, Terry A.; DiMauro, Louis F.; Lin, C. D.			Imaging ultrafast molecular dynamics with laser-induced electron diffraction	NATURE			English	Article								Establishing the structure of molecules and solids has always had an essential role in physics, chemistry and biology. The methods of choice are X-ray and electron diffraction, which are routinely used to determine atomic positions with sub-a ngstrom spatial resolution. Although both methods are currently limited to probing dynamics on timescales longer than a picosecond, the recent development of femtosecond sources of X-ray pulses and electron beams suggests that they might soon be capable of taking ultrafast snapshots of biological molecules(1,2) and condensed-phase systems(3-6) undergoing structural changes. The past decade has also witnessed the emergence of an alternative imaging approach based on laser-ionized bursts of coherent electron wave packets that self-interrogate the parent molecular structure(7-11). Here we show that this phenomenon can indeed be exploited for laser-induced electron diffraction(10) (LIED), to image molecular structures with subangstrom precision and exposure times of a few femtoseconds. We apply the method to oxygen and nitrogen molecules, which on strong-field ionization at three mid-infrared wavelengths (1.7, 2.0 and 2.3 mu m) emit photoelectrons with a momentum distribution from which we extract diffraction patterns. The long wavelength is essential for achieving atomic-scale spatial resolution, and the wavelength variation is equivalent to taking snapshots at different times. We show that the method has the sensitivity to measure a 0.1 angstrom displacement in the oxygen bond length occurring in a time interval of similar to 5 fs, which establishes LIED as a promising approach for the imaging of gas-phase molecules with unprecedented spatio-temporal resolution.	[Blaga, Cosmin I.; DiChiara, Anthony D.; Sistrunk, Emily; Zhang, Kaikai; Agostini, Pierre; DiMauro, Louis F.] Ohio State Univ, Dept Phys, Columbus, OH 43210 USA; [Xu, Junliang; Lin, C. D.] Kansas State Univ, Dept Phys, Manhattan, KS 66506 USA; [Miller, Terry A.] Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Kansas State University; University System of Ohio; Ohio State University	Blaga, CI (corresponding author), Ohio State Univ, Dept Phys, 174 W 18th Ave, Columbus, OH 43210 USA.	cblaga@mps.ohio-state.edu	Lin, c d/D-7312-2012; Miller, Terry A/F-6607-2014	Lin, c d/0000-0003-4847-8938; Miller, Terry A/0000-0003-0731-8006	DOE/BES [DE-FG02-06ER15833, DE-FG02-06ER15832]; Hagenlocker chair	DOE/BES(United States Department of Energy (DOE)); Hagenlocker chair	The work at The Ohio State University and Kansas State University was performed under DOE/BES contracts DE-FG02-06ER15833 and DE-FG02-06ER15832, respectively. L.F.D. acknowledges support from the Hagenlocker chair.	Baker S, 2006, SCIENCE, V312, P424, DOI 10.1126/science.1123904; Chapman HN, 2011, NATURE, V470, P73, DOI 10.1038/nature09750; Chen ZJ, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.033409; Colosimo P, 2008, NAT PHYS, V4, P386, DOI 10.1038/nphys914; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; Cornaggia C, 2009, J PHYS B-AT MOL OPT, V42, DOI 10.1088/0953-4075/42/16/161002; Dekock R. L., 1989, CHEM STRUCTURE BONDI, V229; DUBOIS RD, 1976, J PHYS B-AT MOL OPT, V9, P2657, DOI 10.1088/0022-3700/9/15/016; Eichberger M, 2010, NATURE, V468, P799, DOI 10.1038/nature09539; Elsaesser T, 2010, ACTA CRYSTALLOGR A, V66, P168, DOI 10.1107/S0108767309048181; Hargittai I., 1998, STEREOCHEMICAL APPL; Itatani J, 2004, NATURE, V432, P867, DOI 10.1038/nature03183; Li W, 2008, SCIENCE, V322, P1207, DOI 10.1126/science.1163077; Lin CD, 2010, J PHYS B-AT MOL OPT, V43, DOI 10.1088/0953-4075/43/12/122001; Meckel M, 2008, SCIENCE, V320, P1478, DOI 10.1126/science.1157980; Morishita T, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013903; Niikura H, 2002, NATURE, V417, P917, DOI 10.1038/nature00787; Okunishi M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.143001; Okunishi M, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.063001; Ray D, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.143002; Reckenthaeler P, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.213001; SCHAFER KJ, 1993, PHYS REV LETT, V70, P1599, DOI 10.1103/PhysRevLett.70.1599; Sciaini G, 2011, REP PROG PHYS, V74, DOI 10.1088/0034-4885/74/9/096101; Seibert MM, 2011, NATURE, V470, P78, DOI 10.1038/nature09748; Tate J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.013901; Torres R, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.051802; Xu JL, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.033403; Zewail A. H., 2010, 4D ELECT MICROSCOPY; Zewail AH, 2000, ANGEW CHEM INT EDIT, V39, P2587	29	457	463	8	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 8	2012	483	7388					194	197		10.1038/nature10820	http://dx.doi.org/10.1038/nature10820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904DT	22398558				2022-12-28	WOS:000301174900034
J	Hinton, JW; Cummings, JRF				Hinton, Jonathan W.; Cummings, J. R. Fraser			CASE REPORT A man with bloody diarrhoea	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SEVERE ULCERATIVE-COLITIS; MANAGEMENT		[Hinton, Jonathan W.; Cummings, J. R. Fraser] Southampton Univ Hosp NHS Trust, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Cummings, JRF (corresponding author), Southampton Univ Hosp NHS Trust, Southampton SO16 6YD, Hants, England.	fraser.cummings@suht.swest.nhs.uk						[Anonymous], 2010, BRIT NATL FORMULARY; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; Bojic D, 2009, INFLAMM BOWEL DIS, V15, P823, DOI 10.1002/ibd.20843; Carter MJ, 2004, GUT, V53, DOI 10.1136/gut.2004.043372; Collins P, 2006, BMJ-BRIT MED J, V333, P340, DOI 10.1136/bmj.333.7563.340; Cummings JRF, 2008, BMJ-BRIT MED J, V336, P1062, DOI 10.1136/bmj.39547.603218.AE; Daperno M, 2002, ALIMENT PHARM THER, V16, P7, DOI 10.1046/j.1365-2036.16.s4.2.x; Dinesen LC, 2010, J CROHNS COLITIS, V4, P431, DOI 10.1016/j.crohns.2010.02.001; Dunn DC, 1999, DUNNS SURG DIAGNOSIS; Hawthorne AB, 2002, GUT, V50, pA16; Lawson MM, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005112.PUB2; Longmore M., 2010, OXFORD HDB CLIN MED, V8th; Nayar M, 2004, POSTGRAD MED J, V80, P206, DOI 10.1136/pgmj.2003.013722; Shibolet O, 2005, COCHRANE DB SYST REV, V1; Solem CA, 2004, AM J GASTROENTEROL, V99, P97, DOI 10.1046/j.1572-0241.2003.04026.x; Travis SPL, 2008, J CROHNS COLITIS, V2, P24, DOI 10.1016/j.crohns.2007.11.002; Travis SPL, 1996, GUT, V38, P905, DOI 10.1136/gut.38.6.905; Travis SPL, 2005, POCKET CONSULTANT GA; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; Turner D, 2007, CLIN GASTROENTEROL H, V5, P103, DOI 10.1016/j.cgh.2006.09.033; Van Assche G, 2003, GASTROENTEROLOGY, V125, P1025, DOI 10.1016/S0016-5085(03)01214-9; Van Assche G, 2008, WORLD J GASTROENTERO, V14, P5508, DOI 10.3748/wjg.14.5508; Van Assche G, 2011, GUT, V60, P130, DOI 10.1136/gut.2009.192765; Waller D. G., 2005, MED PHARM THERAPEUTI	24	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2012	344								e978	10.1136/bmj.e978	http://dx.doi.org/10.1136/bmj.e978			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GV	22399714				2022-12-28	WOS:000301479800013
J	Schauer, PR; Kashyap, SR; Wolski, K; Brethauer, SA; Kirwan, JP; Pothier, CE; Thomas, S; Abood, B; Nissen, SE; Bhatt, DL				Schauer, Philip R.; Kashyap, Sangeeta R.; Wolski, Kathy; Brethauer, Stacy A.; Kirwan, John P.; Pothier, Claire E.; Thomas, Susan; Abood, Beth; Nissen, Steven E.; Bhatt, Deepak L.			Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; RISK-FACTORS; MELLITUS; MANAGEMENT; GLUCOSE	Background Observational studies have shown improvement in patients with type 2 diabetes mellitus after bariatric surgery. Methods In this randomized, nonblinded, single-center trial, we evaluated the efficacy of intensive medical therapy alone versus medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 obese patients with uncontrolled type 2 diabetes. The mean (+/- SD) age of the patients was 49 +/- 8 years, and 66% were women. The average glycated hemoglobin level was 9.2 +/- 1.5%. The primary end point was the proportion of patients with a glycated hemoglobin level of 6.0% or less 12 months after treatment. Results Of the 150 patients, 93% completed 12 months of follow-up. The proportion of patients with the primary end point was 12% (5 of 41 patients) in the medical-therapy group versus 42% (21 of 50 patients) in the gastric-bypass group (P = 0.002) and 37% (18 of 49 patients) in the sleeve-gastrectomy group (P = 0.008). Glycemic control improved in all three groups, with a mean glycated hemoglobin level of 7.5 +/- 1.8% in the medical-therapy group, 6.4 +/- 0.9% in the gastric-bypass group (P<0.001), and 6.6 +/- 1.0% in the sleeve-gastrectomy group (P = 0.003). Weight loss was greater in the gastric-bypass group and sleeve-gastrectomy group (-29.4 +/- 9.0 kg and -25.1 +/- 8.5 kg, respectively) than in the medical-therapy group (-5.4 +/- 8.0 kg) (P<0.001 for both comparisons). The use of drugs to lower glucose, lipid, and blood-pressure levels decreased significantly after both surgical procedures but increased in patients receiving medical therapy only. The index for homeostasis model assessment of insulin resistance (HOMA-IR) improved significantly after bariatric surgery. Four patients underwent reoperation. There were no deaths or life-threatening complications. Conclusions In obese patients with uncontrolled type 2 diabetes, 12 months of medical therapy plus bariatric surgery achieved glycemic control in significantly more patients than medical therapy alone. Further study will be necessary to assess the durability of these results. (Funded by Ethicon Endo-Surgery and others; ClinicalTrials.gov number, NCT00432809.)	[Schauer, Philip R.; Brethauer, Stacy A.; Thomas, Susan; Abood, Beth] Cleveland Clin, Bariatr & Metab Inst, Cleveland, OH 44195 USA; [Kashyap, Sangeeta R.] Cleveland Clin, Inst Endocrinol, Cleveland, OH 44195 USA; [Wolski, Kathy; Pothier, Claire E.] Cleveland Clin, Coordinating Ctr Clin Res, Cleveland, OH 44195 USA; [Nissen, Steven E.] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH 44195 USA; [Kirwan, John P.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA; [Bhatt, Deepak L.] Brigham & Womens Hosp, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA; [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Harvard Medical School	Schauer, PR (corresponding author), Cleveland Clin, Bariatr & Metab Inst, M61,9500 Euclid Ave, Cleveland, OH 44195 USA.	schauep@ccf.org	Kirwan, John P/G-6942-2012	Kashyap, Sangeeta/0000-0002-7489-6650; Schauer, Philip/0000-0002-4029-7537	Ethicon Endo-Surgery [EES IIS 19900]; National Institutes of Health, and LifeScan [R01-DK089547]; Ethicon Endo-Surgery; Stryker; Gore; Carefusion; Allergan; Cinemed; Quadrant Healthcare; Covidien; Nestle; ScottCare; Orexigen; Vivus; Amarin; Bristol-Myers Squibb; Eisai; Sanofi Aventis; Medtronic and the Medicines Company; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK089547] Funding Source: NIH RePORTER	Ethicon Endo-Surgery; National Institutes of Health, and LifeScan; Ethicon Endo-Surgery; Stryker; Gore; Carefusion; Allergan(AbbVieAllergan); Cinemed; Quadrant Healthcare; Covidien; Nestle(Nestle SA); ScottCare; Orexigen; Vivus; Amarin; Bristol-Myers Squibb(Bristol-Myers Squibb); Eisai(Eisai Co Ltd); Sanofi Aventis(Sanofi-Aventis); Medtronic and the Medicines Company; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by a grant (EES IIS 19900) from Ethicon Endo-Surgery, a grant (R01-DK089547) from the National Institutes of Health, and LifeScan.; Dr. Schauer reports receiving payment for board membership from Ethicon Endo-Surgery, Surgiquest, Barosense, RemedyMD, and Stryker, consulting fees from Ethicon Endo-Surgery, Stryker, Gore, and Carefusion, payment for expert testimony from Physicians Review of Surgery, and lecture fees from Ethicon Endo-Surgery, Allergan, Cinemed, and Quadrant Healthcare, holding a patent for a medical device to enhance weight loss in codevelopment with the Cleveland Clinic, royalties from Springer, having an equity interest in Intuitive Surgical, Barosense, Surgiquest, and RemedyMD, and receiving institutional grant support (to the Cleveland Clinic) from Ethicon Endo-Surgery and Bard Davol; Dr. Kashyap, receiving consulting fees from Ethicon; Dr. Brethauer, receiving consulting fees, lecture fees, and payment for board membership from Ethicon Endo-Surgery and lecture fees from Covidien; Dr. Kirwan, receiving grant support from Nestle and ScottCare; Dr. Nissen, receiving institutional grant support (to the Cleveland Clinic) from Orexigen and Vivus; and Dr. Bhatt, receiving institutional grant support (to Brigham and Women's Hospital) from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, and Sanofi Aventis and from Medtronic and the Medicines Company (to Boston VA Research Institute) and serving as the international principal investigator for the CRESCENDO cardiovascular outcome trial of the weight-loss drug rimonabant versus placebo. The Cleveland Clinic had received a grant from Sanofi Aventis for the CRESCENDO trial. No other potential conflict of interest relevant to this article was reported.	Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041; Cummings David E, 2005, Surg Obes Relat Dis, V1, P358, DOI 10.1016/j.soard.2005.03.208; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Dixon JB, 2008, JAMA-J AM MED ASSOC, V299, P316, DOI 10.1001/jama.299.3.316; Eldar S, 2011, SURG-J R COLL SURG E, V9, P273, DOI 10.1016/j.surge.2011.04.002; Espeland M, 2007, DIABETES CARE, V30, P1374; Flum DR, 2009, NEW ENGL J MED, V361, P445, DOI 10.1056/NEJMoa0901836; Gill RS, 2010, SURG OBES RELAT DIS, V6, P707, DOI 10.1016/j.soard.2010.07.011; Kashyap S. R., 2010, International Journal of Obesity, V34, P462, DOI 10.1038/ijo.2009.254; Kashyap SR, 2010, DIABETES OBES METAB, V12, P452, DOI 10.1111/j.1463-1326.2009.01172.x; Korner J, 2007, SURG OBES RELAT DIS, V3, P597, DOI 10.1016/j.soard.2007.08.004; Laferrere B, 2007, DIABETES CARE, V30, P1709, DOI 10.2337/dc06-1549; Lee WJ, 2011, ARCH SURG-CHICAGO, V146, P143, DOI 10.1001/archsurg.2010.326; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335; Schauer PR, 2003, ANN SURG, V238, P467, DOI 10.1097/01.sla.0000089851.41115.1b; Schauer PR, 2003, J LAPAROENDOSC ADV A, V13, P229, DOI 10.1089/109264203322333557; Scopinaro N, 2005, DIABETES CARE, V28, P2406, DOI 10.2337/diacare.28.10.2406; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622	22	1499	1601	3	200	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2012	366	17					1567	1576		10.1056/NEJMoa1200225	http://dx.doi.org/10.1056/NEJMoa1200225			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931FC	22449319	Green Accepted			2022-12-28	WOS:000303200100005
J	Weintraub, WS; Grau-Sepulveda, MV; Weiss, JM; O'Brien, SM; Peterson, ED; Kolm, P; Zhang, ZG; Klein, LW; Shaw, RE; McKay, C; Ritzenthaler, LL; Popma, JJ; Messenger, JC; Shahian, DM; Grover, FL; Mayer, JE; Shewan, CM; Garratt, KN; Moussa, ID; Dangas, GD; Edwards, FH				Weintraub, William S.; Grau-Sepulveda, Maria V.; Weiss, Jocelyn M.; O'Brien, Sean M.; Peterson, Eric D.; Kolm, Paul; Zhang, Zugui; Klein, Lloyd W.; Shaw, Richard E.; McKay, Charles; Ritzenthaler, Laura L.; Popma, Jeffrey J.; Messenger, John C.; Shahian, David M.; Grover, Frederick L.; Mayer, John E.; Shewan, Cynthia M.; Garratt, Kirk N.; Moussa, Issam D.; Dangas, George D.; Edwards, Fred H.			Comparative Effectiveness of Revascularization Strategies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY-BYPASS-SURGERY; PERCUTANEOUS CORONARY INTERVENTION; FOLLOW-UP; MULTIVESSEL DISEASE; RANDOMIZED-TRIAL; ANGIOPLASTY; SELECTION; SURVIVAL; OUTCOMES; STENTS	Background Questions persist concerning the comparative effectiveness of percutaneous coronary intervention (PCI) and coronary-artery bypass grafting (CABG). The American College of Cardiology Foundation (ACCF) and the Society of Thoracic Surgeons (STS) collaborated to compare the rates of long-term survival after PCI and CABG. Methods We linked the ACCF National Cardiovascular Data Registry and the STS Adult Cardiac Surgery Database to claims data from the Centers for Medicare and Medicaid Services for the years 2004 through 2008. Outcomes were compared with the use of propensity scores and inverse-probability-weighting adjustment to reduce treatment-selection bias. Results Among patients 65 years of age or older who had two-vessel or three-vessel coronary artery disease without acute myocardial infarction, 86,244 underwent CABG and 103,549 underwent PCI. The median follow-up period was 2.67 years. At 1 year, there was no significant difference in adjusted mortality between the groups (6.24% in the CABG group as compared with 6.55% in the PCI group; risk ratio, 0.95; 95% confidence interval [CI], 0.90 to 1.00). At 4 years, there was lower mortality with CABG than with PCI (16.4% vs. 20.8%; risk ratio, 0.79; 95% CI, 0.76 to 0.82). Similar results were noted in multiple subgroups and with the use of several different analytic methods. Residual confounding was assessed by means of a sensitivity analysis. Conclusions In this observational study, we found that, among older patients with multivessel coronary disease that did not require emergency treatment, there was a long-term survival advantage among patients who underwent CABG as compared with patients who underwent PCI. (Funded by the National Heart, Lung, and Blood Institute.)	[Weintraub, William S.] Christiana Care Hlth Syst, Cardiol Sect, Newark, DE 19718 USA; [Grau-Sepulveda, Maria V.; O'Brien, Sean M.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA; [Weiss, Jocelyn M.; Ritzenthaler, Laura L.] Amer Coll Cardiol, Washington, DC USA; [Klein, Lloyd W.] Advocate Illinois Masonic Med Ctr, Chicago, IL USA; [Shewan, Cynthia M.] Soc Thorac Surg, Chicago, IL USA; [Shaw, Richard E.] Calif Pacific Med Ctr, San Francisco, CA USA; [McKay, Charles] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Shahian, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Popma, Jeffrey J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Mayer, John E.] Childrens Hosp, Boston, MA 02115 USA; [Messenger, John C.; Grover, Frederick L.] Univ Colorado, Sch Med, Aurora, CO USA; [Grover, Frederick L.] Denver Vet Affairs Med Ctr, Denver, CO USA; [Garratt, Kirk N.] Lenox Hill Heart & Vasc Inst New York, New York, NY USA; [Dangas, George D.] Mt Sinai Med Ctr, New York, NY 10029 USA; [Moussa, Issam D.] Mayo Clin, Jacksonville, FL USA; [Edwards, Fred H.] Univ Florida, Jacksonville, FL USA	Christiana Care Health System; Duke University; American College of Cardiology; Society of Thoracic Surgeons; California Pacific Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Lenox Hill Heart & Vascular Institute of New York; Icahn School of Medicine at Mount Sinai; Mayo Clinic; State University System of Florida; University of Florida	Weintraub, WS (corresponding author), Christiana Care Hlth Syst, Cardiol Sect, 4755 Ogletown Stanton Rd, Newark, DE 19718 USA.	wweintraub@christianacare.org	Barkema, Herman/B-9583-2008; Schukken, Ynte H/C-3405-2008; 刘, 李陆/H-8469-2015; Peterson, Eric David/ABF-5033-2021; O'Brien, Sean/H-6268-2013; Mayer, Jiri/I-2377-2014; Schukken, Ynte/ABD-3352-2021	Barkema, Herman/0000-0002-9678-8378; Schukken, Ynte H/0000-0002-8250-4194; Schukken, Ynte/0000-0002-8250-4194	National Heart, Lung, and Blood Institute [RC2HL101489]; Abbott Vascular; Boston Scientific; Covidien; Abiomed; Cordis; Medtronic; AstraZeneca; Eli Lilly; Johnson Johnson; Ogilvy; Bristol-Myers Squibb; Daichi-Sankyo; Medicines Company; Sanofi-Aventis; Bracco; Guerbet; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101489] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Abbott Vascular(Abbott Laboratories); Boston Scientific(Boston Scientific); Covidien; Abiomed; Cordis; Medtronic(Medtronic); AstraZeneca(AstraZeneca); Eli Lilly(Eli Lilly); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Ogilvy; Bristol-Myers Squibb(Bristol-Myers Squibb); Daichi-Sankyo; Medicines Company; Sanofi-Aventis(Sanofi-Aventis); Bracco; Guerbet; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant (RC2HL101489) from the National Heart, Lung, and Blood Institute.; Dr. Popma reports receiving consulting fees from Abbott Vascular, Boston Scientific, and Covidien and grant support from Abbott Vascular, Abiomed, Boston Scientific, Cordis, and Medtronic; Dr. Messenger, receiving grant support from Medtronic; Dr. Mayer, receiving honoraria and reimbursement for travel expenses from CHMC Cardiovascular Surgical Foundation; Dr. Dangas, receiving consulting fees from Abbott Vascular, AstraZeneca, Eli Lilly, Johnson & Johnson, and Ogilvy, providing expert testimony regarding stroke in a patient after cardioversion for atrial fibrillation and regarding infection after heart-valve implantation, and receiving grant support from Bristol-Myers Squibb, Eli Lilly, Daichi-Sankyo, the Medicines Company, and Sanofi-Aventis, lecture fees from Abbott Vascular, AstraZeneca, Boston Scientific, Bracco, Bristol-Myers Squibb, Guerbet, Eli Lilly, Johnson & Johnson, the Medicines Company, and Sanofi-Aventis, royalties from Wiley and Informa, and reimbursement for travel expenses from the Cardiovascular Research Foundation; and Dr. Edwards, being an employee of the Society of Thoracic Surgeons. No other potential conflict of interest relevant to this article was reported.	Alderman EL, 1996, NEW ENGL J MED, V335, P217; Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122; Booth J, 2008, CIRCULATION, V118, P381, DOI 10.1161/CIRCULATIONAHA.107.739144; Brener SJ, 2004, CIRCULATION, V109, P2290, DOI 10.1161/01.CIR.0000126826.58526.14; Carrie D, 1997, CIRCULATION, V96, P1; Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004; Curtis LH, 2007, MED CARE, V45, pS103, DOI 10.1097/MLR.0b013e31806518ac; Douglas PS, 2009, J AM COLL CARDIOL, V53, P1629, DOI 10.1016/j.jacc.2009.03.005; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Hannan EL, 2008, NEW ENGL J MED, V358, P331, DOI 10.1056/NEJMoa071804; Hannan EL, 2005, NEW ENGL J MED, V352, P2174, DOI 10.1056/NEJMoa040316; Hirano K., 2001, HLTH SERVICES OUTCOM, V2, P259, DOI [10.1023/A:1020371312283, DOI 10.1023/A:1020371312283]; Hlatky MA, 2009, LANCET, V373, P1190, DOI 10.1016/S0140-6736(09)60552-3; Hueb W, 2007, CIRCULATION, V115, P1082, DOI 10.1161/CIRCULATIONAHA.106.625475; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kappetein AP, 2011, EUR HEART J, V32, P2125, DOI 10.1093/eurheartj/ehr213; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Malenka DJ, 2005, CIRCULATION, V112, pI371, DOI 10.1161/CIRCULATIONAHA.104.526392; McNulty EJ, 2011, JACC-CARDIOVASC INTE, V4, P1020, DOI 10.1016/j.jcin.2011.06.010; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P973; ROSENBAUM PR, 1987, J AM STAT ASSOC, V82, P387, DOI 10.2307/2289440; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Sigwart U, 2002, LANCET, V360, P965; Singh M, 2011, CIRC-CARDIOVASC QUAL, V4, P496, DOI 10.1161/CIRCOUTCOMES.111.961375; Smith PK, 2006, ANN THORAC SURG, V82, P1420, DOI 10.1016/j.athoracsur.2006.04.044; The Bypass Angioplasty Revascularization Investigation (BARI) Investigators, 1997, NEW ENGL J MED, V336, P147; Therneau TM, 2000, MODELING SURVIVAL DA; van Domburg RT, 2005, ANN THORAC SURG, V79, P1563, DOI 10.1016/j.athoracsur.2004.11.031	34	410	442	3	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2012	366	16					1467	1476		10.1056/NEJMoa1110717	http://dx.doi.org/10.1056/NEJMoa1110717			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927UE	22452338	Green Accepted			2022-12-28	WOS:000302934800004
J	Han, JM; Jeong, SJ; Park, MC; Kim, G; Kwon, NH; Kim, HK; Ha, SH; Ryu, SH; Kim, S				Han, Jung Min; Jeong, Seung Jae; Park, Min Chul; Kim, Gyuyoup; Kwon, Nam Hoon; Kim, Hoi Kyoung; Ha, Sang Hoon; Ryu, Sung Ho; Kim, Sunghoon			Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway	CELL			English	Article							GTP-BINDING PROTEINS; AMINO-ACIDS; MAMMALIAN TARGET; CRYSTAL-STRUCTURE; RAG GTPASES; COMPLEX; MTOR; SEQUENCE; RAPAMYCIN; TRANSLATION	Amino acids are required for activation of the mammalian target of rapamycin (mTOR) kinase, which regulates protein translation, cell size, and autophagy. However, the amino acid sensor that directly couples intracellular amino acid-mediated signaling to mTORC1 is unknown. Here we show that leucyl-tRNA synthetase (LRS) plays a critical role in amino acid-induced mTORC1 activation by sensing intracellular leucine concentration and initiating molecular events leading to mTORC1 activation. Mutation of LRS amino acid residues important for leucine binding renders the mTORC1 pathway insensitive to intracellular levels of amino acids. We show that LRS directly binds to Rag GTPase, the mediator of amino acid signaling to mTORC1, in an amino acid-dependent manner and functions as a GTPase-activating protein (GAP) for Rag GTPase to activate mTORC1. This work demonstrates that LRS is a key mediator for amino acid signaling to mTORC1.	[Han, Jung Min; Jeong, Seung Jae; Park, Min Chul; Kim, Gyuyoup; Kwon, Nam Hoon; Kim, Hoi Kyoung; Kim, Sunghoon] Seoul Natl Univ, Med Bioconvergence Res Ctr, Seoul 151742, South Korea; [Ha, Sang Hoon; Ryu, Sung Ho] POSTECH, Div Mol & Life Sci, Pohang 790784, South Korea; [Kim, Sunghoon] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, WCU Dept Mol Med & Biopharmaceut Sci, Suwon 443270, South Korea	Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Kim, S (corresponding author), Seoul Natl Univ, Med Bioconvergence Res Ctr, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020	kim, sunghoon/0000-0002-1570-3230; Ryu, Sung Ho/0000-0003-0913-3048; Kim, Gyuyoup/0000-0002-4261-9958; Han, Jung Min/0000-0003-3372-7575	Global Frontier Project [NRF-M1AXA002-2011-0028417]; WCU of the MEST [R31-2008-000-10103-0]	Global Frontier Project; WCU of the MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank D. M. Sabatini, Y. Sancak, and J. Chung for advice. This work was supported by the Global Frontier Project grant NRF-M1AXA002-2011-0028417 and by R31-2008-000-10103-0 from the WCU project of the MEST. J. M. H., conception and design, collection and analysis of data, manuscript writing, final approval of manuscript; S. J. J., M. C. P., G. K., N.H.K., H. K. K., and S. H. H., collection and analysis of data; S. H. R, conception and design; S. K., conception and design, financial support, manuscript writing, and final approval of manuscript.	Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; AUSTIN SA, 1986, EUR J BIOCHEM, V157, P39, DOI 10.1111/j.1432-1033.1986.tb09635.x; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Binda M, 2009, MOL CELL, V35, P563, DOI 10.1016/j.molcel.2009.06.033; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Chen X, 2011, NUCLEIC ACIDS RES, V39, P235, DOI 10.1093/nar/gkq763; Crozier SJ, 2005, J NUTR, V135, P376, DOI 10.1093/jn/135.3.376; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Ling C, 2005, J BIOL CHEM, V280, P34755, DOI 10.1074/jbc.M413511200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Park SG, 2008, P NATL ACAD SCI USA, V105, P11043, DOI 10.1073/pnas.0802862105; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; ROUGET P, 1968, EUR J BIOCHEM, V4, P310, DOI 10.1111/j.1432-1033.1968.tb00210.x; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Stipanuk MH, 2007, NUTR REV, V65, P122, DOI [10.1301/nr.2007.mar.122-129, 10.1111/j.1753-4887.2007.tb00289.x]; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tukalo M, 2005, NAT STRUCT MOL BIOL, V12, P923, DOI 10.1038/nsmb986; Tzima E, 2005, J BIOL CHEM, V280, P2405, DOI 10.1074/jbc.C400431200; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009; Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200; Xin Y, 2000, BIOCHEMISTRY-US, V39, P340, DOI 10.1021/bi991675l; Zhou QS, 2010, NAT STRUCT MOL BIOL, V17, P57, DOI 10.1038/nsmb.1706	41	542	580	3	81	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 13	2012	149	2					410	424		10.1016/j.cell.2012.02.044	http://dx.doi.org/10.1016/j.cell.2012.02.044			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	926BF	22424946	Bronze			2022-12-28	WOS:000302805600019
J	Lomstein, BA; Langerhuus, AT; D'Hondt, S; Jorgensen, BB; Spivack, AJ				Lomstein, Bente Aa; Langerhuus, Alice T.; D'Hondt, Steven; Jorgensen, Bo B.; Spivack, Arthur J.			Endospore abundance, microbial growth and necromass turnover in deep sub-seafloor sediment	NATURE			English	Article							AMINO-ACIDS; PERU MARGIN; SUBSEAFLOOR; BACTERIA; MAJORITY; BIOMASS	Two decades of scientific ocean drilling have demonstrated widespread microbial life in deep sub-seafloor sediment, and surprisingly high microbial-cell numbers. Despite the ubiquity of life in the deep biosphere, the large community sizes and the low energy fluxes in this vast buried ecosystemare not yet understood(1,2). It is not known whether organisms of the deep biosphere are specifically adapted to extremely low energy fluxes or whether most of the observed cells are in a dormant, spore-like state(3). Here we apply a new approach-the D:L-amino-acid model-to quantify the distributions and turnover times of living microbial biomass, endospores and microbial necromass, as well as to determine their role in the sub-seafloor carbon budget. The approach combines sensitive analyses of unique bacterial markers (muramic acid and D-amino acids) and the bacterial endospore marker, dipicolinic acid, with racemization dynamics of stereo-isomeric amino acids. Endospores are as abundant as vegetative cells and microbial activity is extremely low, leading to microbial biomass turnover times of hundreds to thousands of years. We infer from model calculations that biomass production is sustained by organic carbon deposited from the surface photosynthetic world millions of years ago and that microbial necromass is recycled over timescales of hundreds of thousands of years.	[Lomstein, Bente Aa; Langerhuus, Alice T.] Aarhus Univ, Microbiol Sect, Dept Biosci, DK-8000 Aarhus C, Denmark; [D'Hondt, Steven; Spivack, Arthur J.] Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; [Jorgensen, Bo B.] Aarhus Univ, Dept Biosci, Ctr Geomicrobiol, DK-8000 Aarhus C, Denmark	Aarhus University; University of Rhode Island; Aarhus University	Lomstein, BA (corresponding author), Aarhus Univ, Microbiol Sect, Dept Biosci, Bldg 1540,Ny Munkegade 114, DK-8000 Aarhus C, Denmark.	bente.lomstein@biology.au.dk	Lomstein, Bente/I-7684-2013; Jorgensen, Bo B/C-2214-2013	Jorgensen, Bo B/0000-0001-9398-8027	US National Science Foundation; Max Planck Society; Danish National Research Foundation; Danish National Science Research Council; Danish Agency for Science, Technology and Innovation; Faculty of Science and Technology at the University of Aarhus	US National Science Foundation(National Science Foundation (NSF)); Max Planck Society(Max Planck Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish National Science Research Council; Danish Agency for Science, Technology and Innovation; Faculty of Science and Technology at the University of Aarhus	Bacterial cultures were provided by H. Cypionka. We thank members of the Leg 201 cruise for assistance in obtaining and processing samples. This research used samples and data provided by the Ocean Drilling Program (http://www-odp.tamu.edu/publications/201_IR/201ir.htm). The ODP was sponsored by the US National Science Foundation and participating countries under the management of Joint Oceanographic Institutions. We thank R. O. Holm and L. Poulsen for technical assistance and guidance with high-performance liquid chromatographic analyses. We thank D. L. Valentine for comments and suggestions to improve the manuscript. Financial support was provided by the Max Planck Society, the Danish National Research Foundation, the Danish National Science Research Council, the Danish Agency for Science, Technology and Innovation, the Faculty of Science and Technology at the University of Aarhus, and the US National Science Foundation.	BADA JL, 1982, INTERDISCIPL SCI REV, V7, P30, DOI 10.1179/030801882789801304; Biddle JF, 2008, P NATL ACAD SCI USA, V105, P10583, DOI 10.1073/pnas.0709942105; D'Hondt S, 2004, SCIENCE, V306, P2216, DOI 10.1126/science.1101155; D'Hondt S.L., 2003, INITIAL REPORTS, V201, P1, DOI DOI 10.2973/ODP.PROC.IR.201.111.2003; ER C, 1987, GEOMICROBIOL J, V5, P57, DOI 10.1080/01490458709385957; Fichtel J, 2007, FEMS MICROBIOL ECOL, V61, P522, DOI 10.1111/j.1574-6941.2007.00354.x; HARTGERS WA, 1994, NATURE, V369, P224, DOI 10.1038/369224a0; HEIJNEN JJ, 1992, BIOTECHNOL BIOENG, V39, P833, DOI 10.1002/bit.260390806; HSIEH LK, 1975, J BACTERIOL, V123, P463, DOI 10.1128/JB.123.2.463-470.1975; JORGENSEN BB, 2006, P OCEAN DRILLING PRO, V0201; Jorgensen BB, 2006, SCIENCE, V314, P932, DOI 10.1126/science.1133796; Leloup J, 2009, ENVIRON MICROBIOL, V11, P1278, DOI 10.1111/j.1462-2920.2008.01855.x; Lipp JS, 2008, NATURE, V454, P991, DOI 10.1038/nature07174; Lomstein B. A., LIMNOL OCEA IN PRESS; Lomstein BA, 2006, GEOCHIM COSMOCHIM AC, V70, P2970, DOI 10.1016/j.gca.2006.03.015; Lomstein BA, 2009, LIMNOL OCEANOGR, V54, P1139, DOI 10.4319/lo.2009.54.4.1139; Madigan M. T., 2006, BROCK BIOL MICROORG; PARKES RJ, 1993, MAR GEOL, V113, P55, DOI 10.1016/0025-3227(93)90149-P; Schichnes Denise, 2006, Microscope, V54, P91; Schippers A, 2005, NATURE, V433, P861, DOI 10.1038/nature03302; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schrenk MO, 2010, ANNU REV MAR SCI, V2, P279, DOI 10.1146/annurev-marine-120308-081000; Takano Y, 2003, ORG GEOCHEM, V34, P1491, DOI 10.1016/S0146-6380(03)00175-X; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578	24	210	213	5	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					101	104		10.1038/nature10905	http://dx.doi.org/10.1038/nature10905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22425999				2022-12-28	WOS:000302343400042
J	Friedlander, M				Friedlander, Michael			A century of cosmic rays	NATURE			English	Editorial Material									Washington Univ, Dept Phys, St Louis, MO 63130 USA	Washington University (WUSTL)	Friedlander, M (corresponding author), Washington Univ, Dept Phys, St Louis, MO 63130 USA.	mwf@wuphys.wustl.edu						DAVIES JH, 1955, IL NUOVO CIMENTO, V2, P1063	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					400	401		10.1038/483400a	http://dx.doi.org/10.1038/483400a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437594	Bronze			2022-12-28	WOS:000301771200016
J	Koopman, WJH; Willems, PHGM; Smeitink, JAM				Koopman, Werner J. H.; Willems, Peter H. G. M.; Smeitink, Jan A. M.			Monogenic Mitochondrial Disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UBIQUINONE OXIDOREDUCTASE DEFICIENCY; COMPLEX-I DEFICIENCY; MOUSE MODELS; HUMAN NADH; DYSFUNCTION; DISEASE; APOPTOSIS; MECHANISMS; MICE; CYCLOSPORINE		[Smeitink, Jan A. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands; [Koopman, Werner J. H.; Willems, Peter H. G. M.] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Smeitink, JAM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Geert Grootepl Zuid 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.smeitink@cukz.umcn.nl	Willems, P.H.G.M./L-4759-2015; Smeitink, Jan/C-1351-2013; Koopman, Werner J.H./D-3592-2009; Koopman, Werner J.H./AAC-9668-2020	Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747				Angelin A, 2007, P NATL ACAD SCI USA, V104, P991, DOI 10.1073/pnas.0610270104; Azzu V, 2010, TRENDS BIOCHEM SCI, V35, P298, DOI 10.1016/j.tibs.2009.11.001; Bastin J, 2011, HUM MOL GENET, V20, P2048, DOI 10.1093/hmg/ddr089; Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000; Benit P, 2010, TRENDS MOL MED, V16, P210, DOI 10.1016/j.molmed.2010.03.001; Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983; Blanchet L, 2011, CURR PHARM DESIGN, V17, P4023, DOI 10.2174/138161211798764870; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Camara AKS, 2010, ANTIOXID REDOX SIGN, V13, P279, DOI 10.1089/ars.2009.2788; Cardoso AR, 2010, BBA-BIOENERGETICS, V1797, P832, DOI 10.1016/j.bbabio.2009.12.017; Chacko BK, 2010, BIOCHEM J, V432, P9, DOI 10.1042/BJ20100308; Chinnery P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub2; Cohen BH, 2010, DEV DISABIL RES REV, V16, P189, DOI 10.1002/ddrr.106; Cortassa S, 2004, BIOPHYS J, V87, P2060, DOI 10.1529/biophysj.104.041749; Coskun P, 2011, BIOCH BIOPHYS A 0816; Craven L, 2011, HUM MOL GENET, V20, pR168, DOI 10.1093/hmg/ddr373; Dieteren CEJ, 2011, P NATL ACAD SCI USA, V108, P8657, DOI 10.1073/pnas.1017581108; DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302; DiMauro S, 2009, BBA-MOL BASIS DIS, V1792, P1159, DOI 10.1016/j.bbadis.2008.10.015; Distelmaier F, 2008, CYTOM PART A, V73A, P129, DOI 10.1002/cyto.a.20503; Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058; Erol A, 2011, CELL SIGNAL, V23, P1076, DOI 10.1016/j.cellsig.2010.11.023; Finsterer J, 2010, DRUG CHEM TOXICOL, V33, P138, DOI 10.3109/01480540903207076; Forkink M, 2010, BBA-BIOENERGETICS, V1797, P1034, DOI 10.1016/j.bbabio.2010.01.022; Gredilla R, 2010, EXP GERONTOL, V45, P478, DOI 10.1016/j.exger.2010.01.017; Hoppel CL, 2009, INT J BIOCHEM CELL B, V41, P1949, DOI 10.1016/j.biocel.2009.05.004; Imamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x; Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170; Koene S, 2011, J INHERIT METAB DIS, V34, P293, DOI 10.1007/s10545-009-9005-x; Koene S, 2011, J INHERIT METAB DIS, V34, P315, DOI 10.1007/s10545-010-9162-y; Koopman WJH, 2008, BBA-BIOENERGETICS, V1777, P853, DOI 10.1016/j.bbabio.2008.03.028; Koopman WJH, 2007, AM J PHYSIOL-CELL PH, V293, pC22, DOI 10.1152/ajpcell.00194.2006; Koopman Werner J H, 2010, Antioxid Redox Signal, V12, P1431, DOI 10.1089/ars.2009.2743; Koopman WJH, 2008, METHODS, V46, P304, DOI 10.1016/j.ymeth.2008.09.018; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V289, pC881, DOI 10.1152/ajpcell.00104.2005; Kourtis N, 2011, EMBO J, V30, P2520, DOI 10.1038/emboj.2011.162; Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004; Lonnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; McCoy MK, 2011, ANTIOXID REDOX  0707; Merlini L, 2008, P NATL ACAD SCI USA, V105, P5225, DOI 10.1073/pnas.0800962105; Mochel F, 2011, J CLIN INVEST, V121, P493, DOI 10.1172/JCI45691; Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54; Murphy MP, 2011, CELL METAB, V13, P361, DOI 10.1016/j.cmet.2011.03.010; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Picard M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018317; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Rapoport M, 2011, J MOL MED, V89, P161, DOI 10.1007/s00109-010-0693-3; Roestenberg P, 2012, MITOCHONDRION, V12, P57, DOI 10.1016/j.mito.2011.06.011; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Schiff M, 2011, NUTR REV, V69, P65, DOI 10.1111/j.1753-4887.2010.00363.x; Schmidt S, 2011, HUM MOL GENET, V20, P1197, DOI 10.1093/hmg/ddq564; Shokolenko IN, 2010, ENVIRON MOL MUTAGEN, V51, P451, DOI 10.1002/em.20570; Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571; Skulachev MV, 2011, CURR DRUG TARGETS, V12, P800; Sleigh A, 2011, J CLIN INVEST, V121, P2457, DOI 10.1172/JCI46405; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969; Spencer SL, 2011, CELL, V144, P926, DOI 10.1016/j.cell.2011.03.002; Stacpoole PW, 2011, MITOCHONDRION, V11, P679, DOI 10.1016/j.mito.2011.05.002; Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354; Swerdlow RH, 2011, ANTIOXID REDOX  0525; Swerdlow RH, 2009, PHARMACEUTICALS-BASE, V2, P150, DOI 10.3390/ph2030150; Tseng YH, 2010, NAT REV DRUG DISCOV, V9, P465, DOI 10.1038/nrd3138; Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779; Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242; Valsecchi F, 2010, DEV DISABIL RES REV, V16, P175, DOI 10.1002/ddrr.107; Verkaart S, 2007, BBA-MOL BASIS DIS, V1772, P1041, DOI 10.1016/j.bbadis.2007.05.004; Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314; Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909; Wang C, 2011, EXPERT OPIN THER TAR, V15, P647, DOI 10.1517/14728222.2011.561321; Wenz T, 2010, DEV DISABIL RES REV, V16, P219, DOI 10.1002/ddrr.109; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Won YW, 2011, J CONTROL RELEASE, V152, P99, DOI 10.1016/j.jconrel.2011.01.013; Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Yousif LF, 2009, CHEMBIOCHEM, V10, P2081, DOI 10.1002/cbic.200900017; Zanella F, 2010, TRENDS BIOTECHNOL, V28, P237, DOI 10.1016/j.tibtech.2010.02.005; Zhang EL, 2011, DRUG DISCOV TODAY, V16, P140, DOI 10.1016/j.drudis.2010.12.006	86	337	350	6	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1132	1141		10.1056/NEJMra1012478	http://dx.doi.org/10.1056/NEJMra1012478			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435372	Green Published			2022-12-28	WOS:000301769700012
J	Marazzi, I; Ho, JSY; Kim, J; Manicassamy, B; Dewell, S; Albrecht, RA; Seibert, CW; Schaefer, U; Jeffrey, KL; Prinjha, RK; Lee, K; Garcia-Sastre, A; Roeder, RG; Tarakhovsky, A				Marazzi, Ivan; Ho, Jessica S. Y.; Kim, Jaehoon; Manicassamy, Balaji; Dewell, Scott; Albrecht, Randy A.; Seibert, Chris W.; Schaefer, Uwe; Jeffrey, Kate L.; Prinjha, Rab K.; Lee, Kevin; Garcia-Sastre, Adolfo; Roeder, Robert G.; Tarakhovsky, Alexander			Suppression of the antiviral response by an influenza histone mimic	NATURE			English	Article							VIRUS NS1 PROTEIN; RNA-POLYMERASE; PAF1 COMPLEX; TRANSCRIPTION ELONGATION; CHROMATIN; H3; METHYLATION; LYSINE-4; BINDING; ACETYLATION	Viral infection is commonly associated with virus-driven hijacking of host proteins. Here we describe a novel mechanism by which influenza virus affects host cells through the interaction of influenza non-structural protein 1 (NS1) with the infected cell epigenome. We show that the NS1 protein of influenza A H3N2 subtype possesses a histone-like sequence (histone mimic) that is used by the virus to target the human PAF1 transcription elongation complex (hPAF1C). We demonstrate that binding of NS1 to hPAF1C depends on the NS1 histone mimic and results in suppression of hPAF1C-mediated transcriptional elongation. Furthermore, human PAF1 has a crucial role in the antiviral response. Loss of hPAF1C binding by NS1 attenuates influenza infection, whereas hPAF1C deficiency reduces antiviral gene expression and renders cells more susceptible to viruses. We propose that the histone mimic in NS1 enables the influenza virus to affect inducible gene expression selectively, thus contributing to suppression of the antiviral response.	[Marazzi, Ivan; Ho, Jessica S. Y.; Schaefer, Uwe; Jeffrey, Kate L.; Tarakhovsky, Alexander] Rockefeller Univ, Lab Immune Cell Epigenet & Signaling, New York, NY 10065 USA; [Kim, Jaehoon; Roeder, Robert G.] Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10065 USA; [Manicassamy, Balaji; Albrecht, Randy A.; Seibert, Chris W.; Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Manicassamy, Balaji; Albrecht, Randy A.; Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Global Hlth & Infect Pathogens Inst, New York, NY 10029 USA; [Dewell, Scott] Rockefeller Univ, Genom Resource Ctr, New York, NY 10065 USA; [Prinjha, Rab K.; Lee, Kevin] GlaxoSmithKline, Immunoinflammat Ctr Excellence Drug Discovery, Epinova DPU, Med Res Ctr, Stevenage SG1 2NY, Herts, England; [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Div Infect Dis, Dept Med, New York, NY 10029 USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; GlaxoSmithKline; Icahn School of Medicine at Mount Sinai	Marazzi, I (corresponding author), Rockefeller Univ, Lab Immune Cell Epigenet & Signaling, 1230 York Ave, New York, NY 10065 USA.	imarazzi@rockefeller.edu; tarakho@rockefeller.edu	Albrecht, Randy A./H-5119-2019; Kim, Jaehoon/G-2711-2011	Albrecht, Randy A./0000-0003-4008-503X; Kim, Jaehoon/0000-0003-4035-0438; Garcia-Sastre, Adolfo/0000-0002-6551-1827; marazzi, ivan/0000-0003-3376-0922; Jeffrey, Kate/0000-0001-5746-0153; Manicassamy, Balaji/0000-0003-1964-0967; Ho, Jessica Sook Yuin/0000-0003-2234-2602	NIH/NIAID [1K99AI095320-01]; NIAID [R01AI046954, U19AI083025, HHSN266200700010C]; CRIP (Center for Research in Influenza Pathogenesis); NIH [CA129325, R01AI068058]; Charles H. Revson Foundation; American Italian Cancer Foundation; Agency for Science, Technology and Research (A*STAR), Singapore; Starr Cancer Consortium; NATIONAL CANCER INSTITUTE [R01CA129325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI083025, R01AI068058, R01AI046954, K99AI095320] Funding Source: NIH RePORTER	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CRIP (Center for Research in Influenza Pathogenesis); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles H. Revson Foundation; American Italian Cancer Foundation; Agency for Science, Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR)); Starr Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank P. deGross and A. Rudensky for the mass spectroscopy analysis of the NS1 binding proteins. A. Rojas Soto, D. Reinberg, M. Dobenecker and T. Zhanyun provided us with recombinant CHD1 (A. R. S., D. R.), recombinant Set7/9 (M. D.) and Set1C (T.Z.). F. Casadio, P. Lewis, O. Binda, O. Gozani, N. Levenkova, A. Mele, R. Darnell, L. Core, J. Lis and P. Palese gave us valuable technical advice and help with data analysis. We acknowledge the Rockefeller University Genomics Resource Center for technical support. We thank R. Cadagan, A. Santana, W. Huang, R. Chandramouli and H. Zebronsky for technical assistance, R. Rizzo for help with manuscript preparation and C. Nathan for discussion. L. M. K. for artwork. B.M is supported by NIH/NIAID K99 Pathway to Independence award (1K99AI095320-01). A.G.-S. is partially supported by NIAID grants R01AI046954, U19AI083025 and by CRIP (Center for Research in Influenza Pathogenesis), an NIAID funded Center of Excellence for Influenza Research and Surveillance, HHSN266200700010C. R. G. R. is supported by NIH grant CA129325. J. K. is supported by Charles H. Revson Foundation. I. M. is supported by American Italian Cancer Foundation. J. H. is supported by the Agency for Science, Technology and Research (A*STAR), Singapore. A. T. is supported by the NIH grant R01AI068058 and by Starr Cancer Consortium.	Becker P. B., 2007, BMC MOL BIOL, V8; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Chen YX, 2009, GENE DEV, V23, P2765, DOI 10.1101/gad.1834709; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Das K, 2008, P NATL ACAD SCI USA, V105, P13093, DOI 10.1073/pnas.0805213105; Elde NC, 2009, NAT REV MICROBIOL, V7, P787, DOI 10.1038/nrmicro2222; Engelhardt OG, 2005, J VIROL, V79, P5812, DOI 10.1128/JVI.79.9.5812-5818.2005; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gack MU, 2009, CELL HOST MICROBE, V5, P439, DOI 10.1016/j.chom.2009.04.006; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Guillemette B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001354; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Hale BG, 2008, VIROLOGY, V378, P1, DOI 10.1016/j.virol.2008.05.026; Hale BG, 2006, P NATL ACAD SCI USA, V103, P14194, DOI 10.1073/pnas.0606109103; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Jackson D, 2008, P NATL ACAD SCI USA, V105, P4381, DOI 10.1073/pnas.0800482105; Jaehning JA, 2010, BBA-GENE REGUL MECH, V1799, P379, DOI 10.1016/j.bbagrm.2010.01.001; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kim J, 2010, CELL, V140, P491, DOI 10.1016/j.cell.2009.12.050; Kim KY, 2011, CELL, V144, P745, DOI 10.1016/j.cell.2011.01.034; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Loucaides EM, 2009, VIROLOGY, V394, P154, DOI 10.1016/j.virol.2009.08.015; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mapendano CK, 2010, MOL CELL, V40, P410, DOI 10.1016/j.molcel.2010.10.012; Min IM, 2011, GENE DEV, V25, P742, DOI 10.1101/gad.2005511; Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nishiyama A, 2008, FEBS LETT, V582, P1501, DOI 10.1016/j.febslet.2008.03.044; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Satterly N, 2007, P NATL ACAD SCI USA, V104, P1853, DOI 10.1073/pnas.0610977104; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang PF, 2009, MOL CELL BIOL, V29, P6074, DOI 10.1128/MCB.00924-09; Wysocka J, 2006, METHODS, V40, P339, DOI 10.1016/j.ymeth.2006.05.028; Xhemalce B, 2010, GENE DEV, V24, P647, DOI 10.1101/gad.1881710; Yang Y, 2009, SCIENCE, V326, P729, DOI 10.1126/science.1177373	50	215	221	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					428	433		10.1038/nature10892	http://dx.doi.org/10.1038/nature10892			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22419161	Green Accepted			2022-12-28	WOS:000301771200035
J	Schrag, A; Schott, JM				Schrag, Anette; Schott, Jonathan M.			Kayser-Fleischer Rings in Wilson's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Schrag, Anette; Schott, Jonathan M.] UCL, London, England	University of London; University College London	Schrag, A (corresponding author), UCL, London, England.		Schott, Jonathan M/A-9065-2011; Schrag, Anette/AAA-9344-2020; Schrag, Anette E/B-4181-2011	Schott, Jonathan M/0000-0003-2059-024X; Schrag, Anette/0000-0002-9872-6680; Schrag, Anette E/0000-0002-9872-6680					0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					E18	E18		10.1056/NEJMicm1101534	http://dx.doi.org/10.1056/NEJMicm1101534			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435386				2022-12-28	WOS:000301769700002
J	Clark, CE; Taylor, RS; Shore, AC; Campbell, JL				Clark, Christopher E.; Taylor, Rod S.; Shore, Angela C.; Campbell, John L.			The difference in blood pressure readings between arms and survival: primary care cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BILATERAL INDIRECT; CARDIOVASCULAR EVENTS; GENERAL-PRACTICE; WORKING PARTY; RISK-FACTORS; HYPERTENSION; PREVALENCE; MANAGEMENT; GUIDELINES; RECORDINGS	Objective To determine whether a difference in systolic blood pressure readings between arms can predict a reduced event free survival after 10 years. Design Cohort study. Setting Rural general practice in Devon, United Kingdom. Participants 230 people receiving treatment for hypertension in primary care. Intervention Bilateral blood pressure measurements recorded at three successive surgery attendances. Main outcome measures Cardiovascular events and deaths from all causes during a median follow-up of 9.8 years. Results At recruitment 24% (55/230) of participants had a mean interarm difference in systolic blood pressure of 10 mm Hg or more and 9% (21/230) of 15 mm Hg or more; these differences were associated with an increased risk of all cause mortality (adjusted hazard ratio 3.6, 95% confidence interval 2.0 to 6.5 and 3.1, 1.6 to 6.0, respectively). The risk of death was also increased in 183 participants without pre-existing cardiovascular disease with an interarm difference in systolic blood pressure of 10 mm Hg or more or 15 mm Hg or more (2.6, 1.4 to 4.8 and 2.7, 1.3 to 5.4). An interarm difference in diastolic blood pressure of 10 mm Hg or more was weakly associated with an increased risk of cardiovascular events or death. Conclusions Differences in systolic blood pressure between arms can predict an increased risk of cardiovascular events and all cause mortality over 10 years in people with hypertension. This difference could be a valuable indicator of increased cardiovascular risk. Bilateral blood pressure measurements should become a routine part of cardiovascular assessment in primary care.	[Clark, Christopher E.; Taylor, Rod S.; Campbell, John L.] Univ Exeter, Primary Care Res Grp, Inst Hlth Serv Res, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Shore, Angela C.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Shore, Angela C.] Univ Exeter, Peninsula NIHR Clin Res Facil, Exeter EX1 2LU, Devon, England	University of Exeter; University of Plymouth; University of Exeter; University of Plymouth; University of Exeter	Clark, CE (corresponding author), Univ Exeter, Primary Care Res Grp, Inst Hlth Serv Res, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England.	christopher.clark@pms.ac.uk	Taylor, Rod/R-9581-2019	Taylor, Rod/0000-0002-3043-6011; Campbell, John/0000-0002-6752-3493; Shore, Angela/0000-0003-3039-308X	Mid Devon Medical Practice; Scientific Foundation Board of the Royal College of General Practitioners [SFB-2009-06]; South West GP Trust; National Institute for Health Research (NIHR) Peninsula Collaboration for Leadership in Applied Health Research and Care; NIHR	Mid Devon Medical Practice; Scientific Foundation Board of the Royal College of General Practitioners; South West GP Trust; National Institute for Health Research (NIHR) Peninsula Collaboration for Leadership in Applied Health Research and Care; NIHR(National Institute for Health Research (NIHR))	We thank the staff and patients of the Mid Devon Medical Practice for their support and participation in this study.; This research was supported by the Scientific Foundation Board of the Royal College of General Practitioners (grant No SFB-2009-06), the South West GP Trust, and the National Institute for Health Research (NIHR) Peninsula Collaboration for Leadership in Applied Health Research and Care, a NIHR funded collaboration of the Peninsula College of Medicine and Dentistry, University of Exeter, University of Plymouth, and NHS South West. The project was also supported by the NIHR Peninsula Clinical Research Facility. The views and opinions expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	Aboyans V, 2007, J AM COLL CARDIOL, V49, P1540, DOI 10.1016/j.jacc.2006.09.055; Aboyans V, 2010, ATHEROSCLEROSIS, V211, P266, DOI 10.1016/j.atherosclerosis.2010.01.013; Agarwal R, 2008, HYPERTENSION, V51, P657, DOI 10.1161/HYPERTENSIONAHA.107.104943; Amsterdam B., 1943, NY STATE J MED, V43, P6; Anekwe L, 2007, PULSE, V10, P17; Banks MJ, 2001, J HUM HYPERTENS, V15, P573, DOI 10.1038/sj.jhh.1001247; Baribeau Y, 2002, CIRCULATION, V106, pI11, DOI 10.1161/01.cir.0000032894.55215.32; Beevers G, 2001, BRIT MED J, V322, P981, DOI 10.1136/bmj.322.7292.981; Cassidy P, 2001, J HUM HYPERTENS, V15, P519, DOI 10.1038/sj.jhh.1001224; Clark CE, 2007, J HUM HYPERTENS, V21, P633, DOI 10.1038/sj.jhh.1002209; Clark CE, 2006, J HUM HYPERTENS, V20, P923, DOI 10.1038/sj.jhh.1002093; Clark CE, 2011, J HUM HYPERTENS, V25, P630; Clark CE, 2002, FAM PRACT, V19, P439, DOI 10.1093/fampra/19.5.439; Clark CE, 2001, BRIT MED J, V323, P399, DOI 10.1136/bmj.323.7309.399; Clark CE, 2009, DIABETIC MED S1, V26, P128; Clark CE, LANCET; Clark CE, 2007, FAM PRACT, V24, P420, DOI 10.1093/fampra/cmm035; Clark CE, 2011, AM J HYPERTENS, V24, P1189, DOI 10.1038/ajh.2011.139; Clark CE, 2009, BRIT J GEN PRACT, V59, P428, DOI 10.3399/bjgp09X420752; Collett, 2003, MODELLING SURVIVAL D; Criqui M H, 1997, Vasc Med, V2, P221; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Department of Health, 2008, PUTT PREV 1 VASC CHE; Eguchi K, 2007, ARCH INTERN MED, V167, P388, DOI 10.1001/archinte.167.4.388; FOTHERBY MD, 1993, POSTGRAD MED J, V69, P194, DOI 10.1136/pgmj.69.809.194; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; Fowkes FGR, 2010, JAMA-J AM MED ASSOC, V303, P841, DOI 10.1001/jama.2010.221; FRANK SM, 1991, ANESTHESIOLOGY, V75, P457, DOI 10.1097/00000542-199109000-00013; Gosse P, 2002, J HYPERTENS, V20, P1045, DOI 10.1097/00004872-200206000-00004; GOULD BA, 1985, CLIN CARDIOL, V8, P423, DOI 10.1002/clc.4960080803; HARRISON EG, 1960, CIRCULATION, V22, P419, DOI 10.1161/01.CIR.22.3.419; HASHIMOTO F, 1984, WESTERN J MED, V141, P189; Heneghan C, 2007, BRIT J GEN PRACT, V57, P948, DOI 10.3399/096016407782604965; Hingorani AD, 1999, BMJ-BRIT MED J, V318, P101, DOI 10.1136/bmj.318.7176.101; Igarashi Yuko, 2007, J Cardiol, V50, P281; Israel E, 1944, ACTA MED ORIENT, V3, P86; Kawamura T, 2008, ARQ BRAS CARDIOL, V90, P322, DOI 10.1590/S0066-782X2008000500003; Kay W E, 1930, Cal West Med, V33, P578; Kleefstra N, 2007, Ned Tijdschr Geneeskd, V151, P1509; Korns HM, 1933, J CLIN INVEST, V12, P143, DOI 10.1172/JCI100485; KRISTENSEN BO, 1982, ACTA MED SCAND, P69; Lane D, 2002, J HYPERTENS, V20, P1089, DOI 10.1097/00004872-200206000-00019; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Materson BJ, 2004, J HYPERTENS, V22, P2267, DOI 10.1097/00004872-200412000-00006; National Centre for Social Research, 2003, HLTH SURV ENGL 2003; National Institute for Health and Clinical Excellence, 2011, HYPERT CLIN MAN PRI; O'Shea JC, 2000, J HUM HYPERTENS, V14, P227, DOI 10.1038/sj.jhh.1000998; Orme S, 1999, AGE AGEING, V28, P537, DOI 10.1093/ageing/28.6.537; Parker E, 2009, BRIT J GEN PRACT, V59, P206, DOI 10.3399/bjgp09X395012; Pesola GR, 2002, ACAD EMERG MED, V9, P342, DOI 10.1111/j.1553-2712.2002.tb01333.x; Pesola GR, 2001, AM J EMERG MED, V19, P43, DOI 10.1053/ajem.2001.20021; Poon LCY, 2008, BJOG-INT J OBSTET GY, V115, P1122, DOI 10.1111/j.1471-0528.2008.01756.x; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; RAY SA, 1994, BRIT J SURG, V81, P188, DOI 10.1002/bjs.1800810208; Ray W T, 2000, AANA J, V68, P525; RUEGER MJ, 1951, ANN INTERN MED, V35, P1023, DOI 10.7326/0003-4819-35-5-1023; SCHILLACI G, 1994, AM J CARDIOL, V74, P714, DOI 10.1016/0002-9149(94)90316-6; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Shadman R, 2004, J AM COLL CARDIOL, V44, P618, DOI 10.1016/j.jacc.2004.04.044; Sin Lau Y, 2005, MODERN HYPERTENSION, V5, P9; Singer AJ, 1996, ARCH INTERN MED, V156, P2005, DOI 10.1001/archinte.156.17.2005; Southby R, 1935, MED J AUSTRALIA, V2, P580, DOI DOI 10.5694/J.1326-5377.1935.TB43281.X; Verberk WJ, 2011, AM J HYPERTENS, V24, P1201, DOI 10.1038/ajh.2011.125; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988	65	84	92	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2012	344								e1327	10.1136/bmj.e1327	http://dx.doi.org/10.1136/bmj.e1327			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CJ	22433975	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000301848700002
J	Fellinger, J; Holzinger, D; Pollard, R				Fellinger, Johannes; Holzinger, Daniel; Pollard, Robert			Mental health of deaf people	LANCET			English	Review							QUALITY-OF-LIFE; HEARING-IMPAIRED CHILDREN; AMERICAN SIGN-LANGUAGE; COCHLEAR IMPLANTATION; SELF-ESTEEM; BEHAVIOR PROBLEMS; ADULTS; PREVALENCE; COMMUNICATION; CHILDHOOD	Deafness is a heterogeneous condition with far-reaching effects on social, emotional, and cognitive development. Onset before language has been established happens in about seven per 10 000 people. Increased rates of mental health problems are reported in deaf people. Many regard themselves as members of a cultural minority who use sign language. In this Review, we describe discrepancies between a high burden of common mental health disorders and barriers to health care. About a quarter of deaf individuals have additional disabilities and a high probability of complex mental health needs. Research into factors affecting mental health of deaf children shows that early access to effective communication with family members and peers is desirable. Improved access to health and mental health care can be achieved by provision of specialist services with professionals trained to directly communicate with deaf people and with sign-language interpreters.	[Fellinger, Johannes; Holzinger, Daniel] Hosp St John God, Inst Neurol Senses & Language, Hlth Ctr Deaf, A-4021 Linz, Austria; [Fellinger, Johannes] Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria; [Holzinger, Daniel] Karl Franzens Univ Graz, Dept Linguist, Graz, Austria; [Pollard, Robert] Univ Rochester, Sch Med, Deaf Wellness Ctr, Rochester, NY USA	Medical University of Vienna; University of Graz; University of Rochester	Fellinger, J (corresponding author), Hosp St John God, Inst Neurol Senses & Language, Hlth Ctr Deaf, Bischofstr 11, A-4021 Linz, Austria.	johannes.fellinger@bblinz.at		Holzinger, Daniel/0000-0001-6634-6117				Agrawal Y, 2008, ARCH INTERN MED, V168, P1522, DOI 10.1001/archinte.168.14.1522; Baines D, 2010, J DEAF STUD DEAF EDU, V15, P179, DOI 10.1093/deafed/enq003; Barker DH, 2009, DEV PSYCHOPATHOL, V21, P373, DOI 10.1017/S0954579409000212; Barnett S, 2011, AM J PUBLIC HEALTH, V101, P2235, DOI 10.2105/AJPH.2011.300247; Beresford B, 2010, J MENT HEALTH, V19, P193, DOI 10.3109/09638230902968159; Black PA, 2006, J DEAF STUD DEAF EDU, V11, P303, DOI 10.1093/deafed/enj042; BOOTHROYD A, 1991, EAR HEARING, V12, pS81, DOI 10.1097/00003446-199108001-00010; Brauer B.A., 1998, TEST INTERPRETATION, P297, DOI [DOI 10.1037/10279-011, 10.1037/10279-011]; BRAUER BA, 1993, REHABIL PSYCHOL, V38, P247, DOI 10.1037/0090-5550.38.4.247; Bridgman G., 2000, METAL HLTH SERVICES, P216; Brown AS, 2000, AM J PSYCHIAT, V157, P438, DOI 10.1176/appi.ajp.157.3.438; Bubbico L, 2007, Acta Otorhinolaryngol Ital, V27, P17; Cornes A, 2006, AUST NZ J PSYCHIAT, V40, P665, DOI 10.1111/j.1440-1614.2006.01866.x; Damen GWJA, 2007, OTOLARYNG HEAD NECK, V136, P597, DOI 10.1016/j.otohns.2006.11.044; Dammeyer J, 2010, J DEAF STUD DEAF EDU, V15, P50, DOI 10.1093/deafed/enp024; de Graaf R, 2002, PSYCHOSOM MED, V64, P61, DOI 10.1097/00006842-200201000-00009; Dean R., 2001, PERSPECTIVES DEAFNES, P259, DOI [DOI 10.1093/ACPROF/9780195176940.003.0011, 10.1093/acprof/9780195176940.003.0011]; DENMARK JC, 1985, BRIT J PSYCHIAT, V146, P282, DOI 10.1192/bjp.146.3.282; Department of Health, 2005, MENT HLTH DEAFN EQ A; Dillon CM, 2004, CLIN LINGUIST PHONET, V18, P39, DOI 10.1080/0269920031000151669; Estrada B, 2007, J FAM PSYCHOTHER, V18, P45, DOI 10.1300/J085v18n03_04; Feldman DM, 2007, AM ANN DEAF, V152, P391, DOI 10.1353/aad.2008.0001; Fellinger J, 2007, ACTA PSYCHIAT SCAND, V115, P243, DOI 10.1111/j.1600-0447.2006.00976.x; Fellinger J, 2005, SOC PSYCH PSYCH EPID, V40, P737, DOI 10.1007/s00127-005-0936-8; Fellinger J, 2005, SOC PSYCH PSYCH EPID, V40, P245, DOI 10.1007/s00127-005-0862-9; Fellinger J, 2005, NERVENARZT, V76, P43, DOI 10.1007/s00115-004-1708-5; Fellinger J, 2009, ACTA PSYCHIAT SCAND, V120, P153, DOI 10.1111/j.1600-0447.2009.01350.x; Fellinger J, 2008, EUR CHILD ADOLES PSY, V17, P414, DOI 10.1007/s00787-008-0683-y; Fellinger J, 2009, DEV MED CHILD NEUROL, V51, P635, DOI 10.1111/j.1469-8749.2008.03218.x; Gallaudet Research Institute, 2013, REG NAT SUMM REP DAT; Geers AE, 2003, EAR HEARING, V24, p46S, DOI 10.1097/01.AUD.0000051689.57380.1B; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; Glickman N, 2007, J DEAF STUD DEAF EDU, V12, P127, DOI 10.1093/deafed/enm001; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Gournaris M. J., 2004, JADARA, V37, P20; Haskins BG, 2004, PSYCHIAT SERV, V55, P439, DOI 10.1176/appi.ps.55.4.439; Hauser PC, 2010, AM ANN DEAF, V154, P486, DOI 10.1353/aad.0.0120; Hindley P, 2000, MENTAL HLTH DEAFNESS, P42; Hintermair M, 2008, J DEAF STUD DEAF EDU, V13, P278, DOI 10.1093/deafed/enm054; Hintermair M, 2007, AM ANN DEAF, V152, P320, DOI 10.1353/aad.2007.0028; Hintermair M, 2006, J DEAF STUD DEAF EDU, V11, P493, DOI 10.1093/deafed/enl005; Hirschfelder A, 2008, OTOLARYNG HEAD NECK, V138, P357, DOI 10.1016/j.otohns.2007.10.019; Huttunen K, 2009, INT J PEDIATR OTORHI, V73, P1786, DOI 10.1016/j.ijporl.2009.09.038; Jambor E, 2005, J DEAF STUD DEAF EDU, V10, P63, DOI 10.1093/deafed/eni004; JURE R, 1991, DEV MED CHILD NEUROL, V33, P1062; Keilmann A, 2007, INT J PEDIATR OTORHI, V71, P1747, DOI 10.1016/j.ijporl.2007.07.013; Knutson JF, 2004, CHILD ABUSE NEGLECT, V28, P925, DOI 10.1016/j.chiabu.2004.04.005; Koo D, 2008, ANN NY ACAD SCI, V1145, P83, DOI 10.1196/annals.1416.025; Korver AMH, 2011, LARYNGOSCOPE, V121, P409, DOI 10.1002/lary.21377; Kral A, 2010, NEW ENGL J MED, V363, P1438, DOI 10.1056/NEJMra0911225; Kvam MH, 2007, J DEAF STUD DEAF EDU, V12, P1, DOI 10.1093/deafed/enl015; Kvam MH, 2004, CHILD ABUSE NEGLECT, V28, P241, DOI 10.1016/j.chiabu.2003.09.017; Landsberger SA, 2011, CURR PSYCHIAT REP, V13, P198, DOI 10.1007/s11920-011-0186-2; Landsberger SA, 2010, PSYCHIAT SERV, V61, P196, DOI 10.1176/ps.2010.61.2.196; MACKINNEY TG, 1995, J GEN INTERN MED, V10, P133, DOI 10.1007/BF02599667; Margellos-Anast H, 2006, PREV MED, V42, P235, DOI 10.1016/j.ypmed.2005.12.012; McLaughlin KA, 2010, ARCH GEN PSYCHIAT, V67, P124, DOI 10.1001/archgenpsychiatry.2009.187; Middleton A, 2010, J EVAL CLIN PRACT, V16, P811, DOI 10.1111/j.1365-2753.2009.01207.x; Mitchell RE, 2006, J DEAF STUD DEAF EDU, V11, P112, DOI 10.1093/deafed/enj004; Morzaria S, 2004, INT J PEDIATR OTORHI, V68, P1193, DOI 10.1016/j.ijporl.2004.04.013; Munro L, 2008, J DEAF STUD DEAF EDU, V13, P307, DOI 10.1093/deafed/enn001; Munro L, 2009, AUST NZ J PSYCHIAT, V43, P332, DOI 10.1080/00048670902721111; Niparko JK, 2010, JAMA-J AM MED ASSOC, V303, P1498, DOI 10.1001/jama.2010.451; O'Rourke S, 2005, J FORENSIC PSYCHI PS, V16, P671, DOI 10.1080/14789940500279877; OHearn A. M., 2006, COGN BEHAV PRACT, V15, P400; Padden C, 2006, INSIDE DEAF CULTURE; Paul P., 1998, LITERACY DEAFNESS DE; Percy-Smith L, 2008, INT J PEDIATR OTORHI, V72, P1113, DOI 10.1016/j.ijporl.2008.03.028; Pipp-Siegel S, 1998, VOLTA REV, V100, P237; Pisoni DB, 2008, DEAF COGNITION; Polat Filiz, 2003, J Deaf Stud Deaf Educ, V8, P325, DOI 10.1093/deafed/eng018; Pollard R.Q., 1992, J AM DEAFNESS REHABI, V26, P32; Pollard RQ, 2007, REHABIL PSYCHOL, V52, P11, DOI 10.1037/0090-5550.52.1.11; Pollard RQ, 2009, REHABIL PSYCHOL, V54, P182, DOI 10.1037/a0015771; Pollard RQ, 2005, REHABIL PSYCHOL, V50, P258, DOI 10.1037/0090-5550.50.3.258; Pressman LJ, 1998, VOLTA REV, V100, P251; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; Rydberg E, 2010, AM ANN DEAF, V155, P68; Sinkkonen, 1994, PSYCHIAT FENNICA, V25, P52; Stefanis N, 2006, SCHIZOPHR RES, V85, P266, DOI 10.1016/j.schres.2006.03.036; Steinberg AG, 2006, J GEN INTERN MED, V21, P260, DOI 10.1111/j.1525-1497.2006.00340.x; Stevenson J, 2011, DEV MED CHILD NEUROL, V53, P269, DOI 10.1111/j.1469-8749.2010.03839.x; Stevenson J, 2010, J CHILD PSYCHOL PSYC, V51, P77, DOI 10.1111/j.1469-7610.2009.02124.x; Sullivan PM, 2000, CHILD ABUSE NEGLECT, V24, P1257, DOI 10.1016/S0145-2134(00)00190-3; TAMBS K, 1993, ACTA PSYCHIAT SCAND, V87, P364, DOI 10.1111/j.1600-0447.1993.tb03388.x; THACKER AJ, 1994, BRIT J PSYCHIAT, V165, P818, DOI 10.1192/bjp.165.6.818; Thewissen V, 2005, SCHIZOPHR RES, V76, P99, DOI 10.1016/j.schres.2004.10.013; Thomas C., 2006, J MENTAL HLTH, V15, P301; Titus JC, 2008, J DEAF STUD DEAF EDU, V13, P336, DOI 10.1093/deafed/enm068; Traxler C.B., 2000, J DEAF STUD DEAF EDU, V5, P337, DOI DOI 10.1093/DEAFED/5.4.337; Beria J, 2007, REV PANAM SALUD PUBL, V21, P381, DOI 10.1590/S1020-49892007000500006; United Nations Convention on the Rights of Persons with Disabilities (UNCRPD), 2006, CONV RIGHTS PERS DIS; van Gent T, 2007, J CHILD PSYCHOL PSYC, V48, P950, DOI 10.1111/j.1469-7610.2007.01775.x; Van Naarden K, 1999, PEDIATRICS, V103, P570, DOI 10.1542/peds.103.3.570; Vernon M, 2007, AM ANN DEAF, V152, P374, DOI 10.1353/aad.2008.0005; Warner-Czyz AD, 2011, INT J PEDIATR OTORHI, V75, P95, DOI 10.1016/j.ijporl.2010.10.018; Warner-Czyz AD, 2009, INT J PEDIATR OTORHI, V73, P1423, DOI 10.1016/j.ijporl.2009.07.009; Werngren-Elgstrom M, 2003, ARCH GERONTOL GERIAT, V37, P13, DOI 10.1016/S0167-4943(03)00003-7; Wilson JAB, 2009, J DEAF STUD DEAF EDU, V14, P386, DOI 10.1093/deafed/enp008; World health organization, 2009, NMH FACT SHEET JAN 2; Zazove P, 2006, J AM BOARD FAM MED, V19, P141, DOI 10.3122/jabfm.19.2.141	101	225	230	5	72	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1037	1044		10.1016/S0140-6736(11)61143-4	http://dx.doi.org/10.1016/S0140-6736(11)61143-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22423884				2022-12-28	WOS:000301712300032
J	Garcia, GG; Harden, P; Chapman, J				Garcia Garcia, Guillermo; Harden, Paul; Chapman, Jeremy		World Kidney Day Steering Comm 201	The global role of kidney transplantation	LANCET			English	Editorial Material									[Garcia Garcia, Guillermo] Univ Guadalajara, Hlth Sci Ctr, Hosp 278, Hosp Civil Guadalajara,Nephrol Serv, Guadalajara 44430, Jalisco, Mexico; [Harden, Paul] Churchill Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England; [Harden, Paul] Churchill Hosp, Oxford Transplant Ctr, Oxford OX3 7LJ, England; [Chapman, Jeremy] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Ctr Transplant & Renal Res, Sydney, NSW 2006, Australia; Int Soc Nephrol, B-1000 Brussels, Belgium	Universidad de Guadalajara; University of Oxford; University of Oxford; University of Sydney; Westmead Institute for Medical Research	Garcia, GG (corresponding author), Univ Guadalajara, Hlth Sci Ctr, Hosp 278, Hosp Civil Guadalajara,Nephrol Serv, Guadalajara 44430, Jalisco, Mexico.	smartin@theisn.org		Garcia Garcia, Guillermo/0000-0003-0558-0035					0	63	70	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					E36	E38		10.1016/S0140-6736(12)60202-5	http://dx.doi.org/10.1016/S0140-6736(12)60202-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22405254				2022-12-28	WOS:000301712300001
J	Goldberg, DE; Siliciano, RF; Jacobs, WR				Goldberg, Daniel E.; Siliciano, Robert F.; Jacobs, William R., Jr.			Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV	CELL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; MICROBIAL ENUMERATION TECHNIQUE; PLASMODIUM-FALCIPARUM MALARIA; TRANSMEMBRANE PROTEIN PFCRT; SINGLE-DOSE NEVIRAPINE; TO-CHILD TRANSMISSION; RESPONSE CURVE SLOPE; MYCOBACTERIUM-TUBERCULOSIS; CHLOROQUINE RESISTANCE; ANTIRETROVIRAL THERAPY	Although caused by vastly different pathogens, the world's three most serious infectious diseases, tuberculosis, malaria, and HIV-1 infection, share the common problem of drug resistance. The pace of drug development has been very slow for tuberculosis and malaria and rapid for HIV-1. But for each disease, resistance to most drugs has appeared quickly after the introduction of the drug. Learning how to manage and prevent resistance is a major medical challenge that requires an understanding of the evolutionary dynamics of each pathogen. This Review summarizes the similarities and differences in the evolution of drug resistance for these three pathogens.	[Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; [Goldberg, Daniel E.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Goldberg, Daniel E.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; [Jacobs, William R., Jr.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Jacobs, William R., Jr.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Jacobs, William R., Jr.] Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu		Jacobs, William/0000-0003-3321-3080	Howard Hughes Medical Institute; NIH [AI081600]; Einstein CFAR [NIH AI51519]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081600, P30AI051519] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Einstein CFAR; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Howard Hughes Medical Institute and by NIH grant AI081600 to R.F.S. Additional support came from the Einstein CFAR Grant NIH AI51519. Thanks to Brian Weinrick, Pradip Rathod, and Dhinakaran Samdbandan for their helpful discussions and suggestions.	Acosta-Hoyos AJ, 2010, VIRUSES-BASEL, V2, P372, DOI 10.3390/v2020372; Adams KN, 2011, CELL, V145, P39, DOI 10.1016/j.cell.2011.02.022; Ahmad Z, 2011, PROG RESPIR RES, V40, P2; Almeida D, 2009, ANTIMICROB AGENTS CH, V53, P4178, DOI 10.1128/AAC.00830-09; Anderson TJC, 2009, TRENDS PARASITOL, V25, P336, DOI 10.1016/j.pt.2009.04.005; Andrews JR, 2008, J INFECT DIS, V198, P1582, DOI 10.1086/592991; Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; [Anonymous], 1972, LANCET, V1, P1079; [Anonymous], 1950, Br Med J, V2, P1073; [Anonymous], 1952, Br Med J, V2, P735; [Anonymous], 1948, Br Med J, V2, P769; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bierman WFW, 2009, AIDS, V23, P279, DOI 10.1097/QAD.0b013e32831c54e5; Bonhoeffer S, 1997, P ROY SOC B-BIOL SCI, V264, P631; Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10; Boyd MA, 2009, CURR OPIN HIV AIDS, V4, P194, DOI 10.1097/COH.0b013e328329fc8d; Bray PG, 2005, MOL MICROBIOL, V56, P323, DOI 10.1111/j.1365-2958.2005.04556.x; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P921; CLARK S, 2007, HIV SEQUENCE COMPEND, P58; Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Deeks SG, 2009, CLIN INFECT DIS, V49, P1582, DOI 10.1086/644768; deVries PJ, 1996, DRUGS, V52, P818, DOI 10.2165/00003495-199652060-00004; DICKINSON JM, 1977, AM REV RESPIR DIS, V116, P627, DOI 10.1164/arrd.1977.116.4.627; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; DUNNER E, 1949, DIS CHEST, V16, P661, DOI 10.1378/chest.16.6.661; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Flys TS, 2007, J INFECT DIS, V195, P711, DOI 10.1086/511433; Ford CB, 2011, NAT GENET, V43, P482, DOI 10.1038/ng.811; Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2; Gandotra S, 2007, NAT MED, V13, P1515, DOI 10.1038/nm1683; Gil O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010030; Gill WP, 2009, NAT MED, V15, P211, DOI 10.1038/nm.1915; Ginsberg A, 2011, FUTURE MED CHEM, V3, P1247, DOI [10.4155/fmc.11.82, 10.4155/FMC.11.82]; GROSSET J, 1992, ANTIMICROB AGENTS CH, V36, P548, DOI 10.1128/AAC.36.3.548; Guantai Eric, 2010, Current Drug Delivery, V7, P312, DOI 10.2174/156720110793360577; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrington WE, 2009, P NATL ACAD SCI USA, V106, P9027, DOI 10.1073/pnas.0901415106; HINSHAW HC, 1946, JAMA-J AM MED ASSOC, V132, P778; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hyde JE, 2005, TRENDS PARASITOL, V21, P494, DOI 10.1016/j.pt.2005.08.020; Istvan ES, 2011, P NATL ACAD SCI USA, V108, P1627, DOI 10.1073/pnas.1011560108; Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649; Johnson R, 2006, CURR ISSUES MOL BIOL, V8, P97; Johnson Victoria A, 2010, Top HIV Med, V18, P156; Kaneko T, 2011, FUTURE MED CHEM, V3, P1373, DOI [10.4155/fmc.11.115, 10.4155/FMC.11.115]; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Koenderink JB, 2010, TRENDS PARASITOL, V26, P440, DOI 10.1016/j.pt.2010.05.002; Koul A, 2008, J BIOL CHEM, V283, P25273, DOI 10.1074/jbc.M803899200; Krishnan L, 2010, P NATL ACAD SCI USA, V107, P15910, DOI 10.1073/pnas.1002346107; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032; LEHMANN J, 1946, LANCET, V250, P15; Lin G, 2009, NATURE, V461, P621, DOI 10.1038/nature08357; Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Lobritz MA, 2010, VIRUSES-BASEL, V2, P1069, DOI 10.3390/v2051069; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Margeridon-Thermet S, 2010, VIRUSES-BASEL, V2, P2696, DOI 10.3390/v2122696; Martin RE, 2009, SCIENCE, V325, P1680, DOI 10.1126/science.1175667; Mathys V, 2009, ANTIMICROB AGENTS CH, V53, P2100, DOI 10.1128/AAC.01197-08; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; MCCUNE RM, 1956, J EXP MED, V104, P737, DOI 10.1084/jem.104.5.737; Muller IB, 2010, FUTURE MICROBIOL, V5, P1857, DOI 10.2217/FMB.10.136; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; Nowak MA, 1997, J VIROL, V71, P7518, DOI 10.1128/JVI.71.10.7518-7525.1997; Ntemgwa ML, 2009, ANTIMICROB AGENTS CH, V53, P3611, DOI 10.1128/AAC.00154-09; Ockenhouse Christian F, 2005, Mil Med, V170, P12; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Panel on antiretroviral guidelines for adults and adolescents, 2009, GUID US ANT AG HIV 1, P1, DOI DOI 10.1111/J.1468-1293.2008.00636.X; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Pichugin AV, 2009, AM J PATHOL, V174, P2190, DOI 10.2353/ajpath.2009.081075; QUINONESMATEU ME, 2001, HIV SEQUENCE COMPEND, P134; Rathod PK, 1997, J PHARM PHARMACOL, V49, P65, DOI 10.1111/j.2042-7158.1997.tb06163.x; Rocco F., 2004, MIRACULOUS FEVER TRE; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765; Sampah MES, 2011, P NATL ACAD SCI USA, V108, P7613, DOI 10.1073/pnas.1018360108; Sarafianos SG, 2004, CURR OPIN STRUC BIOL, V14, P716, DOI 10.1016/j.sbi.2004.10.013; Schatz A, 1944, P SOC EXP BIOL MED, V55, P66, DOI 10.3181/00379727-55-14461; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777; Shen L, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002304; Shi WL, 2011, SCIENCE, V333, P1630, DOI 10.1126/science.1208813; Slavic K, 2011, ANTIMICROB AGENTS CH, V55, P2824, DOI 10.1128/AAC.01739-10; Spigelman MK, 2007, J INFECT DIS, V196, pS28, DOI 10.1086/518663; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677, DOI 10.1128/AAC.41.8.1677; Srivastava S, 2011, ANTIMICROB AGENTS CH, V55, P5085, DOI 10.1128/AAC.00269-11; Srivastava S, 2010, J INFECT DIS, V201, P1225, DOI 10.1086/651377; SWEANY HC, 1949, DIS CHEST, V16, P633, DOI 10.1378/chest.16.6.633; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Teuscher F, 2010, J INFECT DIS, V202, P1362, DOI 10.1086/656476; THOMAS JP, 1961, AM REV RESPIR DIS, V83, P891; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471; Vaidya AB, 2000, DRUG RESIST UPDATE, V3, P283, DOI 10.1054/drup.2000.0157; Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346; Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466; Vinayak S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000830; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003; Wheeler WH, 2010, AIDS, V24, P1203, DOI 10.1097/QAD.0b013e3283388742; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; WHO, 2010, MULT EXT DRUG RES TU; Wodarz D, 2002, BIOESSAYS, V24, P1178, DOI 10.1002/bies.10196; YEAGER RL, 1952, AM REV TUBERC PULM, V65, P523; Zhang M, 2011, AM J RESP CRIT CARE, V183, P1254, DOI 10.1164/rccm.201012-1949OC; Zimhony O, 2000, NAT MED, V6, P1043, DOI 10.1038/79558	119	124	132	1	96	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1271	1283		10.1016/j.cell.2012.02.021	http://dx.doi.org/10.1016/j.cell.2012.02.021			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424234	Green Accepted, Bronze			2022-12-28	WOS:000301889500021
J	Hooton, TM				Hooton, Thomas M.			Uncomplicated Urinary Tract Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; RISK-FACTORS; ACUTE PYELONEPHRITIS; CONTROLLED-TRIAL; DOUBLE-BLIND; PLACEBO; WOMEN; CIPROFLOXACIN; EPIDEMIOLOGY; GUIDELINES	A 30-year-old woman calls you to report a 2-day history of worsening dysuria and urinary urgency and frequency. She reports having no fever, chills, back pain, or vaginal irritation or discharge. One month ago, you treated her with a 3-day course of trimethoprim-sulfamethoxazole for presumptive cystitis, and her symptoms resolved. She is otherwise healthy, but this is her third episode in the past year. How should her case be managed?	Univ Miami, Dept Med, Miller Sch Med, Miami, FL 33136 USA	University of Miami	Hooton, TM (corresponding author), Univ Miami, Dept Med, Miller Sch Med, Clin Res Bldg,1120 NW 14th St,Suite 310G, Miami, FL 33136 USA.	thooton@med.miami.edu	Hug, Balthasar L./G-1568-2010; Franzeck, Fabian C/B-5055-2011		Pinnacle Pharmaceuticals; Pfizer; Alita Pharmaceuticals	Pinnacle Pharmaceuticals; Pfizer(Pfizer); Alita Pharmaceuticals	Dr. Hooton reports receiving consulting fees from Pinnacle Pharmaceuticals, Pfizer, and Alita Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.	Barbosa-Cesnik C, 2011, CLIN INFECT DIS, V52, P23, DOI 10.1093/cid/ciq073; Barrons R, 2008, CLIN THER, V30, P453, DOI 10.1016/j.clinthera.2008.03.013; Bent S, 2002, JAMA-J AM MED ASSOC, V287, P2701, DOI 10.1001/jama.287.20.2701; Bleidorn J, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-30; Christiaens TCM, 2002, BRIT J GEN PRACT, V52, P729; Czaja CA, 2009, J INFECT DIS, V200, P528, DOI 10.1086/600385; Czaja CA, 2007, CLIN INFECT DIS, V45, P273, DOI 10.1086/519268; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Falagas ME, 2010, LANCET INFECT DIS, V10, P43, DOI 10.1016/S1473-3099(09)70325-1; Ferry SA, 2007, SCAND J PRIM HEALTH, V25, P49, DOI 10.1080/02813430601183074; Foxman B, 2000, AM J EPIDEMIOL, V151, P1194, DOI 10.1093/oxfordjournals.aje.a010170; Foxman B, 2003, INFECT DIS CLIN N AM, V17, P227, DOI 10.1016/S0891-5520(03)00005-9; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; Foxman B, 2010, NAT REV UROL, V7, P653, DOI 10.1038/nrurol.2010.190; Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; Gupta K, 2001, ANN INTERN MED, V135, P9, DOI 10.7326/0003-4819-135-1-200107030-00004; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hooton TM, 2003, INFECT DIS CLIN N AM, V17, P303, DOI 10.1016/S0891-5520(03)00004-7; Hooton TM, 2001, INT J ANTIMICROB AG, V17, P259, DOI 10.1016/S0924-8579(00)00350-2; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; Ikaheimo R, 1996, CLIN INFECT DIS, V22, P91, DOI 10.1093/clinids/22.1.91; Jackson SL, 2004, AM J MED, V117, P903, DOI 10.1016/j.amjmed.2004.07.045; Jepson RG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub4; Johansen TEB, 2011, INT J ANTIMICROB AG, V38, P64, DOI 10.1016/j.ijantimicag.2011.09.009; Johnson JR, 2003, INFECT DIS CLIN N AM, V17, P261, DOI 10.1016/S0891-5520(03)00027-8; Kallen AJ, 2006, ARCH INTERN MED, V166, P635, DOI 10.1001/archinte.166.6.635; Katchman EA, 2005, AM J MED, V118, P1196, DOI 10.1016/j.amjmed.2005.02.005; Klausner HA, 2007, CURR MED RES OPIN, V23, P2637, DOI 10.1185/030079907X233340; Klimberg I, 2005, CURR MED RES OPIN, V21, P1241, DOI 10.1185/030079905X56358; Lundstedt AC, 2007, J INFECT DIS, V195, P1227, DOI 10.1086/512620; Meier S, 2011, INFECTION, V39, P333, DOI 10.1007/s15010-011-0132-6; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Nicolle LE, 2005, CLIN INFECT DIS, V40, P1556; Nicolle LE, 2005, CLIN INFECT DIS, V40, P643, DOI 10.1086/427507; Nicolle LE, 2008, UROL CLIN N AM, V35, P1, DOI 10.1016/j.ucl.2007.09.004; Nicolle Lindsay E, 2011, Curr Infect Dis Rep, V13, P552, DOI 10.1007/s11908-011-0212-x; Nielubowicz GR, 2010, NAT REV UROL, V7, P430, DOI 10.1038/nrurol.2010.101; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; Rosen DA, 2007, PLOS MED, V4, P1949, DOI 10.1371/journal.pmed.0040329; Rudenko N, 2005, ARZNEIMITTELFORSCH, V55, P420; Schappert Susan M, 2011, Vital Health Stat 13, P1; Scholes D, 2000, J INFECT DIS, V182, P1177, DOI 10.1086/315827; Scholes D, 2005, ANN INTERN MED, V142, P20, DOI 10.7326/0003-4819-142-1-200501040-00008; Scholes D, 2010, J UROLOGY, V184, P564, DOI 10.1016/j.juro.2010.03.139; Sivick KE, 2010, INFECT IMMUN, V78, P568, DOI 10.1128/IAI.01000-09; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STAPLETON A, 1990, JAMA-J AM MED ASSOC, V264, P703, DOI 10.1001/jama.264.6.703; Stapleton AE, 2011, CLIN INFECT DIS, V52, P1212, DOI 10.1093/cid/cir183; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; Wagenlehner FME, 2011, DTSCH ARZTEBL INT, V108, P415, DOI 10.3238/arztebl.2011.0415; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Wellens A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002040	54	407	439	1	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1028	1037		10.1056/NEJMcp1104429	http://dx.doi.org/10.1056/NEJMcp1104429			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417256				2022-12-28	WOS:000301482800006
J	Ferner, R				Ferner, Robin			DRUG TALES AND OTHER STORIES Boundaries	BRITISH MEDICAL JOURNAL			English	Editorial Material									Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				2012, FORENSIC SCI INT, V214, pE51	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e2028	10.1136/bmj.e2028	http://dx.doi.org/10.1136/bmj.e2028			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418423				2022-12-28	WOS:000301847600023
J	Chahroudi, A; Bosinger, SE; Vanderford, TH; Paiardini, M; Silvestri, G				Chahroudi, Ann; Bosinger, Steven E.; Vanderford, Thomas H.; Paiardini, Mirko; Silvestri, Guido			Natural SIV Hosts: Showing AIDS the Door	SCIENCE			English	Review							SIMIAN-IMMUNODEFICIENCY-VIRUS; AFRICAN-GREEN MONKEYS; CD4(+) T-CELLS; INFECTED SOOTY MANGABEYS; NONHUMAN PRIMATE HOSTS; IMMUNE ACTIVATION; MICROBIAL TRANSLOCATION; VIRAL REPLICATION; TYPE-1 INFECTION; HIV-1 INFECTION	Many species of African nonhuman primates are naturally infected with simian immunodeficiency viruses (SIVs) in the wild and in captivity. In contrast to HIV-infected humans, these natural SIV hosts typically do not develop AIDS, despite chronic infection with a highly replicating virus. In this Review, we discuss the most recent advances on the mechanisms of protection from disease progression in natural SIV hosts, with emphasis on how they differ from pathogenic HIV/SIV infections of humans and rhesus macaques. These mechanisms include: (i) resolution of immune activation after acute infection, (ii) restricted pattern of target cell infection, and (iii) protection from mother-to-infant transmission. We highlight the areas that should be pursued in future studies, focusing on potential applications for the treatment and prevention of HIV infection.	[Paiardini, Mirko; Silvestri, Guido] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Chahroudi, Ann] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Chahroudi, Ann; Bosinger, Steven E.; Vanderford, Thomas H.; Paiardini, Mirko; Silvestri, Guido] Emory Univ, YNPRC, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Paiardini, M (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.	mirko.paiardini@emory.edu; gsilves@emory.edu	Serei, Virian D/B-4616-2015		Division of AIDS of the National Institute of Allergy and Infectious Diseases, NIH; NIH [R01-AI066998, P51-RR00165]; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084836, R01AI066998] Funding Source: NIH RePORTER	Division of AIDS of the National Institute of Allergy and Infectious Diseases, NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We gratefully thank the following individuals, whose unparalleled scientific insight and dedication have contributed substantially to our understanding of the natural SIV hosts: J. Allan, R. Amara, A. Ansari, C. Apetrei, J. Brenchley, L. Chakrabarti, R. Collman, M. Davenport, C. Derdeyn, D. Douek, J. Else, J. Estes, M. Feinberg, R. Grant, A. Haase, B. Hahn, V. Hirsch, A. Kaur, F. Kirchhoff, M. Lederman, P. Marx, M. Muller-Trutwin, I. Pandrea, L. Picker, D. Sodora, J. Schmitz, S. Staprans, R. Veazey, and F. Villinger. We apologize that, due to space constraints, we were only able to cite selected works from these and other authors. We also thank C. Dieffenbach, S. Plaeger, J. Young, A. Embry, and D. Finzi at the Division of AIDS of the National Institute of Allergy and Infectious Diseases, NIH for their continuous intellectual and logistical support of this work. This work was supported by NIH grants R01-AI066998 to G.S. and P51-RR00165 to YNPRC.	Apetrei C, 2011, J VIROL, V85, P13077, DOI 10.1128/JVI.05693-11; Beaumier CM, 2009, NAT MED, V15, P879, DOI 10.1038/nm.1970; Beer B, 1998, J ACQ IMMUN DEF SYND, V18, P210, DOI 10.1097/00042560-199807010-00003; Bosinger SE, 2009, J CLIN INVEST, V119, P3556, DOI 10.1172/JCI40115; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2010, IMMUNITY, V32, P737, DOI 10.1016/j.immuni.2010.06.004; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; Chahroudi A, 2011, J VIROL, V85, P5757, DOI 10.1128/JVI.02690-10; Chakrabarti LA, 2000, J VIROL, V74, P1209, DOI 10.1128/JVI.74.3.1209-1223.2000; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Diop OM, 2000, J VIROL, V74, P7538, DOI 10.1128/JVI.74.16.7538-7547.2000; Dunham R, 2006, BLOOD, V108, P209, DOI 10.1182/blood-2005-12-4897; Estes JD, 2008, J IMMUNOL, V180, P6798, DOI 10.4049/jimmunol.180.10.6798; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Goldstein S, 2006, J VIROL, V80, P4868, DOI 10.1128/JVI.80.10.4868-4877.2006; Gordon SN, 2008, J VIROL, V82, P3725, DOI 10.1128/JVI.02408-07; Gordon SN, 2007, J IMMUNOL, V179, P3026, DOI 10.4049/jimmunol.179.5.3026; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Harris LD, 2010, J VIROL, V84, P7886, DOI 10.1128/JVI.02612-09; HEENEY JL, 1995, IMMUNOL TODAY, V16, P515, DOI 10.1016/0167-5699(95)80043-3; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06; Jacquelin B, 2012, MODELS OF PROTECTION AGAINST HIV/SIV: AVOIDING AIDS IN HUMANS AND MONKEYS, P47, DOI 10.1016/B978-0-12-387715-4.00002-2; Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093; Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200; Klatt NR, 2008, J CLIN INVEST, V118, P2039, DOI 10.1172/JCI33814; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lederer S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000296; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; Li B, 2010, J VIROL, V84, P6248, DOI 10.1128/JVI.00295-10; Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07; Meythaler M, 2011, J IMMUNOL, V186, P5151, DOI 10.4049/jimmunol.1004110; Milush JM, 2007, J IMMUNOL, V179, P3047, DOI 10.4049/jimmunol.179.5.3047; Milush JM, 2011, J CLIN INVEST, V121, P1102, DOI 10.1172/JCI44876; Okoye A, 2007, J EXP MED, V204, P2171, DOI 10.1084/jem.20070567; Ortiz AM, 2011, J CLIN INVEST, V121, P4433, DOI 10.1172/JCI46023; OTSYULA MG, 1995, ANN TROP MED PARASIT, V89, P573, DOI 10.1080/00034983.1995.11812990; Paiardini M, 2011, NAT MED, V17, P830, DOI 10.1038/nm.2395; Paiardini M, 2009, BLOOD, V113, P612, DOI 10.1182/blood-2008-06-159442; Pandrea I, 2008, J IMMUNOL, V181, P6687, DOI 10.4049/jimmunol.181.10.6687; Pandrea I, 2008, J VIROL, V82, P5501, DOI 10.1128/JVI.02555-07; Pandrea I, 2008, J VIROL, V82, P3713, DOI 10.1128/JVI.02402-07; Pandrea I, 2007, BLOOD, V109, P1069, DOI 10.1182/blood-2006-05-024364; Pandrea I, 2006, J MED PRIMATOL, V35, P194, DOI 10.1111/j.1600-0684.2006.00168.x; Pandrea I, 2006, J VIROL, V80, P4858, DOI 10.1128/JVI.80.10.4858-4867.2006; Pandrea IV, 2007, J IMMUNOL, V179, P3035, DOI 10.4049/jimmunol.179.5.3035; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Pepper M, 2011, NAT IMMUNOL, V12, P467, DOI 10.1038/ni.2038; Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Riddick NE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001064; Rotger M, 2011, J CLIN INVEST, V121, P2391, DOI 10.1172/JCI45235; Sauter D, 2009, CELL HOST MICROBE, V6, P409, DOI 10.1016/j.chom.2009.10.004; Schacker TW, 2002, J CLIN INVEST, V110, P1133, DOI [10.1172/JCI200216413, 10.1172/JCI0216413]; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Sedaghat AR, 2008, J VIROL, V82, P1870, DOI 10.1128/JVI.02228-07; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Sodora DL, 2008, AIDS, V22, P439, DOI 10.1097/QAD.0b013e3282f2dbe7; Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013; Sumpter B, 2007, J IMMUNOL, V178, P1680, DOI 10.4049/jimmunol.178.3.1680; VandeWoude S, 2006, CLIN MICROBIOL REV, V19, P728, DOI 10.1128/CMR.00009-06; Wang ZC, 2006, J VIROL, V80, P2771, DOI 10.1128/JVI.80.6.2771-2783.2006; Worobey M, 2010, SCIENCE, V329, P1487, DOI 10.1126/science.1193550; Zeng M, 2011, J CLIN INVEST, V121, P998, DOI 10.1172/JCI45157	69	185	189	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2012	335	6073					1188	1193		10.1126/science.1217550	http://dx.doi.org/10.1126/science.1217550			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403383	Green Accepted			2022-12-28	WOS:000301225100035
J	Wada, K; Kondo, N; Gilmour, S; Ichida, Y; Fujino, Y; Satoh, T; Shibuya, K				Wada, Koji; Kondo, Naoki; Gilmour, Stuart; Ichida, Yukinobu; Fujino, Yoshihisa; Satoh, Toshihiko; Shibuya, Kenji			Trends in cause specific mortality across occupations in Japanese men of working age during period of economic stagnation, 1980-2005: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC INEQUALITIES; HEALTH INEQUALITIES; EUROPEAN COUNTRIES; DEATH; POPULATION; RECESSION; EMPLOYEES; FINLAND	Objective To assess the temporal trends in occupation specific all causes and cause specific mortality in Japan between 1980 and 2005. Design Longitudinal analysis of individual death certificates by last occupation before death. Data on population by age and occupation were derived from the population census. Setting Government records, Japan. Participants Men aged 30-59. Main outcome measures Age standardised mortality rate for all causes, all cancers, cerebrovascular disease, ischaemic heart disease, unintentional injuries, and suicide. Results Age standardised mortality rates for all causes and for the four leading causes of death (cancers, ischaemic heart disease, cerebrovascular disease, and unintentional injuries) steadily decreased from 1980 to 2005 among all occupations except for management and professional workers, for whom rates began to rise in the late 1990s (P<0.001). During the study period, the mortality rate was lowest in other occupations such as production/labour, clerical, and sales workers, although overall variability of the age standardised mortality rate across occupations widened. The rate for suicide rapidly increased since the late 1990s, with the greatest increase being among management and professional workers. Conclusions Occupational patterns in cause specific mortality changed dramatically in Japan during the period of its economic stagnation and resulted in the reversal of occupational patterns in mortality that have been well established in western countries. A significant negative effect on the health of management and professional workers rather than clerks and blue collar workers could be because of increased job demands and more stressful work environments and could have eliminated or even reversed the health inequality across occupations that had existed previously.	[Wada, Koji] Kitasato Univ, Dept Publ Hlth, Sch Med, Minami Ku, Sagamihara, Kanagawa 2520374, Japan; [Kondo, Naoki] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Hlth Sci, Chuo, Yamanashi 4093898, Japan; [Gilmour, Stuart; Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Bunkyo Ku, Tokyo 1130033, Japan; [Ichida, Yukinobu] Nihon Fukushi Univ, Ctr Well Being & Soc, Naka Ku, Nagoya, Aichi 4600012, Japan; [Fujino, Yoshihisa] Univ Occupat & Environm Hlth, Dept Prevent Med & Community Hlth, Yahatanishi Ku, Fukuoka 8078555, Japan; [Satoh, Toshihiko] Kitasato Univ, Sch Med, Kitasato Clin Res Ctr, Minami Ku, Sagamihara, Kanagawa 2520374, Japan	Kitasato University; University of Yamanashi; University of Tokyo; University of Occupational & Environmental Health - Japan; Kitasato University	Wada, K (corresponding author), Kitasato Univ, Dept Publ Hlth, Sch Med, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	kwada-sgy@umin.ac.jp	Kondo, Naoki/K-3898-2012; Fujino, Yoshihisa/F-3054-2010; Kondo, Naoki/ABC-5865-2020	Kondo, Naoki/0000-0002-6425-6844; Fujino, Yoshihisa/0000-0002-9126-206X; Kondo, Naoki/0000-0002-6425-6844; Shibuya, Kenji/0000-0003-2528-7530	Ministry of Education, Culture, Sports, Science, and Technology [22390130, 22119504]; Ministry of Health, Labour and Welfare [H23-seisaku-shitei-033]	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan)	This study was funded by the Ministry of Education, Culture, Sports, Science, and Technology (Grant-in-Aid for Scientific Research (B) No 22390130 and Grant-in-Aid for Scientific Research on Innovative Areas No 22119504) and the Ministry of Health, Labour and Welfare (H23-seisaku-shitei-033). The funders had no role in study design, data collection and analysis, and the decision to publish.	Blakely T, 2008, BRIT MED J, V336, P371, DOI 10.1136/bmj.39455.596181.25; Darr W, 2008, J OCCUP HEALTH PSYCH, V13, P293, DOI 10.1037/a0012639; Fujino Y, 2005, SUICIDE LIFE-THREAT, V35, P227, DOI 10.1521/suli.35.2.227.62876; Granados JAT, 2008, DEMOGRAPHY, V45, P323, DOI 10.1353/dem.0.0008; Harding S, 1995, Popul Trends, P31; Ikeda N, 2011, LANCET, V378, P1094, DOI 10.1016/S0140-6736(11)61055-6; Ito T., 2005, REVIVING JAPANS EC P; Kagamimori S, 2009, SOC SCI MED, V68, P2152, DOI 10.1016/j.socscimed.2009.03.030; KAWAKAMI N, 1992, SOC PSYCH PSYCH EPID, V27, P198, DOI 10.1007/BF00789006; Khang YH, 2004, J EPIDEMIOL COMMUN H, V58, P308, DOI 10.1136/jech.2003.012989; Kondo N, 2008, J EPIDEMIOL COMMUN H, V62, P869, DOI 10.1136/jech.2007.070334; Kunst AE, 1999, AM J PUBLIC HEALTH, V89, P47, DOI 10.2105/AJPH.89.1.47; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; Martikainen P, 2001, J EPIDEMIOL COMMUN H, V55, P494, DOI 10.1136/jech.55.7.494; McCurry J, 2008, LANCET, V371, P2071, DOI 10.1016/S0140-6736(08)60900-9; *MIN HLTH LAB WELF, 2004, COMPR SURV LIV COND; Ministry of Health Labour and Welfare Japan, 2009, VIT STAT JAP 1950 20; Ministry of Internal Affairs and Communications, 1997, JAP STAND OCC CLASS; Ministry of Internal Affairs and Communications, 2010, LAB FORC SURV; Ministry of Internal Affairs and Communications, 1995, POP CENS; Ministry of Internal Affairs and Communications Japan, SURV LAB FORC JAP; Ministry of Internal Affairs and Communications Japan, 2006, POP JAP; Naghavi M, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-9; National Cancer Centre Japan, 2010, CANC STAT JAP; Organisation for Economic Co-operation and Development, 1989, EMPL OUTL; Ruhm CJ, 2005, INT J EPIDEMIOL, V34, P1206, DOI 10.1093/ije/dyi143; Statistics and Information Department Minister's Secretariat, 1980, VIT STAT; Statistics of Finland, 2010, CLASS OCC 2010; Tachibanaki T., 2005, CONFRONTING INCOME I; Takao S, 2003, SOC SCI MED, V57, P2281, DOI 10.1016/S0277-9536(03)00134-5; Takashima Y, 1998, J Epidemiol, V8, P216; Valkonen T, 2000, EUR J PUBLIC HEALTH, V10, P274, DOI 10.1093/eurpub/10.4.274; *WHO, 2010, WHO MORT DAT; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; Williams GM, 2006, B WORLD HEALTH ORGAN, V84, P198, DOI 10.2471/BLT.05.028894; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	37	76	76	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2012	344								e1191	10.1136/bmj.e1191	http://dx.doi.org/10.1136/bmj.e1191			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GM	22396155	Green Published, hybrid			2022-12-28	WOS:000301478900002
J	Palmerini, T; Biondi-Zoccai, G; Della Riva, D; Stettler, C; Sangiorgi, D; D'Ascenzo, F; Kimura, T; Briguori, C; Sabate, M; Kim, HS; De Waha, A; Kedhi, E; Smits, PC; Kaiser, C; Sardella, G; Marullo, A; Kirtane, AJ; Leon, MB; Stone, GW				Palmerini, Tullio; Biondi-Zoccai, Giuseppe; Della Riva, Diego; Stettler, Christoph; Sangiorgi, Diego; D'Ascenzo, Fabrizio; Kimura, Takeshi; Briguori, Carlo; Sabate, Manel; Kim, Hyo-Soo; De Waha, Antoinette; Kedhi, Elvin; Smits, Pieter C.; Kaiser, Christoph; Sardella, Gennaro; Marullo, Antonino; Kirtane, Ajay J.; Leon, Martin B.; Stone, Gregg W.			Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis	LANCET			English	Article							CORONARY; PREDICTORS; RECOVERY; LESIONS; TRIALS; SAFETY	Background The relative safety of drug-eluting stents and bare-metal stents, especially with respect to stent thrombosis, continues to be debated. In view of the overall low frequency of stent thrombosis, large sample sizes are needed to accurately estimate treatment differences between stents. We compared the risk of thrombosis between bare-metal and drug-eluting stents. Methods For this network meta-analysis, randomised controlled trials comparing different drug-eluting stents or drug-eluting with bare-metal stents currently approved in the USA were identified through Medline, Embase, Cochrane databases, and proceedings of international meetings. Information about study design, inclusion and exclusion criteria, sample characteristics, and clinical outcomes was extracted. Findings 49 trials including 50 844 patients randomly assigned to treatment groups were analysed. 1-year definite stent thrombosis was significantly lower with cobalt-chromium everolimus eluting stents (CoCr-EES) than with bare-metal stents (odds ratio [OR] 0.23, 95% CI 0.13-0.41). The significant difference in stent thrombosis between CoCr-EES and bare-metal stents was evident as early as 30 days (OR 0.21, 95% CI 0.11-0.42) and was also significant between 31 days and 1 year (OR 0.27, 95% CI 0.08-0.74). CoCr-EES were also associated with significantly lower rates of 1-year definite stent thrombosis compared with paclitaxel-eluting stents (OR 0.28, 95% CI 0.16-0.48), permanent polymer-based sirolimus-eluting stents (OR 0.41, 95% CI 0.24-0.70), phosphorylcholine-based zotarolimus-eluting stents (OR 0.21, 95% CI 0.10-0.44), and Resolute zotarolimus-eluting stents (OR 0.14, 95% CI 0.03-0.47). At 2-year follow-up, CoCr-EES were still associated with significantly lower rates of definite stent thrombosis than were bare-metal (OR 0.35, 95% CI 0.17-0.69) and paclitaxel-eluting stents (OR 0.34, 95% CI 0.19-0.62). No other drug-eluting stent had lower definite thrombosis rates compared with bare-metal stents at 2-year follow-up. Interpretation In randomised studies completed to date, CoCr-EES has the lowest rate of stent thrombosis within 2 years of implantation. The finding that CoCr-EES also reduced stent thrombosis compared with bare-metal stents, if confirmed in future randomised trials, represents a paradigm shift.	[Stone, Gregg W.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Cardiovasc Res Fdn, New York, NY 10022 USA; [Palmerini, Tullio; Della Riva, Diego; Sangiorgi, Diego] Policlin S Orsola, Ist Cardiol, Bologna, Italy; [Biondi-Zoccai, Giuseppe; Marullo, Antonino] Univ Roma La Sapienza, Dept Med Surg Sci & Biotechnol, Latina, Italy; [Sardella, Gennaro] Univ Roma La Sapienza, Umberto I Hosp, Cardiovasc Resp Geriatr & Nephrol Sci Dept, Latina, Italy; [Stettler, Christoph] Univ Hosp Bern, Div Endocrinol Diabet & Clin Nutr, CH-3010 Bern, Switzerland; [Stettler, Christoph] Univ Bern, Bern, Switzerland; [D'Ascenzo, Fabrizio] Univ Turin, Div Cardiol, Turin, Italy; [Kimura, Takeshi] Kyoto Univ, Grad Sch Med, Kyoto, Japan; [Briguori, Carlo] Clin Mediterranea, Dept Cardiol, Naples, Italy; [Sabate, Manel] Hosp Clin Barcelona, Barcelona, Spain; [Kim, Hyo-Soo] Seoul Natl Univ Hosp, Ctr Cardiovasc, Seoul 110744, South Korea; [De Waha, Antoinette] Tech Univ Munich, Deutsch Herzzentrum, ISAR Res Ctr, Munich, Germany; [Kedhi, Elvin; Smits, Pieter C.] Maasstad Ziekenhuis, Dept Cardiol, Rotterdam, Netherlands; [Kaiser, Christoph] Univ Basel Hosp, CH-4031 Basel, Switzerland	Cardiovascular Research Foundation (CRF); Columbia University; NewYork-Presbyterian Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Sapienza University Rome; Sapienza University Rome; University of Bern; University Hospital of Bern; University of Bern; University of Turin; Kyoto University; Mediterranean Clinic; University of Barcelona; Hospital Clinic de Barcelona; Seoul National University (SNU); Seoul National University Hospital; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Maasstad Hospital; University of Basel	Stone, GW (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, Cardiovasc Res Fdn, New York, NY 10022 USA.	gs2184@columbia.edu	D'Ascenzo, Fabrizio/D-2447-2012; Biondi-Zoccai, Giuseppe/C-9670-2012; Sabate, Manel/AAX-7245-2021; Palmerini, Tullio/K-4543-2016; Kaiser, Christoph/AAA-9284-2022; Kedhi, Elvin/GNW-5801-2022	D'Ascenzo, Fabrizio/0000-0002-6646-9317; Biondi-Zoccai, Giuseppe/0000-0001-6103-8510; Marullo, Antonino GM/0000-0003-2565-832X; Stettler, Christoph/0000-0003-1691-6059	Abbott; Cordis; Medtronic; Abbott Vascular; Terumo; Biotronik Switzerland; Abbott Vascular Switzerland; Daiichi Sankyo Switzerland; Eli Lilly Switzerland; AstraZeneca Switzerland; Cardiovascular Research Foundation (New York, NY, USA); Cardiovascular Research Foundation	Abbott(Abbott Laboratories); Cordis; Medtronic(Medtronic); Abbott Vascular(Abbott Laboratories); Terumo; Biotronik Switzerland; Abbott Vascular Switzerland; Daiichi Sankyo Switzerland(Daiichi Sankyo Company Limited); Eli Lilly Switzerland(Eli Lilly); AstraZeneca Switzerland(AstraZeneca); Cardiovascular Research Foundation (New York, NY, USA); Cardiovascular Research Foundation	The Cardiovascular Research Foundation.; TP has received speakers' fees from Abbott. GB-Z has lectured or consulted for Abbott Vascular, Boston Scientific, Cordis, and Medtronic. TK is an advisory board member for Cordis Cardiology and Abbott Vascular. MS has received speakers' fees from Cordis, Abbott, and Medtronic. PS has received speaking and travel fees from Abbott Vascular and Terumo and has a consultant agreement with Blue Medical. CK is on the advisory board of Daichii Sankyo Switzerland, Eli Lilly Switzerland, AstraZeneca Switzerland, STENTYS, and has received speakers' fees from Biotronik Switzerland, Abbott Vascular Switzerland, Daiichi Sankyo Switzerland, Eli Lilly Switzerland, and AstraZeneca Switzerland. ML is a member (non-paid) of scientific advisory boards for Abbott, Boston Scientific, and Medtronic. GWS reports having served as a consultant for Atrium Medical, Osprey, Reva, Merck, Abbott Vascular, Boston Scientific, Evalve, AstraZeneca, Eli Lilly-Daiichi Sankyo partnership, Bristol-Meyers Squibb-Sanofi partnership, Otsuka, The Medicines Company, Ortho-McNeil, Gilead, InspireMD, TherOx, Volcano, InfraReDx, Medtronic, Genentech, GlaxoSmithKline, Miracor, MPP group, and Lutonix, having received honoraria from Edwards and Vascular Solutions, and holding stock or stock options from CoreValve, Savacor, Biostar I and II funds, MedFocus I, II, and Accelerator funds, Caliber, Flowcardia, Mediguide, Guided Delivery Systems, Ovalum, Arstasis, Micardia, Access Closure, Embrella, and VNT. CS, DDR, FD'A, CB, AK, EK, ADW, H-SK, GS, AM, and DS declare that they have no conflicts of interest.; We thank Peter Juni for his thorough review of this report and thoughtful suggestions. The present study was supported by The Cardiovascular Research Foundation (New York, NY, USA), without external funding.	Airoldi F, 2007, CIRCULATION, V116, P745, DOI 10.1161/CIRCULATIONAHA.106.686048; Chin-Quee SL, 2010, BIOMATERIALS, V31, P648, DOI 10.1016/j.biomaterials.2009.09.079; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; de Waha A, 2011, CIRC-CARDIOVASC INTE, V4, P371, DOI 10.1161/CIRCINTERVENTIONS.111.963256; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Jensen LO, 2012, CIRCULATION, V125, P1246, DOI 10.1161/CIRCULATIONAHA.111.063644; Joner M, 2008, J AM COLL CARDIOL, V52, P333, DOI 10.1016/j.jacc.2008.04.030; Joner M, 2006, J AM COLL CARDIOL, V48, P193, DOI 10.1016/j.jacc.2006.03.042; Kaiser C, 2010, NEW ENGL J MED, V363, P2310, DOI 10.1056/NEJMoa1009406; Kedhi E, 2010, LANCET, V375, P201, DOI 10.1016/S0140-6736(09)62127-9; Kolandaivelu K, 2011, CIRCULATION, V123, P1400, DOI 10.1161/CIRCULATIONAHA.110.003210; Krone RJ, 2010, JACC-CARDIOVASC INTE, V3, P902, DOI 10.1016/j.jcin.2010.06.014; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin JC, 2000, J BIOMAT SCI-POLYM E, V11, P701, DOI 10.1163/156856200743968; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Nakazawa G, 2010, J AM COLL CARDIOL, V55, P1679, DOI 10.1016/j.jacc.2010.01.021; Palmerini T, 2011, CIRC-CARDIOVASC INTE, V4, P577, DOI 10.1161/CIRCINTERVENTIONS.111.963884; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; Raber L, 2011, J AM COLL CARDIOL, V57, P2143, DOI 10.1016/j.jacc.2011.01.023; Sabate M, 2011, C EUR SOC CARD AUG 2; Schampaert E, 2004, J AM COLL CARDIOL, V43, P1110, DOI 10.1016/j.jacc.2004.01.024; Serruys PW, 2010, NEW ENGL J MED, V363, P136, DOI 10.1056/NEJMoa1004130; Song F, 2008, J CLIN EPIDEMIOL, V61, P455, DOI 10.1016/j.jclinepi.2007.06.006; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stone GW, 2008, JAMA-J AM MED ASSOC, V299, P1903, DOI 10.1001/jama.299.16.1903; Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193; Stone GW, 2010, NEW ENGL J MED, V362, P1663, DOI 10.1056/NEJMoa0910496; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Tu JV, 2007, NEW ENGL J MED, V357, P1393, DOI 10.1056/NEJMoa071076; von Birgelen C, 2011, TRANSC CARD THER TCT	31	736	750	6	163	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2012	379	9824					1393	1402		10.1016/S0140-6736(12)60324-9	http://dx.doi.org/10.1016/S0140-6736(12)60324-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926BR	22445239				2022-12-28	WOS:000302806800027
J	Mosca, TJ; Hong, WZ; Dani, VS; Favaloro, V; Luo, LQ				Mosca, Timothy J.; Hong, Weizhe; Dani, Vardhan S.; Favaloro, Vincenzo; Luo, Liqun			Trans-synaptic Teneurin signalling in neuromuscular synapse organization and target choice	NATURE			English	Article							MOSAIC ANALYSIS; BETA-SPECTRIN; PAIR-RULE; IN-VIVO; DROSOPHILA; GENE; JUNCTION; GROWTH; LOCALIZATION; SPECIFICITY	Synapse assembly requires trans-synaptic signals between the pre- and postsynapse(1), but our understanding of the essential organizational molecules involved in this process remains incomplete(2). Teneurin proteins are conserved, epidermal growth factor (EGF)-repeat-containing transmembrane proteins with large extracellular domains(3). Here we show that two Drosophila Teneurins, Ten-m and Ten-a, are required for neuromuscular synapse organization and target selection. Ten-a is presynaptic whereas Ten-m is mostly postsynaptic; neuronal Ten-a and muscle Ten-m form a complex in vivo. Pre- or postsynaptic Teneurin perturbations cause severe synapse loss and impair many facets of organization trans-synaptically and cell autonomously. These include defects in active zone apposition, release sites, membrane and vesicle organization, and synaptic transmission. Moreover, the presynaptic microtubule and postsynaptic spectrin cytoskeletons are severely disrupted, suggesting a mechanism whereby Teneurins organize the cytoskeleton, which in turn affects other aspects of synapse development. Supporting this, Ten-m physically interacts with a-Spectrin. Genetic analyses of teneurin and neuroligin reveal that they have differential roles that synergize to promote synapse assembly. Finally, at elevated endogenous levels, Ten-m regulates target selection between specific motor neurons and muscles. Our study identifies the Teneurins as a key bi-directional trans-synaptic signal involved in general synapse organization, and demonstrates that proteins such as these can also regulate target selection.	[Mosca, Timothy J.; Hong, Weizhe; Dani, Vardhan S.; Favaloro, Vincenzo; Luo, Liqun] Stanford Univ, Howard Hughes Med Inst, Dept Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Mosca, TJ (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biol, Stanford, CA 94305 USA.	tmosca@stanford.edu	Hong, Weizhe/AAD-7172-2020; Hong, Weizhe/E-3164-2010	Hong, Weizhe/0000-0003-1523-8575; Hong, Weizhe/0000-0003-1523-8575; Mosca, Timothy/0000-0003-3485-0719; Luo, Liqun/0000-0001-5467-9264	National Institutes of Health (NIH) [R01 DC-005982, 5T32 NS007280, HD007249]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005982] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank H. Aberle, V. Budnik, A. DiAntonio, R. Dubreuil, D. Featherstone, N. Reist, T. Schwarz, S. Stowers, D. Van Vactor, R. Wides, the Bloomington Stock Center and the Developmental Studies Hybridoma Bank for fly stocks, antibodies and reagents; J. Perrino and D. Luginbuhl for technical assistance; K. Shen, K. Zinn, D. Banovic, D. Berns, Y. Chou, C. A. Frank, X. Gao, S. Hippenmeyer, K. Miyamichi, K. Sillar, B. Tasic, X. Yu and S. Zosimus for critiques. Supported by a National Institutes of Health (NIH) grant (R01 DC-005982 to L.L.), and Epilepsy, Neonatology and Developmental Biology Training Grants (NIH 5T32 NS007280 and HD007249 to T.J.M.). L.L. is an investigator of the Howard Hughes Medical Institute.	Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; Banovic D, 2010, NEURON, V66, P724, DOI 10.1016/j.neuron.2010.05.020; Ben-Yaacov S, 2001, J CELL BIOL, V152, P1, DOI 10.1083/jcb.152.1.1; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; Craig AM, 2007, CURR OPIN NEUROBIOL, V17, P43, DOI 10.1016/j.conb.2007.01.011; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Featherstone DE, 2001, J NEUROSCI, V21, P4215, DOI 10.1523/JNEUROSCI.21-12-04215.2001; Giagtzoglou N, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003079; Higashi-Kovtun ME, 2010, J NEUROSCI, V30, P5253, DOI 10.1523/JNEUROSCI.3739-09.2010; Kenzelmann D, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-30; Kittel RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/science.1126308; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kurusu M, 2008, NEURON, V59, P972, DOI 10.1016/j.neuron.2008.07.037; Laissue PP, 1999, J COMP NEUROL, V405, P543; Landgraf M, 1999, NEURON, V22, P43, DOI 10.1016/S0896-6273(00)80677-7; Leamey CA, 2007, PLOS BIOL, V5, P2077, DOI 10.1371/journal.pbio.0050241; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Li H, 2006, MOL CELL NEUROSCI, V33, P136, DOI 10.1016/j.mcn.2006.06.012; Li J, 2007, NEURON, V55, P741, DOI 10.1016/j.neuron.2007.08.002; Liebl FLW, 2006, J NEUROBIOL, V66, P332, DOI 10.1002/neu.20229; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lnenicka GA, 2003, J NEUROBIOL, V54, P337, DOI 10.1002/neu.10133; Loewen CA, 2001, GENESIS, V31, P30, DOI 10.1002/gene.10002; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Markstein M, 2008, NAT GENET, V40, P476, DOI 10.1038/ng.101; Marrus SB, 2004, J NEUROSCI, V24, P1406, DOI 10.1523/JNEUROSCI.1575-03.2004; MARTIN AR, 1955, J PHYSIOL-LONDON, V130, P114, DOI 10.1113/jphysiol.1955.sp005397; Miech C, 2008, J NEUROSCI, V28, P10875, DOI 10.1523/JNEUROSCI.0164-08.2008; Mosca TJ, 2010, NAT NEUROSCI, V13, P935, DOI 10.1038/nn.2593; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Owald D, 2010, J CELL BIOL, V188, P565, DOI 10.1083/jcb.200908055; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; Petersen LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024531; Pielage J, 2006, J CELL BIOL, V175, P491, DOI 10.1083/jcb.200607036; Pielage J, 2011, NEURON, V69, P1114, DOI 10.1016/j.neuron.2011.02.007; Potter CJ, 2010, CELL, V141, P536, DOI 10.1016/j.cell.2010.02.025; Rakovitsky N, 2007, MECH DEVELOP, V124, P911, DOI 10.1016/j.mod.2007.08.003; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; Sanes JR, 2009, ANNU REV CELL DEV BI, V25, P161, DOI 10.1146/annurev.cellbio.24.110707.175402; Silva JP, 2011, P NATL ACAD SCI USA, V108, P12113, DOI 10.1073/pnas.1019434108; Sone M, 2000, DEVELOPMENT, V127, P4157; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Sun BH, 1999, P NATL ACAD SCI USA, V96, P10438, DOI 10.1073/pnas.96.18.10438; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Verstreken Patrik, 2008, V440, P349, DOI 10.1007/978-1-59745-178-9_26; Wagh DA, 2006, NEURON, V49, P833, DOI 10.1016/j.neuron.2006.02.008; Wichmann C, 2010, J NEUROGENET, V24, P133, DOI 10.3109/01677063.2010.489626; Williams ME, 2010, NEURON, V68, P9, DOI 10.1016/j.neuron.2010.09.007; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Young TR, 2009, INT J BIOCHEM CELL B, V41, P990, DOI 10.1016/j.biocel.2008.06.014; Zheng LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022956; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	57	139	145	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					237	U122		10.1038/nature10923	http://dx.doi.org/10.1038/nature10923			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22426000	Green Accepted			2022-12-28	WOS:000303149900034
J	Firestone, AJ; Weinger, JS; Maldonado, M; Barlan, K; Langston, LD; O'Donnell, M; Gelfand, VI; Kapoor, TM; Chen, JK				Firestone, Ari J.; Weinger, Joshua S.; Maldonado, Maria; Barlan, Kari; Langston, Lance D.; O'Donnell, Michael; Gelfand, Vladimir I.; Kapoor, Tarun M.; Chen, James K.			Small-molecule inhibitors of the AAA plus ATPase motor cytoplasmic dynein	NATURE			English	Article							PRIMARY CILIUM; IN-VITRO; DYNACTIN; KINETOCHORE; ORGANIZATION; CENTROSOMES; TRANSPORT; PROTEINS; MOTILITY; KINESIN	The conversion of chemical energy into mechanical force by AAA+ (ATPases associated with diverse cellular activities) ATPases is integral to cellular processes, including DNA replication, protein unfolding, cargo transport and membrane fusion(1). The AAA+ ATPase motor cytoplasmic dynein regulates ciliary trafficking(2), mitotic spindle formation(3) and organelle transport(4), and dissecting its precise functions has been challenging because of its rapid timescale of action and the lack of cell-permeable, chemical modulators. Here we describe the discovery of ciliobrevins, the first specific small-molecule antagonists of cytoplasmic dynein. Ciliobrevins perturb protein trafficking within the primary cilium, leading to their malformation and Hedgehog signalling blockade. Ciliobrevins also prevent spindle pole focusing, kinetochore-microtubule attachment, melanosome aggregation and peroxisome motility in cultured cells. We further demonstrate the ability of ciliobrevins to block dynein-dependent microtubule gliding and ATPase activity in vitro. Ciliobrevins therefore will be useful reagents for studying cellular processes that require this microtubule motor and may guide the development of additional AAA+ ATPase superfamily inhibitors.	[Firestone, Ari J.; Chen, James K.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Weinger, Joshua S.; Maldonado, Maria; Langston, Lance D.; O'Donnell, Michael; Kapoor, Tarun M.] Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA; [Barlan, Kari; Gelfand, Vladimir I.] Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Stanford University; Rockefeller University; Northwestern University	Chen, JK (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA.	kapoor@rockefeller.edu; jameschen@stanford.edu	Chen, James/G-9972-2011; Gelfand, Vladimir/M-1974-2019; Gelfand, Vladimir I/D-2545-2013	Chen, James/0000-0002-9220-8436; Gelfand, Vladimir/0000-0002-6361-2798; Gelfand, Vladimir I/0000-0002-6361-2798; O'Donnell, Michael/0000-0001-9002-4214; Langston, Lance/0000-0002-2736-9284; Maldonado, Maria/0000-0002-3428-1053; Firestone, Ari/0000-0001-9902-443X	National Institutes of Health [R01 CA136574, R01 GM65933, R01 GM71772, R01 GM52111]; NATIONAL CANCER INSTITUTE [R01CA136574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R01GM052111, R01GM065933] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Caspary for anti-Arl13b antibodies, W. Brinkley for human CREST anti-serum, T. Yen for anti-CENP-E antibodies, U. Peters for purified bovine dynein, S. Wacker for human kinesin-5 motor domain, R. Vallee for a pVL1393 baculovirus expression vector containing the rat dynein motor domain, and K. Bersuker and R. Kopito for TCR-alpha-GFP-expressing cells. This work was supported by funding from the National Institutes of Health (R01 CA136574 to J.K.C.; R01 GM65933 to T.M.K.; R01 GM71772 to T.M.K. and V.I.G.; R01 GM52111 to V.I.G.)	Akhmanova A, 2010, CURR OPIN CELL BIOL, V22, P479, DOI 10.1016/j.ceb.2010.04.008; Arasaki K, 2007, MOL PHARMACOL, V71, P454, DOI 10.1124/mol.106.029611; BOUCHARD P, 1981, P NATL ACAD SCI-BIOL, V78, P1033, DOI 10.1073/pnas.78.2.1033; Chou TF, 2011, P NATL ACAD SCI USA, V108, P4834, DOI 10.1073/pnas.1015312108; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hook P, 2005, J BIOL CHEM, V280, P33045, DOI 10.1074/jbc.M504693200; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; Kim H, 2007, J CELL BIOL, V176, P641, DOI 10.1083/jcb.200608128; Kim J, 2009, P NATL ACAD SCI USA, V106, P21666, DOI 10.1073/pnas.0912180106; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; Maldonado M, 2011, NAT CELL BIOL, V13, P475, DOI 10.1038/ncb2223; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Park S, 1998, CANCER LETT, V127, P23, DOI 10.1016/S0304-3835(97)00543-0; SCHLIWA M, 1984, P NATL ACAD SCI-BIOL, V81, P6044, DOI 10.1073/pnas.81.19.6044; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Varma D, 2008, J CELL BIOL, V182, P1045, DOI 10.1083/jcb.200710106; White SR, 2007, TRAFFIC, V8, P1657, DOI 10.1111/j.1600-0854.2007.00642.x; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zhu GY, 2006, J MED CHEM, V49, P2063, DOI 10.1021/jm051030l	30	270	272	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					125	129		10.1038/nature10936	http://dx.doi.org/10.1038/nature10936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22425997	Green Accepted			2022-12-28	WOS:000302343400047
J	Johnson, ZL; Cheong, CG; Lee, SY				Johnson, Zachary Lee; Cheong, Cheom-Gil; Lee, Seok-Yong			Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 angstrom	NATURE			English	Article							CONSERVED GLUTAMATE RESIDUES; CNT FAMILY; DRUGS; IDENTIFICATION; COTRANSPORT; PYRIMIDINE; RESISTANCE; HOMOLOG; REVEALS; PROTEIN	Nucleosides are required for DNA and RNA synthesis, and the nucleoside adenosine has a function in a variety of signalling processes(1,2). Transport of nucleosides across cell membranes provides the major source of nucleosides in many cell types and is also responsible for the termination of adenosine signalling. As a result of their hydrophilic nature, nucleosides require a specialized class of integral membrane proteins, known as nucleoside transporters (NTs), for specific transport across cell membranes. In addition to nucleosides, NTs are important determinants for the transport of nucleoside-derived drugs across cell membranes(3-5). A wide range of nucleoside-derived drugs, including anticancer drugs (such as Ara-C and gemcitabine) and antiviral drugs (such as zidovudine and ribavirin), have been shown to depend, at least in part, on NTs for transport across cell membranes(4,6-13). Concentrative nucleoside transporters, members of the solute carrier transporter superfamily SLC28, use an ion gradient in the active transport of both nucleosides and nucleoside-derived drugs against their chemical gradients. The structural basis for selective ion-coupled nucleoside transport by concentrative nucleoside transporters is unknown. Here we present the crystal structure of a concentrative nucleoside transporter from Vibrio cholerae in complex with uridine at 2.4 angstrom. Our functional data show that, like its human orthologues, the transporter uses a sodium-ion gradient for nucleoside transport. The structure reveals the overall architecture of this class of transporter, unravels the molecular determinants for nucleoside and sodium binding, and provides a framework for understanding the mechanism of nucleoside and nucleoside drug transport across cell membranes.	[Johnson, Zachary Lee; Cheong, Cheom-Gil; Lee, Seok-Yong] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; [Johnson, Zachary Lee; Cheong, Cheom-Gil; Lee, Seok-Yong] Duke Univ, Med Ctr, Ion Channel Res Unit, Durham, NC 27710 USA	Duke University; Duke University	Lee, SY (corresponding author), Duke Univ, Med Ctr, Dept Biochem, 2 Genome Court, Durham, NC 27710 USA.	sylee@biochem.duke.edu			Duke University Medical Center; McKnight Endowment Fund for Neuroscience; Alfred P. Sloan Foundation; Klingenstein Fund; Mallinckrodt foundation; March of Dimes Foundation [5-FY10-473]; National Institutes of Health [1 DP2 OD008380-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100984] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008380] Funding Source: NIH RePORTER	Duke University Medical Center; McKnight Endowment Fund for Neuroscience; Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Klingenstein Fund(Klingenstein Philanthropies); Mallinckrodt foundation; March of Dimes Foundation(March of Dimes); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Data for this study were collected at beamlines SER-CAT BM22/ID22 and NE-CAT ID 24-C at the Advanced Photon Source. We thank R. MacKinnon and J. Butterwick for critical reading; R. Lefkowitz and A. Shukla for providing access and technical support for the radioactive flux assay; S. Lockless for advice on experiments; and C. Pemble for help with remote data collection. This work was supported by start-up funds from the Duke University Medical Center, the McKnight Endowment Fund for Neuroscience, the Alfred P. Sloan Foundation, the Klingenstein Fund, the Mallinckrodt foundation, the Basil O'Connor Starter Scholar Research Award 5-FY10-473 from the March of Dimes Foundation, and the National Institutes of Health Director's New Innovator Award 1 DP2 OD008380-01 (all to S.-Y.L.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Cano-Soldado P, 2008, BIOCHEM PHARMACOL, V75, P639, DOI 10.1016/j.bcp.2007.10.005; Cao Y, 2011, NATURE, V473, P50, DOI 10.1038/nature09939; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Errasti-Murugarren E, 2010, PHARMACOGENOMICS, V11, P809, DOI [10.2217/pgs.10.70, 10.2217/PGS.10.70]; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Jordheim LP, 2007, BBA-REV CANCER, V1776, P138, DOI 10.1016/j.bbcan.2007.07.004; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Koszelak-Rosenblum M, 2009, PROTEIN SCI, V18, P1828, DOI 10.1002/pro.193; Krishnamurthy H, 2009, NATURE, V459, P347, DOI 10.1038/nature08143; Lee SY, 2009, J MOL BIOL, V387, P1055, DOI 10.1016/j.jmb.2009.02.034; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 2002, CLIN CANCER RES, V8, P110; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Molina-Arcas M, 2009, CURR VASC PHARMACOL, V7, P426, DOI 10.2174/157016109789043892; Nagai K, 2005, CANCER CHEMOTH PHARM, V55, P222, DOI 10.1007/s00280-004-0861-7; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; Pastor-Anglada M, 2004, LEUKEMIA, V18, P385, DOI 10.1038/sj.leu.2403271; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Rose JB, 2008, PHYSIOLOGY, V23, P41, DOI 10.1152/physiol.00036.2007; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Slugoski MD, 2009, J BIOL CHEM, V284, P17281, DOI 10.1074/jbc.M109.009704; Slugoski MD, 2009, J BIOL CHEM, V284, P17266, DOI 10.1074/jbc.M109.009613; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yao SYM, 2007, J BIOL CHEM, V282, P30607, DOI 10.1074/jbc.M703285200; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476; Zhang J, 2007, CANCER METAST REV, V26, P85, DOI 10.1007/s10555-007-9044-4	39	89	91	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					489	U150		10.1038/nature10882	http://dx.doi.org/10.1038/nature10882			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22407322	Green Accepted			2022-12-28	WOS:000301771200048
J	Penney, HD; Hassall, C; Skevington, JH; Abbott, KR; Sherratt, TN				Penney, Heather D.; Hassall, Christopher; Skevington, Jeffrey H.; Abbott, Kevin R.; Sherratt, Thomas N.			A comparative analysis of the evolution of imperfect mimicry	NATURE			English	Article							SYRPHIDAE DIPTERA; PHYLOGENY; SIZE; HOVERFLIES; PIGEONS; MTDNA	Although exceptional examples of adaptation are frequently celebrated, some outcomes of natural selection seem far from perfect. For example, many hoverflies (Diptera: Syrphidae) are harmless (Batesian(1)) mimics of stinging Hymenoptera(2). However, although some hoverfly species are considered excellent mimics, other species bear only a superficial resemblance to their models(3) and it is unclear why this is so. To evaluate hypotheses that have been put forward to explain interspecific variation in the mimetic fidelity of Palearctic Syrphidae we use a comparative approach. We show that the most plausible explanation is that predators impose less selection for mimetic fidelity on smaller hoverfly species because they are less profitable prey items. In particular, our findings, in combination with previous results, allow us to reject several key hypotheses for imperfect mimicry: first, human ratings of mimetic fidelity are positively correlated with both morphometric measures and avian rankings, indicating that variation in mimetic fidelity is not simply an illusion based on human perception(4); second, no species of syrphid maps out in multidimensional space as being intermediate in appearance between several different hymenopteran model species, as the multimodel hypothesis(5) requires; and third, we find no evidence for a negative relationship between mimetic fidelity and abundance, which calls into question the kin-selection(6) hypothesis. By contrast, a strong positive relationship between mimetic fidelity and body size supports the relaxed-selection hypothesis(7,8), suggesting that reduced predation pressure on less profitable prey species limits the selection for mimetic perfection.	[Penney, Heather D.; Hassall, Christopher; Skevington, Jeffrey H.; Abbott, Kevin R.; Sherratt, Thomas N.] Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; [Skevington, Jeffrey H.] Agr & Agri Food Canada, Canadian Natl Collect Insects Arachnids & Nematod, Ottawa, ON K1A 0C6, Canada	Carleton University; Agriculture & Agri Food Canada	Sherratt, TN (corresponding author), Carleton Univ, Dept Biol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.	sherratt@connect.carleton.ca	Hassall, Christopher/H-2469-2013	Hassall, Christopher/0000-0002-3510-0728; Abbott, Kevin/0000-0003-0682-2024; Penney, Heather/0000-0001-7259-3931	Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation; Ontario Innovation Trust; Agriculture and Agri-Food Canada; Canadian Centre for DNA Barcoding; NSERC Canpolin; Ontario MRI	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Ontario Innovation Trust; Agriculture and Agri-Food Canada(Agriculture & Agri Food Canada); Canadian Centre for DNA Barcoding; NSERC Canpolin; Ontario MRI	We thank W. Knee for help with the Bayesian analysis, and R. Laird, G. Ruxton and M. Speed for comments on the manuscript. The human aspect of this research was approved by the Carleton University Research Ethics Committee and conducted according to the guidelines set out in the Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans; subjects gave informed consent. The work was supported by grants to T.N.S. from the Natural Sciences and Engineering Research Council of Canada (NSERC), the Canada Foundation for Innovation and the Ontario Innovation Trust, and to J.H.S. from Agriculture and Agri-Food Canada, the Canadian Centre for DNA Barcoding and NSERC Canpolin. C. H. was supported by an Ontario MRI Fellowship.	[Anonymous], 2010, R LANG ENV STAT COMP; [Anonymous], 2015, PHYTOPATHOLOGY, DOI DOI 10.1094/PHYTO-04-15-0101-RVW; Bain RS, 2007, P R SOC B, V274, P1949, DOI 10.1098/rspb.2007.0458; Bates H.W., 1862, T LINN SOC LOND, V23, P495; Chittka L, 2007, PLOS BIOL, V5, P2754, DOI 10.1371/journal.pbio.0050339; CUTHILL IC, 1993, P ROY SOC B-BIOL SCI, V253, P203, DOI 10.1098/rspb.1993.0103; DITTRICH W, 1993, P ROY SOC B-BIOL SCI, V251, P195, DOI 10.1098/rspb.1993.0029; DUNCAN C. J., 1965, BEHAVIOUR, V24, P269, DOI 10.1163/156853965X00066; Edmunds M, 2000, BIOL J LINN SOC, V70, P459; Edmunds M, 2006, BIOL J LINN SOC, V88, P645, DOI 10.1111/j.1095-8312.2006.00649.x; Fletcher T. D., 2010, PSYCHOMETRIC APPL PS; Friendly M, 2010, CANDISC GEN CANONICA; Gibson JF, 2010, MOL PHYLOGENET EVOL, V56, P91, DOI 10.1016/j.ympev.2010.03.026; GILBERT F, 1990, J ANIM ECOL, V59, P21, DOI 10.2307/5156; Gilbert Francis, 2005, P231, DOI 10.1079/9780851998121.0231; Green PR, 1999, BEHAV PROCESS, V46, P97, DOI 10.1016/S0376-6357(99)00022-4; Hagman M, 2003, EVOLUTION, V57, P2904; Harper GR, 2007, P R SOC B, V274, P1955, DOI 10.1098/rspb.2007.0558; Holen OH, 2004, AM NAT, V164, P598, DOI 10.1086/424972; Iserbyt A, 2011, P ROY SOC B-BIOL SCI, V278, P3116, DOI 10.1098/rspb.2011.0126; Janzen DH, 2010, P NATL ACAD SCI USA, V107, P11659, DOI 10.1073/pnas.0912122107; Johnstone RA, 2002, NATURE, V418, P524, DOI 10.1038/nature00845; MARPLES NM, 1993, ANIM BEHAV, V46, P347, DOI 10.1006/anbe.1993.1196; Mengual X, 2008, CLADISTICS, V24, P543, DOI 10.1111/j.1096-0031.2008.00200.x; Mostler G, 1935, Z MORPH OEKOL TIERE, V29, P381, DOI DOI 10.1007/BF00403719); Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412; Pinheiro J., 2011, NLME LINEAR NONLINEA; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rotheray G, 1999, ZOOL J LINN SOC-LOND, V127, P1, DOI 10.1111/j.1096-3642.1999.tb01305.x; Ruxton GD, 2004, AVOIDING ATTACK EVOL; Schwartz, 2010, P GAT COMP ENV WORKS; Sherratt TN, 2002, BEHAV ECOL, V13, P821, DOI 10.1093/beheco/13.6.821; Skevington JH, 2000, MOL PHYLOGENET EVOL, V16, P212, DOI 10.1006/mpev.2000.0787; Stahls G, 2003, SYST ENTOMOL, V28, P433, DOI 10.1046/j.1365-3113.2003.00225.x; SUTHERLAND WJ, 1982, ANIM BEHAV, V30, P857, DOI 10.1016/S0003-3472(82)80159-0; Vereecken NJ, 2008, P NATL ACAD SCI USA, V105, P7484, DOI 10.1073/pnas.0800194105; [No title captured]	37	139	140	4	234	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					461	U110		10.1038/nature10961	http://dx.doi.org/10.1038/nature10961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22437614	Green Accepted, Green Submitted			2022-12-28	WOS:000301771200042
J	Moreno, S				Moreno, Santiago			Earlier initiation of antiretroviral therapy after start of antituberculosis therapy reduced mortality in HIV	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUBERCULOSIS		Hosp Ramon & Cajal, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Moreno, S (corresponding author), Hosp Ramon & Cajal, E-28034 Madrid, Spain.							Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607; Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848; Torok ME, 2011, CLIN INFECT DIS, V52, P1374, DOI 10.1093/cid/cir230	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-2	10.7326/0003-4819-156-6-201203200-02002	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431688				2022-12-28	WOS:000303150900001
J	Burke, T				Burke, Tom			Climate change: what needs to be done	BRITISH MEDICAL JOURNAL			English	Article									E3G, London SE1 0ES, England		Burke, T (corresponding author), E3G, 47 Great Guildford St, London SE1 0ES, England.	Tom.Burke@riotinto.com							0	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1358	10.1136/bmj.e1358	http://dx.doi.org/10.1136/bmj.e1358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431660	Bronze			2022-12-28	WOS:000301848400006
J	Dhuime, B; Hawkesworth, CJ; Cawood, PA; Storey, CD				Dhuime, Bruno; Hawkesworth, Chris J.; Cawood, Peter A.; Storey, Craig D.			A Change in the Geodynamics of Continental Growth 3 Billion Years Ago	SCIENCE			English	Article							CRUSTAL EVOLUTION; SUBDUCTION ZONES; OXYGEN ISOTOPES; PLATE-TECTONICS; ZIRCON; MANTLE; PRESERVATION; HF; SUPERCONTINENTS; GEOCHEMISTRY	Models for the growth of continental crust rely on knowing the balance between the generation of new crust and the reworking of old crust throughout Earth's history. The oxygen isotopic composition of zircons, for which uranium-lead and hafnium isotopic data provide age constraints, is a key archive of crustal reworking. We identified systematic variations in hafnium and oxygen isotopes in zircons of different ages that reveal the relative proportions of reworked crust and of new crust through time. Growth of continental crust appears to have been a continuous process, albeit at variable rates. A marked decrease in the rate of crustal growth at similar to 3 billion years ago may be linked to the onset of subduction-driven plate tectonics.	[Dhuime, Bruno; Hawkesworth, Chris J.; Cawood, Peter A.] Univ St Andrews, Dept Earth Sci, St Andrews KY16 9AL, Fife, Scotland; [Dhuime, Bruno] Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; [Storey, Craig D.] Univ Portsmouth, Sch Earth & Environm Sci, Portsmouth PO1 3QL, Hants, England	University of St Andrews; University of Bristol; University of Portsmouth	Dhuime, B (corresponding author), Univ St Andrews, Dept Earth Sci, North St, St Andrews KY16 9AL, Fife, Scotland.	b.dhuime@bristol.ac.uk	Dhuime, Bruno/A-6262-2016; Storey, Craig/AAC-7832-2020; Facility, Edinburgh Ion Microprobe/AAD-8512-2020	Dhuime, Bruno/0000-0002-4146-4739; Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Cawood, Peter/0000-0003-1200-3826; Storey, Craig/0000-0002-4945-7381	Natural Environment Research Council (NERC) [NE/E005225/1]; University of St. Andrews; NERC [NE/D008891/2, IMF010001] Funding Source: UKRI; Natural Environment Research Council [IMF010001, NE/D008891/2] Funding Source: researchfish	Natural Environment Research Council (NERC)(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); University of St. Andrews; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by the Natural Environment Research Council (NERC, NE/E005225/1) and the University of St. Andrews. The data reported in this paper are archived in the supporting online material. We are grateful to staff members of Edinburgh Ion Microprobe Facility (EIMF) for technical assistance with oxygen isotope analysis. The comments of the anonymous referees and the discussions with T. Kemp and T. Elliott during the revision of this article have been greatly appreciated.	ALLEGRE CJ, 1984, EARTH PLANET SC LETT, V67, P19, DOI 10.1016/0012-821X(84)90035-9; ARNDT NT, 1987, GEOLOGY, V15, P893, DOI 10.1130/0091-7613(1987)15<893:UAAOCA>2.0.CO;2; Belousova EA, 2010, LITHOS, V119, P457, DOI 10.1016/j.lithos.2010.07.024; Campbell IH, 2008, NAT GEOSCI, V1, P554, DOI 10.1038/ngeo259; Cawood P. A., 2006, GSA TODAY, V16, P4, DOI [10.1130/GSAT01607.1, DOI 10.1130/GSAT01607.1]; Condie KC, 1998, EARTH PLANET SC LETT, V163, P97, DOI 10.1016/S0012-821X(98)00178-2; Condie KC, 2011, GEOL SOC AM BULL, V123, P951, DOI 10.1130/B30344.1; DEPAOLO DJ, 1981, NATURE, V291, P193, DOI 10.1038/291193a0; Dhuime B, 2011, GEOLOGY, V39, P407, DOI 10.1130/G31785.1; Dhuime B, 2011, SCIENCE, V331, P154, DOI 10.1126/science.1201245; Foley SF, 2003, NATURE, V421, P249, DOI 10.1038/nature01319; Hawkesworth CJ, 2010, J GEOL SOC LONDON, V167, P229, DOI 10.1144/0016-76492009-072; Hawkesworth C, 2009, SCIENCE, V323, P49, DOI 10.1126/science.1168549; Hawkesworth CJ, 2006, CHEM GEOL, V226, P144, DOI 10.1016/j.chemgeo.2005.09.018; Kemp AIS, 2007, SCIENCE, V315, P980, DOI 10.1126/science.1136154; Kemp AIS, 2006, NATURE, V439, P580, DOI 10.1038/nature04505; Lancaster PJ, 2011, EARTH PLANET SC LETT, V305, P405, DOI 10.1016/j.epsl.2011.03.022; Pietranik AB, 2008, GEOLOGY, V36, P875, DOI 10.1130/G24861A.1; Rapela CW, 2011, GONDWANA RES, V20, P673, DOI 10.1016/j.gr.2011.05.001; Scholl DW, 2007, GEOL SOC AM MEM, V200, P9, DOI 10.1130/2007.1200(02); Scholl DW, 2009, GEOL SOC SPEC PUBL, V318, P105, DOI 10.1144/SP318.4; Shirey SB, 2011, SCIENCE, V333, P434, DOI 10.1126/science.1206275; Valley JW, 1998, CONTRIB MINERAL PETR, V133, P1, DOI 10.1007/s004100050432; Valley JW, 2005, CONTRIB MINERAL PETR, V150, P561, DOI 10.1007/s00410-005-0025-8; Van Kranendonk MJ, 2011, SCIENCE, V333, P413, DOI 10.1126/science.1208766; Van Kranendonk MJ, 2010, AM J SCI, V310, P1187, DOI 10.2475/10.2010.01; Voice PJ, 2011, J GEOL, V119, P109, DOI 10.1086/658295; Wang CY, 2011, GEOCHIM COSMOCHIM AC, V75, P1308, DOI 10.1016/j.gca.2010.12.010; Wang CY, 2009, GEOCHIM COSMOCHIM AC, V73, P712, DOI 10.1016/j.gca.2008.10.037	29	580	597	11	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1334	1336		10.1126/science.1216066	http://dx.doi.org/10.1126/science.1216066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422979				2022-12-28	WOS:000301531600043
J	Dow, LE; Lowe, SW				Dow, Lukas E.; Lowe, Scott W.			Life in the Fast Lane: Mammalian Disease Models in the Genomics Era	CELL			English	Review							PLURIPOTENT STEM-CELLS; ZINC-FINGER NUCLEASES; ENGINEERED MOUSE MODELS; IN-VIVO; HUMANIZED MICE; KNOCKOUT RATS; EMBRYO MICROINJECTION; RNA INTERFERENCE; GENE CORRECTION; LIVER-CANCER	Analyses of the human genome have proven extremely successful in identifying changes that contribute to human disease. Genetically engineered mice provide a powerful tool to analyze these changes, although they are slow and costly and do not always recapitulate human biology. Recent advances in genomic technologies, rodent-modeling approaches, and the production of patient-derived reprogrammed cell lines now provide a plethora of complementary systems to study disease states and test new therapies. Continued evolution and integration of these model systems will be the key to realizing the benefits of the genomic revolution and refining our understanding and treatment of human diseases.	[Dow, Lukas E.; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Lowe, Scott W.] Howard Hughes Med Inst, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.	lowes@mskcc.org		Dow, Lukas/0000-0001-7048-1418	National Health & Medical Research Council of Australia; National Cancer Institute; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Amaia Lujambio for critical input and apologize to those authors whose work was not cited due to space constraints. L.E.D. was supported by an Overseas Biomedical Training fellowship from National Health & Medical Research Council of Australia, and S.W.L. is an investigator of the Howard Hughes Medical Institute. This work was supported by a consortium grant from the National Cancer Institute. S.W.L. is one of the founders of Mirimus Inc., a company that has licensed technology relating to the development of shRNA transgenic mice.	Adams DJ, 2004, NAT GENET, V36, P867, DOI 10.1038/ng1388; Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Beronja S, 2010, NAT MED, V16, P821, DOI 10.1038/nm.2167; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; Carroll D, 2011, GENETICS, V188, P773, DOI 10.1534/genetics.111.131433; Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513; Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106; Copeland NG, 2010, NAT REV CANCER, V10, P696, DOI 10.1038/nrc2916; Dolgin E, 2010, NAT MED, V16, P254, DOI 10.1038/nm0310-254; Dow LE, 2012, NAT PROTOC, V7, P374, DOI 10.1038/nprot.2011.446; Driver JP, 2011, SEMIN IMMUNOPATHOL, V33, P67, DOI 10.1007/s00281-010-0204-1; Fellmann C, 2011, MOL CELL, V41, P733, DOI 10.1016/j.molcel.2011.02.008; Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192; Geurts AM, 2009, SCIENCE, V325, P433, DOI 10.1126/science.1172447; Hambardzumyan D, 2009, TRANSL ONCOL, V2, P89, DOI 10.1593/tlo.09100; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Heyer J, 2010, NAT REV CANCER, V10, P470, DOI 10.1038/nrc2877; Hitz C, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm475; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927; Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663; Huijbers IJ, 2011, BIOESSAYS, V33, P701, DOI 10.1002/bies.201100018; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kile BT, 2005, NAT REV GENET, V6, P557, DOI 10.1038/nrg1636; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Kool J, 2009, NAT REV CANCER, V9, P389, DOI 10.1038/nrc2647; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Matera I, 2007, PIGM CELL RES, V20, P210, DOI 10.1111/j.1600-0749.2007.00371.x; McDermott SP, 2010, BLOOD, V116, P193, DOI 10.1182/blood-2010-02-271841; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; Miller JC, 2011, NAT BIOTECHNOL, V29, P143, DOI 10.1038/nbt.1755; Mordes JP, 2004, ILAR J, V45, P278, DOI 10.1093/ilar.45.3.278; Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679; Nichols J, 2009, NAT MED, V15, P814, DOI 10.1038/nm.1996; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410; Pinto YM, 1998, CARDIOVASC RES, V39, P77, DOI 10.1016/S0008-6363(98)00077-7; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Rhee YH, 2011, J CLIN INVEST, V121, P2326, DOI 10.1172/JCI45794; Richmond A, 2008, DIS MODEL MECH, V1, P78, DOI 10.1242/dmm.000976; Sacco A, 2010, CELL, V143, P1059, DOI 10.1016/j.cell.2010.11.039; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Sebastiano V, 2011, STEM CELLS, V29, P1717, DOI 10.1002/stem.718; Seibler J, 1998, BIOCHEMISTRY-US, V37, P6229, DOI 10.1021/bi980288t; Seibler J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm122; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Stottmann RW, 2011, GENETICS, V188, P615, DOI 10.1534/genetics.111.126862; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929; Tchekneva EE, 2007, J AM SOC NEPHROL, V18, P103, DOI 10.1681/ASN.2006020164; Tesson L, 2011, NAT BIOTECHNOL, V29, P695, DOI 10.1038/nbt.1940; Tong C, 2010, NATURE, V467, P211, DOI 10.1038/nature09368; Townsend JA, 2009, NATURE, V459, P442, DOI 10.1038/nature07845; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wood AJ, 2011, SCIENCE, V333, P307, DOI 10.1126/science.1207773; Yu CI, 2008, BLOOD, V112, P3671, DOI 10.1182/blood-2008-05-157016; Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005; Zhou YH, 2010, NAT BIOTECHNOL, V28, P71, DOI 10.1038/nbt.1595; Zou JZ, 2011, BLOOD, V118, P4599, DOI 10.1182/blood-2011-02-335554; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	82	57	60	0	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 16	2012	148	6					1099	1109		10.1016/j.cell.2012.02.023	http://dx.doi.org/10.1016/j.cell.2012.02.023			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424222	Bronze, Green Accepted			2022-12-28	WOS:000301889500009
J	Pickrell, JK; Gilad, Y; Pritchard, JK				Pickrell, Joseph K.; Gilad, Yoav; Pritchard, Jonathan K.			Comment on "Widespread RNA and DNA Sequence Differences in the Human Transcriptome"	SCIENCE			English	Editorial Material							IDENTIFICATION; ERROR		[Pickrell, Joseph K.; Gilad, Yoav; Pritchard, Jonathan K.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Pritchard, Jonathan K.] Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Pickrell, JK (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 507, Chicago, IL 60637 USA.	pickrell@uchicago.edu			NIGMS NIH HHS [GM077959, R01 GM077959] Funding Source: Medline; NIMH NIH HHS [MH084703, R01 MH084703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH084703] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Erlich Y, 2008, NAT METHODS, V5, P679, DOI 10.1038/nmeth.1230; Kiran A, 2010, BIOINFORMATICS, V26, P1772, DOI 10.1093/bioinformatics/btq285; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018; Meacham F, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-451; Nakamura K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr344	12	132	133	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2012	335	6074								10.1126/science.1210484	http://dx.doi.org/10.1126/science.1210484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422963	Bronze, Green Accepted			2022-12-28	WOS:000301531600025
J	Albeldawi, M; Makkar, R				Albeldawi, Mazen; Makkar, Rohit			Barium Aspiration	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Albeldawi, Mazen; Makkar, Rohit] Cleveland Clin, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Albeldawi, M (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.								0	15	16	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1038	1038		10.1056/NEJMicm1108468	http://dx.doi.org/10.1056/NEJMicm1108468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417257				2022-12-28	WOS:000301482800007
J	Buratowski, S				Buratowski, Stephen			GENE EXPRESSION Transcription initiation unwrapped	NATURE			English	Editorial Material							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; BIDIRECTIONAL PROMOTERS; YEAST		Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	steveb@hms.harvard.edu			NIGMS NIH HHS [R01 GM046498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Mayer A, 2010, NAT STRUCT MOL BIOL, V17, P1272, DOI 10.1038/nsmb.1903; Neil H, 2009, NATURE, V457, P1038, DOI 10.1038/nature07747; Rhee HS, 2012, NATURE, V483, P295, DOI 10.1038/nature10799; Rhee HS, 2011, CELL, V147, P1408, DOI 10.1016/j.cell.2011.11.013; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Singh BN, 2007, MOL CELL, V27, P806, DOI 10.1016/j.molcel.2007.07.013; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Xu ZY, 2009, NATURE, V457, P1033, DOI 10.1038/nature07728	11	3	3	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					286	287		10.1038/483286a	http://dx.doi.org/10.1038/483286a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422261	Green Accepted			2022-12-28	WOS:000301481800039
J	Mills, NL; Lee, KK; McAllister, DA; Churchhouse, AMD; MacLeod, M; Stoddart, M; Walker, S; Denvir, MA; Fox, KAA; Newby, DE				Mills, Nicholas L.; Lee, Kuan Ken; McAllister, David A.; Churchhouse, Antonia M. D.; MacLeod, Margaret; Stoddart, Mary; Walker, Simon; Denvir, Martin A.; Fox, Keith A. A.; Newby, David E.			Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE CORONARY SYNDROMES; ARTERY-DISEASE; T ASSAY; I LEVELS; RISK; POPULATION; MARKERS; PERFORMANCE; DEFINITION; MORTALITY	Objective To assess the relation between troponin concentration, assay precision, and clinical outcomes in patients with suspected acute coronary syndrome. Design Cohort study. Setting Tertiary centre in Scotland. Participants 2092 consecutive patients admitted with suspected acute coronary syndrome were stratified with a sensitive troponin I assay into three groups (<0.012, 0.012-0.049, and >= 0.050 mu g/L) based on the 99th centile for troponin concentration (0.012 mu g/L; coefficient of variation 20.8%) and the diagnostic threshold (0.050 mu g/L; 7.2%). Main outcome measure One year survival without events (recurrent myocardial infarction, death) in patients grouped by troponin concentration. Results Troponin I concentrations were <0.012 mu g/L in 988 patients (47%), 0.012-0.049 mu g/L in 352 patients (17%), and >= 0.050 mu g/L in 752 patients (36%). Adoption of the 99th centile would increase the number of people receiving a diagnosis of myocardial infarction from 752 to 1104: a relative increase of 47%. At one year, patients with troponin concentrations of 0.012-0.049 mu g/L were more likely to be dead or readmitted with recurrent myocardial infarction than those with troponin concentrations <0.012 mu g/L (13% v 3%, P<0.001; odds ratio 4.7, 95% confidence interval 2.9 to 7.9). Compared with troponin >= 0.050 mu g/L, patients with troponin 0.012-0.049 mu g/L had a higher risk profile but were less likely to have a diagnosis of, or be investigated and treated for, acute coronary syndrome. Conclusion Lowering the diagnostic threshold to the 99th centile and accepting greater assay imprecision would identify more patients with acute coronary syndrome at risk of recurrent myocardial infarction and death but would increase the diagnosis of myocardial infarction by 47%. It remains to be established whether reclassification of these patients and treatment for myocardial infarction would improve outcome.	[Mills, Nicholas L.; Lee, Kuan Ken; Churchhouse, Antonia M. D.; Denvir, Martin A.; Fox, Keith A. A.; Newby, David E.] Univ Edinburgh, BHF Univ Ctr Cardiovasc Sci, Edinburgh EH16 4SU, Midlothian, Scotland; [McAllister, David A.] Univ Edinburgh, Edinburgh EH8 9AG, Midlothian, Scotland; [MacLeod, Margaret] Royal Infirm Edinburgh NHS Trust, Edinburgh Heart Ctr, Edinburgh EH16 4SA, Midlothian, Scotland; [Stoddart, Mary; Walker, Simon] Royal Infirm Edinburgh NHS Trust, Dept Clin Biochem, Edinburgh EH16 4SA, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Mills, NL (corresponding author), Univ Edinburgh, BHF Univ Ctr Cardiovasc Sci, Chancellors Bldg, Edinburgh EH16 4SB, Midlothian, Scotland.	nick.mills@ed.ac.uk	Denvir, Martin A/ABA-3141-2021; Fox, keith A A/I-3742-2013; Newby, David Ernest/AAB-1364-2019	Fox, Keith/0000-0002-0140-2752; McAllister, David/0000-0003-3550-1764; Churchhouse, Antonia/0000-0002-2321-2140; Mills, Nicholas/0000-0003-0533-7991	British Heart Foundation (BHF) [FS/10/024/28266, CH/92010/6773, CH/09/002/26360]; British Heart Foundation [FS/10/024/28266] Funding Source: researchfish	British Heart Foundation (BHF)(British Heart Foundation); British Heart Foundation(British Heart Foundation)	This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. NLM is supported by an intermediate clinical research fellowship from the British Heart Foundation (BHF) (FS/10/024/28266). KAAF and DEN are supported by BHF Chair Awards (CH/92010/6773 and CH/09/002/26360, respectively).	Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 2010, CLIN BIOCHEM, V43, P1034, DOI 10.1016/j.clinbiochem.2010.05.014; Apple FS, 2009, CLIN CHEM, V55, P1303, DOI 10.1373/clinchem.2009.128363; Bauer A, 2009, NEW ENGL J MED, V361, P2575, DOI 10.1056/NEJMc0909215; Body R, 2011, J AM COLL CARDIOL, V58, P1333, DOI 10.1016/j.jacc.2011.06.026; Bonaca M, 2010, J AM COLL CARDIOL, V55, P2118, DOI 10.1016/j.jacc.2010.01.044; Collinson P, 2012, HEART, V98, P312, DOI 10.1136/heartjnl-2011-300723; Eggers KM, 2008, EUR HEART J, V29, P2252, DOI 10.1093/eurheartj/ehn327; Eggers KM, 2009, CLIN CHEM, V55, P85, DOI 10.1373/clinchem.2007.101683; Jaffe AS, 2010, CLIN CHEM, V56, P941, DOI 10.1373/clinchem.2010.143958; Koerbin G, 2010, ANN CLIN BIOCHEM, V47, P524, DOI 10.1258/acb.2010.010033; Kupchak P, 2006, CLIN CHEM, V52, P752, DOI 10.1373/clinchem.2005.064477; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; Lindahl B, 2010, AM HEART J, V160, P224, DOI 10.1016/j.ahj.2010.05.023; Meune C, 2011, HEART, V97, P1479, DOI 10.1136/hrt.2010.220988; Mills NL, 2011, JAMA-J AM MED ASSOC, V305, P1210, DOI 10.1001/jama.2011.338; Mingels A, 2009, CLIN CHEM, V55, P101, DOI 10.1373/clinchem.2008.106427; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; Morrow DA, 2007, CLIN CHEM, V53, P552, DOI 10.1373/clinchem.2006.084194; Morrow DA, 2009, NEW ENGL J MED, V361, P913, DOI 10.1056/NEJMe0905790; Myocardial Ischaemia National Audit Project (MINAP), 2011, NHS CAR PAT HEART AT, Vxx, P1; NHS National Services Scotland: Information Services Division (ISD), 2011, HOSP ACT COR HEART D, Vxx, P1; Omland T, 2009, NEW ENGL J MED, V361, P2538, DOI 10.1056/NEJMoa0805299; Sabatine MS, 2009, EUR HEART J, V30, P162, DOI 10.1093/eurheartj/ehn504; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Venge P, 2009, J AM COLL CARDIOL, V54, P1165, DOI 10.1016/j.jacc.2009.05.051	27	71	81	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2012	344								e1533	10.1136/bmj.e1533	http://dx.doi.org/10.1136/bmj.e1533			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CD	22422871	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-28	WOS:000301848100005
J	Spence, D				Spence, Des			FROM THE FRONTLINE Are nurses better than doctors?	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						British Medical Association (BMA), 2010, BRIEF PAP GEN PRACT; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; Laurant M, 2009, COCHRANE REV    0121; Royal College of Nursing, 2005, NURS EMPL GPS RCN GU	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e2010	10.1136/bmj.e2010	http://dx.doi.org/10.1136/bmj.e2010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418421				2022-12-28	WOS:000301847600020
J	Fahy, N				Fahy, Nick			Who is shaping the future of European health systems?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Nick Fahy Consulting, Tunbridge Wells TN1 2HX, England		Fahy, N (corresponding author), Nick Fahy Consulting, Tunbridge Wells TN1 2HX, England.	nick@nmfahy.eu	Fahy, Nick/R-1804-2018	Fahy, Nick/0000-0003-4957-0189				[Anonymous], 2010, OJ; [Anonymous], EU OP METH COORD HLT; Busse R, 2008, HEALTH ECON, V17, pS1, DOI 10.1002/hec.1330; EC Directorate-General for Economic and Financial Affairs, 2011, 87 EC DIR GEN EC FIN; EC (Directorate-General for Economic and Financial Affairs), 2010, 72 EC DIR GEN EC FIN; EC Directorate-General for Economic and Financial Affairs, 2009, 2009 AG REP EC BUDG; European Commission, 2011, MEMO11898 EUR COMM; European Commission Directorate-General for Economic and Financial Affairs, 2011, 76 EUR COMM DIR GEN; European Commission (Directorate-General for Economic and Financial Affairs), 2011, 79 EC DIR GEN EC FIN; European Commission (Directorate-General for Economic and Financial Affairs), 2011, 89 EC DIR GEN EC FIN; European Council, 2012, TREAT STAB COORD GOV; European Council, 2011, STAT EUR HEADS STAT; Kentikelenis A, 2012, EUR J PUBLIC HEALTH, V22, P4, DOI 10.1093/eurpub/ckr190; OECD, 2011, HLTH GLANC 2011 OECD; Office for Budget Responsibility, 2011, FISC SUST REP; Organisation for Economic Co-operation and Development, 2010, HLTH GLANC EUR 2010	16	24	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2012	344								e1712	10.1136/bmj.e1712	http://dx.doi.org/10.1136/bmj.e1712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BR	22415953				2022-12-28	WOS:000301846900005
J	Berenson, RA; Paulus, RA; Kalman, NS				Berenson, Robert A.; Paulus, Ronald A.; Kalman, Noah S.			Medicare's Readmissions-Reduction Program - A Positive Alternative	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REHOSPITALIZATIONS		[Berenson, Robert A.] Urban Inst, Washington, DC 20037 USA; [Paulus, Ronald A.] Mission Hlth Syst, Asheville, NC USA; [Kalman, Noah S.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA	Urban Institute; Duke University	Berenson, RA (corresponding author), Urban Inst, Washington, DC 20037 USA.							Chollet D., 2011, REDUCING HOSP READMI; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Medicare Payment Advisory Commission, 2011, PUBL M DEC 15	6	173	174	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1364	1366		10.1056/NEJMp1201268	http://dx.doi.org/10.1056/NEJMp1201268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22455754				2022-12-28	WOS:000302608600012
J	Rosenbaum, S				Rosenbaum, Sara			Suing States over Threatened Access to Care - The Douglas Decision	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									George Washington Univ, Dept Hlth Policy, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA	George Washington University	Rosenbaum, S (corresponding author), George Washington Univ, Dept Hlth Policy, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15								10.1056/NEJMp1202223	http://dx.doi.org/10.1056/NEJMp1202223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22455753				2022-12-28	WOS:000302608600014
J	McKnight, S; Beyer, A; Gall, J				McKnight, Steven; Beyer, Ann; Gall, Joseph			Oscar Miller (1925-2012) RETROSPECTIVE	SCIENCE			English	Biographical-Item									[McKnight, Steven] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Beyer, Ann] Univ Virginia, Dept Microbiol, Charlottesville, VA 22904 USA; [Gall, Joseph] Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21218 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Virginia; Carnegie Institution for Science	McKnight, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.	steven.mcknight@utsouthwestern.edu	Gall, Joseph/AAF-6789-2020					MILLER OJ, PUBLICATION LIST	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 23	2012	335	6075					1457	1457		10.1126/science.1220681	http://dx.doi.org/10.1126/science.1220681			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442474				2022-12-28	WOS:000301837000035
J	Lin, FR				Lin, Frank R.			Hearing Loss in Older Adults Who's Listening?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Epidemiol, Baltimore, MD 21205 USA; [Lin, Frank R.] Johns Hopkins Med Inst, Ctr Aging & Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine	Lin, FR (corresponding author), Johns Hopkins Ctr Aging & Hlth, 2024 E Monument St,Ste 2-700, Baltimore, MD 21205 USA.	flin1@jhmi.edu			NIDCD NIH HHS [K23 DC011279, K23DC011279] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC011279] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Cacioppo JT, 2011, ANN NY ACAD SCI, V1231, P17, DOI 10.1111/j.1749-6632.2011.06028.x; Chien W, 2012, ARCH INTERN MED, V172, P292, DOI 10.1001/archinternmed.2011.1408; Chou R, 2011, ANN INTERN MED, V154, P347, DOI 10.7326/0003-4819-154-5-201103010-00009; Lin FR, 2011, NEUROPSYCHOLOGY, V25, P763, DOI 10.1037/a0024238; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; Pacala JT, 2012, JAMA-J AM MED ASSOC, V307, P1185, DOI 10.1001/jama.2012.305; Peelle JE, 2011, J NEUROSCI, V31, P12638, DOI 10.1523/JNEUROSCI.2559-11.2011; US Department of Justice, 2010, 2010 ADA STAND ACC D; Wingfield A, 2005, CURR DIR PSYCHOL SCI, V14, P144, DOI 10.1111/j.0963-7214.2005.00356.x	10	70	74	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1147	1148		10.1001/jama.2012.321	http://dx.doi.org/10.1001/jama.2012.321			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911HN	22436953	Green Accepted			2022-12-28	WOS:000301708000021
J	Anderson, DC				Anderson, David C.			Review: Statins do not increase risk for intracerebral hemorrhage	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Hennepin Cty Med Ctr UMN, Minneapolis, MN USA	Hennepin County Medical Center	Anderson, DC (corresponding author), Hennepin Cty Med Ctr UMN, Minneapolis, MN USA.			Anderson, David/0000-0001-9874-5649				Amarenco P, 2006, NEW ENGL J MED, V355, P549; Hackam DG, 2012, ARCH NEUROL-CHICAGO, V69, P39, DOI 10.1001/archneurol.2011.228; Westover MB, 2011, ARCH NEUROL-CHICAGO, V68, P573, DOI 10.1001/archneurol.2010.356	3	3	3	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-6	10.7326/0003-4819-156-6-201203200-02006	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431692				2022-12-28	WOS:000303150900005
J	Dentali, F				Dentali, Francesco			Less-frequent warfarin dose assessment was noninferior for patients with stable INRs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OUTCOMES; THERAPY		Univ Insubria, Varese, Italy	University of Insubria	Dentali, F (corresponding author), Univ Insubria, Varese, Italy.							Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239; Witt DM, 2009, BLOOD, V114, P952, DOI 10.1182/blood-2009-02-207928	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6							JC3-3	10.7326/0003-4819-156-6-201203200-02003	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431689				2022-12-28	WOS:000303150900002
J	Schroder, FH; Hugosson, J; Roobol, MJ; Tammela, TLJ; Ciatto, S; Nelen, V; Kwiatkowski, M; Lujan, M; Lilja, H; Zappa, M; Denis, LJ; Recker, F; Paez, A; Maattanen, L; Bangma, CH; Aus, G; Carlsson, S; Villers, A; Rebillard, X; van der Kwast, T; Kujala, PM; Blijenberg, BG; Stenman, UH; Huber, A; Taari, K; Hakama, M; Moss, SM; de Koning, HJ; Auvinen, A				Schroder, Fritz H.; Hugosson, Jonas; Roobol, Monique J.; Tammela, Teuvo L. J.; Ciatto, Stefano; Nelen, Vera; Kwiatkowski, Maciej; Lujan, Marcos; Lilja, Hans; Zappa, Marco; Denis, Louis J.; Recker, Franz; Paez, Alvaro; Maattanen, Liisa; Bangma, Chris H.; Aus, Gunnar; Carlsson, Sigrid; Villers, Arnauld; Rebillard, Xavier; van der Kwast, Theodorus; Kujala, Paula M.; Blijenberg, Bert G.; Stenman, Ulf-Hakan; Huber, Andreas; Taari, Kimmo; Hakama, Matti; Moss, Sue M.; de Koning, Harry J.; Auvinen, Anssi		ERSPC Investigators	Prostate-Cancer Mortality at 11 Years of Follow-up	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERVICES TASK-FORCE; CONTAMINATION; TIME	Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up. Methods The study involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered such screening. The primary outcome was mortality from prostate cancer. Results After a median follow-up of 11 years in the core age group, the relative reduction in the risk of death from prostate cancer in the screening group was 21% (rate ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P = 0.001), and 29% after adjustment for noncompliance. The absolute reduction in mortality in the screening group was 0.10 deaths per 1000 person-years or 1.07 deaths per 1000 men who underwent randomization. The rate ratio for death from prostate cancer during follow-up years 10 and 11 was 0.62 (95% CI, 0.45 to 0.85; P = 0.003). To prevent one death from prostate cancer at 11 years of follow-up, 1055 men would need to be invited for screening and 37 cancers would need to be detected. There was no significant between-group difference in all-cause mortality. Conclusions Analyses after 2 additional years of follow-up consolidated our previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality. (Current Controlled Trials number, ISRCTN49127736.)	[Schroder, Fritz H.; Roobol, Monique J.; Bangma, Chris H.] Erasmus Univ, Dept Urol, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [van der Kwast, Theodorus] Erasmus Univ, Dept Pathol, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Blijenberg, Bert G.] Erasmus Univ, Dept Clin Chem, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [de Koning, Harry J.] Erasmus Univ, Dept Publ Hlth, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Hugosson, Jonas] Univ Gothenburg, Dept Urol, Sahlgrenska Acad, Gothenburg, Sweden; [Aus, Gunnar] Capio Lundby Sjukhus, Urologkliniken, Gothenburg, Sweden; [Tammela, Teuvo L. J.] Tampere Univ Hosp, Dept Urol, Tampere, Finland; [Kujala, Paula M.] Tampere Univ Hosp, Dept Pathol, Tampere, Finland; [Hakama, Matti; Auvinen, Anssi] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; Ctr Studio & Prevenz Oncol, Dept Diagnost Med Imaging, I-50131 Florence, Italy; [Zappa, Marco] Ctr Studio & Prevenz Oncol, Unit Clin & Descript Epidemiol, I-50131 Florence, Italy; [Nelen, Vera] Prov Inst Hyg, Antwerp, Belgium; [Denis, Louis J.] Oncol Ctr Antwerp, Antwerp, Belgium; [Kwiatkowski, Maciej; Recker, Franz] Kantonsspital Aarau, Dept Urol, Aarau, Switzerland; [Huber, Andreas] Kantonsspital Aarau, Ctr Lab Med, Aarau, Switzerland; [Lujan, Marcos] Hosp Infanta Cristina, Unidad Urol, Madrid, Spain; [Paez, Alvaro] Hosp Univ Fuenlabrada, Serv Urol, Madrid, Spain; [Lilja, Hans] Mem Sloan Kettering Canc Ctr, Dept Lab Med, New York, NY 10021 USA; [Lilja, Hans] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Lilja, Hans] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Maattanen, Liisa; Hakama, Matti] Finnish Canc Registry, FIN-00170 Helsinki, Finland; [Stenman, Ulf-Hakan] Univ Helsinki, Dept Clin Chem, Cent Hosp, Lab Div, SF-00100 Helsinki, Finland; [Taari, Kimmo] Univ Helsinki, Dept Neurol, Cent Hosp, Lab Div, Helsinki, Finland; [Villers, Arnauld] Ctr Hosp Univ Lille, Dept Urol, Lille, France; [Rebillard, Xavier] Clin Beau Soleil, Serv Urol, Montpellier, France; [Moss, Sue M.] Queen Mary Univ London, Ctr Canc Prevent, London, England; [Lilja, Hans] Lund Univ, Dept Lab Med, Malmo, Sweden	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Gothenburg; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA); Hospital Infanta Cristina; Hospital Universitario Fuenlabrada; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Universite de Lille - ISITE; CHU Lille; Beau Soleil Clinic; Universite de Montpellier; University of London; Queen Mary University London; Lund University	Schroder, FH (corresponding author), Erasmus Univ, Dept Urol, Med Ctr, NH-224,Rochussenstr 125, NL-3000 CA Rotterdam, Netherlands.	secr.schroder@erasmusmc.nl	de+Koning, Harry/AAF-9062-2019; Rubeca, Tiziana/J-5280-2018; PAEZ, ALVARO/G-5458-2012; Zhu, Xiaoye/P-5629-2018; zappa, marco/AAB-3294-2019; Auvinen, Anssi/AAL-2111-2020; NEELS, Hugo M/B-4721-2017; Auvinen, Anssi/AAD-9311-2020; Lilja, Hans/S-9703-2019; Grosclaude, Pascale/B-6079-2015; Arnauld, VILLERS A/K-6629-2016; Hug, Balthasar L./G-1568-2010	de+Koning, Harry/0000-0003-4682-3646; Rubeca, Tiziana/0000-0002-1870-4722; Zhu, Xiaoye/0000-0001-5705-6660; zappa, marco/0000-0002-6606-9786; Auvinen, Anssi/0000-0003-1125-4818; NEELS, Hugo M/0000-0002-9034-168X; Lilja, Hans/0000-0001-5871-7846; Arnauld, VILLERS A/0000-0002-6298-7758; Taari, Kimmo/0000-0002-0077-4896; Kilpelainen, Tuomas P./0000-0002-7697-0148; Carlsson, Sigrid/0000-0003-3553-5710; grosclaude, pascale/0000-0002-6755-5970; Van der Kwast, Theodorus/0000-0001-8640-5786; Venderbos, Lionne/0000-0002-4269-0623; Stranne, Johan/0000-0002-4295-6524; Rietbergen, John/0000-0002-3840-0873; Grobholz, Rainer/0000-0002-1901-7967; Holmberg, Erik/0000-0001-5107-4550	GlaxoSmithKline; Ferring; Societe International d'Urologie; European Association of Urology; Orion Pharma; Astellas; Amgen; AstraZeneca; Takeda; Janssen; Ipsen; Pierre Fabre Medicament; Beckman Coulter; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Ferring(Ferring Pharmaceuticals); Societe International d'Urologie; European Association of Urology; Orion Pharma; Astellas(Astellas Pharmaceuticals); Amgen(Amgen); AstraZeneca(AstraZeneca); Takeda(Takeda Pharmaceutical Company Ltd); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Ipsen(Ipsen); Pierre Fabre Medicament; Beckman Coulter; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr. Schroder reports serving as a board member of European Urology, receiving consulting fees from GlaxoSmithKline and Ferring, and receiving lecture fees and travel support from GlaxoSmithKline, Ferring, Societe International d'Urologie, and the European Association of Urology; Dr. Tammela, serving as a board member for Astellas, Amgen, Pfizer, and GlaxoSmithKline, receiving consulting fees from Orion Pharma, receiving lecture fees from Astellas and Amgen, receiving payment for developing educational presentations from GlaxoSmithKline, and receiving travel support from Amgen; Dr. Kwiatkowski, receiving consulting fees from GlaxoSmithKline; Drs. Lilja and Stenman, holding a patent for a PSA assay, and Dr. Stenman, receiving royalties from the patent; Dr. Aus, receiving lecture fees from AstraZeneca; Dr. Villers, receiving consulting fees from Astellas, Ferring, and Takeda, grant support from Janssen, lecture fees from Ipsen, and payment for the development of educational presentations from Pierre Fabre Medicament; Dr. Taari, receiving consulting fees from Astellas, GlaxoSmithKline, Ferring, and Amgen, receiving grant support from Amgen, receiving lecture fees from GlaxoSmithKline, being an employee of Medivation, and receiving travel support from Sanofi-Aventis, Pfizer, and Astellas; and Dr. de Koning, receiving consulting fees from Beckman Coulter. No other potential conflict of interest relevant to this article was reported.	AALEN O, 1978, ANN STAT, V6, P701, DOI 10.1214/aos/1176344247; Bill-Axelson A, 2011, NEW ENGL J MED, V364, P1708, DOI 10.1056/NEJMoa1011967; Boevee SJ, 2010, EUR J CANCER, V46, P3082, DOI 10.1016/j.ejca.2010.09.033; Brett AS, 2011, NEW ENGL J MED, V365, P1949, DOI 10.1056/NEJMp1112191; Ciatto S, 2003, BJU INT, V92, P97, DOI 10.1111/j.1464-410X.2003.04407.x; Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V; de Koning HJ, 2002, INT J CANCER, V98, P268, DOI 10.1002/ijc.10188; De Koning HJ, 2003, BJU INT, V92, P71, DOI 10.1111/j.1465-5101.2003.04402.x; De Koning HJ, 2003, BJU INT, V92, P112, DOI 10.1111/j.1464-410X.2003.4410x.x; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Draisma G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/jnci/95.12.868; European Randomized Study of Screening for Prostate Cancer, EUR RAND STUD SCREEN; Gulati R, 2011, J CLIN EPIDEMIOL, V64, P1412, DOI 10.1016/j.jclinepi.2011.06.011; Hugosson J, 2010, LANCET ONCOL, V11, P725, DOI 10.1016/S1470-2045(10)70146-7; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Loeb S, 2011, J UROLOGY, V186, P1830, DOI 10.1016/j.juro.2011.06.057; Loeb S, 2011, J CLIN ONCOL, V29, P464, DOI 10.1200/JCO.2010.30.6373; McNaughton-Collins MF, 2011, NEW ENGL J MED, V365, P1951, DOI 10.1056/NEJMp1111894; Otto SJ, 2003, INT J CANCER, V105, P394, DOI 10.1002/ijc.11074; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; Rockville MD, 2008, SCREEN PROST CANC RO; Schroder FH, 2003, BJU INT, V92, P1, DOI 10.1111/j.1464-410X.2003.04389.x; Schroder FH, 2011, NEW ENGL J MED, V365, P1953, DOI 10.1056/NEJMp1112140; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; STAMEY TA, 1995, UROLOGY, V45, P2, DOI 10.1016/S0090-4295(95)96168-2; Wilt T, 2011, ANN M AM UROL ASS WA; Wolters T, 2010, INT J CANCER, V126, P2387, DOI 10.1002/ijc.24870; Wu GH, 2011, BIOM J          1223	29	926	952	1	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					981	990		10.1056/NEJMoa1113135	http://dx.doi.org/10.1056/NEJMoa1113135			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417251	Green Accepted			2022-12-28	WOS:000301482800001
J	Segal, M				Segal, Michael			MATERIAL HISTORY Learning from silicon	NATURE			English	Editorial Material							TRANSISTORS; GRAPHENE; FILMS											Bae S, 2010, NAT NANOTECHNOL, V5, P574, DOI [10.1038/nnano.2010.132, 10.1038/NNANO.2010.132]; Britnell L, SCIENCE; Lin YM, 2010, SCIENCE, V327, P662, DOI 10.1126/science.1184289; Moore G. E., 2006, MOORES LAW 40; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]; Schwierz F, 2010, NAT NANOTECHNOL, V5, P487, DOI [10.1038/NNANO.2010.89, 10.1038/nnano.2010.89]; Seitz Frederick, 1998, ELECT GENIE TANGLED	8	25	25	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S43	S44		10.1038/483S43a	http://dx.doi.org/10.1038/483S43a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419214	Bronze			2022-12-28	WOS:000301481800008
J	Armstrong, K				Armstrong, Katrina			Can Genomics Bend the Cost Curve?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; IMPACT; ASSAY; CARE		Univ Penn, Perelman Sch Med, Dept Med, Ctr Comparat Effectiveness Genom Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Armstrong, K (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Ctr Comparat Effectiveness Genom Med, 1220 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	karmstro@mail.med.upenn.edu						Bodenheimer T, 2005, ANN INTERN MED, V142, P932, DOI 10.7326/0003-4819-142-11-200506070-00012; Brook RH, 2011, JAMA-J AM MED ASSOC, V306, P2020, DOI 10.1001/jama.2011.1621; Hillner BE, 2007, J CLIN ONCOL, V25, P611, DOI 10.1200/JCO.2006.09.3542; Lo SS, 2010, J CLIN ONCOL, V28, P1671, DOI 10.1200/JCO.2008.20.2119; Lyman GH, 2007, CANCER-AM CANCER SOC, V109, P1011, DOI 10.1002/cncr.22506; McDermott U, 2011, NEW ENGL J MED, V364, P340, DOI 10.1056/NEJMra0907178; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161	8	23	23	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1031	1032		10.1001/jama.2012.261	http://dx.doi.org/10.1001/jama.2012.261			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416096				2022-12-28	WOS:000301479700021
J	Holmes, D				Holmes, David			Paolo Macchiarini: crossing frontiers	LANCET			English	Biographical-Item																			0	4	4	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 10	2012	379	9819					886	886		10.1016/S0140-6736(12)60382-1	http://dx.doi.org/10.1016/S0140-6736(12)60382-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	906NY	22405786	Bronze			2022-12-28	WOS:000301353700016
J	Chen, XS; Chen, ZD; Chen, H; Su, ZJ; Yang, JF; Lin, FQ; Shi, SH; He, XL				Chen, Xiaoshu; Chen, Zhidong; Chen, Han; Su, Zhijian; Yang, Jianfeng; Lin, Fangqin; Shi, Suhua; He, Xionglei			Nucleosomes Suppress Spontaneous Mutations Base-Specifically in Eukaryotes	SCIENCE			English	Article							CYTOSINE DEAMINATION; DNA; GENOME; ORGANIZATION; CHROMATIN; SUBSTITUTION; PROTECTION; OCCUPANCY; SPECTRUM; ORIGINS	It is unknown how the composition and structure of DNA within the cell affect spontaneous mutations. Theory suggests that in eukaryotic genomes, nucleosomal DNA undergoes fewer C -> T mutations because of suppressed cytosine hydrolytic deamination relative to nucleosome-depleted DNA. Comparative genomic analyses and a mutation accumulation experiment showed that nucleosome occupancy nearly eliminated cytosine deamination, resulting in an similar to 50% decrease of the C -> T mutation rate in nucleosomal DNA. Furthermore, the rates of G -> T and A -> T mutations were also about twofold suppressed by nucleosomes. On the basis of these results, we conclude that nucleosome-dependent mutation spectra affect eukaryotic genome structure and evolution and may have implications for understanding the origin of mutations in cancers and in induced pluripotent stem cells.	[Chen, Xiaoshu; Chen, Zhidong; Chen, Han; Su, Zhijian; Yang, Jianfeng; Lin, Fangqin; Shi, Suhua; He, Xionglei] Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [Chen, Xiaoshu; He, Xionglei] Sun Yat Sen Univ, Coll Life Sci, Minist Educ, Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China; [Su, Zhijian] Jinan Univ, Gungdong Prov Key Lab Bioengn Med, Guangzhou 510632, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Jinan University	He, XL (corresponding author), Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, 135 Xingang W, Guangzhou 510275, Guangdong, Peoples R China.	hexiongl@mail.sysu.edu.cn			National Basic Research Program of China [2010CB126200]; National Natural Science Foundation of China [40930212]; Science and Technology Planning Project of Guangdong Province [2009B080701090]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province	We thank J. Zhang, M. Bakewell, W. Qian, and C.-I. Wu for comments and critical reading of the manuscript. This work was supported by research grants from the National Basic Research Program of China (no. 2010CB126200), the National Natural Science Foundation of China (no. 40930212), and the Science and Technology Planning Project of Guangdong Province (no. 2009B080701090). Data are deposited in NCBI Short Read Archive (SRA040058).	Arnheim N, 2009, NAT REV GENET, V10, P478, DOI 10.1038/nrg2529; Ataian Y, 2006, BIOCHEM CELL BIOL, V84, P490, DOI 10.1139/O06-075; Baer CF, 2007, NAT REV GENET, V8, P619, DOI 10.1038/nrg2158; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.genet.23.1.637; Chen CL, 2010, GENOME RES, V20, P447, DOI 10.1101/gr.098947.109; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; Ercan S, 2011, GENOME RES, V21, P237, DOI 10.1101/gr.115931.110; Fryxell KJ, 2000, MOL BIOL EVOL, V17, P1371, DOI 10.1093/oxfordjournals.molbev.a026420; Getun IV, 2010, EMBO REP, V11, P555, DOI 10.1038/embor.2010.79; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522; Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M, 2008, P NATL ACAD SCI USA, V105, P9272, DOI 10.1073/pnas.0803466105; Maki H, 2002, ANNU REV GENET, V36, P279, DOI 10.1146/annurev.genet.36.042602.094806; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; PROFFITT JH, 1984, MOL CELL BIOL, V4, P985, DOI 10.1128/MCB.4.5.985; Sasaki S, 2009, SCIENCE, V323, P401, DOI 10.1126/science.1163183; Segal E, 2009, CURR OPIN STRUC BIOL, V19, P65, DOI 10.1016/j.sbi.2009.01.004; Sohail A, 2002, BIOCHEMISTRY-US, V41, P11325, DOI 10.1021/bi026332t; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tillo D, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-442; Weber KP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013922; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0	28	65	67	4	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1235	1238		10.1126/science.1217580	http://dx.doi.org/10.1126/science.1217580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403392				2022-12-28	WOS:000301225100048
J	Wieczorek, MA; Weiss, BP; Stewart, ST				Wieczorek, Mark A.; Weiss, Benjamin P.; Stewart, Sarah T.			An Impactor Origin for Lunar Magnetic Anomalies	SCIENCE			English	Article							DYNAMO DRIVEN; MELT BRECCIAS; CORE DYNAMO; PROSPECTOR; IDENTIFICATION; METEORITES; PROJECTILE; DICHOTOMY; COMPONENT; INTERIOR	The Moon possesses strong magnetic anomalies that are enigmatic given the weak magnetism of lunar rocks. We show that the most prominent grouping of anomalies can be explained by highly magnetic extralunar materials from the projectile that formed the largest and oldest impact crater on the Moon: the South Pole-Aitken basin. The distribution of projectile materials from a model oblique impact coincides with the distribution of magnetic anomalies surrounding this basin, and the magnetic properties of these materials can account for the intensity of the observed anomalies if they were magnetized in a core dynamo field. Distal ejecta from this event can explain the origin of isolated magnetic anomalies far from this basin.	[Wieczorek, Mark A.] Univ Paris Diderot, Inst Phys Globe Paris, F-94100 St Maur Des Fosses, France; [Weiss, Benjamin P.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [Stewart, Sarah T.] Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	UDICE-French Research Universities; Universite Paris Cite; Massachusetts Institute of Technology (MIT); Harvard University	Wieczorek, MA (corresponding author), Univ Paris Diderot, Inst Phys Globe Paris, F-94100 St Maur Des Fosses, France.	wieczor@ipgp.fr	Wieczorek, Mark A/G-6427-2010	Wieczorek, Mark A/0000-0001-7007-4222; Stewart, Sarah/0000-0001-9606-1593	CNRS; MIT-France; NASA Lunar Science Institute; NASA; FAS Science Division Research Computing Group at Harvard University	CNRS(Centre National de la Recherche Scientifique (CNRS)); MIT-France; NASA Lunar Science Institute; NASA(National Aeronautics & Space Administration (NASA)); FAS Science Division Research Computing Group at Harvard University	Supported by CNRS, the MIT-France Seed Funds program, the NASA Lunar Science Institute, and the NASA Lunar Advanced Science and Exploration Research Program. The cratering calculations were run on the Odyssey cluster supported by the FAS Science Division Research Computing Group at Harvard University. We thank B. Carbone for administrative help. All author modifications of the CTH code (available by licensing from Sandia National Laboratory) are available upon request.	Andrews-Hanna JC, 2008, NATURE, V453, P1212, DOI 10.1038/nature07011; BRECHER A, 1977, J GEOMAGN GEOELECTR, V29, P379, DOI 10.5636/jgg.29.379; Connerney JEP, 2001, GEOPHYS RES LETT, V28, P4015, DOI 10.1029/2001GL013619; Crawford DA, 1999, INT J IMPACT ENG, V23, P169, DOI 10.1016/S0734-743X(99)00070-6; DAILY WD, 1979, PHYS EARTH PLANET IN, V20, P255, DOI 10.1016/0031-9201(79)90049-9; Dunlop DJ, 2005, J GEOPHYS RES-PLANET, V110, P1, DOI 10.1029/2005JE002404; Dwyer CA, 2011, NATURE, V479, P212, DOI 10.1038/nature10564; DYAL P, 1974, REV GEOPHYS, V12, P568, DOI 10.1029/RG012i004p00568; Fuller M., 1987, GEOMAGN AERON, V2, P307; Garrick-Bethell I, 2009, ICARUS, V204, P399, DOI 10.1016/j.icarus.2009.05.032; Garrick-Bethell I, 2009, SCIENCE, V323, P356, DOI 10.1126/science.1166804; Gattacceca J, 2010, EARTH PLANET SC LETT, V299, P42, DOI 10.1016/j.epsl.2010.08.011; Halekas JS, 2003, METEORIT PLANET SCI, V38, P565, DOI 10.1111/j.1945-5100.2003.tb00027.x; Halekas JS, 2001, J GEOPHYS RES-PLANET, V106, P27841, DOI 10.1029/2000JE001380; Hood LL, 2001, J GEOPHYS RES-PLANET, V106, P27825, DOI 10.1029/2000JE001366; HOOD LL, 1991, J GEOPHYS RES-SOLID, V96, P9837, DOI 10.1029/91JB00308; Hood LL, 2008, ICARUS, V193, P485, DOI 10.1016/j.icarus.2007.08.023; Hood LL, 2011, ICARUS, V211, P1109, DOI 10.1016/j.icarus.2010.08.012; KOROTEV RL, 1987, J GEOPHYS RES-SOLID, V92, pE491, DOI 10.1029/JB092iB04p0E491; Korotev RL, 2000, J GEOPHYS RES-PLANET, V105, P4317, DOI 10.1029/1999JE001063; Le Bars M, 2011, NATURE, V479, P215, DOI 10.1038/nature10565; Marinova MM, 2008, NATURE, V453, P1216, DOI 10.1038/nature07070; Mitchell DL, 2008, ICARUS, V194, P401, DOI 10.1016/j.icarus.2007.10.027; Pierazzo E, 2000, METEORIT PLANET SCI, V35, P117, DOI 10.1111/j.1945-5100.2000.tb01979.x; Purucker ME, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2010JE003650; Rochette P, 2010, EARTH PLANET SC LETT, V292, P383, DOI 10.1016/j.epsl.2010.02.007; Senft LE, 2009, EARTH PLANET SC LETT, V287, P471, DOI 10.1016/j.epsl.2009.08.033; Shea EK, 2012, SCIENCE, V335, P453, DOI 10.1126/science.1215359; Smith DE, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043751; Stegman DR, 2003, NATURE, V421, P143, DOI 10.1038/nature01267; Tagle R, 2009, GEOCHIM COSMOCHIM AC, V73, P4891, DOI 10.1016/j.gca.2009.05.044; Tagle R, 2006, METEORIT PLANET SCI, V41, P1721, DOI 10.1111/j.1945-5100.2006.tb00448.x; Wang DM, 2005, GEOSPHERE, V1, P138, DOI 10.1130/GES00024.1; Wieczorek MA, 2006, REV MINERAL GEOCHEM, V60, P221, DOI 10.2138/rmg.2006.60.3	34	86	87	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1212	1215		10.1126/science.1214773	http://dx.doi.org/10.1126/science.1214773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403388				2022-12-28	WOS:000301225100041
J	Pollock, AM; Price, D; Roderick, P				Pollock, Allyson M.; Price, David; Roderick, Peter			Health and Social Care Bill 2011: a legal basis for charging and providing fewer health services to people in England	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Pollock, Allyson M.; Price, David] Univ London, Ctr Primary Care & Publ Hlth, London E1 4NS, England	University of London	Pollock, AM (corresponding author), Univ London, Ctr Primary Care & Publ Hlth, London E1 4NS, England.	a.pollock@qmul.ac.uk						HM Government, 2011, CM8134, V8134; House of Lords Select Committee on the Constitution, 2011, 240 HL SEL COMM CONS	2	11	11	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 8	2012	344								e1729	10.1136/bmj.e1729	http://dx.doi.org/10.1136/bmj.e1729			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908HL	22403268				2022-12-28	WOS:000301481400012
J	Schwarz, L; Scotte, M				Schwarz, Lilian; Scotte, Michel			Multiple endocrine carcinomas of the ileum	LANCET			English	Editorial Material									[Schwarz, Lilian; Scotte, Michel] Rouen Univ Hosp, Dept Digest Surg, Rouen, France	CHU de Rouen	Scotte, M (corresponding author), Charles Nicolle Hosp, Dept Digest Surg, 1 Rue Germont, F-76031 Rouen, France.	michel.scotte@chu-rouen.fr	schwarz, lilian/H-8837-2017	scotte, michel/0000-0001-9519-7632					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 16	2012	379	9833					E55	E55		10.1016/S0140-6736(11)61611-5	http://dx.doi.org/10.1016/S0140-6736(11)61611-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	962AM	22405730				2022-12-28	WOS:000305511400001
J	Perin, EC; Willerson, JT; Pepine, CJ; Henry, TD; Ellis, SG; Zhao, DXM; Silva, GV; Lai, DJ; Thomas, JD; Kronenberg, MW; Martin, AD; Anderson, RD; Traverse, JH; Penn, MS; Anwaruddin, S; Hatzopoulos, AK; Gee, AP; Taylor, DA; Cogle, CR; Smith, D; Westbrook, L; Chen, J; Handberg, E; Olson, RE; Geither, C; Bowman, S; Francescon, J; Baraniuk, S; Piller, LB; Simpson, LM; Loghin, C; Aguilar, D; Richman, S; Zierold, C; Bettencourt, J; Sayre, SL; Vojvodic, RW; Skarlatos, SI; Gordon, DJ; Ebert, RF; Kwak, M; Moye, LA; Simari, RD				Perin, Emerson C.; Willerson, James T.; Pepine, Carl J.; Henry, Timothy D.; Ellis, Stephen G.; Zhao, David X. M.; Silva, Guilherme V.; Lai, Dejian; Thomas, James D.; Kronenberg, Marvin W.; Martin, A. Daniel; Anderson, R. David; Traverse, Jay H.; Penn, Marc S.; Anwaruddin, Saif; Hatzopoulos, Antonis K.; Gee, Adrian P.; Taylor, Doris A.; Cogle, Christopher R.; Smith, Deirdre; Westbrook, Lynette; Chen, James; Handberg, Eileen; Olson, Rachel E.; Geither, Carrie; Bowman, Sherry; Francescon, Judy; Baraniuk, Sarah; Piller, Linda B.; Simpson, Lara M.; Loghin, Catalin; Aguilar, David; Richman, Sara; Zierold, Claudia; Bettencourt, Judy; Sayre, Shelly L.; Vojvodic, Rachel W.; Skarlatos, Sonia I.; Gordon, David J.; Ebert, Ray F.; Kwak, Minjung; Moye, Lemuel A.; Simari, Robert D.		Cardiovasc Cell Therapy Res Networ	Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure The FOCUS-CCTRN Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; RESEARCH NETWORK CCTRN; STEM-CELLS; PROGENITOR CELLS; TRANSCORONARY TRANSPLANTATION; INTRAMYOCARDIAL INJECTION; F-18 FLUORODEOXYGLUCOSE; METABOLIC-ACTIVITY	Context Previous studies using autologous bone marrow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy have demonstrated safety and suggested efficacy. Objective To determine if administration of BMCs through transendocardial injections improves myocardial perfusion, reduces left ventricular end-systolic volume (LVESV), or enhances maximal oxygen consumption in patients with coronary artery disease or LV dysfunction, and limiting heart failure or angina. Design, Setting, and Patients Aphase 2 randomized double-blind, placebo-controlled trial of symptomatic patients (New York Heart Association classification II-III or Canadian Cardiovascular Society classification II-IV) with a left ventricular ejection fraction of 45% or less, a perfusion defect by single-photon emission tomography (SPECT), and coronary artery disease not amenable to revascularization who were receiving maximal medical therapy at 5 National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network (CCTRN) sites between April 29, 2009, and April 18, 2011. Intervention Bone marrow aspiration (isolation of BMCs using a standardized automated system performed locally) and transendocardial injection of 100 million BMCs or placebo (ratio of 2 for BMC group to 1 for placebo group). Main Outcome Measures Co-primary end points assessed at 6 months: changes in LVESV assessed by echocardiography, maximal oxygen consumption, and reversibility on SPECT. Phenotypic and functional analyses of the cell product were performed by the CCTRN biorepository core laboratory. Results Of 153 patients who provided consent, a total of 92 (82 men; average age: 63 years) were randomized (n=61 in BMC group and n=31 in placebo group). Changes in LVESV index (-0.9 mL/m(2) [95% CI, -6.1 to 4.3]; P=.73), maximal oxygen consumption (1.0 [95% CI, -0.42 to 2.34]; P=.17), and reversible defect (-1.2 [95% CI, -12.50 to 10.12]; P=.84) were not statistically significant. There were no differences found in any of the secondary outcomes, including percent myocardial defect, total defect size, fixed defect size, regional wall motion, and clinical improvement. Conclusion Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.	[Lai, Dejian; Baraniuk, Sarah; Piller, Linda B.; Simpson, Lara M.; Bettencourt, Judy; Sayre, Shelly L.; Vojvodic, Rachel W.; Moye, Lemuel A.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA; [Loghin, Catalin] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Penn, Marc S.] NE Ohio Med Univ, Akron, OH USA; [Anwaruddin, Saif] Univ Penn, Penn Heart & Vasc Hosp, Philadelphia, PA 19104 USA; [Gee, Adrian P.; Aguilar, David; Richman, Sara] Baylor Univ, Coll Med, Houston, TX 77030 USA; [Skarlatos, Sonia I.; Gordon, David J.; Ebert, Ray F.; Kwak, Minjung] NHLBI, Bethesda, MD 20892 USA; [Simari, Robert D.] Mayo Clin, Rochester, MN USA; [Perin, Emerson C.; Willerson, James T.; Silva, Guilherme V.; Smith, Deirdre; Westbrook, Lynette] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA; [Pepine, Carl J.; Anderson, R. David; Cogle, Christopher R.; Handberg, Eileen] Univ Florida, Sch Med, Gainesville, FL USA; [Martin, A. Daniel] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA; [Henry, Timothy D.; Traverse, Jay H.; Olson, Rachel E.] Abbott NW Hosp, Minneapolis Heart Inst, Minneapolis, MN 55407 USA; [Henry, Timothy D.; Traverse, Jay H.; Taylor, Doris A.; Zierold, Claudia] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Ellis, Stephen G.; Thomas, James D.; Geither, Carrie] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Zhao, David X. M.; Kronenberg, Marvin W.; Hatzopoulos, Antonis K.; Bowman, Sherry; Francescon, Judy] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; Northeast Ohio Medical University (NEOMED); University of Pennsylvania; Baylor University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic; Saint Lukes Episcopal Hospital; Texas Heart Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; Vanderbilt University	Moye, LA (corresponding author), Univ Texas Houston, Sch Publ Hlth, 1200 Pressler,W-848, Houston, TX 77030 USA.	lemmoye@msn.com	Aguilar, David/GZM-1928-2022; Hatzopoulos, Antonis/D-2049-2010; Loghin, Catalin/AAU-9519-2020; Hatzopoulos, Antonis/X-2043-2019; Cogle, Christopher/H-1746-2016	Aguilar, David/0000-0002-0916-2722; Hatzopoulos, Antonis/0000-0001-5610-0017; Cogle, Christopher/0000-0001-5422-6863; Anderson, R. David/0000-0003-3490-3286; Handberg, Eileen/0000-0002-7805-9577	National Heart, Lung, and Blood Institute (NHLBI); Amarin Pharma; Amorycyte; Angioblast/Mesoblast; Baxter Healthcare; Bayer Healthcare; Daiichi-Sankyo; GlaxoSmithKline; Lilly; Merck; National Institutes of Health; National Heart, Lung; Blood Institute; Pfizer; sanofi-aventis; Viron Therapeutics; Aastrom; Mesoblast; NHLBI [5 U01 HL087318-04, N01-HB-37164, HHSN268201000008C, N01-HB-37163, HHSN268201000007C]; National Center for Research Resources CTSA [UL1 TR000064]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087318, UM1HL087318] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Amarin Pharma; Amorycyte; Angioblast/Mesoblast; Baxter Healthcare; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Daiichi-Sankyo(Daiichi Sankyo Company Limited); GlaxoSmithKline(GlaxoSmithKline); Lilly(Eli Lilly); Merck(Merck & Company); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Blood Institute; Pfizer(Pfizer); sanofi-aventis(Sanofi-Aventis); Viron Therapeutics; Aastrom; Mesoblast; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)NIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. All of the authors reported receiving research grant funding and support for travel expenses to meetings for the Cardiovascular Cell Therapy Research Network (CCTRN) from the National Heart, Lung, and Blood Institute (NHLBI). Dr Perin reported serving as a consultant to Amorcyte, Teva, Cytori, and Aldagen. Dr Pepine reported receiving research grants from Amarin Pharma, Amorycyte, Angioblast/Mesoblast, Baxter Healthcare, Bayer Healthcare, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, the National Institutes of Health, the National Heart, Lung, and Blood Institute, Pfizer, sanofi-aventis, Viron Therapeutics; serving as a consultant to Aastrom, Amarin Pharma, Amorycyte (scientific advisory board), Angioblast Systems (data and safety monitoring board), Lilly and County Community Foundation (data and safety monitoring board), and SLACK Inc; and holding 2 patents with the University of Florida. Dr Henry reported serving on steering committees for and receiving research grants from Aastrom and Mesoblast. Dr Martin reported receiving research grants from the University of Texas to provide an exercise testing core laboratory and received financial support for travel expenses. Dr Penn reported receiving research grants from Athersys Inc; serving as a board member for Juventas Therapeutics; serving as a consultant to Juventas Therapeutics and Aastrom Biosciences; and holding patents, receiving royalties, and owning stock in Juventas Therapeutics. Dr Hatzopoulos reported receiving payment for lectures from Washington University, University of Minnesota, and Tennessee State University. Dr Taylor reported receiving payment for a lecture at an annual meeting of the Cell Society. Dr Handberg reported receiving grants from Baxter, BDI, Amrin, Angioblast, Neostem, Harvest Technologies, Daiichi Sankyo, Pfizer, Gilead Sciences, and GlaxoSmithKline. Ms Olson reported receiving research grants from Mesoblast and Aastrom. Ms Geither reported receiving support for travel expenses to meetings from the Cleveland Clinic. Dr Aguilar reported being a consultant to Amylin Pharmaceutical in the area of diabetes and heart failure.; Funding for this trial was provided by the NHLBI under cooperative agreement 5 U01 HL087318-04. It also was supported in part by NHLBI contracts N01-HB-37164 and HHSN268201000008C awarded to the Molecular and Cellular Therapeutics Facility, University of Minnesota, and N01-HB-37163 and HHSN268201000007C awarded to the Cell Processing Facility, Baylor College of Medicine, and National Center for Research Resources CTSA grant UL1 TR000064 awarded to the University of Florida. The CCTRN also acknowledges its industry partners: Biosafe, Biologics Delivery Systems Group, and Cordis Corporation for their contributions of equipment and technical support during the conduct of the trial.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2007, CIRC RES, V100, P1234, DOI 10.1161/01.RES.0000264508.47717.6b; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Beeres SLMA, 2007, AM J CARDIOL, V100, P1094, DOI 10.1016/j.amjcard.2007.04.056; Beeres SLMA, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.07.018; BONOW RO, 1991, CIRCULATION, V83, P26, DOI 10.1161/01.CIR.83.1.26; Briguori C, 2006, AM HEART J, V151, P674, DOI 10.1016/j.ahj.2005.04.033; BRUNKEN R, 1987, J AM COLL CARDIOL, V10, P557, DOI 10.1016/S0735-1097(87)80198-5; Burt RK, 2008, JAMA-J AM MED ASSOC, V299, P925, DOI 10.1001/jama.299.8.925; Ciraci E, 2011, BLOOD, V118, P2105, DOI 10.1182/blood-2010-10-316596; DILSIZIAN V, 1994, CIRCULATION, V89, P578, DOI 10.1161/01.CIR.89.2.578; Erbs S, 2005, CIRC RES, V97, P756, DOI 10.1161/01.RES.0000185811.71306.8b; Fuchs S, 2006, AM J CARDIOL, V97, P823, DOI 10.1016/j.amjcard.2005.09.132; Gee AP, 2010, CYTOTHERAPY, V12, P684, DOI 10.3109/14653249.2010.487900; Heeschen C, 2004, CIRCULATION, V109, P1615, DOI 10.1161/01.CIR.0000124476.32871.E3; Hendrikx M, 2006, CIRCULATION, V114, pI101, DOI 10.1161/CIRCULATIONAHA.105.000505; Kissel CK, 2007, J AM COLL CARDIOL, V49, P2341, DOI 10.1016/j.jacc.2007.01.095; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lipinski MJ, 2007, J AM COLL CARDIOL, V50, P1761, DOI 10.1016/j.jacc.2007.07.041; Losordo DW, 2007, CIRCULATION, V115, P3165, DOI 10.1161/CIRCULATIONAHA.106.687376; Losordo DW, 2011, CIRC RES, V109, P428, DOI 10.1161/CIRCRESAHA.111.245993; Mackie AR, 2011, TEX HEART I J, V38, P474; Maret E, 2008, CARDIOVASC ULTRASOUN, V6, DOI 10.1186/1476-7120-6-55; Martin-Rendon E, 2008, EUR HEART J, V29, P1807, DOI 10.1093/eurheartj/ehn220; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Paprocka M, 2011, CYTOM PART A, V79A, P594, DOI 10.1002/cyto.a.21092; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Perin EC, 2004, CIRCULATION, V110, pII213, DOI 10.1161/01.CIR.0000138398.77550.62; Perin EC, 2011, AM HEART J, V161, P1078, DOI 10.1016/j.ahj.2011.01.028; SAS Publishing, 2009, SAS 9 2 LANG REF DIC; Simari RD, 2010, J CARDIOVASC TRANSL, V3, P30, DOI 10.1007/s12265-009-9160-3; TAMAKI N, 1988, AM J CARDIOL, V62, P202, DOI 10.1016/0002-9149(88)90212-3; Traverse JH, 2011, JAMA-J AM MED ASSOC, V306, P2110, DOI 10.1001/jama.2011.1670; Tse HF, 2007, EUR HEART J, V28, P2998, DOI 10.1093/eurheartj/ehm485; Tse HF, 2006, AM J CARDIOL, V98, P60, DOI 10.1016/j.amjcard.2006.01.056; van Ramshorst J, 2009, JAMA-J AM MED ASSOC, V301, P1997, DOI 10.1001/jama.2009.685; Willerson JT, 2010, AM HEART J, V160, P215, DOI 10.1016/j.ahj.2010.03.029; Yao K, 2008, HEART, V94, P1147, DOI 10.1136/hrt.2007.137919; Zierold C, 2011, AM HEART J, V162, P973, DOI 10.1016/j.ahj.2011.05.024	41	325	341	3	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2012	307	16					1717	1726		10.1001/jama.2012.418	http://dx.doi.org/10.1001/jama.2012.418			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930OA	22447880	Green Accepted, Bronze			2022-12-28	WOS:000303147500025
J	Zuber, MT; Smith, DE; Phillips, RJ; Solomon, SC; Neumann, GA; Hauck, SA; Peale, SJ; Barnouin, OS; Head, JW; Johnson, CL; Lemoine, FG; Mazarico, E; Sun, XL; Torrence, MH; Freed, AM; Klimczak, C; Margot, JL; Oberst, J; Perry, ME; McNutt, RL; Balcerski, JA; Michel, N; Talpe, MJ; Yang, D				Zuber, Maria T.; Smith, David E.; Phillips, Roger J.; Solomon, Sean C.; Neumann, Gregory A.; Hauck, Steven A., II; Peale, Stanton J.; Barnouin, Olivier S.; Head, James W.; Johnson, Catherine L.; Lemoine, Frank G.; Mazarico, Erwan; Sun, Xiaoli; Torrence, Mark H.; Freed, Andrew M.; Klimczak, Christian; Margot, Jean-Luc; Oberst, Juergen; Perry, Mark E.; McNutt, Ralph L., Jr.; Balcerski, Jeffrey A.; Michel, Nathalie; Talpe, Matthieu J.; Yang, Di			Topography of the Northern Hemisphere of Mercury from MESSENGER Laser Altimetry	SCIENCE			English	Article							LOBATE SCARPS; CALORIS BASIN; FLYBYS 1; SURFACE; GEOLOGY; SHAPE; VIEW; MARS	Laser altimetry by the MESSENGER spacecraft has yielded a topographic model of the northern hemisphere of Mercury. The dynamic range of elevations is considerably smaller than those of Mars or the Moon. The most prominent feature is an extensive lowland at high northern latitudes that hosts the volcanic northern plains. Within this lowland is a broad topographic rise that experienced uplift after plains emplacement. The interior of the 1500-km-diameter Caloris impact basin has been modified so that part of the basin floor now stands higher than the rim. The elevated portion of the floor of Caloris appears to be part of a quasi-linear rise that extends for approximately half the planetary circumference at mid-latitudes. Collectively, these features imply that long-wavelength changes to Mercury's topography occurred after the earliest phases of the planet's geological history.	[Zuber, Maria T.; Smith, David E.; Mazarico, Erwan; Talpe, Matthieu J.; Yang, Di] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [Phillips, Roger J.] SW Res Inst, Planetary Sci Directorate, Boulder, CO 80302 USA; [Solomon, Sean C.; Klimczak, Christian] Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; [Neumann, Gregory A.; Lemoine, Frank G.; Mazarico, Erwan; Sun, Xiaoli; Torrence, Mark H.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Hauck, Steven A., II; Balcerski, Jeffrey A.; Michel, Nathalie] Case Western Reserve Univ, Dept Earth Environm & Planetary Sci, Cleveland, OH 44106 USA; [Peale, Stanton J.] Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; [Barnouin, Olivier S.; Perry, Mark E.; McNutt, Ralph L., Jr.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; [Head, James W.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Johnson, Catherine L.] Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; [Torrence, Mark H.] Stinger Ghaffarian Technol Inc, Greenbelt, MD 20770 USA; [Freed, Andrew M.] Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA; [Margot, Jean-Luc] Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; [Oberst, Juergen] German Aerosp Ctr, Inst Planetary Res, D-12489 Berlin, Germany	Massachusetts Institute of Technology (MIT); Carnegie Institution for Science; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Case Western Reserve University; University of California System; University of California Santa Barbara; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Brown University; University of British Columbia; Stinger Ghaffarian Technologies, Inc. (SGT); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Los Angeles; Helmholtz Association; German Aerospace Centre (DLR)	Zuber, MT (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	zuber@mit.edu	Hauck, Steven A/A-7865-2008; Mazarico, Erwan/N-6034-2014; Neumann, Gregory A/I-5591-2013; Sun, Xiaoli/B-5120-2013; Barnouin, Olivier S/I-7475-2015; Margot, Jean-Luc/A-6154-2012; McNutt, Ralph L/E-8006-2010; Perry, Mark E./B-8870-2016; Johnson, Catherine L./AAZ-7295-2020; Lemoine, Frank/D-1215-2013	Hauck, Steven A/0000-0001-8245-146X; Mazarico, Erwan/0000-0003-3456-427X; Neumann, Gregory A/0000-0003-0644-9944; Barnouin, Olivier S/0000-0002-3578-7750; Margot, Jean-Luc/0000-0001-9798-1797; McNutt, Ralph L/0000-0002-4722-9166; Perry, Mark E./0000-0003-1600-6856; Lemoine, Frank G./0000-0002-3051-1456	NASA [NAS5-97271, NASW-00002]	NASA(National Aeronautics & Space Administration (NASA))	The MESSENGER project is supported by the NASA Discovery Program under contracts NAS5-97271 to the Johns Hopkins University Applied Physics Laboratory and NASW-00002 to the Carnegie Institution of Washington. We are grateful for the myriad contributions from the MLA instrument and MESSENGER spacecraft teams, and we appreciate three helpful reviews of an earlier version of the paper.	Cavanaugh JF, 2007, SPACE SCI REV, V131, P451, DOI 10.1007/s11214-007-9273-4; Dombard A. J., 2001, LUNAR PLANET SCI, V32; Fassett C. I., 2011, GEOL SOC AM ANN M MI; Fassett CI, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047294; GOLDREICH P, 1969, J GEOPHYS RES, V74, P2555, DOI 10.1029/JB074i010p02555; Hauck SA, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030793; Head JW, 2007, SPACE SCI REV, V131, P41, DOI 10.1007/s11214-007-9263-6; Head JW, 2011, SCIENCE, V333, P1853, DOI 10.1126/science.1211997; King SD, 2008, NAT GEOSCI, V1, P229, DOI 10.1038/ngeo152; Klimczak C., 2011, GEOL SOC AM ANN M MI; Kreslavsky MA, 2000, J GEOPHYS RES-PLANET, V105, P26695, DOI 10.1029/2000JE001259; Michel N., 2011, AM GEOPH UN FALL M S; Murchie SL, 2008, SCIENCE, V321, P73, DOI 10.1126/science.1159261; Nittler LR, 2011, SCIENCE, V333, P1847, DOI 10.1126/science.1211567; Nittler LR., 2011, INTERACTIVE PROCESSI; Oberst J, 2010, ICARUS, V209, P230, DOI 10.1016/j.icarus.2010.03.009; Smith DE, 2012, SCIENCE, V336, P214, DOI 10.1126/science.1218809; Smith DE, 2010, ICARUS, V209, P88, DOI 10.1016/j.icarus.2010.04.007; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Solomon SC, 2008, SCIENCE, V321, P59, DOI 10.1126/science.1159706; Solomon SC, 2007, SPACE SCI REV, V131, P3, DOI 10.1007/s11214-007-9247-6; Spudis P.D., 1988, MERCURY, P118; Zhong SJ, 2000, J GEOPHYS RES-PLANET, V105, P4153, DOI 10.1029/1999JE001075; Zuber MT, 2008, SCIENCE, V321, P77, DOI 10.1126/science.1159086; Zuber MT, 2010, ICARUS, V209, P247, DOI 10.1016/j.icarus.2010.02.026; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	26	134	137	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 13	2012	336	6078					217	220		10.1126/science.1218805	http://dx.doi.org/10.1126/science.1218805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924PN	22438510				2022-12-28	WOS:000302703900047
J	Kelleher, CM; Forcione, DG; Gee, MS; Mino-Kenudson, M				Kelleher, Cassandra M.; Forcione, David G.; Gee, Michael S.; Mino-Kenudson, Mari			Case 10-2012: A 16-Year-Old Boy with Epigastric Pain and a Mediastinal Mass Esophageal duplication cyst with chronic inflammation, necrosis, and calcification.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHOGENIC CYSTS; LYMPHANGIOMA; MYELOMENINGOCELE; DIAGNOSIS; RESECTION; ADULT; FNA; EUS		[Kelleher, Cassandra M.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; [Forcione, David G.] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA; [Gee, Michael S.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Kelleher, Cassandra M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Forcione, David G.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Gee, Michael S.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kelleher, CM (corresponding author), Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.							Azzie Georges, 2003, Semin Pediatr Surg, V12, P46, DOI 10.1053/spsu.2003.50000; Banerjee S, 2008, GASTROINTEST ENDOSC, V67, P791, DOI 10.1016/j.gie.2008.02.068; BILL AH, 1965, SURG GYNECOL OBSTETR, V120, P79; Borcek AO, 2005, J NEUROSURG, V103, P79; Bratu L, 2005, J PEDIATR SURG, V40, P138, DOI 10.1016/j.jpedsung.2004.09.025; Detaille T, 2010, AM J EMERG MED, V28, DOI 10.1016/j.ajem.2010.01.031; Diehl DL, 2010, INTERACT CARDIOV TH, V10, P338, DOI 10.1510/icvts.2009.217067; Faul JL, 2000, AM J RESP CRIT CARE, V161, P1037, DOI 10.1164/ajrccm.161.3.9904056; Fazel A, 2005, GASTROINTEST ENDOSC, V62, P575, DOI 10.1016/j.gie.2005.06.014; Fenoglio-Preiser C.M., 2008, GASTROINTESTINAL PAT, V3rd ed.; Fitch S J, 1986, Radiographics, V6, P189; GHARAGOZLOO F, 1995, CHEST, V108, P880, DOI 10.1378/chest.108.3.880; HANCOCK BJ, 1992, J PEDIATR SURG, V27, P220, DOI 10.1016/0022-3468(92)90316-Y; Hirose S, 2006, J LAPAROENDOSC ADV S, V16, P526, DOI 10.1089/lap.2006.16.526; KRANSDORF MJ, 1995, AM J ROENTGENOL, V164, P395, DOI 10.2214/ajr.164.2.7839977; Lee MY, 1998, AM J CLIN ONCOL-CANC, V21, P64, DOI 10.1097/00000421-199802000-00014; NAKAZATO Y, 1995, AM HEART J, V129, P406, DOI 10.1016/0002-8703(95)90027-6; Nobuhara KK, 1997, J PEDIATR SURG, V32, P1408, DOI 10.1016/S0022-3468(97)90550-9; Park JG, 2006, MAYO CLIN PROC, V81, P1197, DOI 10.4065/81.9.1197; PATEL SR, 1994, CHEST, V106, P79, DOI 10.1378/chest.106.1.79; Savage JJ, 2010, J CRANIOVERTEBRAL JU, V1, P58, DOI 10.4103/0974-8237.65484; Shaer CM, 2007, OBSTET GYNECOL SURV, V62, P471, DOI 10.1097/01.ogx.0000268628.82123.90; Singh S, 2001, DIS ESOPHAGUS, V14, P258, DOI 10.1046/j.1442-2050.2001.00204.x; Takeda S, 2003, CHEST, V124, P125, DOI 10.1378/chest.124.1.125; Wildi SM, 2003, GASTROINTEST ENDOSC, V58, P362, DOI 10.1067/S0016-5107(03)00009-9; Wright Cameron D, 2009, Thorac Surg Clin, V19, P47, DOI 10.1016/j.thorsurg.2008.09.014; Zdenek K, 2007, SURG LAPARO ENDO PER, V17, P311, DOI 10.1097/SLE.0b013e31805b7f26	27	1	1	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1241	1249		10.1056/NEJMcpc1110055	http://dx.doi.org/10.1056/NEJMcpc1110055			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455419				2022-12-28	WOS:000302005100014
J	Wahbi, K; Meune, C; Porcher, R; Becane, HM; Lazarus, A; Laforet, P; Stojkovic, T; Behin, A; Radvanyi-Hoffmann, H; Eymard, B; Duboc, D				Wahbi, Karim; Meune, Christophe; Porcher, Raphael; Becane, Henri Marc; Lazarus, Arnaud; Laforet, Pascal; Stojkovic, Tanya; Behin, Anthony; Radvanyi-Hoffmann, Helene; Eymard, Bruno; Duboc, Denis			Electrophysiological Study With Prophylactic Pacing and Survival in Adults With Myotonic Dystrophy and Conduction System Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPENSITY-SCORE; MONTE-CARLO; MUTATION; DEATH; MULTIVARIATE; IMPUTATION; REPEAT; TYPE-1; MODEL; GENE	Context Up to one-third of patients with myotonic dystrophy type 1 die suddenly. Thus far, no intervention has effectively prevented sudden death. Objective To determine whether an invasive strategy based on systematic electrophysiological studies and prophylactic permanent pacing is associated with longer survival in patients presenting with myotonic dystrophy type 1 and major infranodal conduction delays than a noninvasive strategy. Design, Setting, and Patients A retrospective study, the DM1 Heart Registry included 914 consecutive patients older than 18 years with genetically confirmed myotonic dystrophy type 1 who were admitted to the Neurological Unit of the Myology Institute of Pitie-Salpetriere Hospital, a teaching medical center in Paris, France, between January 2000 and December 2009. Interventions Among 486 patients whose electrocardiogram showed a PR interval greater than 200 milliseconds, a QRS duration greater than 100 milliseconds, or both, the outcome of 341 (70.2%) who underwent an invasive strategy was compared with 145 (29.8%) who underwent a noninvasive strategy. A propensity score risk adjustment and propensity-based matching analysis was used to account for selection biases. Main Outcome Measures Rates of overall survival (main outcome measure) and sudden death, respiratory death, and other deaths (secondary outcome measures). Results Over a median follow-up of 7.4 years (range, 0-9.9 years), 50 patients died in the invasive strategy group and 30 died in the noninvasive strategy group (hazard ratio [HR], 0.74 [95 CI, 0.47-1.16]; P=. 19), corresponding to an overall 9-year survival of 74.4% (95% CI, 69.2%-79.9%). Regardless of the technique used to adjust for between-group differences in baseline characteristics, the invasive strategy was associated with a longer survival, with adjusted HRs ranging from 0.47 (95% CI, 0.26-0.84; P=. 01) for a covariate-adjusted analysis of propensitymatched data to 0.61 (95% CI, 0.38-0.99; P=. 047) for an analysis adjusted for propensity score quintiles. The survival difference was largely attributable to a lower incidence of sudden death, which occurred in 10 patients in the invasive strategy group and in 16 patients in the noninvasive strategy group, with HRs ranging from 0.24 (95% CI, 0.10-0.56; P=. 001) for an analysis adjusted for propensity score quintiles and covariates to 0.28 (95% CI, 0.13-0.61; P=. 001) for an unadjusted analysis of propensity-matched data. Conclusion Among patients with myotonic dystrophy type 1, an invasive strategy was associated with a higher rate of 9-year survival than a noninvasive strategy.	[Wahbi, Karim; Meune, Christophe; Lazarus, Arnaud; Duboc, Denis] Cochin Hosp, AP HP, Dept Cardiol, F-75679 Paris 14, France; [Wahbi, Karim; Laforet, Pascal; Eymard, Bruno] Univ Paris 06, Myol Inst, Pitie Salpetriere Hosp, F-75013 Paris, France; [Wahbi, Karim; Becane, Henri Marc; Laforet, Pascal; Stojkovic, Tanya; Behin, Anthony; Eymard, Bruno; Duboc, Denis] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France; [Meune, Christophe; Duboc, Denis] Sorbonne Paris Cite Univ, F-75006 Paris, France; [Porcher, Raphael] St Louis Hosp, AP HP, Biostat & Med Informat Technol Dept, Paris, France; [Porcher, Raphael] Univ Paris 07, Paris, France; [Lazarus, Arnaud] InParys Clin Res Grp, St Cloud, France; [Radvanyi-Hoffmann, Helene] Ambroise Pare Hosp, AP HP, Dept Mol Genet, Boulogne, France; [Duboc, Denis] Univ Paris 06, INSERM, UMRS 974, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Wahbi, K (corresponding author), Cochin Hosp, AP HP, Dept Cardiol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.	karim.wahbi@cch.aphp.fr	STOJKOVIC, Tanya/AAA-3967-2021	Porcher, Raphael/0000-0002-5277-4679; Behin, Anthony/0000-0001-7179-5152; wahbi, karim/0000-0001-7682-7387	Association Francaise Contre les Myopathies (French Alliance Against Myopathies)	Association Francaise Contre les Myopathies (French Alliance Against Myopathies)	This study was funded by grants from the Association Francaise Contre les Myopathies (French Alliance Against Myopathies).	Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; ASHIZAWA T, 1991, LANCET, V338, P642, DOI 10.1016/0140-6736(91)90659-D; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Austin PC, 2007, STAT MED, V26, P754, DOI 10.1002/sim.2618; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Austin PC, 2009, BIOMETRICAL J, V51, P171, DOI 10.1002/bimj.200810488; D'Agostino RB, 2007, JAMA-J AM MED ASSOC, V297, P314, DOI 10.1001/jama.297.3.314; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; de Die-Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; Epstein AE, 2008, CIRCULATION, V117, pE350, DOI 10.1161/CIRCUALTIONAHA.108.189742; European Heart Rhythm Association, 2006, J Am Coll Cardiol, V48, pe247, DOI 10.1016/j.jacc.2006.07.010; Gagnon C, 2010, NEUROMUSCULAR DISORD, V20, P847, DOI 10.1016/j.nmd.2010.08.006; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Groh WJ, 2008, NEW ENGL J MED, V358, P2688, DOI 10.1056/NEJMoa062800; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lazarus A, 1999, CIRCULATION, V99, P1041, DOI 10.1161/01.CIR.99.8.1041; Lazarus A, 2002, J AM COLL CARDIOL, V40, P1645, DOI 10.1016/S0735-1097(02)02339-2; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Mathieu J, 1999, NEUROLOGY, V52, P1658, DOI 10.1212/WNL.52.8.1658; Mathieu J, 2001, NEUROLOGY, V56, P336, DOI 10.1212/WNL.56.3.336; PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374; R Foundation for Statistical Computing, R LANG ENV STAT COMP; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Sekhon JS, 2011, J STAT SOFTW, V42, P1; van Buuren S, 2011, J STAT SOFTW, V45, P1; Walton J, 1994, DISORDERS VOLUNTARY, P1771; White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618	31	95	98	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1292	1301		10.1001/jama.2012.346	http://dx.doi.org/10.1001/jama.2012.346			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22453570				2022-12-28	WOS:000301978400025
J	Su, YQ; Sugiura, K; Sun, FY; Pendola, JK; Cox, GA; Handel, MA; Schimenti, JC; Eppig, JJ				Su, You-Qiang; Sugiura, Koji; Sun, Fengyun; Pendola, Janice K.; Cox, Gregory A.; Handel, Mary Ann; Schimenti, John C.; Eppig, John J.			MARF1 Regulates Essential Oogenic Processes in Mice	SCIENCE			English	Article							TRANSPOSABLE ELEMENTS; DNA-DAMAGE; OOCYTES	Development of fertilization-competent oocytes depends on integrated processes controlling meiosis, cytoplasmic development, and maintenance of genomic integrity. We show that meiosis arrest female 1 (MARF1) is required for these processes in mammalian oocytes. Mutations of Marf1 cause female infertility characterized by up-regulation of a cohort of transcripts, increased retrotransposon expression, defective cytoplasmic maturation, and meiotic arrest. Up-regulation of protein phosphatase 2 catalytic subunit (PPP2CB) is key to the meiotic arrest phenotype. Moreover, Iap and Line1 retrotransposon messenger RNAs are also up-regulated, and, concomitantly, DNA double-strand breaks are elevated in mutant oocytes. Therefore MARF1, by suppressing levels of specific transcripts, is an essential regulator of important oogenic processes leading to female fertility and the development of healthy offspring.	[Su, You-Qiang; Sugiura, Koji; Sun, Fengyun; Pendola, Janice K.; Cox, Gregory A.; Handel, Mary Ann; Eppig, John J.] Jackson Lab, Bar Harbor, ME 04609 USA; [Schimenti, John C.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA	Jackson Laboratory; Cornell University	Eppig, JJ (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	John.Eppig@jax.org	Su, You-Qiang/C-6160-2019; Sugiura, Koji/AAE-2966-2019	Su, You-Qiang/0000-0003-3537-6246; Sugiura, Koji/0000-0001-8945-3353	NIH [HD42137]; National Cancer Institute [CA34196]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD042137] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. Conti for providing the Cdc25b plasmid and Gpr3<SUP>-/-</SUP> mice and K. Wigglesworth and M. O'Brien for technical assistance. Supported by NIH grant HD42137 (Y.-Q.S., K.S., F.S., J.K.P., M.A.H., J.C.S., and J.J.E.) and Scientific Services by grant CA34196 from the National Cancer Institute. Microarray data are deposited in the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo, data set GSE 31985).	Anantharaman V, 2010, BIOL DIRECT, V5, DOI 10.1186/1745-6150-5-13; Callebaut I, 2010, BIOINFORMATICS, V26, P1140, DOI 10.1093/bioinformatics/btq122; Di Giacomo M, 2005, P NATL ACAD SCI USA, V102, P737, DOI 10.1073/pnas.0406212102; Eppig JJ, 1996, REPROD FERT DEVELOP, V8, P485, DOI 10.1071/RD9960485; Hedges DJ, 2007, MUTAT RES-FUND MOL M, V616, P46, DOI 10.1016/j.mrfmmm.2006.11.021; Ma L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000635; Murchison EP, 2007, GENE DEV, V21, P682, DOI 10.1101/gad.1521307; Soper SFC, 2008, DEV CELL, V15, P285, DOI 10.1016/j.devcel.2008.05.015; Swain JE, 2008, HUM REPROD UPDATE, V14, P431, DOI 10.1093/humupd/dmn025; Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904; Tatone C, 2011, HUM REPROD, V26, P1843, DOI 10.1093/humrep/der140; Voronina E, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002774; Yan Y, 2010, ONCOGENE, V29, P4317, DOI 10.1038/onc.2010.187; Zamudio N, 2010, HEREDITY, V105, P92, DOI 10.1038/hdy.2010.53	14	74	79	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1496	1499		10.1126/science.1214680	http://dx.doi.org/10.1126/science.1214680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442484	Green Accepted			2022-12-28	WOS:000301837000049
J	Kaufman, DS; Zietman, AL; McDougal, WS; Dahl, DM; Harisinghani, MG; Wu, CL				Kaufman, Donald S.; Zietman, Anthony L.; McDougal, W. Scott; Dahl, Douglas M.; Harisinghani, Mukesh G.; Wu, Chin-Lee			Case 9-2012: A 67-Year-Old Man with a Persistently Elevated PSA Level	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSTATE-CANCER; BIOPSY		[Kaufman, Donald S.] Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02114 USA; [Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [McDougal, W. Scott; Dahl, Douglas M.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Kaufman, Donald S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Zietman, Anthony L.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; [McDougal, W. Scott; Dahl, Douglas M.] Harvard Univ, Sch Med, Dept Urol, Boston, MA USA; [Harisinghani, Mukesh G.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; [Wu, Chin-Lee] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; [Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kaufman, DS (corresponding author), Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02114 USA.		Harisinghani, Mukesh/D-7590-2011					Al-Ahmadie HA, 2008, AM J SURG PATHOL, V32, P229, DOI 10.1097/PAS.0b013e31812f7b27; [Anonymous], 2010, AJCC CANC STAG MAN; Barry MJ, 2012, J CLIN ONCOL    0103; Bittner N, 2009, UROLOGY, V74, P171, DOI 10.1016/j.urology.2008.12.013; Bott SRJ, 2002, BJU INT, V89, P886, DOI 10.1046/j.1464-410X.2002.02796.x; Eichler K, 2006, J UROLOGY, V175, P1605, DOI 10.1016/S0022-5347(05)00957-2; Gershman B, UROL ONCOL IN PRESS; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Magheli A, 2011, BJU INT, V107, P1956, DOI 10.1111/j.1464-410X.2010.09795.x; Merrick GS, 2008, BJU INT, V101, P1524, DOI 10.1111/j.1464-410X.2008.07542.x; Philip J, 2005, PROSTATE, V64, P200, DOI 10.1002/pros.20239; Reuter VE, 1997, UROLOGY, V49, P16, DOI 10.1016/S0090-4295(97)00164-7; Satoh T, 2005, UROLOGY, V66, P114, DOI 10.1016/j.urology.2005.01.051; Taira AV, 2010, PROSTATE CANCER P D, V13, P71, DOI 10.1038/pcan.2009.42	14	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1143	1150		10.1056/NEJMcpc1104320	http://dx.doi.org/10.1056/NEJMcpc1104320			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435374				2022-12-28	WOS:000301769700014
J	Sethi, S; Fervenza, FC				Sethi, Sanjeev; Fervenza, Fernando C.			Membranoproliferative Glomerulonephritis - A New Look at an Old Entity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DENSE DEPOSIT DISEASE; ALTERNATE-DAY PREDNISONE; ISOLATED C3 DEPOSITS; FACTOR-H DEFICIENCY; MESANGIOCAPILLARY GLOMERULONEPHRITIS; MYCOPHENOLATE-MOFETIL; MONOCLONAL GAMMOPATHY; GLOMERULAR-DISEASES; PROLIFERATIVE GLOMERULONEPHRITIS; CHANGING INCIDENCE		[Sethi, Sanjeev] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Fervenza, Fernando C.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Sethi, S (corresponding author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	sethi.sanjeev@mayo.edu	Fervenza, Fernando/AAK-2400-2020; Hug, Balthasar L./G-1568-2010					Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315; Abrera-Abeleda MA, 2011, J AM SOC NEPHROL, V22, P1551, DOI 10.1681/ASN.2010080795; Ades L, 1998, TRANSPLANTATION, V66, P653, DOI 10.1097/00007890-199809150-00019; Alchi B, 2010, PEDIATR NEPHROL, V25, P1409, DOI 10.1007/s00467-009-1322-7; Altiparmak MR, 2002, SCAND J INFECT DIS, V34, P477, DOI 10.1080/003655402320170354; Andresdottir MB, 1997, TRANSPLANTATION, V63, P1628, DOI 10.1097/00007890-199706150-00016; Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078; Athanasiou Y, 2011, CLIN J AM SOC NEPHRO, V6, P1436, DOI 10.2215/CJN.09541010; Bagheri Nazila, 2008, Arch Iran Med, V11, P26; Bahat E, 2007, J NEPHROL, V20, P234; Bayazit AK, 2004, CLIN NEPHROL, V61, P25; BERGSTEIN JM, 1995, PEDIATR NEPHROL, V9, P268, DOI 10.1007/BF02254181; Bonarek H, 1999, NEPHROL DIAL TRANSPL, V14, P1771, DOI 10.1093/ndt/14.7.1771; Boseman P, 2008, AM J KIDNEY DIS, V51, P697, DOI 10.1053/j.ajkd.2007.08.031; Braden GL, 2000, AM J KIDNEY DIS, V35, P878, DOI 10.1016/S0272-6386(00)70258-7; Bridoux F, 2011, CLIN J AM SOC NEPHRO, V6, P2165, DOI 10.2215/CJN.06180710; Briganti EM, 2001, NEPHROL DIAL TRANSPL, V16, P1364, DOI 10.1093/ndt/16.7.1364; CAMERON JS, 1983, AM J MED, V74, P175, DOI 10.1016/0002-9343(83)90606-X; CATTRAN DC, 1991, CLIN NEPHROL, V35, pS43; CATTRAN DC, 1985, KIDNEY INT, V27, P436, DOI 10.1038/ki.1985.28; CHAPMAN SJ, 1980, ARCH DIS CHILD, V55, P446, DOI 10.1136/adc.55.6.446; Choi MJ, 2002, KIDNEY INT, V61, P1098, DOI 10.1046/j.1523-1755.2002.00214.x; CORTEZ MS, 1995, AM J KIDNEY DIS, V25, P632, DOI 10.1016/0272-6386(95)90136-1; DAMICO G, 1992, J AM SOC NEPHROL, V2, pS159; DATHAN JRE, 1975, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5954.376; Laso MD, 2006, PEDIATR NEPHROL, V21, P1483, DOI 10.1007/s00467-006-0179-2; DONADIO JV, 1989, AM J KIDNEY DIS, V14, P445, DOI 10.1016/S0272-6386(89)80143-X; DONADIO JV, 1984, NEW ENGL J MED, V310, P1421, DOI 10.1056/NEJM198405313102203; DOUTRELEPONT JM, 1993, LANCET, V341, P317, DOI 10.1016/0140-6736(93)92680-R; Elmaci I, 2007, J CLIN MICROBIOL, V45, P2072, DOI 10.1128/JCM.01358-06; Emre Sevinc, 1995, Acta Paediatrica Japonica, V37, P626; FAEDDA R, 1994, NEPHRON, V67, P59, DOI 10.1159/000187889; Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85; Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007; FORD DM, 1992, KIDNEY INT, V41, P1606, DOI 10.1038/ki.1992.232; Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8; Glassock RJ, 2009, TREATMENT PRIMARY GL, P375; Goldberg RJ, 2010, AM J KIDNEY DIS, V56, P1168, DOI 10.1053/j.ajkd.2010.06.006; Goules A, 2000, MEDICINE, V79, P241, DOI 10.1097/00005792-200007000-00005; Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959; Guiard E, 2011, CLIN J AM SOC NEPHRO, V6, P1609, DOI 10.2215/CJN.10611110; Habbig S, 2009, KIDNEY INT, V75, P1230, DOI 10.1038/ki.2008.354; Haddad M, 2007, PEDIATR NEPHROL, V22, P1787, DOI 10.1007/s00467-007-0523-1; Haffner D, 1997, NEPHROL DIAL TRANSPL, V12, P1143, DOI 10.1093/ndt/12.6.1143; Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108; HULTON SA, 1992, PEDIATR NEPHROL, V6, P239, DOI 10.1007/BF00878356; Jennette JC, 2007, HEPTINSTALLS PATHOLO; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; Jones G, 2004, NEPHROL DIAL TRANSPL, V19, P3160, DOI 10.1093/ndt/gfh526; Jose MD, 1998, NEPHROL DIAL TRANSPL, V13, P2628, DOI 10.1093/ndt/13.10.2628; Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008; Kai H, 2006, J NEPHROL, V19, P215; Karakayali FY, 2006, TRANSPLANT P, V38, P470, DOI 10.1016/j.transproceed.2006.01.028; Kumar V., 2010, PATHOLOGIC BASIS DIS; Lapeyraque AL, 2011, PEDIATR NEPHROL, V26, P621, DOI 10.1007/s00467-010-1719-3; Lau KK, 2008, CLIN EXP NEPHROL, V12, P228, DOI 10.1007/s10157-008-0031-z; Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269; Licht C, 2005, AM J KIDNEY DIS, V45, P415, DOI 10.1053/j.ajkd.2004.10.018; Lorenz EC, 2010, KIDNEY INT, V77, P721, DOI 10.1038/ki.2010.1; Maisonneuve P, 2000, AM J KIDNEY DIS, V35, P157, DOI 10.1016/S0272-6386(00)70316-7; MARTINELLI R, 1989, KIDNEY INT, V35, P1227, DOI 10.1038/ki.1989.114; Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343; Matsumoto H, 1995, Nihon Jinzo Gakkai Shi, V37, P258; MCENERY PT, 1990, J PEDIATR-US, V116, pS109, DOI 10.1016/S0022-3476(05)82712-X; MCENERY PT, 1985, MEDICINE, V64, P401, DOI 10.1097/00005792-198511000-00005; Nasr SH, 2009, J AM SOC NEPHROL, V20, P2055, DOI 10.1681/ASN.2009010110; Nester C, 2011, CLIN J AM SOC NEPHRO, V6, P1488, DOI 10.2215/CJN.10181110; Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814; Ohara S, 2006, PEDIATR NEPHROL, V21, P427, DOI 10.1007/s00467-005-2124-1; PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x; Pecchini F, 1997, CLIN NEPHROL, V47, P63; Pickering M, 2011, CURR OPIN NEPHROL HY, V20, P271, DOI 10.1097/MNH.0b013e328345848b; RENNKE HG, 1995, KIDNEY INT, V47, P643, DOI 10.1038/ki.1995.82; RINCON B, 1993, NEPHROL DIAL TRANSPL, V8, P783, DOI 10.1093/ndt/8.8.783; Roccatello D, 2007, AM J KIDNEY DIS, V49, P69, DOI 10.1053/j.ajkd.2006.09.015; Rodrigues VL, 2010, REV SOC BRAS MED TRO, V43, P638, DOI 10.1590/S0037-86822010000600007; Salant DJ, 2007, CLIN J AM SOC NEPHRO, V2, P858, DOI 10.2215/CJN.00970207; SCHENA FP, 1988, AM J MED, V85, P315, DOI 10.1016/0002-9343(88)90580-3; Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328; Servais A, 2011, HUM PATHOL, V42, P1305, DOI 10.1016/j.humpath.2010.11.023; Sethi S, 2011, SEMIN NEPHROL, V31, P341, DOI 10.1016/j.semnephrol.2011.06.005; Sethi S, 2011, CLIN J AM SOC NEPHRO, V6, P1009, DOI 10.2215/CJN.07110810; Sethi S, 2010, AM J KIDNEY DIS, V56, P977, DOI 10.1053/j.ajkd.2010.06.021; Sethi S, 2010, CLIN J AM SOC NEPHRO, V5, P770, DOI 10.2215/CJN.06760909; Sethi S, 2009, KIDNEY INT, V75, P952, DOI 10.1038/ki.2008.657; Smith KD, 2005, CURR OPIN NEPHROL HY, V14, P396, DOI 10.1097/01.mnh.0000172729.60122.f9; Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356; Strobel S, 2010, MOL IMMUNOL, V47, P1476, DOI 10.1016/j.molimm.2010.02.002; Suzuki H, 1996, BRIT J RHEUMATOL, V35, P72; Swaminathan S, 2006, CLIN J AM SOC NEPHRO, V1, P483, DOI 10.2215/CJN.00710805; TARSHISH P, 1992, PEDIATR NEPHROL, V6, P123, DOI 10.1007/BF00866289; TING HC, 1977, BRIT MED J, V1, P270, DOI 10.1136/bmj.1.6056.270-a; Vella J, 1995, QJM-MON J ASSOC PHYS, V88, P911; Vilayur E, 2009, NAT CLIN PRACT NEPHR, V5, P54, DOI 10.1038/ncpneph0989; Walker PD, 2007, MODERN PATHOL, V20, P605, DOI 10.1038/modpathol.3800773; Weening JJ, 2004, J AM SOC NEPHROL, V15, P835; Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D; Zhang YZ, 2012, CLIN J AM SOC NEPHRO, V7, P265, DOI 10.2215/CJN.07900811; Zhou FD, 2009, NEPHROL DIAL TRANSPL, V24, P870, DOI 10.1093/ndt/gfn554; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620; Zipfel PF, 2009, NEPHROL DIAL TRANSPL, V24, P385, DOI 10.1093/ndt/gfn652	101	294	323	2	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1119	1131		10.1056/NEJMra1108178	http://dx.doi.org/10.1056/NEJMra1108178			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435371				2022-12-28	WOS:000301769700011
J	Patel, K				Patel, Kinesh			STARTING OUT Whose data are they anyway?	BRITISH MEDICAL JOURNAL			English	Editorial Material												kinesh_patel@yahoo.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	2012	344								e2135	10.1136/bmj.e2135	http://dx.doi.org/10.1136/bmj.e2135			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913CO	22438392				2022-12-28	WOS:000301849200014
J	Kavousi, M; Elias-Smale, S; Rutten, JHW; Leening, MJG; Vliegenthart, R; Verwoert, GC; Krestin, GP; Oudkerk, M; de Maat, MPM; Leebeek, FWG; Mattace-Raso, FUS; Lindemans, J; Hofman, A; Steyerberg, EW; van der Lugt, A; van den Meiracker, AH; Witteman, JCM				Kavousi, Maryam; Elias-Smale, Suzette; Rutten, Joost H. W.; Leening, Maarten J. G.; Vliegenthart, Rozemarijn; Verwoert, Germaine C.; Krestin, Gabriel P.; Oudkerk, Matthijs; de Maat, Moniek P. M.; Leebeek, Frank W. G.; Mattace-Raso, Francesco U. S.; Lindemans, Jan; Hofman, Albert; Steyerberg, Ewout W.; van der Lugt, Aad; van den Meiracker, Anton H.; Witteman, Jacqueline C. M.			Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; C-REACTIVE PROTEIN; CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS RISK; MULTIPLE BIOMARKERS; ARTERIAL STIFFNESS; CALCIUM SCORE; PREDICTION; RECLASSIFICATION; STROKE	Background: Whether newer risk markers for coronary heart disease (CHD) improve CHD risk prediction remains unclear. Objective: To assess whether newer risk markers for CHD risk prediction and stratification improve Framingham risk score (FRS) predictions. Design: Prospective population-based study. Setting: The Rotterdam Study, Rotterdam, the Netherlands. Participants: 5933 asymptomatic, community-dwelling participants (mean age, 69.1 years [SD, 8.5]). Measurements: Traditional CHD risk factors used in the FRS (age, sex, systolic blood pressure, treatment of hypertension, total and high-density lipoprotein cholesterol levels, smoking, and diabetes) and newer CHD risk factors (N-terminal fragment of prohormone B-type natriuretic peptide levels, von Willebrand factor antigen levels, fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive protein levels, homocysteine levels, uric acid levels, coronary artery calcium [CAC] scores, carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity). Results: Adding CAC scores to the FRS improved the accuracy of risk predictions (c-statistic increase, 0.05 [95% CI, 0.02 to 0.06]; net reclassification index, 19.3% overall [39.3% in those at intermediate risk, by FRS]). Levels of N-terminal fragment of prohormone B-type natriuretic peptide also improved risk predictions but to a lesser extent (c-statistic increase, 0.02 [CI, 0.01 to 0.04]; net reclassification index, 7.6% overall [33.0% in those at intermediate risk, by FRS]). Improvements in predictions with other newer markers were marginal. Limitation: The findings may not be generalizable to younger or nonwhite populations. Conclusion: Among 12 CHD risk markers, improvements in FRS predictions were most statistically and clinically significant with the addition of CAC scores. Further investigation is needed to assess whether risk refinements using CAC scores lead to a meaningful change in clinical outcome. Whether to use CAC score screening as a more routine test for risk prediction requires full consideration of the financial and clinical costs of performing versus not performing the test for both persons and health systems.	[Witteman, Jacqueline C. M.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3015 GE Rotterdam, Netherlands; Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Groningen	Witteman, JCM (corresponding author), Erasmus Univ, Med Ctr, Dept Epidemiol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	j.witteman@erasmusmc.nl	Elias-Smale, Suzette/F-2410-2014; Rutten, Joost/L-4618-2015; Kavousi, Maryam/F-1174-2018; Raso, Francesco Mattace-/L-2541-2015; Steyerberg, Ewout/C-1509-2018	Rutten, Joost/0000-0002-5259-9794; Kavousi, Maryam/0000-0001-5976-6519; Steyerberg, Ewout/0000-0002-7787-0122; Mattace-Raso, Francesco/0000-0002-1688-6497; Leening, Maarten J. G./0000-0002-4143-4839; Oudkerk, Matthijs/0000-0003-2800-4110	Erasmus University Medical Center; Erasmus University, Rotterdam, the Netherlands; Research Institute for Diseases in the Elderly; Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission (DG XII); Municipality of Rotterdam; Netherlands Heart Foundation [2003B179, 2007B159]; Netherlands Organization for Scientific Research (NWO); Netherlands Organization for Health Research and Development (ZonMw) [918.76.619]; Netherlands Consortium for Healthy Ageing; Vereniging Trustfonds Erasmus Universiteit Rotterdam	Erasmus University Medical Center; Erasmus University, Rotterdam, the Netherlands(Netherlands Government); Research Institute for Diseases in the Elderly; Ministry of Education, Culture and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry for Health, Welfare and Sports; European Commission (DG XII)(European CommissionEuropean Commission Joint Research Centre); Municipality of Rotterdam; Netherlands Heart Foundation(Netherlands Heart Foundation); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Netherlands Consortium for Healthy Ageing; Vereniging Trustfonds Erasmus Universiteit Rotterdam	The Rotterdam Study is funded by Erasmus University Medical Center and Erasmus University, Rotterdam, the Netherlands; the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. This study was supported by grants from the Netherlands Heart Foundation (2003B179 [Dr. Witteman], 2007B159 [Dr. Leebeek]), the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw) (Vici grant 918.76.619), and the Netherlands Consortium for Healthy Ageing. The authors received additional funding from Vereniging Trustfonds Erasmus Universiteit Rotterdam.	Elias-Smale SE, 2010, J AM COLL CARDIOL, V56, P1407, DOI 10.1016/j.jacc.2010.06.029; Erbel R, 2010, J AM COLL CARDIOL, V56, P1397, DOI 10.1016/j.jacc.2010.06.030; Folsom AR, 2008, ARCH INTERN MED, V168, P1333, DOI 10.1001/archinte.168.12.1333; Folsom AR, 2006, ARCH INTERN MED, V166, P1368, DOI 10.1001/archinte.166.13.1368; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Helfand M, 2009, ANN INTERN MED, V151, P496, DOI 10.7326/0003-4819-151-7-200910060-00010; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5; Kim HC, 2010, J AM COLL CARDIOL, V55, P2080, DOI 10.1016/j.jacc.2009.12.047; Mattace-Raso FUS, 2006, CIRCULATION, V113, P657, DOI 10.1161/CIRCULATIONAHA.105.555235; Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943; Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655; Nambi V, 2010, J AM COLL CARDIOL, V55, P1600, DOI 10.1016/j.jacc.2009.11.075; Pearte CA, 2006, CIRCULATION, V113, P2177, DOI 10.1161/CIRCULATIONAHA.105.610352; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; Polonsky TS, 2010, JAMA-J AM MED ASSOC, V303, P1610, DOI 10.1001/jama.2010.461; Rana JS, 2009, HEART, V95, P1682, DOI 10.1136/hrt.2009.170134; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Rutten JHW, 2010, HYPERTENSION, V55, P785, DOI 10.1161/HYPERTENSIONAHA.109.143313; Steyerberg EW, 2009, CLIN PREDICTION MODE, DOI 10.1007/978-0-387-77244-8; Steyerberg EW, 2010, ANN INTERN MED, V152, P195, DOI 10.7326/0003-4819-152-3-201002020-00019; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Tzoulaki I, 2007, CIRCULATION, V115, P2119, DOI 10.1161/CIRCULATIONAHA.106.635029; Tzoulaki I, 2009, JAMA-J AM MED ASSOC, V302, P2345, DOI 10.1001/jama.2009.1757; Vasan RS, 2006, CIRCULATION, V113, P2335, DOI 10.1161/CIRCULATIONAHA.104.482570; Wang TJ, 2006, NEW ENGL J MED, V355, P2631, DOI 10.1056/NEJMoa055373; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; Wilson PWF, 2008, CIRC-CARDIOVASC QUAL, V1, P92, DOI 10.1161/CIRCOUTCOMES.108.831198; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Woodward M, 2007, J THROMB HAEMOST, V5, P1795, DOI 10.1111/j.1538-7836.2007.02677.x; Zethelius B, 2008, NEW ENGL J MED, V358, P2107, DOI 10.1056/NEJMoa0707064	33	280	282	2	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					438	U88		10.7326/0003-4819-156-6-201203200-00006	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22431676				2022-12-28	WOS:000303150900016
J	Cane, DE				Cane, David E.			BIOCHEMISTRY Favouring the unfavoured	NATURE			English	Editorial Material							GENE-CLUSTER; RING-CLOSURE; BIOSYNTHESIS		Brown Univ, Dept Chem, Providence, RI 02912 USA	Brown University	Cane, DE (corresponding author), Brown Univ, Dept Chem, Providence, RI 02912 USA.	david_cane@brown.edu						BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734; Callaway T R, 2003, Curr Issues Intest Microbiol, V4, P43; CANE DE, 1983, J AM CHEM SOC, V105, P3594, DOI 10.1021/ja00349a040; Hotta K, 2012, NATURE, V483, P355, DOI 10.1038/nature10865; Liu TG, 2009, METHOD ENZYMOL, V459, P187, DOI 10.1016/S0076-6879(09)04609-6; Migita A, 2009, BIOSCI BIOTECH BIOCH, V73, P169, DOI 10.1271/bbb.80631; Minami A, 2011, ORG LETT, V13, P1638, DOI 10.1021/ol200100e; Oliynyk M, 2003, MOL MICROBIOL, V49, P1179, DOI 10.1046/j.1365-2958.2003.03571.x; Smith L, 2008, CHEMBIOCHEM, V9, P2967, DOI 10.1002/cbic.200800585; Sun YH, 2003, CHEM BIOL, V10, P431, DOI 10.1016/S1074-5521(03)00092-9	10	0	0	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					285	286		10.1038/483285a	http://dx.doi.org/10.1038/483285a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422260				2022-12-28	WOS:000301481800038
J	Simon, J; Greiner, M				Simon, Jonathan; Greiner, Markus			CONDENSED-MATTER PHYSICS A duo of graphene mimics	NATURE			English	Editorial Material							MAGNETIC-FIELDS		[Simon, Jonathan; Greiner, Markus] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University	Simon, J (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	simon@physics.harvard.edu; greiner@physics.harvard.edu	Greiner, Markus/A-8502-2010; Greiner, Markus/E-9512-2017					Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885; Gomes KK, 2012, NATURE, V483, P306, DOI 10.1038/nature10941; Hasegawa Y, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.033413; Kitagawa T, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.235114; Levy N, 2010, SCIENCE, V329, P544, DOI 10.1126/science.1191700; Lin YJ, 2009, NATURE, V462, P628, DOI 10.1038/nature08609; Montambaux G, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.153412; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Tarruell L, 2012, NATURE, V483, P302, DOI 10.1038/nature10871; Wunsch B, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/10/103027; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	11	9	9	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					282	284		10.1038/483282a	http://dx.doi.org/10.1038/483282a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422259				2022-12-28	WOS:000301481800036
J	Appleby, J				Appleby, John			DATA BRIEFING Hospitals: what do they do and how much does it cost?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1G 0AN, England		Appleby, J (corresponding author), Kings Fund, London W1G 0AN, England.	j.appleby@kingsfund.org.uk						Barts and the London, HIST STBARTH HOSP; Department of Health, 2012, BEDS OP OV; Department of Health, 2009, NAT REF COSTS 2009 1	3	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e1759	10.1136/bmj.e1759	http://dx.doi.org/10.1136/bmj.e1759			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22419789				2022-12-28	WOS:000301847600004
J	Baglioni, P; Malik, M; Okosieme, OE				Baglioni, Piero; Malik, Manzar; Okosieme, Onyebuchi E.			EASILY MISSED? Acute Charcot foot	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							FEET		[Baglioni, Piero; Okosieme, Onyebuchi E.] Prince Charles Hosp, Dept Endocrinol & Diabet, Cwm Taf Local Hlth Board, Merthyr Tydfil CF47 9DT, M Glam, Wales; [Malik, Manzar] Prince Charles Hosp, Dept Radiol, Merthyr Tydfil CF47 9DT, M Glam, Wales		Okosieme, OE (corresponding author), Prince Charles Hosp, Dept Endocrinol & Diabet, Cwm Taf Local Hlth Board, Merthyr Tydfil CF47 9DT, M Glam, Wales.	Onyebuchi.Okosieme@Wales.nhs.uk						CAVANAGH PR, 1994, DIABETES CARE, V17, P201, DOI 10.2337/diacare.17.3.201; Chantelau E, 2005, DIABETIC MED, V22, P1707, DOI 10.1111/j.1464-5491.2005.01677.x; Edmonds M, 2008, PRACTICAL MANUAL DIA, P63; Fabrin J, 2000, DIABETES CARE, V23, P796, DOI 10.2337/diacare.23.6.796; Hartemann-Heurtier A, 2002, LANCET, V360, P1776, DOI 10.1016/S0140-6736(02)11671-0; Jeffcoate WJ, 2009, DIABETOLOGIA, V52, P2478, DOI 10.1007/s00125-009-1521-6; Matricali GA, 2007, TRANSPLANTATION, V83, P245, DOI 10.1097/01.tp.0000244730.95416.c6; Rogers LC, 2011, DIABETES CARE, V34, P2123, DOI 10.2337/dc11-0844; Rogers Lee C, 2008, Clin Podiatr Med Surg, V25, P263, DOI 10.1016/j.cpm.2008.01.002; Sohn MW, 2010, DIABETES CARE, V33, P98, DOI 10.2337/dc09-1497; van Baal J, 2010, DIABETES CARE, V33, P1086, DOI 10.2337/dc09-1428; Wukich DK, 2011, DIABETIC MED, V28, P195, DOI 10.1111/j.1464-5491.2010.03141.x	12	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	2012	344								e1397	10.1136/bmj.e1397	http://dx.doi.org/10.1136/bmj.e1397			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22419788	Green Accepted			2022-12-28	WOS:000301847600002
J	Simpson, J; Robinson, K; Creighton, SM; Hodes, D				Simpson, Jane; Robinson, Kerry; Creighton, Sarah M.; Hodes, Deborah			Female genital mutilation: the role of health professionals in prevention, assessment, and management	BRITISH MEDICAL JOURNAL			English	Review							COUNTRIES; SEXUALITY		[Creighton, Sarah M.] Univ Coll London Hosp, Dept Womens Hlth, London NW1 2PG, England; [Simpson, Jane] Whittington Hosp, London N19 5NF, England; [Robinson, Kerry] Great Ormond St Hosp Sick Children, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Creighton, SM (corresponding author), Univ Coll London Hosp, Dept Womens Hlth, London NW1 2PG, England.	sarah.creighton@uclh.nhs.uk						Banks E, 2006, LANCET, V367, P1835, DOI 10.1016/S0140-6736(06)68805-3; Bell K, 2005, MED ANTHROPOL Q, V19, P125, DOI 10.1525/maq.2005.19.2.125; Conroy RM, 2006, BRIT MED J, V333, P106, DOI 10.1136/bmj.333.7559.106; Department for Children Schools and Families, DCSF0030520102010513; Department of Health, 2010, REP TASKF HLTH ASP V; Dorkenoo E, 2007, STAT STUDY ESTIMATE; Elmusharaf S, 2006, BRIT MED J, V333, P7559; Foreign and Commonwealth Office, 2011, MULT PRACT GUID FEM; General Medical Council, GUID DOCT 2009 CONF, P54; Leye E, 2007, CRIME LAW SOCIAL CH, V47, P1, DOI 10.1007/s10611-007-9055-7; Liao LM, 2007, BMJ-BRIT MED J, V334, P1090, DOI 10.1136/bmj.39206.422269.BE; London Safeguarding Children Board, FGM PROC SAF CHILDR; Obermeyer CM, 2005, CULT HEALTH SEX, V7, P443, DOI 10.1080/14789940500181495; Shaaban LM, 2005, LANCET, V366, P347, DOI 10.1016/S0140-6736(05)67003-1; UNICEF, FACT SHEET SUMM RIGH; WHO, 2011, WHORHR11182011; Women's Islamic Initiative in Spirituality and Equality (WISE), 2010, FEM GEN MUT HARMF UN; World Health Organisation, 2012, FEM GEN MUT; World Health Organization, 2008, EL FEM GEN MUT INT S; World Health Organization, 2010, GLOB STRAT STOP HLTH; Yoder P.S, 2008, 39 DHS; Yoder PS, 2004, FEMALE GENITAL CUTTI	22	26	26	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e1361	10.1136/bmj.e1361	http://dx.doi.org/10.1136/bmj.e1361			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22419787				2022-12-28	WOS:000301847600001
J	Ilic, D; Polak, J				Ilic, Dusko; Polak, Julia			Stem cell based therapy-where are we going?	LANCET			English	Editorial Material							DELIVERY		[Ilic, Dusko] Kings Coll London, Sch Med, Guys Assisted Concept Unit, Embryon Stem Cell Labs,Div Womens Hlth, London SE1 9RT, England; [Polak, Julia] Univ London Imperial Coll Sci Technol & Med, Dept Chem Engn, Fac Med, London SW7 2AZ, England	University of London; King's College London; Imperial College London	Ilic, D (corresponding author), Kings Coll London, Sch Med, Guys Assisted Concept Unit, Embryon Stem Cell Labs,Div Womens Hlth, London SE1 9RT, England.	dusko.ilic@kcl.ac.uk		ILIC, DUSKO/0000-0003-1647-0026	Medical Research Council [G0801061] Funding Source: Medline; MRC [G0801061] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Badylak SF, 2012, LANCET, V379, P943, DOI 10.1016/S0140-6736(12)60073-7; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Brindley D, 2012, REGEN MED, V7, P17, DOI 10.2217/rme.11.115; Brindley DA, 2011, CELL STEM CELL, V9, P397, DOI 10.1016/j.stem.2011.10.010; Burridge PW, 2012, CELL STEM CELL, V10, P16, DOI 10.1016/j.stem.2011.12.013; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Elliott RB, 2007, XENOTRANSPLANTATION, V14, P157, DOI 10.1111/j.1399-3089.2007.00384.x; Jungebluth P, 2011, LANCET, V378, P1997, DOI 10.1016/S0140-6736(11)61715-7; Lau D, 2008, CELL STEM CELL, V3, P591, DOI 10.1016/j.stem.2008.11.001; MATHE G, 1959, REV FR ETUD CLIN BIO, V4, P226; Mozid AM, 2011, BRIT MED BULL, V98, P143, DOI 10.1093/bmb/ldr014; Ptaszek LM, 2012, LANCET, V379, P933, DOI 10.1016/S0140-6736(12)60075-0; Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761; Salaway T, 2008, REGEN MED, V3, P83, DOI 10.2217/17460751.3.1.83; Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhi ZL, 2010, BIOMACROMOLECULES, V11, P610, DOI 10.1021/bm901152k	17	20	24	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 10	2012	379	9819					877	878		10.1016/S0140-6736(12)60155-X	http://dx.doi.org/10.1016/S0140-6736(12)60155-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	906NY	22405784				2022-12-28	WOS:000301353700011
J	Amelino-Camelia, G				Amelino-Camelia, Giovanni			No theory is too special to question	NATURE			English	Editorial Material									Univ Roma La Sapienza, Rome, Italy	Sapienza University Rome	Amelino-Camelia, G (corresponding author), Univ Roma La Sapienza, Rome, Italy.	giovanni.amelino-camelia@roma1.infn.it							0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					125	125		10.1038/483125a	http://dx.doi.org/10.1038/483125a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	904DT	22398518	Green Published			2022-12-28	WOS:000301174900004
J	Berut, A; Arakelyan, A; Petrosyan, A; Ciliberto, S; Dillenschneider, R; Lutz, E				Berut, Antoine; Arakelyan, Artak; Petrosyan, Artyom; Ciliberto, Sergio; Dillenschneider, Raoul; Lutz, Eric			Experimental verification of Landauer's principle linking information and thermodynamics	NATURE			English	Article							MAXWELLS DEMON; LOGICAL REVERSIBILITY; HEAT-GENERATION; PHYSICAL LIMITS; COMPUTATION; DISSIPATION; ENERGY; ERASURE	In 1961, Rolf Landauer argued that the erasure of information is a dissipative process(1). A minimal quantity of heat, proportional to the thermal energy and called the Landauer bound, is necessarily produced when a classical bit of information is deleted. A direct consequence of this logically irreversible transformation is that the entropy of the environment increases by a finite amount. Despite its fundamental importance for information theory and computer science(2-5), the erasure principle has not been verified experimentally so far, the main obstacle being the difficulty of doing single-particle experiments in the low-dissipation regime. Here we experimentally show the existence of the Landauer bound in a generic model of a one-bit memory. Using a system of a single colloidal particle trapped in a modulated double-well potential, we establish that the mean dissipated heat saturates at the Landauer bound in the limit of long erasure cycles. This result demonstrates the intimate link between information theory and thermodynamics. It further highlights the ultimate physical limit of irreversible computation.	[Berut, Antoine; Arakelyan, Artak; Petrosyan, Artyom; Ciliberto, Sergio] Ecole Normale Super Lyon, Phys Lab, CNRS, UMR5672, F-69364 Lyon, France; [Dillenschneider, Raoul] Univ Kaiserslautern, Dept Phys, D-67663 Kaiserslautern, Germany; [Dillenschneider, Raoul] Univ Kaiserslautern, Res Ctr OPTIMAS, D-67663 Kaiserslautern, Germany; [Lutz, Eric] Univ Augsburg, Dept Phys, D-86135 Augsburg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Ecole Normale Superieure de Lyon (ENS de LYON); University of Kaiserslautern; University of Kaiserslautern; University of Augsburg	Lutz, E (corresponding author), Free Univ Berlin, Dahlem Ctr Complex Quantum Syst, D-14195 Berlin, Germany.	eric.lutz@fu-berlin.de	Lutz, Eric/C-2713-2008	Berut, Antoine/0000-0001-8549-086X	DFG [LU1382/1-1]; Cluster of Excellence Nanosystems Initiative Munich (NIM), DAAD; Research Center of the DFG [Transregio 49]	DFG(German Research Foundation (DFG)); Cluster of Excellence Nanosystems Initiative Munich (NIM), DAAD; Research Center of the DFG(German Research Foundation (DFG))	This work was supported by the Emmy Noether Program of the DFG (contract no. LU1382/1-1), the Cluster of Excellence Nanosystems Initiative Munich (NIM), DAAD, and the Research Center Transregio 49 of the DFG.	BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; BENNETT CH, 1973, IBM J RES DEV, V17, P525, DOI 10.1147/rd.176.0525; Blickle V, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.070603; Brillouin L., 1956, SCI INFORM THEORY; Dillenschneider R, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.210601; Earman J, 1999, STUD HIST PHILOS M P, V30B, P1, DOI 10.1016/S1355-2198(98)00026-4; Frank MP, 2002, COMPUT SCI ENG, V4, P16, DOI 10.1109/5992.998637; Gomez-Solano JR, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.040601; Jop P, 2008, EPL-EUROPHYS LETT, V81, DOI 10.1209/0295-5075/81/50005; LANDAUER R, 1961, IBM J RES DEV, V5, P183, DOI 10.1147/rd.53.0183; LANDAUER R, 1988, NATURE, V335, P779, DOI 10.1038/335779a0; Leff HS., 2003, MAXWELLS DEMON, V2; Lloyd S, 2000, NATURE, V406, P1047, DOI 10.1038/35023282; Maroney OJE, 2005, STUD HIST PHILOS M P, V36B, P355, DOI 10.1016/j.shpsb.2004.11.006; Maruyama K, 2009, REV MOD PHYS, V81, P1, DOI 10.1103/RevModPhys.81.1; Meindl JD, 2000, IEEE J SOLID-ST CIRC, V35, P1515, DOI 10.1109/4.871332; Norton JD, 2005, STUD HIST PHILOS M P, V36B, P375, DOI 10.1016/j.shpsb.2004.12.002; Norton JD, 2011, STUD HIST PHILOS M P, V42, P184, DOI 10.1016/j.shpsb.2011.05.002; Penrose O, 1970, FDN STAT MECH DEDUCT; Piechocinska P., 2000, PHYS REV A, V61; Plenio MB, 2001, CONTEMP PHYS, V42, P25, DOI 10.1080/00107510010018916; Pop E, 2010, NANO RES, V3, P147, DOI 10.1007/s12274-010-1019-z; Sagawa T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.250602; Sekimoto K, 2010, LECT NOTES PHYS, V799, P1, DOI 10.1007/978-3-642-05411-2; Sekimoto K, 1997, J PHYS SOC JPN, V66, P3326, DOI 10.1143/JPSJ.66.3326; Shenker O, 2000, LOGIC ENTROPY; SHIZUME K, 1995, PHYS REV E, V52, P3495, DOI 10.1103/PhysRevE.52.3495; Szilard L, 1929, Z PHYS, V53, P840, DOI 10.1007/BF01341281; Toyabe S, 2010, NAT PHYS, V6, P988, DOI 10.1038/NPHYS1821; Wang GM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.050601	30	637	644	7	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 8	2012	483	7388					187	U1500		10.1038/nature10872	http://dx.doi.org/10.1038/nature10872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904DT	22398556				2022-12-28	WOS:000301174900032
J	David, WS; Chad, DA; Kambadakone, A; Hedley-Whyte, ET				David, William S.; Chad, David A.; Kambadakone, Avinash; Hedley-Whyte, E. Tessa			Case 7-2012: A 79-Year-Old Man with Pain and Weakness in the Legs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDIATED NECROTIZING MYOPATHY; 000 STATIN USERS; THERAPY; RHABDOMYOLYSIS; ROSUVASTATIN; SAFETY		[David, William S.; Chad, David A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Kambadakone, Avinash] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Hedley-Whyte, E. Tessa] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [David, William S.; Chad, David A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Kambadakone, Avinash] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Hedley-Whyte, E. Tessa] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	David, WS (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905				Garcia-Rodriguez LA, 2008, PHARMACOEPIDEM DR S, V17, P953, DOI 10.1002/pds.1602; Garcia-Rodriguez LA, 2008, PHARMACOEPIDEM DR S, V17, P943, DOI 10.1002/pds.1603; Christopher-Stine L, 2010, ARTHRITIS RHEUM-US, V62, P2757, DOI 10.1002/art.27572; Grable-Esposito P, 2010, MUSCLE NERVE, V41, P185, DOI 10.1002/mus.21486; Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585; Mammen AL, 2011, ARTHRITIS RHEUM-US, V63, P713, DOI 10.1002/art.30156; Mammen AL, 2010, CURR OPIN RHEUMATOL, V22, P644, DOI 10.1097/BOR.0b013e32833f0fc7; Mastaglia FL, 2010, CURR OPIN NEUROL, V23, P445, DOI 10.1097/WCO.0b013e32833c2054; Needham M, 2007, NEUROMUSCULAR DISORD, V17, P194, DOI 10.1016/j.nmd.2006.10.007; Nichols GA, 2007, CLIN THER, V29, P1761, DOI 10.1016/j.clinthera.2007.08.022; Rowan C, 2009, PHARMACOEPIDEM DR S, V18, P301, DOI 10.1002/pds.1711; Silva M, 2007, CLIN THER, V29, P253, DOI 10.1016/j.clinthera.2007.02.008	12	2	3	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					944	954		10.1056/NEJMcpc1110052	http://dx.doi.org/10.1056/NEJMcpc1110052			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397657				2022-12-28	WOS:000301172500013
J	Tinetti, ME				Tinetti, Mary E.			The Retreat From Advanced Care Planning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							END; MEDICARE		Yale Univ, Sch Med, Dept Internal Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sch Epidemiol & Publ Hlth, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu						Conway PH, 2011, JAMA-J AM MED ASSOC, V306, P2256, DOI 10.1001/jama.2011.1611; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; Pear Robert, 2010, N Y TIMES; RUTENBERG J, 2009, NY TIMES        0501, pA1; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	8	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					915	916		10.1001/jama.2012.229	http://dx.doi.org/10.1001/jama.2012.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396510				2022-12-28	WOS:000301172100016
J	van Ginneken, E; Groenewegen, PP; McKee, M				van Ginneken, Ewout; Groenewegen, Peter P.; McKee, Martin			Personal healthcare budgets: what can England learn from the Netherlands?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[McKee, Martin] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Groenewegen, Peter P.] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands	University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Netherlands Institute for Health Services Research	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	martin.mckee@lshtm.ac.uk	Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011; Groenewegen, Peter/I-1574-2013	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; Groenewegen, Peter/0000-0003-2127-8442				Boer L, 2010, ACHTERGRONDEN MOTIEV; Chevreul K., 2010, HLTH SYST TRANSIT, V12, P1, DOI DOI 10.1038/KI.2015.25; Dixon J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6608; Health Foundation, 2010, PERS HLTH BUDG RES S; Irvine A., 2011, PERSONAL HLTH BUDGET; Johnstone R, 2011, PUBLIC FINANCE  1005; Lansley A, 2011, COMMUNICATION   1004; McKee M, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e399; Ministry of Health, 2011, DLZKZU3067294 MIN HL; Ministry of Health, 2011, DLZU3070332 MIN HLTH; NHS Confederation, 2011, PERS HLTH BUDG COUNT; Ramakers C, 2010, WEG NAAR SOLIDE PGB; Ramakers C., 2007, EVALUATIE PERSOONGEB; Sadiraj K., 2011, OPMARS PGB ONTWIKKEL; Social Care Institute for Excellence, 2009, SCIE RES BRIEF 20 IM; The Health Foundation, 2011, PERS TOUCH DUTCH EXP	16	22	22	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2012	344								e1383	10.1136/bmj.e1383	http://dx.doi.org/10.1136/bmj.e1383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GM	22396156	Green Submitted			2022-12-28	WOS:000301478900014
J	Wang, YC; Khan, Z; Kaschube, M; Wieschaus, EF				Wang, Yu-Chiun; Khan, Zia; Kaschube, Matthias; Wieschaus, Eric F.			Differential positioning of adherens junctions is associated with initiation of epithelial folding	NATURE			English	Article							APICAL CONSTRICTION; CELL-SHAPE; DROSOPHILA; BAZOOKA; POLARITY; PAR-1; ESTABLISHMENT; LOCALIZATION; ALGORITHM; STARDUST	During tissue morphogenesis, simple epithelial sheets undergo folding to form complex structures. The prevailing model underlying epithelial folding involves cell shape changes driven by myosin-dependent apical constriction(1). Here we describe an alternative mechanism that requires differential positioning of adherens junctions controlled by modulation of epithelial apical-basal polarity. Using live embryo imaging, we show that before the initiation of dorsal transverse folds during Drosophila gastrulation, adherens junctions shift basally in the initiating cells, but maintain their original subapical positioning in the neighbouring cells. Junctional positioning in the dorsal epithelium depends on the polarity proteins Bazooka and Par-1. In particular, the basal shift that occurs in the initiating cells is associated with a progressive decrease in Par-1 levels. We show that uniform reduction of the activity of Bazooka or Par-1 results in uniform apical or lateral positioning of junctions and in each case dorsal fold initiation is abolished. In addition, an increase in the Bazooka/Par-1 ratio causes formation of ectopic dorsal folds. The basal shift of junctions not only alters the apical shape of the initiating cells, but also forces the lateral membrane of the adjacent cells to bend towards the initiating cells, thereby facilitating tissue deformation. Our data thus establish a direct link between modification of epithelial polarity and initiation of epithelial folding.	[Wang, Yu-Chiun; Wieschaus, Eric F.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Wang, Yu-Chiun; Wieschaus, Eric F.] Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; [Khan, Zia] Princeton Univ, Dept Comp Sci, Princeton, NJ 08540 USA; [Khan, Zia; Kaschube, Matthias] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA	Princeton University; Howard Hughes Medical Institute; Princeton University; Princeton University; Princeton University	Wieschaus, EF (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	efw@princeton.edu	Wang, Yu-Chiun/N-6541-2015	Wang, Yu-Chiun/0000-0002-3797-4138; Khan, Zia/0000-0002-7859-3489	Helen Hay Whitney Foundation; National Institutes of Health/National Institute of General Medical Sciences [GM071508]; National Institute of Child Health and Human Development [5R37HD15587]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD015587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER	Helen Hay Whitney Foundation; National Institutes of Health/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Martin, J. McDonald, D. St Johnston and J. Zallen for providing flies and antibodies; J. Goodhouse and S. Thiberge for assistance in microscopy; G. Deshpande, members of the Wieschaus and Schupbach laboratories for helpful comments on the manuscript and discussion. This work is supported by a postdoctoral fellowship from the Helen Hay Whitney Foundation to Y.-C.W., a National Institutes of Health/National Institute of General Medical Sciences P50 grant (GM071508) to Z.K. and M. K., and a National Institute of Child Health and Human Development grant (5R37HD15587) to E. F. W. E. F. W. is an investigator of the Howard Hughes Medical Institute.	Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Beucher S., 1993, MATH MORPHOLOGY IMAG, P433, DOI DOI 10.1201/9781482277234-12; Cavey M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002998; COHEN LD, 1993, IEEE T PATTERN ANAL, V15, P1131, DOI 10.1109/34.244675; Harris TJC, 2005, J CELL BIOL, V170, P813, DOI 10.1083/jcb.200505127; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Kametani Y, 2007, NAT CELL BIOL, V9, P92, DOI 10.1038/ncb1520; Krahn MP, 2010, J CELL BIOL, V190, P751, DOI 10.1083/jcb.201006029; Lecuit T, 2007, NAT REV MOL CELL BIO, V8, P633, DOI 10.1038/nrm2222; Lighthouse DV, 2008, DEV BIOL, V317, P59, DOI 10.1016/j.ydbio.2008.02.009; Lorensen W.E., 1987, ACM SIGGRAPH COMPUTE, V21, P163, DOI [DOI 10.1145/37402.37422, 10.1145/37401.37422]; MARR D, 1980, PROC R SOC SER B-BIO, V207, P187, DOI 10.1098/rspb.1980.0020; Martin AC, 2010, J CELL BIOL, V188, P735, DOI 10.1083/jcb.200910099; Martin AC, 2009, NATURE, V457, P495, DOI 10.1038/nature07522; Maurer CR, 2003, IEEE T PATTERN ANAL, V25, P265, DOI 10.1109/TPAMI.2003.1177156; McDonald JA, 2008, CURR BIOL, V18, P1659, DOI 10.1016/j.cub.2008.09.041; McGill MA, 2009, J CELL BIOL, V185, P787, DOI 10.1083/jcb.200812146; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Oda H, 2001, J CELL SCI, V114, P493; Palagyi K., 2001, Information Processing in Medical Imaging. 17th International Conference, IPMI 2001. Proceedings (Lecture Notes in Computer Science Vol.2082), P409; Royou A, 2002, J CELL BIOL, V158, P127, DOI 10.1083/jcb.200203148; Sawyer JM, 2010, DEV BIOL, V341, P5, DOI 10.1016/j.ydbio.2009.09.009; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Simoes SD, 2010, DEV CELL, V19, P377, DOI 10.1016/j.devcel.2010.08.011; SWEETON D, 1991, DEVELOPMENT, V112, P775; VINCENT L, 1991, IEEE T PATTERN ANAL, V13, P583, DOI 10.1109/34.87344; Walther RF, 2010, CURR BIOL, V20, P1065, DOI 10.1016/j.cub.2010.04.049	30	112	112	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2012	484	7394					390	393		10.1038/nature10938	http://dx.doi.org/10.1038/nature10938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927YM	22456706	Green Accepted			2022-12-28	WOS:000302946500036
J	Wang, MX; Liu, CH; Xu, JP; Yang, F; Miao, L; Yao, MY; Gao, CL; Shen, CY; Ma, XC; Chen, X; Xu, ZA; Liu, Y; Zhang, SC; Qian, D; Jia, JF; Xue, QK				Wang, Mei-Xiao; Liu, Canhua; Xu, Jin-Peng; Yang, Fang; Miao, Lin; Yao, Meng-Yu; Gao, C. L.; Shen, Chenyi; Ma, Xucun; Chen, X.; Xu, Zhu-An; Liu, Ying; Zhang, Shou-Cheng; Qian, Dong; Jia, Jin-Feng; Xue, Qi-Kun			The Coexistence of Superconductivity and Topological Order in the Bi2Se3 Thin Films	SCIENCE			English	Article							SINGLE DIRAC CONE; INSULATOR	Three-dimensional topological insulators (TIs) are characterized by their nontrivial surface states, in which electrons have their spin locked at a right angle to their momentum under the protection of time-reversal symmetry. The topologically ordered phase in TIs does not break any symmetry. The interplay between topological order and symmetry breaking, such as that observed in superconductivity, can lead to new quantum phenomena and devices. We fabricated a superconducting TI/superconductor heterostructure by growing dibismuth triselenide (Bi2Se3) thin films on superconductor niobium diselenide substrate. Using scanning tunneling microscopy and angle-resolved photoemission spectroscopy, we observed the superconducting gap at the Bi2Se3 surface in the regime of Bi2Se3 film thickness where topological surface states form. This observation lays the groundwork for experimentally realizing Majorana fermions in condensed matter physics.	[Wang, Mei-Xiao; Liu, Canhua; Xu, Jin-Peng; Yang, Fang; Miao, Lin; Yao, Meng-Yu; Gao, C. L.; Qian, Dong; Jia, Jin-Feng] Shanghai Jiao Tong Univ, Key Lab Artificial Struct & Quantum Control, Minist Educ, Dept Phys, Shanghai 200240, Peoples R China; [Shen, Chenyi; Xu, Zhu-An] Zhejiang Univ, Dept Phys, Hangzhou 310027, Zhejiang, Peoples R China; [Ma, Xucun] Chinese Acad Sci, Inst Phys, Beijing 100190, Peoples R China; [Chen, X.; Xue, Qi-Kun] Tsinghua Univ, State Key Lab Low Dimens Quantum Phys, Dept Phys, Beijing 100084, Peoples R China; [Liu, Ying] Penn State Univ, Dept Phys, University Pk, PA 16802 USA; [Zhang, Shou-Cheng] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Zhang, Shou-Cheng] Tsinghua Univ, Ctr Adv Study, Beijing 100084, Peoples R China	Shanghai Jiao Tong University; Zhejiang University; Chinese Academy of Sciences; Institute of Physics, CAS; Tsinghua University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Stanford University; Tsinghua University	Qian, D (corresponding author), Shanghai Jiao Tong Univ, Key Lab Artificial Struct & Quantum Control, Minist Educ, Dept Phys, Shanghai 200240, Peoples R China.	dqian@sjtu.edu.cn; jfjia@sjtu.edu.cn	Miao, Lin/D-4357-2014; Liu, Canhua/O-3341-2015; Xu, Zhu'an/B-1419-2009; Qian, Dong/O-1028-2015; Zhang, Shou-Cheng/B-2794-2010; Xu, Jin-Peng/A-9627-2018; Jia, Jinfeng/O-2356-2015; yang, fang/AAK-6333-2020; Liu, Canhua/B-8792-2013	Liu, Canhua/0000-0003-2240-3559; Xu, Zhu'an/0000-0001-9290-2762; Jia, Jinfeng/0000-0002-9900-281X; 	National Basic Research Program of China [2011CBA00103, 2011CB921902, 2012CB927401, 2012CB927403]; National Natural Science Foundation of China [91021002, 10928408, 10874116, 10904090, 11174199, 11134008]; Shanghai Committee of Science and Technology, China [09JC1407500, 10QA1403300, 10JC1407100, 10PJ1405700]; Chinese Academy of Sciences [KJCX2.YW.W10]; Program for New Century Excellent Talents in University; Shanghai Municipal Education Commission; Shanghai Education Development Foundation; Shanghai Institutions of Higher Learning; U.S. NSF [DMR 0908700]; Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy [DE-AC02-05CH11231]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee); Chinese Academy of Sciences(Chinese Academy of Sciences); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Shanghai Education Development Foundation; Shanghai Institutions of Higher Learning; U.S. NSF(National Science Foundation (NSF)); Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy(United States Department of Energy (DOE))	This work is supported by National Basic Research Program of China (grants 2011CBA00103, 2011CB921902, 2012CB927401, and 2012CB927403), National Natural Science Foundation of China (grants 91021002, 10928408, 10874116, 10904090, 11174199, and 11134008), Shanghai Committee of Science and Technology, China (grants 09JC1407500, 10QA1403300, 10JC1407100, and 10PJ1405700), the Project "Knowledge Innovation Program" of Chinese Academy of Sciences (grant KJCX2.YW.W10), and the Program for New Century Excellent Talents in University. D.Q. acknowledges support from the "Shu Guang" project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning. Y.L. acknowledges support from the U.S. NSF under grant DMR 0908700. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under contract DE-AC02-05CH11231.	Akhmerov AR, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.216404; ARNOLD GB, 1978, PHYS REV B, V18, P1076, DOI 10.1103/PhysRevB.18.1076; Bernevig BA, 2006, SCIENCE, V314, P1757, DOI 10.1126/science.1133734; Chen YL, 2009, SCIENCE, V325, P178, DOI 10.1126/science.1173034; Chiu CK, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.144507; Fu L, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.045302; Fu LA, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.097001; Fu L, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.096407; Hasan MZ, 2010, REV MOD PHYS, V82, P3045, DOI 10.1103/RevModPhys.82.3045; Hor YS, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.057001; Hosur P, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.097001; Hsieh D, 2008, NATURE, V452, P970, DOI 10.1038/nature06843; Kriener M, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.127004; Linder J, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.067001; Nayak C, 2008, REV MOD PHYS, V80, P1083, DOI 10.1103/RevModPhys.80.1083; Pitaevskii L., 2008, SUPERCONDUCTIVITY, V1; Qi XL, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.184516; Qi XL, 2010, PHYS TODAY, V63, P33, DOI 10.1063/1.3293411; Qi XL, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.187001; Sacepe B, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1586; Schnyder AP, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.195125; Teo JCY, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.046401; Wray LA, 2010, NAT PHYS, V6, P855, DOI [10.1038/NPHYS1762, 10.1038/nphys1762]; Xia Y, 2009, NAT PHYS, V5, P398, DOI 10.1038/NPHYS1274; Yu R, 2010, SCIENCE, V329, P61, DOI 10.1126/science.1187485; Zhang DM, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.165120; Zhang HJ, 2009, NAT PHYS, V5, P438, DOI 10.1038/NPHYS1270; Zhang JL, 2011, P NATL ACAD SCI USA, V108, P24, DOI 10.1073/pnas.1014085108; Zhang YB, 2010, NAT PHYS, V6, P74, DOI 10.1038/nphys1502	29	394	403	37	674	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 6	2012	336	6077					52	55		10.1126/science.1216466	http://dx.doi.org/10.1126/science.1216466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920LG	22422860				2022-12-28	WOS:000302405400047
J	Clare, DK; Vasishtan, D; Stagg, S; Quispe, J; Farr, GW; Topf, M; Horwich, AL; Saibil, HR				Clare, Daniel K.; Vasishtan, Daven; Stagg, Scott; Quispe, Joel; Farr, George W.; Topf, Maya; Horwich, Arthur L.; Saibil, Helen R.			ATP-Triggered Conformational Changes Delineate Substrate-Binding and -Folding Mechanics of the GroEL Chaperonin	CELL			English	Article							2.8 ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ALLOSTERIC TRANSITIONS; ELECTRON-MICROSCOPY; KINETIC-ANALYSIS; FOLDED PROTEIN; CENTRAL CAVITY; UCSF CHIMERA; OPEN RING; POLYPEPTIDE	The chaperonin GroEL assists the folding of nascent or stress-denatured polypeptides by actions of binding and encapsulation. ATP binding initiates a series of conformational changes triggering the association of the cochaperonin GroES, followed by further large movements that eject the substrate polypeptide from hydrophobic binding sites into a GroES-capped, hydrophilic folding chamber. We used cryo-electron microscopy, statistical analysis, and flexible fitting to resolve a set of distinct GroEL-ATP conformations that can be ordered into a trajectory of domain rotation and elevation. The initial conformations are likely to be the ones that capture polypeptide substrate. Then the binding domains extend radially to separate from each other but maintain their binding surfaces facing the cavity, potentially exerting mechanical force upon kinetically trapped, misfolded substrates. The extended conformation also provides a potential docking site for GroES, to trigger the final, 100 degrees domain rotation constituting the "power stroke" that ejects substrate into the folding chamber.	[Clare, Daniel K.; Vasishtan, Daven; Topf, Maya; Saibil, Helen R.] Univ London Birkbeck Coll, Crystallog & Inst Struct & Mol Biol, London WC1E 7HX, England; [Stagg, Scott; Quispe, Joel] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Horwich, Arthur L.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Farr, George W.; Horwich, Arthur L.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Farr, George W.; Horwich, Arthur L.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of London; Birkbeck University London; Scripps Research Institute; Scripps Research Institute; Yale University; Howard Hughes Medical Institute; Yale University	Saibil, HR (corresponding author), Univ London Birkbeck Coll, Crystallog & Inst Struct & Mol Biol, Malet St, London WC1E 7HX, England.	h.saibil@mail.cryst.bbk.ac.uk	Stagg, Scott/AAW-9294-2020	Topf, Maya/0000-0002-8185-1215; Clare, daniel/0000-0002-3372-8378	National Institutes of Health though the National Center for Research Resources at Crystallography, Department of Biological Sciences and ISMB, Birkbeck College [RR017573]; Wellcome Trust [070776, 089050]; BBSRC; MRC [G0600084]; Human Frontier Science Program [RGY0079/2009-C]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR017573] Funding Source: NIH RePORTER; Medical Research Council [G0600084] Funding Source: researchfish	National Institutes of Health though the National Center for Research Resources at Crystallography, Department of Biological Sciences and ISMB, Birkbeck College(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Human Frontier Science Program(Human Frontier Science Program); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Richard Westlake, Dave Houldershaw, and Luchun Wang for computing and EM support; Wayne Fenton and Elena Orlova for discussion; and Helene Launay for help with the initial part of data analysis. We also thank Bridget Carragher, Clint Potter, Anchi Cheng, and the Leginon team for their help and access to the NRAMM facility at the Scripps Research Institute. This work was carried out at the National Resource for Automated Molecular Microscopy, supported by the National Institutes of Health though the National Center for Research Resources P41 program (RR017573) and at Crystallography, Department of Biological Sciences and ISMB, Birkbeck College, supported by Wellcome Trust programme grants (070776 and 089050) to H.R.S. D.V. was supported by a BBSRC PhD studentship. M.T. is supported by an MRC Career Development Award (G0600084) and the Human Frontier Science Program (RGY0079/2009-C).	BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brocchieri L, 2000, PROTEIN SCI, V9, P476; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chaudhry C, 2004, J MOL BIOL, V342, P229, DOI 10.1016/j.jmb.2004.07.015; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; Clare DK, 2009, NATURE, V457, P107, DOI 10.1038/nature07479; Clare DK, 2008, STRUCTURE, V16, P528, DOI 10.1016/j.str.2008.01.016; Cliff MJ, 2006, J BIOL CHEM, V281, P21266, DOI 10.1074/jbc.M601605200; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Danziger O, 2006, PROTEIN SCI, V15, P1270, DOI 10.1110/ps.062100606; Elad N, 2008, J STRUCT BIOL, V162, P108, DOI 10.1016/j.jsb.2007.11.007; Elad N, 2007, MOL CELL, V26, P415, DOI 10.1016/j.molcel.2007.04.004; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Foloppe N, 2000, J COMPUT CHEM, V21, P86, DOI 10.1002/(SICI)1096-987X(20000130)21:2<86::AID-JCC2>3.0.CO;2-G; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horovitz A, 2002, P NATL ACAD SCI USA, V99, P14095, DOI 10.1073/pnas.222303299; Horwich AL, 2009, Q REV BIOPHYS, V42, P83, DOI 10.1017/S0033583509004764; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Huo YW, 2010, STRUCTURE, V18, P1270, DOI 10.1016/j.str.2010.07.009; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Lin Z, 2004, MOL CELL, V16, P23, DOI 10.1016/j.molcel.2004.09.003; Lin Z, 2008, NAT STRUCT MOL BIOL, V15, P303, DOI 10.1038/nsmb.1394; Ma JP, 2000, J MOL BIOL, V302, P303, DOI 10.1006/jmbi.2000.4014; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Miyazaki T, 2002, J BIOL CHEM, V277, P50621, DOI 10.1074/jbc.M209183200; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Nojima T, 2009, J BIOL CHEM, V284, P22834, DOI 10.1074/jbc.M109.020057; Orlova EV, 2010, METHOD ENZYMOL, V482, P321, DOI [10.1016/S0076-6879(10)82013_0, 10.1016/S0076-6879(10)82013-0]; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Ranson NA, 2006, NAT STRUCT MOL BIOL, V13, P147, DOI 10.1038/nsmb1046; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Roseman AM, 2004, J STRUCT BIOL, V145, P91, DOI 10.1016/j.jsb.2003.11.007; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Smith JM, 1999, J STRUCT BIOL, V125, P223, DOI 10.1006/jsbi.1998.4073; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; Taniguchi M, 2004, J BIOL CHEM, V279, P16368, DOI 10.1074/jbc.M311806200; Tehver R, 2009, J MOL BIOL, V387, P390, DOI 10.1016/j.jmb.2008.12.032; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Topf M, 2008, STRUCTURE, V16, P295, DOI 10.1016/j.str.2007.11.016; Tyagi NK, 2009, P NATL ACAD SCI USA, V106, P20264, DOI 10.1073/pnas.0911556106; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yang Z, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000360; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	60	123	125	0	73	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 30	2012	149	1					113	123		10.1016/j.cell.2012.02.047	http://dx.doi.org/10.1016/j.cell.2012.02.047			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	918FT	22445172	Green Published, hybrid			2022-12-28	WOS:000302235400014
J	Fiore, MC; Goplerud, E; Schroeder, SA				Fiore, Michael C.; Goplerud, Eric; Schroeder, Steven A.			The Joint Commission's New Tobacco-Cessation Measures - Will Hospitals Do the Right Thing?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Fiore, Michael C.] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Schroeder, Steven A.] Univ Calif San Francisco, Smoking Cessat Leadership Ctr, San Francisco, CA 94143 USA; [Goplerud, Eric] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; Univ Arkansas, Dept Food Sci, Fayetteville, AR 72703 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of Chicago; University of Arkansas System; University of Arkansas Fayetteville	Fiore, MC (corresponding author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53706 USA.				NCI NIH HHS [P50 CA143188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA143188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fiore MC, 2008, TREATING TOBACCO USE; Fiore MC, 2011, NEW ENGL J MED, V365, P1222, DOI 10.1056/NEJMcp1101512; Jonk YC, 2005, AM J MANAG CARE, V11, P77; Levy DE, 2011, ARCH INTERN MED, V171, P1682, DOI 10.1001/archinternmed.2011.451; Williams SC, 2005, J CLIN OUTCOMES MANA, V12, P345	5	108	110	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					1172	1174		10.1056/NEJMp1115176	http://dx.doi.org/10.1056/NEJMp1115176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915DW	22417200	Green Accepted			2022-12-28	WOS:000302005100002
J	Yang, QH; Cogswell, ME; Flanders, WD; Hong, YL; Zhang, ZF; Loustalot, F; Gillespie, C; Merritt, R; Hu, FB				Yang, Quanhe; Cogswell, Mary E.; Flanders, W. Dana; Hong, Yuling; Zhang, Zefeng; Loustalot, Fleetwood; Gillespie, Cathleen; Merritt, Robert; Hu, Frank B.			Trends in Cardiovascular Health Metrics and Associations With All-Cause and CVD Mortality Among US Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; PHYSICAL-ACTIVITY; NATIONAL-HEALTH; SCIENTIFIC STATEMENT; BLOOD-PRESSURE; RISK-FACTORS; PREVALENCE; POPULATION; DISEASE; NUTRITION	Context Recent recommendations from the American Heart Association aim to improve cardiovascular health by encouraging the general population to meet 7 cardiovascular health metrics: not smoking; being physically active; having normal blood pressure, blood glucose and total cholesterol levels, and weight; and eating a healthy diet. Objective To examine time trends in cardiovascular health metrics and to estimate joint associations and population-attributable fractions of these metrics in relation to all-cause and cardiovascular disease (CVD) mortality risk. Design, Setting, and Participants Study of a nationally representative sample of 44 959 US adults (>20 years), using data from the National Health and Nutrition Examination Survey (NHANES) 1988-1994, 1999-2004, and 2005-2010 and the NHANES III Linked Mortality File (through 2006). Main Outcome Measures All-cause, CVD, and ischemic heart disease (IHD) mortality. Results Few participants met all 7 cardiovascular health metrics (2.0% [95% CI, 1.5%-2.5%] in 1988-1994, 1.2% [95% CI, 0.8%-1.9%] in 2005-2010). Among NHANES III participants, 2673 all-cause, 1085 CVD, and 576 IHD deaths occurred (median follow-up, 14.5 years). Among participants who met 1 or fewer cardiovascular health metrics, age-and sex-standardized absolute risks were 14.8 (95% CI, 13.2-16.5) deaths per 1000 person-years for all-cause mortality, 6.5 (95% CI, 5.5-7.6) for CVD mortality, and 3.7 (95% CI, 2.8-4.5) for IHD mortality. Among those who met 6 or more metrics, corresponding risks were 5.4 (95% CI, 3.6-7.3) for all-cause mortality, 1.5 (95% CI, 0.5-2.5) for CVD mortality, and 1.1 (95% CI, 0.7-2.0) for IHD mortality. Adjusted hazard ratios were 0.49 (95% CI, 0.33-0.74) for all-cause mortality, 0.24 (95% CI, 0.13-0.47) for CVD mortality, and 0.30 (95% CI, 0.13-0.68) for IHD mortality, comparing participants who met 6 or more vs 1 or fewer cardiovascular health metrics. Adjusted population-attributable fractions were 59% (95% CI, 33%-76%) for all-cause mortality, 64% (95% CI, 28%-84%) for CVD mortality, and 63% (95% CI, 5%-89%) for IHD mortality. Conclusion Meeting a greater number of cardiovascular health metrics was associated with a lower risk of total and CVD mortality, but the prevalence of meeting all 7 cardiovascular health metrics was low in the study population. JAMA. 2012;307(12):1273-1283 Published online March 16, 2012. doi: 10.1001/jama.2012.339 www.jama.com	[Yang, Quanhe; Cogswell, Mary E.; Hong, Yuling; Zhang, Zefeng; Loustalot, Fleetwood; Gillespie, Cathleen; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA; [Flanders, W. Dana] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Yang, QH (corresponding author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA.	qay0@cdc.gov		Gillespie, Cathleen/0000-0003-1878-1055	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Artinian NT, 2010, CIRCULATION, V122, P406, DOI 10.1161/CIR.0b013e3181e8edf1; Bassuk SS, 2010, NUTR METAB CARDIOVAS, V20, P467, DOI 10.1016/j.numecd.2009.12.015; Bassuk SS, 2005, J APPL PHYSIOL, V99, P1193, DOI 10.1152/japplphysiol.00160.2005; Bazzano AT, 2009, AM J PREV MED, V37, pS201, DOI 10.1016/j.amepre.2009.08.005; Beddhu S, 2009, CLIN J AM SOC NEPHRO, V4, P1901, DOI 10.2215/CJN.01970309; Berry JD, 2012, NEW ENGL J MED, V366, P321, DOI 10.1056/NEJMoa1012848; Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29; Buttar Harpal S, 2005, Exp Clin Cardiol, V10, P229; Centers for Disease Control and Prevention, 3 NAT HLTH NUTR EX S; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P764; Cowie CC, 2006, DIABETES CARE, V29, P1263, DOI 10.2337/dc06-0062; Cowie CC, 2010, DIABETES CARE, V33, P562, DOI 10.2337/dc09-1524; Cowie CC, 2009, DIABETES CARE, V32, P287, DOI 10.2337/dc08-1296; Daviglus ML, 2004, JAMA-J AM MED ASSOC, V292, P1588, DOI 10.1001/jama.292.13.1588; Drescher K, 1997, BIOMETRICS, V53, P1170, DOI 10.2307/2533576; Dube S. R., 2010, Morbidity and Mortality Weekly Report, V59, P1135; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Farley TA, 2010, AM J PREV MED, V38, P600, DOI 10.1016/j.amepre.2010.02.016; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Folsom AR, 2011, J AM COLL CARDIOL, V57, P1690, DOI 10.1016/j.jacc.2010.11.041; Ford ES, 2011, AM J PUBLIC HEALTH, V101, P1922, DOI [10.2105/AJPH.2011.300167, 10.2105//AJPH.2011.300167]; Ford ES, 2009, CIRCULATION, V120, P1181, DOI 10.1161/CIRCULATIONAHA.108.835728; Ford ES, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.111.049122, DOI 10.1161/CIRCULATIONAHA.111.04]; Frieden TR, 2011, NEW ENGL J MED, V365, DOI [10.1056/NEJMp1110421, 10.1056/NEJMP1110421]; Garrett Bridgette E., 2011, Morbidity and Mortality Weekly Report, V60, P109; Gillespie C., 2011, Morbidity and Mortality Weekly Report, V60, P103; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Ham S. A., 2004, Morbidity and Mortality Weekly Report, V53, P82; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hu FB, 2008, OBESITY EPIDEMIOLOGY; Jackson L, 2009, DIABETES EDUCATOR, V35, P309, DOI 10.1177/0145721708330153; Kruger J., 2007, Morbidity and Mortality Weekly Report, V56, P1209; Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158; Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885; National Center for Health Statistics, 1988, 3 NAT HLTH NUTR EX S; National Center for Health Statistics, NAT HLTH NUTR EX SUR; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sacks FM, 2010, NEW ENGL J MED, V362, P2102, DOI 10.1056/NEJMct0911013; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Shah VB, 2005, SUDAAN USERS MANUAL; Shay CM, 2012, CIRCULATION, V125, P45, DOI 10.1161/CIRCULATIONAHA.111.035733; Sherry B., 2010, Morbidity and Mortality Weekly Report, V59, P951; Spiegelman D, 2007, CANCER CAUSE CONTROL, V18, P571, DOI 10.1007/s10552-006-0090-y; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Tomaselli GF, 2011, CIRCULATION, V124, P1795, DOI 10.1161/CIR.0b013e3182327084; Tooze JA, 2010, STAT MED, V29, P2857, DOI 10.1002/sim.4063; Valderrama Amy L., 2011, Morbidity and Mortality Weekly Report, V60, P1248; Wang YF, 2008, OBESITY, V16, P2323, DOI 10.1038/oby.2008.351	64	520	543	11	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1273	1283		10.1001/jama.2012.339	http://dx.doi.org/10.1001/jama.2012.339			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914UP	22427615	Green Accepted			2022-12-28	WOS:000301978400023
J	MacMahon, E				MacMahon, Eithne			PRACTICE POINTER Investigating the pregnant woman exposed to a child with a rash	BRITISH MEDICAL JOURNAL			English	Editorial Material							VARICELLA; RUBELLA; MEASLES; ZOSTER; WOMEN		[MacMahon, Eithne] Guys & St Thomas NHS Fdn Trust, Dept Infect Dis, St Thomas Hosp, Directorate Infect, London SE1 7EH, England; [MacMahon, Eithne] Kings Coll London, Dept Infect Dis, Sch Med, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	MacMahon, E (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept Infect Dis, St Thomas Hosp, Directorate Infect, London SE1 7EH, England.	eithne.macmahon@gstt.nhs.uk						Asaria P, 2006, BRIT MED J, V333, P890, DOI 10.1136/bmj.38989.445845.7C; Banatvala JE, 2004, LANCET, V363, P1127, DOI 10.1016/S0140-6736(04)15897-2; Boxall EH, 2011, EUR J CLIN MICROBIOL, V30, P1193, DOI 10.1007/s10096-011-1211-4; de Jong EP, 2011, PRENATAL DIAG, V31, P419, DOI 10.1002/pd.2714; Department of Health, 2011, IMM INF DIS GREEN BO; ENDERS G, 1994, LANCET, V343, P1548, DOI 10.1016/S0140-6736(94)92943-2; Health Protection Agency, 2011, GUID VIR RASH PREGN; MacMahon E, 2004, BRIT MED J, V329, P551, DOI 10.1136/bmj.38170.691956.AE; Manikkavasagan G, 2009, J OBSTET GYNAECOL, V29, P572, DOI 10.1080/01443610903104478; Maple PAC, 2009, J VIROL METHODS, V155, P143, DOI 10.1016/j.jviromet.2008.09.032; Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1; Miller E., 1993, Reviews in Medical Microbiology, V4, P222; Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840; Zimmerman LA, 2011, J INFECT DIS, V204, pS381, DOI 10.1093/infdis/jir104	14	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 26	2012	344								e1790	10.1136/bmj.e1790	http://dx.doi.org/10.1136/bmj.e1790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923DY	22451478				2022-12-28	WOS:000302600700009
J	Smith, MS				Smith, Mark Stafford			Change the approach to sustainable development	NATURE			English	Editorial Material									Commonwealth Sci & Ind Res Org Climate Adaptat Fl, Canberra, ACT, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Smith, MS (corresponding author), Commonwealth Sci & Ind Res Org Climate Adaptat Fl, Canberra, ACT, Australia.	mark.staffordsmith@csiro.au	Smith, Mark Stafford/G-1680-2010	Smith, Mark Stafford/0000-0002-1333-3651					0	3	4	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2012	483	7390					375	375		10.1038/483375a	http://dx.doi.org/10.1038/483375a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	912CC	22437572	Bronze			2022-12-28	WOS:000301771200004
J	Wilson, GP; Evans, AR; Corfe, IJ; Smits, PD; Fortelius, M; Jernvall, J				Wilson, Gregory P.; Evans, Alistair R.; Corfe, Ian J.; Smits, Peter D.; Fortelius, Mikael; Jernvall, Jukka			Adaptive radiation of multituberculate mammals before the extinction of dinosaurs	NATURE			English	Article							DIVERSITY; EVOLUTION	The Cretaceous-Paleogene mass extinction approximately 66 million years ago is conventionally thought to have been a turning point in mammalian evolution(1,2). Prior to that event and for the first two-thirds of their evolutionary history, mammals were mostly confined to roles as generalized, small-bodied, nocturnal insectivores(3), presumably under selection pressures from dinosaurs(4). Release from these pressures, by extinction of non-avian dinosaurs at the Cretaceous-Paleogene boundary, triggered ecological diversification of mammals(1,2). Although recent individual fossil discoveries have shown that some mammalian lineages diversified ecologically during the Mesozoic era(5), comprehensive ecological analyses of mammalian groups crossing the Cretaceous-Paleogene boundary are lacking. Such analyses are needed because diversification analyses of living taxa(6,7) allow only indirect inferences of past ecosystems. Here we show that in arguably the most evolutionarily successful clade of Mesozoic mammals, the Multituberculata, an adaptive radiation began at least 20 million years before the extinction of non-avian dinosaurs and continued across the Cretaceous-Paleogene boundary. Disparity in dental complexity, which relates to the range of diets, rose sharply in step with generic richness and disparity in body size. Moreover, maximum dental complexity and body size demonstrate an adaptive shift towards increased herbivory. This dietary expansion tracked the ecological rise of angiosperms(8) and suggests that the resources that were available to multituberculates were relatively unaffected by the Cretaceous-Paleogene mass extinction. Taken together, our results indicate that mammals were able to take advantage of new ecological opportunities in the Mesozoic and that at least some of these opportunities persisted through the Cretaceous-Paleogene mass extinction. Similar broad-scale ecomorphological inventories of other radiations may help to constrain the possible causes of mass extinctions(9,10).	[Wilson, Gregory P.; Smits, Peter D.] Univ Washington, Dept Biol, Seattle, WA 98195 USA; [Evans, Alistair R.; Smits, Peter D.] Monash Univ, Sch Biol Sci, Clayton, Vic 3800, Australia; [Corfe, Ian J.; Fortelius, Mikael; Jernvall, Jukka] Univ Helsinki, Inst Biotechnol, Dev Biol Program, FIN-00014 Helsinki, Finland; [Fortelius, Mikael] Univ Helsinki, Dept Geosci & Geog, FIN-00014 Helsinki, Finland	University of Washington; University of Washington Seattle; Monash University; University of Helsinki; University of Helsinki	Wilson, GP (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.	gpwilson@u.washington.edu	Evans, Alistair R/D-4239-2011; Wilson, Gregory P/A-2363-2009; Corfe, Ian/GSN-6109-2022	Evans, Alistair R/0000-0002-4078-4693; Fortelius, Mikael/0000-0002-4851-783X; Wilson Mantilla, Gregory/0000-0003-3604-5473; Smits, Peter D/0000-0003-4074-1447; Corfe, Ian/0000-0002-1824-755X	National Science Foundation; Denver Museum; University of Washington; Australian Research Council; Monash University; Academy of Finland; EU SYNTHESYS [GB-TAF-4779]	National Science Foundation(National Science Foundation (NSF)); Denver Museum; University of Washington(University of Washington); Australian Research Council(Australian Research Council); Monash University(Monash University); Academy of Finland(Academy of Finland); EU SYNTHESYS	We thank museums, institutions and individuals that made specimens available for this study (full list is available in Supplementary Information). Funding was provided by the National Science Foundation, Denver Museum, the University of Washington (G. P. W. and P. D. S.), the Australian Research Council, Monash University (A. R. E.), the Academy of Finland (A. R. E., M. F. and J.J.) and the EU SYNTHESYS program (project GB-TAF-4779) (I.J.C.).	Alroy J, 1999, SYST BIOL, V48, P107, DOI 10.1080/106351599260472; Archibald JD, 2010, SCIENCE, V328, P973, DOI 10.1126/science.328.5981.973-a; Barrett PM, 2009, P ROY SOC B-BIOL SCI, V276, P2667, DOI 10.1098/rspb.2009.0352; Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634; Cope E. D., 1884, American Naturalist, Vxviii, P686; Evans AR, 2007, NATURE, V445, P78, DOI 10.1038/nature05433; Feild TS, 2011, P NATL ACAD SCI USA, V108, P8363, DOI 10.1073/pnas.1014456108; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Gingerich P.D., 1977, PATTERNS EVOLUTION I, V5, P591, DOI DOI 10.1016/S0920-5446(08)70335-2; Grimaldi D, 1999, ANN MO BOT GARD, V86, P373, DOI 10.2307/2666181; Jernvall J, 2008, DEV PRIMATOL-PROG PR, P335, DOI 10.1007/978-0-387-73896-3_22; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; KRAUSE DW, 1982, PALEOBIOLOGY, V8, P265, DOI 10.1017/S0094837300006989; KRAUSE DW, 1986, VERTEBRATES PHYLOGEN, P119; Luo ZX, 2007, NATURE, V450, P1011, DOI 10.1038/nature06277; Lupia R, 1999, PALEOBIOLOGY, V25, P305, DOI 10.1017/S009483730002131X; Meredith RW, 2011, SCIENCE, V334, P521, DOI 10.1126/science.1211028; Prideaux GJ, 2004, U CALIF PUBL GEOL SC, V146, P1; Rich TH, 2009, ACTA PALAEONTOL POL, V54, P1, DOI 10.4202/app.2009.0101; Santana SE, 2011, FUNCT ECOL, V25, P839, DOI 10.1111/j.1365-2435.2011.01832.x; Schneider H, 2004, NATURE, V428, P553, DOI 10.1038/nature02361; Schulte P, 2010, SCIENCE, V327, P1214, DOI 10.1126/science.1177265; SIMPSON GEORGE GAYLORD, 1933, JOUR MAMMALOGY, V14, P97, DOI 10.2307/1374012; Smith FA, 2010, SCIENCE, V330, P1216, DOI 10.1126/science.1194830; van Valen L, 1977, Evolutionary Theory, V2, P37; Weil A, 2008, EVOLUTION OF TERTIARY MAMMALS OF NORTH AMERICA, VOL 2, P19; Wilson Gregory P., 2005, Journal of Mammalian Evolution, V12, P53, DOI 10.1007/s10914-005-6943-4; Wing S.L., 1987, P203; Wing SL, 1998, ANNU REV EARTH PL SC, V26, P379, DOI 10.1146/annurev.earth.26.1.379	29	171	176	4	165	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					457	460		10.1038/nature10880	http://dx.doi.org/10.1038/nature10880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22419156				2022-12-28	WOS:000301771200041
J	Pujadas, E; Feinberg, AP				Pujadas, Elisabet; Feinberg, Andrew P.			Regulated Noise in the Epigenetic Landscape of Development and Disease	CELL			English	Review							EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; DNA METHYLATION; ACTIVE CHROMATIN; CANCER; VARIABILITY; HSP90; STOCHASTICITY; ENVIRONMENT; PLASTICITY	In this Perspective, we synthesize past and present observations in the field of epigenetics to propose a model in which the epigenome can modulate cellular plasticity in development and disease by regulating the effects of noise. In this model, the epigenome facilitates phase transitions in development and reprogramming and mediates canalization, or the ability to produce a consistent phenotypic outcome despite being challenged by variable conditions, during cell fate commitment. After grounding our argument in a discussion of stochastic noise and nongenetic heterogeneity, we explore the hypothesis that distinct chromatin domains, which are known to be dysregulated in disease and remodeled during development, might underlie cellular plasticity more generally. We then present a modern portrayal of Waddington's epigenetic landscape through a mathematical formalism. We speculate that this new framework might impact how we approach disease mechanisms. In particular, it may help to explain the observation that the variability of DNA methylation and gene expression are increased in cancer, thus contributing to tumor cell heterogeneity.	[Pujadas, Elisabet; Feinberg, Andrew P.] Johns Hopkins Univ, Ctr Epigenet, Baltimore, MD 21205 USA	Johns Hopkins University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Ctr Epigenet, 570 Rangos,855 N Wolfe St, Baltimore, MD 21205 USA.	afeinberg@jhu.edu	Feinberg, Andrew/AAY-7666-2020; Pujadas, Elisabet/AAC-2138-2021	Pujadas, Elisabet/0000-0003-4795-7945; Feinberg, Andrew/0000-0002-8364-1991	NIH [DP1OD008324]; NIGMS [T32-GM007309]; NATIONAL CANCER INSTITUTE [R01CA054358] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG003233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [DP1ES022579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD008324] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Sean Taverna, Andre Levchenko, Winston Timp, Roger Reeves, Rolf Ohlsson, Tomas Ekstrom, Claes Wahlestedt, Brian Herb, Yun Liu, Michael Multhaup, Amy Unterman, Namyoung Jung, Onur Kilic, and Karen Reddy for reading and helpful comments during preparation of the manuscript. This work was supported by NIH Director's Pioneer Award DP1OD008324 to A.F. and NIGMS Medical Scientist Training Program Award T32-GM007309 to E.P.	Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Bao XM, 2007, GENETICA, V129, P339, DOI 10.1007/s10709-006-0012-7; Barchuk AR, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-70; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Burga A, 2011, NATURE, V480, P250, DOI 10.1038/nature10665; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cheong R, 2011, SCIENCE, V334, P354, DOI 10.1126/science.1204553; Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007; Delbruck M., 1940, J CHEM PHYS, V8, P5; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Ebert A, 2004, GENE DEV, V18, P2973, DOI 10.1101/gad.323004; Ebert A, 2006, CHROMOSOME RES, V14, P377, DOI 10.1007/s10577-006-1066-1; Elberg G, 2006, NEPHRON EXP NEPHROL, V102, pE113, DOI 10.1159/000090070; Eldar A, 2010, NATURE, V467, P167, DOI 10.1038/nature09326; Fedoroff N, 2002, SCIENCE, V297, P1129, DOI 10.1126/science.1075988; Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107; GARTNER K, 1990, LAB ANIM, V24, P71, DOI 10.1258/002367790780890347; Girton JR, 2008, ADV GENET, V61, P1, DOI 10.1016/S0065-2660(07)00001-6; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; He LM, 1998, ONCOGENE, V16, P113, DOI 10.1038/sj.onc.1201501; Horsthemke W, 2006, NOISE INDUCED TRANSI; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Iwamoto K, 2011, GENOME RES, V21, P688, DOI 10.1101/gr.112755.110; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286; Korobkova E, 2004, NATURE, V428, P574, DOI 10.1038/nature02404; Kucharski R, 2008, SCIENCE, V319, P1827, DOI 10.1126/science.1153069; Li CCY, 2011, PLOS GENET, V7, DOI [10.1371/journal.pgen.1001380, 10.1371/journal.pgen.1002196]; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946; Losick R, 2008, SCIENCE, V320, P65, DOI 10.1126/science.1147888; Maamar H, 2007, SCIENCE, V317, P526, DOI 10.1126/science.1140818; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mar JC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002207; McCullagh E, 2010, NAT CELL BIOL, V12, P954, DOI 10.1038/ncb2097; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Miller-Jensen K, 2011, TRENDS BIOTECHNOL, V29, P517, DOI 10.1016/j.tibtech.2011.05.004; Mukasa R, 2010, IMMUNITY, V32, P616, DOI 10.1016/j.immuni.2010.04.016; Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238; OMHOLT SW, 2004, SCI AGING KNOWLEDGE, pE28; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Pirola L., 2010, CELL STEM CELL, V6, p[665, 5]; Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; Riccio A, 2010, NAT NEUROSCI, V13, P1330, DOI 10.1038/nn.2671; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Southworth LK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000776; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Tariq M, 2009, P NATL ACAD SCI USA, V106, P1157, DOI 10.1073/pnas.0809669106; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thompson RF, 2010, AGING CELL, V9, P506, DOI 10.1111/j.1474-9726.2010.00577.x; Vaquero A, 2009, GENE DEV, V23, P1849, DOI 10.1101/gad.1807009; Villeneuve LM, 2008, P NATL ACAD SCI USA, V105, P9047, DOI 10.1073/pnas.0803623105; Vogt G, 2008, J EXP BIOL, V211, P510, DOI 10.1242/jeb.008755; Waddington C H, 1957, STRATEGY GENES DISCU; Waddington C.H., 1942, NATURE, V150, P3; WADDINGTON CH, 1959, NATURE, V183, P1654, DOI 10.1038/1831654a0; Whitelaw NC, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-11-r111; Wittmann M, 2009, J NEUROSCI, V29, P14687, DOI 10.1523/JNEUROSCI.1160-09.2009; Yeyati PL, 2007, PLOS GENET, V3, P431, DOI 10.1371/journal.pgen.0030043	70	162	168	1	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1123	1131		10.1016/j.cell.2012.02.045	http://dx.doi.org/10.1016/j.cell.2012.02.045			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424224	Bronze, Green Accepted			2022-12-28	WOS:000301889500011
J	Savage, N				Savage, Neil			MATERIALS SCIENCE Super carbon	NATURE			English	Editorial Material																			0	71	72	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					S30	S30		10.1038/483S30a	http://dx.doi.org/10.1038/483S30a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	908HP	22419207	Bronze			2022-12-28	WOS:000301481800001
J	Collins, GS				Collins, Gareth S.			Moonstruck Magnetism	SCIENCE			English	Editorial Material							LUNAR CORE DYNAMO; DRIVEN; SURFACE; FIELD; MOON		Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, London SW7 2AZ, England	Imperial College London	Collins, GS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, London SW7 2AZ, England.	g.collins@imperial.ac.uk		Collins, Gareth/0000-0002-6087-6149	Natural Environment Research Council [NE/E013589/1] Funding Source: researchfish; Science and Technology Facilities Council [ST/J001260/1, ST/G002452/1] Funding Source: researchfish; NERC [NE/E013589/1] Funding Source: UKRI; STFC [ST/G002452/1, ST/J001260/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Cisowski S. M., 1983, Journal of Geophysical Research, V88, P691, DOI 10.1029/JB088iS02p0A691; Dwyer CA, 2011, NATURE, V479, P212, DOI 10.1038/nature10564; DYAL P, 1970, SCIENCE, V169, P762, DOI 10.1126/science.169.3947.762; Fuller M., 1987, GEOMAGN AERON, V2, P307; Garrick-Bethell I, 2009, SCIENCE, V323, P356, DOI 10.1126/science.1166804; Hood LL, 2008, ICARUS, V193, P485, DOI 10.1016/j.icarus.2007.08.023; Hood LL, 2011, ICARUS, V211, P1109, DOI 10.1016/j.icarus.2010.08.012; Lawrence K, 2008, PHYS EARTH PLANET IN, V168, P71, DOI 10.1016/j.pepi.2008.05.007; Le Bars M, 2011, NATURE, V479, P215, DOI 10.1038/nature10565; LIN RP, 1988, ICARUS, V74, P529, DOI 10.1016/0019-1035(88)90119-4; Rochette P, 2010, EARTH PLANET SC LETT, V292, P383, DOI 10.1016/j.epsl.2010.02.007; Shea EK, 2012, SCIENCE, V335, P453, DOI 10.1126/science.1215359; Stegman DR, 2003, NATURE, V421, P143, DOI 10.1038/nature01267; Weber RC, 2011, SCIENCE, V331, P309, DOI 10.1126/science.1199375; Wieczorek MA, 2012, SCIENCE, V335, P1212, DOI 10.1126/science.1214773	15	2	2	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1176	1177		10.1126/science.1217681	http://dx.doi.org/10.1126/science.1217681			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403376				2022-12-28	WOS:000301225100028
J	Makkar, RR; Fontana, GP; Jilaihawi, H; Kapadia, S; Pichard, AD; Douglas, PS; Thourani, VH; Babaliaros, VC; Webb, JG; Herrmann, HC; Bavaria, JE; Kodali, S; Brown, DL; Bowers, B; Dewey, TM; Svensson, LG; Tuzcu, M; Moses, JW; Williams, MR; Siegel, RJ; Akin, JJ; Anderson, WN; Pocock, S; Smith, CR; Leon, MB				Makkar, Raj R.; Fontana, Gregory P.; Jilaihawi, Hasan; Kapadia, Samir; Pichard, Augusto D.; Douglas, Pamela S.; Thourani, Vinod H.; Babaliaros, Vasilis C.; Webb, John G.; Herrmann, Howard C.; Bavaria, Joseph E.; Kodali, Susheel; Brown, David L.; Bowers, Bruce; Dewey, Todd M.; Svensson, Lars G.; Tuzcu, Murat; Moses, Jeffrey W.; Williams, Matthew R.; Siegel, Robert J.; Akin, Jodi J.; Anderson, William N.; Pocock, Stuart; Smith, Craig R.; Leon, Martin B.		PARTNER Trial Investigators	Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; HIGH-RISK; COST-EFFECTIVENESS; IMPLANTATION; OUTCOMES; INTERVENTIONS; REGISTRY; COHORT; DISEASE; SURGERY	Background Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates for surgery. The outcomes beyond 1 year in such patients are not known. Methods We randomly assigned patients to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty). Data on 2-year outcomes were analyzed. Results A total of 358 patients underwent randomization at 21 centers. The rates of death at 2 years were 43.3% in the TAVR group and 68.0% in the standard-therapy group (P<0.001), and the corresponding rates of cardiac death were 31.0% and 62.4% (P<0.001). The survival advantage associated with TAVR that was seen at 1 year remained significant among patients who survived beyond the first year (hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.92; P=0.02 with the use of the log-rank test). The rate of stroke was higher after TAVR than with standard therapy (13.8% vs. 5.5%, P=0.01), owing, in the first 30 days, to the occurrence of more ischemic events in the TAVR group (6.7% vs. 1.7%, P=0.02) and, beyond 30 days, to the occurrence of more hemorrhagic strokes in the TAVR group (2.2% vs. 0.6%, P=0.16). At 2 years, the rate of rehospitalization was 35.0% in the TAVR group and 72.5% in the standard-therapy group (P<0.001). TAVR, as compared with standard therapy, was also associated with improved functional status (P<0.001). The data suggest that the mortality benefit after TAVR may be limited to patients who do not have extensive coexisting conditions. Echocardiographic analysis showed a sustained increase in aortic-valve area and a decrease in aortic-valve gradient, with no worsening of para-valvular aortic regurgitation. Conclusions Among appropriately selected patients with severe aortic stenosis who were not suitable candidates for surgery, TAVR reduced the rates of death and hospitalization, with a decrease in symptoms and an improvement in valve hemodynamics that were sustained at 2 years of follow-up. The presence of extensive coexisting conditions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.)	[Leon, Martin B.] Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, New York, NY 10032 USA; [Kodali, Susheel; Moses, Jeffrey W.; Williams, Matthew R.; Smith, Craig R.; Leon, Martin B.] New York Presbyterian Hosp, New York, NY USA; [Makkar, Raj R.; Jilaihawi, Hasan; Siegel, Robert J.] Cedars Sinai Heart Inst, Los Angeles, CA USA; [Fontana, Gregory P.] Lenox Hill Heart & Vasc Inst, New York, NY USA; [Kapadia, Samir; Svensson, Lars G.; Tuzcu, Murat] Cleveland Clin Fdn, Cleveland, OH USA; [Pichard, Augusto D.] Washington Hosp Ctr, Washington, DC 20010 USA; [Douglas, Pamela S.] Duke Univ, Sch Med, Durham, NC USA; [Thourani, Vinod H.; Babaliaros, Vasilis C.] Emory Univ, Sch Med, Atlanta, GA USA; [Webb, John G.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Webb, John G.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Herrmann, Howard C.; Bavaria, Joseph E.] Hosp Univ Penn, Philadelphia, PA 19104 USA; [Brown, David L.; Bowers, Bruce] Baylor Healthcare Syst, Dallas, TX USA; [Dewey, Todd M.] Med City Dallas, Dallas, TX USA; [Akin, Jodi J.; Anderson, William N.] Edwards Lifesci, Irvine, CA USA; [Pocock, Stuart] London Sch Hyg & Trop Med, London, England	Columbia University; NewYork-Presbyterian Hospital; Cedars Sinai Medical Center; Lenox Hill Heart & Vascular Institute of New York; Cleveland Clinic Foundation; MedStar Washington Hospital Center; Duke University; Emory University; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of Pennsylvania; Pennsylvania Medicine; Baylor Health Care System; Medical City Dallas Hospital; Edwards Lifesciences; University of London; London School of Hygiene & Tropical Medicine	Leon, MB (corresponding author), Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, 161 Ft Washington Ave,6th Fl, New York, NY 10032 USA.	mleon@crf.org	thourani, vinod/AAP-5968-2020; Doğan, Ali/AAN-5331-2020; Asch, Federico/AAS-7653-2021; Heldman, Alan W./K-8784-2012	Asch, Federico/0000-0002-1744-5271; Heldman, Alan W./0000-0002-1615-3883; Williams, Mathew/0000-0003-2055-8741; Douglas, Pamela/0000-0001-9876-4049	Edwards Lifesciences	Edwards Lifesciences	Supported by Edwards Lifesciences.	Abdel-Wahab M, 2011, HEART, V97, P899, DOI 10.1136/hrt.2010.217158; Amat-Santos IJ, 2012, J AM COLL CARDIOL, V59, P178, DOI 10.1016/j.jacc.2011.09.061; Buellesfeld L, 2011, J AM COLL CARDIOL, V57, P1650, DOI 10.1016/j.jacc.2010.11.044; Carabello BA, 2009, LANCET, V373, P956, DOI 10.1016/S0140-6736(09)60211-7; Clavel MA, 2009, J AM COLL CARDIOL, V53, P1883, DOI 10.1016/j.jacc.2009.01.060; Daneault B, 2011, J AM COLL CARDIOL, V58, P2143, DOI 10.1016/j.jacc.2011.08.024; Etienne PY, 2011, ANN THORAC SURG, V92, pE95, DOI 10.1016/j.athoracsur.2011.05.109; Ghanem A, 2010, J AM COLL CARDIOL, V55, P1427, DOI 10.1016/j.jacc.2009.12.026; Gurvitch R, 2010, CIRCULATION, V122, P1319, DOI 10.1161/CIRCULATIONAHA.110.948877; Kahlert P, 2010, CIRCULATION, V121, P870, DOI 10.1161/CIRCULATIONAHA.109.855866; KELLY TA, 1988, AM J CARDIOL, V61, P123, DOI 10.1016/0002-9149(88)91317-3; Kodali SK, 2012, NEW ENGL J MED, V366, P1686, DOI 10.1056/NEJMoa1200384; Krane M, 2010, AM HEART J, V160, P451, DOI 10.1016/j.ahj.2010.05.038; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; Moat NE, 2011, J AM COLL CARDIOL, V58, P2130, DOI 10.1016/j.jacc.2011.08.050; Nietlispach F, 2010, JACC-CARDIOVASC INTE, V3, P1133, DOI 10.1016/j.jcin.2010.05.022; Reynolds MR, 2012, CIRCULATION, V125, P1102, DOI 10.1161/CIRCULATIONAHA.111.054072; Reynolds MR, 2011, CIRCULATION, V124, P1964, DOI 10.1161/CIRCULATIONAHA.111.040022; Ross Jr J, 1968, CIRCULATION S5, V38, P61; Schueler R, 2010, HEART, V96, P1831, DOI 10.1136/hrt.2010.202663; Tamburino C, 2011, CIRCULATION, V123, P299, DOI 10.1161/CIRCULATIONAHA.110.946533; Tay ELW, 2011, JACC-CARDIOVASC INTE, V4, P1290, DOI 10.1016/j.jcin.2011.08.012; Thomas M, 2011, CIRCULATION, V124, P425, DOI 10.1161/CIRCULATIONAHA.110.001545; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307; Ussia GP, 2011, AM J CARDIOL, V108, P1772, DOI 10.1016/j.amjcard.2011.07.049; Ussia GP, 2011, EUROINTERVENTION, V7, P573, DOI 10.4244/EIJV7I5A93; Ussia GP, 2009, EUR HEART J, V30, P1790, DOI 10.1093/eurheartj/ehp171; Ussia GP, 2012, EUR HEART J     0112; Warnes CA, 2008, J AM COLL CARDIOL, V52, pE1, DOI 10.1016/j.jacc.2008.10.001; Watt M, 2012, HEART, V98, P370, DOI 10.1136/heartjnl-2011-300444; Wenaweser P, 2011, J AM COLL CARDIOL, V58, P2151, DOI 10.1016/j.jacc.2011.05.063	31	950	975	0	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 3	2012	366	18					1696	1704		10.1056/NEJMoa1202277	http://dx.doi.org/10.1056/NEJMoa1202277			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	934HH	22443478	Green Accepted			2022-12-28	WOS:000303434300009
J	Hsu, YC; Lin, JT				Hsu, Yao-Chun; Lin, Jaw-Town			Intestinal Infestation with Ancylostoma ceylanicum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hsu, Yao-Chun] E Da Hosp, Kaohsiung, Taiwan; [Lin, Jaw-Town] Natl Taiwan Univ Hosp, Taipei, Taiwan	E-Da Hospital; National Taiwan University; National Taiwan University Hospital	Hsu, YC (corresponding author), E Da Hosp, Kaohsiung, Taiwan.	jawtown@ntu.edu.tw							0	26	27	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2012	366	13					E20	E20		10.1056/NEJMicm1101717	http://dx.doi.org/10.1056/NEJMicm1101717			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915DW	22455438				2022-12-28	WOS:000302005100013
J	Karaca-Mandic, P; Jena, AB; Joyce, GF; Goldman, DP				Karaca-Mandic, Pinar; Jena, Anupam B.; Joyce, Geoffrey F.; Goldman, Dana P.			Out-of-Pocket Medication Costs and Use of Medications and Health Care Services Among Children With Asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INHALED CORTICOSTEROIDS; PHARMACY BENEFITS; INSURANCE; DRUGS; CAPS	Context Health plans have implemented policies to restrain prescription medication spending by shifting costs toward patients. It is unknown how these policies have affected children with chronic illness. Objective To analyze the association of medication cost sharing with medication and hospital services utilization among children with asthma, the most prevalent chronic disease of childhood. Design, Setting, and Patients Retrospective study of insurance claims for 8834 US children with asthma who initiated asthma control therapy between 1997 and 2007. Using variation in out-of-pocket costs for a fixed "basket" of asthma medications across 37 employers, we estimated multivariate models of asthma medication use, asthma-related hospitalization, and emergency department (ED) visits with respect to out-of-pocket costs and child and family characteristics. Main Outcome Measures Asthma medication use, asthma-related hospitalizations, and ED visits during 1-year follow-up. Results The mean annual out-of-pocket asthma medication cost was $154 (95% CI, $152-$156) among children aged 5 to 18 years and $151 (95% CI, $148-$153) among those younger than 5 years. Among 5913 children aged 5 to 18 years, filled asthma prescriptions covered a mean of 40.9% of days (95% CI, 40.2%-41.5%). During 1-year follow-up, 121 children (2.1%) had an asthma-related hospitalization and 220 (3.7%) had an ED visit. Among 2921 children younger than 5 years, mean medication use was 46.2% of days (95% CI, 45.2%-47.1%); 136 children (4.7%) had an asthma-related hospitalization and 231 (7.9%) had an ED visit. An increase in out-of-pocket medication costs from the 25th to the 75th percentile was associated with a reduction in adjusted medication use among children aged 5 to 18 years (41.7% [95% CI, 40.7%-42.7%] vs 40.3% [95% CI, 39.4%-41.3%] of days; P=.02) but no change among younger children. Adjusted rates of asthma-related hospitalization were higher for children aged 5 to 18 years in the top quartile of out-of-pocket costs (2.4 [95% CI, 1.9-2.8] hospitalizations per 100 children vs 1.7 [95% CI, 1.3-2.1] per 100 in bottom quartile; P=.004) but not for younger children. Annual adjusted rates of ED use did not vary across out-of-pocket quartiles for either age group. Conclusion Greater cost sharing for asthma medications was associated with a slight reduction in medication use and higher rates of asthma hospitalization among children aged 5 years or older. JAMA. 2012;307(12):1284-1291 www.jama.com	[Jena, Anupam B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wang Ambulatory Care Ctr,Dept Med, Boston, MA 02114 USA; [Karaca-Mandic, Pinar] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA; [Joyce, Geoffrey F.; Goldman, Dana P.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Southern California	Jena, AB (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wang Ambulatory Care Ctr,Dept Med, 15 Parkman St, Boston, MA 02114 USA.	jena.anupam@mgh.harvard.edu	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396	National Institute of Child Health and Human Development [1R03HD058203-01A1]; National Institute on Aging [7R01AG02514]; Roybal Center for Health Policy Simulation [5P30AG024968]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD058203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024968] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Roybal Center for Health Policy Simulation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Support was provided by the National Institute of Child Health and Human Development (grant 1R03HD058203-01A1), the National Institute on Aging (grant 7R01AG02514), and the Roybal Center for Health Policy Simulation (grant 5P30AG024968).	Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Akinbami Lara, 2006, Adv Data, P1; [Anonymous], 2010, FED REGISTER, V75, P41726; Bethell CD, 2008, MATERN CHILD HLTH J, V12, P1, DOI 10.1007/s10995-007-0220-5; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Chandra A, 2010, AM ECON REV, V100, P193, DOI 10.1257/aer.100.1.193; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; Erickson SR, 2001, ANN PHARMACOTHER, V35, P997, DOI 10.1345/aph.10379; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Goldman DP, 2006, HEALTH AFFAIR, V25, P1319, DOI 10.1377/hlthaff.25.5.1319; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Goldman DP, 2006, AM J MANAG CARE, V12, P21; Halterman JS, 2000, PEDIATRICS, V105, P272; HENRY RL, 1995, J PAEDIATR CHILD H, V31, P95, DOI 10.1111/j.1440-1754.1995.tb00754.x; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Huskamp HA, 2005, ARCH GEN PSYCHIAT, V62, P435, DOI 10.1001/archpsyc.62.4.435; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; Johnson TJ, 2006, AM J PUBLIC HEALTH, V96, P709, DOI 10.2105/AJPH.2004.059758; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Karaca-Mandic P, 2010, HEALTH SERV RES, V45, P1227, DOI 10.1111/j.1475-6773.2010.01117.x; Kogan MD, 2010, NEW ENGL J MED, V363, P841, DOI 10.1056/NEJMsa0909994; Kozyrskyj AL, 2003, PEDIATR PULM, V36, P241, DOI 10.1002/ppul.10335; Kozyrskyj AL, 2001, ARCH PEDIAT ADOL MED, V155, P1219; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; Ungar WJ, 2008, ARCH PEDIAT ADOL MED, V162, P104, DOI 10.1001/archpediatrics.2007.21; Ungar WJ, 2011, ANN ALLERG ASTHMA IM, V106, P17, DOI 10.1016/j.anai.2010.10.006; US Census Bureau, 2010, CURR POP SURV ANN SO	32	81	81	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1284	1291		10.1001/jama.2012.340	http://dx.doi.org/10.1001/jama.2012.340			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	914UP	22453569	Bronze, Green Accepted			2022-12-28	WOS:000301978400024
J	Schaller, T; Goujon, C; Malim, MH				Schaller, Torsten; Goujon, Caroline; Malim, Michael H.			HIV Interplay with SAMHD1	SCIENCE			English	Editorial Material							RESTRICTION FACTOR SAMHD1; IMMUNODEFICIENCY-VIRUS TYPE-1; DENDRITIC CELLS; VPX; PROTEIN; INFECTION		[Schaller, Torsten; Goujon, Caroline; Malim, Michael H.] Kings Coll London, Guys Hosp, Sch Med, Dept Infect Dis, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Schaller, T (corresponding author), Kings Coll London, Guys Hosp, Sch Med, Dept Infect Dis, London SE1 9RT, England.	michael.malim@kcl.ac.uk	Goujon, Caroline/B-3914-2014; Schaller, Torsten/ABC-9153-2020	Goujon, Caroline/0000-0001-8571-1108; Schaller, Torsten/0000-0001-9597-4112; Malim, Michael/0000-0002-7699-2064	Medical Research Council [G0401570, G1000196, G1001081] Funding Source: Medline; MRC [G1000196, G1001081, G0401570] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berger A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002425; Genovesio A, 2011, J BIOMOL SCREEN, V16, P945, DOI 10.1177/1087057111415521; Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623; Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Laguette N, 2012, CELL HOST MICROBE, V11, P205, DOI 10.1016/j.chom.2012.01.007; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236; Lim ES, 2012, CELL HOST MICROBE, V11, P194, DOI 10.1016/j.chom.2012.01.004; Malim M. H., 2012, HIV BIOL PREVENTION, P119; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628; Yan N, 2010, NAT IMMUNOL, V11, P1005, DOI 10.1038/ni.1941	13	16	17	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1313	1314		10.1126/science.1221057	http://dx.doi.org/10.1126/science.1221057			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422971				2022-12-28	WOS:000301531600035
J	Comi, G; Jeffery, D; Kappos, L; Montalban, X; Boyko, A; Rocca, MA; Filippi, M				Comi, Giancarlo; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Alexey; Rocca, Maria A.; Filippi, Massimo		ALLEGRO Study Grp	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; MULTICENTER; MS	BACKGROUND Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing-remitting multiple sclerosis. METHODS We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients with relapsing-remitting multiple sclerosis were randomly assigned in a 1: 1 ratio to receive oral laquinimod at a dose of 0.6 mg once daily or placebo for 24 months. The primary end point was the annualized relapse rate during the 24-month period. Secondary end points included confirmed disability progression (defined as an increase in the score on the Expanded Disability Status Scale that was sustained for at least 3 months) and the cumulative number of gadolinium-enhancing lesions and new or enlarging lesions on T-2-weighted magnetic resonance imaging. RESULTS Treatment with laquinimod as compared with placebo was associated with a modest reduction in the mean (+/- SE) annualized relapse rate (0.30 +/- 0.02 vs. 0.39 +/- 0.03, P = 0.002) and with a reduction in the risk of confirmed disability progression (11.1% vs. 15.7%; hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.91; P = 0.01). The mean cumulative numbers of gadolinium-enhancing lesions and new or enlarging lesions on T-2-weighted images were lower for patients receiving laquinimod than for those receiving placebo (1.33 +/- 0.14 vs. 2.12 +/- 0.22 and 5.03 +/- 0.08 vs. 7.14 +/- 0.07, respectively; P<0.001 for both comparisons). Transient elevations in alanine aminotransferase levels to greater than three times the upper limit of the normal range were observed in 24 patients receiving laquinimod (5%) and 8 receiving placebo (2%). CONCLUSIONS In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis. (Funded by Teva Pharmaceutical Industries; ClinicalTrials.gov number, NCT00509145.)	[Comi, Giancarlo; Filippi, Massimo] Univ Vita Salute San Raffaele, Dept Neurol, Milan, Italy; [Comi, Giancarlo; Filippi, Massimo] Univ Vita Salute San Raffaele, Inst Expt Neurol, Milan, Italy; [Rocca, Maria A.; Filippi, Massimo] Inst Expt Neurol, Neuroimaging Res Unit, Milan, Italy; [Jeffery, Douglas] Advance Neurol & Pain, Advance, NC USA; [Kappos, Ludwig] Univ Basel, Dept Neurol, Univ Hosp, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Dept Biomed, Univ Hosp, Basel, Switzerland; [Montalban, Xavier] Vall dHebron Univ Hosp, Unit Clin Neuroimmunol, Barcelona, Spain; [Montalban, Xavier] Univ Autonoma Barcelona, E-08193 Barcelona, Spain; [Boyko, Alexey] Russian State Med Univ, Dept Neurol & Neurosurg, Moscow 117437, Russia; [Boyko, Alexey] Moscow Multiple Sclerosis Ctr, Moscow, Russia	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; University of Basel; University of Basel; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Pirogov Russian National Research Medical University	Comi, G (corresponding author), Univ Vita Salute, Inst Expt Neurol, Dept Neurol, San Raffaele Sci Inst, Via Olgettina 48, I-20132 Milan, Italy.	comi.giancarlo@hsr.it	Nehrych, Tetyana I/L-7555-2016; Loganovsky, Konstantin/E-2136-2016; absinta, martina/Z-1698-2019; Boyko, Alexey N/Z-2106-2018; Brola, Waldemar/D-8813-2014; Filippi, Massimo/K-1755-2018; Rocca, Maria Assunta/K-1619-2018; Calabrese, Massimiliano/I-6195-2012; Aladro, Yolanda/GSE-3319-2022; Kremenchutzky, Marcelo/B-6413-2015; LICEND, CEMND/F-1296-2015; Ruiz, Luis Brieva/C-3812-2011; Macedo, Ana/L-9912-2018; Montalban, Xavier/J-5938-2016; Milanov, Ivan/D-4318-2015	Nehrych, Tetyana I/0000-0003-0170-511X; Loganovsky, Konstantin/0000-0002-0680-8882; absinta, martina/0000-0003-0276-383X; Brola, Waldemar/0000-0002-7955-3454; Filippi, Massimo/0000-0002-5485-0479; Rocca, Maria Assunta/0000-0003-2358-4320; Aladro, Yolanda/0000-0001-9459-5452; Ruiz, Luis Brieva/0000-0002-5871-6189; Macedo, Ana/0000-0002-6978-8989; Montalban, Xavier/0000-0002-0098-9918; Moskovko, Sergii/0000-0003-3910-2672; Chan, Andrew/0000-0003-3434-7283; Taba, Pille/0000-0002-1315-1065; Boyko, Alexei/0000-0003-3306-9541; Milanov, Ivan/0000-0002-4522-4070; Karni, Arnonk/0000-0002-5625-7900; Jasinska, Elzbieta/0000-0003-0016-9896	Teva Pharmaceutical Industries [NCT00509145]	Teva Pharmaceutical Industries(Teva Pharmaceutical Industries)	Funded by Teva Pharmaceutical Industries; ClinicalTrials.gov number, NCT00509145.); Supported by Teva Pharmaceutical Industries.	Brueck W, 2011, J NEUROL SCI, V306, P173, DOI 10.1016/j.jns.2011.02.019; Comi G, 2008, LANCET, V371, P2085, DOI 10.1016/S0140-6736(08)60918-6; Comi G, 2010, MULT SCLER, V16, P1360, DOI 10.1177/1352458510378127; Comi G, 2009, MULT SCLER, V15, pS127; Cutter GR, 1999, BRAIN, V122, P871, DOI 10.1093/brain/122.5.871; Jonsson S, 2004, J MED CHEM, V47, P2075, DOI 10.1021/jm031044w; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Noseworthy JH, 2000, NEUROLOGY, V54, P1726, DOI 10.1212/WNL.54.9.1726; Polman C, 2005, NEUROLOGY, V64, P987, DOI 10.1212/01.WNL.0000154520.48391.69; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Preiningerova J, 2009, EXPERT OPIN INV DRUG, V18, P985, DOI 10.1517/13543780903044944; SIENA and SIENAX, SIENA SIENAX OXF UK; Temple R, 2006, PHARMACOEPIDEM DR S, V15, P241, DOI 10.1002/pds.1211	13	286	297	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2012	366	11					1000	1009		10.1056/NEJMoa1104318	http://dx.doi.org/10.1056/NEJMoa1104318			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HZ	22417253	Green Published, Green Submitted			2022-12-28	WOS:000301482800003
J	Coric, I; List, B				Coric, Ilija; List, Benjamin			Asymmetric spiroacetalization catalysed by confined Bronsted acids	NATURE			English	Article							TRANSITION-METAL CATALYSIS; DACUS-OLEAE; SPIROKETALS; TRANSACETALIZATION; PHOSPHORAMIDE; DERIVATIVES; PHEROMONE; ALDEHYDES; DESIGN	Acetals are molecular substructures that contain two oxygencarbon single bonds at the same carbon atom, and are used in cells to construct carbohydrates and numerous other molecules. A distinctive subgroup are spiroacetals, acetals joining two rings, which occur in a broad range of biologically active compounds, including small insect pheromones and more complex macrocycles(1,2). Despite numerous methods for the catalytic asymmetric formation of other commonly occurring stereocentres, there are few approaches that exclusively target the chiral acetal centre and none for spiroacetals(3,4). Here we report the design and synthesis of confined Bronsted acids based on a C-2-symmetric imidodiphosphoric acid motif, enabling a catalytic enantioselective spiroacetalization reaction. These rationally constructed Bronsted acids possess an extremely sterically demanding chiral microenvironment, with a single catalytically relevant and geometrically constrained bifunctional active site. Our catalyst design is expected to be of broad utility in catalytic asymmetric reactions involving small and structurally or functionally unbiased substrates.	[Coric, Ilija; List, Benjamin] Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany	Max Planck Society	List, B (corresponding author), Max Planck Inst Kohlenforsch, Kaiser Wilhelm Pl 1, D-45470 Mulheim, Germany.	list@kofo.mpg.de	Coric, Ilija/AFP-1494-2022; List, Benjamin/A-2121-2014	Coric, Ilija/0000-0002-0435-1313; 	Max Planck Sociey; European Research Council	Max Planck Sociey(Max Planck Society); European Research Council(European Research Council (ERC)European Commission)	We thank A. Dreier and R. Goddard for crystal structure analysis of catalyst 6a. S. Vellalath and S. Muller are acknowledged for donating several previously described catalysts, and N. Wippich and S. Dehn for technical assistance. We gratefully acknowledge support from the Max Planck Sociey and the European Research Council.	Aho JE, 2005, CHEM REV, V105, P4406, DOI 10.1021/cr050559n; Akiyama T, 2004, ANGEW CHEM INT EDIT, V43, P1566, DOI 10.1002/anie.200353240; Akiyama T, 2007, CHEM REV, V107, P5744, DOI 10.1021/cr068374j; Audrain H, 2000, J ORG CHEM, V65, P4487, DOI 10.1021/jo9918596; Brasholz M, 2007, EUR J ORG CHEM, V2007, P3801, DOI 10.1002/ejoc.200601054; Coric I, 2010, J AM CHEM SOC, V132, P17370, DOI 10.1021/ja108642s; Coric I, 2010, J AM CHEM SOC, V132, P8536, DOI 10.1021/ja102753d; Doyle AG, 2007, CHEM REV, V107, P5713, DOI 10.1021/cr068373r; Hamilton GL, 2007, SCIENCE, V317, P496, DOI 10.1126/science.1145229; HANIOTAKIS G, 1986, J CHEM ECOL, V12, P1559, DOI 10.1007/BF01012372; Hastings CJ, 2010, J AM CHEM SOC, V132, P6938, DOI 10.1021/ja102633e; Huang Y, 2003, NATURE, V424, P146, DOI 10.1038/424146a; Klussmann M, 2010, SYNLETT, P2189, DOI 10.1055/s-0030-1258505; Mayer S, 2006, ANGEW CHEM INT EDIT, V45, P4193, DOI 10.1002/anie.200600512; Moilanen SB, 2006, J AM CHEM SOC, V128, P1792, DOI 10.1021/ja057908f; Mukherjee S, 2007, J AM CHEM SOC, V129, P11336, DOI 10.1021/ja074678r; Nagano H, 2002, CHEM LETT, P782, DOI 10.1246/cl.2002.782; Nakashima D, 2006, J AM CHEM SOC, V128, P9626, DOI 10.1021/ja062508t; PERRON F, 1989, CHEM REV, V89, P1617, DOI 10.1021/cr00097a015; REDLICH H, 1984, ANGEW CHEM INT EDIT, V23, P519, DOI 10.1002/anie.198405191; Shapiro ND, 2011, NATURE, V470, P245, DOI 10.1038/nature09723; Shenoy SR, 2008, J AM CHEM SOC, V130, P5658, DOI 10.1021/ja801107r; Takahashi S, 2011, NAT CHEM BIOL, V7, P461, DOI [10.1038/NCHEMBIO.583, 10.1038/nchembio.583]; Takaoka LR, 2005, J AM CHEM SOC, V127, P528, DOI 10.1021/ja044642o; Uraguchi D, 2004, J AM CHEM SOC, V126, P5356, DOI 10.1021/ja0491533; Vellalath S, 2010, ANGEW CHEM INT EDIT, V49, P9749, DOI 10.1002/anie.201005347; WALL ME, 1954, J AM CHEM SOC, V76, P2849, DOI 10.1021/ja01639a086; Xu FX, 2010, J ORG CHEM, V75, P8677, DOI 10.1021/jo101640z; Zhang QW, 2009, ANGEW CHEM INT EDIT, V48, P8572, DOI 10.1002/anie.200904565; Zinzalla G, 2006, ORG BIOMOL CHEM, V4, P1977, DOI 10.1039/b603015g	30	321	324	8	290	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					315	319		10.1038/nature10932	http://dx.doi.org/10.1038/nature10932			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22422266				2022-12-28	WOS:000301481800045
J	Stark, J				Stark, James			MEDICAL CLASSICS A New Electronic Theory of Life (1925)	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Stark, James] Univ Leeds, Leeds, W Yorkshire, England; [Stark, James] Thackray Museum, Leeds, W Yorkshire, England	University of Leeds	Stark, J (corresponding author), Univ Leeds, Leeds, W Yorkshire, England.	J.F.Stark@leeds.ac.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e2032	10.1136/bmj.e2032	http://dx.doi.org/10.1136/bmj.e2032			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418425				2022-12-28	WOS:000301847600025
J	Lindhardsen, J; Ahlehoff, O; Gislason, GH; Madsen, OR; Olesen, JB; Svendsen, JH; Torp-Pedersen, C; Hansen, PR				Lindhardsen, Jesper; Ahlehoff, Ole; Gislason, Gunnar Hilmar; Madsen, Ole Rintek; Olesen, Jonas Bjerring; Svendsen, Jesper Hastrup; Torp-Pedersen, Christian; Hansen, Peter Riis			Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK; HEART-FAILURE; INFLAMMATION; MORTALITY; DISEASE; PERPETUATION; PREVALENCE; REGISTER; ALCOHOL	Objectives To determine if patients with rheumatoid arthritis have increased risk of atrial fibrillation and stroke. Design Longitudinal nationwide register based cohort study. Setting Inpatient and outpatient hospital care in Denmark from 1997 to 2009. Participants Entire Danish population aged over 15 years without rheumatoid arthritis, atrial fibrillation, or stroke before 1997. Participants with rheumatoid arthritis were identified by individual level linkage of diagnoses and rheumatoid arthritis treatment. Main outcome measures Rates of atrial fibrillation and stroke. Results Of 4 182 335 participants included in the cohort, 18 247 were identified as having rheumatoid arthritis during follow-up, with a mean age at disease onset of 59.2 years and a median follow-up of 4.8 years. A total of 156 484 people, including 774 with rheumatoid arthritis, were diagnosed as having atrial fibrillation (age and sex matched event rates of 8.2 per 1000 person years in rheumatoid arthritis patients and 6.0 per 1000 person years in the general population), with an adjusted incidence rate ratio of 1.41 (95% confidence interval 1.31 to 1.51). In addition, 165 343 people, including 718 with rheumatoid arthritis, had a stroke (7.6 per 1000 person years in rheumatoid arthritis and 5.7 per 1000 person years in the general population), with a resultant rate ratio of 1.32 (1.22 to 1.42). For both atrial fibrillation and stroke, relative risks were increased in all strata based on thirds of sex and age, with higher relative risks in younger patients but higher absolute risk differences in older patients. Conclusions Rheumatoid arthritis was associated with an increased incidence of atrial fibrillation and stroke. The novel finding of increased risk of atrial fibrillation in rheumatoid arthritis suggests that this arrhythmia is relevant in cardiovascular risk assessment of these patients.	[Lindhardsen, Jesper; Ahlehoff, Ole; Gislason, Gunnar Hilmar; Olesen, Jonas Bjerring; Torp-Pedersen, Christian; Hansen, Peter Riis] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark; [Madsen, Ole Rintek] Univ Copenhagen, Gentofte Hosp, Dept Internal Med, Rheumatol Sect, DK-2900 Hellerup, Denmark; [Svendsen, Jesper Hastrup] Copenhagen Univ Hosp, Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen O, Denmark; [Svendsen, Jesper Hastrup] Danish Natl Res Fdn Ctr Cardiac Arrhythmia DARC, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Lindhardsen, J (corresponding author), Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark.	jeslin01@geh.regionh.dk	Gislason, Gunnar/B-7561-2009; Svendsen, Jesper Hastrup/G-8573-2017; Hansen, Peter Riis/AAR-7659-2020	Gislason, Gunnar/0000-0002-0548-402X; Svendsen, Jesper Hastrup/0000-0001-8466-8515; Hansen, Peter Riis/0000-0002-9056-535X	Danish Rheumatism Association	Danish Rheumatism Association	JL has received an unrestricted grant from the Danish Rheumatism Association. The funding source had no influence on the study design, interpretation of results, or decision to submit the article. Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Andersen TF, 1999, DAN MED BULL, V46, P263; Boyer JF, 2011, JOINT BONE SPINE, V78, P179, DOI 10.1016/j.jbspin.2010.07.016; Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Christiansen CF, 2009, ARCH INTERN MED, V169, P1677, DOI 10.1001/archinternmed.2009.297; De Caterina R, 2010, ARCH INTERN MED, V170, P1450, DOI 10.1001/archinternmed.2010.305; Engelmann MDM, 2005, EUR HEART J, V26, P2083, DOI 10.1093/eurheartj/ehi350; Frost L, 2004, ARCH INTERN MED, V164, P1993, DOI 10.1001/archinte.164.18.1993; Frost L, 2007, AM J MED, V120, P47, DOI 10.1016/j.amjmed.2005.12.027; Gaist D, 1997, DAN MED BULL, V44, P445; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Goulenok TM, 2010, JOINT BONE SPINE, V77, P146, DOI 10.1016/j.jbspin.2010.01.001; Guler H, 2007, RHEUMATOL INT, V27, P813, DOI 10.1007/s00296-007-0307-8; Hannawi S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2323; Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825; Holmqvist ME, 2010, ANN RHEUM DIS     S3, V69, P109; Issac TT, 2007, J AM COLL CARDIOL, V50, P2021, DOI 10.1016/j.jacc.2007.06.054; Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143; Levy L, 2008, CLIN EXP RHEUMATOL, V26, P673; Liang KP, 2006, ARTHRITIS RHEUM-US, V54, P642, DOI 10.1002/art.21628; Liu T, 2007, J AM COLL CARDIOL, V49, P1642, DOI 10.1016/j.jacc.2006.12.042; Mahrholdt H, 2007, HEART, V93, P122, DOI 10.1136/hrt.2005.071290; Maki-Petaja KM, 2010, ARTERY RES, V4, P99, DOI 10.1016/j.artres.2010.10.002; Meune C, 2010, ARCH CARDIOVASC DIS, V103, P253, DOI 10.1016/j.acvd.2010.03.007; Meune C, 2009, RHEUMATOLOGY, V48, P1309, DOI 10.1093/rheumatology/kep252; Mitchell GF, 2007, JAMA-J AM MED ASSOC, V297, P709, DOI 10.1001/jama.297.7.709; Mukamal KJ, 2005, CIRCULATION, V112, P1736, DOI 10.1161/CIRCULATIONAHA.105.547844; Nicola PJ, 2006, ARTHRITIS RHEUM-US, V54, P60, DOI 10.1002/art.21560; Olesen Jonas Bjerring, 2011, BMJ, V342, pd124, DOI 10.1136/bmj.d124; Pedersen Jens K, 2007, Open Rheumatol J, V1, P18, DOI 10.2174/1874312900701010018; Peters MJL, 2010, ANN RHEUM DIS, V69, P325, DOI 10.1136/ard.2009.113696; Singh JA, 2004, ARTHRIT RHEUM-ARTHR, V51, P952, DOI 10.1002/art.20827; Sodergren A, 2009, CLIN EXP RHEUMATOL, V27, P641; Solomon DH, 2006, ANN RHEUM DIS, V65, P1608, DOI 10.1136/ard.2005.050377; Solomon DH, 2010, ANN RHEUM DIS, V69, P1920, DOI 10.1136/ard.2009.122226; Solomon DH, 2003, CIRCULATION, V107, P1303, DOI 10.1161/01.CIR.0000054612.26458.B2; Tanasescu C, 2009, EUR J INTERN MED, V20, P348, DOI 10.1016/j.ejim.2008.09.005; TLUSTOCHOWICZ W, 1995, EUR HEART J, V16, P848, DOI 10.1093/oxfordjournals.eurheartj.a061005; van Eijk IC, 2011, CLIN RHEUMATOL, V30, P1113, DOI 10.1007/s10067-011-1750-1; van Sijl AM, 2011, SEMIN ARTHRITIS RHEU, V40, P389, DOI 10.1016/j.semarthrit.2010.06.006; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Weber T, 2010, ARTERY RES, V4, P122, DOI 10.1016/j.artres.2010.10.033; Wislowska M, 1999, RHEUMATOL INT, V18, P163, DOI 10.1007/s002960050079; Wolfe F, 2004, AM J MED, V116, P305, DOI 10.1016/j.amjmed.2003.09.039; Wolfe F, 2003, J RHEUMATOL, V30, P36; Yavuzkir M, 2007, J INT MED RES, V35, P796, DOI 10.1177/147323000703500608	45	115	120	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 8	2012	344								e1257	10.1136/bmj.e1257	http://dx.doi.org/10.1136/bmj.e1257			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908HL	22403267	hybrid, Green Published			2022-12-28	WOS:000301481400002
J	Dupuis-Girod, S; Ginon, I; Saurin, JC; Marion, D; Guillot, E; Decullier, E; Roux, A; Carette, MF; Gilbert-Dussardier, B; Hatron, PY; Lacombe, P; Lorcerie, B; Riviere, S; Corre, R; Giraud, S; Bailly, S; Paintaud, G; Ternant, D; Valette, PJ; Plauchu, H; Faure, F				Dupuis-Girod, Sophie; Ginon, Isabelle; Saurin, Jean-Christophe; Marion, Denis; Guillot, Elsa; Decullier, Evelyne; Roux, Adeline; Carette, Marie-France; Gilbert-Dussardier, Brigitte; Hatron, Pierre-Yves; Lacombe, Pascal; Lorcerie, Bernard; Riviere, Sophie; Corre, Romain; Giraud, Sophie; Bailly, Sabine; Paintaud, Gilles; Ternant, David; Valette, Pierre-Jean; Plauchu, Henri; Faure, Frederic			Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NASAL-SEPTUM PERFORATION; QUALITY-OF-LIFE; LIVER-TRANSPLANTATION; INVOLVEMENT; FLUOROURACIL; LEUCOVORIN; MUTATIONS; DOPPLER; GENE	Context The only treatment available to restore normal cardiac output in patients with hereditary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant. Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment. Objectives To test the efficacy of bevacizumab in reducing high cardiac output in severe hepatic forms of HHT and to assess improvement in epistaxis duration and quality of life. Design, Setting, and Patients Single-center, phase 2 trial with national recruitment from the French HHT Network. Patients were 18 to 70 years old and had confirmed HHT, severe liver involvement, and a high cardiac index related to HHT. Intervention Bevacizumab, 5 mg per kg, every 14 days for a total of 6 injections. The total duration of the treatment was 2.5 months; patients were followed up for 6 months after the beginning of the treatment. Main Outcome Measure Decrease in cardiac output at 3 months after the first injection, evaluated by echocardiography. Results A total of 25 patients were included between March 2009 and November 2010. Of the 24 patients who had echocardiograms available for reread, there was a response in 20 of 24 patients with normalization of cardiac index (complete response [CR]) in 3 of 24, partial response (PR) in 17 of 24, and no response in 4 cases. Median cardiac index at beginning of the treatment was 5.05 L/min/m(2) (range, 4.1-6.2) and significantly decreased at 3 months after the beginning of the treatment with a median cardiac index of 4.2 L/min/m(2) (range, 2.9-5.2; P<.001). Median cardiac index at 6 months was significantly lower than before treatment (4.1 L/min/m(2); range, 3.0-5.1). Among 23 patients with available data at 6 months, we observed CR in 5 cases, PR in 15 cases, and no response in 3 cases. Mean duration of epistaxis, which was 221 minutes per month (range, 0-947) at inclusion, had significantly decreased at 3 months (134 minutes; range, 0-656) and 6 months (43 minutes; range, 0-310) (P=.008). Quality of life had significantly improved. The most severe adverse events were 2 cases of grade 3 systemic hypertension, which were successfully treated. Conclusion In this preliminary study of patients with HHT associated with severe hepatic vascular malformations and high cardiac output, administration of bevacizumab was associated with a decrease in cardiac output and reduced duration and number of episodes of epistaxis.	[Dupuis-Girod, Sophie; Plauchu, Henri] Hop Louis Pradel, Hosp Civils Lyon, Dept Genet, F-69677 Bron, France; [Dupuis-Girod, Sophie; Plauchu, Henri] Natl Reference Ctr Rendu Osler Dis, Bron, France; [Dupuis-Girod, Sophie; Decullier, Evelyne; Plauchu, Henri] Univ Lyon 1, Sch Med, F-69622 Villeurbanne, France; [Ginon, Isabelle] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Dept Cardiol, F-69310 Pierre Benite, France; [Marion, Denis; Guillot, Elsa; Valette, Pierre-Jean] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Dept Radiol, F-69310 Pierre Benite, France; [Saurin, Jean-Christophe] Hop Edouard Herriot, Hosp Civils Lyon, Hepatogastroenterol Dept, Lyon, France; [Faure, Frederic] Hop Edouard Herriot, Hosp Civils Lyon, Dept Head & Neck Surg, Lyon, France; [Decullier, Evelyne; Roux, Adeline] Pole IMER, Hosp Civils Lyon, Lyon, France; [Carette, Marie-France] Univ Paris 06, Hop Tenon, AP HP, Dept Radiol, Paris, France; [Gilbert-Dussardier, Brigitte] CHU La Miletrie, Dept Genet, Poitiers, France; [Hatron, Pierre-Yves] Univ Lille 2, CHRU Lille, Dept Internal Med, Lille, France; [Lacombe, Pascal] Univ Boulogne, Hop Ambroise Pare, AP HP, Dept Radiol, Paris Ile France Ouest, France; [Lorcerie, Bernard] Hop Dijon, Dept Internal Med, Dijon, France; [Riviere, Sophie] CHU Montpellier, Dept Internal Med, Montpellier, France; [Corre, Romain] Hop Pontchaillou, Rennes, France; [Giraud, Sophie] Hop Edouard Herriot, Hosp Civils Lyon, Mol Biol Lab, Lyon, France; [Bailly, Sabine] INSERM, U1036, Grenoble, France; [Paintaud, Gilles; Ternant, David] Univ Tours, CNRS, UMR 6239, Tours, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Franche-Comte; CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Universite de Montpellier; CHU de Montpellier; CHU Rennes; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Tours	Dupuis-Girod, S (corresponding author), Hop Louis Pradel, Hosp Civils Lyon, Dept Genet, F-69677 Bron, France.	sophie.dupuis-girod@chu-lyon.fr	Dupuis-Girod, Sophie/D-6268-2014; Gilly, François Noël FN/C-9450-2014; saurin, jean christophe/AAB-4077-2020; bailly, sabine/G-3540-2013; decullier, evelyne/AAL-5861-2021	Gilly, François Noël FN/0000-0003-3808-6244; bailly, sabine/0000-0003-1043-7030; Dupuis-Girod, Sophie/0000-0002-8834-5526; PAINTAUD, Gilles/0000-0003-0158-1356; GILBERT-DUSSARDIER, Brigitte/0000-0001-7182-9914	Hospices Civils de Lyon; National Research Program; Roche Laboratories; European Union; European Regional Development Fund	Hospices Civils de Lyon; National Research Program; Roche Laboratories; European Union(European Commission); European Regional Development Fund(European Commission)	This work was financed by the institution (Hospices Civils de Lyon) with a grant supported by the National Research Program (PHRC 2009 and 2010) and by Roche Laboratories, which also provided the drug. Measurement of bevacizumab serum concentrations were carried out within the CePiBAc platform. CePiBAc is cofinanced by the European Union. Europe is committed to the region Centre with the European Regional Development Fund.	Buonamico P, 2008, J HEPATOL, V48, P811, DOI 10.1016/j.jhep.2007.12.022; Buscarini E, 2004, ULTRASCHALL MED, V25, P348, DOI 10.1055/s-2004-813549; Buscarini E, 2006, LIVER INT, V26, P1040, DOI 10.1111/j.1478-3231.2006.01340.x; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Dupuis-Girod S, 2010, LIVER TRANSPLANT, V16, P340, DOI 10.1002/lt.21990; Fakih MG, 2006, ONCOLOGIST, V11, P85, DOI 10.1634/theoncologist.11-1-85; Faughnan ME, 2011, J MED GENET, V48, P73, DOI 10.1136/jmg.2009.069013; Faughnan ME, 2009, EUR RESPIR J, V33, P1186, DOI 10.1183/09031936.00061308; Flieger D, 2006, ANN HEMATOL, V85, P631, DOI 10.1007/s00277-006-0147-8; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Garcia-Tsao G, 2007, J HEPATOL, V46, P499, DOI 10.1016/j.jhep.2006.12.008; GEHAN EA, 1961, J CHRON DIS, V13, P346, DOI 10.1016/0021-9681(61)90060-1; Geisthoff UW, 2007, OTOLARYNG HEAD NECK, V136, P726, DOI 10.1016/j.otohns.2006.12.019; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Khalid SK, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.037; Lerut J, 2006, ANN SURG, V244, P854, DOI 10.1097/01.sla.0000247258.35406.a4; Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mitchell A, 2008, LIVER TRANSPLANT, V14, P210, DOI 10.1002/lt.21417; Pasculli G, 2004, QUAL LIFE RES, V13, P1715, DOI 10.1007/s11136-004-7865-y; Ruiz N, 2007, J CLIN ONCOL, V25, P3376, DOI 10.1200/JCO.2007.12.0006; Saif MW, 2006, EXPERT OPIN DRUG SAF, V5, P553, DOI 10.1517/14740338.5.4.553; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; Simonds J, 2009, LARYNGOSCOPE, V119, P988, DOI 10.1002/lary.20159; Ternant D, 2010, THER DRUG MONIT, V32, P647, DOI 10.1097/FTD.0b013e3181ef582a; Traina TA, 2006, ONCOLOGIST, V11, P1070, DOI 10.1634/theoncologist.11-10-1070; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	30	222	235	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					948	955		10.1001/jama.2012.250	http://dx.doi.org/10.1001/jama.2012.250			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396517	Bronze			2022-12-28	WOS:000301172100023
J	Metzger, T; Gache, V; Xu, M; Cadot, B; Folker, ES; Richardson, BE; Gomes, ER; Baylies, MK				Metzger, Thomas; Gache, Vincent; Xu, Mu; Cadot, Bruno; Folker, Eric S.; Richardson, Brian E.; Gomes, Edgar R.; Baylies, Mary K.			MAP and kinesin-dependent nuclear positioning is required for skeletal muscle function	NATURE			English	Article							DROSOPHILA-MELANOGASTER; NEUROMUSCULAR-JUNCTION; MYOBLAST FUSION; PROTEIN; IDENTIFICATION; CELLS; LOCALIZATION; MICROTUBULES; MICE; DIFFERENTIATION	The basic unit of skeletal muscle in all metazoans is the multinucleate myofibre, within which individual nuclei are regularly positioned(1). The molecular machinery responsible for myonuclear positioning is not known. Improperly positioned nuclei are a hallmark of numerous diseases of muscle(2), including centronuclear myopathies(3), but it is unclear whether correct nuclear positioning is necessary for muscle function. Here we identify the microtubule-associated protein ensconsin (Ens)/microtubule-associated protein 7 (MAP7) and kinesin heavy chain (Khc)/Kif5b as essential, evolutionarily conserved regulators of myonuclear positioning in Drosophila and cultured mammalian myotubes. We find that these proteins interact physically and that expression of the Kif5b motor domain fused to the MAP7 microtubule-binding domain rescues nuclear positioning defects in MAP7-depleted cells. This suggests that MAP7 links Kif5b to the microtubule cytoskeleton to promote nuclear positioning. Finally, we show that myonuclear positioning is physiologically important. Drosophila ens mutant larvae have decreased locomotion and incorrect myonuclear positioning, and these phenotypes are rescued by muscle-specific expression of Ens. We conclude that improper nuclear positioning contributes to muscle dysfunction in a cell-autonomous fashion.	[Gache, Vincent; Cadot, Bruno; Gomes, Edgar R.] Univ Paris 06, INSERM, UMR S 787, F-75634 Paris, France; [Metzger, Thomas; Xu, Mu; Folker, Eric S.; Richardson, Brian E.; Baylies, Mary K.] Sloan Kettering Inst, Program Dev Biol, New York, NY 10065 USA; [Metzger, Thomas; Baylies, Mary K.] Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10065 USA; [Gomes, Edgar R.] Grp Hosp Pitie Salpetriere, Inst Myol, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Memorial Sloan Kettering Cancer Center; Cornell University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Gomes, ER (corresponding author), Univ Paris 06, INSERM, UMR S 787, F-75634 Paris, France.	edgar.gomes@upmc.fr; m-baylies@ski.mskcc.org	Gomes, Edgar/ABH-7441-2020; GACHE, vincent/L-1990-2019; CADOT, bruno/E-1710-2013; Gomes, Edgar r/D-9000-2015; GACHE, Vincent/M-9556-2015	Gomes, Edgar/0000-0002-6941-4872; GACHE, vincent/0000-0002-2928-791X; CADOT, bruno/0000-0002-1888-3898; Gomes, Edgar r/0000-0002-6941-4872; GACHE, Vincent/0000-0002-2928-791X; Folker, Eric/0000-0003-1619-7330	National Institutes of Health (NIH) [GM056989, GM0781318]; Muscular Dystrophy Association (MDA); NIH [T32 BM008539]; Fondation pour la Recherche Medicale (FRM); Region Ile-de-France; INSERM Avenir; Agence Nationale de la Recherche (ANR); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008539, R01GM078318, R01GM056989] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Region Ile-de-France(Region Ile-de-France); INSERM Avenir(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Anderson, K. Hadjantonakis, A. Hall and D. Sassoon for comments on the manuscript. We thank the Baylies and Gomes Laboratories for discussions, and R. Fernandez-Gonzalez for his assistance in computational analysis. The initial screens in Drosophila were supported by National Institutes of Health (NIH) grants GM056989 and GM0781318 to M.B.; the Drosophila nuclear positioning analysis was supported by a Muscular Dystrophy Association (MDA) grant to M.B. T.M. was supported initially by NIH Training Grant T32 BM008539. B.C. was supported initially by a Fondation pour la Recherche Medicale (FRM) fellowship. V.G. was supported initially by a Region Ile-de-France fellowship. Mammalian work was supported by Muscular Dystrophy Association (MDA), INSERM Avenir programme and Agence Nationale de la Recherche (ANR) grants to E.R.G.	Bai J, 2007, DEV CELL, V13, P828, DOI 10.1016/j.devcel.2007.10.003; Beckett K, 2006, INT REV NEUROBIOL, V75, P55, DOI 10.1016/S0074-7742(06)75003-6; Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brent J., 2009, J VIS EXP, V1108, DOI [DOI 10.3791/1108, 10.3791/1108]; Brent Jonathan, 2009, J Vis Exp, DOI 10.3791/1108; Bruusgaard JC, 2003, J PHYSIOL-LONDON, V551, P467, DOI 10.1113/jphysiol.2003.045328; Bugnard E, 2005, CELL MOTIL CYTOSKEL, V60, P1, DOI 10.1002/cm.20042; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; De Palma C, 2010, CELL DEATH DIFFER, V17, P1684, DOI 10.1038/cdd.2010.48; FENG GP, 1995, GENETICS, V139, P1679; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Grady RM, 2005, P NATL ACAD SCI USA, V102, P4359, DOI 10.1073/pnas.0500711102; Guerin CM, 2009, DEVELOPMENT, V136, P1411, DOI 10.1242/dev.031823; Halfon MS, 2002, GENESIS, V34, P135, DOI 10.1002/gene.10136; Jungbluth H, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-26; Khatau SB, 2009, P NATL ACAD SCI USA, V106, P19017, DOI 10.1073/pnas.0908686106; Lei K, 2009, P NATL ACAD SCI USA, V106, P10207, DOI 10.1073/pnas.0812037106; Lewis E., 1968, METHOD FEEDING ETHAN; Louis M., 2008, J VIS, pe638, DOI [10.3791/638, DOI 10.3791/638]; Louis M, 2008, NAT NEUROSCI, V11, P187, DOI 10.1038/nn2031; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; McCabe BD, 2003, NEURON, V39, P241, DOI 10.1016/S0896-6273(03)00426-4; Meyerzon M, 2009, DEVELOPMENT, V136, P2725, DOI 10.1242/dev.038596; Mitchell KJ, 2010, NAT CELL BIOL, V12, P257, DOI 10.1038/ncb2025; Parlakian A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009299; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PENA P, 1993, BIOCHEM BIOPH RES CO, V195, P785, DOI 10.1006/bbrc.1993.2114; Prokop A, 1998, DEV BIOL, V196, P58, DOI 10.1006/dbio.1997.8830; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; Richardson BE, 2007, DEVELOPMENT, V134, P4357, DOI 10.1242/dev.010678; Richardson Brian E., 2008, V475, P263, DOI 10.1007/978-1-59745-250-2_15; Sung HH, 2008, DEV CELL, V15, P866, DOI 10.1016/j.devcel.2008.10.006; TASSIN AM, 1985, J CELL BIOL, V100, P35, DOI 10.1083/jcb.100.1.35; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Volk T, 1999, TRENDS GENET, V15, P448, DOI 10.1016/S0168-9525(99)01862-4; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	39	168	169	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					120	+		10.1038/nature10914	http://dx.doi.org/10.1038/nature10914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22425998	Green Accepted			2022-12-28	WOS:000302343400046
J	Garcia-Cao, I; Song, MS; Hobbs, RM; Laurent, G; Giorgi, C; de Boer, VCJ; Anastasiou, D; Ito, K; Sasaki, AT; Rameh, L; Carracedo, A; Vander Heiden, MG; Cantley, LC; Pinton, P; Haigis, MC; Pandolfi, PP				Garcia-Cao, Isabel; Song, Min Sup; Hobbs, Robin M.; Laurent, Gaelle; Giorgi, Carlotta; de Boer, Vincent C. J.; Anastasiou, Dimitrios; Ito, Keisuke; Sasaki, Atsuo T.; Rameh, Lucia; Carracedo, Arkaitz; Vander Heiden, Matthew G.; Cantley, Lewis C.; Pinton, Paolo; Haigis, Marcia C.; Pandolfi, Pier Paolo			Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State	CELL			English	Article							DNA-DAMAGE RESPONSE; C-MYC; CELL-SIZE; SIGNALING PATHWAY; PYRUVATE-KINASE; PHOSPHOINOSITIDE 3-KINASE; CANCER SUSCEPTIBILITY; GROWTH; DROSOPHILA; EXPRESSION	Decremental loss of PTEN results in cancer susceptibility and tumor progression. PTEN elevation might therefore be an attractive option for cancer prevention and therapy. We have generated several transgenic mouse lines with PTEN expression elevated to varying levels by taking advantage of bacterial artificial chromosome (BAC)-mediated transgenesis. The "Super-PTEN" mutants are viable and show reduced body size due to decreased cell number, with no effect on cell size. Unexpectedly, PTEN elevation at the organism level results in healthy metabolism characterized by increased energy expenditure and reduced body fat accumulation. Cells derived from these mice show reduced glucose and glutamine uptake and increased mitochondrial oxidative phosphorylation and are resistant to oncogenic transformation. Mechanistically we find that PTEN elevation orchestrates this metabolic switch by regulating PI3K-dependent and -independent pathways and negatively impacting two of the most pronounced metabolic features of tumor cells: glutaminolysis and the Warburg effect.	[Garcia-Cao, Isabel; Song, Min Sup; Hobbs, Robin M.; Ito, Keisuke; Carracedo, Arkaitz; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med, Boston, MA 02215 USA; [Garcia-Cao, Isabel; Song, Min Sup; Hobbs, Robin M.; Ito, Keisuke; Carracedo, Arkaitz; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Med Ctr, Boston, MA 02215 USA; [Laurent, Gaelle; de Boer, Vincent C. J.; Haigis, Marcia C.] Harvard Univ, Sch Med, Dept Cell Biol, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA; [Giorgi, Carlotta; Pinton, Paolo] Univ Ferrara, ICSI, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; [Giorgi, Carlotta; Pinton, Paolo] Univ Ferrara, LTTA Ctr, I-44100 Ferrara, Italy; [Anastasiou, Dimitrios; Sasaki, Atsuo T.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol,Beth Israel Deaconess Med Ctr, Dept Med,Div Signal Transduct, Boston, MA 02115 USA; [Rameh, Lucia] Boston Biomed Res Inst, Watertown, MA 02472 USA; [Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Ferrara; University of Ferrara; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston Biomedical Research Institute; Massachusetts Institute of Technology (MIT)	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014; Pinton, Paolo/J-8025-2012; de Boer, Vincent CJ/L-2196-2016; de Boer, Vincent C.J./F-4879-2010; Carracedo, Arkaitz/F-7029-2011; Giorgi, Carlotta/K-4649-2016; Hobbs, Robin/I-2577-2014	Cantley, Lewis C/0000-0002-1298-7653; Pinton, Paolo/0000-0001-7108-6508; de Boer, Vincent CJ/0000-0001-9928-1698; de Boer, Vincent C.J./0000-0001-9928-1698; Carracedo, Arkaitz/0000-0001-5957-1260; Sasaki, Atsuo/0000-0003-2963-4501; Anastasiou, Dimitrios/0000-0002-1269-843X; Pandolfi, Pier Paolo/0000-0002-5352-5295; Hobbs, Robin/0000-0002-3853-2614; Giorgi, Carlotta/0000-0002-2494-7405	Human Frontier Science Program (HFSP); Spanish Ministry of Education and Science (MEC); NIH [R01 CA-82328-09, P01-CA089021, R01-GM41890]; Italian Association for Cancer Research (AIRC); NATIONAL CANCER INSTITUTE [P01CA089021, R01CA082328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	Human Frontier Science Program (HFSP)(Human Frontier Science Program); Spanish Ministry of Education and Science (MEC)(Spanish Government); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Bhasin for help with microarray analysis, C. Clower for assistance with PKM splicing assays, W.J. Haveman for mouse genotyping, and Kaitlyn Webster for IHC analysis. I.G.-C. was supported by fellowships from the Human Frontier Science Program (HFSP) and the Spanish Ministry of Education and Science (MEC). This work was supported by NIH grants R01 CA-82328-09 to P.P.P., P01-CA089021 and R01-GM41890 to L.C.C., and Italian Association for Cancer Research (AIRC) grant to P.P.P.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Atsumi T, 2002, CANCER RES, V62, P5881; Banito A, 2010, EMBO REP, V11, P353, DOI 10.1038/embor.2010.47; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Colombo SL, 2010, P NATL ACAD SCI USA, V107, P18868, DOI 10.1073/pnas.1012362107; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2006, J BIOL CHEM, V281, P37372, DOI 10.1074/jbc.M608372200; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Nardo A, 2009, J NEUROSCI, V29, P5926, DOI 10.1523/JNEUROSCI.0778-09.2009; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Huang H, 1999, DEVELOPMENT, V126, P5365; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; King A, 2009, CURR OPIN CELL BIOL, V21, P885, DOI 10.1016/j.ceb.2009.09.009; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Li M, 2008, NAT CELL BIOL, V10, P1083, DOI 10.1038/ncb1768; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Liu WB, 2010, BIOCHEM BIOPH RES CO, V402, P507, DOI 10.1016/j.bbrc.2010.10.061; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Najafov A, 2010, P NATL ACAD SCI USA, V107, P19135, DOI 10.1073/pnas.1014047107; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ravitz MJ, 2007, CANCER RES, V67, P11209, DOI 10.1158/0008-5472.CAN-06-4351; Ruderman N, 2001, SCIENCE, V291, P2558, DOI 10.1126/science.1060277; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; WEXLER H, 1979, J NATL CANCER I, V63, P1393; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025; Zundel W, 2000, GENE DEV, V14, P391	74	260	271	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 30	2012	149	1					49	62		10.1016/j.cell.2012.02.030	http://dx.doi.org/10.1016/j.cell.2012.02.030			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	918FT	22401813	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000302235400009
J	Bretler, DM; Hansen, PR; Sorensen, R; Lindhardsen, J; Ahlehoff, O; Andersson, C; Abildstrom, SZ; Torp-Pedersen, C; Gislason, GH				Bretler, Ditte-Marie; Hansen, Peter Riis; Sorensen, Rikke; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Abildstrom, Steen Zabell; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar			Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; POSTMENOPAUSAL WOMEN; GUIDELINES; MORTALITY; INFLAMMATION; ASSOCIATION; PREVENTION; DIAGNOSIS	Objective To assess the risk of adverse cardiovascular events in women who discontinue hormone replacement therapy after myocardial infarction compared with those who continue. Design Nationwide register based cohort study. Setting All hospitals in Denmark. Population All 3322 women aged 40 years or over who survived 30 days after a myocardial infarction and were prescribed hormone replacement therapy at the time of myocardial infarction in the period 1997 to 2008. Main outcome measures Reinfarction, cardiovascular mortality, and all cause mortality 30 to 360 days after discharge. Results A total of 282 (8.5%) women had a reinfarction, 218 (6.6%) died of cardiovascular causes, and 357 (10.7%) died of any cause during follow-up. Women who discontinued overall hormone replacement therapy in the first year after myocardial infarction did not have a significantly different risk of reinfarction (hazard ratio 0.90, 95% confidence interval 0.68 to 1.19), cardiovascular mortality (1.21, 0.90 to 1.62), or all cause mortality (1.22, 0.97 to 1.53) than women who continued use. However, discontinuation of vaginal oestrogen was associated with a lower risk of reinfarction (hazard ratio 0.54, 0.34 to 0.86). Conclusion No certain conclusions can be drawn regarding increased or decreased risk of adverse cardiovascular events with continuing hormone replacement therapy after myocardial infarction. The results rule out neither a modest benefit nor a worrisome increase in risk. These figures may be valuable when a possible cardiovascular risk of hormone replacement therapy needs to be balanced with menopausal symptoms for the individual patient.	[Bretler, Ditte-Marie; Hansen, Peter Riis; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar] Copenhagen Univ Hosp Gentofte, Dept Cardiol, Copenhagen, Denmark; [Sorensen, Rikke; Abildstrom, Steen Zabell] Univ Copenhagen, Dept Cardiol, Bispebjerg Hosp, Copenhagen, Denmark; [Torp-Pedersen, Christian] Univ Copenhagen, Panum Inst, Fac Hlth Sci, DK-2200 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Bretler, DM (corresponding author), Copenhagen Univ Hosp Gentofte, Dept Cardiol, Copenhagen, Denmark.	dimabr01@geh.regionh.dk	Hansen, Peter Riis/AAR-7659-2020; Gislason, Gunnar/B-7561-2009; Andersson, Charlotte/P-4849-2014	Gislason, Gunnar/0000-0002-0548-402X; Hansen, Peter Riis/0000-0002-9056-535X; Sorensen, Rikke/0000-0001-9238-6681	Danish Heart Foundation [08-4-R65-A1904-B844-22440F]; Lundbeck Foundation [R31-A2566]; Sanofi; Neurosearch; Cardiome; Merck	Danish Heart Foundation; Lundbeck Foundation(Lundbeckfonden); Sanofi; Neurosearch; Cardiome; Merck(Merck & Company)	D-MB was supported by the Danish Heart Foundation (grant 08-4-R65-A1904-B844-22440F) and the Lundbeck Foundation (grant R31-A2566). None of the funding sponsors were involved in the design and conduct of the study; in collection, management, analysis, and interpretation of the data; or in preparation, review, and approval of the manuscript.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: CT-P has received consultant fees from Sanofi, Neurosearch, Cardiome, and Merck. All other authors declare no support from any organisations for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Bretler DM, 2011, BRIT J CLIN PHARMACO, V71, P105, DOI 10.1111/j.1365-2125.2010.03790.x; Buch P, 2007, HEART, V93, P210, DOI 10.1136/hrt.2006.092213; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Collet JP, 2009, ARCH CARDIOVASC DIS, V102, P485, DOI 10.1016/j.acvd.2009.03.012; Fichtlscherer S, 2004, CIRCULATION, V110, P1926, DOI 10.1161/01.CIR.0000143378.58099.8C; Gaist D, 1997, DAN MED BULL, V44, P445; Gislason GH, 2006, EUR HEART J, V27, P1153, DOI 10.1093/eurheartj/ehi705; Gorodeski EZ, 2010, MENOPAUSE, V17, P443, DOI 10.1097/gme.0b013e3181d0edaa; GRADY D, 1992, ANN INTERN MED, V117, P1038; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; Greiner DZ, 1999, AM J CARDIOL, V83, P247, DOI 10.1016/S0002-9149(98)00828-5; Haimov-Kochman R, 2006, HUM REPROD, V21, P2450, DOI 10.1093/humrep/del191; Horner E, 2006, CLIMACTERIC, V9, P459, DOI 10.1080/13697130601024629; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kalela A, 2006, EUR J OBSTET GYN R B, V125, P217, DOI 10.1016/j.ejogrb.2005.10.010; Khan MA, 2000, AM J CARDIOL, V86, P330, DOI 10.1016/S0002-9149(00)00926-7; Kumler T, 2008, EUR J HEART FAIL, V10, P658, DOI 10.1016/j.ejheart.2008.05.006; Labrie F, 2009, MENOPAUSE, V16, P30, DOI 10.1097/gme.0b013e31817b6132; Lokkegaard E, 2008, EUR HEART J, V29, P2660, DOI 10.1093/eurheartj/ehn408; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mosca L, 2004, J AM COLL CARDIOL, V43, P900, DOI 10.1016/j.jacc.2004.02.001; Mosca L, 2007, J AM COLL CARDIOL, V49, P1230, DOI 10.1016/j.jacc.2007.02.020; Naftolin F, 2004, CLIMACTERIC, V7, P333, DOI 10.1080/13697130400014615; Nordic Medico-Statistical Committee (NOMESCO), 2010, NOMESCO CLASS SURG P; Olesen JB, 2011, PHARMACOEPIDEM DR S, V20, P146, DOI 10.1002/pds.2073; Pettee KK, 2007, AM J PREV MED, V32, P483, DOI 10.1016/j.amepre.2007.02.019; Raunso J, 2011, EUR HEART J; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414; Simpson SH, 2006, BMJ-BRIT MED J, V333, P15, DOI 10.1136/bmj.38875.675486.55; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Vehkavaara S, 2001, THROMB HAEMOSTASIS, V85, P619, DOI 10.1055/s-0037-1615643; Vehkavaara S, 2000, CIRCULATION, V102, P2687, DOI 10.1161/01.CIR.102.22.2687; Vermeulen MJ, 2007, J CLIN EPIDEMIOL, V60, P971, DOI 10.1016/j.jclinepi.2006.12.009; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Vongpatanasin W, 2003, J AM COLL CARDIOL, V41, P1358, DOI 10.1016/S0735-1097(03)00156-6; Vrablik M, 2008, METABOLISM, V57, P1088, DOI 10.1016/j.metabol.2008.03.012; Welton AJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1190; Yeboah J, 2008, MENOPAUSE, V15, P1060, DOI 10.1097/gme.0b013e31816d8171	45	7	8	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2012	344								e1802	10.1136/bmj.e1802	http://dx.doi.org/10.1136/bmj.e1802			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923EV	22453184	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000302603100001
J	Gur, I; Sawyer, K; Prasher, R				Gur, Ilan; Sawyer, Karma; Prasher, Ravi			Searching for a Better Thermal Battery	SCIENCE			English	Editorial Material									[Gur, Ilan; Sawyer, Karma; Prasher, Ravi] US DOE, Adv Res Projects Agcy, Washington, DC 20585 USA; [Gur, Ilan] Univ Calif Berkeley, Energy Inst, Haas Sch Business, Berkeley, CA 94720 USA; [Prasher, Ravi] Arizona State Univ, Sch Engn Matter Transport & Energy, Tempe, AZ 85287 USA	United States Department of Energy (DOE); University of California System; University of California Berkeley; Arizona State University; Arizona State University-Tempe	Gur, I (corresponding author), US DOE, Adv Res Projects Agcy, 1000 Independence Ave SW, Washington, DC 20585 USA.	ilan.gur@hq.doe.gov; karma.sawyer@hq.doe.gov; ravi.prasher@hq.doe.gov						Armand M, 2008, NATURE, V451, P652, DOI 10.1038/451652a; Banerjee R, 2008, SCIENCE, V319, P939, DOI 10.1126/science.1152516; Cartlidge E, 2011, SCIENCE, V334, P922, DOI 10.1126/science.334.6058.922; Farrington R, 2000, NRELCP54028960; Gurkan BE, 2010, J AM CHEM SOC, V132, P2116, DOI 10.1021/ja909305t; Kolpak AM, 2011, NANO LETT, V11, P3156, DOI 10.1021/nl201357n; Kunze K, 2006, 2006011450 SAE; KWART H, 1968, CHEM REV, V68, P415, DOI 10.1021/cr60254a002; Laughlin R., 2011, POWERING FUTURE, P94; Losada-Perez P, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3374819; Taneja J., 2010, P IEEE SMARTGRIDCOMM	11	177	181	10	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2012	335	6075					1454	1455		10.1126/science.1218761	http://dx.doi.org/10.1126/science.1218761			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912YG	22442472				2022-12-28	WOS:000301837000033
J	Parsons, M; Spratt, N; Bivard, A; Campbell, B; Chung, K; Miteff, F; O'Brien, B; Bladin, C; McElduff, P; Allen, C; Bateman, G; Donnan, G; Davis, S; Levi, C				Parsons, Mark; Spratt, Neil; Bivard, Andrew; Campbell, Bruce; Chung, Kong; Miteff, Ferdinand; O'Brien, Bill; Bladin, Christopher; McElduff, Patrick; Allen, Chris; Bateman, Grant; Donnan, Geoffrey; Davis, Stephen; Levi, Christopher			A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFUSION COMPUTED-TOMOGRAPHY; TISSUE-PLASMINOGEN ACTIVATOR; INTRAVENOUS THROMBOLYSIS; RECANALIZATION; EPITHET; ECASS; REPERFUSION; OUTCOMES; THERAPY; EXTENT	BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less than 6 hours after the onset of ischemic stroke. To favor the selection of patients most likely to benefit from thrombolytic therapy, the eligibility criteria were a perfusion lesion at least 20% greater than the infarct core on computed tomographic (CT) perfusion imaging at baseline and an associated vessel occlusion on CT angiography. The coprimary end points were the proportion of the perfusion lesion that was reperfused at 24 hours on perfusion-weighted magnetic resonance imaging and the extent of clinical improvement at 24 hours as assessed on the National Institutes of Health Stroke Scale (NIHSS, a 42-point scale on which higher scores indicate more severe neurologic deficits). RESULTS The three treatment groups each comprised 25 patients. The mean (+/- SD) NIHSS score at baseline for all patients was 14.4 +/- 2.6, and the time to treatment was 2.9 +/- 0.8 hours. Together, the two tenecteplase groups had greater reperfusion (P=0.004) and clinical improvement (P<0.001) at 24 hours than the alteplase group. There were no significant between-group differences in intracranial bleeding or other serious adverse events. The higher dose of tenecteplase (0.25 mg per kilogram) was superior to the lower dose and to alteplase for all efficacy outcomes, including absence of serious disability at 90 days (in 72% of patients, vs. 40% with alteplase; P=0.02). CONCLUSIONS Tenecteplase was associated with significantly better reperfusion and clinical outcomes than alteplase in patients with stroke who were selected on the basis of CT perfusion imaging. (Funded by the Australian National Health and Medical Research Council; Australia New Zealand Clinical Trials Registry number, ACTRN12608000466347.)	[Parsons, Mark; Spratt, Neil; Bivard, Andrew; Chung, Kong; Miteff, Ferdinand; O'Brien, Bill; Levi, Christopher] John Hunter Hosp, Dept Neurol, Hunter Med Res Inst, Newcastle, NSW 2310, Australia; [McElduff, Patrick] John Hunter Hosp, Dept Clin Res Design Informat Technol & Stat Supp, Hunter Med Res Inst, Newcastle, NSW 2310, Australia; [Allen, Chris; Bateman, Grant] John Hunter Hosp, Dept Radiol, Hunter Med Res Inst, Newcastle, NSW 2310, Australia; [Campbell, Bruce; Davis, Stephen] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic 3050, Australia; [Donnan, Geoffrey] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic 3050, Australia; [Bladin, Christopher] Monash Univ, Dept Neurosci, Box Hill Hosp Eastern Hlth, Melbourne, Vic 3004, Australia	Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; Royal Melbourne Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Box Hill Hospital; Monash University	Parsons, M (corresponding author), John Hunter Hosp, Dept Neurol, Hunter Reg Mail Ctr, Locked Bag 1, Newcastle, NSW 2310, Australia.	mark.parsons@hnehealth.nsw.gov.au	Parsons, Mark W./G-3750-2014; Campbell, Bruce/J-1220-2019; bladin, chris/B-9136-2013; Davis, Stephen M/L-5260-2013; Spratt, Neil J/K-4208-2012	Campbell, Bruce/0000-0003-3632-9433; Davis, Stephen M/0000-0003-0962-2300; Spratt, Neil J/0000-0002-9023-6177; Donnan, Geoffrey/0000-0001-6324-3403; Levi, Christopher/0000-0002-9474-796X; Bateman, Grant/0000-0003-3095-9047	Australian National Health and Medical Research Council; Bayer Australia; Lundbeck; Cardiovascular Lipid Australia; Orsan Technologies; Ever Pharma; Boehringer Ingelheim Australia	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Bayer Australia; Lundbeck(Lundbeck Corporation); Cardiovascular Lipid Australia; Orsan Technologies; Ever Pharma; Boehringer Ingelheim Australia(Boehringer Ingelheim)	Supported by a grant from the Australian National Health and Medical Research Council.; Dr. Parsons reports receiving advisory-board fees from Bayer Australia; Dr. Campbell, consultancy fees from Lundbeck, speaker payments from Boehringer Ingelheim Australia, and grant support from Cardiovascular Lipid Australia; Dr. Bladin, advisory-board fees from Bayer Australia; Dr. Donnan, consultancy fees from Boehringer Ingelheim Australia and Bayer Australia; Dr. Davis, consultancy fees from Orsan Technologies and Ever Pharma; and Dr. Levi, consultancy fees from Boehringer Ingelheim Australia. No other potential conflict of interest relevant to this article was reported.	Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Bivard A, 2011, BRAIN, V134, P3408, DOI 10.1093/brain/awr257; Bivard A, 2011, CEREBROVASC DIS, V31, P238, DOI 10.1159/000321897; Brown DL, 2004, STROKE, V35, P147, DOI 10.1161/01.STR.000010539.93273.72; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; De Silva DA, 2009, STROKE, V40, P2872, DOI 10.1161/STROKEAHA.108.543595; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Haley EC, 2010, STROKE, V41, P707, DOI 10.1161/STROKEAHA.109.572040; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Khatri P, 2005, STROKE, V36, P2400, DOI 10.1161/01.STR.0000185698.45720.58; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Neumann-Haefelin T, 2004, STROKE, V35, P109, DOI 10.1161/01.STR.0000106482.31425.D1; Parsons MW, 2007, NEUROLOGY, V68, P730, DOI 10.1212/01.wnl.0000256366.86353.ff; Parsons MW, 2009, NEUROLOGY, V72, P915, DOI 10.1212/01.wnl.0000344168.05315.9d; Parsons MW, 2005, ANN NEUROL, V58, P672, DOI 10.1002/ana.20638; Simpson MA, 2010, MED J AUSTRALIA, V193, P439, DOI 10.5694/j.1326-5377.2010.tb03996.x; Soares BP, 2010, STROKE, V41, pE34, DOI 10.1161/STROKEAHA.109.568766; Tanswell P, 2002, CLIN PHARMACOKINET, V41, P1229, DOI 10.2165/00003088-200241150-00001; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Wintermark M, 2008, STROKE, V39, P1621, DOI 10.1161/STROKEAHA.107.512319	22	386	403	5	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2012	366	12					1099	1107		10.1056/NEJMoa1109842	http://dx.doi.org/10.1056/NEJMoa1109842			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912BO	22435369	Green Published			2022-12-28	WOS:000301769700009
J	Raymo, ME; Mitrovica, JX				Raymo, Maureen E.; Mitrovica, Jerry X.			Collapse of polar ice sheets during the stage 11 interglacial	NATURE			English	Article							MARINE ISOTOPE STAGE-11; SEA-LEVEL HIGHSTAND; MANTLE VISCOSITY; MASS-LOSS; PLEISTOCENE; HOLOCENE; BERMUDA; ANALOG; RISE	Contentious observations of Pleistocene shoreline features on the tectonically stable islands of Bermuda and the Bahamas have suggested that sea level about 400,000 years ago was more than 20 metres higher than it is today(1-4). Geochronologic and geomorphic evidence indicates that these features formed during interglacial marine isotope stage (MIS) 11, an unusually long interval of warmth during the ice age(1-4). Previous work has advanced two divergent hypotheses for these shoreline features: first, significant melting of the East Antarctic Ice Sheet, in addition to the collapse of the West Antarctic Ice Sheet and the Greenland Ice Sheet(1-3); or second, emplacement by a mega-tsunami during MIS 11 (ref. 4, 5). Here we show that the elevations of these features are corrected downwards by similar to 10 metres when we account for post-glacial crustal subsidence of these sites over the course of the anomalously long interglacial. On the basis of this correction, we estimate that eustatic sea level rose to similar to 6-13 m above the present-day value in the second half of MIS 11. This suggests that both the Greenland Ice Sheet and the West Antarctic Ice Sheet collapsed during the protracted warm period while changes in the volume of the East Antarctic Ice Sheet were relatively minor, thereby resolving the long-standing controversy over the stability of the East Antarctic Ice Sheet during MIS 11.	[Raymo, Maureen E.] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; [Mitrovica, Jerry X.] Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Columbia University; Harvard University	Raymo, ME (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, POB 1000,61 Route 9W, Palisades, NY 10964 USA.	raymo@ldeo.columbia.edu	Raymo, Maureen E/A-1270-2012		Harvard University; Canadian Institute for Advanced Research;  [NSF-OCE-0825293];  [OCE-1202632]; Division Of Ocean Sciences [1238405] Funding Source: National Science Foundation	Harvard University; Canadian Institute for Advanced Research(Canadian Institute for Advanced Research (CIFAR)); ; ; Division Of Ocean Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank P. Hearty and D. Bowen for discussions of MIS 11 field data, and J. L. Davis for suggestions regarding data analysis. Support for this research was provided by NSF-OCE-0825293 and OCE-1202632 (M. E. R.), Harvard University (J. X. M.) and the Canadian Institute for Advanced Research (J.X.M.).	Bamber JL, 2009, SCIENCE, V324, P901, DOI 10.1126/science.1169335; Bowen DQ, 2010, CLIM PAST, V6, P19, DOI 10.5194/cp-6-19-2010; Chen JL, 2009, NAT GEOSCI, V2, P859, DOI 10.1038/ngeo694; Hearty PJ, 1999, GEOLOGY, V27, P375, DOI 10.1130/0091-7613(1999)027<0375:AMMPSL>2.3.CO;2; Jansen E, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P433; Kendall RA, 2005, GEOPHYS J INT, V161, P679, DOI 10.1111/j.1365-246X.2005.02553.x; Kopp RE, 2009, NATURE, V462, P863, DOI 10.1038/nature08686; Lambeck K, 1998, GEOPHYS J INT, V134, P102, DOI 10.1046/j.1365-246x.1998.00541.x; Lisiecki LE, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001071; Loutre MF, 2003, GLOBAL PLANET CHANGE, V36, P209, DOI 10.1016/S0921-8181(02)00186-8; Luthcke SB, 2006, SCIENCE, V314, P1286, DOI 10.1126/science.1130776; McKay NP, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048280; McManus J., 2003, GEOPHYS MONOGRAPHS, V137, P69, DOI DOI 10.1029/137GM06; McMurtry GM, 2007, SEDIMENT GEOL, V200, P155, DOI 10.1016/j.sedgeo.2006.10.009; Mitrovica JX, 2002, QUATERNARY SCI REV, V21, P2179, DOI 10.1016/S0277-3791(02)00080-X; Mitrovica JX, 2004, EARTH PLANET SC LETT, V225, P177, DOI 10.1016/j.epsl.2004.06.005; Muhs DR, 2011, QUATERNARY SCI REV, V30, P570, DOI 10.1016/j.quascirev.2010.12.019; NAKADA M, 1989, GEOPHYS J INT, V96, P497, DOI 10.1111/j.1365-246X.1989.tb06010.x; Olson SL, 2009, QUATERNARY SCI REV, V28, P271, DOI 10.1016/j.quascirev.2008.11.001; Otto-Bliesner BL, 2006, SCIENCE, V311, P1751, DOI 10.1126/science.1120808; Peltier WR, 2004, ANNU REV EARTH PL SC, V32, P111, DOI 10.1146/annurev.earth.32.082503.144359; Rignot E, 2008, NAT GEOSCI, V1, P106, DOI 10.1038/ngeo102; Rohling EJ, 2010, EARTH PLANET SC LETT, V291, P97, DOI 10.1016/j.epsl.2009.12.054; Shepherd A, 2007, SCIENCE, V315, P1529, DOI 10.1126/science.1136776; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; van Hengstum PJ, 2009, QUATERNARY SCI REV, V28, P1850, DOI 10.1016/j.quascirev.2009.05.017; Velicogna I, 2006, SCIENCE, V311, P1754, DOI 10.1126/science.1123785; Velicogna I, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040222	28	154	157	0	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 22	2012	483	7390					453	456		10.1038/nature10891	http://dx.doi.org/10.1038/nature10891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	912CC	22419155	Green Published			2022-12-28	WOS:000301771200040
J	Jakob, SM; Ruokonen, E; Grounds, RM; Sarapohja, T; Garratt, C; Pocock, SJ; Bratty, JR; Takala, J				Jakob, Stephan M.; Ruokonen, Esko; Grounds, R. Michael; Sarapohja, Toni; Garratt, Chris; Pocock, Stuart J.; Bratty, J. Raymond; Takala, Jukka		Dexmedetomidine Long-Term Sedation	Dexmedetomidine vs Midazolam or Propofol for Sedation During Prolonged Mechanical Ventilation Two Randomized Controlled Trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; INTENSIVE-CARE; DAILY INTERRUPTION; LORAZEPAM; MULTICENTER; PROTOCOL; DELIRIUM; ICU; RELIABILITY	Context Long-term sedation with midazolam or propofol in intensive care units (ICUs) has serious adverse effects. Dexmedetomidine, an alpha(2)-agonist available for ICU sedation, may reduce the duration of mechanical ventilation and enhance patient comfort. Objective To determine the efficacy of dexmedetomidine vs midazolam or propofol (preferred usual care) in maintaining sedation; reducing duration of mechanical ventilation; and improving patients' interaction with nursing care. Design, Setting, and Patients Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010. The MIDEX trial compared midazolam with dexmedetomidine in ICUs of 44 centers in 9 European countries; the PRODEX trial compared propofol with dexmedetomidine in 31 centers in 6 European countries and 2 centers in Russia. Included were adult ICU patients receiving mechanical ventilation who needed light to moderate sedation for more than 24 hours (midazolam, n=251, vs dexmedetomidine, n=249; propofol, n=247, vs dexmedetomidine, n=251). Interventions Sedation with dexmedetomidine, midazolam, or propofol; daily sedation stops; and spontaneous breathing trials. Main Outcome Measures For each trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of time at target sedation level (measured by Richmond Agitation-Sedation Scale) and superior to control with respect to duration of mechanical ventilation. Secondary end points were patients' ability to communicate pain (measured using a visual analogue scale [VAS]) and length of ICU stay. Time at target sedation was analyzed in per-protocol population (midazolam, n=233, vs dexmedetomidine, n=227; propofol, n=214, vs dexmedetomidine, n=223). Results Dexmedetomidine/midazolam ratio in time at target sedation was 1.07 (95% CI, 0.97-1.18) and dexmedetomidine/propofol, 1.00 (95% CI, 0.92-1.08). Median duration of mechanical ventilation appeared shorter with dexmedetomidine (123 hours [IQR, 67-337]) vs midazolam (164 hours [IQR, 92-380]; P=.03) but not with dexmedetomidine (97 hours [IQR, 45-257]) vs propofol (118 hours [IQR, 48-327]; P=.24). Patients' interaction (measured using VAS) was improved with dexmedetomidine (estimated score difference vs midazolam, 19.7 [95% CI, 15.2-24.2]; P < .001; and vs propofol, 11.2 [95% CI, 6.4-15.9]; P < .001). Length of ICU and hospital stay and mortality were similar. Dexmedetomidine vs midazolam patients had more hypotension (51/247 [20.6%] vs 29/250 [11.6%]; P=.007) and bradycardia (35/247 [14.2%] vs 13/250 [5.2%]; P < .001). Conclusions Among ICU patients receiving prolonged mechanical ventilation, dexmedetomidine was not inferior to midazolam and propofol in maintaining light to moderate sedation. Dexmedetomidine reduced duration of mechanical ventilation compared with midazolam and improved patients' ability to communicate pain compared with midazolam and propofol. More adverse effects were associated with dexmedetomidine.	[Jakob, Stephan M.; Takala, Jukka] Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Jakob, Stephan M.; Takala, Jukka] Univ Bern, Bern, Switzerland; [Ruokonen, Esko] Kuopio Univ Hosp, Dept Anesthesiol & Intens Care Med, SF-70210 Kuopio, Finland; [Grounds, R. Michael] St George Hosp, Adult Intens Care Unit, London, England; [Sarapohja, Toni; Garratt, Chris; Bratty, J. Raymond] Orion Pharma, Espoo, Finland; [Pocock, Stuart J.] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England	University of Bern; University Hospital of Bern; University of Bern; Kuopio University Hospital; University of Eastern Finland; St Georges University London; Orion Corporation; University of London; London School of Hygiene & Tropical Medicine	Takala, J (corresponding author), Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland.	jukka.takala@insel.ch	Chiche, Jean-Daniel/P-5220-2017; Grigoryev, Evgeny/A-2321-2017; Zabolotskikh, Igor Borisovich/O-2705-2014	Chiche, Jean-Daniel/0000-0002-6433-6254; Grigoryev, Evgeny/0000-0001-8370-3083; Zabolotskikh, Igor Borisovich/0000-0002-3623-2546; Maggiorini, Marco/0000-0001-8180-2117; Vincent, Jean-Louis/0000-0001-6011-6951	Orion Pharma, Espoo, Finland; Abbott Nutrition International; B. Braun Medical; CSEM; Edwards Life-sciences Services; Kenta Biotech; Maquet Critical Care; Omnicare Clinical Research; Berner Forum for Intensive Care; Fresenius Kabi; MSD; Lilly; Baxter; Astellas; AstraZeneca; B. Braun; CSL Behring; Maquet; Novartis; Covidien; Mycomed; RobaPharma; Orion Pharma; Orion	Orion Pharma, Espoo, Finland; Abbott Nutrition International; B. Braun Medical; CSEM; Edwards Life-sciences Services; Kenta Biotech; Maquet Critical Care; Omnicare Clinical Research; Berner Forum for Intensive Care; Fresenius Kabi; MSD; Lilly(Eli Lilly); Baxter; Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); B. Braun; CSL Behring; Maquet; Novartis(Novartis); Covidien; Mycomed; RobaPharma; Orion Pharma; Orion	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. This study was sponsored by Orion Pharma, Espoo, Finland, through research contracts negotiated directly with the participating hospitals. Orion Pharma, Orion Corporation, is the originator of dexmedetomidine. On behalf of Drs Jakob and Takala, a grant and consulting fees were paid to the Bern University Hospital Department of Intensive Care Medicine to cover the costs of performing the study. The department was reimbursed for the authors' travel costs to publication committee meetings. Dr Jakob served as an expert for preparing the regulatory filing of the drug; the money was also paid into a departmental fund. Additionally, the Department of Intensive Care Medicine has, or has had in the past, research contracts with Abbott Nutrition International, B. Braun Medical, CSEM, Edwards Life-sciences Services, Kenta Biotech, Maquet Critical Care, and Omnicare Clinical Research and research and development or consulting contracts with Edwards Life-sciences, Maquet Critical Care, and Nestle. The money is or was paid into a departmental fund; no author received any personal financial gain. The department has received unrestricted educational grants from the following organizations for organizing a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care: Fresenius Kabi, MSD, Lilly, Baxter, Astellas, AstraZeneca, B. Braun, CSL Behring, Maquet, Novartis, Covidien, Mycomed, and RobaPharma. Dr Grounds received a consulting fee from Orion Pharma during planning and execution of the study. He and members of his clinical staff at St George's Hospital received monetary support from Orion for travel to study-related meetings to ensure compliance with the study protocol. His department received payment of a fee per patient recruited to the study, as well as drugs used in the study and support personnel to assist with data input. Dr Ruokonen's institution, Kuopio University, received a grant from Orion to carry out the study, as well as consulting fees and reimbursement of travel funds. Messrs Sarapohja, Garratt, and Bratty were full-time employees of Orion Pharma throughout the period of the project. Their routine travel expenses were reimbursed as part of their employment. Dr Pocock of the London School of Hygiene and Tropical Medicine received a consulting fee from Orion in connection with the study, and his institution received a grant. London School of Hygiene and Tropical Medicine also received a grant for independent statistical review performed by Dr Duolao Wang.	Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Carson SS, 2006, CRIT CARE MED, V34, P1326, DOI 10.1097/01.CCM.0000215513.63207.7F; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Mehta S, 2007, J CRIT CARE, V22, P191, DOI 10.1016/j.jcrc.2006.11.006; Mirski MA, 2010, INTENS CARE MED, V36, P1505, DOI 10.1007/s00134-010-1874-9; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Swart EL, 2006, EUR J CLIN PHARMACOL, V62, P185, DOI 10.1007/s00228-005-0085-8; Sydow M, 1999, INTENS CARE MED, V25, P634, DOI 10.1007/s001340050917; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156	25	551	610	5	86	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1151	1160		10.1001/jama.2012.304	http://dx.doi.org/10.1001/jama.2012.304			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436955	Bronze			2022-12-28	WOS:000301708000023
J	Alder, A; Jamil, M; Marzorati, M; Bruno, M; Vermathen, M; Bigler, P; Ghisla, S; Bouwmeester, H; Beyer, P; Al-Babili, S				Alder, Adrian; Jamil, Muhammad; Marzorati, Mattia; Bruno, Mark; Vermathen, Martina; Bigler, Peter; Ghisla, Sandro; Bouwmeester, Harro; Beyer, Peter; Al-Babili, Salim			The Path from beta-Carotene to Carlactone, a Strigolactone-Like Plant Hormone	SCIENCE			English	Article							CLEAVAGE OXYGENASES; BIOSYNTHESIS; GERMINATION; STRIGA; INHIBITION; METABOLISM; OROBANCHE; CATALYZE; ENZYMES	Strigolactones, phytohormones with diverse signaling activities, have a common structure consisting of two lactones connected by an enol-ether bridge. Strigolactones derive from carotenoids via a pathway involving the carotenoid cleavage dioxygenases 7 and 8 (CCD7 and CCD8) and the iron-binding protein D27. We show that D27 is a beta-carotene isomerase that converts all-trans-beta-carotene into 9-cis-beta-carotene, which is cleaved by CCD7 into a 9-cis-configured aldehyde. CCD8 incorporates three oxygens into 9-cis-beta-apo-10'-carotenal and performs molecular rearrangement, linking carotenoids with strigolactones and producing carlactone, a compound with strigolactone-like biological activities. Knowledge of the structure of carlactone will be crucial for understanding the biology of strigolactones and may have applications in combating parasitic weeds.	[Alder, Adrian; Bruno, Mark; Beyer, Peter; Al-Babili, Salim] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Jamil, Muhammad; Bouwmeester, Harro] Wageningen Univ, Lab Plant Physiol, NL-6700 AR Wageningen, Netherlands; [Marzorati, Mattia; Vermathen, Martina; Bigler, Peter] Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; [Ghisla, Sandro] Univ Konstanz, Dept Biol, D-78457 Constance, Germany; [Bouwmeester, Harro] Ctr Biosyst Genom, NL-6700 AR Wageningen, Netherlands; [Beyer, Peter; Al-Babili, Salim] Ctr Biol Signalling Studies Bioss, D-79104 Freiburg, Germany	University of Freiburg; Wageningen University & Research; University of Bern; University of Konstanz; Centre for BioSystems Genomics	Al-Babili, S (corresponding author), Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany.	salim.albabili@biologie.uni-freiburg.de	Vermathen, Martina/ABA-1385-2020; Bouwmeester, Harro J/C-1414-2008; Jamil, Muhammad/M-8923-2015; Jamil, Muhammad/D-8395-2014	Jamil, Muhammad/0000-0003-0221-518X; Jamil, Muhammad/0000-0001-5127-7454; Bouwmeester, Harro/0000-0003-0907-2732; Al-Babili, Salim/0000-0003-4823-2882; Vermathen, Martina/0000-0002-0796-1643	Deutsche Forschungsgemeinschaft [AL892/1-4, Graduiertenkolleg 1305]; Higher Education Commission of Pakistan; Netherlands Organization for Scientific Research [865.06.002, 834.08.001]; Centre for BioSystems Genomics, Netherlands Genomics Initiative/Netherlands Organization for Scientific Research	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Centre for BioSystems Genomics, Netherlands Genomics Initiative/Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	We thank S. Schurch and C. Buhr for technical help with ESI-MS analysis, E. Decker for valuable discussions, B. Zwanenburg for supplying GR24, W. Boland for beta-apo-13-carotenone, Y. Wang for seeds of rice d27, L. Zhu for seeds of htd-1, and J. Kyozuka for seeds of d3 and d10 mutants. Supported by the Deutsche Forschungsgemeinschaft (grant AL892/1-4 and the Graduiertenkolleg 1305 "Plant Signal Systems"), the Higher Education Commission of Pakistan, the Netherlands Organization for Scientific Research (VICI grant 865.06.002 and equipment grant 834.08.001), and the Centre for BioSystems Genomics, a part of the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research. Materials are available under an MTA agreement with the University of Freiburg. The University of Freiburg has filed European patent application (number 11 003 470.9) on carlactone and its applications.	*ADV CHEM DEV INC, 2008, ACD SHIFT PRED SOFTW; Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608; Alder A, 2008, BIOCHEM J, V416, P289, DOI 10.1042/BJ20080568; Auldridge ME, 2006, CURR OPIN PLANT BIOL, V9, P315, DOI 10.1016/j.pbi.2006.03.005; Bartley GE, 1999, EUR J BIOCHEM, V259, P396, DOI 10.1046/j.1432-1327.1999.00051.x; Beveridge CA, 2010, CURR OPIN PLANT BIOL, V13, P34, DOI 10.1016/j.pbi.2009.10.003; Bouvier F, 2005, TRENDS PLANT SCI, V10, P187, DOI 10.1016/j.tplants.2005.02.007; Chojnacka K, 2011, ORG BIOMOL CHEM, V9, P5350, DOI 10.1039/c1ob05751k; COOK CE, 1966, SCIENCE, V154, P1189, DOI 10.1126/science.154.3753.1189; DellaPenna D, 2006, ANNU REV PLANT BIOL, V57, P711, DOI 10.1146/annurev.arplant.56.032604.144301; Englert G, 1995, CAROTENOIDS B, V1B; Gomez-Roldan V, 2008, NATURE, V455, P189, DOI 10.1038/nature07271; Leyser O, 2008, DEV CELL, V15, P337, DOI 10.1016/j.devcel.2008.08.008; Leyser O, 2009, PLANT CELL ENVIRON, V32, P694, DOI 10.1111/j.1365-3040.2009.01930.x; Lin H, 2009, PLANT CELL, V21, P1512, DOI 10.1105/tpc.109.065987; Matusova R, 2005, PLANT PHYSIOL, V139, P920, DOI 10.1104/pp.105.061382; Medina HR, 2011, MOL MICROBIOL, V82, P199, DOI 10.1111/j.1365-2958.2011.07805.x; Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006; Parker C, 2009, PEST MANAG SCI, V65, P453, DOI 10.1002/ps.1713; Schlicht M, 2008, PLANT J, V55, P709, DOI 10.1111/j.1365-313X.2008.03543.x; Schwartz SH, 2004, J BIOL CHEM, V279, P46940, DOI 10.1074/jbc.M409004200; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Umehara M, 2008, NATURE, V455, P195, DOI 10.1038/nature07272; von Lintig J, 2010, ANNU REV NUTR, V30, P35, DOI 10.1146/annurev-nutr-080508-141027; Walter MH, 2011, NAT PROD REP, V28, P663, DOI 10.1039/c0np00036a; Wang YH, 2011, CURR OPIN PLANT BIOL, V14, P94, DOI 10.1016/j.pbi.2010.11.002; Xie XN, 2010, ANNU REV PHYTOPATHOL, V48, P93, DOI 10.1146/annurev-phyto-073009-114453; Yoneyama K, 2009, PEST MANAG SCI, V65, P467, DOI 10.1002/ps.1726; Yu QJ, 2011, J BIOL CHEM, V286, P8666, DOI 10.1074/jbc.M110.208017; Zechmeister L., 1962, CIS T ISOMERIC CAROT; Zwanenburg B, 2009, PEST MANAG SCI, V65, P478, DOI 10.1002/ps.1706	32	555	606	21	326	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1348	1351		10.1126/science.1218094	http://dx.doi.org/10.1126/science.1218094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22422982	Green Submitted			2022-12-28	WOS:000301531600047
J	Koch, T				Koch, Tom			Knowing its place: mapping as medical investigation	LANCET			English	Editorial Material									Univ British Columbia, Dept Med Geog, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Koch, T (corresponding author), Univ British Columbia, Dept Med Geog, Vancouver, BC V5Z 1M9, Canada.	tomkoch@kochworks.com						[Anonymous], 1831, LANCET, V1, P241; Gould P, 1993, SLOW PLAGUE GEOGRAPH; Koch T, 2005, CARTOGRAPHIES DIS MA; Koch T., 2011, DIS MAPS EPIDEMICS G; MAXCY KF, 1941, PAPERS WADE HAMPTON; VERGHESE A, 1989, J INFECT DIS, V160, P1051, DOI 10.1093/infdis/160.6.1051	6	4	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 10	2012	379	9819					887	888		10.1016/S0140-6736(12)60383-3	http://dx.doi.org/10.1016/S0140-6736(12)60383-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	906NY	22413142				2022-12-28	WOS:000301353700017
J	Kyriakou, G; Boucher, MB; Jewell, AD; Lewis, EA; Lawton, TJ; Baber, AE; Tierney, HL; Flytzani-Stephanopoulos, M; Sykes, ECH				Kyriakou, Georgios; Boucher, Matthew B.; Jewell, April D.; Lewis, Emily A.; Lawton, Timothy J.; Baber, Ashleigh E.; Tierney, Heather L.; Flytzani-Stephanopoulos, Maria; Sykes, E. Charles H.			Isolated Metal Atom Geometries as a Strategy for Selective Heterogeneous Hydrogenations	SCIENCE			English	Article							CORE-SHELL NANOPARTICLES; NEAR-SURFACE ALLOYS; LOW-TEMPERATURE; MOLECULAR-HYDROGEN; ADSORPTION; PD; CATALYSTS; CU(111); OXIDATION; KINETICS	Facile dissociation of reactants and weak binding of intermediates are key requirements for efficient and selective catalysis. However, these two variables are intimately linked in a way that does not generally allow the optimization of both properties simultaneously. By using desorption measurements in combination with high-resolution scanning tunneling microscopy, we show that individual, isolated Pd atoms in a Cu surface substantially lower the energy barrier to both hydrogen uptake on and subsequent desorption from the Cu metal surface. This facile hydrogen dissociation at Pd atom sites and weak binding to Cu allow for very selective hydrogenation of styrene and acetylene as compared with pure Cu or Pd metal alone.	[Kyriakou, Georgios; Jewell, April D.; Lewis, Emily A.; Lawton, Timothy J.; Baber, Ashleigh E.; Tierney, Heather L.; Sykes, E. Charles H.] Tufts Univ, Dept Chem, Medford, MA 02155 USA; [Boucher, Matthew B.; Flytzani-Stephanopoulos, Maria] Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02144 USA	Tufts University; Tufts University	Sykes, ECH (corresponding author), Tufts Univ, Dept Chem, 62 Talbot Ave, Medford, MA 02155 USA.	charles.sykes@tufts.edu	Kyriakou, Georgios/GQI-1405-2022; Kyriakou, Georgios/AAW-6257-2021	Kyriakou, Georgios/0000-0001-6295-844X; Kyriakou, Georgios/0000-0001-6295-844X; Baber, Ashleigh/0000-0003-3757-8562	U.S. Department of Energy [FG02-10ER16170]; NSF [CBET 0828666]; Department of Education; Tufts University	U.S. Department of Energy(United States Department of Energy (DOE)); NSF(National Science Foundation (NSF)); Department of Education(US Department of Education); Tufts University	We thank the U.S. Department of Energy (FG02-10ER16170) for financial support, NSF (CBET 0828666) for partial support (M.B.B.) and for a Graduate Research Fellowship (A.D.J.), the Department of Education for a Graduate Assistance in Areas of National Need fellowship (E.A.L.), and Tufts University for a Tufts Collaborates Seed Grant (E.C.H.S., M.F.-S., and G.K.).	Aaen AB, 1998, SURF SCI, V408, P43, DOI 10.1016/S0039-6028(98)00124-1; Abbet S, 2000, J AM CHEM SOC, V122, P3453, DOI 10.1021/ja9922476; Alayoglu S, 2008, NAT MATER, V7, P333, DOI 10.1038/nmat2156; Anderson JA, 1996, J CATAL, V164, P477, DOI 10.1006/jcat.1996.0404; ANGER G, 1989, SURF SCI, V220, P1, DOI 10.1016/0039-6028(89)90459-7; Bellisario DO, 2009, J PHYS CHEM C, V113, P12863, DOI 10.1021/jp903541k; Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913; Brandt B, 2008, J PHYS CHEM C, V112, P11408, DOI 10.1021/jp800205j; Chopra IS, 2011, NAT MATER, V10, P884, DOI [10.1038/NMAT3123, 10.1038/nmat3123]; Fierro-Gonzalez JC, 2005, CHEM COMMUN, P5275, DOI 10.1039/b509629d; GDOWSKI GE, 1987, SURF SCI, V181, pL147, DOI 10.1016/0039-6028(87)90187-7; Greeley J, 2005, J PHYS CHEM B, V109, P3460, DOI 10.1021/jp046540q; Greeley J, 2004, NAT MATER, V3, P810, DOI 10.1038/nmat1223; Jiang HL, 2011, J MATER CHEM, V21, P13705, DOI 10.1039/c1jm12020d; Kammler T, 1999, J CHEM PHYS, V111, P8115, DOI 10.1063/1.480145; Knudsen J, 2007, J AM CHEM SOC, V129, P6485, DOI 10.1021/ja0700855; Kyriakou G, 2005, J PHYS CHEM B, V109, P10952, DOI 10.1021/jp044213c; Lauhon LJ, 2000, PHYS REV LETT, V85, P4566, DOI 10.1103/PhysRevLett.85.4566; Mitsui T, 2003, NATURE, V422, P705, DOI 10.1038/nature01557; Priyadarshini D, 2011, J PHYS CHEM C, V115, P10155, DOI 10.1021/jp201793d; ROBERTS JT, 1988, J AM CHEM SOC, V110, P8540, DOI 10.1021/ja00233a038; Roudgar A, 2005, SURF SCI, V597, P42, DOI 10.1016/j.susc.2004.02.040; Skoplyak O, 2006, J PHYS CHEM B, V110, P1686, DOI 10.1021/jp0548927; Sousa C, 2001, J PHYS CHEM B, V105, P1817, DOI 10.1021/jp003349h; Tao F, 2008, SCIENCE, V322, P932, DOI 10.1126/science.1164170; Thomas JM, 2011, TOP CATAL, V54, P588, DOI 10.1007/s11244-011-9677-y; Tierney HL, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.246102; Tierney HL, 2009, J PHYS CHEM C, V113, P7246, DOI 10.1021/jp809766d; Tysoe W. T., 1983, CHEM COMMUN, V11, P623; Wittstock A, 2010, SCIENCE, V327, P319, DOI 10.1126/science.1183591; Zhai YP, 2010, SCIENCE, V329, P1633, DOI 10.1126/science.1192449	31	961	971	65	1303	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1209	1212		10.1126/science.1215864	http://dx.doi.org/10.1126/science.1215864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22403387				2022-12-28	WOS:000301225100040
J	Postow, MA; Callahan, MK; Barker, CA; Yamada, Y; Yuan, JD; Kitano, S; Mu, ZY; Rasalan, T; Adamow, M; Ritter, E; Sedrak, C; Jungbluth, AA; Chua, R; Yang, AS; Roman, RA; Rosner, S; Benson, B; Allison, JP; Lesokhin, AM; Gnjatic, S; Wolchok, JD				Postow, Michael A.; Callahan, Margaret K.; Barker, Christopher A.; Yamada, Yoshiya; Yuan, Jianda; Kitano, Shigehisa; Mu, Zhenyu; Rasalan, Teresa; Adamow, Matthew; Ritter, Erika; Sedrak, Christine; Jungbluth, Achim A.; Chua, Ramon; Yang, Arvin S.; Roman, Ruth-Ann; Rosner, Samuel; Benson, Brenna; Allison, James P.; Lesokhin, Alexander M.; Gnjatic, Sacha; Wolchok, Jedd D.			Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-CELL CARCINOMA; MALIGNANT-MELANOMA; CTLA-4 BLOCKADE; CANCER-PATIENTS; LUNG-CANCER; RADIATION; ANTIBODY; RESPONSES; NY-ESO-1; RADIOTHERAPY	The abscopal effect is a phenomenon in which local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site. The abscopal effect may be mediated by activation of the immune system. Ipilimumab is a monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage with antibody responses to the cancertestis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibody responses to other antigens after radiotherapy. (Funded by the National Institutes of Health and others.)	[Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Dept Med, Melanoma & Sarcoma Serv, New York, NY 10065 USA; [Barker, Christopher A.; Yuan, Jianda] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Yuan, Jianda; Kitano, Shigehisa; Mu, Zhenyu; Rasalan, Teresa; Adamow, Matthew; Allison, James P.; Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, Program Immunol, New York, NY 10065 USA; [Roman, Ruth-Ann] Mem Sloan Kettering Canc Ctr, Dept Nursing, New York, NY 10065 USA; [Ritter, Erika; Sedrak, Christine; Jungbluth, Achim A.; Chua, Ramon; Gnjatic, Sacha; Wolchok, Jedd D.] Ludwig Inst Canc Res, New York Branch, New York, NY USA; [Rosner, Samuel] SUNY Stony Brook, Stony Brook, NY 11794 USA; [Postow, Michael A.; Callahan, Margaret K.; Barker, Christopher A.; Yamada, Yoshiya; Allison, James P.; Lesokhin, Alexander M.; Wolchok, Jedd D.] Weill Cornell Med Coll, New York, NY USA; [Yang, Arvin S.] Bristol Myers Squibb Co, Princeton, NJ USA; [Benson, Brenna] Colorado State Univ, Ft Collins, CO 80523 USA; [Allison, James P.] Howard Hughes Med Inst, Chevy Chase, MD USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Bristol-Myers Squibb; Colorado State University; Howard Hughes Medical Institute	Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Melanoma & Sarcoma Serv, 1275 York Ave, New York, NY 10065 USA.	wolchokj@mskcc.org	Barker, Christopher/I-9477-2012	Kitano, Shigehisa/0000-0002-4041-8298; Ritter, Erika/0000-0002-5161-7874; Allison, James/0000-0001-8980-5697; Gnjatic, Sacha/0000-0001-5643-9520; Barker, Christopher/0000-0003-1882-1088; Adamow, Matthew/0000-0002-7709-0126	National Institutes of Health [RC2CA148468]; American Cancer Society [MRSG-11-054-01-LIB]; Melanoma Research Alliance; Swim Across America; Cancer Research Institute; Virginia and D.K. Ludwig Fund for Cancer Research; Lita Annenberg Hazen Foundation; Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [RC2CA148468, P30CA008748, R01CA056821] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Melanoma Research Alliance; Swim Across America; Cancer Research Institute; Virginia and D.K. Ludwig Fund for Cancer Research; Lita Annenberg Hazen Foundation; Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health (RC2CA148468, to Drs. Gnjatic and Wolchok), the American Cancer Society (MRSG-11-054-01-LIB, to Dr. Lesokhin), the Melanoma Research Alliance (to Drs. Gnjatic, Lesokhin, and Wolchok), Swim Across America (to Dr. Wolchok), the Cancer Research Institute (to Drs. Gnjatic and Wolchok), the Virginia and D.K. Ludwig Fund for Cancer Research (to Dr. Allison), the Lita Annenberg Hazen Foundation (to Dr. Wolchok), and the Commonwealth Foundation for Cancer Research (to Dr. Wolchok).	Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Chakravarty PK, 1999, CANCER RES, V59, P6028; Demaria S, 2005, CLIN CANCER RES, V11, P728; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Drake CG, 2011, CURR CANCER RES, P251, DOI 10.1007/978-1-4419-8044-1_12; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Gnjatic Sacha, 2009, V520, P11, DOI 10.1007/978-1-60327-811-9_2; Gnjatic S, 2009, J IMMUNOL METHODS, V341, P50, DOI 10.1016/j.jim.2008.10.016; Hodi FS, 2010, NEW ENGL J MED, V363, P1290; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jager E, 1999, INT J CANCER, V84, P506, DOI 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6; Jungbluth AA, 2002, INT J CANCER, V97, P878, DOI 10.1002/ijc.10199; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kahana O, 2002, ONCOGENE, V21, P3969, DOI 10.1038/sj.onc.1205472; KINGSLEY DPE, 1975, BRIT J RADIOL, V48, P863, DOI 10.1259/0007-1285-48-574-863; Lesokhin A, 2011, CANC RES        1215; MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; ROBINS HI, 1981, MED PEDIATR ONCOL, V9, P473, DOI 10.1002/mpo.2950090510; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Wersall PJ, 2006, ACTA ONCOL, V45, P493, DOI 10.1080/02841860600604611; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Yuan JD, 2011, P NATL ACAD SCI USA, V108, P16723, DOI 10.1073/pnas.1110814108; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	26	1472	1524	6	159	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					925	931		10.1056/NEJMoa1112824	http://dx.doi.org/10.1056/NEJMoa1112824			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397654	Green Accepted			2022-12-28	WOS:000301172500009
J	Powell, K				Powell, Kendall			Egg-making stem cells found in adult ovaries	NATURE			English	News Item																		Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; White Y. A. R., 2012, NATURE MED; Zou K, 2009, NAT CELL BIOL, V11, P631, DOI 10.1038/ncb1869	3	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 1	2012	483	7387					16	17		10.1038/483016a	http://dx.doi.org/10.1038/483016a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900HP	22382955	Bronze			2022-12-28	WOS:000300877900018
